"name";"identifier";"SMILES";"inchikey";"MW";"LogP";"pubchem";"chEMBL";"membrane";"method";"temperature";"charge";"note";"LogK";"LogPerm_molmedb_value";"primary_reference";"method_label";"Perm"
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"CACO";"ECACO";"25";"0";;;-4.48;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204";"CACO-2";0.000033113112148259076
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"CACO";"ECACO";"25";"0";;;-4.6;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204";"CACO-2";0.000025118864315095822
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"CACO";"ECACO";"25";"0";;;-4.92;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204";"CACO-2";0.000012022644346174132
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"CACO";"ECACO";"25";"0";;;-4.63;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204";"CACO-2";0.00002344228815319923
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"CACO";"ECACO";"25";"0";;;-6.4;"Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Europ. J. Pharm. Sci. 2000, 10(3) 195-204";"CACO-2";0.0000003981071705534969
"Acebutolol";"MM00437";"CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1";"GOEMGAFJFRBGGG-OAHLLOKOSA-N";336.43;2.37;"1978";"CHEMBL642";"CACO";"ECACO";"25";;;;-5.42;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000003801893963205613
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"CACO";"ECACO";"25";;;;-4;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0001
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"CACO";"ECACO";"25";;;;-5.66;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000021877616239495517
"Acrivastine";"MM00715";"Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1";"PWACSDKDOHSSQD-IUTFFREVSA-N";348.45;4.02;"5284514";"CHEMBL1224";"CACO";"ECACO";"25";;;;-5.72;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000019054607179632483
"Alprenolol";"MM00440";"C=CCc1ccccc1OC[C@H](O)CNC(C)C";"PAZJSJFMUHDSTF-CQSZACIVSA-N";249.35;2.15;"2119";"CHEMBL266195";"CACO";"ECACO";"25";;;;-3.77;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00016982436524617443
"Amoxicillin";"MM00716";"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O";"LSQZJLSUYDQPKJ-NJBDSQKTSA-N";365.41;0.02;"33613";"CHEMBL1082";"CACO";"ECACO";"25";;;;-7.68;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000000020892961308540408
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"CACO";"ECACO";"25";;;;-3.82;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00015135612484362088
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";;;;-5.48;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000033113112148259077
"Zidovudine";"MM00077";"Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O";"HBOMLICNUCNMMY-UHFFFAOYSA-N";267.25;-0.2;"35370";"CHEMBL129";"CACO";"ECACO";"25";;;;-4.55;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00002818382931264455
"Bupropion";"MM00455";"C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1";"SNPPWIUOZRMYNY-VIFPVBQESA-N";239.75;3.3;"444";"CHEMBL894";"CACO";"ECACO";"25";;;;-3.82;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00015135612484362088
"Cefuroxime";"MM01507";"CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(N)=O)CSC12)c1ccco1";"JFPVXVDWJQMJEE-UHFFFAOYSA-N";424.39;-0.54;;;"CACO";"ECACO";"25";;;;-6.42;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00000038018939632056126
"Cephalexin";"MM00721";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1";"ZAIPMKNFIOOWCQ-UHFFFAOYSA-N";347.4;0.44;"27447";"CHEMBL1727";"CACO";"ECACO";"25";;;;-6.57;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000002691534803926914
"Chlorothiazide";"MM00641";"NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O";"JBMKAUGHUNFTOL-UHFFFAOYSA-N";295.73;0.13;"2720";"CHEMBL842";"CACO";"ECACO";"25";;;;-6.49;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000003235936569296281
"Corticosterone";"MM00346";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12";"OMFXVFTZEKFJBZ-UHFFFAOYSA-N";346.47;2.67;"5753";"CHEMBL110739";"CACO";"ECACO";"25";;;;-3.92;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00012022644346174131
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"CACO";"ECACO";"25";;;;-4.4;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000039810717055349695
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"CACO";"ECACO";"25";;;;-6.85;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00000014125375446227555
"Gabapentin";"MM00737";"NCC1(CC(=O)O)CCCCC1";"UGJMXCAKCUNAIE-UHFFFAOYSA-N";171.24;1.37;"3446";"CHEMBL940";"CACO";"ECACO";"25";;;;-8;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00000001
"Guanabenz";"MM00497";"N=C(N)NN=Cc1c(Cl)cccc1Cl";"WDZVGELJXXEGPV-UHFFFAOYSA-N";231.09;1.81;"5702063";"CHEMBL420";"CACO";"ECACO";"25";;;;-4;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0001
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"CACO";"ECACO";"25";;;;-6.04;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000009120108393559096
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"CACO";"ECACO";"25";;;;-4.25;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00005623413251903491
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"CACO";"ECACO";"25";;;;-4.03;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00009332543007969905
"Labetalol";"MM00507";"CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1";"SGUAFYQXFOLMHL-UHFFFAOYSA-N";328.41;2.14;"3869";"CHEMBL429";"CACO";"ECACO";"25";;;;-4.11;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00007762471166286911
"Lamotrigine";"MM00383";"Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1";"PYZRQGJRPPTADH-UHFFFAOYSA-N";256.1;2.01;"3878";"CHEMBL741";"CACO";"ECACO";"25";;;;-3.96;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00010964781961431851
"Lisinopril";"MM00763";"NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O";"RLAWWYSOJDYHDC-UHFFFAOYSA-N";405.5;1.24;"5362119";"CHEMBL1237";"CACO";"ECACO";"25";;;;-6.66;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000002187761623949552
"Loracarbef";"MM01552";"NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CCC12)c1ccccc1";"JAPHQRWPEGVNBT-UHFFFAOYSA-N";349.77;0.71;"5284585";;"CACO";"ECACO";"25";;;;-6.62;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000000239883291901949
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";;;;-6.24;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000005754399373371567
"Methylprednisolone";"MM00388";"CC1CC2C(C(O)CC3(C)C2CCC3(O)C(=O)CO)C2(C)C=CC(=O)C=C12";"VHRSUDSXCMQTMA-UHFFFAOYSA-N";374.48;1.8;"6741";"CHEMBL650";"CACO";"ECACO";"25";;;;-4.6;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000025118864315095822
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"CACO";"ECACO";"25";;;;-3.85;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0001412537544622754
"Nadolol";"MM00525";"CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2";"VWPOSFSPZNDTMJ-UHFFFAOYSA-N";309.41;0.63;"39147";"CHEMBL649";"CACO";"ECACO";"25";;;;-6.41;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000003890451449942805
"Netivudine";"MM00395";"CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O";"QLOCVMVCRJOTTM-SDNRWEOFSA-N";282.25;-2.48;"55281";"CHEMBL1097615";"CACO";"ECACO";"25";;;;-6.17;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000006760829753919819
"Olsalazine";"MM01437";"O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O";"QQBDLJCYGRGAKP-FOCLMDBBSA-N";302.24;2.91;"22419";"CHEMBL1201013";"CACO";"ECACO";"25";;;;-7.8;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000000015848931924611143
"Ondansetron";"MM00531";"Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O";"FELGMEQIXOGIFQ-UHFFFAOYSA-N";293.37;3.13;"4595";"CHEMBL46";"CACO";"ECACO";"25";;;;-3.96;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00010964781961431851
"Phenytoin";"MM00406";"O=C1N=C(O)NC1(c1ccccc1)c1ccccc1";"CXOFVDLJLONNDW-UHFFFAOYSA-N";252.27;1.97;"1775";"CHEMBL16";"CACO";"ECACO";"25";;;;-3.8;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00015848931924611142
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"CACO";"ECACO";"25";;;;-4.01;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00009772372209558111
"Practolol";"MM00544";"CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1";"DURULFYMVIFBIR-UHFFFAOYSA-N";266.34;1.38;"4883";"CHEMBL6995";"CACO";"ECACO";"25";;;;-5.21;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000006165950018614822
"Progesterone";"MM00198";"CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C";"RJKFOVLPORLFTN-UHFFFAOYSA-N";314.47;4.72;"5994";"CHEMBL103";"CACO";"ECACO";"25";;;;-4.01;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00009772372209558111
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";;;;-3.96;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00010964781961431851
"6-propyl-2-sulfanylidene-1H-pyrimidin-4-one";"MM00415";"CCCc1cc(=O)[nH]c(=S)[nH]1";"KNAHARQHSZJURB-UHFFFAOYSA-N";170.24;1.38;"657298";"CHEMBL1518";"CACO";"ECACO";"25";;;;-4.02;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00009549925860214369
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"CACO";"ECACO";"25";;;;-4.89;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000012882495516931348
"Sotalol";"MM00567";"CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1";"ZBMZVLHSJCTVON-UHFFFAOYSA-N";272.37;1.09;"5253";"CHEMBL471";"CACO";"ECACO";"25";;;;-5.3;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.000005011872336272725
"Sulfasalazine";"MM00690";"O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O";"NCEXYHBECQHGNR-UHFFFAOYSA-N";398.4;3.7;"5359476";"CHEMBL421";"CACO";"ECACO";"25";;;;-6.22;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0000006025595860743581
"5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol";"MM00306";"CC(C)(C)NCC(O)c1cc(O)cc(O)c1";"XWTYSIMOBUGWOL-UHFFFAOYSA-N";225.29;1.52;"5403";"CHEMBL1760";"CACO";"ECACO";"25";;;;-6.39;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00000040738027780411303
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"CACO";"ECACO";"25";;;;-4;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0001
"(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol";"MM00573";"CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1";"BLJRIMJGRPQVNF-UHFFFAOYSA-N";316.43;0.5;"33624";"CHEMBL499";"CACO";"ECACO";"25";;;;-4;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.0001
"Trimethoprim";"MM00581";"COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC";"IEDVJHCEMCRBQM-UHFFFAOYSA-N";290.32;1.26;"5578";"CHEMBL22";"CACO";"ECACO";"25";;;;-4.06;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00008709635899560814
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"CACO";"ECACO";"25";;;;-4.02;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"CACO-2";0.00009549925860214369
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"CACO";"ECACO";"25";;;;-5.89;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020";"CACO-2";0.000001288249551693135
"Quinidine";"MM00558";"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-LHHVKLHASA-N";324.42;3.17;"441074";"CHEMBL1294";"CACO";"ECACO";"25";;;;-4.5;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020";"CACO-2";0.000031622776601683795
"Methotrexate";"MM00270";"CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1";"FBOZXECLQNJBKD-UHFFFAOYSA-N";454.45;0.27;"126941";"CHEMBL34259";"CACO";"ECACO";"25";;;;-6.54;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020";"CACO-2";0.00000028840315031266057
"MM476428";"MM476428";"CN(C)C(=O)Cn1c(-c2ccoc2)c(C2CCCCC2)c2ccc(C(=O)O)cc21";"WMWCGYUJKNEVBP-UHFFFAOYSA-N";394.47;4.74;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067063/target=_blank>CHEMBL1067063</a>";;-4.89;"Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, KĂĽhn P, LagacĂ© L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G.: N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.000012882495516931348
"MM476430";"MM476430";"COCC[C@H](CC1(C(=O)NCCCc2ccc(F)cc2)CCCC1)C(=O)O";"MPWCDZKWKGSZCI-QGZVFWFLSA-N";379.47;3.56;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL914047/target=_blank>CHEMBL914047</a>";;-4.92;"Pryde DC, Cook AS, Burring DJ, Jones LH, Foll S, Platts MY, Sanderson V, Corless M, Stobie A, Middleton DS, Foster L, Barker L, Van Der Graaf P, Stacey P, Kohl C, Coggon S, Beaumont K.: Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.000012022644346174132
"MM476440";"MM476440";"COCC[C@H](CC1(C(=O)N[C@@H]2C[C@H]2c2ccc(OC)cc2)CCCC1)C(=O)O";"WAFMGROHMCCENJ-NZSAHSFTSA-N";389.49;3.36;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL914047/target=_blank>CHEMBL914047</a>";;-5.15;"Pryde DC, Cook AS, Burring DJ, Jones LH, Foll S, Platts MY, Sanderson V, Corless M, Stobie A, Middleton DS, Foster L, Barker L, Van Der Graaf P, Stacey P, Kohl C, Coggon S, Beaumont K.: Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.000007079457843841373
"MM476448";"MM476448";"O=C(O)c1ccc2c(C3CCCCC3)c(-c3ccoc3)n(CC(=O)N3CCC(N4CCCC4)CC3)c2c1";"AXCDCTDPQGHPHW-UHFFFAOYSA-N";503.64;5.73;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067063/target=_blank>CHEMBL1067063</a>";;-5.85;"Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, KĂĽhn P, LagacĂ© L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G.: N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.0000014125375446227554
"MM476449";"MM476449";"O=C(O)c1ccc2c(C3CCCCC3)c(-c3cccs3)n(CC(=O)N3CCC(N4CCCC4)CC3)c2c1";"UYKGLIHNWJZRAE-UHFFFAOYSA-N";519.71;6.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067063/target=_blank>CHEMBL1067063</a>";;-6.7;"Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, KĂĽhn P, LagacĂ© L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G.: N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.00000019952623149688787
"MM476450";"MM476450";"CCN1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1";"RUNGOSGEIDQARZ-UHFFFAOYSA-N";463.58;4.81;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067063/target=_blank>CHEMBL1067063</a>";;-5.19;"Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, KĂĽhn P, LagacĂ© L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G.: N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.000006456542290346549
"MM476451";"MM476451";"CC(C)N1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1";"OLJMSYJNZOXIEK-UHFFFAOYSA-N";477.61;5.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067063/target=_blank>CHEMBL1067063</a>";;-5.15;"Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, KĂĽhn P, LagacĂ© L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G.: N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.000007079457843841373
"MM476452";"MM476452";"CN1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1";"PVPJOOULWFAITO-UHFFFAOYSA-N";449.55;4.42;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067063/target=_blank>CHEMBL1067063</a>";;-5.77;"Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, KĂĽhn P, LagacĂ© L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G.: N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.000001698243652461746
"MM476453";"MM476453";"CN1CCC(N(C)C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1";"PDPAKDRWKAZOJT-UHFFFAOYSA-N";477.61;5.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067063/target=_blank>CHEMBL1067063</a>";;-6.7;"Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, KĂĽhn P, LagacĂ© L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G.: N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.00000019952623149688787
"MM476454";"MM476454";"O=C(O)c1ccc2c(C3CCCCC3)c(-c3ccoc3)n(CC(=O)N3CCOCC3)c2c1";"KDYXOWBSSDOZCK-UHFFFAOYSA-N";436.51;4.51;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067063/target=_blank>CHEMBL1067063</a>";;-5.28;"Beaulieu PL, Jolicoeur E, Gillard J, Brochu C, Coulombe R, Dansereau N, Duan J, Garneau M, Jakalian A, KĂĽhn P, LagacĂ© L, LaPlante S, McKercher G, Perrault S, Poirier M, Poupart MA, Stammers T, Thauvette L, Thavonekham B, Kukolj G.: N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.000005248074602497723
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL933017/target=_blank>CHEMBL933017</a>";;-4.92;"Colabufo NA, Abate C, Contino M, Inglese C, Niso M, Berardi F, Perrone R.: PB183, a sigma receptor ligand, as a potential PET probe for the imaging of prostate adenocarcinoma. Bioorg Med Chem Lett, Volume 18 (6), 2008";"CACO-2";0.000012022644346174132
"MM476455";"MM476455";"COc1cccc2c(CCCN3CCN(C4CCCCC4)CC3)cccc12";"OAXSBEWCGPXYFN-UHFFFAOYSA-N";366.55;4.73;;;"CACO";"ECACO";"25";"0";"fromAtoB,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL933017/target=_blank>CHEMBL933017</a>";;-5.2;"Colabufo NA, Abate C, Contino M, Inglese C, Niso M, Berardi F, Perrone R.: PB183, a sigma receptor ligand, as a potential PET probe for the imaging of prostate adenocarcinoma. Bioorg Med Chem Lett, Volume 18 (6), 2008";"CACO-2";0.00000630957344480193
"MM476437";"MM476437";"CCC[C@H](CC1(C(=O)Nc2nnc(C)s2)CCCC1)C(=O)O";"FEIWTOVFMGPLGF-LLVKDONJSA-N";325.43;3.24;;;"CACO";"ECACO";"25";"0";"fromBtoA,ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL862879/target=_blank>CHEMBL862879</a>";;-5.7;"Pryde DC, Maw GN, Planken S, Platts MY, Sanderson V, Corless M, Stobie A, Barber CG, Russell R, Foster L, Barker L, Wayman C, Van Der Graaf P, Stacey P, Morren D, Kohl C, Beaumont K, Coggon S, Tute M.: Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides. J Med Chem, Volume 49 (14), 2006";"CACO-2";0.0000019952623149688787
"MM476439";"MM476439";"Cc1ccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)c1";"RLMADYPUXGWZSL-UHFFFAOYSA-N";451.54;3.87;;;"CACO";"ECACO";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL862323/target=_blank>CHEMBL862323</a>";;-5.3;"Geneste H, Amberg W, Backfisch G, Beyerbach A, Braje WM, Delzer J, Haupt A, Hutchins CW, King LL, Sauer DR, Unger L, Wernet W.: Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme. Bioorg Med Chem Lett, Volume 16 (7), 2006";"CACO-2";0.000005011872336272725
"MM475122";"MM475122";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2";"DEKOYVOWOVJMPM-RLHIPHHXSA-N";560.63;2.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1112197/target=_blank>CHEMBL1112197</a>";;-5.89;"Ruebsam F, Murphy DE, Tran CV, Li LS, Zhao J, Dragovich PS, McGuire HM, Xiang AX, Sun Z, Ayida BK, Blazel JK, Kim SH, Zhou Y, Han Q, Kissinger CR, Webber SE, Showalter RE, Shah AM, Tsan M, Patel RA, Thompson PA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Khandurina J, Brooks J, Okamoto E, Kirkovsky L.: Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (22), 2009";"CACO-2";0.000001288249551693135
"MM475123";"MM475123";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@H]3[C@@H]4CC[C@@H](C4)[C@H]3N(Cc3ccc(F)cc3)C1=O)N2";"DEKOYVOWOVJMPM-SVBQBFEESA-N";560.63;2.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1112197/target=_blank>CHEMBL1112197</a>";;-5.05;"Ruebsam F, Murphy DE, Tran CV, Li LS, Zhao J, Dragovich PS, McGuire HM, Xiang AX, Sun Z, Ayida BK, Blazel JK, Kim SH, Zhou Y, Han Q, Kissinger CR, Webber SE, Showalter RE, Shah AM, Tsan M, Patel RA, Thompson PA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Khandurina J, Brooks J, Okamoto E, Kirkovsky L.: Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (22), 2009";"CACO-2";0.00000891250938133746
"MM475124";"MM475124";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3N(Cc3ccc(F)c(F)c3)C1=O)N2";"POXSEBOSMJMBJD-VQXITPLLSA-N";578.62;3.12;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1112197/target=_blank>CHEMBL1112197</a>";;-5.98;"Ruebsam F, Murphy DE, Tran CV, Li LS, Zhao J, Dragovich PS, McGuire HM, Xiang AX, Sun Z, Ayida BK, Blazel JK, Kim SH, Zhou Y, Han Q, Kissinger CR, Webber SE, Showalter RE, Shah AM, Tsan M, Patel RA, Thompson PA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Khandurina J, Brooks J, Okamoto E, Kirkovsky L.: Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (22), 2009";"CACO-2";0.0000010471285480508985
"MM475125";"MM475125";"Cc1cc(CN2C(=O)C(C3=NS(=O)(=O)c4cc(NS(C)(=O)=O)ccc4N3)=C(O)[C@@H]3[C@H]4CC[C@H](C4)[C@@H]32)ccc1F";"KSLLJELXHJQTBA-FACYHLHNSA-N";574.66;3.29;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1112197/target=_blank>CHEMBL1112197</a>";;-5.4;"Ruebsam F, Murphy DE, Tran CV, Li LS, Zhao J, Dragovich PS, McGuire HM, Xiang AX, Sun Z, Ayida BK, Blazel JK, Kim SH, Zhou Y, Han Q, Kissinger CR, Webber SE, Showalter RE, Shah AM, Tsan M, Patel RA, Thompson PA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Khandurina J, Brooks J, Okamoto E, Kirkovsky L.: Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (22), 2009";"CACO-2";0.000003981071705534969
"MM475126";"MM475126";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3[C@@H]([C@H]4CC[C@@H]3O4)N(Cc3ccc(F)cc3)C1=O)N2";"VVJGOBZVAYNTLT-ZDWTUXFCSA-N";562.6;2.11;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1112197/target=_blank>CHEMBL1112197</a>";;-7.1;"Ruebsam F, Murphy DE, Tran CV, Li LS, Zhao J, Dragovich PS, McGuire HM, Xiang AX, Sun Z, Ayida BK, Blazel JK, Kim SH, Zhou Y, Han Q, Kissinger CR, Webber SE, Showalter RE, Shah AM, Tsan M, Patel RA, Thompson PA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Khandurina J, Brooks J, Okamoto E, Kirkovsky L.: Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (22), 2009";"CACO-2";0.00000007943282347242822
"MM475127";"MM475127";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@H]3[C@H]4CC[C@H](C4)[C@H]3N(Cc3ccc(F)cc3)C1=O)N2";"DEKOYVOWOVJMPM-GDZMOAKWSA-N";560.63;2.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1112197/target=_blank>CHEMBL1112197</a>";;-5.7;"Ruebsam F, Murphy DE, Tran CV, Li LS, Zhao J, Dragovich PS, McGuire HM, Xiang AX, Sun Z, Ayida BK, Blazel JK, Kim SH, Zhou Y, Han Q, Kissinger CR, Webber SE, Showalter RE, Shah AM, Tsan M, Patel RA, Thompson PA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Khandurina J, Brooks J, Okamoto E, Kirkovsky L.: Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (22), 2009";"CACO-2";0.0000019952623149688787
"MM475132";"MM475132";"CCCCC1N(CC2CCCCC2)C(=O)OC12CCN(C1(C)CCN(C(=O)c3c(C)cccc3C)CC1)CC2";"FRWMBAREYKAXIM-UHFFFAOYSA-N";537.79;6.72;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1116697/target=_blank>CHEMBL1116697</a>";;-4.85;"Rotstein DM, Gabriel SD, Makra F, Filonova L, Gleason S, Brotherton-Pleiss C, Setti LQ, Trejo-Martin A, Lee EK, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Weller P, Mau CI.: Spiropiperidine CCR5 antagonists. Bioorg Med Chem Lett, Volume 19 (18), 2009";"CACO-2";0.000014125375446227555
"MM475134";"MM475134";"CCCCC1N(CC2CCOCC2)C(=O)OC12CCN(C1(C)CCN(C(=O)c3c(C)ncnc3C)CC1)CC2";"KQLSXCNTMVFPSL-UHFFFAOYSA-N";541.74;4.36;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1116697/target=_blank>CHEMBL1116697</a>";;-6.22;"Rotstein DM, Gabriel SD, Makra F, Filonova L, Gleason S, Brotherton-Pleiss C, Setti LQ, Trejo-Martin A, Lee EK, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Weller P, Mau CI.: Spiropiperidine CCR5 antagonists. Bioorg Med Chem Lett, Volume 19 (18), 2009";"CACO-2";0.0000006025595860743581
"MM475149";"MM475149";"CCCCC1CN(C2CCOCC2)C(=O)N1C1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)CC1";"HWJLBUCAKPCIRM-UHFFFAOYSA-N";540.75;4.03;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.4;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000003981071705534969
"MM475150";"MM475150";"COc1cc(F)c2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N(C)CCN(C)C)cc5)cc4C3=O)c2c1";"YKPMNBJYASHWAN-ZCTHSVRISA-N";679.75;6.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119667/target=_blank>CHEMBL1119667</a>";;-6.52;"Zhang N, Ayral-Kaloustian S, Anderson JT, Nguyen T, Das S, Venkatesan AM, Brooijmans N, Lucas J, Yu K, Hollander I, Mallon R.: 5-ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-alpha and mTOR for the treatment of breast cancer. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.0000003019951720402019
"MM475152";"MM475152";"Cc1cc(C#N)nc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(C)C[C@H]3c3ccccc3)CC2)CC1";"UAQHXCHBMPJOKD-SANMLTNESA-N";514.67;4.14;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.22;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000006025595860743581
"MM475156";"MM475156";"CCCCC1CN(CC2CCOCC2)C(=O)N1C1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)CC1";"WWQMRSATUNQSKQ-UHFFFAOYSA-N";554.78;4.28;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.4;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000003981071705534969
"MM475157";"MM475157";"O=C(CCCCCNC(=O)NC(=O)c1ccccc1)NO";"VQLQZMGNGMOMPU-UHFFFAOYSA-N";293.32;1.19;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119918/target=_blank>CHEMBL1119918</a>";;-5.51;"Wang H, Lim ZY, Zhou Y, Ng M, Lu T, Lee K, Sangthongpitag K, Goh KC, Wang X, Wu X, Khng HH, Goh SK, Ong WC, Bonday Z, Sun ET.: Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.000003090295432513592
"MM475161";"MM475161";"Cc1ccc(-c2ccc(C(=O)NC3(C(=O)N[C@@H](CCCN4CCN(CC5CCOCC5)CC4)Cc4ccccc4)CCCC3)cc2)cc1";"OTCVPAOGBITYCE-LHEWISCISA-N";650.91;6.26;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-5.15;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.000007079457843841373
"MM475162";"MM475162";"O=C(NC1(C(=O)N[C@@H](CCCN2CCN(CC3CCOCC3)CC2)Cc2ccccc2)CCCC1)c1ccc(-c2ccccc2)cc1";"PGRZDFUKUNJXDD-QNGWXLTQSA-N";636.88;5.95;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-4.87;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.000013489628825916533
"MM475163";"MM475163";"O=C(NC1(C(=O)N[C@@H](CCCN2CCN(CC3CCOCC3)CC2)Cc2ccccc2)CCCC1)c1ccc2ccccc2c1";"ZXRIWIVIXXWDGK-DHUJRADRSA-N";610.84;5.43;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-4.84;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.00001445439770745928
"MM475165";"MM475165";"O=C(NC1(C(=O)N[C@@H](CCCN2CCN(CC3CCOCC3)CC2)Cc2ccccc2)CCCC1)c1cc2cc(Cl)ccc2o1";"QXHSKALBSZTNEQ-HKBQPEDESA-N";635.25;5.68;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-4.86;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.000013803842646028839
"MM475166";"MM475166";"COc1ccc2oc(C(=O)NC3(C(=O)N[C@@H](CCCN4CCN(CC5CCOCC5)CC4)Cc4ccccc4)CCCC3)cc2c1";"MWXNEDJGFIJNMF-HKBQPEDESA-N";630.83;5.04;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-5.07;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.00000851138038202376
"MM475167";"MM475167";"Cc1ccc2oc(C(=O)NC3(C(=O)N[C@@H](CCCN4CCN(CC5CCOCC5)CC4)Cc4ccccc4)CCCC3)cc2c1";"POQVHRORJJLKKH-YTTGMZPUSA-N";614.83;5.34;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-4.52;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.000030199517204020192
"MM475168";"MM475168";"O=C(NC1(C(=O)N[C@@H](CCCN2CCN(CC3CCOCC3)CC2)Cc2ccccc2)CCCC1)c1cc2ccccc2s1";"IFLAJVCAIZJOPG-HKBQPEDESA-N";616.87;5.5;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-4.96;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.000010964781961431852
"MM475169";"MM475169";"Cc1ccc2cc(C(=O)NC3(C(=O)N[C@@H](CCCN4CCN(CC5CCOCC5)CC4)Cc4ccccc4)CCCC3)sc2c1";"MYXKMTKFUPOTOZ-YTTGMZPUSA-N";630.9;5.8;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-4.95;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.00001122018454301963
"MM475171";"MM475171";"O=C(NC1(C(=O)N[C@@H](CCCN2CCN(CC3CCOCC3)CC2)Cc2ccccc2)CCCC1)c1cc2ccccc2o1";"FOXUTIZHAYSOSZ-HKBQPEDESA-N";600.8;5.03;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120422/target=_blank>CHEMBL1120422</a>";;-4.69;"Fattori D, Porcelloni M, D'Andrea P, Catalioto RM, Ettorre A, Giuliani S, Marastoni E, Mauro S, Meini S, Rossi C, Altamura M, Maggi CA.: Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. J Med Chem, Volume 53 (10), 2010";"CACO-2";0.000020417379446695274
"MM473078";"MM473078";"NS(=O)(=O)c1ccc(Nc2nccc(-c3ccsc3)n2)cc1";"JUIXZPWSSOKEIF-UHFFFAOYSA-N";332.41;2.6;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120485/target=_blank>CHEMBL1120485</a>";;-4.28;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.00005248074602497723
"MM475173";"MM475173";"CNC(=O)N1CCC(CN2C[C@@H](c3ccccc3)N(C3CCN(C4(C)CCN(C(=O)c5c(C)cc(C#N)nc5C)CC4)CC3)C2=O)CC1";"JIJRESHTPMIRAN-YTTGMZPUSA-N";654.86;4.56;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.15;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000007079457843841374
"MM475174";"MM475174";"Cc1ncnc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(C4CCOCC4)C[C@H]3c3ccccc3)CC2)CC1";"CAXOWROVDBCIRL-NDEPHWFRSA-N";560.74;4.21;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.22;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000006025595860743581
"MM475175";"MM475175";"COC(=O)N1CCC(CN2C[C@@H](c3ccccc3)N(C3CCN(C4(C)CCN(C(=O)c5c(C)ncnc5C)CC4)CC3)C2=O)CC1";"HMSKCYWJITUINI-PMERELPUSA-N";631.82;4.51;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.52;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000003019951720402019
"MM475176";"MM475176";"Cc1ncnc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(CC4CCN(S(C)(=O)=O)CC4)C[C@H]3c3ccccc3)CC2)CC1";"BFXOQLCQTRNAKB-PMERELPUSA-N";651.88;3.7;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.7;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.00000019952623149688787
"MM475177";"MM475177";"CNC(=O)N1CCC(CN2C[C@@H](c3ccccc3)N(C3CCN(C4(C)CCN(C(=O)c5c(C)ncnc5C)CC4)CC3)C2=O)CC1";"PEYUSKSYYONOAP-PMERELPUSA-N";630.84;4.08;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-7;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000001
"MM475178";"MM475178";"CO[C@H]1CC[C@H](CN2C[C@@H](c3ccccc3)N(C3CCN(C4(C)CCN(C(=O)c5c(C)ncnc5C)CC4)CC3)C2=O)CC1";"NJZLCVZALWTNEZ-NAYUSWPISA-N";602.82;5.24;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-5.85;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000014125375446227554
"MM475179";"MM475179";"CCO[C@H]1CC[C@H](CN2C[C@@H](c3ccccc3)N(C3CCN(C4(C)CCN(C(=O)c5c(C)ncnc5C)CC4)CC3)C2=O)CC1";"XDWQGHWYCJPLGB-MHDHXZMLSA-N";616.85;5.63;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-5.52;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000030199517204020193
"MM475180";"MM475180";"Cc1ncnc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(C[C@H]4CC[C@H](O)CC4)C[C@H]3c3ccccc3)CC2)CC1";"QIFLDOWZTQMVPY-NSGJQZOKSA-N";588.8;4.58;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.7;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.00000019952623149688787
"MM475181";"MM475181";"Cc1cc(C#N)nc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(CC4CCOCC4)C[C@H]3c3ccccc3)CC2)CC1";"VCDAYNSEVSLHGF-HKBQPEDESA-N";598.79;4.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.000001
"MM475182";"MM475182";"Cc1ncnc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(CCC4CCOCC4)C[C@H]3c3ccccc3)CC2)CC1";"FGJLSESRUCPLFO-PMERELPUSA-N";588.8;4.85;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.1;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000007943282347242822
"MM475183";"MM475183";"Cc1ncnc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(CC4CCOCC4)C[C@H]3c3ccccc3)CC2)CC1";"LEIJVPCQIOHXMZ-LJAQVGFWSA-N";574.77;4.46;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.3;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000005011872336272725
"MM475184";"MM475184";"Cc1cc(C#N)nc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(C4CCOCC4)C[C@H]3c3ccccc3)CC2)CC1";"CAWUSVSAJWVLIE-PMERELPUSA-N";584.77;4.69;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.000001
"MM475185";"MM475185";"Cc1cc(C#N)nc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(C[C@H]4CC[C@H](O)CC4)C[C@H]3c3ccccc3)CC2)CC1";"IAGCLSUYXYTYDJ-GFLPGQDNSA-N";612.82;5.06;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.4;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000003981071705534969
"MM473079";"MM473079";"NS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccsc2CC3)cc1";"MTDWGYRUUAGIEQ-UHFFFAOYSA-N";358.45;2.69;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120485/target=_blank>CHEMBL1120485</a>";;-4.47;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.000033884415613920276
"MM475186";"MM475186";"Cc1cc(C#N)nc(C)c1C(=O)N1CCC(C)(N2CCC(N3C(=O)N(CC4CCOCC4)C[C@@H]3c3ccccn3)CC2)CC1";"MTYIHUHFILXRRS-SSEXGKCCSA-N";599.78;4.33;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-7;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000001
"MM475187";"MM475187";"CCO[C@H]1CC[C@H](CN2C[C@H](c3ccccn3)N(C3CCN(C4(C)CCN(C(=O)c5c(C)cc(C#N)nc5C)CC4)CC3)C2=O)CC1";"SWLYMHKXSNTLKZ-INJYMACJSA-N";641.86;5.5;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6.3;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.0000005011872336272725
"MM475188";"MM475188";"CCCCC1CN(C2CCOCC2)C(=O)N1C1CCN(C2(C)CCN(C(=O)c3c(C)cc(C#N)nc3C)CC2)CC1";"QHLYRYUVLUPASE-UHFFFAOYSA-N";564.78;4.5;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1119778/target=_blank>CHEMBL1119778</a>";;-6;"Rotstein DM, Gabriel SD, Manser N, Filonova L, Padilla F, Sankuratri S, Ji C, deRosier A, Dioszegi M, Heilek G, Jekle A, Weller P, Berry P.: Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (11), 2010";"CACO-2";0.000001
"MM475197";"MM475197";"CC(C)N(C)[C@@H]1CC[C@H](N2CC(C)(C)[C@H](NC(=O)c3cccc(C(F)(F)F)c3)C2=O)[C@H](CS(=O)(=O)c2ccccc2)C1";"FMQBTPGTROTRJJ-UICHKGEESA-N";607.74;5.02;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1104434/target=_blank>CHEMBL1104434</a>";;-5.82;"Cherney RJ, Mo R, Meyer DT, Voss ME, Yang MG, Santella JB, Duncia JV, Lo YC, Yang G, Miller PB, Scherle PA, Zhao Q, Mandlekar S, Cvijic ME, Barrish JC, Decicco CP, Carter PH.: gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists. Bioorg Med Chem Lett, Volume 20 (8), 2010";"CACO-2";0.0000015135612484362072
"MM475199";"MM475199";"Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O";"OIRDTQYFTABQOQ-UHTZMRCNSA-N";267.25;-1.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL942586/target=_blank>CHEMBL942586</a>";;-7.08;"Shen W, Kim JS, Kish PE, Zhang J, Mitchell S, Gentry BG, Breitenbach JM, Drach JC, Hilfinger J.: Design and synthesis of vidarabine prodrugs as antiviral agents. Bioorg Med Chem Lett, Volume 19 (3), 2009";"CACO-2";0.00000008317637711026709
"MM475201";"MM475201";"CC(C)N(C)[C@@H]1CC[C@H](N2C(=O)C[C@H](NC(=O)c3cccc(C(F)(F)F)c3)C2=O)[C@H](CS(=O)(=O)c2ccccc2)C1";"MNJLHCYPHRHQLE-OZTAZYLFSA-N";593.67;3.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1104434/target=_blank>CHEMBL1104434</a>";;-5.66;"Cherney RJ, Mo R, Meyer DT, Voss ME, Yang MG, Santella JB, Duncia JV, Lo YC, Yang G, Miller PB, Scherle PA, Zhao Q, Mandlekar S, Cvijic ME, Barrish JC, Decicco CP, Carter PH.: gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists. Bioorg Med Chem Lett, Volume 20 (8), 2010";"CACO-2";0.0000021877616239495517
"MM475208";"MM475208";"CSc1ccc(S(=O)(=O)C[C@@H]2C[C@H](N(C)C(C)C)CC[C@@H]2N2CCC(C)(NC(=O)c3cccc(C(F)(F)F)c3)C2=O)cc1";"XPXVRXYTAFCHFC-YFTHUZBXSA-N";639.81;5.5;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1104434/target=_blank>CHEMBL1104434</a>";;-5.82;"Cherney RJ, Mo R, Meyer DT, Voss ME, Yang MG, Santella JB, Duncia JV, Lo YC, Yang G, Miller PB, Scherle PA, Zhao Q, Mandlekar S, Cvijic ME, Barrish JC, Decicco CP, Carter PH.: gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists. Bioorg Med Chem Lett, Volume 20 (8), 2010";"CACO-2";0.0000015135612484362072
"MM475212";"MM475212";"Cc1ncnc(C)c1C(=O)N1C[C@H]2CN(CC[C@H](NC(=O)C3CCCC3)c3ccccc3)C[C@H]2C1";"NOQUFNXYRUTQRV-GVAUOCQISA-N";475.64;3.54;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1106477/target=_blank>CHEMBL1106477</a>";;-5.89;"Rotstein DM, Melville CR, Padilla F, Cournoyer D, Lee EK, Lemoine R, Petersen AC, Setti LQ, Wanner J, Chen L, Filonova L, Loughhead DG, Manka J, Lin XF, Gleason S, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Mau CI, Weller P.: Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (10), 2010";"CACO-2";0.000001288249551693135
"MM475213";"MM475213";"Cc1cc(=O)[nH]c(C)c1C(=O)N1C[C@H]2CN(CC[C@H](NC(=O)C3CCCC3)c3ccccc3)C[C@H]2C1";"WWQVMNYCPDEQDJ-GVAUOCQISA-N";490.65;3.43;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1106477/target=_blank>CHEMBL1106477</a>";;-6.3;"Rotstein DM, Melville CR, Padilla F, Cournoyer D, Lee EK, Lemoine R, Petersen AC, Setti LQ, Wanner J, Chen L, Filonova L, Loughhead DG, Manka J, Lin XF, Gleason S, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Mau CI, Weller P.: Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (10), 2010";"CACO-2";0.0000005011872336272725
"MM475214";"MM475214";"Cc1cc(C#N)nc(C)c1C(=O)N1C[C@H]2CN(CC[C@H](NC(=O)C3CCCC3)c3ccccc3)C[C@H]2C1";"JZDHTZPWSFVURY-WEWMWRJBSA-N";499.66;4.01;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1106477/target=_blank>CHEMBL1106477</a>";;-5.52;"Rotstein DM, Melville CR, Padilla F, Cournoyer D, Lee EK, Lemoine R, Petersen AC, Setti LQ, Wanner J, Chen L, Filonova L, Loughhead DG, Manka J, Lin XF, Gleason S, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Mau CI, Weller P.: Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (10), 2010";"CACO-2";0.0000030199517204020193
"MM475215";"MM475215";"Cc1cccc(C)c1C(=O)N1C[C@H]2CN(CC[C@H](NC(=O)C3CCCC3)c3ccccc3)C[C@H]2C1";"KOSURTOZOCPWIN-VJGNERBWSA-N";473.66;4.75;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1106477/target=_blank>CHEMBL1106477</a>";;-5.4;"Rotstein DM, Melville CR, Padilla F, Cournoyer D, Lee EK, Lemoine R, Petersen AC, Setti LQ, Wanner J, Chen L, Filonova L, Loughhead DG, Manka J, Lin XF, Gleason S, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Mau CI, Weller P.: Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (10), 2010";"CACO-2";0.000003981071705534969
"MM475217";"MM475217";"Cc1ccnc(C)c1C(=O)N1C[C@H]2CN(CC[C@H](NC(=O)C3CCCC3)c3ccccc3)C[C@H]2C1";"IWRAPSCFSVGRAI-NXCFDTQHSA-N";474.65;4.14;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1106477/target=_blank>CHEMBL1106477</a>";;-5.4;"Rotstein DM, Melville CR, Padilla F, Cournoyer D, Lee EK, Lemoine R, Petersen AC, Setti LQ, Wanner J, Chen L, Filonova L, Loughhead DG, Manka J, Lin XF, Gleason S, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Mau CI, Weller P.: Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (10), 2010";"CACO-2";0.000003981071705534969
"MM475219";"MM475219";"COc1cc(C)c(C(=O)N2C[C@H]3CN(CC[C@H](NC(=O)C4CCCC4)c4ccccc4)C[C@H]3C2)c(C)c1";"XAXDOVSBAFYIDI-REUBFRLUSA-N";503.69;4.75;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1106477/target=_blank>CHEMBL1106477</a>";;-4.48;"Rotstein DM, Melville CR, Padilla F, Cournoyer D, Lee EK, Lemoine R, Petersen AC, Setti LQ, Wanner J, Chen L, Filonova L, Loughhead DG, Manka J, Lin XF, Gleason S, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Mau CI, Weller P.: Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. Bioorg Med Chem Lett, Volume 20 (10), 2010";"CACO-2";0.000033113112148259076
"Saquinavir";"MM00563";"CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(O)C(Cc1ccccc1)NC(=O)C(CC(N)=O)NC(=O)c1ccc2ccccc2n1";"QWAXKHKRTORLEM-UHFFFAOYSA-N";670.86;3.09;"441243";"CHEMBL114";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL944659/target=_blank>CHEMBL944659</a>";;-5.4;"Roche D, Greiner J, Aubertin AM, Vierling P.: Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors. Eur J Med Chem, Volume 43 (7), 2008";"CACO-2";0.000003981071705534969
"MM475228";"MM475228";"CCCN(Cc1ccoc1)C(=O)c1cc(C)cc(OCC2(CON=C(N)N)CC2)c1";"RNECCXZBIIYSBX-UHFFFAOYSA-N";414.51;3;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL934697/target=_blank>CHEMBL934697</a>";;-5.39;"Kreutter KD, Lu T, Lee L, Giardino EC, Patel S, Huang H, Xu G, Fitzgerald M, Haertlein BJ, Mohan V, Crysler C, Eisennagel S, Dasgupta M, McMillan M, Spurlino JC, Huebert ND, Maryanoff BE, Tomczuk BE, Damiano BP, Player MR.: Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. Bioorg Med Chem Lett, Volume 18 (9), 2008";"CACO-2";0.000004073802778041131
"Prednisolone";"MM00297";"CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"OIGNJSKKLXVSLS-UHFFFAOYSA-N";360.45;1.56;"5755";"CHEMBL131";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL973474/target=_blank>CHEMBL973474</a>";;-5.12;"Ruiz JF, Radics G, Windle H, Serra HO, SimplĂ­cio AL, Kedziora K, Fallon PG, Kelleher DP, Gilmer JF.: Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease. J Med Chem, Volume 52 (10), 2009";"CACO-2";0.000007585775750291836
"Digoxin";"MM00357";"CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O";"LTMHDMANZUZIPE-UHFFFAOYSA-N";780.95;2.22;"2724385";"CHEMBL1751";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-6;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000001
"Losartan";"MM00665";"CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1";"PSIFNNKUMBGKDQ-UHFFFAOYSA-N";422.92;4.27;"3961";"CHEMBL191";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL908920/target=_blank>CHEMBL908920</a>";;-5.94;"Cappelli A, Pericot Mohr Gl, Giuliani G, Galeazzi S, Anzini M, Mennuni L, Ferrari F, Makovec F, Kleinrath EM, Langer T, Valoti M, Giorgi G, Vomero S.: Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds. J Med Chem, Volume 49 (22), 2006";"CACO-2";0.0000011481536214968817
"Losartan";"MM00665";"CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1";"PSIFNNKUMBGKDQ-UHFFFAOYSA-N";422.92;4.27;"3961";"CHEMBL191";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925711/target=_blank>CHEMBL925711</a>";;-5.94;"Cappelli A, Nannicini C, Gallelli A, Giuliani G, Valenti S, Mohr Gl, Anzini M, Mennuni L, Ferrari F, Caselli G, Giordani A, Peris W, Makovec F, Giorgi G, Vomero S.: Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.0000011481536214968817
"MM475331";"MM475331";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-QFEUDJFPSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864126/target=_blank>CHEMBL864126</a>";;-6.62;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.000000239883291901949
"MM475331";"MM475331";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-QFEUDJFPSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864127/target=_blank>CHEMBL864127</a>";;-6.32;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.000000478630092322638
"MM475331";"MM475331";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-QFEUDJFPSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864131/target=_blank>CHEMBL864131</a>";;-5.98;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000010471285480508985
"MM475331";"MM475331";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-QFEUDJFPSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865285/target=_blank>CHEMBL865285</a>";;-7.03;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.00000009332543007969905
"MM475365";"MM475365";"NC(=O)c1sc2ncccc2c1N";"XZIZYTUIRQMBPN-UHFFFAOYSA-N";193.23;0.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865085/target=_blank>CHEMBL865085</a>";;-4.89;"Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz A, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL.: Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem, Volume 49 (10), 2006";"CACO-2";0.000012882495516931348
"MM475367";"MM475367";"NC(=O)c1sc(-c2ccccc2)cc1N";"DYRYDYQWWQHRQE-UHFFFAOYSA-N";218.28;2.1;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865085/target=_blank>CHEMBL865085</a>";;-5.03;"Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz A, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL.: Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem, Volume 49 (10), 2006";"CACO-2";0.000009332543007969906
"MM475368";"MM475368";"NC(=O)c1sc(-c2ccc(F)cc2)cc1N";"VRUAXQODZDRLMI-UHFFFAOYSA-N";236.27;2.24;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865085/target=_blank>CHEMBL865085</a>";;-4.71;"Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz A, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL.: Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem, Volume 49 (10), 2006";"CACO-2";0.000019498445997580456
"MM475372";"MM475372";"CC(C)C[C@H](NC(=S)Nc1ccccc1)C(=O)N[C@H]1CCOC1O";"DFTOOBKXSNAAPW-ADTLFGHVSA-N";351.47;1.61;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL863675/target=_blank>CHEMBL863675</a>";;-4.84;"Shirasaki Y, Nakamura M, Yamaguchi M, Miyashita H, Sakai O, Inoue J.: Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives. J Med Chem, Volume 49 (13), 2006";"CACO-2";0.00001445439770745928
"MM475376";"MM475376";"NC(=O)c1nc(-c2ccccc2)oc1N";"UPWLRKVVLBSIPK-UHFFFAOYSA-N";203.2;1.02;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865085/target=_blank>CHEMBL865085</a>";;-5.19;"Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz A, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL.: Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem, Volume 49 (10), 2006";"CACO-2";0.000006456542290346549
"MM475381";"MM475381";"COc1cnn(C)c(=O)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1";"WYHTUAPAMDIATI-INIZCTEOSA-N";476.32;3.19;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL947948/target=_blank>CHEMBL947948</a>";;-6.89;"Gong Y, Kent Barbay J, Kimball ES, Santulli RJ, Carolyn Fisher M, Dyatkin AB, Miskowski TA, Hornby PJ, He W.: Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists. Bioorg Med Chem Lett, Volume 18 (4), 2008";"CACO-2";0.00000012882495516931348
"MM471804";"MM471804";"O=C(O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)c(Cl)c(Cl)c1O";"SMIZKRHOEQTUGE-LURJTMIESA-N";374.63;2.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868185/target=_blank>CHEMBL868185</a>";;-6.4;"Gopalsamy A, Chopra R, Lim K, Ciszewski G, Shi M, Curran KJ, Sukits SF, Svenson K, Bard J, Ellingboe JW, Agarwal A, Krishnamurthy G, Howe AY, Orlowski M, Feld B, O'Connell J, Mansour TS.: Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. J Med Chem, Volume 49 (11), 2006";"CACO-2";0.0000003981071705534969
"MM475390";"MM475390";"Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](N)CC(C)C)c1";"RZLPZBLBQNNVLZ-YKSBVNFPSA-N";442.05;5.22;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901398/target=_blank>CHEMBL901398</a>";;-5.74;"Tran JA, Jiang W, Tucci FC, Fleck BA, Wen J, Sai Y, Madan A, Chen TK, Markison S, Foster AC, Hoare SR, Marks D, Harman J, Chen CW, Arellano M, Marinkovic D, Bozigian H, Saunders J, Chen C.: Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor. J Med Chem, Volume 50 (25), 2007";"CACO-2";0.0000018197008586099826
"MM30965";"MM30965";"COc1ccccc1CC(c1ccccc1)N1CCNCC1";"PFTJCYRHNKTTTO-UHFFFAOYSA-N";296.41;2.88;;"CHEMBL214335";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120626/target=_blank>CHEMBL1120626</a>";;-4.54;"Fray MJ, Fish PV, Allan GA, Bish G, Clarke N, Eccles R, Harrison AC, Le Net JL, Phillips SC, Regan N, Sobry C, Stobie A, Wakenhut F, Westbrook D, Westbrook SL, Whitlock GA.: Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.000028840315031266056
"MM475403";"MM475403";"CCc1nc2c(C)cc(C)nc2n1Cc1ccc(-c2c(C(=O)O)n(C)c(=O)c3ccccc23)cc1";"UUTPXLIURPXEIR-UHFFFAOYSA-N";466.54;4.88;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL908920/target=_blank>CHEMBL908920</a>";;-7.52;"Cappelli A, Pericot Mohr Gl, Giuliani G, Galeazzi S, Anzini M, Mennuni L, Ferrari F, Makovec F, Kleinrath EM, Langer T, Valoti M, Giorgi G, Vomero S.: Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds. J Med Chem, Volume 49 (22), 2006";"CACO-2";0.000000030199517204020194
"MM475405";"MM475405";"CCCCc1nc2c(C)cc(C)nc2n1Cc1ccc(-c2c(C(=O)O)n(C)c(=O)c3ccccc23)cc1";"YUDQFUUZTCMUCN-UHFFFAOYSA-N";494.6;5.66;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL908920/target=_blank>CHEMBL908920</a>";;-8;"Cappelli A, Pericot Mohr Gl, Giuliani G, Galeazzi S, Anzini M, Mennuni L, Ferrari F, Makovec F, Kleinrath EM, Langer T, Valoti M, Giorgi G, Vomero S.: Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds. J Med Chem, Volume 49 (22), 2006";"CACO-2";0.00000001
"MM475420";"MM475420";"O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21";"XJJYJNMNYDNXNO-UHFFFAOYSA-N";307.33;3.17;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL904800/target=_blank>CHEMBL904800</a>";;-5.02;"Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ.: Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem, Volume 50 (11), 2007";"CACO-2";0.000009549925860214369
"MM475426";"MM475426";"N=C(N)NCCC[C@H](NC(=O)c1ccc(C(c2ccccc2)c2ccccc2)o1)C(=O)O";"KQTJPESSNDKYIC-SFHVURJKSA-N";434.5;2.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889069/target=_blank>CHEMBL889069</a>";;-6.4;"Denonne F, Binet S, Burton M, Collart P, Dipesa A, Ganguly T, Giannaras A, Kumar S, Lewis T, Maounis F, Nicolas JM, Mansley T, Pasau P, Preda D, Stebbins K, Volosov A, Zou D.: Discovery of new C3aR ligands. Part 1: arginine derivatives. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.0000003981071705534969
"MM475428";"MM475428";"C[C@H](Cc1cccc(CC(=O)NC2Cc3ccccc3C2)c1)NC[C@H](O)c1ccc(O)c(CO)c1";"FNEGAPIEQCNGCS-GDJIYFAZSA-N";474.6;2.96;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889146/target=_blank>CHEMBL889146</a>";;-6;"Brown AD, Bunnage ME, Glossop PA, James K, Jones R, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Trevethick M, Webster R.: The discovery of long acting beta2-adrenoreceptor agonists. Bioorg Med Chem Lett, Volume 17 (14), 2007";"CACO-2";0.000001
"MM475429";"MM475429";"C[C@H](Cc1cccc(CC(=O)NCc2cc(C(F)(F)F)ccc2F)c1)NC[C@H](O)c1ccc(O)c(CO)c1";"SKXGMLMLOXYJKI-QUGAMOGWSA-N";534.55;4.16;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889146/target=_blank>CHEMBL889146</a>";;-5.7;"Brown AD, Bunnage ME, Glossop PA, James K, Jones R, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Trevethick M, Webster R.: The discovery of long acting beta2-adrenoreceptor agonists. Bioorg Med Chem Lett, Volume 17 (14), 2007";"CACO-2";0.0000019952623149688787
"MM475430";"MM475430";"C[C@H](Cc1cccc(CC(=O)NCc2ccc(Cl)c(Cl)c2)c1)NC[C@H](O)c1ccc(O)c(CO)c1";"AOJZKEWJJYTGIX-QUGAMOGWSA-N";517.45;4.3;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889146/target=_blank>CHEMBL889146</a>";;-6;"Brown AD, Bunnage ME, Glossop PA, James K, Jones R, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Trevethick M, Webster R.: The discovery of long acting beta2-adrenoreceptor agonists. Bioorg Med Chem Lett, Volume 17 (14), 2007";"CACO-2";0.000001
"MM475433";"MM475433";"C[C@H](Cc1cccc(CC(=O)NCc2cc(Cl)cc(Cl)c2)c1)NC[C@H](O)c1ccc(O)c(CO)c1";"RQMJXRIKISIBQH-QUGAMOGWSA-N";517.45;4.3;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889146/target=_blank>CHEMBL889146</a>";;-6;"Brown AD, Bunnage ME, Glossop PA, James K, Jones R, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Trevethick M, Webster R.: The discovery of long acting beta2-adrenoreceptor agonists. Bioorg Med Chem Lett, Volume 17 (14), 2007";"CACO-2";0.000001
"MM475434";"MM475434";"Cn1cncc1CN1CC(N(CC2CCN(C(=O)OC(C)(C)C)CC2)S(=O)(=O)c2ccccn2)Cc2cc(C#N)ccc21";"FQLPAFFYSWNCAX-UHFFFAOYSA-N";605.77;3.96;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-4.81;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.000015488166189124828
"MM475436";"MM475436";"COC(=O)N1CCC(CN(C2Cc3cc(C#N)ccc3N(Cc3cncn3C)C2)S(=O)(=O)c2ccccn2)CC1";"BRIVIXLMMUIBJY-UHFFFAOYSA-N";563.68;2.79;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-5.96;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.000001096478196143185
"MM475438";"MM475438";"CCOC(=O)N1CCC(CN(C2Cc3cc(C#N)ccc3N(Cc3cncn3C)C2)S(=O)(=O)c2ccccn2)CC1";"OAERLEDUYZOGEV-UHFFFAOYSA-N";577.71;3.18;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-5.59;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.0000025703957827688647
"MM475452";"MM475452";"CC(=O)N1CCC(CN(C2Cc3cc(C#N)ccc3N(Cc3cncn3C)C2)S(=O)(=O)c2ccccn2)CC1";"BBWLVKQTRNHDFL-UHFFFAOYSA-N";547.69;2.57;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-6.3;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.0000005011872336272725
"MM475494";"MM475494";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"CAJZACFJOXOVAH-UHFFFAOYSA-N";455.47;2.78;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.2;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.00000630957344480193
"MM475496";"MM475496";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1ccc(F)c(F)c1)O2";"UGOGQLRJKMMHMF-UHFFFAOYSA-N";483.52;3.83;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-4.77;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.00001698243652461746
"MM475498";"MM475498";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccc(Cl)cc1)O2";"HOBWYNFQYPRIDL-UHFFFAOYSA-N";494.98;3.3;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-4.47;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.000033884415613920276
"MM475499";"MM475499";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@@](C)(c1ccccc1)O2";"UQHQDWYHACOCCN-RUZDIDTESA-N";460.54;2.65;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.72;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.0000019054607179632483
"MM475500";"MM475500";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(c1cc(F)cc(F)c1)O2";"ICDYHYNUXPDZEQ-UHFFFAOYSA-N";497.55;4.22;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-4.77;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.00001698243652461746
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL936685/target=_blank>CHEMBL936685</a>";;-6.4;"Li LS, Zhou Y, Murphy DE, Stankovic N, Zhao J, Dragovich PS, Bertolini T, Sun Z, Ayida B, Tran CV, Ruebsam F, Webber SE, Shah AM, Tsan M, Showalter RE, Patel R, Lebrun LA, Bartkowski DM, Nolan TG, Norris DA, Kamran R, Brooks J, Sergeeva MV, Kirkovsky L, Zhao Q, Kissinger CR.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000003981071705534969
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.4;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000003981071705534969
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927015/target=_blank>CHEMBL927015</a>";;-6.4;"Ruebsam F, Webber SE, Tran MT, Tran CV, Murphy DE, Zhao J, Dragovich PS, Kim SH, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (12), 2008";"CACO-2";0.0000003981071705534969
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997017/target=_blank>CHEMBL997017</a>";;-6.4;"Ellis DA, Blazel JK, Webber SE, Tran CV, Dragovich PS, Sun Z, Ruebsam F, McGuire HM, Xiang AX, Zhao J, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000003981071705534969
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953074/target=_blank>CHEMBL953074</a>";;-6.4;"Ruebsam F, Sun Z, Ayida BK, Webber SE, Zhou Y, Zhao Q, Kissinger CR, Showalter RE, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.0000003981071705534969
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1115404/target=_blank>CHEMBL1115404</a>";;-6.39;"Zhou Y, Liu G, Chen J, Reddy PS, Yoon IS, Zhang M, Zhang B, Barber JR, Ng SC.: Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives: their cytoprotection effect from rotenone toxicity and preliminary DMPK properties. Bioorg Med Chem Lett, Volume 19 (21), 2009";"CACO-2";0.00000040738027780411303
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050861/target=_blank>CHEMBL1050861</a>";;-5.92;"Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, Prast-Nielsen S, Jadhav A, Leister W, Shen M, Inglese J, Austin CP, Keefer L, ArnĂ©r ES, Simeonov A, Maloney DJ, Williams DL, Thomas CJ.: Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem, Volume 52 (20), 2009";"CACO-2";0.0000012022644346174132
"MM475505";"MM475505";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)CO)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"AHPZPEPKIIZAJI-UHFFFAOYSA-N";512.52;1.9;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.82;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.0000015135612484362072
"MM475509";"MM475509";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)NC)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"YHWFSBOTUBZNFO-UHFFFAOYSA-N";496.52;2.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.29;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.000005128613839913648
"MM475512";"MM475512";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNS(C)(=O)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"WAMCIKGNVJZNAS-UHFFFAOYSA-N";532.57;2.34;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.74;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.0000018197008586099826
"MM475515";"MM475515";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)OC)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"MNEZWRIUOPOINT-UHFFFAOYSA-N";512.52;3.15;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.68;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.0000020892961308540407
"MM475518";"MM475518";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCOCC(F)(F)F)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"FJQHVRLZNOVKOO-UHFFFAOYSA-N";537.49;4.37;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.55;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.000002818382931264455
"MM475519";"MM475519";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC(F)(F)F)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"UERMDDSMFCIPGD-UHFFFAOYSA-N";521.49;5.13;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.05;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.00000891250938133746
"MM475546";"MM475546";"Cc1cc(O)cc(C)c1CC(N)C(=O)NCCCCc1nc(O)c(CCCCNC(=O)C(N)Cc2c(C)cc(O)cc2C)nc1C";"UJIOBODRTCVNNE-UHFFFAOYSA-N";634.82;3.15;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886598/target=_blank>CHEMBL886598</a>";;-6.07;"Koda Y, Shiotani K, Toth I, Tsuda Y, Okada Y, Blanchfield JT.: Comparison of the in vitro apparent permeability and stability of opioid mimetic compounds with that of the native peptide. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000008511380382023759
"MM475547";"MM475547";"Cc1cc(O)cc(C)c1CC(N)C(=O)NCCCc1nc(O)c(CCCNC(=O)C(N)Cc2c(C)cc(O)cc2C)nc1C";"BRPKWONOOSMJCB-UHFFFAOYSA-N";606.77;2.37;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886598/target=_blank>CHEMBL886598</a>";;-6.26;"Koda Y, Shiotani K, Toth I, Tsuda Y, Okada Y, Blanchfield JT.: Comparison of the in vitro apparent permeability and stability of opioid mimetic compounds with that of the native peptide. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000005495408738576248
"MM475549";"MM475549";"COc1cc2c(Cc3nc4c([nH]3)c(=O)n(C)c(=O)n4CC(C)C)cnc(C)c2cc1OC";"OSJLVSRRJGXCFA-UHFFFAOYSA-N";437.5;2.54;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886857/target=_blank>CHEMBL886857</a>";;-6.05;"Arnold NJ, Arnold R, Beer D, Bhalay G, Collingwood SP, Craig S, Devereux N, Dodds M, Dunstan AR, Fairhurst RA, Farr D, Fullerton JD, Glen A, Gomez S, Haberthuer S, Hatto JD, Howes C, Jones D, Keller TH, Leuenberger B, Moser HE, Muller I, Naef R, Nicklin PA, Sandham DA, Turner KL, Tweed MF, Watson SJ, Zurini M.: Potent and selective xanthine-based inhibitors of phosphodiesterase 5. Bioorg Med Chem Lett, Volume 17 (8), 2007";"CACO-2";0.0000008912509381337459
"MM475551";"MM475551";"COc1cc2cncc(Cc3nc4c([nH]3)c(=O)n(C)c(=O)n4CC(C)(C)C)c2cc1OC";"JRWLXSPESACIOZ-UHFFFAOYSA-N";437.5;2.63;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886857/target=_blank>CHEMBL886857</a>";;-4.63;"Arnold NJ, Arnold R, Beer D, Bhalay G, Collingwood SP, Craig S, Devereux N, Dodds M, Dunstan AR, Fairhurst RA, Farr D, Fullerton JD, Glen A, Gomez S, Haberthuer S, Hatto JD, Howes C, Jones D, Keller TH, Leuenberger B, Moser HE, Muller I, Naef R, Nicklin PA, Sandham DA, Turner KL, Tweed MF, Watson SJ, Zurini M.: Potent and selective xanthine-based inhibitors of phosphodiesterase 5. Bioorg Med Chem Lett, Volume 17 (8), 2007";"CACO-2";0.00002344228815319923
"MM475552";"MM475552";"Cc1c(CN(CCc2ccccn2)C2CCN(C(=O)c3c(F)cccc3F)CC2)c(=O)n(-c2ccc(F)cc2)n1C";"QBWZPEOEGKGJMR-UHFFFAOYSA-N";563.62;4.65;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL888299/target=_blank>CHEMBL888299</a>";;-5.85;"PĂ©gurier C, Collart P, Danhaive P, Defays S, Gillard M, Gilson F, Kogej T, Pasau P, Van Houtvin N, Van Thuyne M, van Keulen B.: Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists. Bioorg Med Chem Lett, Volume 17 (15), 2007";"CACO-2";0.0000014125375446227554
"MM475561";"MM475561";"COc1ccc2cncc(Cc3nc4c([nH]3)c(=O)n(C)c(=O)n4CC(C)C)c2c1";"NMTKJEZOWHRAQY-UHFFFAOYSA-N";393.45;2.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886857/target=_blank>CHEMBL886857</a>";;-4.86;"Arnold NJ, Arnold R, Beer D, Bhalay G, Collingwood SP, Craig S, Devereux N, Dodds M, Dunstan AR, Fairhurst RA, Farr D, Fullerton JD, Glen A, Gomez S, Haberthuer S, Hatto JD, Howes C, Jones D, Keller TH, Leuenberger B, Moser HE, Muller I, Naef R, Nicklin PA, Sandham DA, Turner KL, Tweed MF, Watson SJ, Zurini M.: Potent and selective xanthine-based inhibitors of phosphodiesterase 5. Bioorg Med Chem Lett, Volume 17 (8), 2007";"CACO-2";0.000013803842646028839
"MM475568";"MM475568";"COc1cccc(CN(c2c(Cl)c(Cl)cc3[nH]c(=O)c(=O)[nH]c23)S(C)(=O)=O)c1";"PWASGNSKQZGAOY-UHFFFAOYSA-N";444.3;2.5;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-5.46;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.000003467368504525317
"MM475569";"MM475569";"COc1cc2cncc(Cc3nc4c([nH]3)c(=O)n(C)c(=O)n4CC(C)C)c2cc1OC";"YYABRKAKAPIQDP-UHFFFAOYSA-N";423.47;2.24;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886857/target=_blank>CHEMBL886857</a>";;-4.5;"Arnold NJ, Arnold R, Beer D, Bhalay G, Collingwood SP, Craig S, Devereux N, Dodds M, Dunstan AR, Fairhurst RA, Farr D, Fullerton JD, Glen A, Gomez S, Haberthuer S, Hatto JD, Howes C, Jones D, Keller TH, Leuenberger B, Moser HE, Muller I, Naef R, Nicklin PA, Sandham DA, Turner KL, Tweed MF, Watson SJ, Zurini M.: Potent and selective xanthine-based inhibitors of phosphodiesterase 5. Bioorg Med Chem Lett, Volume 17 (8), 2007";"CACO-2";0.000031622776601683795
"MM475576";"MM475576";"Cc1c(CN(CCc2ccc(Cl)cc2)C2CCN(C(=O)c3c(F)cccc3F)CC2)c(=O)n(-c2ccc(F)cc2)n1C";"GKXOETCIZGEUHB-UHFFFAOYSA-N";597.08;5.9;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL888299/target=_blank>CHEMBL888299</a>";;-5.09;"PĂ©gurier C, Collart P, Danhaive P, Defays S, Gillard M, Gilson F, Kogej T, Pasau P, Van Houtvin N, Van Thuyne M, van Keulen B.: Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists. Bioorg Med Chem Lett, Volume 17 (15), 2007";"CACO-2";0.000008128305161640995
"MM475578";"MM475578";"CS(=O)(=O)N(Cc1cccc(F)c1)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12";"GWNYHPWPLXZFSR-UHFFFAOYSA-N";432.26;2.63;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-5.76;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.0000017378008287493763
"MM475579";"MM475579";"CS(=O)(=O)N(CC1CCCO1)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12";"SWFKXMNJMPJPOU-UHFFFAOYSA-N";408.26;1.47;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-5.82;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.0000015135612484362072
"MM475580";"MM475580";"COCCN(c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12)S(C)(=O)=O";"RPBJCAXNIIFIFD-UHFFFAOYSA-N";382.23;0.94;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-8;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.00000001
"MM475581";"MM475581";"CCOCCN(c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12)S(C)(=O)=O";"QWEWDXWTGWPOGC-UHFFFAOYSA-N";396.25;1.33;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-5;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.00001
"MM475582";"MM475582";"CS(=O)(=O)N(CCC(F)(F)F)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12";"YFJDLZNHABYACJ-UHFFFAOYSA-N";420.2;2.24;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-6.39;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.00000040738027780411303
"MM475583";"MM475583";"COCCN(c1c(Cl)c(C)cc2[nH]c(=O)c(=O)[nH]c12)S(C)(=O)=O";"BCDCSJRVBJPNBV-UHFFFAOYSA-N";361.81;0.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-6.85;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.00000014125375446227555
"MM475584";"MM475584";"COCCN(c1c(C)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12)S(C)(=O)=O";"QAEGBUUUKIIAML-UHFFFAOYSA-N";361.81;0.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-8;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.00000001
"MM475585";"MM475585";"CCc1cc2[nH]c(=O)c(=O)[nH]c2c(N(CCCOC)S(C)(=O)=O)c1Cl";"YIKXBWQRHOAYSJ-UHFFFAOYSA-N";389.86;1.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-8;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.00000001
"MM475613";"MM475613";"CN(c1ccc2c(c1)S(=O)(=O)N=C(c1c(O)c(-c3cccs3)nn(CCC(C)(C)C)c1=O)N2)S(C)(=O)=O";"XISZSFJEMVMFNT-UHFFFAOYSA-N";565.7;3.07;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-8;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.00000001
"MM475614";"MM475614";"CC(C)CCn1c(=O)c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2cccn21";"MKIYWVGTUYBHQX-UHFFFAOYSA-N";400.46;2.41;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927015/target=_blank>CHEMBL927015</a>";;-4.96;"Ruebsam F, Webber SE, Tran MT, Tran CV, Murphy DE, Zhao J, Dragovich PS, Kim SH, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (12), 2008";"CACO-2";0.000010964781961431852
"MM475617";"MM475617";"N#Cc1ccc(NCc2cccc3cccnc23)c(F)c1CC(=O)NCCONC(=N)N";"MEXWAUWKSSBECY-UHFFFAOYSA-N";435.46;1.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL934697/target=_blank>CHEMBL934697</a>";;-5.77;"Kreutter KD, Lu T, Lee L, Giardino EC, Patel S, Huang H, Xu G, Fitzgerald M, Haertlein BJ, Mohan V, Crysler C, Eisennagel S, Dasgupta M, McMillan M, Spurlino JC, Huebert ND, Maryanoff BE, Tomczuk BE, Damiano BP, Player MR.: Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. Bioorg Med Chem Lett, Volume 18 (9), 2008";"CACO-2";0.000001698243652461746
"MM475619";"MM475619";"CC(C)CCn1nc(CC2CC2)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"DKHIVVANSNYJCZ-UHFFFAOYSA-N";509.61;1.88;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.31;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000004897788193684466
"MM475620";"MM475620";"CC(C)CCn1nc(CC2CCCC2)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"AZMJERYDFSFNSJ-UHFFFAOYSA-N";537.66;2.66;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.07;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000008511380382023759
"MM475623";"MM475623";"CC(C)CCn1c(=O)c(C2=NS(=O)(=O)c3cc(N(C)S(C)(=O)=O)ccc3N2)c(O)c2cccn21";"YJRVHWRIEFZUAP-UHFFFAOYSA-N";507.59;1.81;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927015/target=_blank>CHEMBL927015</a>";;-5.37;"Ruebsam F, Webber SE, Tran MT, Tran CV, Murphy DE, Zhao J, Dragovich PS, Kim SH, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (12), 2008";"CACO-2";0.000004265795188015926
"MM475627";"MM475627";"CN(c1ccc2c(c1)S(=O)(=O)N=C(c1c(O)c3cccn3n(Cc3ccc(F)cc3)c1=O)N2)S(C)(=O)=O";"MMEQHJXFBYSCEV-UHFFFAOYSA-N";545.57;1.95;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927015/target=_blank>CHEMBL927015</a>";;-6.05;"Ruebsam F, Webber SE, Tran MT, Tran CV, Murphy DE, Zhao J, Dragovich PS, Kim SH, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (12), 2008";"CACO-2";0.0000008912509381337459
"MM475628";"MM475628";"O=C(N[C@@H]1CCOC[C@@H]1C(=O)NO)c1ccc(Cc2c(C(F)(F)F)nc3ccccn23)cc1";"UWFRWYGMHWPIMQ-JKSUJKDBSA-N";462.43;2.58;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL934171/target=_blank>CHEMBL934171</a>";;-7.3;"Lu Z, Ott GR, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos J, Duan JJ.: Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents. Bioorg Med Chem Lett, Volume 18 (6), 2008";"CACO-2";0.00000005011872336272725
"MM475633";"MM475633";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(C(=O)OC(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"BEMAWHUATSKVDF-LADGPHEKSA-N";506.56;3.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-5.77;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.000001698243652461746
"MM475634";"MM475634";"Cc1cc(COc2ccc(C(=O)N[C@@H]3COC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"NASYCHQKVXYGPX-PZJWPPBQSA-N";421.45;2.37;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-6;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.000001
"MM475635";"MM475635";"COc1cnn(C)c(=O)c1-c1ccc(C[C@@H](CO)NC(=O)c2c(Cl)cccc2Cl)cc1";"DSRYWCFQVDZVPR-HNNXBMFYSA-N";462.33;3.1;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL947948/target=_blank>CHEMBL947948</a>";;-5.6;"Gong Y, Kent Barbay J, Kimball ES, Santulli RJ, Carolyn Fisher M, Dyatkin AB, Miskowski TA, Hornby PJ, He W.: Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists. Bioorg Med Chem Lett, Volume 18 (4), 2008";"CACO-2";0.0000025118864315095823
"MM475637";"MM475637";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(S(C)(=O)=O)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"YURFZWNLXFKRFO-RBBKRZOGSA-N";498.56;1.62;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-6.52;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000003019951720402019
"MM475638";"MM475638";"COC(=O)N1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"TTZQPUPTVJAEIJ-RBBKRZOGSA-N";478.51;2.42;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-6.4;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000003981071705534969
"MM475639";"MM475639";"Cc1cccc(S(=O)(=O)Nc2ccc(C)n(CC(=O)NCCONC(=N)N)c2=O)c1";"GHCPCZIUEYRYJT-UHFFFAOYSA-N";436.49;-0.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL934697/target=_blank>CHEMBL934697</a>";;-6.15;"Kreutter KD, Lu T, Lee L, Giardino EC, Patel S, Huang H, Xu G, Fitzgerald M, Haertlein BJ, Mohan V, Crysler C, Eisennagel S, Dasgupta M, McMillan M, Spurlino JC, Huebert ND, Maryanoff BE, Tomczuk BE, Damiano BP, Player MR.: Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. Bioorg Med Chem Lett, Volume 18 (9), 2008";"CACO-2";0.0000007079457843841374
"MM475640";"MM475640";"CC(C)(C)CCn1nc(C2=CCCC2)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"RWNCIIKAMWVKLG-UHFFFAOYSA-N";535.65;2.88;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-7.52;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000000030199517204020194
"MM475642";"MM475642";"CC(C)CCn1nc(C(C)(C)C)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"AZUZVBMJZJMIEH-UHFFFAOYSA-N";511.63;2.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.24;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000005754399373371567
"MM475646";"MM475646";"Cc1cc(COc2ccc(C(=O)N[C@@H]3C[C@@H](N(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"LSEJNPTVWWYHHK-NGYIFUPDSA-N";462.55;3.07;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-7;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000001
"MM475648";"MM475648";"CC(C)CCn1nc(CC(C)(C)C)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"PEBFIVIHOBYECP-UHFFFAOYSA-N";525.65;2.52;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.54;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.00000028840315031266057
"MM475650";"MM475650";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(c1c(O)c(C3=CCCC3)nn(CCC3CC3)c1=O)N2";"CLCXAYCXXFZWQG-UHFFFAOYSA-N";519.61;2.25;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.23;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000005888436553555884
"MM475651";"MM475651";"CC(C)=Cc1nn(CCC(C)(C)C)c(=O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1O";"ODPIHZDAKWIIIO-UHFFFAOYSA-N";523.64;2.74;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000001
"MM475652";"MM475652";"CC(C)(C)CCn1nc(CC(C)(C)C)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"CRDSEKPXMWCCTN-UHFFFAOYSA-N";539.68;2.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.82;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.00000015135612484362072
"MM475654";"MM475654";"Cn1ncc(-c2ccc(F)cc2)c(-c2ccc(C[C@H](NC(=O)c3c(Cl)cccc3Cl)C(=O)O)cc2)c1=O";"YZOVQSYKZPZDRM-QFIPXVFZSA-N";540.38;4.99;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL947948/target=_blank>CHEMBL947948</a>";;-6.8;"Gong Y, Kent Barbay J, Kimball ES, Santulli RJ, Carolyn Fisher M, Dyatkin AB, Miskowski TA, Hornby PJ, He W.: Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists. Bioorg Med Chem Lett, Volume 18 (4), 2008";"CACO-2";0.0000001584893192461114
"MM475659";"MM475659";"CC(C)(C)CCn1nc(-c2cccs2)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"BNKHUPLFRJHZRH-UHFFFAOYSA-N";551.67;3.05;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL936685/target=_blank>CHEMBL936685</a>";;-7.22;"Li LS, Zhou Y, Murphy DE, Stankovic N, Zhao J, Dragovich PS, Bertolini T, Sun Z, Ayida B, Tran CV, Ruebsam F, Webber SE, Shah AM, Tsan M, Showalter RE, Patel R, Lebrun LA, Bartkowski DM, Nolan TG, Norris DA, Kamran R, Brooks J, Sergeeva MV, Kirkovsky L, Zhao Q, Kissinger CR.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.00000006025595860743581
"MM475660";"MM475660";"O=C(c1cc2c(cc1F)O[C@](c1ccc(F)cc1)(c1ccc(Cl)cc1Cl)O2)N1CCOCC1";"VUCKSZWMRCSPME-XMMPIXPASA-N";492.31;5.42;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL933474/target=_blank>CHEMBL933474</a>";;-4.97;"Alig L, Alsenz J, Andjelkovic M, Bendels S, BĂ©nardeau A, Bleicher K, Bourson A, David-Pierson P, Guba W, Hildbrand S, Kube D, LĂĽbbers T, Mayweg AV, Narquizian R, Neidhart W, Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, RĂ¶ver S, Schneider G, Taylor S, Waldmeier P.: Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.00001071519305237607
"MM475663";"MM475663";"CCCCn1c(=O)c2cccnc2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1";"BWKIOYBQMPZRBR-UHFFFAOYSA-N";425.5;3.89;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925711/target=_blank>CHEMBL925711</a>";;-5.75;"Cappelli A, Nannicini C, Gallelli A, Giuliani G, Valenti S, Mohr Gl, Anzini M, Mennuni L, Ferrari F, Caselli G, Giordani A, Peris W, Makovec F, Giorgi G, Vomero S.: Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.000001778279410038923
"Milnacipran";"MM16841";"CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2";"GJJFMKBJSRMPLA-UHFFFAOYSA-N";246.35;1.77;"65833";;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-5.05;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.00000891250938133746
"MM475664";"MM475664";"CCCCn1c2ncccc2c(=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1";"NEJFAMVNQNXGLG-UHFFFAOYSA-N";425.5;3.89;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925711/target=_blank>CHEMBL925711</a>";;-5.44;"Cappelli A, Nannicini C, Gallelli A, Giuliani G, Valenti S, Mohr Gl, Anzini M, Mennuni L, Ferrari F, Caselli G, Giordani A, Peris W, Makovec F, Giorgi G, Vomero S.: Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.0000036307805477010103
"MM18934";"MM18934";"COc1cc2c(cc1OC)CN(CCCC1CCCc3cc(OC)c(OC)cc31)CC2";"ILEQWDOJJVJXBN-UHFFFAOYSA-N";425.57;4.98;"24945196";"CHEMBL259366";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.06;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00008709635899560814
"MM19075";"MM19075";"COc1ccc2c(c1)CCCC2CCCN1CCc2cc(OC)c(OC)cc2C1";"HJBMLYTXOFQZDS-UHFFFAOYSA-N";395.54;4.97;"24945194";"CHEMBL259367";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.08;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00008317637711026709
"MM18933";"MM18933";"COc1cc2c(cc1OC)CN(CCCC1CCCc3c(OC)cccc31)CC2";"HHPVCRYYLOFYGE-UHFFFAOYSA-N";395.54;4.97;"44451264";;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-5.25;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.000005623413251903491
"MM19074";"MM19074";"COc1ccc2c(c1)CCC=C2CCCN1CCc2cc(OC)c(OC)cc2C1";"CIZNGVIPVFMLRQ-UHFFFAOYSA-N";393.53;4.88;"24945109";"CHEMBL260377";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.39;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.0000407380277804113
"MM19071";"MM19071";"COc1ccc2c(c1)C(CCCN1CCc3cc(OC)c(OC)cc3C1)=CCC2";"NLSOIGZWHUMJEN-UHFFFAOYSA-N";393.53;4.88;"24945108";"CHEMBL260499";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.21;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00006165950018614822
"MM475674";"MM475674";"COc1cc2c(cc1OC)CN(CC/C=C1\CCCc3c(OC)cccc31)CC2";"QBMVDXXIQASRIE-QGMBQPNBSA-N";393.53;4.88;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.63;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00002344228815319923
"MM475674";"MM475674";"COc1cc2c(cc1OC)CN(CC/C=C1\CCCc3c(OC)cccc31)CC2";"QBMVDXXIQASRIE-QGMBQPNBSA-N";393.53;4.88;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL923495/target=_blank>CHEMBL923495</a>";;-4.63;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Paradiso A.: 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.00002344228815319923
"MM18932";"MM18932";"COc1cc2c(cc1OC)CN(CCCC1=CCCc3cc(OC)c(OC)cc31)CC2";"BVIGBAHRVHMUBL-UHFFFAOYSA-N";423.55;4.89;"24945110";"CHEMBL261802";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.17;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00006760829753919819
"MM475678";"MM475678";"CCCCn1c(=O)c2cc(Cl)cnc2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1";"TUEKJIBMPXTDMM-UHFFFAOYSA-N";459.94;4.55;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925711/target=_blank>CHEMBL925711</a>";;-4.97;"Cappelli A, Nannicini C, Gallelli A, Giuliani G, Valenti S, Mohr Gl, Anzini M, Mennuni L, Ferrari F, Caselli G, Giordani A, Peris W, Makovec F, Giorgi G, Vomero S.: Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.00001071519305237607
"MM475683";"MM475683";"COc1cccc2c1CCC/C2=C\CCN1CCCCC1";"OQZQEGAAANHHRE-CXUHLZMHSA-N";285.43;4.29;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.23;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00005888436553555884
"MM475684";"MM475684";"CCCCn1c2nc(C)ccc2c(=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1";"KTPNSHNJZAUHMY-UHFFFAOYSA-N";439.52;4.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925711/target=_blank>CHEMBL925711</a>";;-5.06;"Cappelli A, Nannicini C, Gallelli A, Giuliani G, Valenti S, Mohr Gl, Anzini M, Mennuni L, Ferrari F, Caselli G, Giordani A, Peris W, Makovec F, Giorgi G, Vomero S.: Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.000008709635899560814
"MM475689";"MM475689";"CC(C)(C)CCn1nc(C2CC2)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"BYBUTAGNNSBLGN-UHFFFAOYSA-N";509.61;2.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.02;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000009549925860214369
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL936685/target=_blank>CHEMBL936685</a>";;-5;"Li LS, Zhou Y, Murphy DE, Stankovic N, Zhao J, Dragovich PS, Bertolini T, Sun Z, Ayida B, Tran CV, Ruebsam F, Webber SE, Shah AM, Tsan M, Showalter RE, Patel R, Lebrun LA, Bartkowski DM, Nolan TG, Norris DA, Kamran R, Brooks J, Sergeeva MV, Kirkovsky L, Zhao Q, Kissinger CR.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.00001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-5;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.00001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927015/target=_blank>CHEMBL927015</a>";;-5;"Ruebsam F, Webber SE, Tran MT, Tran CV, Murphy DE, Zhao J, Dragovich PS, Kim SH, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (12), 2008";"CACO-2";0.00001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997017/target=_blank>CHEMBL997017</a>";;-5;"Ellis DA, Blazel JK, Webber SE, Tran CV, Dragovich PS, Sun Z, Ruebsam F, McGuire HM, Xiang AX, Zhao J, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.00001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953074/target=_blank>CHEMBL953074</a>";;-5;"Ruebsam F, Sun Z, Ayida BK, Webber SE, Zhou Y, Zhao Q, Kissinger CR, Showalter RE, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.00001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1108561/target=_blank>CHEMBL1108561</a>";;-4.41;"Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT, Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein H, Zeng J, Wilks AF.: Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett, Volume 19 (20), 2009";"CACO-2";0.000038904514499428046
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1115404/target=_blank>CHEMBL1115404</a>";;-4.29;"Zhou Y, Liu G, Chen J, Reddy PS, Yoon IS, Zhang M, Zhang B, Barber JR, Ng SC.: Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives: their cytoprotection effect from rotenone toxicity and preliminary DMPK properties. Bioorg Med Chem Lett, Volume 19 (21), 2009";"CACO-2";0.00005128613839913648
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050861/target=_blank>CHEMBL1050861</a>";;-4.69;"Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, Prast-Nielsen S, Jadhav A, Leister W, Shen M, Inglese J, Austin CP, Keefer L, ArnĂ©r ES, Simeonov A, Maloney DJ, Williams DL, Thomas CJ.: Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem, Volume 52 (20), 2009";"CACO-2";0.000020417379446695274
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-4.54;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.000028840315031266056
"MM475693";"MM475693";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(C(=O)C(C)(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"OYFJDPJIGCMKKI-LADGPHEKSA-N";504.59;3.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-6.52;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000003019951720402019
"MM475694";"MM475694";"C=CCN1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"CNSXDPYRIAFYKG-LADGPHEKSA-N";460.53;2.84;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-7;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000001
"MM475695";"MM475695";"CC(C)(C)c1nn2ccccc2c1Cc1ccc(C(=O)N[C@@H]2CCOC[C@@H]2C(=O)NO)cc1";"KCBXQUWPZNVZIG-VQTJNVASSA-N";450.54;2.86;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL934171/target=_blank>CHEMBL934171</a>";;-5.37;"Lu Z, Ott GR, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos J, Duan JJ.: Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents. Bioorg Med Chem Lett, Volume 18 (6), 2008";"CACO-2";0.000004265795188015926
"MM475696";"MM475696";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(C(=O)C(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"SVLPSGKSYVCBRQ-LADGPHEKSA-N";490.56;2.84;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-7;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000001
"MM475698";"MM475698";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(C4CCC4)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"NTFMFANVPWIUGQ-UKILVPOCSA-N";474.56;3.21;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-7;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000001
"MM475699";"MM475699";"C#CCN1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"SIICAQVADMFEDB-LADGPHEKSA-N";458.52;2.29;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-5.49;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.000003235936569296281
"MM475701";"MM475701";"Cc1ccc(N2CCN(C(=O)[C@@H]3CN(C4CCOCC4)C[C@H]3c3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1";"XJIWJTAALOWWFJ-UKAHRKLESA-N";638.3;4.96;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946099/target=_blank>CHEMBL946099</a>";;-6.8;"Chen C, Jiang W, Tran JA, Tucci FC, Fleck BA, Markison S, Wen J, Madan A, Hoare SR, Foster AC, Marinkovic D, Chen CW, Arellano M, Saunders J.: Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.0000001584893192461114
"MM475702";"MM475702";"COc1cnn(C)c(=O)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)c2nnn[nH]2)cc1";"FOUDHXTZQKEKBC-INIZCTEOSA-N";500.35;2.99;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL947948/target=_blank>CHEMBL947948</a>";;-7.7;"Gong Y, Kent Barbay J, Kimball ES, Santulli RJ, Carolyn Fisher M, Dyatkin AB, Miskowski TA, Hornby PJ, He W.: Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists. Bioorg Med Chem Lett, Volume 18 (4), 2008";"CACO-2";0.000000019952623149688786
"MM475713";"MM475713";"CC(C)C[C@@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C";"WSJWUIDLGZAXID-HOCLYGCPSA-N";372.46;1.86;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL863675/target=_blank>CHEMBL863675</a>";;-5.59;"Shirasaki Y, Nakamura M, Yamaguchi M, Miyashita H, Sakai O, Inoue J.: Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives. J Med Chem, Volume 49 (13), 2006";"CACO-2";0.0000025703957827688647
"Cimetidine";"MM00463";"CNC(=NCCSCc1nc[nH]c1C)NC#N";"AQIXAKUUQRKLND-UHFFFAOYSA-N";252.35;0.6;"2756";"CHEMBL30";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1016134/target=_blank>CHEMBL1016134</a>";;-6.25;"Ettari R, Micale N, Schirmeister T, Gelhaus C, Leippe M, Nizi E, Di Francesco ME, Grasso S, ZappalĂ  M.: Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. J Med Chem, Volume 52 (7), 2009";"CACO-2";0.000000562341325190349
"MM475733";"MM475733";"NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1";"ZEXLJFNSKAHNFH-SYKYGTKKSA-N";610.72;1.67;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955665/target=_blank>CHEMBL955665</a>";;-6.35;"Koda Y, Del Borgo M, Wessling ST, Lazarus LH, Okada Y, Toth I, Blanchfield JT.: Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem, Volume 16 (11), 2008";"CACO-2";0.0000004466835921509635
"MM475740";"MM475740";"NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1";"XIJHWXXXIMEHKW-LJWNLINESA-N";571.68;1.19;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886598/target=_blank>CHEMBL886598</a>";;-7.19;"Koda Y, Shiotani K, Toth I, Tsuda Y, Okada Y, Blanchfield JT.: Comparison of the in vitro apparent permeability and stability of opioid mimetic compounds with that of the native peptide. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.00000006456542290346549
"MM475799";"MM475799";"Cc1cc(Nc2ncnc3cnc(N4CCOCC4)cc23)ccc1Oc1ccc(C(=O)NCC(C)(C)C)cc1";"KKWBRQPIXLDPAR-UHFFFAOYSA-N";526.64;5.48;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887695/target=_blank>CHEMBL887695</a>";;-4.81;"Lippa B, Kauffman GS, Arcari J, Kwan T, Chen J, Hungerford W, Bhattacharya S, Zhao X, Williams C, Xiao J, Pustilnik L, Su C, Moyer JD, Ma L, Campbell M, Steyn S.: The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer. Bioorg Med Chem Lett, Volume 17 (11), 2007";"CACO-2";0.000015488166189124828
"MM475802";"MM475802";"Cc1cc(C)c2c(N)c(C(N)=O)sc2n1";"SDMLKCQDZJOSDN-UHFFFAOYSA-N";221.29;1.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865085/target=_blank>CHEMBL865085</a>";;-4.87;"Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz A, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL.: Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem, Volume 49 (10), 2006";"CACO-2";0.000013489628825916533
"MM475805";"MM475805";"NC(=O)c1nc(-c2ccc(C(F)(F)F)cc2)oc1N";"DPUNFIBGNOBPIM-UHFFFAOYSA-N";271.2;2.04;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865085/target=_blank>CHEMBL865085</a>";;-4.72;"Morwick T, Berry A, Brickwood J, Cardozo M, Catron K, DeTuri M, Emeigh J, Homon C, Hrapchak M, Jacober S, Jakes S, Kaplita P, Kelly TA, Ksiazek J, Liuzzi M, Magolda R, Mao C, Marshall D, McNeil D, Prokopowicz A, Sarko C, Scouten E, Sledziona C, Sun S, Watrous J, Wu JP, Cywin CL.: Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem, Volume 49 (10), 2006";"CACO-2";0.000019054607179632484
"MM475821";"MM475821";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ADEWZYKOSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864126/target=_blank>CHEMBL864126</a>";;-6.89;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.00000012882495516931348
"MM475821";"MM475821";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ADEWZYKOSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864127/target=_blank>CHEMBL864127</a>";;-6.19;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.000000645654229034655
"MM475821";"MM475821";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ADEWZYKOSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864131/target=_blank>CHEMBL864131</a>";;-5.98;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000010471285480508985
"MM475821";"MM475821";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ADEWZYKOSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865285/target=_blank>CHEMBL865285</a>";;-6.85;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.00000014125375446227555
"MM475826";"MM475826";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-SDPVFGLVSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864126/target=_blank>CHEMBL864126</a>";;-6.6;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.00000025118864315095823
"MM475826";"MM475826";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-SDPVFGLVSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864127/target=_blank>CHEMBL864127</a>";;-6.29;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000005128613839913648
"MM475826";"MM475826";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-SDPVFGLVSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864131/target=_blank>CHEMBL864131</a>";;-6.08;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000008317637711026709
"MM475826";"MM475826";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-SDPVFGLVSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865285/target=_blank>CHEMBL865285</a>";;-6.7;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.00000019952623149688787
"MM472519";"MM472519";"c1ccc(Nc2ccccc2)cc1";"DMBHHRLKUKUOEG-UHFFFAOYSA-N";169.23;3.43;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905616/target=_blank>CHEMBL905616</a>";;-4.4;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"CACO-2";0.000039810717055349695
"MM472529";"MM472529";"CC(C)OP(=O)(OC(C)C)SCc1ccccc1";"FCOAHACKGGIURQ-UHFFFAOYSA-N";288.35;4.88;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905616/target=_blank>CHEMBL905616</a>";;-4.28;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"CACO-2";0.00005248074602497723
"MM475850";"MM475850";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@](C)(c1ccccc1)O2";"UQHQDWYHACOCCN-VWLOTQADSA-N";460.54;2.65;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.68;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.0000020892961308540407
"MM475862";"MM475862";"CC(C)COC(=O)N1CCC(CN(C2Cc3cc(C#N)ccc3N(Cc3cncn3C)C2)S(=O)(=O)c2ccccn2)CC1";"KMDYZZOYCZPGES-UHFFFAOYSA-N";605.77;3.81;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-5.12;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.000007585775750291836
"MM475872";"MM475872";"CCOCCCN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21";"IPXPSGDBCIRUBU-UHFFFAOYSA-N";497.55;4.22;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-4.89;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.000012882495516931348
"MM475873";"MM475873";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"BZQDCQHUEYPQIB-UHFFFAOYSA-N";469.49;3.17;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.00001
"MM475877";"MM475877";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cccc(C(F)(F)F)c1)O2";"ONRGYKGRPVMXIR-UHFFFAOYSA-N";528.54;3.67;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.06;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.000008709635899560814
"MM475881";"MM475881";"Cn1cncc1CN1CC(N(CC2CCN(C(=O)C(C)(C)C)CC2)S(=O)(=O)c2ccccn2)Cc2cc(C#N)ccc21";"CELUTJFWLRRYCZ-UHFFFAOYSA-N";589.77;3.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-6.3;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.0000005011872336272725
"MM475905";"MM475905";"C[C@H](Cc1cccc(CC(=O)NCc2c(F)cccc2Cl)c1)NC[C@H](O)c1ccc(O)c(CO)c1";"NQVMGLYGFGYGNF-QUGAMOGWSA-N";501;3.79;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889146/target=_blank>CHEMBL889146</a>";;-6;"Brown AD, Bunnage ME, Glossop PA, James K, Jones R, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Trevethick M, Webster R.: The discovery of long acting beta2-adrenoreceptor agonists. Bioorg Med Chem Lett, Volume 17 (14), 2007";"CACO-2";0.000001
"MM475913";"MM475913";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"OJPCZEDCYHLAEY-UHFFFAOYSA-N";496.52;2.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-5.85;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.0000014125375446227554
"MM475915";"MM475915";"CCNC(=O)CN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21";"YSDAMWLCNDERLC-UHFFFAOYSA-N";496.52;2.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-4.68;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.00002089296130854041
"Hesperetin";"MM00371";"COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O";"AIONOLUJZLIMTK-AWEZNQCLSA-N";302.28;2.52;"72281";"CHEMBL399121";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988136/target=_blank>CHEMBL988136</a>";;-4.33;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.00004677351412871981
"MM475918";"MM475918";"CCOCCOCCN(c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12)S(C)(=O)=O";"ILSICJGDEGZBHX-UHFFFAOYSA-N";440.31;1.34;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-6.01;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.000000977237220955811
"MM475919";"MM475919";"COCCCN(c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12)S(C)(=O)=O";"HCVVJCJMDGFGMO-UHFFFAOYSA-N";396.25;1.33;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-5.69;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.0000020417379446695273
"MM475923";"MM475923";"COCCCN(c1cc(Cl)cc2[nH]c(=O)c(=O)[nH]c12)S(C)(=O)=O";"WNWRXBNCDMTPAX-UHFFFAOYSA-N";361.81;0.67;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-8;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.00000001
"MM475924";"MM475924";"CC(C)C(=O)N1CCC(CN(C2Cc3cc(C#N)ccc3N(Cc3cncn3C)C2)S(=O)(=O)c2ccccn2)CC1";"DEHIYUGCSWNGFV-UHFFFAOYSA-N";575.74;3.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-6.3;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.0000005011872336272725
"MM475927";"MM475927";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(C)O2";"WPAPODFGOZXFLG-UHFFFAOYSA-N";385.47;2.41;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-4.72;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.000019054607179632484
"MM475929";"MM475929";"CCOCCCN(c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12)S(C)(=O)=O";"GBHJMZUFJRCQDB-UHFFFAOYSA-N";410.28;1.72;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887327/target=_blank>CHEMBL887327</a>";;-6.36;"Deur C, Agrawal AK, Baum H, Booth J, Bove S, Brieland J, Bunker A, Connolly C, Cornicelli J, Dumin J, Finzel B, Gan X, Guppy S, Kamilar G, Kilgore K, Lee P, Loi CM, Lou Z, Morris M, Philippe L, Przybranowski S, Riley F, Samas B, Sanchez B, Tecle H, Wang Z, Welch K, Wilson M, Yates K.: N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-D-aspartate receptor antagonists for the treatment of pain. Bioorg Med Chem Lett, Volume 17 (16), 2007";"CACO-2";0.00000043651583224016567
"MM475939";"MM475939";"CC(C)(C)Cc1nn(CCC2CC2)c(=O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1O";"JDTMXJSWZGMLDD-UHFFFAOYSA-N";523.64;2.27;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL935710/target=_blank>CHEMBL935710</a>";;-6.15;"Sergeeva MV, Zhou Y, Bartkowski DM, Nolan TG, Norris DA, Okamoto E, Kirkovsky L, Kamran R, Lebrun LA, Tsan M, Patel R, Shah AM, Lardy M, Gobbi A, Li LS, Zhao J, Bertolini T, Stankovic N, Sun Z, Murphy DE, Webber SE, Dragovich PS.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000007079457843841374
"MM475941";"MM475941";"CC(=O)N1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"DIZGMOHGYCJEBO-JTHBVZDNSA-N";462.51;2.2;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-6.7;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.00000019952623149688787
"MM475945";"MM475945";"O=C(N[C@@H]1CCOC[C@@H]1C(=O)NO)c1ccc(Cc2c(C(F)(F)F)nn3ccccc23)cc1";"SXDMGWZDRWQMPS-DLBZAZTESA-N";462.43;2.58;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL934171/target=_blank>CHEMBL934171</a>";;-5.74;"Lu Z, Ott GR, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos J, Duan JJ.: Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents. Bioorg Med Chem Lett, Volume 18 (6), 2008";"CACO-2";0.0000018197008586099826
"MM475954";"MM475954";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(C(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"GIYCAHCPFIZYMQ-LADGPHEKSA-N";462.55;3.07;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-5.89;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.000001288249551693135
"Chembl403441";"MM468380";"CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1";"CVFBVSUFNWOPLD-LJQANCHMSA-N";310.44;3.27;;"Chembl403441";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120626/target=_blank>CHEMBL1120626</a>";;-4.48;"Fray MJ, Fish PV, Allan GA, Bish G, Clarke N, Eccles R, Harrison AC, Le Net JL, Phillips SC, Regan N, Sobry C, Stobie A, Wakenhut F, Westbrook D, Westbrook SL, Whitlock GA.: Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.000033113112148259076
"MM475957";"MM475957";"CC(C)(C)CCn1c(=O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c(O)c2cccn21";"FCKKBGLFVWWSIL-UHFFFAOYSA-N";507.59;2.18;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927015/target=_blank>CHEMBL927015</a>";;-6.15;"Ruebsam F, Webber SE, Tran MT, Tran CV, Murphy DE, Zhao J, Dragovich PS, Kim SH, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (12), 2008";"CACO-2";0.0000007079457843841374
"MM475962";"MM475962";"CC(C)CCn1c(=O)c(C2=NS(=O)(=O)c3cc(NS(=O)(=O)C4CC4)ccc3N2)c(O)c2cccn21";"PKDHYLKVSMYIBX-UHFFFAOYSA-N";519.61;2.32;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927015/target=_blank>CHEMBL927015</a>";;-6.1;"Ruebsam F, Webber SE, Tran MT, Tran CV, Murphy DE, Zhao J, Dragovich PS, Kim SH, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (12), 2008";"CACO-2";0.0000007943282347242822
"MM475963";"MM475963";"C=C(C)CN1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"JJARNQDLIPGYKD-UKILVPOCSA-N";474.56;3.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-5.01;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.000009772372209558111
"MM19072";"MM19072";"COc1ccc2c(c1)C(CCCN1CCc3cc(OC)c(OC)cc3C1)CCC2";"CRXITWCKFZMSFG-UHFFFAOYSA-N";395.54;4.97;"24945195";"CHEMBL405372";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.34;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.000045708818961487516
"MM18929";"MM18929";"COc1cc2c(cc1OC)CN(CCC=C1CCCCC1)CC2";"NERQQHBBXMVPQY-UHFFFAOYSA-N";315.46;4.34;"44451249";"CHEMBL408993";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.11;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00007762471166286911
"MM475974";"MM475974";"CCCCC1c2ncccc2C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1";"PNNHQGDWIIUMFS-UHFFFAOYSA-N";424.51;4.82;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925711/target=_blank>CHEMBL925711</a>";;-5.25;"Cappelli A, Nannicini C, Gallelli A, Giuliani G, Valenti S, Mohr Gl, Anzini M, Mennuni L, Ferrari F, Caselli G, Giordani A, Peris W, Makovec F, Giorgi G, Vomero S.: Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.000005623413251903491
"MM18931";"MM18931";"COc1cc2c(cc1OC)CN(CCCC1=CCCc3c(OC)cccc31)CC2";"BKLBMMUVHQYDCN-UHFFFAOYSA-N";393.53;4.88;"24945105";"CHEMBL415560";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.8;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00001584893192461114
"MM476002";"MM476002";"CCC(=O)N1CCC(CN(C2Cc3cc(C#N)ccc3N(Cc3cncn3C)C2)S(=O)(=O)c2ccccn2)CC1";"UPFFGPDGKQDRRF-UHFFFAOYSA-N";561.71;2.96;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967838/target=_blank>CHEMBL967838</a>";;-6.3;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.0000005011872336272725
"MM476004";"MM476004";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"NAJFOBIBNBUZAN-UHFFFAOYSA-N";483.52;3.56;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-4.97;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.00001071519305237607
"MM476005";"MM476005";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"MUYREESVDCFSSL-RBBKRZOGSA-N";434.5;2.29;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-6.7;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.00000019952623149688787
"MM476006";"MM476006";"CCc1nn2ccccc2c1Cc1ccc(C(=O)N[C@@H]2CCOC[C@@H]2C(=O)NO)cc1";"ITVUSPVMUHFUQB-AZUAARDMSA-N";422.49;2.13;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL934171/target=_blank>CHEMBL934171</a>";;-5.96;"Lu Z, Ott GR, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos J, Duan JJ.: Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents. Bioorg Med Chem Lett, Volume 18 (6), 2008";"CACO-2";0.000001096478196143185
"MM476012";"MM476012";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ULBASCLCSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864126/target=_blank>CHEMBL864126</a>";;-6.7;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.00000019952623149688787
"MM476012";"MM476012";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ULBASCLCSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864127/target=_blank>CHEMBL864127</a>";;-6.4;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000003981071705534969
"MM476012";"MM476012";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ULBASCLCSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864131/target=_blank>CHEMBL864131</a>";;-6.29;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000005128613839913648
"MM476012";"MM476012";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ULBASCLCSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865285/target=_blank>CHEMBL865285</a>";;-7.02;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.00000009549925860214369
"MM476024";"MM476024";"Cc1cc(O)cc(C)c1CC(N)C(=O)NCCCCNC(=O)C(N)Cc1c(C)cc(O)cc1C";"XNDDFGCHFYFKSW-UHFFFAOYSA-N";470.61;1.78;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886598/target=_blank>CHEMBL886598</a>";;-6.86;"Koda Y, Shiotani K, Toth I, Tsuda Y, Okada Y, Blanchfield JT.: Comparison of the in vitro apparent permeability and stability of opioid mimetic compounds with that of the native peptide. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000001380384264602884
"MM476028";"MM476028";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(Cc4ccco4)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"LBCLZTXMMZKWOQ-AZGAKELHSA-N";500.56;3.45;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-5.96;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.000001096478196143185
"MM476033";"MM476033";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(CC(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"QFAVBCHJZGCQGB-UKILVPOCSA-N";476.58;3.31;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930649/target=_blank>CHEMBL930649</a>";;-6.52;"Ott GR, Asakawa N, Lu Z, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Traskos JM, Decicco CP, Duan JJ.: Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000003019951720402019
"MM476037";"MM476037";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3ccccc3)nc2c1";"QMIKWBVYFVNXEF-VOWYLFBBSA-N";686.83;4.37;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972559/target=_blank>CHEMBL972559</a>";;-5.42;"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, WĂ¤hling H, WickstrĂ¶m K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K.: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, Volume 18 (17), 2008";"CACO-2";0.000003801893963205613
"MM476040";"MM476040";"CCSc1ccc(C(=O)NC2(C(=O)N[C@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)cc1";"VYPVPVGKTHZWSY-JGCGQSQUSA-N";634.89;4.82;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-6.22;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000006025595860743581
"MM476041";"MM476041";"COc1cccc(/C=C/C(=O)NC2(C(=O)N[C@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)c1";"OKBAFCQNMCNFRD-YETSWHHASA-N";630.83;4.12;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-5.85;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000014125375446227554
"MM472936";"MM472936";"CCCCc1ccc(C(=O)NC2(C(=O)N[C@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)nc1";"NUEAGESSSAENGD-MGBGTMOVSA-N";631.86;4.45;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-4.75;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.00001778279410038923
"MM476046";"MM476046";"CSc1ccc(/C=C/C(=O)NC2(C(=O)N[C@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)cc1";"VGEWWRRLVWLZAP-JMRYHUDMSA-N";646.9;4.83;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-5.33;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.000004677351412871981
"MM476047";"MM476047";"O=C(/C=C/c1cccc(F)c1)NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1";"KKZRKZNMXQNBRI-AVUDXHPJSA-N";618.79;4.25;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-5.68;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000020892961308540407
"MM476049";"MM476049";"O=C(Nc1ccc2c(c1)NC(=O)C(CCO)O2)C1CCN(c2cc(F)c(F)c(F)c2)CC1";"OSJROQUTACPGAR-UHFFFAOYSA-N";449.43;3.04;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997026/target=_blank>CHEMBL997026</a>";;-5.82;"Cheung WS, Calvo RR, Tounge BA, Zhang SP, Stone DR, Brandt MR, Hutchinson T, Flores CM, Player MR.: Discovery of piperidine carboxamide TRPV1 antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000015135612484362072
"MM476050";"MM476050";"Cc1ccccc1/C=C/C(=O)NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1";"AHBIKCVHRSENAB-QXORNKNPSA-N";614.83;4.42;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-6.1;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000007943282347242822
"MM476058";"MM476058";"Cc1c(-c2cccc(OCCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F";"MEXADSOJSYPZRE-MHZLTWQESA-N";613.61;5.53;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL995205/target=_blank>CHEMBL995205</a>";;-7;"Regan CF, Guo Z, Chen Y, Huang CQ, Chen M, Jiang W, Rueter JK, Coon T, Chen C, Saunders J, Brown MS, Betz SF, Struthers RS, Yang C, Wen J, Madan A, Zhu YF.: Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000001
"MM476060";"MM476060";"Cc1cccc(/C=C/C(=O)NC2(C(=O)N[C@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)c1";"YXAJZLPBUIOCEH-YETSWHHASA-N";614.83;4.42;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-5.68;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000020892961308540407
"MM476062";"MM476062";"CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1";"PCOIOMHQQCRCRU-SANMLTNESA-N";645.63;5.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL995205/target=_blank>CHEMBL995205</a>";;-5.92;"Regan CF, Guo Z, Chen Y, Huang CQ, Chen M, Jiang W, Rueter JK, Coon T, Chen C, Saunders J, Brown MS, Betz SF, Struthers RS, Yang C, Wen J, Madan A, Zhu YF.: Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000012022644346174132
"MM476063";"MM476063";"O=C(/C=C/c1ccc(Cl)cc1)NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1";"DGRSZZUQODVHRP-AYOQVULOSA-N";635.25;4.76;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-5.55;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.000002818382931264455
"MM476065";"MM476065";"Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F";"VUFHHJKMMITIBF-VWLOTQADSA-N";631.6;5.66;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL995205/target=_blank>CHEMBL995205</a>";;-7;"Regan CF, Guo Z, Chen Y, Huang CQ, Chen M, Jiang W, Rueter JK, Coon T, Chen C, Saunders J, Brown MS, Betz SF, Struthers RS, Yang C, Wen J, Madan A, Zhu YF.: Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000001
"MM476067";"MM476067";"COc1ccc(-n2nc(S(C)(=O)=O)c3c2C(=O)N(c2ccc(C4(CN5CCCC5=O)CC4)cc2)CC3)cc1";"LETIREDJFXZCNR-UHFFFAOYSA-N";534.64;3.14;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-5.7;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000019952623149688787
"MM476068";"MM476068";"CC(C)CCn1nc(-c2cccs2)c(O)c(C2=CS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"NKZVGAIIVIHTCD-UHFFFAOYSA-N";536.66;3.29;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997017/target=_blank>CHEMBL997017</a>";;-7.92;"Ellis DA, Blazel JK, Webber SE, Tran CV, Dragovich PS, Sun Z, Ruebsam F, McGuire HM, Xiang AX, Zhao J, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.00000001202264434617413
"MM476069";"MM476069";"CC(C)CCn1nc(-c2ccccc2)c(O)c(C2=CS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"PQKZAMZNEBXXRF-UHFFFAOYSA-N";530.63;3.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997017/target=_blank>CHEMBL997017</a>";;-7.72;"Ellis DA, Blazel JK, Webber SE, Tran CV, Dragovich PS, Sun Z, Ruebsam F, McGuire HM, Xiang AX, Zhao J, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.000000019054607179632482
"MM476070";"MM476070";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(C4(CN5CCOCC5)CC4)cc2)CC3)cc1";"DCIYDOCFGAWFEH-UHFFFAOYSA-N";501.59;2.55;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-5.05;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.00000891250938133746
"MM476071";"MM476071";"COc1ccc(-n2nc(C#N)c3c2C(=O)N(c2ccc(C4(CN5CCOCC5)CC4)cc2)CC3)cc1";"MQGZRCWHRHRCSR-UHFFFAOYSA-N";483.57;3.32;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-4.86;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.000013803842646028839
"MM476078";"MM476078";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(C4(CN(C)C)CC4)cc2)CC3)cc1";"VJOHYLCQRVQUEC-UHFFFAOYSA-N";459.55;2.78;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-6.3;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000005011872336272725
"MM476079";"MM476079";"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1";"GLBZSOQDAOLMGC-UHFFFAOYSA-N";539.59;4.71;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL985584/target=_blank>CHEMBL985584</a>";;-4.49;"Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry L, Huang L, Teffera Y, Yang Y, Zhang Y, Bellon SF, Lee M, Shimanovich R, Bak A, Dominguez C, Norman MH, Harmange JC, Dussault I, Kim TS.: Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem, Volume 51 (13), 2008";"CACO-2";0.00003235936569296281
"MM476081";"MM476081";"CNCC1(c2ccc(N3CCc4c(C(F)(F)F)nn(-c5ccc(OC)cc5)c4C3=O)cc2)CC1";"GXPIFAHKQNGNSM-UHFFFAOYSA-N";470.5;4.35;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-5.59;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000025703957827688647
"MM476082";"MM476082";"COc1ccc(-n2nc(C(F)(F)F)c3c2C(=O)N(c2ccc(C4(CN5CCCC5)CC4)cc2)CC3)cc1";"VNHRSGCBTKUBAX-UHFFFAOYSA-N";510.56;5.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-5.15;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.000007079457843841373
"MM476083";"MM476083";"NC(=O)[C@@]1(Cc2ccc(OCc3cc(-c4ccccc4)nc4ccccc34)c(F)c2)C[C@@H]1C(=O)NO";"ZVRPHGZPZLMEPV-PIKZIKFNSA-N";485.52;4.16;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1002004/target=_blank>CHEMBL1002004</a>";;-6.52;"Mazzola RD, Zhu Z, Sinning L, McKittrick B, Lavey B, Spitler J, Kozlowski J, Neng-Yang S, Zhou G, Guo Z, Orth P, Madison V, Sun J, Lundell D, Niu X.: Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket. Bioorg Med Chem Lett, Volume 18 (21), 2008";"CACO-2";0.0000003019951720402019
"MM476085";"MM476085";"COc1ccc(N2N=C(S(C)(=O)=O)C3CCN(c4ccc(C5(CN(C)C)CC5)cc4)C(=O)C32)cc1";"JCWCHQSJMSXHAQ-UHFFFAOYSA-N";496.63;2.89;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-6.1;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000007943282347242822
"MM476101";"MM476101";"CNCC1(c2ccc(N3CCc4c(C(N)=O)nn(-c5ccc(OC)cc5)c4C3=O)cc2)CC1";"GXFDTYKWAIFLIR-UHFFFAOYSA-N";445.52;2.43;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-7;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000001
"MM476104";"MM476104";"C=C(F)CN(CC)C(=O)[C@@]1(c2cccs2)C[C@H]1CN";"MGQRODBGBVCRHA-FZMZJTMJSA-N";282.38;2.3;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-4.78;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000016595869074375598
"MM476105";"MM476105";"C=CCN(C(=O)[C@@]1(c2cccs2)C[C@H]1CN)C1CC1";"OZOIMHBDGJFSOJ-NHYWBVRUSA-N";276.41;2.14;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-4.75;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.00001778279410038923
"MM476106";"MM476106";"CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@H]1CN";"GJJFMKBJSRMPLA-ZFWWWQNUSA-N";246.35;1.77;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-5.29;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000005128613839913648
"MM476107";"MM476107";"C=CCN(CC)C(=O)[C@@]1(c2cccs2)C[C@H]1CN";"VXBRIAOTINONRK-FZMZJTMJSA-N";264.39;2;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-4.86;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000013803842646028839
"MM476108";"MM476108";"NC[C@@H]1C[C@@]1(C(=O)N1Cc2ccccc2C1)c1cccs1";"ASCGGWXVCATSKL-YOEHRIQHSA-N";298.41;2.51;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-5.08;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.00000831763771102671
"MM476109";"MM476109";"COc1ccc(-n2nc(C(F)(F)F)c3c2C(=O)N(c2ccc(C4(Cn5ccnc5C)CC4)cc2)CC3)cc1";"ZDHSUHHKRRWGLY-UHFFFAOYSA-N";521.54;5.34;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-5.15;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.000007079457843841373
"MM476111";"MM476111";"CCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O";"ISXFTRWXVQNDLR-OINPDUSQSA-N";751.93;3.13;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955665/target=_blank>CHEMBL955665</a>";;-5.45;"Koda Y, Del Borgo M, Wessling ST, Lazarus LH, Okada Y, Toth I, Blanchfield JT.: Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem, Volume 16 (11), 2008";"CACO-2";0.000003548133892335753
"MM476112";"MM476112";"C#CCN(CC)C(=O)[C@@]1(c2cccs2)C[C@H]1CN";"DBDIPFBJGDKNIO-FZMZJTMJSA-N";262.38;1.45;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-4.69;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000020417379446695274
"Dofetilide";"MM16908";"CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C";"IXTMWRCNAAVVAI-UHFFFAOYSA-N";441.58;1.98;"71329";;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889311/target=_blank>CHEMBL889311</a>";;-4.8;"Singleton DH, Boyd H, Steidl-Nichols JV, Deacon M, Groot MJ, Price D, Nettleton DO, Wallace NK, Troutman MD, Williams C, Boyd JG.: Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel. J Med Chem, Volume 50 (13), 2007";"CACO-2";0.00001584893192461114
"MM476113";"MM476113";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@H]3CCCC[C@H]3N(Cc3ccc(F)cc3)C1=O)N2";"KMSYAEIZBCDWRW-PKOBYXMFSA-N";548.62;3.12;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-6.17;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000006760829753919819
"MM476114";"MM476114";"Nc1ncnc2c1ncn2[C@@H]1O[C@H](COC(=O)[C@@H](N)Cc2ccccc2)[C@@H](O)[C@@H]1O";"IMSXVJLTCFJFIR-PMSSTTEUSA-N";414.42;-0.86;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL942586/target=_blank>CHEMBL942586</a>";;-6.18;"Shen W, Kim JS, Kish PE, Zhang J, Mitchell S, Gentry BG, Breitenbach JM, Drach JC, Hilfinger J.: Design and synthesis of vidarabine prodrugs as antiviral agents. Bioorg Med Chem Lett, Volume 19 (3), 2009";"CACO-2";0.0000006606934480075964
"MM476115";"MM476115";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@H]3CCC[C@H]3N(Cc3ccc(F)c(F)c3)C1=O)N2";"FUYGFKRYXHLTKS-KBXCAEBGSA-N";552.58;2.87;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-6.08;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000008317637711026709
"MM476116";"MM476116";"CC(C)[C@@H](N)C(=O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H](O)[C@@H]1O";"BMEANLWXFGBEDK-UDTSGEQISA-N";366.38;-1.45;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL942586/target=_blank>CHEMBL942586</a>";;-6.22;"Shen W, Kim JS, Kish PE, Zhang J, Mitchell S, Gentry BG, Breitenbach JM, Drach JC, Hilfinger J.: Design and synthesis of vidarabine prodrugs as antiviral agents. Bioorg Med Chem Lett, Volume 19 (3), 2009";"CACO-2";0.0000006025595860743581
"MM476120";"MM476120";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)C3CCCCCC3N(Cc3ccc(F)cc3)C1=O)N2";"YDSARQVEDLUCKQ-UHFFFAOYSA-N";562.65;3.51;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-6.02;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000009549925860214369
"MM476121";"MM476121";"CC(C)(C)CCN1C(=O)C(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C(O)C2CCCC21";"FMBGSDDLWWWFEX-UHFFFAOYSA-N";510.64;2.83;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-5.38;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.000004168693834703355
"MM476123";"MM476123";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@H]3CCC[C@H]3N(Cc3ccc(F)cc3)C1=O)N2";"PAEBVIJMNXTTAT-FUHWJXTLSA-N";534.59;2.73;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-5.8;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.000001584893192461114
"MM476127";"MM476127";"CC(C)(C)CCN1C(=O)C(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C(O)C2CCCCC21";"QTDPGMAKDPBABE-UHFFFAOYSA-N";524.67;3.22;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-5.51;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.000003090295432513592
"MM473730";"MM473730";"CCC(CC)[C@@H](CO)NS(=O)(=O)c1ccc(Cl)s1";"PYZFRRVBPNGCBX-SECBINFHSA-N";311.86;2.48;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL999315/target=_blank>CHEMBL999315</a>";;-4.3;"Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, Atchison K, Chlenov M, Cole DC, Comery T, Diamantidis G, Ellingboe J, Fan K, Galante R, Gonzales C, Ho DM, Hoke ME, Hu Y, Huryn D, Jain U, Jin M, Kremer K, Kubrak D, Lin M, Lu P, Magolda R, Martone R, Moore W, Oganesian A, Pangalos MN, Porte A, Reinhart P, Resnick L, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Wang T, Woller K, Xu Z, Zaleska MM, Zeldis J, Zhang M, Zhou H, Jacobsen JS.: Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem, Volume 51 (23), 2008";"CACO-2";0.00005011872336272725
"MM473730";"MM473730";"CCC(CC)[C@@H](CO)NS(=O)(=O)c1ccc(Cl)s1";"PYZFRRVBPNGCBX-SECBINFHSA-N";311.86;2.48;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111684/target=_blank>CHEMBL1111684</a>";;-4.3;"Kreft AF, Martone R, Porte A.: Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem, Volume 52 (20), 2009";"CACO-2";0.00005011872336272725
"MM476138";"MM476138";"COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1F";"MHSIRMSFRHMBDY-UHFFFAOYSA-N";355.37;3.05;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL950432/target=_blank>CHEMBL950432</a>";;-4.59;"Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O'Brien Z, Stotz CE, Crespo MI, DĂ­az JL, Slee DH.: Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000025703957827688645
"MM476139";"MM476139";"COc1cc(OC)cc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1";"XGFRRYAZOMJDQL-UHFFFAOYSA-N";367.41;2.92;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL950432/target=_blank>CHEMBL950432</a>";;-5.62;"Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O'Brien Z, Stotz CE, Crespo MI, DĂ­az JL, Slee DH.: Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.0000023988329190194897
"MM476149";"MM476149";"COc1cc(C(C)C)c(Oc2cnc(NC(CO)CO)nc2N)cc1I";"PAYROHWFGZADBR-UHFFFAOYSA-N";474.3;2.35;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1017982/target=_blank>CHEMBL1017982</a>";;-5.03;"Jahangir A, Alam M, Carter DS, Dillon MP, Bois DJ, Ford AP, Gever JR, Lin C, Wagner PJ, Zhai Y, Zira J.: Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett, Volume 19 (6), 2009";"CACO-2";0.000009332543007969906
"MM476157";"MM476157";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)C3CCCCN3N(Cc3ccc(F)cc3)C1=O)N2";"UWHLIQKODYRVHR-UHFFFAOYSA-N";549.61;2.33;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953074/target=_blank>CHEMBL953074</a>";;-7;"Ruebsam F, Sun Z, Ayida BK, Webber SE, Zhou Y, Zhao Q, Kissinger CR, Showalter RE, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.0000001
"MM476163";"MM476163";"CN(c1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)C3CCCN3N(CCC(C)(C)C)C1=O)N2)S(C)(=O)=O";"LKFUDBIQCHYGLB-UHFFFAOYSA-N";525.65;2.07;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953074/target=_blank>CHEMBL953074</a>";;-5.7;"Ruebsam F, Sun Z, Ayida BK, Webber SE, Zhou Y, Zhao Q, Kissinger CR, Showalter RE, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.0000019952623149688787
"MM476164";"MM476164";"CC(C)(C)CCN1C(=O)C(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C(O)C2(C)CCCN12";"ACOGLHDMMGUBOE-UHFFFAOYSA-N";525.65;2.43;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953074/target=_blank>CHEMBL953074</a>";;-6.22;"Ruebsam F, Sun Z, Ayida BK, Webber SE, Zhou Y, Zhao Q, Kissinger CR, Showalter RE, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.0000006025595860743581
"MM476165";"MM476165";"CC(C)(C)CCN1C(=O)C(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C(O)C2CCCCN21";"BQPZAFXWOOYNCK-UHFFFAOYSA-N";525.65;2.43;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953074/target=_blank>CHEMBL953074</a>";;-6.51;"Ruebsam F, Sun Z, Ayida BK, Webber SE, Zhou Y, Zhao Q, Kissinger CR, Showalter RE, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.0000003090295432513592
"MM476167";"MM476167";"CC(C)(C)CCn1c(=O)c(C2=CS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c(O)c2cccn21";"IFOIHAHIQJSCGH-UHFFFAOYSA-N";506.61;2.81;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997017/target=_blank>CHEMBL997017</a>";;-6.52;"Ellis DA, Blazel JK, Webber SE, Tran CV, Dragovich PS, Sun Z, Ruebsam F, McGuire HM, Xiang AX, Zhao J, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000003019951720402019
"MM476170";"MM476170";"Cc1ccc(-c2nn(Cc3ccccc3)c(=O)c(C3=CS(=O)(=O)c4ccccc4N3)c2O)s1";"HFCBLGLYMIRSDK-UHFFFAOYSA-N";477.57;4.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997017/target=_blank>CHEMBL997017</a>";;-6.52;"Ellis DA, Blazel JK, Webber SE, Tran CV, Dragovich PS, Sun Z, Ruebsam F, McGuire HM, Xiang AX, Zhao J, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.0000003019951720402019
"MM476171";"MM476171";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)C3CCCN3N(Cc3ccc(F)cc3)C1=O)N2";"UBNPIDCXPURCPQ-UHFFFAOYSA-N";535.58;1.94;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953074/target=_blank>CHEMBL953074</a>";;-6.7;"Ruebsam F, Sun Z, Ayida BK, Webber SE, Zhou Y, Zhao Q, Kissinger CR, Showalter RE, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.00000019952623149688787
"MM476174";"MM476174";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-n3ccc(C(C)C)n3)nc2c1C";"YOUAQFKLUWJMGK-ZEIZKYAPSA-N";732.9;4.32;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972559/target=_blank>CHEMBL972559</a>";;-4.82;"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, WĂ¤hling H, WickstrĂ¶m K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K.: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, Volume 18 (17), 2008";"CACO-2";0.000015135612484362071
"MM476176";"MM476176";"C=CC1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3csc(NC(C)C)n3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)P(=O)(O)O";"BQXDWZQXORQBLV-HNFUVXBTSA-N";798.9;5.82;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1004175/target=_blank>CHEMBL1004175</a>";;-6.7;"Sheng XC, Pyun HJ, Chaudhary K, Wang J, Doerffler E, Fleury M, McMurtrie D, Chen X, Delaney WE, Kim CU.: Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors. Bioorg Med Chem Lett, Volume 19 (13), 2009";"CACO-2";0.00000019952623149688787
"MM476178";"MM476178";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1";"SQRWDJFVRRUGCD-PEYMYBIGSA-N";735.93;4.95;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972559/target=_blank>CHEMBL972559</a>";;-4.89;"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, WĂ¤hling H, WickstrĂ¶m K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K.: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, Volume 18 (17), 2008";"CACO-2";0.000012882495516931348
"MM476180";"MM476180";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C";"JTZZSQYMACOLNN-VDWJNHBNSA-N";749.96;5.25;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972559/target=_blank>CHEMBL972559</a>";;-5.08;"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, WĂ¤hling H, WickstrĂ¶m K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K.: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, Volume 18 (17), 2008";"CACO-2";0.00000831763771102671
"MM476183";"MM476183";"Cc1nc(C(=O)N2c3cccc(O)c3NC3=C(C(=O)CC(C)(C)C3)[C@@H]2c2ccc(OCc3ccccc3)cc2F)c(C)o1";"CFUGIIBOYXFYRK-YTTGMZPUSA-N";581.64;7.17;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972372/target=_blank>CHEMBL972372</a>";;-4.96;"McGowan D, Nyanguile O, Cummings MD, Vendeville S, Vandyck K, Van den Broeck W, Boutton CW, De Bondt H, Quirynen L, Amssoms K, Bonfanti JF, Last S, Rombauts K, Tahri A, Hu L, Delouvroy F, Vermeiren K, Vandercruyssen G, Van der Helm L, Cleiren E, Mostmans W, Lory P, Pille G, Van Emelen K, Fanning G, Pauwels F, Lin TI, Simmen K, Raboisson P.: 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (9), 2009";"CACO-2";0.000010964781961431852
"MM476184";"MM476184";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1Cl";"FSFUVODFJRFRKJ-INIBMZLISA-N";770.37;5.6;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972559/target=_blank>CHEMBL972559</a>";;-5.24;"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, WĂ¤hling H, WickstrĂ¶m K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K.: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, Volume 18 (17), 2008";"CACO-2";0.000005754399373371567
"MM476186";"MM476186";"CCCCCCC(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O";"IMYCMDVCSHAEQG-WBHZCIDJSA-N";751.93;3.13;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955665/target=_blank>CHEMBL955665</a>";;-6.08;"Koda Y, Del Borgo M, Wessling ST, Lazarus LH, Okada Y, Toth I, Blanchfield JT.: Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem, Volume 16 (11), 2008";"CACO-2";0.0000008317637711026709
"MM476194";"MM476194";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CCCCCC(=O)N4C3)cc(-c3nc(C(C)C)cs3)nc2c1Cl";"ZALNWWKHXDKCGG-NBDVMRGUSA-N";770.37;5.89;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952255/target=_blank>CHEMBL952255</a>";;-4.95;"Raboisson P, Lin TI, Kock Hd, Vendeville S, Vreken WV, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Surleraux D, Wigerinck P, Nilsson M, Rosenquist S, Samuelsson B, Simmen K.: Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.00001122018454301963
"MM472937";"MM472937";"CCCCc1ccc(C(=O)NC2(C(=O)N[C@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)cc1";"FNWMFLJWSOZBPX-UUWRZZSWSA-N";630.87;5.05;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-5.03;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.000009332543007969906
"MM476197";"MM476197";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nccs3)nc2c1";"UPCUFWLSYBBVRL-XFWJKKJESA-N";693.85;3.82;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972559/target=_blank>CHEMBL972559</a>";;-5.8;"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, WĂ¤hling H, WickstrĂ¶m K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K.: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, Volume 18 (17), 2008";"CACO-2";0.000001584893192461114
"MM476198";"MM476198";"O=C(/C=C/c1ccccc1Cl)NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1";"CUBUOUCVDQTAQY-JWJPGYJNSA-N";635.25;4.76;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967979/target=_blank>CHEMBL967979</a>";;-6;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.000001
"MM476200";"MM476200";"Cc1cccc(C(=O)N2c3cccc(O)c3NC3=C(C(=O)CC(C)(C)C3)[C@@H]2c2ccc(OCc3ccccc3)cc2F)n1";"QIRFXOXAHTWAEQ-XIFFEERXSA-N";577.66;7.27;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972372/target=_blank>CHEMBL972372</a>";;-4.94;"McGowan D, Nyanguile O, Cummings MD, Vendeville S, Vandyck K, Van den Broeck W, Boutton CW, De Bondt H, Quirynen L, Amssoms K, Bonfanti JF, Last S, Rombauts K, Tahri A, Hu L, Delouvroy F, Vermeiren K, Vandercruyssen G, Van der Helm L, Cleiren E, Mostmans W, Lory P, Pille G, Van Emelen K, Fanning G, Pauwels F, Lin TI, Simmen K, Raboisson P.: 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (9), 2009";"CACO-2";0.000011481536214968817
"MM476201";"MM476201";"C=CCN(Cc1nccs1)C(=O)[C@@]1(c2cccs2)C[C@H]1CN";"JOHKRZVJVWMMNT-LRDDRELGSA-N";333.48;2.64;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-5.19;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000006456542290346549
"MM476202";"MM476202";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3cccc(C(C)C)n3)nc2c1C";"QHRCGENNUXALBT-GNZLCGGJSA-N";743.93;5.19;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972559/target=_blank>CHEMBL972559</a>";;-4.92;"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, WĂ¤hling H, WickstrĂ¶m K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K.: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, Volume 18 (17), 2008";"CACO-2";0.000012022644346174132
"MM476205";"MM476205";"Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@@H](c2ccccc2)N(C)C)c(=O)n1Cc1c(F)cccc1C(F)(F)F";"NSBUNJVFFBYJER-MHZLTWQESA-N";659.65;6.27;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL995205/target=_blank>CHEMBL995205</a>";;-4.77;"Regan CF, Guo Z, Chen Y, Huang CQ, Chen M, Jiang W, Rueter JK, Coon T, Chen C, Saunders J, Brown MS, Betz SF, Struthers RS, Yang C, Wen J, Madan A, Zhu YF.: Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.00001698243652461746
"MM476207";"MM476207";"CNCC1(c2ccc(N3CCC4C(S(C)(=O)=O)=NN(c5ccc(OC)cc5)C4C3=O)cc2)CC1";"QEGUWDCBAMUNMT-UHFFFAOYSA-N";482.61;2.55;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-7;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000001
"MM476208";"MM476208";"C=CCN(CC=C)C(=O)[C@@]1(c2cccs2)C[C@H]1CN";"XCOOHOIRZJLJRQ-WFASDCNBSA-N";276.41;2.17;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-4.78;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000016595869074375598
"MM476210";"MM476210";"C#CCN(CC#C)C(=O)[C@@]1(c2cccs2)C[C@H]1CN";"DDNDQTODRFYZEU-WFASDCNBSA-N";272.37;1.06;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-4.6;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000025118864315095822
"MM476211";"MM476211";"CC(C)CCN1C(=O)C(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C(O)C2CCCC21";"WNJBKXXSMIADKQ-UHFFFAOYSA-N";496.61;2.44;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-5.48;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000033113112148259077
"MM476213";"MM476213";"CC[C@H](C)[C@H](N)C(=O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H](O)[C@@H]1O";"CAROJMQVDXUOOR-QETZTWOHSA-N";380.41;-1.06;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL942586/target=_blank>CHEMBL942586</a>";;-5.99;"Shen W, Kim JS, Kish PE, Zhang J, Mitchell S, Gentry BG, Breitenbach JM, Drach JC, Hilfinger J.: Design and synthesis of vidarabine prodrugs as antiviral agents. Bioorg Med Chem Lett, Volume 19 (3), 2009";"CACO-2";0.0000010232929922807537
"MM476214";"MM476214";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)[C@@H]3CCCC[C@@H]3N(Cc3ccc(F)cc3)C1=O)N2";"KMSYAEIZBCDWRW-MJGOQNOKSA-N";548.62;3.12;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-6;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.000001
"MM476216";"MM476216";"CC(C)CCN1C(=O)C(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C(O)C2CCCCC21";"VDOHZTYEUXWZCP-UHFFFAOYSA-N";510.64;2.83;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955142/target=_blank>CHEMBL955142</a>";;-5.51;"Ruebsam F, Tran CV, Li LS, Kim SH, Xiang AX, Zhou Y, Blazel JK, Sun Z, Dragovich PS, Zhao J, McGuire HM, Murphy DE, Tran MT, Stankovic N, Ellis DA, Gobbi A, Showalter RE, Webber SE, Shah AM, Tsan M, Patel RA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.000003090295432513592
"MM476217";"MM476217";"CNCC1(c2ccc(N3CCc4c(C#N)nn(-c5ccc(OC)cc5)c4C3=O)cc2)CC1";"BDUIPRZETCZQER-UHFFFAOYSA-N";427.51;3.21;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010166/target=_blank>CHEMBL1010166</a>";;-6.22;"Qiao JX, King SR, He K, Wong PC, Rendina AR, Luettgen JM, Xin B, Knabb RM, Wexler RR, Lam PY.: Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties. Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.0000006025595860743581
"MM476227";"MM476227";"CC(C)CCn1c(=O)c(C2=CS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c(O)c2cccn21";"LLRZXFYVJFNKSK-UHFFFAOYSA-N";492.58;2.42;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997017/target=_blank>CHEMBL997017</a>";;-7.57;"Ellis DA, Blazel JK, Webber SE, Tran CV, Dragovich PS, Sun Z, Ruebsam F, McGuire HM, Xiang AX, Zhao J, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.00000002691534803926914
"MM476228";"MM476228";"CC(C)CCN1C(=O)C(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C(O)C2CCCN21";"WVYWJPVQLJUDGR-UHFFFAOYSA-N";497.6;1.65;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953074/target=_blank>CHEMBL953074</a>";;-6.7;"Ruebsam F, Sun Z, Ayida BK, Webber SE, Zhou Y, Zhao Q, Kissinger CR, Showalter RE, Shah AM, Tsan M, Patel R, Lebrun LA, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Kirkovsky L.: Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (18), 2008";"CACO-2";0.00000019952623149688787
"MM476229";"MM476229";"CC(C)CCn1c(=O)c(C2=CS(=O)(=O)c3cc(N(C)S(C)(=O)=O)ccc3N2)c(O)c2cccn21";"GJFKHZTVVWBWPS-UHFFFAOYSA-N";506.61;2.45;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL997017/target=_blank>CHEMBL997017</a>";;-7.92;"Ellis DA, Blazel JK, Webber SE, Tran CV, Dragovich PS, Sun Z, Ruebsam F, McGuire HM, Xiang AX, Zhao J, Li LS, Zhou Y, Han Q, Kissinger CR, Showalter RE, Lardy M, Shah AM, Tsan M, Patel R, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (16), 2008";"CACO-2";0.00000001202264434617413
"MM476230";"MM476230";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3csc(NC(C)C)n3)nc2c1";"VYSDFYMUIDAAMX-PEYMYBIGSA-N";750.94;4.64;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL972559/target=_blank>CHEMBL972559</a>";;-5.85;"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, Roue N, Ivanov V, WĂ¤hling H, WickstrĂ¶m K, Hamelink E, Edlund M, Vrang L, Vendeville S, Van de Vreken W, McGowan D, Tahri A, Hu L, Boutton C, Lenz O, Delouvroy F, Pille G, Surleraux D, Wigerinck P, Samuelsson B, Simmen K.: Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, Volume 18 (17), 2008";"CACO-2";0.0000014125375446227554
"1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine";"MM18286";"COc1cccc2c1CCCC2CCCN1CCN(C2CCCCC2)CC1";"PHRCDWVPTULQMT-UHFFFAOYSA-N";370.58;4.85;"10474335";"CHEMBL53325";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-3.6;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00025118864315095795
"MM476252";"MM476252";"Cn1c(C2=CCN(CCCN3c4ccccc4Sc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"SSIZXVUYAOUIQY-UHFFFAOYSA-N";518.64;3.49;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5.33;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.000004677351412871981
"MM476253";"MM476253";"Cn1c(N2CCN(CCCN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"PPLDJNZKOFVZGW-UHFFFAOYSA-N";507.62;2.6;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.00001
"MM476257";"MM476257";"Cn1c(N2CCN(CCCCN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"UQAJLTTZWHXNJH-UHFFFAOYSA-N";521.64;2.99;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-4.69;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.000020417379446695274
"MM476284";"MM476284";"Cn1c(N2CCN(CCCN3c4ccccc4Sc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"BACLISNXCXJOMR-UHFFFAOYSA-N";521.64;2.53;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-4.91;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.00001230268770812381
"MM476285";"MM476285";"Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"YJGZARVVQHKNAU-UHFFFAOYSA-N";535.67;2.92;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5.26;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.0000054954087385762485
"MM476287";"MM476287";"Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(CCC(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"LVQDPXHGLLUJTK-UHFFFAOYSA-N";549.7;3.31;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5.11;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.00000776247116628691
"MM476291";"MM476291";"Cn1c(N2CCCN(CCCN3c4ccccc4Sc4c(C(=O)O)cccc43)CC2)cc(=O)n(C)c1=O";"JONUVZHQXKYZDL-UHFFFAOYSA-N";521.64;2.99;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-6.3;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.0000005011872336272725
"MM476293";"MM476293";"Cn1c(N2CCN(CCCN3c4ccccc4Sc4ccc(CCC(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"RIUIDVINUPJOQH-UHFFFAOYSA-N";535.67;2.92;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5.29;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.000005128613839913648
"MM476296";"MM476296";"CN(CCCN1CCC(CN2c3ccccc3Sc3ccc(C(=O)O)cc32)CC1)c1cc(=O)n(C)c(=O)n1C";"MMKZIPYPZZNRTO-UHFFFAOYSA-N";549.7;3.62;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-6.22;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.0000006025595860743581
"MM476301";"MM476301";"Cn1c(N2CCCN(CCCN3c4ccccc4Sc4cccc(C(=O)O)c43)CC2)cc(=O)n(C)c1=O";"GGTPJIUWVNXICI-UHFFFAOYSA-N";521.64;2.99;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-6.3;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.0000005011872336272725
"MM476303";"MM476303";"Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(C(C)(C)C(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"WEFSNJOGTPXLGH-UHFFFAOYSA-N";563.72;3.65;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.00001
"MM476305";"MM476305";"Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(/C=C\C(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"YJYGESNCQHFTHG-BENRWUELSA-N";547.68;3.39;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5.15;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.000007079457843841373
"MM476308";"MM476308";"Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(OCC(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"FDBNTQCFINBNNL-UHFFFAOYSA-N";551.67;2.75;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-6.3;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.0000005011872336272725
"MM476309";"MM476309";"N[C@@H](CC(=O)N1CCC[C@H]1CNS(=O)(=O)C1CC1)Cc1cc(F)c(F)cc1F";"LSTBCAMTBZQTCR-OLZOCXBDSA-N";419.47;1.44;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060843/target=_blank>CHEMBL1060843</a>";;-6.57;"Nordhoff S, LĂłpez-Canet M, Hoffmann-Enger B, Bulat S, Cerezo-GĂˇlvez S, Hill O, Rosenbaum C, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A.: From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.0000002691534803926914
"MM476310";"MM476310";"Cn1c(NCCCN2CCC(CN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"ZPASDZSMHRZWEN-UHFFFAOYSA-N";535.67;3.6;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-6.4;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.0000003981071705534969
"MM476311";"MM476311";"CCC(C(=O)O)c1ccc2c(c1)N(CCCN1CCCN(c3cc(=O)n(C)c(=O)n3C)CC1)c1ccccc1S2";"MKKJPIHSAMRGEO-UHFFFAOYSA-N";563.72;3.87;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-4.65;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.00002238721138568338
"MM476315";"MM476315";"Cn1c(N2CCN(CCN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"OYGQVRYZRZJCQY-UHFFFAOYSA-N";493.59;2.21;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5.31;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.000004897788193684467
"MM476318";"MM476318";"CCCCn1nc(-c2nc3ccccc3s2)nc2c(=O)n(C)c(=O)nc1-2";"REUQOCZUYLFNNL-UHFFFAOYSA-N";368.42;1.91;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1115404/target=_blank>CHEMBL1115404</a>";;-4.46;"Zhou Y, Liu G, Chen J, Reddy PS, Yoon IS, Zhang M, Zhang B, Barber JR, Ng SC.: Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives: their cytoprotection effect from rotenone toxicity and preliminary DMPK properties. Bioorg Med Chem Lett, Volume 19 (21), 2009";"CACO-2";0.00003467368504525317
"MM476319";"MM476319";"Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O";"UDCCWKBPMHTQIP-UHFFFAOYSA-N";521.64;2.99;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5.33;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.000004677351412871981
"MM476320";"MM476320";"CC(C(=O)O)c1ccc2c(c1)N(CCCN1CCCN(c3cc(=O)n(C)c(=O)n3C)CC1)c1ccccc1S2";"VKAAMGNCPQOWFB-UHFFFAOYSA-N";549.7;3.48;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-5.16;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.0000069183097091893625
"MM476330";"MM476330";"CC(C)CC[C@]1(C)CN(C2CCC2)C(=O)C(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C1O";"XLKQWBFTCKFXAH-HSZRJFAPSA-N";524.67;3.22;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1041711/target=_blank>CHEMBL1041711</a>";;-5.54;"Ellis DA, Blazel JK, Tran CV, Ruebsam F, Murphy DE, Li LS, Zhao J, Zhou Y, McGuire HM, Xiang AX, Webber SE, Zhao Q, Han Q, Kissinger CR, Lardy M, Gobbi A, Showalter RE, Shah AM, Tsan M, Patel RA, LeBrun LA, Kamran R, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L.: 5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (21), 2009";"CACO-2";0.000002884031503126606
"MM476332";"MM476332";"CCCOCCn1c(=O)c(N[C@H]2CC[C@H](O)CC2)nc2cnc(-c3ccc(OC)nc3)cc21";"IVZATIQZZIVIQL-IYARVYRRSA-N";453.54;3;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1046276/target=_blank>CHEMBL1046276</a>";;-4.47;"Hughes RO, Walker JK, Rogier DJ, Heasley SE, Blevis-Bal RM, Benson AG, Jacobsen EJ, Cubbage JW, Fobian YM, Owen DR, Freskos JN, Molyneaux JM, Brown DL, Acker BA, Maddux TM, Tollefson MB, Moon JB, Mischke BV, Rumsey JM, Zheng Y, MacInnes A, Bond BR, Yu Y.: Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000033884415613920276
"Nelfinavir";"MM00528";"Cc1c(O)cccc1C(=O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C";"QAGYKUNXZHXKMR-UHFFFAOYSA-N";567.8;4.75;"64143";"CHEMBL584";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL945651/target=_blank>CHEMBL945651</a>";;-5.99;"Roche D, Greiner J, Aubertin AM, Vierling P.: Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors. Eur J Med Chem, Volume 43 (7), 2008";"CACO-2";0.0000010232929922807537
"MM473023";"MM473023";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl";"VYLVEERKOLDJOU-UHFFFAOYSA-N";451.95;4.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066153/target=_blank>CHEMBL1066153</a>";;-5.11;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.00000776247116628691
"MM473028";"MM473028";"COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC";"ULXYUIOTBNWJFH-UHFFFAOYSA-N";425.53;2.75;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066153/target=_blank>CHEMBL1066153</a>";;-6.3;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.0000005011872336272725
"MM473025";"MM473025";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC";"RUVNTEGYLMYXCF-UHFFFAOYSA-N";459.55;3.87;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066153/target=_blank>CHEMBL1066153</a>";;-6.52;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.0000003019951720402019
"MM476397";"MM476397";"COc1cc(C(=O)Nc2nonc2NCc2ccc(-c3cc(Cl)cc(F)c3-c3noc(C)n3)cc2F)on1";"WEVILATZZMPFBJ-UHFFFAOYSA-N";543.87;4.89;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066284/target=_blank>CHEMBL1066284</a>";;-4.32;"Zischinsky G, Stragies R, Schaudt M, Pfeifer JR, Gibson C, Locardi E, Scharn D, Richter U, Kalkhof H, Dinkel K, Schnatbaum K.: Novel small molecule bradykinin B1 receptor antagonists. Part 2: 5-membered diaminoheterocycles. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.000047863009232263804
"MM473024";"MM473024";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C";"ZHYPMHNQQRIWRP-UHFFFAOYSA-N";431.54;4.25;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066153/target=_blank>CHEMBL1066153</a>";;-5.1;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.000007943282347242822
"MM473026";"MM473026";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC";"OKHVXBABEFQOCR-UHFFFAOYSA-N";420.47;3.38;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066153/target=_blank>CHEMBL1066153</a>";;-6.22;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.0000006025595860743581
"MM476402";"MM476402";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC[C@@H](N)C2)ccc2[nH]ccc12";"KAJIDAUQCMSGGN-XQASTXFUSA-N";400.53;4.31;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067378/target=_blank>CHEMBL1067378</a>";;-6.3;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"CACO-2";0.0000005011872336272725
"MM472279";"MM472279";"COc1ccc(-n2cc(-c3ccc4c(c3)C(=O)NCC4)c(N)n2)cc1";"ZBIFKWQZJMJWRU-UHFFFAOYSA-N";334.38;2.42;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1071095/target=_blank>CHEMBL1071095</a>";;-4.32;"Velcicky J, Feifel R, Hawtin S, Heng R, Huppertz C, Koch G, Kroemer M, Moebitz H, Revesz L, Scheufler C, Schlapbach A.: Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.000047863009232263804
"Atomoxetine";"MM00449";"CNCC[C@@H](Oc1ccccc1C)c1ccccc1";"VHGCDTVCOLNTBX-QGZVFWFLSA-N";255.36;3.72;"54841";"CHEMBL641";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948483/target=_blank>CHEMBL948483</a>";;-4.36;"Dyck B, Tamiya J, Jovic F, Pick RR, Bradbury MJ, O'Brien J, Wen J, Johns M, Madan A, Fleck BA, Foster AC, Li B, Zhang M, Tran JA, Vickers T, Grey J, Saunders J, Chen C.: Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. J Med Chem, Volume 51 (22), 2008";"CACO-2";0.000043651583224016566
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1108561/target=_blank>CHEMBL1108561</a>";;-6.15;"Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT, Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein H, Zeng J, Wilks AF.: Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett, Volume 19 (20), 2009";"CACO-2";0.0000007079457843841374
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921232/target=_blank>CHEMBL921232</a>";;-4.23;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00005888436553555884
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL923495/target=_blank>CHEMBL923495</a>";;-4.23;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Paradiso A.: 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.00005888436553555884
"MM472953";"MM472953";"COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O";"MBNGWHIJMBWFHU-UHFFFAOYSA-N";300.27;2.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988136/target=_blank>CHEMBL988136</a>";;-4.12;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.00007585775750291836
"Fexofenadine";"MM00735";"CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1";"RWTNPBWLLIMQHL-UHFFFAOYSA-N";501.67;5.51;"3348";"CHEMBL914";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059634/target=_blank>CHEMBL1059634</a>";;-6.4;"Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y.: Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists. Bioorg Med Chem Lett, Volume 19 (10), 2009";"CACO-2";0.0000003981071705534969
"Naringenin";"MM00673";"O=C1CC(c2ccc(O)cc2)Oc2cc(O)cc(O)c21";"FTVWIRXFELQLPI-UHFFFAOYSA-N";272.26;2.51;"932";"CHEMBL9352";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988136/target=_blank>CHEMBL988136</a>";;-4.42;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.000038018939632056124
"MM476456";"MM476456";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(C1=C(O)C3C4CCC(C4)C3N(Cc3ccc(F)cc3)C1=O)N2";"DEKOYVOWOVJMPM-UHFFFAOYSA-N";560.63;2.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,meanlogPermvalue,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1112197/target=_blank>CHEMBL1112197</a>";;-5.57;"Ruebsam F, Murphy DE, Tran CV, Li LS, Zhao J, Dragovich PS, McGuire HM, Xiang AX, Sun Z, Ayida BK, Blazel JK, Kim SH, Zhou Y, Han Q, Kissinger CR, Webber SE, Showalter RE, Shah AM, Tsan M, Patel RA, Thompson PA, Lebrun LA, Hou HJ, Kamran R, Sergeeva MV, Bartkowski DM, Nolan TG, Norris DA, Khandurina J, Brooks J, Okamoto E, Kirkovsky L.: Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (22), 2009";"CACO-2";0.0000026915348039269138
"MM476457";"MM476457";"CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2";"UAXNNGUDPWZOKX-UHFFFAOYSA-N";483.52;3.83;;;"CACO";"ECACO";"25";"0";"fromAtoB,meanlogPermvalue,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898578/target=_blank>CHEMBL898578</a>";;-4.53;"Powell NA, Ciske FL, Cai C, Holsworth DD, Mennen K, Van Huis CA, Jalaie M, Day J, Mastronardi M, McConnell P, Mochalkin I, Zhang E, Ryan MJ, Bryant J, Collard W, Ferreira S, Gu C, Collins R, Edmunds JJ.: Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorg Med Chem, Volume 15 (17), 2007";"CACO-2";0.00002951209226666384
"MM476460";"MM476460";"Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O";"GQKWRERWSHSLFH-MCEBTLFFSA-N";638.77;2.29;;;"CACO";"ECACO";"25";"0";"fromAtoB,meanlogPermvalue,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955665/target=_blank>CHEMBL955665</a>";;-7;"Koda Y, Del Borgo M, Wessling ST, Lazarus LH, Okada Y, Toth I, Blanchfield JT.: Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem, Volume 16 (11), 2008";"CACO-2";0.0000001
"MM476461";"MM476461";"CCCCCCC(N)C(=O)N[C@@H](Cc1c(C)cc(O)cc1C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O";"JSEDTOFZZLNMQM-LUIGENPXSA-N";779.98;3.75;;;"CACO";"ECACO";"25";"0";"fromAtoB,meanlogPermvalue,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL955665/target=_blank>CHEMBL955665</a>";;-6.42;"Koda Y, Del Borgo M, Wessling ST, Lazarus LH, Okada Y, Toth I, Blanchfield JT.: Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem, Volume 16 (11), 2008";"CACO-2";0.00000038018939632056126
"MM475170";"MM475170";"COc1ccc(S(=O)(=O)N2C[C@H](C(=O)N3CCCNCC3)c3ccccc32)c2ccccc12";"VZJXKZSVPZSVOQ-NRFANRHFSA-N";465.58;2.96;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1117809/target=_blank>CHEMBL1117809</a>";;-5.33;"Reid M, Carlyle I, Caulfield WL, Clarkson TR, Cusick F, Epemolu O, Gilfillan R, Goodwin R, Jaap D, O'Donnell EC, Presland J, Rankovic Z, Spinks D, Spinks G, Thomson AM, Thomson F, Strain J, Wishart G.: The discovery and SAR of indoline-3-carboxamides--a new series of 5-HT6 antagonists. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.000004677351412871981
"MM473078";"MM473078";"NS(=O)(=O)c1ccc(Nc2nccc(-c3ccsc3)n2)cc1";"JUIXZPWSSOKEIF-UHFFFAOYSA-N";332.41;2.6;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120486/target=_blank>CHEMBL1120486</a>";;-4.41;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.000038904514499428046
"MM473079";"MM473079";"NS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccsc2CC3)cc1";"MTDWGYRUUAGIEQ-UHFFFAOYSA-N";358.45;2.69;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120486/target=_blank>CHEMBL1120486</a>";;-4.68;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.00002089296130854041
"MM473080";"MM473080";"CN(C)CCNS(=O)(=O)c1ccc(Nc2nccc(-c3ccsc3)n2)cc1";"AUZFWDQAVYWVTD-UHFFFAOYSA-N";403.53;2.79;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120486/target=_blank>CHEMBL1120486</a>";;-4.88;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.000013182567385564074
"MM473081";"MM473081";"CN(C)CCNS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccsc2CC3)cc1";"VOKVJALZAMIMIX-UHFFFAOYSA-N";429.57;2.89;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120486/target=_blank>CHEMBL1120486</a>";;-5.51;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.000003090295432513592
"Saquinavir";"MM00563";"CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(O)C(Cc1ccccc1)NC(=O)C(CC(N)=O)NC(=O)c1ccc2ccccc2n1";"QWAXKHKRTORLEM-UHFFFAOYSA-N";670.86;3.09;"441243";"CHEMBL114";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL944660/target=_blank>CHEMBL944660</a>";;-5.96;"Roche D, Greiner J, Aubertin AM, Vierling P.: Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors. Eur J Med Chem, Volume 43 (7), 2008";"CACO-2";0.000001096478196143185
"Prednisolone";"MM00297";"CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"OIGNJSKKLXVSLS-UHFFFAOYSA-N";360.45;1.56;"5755";"CHEMBL131";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL973473/target=_blank>CHEMBL973473</a>";;-4.7;"Ruiz JF, Radics G, Windle H, Serra HO, SimplĂ­cio AL, Kedziora K, Fallon PG, Kelleher DP, Gilmer JF.: Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease. J Med Chem, Volume 52 (10), 2009";"CACO-2";0.000019952623149688786
"MM475331";"MM475331";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-QFEUDJFPSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864081/target=_blank>CHEMBL864081</a>";;-5.46;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.000003467368504525317
"MM475331";"MM475331";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-QFEUDJFPSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864082/target=_blank>CHEMBL864082</a>";;-5.96;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.000001096478196143185
"MM475331";"MM475331";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-QFEUDJFPSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865286/target=_blank>CHEMBL865286</a>";;-6.23;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000005888436553555884
"MM475331";"MM475331";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-QFEUDJFPSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865287/target=_blank>CHEMBL865287</a>";;-6.05;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000008912509381337459
"MM30965";"MM30965";"COc1ccccc1CC(c1ccccc1)N1CCNCC1";"PFTJCYRHNKTTTO-UHFFFAOYSA-N";296.41;2.88;;"CHEMBL214335";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120627/target=_blank>CHEMBL1120627</a>";;-4.43;"Fray MJ, Fish PV, Allan GA, Bish G, Clarke N, Eccles R, Harrison AC, Le Net JL, Phillips SC, Regan N, Sobry C, Stobie A, Wakenhut F, Westbrook D, Westbrook SL, Whitlock GA.: Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.00003715352290971728
"MM475490";"MM475490";"COc1cccc(OC)c1CNC(=O)c1cc2cc(C[C@@H](C)NC[C@H](O)c3ccc(O)c(CO)c3)ccc2[nH]1";"WTBGOYCHEVMMHF-CLYVBNDRSA-N";533.63;3.57;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL899321/target=_blank>CHEMBL899321</a>";;-4.85;"Brown AD, Bunnage ME, Glossop PA, Holbrook M, Jones RD, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Webster R.: The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett, Volume 17 (22), 2007";"CACO-2";0.000014125375446227555
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050862/target=_blank>CHEMBL1050862</a>";;-5.92;"Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, Prast-Nielsen S, Jadhav A, Leister W, Shen M, Inglese J, Austin CP, Keefer L, ArnĂ©r ES, Simeonov A, Maloney DJ, Williams DL, Thomas CJ.: Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem, Volume 52 (20), 2009";"CACO-2";0.0000012022644346174132
"MM18934";"MM18934";"COc1cc2c(cc1OC)CN(CCCC1CCCc3cc(OC)c(OC)cc31)CC2";"ILEQWDOJJVJXBN-UHFFFAOYSA-N";425.57;4.98;"24945196";"CHEMBL259366";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.36;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.0004365158322401661
"MM19075";"MM19075";"COc1ccc2c(c1)CCCC2CCCN1CCc2cc(OC)c(OC)cc2C1";"HJBMLYTXOFQZDS-UHFFFAOYSA-N";395.54;4.97;"24945194";"CHEMBL259367";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.45;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.0003548133892335753
"MM18933";"MM18933";"COc1cc2c(cc1OC)CN(CCCC1CCCc3c(OC)cccc31)CC2";"HHPVCRYYLOFYGE-UHFFFAOYSA-N";395.54;4.97;"44451264";;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.98;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00010471285480508996
"MM19074";"MM19074";"COc1ccc2c(c1)CCC=C2CCCN1CCc2cc(OC)c(OC)cc2C1";"CIZNGVIPVFMLRQ-UHFFFAOYSA-N";393.53;4.88;"24945109";"CHEMBL260377";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.82;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00015135612484362088
"MM19071";"MM19071";"COc1ccc2c(c1)C(CCCN1CCc3cc(OC)c(OC)cc3C1)=CCC2";"NLSOIGZWHUMJEN-UHFFFAOYSA-N";393.53;4.88;"24945108";"CHEMBL260499";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.48;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.0003311311214825911
"MM475674";"MM475674";"COc1cc2c(cc1OC)CN(CC/C=C1\CCCc3c(OC)cccc31)CC2";"QBMVDXXIQASRIE-QGMBQPNBSA-N";393.53;4.88;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-4.41;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.000038904514499428046
"MM475674";"MM475674";"COc1cc2c(cc1OC)CN(CC/C=C1\CCCc3c(OC)cccc31)CC2";"QBMVDXXIQASRIE-QGMBQPNBSA-N";393.53;4.88;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL923494/target=_blank>CHEMBL923494</a>";;-4.41;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Paradiso A.: 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.000038904514499428046
"MM18932";"MM18932";"COc1cc2c(cc1OC)CN(CCCC1=CCCc3cc(OC)c(OC)cc31)CC2";"BVIGBAHRVHMUBL-UHFFFAOYSA-N";423.55;4.89;"24945110";"CHEMBL261802";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.99;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00010232929922807536
"MM475683";"MM475683";"COc1cccc2c1CCC/C2=C\CCN1CCCCC1";"OQZQEGAAANHHRE-CXUHLZMHSA-N";285.43;4.29;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.59;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.0002570395782768865
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1108562/target=_blank>CHEMBL1108562</a>";;-4.31;"Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT, Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein H, Zeng J, Wilks AF.: Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett, Volume 19 (20), 2009";"CACO-2";0.00004897788193684466
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050862/target=_blank>CHEMBL1050862</a>";;-4.76;"Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, Prast-Nielsen S, Jadhav A, Leister W, Shen M, Inglese J, Austin CP, Keefer L, ArnĂ©r ES, Simeonov A, Maloney DJ, Williams DL, Thomas CJ.: Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem, Volume 52 (20), 2009";"CACO-2";0.000017378008287493764
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967839/target=_blank>CHEMBL967839</a>";;-4.08;"Van Voorhis WC, Rivas KL, Bendale P, Nallan L, HornĂ©y C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.: Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother, Volume 51 (10), 2007";"CACO-2";0.00008317637711026709
"Cimetidine";"MM00463";"CNC(=NCCSCc1nc[nH]c1C)NC#N";"AQIXAKUUQRKLND-UHFFFAOYSA-N";252.35;0.6;"2756";"CHEMBL30";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1016135/target=_blank>CHEMBL1016135</a>";;-5.82;"Ettari R, Micale N, Schirmeister T, Gelhaus C, Leippe M, Nizi E, Di Francesco ME, Grasso S, ZappalĂ  M.: Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. J Med Chem, Volume 52 (7), 2009";"CACO-2";0.0000015135612484362072
"MM475821";"MM475821";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ADEWZYKOSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864081/target=_blank>CHEMBL864081</a>";;-5.52;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000030199517204020193
"MM475821";"MM475821";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ADEWZYKOSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864082/target=_blank>CHEMBL864082</a>";;-6.07;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000008511380382023759
"MM475821";"MM475821";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ADEWZYKOSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865286/target=_blank>CHEMBL865286</a>";;-6.15;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000007079457843841374
"MM475821";"MM475821";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ADEWZYKOSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865287/target=_blank>CHEMBL865287</a>";;-5.87;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000013489628825916533
"MM475826";"MM475826";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-SDPVFGLVSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864081/target=_blank>CHEMBL864081</a>";;-5.39;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.000004073802778041131
"MM475826";"MM475826";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-SDPVFGLVSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864082/target=_blank>CHEMBL864082</a>";;-5.92;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000012022644346174132
"MM475826";"MM475826";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-SDPVFGLVSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865286/target=_blank>CHEMBL865286</a>";;-5.48;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000033113112148259077
"MM475826";"MM475826";"CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-SDPVFGLVSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865287/target=_blank>CHEMBL865287</a>";;-5.85;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000014125375446227554
"MM472519";"MM472519";"c1ccc(Nc2ccccc2)cc1";"DMBHHRLKUKUOEG-UHFFFAOYSA-N";169.23;3.43;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905617/target=_blank>CHEMBL905617</a>";;-4.35;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"CACO-2";0.00004466835921509635
"MM472529";"MM472529";"CC(C)OP(=O)(OC(C)C)SCc1ccccc1";"FCOAHACKGGIURQ-UHFFFAOYSA-N";288.35;4.88;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905617/target=_blank>CHEMBL905617</a>";;-4.35;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"CACO-2";0.00004466835921509635
"Hesperetin";"MM00371";"COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O";"AIONOLUJZLIMTK-AWEZNQCLSA-N";302.28;2.52;"72281";"CHEMBL399121";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988138/target=_blank>CHEMBL988138</a>";;-4.57;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.00002691534803926914
"Chembl403441";"MM468380";"CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1";"CVFBVSUFNWOPLD-LJQANCHMSA-N";310.44;3.27;;"Chembl403441";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120627/target=_blank>CHEMBL1120627</a>";;-4.44;"Fray MJ, Fish PV, Allan GA, Bish G, Clarke N, Eccles R, Harrison AC, Le Net JL, Phillips SC, Regan N, Sobry C, Stobie A, Wakenhut F, Westbrook D, Westbrook SL, Whitlock GA.: Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett, Volume 20 (12), 2010";"CACO-2";0.0000363078054770101
"MM19072";"MM19072";"COc1ccc2c(c1)C(CCCN1CCc3cc(OC)c(OC)cc3C1)CCC2";"CRXITWCKFZMSFG-UHFFFAOYSA-N";395.54;4.97;"24945195";"CHEMBL405372";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.77;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00016982436524617443
"MM18929";"MM18929";"COc1cc2c(cc1OC)CN(CCC=C1CCCCC1)CC2";"NERQQHBBXMVPQY-UHFFFAOYSA-N";315.46;4.34;"44451249";"CHEMBL408993";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.62;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.000239883291901949
"MM18931";"MM18931";"COc1cc2c(cc1OC)CN(CCCC1=CCCc3c(OC)cccc31)CC2";"BKLBMMUVHQYDCN-UHFFFAOYSA-N";393.53;4.88;"24945105";"CHEMBL415560";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.94;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.0001148153621496883
"MM476012";"MM476012";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ULBASCLCSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864081/target=_blank>CHEMBL864081</a>";;-5.85;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000014125375446227554
"MM476012";"MM476012";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ULBASCLCSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL864082/target=_blank>CHEMBL864082</a>";;-5.88;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000013182567385564074
"MM476012";"MM476012";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ULBASCLCSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865286/target=_blank>CHEMBL865286</a>";;-6;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.000001
"MM476012";"MM476012";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)/C=C\c2ccccc2OCOC1=O";"CQTYKIZQGJDXFK-ULBASCLCSA-N";727.82;1.91;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865287/target=_blank>CHEMBL865287</a>";;-6.05;"Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.: Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J Med Chem, Volume 49 (4), 2006";"CACO-2";0.0000008912509381337459
"MM476055";"MM476055";"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCc1ccccc1/N=N/c1ccc(O)c(C(=O)O)c1";"ZTPJLOFUXLAVEN-VPPATSFHSA-N";656.73;5.56;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL973473/target=_blank>CHEMBL973473</a>";;-4.85;"Ruiz JF, Radics G, Windle H, Serra HO, SimplĂ­cio AL, Kedziora K, Fallon PG, Kelleher DP, Gilmer JF.: Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease. J Med Chem, Volume 52 (10), 2009";"CACO-2";0.000014125375446227555
"Dofetilide";"MM16908";"CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C";"IXTMWRCNAAVVAI-UHFFFAOYSA-N";441.58;1.98;"71329";;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889310/target=_blank>CHEMBL889310</a>";;-4.84;"Singleton DH, Boyd H, Steidl-Nichols JV, Deacon M, Groot MJ, Price D, Nettleton DO, Wallace NK, Troutman MD, Williams C, Boyd JG.: Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel. J Med Chem, Volume 50 (13), 2007";"CACO-2";0.00001445439770745928
"MM473730";"MM473730";"CCC(CC)[C@@H](CO)NS(=O)(=O)c1ccc(Cl)s1";"PYZFRRVBPNGCBX-SECBINFHSA-N";311.86;2.48;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL999316/target=_blank>CHEMBL999316</a>";;-4.37;"Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, Atchison K, Chlenov M, Cole DC, Comery T, Diamantidis G, Ellingboe J, Fan K, Galante R, Gonzales C, Ho DM, Hoke ME, Hu Y, Huryn D, Jain U, Jin M, Kremer K, Kubrak D, Lin M, Lu P, Magolda R, Martone R, Moore W, Oganesian A, Pangalos MN, Porte A, Reinhart P, Resnick L, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Wang T, Woller K, Xu Z, Zaleska MM, Zeldis J, Zhang M, Zhou H, Jacobsen JS.: Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem, Volume 51 (23), 2008";"CACO-2";0.00004265795188015926
"MM473730";"MM473730";"CCC(CC)[C@@H](CO)NS(=O)(=O)c1ccc(Cl)s1";"PYZFRRVBPNGCBX-SECBINFHSA-N";311.86;2.48;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111685/target=_blank>CHEMBL1111685</a>";;-4.38;"Kreft AF, Martone R, Porte A.: Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem, Volume 52 (20), 2009";"CACO-2";0.00004168693834703355
"1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine";"MM18286";"COc1cccc2c1CCCC2CCCN1CCN(C2CCCCC2)CC1";"PHRCDWVPTULQMT-UHFFFAOYSA-N";370.58;4.85;"10474335";"CHEMBL53325";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-3.36;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.0004365158322401661
"Nelfinavir";"MM00528";"Cc1c(O)cccc1C(=O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C";"QAGYKUNXZHXKMR-UHFFFAOYSA-N";567.8;4.75;"64143";"CHEMBL584";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL945669/target=_blank>CHEMBL945669</a>";;-5.6;"Roche D, Greiner J, Aubertin AM, Vierling P.: Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors. Eur J Med Chem, Volume 43 (7), 2008";"CACO-2";0.0000025118864315095823
"MM476380";"MM476380";"N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1";"MCIPSMFHIWYOIN-UHFFFAOYSA-N";425.49;3.78;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066154/target=_blank>CHEMBL1066154</a>";;-5.06;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.000008709635899560814
"MM473023";"MM473023";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl";"VYLVEERKOLDJOU-UHFFFAOYSA-N";451.95;4.59;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066154/target=_blank>CHEMBL1066154</a>";;-4.34;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.000045708818961487516
"MM473028";"MM473028";"COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC";"ULXYUIOTBNWJFH-UHFFFAOYSA-N";425.53;2.75;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066154/target=_blank>CHEMBL1066154</a>";;-4.54;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.000028840315031266056
"MM473025";"MM473025";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC";"RUVNTEGYLMYXCF-UHFFFAOYSA-N";459.55;3.87;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066154/target=_blank>CHEMBL1066154</a>";;-4.57;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.00002691534803926914
"MM473027";"MM473027";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC";"MMRPIWYTUYGTFQ-UHFFFAOYSA-N";447.54;3.95;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066154/target=_blank>CHEMBL1066154</a>";;-4.84;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.00001445439770745928
"MM473029";"MM473029";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC";"AOTJVGQNGQYEAY-UHFFFAOYSA-N";445.52;3.53;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066154/target=_blank>CHEMBL1066154</a>";;-5.27;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.000005370317963702533
"MM473024";"MM473024";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C";"ZHYPMHNQQRIWRP-UHFFFAOYSA-N";431.54;4.25;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066154/target=_blank>CHEMBL1066154</a>";;-4.51;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.00003090295432513592
"MM473026";"MM473026";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC";"OKHVXBABEFQOCR-UHFFFAOYSA-N";420.47;3.38;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066154/target=_blank>CHEMBL1066154</a>";;-4.79;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.0000162181009735893
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1108562/target=_blank>CHEMBL1108562</a>";;-5.96;"Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT, Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein H, Zeng J, Wilks AF.: Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett, Volume 19 (20), 2009";"CACO-2";0.000001096478196143185
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL921231/target=_blank>CHEMBL921231</a>";;-4.16;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Porcelli L, Paradiso A.: Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem, Volume 16 (1), 2008";"CACO-2";0.00006918309709189363
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL923494/target=_blank>CHEMBL923494</a>";;-4.16;"Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Paradiso A.: 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.00006918309709189363
"MM472953";"MM472953";"COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O";"MBNGWHIJMBWFHU-UHFFFAOYSA-N";300.27;2.59;;;"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988138/target=_blank>CHEMBL988138</a>";;-4.91;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.00001230268770812381
"Naringenin";"MM00673";"O=C1CC(c2ccc(O)cc2)Oc2cc(O)cc(O)c21";"FTVWIRXFELQLPI-UHFFFAOYSA-N";272.26;2.51;"932";"CHEMBL9352";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988138/target=_blank>CHEMBL988138</a>";;-4.29;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.00005128613839913648
"MM475221";"MM475221";"CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(c1ccc(C(=O)O)cn1)C[C@H]2c1ccc(C#N)cc1";"LILGMDXLRPEBNH-HFZDXXHNSA-N";536.38;4.4;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1117465/target=_blank>CHEMBL1117465</a>";;-4.83;"Watterson SH, Xiao Z, Dodd DS, Tortolani DR, Vaccaro W, Potin D, Launay M, Stetsko DK, Skala S, Davis PM, Lee D, Yang X, McIntyre KW, Balimane P, Patel K, Yang Z, Marathe P, Kadiyala P, Tebben AJ, Sheriff S, Chang CY, Ziemba T, Zhang H, Chen BC, DelMonte AJ, Aranibar N, McKinnon M, Barrish JC, Suchard SJ, Murali Dhar TG.: Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521). J Med Chem, Volume 53 (9), 2010";"CACO-2";0.000014791083881682072
"MM475854";"MM475854";"Cc1ccc(N2CCN(C(=O)[C@@H]3CN(C4CCOCC4)C[C@H]3c3ccc(Cl)cc3)CC2)c([C@@H](N)C(C)C)c1";"KHUSEOUYELGLMC-LXQNXJGFSA-N";539.16;4.85;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL899946/target=_blank>CHEMBL899946</a>";;-6.1;"Jiang W, Tran JA, Tucci FC, Fleck BA, Hoare SR, Markison S, Wen J, Chen CW, Marinkovic D, Arellano M, Foster AC, Chen C.: Synthesis and characterization of pyrrolidine derivatives as potent agonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett, Volume 17 (23), 2007";"CACO-2";0.0000007943282347242822
"MM476039";"MM476039";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCCNC(=O)N4C3)cc(-c3nccs3)nc2c1";"YPCUHGLLUJBXAN-NWQREVQSSA-N";694.84;3.51;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL943367/target=_blank>CHEMBL943367</a>";;-6.4;"Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, LindstrĂ¶m S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.: Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.0000003981071705534969
"MM476044";"MM476044";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCCNC(=O)N4C3)cc(-c3nc(C(C)C)cs3)nc2c1Cl";"NSICSOQWNRELKK-ZRLZNKEGSA-N";771.36;5.29;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL943367/target=_blank>CHEMBL943367</a>";;-4.66;"Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, LindstrĂ¶m S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.: Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.00002187761623949552
"MM476144";"MM476144";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CCCCCNC(=O)N4C3)cc(-c3nc(C(C)C)cs3)nc2c1Cl";"IHXGLDBKRROHDN-NBDVMRGUSA-N";785.39;5.68;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL943367/target=_blank>CHEMBL943367</a>";;-4.54;"Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, LindstrĂ¶m S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.: Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.000028840315031266056
"MM476175";"MM476175";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCNC(=O)N4C3)cc(-c3nc(C(C)C)cs3)nc2c1";"JCTLBSKLWYHRLE-WXEJIKOESA-N";722.89;4.25;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL943367/target=_blank>CHEMBL943367</a>";;-5.52;"Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, LindstrĂ¶m S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.: Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.0000030199517204020193
"MM476189";"MM476189";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCCNC(=O)N4C3)cc(-c3nc(C(C)C)cs3)nc2c1C";"FVXYEHGHAUPGHN-AHGLLTTDSA-N";750.94;4.94;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL943367/target=_blank>CHEMBL943367</a>";;-6.4;"Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, LindstrĂ¶m S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.: Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.0000003981071705534969
"MM476192";"MM476192";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CCCCCNC(=O)N4C3)cc(-c3nc(C(C)C)cs3)nc2c1";"TUCCGBYIAGIEQH-JQCZDYRQSA-N";750.94;5.03;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL943367/target=_blank>CHEMBL943367</a>";;-4.52;"Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, LindstrĂ¶m S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.: Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.000030199517204020192
"MM476193";"MM476193";"COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCCNC(=O)N4C3)cc(-c3nc(C(C)C)cs3)nc2c1";"FMBMILUSWDVMGF-XANICHIGSA-N";736.92;4.64;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL943367/target=_blank>CHEMBL943367</a>";;-5;"Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, LindstrĂ¶m S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.: Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.00001
"MM476279";"MM476279";"Cc1c(CC(=O)O)c2cccnc2n1S(=O)(=O)c1ccc(F)c(C#N)c1";"XRMUPVMLIVXXAW-UHFFFAOYSA-N";373.37;2.22;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1051064/target=_blank>CHEMBL1051064</a>";;-5.85;"Sandham DA, Adcock C, Bala K, Barker L, Brown Z, Dubois G, Budd D, Cox B, Fairhurst RA, Furegati M, Leblanc C, Manini J, Profit R, Reilly J, Stringer R, Schmidt A, Turner KL, Watson SJ, Willis J, Williams G, Wilson C.: 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.0000014125375446227554
"MM476379";"MM476379";"O=C(O)Cc1sc(C(c2ccccc2)c2ccccc2)nc1-c1ccc(Cl)cc1";"HIEUVNLETVQMHD-UHFFFAOYSA-N";419.93;6.27;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066576/target=_blank>CHEMBL1066576</a>";;-5.59;"Grimstrup M, Rist Ă�, Receveur JM, Frimurer TM, Ulven T, Mathiesen JM, Kostenis E, HĂ¶gberg T.: Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.0000025703957827688647
"MM471076";"MM471076";"CN(C)C1CCN(C(=O)c2ccc(Cn3c(-c4ccccc4)nc4ccccc43)cc2)C1";"UYKJSYAQDGARFD-UHFFFAOYSA-N";424.55;4.53;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066417/target=_blank>CHEMBL1066417</a>";;-4.07;"Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.: Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 20 (3), 2010";"CACO-2";0.0000851138038202376
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633575/target=_blank>CHEMBL633575</a>";;-5.59;"Ezra A, Hoffman A, Breuer E, Alferiev IS, MĂ¶nkkĂ¶nen J, El Hanany-Rozen N, Weiss G, Stepensky D, Gati I, Cohen H, TĂ¶rmĂ¤lehto S, Amidon GL, Golomb G.: A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem, Volume 43 (20), 2000";"CACO-2";0.0000025703957827688647
"Alendronate Sodium";"MM17162";"NCCCC(O)(P(=O)(O)O)P(=O)(O)O";"OGSPWJRAVKPPFI-UHFFFAOYSA-N";249.1;-1.27;;"CHEMBL870";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638029/target=_blank>CHEMBL638029</a>";;-6.22;"Ezra A, Hoffman A, Breuer E, Alferiev IS, MĂ¶nkkĂ¶nen J, El Hanany-Rozen N, Weiss G, Stepensky D, Gati I, Cohen H, TĂ¶rmĂ¤lehto S, Amidon GL, Golomb G.: A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem, Volume 43 (20), 2000";"CACO-2";0.0000006025595860743581
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638031/target=_blank>CHEMBL638031</a>";;-5.66;"Ezra A, Hoffman A, Breuer E, Alferiev IS, MĂ¶nkkĂ¶nen J, El Hanany-Rozen N, Weiss G, Stepensky D, Gati I, Cohen H, TĂ¶rmĂ¤lehto S, Amidon GL, Golomb G.: A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem, Volume 43 (20), 2000";"CACO-2";0.0000021877616239495517
"Alendronate Sodium";"MM17162";"NCCCC(O)(P(=O)(O)O)P(=O)(O)O";"OGSPWJRAVKPPFI-UHFFFAOYSA-N";249.1;-1.27;;"CHEMBL870";"CACO";"ECACO";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638031/target=_blank>CHEMBL638031</a>";;-6.22;"Ezra A, Hoffman A, Breuer E, Alferiev IS, MĂ¶nkkĂ¶nen J, El Hanany-Rozen N, Weiss G, Stepensky D, Gati I, Cohen H, TĂ¶rmĂ¤lehto S, Amidon GL, Golomb G.: A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem, Volume 43 (20), 2000";"CACO-2";0.0000006025595860743581
"MM475248";"MM475248";"C#CC[C@@H](C(=O)N[C@H](/C=C/C(=O)OC1CCC1)C[C@@H]1CCNC1=O)n1cccc(NC(=O)c2cc(C)on2)c1=O";"NAAPUTBPXQUAAW-ZBVVWYEHSA-N";549.58;1.62;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-4.85;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.000014125375446227555
"MM475249";"MM475249";"CC[C@@H](C(=O)N[C@H](/C=C/C(=O)OC1CCC1)C[C@@H]1CCNC1=O)n1cccc(NC(=O)c2cc(C)on2)c1=O";"FTLNYBZAZFDPEI-MYZOARMXSA-N";539.59;2.01;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-5;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.00001
"MM475250";"MM475250";"C#CC[C@@H](C(=O)N[C@H](/C=C/C(=O)OCc1ccccc1)C[C@@H]1CCNC1=O)n1cccc(NC(=O)c2cc(C)on2)c1=O";"OAMLXQDGOIMGAF-KRGVZGDRSA-N";585.62;2.27;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-4.74;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.000018197008586099827
"MM475251";"MM475251";"C#CC[C@@H](C(=O)N[C@H](/C=C/C(=O)OCC)C[C@@H]1CCNC1=O)n1cccc(NC(=O)c2cc(C)on2)c1=O";"QCUZOJBYWQPLIN-BNMFZAHFSA-N";523.55;1.09;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-5.22;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.000006025595860743581
"MM475252";"MM475252";"CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC)n1cccc(NC(=O)c2cc(C)on2)c1=O";"ULUGRMVVZIBKKS-IAQSFYBOSA-N";513.55;1.48;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-5.3;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.000005011872336272725
"MM475253";"MM475253";"C#CC[C@@H](C(=O)N[C@H](/C=C/C(=O)OC1CCCC1)C[C@@H]1CCNC1=O)n1cccc(NC(=O)c2cc(C)on2)c1=O";"GCPVVDXRFXFHGY-YIWALVRKSA-N";563.61;2.01;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-4.44;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.0000363078054770101
"MM475715";"MM475715";"Cc1cc(C(=O)Nc2cccn([C@@H](Cc3ccc(F)c(F)c3)C(=O)N[C@H](/C=C/C(=O)OC(C)C)C[C@@H]3CCNC3=O)c2=O)no1";"IDEQIHVMYCERBI-QNSPMPMTSA-N";625.63;2.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-4.44;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.0000363078054770101
"MM475716";"MM475716";"CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](Cc1ccc(F)c(F)c1)n1cccc(NC(=O)c2cc(C)on2)c1=O";"DMEUCWDOSVXQPQ-VVVXHSQNSA-N";611.6;2.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-4.46;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.00003467368504525317
"MM475757";"MM475757";"CC[C@@H](C(=O)N[C@H](/C=C/C(=O)OCc1ccccc1)C[C@@H]1CCNC1=O)n1cccc(NC(=O)c2cc(C)on2)c1=O";"JCRZIFCWUXJHSS-CKQBFUQQSA-N";575.62;2.66;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655612/target=_blank>CHEMBL655612</a>";;-4.96;"Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW, Ferre RA.: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem, Volume 46 (21), 2003";"CACO-2";0.000010964781961431852
"MM475310";"MM475310";"COc1ccc(Cn2ccc(C)c(NC(=O)[C@@H](Cc3ccc(C(C)(C)C(=O)O)cc3)NC(=O)C(C)(C)c3ccc4ccccc4c3)c2=O)cc1";"OGCLKLYODLMLLI-UUWRZZSWSA-N";673.81;6.37;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638027/target=_blank>CHEMBL638027</a>";;-5.17;"Proudfoot JR, Betageri R, Cardozo M, Gilmore TA, Glynn S, Hickey ER, Jakes S, Kabcenell A, Kirrane TM, Tibolla AK, Lukas S, Patel UR, Sharma R, Yazdanian M, Moss N, Beaulieu PL, Cameron DR, Ferland JM, Gauthier J, Gillard J, Gorys V, Poirier M, Rancourt J, Wernic D, Llinas-Brunet M.: Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain. J Med Chem, Volume 44 (15), 2001";"CACO-2";0.000006760829753919819
"MM475731";"MM475731";"COc1ccc(Cn2cccc(NC(=O)C(Cc3ccc(CC(=O)O)cc3)NC(=O)Cc3cccc4ccccc34)c2=O)cc1";"OQQWRJKCOLLXFK-UHFFFAOYSA-N";603.68;4.59;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638027/target=_blank>CHEMBL638027</a>";;-6.35;"Proudfoot JR, Betageri R, Cardozo M, Gilmore TA, Glynn S, Hickey ER, Jakes S, Kabcenell A, Kirrane TM, Tibolla AK, Lukas S, Patel UR, Sharma R, Yazdanian M, Moss N, Beaulieu PL, Cameron DR, Ferland JM, Gauthier J, Gillard J, Gorys V, Poirier M, Rancourt J, Wernic D, Llinas-Brunet M.: Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain. J Med Chem, Volume 44 (15), 2001";"CACO-2";0.0000004466835921509635
"MM476414";"MM476414";"COc1ccc(Cn2ccc(C)c(NC(=O)C(Cc3ccc(CC(=O)O)cc3)NC(C)=O)c2=O)cc1";"XBYUDNSCEDCXFW-UHFFFAOYSA-N";491.54;2.53;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634343/target=_blank>CHEMBL634343</a>";;-7;"Proudfoot JR, Betageri R, Cardozo M, Gilmore TA, Glynn S, Hickey ER, Jakes S, Kabcenell A, Kirrane TM, Tibolla AK, Lukas S, Patel UR, Sharma R, Yazdanian M, Moss N, Beaulieu PL, Cameron DR, Ferland JM, Gauthier J, Gillard J, Gorys V, Poirier M, Rancourt J, Wernic D, Llinas-Brunet M.: Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain. J Med Chem, Volume 44 (15), 2001";"CACO-2";0.0000001
"MM476416";"MM476416";"COc1ccc(Cn2ccc(C)c(NC(=O)C(Cc3ccc(C(C)(C)C(=O)O)cc3)NC(=O)C(C)(C)c3cccc4ccccc34)c2=O)cc1";"CYMQEBFIUQXEOJ-UHFFFAOYSA-N";673.81;6.37;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634343/target=_blank>CHEMBL634343</a>";;-5.21;"Proudfoot JR, Betageri R, Cardozo M, Gilmore TA, Glynn S, Hickey ER, Jakes S, Kabcenell A, Kirrane TM, Tibolla AK, Lukas S, Patel UR, Sharma R, Yazdanian M, Moss N, Beaulieu PL, Cameron DR, Ferland JM, Gauthier J, Gillard J, Gorys V, Poirier M, Rancourt J, Wernic D, Llinas-Brunet M.: Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain. J Med Chem, Volume 44 (15), 2001";"CACO-2";0.000006165950018614822
"MM475267";"MM475267";"O=S(=O)(O)c1ccc(Cn2cnc3ccccc32)cc1";"ANPWOYMDYYBWCC-UHFFFAOYSA-N";288.33;2.33;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619361/target=_blank>CHEMBL619361</a>";;-7.1;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00000007943282347242822
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-4.04;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.00009120108393559096
"MM470952";"MM470952";"CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21";"HDOVUKNUBWVHOX-QMMMGPOBSA-N";324.34;-0.8;;"CHEMBL1349";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-5.64;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.0000022908676527677747
"Digoxin";"MM00357";"CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O";"LTMHDMANZUZIPE-UHFFFAOYSA-N";780.95;2.22;"2724385";"CHEMBL1751";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-5.89;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.000001288249551693135
"5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol";"MM00306";"CC(C)(C)NCC(O)c1cc(O)cc(O)c1";"XWTYSIMOBUGWOL-UHFFFAOYSA-N";225.29;1.52;"5403";"CHEMBL1760";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-6.64;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.00000022908676527677748
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-6;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.000001
"Sulpiride";"MM00568";"CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC";"BGRJTUBHPOOWDU-UHFFFAOYSA-N";341.43;0.56;"5355";"CHEMBL26";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-6.68;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.00000020892961308540409
"Alprenolol";"MM00440";"C=CCc1ccccc1OC[C@H](O)CNC(C)C";"PAZJSJFMUHDSTF-CQSZACIVSA-N";249.35;2.15;"2119";"CHEMBL266195";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-3.62;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.000239883291901949
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-3.69;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.00020417379446695296
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-3.67;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.00021379620895022324
"Cimetidine";"MM00463";"CNC(=NCCSCc1nc[nH]c1C)NC#N";"AQIXAKUUQRKLND-UHFFFAOYSA-N";252.35;0.6;"2756";"CHEMBL30";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-6.17;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.0000006760829753919819
"Methotrexate";"MM00270";"CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1";"FBOZXECLQNJBKD-UHFFFAOYSA-N";454.45;0.27;"126941";"CHEMBL34259";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-7.52;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.000000030199517204020194
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-4.26;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.00005495408738576248
"Alfentanil";"MM00439";"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1";"IDBPHNDTYPBSNI-UHFFFAOYSA-N";416.53;1.38;"51263";"CHEMBL634";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851910/target=_blank>CHEMBL851910</a>";;-3.57;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.00026915348039269167
"Nadolol";"MM00525";"CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2";"VWPOSFSPZNDTMJ-UHFFFAOYSA-N";309.41;0.63;"39147";"CHEMBL649";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-6.55;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.0000002818382931264455
"2-amino-3-methyl-4H-imidazol-5-one";"MM00348";"CN1CC(=O)N=C1N";"DDRJAANPRJIHGJ-UHFFFAOYSA-N";113.12;-1.23;"588";"CHEMBL65567";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-5.92;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.0000012022644346174132
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-6.72;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.00000019054607179632483
"Metolazone";"MM00390";"Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C";"AQCHWTWZEMGIFD-UHFFFAOYSA-N";365.84;2.71;"4170";"CHEMBL878";"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851908/target=_blank>CHEMBL851908</a>";;-5.37;"Matsson P, BergstrĂ¶m CA, Nagahara N, Tavelin S, Norinder U, Artursson P.: Exploring the role of different drug transport routes in permeability screening. J Med Chem, Volume 48 (2), 2005";"CACO-2";0.000004265795188015926
"MM475593";"MM475593";"Cc1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CNC[C@@H]2C(=O)NO)cc1";"CHOIXTQDKMNYCU-FUHWJXTLSA-N";393.45;1.22;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000001
"MM475594";"MM475594";"CC(C)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CNC[C@@H]2C(=O)NO)cc1";"UCCRPMLKYDMJAV-PKOBYXMFSA-N";421.5;2.03;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000001
"MM475599";"MM475599";"O=C(N[C@@H]1CCC[C@@H]1C(=O)NO)c1ccc(Cn2c(C3CC3)nc3ccccc32)cc1";"FXFZIKOEGYQWSD-RBUKOAKNSA-N";418.5;3.37;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-5.7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000019952623149688787
"MM475600";"MM475600";"C#CCN1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(Cn3c(C(C)C)nc4ccccc43)cc2)C1";"BYIUYAJXVDVGFA-RBBKRZOGSA-N";459.55;2.38;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000001
"MM475601";"MM475601";"C#CCN1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(Cn3c(C(C)(C)C)nc4ccccc43)cc2)C1";"UVQRQVBDZDEEBU-RBBKRZOGSA-N";473.58;2.55;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-6.4;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000003981071705534969
"MM475602";"MM475602";"O=C(N[C@@H]1C[C@@]2(CCCO2)C[C@@H]1C(=O)NO)c1ccc(Cn2c(C3CC3)nc3ccccc32)cc1";"OHKVFVLOLOFCQJ-ZVUIFXONSA-N";474.56;3.53;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000001
"MM475603";"MM475603";"CC(C)(F)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2C[C@@]3(CCCO3)C[C@@H]2C(=O)NO)cc1";"BEHWVPRIGLRXIG-LPOPLRKUSA-N";494.57;3.85;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-5.62;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000023988329190194897
"MM475607";"MM475607";"CC(C)(F)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CCOC[C@@H]2C(=O)NO)cc1";"NYOFYADPNAWQIO-ZWKOTPCHSA-N";454.5;2.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-6.52;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000003019951720402019
"MM475608";"MM475608";"CC(F)(F)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CCOC[C@@H]2C(=O)NO)cc1";"QCELJPBZUJYPIW-DLBZAZTESA-N";458.47;2.84;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-6.15;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000007079457843841374
"MM475610";"MM475610";"O=C(N[C@@H]1CCOC[C@@H]1C(=O)NO)c1ccc(Cn2c(C(F)(F)F)nc3ccccc32)cc1";"PGVYYPZKXKGBLD-JKSUJKDBSA-N";462.43;2.74;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-6.15;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000007079457843841374
"MM475611";"MM475611";"O=C(N[C@@H]1COC[C@@H]1C(=O)NO)c1ccc(Cn2c(C(F)(F)F)nc3ccccc32)cc1";"JADBDFQEPJQPBJ-GOEBONIOSA-N";448.4;2.35;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000001
"MM475618";"MM475618";"CSc1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CNC[C@@H]2C(=O)NO)cc1";"XUGIQJJECDDGBH-DOTOQJQBSA-N";425.51;1.63;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-6.7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.00000019952623149688787
"MM475946";"MM475946";"CSc1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CN(C(=O)OC(C)(C)C)C[C@@H]2C(=O)NO)cc1";"SDNMPMDMJTYOAW-AZUAARDMSA-N";525.63;3.28;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-6.7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.00000019952623149688787
"MM475951";"MM475951";"Cc1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CN(C(=O)OC(C)(C)C)C[C@@H]2C(=O)NO)cc1";"WMWPLQAXVKBJIC-PZJWPPBQSA-N";493.56;2.86;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000001
"MM475959";"MM475959";"CC(C)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CCOC[C@@H]2C(=O)NO)cc1";"IYGKJIOIZXNZOC-RBUKOAKNSA-N";436.51;2.85;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-6.3;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000005011872336272725
"MM475964";"MM475964";"CC(C)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2C[C@@]3(CCCO3)C[C@@H]2C(=O)NO)cc1";"JFELXNYVJCRVPT-ZVUIFXONSA-N";476.58;3.77;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000001
"MM475966";"MM475966";"CC(C)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CCC[C@@H]2C(=O)NO)cc1";"XNUPVUIWOKTWNU-RBUKOAKNSA-N";420.51;3.61;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000001
"MM476020";"MM476020";"CC(C)(C)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2C[C@@]3(CCCO3)C[C@@H]2C(=O)NO)cc1";"HTUGJHMFYMFUPL-IKCVQBBRSA-N";490.6;3.95;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-5.85;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.0000014125375446227554
"MM476056";"MM476056";"CC(C)c1nc2ccccc2n1Cc1ccc(C(=O)N[C@@H]2CN(C(=O)OC(C)(C)C)C[C@@H]2C(=O)NO)cc1";"HWRTYSUSQVJAGF-RBBKRZOGSA-N";521.62;3.68;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946128/target=_blank>CHEMBL946128</a>";;-6.7;"Ott GR, Asakawa N, Lu Z, Anand R, Liu RQ, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Duan JJ.: Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett, Volume 18 (5), 2008";"CACO-2";0.00000019952623149688787
"MM475409";"MM475409";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NC2CCN(CC3CCOCC3)CC2)CCCC1)c1cc2ccccc2s1";"MQKZHYSKRHHYHY-GDLZYMKVSA-N";616.83;4.68;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.07;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.00000851138038202376
"MM475520";"MM475520";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCCC(=O)N2CCN(CC3CCOCC3)CC2)CCCC1)c1cc2ccccc2s1";"RFCWJFHIOFRISZ-SSEXGKCCSA-N";673.88;3.75;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.57;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.0000026915348039269138
"MM475521";"MM475521";"CN1CCN(C(=O)CCNC(=O)[C@@H](Cc2ccccc2)NC(=O)C2(NC(=O)c3cc4ccccc4s3)CCCC2)CC1";"DRZJIWHMRQXGEA-RUZDIDTESA-N";589.76;2.95;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.7;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.0000019952623149688787
"MM475527";"MM475527";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1)c1cc2ccccc2s1";"WSOXGASXRKLXAB-SSEXGKCCSA-N";630.86;4.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.19;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000006456542290346549
"MM475528";"MM475528";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCCC2CCN(CC3CCOCC3)CC2)CCCC1)c1cc2ccccc2s1";"OCWATCTYAJGRBW-WJOKGBTCSA-N";644.88;5.32;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.41;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000003890451449942805
"MM475529";"MM475529";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(C3CCOCC3)CC2)CCCC1)c1cc2ccccc2s1";"QBTIOECDQQPIDD-GDLZYMKVSA-N";616.83;4.68;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.8;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000001584893192461114
"MM475535";"MM475535";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1)c1cc2ccc(Br)cc2s1";"GXMJPZKEIQCJRX-SSEXGKCCSA-N";709.75;5.69;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-6.1;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.0000007943282347242822
"MM475536";"MM475536";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCCCN2CCOCC2)CCCC1)c1cc2cc(Cl)ccc2s1";"DVEZRJMAJLAJHO-RUZDIDTESA-N";597.18;4.16;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.23;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000005888436553555884
"MM475686";"MM475686";"Cc1ccc2cc(C(=O)NC3(C(=O)N[C@H](Cc4ccccc4)C(=O)NCC4CCN(CC5CCOCC5)CC4)CCCC3)sc2c1";"YQYSVMKCMIUCHY-WJOKGBTCSA-N";644.88;5.23;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.29;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000005128613839913648
"MM475886";"MM475886";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCCCN2CCOCC2)CCCC1)c1sc2ccccc2c1Cl";"VNAHOPJAVRNAKH-XMMPIXPASA-N";597.18;4.16;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-4.82;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000015135612484362071
"MM475887";"MM475887";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCCC(=O)N2CCN(C3CCOCC3)CC2)CCCC1)c1cc2ccccc2s1";"ASOICHOYACLMGC-GDLZYMKVSA-N";659.85;3.5;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.89;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000001288249551693135
"MM475895";"MM475895";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1)c1cc2ccc(F)cc2s1";"HSUKCVLLCGNDMB-SSEXGKCCSA-N";648.85;5.07;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-6.52;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.0000003019951720402019
"MM475896";"MM475896";"O=C(NC1(C(=O)N[C@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1)c1cc2ccc(C(F)(F)F)cc2s1";"APGKRIOUNGEFML-SSEXGKCCSA-N";698.85;5.95;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.19;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000006456542290346549
"MM475897";"MM475897";"COc1ccc2cc(C(=O)NC3(C(=O)N[C@H](Cc4ccccc4)C(=O)NCC4CCN(CC5CCOCC5)CC4)CCCC3)sc2c1";"VSZDNTDZDVKZQL-WJOKGBTCSA-N";660.88;4.93;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5.96;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.000001096478196143185
"MM475898";"MM475898";"CCN(CC)c1ccc2cc(C(=O)NC3(C(=O)N[C@H](Cc4ccccc4)C(=O)NCC4CCN(CC5CCOCC5)CC4)CCCC3)sc2c1";"XASFNZQMINANHS-UUWRZZSWSA-N";701.98;5.77;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895362/target=_blank>CHEMBL895362</a>";;-5;"Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, Nannicini R, Pasqui F, Tramontana M, Triolo A, Maggi CA.: Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem, Volume 50 (20), 2007";"CACO-2";0.00001
"MM475513";"MM475513";"CCCCCCCCCCC(N)C(=O)NC(CCCCCCCCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"OFDHYNAAFGPKGC-QSFUJLIQSA-N";727;5.9;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.51;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.000003090295432513592
"MM475514";"MM475514";"CCCCCCCCCCC(NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"GZXFUPAPUZOJGI-LMOFDZDWSA-N";529.68;2.89;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.33;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.000004677351412871981
"MM475516";"MM475516";"CCCCCCCCC(N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"KEJZGUPEPIHGEE-GFUWAVFVSA-N";501.63;2.11;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.81;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.0000015488166189124828
"MM475517";"MM475517";"CCCCCCCCCCC(N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"AEEKVRMUNAQUGF-BCXZNTRWSA-N";529.68;2.89;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.03;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.000009332543007969906
"MM475688";"MM475688";"CCCCCCCCCCCCC(N)C(=O)NC(CCCCCCCCCCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"BDYDKWJZUKOHAF-MHHLJKJHSA-N";783.11;7.46;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.56;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.000002754228703338169
"MM475866";"MM475866";"CCCCCCCCCCCCC(N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"QYBFUSDXWPHDEF-HUASTKEASA-N";557.74;3.67;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.99;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.0000010232929922807537
"MM475880";"MM475880";"CCCCCCC(N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"PROGFIIVHZJZAO-MFUMQWNRSA-N";473.57;1.33;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.31;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.000004897788193684467
"MM475978";"MM475978";"NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCC(=O)O";"SPXMJXWAOMWMKR-AAEUAGOBSA-N";332.36;-0.13;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.11;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.00000776247116628691
"MM476019";"MM476019";"CCCCCCCCC(N)C(=O)NC(CCCCCCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"WKASDGWAADWFRL-NDJVGUIGSA-N";670.9;4.34;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.75;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.000001778279410038923
"MM476023";"MM476023";"CCCCCCC(NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"WOWYTGIFFYBMBC-SPFPWHRZSA-N";473.57;1.33;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.42;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.000003801893963205613
"MM476027";"MM476027";"CCCCCCC(N)C(=O)NC(CCCCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"KYEWSRJSGDYDNJ-JCRMAMAHSA-N";614.79;2.78;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.08;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.00000831763771102671
"MM476031";"MM476031";"CCCCCCCCC(NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O";"CRZZUGFLFJSFTP-LLLPINGXSA-N";501.63;2.11;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL925032/target=_blank>CHEMBL925032</a>";;-5.4;"Bergeon JA, Toth I.: Enhancement of oral drug absorption-effect of lipid conjugation on the enzymatic stability and intestinal permeability of l-Glu-l-Trp-NH(2). Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.000003981071705534969
"MM475230";"MM475230";"O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1-c1cccs1";"IAXBEEZQRRFFDT-UHFFFAOYSA-N";451.78;6.15;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-4.68;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.00002089296130854041
"MM475233";"MM475233";"O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(F)nc1C(F)(F)F";"UNFFMUXRKGUXDB-UHFFFAOYSA-N";421.19;4.92;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-4.72;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.000019054607179632484
"MM475234";"MM475234";"Cc1nc(Cl)ncc1C(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1";"VORNGVYSIPQDMN-UHFFFAOYSA-N";383.68;4.73;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-4.21;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.00006165950018614822
"MM475679";"MM475679";"CCCc1nc(Cl)ncc1C(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1";"DDFXQPHXKWGYEZ-UHFFFAOYSA-N";411.73;5.37;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-4.51;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.00003090295432513592
"MM475743";"MM475743";"O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1C(F)(F)F";"GHMKQBWHPQMXSH-UHFFFAOYSA-N";437.65;5.44;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-4.96;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.000010964781961431852
"MM475746";"MM475746";"O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1";"HYVDSMGJEYQZQA-UHFFFAOYSA-N";369.65;4.42;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-4.21;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.00006165950018614822
"MM475748";"MM475748";"CCc1nc(Cl)ncc1C(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1";"ODRMXBSDOYWKNE-UHFFFAOYSA-N";397.71;4.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-4.24;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.000057543993733715664
"MM475749";"MM475749";"O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1Cl";"KHEXXENPPWDAHU-UHFFFAOYSA-N";404.1;5.07;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-4.51;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.00003090295432513592
"MM475982";"MM475982";"O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1C(F)(F)C(F)(F)F";"XYMYOQHYWDKQLT-UHFFFAOYSA-N";487.66;6.07;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-5.05;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.00000891250938133746
"MM475986";"MM475986";"O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cnc(Cl)nc1-c1ccccc1";"BFANKIPRJRXYSS-UHFFFAOYSA-N";445.75;6.09;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633578/target=_blank>CHEMBL633578</a>";;-5.05;"Palanki MS, Erdman PE, Gayo-Fung LM, Shevlin GI, Sullivan RW, Goldman ME, Ransone LJ, Bennett BL, Manning AM, Suto MJ.: Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. J Med Chem, Volume 43 (21), 2000";"CACO-2";0.00000891250938133746
"MM475412";"MM475412";"CN(C)CCCN(c1ccncc1)c1ccc(-c2ccc3c(C(N)=O)nn(-c4ccc5onc(N)c5c4)c3c2F)c(F)c1";"BSOGETFZKSQMJK-UHFFFAOYSA-N";582.62;5.28;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926655/target=_blank>CHEMBL926655</a>";;-5.26;"Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.: 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem, Volume 51 (2), 2008";"CACO-2";0.0000054954087385762485
"MM475596";"MM475596";"CN(C)Cc1ccccc1-c1ccc(-c2ccc3c(C(N)=O)nn(-c4ccc5onc(N)c5c4)c3c2F)c(F)c1";"QNAZSARXQYTHPS-UHFFFAOYSA-N";538.56;5.52;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926655/target=_blank>CHEMBL926655</a>";;-5.42;"Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.: 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem, Volume 51 (2), 2008";"CACO-2";0.000003801893963205613
"MM475622";"MM475622";"NC(=O)c1nn(-c2ccc3onc(N)c3c2)c2c(F)c(-c3ccc(N4CCCCC4=O)cc3F)ccc12";"SSQLZVKKFYFNKQ-UHFFFAOYSA-N";502.48;4.31;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926655/target=_blank>CHEMBL926655</a>";;-5.52;"Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.: 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem, Volume 51 (2), 2008";"CACO-2";0.0000030199517204020193
"MM475625";"MM475625";"CN(C)Cc1cnccc1-c1ccc(-c2ccc3c(C(N)=O)nn(-c4ccc5onc(N)c5c4)c3c2F)c(F)c1";"MAQKQDYMLDYTKU-UHFFFAOYSA-N";539.55;4.92;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926655/target=_blank>CHEMBL926655</a>";;-5.17;"Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.: 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem, Volume 51 (2), 2008";"CACO-2";0.000006760829753919819
"MM475626";"MM475626";"CN(C)Cc1ncccc1-c1ccc(-c2ccc3c(C(N)=O)nn(-c4ccc5onc(N)c5c4)c3c2F)c(F)c1";"FFFFWKNRTFCAMK-UHFFFAOYSA-N";539.55;4.92;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926655/target=_blank>CHEMBL926655</a>";;-5.98;"Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.: 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem, Volume 51 (2), 2008";"CACO-2";0.0000010471285480508985
"MM475916";"MM475916";"CN(C)Cc1nccn1-c1ccc(-c2ccc3c(C(N)=O)nn(-c4ccc5onc(N)c5c4)c3c2F)c(F)c1";"MGUDDBRJHXFTEY-UHFFFAOYSA-N";528.52;4.04;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926655/target=_blank>CHEMBL926655</a>";;-5.69;"Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.: 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem, Volume 51 (2), 2008";"CACO-2";0.0000020417379446695273
"MM475917";"MM475917";"CN(C)Cc1[nH]ncc1-c1ccc(-c2ccc3c(C(N)=O)nn(-c4ccc5onc(N)c5c4)c3c2F)c(F)c1";"WSQATAJBAWYABP-UHFFFAOYSA-N";528.52;4.24;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926655/target=_blank>CHEMBL926655</a>";;-5.96;"Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.: 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem, Volume 51 (2), 2008";"CACO-2";0.000001096478196143185
"MM475928";"MM475928";"CN(c1ccncc1)c1ccc(-c2ccc3c(C(N)=O)nn(-c4ccc5onc(N)c5c4)c3c2F)c(F)c1";"BWRIUUBREKWKOF-UHFFFAOYSA-N";511.49;4.96;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926655/target=_blank>CHEMBL926655</a>";;-5.85;"Lee YK, Parks DJ, Lu T, Thieu TV, Markotan T, Pan W, McComsey DF, Milkiewicz KL, Crysler CS, Ninan N, Abad MC, Giardino EC, Maryanoff BE, Damiano BP, Player MR.: 7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem, Volume 51 (2), 2008";"CACO-2";0.0000014125375446227554
"MM475223";"MM475223";"O=C1C(Cl)=C(Nc2ccc(CCO)cc2)C(=O)c2cnccc21";"UBCDSJULIZVLAL-UHFFFAOYSA-N";328.76;2.56;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL917818/target=_blank>CHEMBL917818</a>";;-4.75;"Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY.: Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.00001778279410038923
"MM475224";"MM475224";"COc1ccc(NC2=C(Cl)C(=O)c3ccncc3C2=O)cc1";"DMRNLJKRCVCUHO-UHFFFAOYSA-N";314.73;3.03;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL917818/target=_blank>CHEMBL917818</a>";;-4.66;"Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY.: Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.00002187761623949552
"MM475415";"MM475415";"CCOC(=O)c1ccc2nc3c(nc2c1)C(=O)c1ccncc1C3=O";"IZYPZKYGEDPCKN-UHFFFAOYSA-N";333.3;1.98;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL917818/target=_blank>CHEMBL917818</a>";;-4.8;"Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY.: Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.00001584893192461114
"MM475416";"MM475416";"O=C1C(Cl)=C(Nc2ccc(OC(F)(F)F)cc2)C(=O)c2cnccc21";"WHGKVPAIVGFKQP-UHFFFAOYSA-N";368.7;3.92;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL917818/target=_blank>CHEMBL917818</a>";;-5.65;"Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY.: Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.0000022387211385683376
"MM475417";"MM475417";"O=C1C(Cl)=C(Nc2cccc(F)c2)C(=O)c2cnccc21";"DAAPVSWVGCLXCW-UHFFFAOYSA-N";302.69;3.16;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL917818/target=_blank>CHEMBL917818</a>";;-6.21;"Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY.: Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.0000006165950018614822
"MM475418";"MM475418";"O=C1C(Cl)=C(Nc2cccc(O)c2)C(=O)c2cnccc21";"UQTWBBWLPDUQEO-UHFFFAOYSA-N";300.7;2.73;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL917818/target=_blank>CHEMBL917818</a>";;-4.45;"Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY.: Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.000035481338923357534
"MM475419";"MM475419";"CC(C)c1ccc2nc3c(nc2c1)C(=O)c1ccncc1C3=O";"KWVPCUSAWJOPEE-UHFFFAOYSA-N";303.32;2.92;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL917818/target=_blank>CHEMBL917818</a>";;-4.98;"Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY.: Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.000010471285480508985
"MM475800";"MM475800";"O=C1c2cnccc2C(=O)c2nc3cc(CCO)ccc3nc21";"NONRLXFZTQKVFE-UHFFFAOYSA-N";305.29;1.34;;;"CACO";"ECACO";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL917818/target=_blank>CHEMBL917818</a>";;-4.69;"Kim JS, Rhee HK, Park HJ, Lee IK, Lee SK, Suh ME, Lee HJ, Ryu CK, Choo HY.: Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity. Bioorg Med Chem, Volume 15 (1), 2007";"CACO-2";0.000020417379446695274
"Doramapimod";"MM470891";"CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5";"MVCOAUNKQVWQHZ-UHFFFAOYSA-N";527.67;5.99;"156422";;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927883/target=_blank>CHEMBL927883</a>";;-5;"Cogan DA, Aungst R, Breinlinger EC, Fadra T, Goldberg DR, Hao MH, Kroe R, Moss N, Pargellis C, Qian KC, Swinamer AD.: Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.00001
"MM475120";"MM475120";"O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl";"GFMMXOIFOQCCGU-UHFFFAOYSA-N";478.66;5.04;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963135/target=_blank>CHEMBL963135</a>";;-4.79;"Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA, Smith Y, Warmus JS, Tecle H.: The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett, Volume 18 (24), 2008";"CACO-2";0.0000162181009735893
"MM475121";"MM475121";"COC(=O)c1c(O)cccc1OCCCCNC(=O)[C@H](Cc1ccc(OCC(=O)O)cc1)NC(=O)OC(C)(C)C";"IKOXRHVKSOJWLA-FQEVSTJZSA-N";560.6;3.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655615/target=_blank>CHEMBL655615</a>";;-5;"Xin Z, Liu G, Abad-Zapatero C, Pei Z, Szczepankiewicz BG, Li X, Zhang T, Hutchins CW, Hajduk PJ, Ballaron SJ, Stashko MA, Lubben TH, Trevillyan JM, Jirousek MR.: Identification of a monoacid-based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett, Volume 13 (22), 2003";"CACO-2";0.00001
"MM475128";"MM475128";"O=c1[nH]c2cc(-c3ccncn3)c(-c3ccco3)nc2[nH]1";"MKVQVZUHJKLKRR-UHFFFAOYSA-N";279.26;1.97;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-4.4;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.000039810717055349695
"MM475130";"MM475130";"O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccoc3)n4C3CCCCC3)CCCC2)cc1";"OOLQOYHCEMONID-XNTDXEJSSA-N";566.66;6.58;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100111/target=_blank>CHEMBL1100111</a>";;-5.41;"Beaulieu PL, Dansereau N, Duan J, Garneau M, Gillard J, McKercher G, LaPlante S, LagacĂ©e L, Thauvette L, Kukolj G.: Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series. Bioorg Med Chem Lett, Volume 20 (6), 2010";"CACO-2";0.000003890451449942805
"MM475131";"MM475131";"O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccccn3)n4C3CCCCC3)CCCC2)cc1";"KLAOJPFJEJJZAC-QGOAFFKASA-N";577.69;6.38;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100111/target=_blank>CHEMBL1100111</a>";;-5.02;"Beaulieu PL, Dansereau N, Duan J, Garneau M, Gillard J, McKercher G, LaPlante S, LagacĂ©e L, Thauvette L, Kukolj G.: Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series. Bioorg Med Chem Lett, Volume 20 (6), 2010";"CACO-2";0.000009549925860214369
"MM475136";"MM475136";"C[C@H](Nc1nc(C(=O)N2CCCC2)c2sccc2n1)c1cccnc1";"YSTPWPWIXDYZLT-LBPRGKRZSA-N";353.45;3.5;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1105836/target=_blank>CHEMBL1105836</a>";;-4.48;"Bedford ST, Benwell KR, Brooks T, Chen I, Comer M, Dugdale S, Haymes T, Jordan AM, Kennett GA, Knight AR, Klenke B, LeStrat L, Merrett A, Misra A, Lightowler S, Padfield A, Poullennec K, Reece M, Simmonite H, Wong M, Yule IA.: Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor. Bioorg Med Chem Lett, Volume 19 (20), 2009";"CACO-2";0.000033113112148259076
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619358/target=_blank>CHEMBL619358</a>";;-4.64;"Mandagere AK, Thompson TN, Hwang KK.: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem, Volume 45 (2), 2002";"CACO-2";0.00002290867652767775
"MM475137";"MM475137";"c1coc(-c2nc3[nH]cnc3cc2-c2ccncn2)c1";"NDRMSISLKTZBKD-UHFFFAOYSA-N";263.26;2.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-4.64;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.00002290867652767775
"MM475138";"MM475138";"Cc1cc2[nH]ncc2cc1NC(=O)c1cc(N(CC2CC2)C2CCCCC2)ncn1";"YYDJCLCSBYCSCO-UHFFFAOYSA-N";404.52;4.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1101572/target=_blank>CHEMBL1101572</a>";;-7;"Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, FranĂ§on B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF.: Discovery of a novel series of potent S1P1 agonists. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.0000001
"MM475139";"MM475139";"O=c1[nH][nH]c2nc(-c3ccco3)c(-c3ccncn3)cc12";"ODIWALRZUVNYHC-UHFFFAOYSA-N";279.26;1.97;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-5.46;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.000003467368504525317
"MM475140";"MM475140";"c1coc(-c2nc3[nH]ccc3cc2-c2ccncn2)c1";"SDUHCRWJXFZMQH-UHFFFAOYSA-N";262.27;3.28;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-4.4;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.000039810717055349695
"MM475141";"MM475141";"O=c1[nH]c(=O)c2cc(-c3ccncn3)c(-c3ccco3)nc2[nH]1";"VYTAHRSDFGGCON-UHFFFAOYSA-N";307.27;1.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-4.7;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.000019952623149688786
"MM475142";"MM475142";"CCCN(CC1CC1)c1cc(C(=O)Nc2ccc3[nH]ncc3c2)ncn1";"HAKUBDUVAGUCGC-UHFFFAOYSA-N";350.43;3.23;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1101572/target=_blank>CHEMBL1101572</a>";;-5.07;"Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, FranĂ§on B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF.: Discovery of a novel series of potent S1P1 agonists. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.00000851138038202376
"MM475143";"MM475143";"CCCN(CCC)c1cc(C(=O)Nc2ccc(O)cc2)ncn1";"UWKRVWBQFLKJHP-UHFFFAOYSA-N";314.39;3.06;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1101572/target=_blank>CHEMBL1101572</a>";;-4.67;"Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, FranĂ§on B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF.: Discovery of a novel series of potent S1P1 agonists. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.000021379620895022323
"MM475144";"MM475144";"Cc1cc(O)ccc1NC(=O)c1cc(NC2CCCCC2)ncn1";"BGHQPXFERWTACA-UHFFFAOYSA-N";326.4;3.49;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1101572/target=_blank>CHEMBL1101572</a>";;-4.66;"Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, FranĂ§on B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF.: Discovery of a novel series of potent S1P1 agonists. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.00002187761623949552
"MM475145";"MM475145";"Cn1c(=O)[nH]c2nc(-c3ccco3)c(-c3ccncn3)cc21";"OWBPIGOKYQPEBA-UHFFFAOYSA-N";293.29;1.98;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-4.49;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.00003235936569296281
"MM475146";"MM475146";"O=C(Nc1ccc(-c2ccncn2)c(-c2ccco2)n1)C1CC1";"QLBNYHQORUEQJE-UHFFFAOYSA-N";306.33;3.15;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-4.35;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.00004466835921509635
"Amoxicillin";"MM00716";"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O";"LSQZJLSUYDQPKJ-NJBDSQKTSA-N";365.41;0.02;"33613";"CHEMBL1082";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-6.1;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.0000007943282347242822
"MM475147";"MM475147";"Nc1n[nH]c2nc(-c3ccco3)c(-c3ccncn3)cc12";"CUIYZPCLAYEKMZ-UHFFFAOYSA-N";278.28;2.26;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-4.62;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.0000239883291901949
"MM475148";"MM475148";"c1coc(-c2nc3[nH]ncc3cc2-c2ccncn2)c1";"FUZVDFCUPYVIEA-UHFFFAOYSA-N";263.26;2.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1100692/target=_blank>CHEMBL1100692</a>";;-4.41;"Eastwood P, Gonzalez J, Paredes S, Fonquerna S, CardĂşs A, Alonso JA, Nueda A, Domenech T, Reinoso RF, Vidal B.: Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.000038904514499428046
"MM475151";"MM475151";"Cc1cc(S(=O)(=O)NCCC(=O)O)ccc1NC(=O)c1cc(N(CC2CC2)C2CCCCC2)ncn1";"GZZVZWYVRPVSBJ-UHFFFAOYSA-N";515.64;3.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1101572/target=_blank>CHEMBL1101572</a>";;-5.7;"Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, FranĂ§on B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF.: Discovery of a novel series of potent S1P1 agonists. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.0000019952623149688787
"MM475164";"MM475164";"Cc1cc(CN2CC(C(=O)O)C2)ccc1NC(=O)c1cc(N(CC2CC2)C2CCCCC2)ncn1";"PSYRPGKNBHSBJV-UHFFFAOYSA-N";477.61;4.1;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1101572/target=_blank>CHEMBL1101572</a>";;-5.62;"Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, FranĂ§on B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF.: Discovery of a novel series of potent S1P1 agonists. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.0000023988329190194897
"MM475193";"MM475193";"Cc1cc(S(N)(=O)=O)ccc1NC(=O)c1cc(NC2CCCCC2)ncn1";"UUZYCNGFSOOOSO-UHFFFAOYSA-N";389.48;2.43;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1101572/target=_blank>CHEMBL1101572</a>";;-4.9;"Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, FranĂ§on B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF.: Discovery of a novel series of potent S1P1 agonists. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.000012589254117941661
"MM475200";"MM475200";"O=C(O)CCNCc1ccc(NC(=O)c2cc(N(CC3CC3)C3CCCCC3)ncn2)cc1";"ORHOSJNREFXVLJ-UHFFFAOYSA-N";451.57;3.84;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1101572/target=_blank>CHEMBL1101572</a>";;-6.1;"Crosignani S, Bombrun A, Covini D, Maio M, Marin D, Quattropani A, Swinnen D, Simpson D, Sauer W, FranĂ§on B, Martin T, Cambet Y, Nichols A, Martinou I, Burgat-Charvillon F, Rivron D, Donini C, Schott O, Eligert V, Novo-Perez L, Vitte PA, Arrighi JF.: Discovery of a novel series of potent S1P1 agonists. Bioorg Med Chem Lett, Volume 20 (5), 2010";"CACO-2";0.0000007943282347242822
"MM475205";"MM475205";"CCN1CCC(N(C(=O)NCc2ccc(F)cc2)c2ccc(Cl)cn2)CC1";"HVPUGUKUEQHDMX-UHFFFAOYSA-N";390.89;4.07;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1107886/target=_blank>CHEMBL1107886</a>";;-5.14;"Berlin M, Lee YJ, Boyce CW, Wang Y, Aslanian R, McCormick KD, Sorota S, Williams SM, West RE, Korfmacher W.: Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists. Bioorg Med Chem Lett, Volume 20 (7), 2010";"CACO-2";0.000007244359600749906
"MM475206";"MM475206";"O=C(NCc1ccccc1)N(c1ccc(Br)cc1)C1CCN(Cc2ccnnc2)CC1";"OLGOESKHTHMVLF-UHFFFAOYSA-N";480.41;4.62;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1107886/target=_blank>CHEMBL1107886</a>";;-4.57;"Berlin M, Lee YJ, Boyce CW, Wang Y, Aslanian R, McCormick KD, Sorota S, Williams SM, West RE, Korfmacher W.: Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists. Bioorg Med Chem Lett, Volume 20 (7), 2010";"CACO-2";0.00002691534803926914
"MM475207";"MM475207";"CC(=O)N1CCCC1(Cc1ccc(S(C)(=O)=O)cc1)C(=O)OCc1ccccc1";"XFXZWVGQXNFWDE-UHFFFAOYSA-N";415.51;2.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1105306/target=_blank>CHEMBL1105306</a>";;-4.51;"PĂ©gurier C, Bosman N, Collart P, Delporte ML, Leclercq K, LengelĂ© S, Kanduluru AK, Meunier S, Pacico N, Vadali LR, Wagner A, Wolff C, Provins L.: Benzyl prolinate derivatives as novel selective KCC2 blockers. Bioorg Med Chem Lett, Volume 20 (8), 2010";"CACO-2";0.00003090295432513592
"MM475209";"MM475209";"CCOc1ccc(Cc2cc([C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2C)cc1";"WHSOLWOTCHFFBK-ZQGJOIPISA-N";434.55;2.22;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1109859/target=_blank>CHEMBL1109859</a>";;-4.84;"Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, Arai M, Kawakita Y, Fukasawa Y, Iida I, Hagima N, Takeuchi H, Chino Y, Asami J, Okumura-Kitajima L, Io F, Yamamoto D, Miyata N, Takahashi T, Uchida S, Yamamoto K.: (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem, Volume 53 (8), 2010";"CACO-2";0.00001445439770745928
"MM475210";"MM475210";"O=C(NCc1ccc(F)cc1)N(c1ccc(Br)cc1)C1CCN(C2CCCC2)CC1";"WHBCDNPPOUFKAB-UHFFFAOYSA-N";474.42;5.71;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1107886/target=_blank>CHEMBL1107886</a>";;-4.94;"Berlin M, Lee YJ, Boyce CW, Wang Y, Aslanian R, McCormick KD, Sorota S, Williams SM, West RE, Korfmacher W.: Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists. Bioorg Med Chem Lett, Volume 20 (7), 2010";"CACO-2";0.000011481536214968817
"MM475220";"MM475220";"Cn1nc(C(=O)O)c2c1-c1nc(Nc3ccccc3)ncc1CC2";"ZOBRPBVIEUWYJR-UHFFFAOYSA-N";321.34;2.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1109147/target=_blank>CHEMBL1109147</a>";;-5.57;"Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, Cappella P, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cristiani C, Croci V, De Ponti A, Fachin G, Ferguson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P, Volpi D, Valsasina B.: Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. J Med Chem, Volume 53 (9), 2010";"CACO-2";0.0000026915348039269138
"MM475222";"MM475222";"FC(F)(F)c1cc(COCC(c2ccccc2)N2CCNCC2)cc(C(F)(F)F)c1";"BUBWRIVYXMCTAG-UHFFFAOYSA-N";432.41;4.89;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656466/target=_blank>CHEMBL656466</a>";;-5.68;"Genicot C, Christophe B, Collart P, Gillard M, Goossens L, HĂ©nichart JP, Lassoie MA, Moureau F, Neuwels M, Nicolas JM, Pasau P, QuĂ©rĂ© L, Ryckmans T, Stiernet F, Taverne T, Van Keulen BJ.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg Med Chem Lett, Volume 13 (3), 2003";"CACO-2";0.0000020892961308540407
"Imipramine";"MM00504";"CN(C)CCCN1c2ccccc2CCc2ccccc21";"BCGWQEUPMDMJNV-UHFFFAOYSA-N";280.42;3.88;"3696";"CHEMBL11";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638187/target=_blank>CHEMBL638187</a>";;-5.3;"Wohnsland F, Faller B.: High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem, Volume 44 (6), 2001";"CACO-2";0.000005011872336272725
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-4.41;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000038904514499428046
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655617/target=_blank>CHEMBL655617</a>";;-4.36;"Palanki MS, Erdman PE, Ren M, Suto M, Bennett BL, Manning A, Ransone L, Spooner C, Desai S, Ow A, Totsuka R, Tsao P, Toriumi W.: The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies. Bioorg Med Chem Lett, Volume 13 (22), 2003";"CACO-2";0.000043651583224016566
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015280/target=_blank>CHEMBL1015280</a>";;-4.57;"Ettari R, Micale N, Schirmeister T, Gelhaus C, Leippe M, Nizi E, Di Francesco ME, Grasso S, ZappalĂ  M.: Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. J Med Chem, Volume 52 (7), 2009";"CACO-2";0.00002691534803926914
"MM475225";"MM475225";"CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1";"KXNPVXPOPUZYGB-IOVMHBDKSA-N";508.65;0.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656468/target=_blank>CHEMBL656468</a>";;-6.52;"10.1016/S0960-894X(00)80064-5";"CACO-2";0.0000003019951720402019
"Diazepam";"MM00094";"CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21";"AAOVKJBEBIDNHE-UHFFFAOYSA-N";284.75;3.15;"3016";"CHEMBL12";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-3.92;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00012022644346174131
"Diazepam";"MM00094";"CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21";"AAOVKJBEBIDNHE-UHFFFAOYSA-N";284.75;3.15;"3016";"CHEMBL12";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-3.12;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0007585775750291836
"Alanine";"MM475229";"CC(N)C(=O)O";"QNAYBMKLOCPYGJ-UHFFFAOYSA-N";89.09;-0.58;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-5.42;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000003801893963205613
"MM475231";"MM475231";"c1cc(OCCCN2CCCCC2)ccc1CN1CCCCC1";"PTKHFRNHJULJKT-UHFFFAOYSA-N";316.49;3.93;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638030/target=_blank>CHEMBL638030</a>";;-5.63;"Apodaca R, Dvorak CA, Xiao W, Barbier AJ, Boggs JD, Wilson SJ, Lovenberg TW, Carruthers NI.: A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. J Med Chem, Volume 46 (18), 2003";"CACO-2";0.0000023442288153199226
"MM475232";"MM475232";"COc1cccc2nc(-c3cccs3)nc(NN3C(=O)C=C(C)C3=O)c12";"GZGLPBNOIFLLRE-UHFFFAOYSA-N";366.4;3.01;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655617/target=_blank>CHEMBL655617</a>";;-4.85;"Palanki MS, Erdman PE, Ren M, Suto M, Bennett BL, Manning A, Ransone L, Spooner C, Desai S, Ow A, Totsuka R, Tsao P, Toriumi W.: The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies. Bioorg Med Chem Lett, Volume 13 (22), 2003";"CACO-2";0.000014125375446227555
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-4.19;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00006456542290346549
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-4.04;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00009120108393559096
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619358/target=_blank>CHEMBL619358</a>";;-4.57;"Mandagere AK, Thompson TN, Hwang KK.: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem, Volume 45 (2), 2002";"CACO-2";0.00002691534803926914
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL840608/target=_blank>CHEMBL840608</a>";;-4.74;"Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.: In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem, Volume 48 (3), 2005";"CACO-2";0.000018197008586099827
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-4.04;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.00009120108393559096
"MM475235";"MM475235";"COc1cccc2nc(C(F)(F)F)nc(NN3C(=O)C=C(C)C3=O)c12";"QUNDTWAVFFGEKW-UHFFFAOYSA-N";352.27;2.3;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655617/target=_blank>CHEMBL655617</a>";;-5.83;"Palanki MS, Erdman PE, Ren M, Suto M, Bennett BL, Manning A, Ransone L, Spooner C, Desai S, Ow A, Totsuka R, Tsao P, Toriumi W.: The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies. Bioorg Med Chem Lett, Volume 13 (22), 2003";"CACO-2";0.000001479108388168207
"MM475236";"MM475236";"Cc1cc(C(=O)Nc2ccc(-c3ccccc3S(N)(=O)=O)cc2)n(-c2cccc(CN)c2)n1";"RPHPZHQLDZECGT-UHFFFAOYSA-N";461.55;3.21;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635761/target=_blank>CHEMBL635761</a>";;-6.7;"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 44 (4), 2001";"CACO-2";0.00000019952623149688787
"MM475237";"MM475237";"Cc1cc(COc2ccc(NC(=O)[C@@H]3[C@@H](C(=O)NO)CCCN3C)cc2)c2ccccc2n1";"RJSKOAOWDAMMHR-GMAHTHKFSA-N";448.52;3.28;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-5.68;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.0000020892961308540407
"MM475239";"MM475239";"O=C(O)CN1CCN(C(COCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ccccc2)CC1";"KHANBRBFKNNRSS-UHFFFAOYSA-N";490.44;4.68;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656466/target=_blank>CHEMBL656466</a>";;-5.02;"Genicot C, Christophe B, Collart P, Gillard M, Goossens L, HĂ©nichart JP, Lassoie MA, Moureau F, Neuwels M, Nicolas JM, Pasau P, QuĂ©rĂ© L, Ryckmans T, Stiernet F, Taverne T, Van Keulen BJ.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg Med Chem Lett, Volume 13 (3), 2003";"CACO-2";0.000009549925860214369
"MM475240";"MM475240";"Cc1cc(COc2ccc(NC(=O)[C@H]3CCN(C(=O)NC(C)(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"ZNCOVHFRMJEGMK-ZEQRLZLVSA-N";533.63;4.01;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-6.15;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.0000007079457843841374
"MM475241";"MM475241";"Cc1cc(COc2ccc(NC(=O)[C@H]3CN(C)CC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"XXYKPFAJBJFQQP-VXKWHMMOSA-N";448.52;3.13;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-7;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.0000001
"MM475242";"MM475242";"Cc1cc(COc2ccc(NC(=O)[C@H]3CCN(C(=O)OC4CC4)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"DQLBBYKDXWLUIC-ZEQRLZLVSA-N";518.57;3.8;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-6.7;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.00000019952623149688787
"MM475243";"MM475243";"Cc1cc(COc2ccc(NC(=O)[C@H]3CCN(C(=O)C(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"QOGHJMHAONXOFF-ZEQRLZLVSA-N";504.59;3.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-6.52;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.0000003019951720402019
"MM475244";"MM475244";"C[C@H](OC[C@H](c1ccccc1)N1CCN(CCOCC(=O)O)CC1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1";"VONJODYKTRPIQC-FDDCHVKYSA-N";548.52;5.26;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656466/target=_blank>CHEMBL656466</a>";;-5.06;"Genicot C, Christophe B, Collart P, Gillard M, Goossens L, HĂ©nichart JP, Lassoie MA, Moureau F, Neuwels M, Nicolas JM, Pasau P, QuĂ©rĂ© L, Ryckmans T, Stiernet F, Taverne T, Van Keulen BJ.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg Med Chem Lett, Volume 13 (3), 2003";"CACO-2";0.000008709635899560814
"MM475245";"MM475245";"O=C(O)COCCN1CCN(C(COCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ccccc2)CC1";"ZOXBUIMAXBOWFJ-UHFFFAOYSA-N";534.5;4.7;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656466/target=_blank>CHEMBL656466</a>";;-5.38;"Genicot C, Christophe B, Collart P, Gillard M, Goossens L, HĂ©nichart JP, Lassoie MA, Moureau F, Neuwels M, Nicolas JM, Pasau P, QuĂ©rĂ© L, Ryckmans T, Stiernet F, Taverne T, Van Keulen BJ.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg Med Chem Lett, Volume 13 (3), 2003";"CACO-2";0.000004168693834703355
"MM475246";"MM475246";"NC(=O)CN1CCN([C@@H](COCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ccccc2)CC1";"SQNYJTSIWKBHBD-FQEVSTJZSA-N";489.46;4.09;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656466/target=_blank>CHEMBL656466</a>";;-5.1;"Genicot C, Christophe B, Collart P, Gillard M, Goossens L, HĂ©nichart JP, Lassoie MA, Moureau F, Neuwels M, Nicolas JM, Pasau P, QuĂ©rĂ© L, Ryckmans T, Stiernet F, Taverne T, Van Keulen BJ.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg Med Chem Lett, Volume 13 (3), 2003";"CACO-2";0.000007943282347242822
"MM475247";"MM475247";"COc1ccc(-n2nc(C)cc2C(=O)Nc2ccc(-c3ccccc3S(N)(=O)=O)cc2)cc1";"VHPMRGRQOUULNW-UHFFFAOYSA-N";462.53;3.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638021/target=_blank>CHEMBL638021</a>";;-4.29;"Pruitt JR, Pinto DJ, Galemmo RA, Alexander RS, Rossi KA, Wells BL, Drummond S, Bostrom LL, Burdick D, Bruckner R, Chen H, Smallwood A, Wong PC, Wright MR, Bai S, Luettgen JM, Knabb RM, Lam PY, Wexler RR.: Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1). J Med Chem, Volume 46 (25), 2003";"CACO-2";0.00005128613839913648
"MM475254";"MM475254";"c1ccc(Cn2ccnc2)cc1";"KKKDZZRICRFGSD-UHFFFAOYSA-N";158.2;1.93;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.17;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00006760829753919819
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619358/target=_blank>CHEMBL619358</a>";;-4.42;"Mandagere AK, Thompson TN, Hwang KK.: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem, Volume 45 (2), 2002";"CACO-2";0.000038018939632056124
"MM475255";"MM475255";"COc1ccc(-n2nc(C)cc2C(=O)Nc2ccc(-c3ccccc3S(N)(=O)=O)cn2)cc1";"GIBFSRBTDFHVKQ-UHFFFAOYSA-N";463.52;3.15;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638021/target=_blank>CHEMBL638021</a>";;-5.96;"Pruitt JR, Pinto DJ, Galemmo RA, Alexander RS, Rossi KA, Wells BL, Drummond S, Bostrom LL, Burdick D, Bruckner R, Chen H, Smallwood A, Wong PC, Wright MR, Bai S, Luettgen JM, Knabb RM, Lam PY, Wexler RR.: Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1). J Med Chem, Volume 46 (25), 2003";"CACO-2";0.000001096478196143185
"MM475256";"MM475256";"NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1";"XNSAINXGIQZQOO-SRVKXCTJSA-N";362.39;-1.81;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898108/target=_blank>CHEMBL898108</a>";;-6.83;"Wessling ST, Ross BP, Koda Y, Blanchfield JT, Toth I.: Caco-2 cell permeability and stability of two d-glucopyranuronamide conjugates of thyrotropin-releasing hormone. Bioorg Med Chem, Volume 15 (14), 2007";"CACO-2";0.0000001479108388168207
"MM475257";"MM475257";"CCC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1";"BPENFEPYBVXUII-UHFFFAOYSA-N";280.37;1.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-5.22;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.000006025595860743581
"MM475258";"MM475258";"O=C(NCCNCC(O)COc1ccc(CCOCCOCC2CC2)cc1)N1CCC(O)CC1";"IWACLEHDBMHXHC-UHFFFAOYSA-N";479.62;1.17;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-6.98;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.00000010471285480508985
"MM475259";"MM475259";"NCc1ccccc1-n1nc(C(F)(F)F)cc1C(=O)Nc1ccc(-c2ccccc2S(N)(=O)=O)cc1F";"TYPXEIGMGZWOGB-UHFFFAOYSA-N";533.51;4.06;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638021/target=_blank>CHEMBL638021</a>";;-5.19;"Pruitt JR, Pinto DJ, Galemmo RA, Alexander RS, Rossi KA, Wells BL, Drummond S, Bostrom LL, Burdick D, Bruckner R, Chen H, Smallwood A, Wong PC, Wright MR, Bai S, Luettgen JM, Knabb RM, Lam PY, Wexler RR.: Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1). J Med Chem, Volume 46 (25), 2003";"CACO-2";0.000006456542290346549
"MM475260";"MM475260";"CC(C)NCC(O)COc1ccc(NC=O)cc1";"XRTJUQUBUGUQLA-UHFFFAOYSA-N";252.31;0.99;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-5.43;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.0000037153522909717276
"MM475261";"MM475261";"CS(=O)(=O)c1ccccc1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2cccc(CN)c2)cc1";"KYWBDNUTAGEEDQ-UHFFFAOYSA-N";514.53;4.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635761/target=_blank>CHEMBL635761</a>";;-5.47;"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 44 (4), 2001";"CACO-2";0.0000033884415613920275
"MM475262";"MM475262";"Cc1cc(C(=O)Nc2ccc(-c3ccccc3S(N)(=O)=O)cc2F)n(-c2cccc(CN)c2)n1";"KELNLWXVDRBKCA-UHFFFAOYSA-N";479.54;3.35;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635761/target=_blank>CHEMBL635761</a>";;-6.02;"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 44 (4), 2001";"CACO-2";0.0000009549925860214369
"MM475263";"MM475263";"NCc1cccc(-n2nc(C(F)(F)F)cc2C(=O)Nc2ccc(-c3ccccc3S(N)(=O)=O)cc2F)c1";"NMOZOQNFWYWZQF-UHFFFAOYSA-N";533.51;4.06;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635761/target=_blank>CHEMBL635761</a>";;-6.04;"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 44 (4), 2001";"CACO-2";0.0000009120108393559096
"MM475264";"MM475264";"Cc1cc(C(=O)Nc2ccc(-c3ccccc3S(C)(=O)=O)cc2)n(-c2cccc(CN)c2)n1";"WJIPVTTXLNWLTQ-UHFFFAOYSA-N";460.56;3.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635761/target=_blank>CHEMBL635761</a>";;-5.92;"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 44 (4), 2001";"CACO-2";0.0000012022644346174132
"MM475265";"MM475265";"Nc1nccc2cc(CC(NC(=O)CNS(=O)(=O)c3ccc4ccccc4c3)C(=O)N3CCCCC3)ccc12";"JNGWPAXVXOJMED-UHFFFAOYSA-N";545.67;2.99;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655613/target=_blank>CHEMBL655613</a>";;-5.72;"Rewinkel JB, Lucas H, van Galen PJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (5), 1999";"CACO-2";0.0000019054607179632483
"MM474359";"MM474359";"CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1";"VAAUVRVFOQPIGI-SPQHTLEESA-N";554.59;-1.2;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-6.88;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.00000013182567385564074
"MM475268";"MM475268";"NC(=O)c1cccc(Cc2ncccn2)c1";"VBVDJAQIFQGHBP-UHFFFAOYSA-N";213.24;1.17;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.46;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00003467368504525317
"MM475269";"MM475269";"O=C(O)c1ccc(Cn2cccn2)cc1";"ZHQQRHUITAFMTC-UHFFFAOYSA-N";202.21;1.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-5.44;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.0000036307805477010103
"MM475270";"MM475270";"N#Cc1cccc(Cn2cccn2)c1";"XBYBAGJXNBFJON-UHFFFAOYSA-N";183.21;1.8;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.14;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00007244359600749906
"MM475272";"MM475272";"N#Cc1cccc(Cc2ncccn2)c1";"ORUUEUDAGDOAFE-UHFFFAOYSA-N";195.23;1.94;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.18;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00006606934480075965
"MM475273";"MM475273";"NC(=O)c1cccc(Cn2cccn2)c1";"ASCGVLMPDBVQPU-UHFFFAOYSA-N";201.23;1.03;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.35;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00004466835921509635
"MM475275";"MM475275";"O=C(O)c1ccc(Cc2ncccn2)cc1";"MRWQACAGQLPROF-UHFFFAOYSA-N";214.22;1.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-5.27;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.000005370317963702533
"MM475276";"MM475276";"Nc1cccc(Cn2cnc3ccccc32)c1";"PBCMAQMJRXLGTE-UHFFFAOYSA-N";223.28;2.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.24;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.000057543993733715664
"MM475277";"MM475277";"CS(=O)(=O)Nc1cccc(Cn2cnc3ccccc32)c1";"QJFBALZHOBBCPS-UHFFFAOYSA-N";301.37;2.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.63;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00002344228815319923
"MM475278";"MM475278";"N#Cc1cccc(Cn2ccnc2)c1";"BTCQQQUDIZILEJ-UHFFFAOYSA-N";183.21;1.8;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.17;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00006760829753919819
"MM475279";"MM475279";"N#Cc1cccc(Cn2cnc3ccccc32)c1";"LXWMENDLAGLVFJ-UHFFFAOYSA-N";233.27;2.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.18;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00006606934480075965
"MM475280";"MM475280";"O=C(O)c1cccc(Cn2cccn2)c1";"UMYNAPRDOSIHOY-UHFFFAOYSA-N";202.21;1.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-5.53;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.000002951209226666384
"MM475281";"MM475281";"O=C(O)Cc1ccc(Cn2ccnc2)cc1";"IAPNYZNTJQNQJK-UHFFFAOYSA-N";216.24;1.56;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-6.15;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.0000007079457843841374
"MM475282";"MM475282";"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12";"LUJZZYWHBDHDQX-QFIPXVFZSA-N";530.56;3.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052837/target=_blank>CHEMBL1052837</a>";;-4.67;"Gavai AV, Fink BE, Fairfax DJ, Martin GS, Rossiter LM, Holst CL, Kim SH, Leavitt KJ, Mastalerz H, Han WC, Norris D, Goyal B, Swaminathan S, Patel B, Mathur A, Vyas DM, Tokarski JS, Yu C, Oppenheimer S, Zhang H, Marathe P, Fargnoli J, Lee FY, Wong TW, Vite GD.: Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J Med Chem, Volume 52 (21), 2009";"CACO-2";0.000021379620895022323
"MM475283";"MM475283";"CCC(C)[C@H](NC(=O)[C@@H](C[C@H](O)[C@H](CC1CCCCC1)NC(=O)OC(C)(C)C)C(C)C)C(=O)NCc1ccccn1";"SHXBHHDCBHQKLF-ISYMSECWSA-N";574.81;5.12;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633586/target=_blank>CHEMBL633586</a>";;-4.73;"10.1016/S0960-894X(00)80673-3";"CACO-2";0.000018620871366628657
"MM475284";"MM475284";"CC[C@H](C)[C@H](NC(=O)[C@@H](C[C@H](O)[C@H](CC1CCCCC1)NC(C)=O)C(C)C)C(=O)NCc1ccccn1";"KXAMGWBBXZAXQR-KKASSDGMSA-N";516.73;3.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633586/target=_blank>CHEMBL633586</a>";;-5.92;"10.1016/S0960-894X(00)80673-3";"CACO-2";0.0000012022644346174132
"MM475285";"MM475285";"COc1cccc(-n2c(=O)n(Cc3ccccc3C#N)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F";"BZOJHIQSCLXVAL-FQEVSTJZSA-N";487.49;1.93;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851904/target=_blank>CHEMBL851904</a>";;-4.59;"Guo Z, Wu D, Zhu YF, Tucci FC, Regan CF, Rowbottom MW, Struthers RS, Xie Q, Reijmers S, Sullivan SK, Sai Y, Chen C.: Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists. Bioorg Med Chem Lett, Volume 15 (16), 2005";"CACO-2";0.000025703957827688645
"MM475286";"MM475286";"Cc1nccn1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)c(F)c1";"NSBCPJHADHWACD-UHFFFAOYSA-N";485.4;4.5;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-5.13;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.000007413102413009177
"MM475287";"MM475287";"COc1ccc2ccc(S(=O)(=O)NC(Cc3ccc4ccnc(N)c4c3)C(=O)N3CCC(C)CC3)cc2c1";"IEUYOUGDJWEGKK-UHFFFAOYSA-N";532.67;4.13;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-5.28;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.000005248074602497723
"MM475288";"MM475288";"CS(=O)(=O)c1ccccc1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2cccc(CN)c2)c(F)c1";"ZLUOAFAJSUPHOG-UHFFFAOYSA-N";532.52;4.81;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL885807/target=_blank>CHEMBL885807</a>";;-5.32;"Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.00000478630092322638
"MM475289";"MM475289";"CCc1nccn1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)c(F)c1";"PNEWMVVHZXAPHB-UHFFFAOYSA-N";499.43;4.75;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-5.48;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.0000033113112148259077
"MM475291";"MM475291";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Nc3ccc(-n4ccnc4CN4CCCC4)cc3F)cc12";"GONSXYIFCYXXJP-UHFFFAOYSA-N";554.51;4.79;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-4.64;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.00002290867652767775
"MM475292";"MM475292";"COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F";"CJUWBZDJMYYRDG-QFIPXVFZSA-N";495.5;4.16;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1008937/target=_blank>CHEMBL1008937</a>";;-4.75;"Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS.: Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem, Volume 51 (23), 2008";"CACO-2";0.00001778279410038923
"MM475293";"MM475293";"Cn1ccnc1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)c(F)c1";"JBAZPOYGAUQDAO-UHFFFAOYSA-N";485.4;4.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-5.33;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.000004677351412871981
"MM475294";"MM475294";"Cc1cc(COc2ccc(S(=O)(=O)CC3CN(C(C)C)CCC3C(=O)NO)cc2)c2ccccc2n1";"RLQDDFZTFKMONF-UHFFFAOYSA-N";511.64;3.75;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000001
"MM475295";"MM475295";"C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(OCc2ccccc2)c1";"NOUCOYNKCVTYDV-CLOONOSVSA-N";494.61;4.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838212/target=_blank>CHEMBL838212</a>";;-5.17;"Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S, Oue M, Tsujiuchi H, Furutani Y, Kato S.: Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. Bioorg Med Chem Lett, Volume 15 (4), 2005";"CACO-2";0.000006760829753919819
"MM475296";"MM475296";"C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NC(=O)c2ccccc2)c1";"WYTFAQBIDABWBM-KOSHJBKYSA-N";507.61;4.01;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825373/target=_blank>CHEMBL825373</a>";;-6.05;"Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S, Oue M, Tsujiuchi H, Furutani Y, Kato S.: Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. Bioorg Med Chem Lett, Volume 15 (4), 2005";"CACO-2";0.0000008912509381337459
"MM475297";"MM475297";"Cc1cc(COc2ccc(S(=O)(=O)CC3(CC(=O)NO)CCCN3C)cc2)c2ccccc2n1";"VMEQJHZAHNCRQC-UHFFFAOYSA-N";483.59;3.26;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-5.8;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.000001584893192461114
"MM475298";"MM475298";"Cc1cc(COc2ccc(S(=O)(=O)CC3CCNCC3C(=O)NO)cc2)c2ccccc2n1";"VTKKCTKODCNOOX-UHFFFAOYSA-N";469.56;2.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000001
"MM475299";"MM475299";"Cc1cc(COc2ccc(S(=O)(=O)CC3(CC(=O)NO)CCCO3)cc2)c2ccccc2n1";"LCIIHDPWZSSNGB-UHFFFAOYSA-N";470.55;3.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-5.3;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.000005011872336272725
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-6.15;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.0000007079457843841374
"MM475300";"MM475300";"Cc1cc(COc2ccc(S(=O)(=O)CC3NCCCC3C(=O)NO)cc2)c2ccccc2n1";"QDMJDGKLXWJUSU-UHFFFAOYSA-N";469.56;2.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000001
"MM475301";"MM475301";"Cc1cc(COc2ccc(S(=O)(=O)CC3CN(C)CCC3C(=O)NO)cc2)c2ccccc2n1";"ZLXSMXRIMOZSHG-UHFFFAOYSA-N";483.59;2.97;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000001
"MM475302";"MM475302";"Cc1cc(COc2ccc(S(=O)(=O)CC3(CC(=O)NO)CCN(C(C)C)C3)cc2)c2ccccc2n1";"AENHIDVKFOYIJJ-UHFFFAOYSA-N";511.64;3.89;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-6.7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.00000019952623149688787
"MM475303";"MM475303";"C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(OS(=O)(=O)c2ccccc2)c1";"PGIVEOHZAMQLKP-KOSHJBKYSA-N";544.65;3.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838212/target=_blank>CHEMBL838212</a>";;-5.15;"Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S, Oue M, Tsujiuchi H, Furutani Y, Kato S.: Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. Bioorg Med Chem Lett, Volume 15 (4), 2005";"CACO-2";0.000007079457843841373
"MM475304";"MM475304";"Cc1cc(COc2ccc(S(=O)(=O)CC3(CC(=O)NO)CCNC3)cc2)c2ccccc2n1";"QKSLJJWUWAALHK-UHFFFAOYSA-N";469.56;2.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000001
"MM475305";"MM475305";"Cc1cc(COc2ccc(S(=O)(=O)CC3(CC(=O)NO)CCCN3CC(C)C)cc2)c2ccccc2n1";"JCNKARFKCMFPMK-UHFFFAOYSA-N";525.67;4.28;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-6.15;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000007079457843841374
"MM475306";"MM475306";"CCC(C)N1CCC(C(=O)NO)C(CS(=O)(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"XDBJJTDYSZNDQT-UHFFFAOYSA-N";525.67;4.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-5.74;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000018197008586099826
"MM475307";"MM475307";"C=CCN1CCC(C(=O)NO)C(CS(=O)(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"PGTJOSSSBWAALE-UHFFFAOYSA-N";509.63;3.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-6.01;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.000000977237220955811
"MM475308";"MM475308";"Cc1cc(COc2ccc(S(=O)(=O)CC3NCCC3C(=O)NO)cc2)c2ccccc2n1";"NWEMVUGYMZFTLT-UHFFFAOYSA-N";455.54;2.38;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000001
"MM475309";"MM475309";"Cc1cc(COc2ccc(S(=O)(=O)CC3CCN(C(C)C)CC3C(=O)NO)cc2)c2ccccc2n1";"IFZNBBFLMYGGPO-UHFFFAOYSA-N";511.64;3.75;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-6.19;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.000000645654229034655
"MM475315";"MM475315";"Oc1cccc(-c2ccc3cc(O)ccc3c2)c1";"VHWBXEUHUQDHDH-UHFFFAOYSA-N";236.27;3.92;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL929270/target=_blank>CHEMBL929270</a>";;-5.05;"Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, Fetzer L, Scherer C, MĂĽller-Vieira U, Messinger J, Thole H, Hartmann RW.: Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.00000891250938133746
"MM475317";"MM475317";"CC(=O)c1sc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C";"NDZYPHLNJZSQJY-QNWVGRARSA-N";486.66;5.43;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851906/target=_blank>CHEMBL851906</a>";;-5.22;"De Lucca GV, Kim UT, Vargo BJ, Duncia JV, Santella JB, Gardner DS, Zheng C, Liauw A, Wang Z, Emmett G, Wacker DA, Welch PK, Covington M, Stowell NC, Wadman EA, Das AM, Davies P, Yeleswaram S, Graden DM, Solomon KA, Newton RC, Trainor GL, Decicco CP, Ko SS.: Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.000006025595860743581
"MM475318";"MM475318";"COC(=O)N[C@H](C(=O)NN(Cc1ccc(Br)cc1)C[C@@](O)(Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)C(C)(C)C";"JTIFBCHFPVQSEH-UNMGZEBXSA-N";681.63;3.8;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL867573/target=_blank>CHEMBL867573</a>";;-4.38;"Ekegren JK, Unge T, Safa MZ, Wallberg H, Samuelsson B, Hallberg A.: A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold. J Med Chem, Volume 48 (25), 2005";"CACO-2";0.00004168693834703355
"MM475319";"MM475319";"COc1ccc2onc(N3CCN(CCCCNC(=O)c4ccc(N5CCOCC5)cc4)CC3)c2c1";"DTUIKCYPLPUCPC-UHFFFAOYSA-N";493.61;3.01;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL861802/target=_blank>CHEMBL861802</a>";;-4.44;"Leopoldo M, Lacivita E, De Giorgio P, Colabufo NA, Niso M, Berardi F, Perrone R.: Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors. J Med Chem, Volume 49 (1), 2006";"CACO-2";0.0000363078054770101
"MM475320";"MM475320";"Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc(NC(C)C)c1C#N";"QWHMQQHHLRCLLD-UHFFFAOYSA-N";377.41;3.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL881421/target=_blank>CHEMBL881421</a>";;-4.62;"Liu C, Wrobleski ST, Lin J, Ahmed G, Metzger A, Wityak J, Gillooly KM, Shuster DJ, McIntyre KW, Pitt S, Shen DR, Zhang RF, Zhang H, Doweyko AM, Diller D, Henderson I, Barrish JC, Dodd JH, Schieven GL, Leftheris K.: 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase. J Med Chem, Volume 48 (20), 2005";"CACO-2";0.0000239883291901949
"MM475321";"MM475321";"COc1ccc2onc(N3CCN(CCCCNC(=O)c4ccc(-n5ccnc5)cc4)CC3)c2c1";"VAEZCFWPDODBFF-UHFFFAOYSA-N";474.57;3.35;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL861802/target=_blank>CHEMBL861802</a>";;-5.18;"Leopoldo M, Lacivita E, De Giorgio P, Colabufo NA, Niso M, Berardi F, Perrone R.: Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors. J Med Chem, Volume 49 (1), 2006";"CACO-2";0.000006606934480075964
"MM475324";"MM475324";"COc1ccc2onc(N3CCN(CCCCNC(=O)c4cc(-c5ccco5)[nH]n4)CC3)c2c1";"MQCABDUKZLMPQP-UHFFFAOYSA-N";464.53;3.15;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL861802/target=_blank>CHEMBL861802</a>";;-5.13;"Leopoldo M, Lacivita E, De Giorgio P, Colabufo NA, Niso M, Berardi F, Perrone R.: Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors. J Med Chem, Volume 49 (1), 2006";"CACO-2";0.000007413102413009177
"MM475327";"MM475327";"Cc1cn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)[nH]c1=O";"LRAYIUHUAWSEDX-UHFFFAOYSA-N";468.52;2.55;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL865870/target=_blank>CHEMBL865870</a>";;-5.71;"Geneste H, Backfisch G, Braje W, Delzer J, Haupt A, Hutchins CW, King LL, Kling A, Teschendorf HJ, Unger L, Wernet W.: Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives. Bioorg Med Chem Lett, Volume 16 (3), 2006";"CACO-2";0.0000019498445997580454
"MM475328";"MM475328";"O=C(O)Cc1ccc(C(=O)c2ccc(Oc3ccc(Br)cc3)cc2)cc1";"XVHMPUZJYISELN-UHFFFAOYSA-N";411.25;5.1;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859819/target=_blank>CHEMBL859819</a>";;-5.18;"Salem OI, Frotscher M, Scherer C, Neugebauer A, Biemel K, Streiber M, Maas R, Hartmann RW.: Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem, Volume 49 (2), 2006";"CACO-2";0.000006606934480075964
"MM475329";"MM475329";"CC(C)(C)c1nc(N2CCN(CCCCN3C(=O)CCC(=O)c4ccccc43)CC2)cc(C(F)(F)F)n1";"FKHBHNWGBJHKGW-UHFFFAOYSA-N";517.6;4.7;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853614/target=_blank>CHEMBL853614</a>";;-6.48;"Geneste H, Backfisch G, Braje W, Delzer J, Haupt A, Hutchins CW, King LL, Lubisch W, Steiner G, Teschendorf HJ, Unger L, Wernet W.: Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.geneste@abbott.com. Bioorg Med Chem Lett, Volume 16 (3), 2006";"CACO-2";0.0000003311311214825908
"MM475334";"MM475334";"CN(C(=O)COc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"HQAGTEJQOVMWJI-UHFFFAOYSA-N";407.31;4.04;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.54;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.000028840315031266056
"MM475335";"MM475335";"O=C(Nc1cc(-c2ccnc(Nc3ccccc3)c2)ccn1)C1CCOC1";"YZIQMIAREGGHFQ-UHFFFAOYSA-N";360.42;3.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL862183/target=_blank>CHEMBL862183</a>";;-4.52;"Swahn BM, Xue Y, Arzel E, Kallin E, Magnus A, Plobeck N, Viklund J.: Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett, Volume 16 (5), 2006";"CACO-2";0.000030199517204020192
"MM475336";"MM475336";"CCN(C(=O)c1ccc(C#N)cc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"ZPVWDVAAUFFDHR-UHFFFAOYSA-N";416.32;4.54;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.41;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.000038904514499428046
"MM475337";"MM475337";"CC(C)C(=O)N(CCO)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"KOALTMALKSJVNL-UHFFFAOYSA-N";373.29;2.98;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.28;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.00005248074602497723
"MM475338";"MM475338";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Nc3ccc(-c4ccccc4CN4CCCCC4)cc3F)cc12";"JAMANIGSQMZMOS-UHFFFAOYSA-N";578.57;6.66;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859920/target=_blank>CHEMBL859920</a>";;-5.05;"Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.: Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett, Volume 16 (7), 2006";"CACO-2";0.00000891250938133746
"MM475339";"MM475339";"CNCc1ccccc1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)c(F)c1";"IUCPGZLVLKJARS-UHFFFAOYSA-N";524.48;5.39;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859920/target=_blank>CHEMBL859920</a>";;-5.46;"Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.: Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett, Volume 16 (7), 2006";"CACO-2";0.000003467368504525317
"MM475341";"MM475341";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Nc3ccc(-c4ccccc4CN4CC[C@H](N)C4)cc3F)cc12";"YHIZCAWNRNQWMF-SFHVURJKSA-N";579.56;5.21;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859920/target=_blank>CHEMBL859920</a>";;-5.33;"Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.: Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett, Volume 16 (7), 2006";"CACO-2";0.000004677351412871981
"MM475342";"MM475342";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCCCC3)cc2)c2ccccc2n1";"VRUYZVHIDJWWTM-UHFFFAOYSA-N";447.54;4.45;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-5.44;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000036307805477010103
"MM475344";"MM475344";"CCN(CCCCO)C(=O)N(CC)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"HLBZTKNWROADNW-UHFFFAOYSA-N";430.39;4.04;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.3;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.00005011872336272725
"MM475345";"MM475345";"CCC1=C(c2cccnc2)CCc2ccccc21";"ZKPVULIWDZEZIT-UHFFFAOYSA-N";235.33;4.35;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-4.67;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.000021379620895022323
"MM475346";"MM475346";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(C(C)(C)C)CC3)cc2)c2ccccc2n1";"HBYOIHRPSQTDLO-UHFFFAOYSA-N";504.63;4.38;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-7;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000001
"MM475347";"MM475347";"CN1CCN(Cc2ccccc2-c2ccc(NC(=O)c3cc(C(F)(F)F)nn3-c3ccc4onc(N)c4c3)c(F)c2)CC1";"KDZYVICPZRDOIO-UHFFFAOYSA-N";593.59;5.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859920/target=_blank>CHEMBL859920</a>";;-5.63;"Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.: Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett, Volume 16 (7), 2006";"CACO-2";0.0000023442288153199226
"MM475348";"MM475348";"C1=C(c2cccnc2)Cc2ccccc21";"NNEAKBWZBQOQDH-UHFFFAOYSA-N";193.25;3.18;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-5.18;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.000006606934480075964
"MM475349";"MM475349";"C1=C(c2cccnc2)CCc2ccccc21";"AXLDMZNUHQOZFK-UHFFFAOYSA-N";207.28;3.57;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-4.84;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.00001445439770745928
"MM475350";"MM475350";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(C4=NCCS4)CC3)cc2)c2ccccc2n1";"XNQVZVNWVMQCPC-UHFFFAOYSA-N";533.65;3.68;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-7;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000001
"MM475351";"MM475351";"CCN(C(=O)N1CCOCC1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"ZMHUCHJRHVDHLO-UHFFFAOYSA-N";400.32;3.28;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.17;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.00006760829753919819
"MM475352";"MM475352";"CC1CC(c2cccnc2)=Cc2ccccc21";"HIOBIABFPPEMPT-UHFFFAOYSA-N";221.3;4.13;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-4.79;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.0000162181009735893
"MM475353";"MM475353";"O=C(O)CN(C(=O)CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"RXCYESDNNJKLOO-UHFFFAOYSA-N";449.35;4.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-6.4;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.0000003981071705534969
"MM475354";"MM475354";"CC1=C(c2cccnc2)CCc2ccccc21";"WBEMJRFRGOAAJI-UHFFFAOYSA-N";221.3;3.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-5.47;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.0000033884415613920275
"MM475355";"MM475355";"COc1ccc2c(c1)C=C(c1cccnc1)C2";"KPJYOCDWGFDTFR-UHFFFAOYSA-N";223.28;3.19;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-4.9;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.000012589254117941661
"MM475357";"MM475357";"COc1ccc2c(c1)CCC(c1cccnc1)=C2";"WUTGTMFGCHNUET-UHFFFAOYSA-N";237.3;3.58;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-4.87;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.000013489628825916533
"MM475359";"MM475359";"CC1Cc2ccccc2C=C1c1cccnc1";"ARDWAGDGUKXSPH-UHFFFAOYSA-N";221.3;3.81;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-4.83;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.000014791083881682072
"MM475360";"MM475360";"COC(=O)CCCCN(C(=O)N1CCOCC1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"DKTUEVOKTCNLNR-UHFFFAOYSA-N";486.41;3.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.48;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.000033113112148259076
"MM475361";"MM475361";"O=C(O)CCCCN(C(=O)N1CCOCC1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"NJHMKFSATBCLQS-UHFFFAOYSA-N";472.38;3.51;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-5.77;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.000001698243652461746
"MM475362";"MM475362";"CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO";"MAVDNGWEBZTACC-HNNXBMFYSA-N";414.51;0.45;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL867741/target=_blank>CHEMBL867741</a>";;-5.66;"Levin JI, Chen JM, Laakso LM, Du M, Schmid J, Xu W, Cummons T, Xu J, Jin G, Barone D, Skotnicki JS.: Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett, Volume 16 (6), 2006";"CACO-2";0.0000021877616239495517
"MM475364";"MM475364";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(C(=O)C(C)(C)C)CC3)cc2)c2ccccc2n1";"OVSGONSKJHXDJO-UHFFFAOYSA-N";532.64;4.15;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.06;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000008709635899560814
"MM475366";"MM475366";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(CCF)CC3)cc2)c2ccccc2n1";"MCNQDQIVWJTIBW-UHFFFAOYSA-N";494.57;3.55;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.26;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000005495408738576248
"MM475369";"MM475369";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(c4ccccc4)CC3)cc2)c2ccccc2n1";"FAKDVMIECOUVIL-UHFFFAOYSA-N";524.62;4.79;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.3;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000005011872336272725
"MM475370";"MM475370";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(CC(C)(C)C)CC3)cc2)c2ccccc2n1";"MIUWEXKKKWGHOC-UHFFFAOYSA-N";518.66;4.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-5.62;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000023988329190194897
"MM475371";"MM475371";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCOCC3)cc2)c2ccccc2n1";"NUVSGXIVCJBRBF-UHFFFAOYSA-N";449.51;3.3;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.1;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000007943282347242822
"MM475373";"MM475373";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(C(=O)CC(C)C)CC3)cc2)c2ccccc2n1";"NHMWZOLCOOIQJX-UHFFFAOYSA-N";532.64;4.15;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.25;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.000000562341325190349
"MM475374";"MM475374";"C#CC(C)(C)N1CCC(CC(=O)NO)(NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)CC1";"ALAICNBWAOLDPL-UHFFFAOYSA-N";514.63;3.99;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-5.49;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.000003235936569296281
"MM475375";"MM475375";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(C(=O)C(C)C)CC3)cc2)c2ccccc2n1";"CBKSKDVWCOUHEC-UHFFFAOYSA-N";518.61;3.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.7;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.00000019952623149688787
"MM475377";"MM475377";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(C(=O)CC(C)(C)C)CC3)cc2)c2ccccc2n1";"FQARNXJHFBTHOY-UHFFFAOYSA-N";546.67;4.54;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.1;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000007943282347242822
"MM475378";"MM475378";"CCCN1CCC(CC(=O)NO)(NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)CC1";"ADROOOBIKREWPX-UHFFFAOYSA-N";490.6;3.99;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-7;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000001
"MM475379";"MM475379";"CCS(=O)(=O)CCN1CCC(CC(=O)NO)(NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)CC1";"CTANAKVMPKAIQD-UHFFFAOYSA-N";568.7;3.02;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.26;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000005495408738576248
"MM475380";"MM475380";"CCCOc1ncc(C(C)=O)cc1-c1nc(O)c2nn(C3CN(C(C)C)C3)c(CC)c2n1";"SUNRSIDIGUGCSU-UHFFFAOYSA-N";438.53;3.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860099/target=_blank>CHEMBL860099</a>";;-4.55;"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.: A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem, Volume 49 (12), 2006";"CACO-2";0.00002818382931264455
"Chembl209446";"MM469017";"CN(CCOc1ccccc1Sc1ccccc1)CC(=O)O";"WWTBASXWJHFVNF-UHFFFAOYSA-N";317.41;3.23;;"Chembl209446";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL862964/target=_blank>CHEMBL862964</a>";;-4.48;"Smith G, Mikkelsen G, Eskildsen J, Bundgaard C.: The synthesis and SAR of 2-arylsulfanylphenyl-1-oxyalkylamino acids as GlyT-1 inhibitors. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000033113112148259076
"MM475382";"MM475382";"CCCc1nn(C)c2c(O)nc(-c3cc(C(=O)CN4CCOCC4)ccc3OCC)nc12";"AANJEOKXWMXQIE-UHFFFAOYSA-N";439.52;2.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860099/target=_blank>CHEMBL860099</a>";;-4.48;"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.: A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem, Volume 49 (12), 2006";"CACO-2";0.000033113112148259076
"MM475384";"MM475384";"CCCCOc1ncc(C(C)=O)cc1-c1nc(O)c2nn(Cc3ccccn3)c(CCC)c2n1";"IQOUMUUIJXJPMR-UHFFFAOYSA-N";460.54;4.37;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860099/target=_blank>CHEMBL860099</a>";;-4.38;"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.: A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem, Volume 49 (12), 2006";"CACO-2";0.00004168693834703355
"MM475386";"MM475386";"CCCCOc1ncc(C(C)=O)cc1-c1nc(O)c2nn(C3CN(CC)C3)c(CC)c2n1";"INLBUQIADGPECI-UHFFFAOYSA-N";438.53;3.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860099/target=_blank>CHEMBL860099</a>";;-4.52;"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.: A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem, Volume 49 (12), 2006";"CACO-2";0.000030199517204020192
"MM475387";"MM475387";"CN(C)Cc1ccccc1-c1ccc(N2CCc3c(C(F)(F)F)nn(-c4ccc5onc(N)c5c4)c3C2=O)cc1";"GJINLTTVIZRYJU-UHFFFAOYSA-N";546.55;5.55;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868640/target=_blank>CHEMBL868640</a>";;-5.33;"Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PY.: 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000004677351412871981
"MM475388";"MM475388";"CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O";"IDRHXERJIOHEIJ-SIBCGJTDSA-N";351.36;1.85;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL866148/target=_blank>CHEMBL866148</a>";;-5.62;"Merritt JR, Rokosz LL, Nelson KH, Kaiser B, Wang W, Stauffer TM, Ozgur LE, Schilling A, Li G, Baldwin JJ, Taveras AG, Dwyer MP, Chao J.: Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.0000023988329190194897
"MM475391";"MM475391";"Cc1ccccc1CN(CCN(Cc1cncn1C)c1ccc(-c2ccccc2)cc1)S(=O)(=O)c1cn(C)cn1";"CAZKPPOQQJGGBL-UHFFFAOYSA-N";554.72;5.03;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-6.4;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.0000003981071705534969
"MM475393";"MM475393";"Nc1noc2ccc(-n3nc(C(F)(F)F)c4c3C(=O)N(c3ccc(-c5ccccc5CN5CCC(O)CC5)cc3)CC4)cc12";"KZFKAYHQURWCNL-UHFFFAOYSA-N";602.62;5.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868640/target=_blank>CHEMBL868640</a>";;-6.4;"Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PY.: 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.0000003981071705534969
"MM475394";"MM475394";"O=C(O)[C@@H]1CCCN1CCOc1ccc(-c2ccccc2)cc1Sc1cccc(F)c1";"YHOBMZUBDXFLGN-QFIPXVFZSA-N";437.54;5.57;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL862964/target=_blank>CHEMBL862964</a>";;-4.6;"Smith G, Mikkelsen G, Eskildsen J, Bundgaard C.: The synthesis and SAR of 2-arylsulfanylphenyl-1-oxyalkylamino acids as GlyT-1 inhibitors. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000025118864315095822
"MM475395";"MM475395";"CCC(CC)/N=c1\c(O)c(O)\c1=N/c1cccc(C(=O)N(C)C)c1O";"IIYATGKFFIGIDZ-AXPXABNXSA-N";345.4;1.7;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL866148/target=_blank>CHEMBL866148</a>";;-4.92;"Merritt JR, Rokosz LL, Nelson KH, Kaiser B, Wang W, Stauffer TM, Ozgur LE, Schilling A, Li G, Baldwin JJ, Taveras AG, Dwyer MP, Chao J.: Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000012022644346174132
"MM475397";"MM475397";"CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCC2)c1O";"ODDYNFJMZKNMIO-AXPXABNXSA-N";343.38;1.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL866148/target=_blank>CHEMBL866148</a>";;-5;"Merritt JR, Rokosz LL, Nelson KH, Kaiser B, Wang W, Stauffer TM, Ozgur LE, Schilling A, Li G, Baldwin JJ, Taveras AG, Dwyer MP, Chao J.: Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.00001
"MM475399";"MM475399";"Cn1cnc(S(=O)(=O)N(CCN(Cc2cncn2C)c2ccc(C#N)cc2)Cc2ccc(-n3cccc3)cc2)c1";"ZLSUFGRBWKQUQB-UHFFFAOYSA-N";554.68;3.71;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-5.96;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.000001096478196143185
"MM475400";"MM475400";"Cc1ccccc1CN(CCN(Cc1cncn1C)c1ccc(C#N)cc1)S(=O)(=O)c1cn(C)cn1";"YHWHZGNJXZQUQM-UHFFFAOYSA-N";503.63;3.23;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-6.4;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.0000003981071705534969
"MM475401";"MM475401";"Cn1cncc1CN(CCN(Cc1ccccc1)S(=O)(=O)c1ccccn1)c1ccc(C#N)cc1";"HAVQUHAYFMIFJN-UHFFFAOYSA-N";486.6;3.58;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-5.55;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.000002818382931264455
"MM475402";"MM475402";"Cn1cnc(S(=O)(=O)N(CCN(Cc2cncn2C)c2ccc(C#N)cc2)Cc2ccccc2)c1";"IDHGAQOVWWBGFK-UHFFFAOYSA-N";489.61;2.92;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-5.96;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.000001096478196143185
"MM475407";"MM475407";"CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(C4CCOC4)c4ccccc43)cc1C2";"PDUHSGWCDRILIB-IXXGTQFESA-N";475.51;1.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL911974/target=_blank>CHEMBL911974</a>";;-5.4;"Bell IM, Bednar RA, Fay JF, Gallicchio SN, Hochman JH, McMasters DR, Miller-Stein C, Moore EL, Mosser SD, Pudvah NT, Quigley AG, Salvatore CA, Stump CA, Theberge CR, Wong BK, Zartman CB, Zhang XF, Kane SA, Graham SL, Vacca JP, Williams TM.: Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett, Volume 16 (24), 2006";"CACO-2";0.000003981071705534969
"MM475408";"MM475408";"CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4cncnc4)c4ccccc43)cc1C2";"NRFBJAZUUUIQSC-RUZDIDTESA-N";483.49;1.24;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL911974/target=_blank>CHEMBL911974</a>";;-5.4;"Bell IM, Bednar RA, Fay JF, Gallicchio SN, Hochman JH, McMasters DR, Miller-Stein C, Moore EL, Mosser SD, Pudvah NT, Quigley AG, Salvatore CA, Stump CA, Theberge CR, Wong BK, Zartman CB, Zhang XF, Kane SA, Graham SL, Vacca JP, Williams TM.: Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett, Volume 16 (24), 2006";"CACO-2";0.000003981071705534969
"MM475411";"MM475411";"CCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21";"AZBGLEQDAYJKBP-NSHDSACASA-N";284.28;2.37;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL920384/target=_blank>CHEMBL920384</a>";;-4.67;"Wacker DA, Varnes JG, Malmstrom SE, Cao X, Hung CP, Ung T, Wu G, Zhang G, Zuvich E, Thomas MA, Keim WJ, Cullen MJ, Rohrbach KW, Qu Q, Narayanan R, Rossi K, Janovitz E, Lehman-McKeeman L, Malley MF, Devenny J, Pelleymounter MA, Miller KJ, Robl JA.: Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor. J Med Chem, Volume 50 (6), 2007";"CACO-2";0.000021379620895022323
"MM475413";"MM475413";"CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4ccccn4)c4ccccc43)cc1C2";"BZGALMKCNIYKHV-AREMUKBSSA-N";482.5;1.84;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL911974/target=_blank>CHEMBL911974</a>";;-4.96;"Bell IM, Bednar RA, Fay JF, Gallicchio SN, Hochman JH, McMasters DR, Miller-Stein C, Moore EL, Mosser SD, Pudvah NT, Quigley AG, Salvatore CA, Stump CA, Theberge CR, Wong BK, Zartman CB, Zhang XF, Kane SA, Graham SL, Vacca JP, Williams TM.: Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett, Volume 16 (24), 2006";"CACO-2";0.000010964781961431852
"MM475414";"MM475414";"CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4cnccn4)c4ccccc43)cc1C2";"MLLMYNNPSHKYQO-RUZDIDTESA-N";483.49;1.24;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL911974/target=_blank>CHEMBL911974</a>";;-5.1;"Bell IM, Bednar RA, Fay JF, Gallicchio SN, Hochman JH, McMasters DR, Miller-Stein C, Moore EL, Mosser SD, Pudvah NT, Quigley AG, Salvatore CA, Stump CA, Theberge CR, Wong BK, Zartman CB, Zhang XF, Kane SA, Graham SL, Vacca JP, Williams TM.: Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett, Volume 16 (24), 2006";"CACO-2";0.000007943282347242822
"MM475424";"MM475424";"CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1";"XEVJUIZOZCFECP-UHFFFAOYSA-N";487.58;4.02;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL890383/target=_blank>CHEMBL890383</a>";;-4.49;"Watterson SH, Chen P, Zhao Y, Gu HH, Dhar TG, Xiao Z, Ballentine SK, Shen Z, Fleener CA, Rouleau KA, Obermeier M, Yang Z, McIntyre KW, Shuster DJ, Witmer M, Dambach D, Chao S, Mathur A, Chen BC, Barrish JC, Robl JA, Townsend R, Iwanowicz EJ.: Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419). J Med Chem, Volume 50 (15), 2007";"CACO-2";0.00003235936569296281
"MM475427";"MM475427";"CCOC(=O)CN[C@H](CCc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)NCc1cc(Cl)ccc1CN";"FVYGXQLKUXZGOL-RPWUZVMVSA-N";531.05;2.27;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889058/target=_blank>CHEMBL889058</a>";;-5.05;"DĂ¶nnecke D, Schweinitz A, StĂĽrzebecher A, Steinmetzer P, Schuster M, StĂĽrzebecher U, Nicklisch S, StĂĽrzebecher J, Steinmetzer T.: From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.00000891250938133746
"MM475437";"MM475437";"O=C(NC1CCN(C(=O)CCc2cccnc2)CC1)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1";"MOAKSXYTYAKBNI-UHFFFAOYSA-N";496.44;5.26;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL894525/target=_blank>CHEMBL894525</a>";;-5.2;"Denonne F, Binet S, Burton M, Collart P, Defays S, Dipesa A, Eckert M, Giannaras A, Kumar S, Levine B, Nicolas JM, Pasau P, PĂ©gurier C, Preda D, Van houtvin N, Volosov A, Zou D.: Discovery of new C3aR ligands. Part 2: amino-piperidine derivatives. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.00000630957344480193
"MM475441";"MM475441";"O=c1n(Cc2nc3ccccc3n2CCCCF)c2cnccc2n1CC(F)(F)F";"ZFHZJGWAJOWZGK-UHFFFAOYSA-N";421.4;3.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.61;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000024547089156850286
"MM475442";"MM475442";"O=C(NC1CCN(C(=O)CCc2cccnc2)CC1)C(c1ccccc1)C1CCC(F)(F)CC1";"ICHRXXYYJYXFNM-UHFFFAOYSA-N";469.58;4.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL894525/target=_blank>CHEMBL894525</a>";;-4.8;"Denonne F, Binet S, Burton M, Collart P, Defays S, Dipesa A, Eckert M, Giannaras A, Kumar S, Levine B, Nicolas JM, Pasau P, PĂ©gurier C, Preda D, Van houtvin N, Volosov A, Zou D.: Discovery of new C3aR ligands. Part 2: amino-piperidine derivatives. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.00001584893192461114
"MM475444";"MM475444";"C#CCN1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(Cc3cc(C)nc4ccccc34)cc2)C1";"YIIFUMKWGPMPET-LADGPHEKSA-N";442.52;2.3;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-6.15;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000007079457843841374
"MM475445";"MM475445";"O=C(NC1CCN(C(=O)CCc2cccnc2)CC1)C(c1ccc(Cl)cc1)C1CCCCC1";"MVZBPBBWVBYVKZ-UHFFFAOYSA-N";468.04;5.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL894525/target=_blank>CHEMBL894525</a>";;-5;"Denonne F, Binet S, Burton M, Collart P, Defays S, Dipesa A, Eckert M, Giannaras A, Kumar S, Levine B, Nicolas JM, Pasau P, PĂ©gurier C, Preda D, Van houtvin N, Volosov A, Zou D.: Discovery of new C3aR ligands. Part 2: amino-piperidine derivatives. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.00001
"MM475446";"MM475446";"O=C(Nc1ccc(C(F)(F)F)c(Cl)c1)c1ccnn1CCc1ccncc1";"LMEHSVKTVLMKTO-UHFFFAOYSA-N";394.78;4.45;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897525/target=_blank>CHEMBL897525</a>";;-5.34;"Kiselyov AS, Milligan D, Ouyang X.: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.000004570881896148752
"MM475447";"MM475447";"CC#CCN1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(Cc3cc(C)nc4ccccc34)cc2)C1";"LBHPINDOHXBHHL-UKILVPOCSA-N";456.55;2.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-5.72;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000019054607179632483
"MM475448";"MM475448";"CCCCS(=O)(=O)N1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(Cc3cc(C)nc4ccccc34)cc2)C1";"XDSDBWPXGOPPFL-UKILVPOCSA-N";524.64;2.8;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-6.52;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000003019951720402019
"MM475449";"MM475449";"COC(=O)N1C[C@H](C(=O)NO)[C@H](NC(=O)c2ccc(Cc3cc(C)nc4ccccc34)cc2)C1";"ZASAXMMLZWOHBG-RBBKRZOGSA-N";462.51;2.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-7;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000001
"MM475450";"MM475450";"CC(C)(C)n1c(=O)n(Cc2nc3ccccc3n2CCCC#N)c2cnccc21";"JBFMVOOXTURQJL-UHFFFAOYSA-N";388.48;3.65;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.67;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000021379620895022323
"MM475451";"MM475451";"N#CCCCn1c(Cn2c(=O)n(C3CCC3)c3ccncc32)nc2ccccc21";"VWEPARILXXFAMM-UHFFFAOYSA-N";386.46;3.62;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.77;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.00001698243652461746
"MM475453";"MM475453";"O=C(N[C@H]1CCC[C@H]1NC(=O)c1ccc(Cl)s1)c1ccc(-n2ccccc2=O)cc1";"QCPYHSAHOYXXQK-DLBZAZTESA-N";441.94;3.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897896/target=_blank>CHEMBL897896</a>";;-5.04;"Qiao JX, Wang TC, Wang GZ, Cheney DL, He K, Rendina AR, Xin B, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications. Bioorg Med Chem Lett, Volume 17 (18), 2007";"CACO-2";0.000009120108393559096
"MM475454";"MM475454";"Cc1cc(Cc2cccc(C(=O)N[C@@H]3COC[C@@H]3C(=O)NO)c2)c2ccccc2n1";"UNCGRKPTWVECFJ-PZJWPPBQSA-N";405.45;2.38;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-7;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000001
"MM475455";"MM475455";"Cc1cc(Cc2ccc(C(=O)N[C@@H]3CCOC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"NMHJSIJTDAPUMQ-RBBKRZOGSA-N";419.48;2.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-6.22;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000006025595860743581
"MM475456";"MM475456";"Cc1cc(Cc2ccc(C(=O)N[C@@H]3CN(CC(C)(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"KEGZCMGJDRKBBL-UKILVPOCSA-N";474.61;3.72;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-5.03;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.000009332543007969906
"MM475457";"MM475457";"O=C(NCc1ccccn1)c1ccc2c(c1)Cc1c(-c3ccc(-c4ccc(O)cc4)cc3)n[nH]c1-2";"GALUBKKRBHABCT-UHFFFAOYSA-N";458.52;5.35;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL896352/target=_blank>CHEMBL896352</a>";;-4.88;"Tong Y, Claiborne A, Pyzytulinska M, Tao ZF, Stewart KD, Kovar P, Chen Z, Credo RB, Guan R, Merta PJ, Zhang H, Bouska J, Everitt EA, Murry BP, Hickman D, Stratton TJ, Wu J, Rosenberg SH, Sham HL, Sowin TJ, Lin NH.: 1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.000013182567385564074
"MM475458";"MM475458";"O=C(NC1CCN(C(=O)CCc2ccc(F)nc2)CC1)C(c1ccccc1)C1CCCCC1";"IFFJKARLWFETLS-UHFFFAOYSA-N";451.59;4.62;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL894525/target=_blank>CHEMBL894525</a>";;-4.72;"Denonne F, Binet S, Burton M, Collart P, Defays S, Dipesa A, Eckert M, Giannaras A, Kumar S, Levine B, Nicolas JM, Pasau P, PĂ©gurier C, Preda D, Van houtvin N, Volosov A, Zou D.: Discovery of new C3aR ligands. Part 2: amino-piperidine derivatives. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.000019054607179632484
"MM475459";"MM475459";"O=C(NC1CCN(C(=O)/C=C/c2cccnc2)CC1)C(c1ccccc1)C1CCCCC1";"CENVSZJSDHGUKD-BUHFOSPRSA-N";431.58;4.57;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL894525/target=_blank>CHEMBL894525</a>";;-5.07;"Denonne F, Binet S, Burton M, Collart P, Defays S, Dipesa A, Eckert M, Giannaras A, Kumar S, Levine B, Nicolas JM, Pasau P, PĂ©gurier C, Preda D, Van houtvin N, Volosov A, Zou D.: Discovery of new C3aR ligands. Part 2: amino-piperidine derivatives. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.00000851138038202376
"MM475462";"MM475462";"Cc1cncc(/C=C/C(=O)N2CCC(NC(=O)C(c3ccccc3)C3CCCCC3)CC2)c1";"UDTUOBVREMCEKC-OUKQBFOZSA-N";445.61;4.87;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL894525/target=_blank>CHEMBL894525</a>";;-5.1;"Denonne F, Binet S, Burton M, Collart P, Defays S, Dipesa A, Eckert M, Giannaras A, Kumar S, Levine B, Nicolas JM, Pasau P, PĂ©gurier C, Preda D, Van houtvin N, Volosov A, Zou D.: Discovery of new C3aR ligands. Part 2: amino-piperidine derivatives. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.000007943282347242822
"MM475464";"MM475464";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(-c4ccccc4CN4CC[C@@H](O)C4)cc2)CC3)cc1";"DHISSSXEEMPPQB-XMMPIXPASA-N";537.62;3.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.64;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.0000022908676527677747
"MM475465";"MM475465";"NC(=O)[C@H](Cc1ccccc1)N1CCNC(=O)CCN[C@@H](Cc2ccccc2)C(=O)NCC(=O)NCC(=O)NCC(=O)NCC1=O";"BVUJMINMQKBSIS-ZEQRLZLVSA-N";636.71;-2.9;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.27;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000005370317963702533
"MM475466";"MM475466";"NC(=O)[C@H](Cc1ccccc1)N1CCNC(=O)CCCN[C@@H](Cc2ccccc2)C(=O)NCC(=O)NCC(=O)NCC(=O)NCC1=O";"FJAIODVIAPJCOL-DQEYMECFSA-N";650.74;-2.51;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.56;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000002754228703338169
"MM475467";"MM475467";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N(C)C(C)=O)cc2)CC3)cc1";"FDHXDGIWUSXLEQ-UHFFFAOYSA-N";433.47;2.17;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.6;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.0000025118864315095823
"MM475468";"MM475468";"NC(=O)[C@H](Cc1ccccc1)N1CCNC(=O)CCCCN[C@@H](Cc2ccccc2)C(=O)NCC(=O)NCC(=O)NCC(=O)NCC1=O";"UMMASYNLXGQTLK-UIOOFZCWSA-N";664.76;-2.12;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.82;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000015135612484362072
"MM475469";"MM475469";"CC(C)C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC1=O";"VRTNUMBPIBDYLD-BURNTYAHSA-N";645.72;-2.8;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-7.52;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000000030199517204020194
"MM475470";"MM475470";"CN1CC(=O)N(C)CC(=O)N([C@@H](Cc2ccccc2)C(N)=O)CCNC(=O)CCN[C@@H](Cc2ccccc2)C(=O)N(C)CC(=O)N(C)CC1=O";"LBXJAAVDRRBXBR-NSOVKSMOSA-N";692.82;-1.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.81;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000015488166189124828
"MM475471";"MM475471";"O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccnn1CCc1ccncc1";"PPTQGESVTYQYST-UHFFFAOYSA-N";376.34;3.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897525/target=_blank>CHEMBL897525</a>";;-5.15;"Kiselyov AS, Milligan D, Ouyang X.: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.000007079457843841373
"MM475472";"MM475472";"CC(C)C[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N(C)[C@H](Cc2ccccc2)C(=O)N1C";"OSJUGTDOLQDPEG-CWBXHPNXSA-N";673.77;-2.12;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-7.52;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000000030199517204020194
"MM475473";"MM475473";"O=C(Nc1cccc(OC(F)(F)Cl)c1)c1ccnn1CCc1ccncc1";"ZYNVSINHORTDLH-UHFFFAOYSA-N";392.79;3.94;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897525/target=_blank>CHEMBL897525</a>";;-5.32;"Kiselyov AS, Milligan D, Ouyang X.: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.00000478630092322638
"MM475474";"MM475474";"CC(C)c1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1";"MXTUGQFJAIVHPO-UHFFFAOYSA-N";334.42;3.9;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897525/target=_blank>CHEMBL897525</a>";;-5.09;"Kiselyov AS, Milligan D, Ouyang X.: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.000008128305161640995
"MM475476";"MM475476";"CC(C)C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)CNC1=O";"NCRTXTOOWLTIEL-LRSLUSHPSA-N";659.75;-2.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-7.52;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000000030199517204020194
"MM475477";"MM475477";"CC(C)C[C@H]1C(=O)NCC(=O)N(C)[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C";"KOSFSUYNKQIHHY-BJESRGMDSA-N";673.77;-2.12;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-7.52;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000000030199517204020194
"MM475481";"MM475481";"C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NCCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(CCN)[C@@H](Cc1ccccc1)C(N)=O";"VJCGDOIUXBGBOZ-YPZLOKHQSA-N";710.83;-1.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-6.7;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.00000019952623149688787
"MM475482";"MM475482";"CN[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](Cc1ccccc1)C(N)=O";"JGYBUXQVWOVQDV-BNCSLUSBSA-N";623.76;-0.61;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-6.55;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000002818382931264455
"MM475483";"MM475483";"CNCc1ccccc1-c1ccc(N2CCc3c(C(N)=O)nn(-c4ccc(OC)cc4)c3C2=O)cc1";"WBJAPJNKSSQXAT-UHFFFAOYSA-N";481.56;3.57;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.77;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.000001698243652461746
"MM475484";"MM475484";"CCN(CC)Cc1ccccc1-c1ccc(N2CCc3c(C(N)=O)nn(-c4ccc(OC)cc4)c3C2=O)cc1";"VTHIZWRLBYQAKK-UHFFFAOYSA-N";523.64;4.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.64;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.0000022908676527677747
"MM475485";"MM475485";"CC(C)C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)N(C)C(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)CNC1=O";"HFSFLGRKJKFEHR-CWBXHPNXSA-N";673.77;-2.12;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-7.52;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000000030199517204020194
"MM475486";"MM475486";"CN[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(N)=O";"GDFUCYRWLGGIGG-TZYAJKAJSA-N";595.7;-1.39;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-6.06;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000008709635899560814
"MM475487";"MM475487";"CN[C@@H](Cc1ccccc1)C(=O)N(C)CC(=O)N(C)CC(=O)NCC(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(N)=O";"DMVGHORYUZJPPS-ZEQRLZLVSA-N";595.7;-1.48;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-6.34;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.00000045708818961487516
"MM475488";"MM475488";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(-c4ccccc4CN4CCC(O)CC4)cc2)CC3)cc1";"WYYUKFPDEPUPIJ-UHFFFAOYSA-N";551.65;3.81;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.31;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.000004897788193684467
"MM475489";"MM475489";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(-c4ccccc4CN(CCO)CCO)cc2)CC3)cc1";"OOPKOOPFWNIDJI-UHFFFAOYSA-N";555.64;2.64;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-6.05;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.0000008912509381337459
"MM475491";"MM475491";"CCCCCCC(N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)NC1O[C@H](C(N)=O)[C@@H](O)[C@H](O)[C@H]1O";"PZEIZTBQRJKZDT-OECGIBGPSA-N";695.78;-4.11;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898108/target=_blank>CHEMBL898108</a>";;-4.79;"Wessling ST, Ross BP, Koda Y, Blanchfield JT, Toth I.: Caco-2 cell permeability and stability of two d-glucopyranuronamide conjugates of thyrotropin-releasing hormone. Bioorg Med Chem, Volume 15 (14), 2007";"CACO-2";0.0000162181009735893
"MM475492";"MM475492";"CC(C)C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)N(C)C(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC1=O";"YMUBVNOOHWSKFS-MYGLTJDJSA-N";659.75;-2.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-7.52;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000000030199517204020194
"MM475493";"MM475493";"NC(=O)[C@H]1OC(NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H]2CCC(=O)N2)[C@H](O)[C@@H](O)[C@@H]1O";"MRRQNAPDEGSTKX-BPXHRZAVSA-N";537.53;-4.88;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898108/target=_blank>CHEMBL898108</a>";;-5.29;"Wessling ST, Ross BP, Koda Y, Blanchfield JT, Toth I.: Caco-2 cell permeability and stability of two d-glucopyranuronamide conjugates of thyrotropin-releasing hormone. Bioorg Med Chem, Volume 15 (14), 2007";"CACO-2";0.000005128613839913648
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-6.44;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000000363078054770101
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL945419/target=_blank>CHEMBL945419</a>";;-6.4;"Kim SH, Tran MT, Ruebsam F, Xiang AX, Ayida B, McGuire H, Ellis D, Blazel J, Tran CV, Murphy DE, Webber SE, Zhou Y, Shah AM, Tsan M, Showalter RE, Patel R, Gobbi A, LeBrun LA, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L, Zhao Q, Han Q, Kissinger CR.: Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (14), 2008";"CACO-2";0.0000003981071705534969
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-6.52;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.0000003019951720402019
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-7;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.0000001
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932308/target=_blank>CHEMBL932308</a>";;-5.07;"Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A, Halbfinger E, Lapidot T, Winkler I, Gabinet Y, Faier A, Yarden D, Xiang Z, Portillo FP, Haskell-Luevano C, Gilon C, Hoffman A.: Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem, Volume 51 (4), 2008";"CACO-2";0.00000851138038202376
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1032443/target=_blank>CHEMBL1032443</a>";;-7;"Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW.: Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem, Volume 51 (21), 2008";"CACO-2";0.0000001
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-5.99;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.0000010232929922807537
"MM475523";"MM475523";"CC(C)(O)CCCn1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2ccccc21";"DLEVUSWAQFQDQE-UHFFFAOYSA-N";405.5;3.48;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.84;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.00001445439770745928
"MM475524";"MM475524";"O=c1n(Cc2nc3ccccc3n2CCC2(O)CC2)c2cnccc2n1C1CC1";"KACANZKCEBVPSW-UHFFFAOYSA-N";389.46;2.85;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.86;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000013803842646028839
"MM475525";"MM475525";"CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)nc2ccccc21";"KXNQOQBSLQCPNF-UHFFFAOYSA-N";467.47;2.59;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-5.44;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.0000036307805477010103
"MM475526";"MM475526";"CCS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)nc2ccccc21";"PVHYQHOKILNVBA-UHFFFAOYSA-N";481.5;2.98;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-5.04;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000009120108393559096
"MM475530";"MM475530";"O=c1n(Cc2nc3ccccc3n2CCCO)c2cnccc2n1C1CC1";"ANQAHRBJLMNFAK-UHFFFAOYSA-N";363.42;2.31;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.94;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000011481536214968817
"MM475531";"MM475531";"O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CCC1";"LYXGPAISSWDLNQ-UHFFFAOYSA-N";391.48;3.09;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.79;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.0000162181009735893
"MM475532";"MM475532";"O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CCCC1";"ZUVAIGTVAGNNNK-UHFFFAOYSA-N";405.5;3.48;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.8;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.00001584893192461114
"MM475542";"MM475542";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2)c1C";"LJGUZUROJOJEMI-UHFFFAOYSA-N";395.44;4.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-4.67;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000021379620895022323
"MM475553";"MM475553";"O=C1CC(c2ccc(C[C@H](Nc3nc4cc(F)ccc4s3)c3nc4ccccc4[nH]3)cc2)S(=O)(=O)N1";"RXIGWQFBIHOUIE-AIBWNMTMSA-N";521.6;4.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-5.89;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.000001288249551693135
"MM475554";"MM475554";"O=C1CC(c2ccc(C[C@H](Nc3nc4c(F)cccc4s3)c3nc4ccccc4[nH]3)cc2)S(=O)(=O)N1";"YVHGLSYFEGTDEN-ZQRQZVKFSA-N";521.6;4.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-5.77;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.000001698243652461746
"MM475555";"MM475555";"O=C1Nc2c(C(F)(F)F)cccc2C1(c1ccc(O)cc1)c1ccc(O)cc1";"DOGXFLMCFMBBGH-UHFFFAOYSA-N";385.34;4.4;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887163/target=_blank>CHEMBL887163</a>";;-5.71;"Uddin MK, Reignier SG, Coulter T, Montalbetti C, GrĂĄnĂ¤s C, Butcher S, Krog-Jensen C, Felding J.: Syntheses and antiproliferative evaluation of oxyphenisatin derivatives. Bioorg Med Chem Lett, Volume 17 (10), 2007";"CACO-2";0.0000019498445997580454
"MM475558";"MM475558";"O=C1CC(c2ccc(C[C@H](Nc3nc4ccc(Cl)cc4s3)c3nc4ccccc4[nH]3)cc2)S(=O)(=O)N1";"CXAHPKZMCKBDTC-AIBWNMTMSA-N";538.05;5.11;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.1;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000007943282347242822
"MM475559";"MM475559";"Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)c1";"UEJUKJJOSDYORR-QHCPKHFHSA-N";487.54;3.52;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903513/target=_blank>CHEMBL903513</a>";;-5.19;"Mastalerz H, Chang M, Chen P, Dextraze P, Fink BE, Gavai A, Goyal B, Han WC, Johnson W, Langley D, Lee FY, Marathe P, Mathur A, Oppenheimer S, Ruediger E, Tarrant J, Tokarski JS, Vite GD, Vyas DM, Wong H, Wong TW, Zhang H, Zhang G.: New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.000006456542290346549
"MM475560";"MM475560";"O=C1CC(c2ccc(C[C@H](Nc3nc4cc(Cl)ccc4s3)c3nc4ccccc4[nH]3)cc2)S(=O)(=O)N1";"VZQJVBJXVZHFSN-AIBWNMTMSA-N";538.05;5.11;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.1;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000007943282347242822
"MM475562";"MM475562";"COc1ccc2nc(N[C@@H](Cc3ccc(C4CC(=O)NS4(=O)=O)cc3)c3nc4ccccc4[nH]3)sc2c1";"AGLPLQLLRCCZOB-BBQAJUCSSA-N";533.64;4.47;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.3;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000005011872336272725
"MM475563";"MM475563";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)NC3CCN(c4ccccc4CN4CCCC4)CC3)cc12";"PSPGVVDGXOYNRQ-UHFFFAOYSA-N";553.59;4.61;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL885807/target=_blank>CHEMBL885807</a>";;-5.89;"Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.000001288249551693135
"MM475565";"MM475565";"O=C1CC(c2ccc(C[C@H](Nc3nc4ccc(Br)cc4s3)c3nc4ccccc4[nH]3)cc2)S(=O)(=O)N1";"VBHAFECWGPNXGH-AIBWNMTMSA-N";582.51;5.22;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.7;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.00000019952623149688787
"MM475566";"MM475566";"CCN(C)Cc1ccccc1N1CCC(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)CC1";"AKDHCBCCGAELNG-UHFFFAOYSA-N";541.58;4.47;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL885807/target=_blank>CHEMBL885807</a>";;-5.57;"Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.0000026915348039269138
"MM475570";"MM475570";"O=C1CC(c2ccc(C[C@H](Nc3nc4ccccc4s3)c3nc4cc(C(F)(F)F)ccc4[nH]3)cc2)S(=O)(=O)N1";"FHGPNSZZDVEKMB-AIBWNMTMSA-N";571.61;5.48;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.4;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000003981071705534969
"MM475571";"MM475571";"O=C1CC(c2ccc(C[C@H](Nc3nc4ccccc4s3)c3nc4ccccc4[nH]3)cc2F)S(=O)(=O)N1";"WPUFGGKRENZYJA-AIBWNMTMSA-N";521.6;4.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.1;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000007943282347242822
"MM475573";"MM475573";"Cc1cc(C[C@H](Nc2nc3ccccc3s2)c2nc3ccccc3[nH]2)ccc1C1CC(=O)NS1(=O)=O";"LJCMOUXWPZKLJE-BBQAJUCSSA-N";517.64;4.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.3;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000005011872336272725
"MM475575";"MM475575";"O=C1Nc2c(ccc(F)c2F)C1(c1ccc(O)cc1)c1ccc(O)cc1";"SIWQFOKGDOBJQD-UHFFFAOYSA-N";353.32;3.66;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL887163/target=_blank>CHEMBL887163</a>";;-5.37;"Uddin MK, Reignier SG, Coulter T, Montalbetti C, GrĂĄnĂ¤s C, Butcher S, Krog-Jensen C, Felding J.: Syntheses and antiproliferative evaluation of oxyphenisatin derivatives. Bioorg Med Chem Lett, Volume 17 (10), 2007";"CACO-2";0.000004265795188015926
"MM475586";"MM475586";"CC(=O)c1sc(NC(=O)N[C@@H]2CN(C(C)=O)CC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C";"ZFRLEPMXXGKKBN-WPFOTENUSA-N";529.68;4.11;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL926177/target=_blank>CHEMBL926177</a>";;-5.55;"Pruitt JR, Batt DG, Wacker DA, Bostrom LL, Booker SK, McLaughlin E, Houghton GC, Varnes JG, Christ DD, Covington M, Das AM, Davies P, Graden D, Kariv I, Orlovsky Y, Stowell NC, Vaddi KG, Wadman EA, Welch PK, Yeleswaram S, Solomon KA, Newton RC, Decicco CP, Carter PH, Ko SS.: CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett, Volume 17 (11), 2007";"CACO-2";0.000002818382931264455
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-5.06;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000008709635899560814
"MM475587";"MM475587";"CN(C)Cc1ccccc1-c1ccc2c(c1)CCN2C(=O)c1cc(C(N)=O)nn1-c1ccc2onc(N)c2c1";"YFVYFDBYGVJKHF-UHFFFAOYSA-N";521.58;3.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL941671/target=_blank>CHEMBL941671</a>";;-6.52;"Varnes JG, Wacker DA, Jacobson IC, Quan ML, Ellis CD, Rossi KA, He MY, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. Bioorg Med Chem Lett, Volume 17 (23), 2007";"CACO-2";0.0000003019951720402019
"MM475588";"MM475588";"CCCN1CCO[C@H](c2cccc(O)c2)C1";"WYEGTIGJSHGEID-ZDUSSCGKSA-N";221.3;2.18;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL942053/target=_blank>CHEMBL942053</a>";;-4.42;"Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S.: Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorg Med Chem Lett, Volume 17 (24), 2007";"CACO-2";0.000038018939632056124
"MM475589";"MM475589";"C=CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(P(=O)(c4ccccc4)c4ccccc4)cc3)C[C@@]21C";"BYVDCSLCMPQTKD-LGTDJHALSA-N";588.73;7.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903441/target=_blank>CHEMBL903441</a>";;-5.59;"Jiang W, Fiordeliso JJ, Allan G, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Sui Z.: Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.0000025703957827688647
"MM475590";"MM475590";"NC(=O)c1cc(C(=O)N2CCc3cc(N4CCCCC4=O)ccc32)n(-c2ccc3onc(N)c3c2)n1";"ZUZGHTADXDQMQB-UHFFFAOYSA-N";485.5;2.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL941671/target=_blank>CHEMBL941671</a>";;-7;"Varnes JG, Wacker DA, Jacobson IC, Quan ML, Ellis CD, Rossi KA, He MY, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. Bioorg Med Chem Lett, Volume 17 (23), 2007";"CACO-2";0.0000001
"MM475592";"MM475592";"C=CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(P(=O)(OCC)OCC)cc3)C[C@@]21C";"BBQPRPRCQIFLIO-PABOLRIOSA-N";524.64;6.78;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903441/target=_blank>CHEMBL903441</a>";;-4.84;"Jiang W, Fiordeliso JJ, Allan G, Linton O, Tannenbaum P, Xu J, Zhu P, Gunnet J, Demarest K, Lundeen S, Sui Z.: Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.00001445439770745928
"MM475595";"MM475595";"Cc1cc(COc2ccc(C(=O)N[C@@H]3C[C@]4(CCCO4)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"AZIJSGUGQIBFMD-LLGBQNBKSA-N";475.55;3.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL945137/target=_blank>CHEMBL945137</a>";;-5.82;"Ott GR, Asakawa N, Liu RQ, Covington MB, Qian M, Vaddi K, Newton RC, Trzaskos JM, Christ DD, Galya L, Scholz T, Marshall W, Duan JJ.: Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (4), 2008";"CACO-2";0.0000015135612484362072
"MM475597";"MM475597";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Cc3ccc(-c4ccccc4CN4CCCC4)cc3)cc12";"AALHKJFWUSBUMO-UHFFFAOYSA-N";545.57;6.3;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927724/target=_blank>CHEMBL927724</a>";;-6.05;"Varnes JG, Wacker DA, Pinto DJ, Orwat MJ, Theroff JP, Wells B, Galemo RA, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000008912509381337459
"MM475598";"MM475598";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Cc3ccc(-n4ccccc4=O)cc3F)cc12";"BEEPJZYIKKHTQJ-UHFFFAOYSA-N";497.41;4.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927724/target=_blank>CHEMBL927724</a>";;-5.12;"Varnes JG, Wacker DA, Pinto DJ, Orwat MJ, Theroff JP, Wells B, Galemo RA, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.000007585775750291836
"MM475604";"MM475604";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(C(C)(C)C)CC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"VMOZPKFTEJFSFL-UKILVPOCSA-N";490.6;3.85;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-6.22;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.0000006025595860743581
"MM475605";"MM475605";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CN(CCN(C)C)CC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"GPMYKOGAWSCJCE-AZGAKELHSA-N";505.62;2.61;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-7;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.0000001
"MM475606";"MM475606";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CCOC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"RHKVTWOHZUDRRL-RBBKRZOGSA-N";435.48;2.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-5.64;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.0000022908676527677747
"MM475609";"MM475609";"Cc1cc(COc2ccc(C(=O)N[C@@H]3COCC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"JGFDLAQFMZZGPG-RBBKRZOGSA-N";435.48;2.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-6.4;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.0000003981071705534969
"MM475612";"MM475612";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Cc3ccc(-c4ccccc4S(N)(=O)=O)cc3F)cc12";"GBJUQIHMJNTHNS-UHFFFAOYSA-N";559.5;4.49;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927724/target=_blank>CHEMBL927724</a>";;-4.51;"Varnes JG, Wacker DA, Pinto DJ, Orwat MJ, Theroff JP, Wells B, Galemo RA, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.00003090295432513592
"MM475615";"MM475615";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CCCC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"HYTRMQSKFNHZJQ-JTHBVZDNSA-N";433.51;3.92;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-5.47;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.0000033884415613920275
"MM475616";"MM475616";"Cc1cc(COc2ccc(C(=O)NC3CCC3C(=O)NO)cc2)c2ccccc2n1";"GCUJRHBDOOTROU-UHFFFAOYSA-N";405.45;3.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-6.4;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.0000003981071705534969
"MM475624";"MM475624";"COc1c(NC(=O)c2ccc(C)c(N3C=C(C(=O)NCC(C)(C)CN(C)C)NN3)c2)cc(C(C)(C)C)cc1NS(C)(=O)=O";"HHUYKZMAEVYBRK-UHFFFAOYSA-N";615.8;3.3;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927883/target=_blank>CHEMBL927883</a>";;-4.89;"Cogan DA, Aungst R, Breinlinger EC, Fadra T, Goldberg DR, Hao MH, Kroe R, Moss N, Pargellis C, Qian KC, Swinamer AD.: Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000012882495516931348
"MM475629";"MM475629";"C=CCN(C(=O)[C@@]1(c2ccsc2)C[C@H]1CN)C1CC1";"PUKHAHUSCTVYAW-SWLSCSKDSA-N";276.41;2.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.28;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000005248074602497723
"MM475630";"MM475630";"C#CCN(CC=C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"OMTGXKFSSPIPRK-DZGCQCFKSA-N";274.39;1.61;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.02;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000009549925860214369
"MM475631";"MM475631";"C=CCN(CC=C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"POGCTVQQHWBYLG-DZGCQCFKSA-N";276.41;2.17;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.02;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000009549925860214369
"MM475636";"MM475636";"O=C(O)CC1OC(=O)N(CC(=O)NCC2CCC(Nc3nc4ccccc4[nH]3)CC2)c2ccccc21";"PUNZTUWXCLUSNO-UHFFFAOYSA-N";491.55;3.82;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL949298/target=_blank>CHEMBL949298</a>";;-5.49;"Seitz W, Geneste H, Backfisch G, Delzer J, Graef C, Hornberger W, Kling A, Subkowski T, Zimmermann N.: Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates. Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.000003235936569296281
"MM475641";"MM475641";"NC[C@@H]1C[C@@]1(C(=O)C1NCc2ccccc21)c1ccsc1";"RGPDAGIHVSVOQP-BDBMTWCYSA-N";298.41;2.38;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.33;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000004677351412871981
"MM475643";"MM475643";"C#CCN(CC#C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"XCUFOYFDVQBJRW-DZGCQCFKSA-N";272.37;1.06;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-4.79;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000162181009735893
"MM475644";"MM475644";"C=C(F)CN(CCOC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"WDJLGAAWPRVZRR-DZGCQCFKSA-N";312.41;1.92;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.47;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000033884415613920275
"MM475645";"MM475645";"C#CCN(CCOC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"QRBKUYBUQLQJEH-DZGCQCFKSA-N";292.4;1.07;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.49;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000003235936569296281
"MM475649";"MM475649";"C=CCN(CC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"NYOJDMQJBPXCHG-GXTWGEPZSA-N";264.39;2;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.19;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000006456542290346549
"MM475656";"MM475656";"CC[C@@H](C)Nc1ncc(C(=O)Nc2cc(C(=O)NC)ccc2C)s1";"OYOUIHFZUAKCEF-LLVKDONJSA-N";346.46;3.27;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL929968/target=_blank>CHEMBL929968</a>";;-5.08;"Hynes J, Wu H, Pitt S, Shen DR, Zhang R, Schieven GL, Gillooly KM, Shuster DJ, Taylor TL, Yang X, McIntyre KW, McKinnon M, Zhang H, Marathe PH, Doweyko AM, Kish K, Kiefer SE, Sack JS, Newitt JA, Barrish JC, Dodd J, Leftheris K.: The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. Bioorg Med Chem Lett, Volume 18 (6), 2008";"CACO-2";0.00000831763771102671
"MM475658";"MM475658";"COC(=O)CN(C1CCCN(c2ccc(-n3ccccc3=O)cc2)C1=O)S(=O)(=O)c1cc2ccc(Cl)nc2s1";"GZPHCYJSTRJCEN-UHFFFAOYSA-N";587.08;3.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL933441/target=_blank>CHEMBL933441</a>";;-5.46;"Smallheer JM, Wang S, Laws ML, Nakajima S, Hu Z, Han W, Jacobson I, Luettgen JM, Rossi KA, Rendina AR, Knabb RM, Wexler RR, Lam PY, Quan ML.: Sulfonamidolactam inhibitors of coagulation factor Xa. Bioorg Med Chem Lett, Volume 18 (7), 2008";"CACO-2";0.000003467368504525317
"MM475666";"MM475666";"COc1cccc(CN2C(=O)C[C@]3(C2=O)C(=O)N(CC(=O)O)c2ccc(Cl)cc23)c1";"IJRKCYVJCJRDTH-OAQYLSRUSA-N";428.83;1.98;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL937320/target=_blank>CHEMBL937320</a>";;-6.1;"Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.: Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.0000007943282347242822
"MM475668";"MM475668";"Cc1noc(-c2ccccc2)c1CN1CC2(CC1=O)C(=O)N(CC(=O)O)c1ccc(Cl)cc12";"UJYVUWBBXAPUDC-UHFFFAOYSA-N";465.89;3.4;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL937320/target=_blank>CHEMBL937320</a>";;-5.68;"Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.: Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.0000020892961308540407
"Sulpiride";"MM00568";"CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC";"BGRJTUBHPOOWDU-UHFFFAOYSA-N";341.43;0.56;"5355";"CHEMBL26";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-6.64;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00000022908676527677748
"Sulpiride";"MM00568";"CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC";"BGRJTUBHPOOWDU-UHFFFAOYSA-N";341.43;0.56;"5355";"CHEMBL26";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-6.41;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000003890451449942805
"MM475675";"MM475675";"O=C(O)CN1C(=O)[C@@]2(CC(=O)N(Cc3cc(Cl)ccc3F)C2=O)c2cc(Cl)ccc21";"IXKFWNVFUXXEFY-HXUWFJFHSA-N";451.24;2.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL937320/target=_blank>CHEMBL937320</a>";;-4.58;"Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.: Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.000026302679918953814
"MM475676";"MM475676";"O=C(O)CN1C(=O)[C@@]2(CC(=O)N(Cc3ccccc3F)C2=O)c2cc(Cl)ccc21";"SKLDVYDFQCXARY-HXUWFJFHSA-N";416.79;2.11;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL937320/target=_blank>CHEMBL937320</a>";;-5.62;"Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.: Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.0000023988329190194897
"MM475677";"MM475677";"CCN(CC)C(=O)[C@@]1(c2ccc3c(c2)OCO3)C[C@H]1CN";"PRTQZTFEHWCKDF-BLLLJJGKSA-N";290.36;1.5;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930503/target=_blank>CHEMBL930503</a>";;-5.33;"Tamiya J, Dyck B, Zhang M, Phan K, Fleck BA, Aparicio A, Jovic F, Tran JA, Vickers T, Grey J, Foster AC, Chen C.: Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000004677351412871981
"MM475681";"MM475681";"Nc1noc2ccc(-n3nc(C(F)(F)F)c4c3C(=O)N(c3ccc(-c5ccccc5CN5CC[C@@H](O)C5)cc3F)CC4)cc12";"BABFXZTUINNAIF-HXUWFJFHSA-N";606.58;5.19;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868640/target=_blank>CHEMBL868640</a>";;-4.89;"Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PY.: 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000012882495516931348
"MM475682";"MM475682";"CC(C(=O)O)c1ccc(-c2ccc(C3CCCCC3)cc2)c(F)c1";"KKDPGNCSRACGCK-UHFFFAOYSA-N";326.41;5.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL880472/target=_blank>CHEMBL880472</a>";;-5.3;"Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, Fontanella L, Misiano P, Bigogno C, Rizzi A, Riccardi B, Biscaioli M, Marchetti S, Puccini P, Catinella S, Rondelli I, Cenacchi V, Bolzoni PT, Caruso P, Villetti G, Facchinetti F, Del Giudice E, Moretto N, Imbimbo BP.: Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J Med Chem, Volume 48 (18), 2005";"CACO-2";0.000005011872336272725
"Alprenolol";"MM00440";"C=CCc1ccccc1OC[C@H](O)CNC(C)C";"PAZJSJFMUHDSTF-CQSZACIVSA-N";249.35;2.15;"2119";"CHEMBL266195";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-4.62;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.0000239883291901949
"Alprenolol";"MM00440";"C=CCc1ccccc1OC[C@H](O)CNC(C)C";"PAZJSJFMUHDSTF-CQSZACIVSA-N";249.35;2.15;"2119";"CHEMBL266195";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-3.62;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.000239883291901949
"MM475687";"MM475687";"CN(C(=O)[C@H](Cc1ccc(CN)cc1)NS(=O)(=O)c1ccc2ccccc2c1)C1CCCC1";"IECQKBVHIONTKP-VWLOTQADSA-N";465.62;3.59;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619357/target=_blank>CHEMBL619357</a>";;-4.96;"Lee K, Jung WH, Park CW, Hong CY, Kim IC, Kim S, Oh YS, Kwon OH, Lee SH, Park HD, Kim SW, Lee YH, Yoo YJ.: Benzylamine-based selective and orally bioavailable inhibitors of thrombin. Bioorg Med Chem Lett, Volume 8 (18), 1998";"CACO-2";0.000010964781961431852
"MM475690";"MM475690";"O=C1C(NS(=O)(=O)c2cc3ccc(Cl)nc3s2)CCCN1c1ccc(-n2ccccc2=O)cc1";"XEOZTCMTXQCNRS-UHFFFAOYSA-N";515.02;3.57;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL933441/target=_blank>CHEMBL933441</a>";;-5.7;"Smallheer JM, Wang S, Laws ML, Nakajima S, Hu Z, Han W, Jacobson I, Luettgen JM, Rossi KA, Rendina AR, Knabb RM, Wexler RR, Lam PY, Quan ML.: Sulfonamidolactam inhibitors of coagulation factor Xa. Bioorg Med Chem Lett, Volume 18 (7), 2008";"CACO-2";0.0000019952623149688787
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL945419/target=_blank>CHEMBL945419</a>";;-5;"Kim SH, Tran MT, Ruebsam F, Xiang AX, Ayida B, McGuire H, Ellis D, Blazel J, Tran CV, Murphy DE, Webber SE, Zhou Y, Shah AM, Tsan M, Showalter RE, Patel R, Gobbi A, LeBrun LA, Bartkowski DM, Nolan TG, Norris DA, Sergeeva MV, Kirkovsky L, Zhao Q, Han Q, Kissinger CR.: Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett, Volume 18 (14), 2008";"CACO-2";0.00001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-5;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.00001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638187/target=_blank>CHEMBL638187</a>";;-4.5;"Wohnsland F, Faller B.: High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem, Volume 44 (6), 2001";"CACO-2";0.000031622776601683795
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619358/target=_blank>CHEMBL619358</a>";;-4.38;"Mandagere AK, Thompson TN, Hwang KK.: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem, Volume 45 (2), 2002";"CACO-2";0.00004168693834703355
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL840608/target=_blank>CHEMBL840608</a>";;-4.9;"Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.: In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem, Volume 48 (3), 2005";"CACO-2";0.000012589254117941661
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932308/target=_blank>CHEMBL932308</a>";;-4.6;"Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A, Halbfinger E, Lapidot T, Winkler I, Gabinet Y, Faier A, Yarden D, Xiang Z, Portillo FP, Haskell-Luevano C, Gilon C, Hoffman A.: Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem, Volume 51 (4), 2008";"CACO-2";0.000025118864315095822
"MM475691";"MM475691";"CNC(=O)CN(C1CCCN(c2ccc(-n3ccccc3=O)cc2F)C1=O)S(=O)(=O)c1cc2ccc(Cl)nc2s1";"SGTJKWMCAVDHCK-UHFFFAOYSA-N";604.09;3.17;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL933441/target=_blank>CHEMBL933441</a>";;-7;"Smallheer JM, Wang S, Laws ML, Nakajima S, Hu Z, Han W, Jacobson I, Luettgen JM, Rossi KA, Rendina AR, Knabb RM, Wexler RR, Lam PY, Quan ML.: Sulfonamidolactam inhibitors of coagulation factor Xa. Bioorg Med Chem Lett, Volume 18 (7), 2008";"CACO-2";0.0000001
"MM475692";"MM475692";"COC(=O)N[C@H](C(=O)NN(CCC[C@@](O)(Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)Cc1ccc(-c2ccncc2)cc1)C(C)(C)C";"MXBJTNCGIKKFSM-IBHRRMRLSA-N";707.87;4.88;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048544/target=_blank>CHEMBL1048544</a>";;-5.52;"Mahalingam AK, Axelsson L, Ekegren JK, Wannberg J, KihlstrĂ¶m J, Unge T, Wallberg H, Samuelsson B, Larhed M, Hallberg A.: HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.0000030199517204020193
"MM475697";"MM475697";"O=C1C(NS(=O)(=O)c2cc3ccc(Cl)nc3s2)CCCN1c1ccc(-n2ccccc2=O)cc1F";"RNDGHCNVRQCTJM-UHFFFAOYSA-N";533.01;3.71;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL933441/target=_blank>CHEMBL933441</a>";;-5.08;"Smallheer JM, Wang S, Laws ML, Nakajima S, Hu Z, Han W, Jacobson I, Luettgen JM, Rossi KA, Rendina AR, Knabb RM, Wexler RR, Lam PY, Quan ML.: Sulfonamidolactam inhibitors of coagulation factor Xa. Bioorg Med Chem Lett, Volume 18 (7), 2008";"CACO-2";0.00000831763771102671
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-4.55;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.00002818382931264455
"MM475704";"MM475704";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(-c4ccccc4CN)cc2)CC3)cc1";"GNENBXDFTFJVCO-UHFFFAOYSA-N";467.53;3.31;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.92;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.0000012022644346174132
"MM475705";"MM475705";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)C(=O)CC(F)(F)F)c1C";"TWNPZFARHUKPBV-UHFFFAOYSA-N";548.54;5.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.52;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.0000030199517204020193
"MM475706";"MM475706";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)C(=O)CC(C)(C)C)c1C";"QDKJEEQYGZGXKJ-UHFFFAOYSA-N";536.65;5.81;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.12;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000007585775750291836
"MM475707";"MM475707";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)C(=O)c2ccccc2)c1C";"KMOYVJSVLLXFQU-UHFFFAOYSA-N";542.62;5.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.55;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000002818382931264455
"MM475708";"MM475708";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN2CCN(C)C2=O)c1C";"CTSLPVTWRWISJE-UHFFFAOYSA-N";507.57;4.28;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.7;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.0000019952623149688787
"MM475709";"MM475709";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN2CCCC(C)(C)C2=O)c1C";"FPJPMEXULUCUCB-UHFFFAOYSA-N";534.64;5.56;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.07;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.00000851138038202376
"MM475710";"MM475710";"CC(=O)N(C)Cc1cc(-c2ncco2)ccc1-c1ccccc1S(=O)(=O)Nc1onc(C)c1C";"WOBBXUGAQYJTDY-UHFFFAOYSA-N";480.55;4.39;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638026/target=_blank>CHEMBL638026</a>";;-5.89;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000001288249551693135
"MM475711";"MM475711";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2COC(C)C)c1C";"XJUXAAFCMXUBET-UHFFFAOYSA-N";467.55;5.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-4.87;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000013489628825916533
"4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one";"MM00331";"Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C";"RMMXTBMQSGEXHJ-UHFFFAOYSA-N";231.3;1.55;"6009";"CHEMBL288470";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-4.44;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.0000363078054770101
"MM475714";"MM475714";"N=C(N)NCc1ccccc1";"ABSNGNUGFQIDDO-UHFFFAOYSA-N";149.2;0.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656467/target=_blank>CHEMBL656467</a>";;-5.65;"10.1016/S0960-894X(01)80549-7";"CACO-2";0.0000022387211385683376
"MM475717";"MM475717";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CNCC(F)(F)F)c1C";"ZHRNJYRTUCXIIO-UHFFFAOYSA-N";506.51;5.07;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.07;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.00000851138038202376
"MM475718";"MM475718";"CC(=O)NCc1cc(-c2ncco2)ccc1-c1ccccc1S(=O)(=O)Nc1onc(C)c1C";"XAHBFCGXCQNZHI-UHFFFAOYSA-N";466.52;4.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.89;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000001288249551693135
"MM475719";"MM475719";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2Cc2ncco2)c1C";"QSDFLNIZMIGXOO-UHFFFAOYSA-N";476.51;4.99;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-4.83;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000014791083881682072
"MM475722";"MM475722";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)C(=O)CC2CCCCC2)c1C";"XFVRGRHYQOBYLX-UHFFFAOYSA-N";562.69;6.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.23;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000005888436553555884
"MM475723";"MM475723";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)c2ccccc2)c1C";"HKMVKDPUVNFFAO-UHFFFAOYSA-N";514.61;6.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-4.96;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000010964781961431852
"MM475724";"MM475724";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN2CCC(C)(C)C2=O)c1C";"XPBBDUYWSIZCNR-UHFFFAOYSA-N";520.61;5.17;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.39;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000004073802778041131
"Cimetidine";"MM00463";"CNC(=NCCSCc1nc[nH]c1C)NC#N";"AQIXAKUUQRKLND-UHFFFAOYSA-N";252.35;0.6;"2756";"CHEMBL30";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-5.91;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000012302687708123811
"Cimetidine";"MM00463";"CNC(=NCCSCc1nc[nH]c1C)NC#N";"AQIXAKUUQRKLND-UHFFFAOYSA-N";252.35;0.6;"2756";"CHEMBL30";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-5.92;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000012022644346174132
"MM475725";"MM475725";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2Cn2ccnc2)c1C";"KAIWKTKPOCNWMM-UHFFFAOYSA-N";475.53;4.66;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.12;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000007585775750291836
"MM475726";"MM475726";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)C(=O)c2cc(Cl)cc(Cl)c2)c1C";"LNPRLVTXUXFAEN-UHFFFAOYSA-N";611.51;6.99;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-5.37;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000004265795188015926
"MM475727";"MM475727";"COc1ccc2ccc(S(=O)(=O)N[C@@H](CCCNc3ccccn3)C(=O)N3CCC(C)CC3)cc2c1";"GDANXLYNLCWKHK-VWLOTQADSA-N";510.66;4.04;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656468/target=_blank>CHEMBL656468</a>";;-5.52;"10.1016/S0960-894X(00)80064-5";"CACO-2";0.0000030199517204020193
"MM475728";"MM475728";"CC1CCN(C(=O)[C@H](CCCNc2cnccn2)NS(=O)(=O)c2ccc3ccccc3c2)CC1";"LUYRHAKKGKFCME-QHCPKHFHSA-N";481.62;3.43;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656468/target=_blank>CHEMBL656468</a>";;-4.85;"10.1016/S0960-894X(00)80064-5";"CACO-2";0.000014125375446227555
"MM475732";"MM475732";"CC1CCN(C(=O)C(Cc2cc3c(N)nccc3s2)NS(=O)(=O)c2ccc3ccccc3c2)CC1";"SEFSJIDRHBCMDE-UHFFFAOYSA-N";508.67;4.18;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-4.93;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.000011748975549395302
"MM475734";"MM475734";"COc1ccc2ccc(S(=O)(=O)NC(Cc3cc4c(N)nccc4o3)C(=O)N3CCC(C)CC3)cc2c1";"IVTCEZMAQSROIP-UHFFFAOYSA-N";522.63;3.72;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-6.05;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.0000008912509381337459
"MM475735";"MM475735";"COc1ccc2ccc(S(=O)(=O)NC(Cc3cc4c(N)nccc4s3)C(=O)N3CCC(C(C)=O)CC3)cc2c1";"GNDOAXCVKPOVTI-UHFFFAOYSA-N";566.71;3.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-5.64;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.0000022908676527677747
"MM475736";"MM475736";"COc1cc(C(=O)NCC2CCN(c3ccncc3)CC2)cc(OCCc2ccc(Cl)cc2Cl)c1Cl";"VPVZSERFJANUOF-UHFFFAOYSA-N";548.9;6.32;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL657446/target=_blank>CHEMBL657446</a>";;-7.29;"NazarĂ© M, Matter H, Klingler O, Al-Obeidi F, Schreuder H, Zoller G, Czech J, Lorenz M, Dudda A, Peyman A, Nestler HP, Urmann M, Bauer A, Laux V, Wehner V, Will DW.: Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand. Bioorg Med Chem Lett, Volume 14 (11), 2004";"CACO-2";0.00000005128613839913648
"MM475737";"MM475737";"COc1cc2ccc(S(=O)(=O)NC(Cc3cc4c(N)nccc4s3)C(=O)N3CCC(C)CC3)cc2cc1OC";"HTQPFCPNXGXUIQ-UHFFFAOYSA-N";568.72;4.2;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-5.01;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.000009772372209558111
"MM475741";"MM475741";"CCCCN1CCN(C(COCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ccccc2)CC1";"AHZURDXLPGFUJZ-UHFFFAOYSA-N";488.52;6.4;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656466/target=_blank>CHEMBL656466</a>";;-5.28;"Genicot C, Christophe B, Collart P, Gillard M, Goossens L, HĂ©nichart JP, Lassoie MA, Moureau F, Neuwels M, Nicolas JM, Pasau P, QuĂ©rĂ© L, Ryckmans T, Stiernet F, Taverne T, Van Keulen BJ.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg Med Chem Lett, Volume 13 (3), 2003";"CACO-2";0.000005248074602497723
"MM475742";"MM475742";"O=C(C(=O)N1CCN(C(=O)c2ccccc2)CC1)c1c[nH]c2ccccc12";"GCCPYLCLTHXPRB-UHFFFAOYSA-N";361.4;2.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL956793/target=_blank>CHEMBL956793</a>";;-4.64;"Meanwell NA, Wallace OB, Fang H, Wang H, Deshpande M, Wang T, Yin Z, Zhang Z, Pearce BC, James J, Yeung KS, Qiu Z, Kim Wright JJ, Yang Z, Zadjura L, Tweedie DL, Yeola S, Zhao F, Ranadive S, Robinson BA, Gong YF, Wang HG, Spicer TP, Blair WS, Shi PY, Colonno RJ, Lin PF.: Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns. Bioorg Med Chem Lett, Volume 19 (7), 2009";"CACO-2";0.00002290867652767775
"MM475744";"MM475744";"CC1=CC(=O)N(Nc2nc(-c3cccs3)nc3cc(N(C)C)ccc23)C1=O";"NFDSCEIXHOWVBA-UHFFFAOYSA-N";379.45;3.07;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655617/target=_blank>CHEMBL655617</a>";;-5.85;"Palanki MS, Erdman PE, Ren M, Suto M, Bennett BL, Manning A, Ransone L, Spooner C, Desai S, Ow A, Totsuka R, Tsao P, Toriumi W.: The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies. Bioorg Med Chem Lett, Volume 13 (22), 2003";"CACO-2";0.0000014125375446227554
"MM475745";"MM475745";"CC1=CC(=O)N(Nc2nc(C(F)(F)F)nc3cc(N(C)C)ccc23)C1=O";"JAQNJKSJWBJPRF-UHFFFAOYSA-N";365.32;2.36;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655617/target=_blank>CHEMBL655617</a>";;-5.77;"Palanki MS, Erdman PE, Ren M, Suto M, Bennett BL, Manning A, Ransone L, Spooner C, Desai S, Ow A, Totsuka R, Tsao P, Toriumi W.: The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies. Bioorg Med Chem Lett, Volume 13 (22), 2003";"CACO-2";0.000001698243652461746
"MM475747";"MM475747";"COc1ccc2nc(-c3cccs3)nc(NN3C(=O)C=C(C)C3=O)c2c1";"WAPBQFRODQBNJI-UHFFFAOYSA-N";366.4;3.01;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655617/target=_blank>CHEMBL655617</a>";;-5.79;"Palanki MS, Erdman PE, Ren M, Suto M, Bennett BL, Manning A, Ransone L, Spooner C, Desai S, Ow A, Totsuka R, Tsao P, Toriumi W.: The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies. Bioorg Med Chem Lett, Volume 13 (22), 2003";"CACO-2";0.0000016218100973589298
"MM475750";"MM475750";"Cc1cc(COc2ccc(NC(=O)[C@H]3NCCC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"JNLVNYQWIZOKGL-UNMCSNQZSA-N";434.5;2.93;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-5.66;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.0000021877616239495517
"MM475751";"MM475751";"Cc1cc(COc2ccc(NC(=O)[C@H]3CN(C(=O)c4ccco4)CC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"DENDBTOOZOCPQJ-ZEQRLZLVSA-N";528.57;3.94;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-6.7;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.00000019952623149688787
"MM475752";"MM475752";"O=C(O)CC1c2ccccc2C(=O)N(CC(=O)NCc2ccc(Nc3nc4ccccc4[nH]3)cc2)c2ccccc21";"CBJXBILJNVPTJT-UHFFFAOYSA-N";545.6;5.19;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656464/target=_blank>CHEMBL656464</a>";;-5.8;"Kling A, Backfisch G, Delzer J, Geneste H, Graef C, Holzenkamp U, Hornberger W, Lange UE, Lauterbach A, Mack H, Seitz W, Subkowski T.: Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists. Bioorg Med Chem Lett, Volume 12 (3), 2002";"CACO-2";0.000001584893192461114
"MM475753";"MM475753";"Cc1cc(COc2ccc(NC(=O)[C@H]3CCN(C(=O)C4CC4)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"TZGDIJWAFCVLEH-ZEQRLZLVSA-N";502.57;3.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-6.7;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.00000019952623149688787
"MM475754";"MM475754";"Cc1cc(COc2ccc(NC(=O)[C@H]3CCN(C(=O)c4ccco4)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"FGMZHMTZHZNKCA-ZEQRLZLVSA-N";528.57;3.94;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-7;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.0000001
"MM475755";"MM475755";"O=C(O)CC1c2ccccc2C(=O)N(CC(=O)NC[C@H]2CC[C@H](Nc3nc4ccccc4[nH]3)CC2)c2ccccc21";"YJWMMXDEDCMARP-FPCUACJBSA-N";551.65;4.92;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL657447/target=_blank>CHEMBL657447</a>";;-5.57;"Kling A, Backfisch G, Delzer J, Geneste H, Graef C, Holzenkamp U, Hornberger W, Lange UE, Lauterbach A, Mack H, Seitz W, Subkowski T.: Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists. Bioorg Med Chem Lett, Volume 12 (3), 2002";"CACO-2";0.0000026915348039269138
"MM475756";"MM475756";"FC(F)(F)c1cc(COCC(c2ccccc2)N2CCN(CCCCc3nnn[nH]3)CC2)cc(C(F)(F)F)c1";"VLROGTSVMJUONC-UHFFFAOYSA-N";556.56;5.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656466/target=_blank>CHEMBL656466</a>";;-5.59;"Genicot C, Christophe B, Collart P, Gillard M, Goossens L, HĂ©nichart JP, Lassoie MA, Moureau F, Neuwels M, Nicolas JM, Pasau P, QuĂ©rĂ© L, Ryckmans T, Stiernet F, Taverne T, Van Keulen BJ.: Discovery of orally bioavailable NK1 receptor antagonists. Bioorg Med Chem Lett, Volume 13 (3), 2003";"CACO-2";0.0000025703957827688647
"MM475758";"MM475758";"N=C(N)c1cccc(-n2nc(C(F)(F)F)cc2C(=O)Nc2ncc(-c3ccccc3S(N)(=O)=O)cn2)c1";"CMCYVWKFRRVLKG-UHFFFAOYSA-N";530.49;2.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635761/target=_blank>CHEMBL635761</a>";;-7;"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 44 (4), 2001";"CACO-2";0.0000001
"MM475759";"MM475759";"c1ccc(Cn2cnc3ccccc32)cc1";"MNEIJGDSFRHGMS-UHFFFAOYSA-N";208.26;3.08;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.15;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.00007079457843841373
"MM475761";"MM475761";"O=C(O)Cc1ccc(Cn2cccn2)cc1";"FGOUWZMAKYNJBA-UHFFFAOYSA-N";216.24;1.56;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-5.54;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.000002884031503126606
"MM475763";"MM475763";"O=C(O)c1cccc(Cc2ncccn2)c1";"CZXRPFHLIMKLEM-UHFFFAOYSA-N";214.22;1.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-5.21;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.000006165950018614822
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL840610/target=_blank>CHEMBL840610</a>";;-6.41;"Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.: In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem, Volume 48 (3), 2005";"CACO-2";0.0000003890451449942805
"MM475764";"MM475764";"Cc1c(C)c(S(=O)(=O)NCC(=O)NC(Cc2ccc3c(N)nccc3c2)C(=O)N2CCCCC2)c(C)c2c1OC(C)(C)CC2";"ASSJINMPZYFYOZ-UHFFFAOYSA-N";621.8;3.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655613/target=_blank>CHEMBL655613</a>";;-5.43;"Rewinkel JB, Lucas H, van Galen PJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (5), 1999";"CACO-2";0.0000037153522909717276
"MM475766";"MM475766";"CCC12CCN(CC3(O)CC3)C(Cc3ccc(O)cc31)C2(C)C";"ZDXGFIXMPOUDFF-UHFFFAOYSA-N";315.46;3.22;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-5.1;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000007943282347242822
"MM475768";"MM475768";"NCc1cccc(Cc2ncccn2)c1";"YLFFHNIXEICBHR-UHFFFAOYSA-N";199.26;1.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.6;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.000025118864315095822
"MM475769";"MM475769";"NC(=O)c1cccc(Cn2cnc3ccccc32)c1";"UBHDDHSBVGWOJJ-UHFFFAOYSA-N";251.29;2.18;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-4.6;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.000025118864315095822
"MM475770";"MM475770";"CCC(C)[C@H](NC(=O)[C@@H](C[C@H](O)[C@H](CC1CCCCC1)NC(=O)CC(C)(C)C)C(C)C)C(=O)NCc1ccccn1";"RLQUQIUJPBZNMI-OQXVLSAPSA-N";572.84;5.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633586/target=_blank>CHEMBL633586</a>";;-4.94;"10.1016/S0960-894X(00)80673-3";"CACO-2";0.000011481536214968817
"MM475771";"MM475771";"CC(C)[C@H](NC(=O)c1ccccn1)C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN[C@@H](Cc1ccc(-c2ccccc2)cc1)C(N)=O";"QBBPIOZJQQZCKA-YRCZKMHPSA-N";607.76;3.28;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655616/target=_blank>CHEMBL655616</a>";;-4.99;"NĂ¶teberg D, Hamelink E, HultĂ©n J, Wahlgren M, Vrang L, Samuelsson B, Hallberg A.: Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes. J Med Chem, Volume 46 (5), 2003";"CACO-2";0.000010232929922807536
"MM475772";"MM475772";"CS(=O)(=O)c1ccccc1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2cccc(C(=N)N)c2)c(F)c1";"ZLJCFXPKCSWCGG-UHFFFAOYSA-N";545.52;4.64;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635761/target=_blank>CHEMBL635761</a>";;-6.7;"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 44 (4), 2001";"CACO-2";0.00000019952623149688787
"MM475773";"MM475773";"Cc1cc(COc2ccc(S(=O)(=O)CC3CCN(C)CC3C(=O)NO)cc2)c2ccccc2n1";"UJCQVXJYOKSWGB-UHFFFAOYSA-N";483.59;2.97;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-6.7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.00000019952623149688787
"MM475774";"MM475774";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Nc3ccc(C(=O)N4CCCC4)cc3F)cc12";"XFHPQLVMJVEBAR-UHFFFAOYSA-N";502.43;4.24;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-4.6;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.000025118864315095822
"MM475775";"MM475775";"O=C(O)c1cnc(N(C(=O)c2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C2CCCCC2)s1";"KVOPMRICDIBARO-UHFFFAOYSA-N";504.53;6.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838441/target=_blank>CHEMBL838441</a>";;-4.83;"Shipps GW, Deng Y, Wang T, Popovici-Muller J, Curran PJ, Rosner KE, Cooper AB, Girijavallabhan V, Butkiewicz N, Cable M.: Aminothiazole inhibitors of HCV RNA polymerase. Bioorg Med Chem Lett, Volume 15 (1), 2005";"CACO-2";0.000014791083881682072
"MM475776";"MM475776";"C[C@H]1[C@H](OC(=O)CCC(=O)O)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3";"FIHJKUPKCHIPAT-AHIGJZGOSA-N";384.43;2.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-5.4;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000003981071705534969
"MM475777";"MM475777";"C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(N(C)S(=O)(=O)c2ccccc2)c1";"KLSDKCKHWHCJSM-CLOONOSVSA-N";557.69;3.59;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838212/target=_blank>CHEMBL838212</a>";;-5.33;"Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S, Oue M, Tsujiuchi H, Furutani Y, Kato S.: Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. Bioorg Med Chem Lett, Volume 15 (4), 2005";"CACO-2";0.000004677351412871981
"MM475778";"MM475778";"C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(NCc2ccccc2)c1";"LGHCNFZLEQZRMA-CLOONOSVSA-N";493.63;4.37;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838212/target=_blank>CHEMBL838212</a>";;-5.05;"Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S, Oue M, Tsujiuchi H, Furutani Y, Kato S.: Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. Bioorg Med Chem Lett, Volume 15 (4), 2005";"CACO-2";0.00000891250938133746
"MM475779";"MM475779";"CC(=O)N1CCCC1(CC(=O)NO)CS(=O)(=O)c1ccc(OCc2cc(C)nc3ccccc23)cc1";"SGKYEMLYQFTLEW-UHFFFAOYSA-N";511.6;3.17;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-6.22;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000006025595860743581
"MM475780";"MM475780";"CCCCN1CCC(C(=O)NO)C(CS(=O)(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"IGCXXFVEWDCCKV-UHFFFAOYSA-N";525.67;4.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-5.8;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.000001584893192461114
"MM475781";"MM475781";"Cn1nnnc1-c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1";"HEXTXRMVMKIBQR-RZPFDVGOSA-N";505.64;4.65;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851906/target=_blank>CHEMBL851906</a>";;-5.7;"De Lucca GV, Kim UT, Vargo BJ, Duncia JV, Santella JB, Gardner DS, Zheng C, Liauw A, Wang Z, Emmett G, Wacker DA, Welch PK, Covington M, Stowell NC, Wadman EA, Das AM, Davies P, Yeleswaram S, Graden DM, Solomon KA, Newton RC, Trainor GL, Decicco CP, Ko SS.: Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.0000019952623149688787
"MM475782";"MM475782";"C#CN1CCC(C(=O)NO)C(CS(=O)(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)C1";"VACPECYZKUSTIV-UHFFFAOYSA-N";493.59;2.93;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-5.89;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.000001288249551693135
"MM475783";"MM475783";"Cc1cc(COc2ccc(S(=O)(=O)CC3(CC(=O)NO)CCCN3)cc2)c2ccccc2n1";"TUZYRFJHUHCUNQ-UHFFFAOYSA-N";469.56;2.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-6.4;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000003981071705534969
"MM475784";"MM475784";"C[C@H](Cc1c[nH]c2c(OS(C)(=O)=O)cccc12)NC[C@H](O)c1cccc(CS(=O)(=O)c2ccccc2)c1";"YIAUQEMHLVUETN-CLOONOSVSA-N";542.68;3.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825373/target=_blank>CHEMBL825373</a>";;-6.05;"Sawa M, Mizuno K, Harada H, Tateishi H, Arai Y, Suzuki S, Oue M, Tsujiuchi H, Furutani Y, Kato S.: Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety. Bioorg Med Chem Lett, Volume 15 (4), 2005";"CACO-2";0.0000008912509381337459
"MM475785";"MM475785";"Cc1cc(COc2ccc(S(=O)(=O)CC3(CC(=O)NO)CCCCC3)cc2)c2ccccc2n1";"UXWAVVXCMUJGHD-UHFFFAOYSA-N";482.6;4.74;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-4.66;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.00002187761623949552
"MM475786";"MM475786";"CNCc1nccn1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)c(F)c1";"XHPFWZMUFYSOAQ-UHFFFAOYSA-N";514.44;3.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-6.7;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.00000019952623149688787
"MM475787";"MM475787";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Nc3ccc(-c4ccncc4S(N)(=O)=O)cc3F)cc12";"SIRYBZWAPDLBNE-UHFFFAOYSA-N";561.48;3.72;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-6.27;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.0000005370317963702533
"MM475788";"MM475788";"COc1cccc(-n2c(=O)n(Cc3c(F)cccc3Br)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F";"JPJCBKFCBLFFDG-IBGZPJMESA-N";559.37;2.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851904/target=_blank>CHEMBL851904</a>";;-4.86;"Guo Z, Wu D, Zhu YF, Tucci FC, Regan CF, Rowbottom MW, Struthers RS, Xie Q, Reijmers S, Sullivan SK, Sai Y, Chen C.: Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists. Bioorg Med Chem Lett, Volume 15 (16), 2005";"CACO-2";0.000013803842646028839
"MM475792";"MM475792";"Cc1cc(C(=O)Nc2ccc(-c3ccccc3S(N)(=O)=O)cc2)n(-c2cccc(C(=N)N)c2)n1";"APFKCRTWNKCURW-UHFFFAOYSA-N";474.55;3.03;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638021/target=_blank>CHEMBL638021</a>";;-6.52;"Pruitt JR, Pinto DJ, Galemmo RA, Alexander RS, Rossi KA, Wells BL, Drummond S, Bostrom LL, Burdick D, Bruckner R, Chen H, Smallwood A, Wong PC, Wright MR, Bai S, Luettgen JM, Knabb RM, Lam PY, Wexler RR.: Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1). J Med Chem, Volume 46 (25), 2003";"CACO-2";0.0000003019951720402019
"MM475793";"MM475793";"O=C(O)c1ccc(-c2ccc(Cl)cc2COc2ccc(-c3nc4cc(C(=O)O)ccc4n3C3CCCCC3)cc2)cc1";"KCQLAJFCUNNGOR-UHFFFAOYSA-N";581.07;8.5;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL866683/target=_blank>CHEMBL866683</a>";;-4.63;"Hirashima S, Suzuki T, Ishida T, Noji S, Yata S, Ando I, Komatsu M, Ikeda S, Hashimoto H.: Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem, Volume 49 (15), 2006";"CACO-2";0.00002344228815319923
"MM475794";"MM475794";"CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4cc(F)cc(F)c4)c4ccccc43)cc1C2";"MLXHPMSHFIOVTD-HHHXNRCGSA-N";517.49;2.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL911974/target=_blank>CHEMBL911974</a>";;-4.82;"Bell IM, Bednar RA, Fay JF, Gallicchio SN, Hochman JH, McMasters DR, Miller-Stein C, Moore EL, Mosser SD, Pudvah NT, Quigley AG, Salvatore CA, Stump CA, Theberge CR, Wong BK, Zartman CB, Zhang XF, Kane SA, Graham SL, Vacca JP, Williams TM.: Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett, Volume 16 (24), 2006";"CACO-2";0.000015135612484362071
"MM475796";"MM475796";"CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(C4CCS(=O)(=O)C4)c4ccccc43)cc1C2";"MUJODSURWGPHBP-IXXGTQFESA-N";523.57;0.82;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL911974/target=_blank>CHEMBL911974</a>";;-6.52;"Bell IM, Bednar RA, Fay JF, Gallicchio SN, Hochman JH, McMasters DR, Miller-Stein C, Moore EL, Mosser SD, Pudvah NT, Quigley AG, Salvatore CA, Stump CA, Theberge CR, Wong BK, Zartman CB, Zhang XF, Kane SA, Graham SL, Vacca JP, Williams TM.: Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett, Volume 16 (24), 2006";"CACO-2";0.0000003019951720402019
"MM475798";"MM475798";"CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4nccs4)c4ccccc43)cc1C2";"SXMSIUHHVAMQCA-XMMPIXPASA-N";488.53;1.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL911974/target=_blank>CHEMBL911974</a>";;-4.89;"Bell IM, Bednar RA, Fay JF, Gallicchio SN, Hochman JH, McMasters DR, Miller-Stein C, Moore EL, Mosser SD, Pudvah NT, Quigley AG, Salvatore CA, Stump CA, Theberge CR, Wong BK, Zartman CB, Zhang XF, Kane SA, Graham SL, Vacca JP, Williams TM.: Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists. Bioorg Med Chem Lett, Volume 16 (24), 2006";"CACO-2";0.000012882495516931348
"MM475801";"MM475801";"Cc1cc(OCCCON=C(N)N)cc(OS(=O)(=O)c2ccccc2S(C)(=O)=O)c1";"CFBZFBMYIQZREO-UHFFFAOYSA-N";457.53;1.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL696915/target=_blank>CHEMBL696915</a>";;-5.62;"Tomczuk B, Lu T, Soll RM, Fedde C, Wang A, Murphy L, Crysler C, Dasgupta M, Eisennagel S, Spurlino J, Bone R.: Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors. Bioorg Med Chem Lett, Volume 13 (8), 2003";"CACO-2";0.0000023988329190194897
"MM29821";"MM29821";"CCCS(=O)(=O)N1CCC(CNC(=O)c2ccc(Cl)cc2Cl)(C(=O)N2CCOCC2)CC1";"FQNRAIQUCSDYQF-UHFFFAOYSA-N";506.45;2.4;;"CHEMBL376472";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL909056/target=_blank>CHEMBL909056</a>";;-4.63;"Zhao Z, O'Brien JA, Lemaire W, Williams DL, Jacobson MA, Sur C, Pettibone DJ, Tiller PR, Smith S, Hartman GD, Wolkenberg SE, Lindsley CW.: Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides. Bioorg Med Chem Lett, Volume 16 (23), 2006";"CACO-2";0.00002344228815319923
"MM475803";"MM475803";"CCCc1nn(C)c2c(O)nc(-c3cc(C(C)=O)ccc3OCC)nc12";"YJBDHZKAVGNHET-UHFFFAOYSA-N";354.41;3.29;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860099/target=_blank>CHEMBL860099</a>";;-4.37;"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.: A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem, Volume 49 (12), 2006";"CACO-2";0.00004265795188015926
"MM475804";"MM475804";"COc1ccc(-c2ccc(OCCN3CCC[C@H]3C(=O)O)c(Sc3cccc(F)c3)c2)cc1";"LFGBKELOWUQGSN-QHCPKHFHSA-N";467.56;5.58;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL862964/target=_blank>CHEMBL862964</a>";;-4.58;"Smith G, Mikkelsen G, Eskildsen J, Bundgaard C.: The synthesis and SAR of 2-arylsulfanylphenyl-1-oxyalkylamino acids as GlyT-1 inhibitors. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000026302679918953814
"MM475806";"MM475806";"Nc1noc2ccc(-n3nc(C(F)(F)F)c4c3C(=O)N(c3ccc(-c5ccccc5CN5CC[C@@H](O)C5)cc3)CC4)cc12";"DFRIQJHMGZBFOM-JOCHJYFZSA-N";588.59;5.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868640/target=_blank>CHEMBL868640</a>";;-5.77;"Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PY.: 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000001698243652461746
"MM475807";"MM475807";"CCCCOc1ncc(C(C)=O)cc1-c1nc(O)c2nn(CCN3CCOCC3)c(CC)c2n1";"CNCUTWNMEWCOPN-UHFFFAOYSA-N";468.56;2.87;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860099/target=_blank>CHEMBL860099</a>";;-4.43;"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.: A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem, Volume 49 (12), 2006";"CACO-2";0.00003715352290971728
"MM475813";"MM475813";"CN(C(=O)c1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"NKPNTUSJVYZWLM-UHFFFAOYSA-N";378.27;3.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.39;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.0000407380277804113
"MM475814";"MM475814";"Cc1nn(-c2ccc3onc(N)c3c2)c2c1CCN(c1ccc(-c3ccccc3CN3CC[C@@H](O)C3)cc1)C2=O";"BGSMHNHLTFKRFT-XMMPIXPASA-N";534.62;4.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868640/target=_blank>CHEMBL868640</a>";;-5.21;"Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PY.: 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000006165950018614822
"MM475815";"MM475815";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Nc3ccc(-c4ccccc4CN4CC[C@@H](N)C4)cc3F)cc12";"YHIZCAWNRNQWMF-GOSISDBHSA-N";579.56;5.21;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859920/target=_blank>CHEMBL859920</a>";;-5.31;"Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.: Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett, Volume 16 (7), 2006";"CACO-2";0.000004897788193684467
"MM475818";"MM475818";"CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12";"UTDWJMBRBOKFJV-UHFFFAOYSA-N";397.48;3.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL893607/target=_blank>CHEMBL893607</a>";;-5.44;"Hunt F, Austin C, Austin R, Bonnert R, Cage P, Christie J, Christie M, Dixon C, Hill S, Jewell R, Martin I, Robinson D, Willis P.: SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction. Bioorg Med Chem Lett, Volume 17 (10), 2007";"CACO-2";0.0000036307805477010103
"MM475819";"MM475819";"COC(=O)N[C@H](C(=O)NN(Cc1cccc(-c2cccnc2)c1)C[C@@](O)(Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)C(C)(C)C";"OARKPSCQQRKMKX-NGXTUNLOSA-N";679.82;4.1;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL867712/target=_blank>CHEMBL867712</a>";;-4.96;"Ekegren JK, Ginman N, Johansson A, Wallberg H, Larhed M, Samuelsson B, Unge T, Hallberg A.: Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.000010964781961431852
"MM475820";"MM475820";"CCC(=O)N1CCC(CC(=O)NO)(NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)CC1";"SFSKPKLATIXRLH-UHFFFAOYSA-N";504.59;3.52;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-7;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000001
"MM475822";"MM475822";"CC(=O)N1CCC(CC(=O)NO)(NC(=O)c2ccc(OCc3cc(C)nc4ccccc34)cc2)CC1";"QRWVORUSUQDRRN-UHFFFAOYSA-N";490.56;3.13;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-7;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000001
"MM475824";"MM475824";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(CCS(C)(=O)=O)CC3)cc2)c2ccccc2n1";"MJYOLQLJRBLLML-UHFFFAOYSA-N";554.67;2.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-6.09;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000008128305161640995
"MM475825";"MM475825";"CCN(C(=O)c1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"RNWLFGIPIJCAAQ-UHFFFAOYSA-N";392.3;4.06;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.26;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.00005495408738576248
"MM475827";"MM475827";"CCCCOc1ncc(C(C)=O)cc1-c1nc(O)c2nn(Cc3nccn3C)c(CC)c2n1";"KXBOKGPWEVCLQK-UHFFFAOYSA-N";449.52;3.32;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860099/target=_blank>CHEMBL860099</a>";;-5.3;"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.: A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem, Volume 49 (12), 2006";"CACO-2";0.000005011872336272725
"MM475828";"MM475828";"CCN(C(=O)C(C)C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1";"QKROGJIOEIMFTC-UHFFFAOYSA-N";357.29;4.01;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859663/target=_blank>CHEMBL859663</a>";;-4.16;"Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, Nadzan AM.: Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem, Volume 49 (5), 2006";"CACO-2";0.00006918309709189363
"MM475830";"MM475830";"Cn1cnc(S(=O)(=O)N(CCN(Cc2cncn2C)c2ccc(C#N)cc2)CC2CCN(c3ncccn3)CC2)c1";"UAEKHSFNVUOOPP-UHFFFAOYSA-N";574.72;2.43;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-5.96;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.000001096478196143185
"MM475832";"MM475832";"Cn1cnc(S(=O)(=O)N(CCN(Cc2cncn2C)c2ccc(C#N)cc2)CC2CCN(C(=O)OC(C)(C)C)CC2)c1";"NYTPJJDEMIZHPE-UHFFFAOYSA-N";596.76;3.37;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-6.05;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.0000008912509381337459
"MM475833";"MM475833";"CN(C)C(=O)CN1CCn2c(c(C3CCCCC3)c3ccc(C(=O)O)cc32)-c2ccccc21";"OEMFLNNRPUAOBO-UHFFFAOYSA-N";445.56;4.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL911830/target=_blank>CHEMBL911830</a>";;-4.28;"Ikegashira K, Oka T, Hirashima S, Noji S, Yamanaka H, Hara Y, Adachi T, Tsuruha J, Doi S, Hase Y, Noguchi T, Ando I, Ogura N, Ikeda S, Hashimoto H.: Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. J Med Chem, Volume 49 (24), 2006";"CACO-2";0.00005248074602497723
"MM475834";"MM475834";"Cc1nn(-c2ccc3onc(N)c3c2)c2c1CCN(c1ccc(-c3ccccc3CN(C)C)cc1)C2=O";"RQRUABSSKUUZEJ-UHFFFAOYSA-N";492.58;4.84;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868640/target=_blank>CHEMBL868640</a>";;-5.17;"Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PY.: 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.000006760829753919819
"MM475835";"MM475835";"Cn1cnc(S(=O)(=O)N(CCN(Cc2cncn2C)c2ccc(C#N)cc2)Cc2ccccn2)c1";"MRIVPRZNMCCALI-UHFFFAOYSA-N";490.59;2.32;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-5.74;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.0000018197008586099826
"MM475837";"MM475837";"Cn1cnc(S(=O)(=O)N(CCN(Cc2cncn2C)c2ccc(C#N)cc2)Cc2ccc(-c3ccccc3)cc2)c1";"MUGOBVVTADQYDA-UHFFFAOYSA-N";565.7;4.59;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910296/target=_blank>CHEMBL910296</a>";;-5.96;"Glenn MP, Chang SY, HornĂ©y C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD.: Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem, Volume 49 (19), 2006";"CACO-2";0.000001096478196143185
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-5.03;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.000009332543007969906
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1032443/target=_blank>CHEMBL1032443</a>";;-5.03;"Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW.: Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem, Volume 51 (21), 2008";"CACO-2";0.000009332543007969906
"MM475841";"MM475841";"O=c1n(Cc2nc3ccccc3n2CCCC2(O)CC2)c2cnccc2n1C1CC1";"UOYODLLSYQHHED-UHFFFAOYSA-N";403.49;3.24;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.63;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.00002344228815319923
"MM475842";"MM475842";"CCS(=O)(=O)CCCn1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2ccccc21";"NXXXNNQCMNNNRX-UHFFFAOYSA-N";439.54;2.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-5.47;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.0000033884415613920275
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-4.57;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00002691534803926914
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-4.38;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00004168693834703355
"MM475843";"MM475843";"CC(C)(O)CCn1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2ccccc21";"DCKYJLBTIKJCTP-UHFFFAOYSA-N";391.48;3.09;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.74;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000018197008586099827
"MM475844";"MM475844";"O=C(NC1CCN(C(=O)CCc2cccnc2)CC1)C(c1ccccc1)C1CCCCC1";"RMFOYNMWESQGBZ-UHFFFAOYSA-N";433.6;4.49;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL894525/target=_blank>CHEMBL894525</a>";;-4.92;"Denonne F, Binet S, Burton M, Collart P, Defays S, Dipesa A, Eckert M, Giannaras A, Kumar S, Levine B, Nicolas JM, Pasau P, PĂ©gurier C, Preda D, Van houtvin N, Volosov A, Zou D.: Discovery of new C3aR ligands. Part 2: amino-piperidine derivatives. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.000012022644346174132
"MM475846";"MM475846";"CCOC(=O)CN[C@H](CCc1ccccn1)C(=O)N1CCC[C@H]1C(=O)NCc1cc(Cl)ccc1CN";"UERHFNVGKAURME-PKTZIBPZSA-N";516.04;1.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889058/target=_blank>CHEMBL889058</a>";;-5.62;"DĂ¶nnecke D, Schweinitz A, StĂĽrzebecher A, Steinmetzer P, Schuster M, StĂĽrzebecher U, Nicklisch S, StĂĽrzebecher J, Steinmetzer T.: From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.0000023988329190194897
"MM475847";"MM475847";"O=c1n(Cc2nc3ccccc3n2CCCCCO)c2cnccc2n1C1CC1";"UJEZJTAIDLYMAF-UHFFFAOYSA-N";391.48;3.09;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-5.02;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000009549925860214369
"MM475849";"MM475849";"CC(C)C[C@H]1C(=O)NCC(=O)N(C)[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N(C)[C@H](Cc2ccccc2)C(=O)N1C";"BUJLFEPBWLGNBZ-NEWJYFPISA-N";687.8;-1.78;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-7.52;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000000030199517204020194
"MM475851";"MM475851";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(-c4ccccc4CN(C)C)cc2)CC3)cc1";"WDTKVYDFBNLOOJ-UHFFFAOYSA-N";495.58;3.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.64;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.0000022908676527677747
"MM475853";"MM475853";"O=C1CC(c2ccc(C[C@H](Nc3nc4ccc(F)cc4s3)c3nc4ccccc4[nH]3)cc2)S(=O)(=O)N1";"YXMKDYBKIKKMKC-AIBWNMTMSA-N";521.6;4.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.05;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000008912509381337459
"MM475855";"MM475855";"C[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccccc2)NCCC(=O)NCCN([C@@H](Cc2ccccc2)C(N)=O)C(=O)[C@H](C)NC(=O)[C@H](C)NC1=O";"PQPSEMWNMBJLKW-YPZLOKHQSA-N";692.82;-1.35;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.83;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000001479108388168207
"MM475856";"MM475856";"C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NCCC(=O)NCCN([C@@H](Cc2ccccc2)C(N)=O)C(=O)CNC(=O)CNC(=O)CNC1=O";"IQJDHWMIWQDFED-TUSQITKMSA-N";650.74;-2.51;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.72;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000019054607179632483
"MM475857";"MM475857";"C[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccccc2)NCCC(=O)NCCN([C@@H](Cc2ccccc2)C(N)=O)C(=O)CNC(=O)CNC1=O";"ZOTAYMIEWXSZNI-JPMIEVGJSA-N";664.76;-2.13;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.49;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000003235936569296281
"MM475859";"MM475859";"CN1CC(=O)NCC(=O)NCC(=O)N([C@@H](Cc2ccccc2)C(N)=O)CCNC(=O)CCN[C@@H](Cc2ccccc2)C(=O)N(C)CC1=O";"WMWLTEZGRIRKNS-UIOOFZCWSA-N";664.76;-2.22;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.61;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000024547089156850284
"MM475863";"MM475863";"Cc1cc(Cc2ccc(C(=O)N[C@@H]3CN(CC(C)C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"VMWZNZVYBAZMKQ-UKILVPOCSA-N";460.58;3.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-5.82;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000015135612484362072
"MM475865";"MM475865";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(C2CCN(c4ccccc4S(C)(=O)=O)CC2)CC3)cc1";"PJHHSGILIGVDLH-UHFFFAOYSA-N";523.62;2.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL885807/target=_blank>CHEMBL885807</a>";;-5.82;"Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.0000015135612484362072
"MM475869";"MM475869";"O=C(Nc1ccc(C(F)(F)F)cc1)c1ccnn1CCc1ccncc1";"ZAMPINLTBPKGEY-UHFFFAOYSA-N";360.34;3.79;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897525/target=_blank>CHEMBL897525</a>";;-5.19;"Kiselyov AS, Milligan D, Ouyang X.: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.000006456542290346549
"MM475870";"MM475870";"CCc1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1";"SWHBXSXTFLWDOB-UHFFFAOYSA-N";320.4;3.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897525/target=_blank>CHEMBL897525</a>";;-5.01;"Kiselyov AS, Milligan D, Ouyang X.: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.000009772372209558111
"MM475879";"MM475879";"CN[C@@H](Cc1ccccc1)C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(N)=O";"BGSZSRNMQIWHNF-VXKWHMMOSA-N";567.65;-2.16;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.74;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000018197008586099826
"MM475883";"MM475883";"O=C1CC(c2ccc(C[C@H](Nc3nc4cc(Br)ccc4s3)c3nc4ccccc4[nH]3)cc2)S(=O)(=O)N1";"GDVCJUYCAGOQOZ-AIBWNMTMSA-N";582.51;5.22;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-5.89;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.000001288249551693135
"MM475884";"MM475884";"CC(C)C[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C";"AXPXTJPQSSUWFY-KJJMTIBFSA-N";659.75;-2.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-7.52;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000000030199517204020194
"MM475885";"MM475885";"NCc1ccc(Cl)cc1CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](CCc1ccccn1)NCC(=O)O";"NYKOPIYZICLSFY-RTWAWAEBSA-N";487.99;1.48;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL889058/target=_blank>CHEMBL889058</a>";;-5.3;"DĂ¶nnecke D, Schweinitz A, StĂĽrzebecher A, Steinmetzer P, Schuster M, StĂĽrzebecher U, Nicklisch S, StĂĽrzebecher J, Steinmetzer T.: From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. Bioorg Med Chem Lett, Volume 17 (12), 2007";"CACO-2";0.000005011872336272725
"MM475889";"MM475889";"N#CCCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)nc2ccccc21";"RMNMUWNNOBHYLU-UHFFFAOYSA-N";414.39;3.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.71;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000019498445997580456
"MM475890";"MM475890";"COc1ccc(-n2nc(Cn3cnnn3)c3c2C(=O)N(c2ccc(-c4ccccc4CN4CC[C@@H](O)C4)cc2)CC3)cc1";"XSEZTBVLOUTJTF-AREMUKBSSA-N";576.66;3.35;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-6.05;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.0000008912509381337459
"MM475891";"MM475891";"N#Cc1cc(C[C@H](Nc2nc3ccccc3s2)c2nc3ccccc3[nH]2)ccc1C1CC(=O)NS1(=O)=O";"ACQAZSOWCXPIAZ-BBQAJUCSSA-N";528.62;4.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.3;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000005011872336272725
"MM475893";"MM475893";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)NC3CCN(c4ccccc4CN4CCC[C@H]4O)CC3)cc12";"IYCGPDFYFRTXIV-RUZDIDTESA-N";569.59;3.93;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL885807/target=_blank>CHEMBL885807</a>";;-6.7;"Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.00000019952623149688787
"MM475900";"MM475900";"O=C1CC(c2ccc(C[C@H](Nc3nc4ccccc4s3)c3nc4cc(Cl)ccc4[nH]3)cc2)S(=O)(=O)N1";"YAYDJMKEWVNQFY-AIBWNMTMSA-N";538.05;5.11;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.1;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000007943282347242822
"MM475901";"MM475901";"N#Cc1ccc2[nH]c([C@H](Cc3ccc(C4CC(=O)NS4(=O)=O)cc3)Nc3nc4ccccc4s3)nc2c1";"KURDXZVTVJKSSE-BBQAJUCSSA-N";528.62;4.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.4;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000003981071705534969
"MM475904";"MM475904";"CNCc1ccccc1N1CCC(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)CC1";"JNNNQOVXXHMSBM-UHFFFAOYSA-N";513.52;3.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL885807/target=_blank>CHEMBL885807</a>";;-7;"Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.0000001
"MM475907";"MM475907";"O=C(Nc1ccc(Cl)cc1)c1ccnn1CCc1ccncc1";"RDCNEJGSOLCHQO-UHFFFAOYSA-N";326.79;3.43;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897525/target=_blank>CHEMBL897525</a>";;-5.16;"Kiselyov AS, Milligan D, Ouyang X.: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.0000069183097091893625
"MM475910";"MM475910";"N#Cc1ccc2nc(N[C@@H](Cc3ccc(C4CC(=O)NS4(=O)=O)cc3)c3nc4ccccc4[nH]3)sc2c1";"MIBJOQNZLGSJQS-BBQAJUCSSA-N";528.62;4.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.4;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000003981071705534969
"MM475914";"MM475914";"O=c1n(Cc2nc3ccccc3n2CCCCF)c2cnccc2n1C1CC1";"HRZCSWIVEIQDQW-UHFFFAOYSA-N";379.44;3.68;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.61;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000024547089156850286
"MM475920";"MM475920";"NC(=O)c1cc(C(=O)N2CCc3cc(-c4ccccc4CN4CCCC4)ccc32)n(-c2ccc3onc(N)c3c2)n1";"YEIXBTGYWGRTKX-UHFFFAOYSA-N";547.62;4.16;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL941671/target=_blank>CHEMBL941671</a>";;-6.15;"Varnes JG, Wacker DA, Jacobson IC, Quan ML, Ellis CD, Rossi KA, He MY, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. Bioorg Med Chem Lett, Volume 17 (23), 2007";"CACO-2";0.0000007079457843841374
"MM475921";"MM475921";"NC(=O)c1cc(C(=O)N2CCc3cc(-n4ccccc4=O)ccc32)n(-c2ccc3onc(N)c3c2)n1";"UQHLDZFSQPJXIW-UHFFFAOYSA-N";481.47;2.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL941671/target=_blank>CHEMBL941671</a>";;-7;"Varnes JG, Wacker DA, Jacobson IC, Quan ML, Ellis CD, Rossi KA, He MY, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. Bioorg Med Chem Lett, Volume 17 (23), 2007";"CACO-2";0.0000001
"MM475922";"MM475922";"CC(C)(C)c1ccc(NC(=O)c2ccnn2CCc2ccncc2)cc1";"AGXYJGOJFCYJET-UHFFFAOYSA-N";348.45;4.07;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897525/target=_blank>CHEMBL897525</a>";;-5.13;"Kiselyov AS, Milligan D, Ouyang X.: Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates. Bioorg Med Chem Lett, Volume 17 (13), 2007";"CACO-2";0.000007413102413009177
"MM475925";"MM475925";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)N3CCc4cc(-c5ccccc5S(N)(=O)=O)ccc43)cc12";"CCFWKNLIRQRUNI-UHFFFAOYSA-N";568.54;4.13;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL941671/target=_blank>CHEMBL941671</a>";;-6.52;"Varnes JG, Wacker DA, Jacobson IC, Quan ML, Ellis CD, Rossi KA, He MY, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. Bioorg Med Chem Lett, Volume 17 (23), 2007";"CACO-2";0.0000003019951720402019
"MM475926";"MM475926";"CC(=O)Nc1cccc(-c2ccc(Cc3ocnc3C(=O)N[C@@H](Cc3ccccc3)C(=O)O)cc2)c1";"YONIHIOBDIZSOE-DEOSSOPVSA-N";483.52;4.32;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL895999/target=_blank>CHEMBL895999</a>";;-5.26;"Brescia MR, Rokosz LL, Cole AG, Stauffer TM, Lehrach JM, Auld DS, Henderson I, Webb ML.: Discovery and preliminary evaluation of 5-(4-phenylbenzyl)oxazole-4-carboxamides as prostacyclin receptor antagonists. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.0000054954087385762485
"MM475931";"MM475931";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CC4(C[C@@H]3C(=O)NO)OCCO4)cc2)c2ccccc2n1";"KRGIXMSVPSMLII-JTHBVZDNSA-N";477.52;2.88;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL945137/target=_blank>CHEMBL945137</a>";;-5.74;"Ott GR, Asakawa N, Liu RQ, Covington MB, Qian M, Vaddi K, Newton RC, Trzaskos JM, Christ DD, Galya L, Scholz T, Marshall W, Duan JJ.: Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (4), 2008";"CACO-2";0.0000018197008586099826
"MM475932";"MM475932";"Cc1cc(Cc2ccc(C(=O)N[C@@H]3CCC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"CKGRNUKOQHVJOB-RBBKRZOGSA-N";403.48;3.54;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-5.92;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000012022644346174132
"MM475933";"MM475933";"Cc1cc(COc2ccc(C(=O)N[C@@H]3C[C@@]4(CCCO4)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"AZIJSGUGQIBFMD-CAKYRVLISA-N";475.55;3.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL945137/target=_blank>CHEMBL945137</a>";;-5.24;"Ott GR, Asakawa N, Liu RQ, Covington MB, Qian M, Vaddi K, Newton RC, Trzaskos JM, Christ DD, Galya L, Scholz T, Marshall W, Duan JJ.: Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorg Med Chem Lett, Volume 18 (4), 2008";"CACO-2";0.000005754399373371567
"MM475935";"MM475935";"CCN(CC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"BJQGGALRPGCIFD-WCQYABFASA-N";252.38;1.83;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.33;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000004677351412871981
"MM475937";"MM475937";"Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12";"ZWVZORIKUNOTCS-OAQYLSRUSA-N";479.97;3.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL980918/target=_blank>CHEMBL980918</a>";;-5.74;"Velaparthi U, Wittman M, Liu P, Carboni JM, Lee FY, Attar R, Balimane P, Clarke W, Sinz MW, Hurlburt W, Patel K, Discenza L, Kim S, Gottardis M, Greer A, Li A, Saulnier M, Yang Z, Zimmermann K, Trainor G, Vyas D.: Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J Med Chem, Volume 51 (19), 2008";"CACO-2";0.0000018197008586099826
"MM475942";"MM475942";"C=C(F)CN(C)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"CMSMRUGCRICBLQ-WCQYABFASA-N";268.36;1.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-4.86;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000013803842646028839
"MM475943";"MM475943";"NC[C@@H]1C[C@@]1(C(=O)N1C=COc2ccccc21)c1ccsc1";"FYGDANPUVIMKMO-SUMWQHHRSA-N";312.39;2.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-4.7;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000019952623149688786
"MM475944";"MM475944";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Cc3ccc(N4CCCCC4=O)cc3)cc12";"RASIDBNWCVIECX-UHFFFAOYSA-N";483.45;4.56;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927724/target=_blank>CHEMBL927724</a>";;-4.64;"Varnes JG, Wacker DA, Pinto DJ, Orwat MJ, Theroff JP, Wells B, Galemo RA, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.00002290867652767775
"MM475947";"MM475947";"C#CCN(CC#C)C(=O)[C@@]1(c2ccc3c(c2)OCCO3)C[C@H]1CN";"GRFLLIUZAGYUSO-HNAYVOBHSA-N";324.38;0.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL930503/target=_blank>CHEMBL930503</a>";;-5.28;"Tamiya J, Dyck B, Zhang M, Phan K, Fleck BA, Aparicio A, Jovic F, Tran JA, Vickers T, Grey J, Foster AC, Chen C.: Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000005248074602497723
"MM475949";"MM475949";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CNCC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"LLSVCNPSBKMSMJ-RBBKRZOGSA-N";434.5;2.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-6.7;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.00000019952623149688787
"MM475950";"MM475950";"COc1ccc(-n2nc(C(N)=O)cc2C(=O)Cc2ccc(-n3ccccc3=O)cc2F)cc1";"MRPLIGSOQUCMBC-UHFFFAOYSA-N";446.44;2.7;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927724/target=_blank>CHEMBL927724</a>";;-5.66;"Varnes JG, Wacker DA, Pinto DJ, Orwat MJ, Theroff JP, Wells B, Galemo RA, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000021877616239495517
"MM475955";"MM475955";"COc1c(NC(=O)c2ccc(C)c(N3C=C(C(=O)NCC(C)(C)O)NN3)c2)cc(C(C)(C)C)cc1NS(C)(=O)=O";"MAUJJOIHXTUXAT-UHFFFAOYSA-N";574.7;2.48;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927883/target=_blank>CHEMBL927883</a>";;-5.13;"Cogan DA, Aungst R, Breinlinger EC, Fadra T, Goldberg DR, Hao MH, Kroe R, Moss N, Pargellis C, Qian KC, Swinamer AD.: Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.000007413102413009177
"MM475956";"MM475956";"C=CCN(CCOC)C(=O)[C@@]1(c2ccsc2)C[C@H]1CN";"RBKMRYYKCJETLF-DZGCQCFKSA-N";294.42;1.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL931359/target=_blank>CHEMBL931359</a>";;-5.62;"Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L, Tang H, Foster AC, Chen C.: Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (11), 2008";"CACO-2";0.0000023988329190194897
"MM475958";"MM475958";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CCNC[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"FAAUHWULQKLSFX-RBBKRZOGSA-N";434.5;2.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-6.7;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.00000019952623149688787
"MM475961";"MM475961";"Cc1cc(COc2ccc(C(=O)N[C@@H]3CCCO[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"JEYWSEIQOOZERG-YADHBBJMSA-N";435.48;2.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927613/target=_blank>CHEMBL927613</a>";;-7.22;"Duan JJ, Chen L, Lu Z, Xue CB, Liu RQ, Covington MB, Qian M, Wasserman ZR, Vaddi K, Christ DD, Trzaskos JM, Newton RC, Decicco CP.: Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett, Volume 18 (1), 2008";"CACO-2";0.00000006025595860743581
"MM475973";"MM475973";"O=C(O)CN1C(=O)[C@]2(CC(=O)N(Cc3cc(Cl)ccc3F)C2)c2cc(Cl)ccc21";"ABVCZPJCOYQLBK-FQEVSTJZSA-N";437.25;3.23;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL937320/target=_blank>CHEMBL937320</a>";;-5.74;"Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.: Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.0000018197008586099826
"MM475975";"MM475975";"O=C(O)CN1C(=O)C2(CC(=O)N(Cc3ccccc3)C2=O)c2cc(Cl)ccc21";"ZCDQMYGMUJCSPB-UHFFFAOYSA-N";398.8;1.97;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL937320/target=_blank>CHEMBL937320</a>";;-5.52;"Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.: Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem, Volume 51 (7), 2008";"CACO-2";0.0000030199517204020193
"MM475979";"MM475979";"CC(C)(C)C(=O)OCOC(=O)/N=C(/NCc1ccccc1)NC(=O)OCOC(=O)C(C)(C)C";"MVNKPEGJEZCHNB-UHFFFAOYSA-N";465.5;3.09;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656467/target=_blank>CHEMBL656467</a>";;-5.43;"10.1016/S0960-894X(01)80549-7";"CACO-2";0.0000037153522909717276
"MM475980";"MM475980";"COc1ccc2ccc(S(=O)(=O)NC(Cc3ccc4c(N)nccc4c3)C(=O)N3CCC(C)CC3)cc2c1";"PYEVADFTHRFWHY-UHFFFAOYSA-N";532.67;4.13;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-5.12;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.000007585775750291836
"MM475981";"MM475981";"COc1ccc2ccc(S(=O)(=O)NC(Cc3cc4c(N)nccc4s3)C(=O)N3CCN(C)CC3)cc2c1";"RWCSWKZHOBWMGP-UHFFFAOYSA-N";539.68;2.7;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-5.66;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.0000021877616239495517
"Sulfasalazine";"MM00690";"O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O";"NCEXYHBECQHGNR-UHFFFAOYSA-N";398.4;3.7;"5359476";"CHEMBL421";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-6.8;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000001584893192461114
"Sulfasalazine";"MM00690";"O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O";"NCEXYHBECQHGNR-UHFFFAOYSA-N";398.4;3.7;"5359476";"CHEMBL421";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-6.8;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000001584893192461114
"MM475983";"MM475983";"O=C(O)Cc1ccc(Cn2cnc3ccccc32)cc1";"PWRPPVIOQOVICQ-UHFFFAOYSA-N";266.3;2.71;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-5.58;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.0000026302679918953817
"MM475984";"MM475984";"Cc1cc(C(=O)Nc2ccc(-c3ccccc3S(C)(=O)=O)cc2F)n(-c2cccc(CN)c2)n1";"QUWOWSNMEUHYIY-UHFFFAOYSA-N";478.55;4.1;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635761/target=_blank>CHEMBL635761</a>";;-5.5;"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PY.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 44 (4), 2001";"CACO-2";0.000003162277660168379
"MM475985";"MM475985";"Cc1cc(COc2ccc(NC(=O)[C@H]3CCN(C(=O)OCc4nccs4)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"JOHYDRPBWMKVTC-ZEQRLZLVSA-N";575.65;4.3;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-7;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.0000001
"MM475988";"MM475988";"Cc1cc(COc2ccc(NC(=O)[C@H]3CCN(S(C)(=O)=O)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"WWXZQIVISJRIMS-VXKWHMMOSA-N";512.59;2.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL655611/target=_blank>CHEMBL655611</a>";;-6.7;"Xue CB, He X, Roderick J, Corbett RL, Duan JJ, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP.: Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization. Bioorg Med Chem Lett, Volume 13 (24), 2003";"CACO-2";0.00000019952623149688787
"MM475989";"MM475989";"COc1ccc2cc(S(=O)(=O)N[C@@H](Cc3ccc(CN)cc3)C(=O)N(C)C3CCCC3)ccc2c1";"BDMUHVMXOXBHES-SANMLTNESA-N";495.65;3.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619357/target=_blank>CHEMBL619357</a>";;-4.97;"Lee K, Jung WH, Park CW, Hong CY, Kim IC, Kim S, Oh YS, Kwon OH, Lee SH, Park HD, Kim SW, Lee YH, Yoo YJ.: Benzylamine-based selective and orally bioavailable inhibitors of thrombin. Bioorg Med Chem Lett, Volume 8 (18), 1998";"CACO-2";0.00001071519305237607
"MM475990";"MM475990";"Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCN(Cc4ccccc4)CC3)cc2)c2ccccc2n1";"PACKAWWLZSBYDP-UHFFFAOYSA-N";538.65;4.78;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL853098/target=_blank>CHEMBL853098</a>";;-7;"Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 16 (10), 2006";"CACO-2";0.0000001
"MM475991";"MM475991";"COc1cccc(-n2c(=O)n(Cc3ccccc3OC(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F";"LJJACIKIUOHOLD-SFHVURJKSA-N";546.48;2.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL851904/target=_blank>CHEMBL851904</a>";;-5.21;"Guo Z, Wu D, Zhu YF, Tucci FC, Regan CF, Rowbottom MW, Struthers RS, Xie Q, Reijmers S, Sullivan SK, Sai Y, Chen C.: Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists. Bioorg Med Chem Lett, Volume 15 (16), 2005";"CACO-2";0.000006165950018614822
"MM475992";"MM475992";"Cc1cc(COc2ccc(S(=O)(=O)CC3CNCCC3C(=O)NO)cc2)c2ccccc2n1";"YCBSBKZAEBKTSY-UHFFFAOYSA-N";469.56;2.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825962/target=_blank>CHEMBL825962</a>";;-7;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000001
"MM475994";"MM475994";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Nc3ccc(-n4ccnc4CO)cc3F)cc12";"PNIJAJQGAGODFB-UHFFFAOYSA-N";501.4;3.68;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-7;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.0000001
"MM475995";"MM475995";"CCCCOc1ncc(C(C)=O)cc1-c1nc(O)c2nn(C3CCN(CC)CC3)c(CC)c2n1";"NYWJLHDQEMYKGW-UHFFFAOYSA-N";466.59;4.19;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860099/target=_blank>CHEMBL860099</a>";;-4.28;"Allerton CM, Barber CG, Beaumont KC, Brown DG, Cole SM, Ellis D, Lane CA, Maw GN, Mount NM, Rawson DJ, Robinson CM, Street SD, Summerhill NW.: A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. J Med Chem, Volume 49 (12), 2006";"CACO-2";0.00005248074602497723
"MM475996";"MM475996";"O=C(O)c1cc(NC(=S)NCCO)ccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12";"RVDKKVUJQIHRCB-UHFFFAOYSA-N";450.47;3.25;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898000/target=_blank>CHEMBL898000</a>";;-6.59;"Hayashi Y, Takayama K, Suehisa Y, Fujita T, Nguyen JT, Futaki S, Yamamoto A, Kiso Y.: Development of oligoarginine-drug conjugates linked to new peptidic self-cleavable spacers toward effective intestinal absorption. Bioorg Med Chem Lett, Volume 17 (18), 2007";"CACO-2";0.0000002570395782768865
"MM475999";"MM475999";"C[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccccc2)NCCC(=O)NCCN([C@@H](Cc2ccccc2)C(N)=O)C(=O)CNC1=O";"RMZDGJIJNVEICU-SAHMVTQPSA-N";678.79;-1.74;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.46;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000003467368504525317
"MM476000";"MM476000";"CS(=O)(=O)c1ccccc1N1CCC(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)CC1";"HADDJWUKDPCVQU-UHFFFAOYSA-N";548.55;3.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL885807/target=_blank>CHEMBL885807</a>";;-5.77;"Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorg Med Chem Lett, Volume 17 (5), 2007";"CACO-2";0.000001698243652461746
"MM476001";"MM476001";"CN1CC(=O)NCC(=O)N([C@@H](Cc2ccccc2)C(N)=O)CCNC(=O)CCN[C@@H](Cc2ccccc2)C(=O)N(C)CC(=O)N(C)CC1=O";"UZIFOEWDSUUZBG-SVBPBHIXSA-N";678.79;-1.88;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.53;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.000002951209226666384
"MM476003";"MM476003";"Cc1cc(Cc2ccc(C(=O)N[C@@H]3CN(C)C[C@@H]3C(=O)NO)cc2)c2ccccc2n1";"VKZVNFAGQVZFTI-RBBKRZOGSA-N";418.5;2.3;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897361/target=_blank>CHEMBL897361</a>";;-6.52;"Chen XT, Ghavimi B, Corbett RL, Xue CB, Liu RQ, Covington MB, Qian M, Vaddi KG, Christ DD, Hartman KD, Ribadeneira MD, Trzaskos JM, Newton RC, Decicco CP, Duan JJ.: A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. Bioorg Med Chem Lett, Volume 17 (7), 2007";"CACO-2";0.0000003019951720402019
"MM476007";"MM476007";"O=C1CC(c2ccc(C[C@H](Nc3nc4ccccc4s3)c3nc4ccccc4[nH]3)cc2Cl)S(=O)(=O)N1";"RIJYEHWCOFFSIP-AIBWNMTMSA-N";538.05;5.11;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6.15;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.0000007079457843841374
"MM476008";"MM476008";"Cc1noc(NS(=O)(=O)c2ccccc2-c2ccc(-c3ncco3)cc2CN(C)CC(F)(F)F)c1C";"CLLGOUWASYEJSI-UHFFFAOYSA-N";520.53;5.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638025/target=_blank>CHEMBL638025</a>";;-4.96;"Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.: Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. J Med Chem, Volume 46 (1), 2003";"CACO-2";0.000010964781961431852
"MM476009";"MM476009";"CCC(C)[C@H](NC(=O)[C@@H](C[C@H](O)[C@H](CC1CCCCC1)NC(=O)c1ccccn1)C(C)C)C(=O)NCc1ccccn1";"UVPQQORJRVVVAL-DXNHQLGUSA-N";579.79;4.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL633586/target=_blank>CHEMBL633586</a>";;-4.77;"10.1016/S0960-894X(00)80673-3";"CACO-2";0.00001698243652461746
"MM476010";"MM476010";"Cc1cc(COc2ccc(S(=O)(=O)CC3(CC(=O)NO)CCN(C)C3)cc2)c2ccccc2n1";"HUNBFLZYPNPINY-UHFFFAOYSA-N";483.59;3.11;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL825963/target=_blank>CHEMBL825963</a>";;-6.52;"Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.: Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett, Volume 14 (17), 2004";"CACO-2";0.0000003019951720402019
"MM476014";"MM476014";"COC(=O)N[C@H](C(=O)NN(Cc1ccccc1)C[C@@](O)(Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)C(C)(C)C";"XSDFQERHLPEHEB-UNMGZEBXSA-N";602.73;3.04;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL867573/target=_blank>CHEMBL867573</a>";;-4.46;"Ekegren JK, Unge T, Safa MZ, Wallberg H, Samuelsson B, Hallberg A.: A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold. J Med Chem, Volume 48 (25), 2005";"CACO-2";0.00003467368504525317
"MM476015";"MM476015";"Nc1noc2ccc(-n3nc(C(F)(F)F)cc3C(=O)Nc3ccc(-c4ccccc4CN4CC[C@@H](O)C4)cc3F)cc12";"HQBRJIGJLJDFHY-LJQANCHMSA-N";580.54;5.24;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859920/target=_blank>CHEMBL859920</a>";;-5.43;"Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.: Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett, Volume 16 (7), 2006";"CACO-2";0.0000037153522909717276
"MM476016";"MM476016";"CN(C)Cc1ccccc1-c1ccc(N2CCc3c(C(F)(F)F)nn(-c4ccc5onc(N)c5c4)c3C2=O)c(F)c1";"DXMUOXUECGPKKS-UHFFFAOYSA-N";564.54;5.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868640/target=_blank>CHEMBL868640</a>";;-5.05;"Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA, Amparo E, Wells B, Ellis C, He MY, Alexander RS, Rossi KA, Smallwood A, Wong PC, Luettgen JM, Rendina AR, Knabb RM, Mersinger L, Kettner C, Bai S, He K, Wexler RR, Lam PY.: 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett, Volume 16 (15), 2006";"CACO-2";0.00000891250938133746
"MM476017";"MM476017";"Cc1nc2cc(C(C)C)c(-c3ccc(Cl)c(OCC4CC4)c3)cc2c(=O)[nH]1";"JERXWDBVRYWKDD-UHFFFAOYSA-N";382.89;5.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL861748/target=_blank>CHEMBL861748</a>";;-5.36;"Culshaw AJ, Bevan S, Christiansen M, Copp P, Davis A, Davis C, Dyson A, Dziadulewicz EK, Edwards L, Eggelte H, Fox A, Gentry C, Groarke A, Hallett A, Hart TW, Hughes GA, Knights S, Kotsonis P, Lee W, Lyothier I, McBryde A, McIntyre P, Paloumbis G, Panesar M, Patel S, Seiler MP, Yaqoob M, Zimmermann K.: Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. J Med Chem, Volume 49 (2), 2006";"CACO-2";0.000004365158322401657
"MM476018";"MM476018";"COc1cccc2sc(N[C@@H](Cc3ccc(C4CC(=O)NS4(=O)=O)cc3)c3nc4ccccc4[nH]3)nc12";"YXMIQQYKUVRJOM-YDNXMHBPSA-N";533.64;4.47;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902513/target=_blank>CHEMBL902513</a>";;-6;"Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.: Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett, Volume 17 (3), 2007";"CACO-2";0.000001
"MM476021";"MM476021";"CCOC(=O)N1C[C@H](NC(=O)c2ccc(-n3ccccc3=O)cc2)[C@H](NC(=O)c2ccc(Cl)s2)C1";"VCOPBIUVMSEQNG-ZWKOTPCHSA-N";514.99;2.92;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL897896/target=_blank>CHEMBL897896</a>";;-5.6;"Qiao JX, Wang TC, Wang GZ, Cheney DL, He K, Rendina AR, Xin B, Luettgen JM, Knabb RM, Wexler RR, Lam PY.: Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications. Bioorg Med Chem Lett, Volume 17 (18), 2007";"CACO-2";0.0000025118864315095823
"MM476025";"MM476025";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O";"GKZKTNFBMYFGNV-JVVMDBNWSA-N";711.82;0.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932308/target=_blank>CHEMBL932308</a>";;-4.92;"Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A, Halbfinger E, Lapidot T, Winkler I, Gabinet Y, Faier A, Yarden D, Xiang Z, Portillo FP, Haskell-Luevano C, Gilon C, Hoffman A.: Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem, Volume 51 (4), 2008";"CACO-2";0.000012022644346174132
"MM476029";"MM476029";"COc1ccc(-n2nc(Cn3ccnn3)c3c2C(=O)N(c2ccc(-c4ccccc4CN4CC[C@@H](O)C4)cc2)CC3)cc1";"WEKJJVKHRKQPFJ-HHHXNRCGSA-N";575.67;3.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.8;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.000001584893192461114
"MM476032";"MM476032";"O=C(O)c1ccc(Cn2cnc3ccccc32)cc1";"KLIANJXCGMBICV-UHFFFAOYSA-N";252.27;2.78;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619363/target=_blank>CHEMBL619363</a>";;-5.5;"Fichert T, Yazdanian M, Proudfoot JR.: A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett, Volume 13 (4), 2003";"CACO-2";0.000003162277660168379
"MM476035";"MM476035";"CN(C)Cc1nccn1-c1ccc(CC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)cc1";"VQBNZDYHKWNFIA-UHFFFAOYSA-N";509.49;4.29;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927724/target=_blank>CHEMBL927724</a>";;-4.62;"Varnes JG, Wacker DA, Pinto DJ, Orwat MJ, Theroff JP, Wells B, Galemo RA, Luettgen JM, Knabb RM, Bai S, He K, Lam PY, Wexler RR.: Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett, Volume 18 (2), 2008";"CACO-2";0.0000239883291901949
"MM476038";"MM476038";"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(-c4ccccc4CN4CCCC4)cc2)CC3)cc1";"AZWOHKZXJMIDFB-UHFFFAOYSA-N";521.62;4.45;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900671/target=_blank>CHEMBL900671</a>";;-5.46;"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY.: Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem, Volume 50 (22), 2007";"CACO-2";0.000003467368504525317
"MM476043";"MM476043";"CC(O)c1nc([C@@H](O)[C@H](O)[C@H](O)CO)c[nH]1";"LJCNCJMBPIMJMH-NPPIPOFDSA-N";232.24;-1.79;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5.39;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000004073802778041131
"MM476045";"MM476045";"Cc1nccn1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2ccc3onc(N)c3c2)cc1";"PYSZDOCTWCNJRK-UHFFFAOYSA-N";467.41;4.36;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL838209/target=_blank>CHEMBL838209</a>";;-6.09;"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.: Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem, Volume 48 (6), 2005";"CACO-2";0.0000008128305161640995
"MM476048";"MM476048";"CC(=O)c1nc([C@@H](O)[C@H](O)[C@H](O)CO)c(C)[nH]1";"IIJRMVGGYOQAMM-FTLITQJKSA-N";244.25;-1.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5.03;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000009332543007969906
"MM476051";"MM476051";"CC(C)n1c(=O)n(Cc2nc3ccccc3n2CCCC#N)c2cnccc21";"HNUBQVDSGLPJTB-UHFFFAOYSA-N";374.45;3.48;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.77;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.00001698243652461746
"MM476054";"MM476054";"Cc1cc(Cn2nnc3c(-c4ccco4)nc(N)nc32)ccc1N";"HQSBCDPYXDGTCL-UHFFFAOYSA-N";321.34;2;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1022274/target=_blank>CHEMBL1022274</a>";;-4.96;"Gillespie RJ, Bamford SJ, Botting R, Comer M, Denny S, Gaur S, Griffin M, Jordan AM, Knight AR, Lerpiniere J, Leonardi S, Lightowler S, McAteer S, Merrett A, Misra A, Padfield A, Reece M, Saadi M, Selwood DL, Stratton GC, Surry D, Todd R, Tong X, Ruston V, Upton R, Weiss SM.: Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem, Volume 52 (1), 2009";"CACO-2";0.000010964781961431852
"MM476059";"MM476059";"CC(=O)c1nc([C@H](O)[C@@H](O)[C@@H](O)CO)c[nH]1";"CQSIXFHVGKMLGQ-FXQIFTODSA-N";230.22;-1.64;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-4.88;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000013182567385564074
"MM476061";"MM476061";"CCc1[nH]c(C(C)=O)nc1[C@@H](O)[C@H](O)[C@H](O)CO";"JSSFRSCXEWEKBV-SZEHBUNVSA-N";258.27;-1.08;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5.1;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000007943282347242822
"MM476066";"MM476066";"C=CC1=C(C)/C(=C/C2=N/C(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O";"QBUVFDKTZJNUPP-BBROENKCSA-N";582.66;4.81;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL975052/target=_blank>CHEMBL975052</a>";;-6;"Bulmer AC, Blanchfield JT, Coombes JS, Toth I.: In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.000001
"MM476066";"MM476066";"C=CC1=C(C)/C(=C/C2=N/C(=C\c3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)C(CCC(=O)O)=C2C)NC1=O";"QBUVFDKTZJNUPP-BBROENKCSA-N";582.66;4.81;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL975053/target=_blank>CHEMBL975053</a>";;-5.43;"Bulmer AC, Blanchfield JT, Coombes JS, Toth I.: In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.0000037153522909717276
"MM476072";"MM476072";"Oc1ccc(-c2ccc(-c3cccc(O)c3)s2)cc1";"PKHBRBMFZXTMIS-UHFFFAOYSA-N";268.34;4.49;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1032443/target=_blank>CHEMBL1032443</a>";;-4.66;"Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW.: Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem, Volume 51 (21), 2008";"CACO-2";0.00002187761623949552
"MM476073";"MM476073";"COC[C@H]1CCCN1c1cc(NC(C)=O)nc(-n2nc(C)cc2C)n1";"FGADYIBOWLXZLA-CQSZACIVSA-N";344.42;1.85;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987761/target=_blank>CHEMBL987761</a>";;-4.15;"Lanier MC, Moorjani M, Luo Z, Chen Y, Lin E, Tellew JE, Zhang X, Williams JP, Gross RS, Lechner SM, Markison S, Joswig T, Kargo W, Piercey J, Santos M, Malany S, Zhao M, Petroski R, Crespo MI, DĂ­az JL, Saunders J, Wen J, O'Brien Z, Jalali K, Madan A, Slee DH.: N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy. J Med Chem, Volume 52 (3), 2009";"CACO-2";0.00007079457843841373
"MM476074";"MM476074";"CCCCC(COC(=O)C(C)(C)C)NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(O)[C@@H]1O)Oc1ccccc1";"QEDHMQRMCWZHDI-DDBBNYBPSA-N";596.62;2.78;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021283/target=_blank>CHEMBL1021283</a>";;-5.85;"Donghi M, Attenni B, Gardelli C, Marco AD, Fiore F, Giuliano C, Laufer R, Leone JF, Pucci V, Rowley M, Narjes F.: Synthesis and evaluation of novel phosphoramidate prodrugs of 2'-methyl cytidine as inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett, Volume 19 (5), 2009";"CACO-2";0.0000014125375446227554
"MM476075";"MM476075";"Oc1ccc(-c2cnc(-c3cccc(O)c3)s2)cc1";"WBUPCNHALRFMCB-UHFFFAOYSA-N";269.33;3.89;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1032443/target=_blank>CHEMBL1032443</a>";;-5.11;"Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW.: Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem, Volume 51 (21), 2008";"CACO-2";0.00000776247116628691
"MM476076";"MM476076";"COc1cc(Nc2nc(N[C@H]3CCCC[C@H]3N)n3cc(-c4ccccc4)nc3c2C(N)=O)cc(OC)c1";"UCDYGVBDFHZXEE-RTWAWAEBSA-N";501.59;3.94;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL992586/target=_blank>CHEMBL992586</a>";;-6.37;"Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Tsuji E, Miyazawa K, Misawa K, Ohnota H, Isaji M.: Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors. Bioorg Med Chem, Volume 16 (20), 2008";"CACO-2";0.00000042657951880159254
"MM476077";"MM476077";"Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12";"VWELCPLMPPEKOL-UHFFFAOYSA-N";512.03;4.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL980918/target=_blank>CHEMBL980918</a>";;-4.96;"Velaparthi U, Wittman M, Liu P, Carboni JM, Lee FY, Attar R, Balimane P, Clarke W, Sinz MW, Hurlburt W, Patel K, Discenza L, Kim S, Gottardis M, Greer A, Li A, Saulnier M, Yang Z, Zimmermann K, Trainor G, Vyas D.: Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J Med Chem, Volume 51 (19), 2008";"CACO-2";0.000010964781961431852
"MM476087";"MM476087";"Oc1ccc(-c2cc(-c3cccc(O)c3)cs2)cc1";"JECPEAXUEYTRPA-UHFFFAOYSA-N";268.34;4.49;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1032443/target=_blank>CHEMBL1032443</a>";;-4.84;"Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW.: Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem, Volume 51 (21), 2008";"CACO-2";0.00001445439770745928
"MM476088";"MM476088";"O=C(Nc1nc(-c2cccc(C(F)(F)F)c2F)cs1)c1ccc(N2CCC(C(=O)O)C2)nc1";"QHDHUEIPKWBLKG-UHFFFAOYSA-N";480.44;4.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL959265/target=_blank>CHEMBL959265</a>";;-5.35;"Munchhof MJ, Antipas AS, Blumberg LC, Brissette WH, Brown MF, Casavant JM, Doty JL, Driscoll J, Harris TM, Wolf-Gouveia LA, Jones CS, Li Q, Linde RG, Lira PD, Marfat A, McElroy E, Mitton-Fry M, McCurdy SP, Reiter LA, Ripp SL, Shavnya A, Thomasco LM, Trevena KA.: The identification of orally bioavailable thrombopoietin agonists. Bioorg Med Chem Lett, Volume 19 (5), 2009";"CACO-2";0.000004466835921509635
"MM476094";"MM476094";"COc1cc(Cl)ccc1C[C@@H](C)C(=O)N1CCN(c2ccc(Cl)cc2[C@@H](NC(=O)[C@@H](C)N)C(C)C)CC1";"BGNHNMCZDLGXJG-UDCNLSRBSA-N";549.54;4.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-5.52;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.0000030199517204020193
"MM476095";"MM476095";"CC(C)[C@H](NC(=O)CCN(C)C)c1cc(Cl)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1";"FISNMOAZOFAUNZ-PIKZIKFNSA-N";547.57;5.29;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-5.05;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.00000891250938133746
"MM476096";"MM476096";"CNCC(=O)N[C@H](c1cccc(F)c1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1)C(C)C";"DJUMIBAWSMGVLY-CLOONOSVSA-N";503.06;4.04;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-6;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.000001
"MM476097";"MM476097";"CNCC(=O)N[C@H](c1cccc(F)c1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2OC)CC1)C(C)C";"IPSFANQKYGITFT-BCHFMIIMSA-N";533.09;4.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-5.7;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.0000019952623149688787
"MM476098";"MM476098";"Cc1nc(C)c(-c2ccnc(Nc3ccc(N(C)C)cc3)n2)s1";"FGGSNQOBRJVAKL-UHFFFAOYSA-N";325.44;4.03;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120038/target=_blank>CHEMBL1120038</a>";;-4.31;"Wang S, Midgley CA, ScaĂ«rou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM, Fischer PM.: Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem, Volume 53 (11), 2010";"CACO-2";0.00004897788193684466
"MM476099";"MM476099";"CNCCN[C@H](c1cccc(F)c1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1)C(C)C";"UPPWDLKGVZSHCS-NLFFAJNJSA-N";489.08;4.51;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-6.4;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.0000003981071705534969
"MM476100";"MM476100";"COc1cc(Cl)ccc1C[C@@H](C)C(=O)N1CCN(c2ccc(Cl)cc2[C@@H](NC(=O)C2CNC2)C(C)C)CC1";"WKJNPGWIMYANRU-WINIVTDRSA-N";561.55;4.56;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-6.52;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.0000003019951720402019
"MM476110";"MM476110";"O=C(O)CC(c1ccc2c(c1)OCO2)N1CCc2cc(Oc3cccc4c3nc3n4CCCN3)ccc2C1=O";"MLCFOKYQRPBDTP-UHFFFAOYSA-N";526.55;4.59;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1029032/target=_blank>CHEMBL1029032</a>";;-5.05;"Letourneau JJ, Liu J, Ohlmeyer MH, Riviello C, Rong Y, Li H, Appell KC, Bansal S, Jacob B, Wong A, Webb ML.: Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5). Bioorg Med Chem Lett, Volume 19 (2), 2009";"CACO-2";0.00000891250938133746
"MM476117";"MM476117";"COc1cc(Nc2nc(N[C@H]3CCCC[C@H]3N)n3ncnc3c2C(N)=O)cc(OC)c1";"RVIMFNLCTIXVKN-CABCVRRESA-N";426.48;1.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL992586/target=_blank>CHEMBL992586</a>";;-6.48;"Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Tsuji E, Miyazawa K, Misawa K, Ohnota H, Isaji M.: Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors. Bioorg Med Chem, Volume 16 (20), 2008";"CACO-2";0.0000003311311214825908
"MM476118";"MM476118";"COc1cc(Nc2nc(N[C@H]3CCCC[C@H]3N)n3cnnc3c2C(N)=O)cc(OC)c1";"JMJSTGZRLYHCCI-CABCVRRESA-N";426.48;1.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL992586/target=_blank>CHEMBL992586</a>";;-8;"Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Tsuji E, Miyazawa K, Misawa K, Ohnota H, Isaji M.: Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors. Bioorg Med Chem, Volume 16 (20), 2008";"CACO-2";0.00000001
"MM476119";"MM476119";"CC(=O)c1cccc([C@@H](O)[C@H](O)[C@H](O)CO)n1";"XBHMEEKJDROEIF-GMTAPVOTSA-N";241.24;-0.97;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-4.87;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000013489628825916533
"MM476122";"MM476122";"CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(c1c(O)c(N3CCCC3)nn(CCC3CC3)c1=O)N2";"KMOJGDJFMHWZFM-UHFFFAOYSA-N";522.61;1.28;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-6.66;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.0000002187761623949552
"MM476125";"MM476125";"CC(C)(C)CCn1nc(N2CCCC2)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"DHEWIAANKVYIMN-UHFFFAOYSA-N";538.65;1.92;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-6.43;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.0000003715352290971728
"MM476126";"MM476126";"CC(C)CCn1nc(N(C)C(C)C)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"HQJVPSGXTRMVJB-UHFFFAOYSA-N";526.64;1.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-6.11;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.0000007762471166286911
"MM476128";"MM476128";"CC(C)CCn1nc(N2CCOCC2)c(O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1=O";"CSQSOLBGPHWFDY-UHFFFAOYSA-N";540.62;0.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-7.68;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.000000020892961308540408
"MM476129";"MM476129";"O=C(Nc1ccc(S(=O)(=O)C(F)(F)F)cc1)C1=CCN(c2ncccc2C(F)(F)F)CC1";"SDUAWRFBHRAFBM-UHFFFAOYSA-N";479.4;4.17;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL990797/target=_blank>CHEMBL990797</a>";;-4.55;"Brown BS, Keddy R, Zheng GZ, Schmidt RG, Koenig JR, McDonald HA, Bianchi BR, Honore P, Jarvis MF, Surowy CS, Polakowski JS, Marsh KC, Faltynek CR, Lee CH.: Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists. Bioorg Med Chem, Volume 16 (18), 2008";"CACO-2";0.00002818382931264455
"MM476130";"MM476130";"Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1";"GPSZYOIFQZPWEJ-UHFFFAOYSA-N";368.47;3.07;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120038/target=_blank>CHEMBL1120038</a>";;-4.33;"Wang S, Midgley CA, ScaĂ«rou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM, Fischer PM.: Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem, Volume 53 (11), 2010";"CACO-2";0.00004677351412871981
"MM476131";"MM476131";"OC[C@@H](O)[C@@H](O)[C@H](O)c1c[nH]c(-c2cocn2)n1";"GXYOUTDQUGPHGF-IWSPIJDZSA-N";255.23;-1.19;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-6.05;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.0000008912509381337459
"MM476132";"MM476132";"OC[C@@H](O)[C@@H](O)[C@H](O)c1c[nH]c(-c2nc[nH]n2)n1";"FQCLVDRYEUMURT-FSDSQADBSA-N";255.23;-2.06;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-6;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000001
"MM476134";"MM476134";"CN(C)C(=O)c1nc([C@@H](O)[C@H](O)[C@H](O)CO)c[nH]1";"PCVMKBXIOOPECB-BWZBUEFSSA-N";259.26;-2.14;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.00001
"MM476135";"MM476135";"Cc1scnc1-c1nc([C@@H](O)[C@H](O)[C@H](O)CO)c[nH]1";"KHBNEDHJPGHGMQ-SZEHBUNVSA-N";285.33;-0.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5.31;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000004897788193684467
"MM476136";"MM476136";"COc1cc(Nc2nc(N[C@H]3CCCC[C@H]3N)n3ccnc3c2C(N)=O)cc(OC)c1";"DVAXQAPODFQWRX-CVEARBPZSA-N";425.49;2.27;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL992586/target=_blank>CHEMBL992586</a>";;-5.48;"Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Tsuji E, Miyazawa K, Misawa K, Ohnota H, Isaji M.: Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors. Bioorg Med Chem, Volume 16 (20), 2008";"CACO-2";0.0000033113112148259077
"MM476140";"MM476140";"COc1ccc(CNc2ncnc3c(CCO)c(OC)c(NC(C)=O)cc23)cc1Cl";"YZMXAIKXCRWLSJ-UHFFFAOYSA-N";430.89;3.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963854/target=_blank>CHEMBL963854</a>";;-4.76;"Kim YH, Choi H, Lee J, Hwang IC, Moon SK, Kim SJ, Lee HW, Im DS, Lee SS, Ahn SK, Kim SW, Han CK, Yoon JH, Lee KJ, Choi NS.: Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.000017378008287493764
"MM476141";"MM476141";"CC(=O)c1nc([C@@H](O)[C@H](O)[C@H](O)CO)c[nH]1";"CQSIXFHVGKMLGQ-BWZBUEFSSA-N";230.22;-1.64;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-4.96;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000010964781961431852
"MM476142";"MM476142";"CC(=O)c1ncc([C@@H](O)[C@H](O)[C@H](O)CO)s1";"DDYLLKRDNVSZQV-LPBLVHEISA-N";247.27;-0.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-4.86;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000013803842646028839
"MM476143";"MM476143";"Oc1ccc(-c2cnc(-c3cccc(O)c3)o2)cc1";"QWBAQAYKEITCRE-UHFFFAOYSA-N";253.26;3.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL958063/target=_blank>CHEMBL958063</a>";;-5.1;"Bey E, Marchais-Oberwinkler S, Kruchten P, Frotscher M, Werth R, Oster A, AlgĂĽl O, Neugebauer A, Hartmann RW.: Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. Bioorg Med Chem, Volume 16 (12), 2008";"CACO-2";0.000007943282347242822
"MM476145";"MM476145";"CC(=O)c1nc([C@@H](O)[C@H](O)[C@H](O)C(=O)N(C)C)c[nH]1";"RFGKBXTYQMUSJY-VGMNWLOBSA-N";271.27;-1.54;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-4.99;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000010232929922807536
"MM476146";"MM476146";"CC(=O)c1nc([C@@H](O)[C@@H](O)[C@H](O)CO)c[nH]1";"CQSIXFHVGKMLGQ-PRJMDXOYSA-N";230.22;-1.64;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.00001
"MM476147";"MM476147";"O[C@@H](CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2CC[C@@H]1c1cccc(OC(F)(F)F)c1)C(F)(F)F";"CMOJRCASVGGDKQ-GGAORHGYSA-N";565.43;7.57;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1010552/target=_blank>CHEMBL1010552</a>";;-5.33;"Rano TA, Sieber-McMaster E, Pelton PD, Yang M, Demarest KT, Kuo GH.: Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett, Volume 19 (9), 2009";"CACO-2";0.000004677351412871981
"MM476150";"MM476150";"O=C(C(=O)N1CCN(C(=O)c2ccccc2)CC1)c1c[nH]c2c(F)ccc(F)c12";"IWOHGNFDYTXSAA-UHFFFAOYSA-N";397.38;2.61;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL956793/target=_blank>CHEMBL956793</a>";;-4.66;"Meanwell NA, Wallace OB, Fang H, Wang H, Deshpande M, Wang T, Yin Z, Zhang Z, Pearce BC, James J, Yeung KS, Qiu Z, Kim Wright JJ, Yang Z, Zadjura L, Tweedie DL, Yeola S, Zhao F, Ranadive S, Robinson BA, Gong YF, Wang HG, Spicer TP, Blair WS, Shi PY, Colonno RJ, Lin PF.: Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns. Bioorg Med Chem Lett, Volume 19 (7), 2009";"CACO-2";0.00002187761623949552
"MM476154";"MM476154";"CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C#N)cc1";"NZPSTYAGNIOCBZ-UHFFFAOYSA-N";461.85;3.29;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL960898/target=_blank>CHEMBL960898</a>";;-4.55;"Swahn BM, Macsari I, Viklund J, Ohberg L, SjĂ¶din J, Neelissen J, Lindquist J.: Liver X receptor agonists with selectivity for LXRbeta; N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides. Bioorg Med Chem Lett, Volume 19 (7), 2009";"CACO-2";0.00002818382931264455
"MM476160";"MM476160";"O=c1c(C2=CS(=O)(=O)c3ccccc3N2)c(O)c2ccccc2n1Cc1ccc(F)cc1";"UQCRWUKAPCLLPC-UHFFFAOYSA-N";448.48;4.09;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1008281/target=_blank>CHEMBL1008281</a>";;-5.36;"Hendricks RT, Fell JB, Blake JF, Fischer JP, Robinson JE, Spencer SR, Stengel PJ, Bernacki AL, Leveque VJ, Le Pogam S, Rajyaguru S, Najera I, Josey JA, Harris JR, Swallow S.: Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. Bioorg Med Chem Lett, Volume 19 (13), 2009";"CACO-2";0.000004365158322401657
"MM476161";"MM476161";"Cc1ccc2c(c1)c(O)c(C1=CS(=O)(=O)c3ccccc3N1)c(=O)n2CCC1CC1";"AVEUJPSFVWFQTK-UHFFFAOYSA-N";422.51;4.01;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1008281/target=_blank>CHEMBL1008281</a>";;-5.03;"Hendricks RT, Fell JB, Blake JF, Fischer JP, Robinson JE, Spencer SR, Stengel PJ, Bernacki AL, Leveque VJ, Le Pogam S, Rajyaguru S, Najera I, Josey JA, Harris JR, Swallow S.: Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. Bioorg Med Chem Lett, Volume 19 (13), 2009";"CACO-2";0.000009332543007969906
"MM476168";"MM476168";"CC(C)[C@H](NC(=O)CCN(C)C)c1cccc(F)c1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1";"ROSDSGGMKIYLIM-ZBLYBZFDSA-N";531.12;4.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-5;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.00001
"MM476169";"MM476169";"CC(C)[C@H](NC(=O)C1CN(C)C1)c1cc(Cl)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1";"SYIWIZYUJLMOJX-HRFSGMKKSA-N";545.56;4.9;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-5.7;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.0000019952623149688787
"(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol";"MM00573";"CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1";"BLJRIMJGRPQVNF-UHFFFAOYSA-N";316.43;0.5;"33624";"CHEMBL499";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619358/target=_blank>CHEMBL619358</a>";;-4.89;"Mandagere AK, Thompson TN, Hwang KK.: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem, Volume 45 (2), 2002";"CACO-2";0.000012882495516931348
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-4.44;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000363078054770101
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-4.26;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00005495408738576248
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-4.26;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.00005495408738576248
"MM476177";"MM476177";"CC(F)(F)c1nc([C@@H](O)[C@H](O)[C@H](O)CO)c[nH]1";"ZDWVFXNHLJHSPG-FSDSQADBSA-N";252.22;-0.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-4.95;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.00001122018454301963
"MM476179";"MM476179";"C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O";"BPYKTIZUTYGOLE-IFADSCNNSA-N";584.67;4.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL975052/target=_blank>CHEMBL975052</a>";;-7.7;"Bulmer AC, Blanchfield JT, Coombes JS, Toth I.: In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.000000019952623149688786
"MM476179";"MM476179";"C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)O)c(CCC(=O)O)c2C)NC1=O";"BPYKTIZUTYGOLE-IFADSCNNSA-N";584.67;4.53;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL975053/target=_blank>CHEMBL975053</a>";;-5.98;"Bulmer AC, Blanchfield JT, Coombes JS, Toth I.: In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.0000010471285480508985
"MM476181";"MM476181";"COC(=O)/C=C/CNC(=O)CN1C(=O)[C@@H](COC(=O)Nc2ccc(Cl)cc2C(F)(F)F)N=C(c2ccccc2)c2ccccc21";"WFLUSHRKBAULOF-KGUVVTLUSA-N";643.02;5.01;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015280/target=_blank>CHEMBL1015280</a>";;-5.42;"Ettari R, Micale N, Schirmeister T, Gelhaus C, Leippe M, Nizi E, Di Francesco ME, Grasso S, ZappalĂ  M.: Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. J Med Chem, Volume 52 (7), 2009";"CACO-2";0.000003801893963205613
"MM476182";"MM476182";"CC(=O)N/N=C(\C)c1nc([C@@H](O)[C@H](O)[C@H](O)CO)c[nH]1";"PKLZIULWTVXTRG-PFVSEMTCSA-N";286.29;-1.98;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5.05;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.00000891250938133746
"MM476185";"MM476185";"Oc1cccc(-c2ccc(-c3cccc(O)c3)cc2)c1";"OKAPKQMESLLPQL-UHFFFAOYSA-N";262.31;4.43;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1032443/target=_blank>CHEMBL1032443</a>";;-4.9;"Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW.: Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem, Volume 51 (21), 2008";"CACO-2";0.000012589254117941661
"MM476187";"MM476187";"COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@@H](c3ccccc3)N(C)CCCC(=O)O)c2=O)c1F";"SSTWFLYMZFXJLL-SANMLTNESA-N";645.63;5.88;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1008937/target=_blank>CHEMBL1008937</a>";;-5.12;"Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS.: Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem, Volume 51 (23), 2008";"CACO-2";0.000007585775750291836
"MM476188";"MM476188";"C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)NCCS(=O)(=O)O)c(CCC(=O)NCCS(=O)(=O)O)c2C)NC1=O";"IVYBPZIDQLNIHQ-VYTBREFCSA-N";798.94;2.37;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL975052/target=_blank>CHEMBL975052</a>";;-6.41;"Bulmer AC, Blanchfield JT, Coombes JS, Toth I.: In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.0000003890451449942805
"MM476188";"MM476188";"C=CC1=C(C)/C(=C/c2[nH]c(Cc3[nH]c(/C=C4\NC(=O)C(C)=C4C=C)c(C)c3CCC(=O)NCCS(=O)(=O)O)c(CCC(=O)NCCS(=O)(=O)O)c2C)NC1=O";"IVYBPZIDQLNIHQ-VYTBREFCSA-N";798.94;2.37;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL975053/target=_blank>CHEMBL975053</a>";;-5.45;"Bulmer AC, Blanchfield JT, Coombes JS, Toth I.: In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem, Volume 16 (7), 2008";"CACO-2";0.000003548133892335753
"MM476195";"MM476195";"Cc1nc(-c2nc([C@@H](O)[C@H](O)[C@H](O)CO)c[nH]2)cs1";"WDQBAYNAZJDXIL-OPRDCNLKSA-N";285.33;-0.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-4.7;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000019952623149688786
"MM476196";"MM476196";"COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F";"AXGALHYEZXVPRS-VWLOTQADSA-N";581.59;4.66;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1008937/target=_blank>CHEMBL1008937</a>";;-6.4;"Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS.: Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem, Volume 51 (23), 2008";"CACO-2";0.0000003981071705534969
"MM476199";"MM476199";"O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F";"SUDAHWBOROXANE-SECBINFHSA-N";482.2;2.47;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963135/target=_blank>CHEMBL963135</a>";;-4.14;"Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA, Smith Y, Warmus JS, Tecle H.: The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett, Volume 18 (24), 2008";"CACO-2";0.00007244359600749906
"MM476203";"MM476203";"c1csc([C@]23CNC[C@H]2C3)c1";"DMILNTFRFSJCOO-VXNVDRBHSA-N";165.26;1.61;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946405/target=_blank>CHEMBL946405</a>";;-4.75;"Zhang M, Jovic F, Vickers T, Dyck B, Tamiya J, Grey J, Tran JA, Fleck BA, Pick R, Foster AC, Chen C.: Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett, Volume 18 (13), 2008";"CACO-2";0.00001778279410038923
"MM476212";"MM476212";"CC(C)CCn1nc(N2CCCC2)c(O)c(C2=Nc3ccc(NS(C)(=O)=O)cc3S(=O)(=O)N2)c1=O";"QUWPELVBLLLYGL-UHFFFAOYSA-N";524.63;1.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-6.49;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.0000003235936569296281
"MM476215";"MM476215";"CCN(CC)c1nn(CCC(C)C)c(=O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1O";"YXHWNTRXNUQAEO-UHFFFAOYSA-N";526.64;1.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-6.52;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.0000003019951720402019
"MM476218";"MM476218";"CCCN(C)c1nn(CCC(C)C)c(=O)c(C2=NS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)c1O";"ZRCJUEIDUCSFEC-UHFFFAOYSA-N";526.64;1.77;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL983545/target=_blank>CHEMBL983545</a>";;-6.92;"Dragovich PS, Blazel JK, Ellis DA, Han Q, Kamran R, Kissinger CR, LeBrun LA, Li LS, Murphy DE, Noble M, Patel RA, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Tran CV, Tsan M, Webber SE, Kirkovsky L, Zhou Y.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett, Volume 18 (20), 2008";"CACO-2";0.00000012022644346174132
"MM476219";"MM476219";"Cc1cc(Cc2ccc(Cl)c(Oc3cc(C#N)cc(C#N)c3)c2F)n[nH]c1=O";"KIZKDBLDDHZHRV-UHFFFAOYSA-N";394.79;4;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL946736/target=_blank>CHEMBL946736</a>";;-4.72;"Elworthy TR, Dunn JP, Hogg JH, Lam G, Saito YD, Silva TM, Stefanidis D, Woroniecki W, Zhornisky E, Zhou AS, Klumpp K.: Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase. Bioorg Med Chem Lett, Volume 18 (24), 2008";"CACO-2";0.000019054607179632484
"MM476220";"MM476220";"OC[C@@H](O)[C@@H](O)[C@H](O)c1c[nH]c(-c2ncn(Cc3ccccc3)n2)n1";"BBNRKROQKWHULU-MGPQQGTHSA-N";345.36;-0.54;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5.29;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000005128613839913648
"MM476221";"MM476221";"OC[C@@H](O)[C@@H](O)[C@H](O)c1c[nH]c(-c2ncc[nH]2)n1";"VNNRJKXUNVVHEK-BWZBUEFSSA-N";254.25;-1.45;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-4.59;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000025703957827688645
"Ibuprofen";"MM00045";"CC(C)Cc1ccc(C(C)C(=O)O)cc1";"HEFNNWSXXWATRW-UHFFFAOYSA-N";206.29;3.07;"3672";"CHEMBL521";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638187/target=_blank>CHEMBL638187</a>";;-4.7;"Wohnsland F, Faller B.: High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem, Volume 44 (6), 2001";"CACO-2";0.000019952623149688786
"MM476222";"MM476222";"CCC(=O)Nc1cc2c(NCc3ccc(OC)c(Cl)c3)ncnc2c(CCO)c1OC";"OXGSPQPAZQTQCO-UHFFFAOYSA-N";444.92;3.8;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963854/target=_blank>CHEMBL963854</a>";;-4.33;"Kim YH, Choi H, Lee J, Hwang IC, Moon SK, Kim SJ, Lee HW, Im DS, Lee SS, Ahn SK, Kim SW, Han CK, Yoon JH, Lee KJ, Choi NS.: Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. Bioorg Med Chem Lett, Volume 18 (23), 2008";"CACO-2";0.00004677351412871981
"MM476223";"MM476223";"c1ccn2cc(-c3ccc(OCCCN4CCCCC4)cc3)cc2c1";"KDEPDSHXUKZUKL-UHFFFAOYSA-N";334.46;4.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL657440/target=_blank>CHEMBL657440</a>";;-4.85;"Chai W, Breitenbucher JG, Kwok A, Li X, Wong V, Carruthers NI, Lovenberg TW, Mazur C, Wilson SJ, Axe FU, Jones TK.: Non-imidazole heterocyclic histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 13 (10), 2003";"CACO-2";0.000014125375446227555
"MM476224";"MM476224";"COc1cc(Cl)ccc1C[C@@H](C)C(=O)N1CCN(c2c(F)cccc2[C@@H](NC(=O)C2CNC2)C(C)C)CC1";"XWVUILPYFRWOKA-BCHFMIIMSA-N";545.1;4.05;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-6.7;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.00000019952623149688787
"7-chloro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one";"MM00964";"O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1";"AKPLHCDWDRPJGD-UHFFFAOYSA-N";270.72;3.13;"2997";;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-4.02;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00009549925860214369
"7-chloro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one";"MM00964";"O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1";"AKPLHCDWDRPJGD-UHFFFAOYSA-N";270.72;3.13;"2997";;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-3.51;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0003090295432513592
"MM476225";"MM476225";"COc1cccc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12";"YONWOVYXYCIVNL-UHFFFAOYSA-N";391.43;2.34;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-5.37;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000004265795188015926
"MM476226";"MM476226";"CNCC(=O)N[C@H](c1cccc(F)c1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2Cl)CC1)C(C)C";"IUHYYYUXPSCOGY-CJAUYULYSA-N";537.51;4.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963797/target=_blank>CHEMBL963797</a>";;-5.7;"Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, Chen T, Johns M, Markison S, Foster AC, Marinkovic D, Chen CW, Arellano M, Harman J, Saunders J, Bozigian H, Marks D.: Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem, Volume 16 (10), 2008";"CACO-2";0.0000019952623149688787
"MM476234";"MM476234";"CC(=O)c1nc([C@@H](O)[C@H](O)[C@H](O)CO)cn1C";"UXVOVMZBOHGDDV-IWSPIJDZSA-N";244.25;-1.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952663/target=_blank>CHEMBL952663</a>";;-5.25;"Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, Yu S, Swaffield J, Wilson A, Main A, Carson KG, Oravecz T, Augeri DJ.: Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem, Volume 52 (13), 2009";"CACO-2";0.000005623413251903491
"MM476235";"MM476235";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C[C@@H](O)CN2CCN(S(C)(=O)=O)CC2)cc2ccccc21";"ABRIRNSRFVVIJK-KIHHCIJBSA-N";559.73;1.25;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.85;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.000014125375446227555
"MM476236";"MM476236";"CCOC(=O)N1CCN(CCCCCCCN2[C@@H]3CC[C@H]2C[C@@H](NC(=O)c2cc4ccccc4n(C(C)C)c2=O)C3)CC1";"ABBXOBHUMXCOGM-PKQPGRETSA-N";593.81;5.03;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.85;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.000014125375446227555
"MM476237";"MM476237";"COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COCc2cccnc2)cc1";"WPYDZJMOARSIDS-RUZDIDTESA-N";491.59;3.6;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL873566/target=_blank>CHEMBL873566</a>";;-4.89;"Powell NA, Clay EH, Holsworth DD, Bryant JW, Ryan MJ, Jalaie M, Edmunds JJ.: Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. Bioorg Med Chem Lett, Volume 15 (21), 2005";"CACO-2";0.000012882495516931348
"MM476238";"MM476238";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCCCCCN2CCN(c3ccccc3)CC2)cc2ccccc21";"OTWJCQNGXQUBEK-IFBCEJQISA-N";597.85;6.08;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.7;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.000019952623149688786
"MM476239";"MM476239";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCCCCCN2CCC[C@@H]2C(N)=O)cc2ccccc21";"WYNXEKYLFMUSEO-GFQWBHFJSA-N";549.76;4.21;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-5.05;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.00000891250938133746
"MM476240";"MM476240";"CC(C)[C@H](NC(=O)C(O)(CCC(=O)Nc1cc(C(=O)N[C@H](C)c2ccccc2)cc(N(C)S(C)(=O)=O)c1)CCc1ccccc1)C(=O)Nc1ccccc1";"ABXPXXXDZPDMFT-BIKMQQNJSA-N";755.94;5.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059108/target=_blank>CHEMBL1059108</a>";;-5.92;"WĂĄngsell F, Russo F, SĂ¤vmarker J, Rosenquist A, Samuelsson B, Larhed M.: Design and synthesis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.0000012022644346174132
"MM476241";"MM476241";"CCOC(=O)N1CCN(CCCN2[C@@H]3CC[C@H]2C[C@@H](NC(=O)c2cc4ccccc4n(C(C)C)c2=O)C3)CC1";"YFJVXDKQWHEAPD-QEIWAGNOSA-N";537.71;3.47;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.51;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.00003090295432513592
"MM476242";"MM476242";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCCCCCN2CCC(CNS(C)(=O)=O)CC2)cc2ccccc21";"UTTJQYGVCBXTDB-RLPLKTQASA-N";627.9;4.52;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-5.7;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.0000019952623149688787
"MM476243";"MM476243";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C[C@H](O)CN2CCN(S(C)(=O)=O)CC2)cc2ccccc21";"ABRIRNSRFVVIJK-UEQSERJNSA-N";559.73;1.25;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.7;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.000019952623149688786
"Oxprenolol";"MM00289";"C=CCOc1ccccc1OCC(O)CNC(C)C";"CEMAWMOMDPGJMB-UHFFFAOYSA-N";265.35;1.99;"4631";"CHEMBL546";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-4.21;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00006165950018614822
"Oxprenolol";"MM00289";"C=CCOc1ccccc1OCC(O)CNC(C)C";"CEMAWMOMDPGJMB-UHFFFAOYSA-N";265.35;1.99;"4631";"CHEMBL546";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-3.92;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00012022644346174131
"Oxprenolol";"MM00289";"C=CCOc1ccccc1OCC(O)CNC(C)C";"CEMAWMOMDPGJMB-UHFFFAOYSA-N";265.35;1.99;"4631";"CHEMBL546";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-3.92;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.00012022644346174131
"MM476244";"MM476244";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCN2CCN(S(C)(=O)=O)CC2)cc2ccccc21";"GIGBLIZJFWVMDM-BKFWDETESA-N";543.73;2.27;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.7;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.000019952623149688786
"MM476245";"MM476245";"COCCCn1c(CN2C(=O)/C(=N/OC)c3ccccc32)nc2ccccc21";"IKJABHMXDXQNBR-BSYVCWPDSA-N";378.43;2.97;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.73;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000018620871366628657
"MM476246";"MM476246";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCN2CCOCC2)cc2ccccc21";"DFERKDOBDPAYJI-NUNAXRQHSA-N";466.63;3.03;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.66;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.00002187761623949552
"MM476247";"MM476247";"CS(=O)(=O)CCCn1c(CN2C(=O)/C(=N/OCCF)c3ccncc32)nc2ccccc21";"NFTZYCXHPRZPHC-LKUDQCMESA-N";459.5;2.1;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-6;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000001
"MM476249";"MM476249";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCCCCCN2CCCCC2)cc2ccccc21";"JREDAYCXSVWBIJ-OUOZDZGXSA-N";520.76;5.74;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.64;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.00002290867652767775
"MM476250";"MM476250";"O=C1/C(=N/OCCF)c2ccncc2N1Cc1nc2ccccc2n1CCCCO";"QKRWDEGUIHPLMZ-LKUDQCMESA-N";411.44;2.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-5.28;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000005248074602497723
"MM476251";"MM476251";"CS(=O)(=O)c1ccc(CO/N=C2/C(=O)N(Cc3nc4ccccc4n3CCCCO)c3ccccc32)cc1";"XVYAYXUMMBBMAP-KDJFERLWSA-N";532.62;3.68;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.82;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000015135612484362071
"MM476254";"MM476254";"COCCCn1c(CN2C(=O)/C(=N/OCC(N)=O)c3ccccc32)nc2ccccc21";"KNXMSZSFJFSEJJ-NJNXFGOHSA-N";421.46;1.83;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-5.82;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.0000015135612484362072
"MM476255";"MM476255";"O=C(C=C1CCN(C(=O)c2ccccc2O)CC1)N[C@@H]1CCN(Cc2ccc3cc(F)ccc3c2)C1";"TVBOHVNCFNQWSW-RUZDIDTESA-N";487.58;4.24;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1055691/target=_blank>CHEMBL1055691</a>";;-5.4;"Sato I, Morihira K, Inami H, Kubota H, Morokata T, Suzuki K, Ohno K, Iura Y, Nitta A, Imaoka T, Takahashi T, Takeuchi M, Ohta M, Tsukamoto S.: Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists. Bioorg Med Chem, Volume 17 (16), 2009";"CACO-2";0.000003981071705534969
"MM476256";"MM476256";"O=C1CCCCN1C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1";"LUSFVKKEBIMJTI-UHFFFAOYSA-N";406.51;4.21;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056695/target=_blank>CHEMBL1056695</a>";;-4.91;"Coon T, Moree WJ, Li B, Yu J, Zamani-Kord S, Malany S, Santos MA, Hernandez LM, Petroski RE, Sun A, Wen J, Sullivan S, Haelewyn J, Hedrick M, Hoare SJ, Bradbury MJ, Crowe PD, Beaton G.: Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett, Volume 19 (15), 2009";"CACO-2";0.00001230268770812381
"MM476260";"MM476260";"COCCCn1c(CN2C(=O)/C(=N/OCc3ccncc3)c3ccccc32)nc2ccccc21";"FUDIJDSZYDLKAI-XLVZBRSZSA-N";455.52;3.94;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.67;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000021379620895022323
"MM476262";"MM476262";"CO/N=C1/C(=O)N(Cc2nc3ccccc3n2CCCCF)c2cnccc21";"UMHGEVBTISKYKG-LYBHJNIJSA-N";381.41;3.08;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.89;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000012882495516931348
"MM476264";"MM476264";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCCCCCN(C)CCCN(C)S(C)(=O)=O)cc2ccccc21";"OZOUMOAFNFHRMX-PKQPGRETSA-N";615.89;4.47;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-5.52;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.0000030199517204020193
"MM476265";"MM476265";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CC(O)CN2CCN(S(C)(=O)=O)CC2)cc2ccccc21";"ABRIRNSRFVVIJK-ACDIJKPMSA-N";559.73;1.25;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.72;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.000019054607179632484
"MM476266";"MM476266";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCN2CCN(c3ccccc3)CC2)cc2ccccc21";"YELQSMXPCPMVON-RHKQRFKBSA-N";541.74;4.52;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.66;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.00002187761623949552
"MM476267";"MM476267";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCN2CCC(CNS(C)(=O)=O)CC2)cc2ccccc21";"VFYJTXFWAIHDFH-OOSCYNTBSA-N";571.79;2.96;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-5.52;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.0000030199517204020193
"MM476268";"MM476268";"CCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(OCCOC)cc(-c3ccccc3)n2)CC1";"PDNVGDXATCGRSB-QHCPKHFHSA-N";570.64;2.82;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1064900/target=_blank>CHEMBL1064900</a>";;-5.96;"Parlow JJ, Burney MW, Case BL, Girard TJ, Hall KA, Harris PK, Hiebsch RR, Huff RM, Lachance RM, Mischke DA, Rapp SR, Woerndle RS, Ennis MD.: Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. J Med Chem, Volume 53 (5), 2010";"CACO-2";0.000001096478196143185
"MM476269";"MM476269";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCCCCCN2CCN(S(C)(=O)=O)CC2)cc2ccccc21";"XJYKGQSAARGRMU-OUOZDZGXSA-N";599.84;3.84;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.66;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.00002187761623949552
"MM476270";"MM476270";"N#CCCCn1c(CN2C(=O)/C(=N/OCC(N)=O)c3ccccc32)nc2ccccc21";"YVSKSGGSFYJMAZ-YYADALCUSA-N";416.44;2.09;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-5.52;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.0000030199517204020193
"MM476271";"MM476271";"CC(=O)OCCCCn1c(CN2C(=O)/C(=N/O)c3cccnc32)nc2ccccc21";"UWJYOOGCMPSHPZ-LYBHJNIJSA-N";407.43;2.5;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-5.92;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.0000012022644346174132
"MM476273";"MM476273";"CO/N=C1/C(=O)N(Cc2nc3ccccc3n2CCCCO)c2cnccc21";"OKWZYYAHUWOXNW-FCDQGJHFSA-N";379.42;2.1;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-5.01;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000009772372209558111
"MM476274";"MM476274";"COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1";"IJOLYFZBLJPKPI-UHFFFAOYSA-N";440.43;4.95;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1035569/target=_blank>CHEMBL1035569</a>";;-4.17;"Lahue BR, Ma Y, Shipps GW, Seghezzi W, Herbst R.: Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors. Bioorg Med Chem Lett, Volume 19 (13), 2009";"CACO-2";0.00006760829753919819
"MM476278";"MM476278";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCN2CCC[C@@H]2C(N)=O)cc2ccccc21";"HIGFKWYFHAAARQ-WTEVXDJOSA-N";493.65;2.65;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-5.7;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.0000019952623149688787
"MM476280";"MM476280";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCN(C)CCCN(C)S(C)(=O)=O)cc2ccccc21";"GSEYLMTUUMJITR-QEIWAGNOSA-N";559.78;2.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-5.4;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.000003981071705534969
"MM476282";"MM476282";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCCCCCN2CCOCC2)cc2ccccc21";"BLFYXJBXIJKCKD-LGKQTMLJSA-N";522.73;4.59;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.55;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.00002818382931264455
"MM476286";"MM476286";"Cn1nc(C(N)=O)c2c1-c1nc(Nc3ccccc3)ncc1CC2";"UTHWBIPHRYUJSU-UHFFFAOYSA-N";320.36;1.82;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1109147/target=_blank>CHEMBL1109147</a>";;-4.23;"Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, Cappella P, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cristiani C, Croci V, De Ponti A, Fachin G, Ferguson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P, Volpi D, Valsasina B.: Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. J Med Chem, Volume 53 (9), 2010";"CACO-2";0.00005888436553555884
"MM476288";"MM476288";"COCCCn1c(CN2C(=O)/C(=N/OCC(F)(F)F)c3ccccc32)nc2ccccc21";"USUGQSNDWDLBSP-NHFJDJAPSA-N";446.43;3.9;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.19;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.00006456542290346549
"MM476290";"MM476290";"O=C1/C(=N/OCCF)c2ccncc2N1Cc1nc2ccccc2n1CCCCF";"VUYIZMZQZDXUBI-LHLOQNFPSA-N";413.43;3.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.8;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.00001584893192461114
"MM476294";"MM476294";"COCCCn1c(CN2C(=O)/C(=N/OCc3ccc(C(=O)N(C)C)cc3)c3ccccc32)nc2ccccc21";"XXLFUTNPXWHRAC-VEWQFJOQSA-N";525.61;4.24;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.63;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.00002344228815319923
"MM476295";"MM476295";"O=C1/C(=N/O)c2ccncc2N1Cc1nc2ccccc2n1CCCCF";"BNAJUPMRHSJZJQ-PTGBLXJZSA-N";367.38;2.91;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-5.57;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.0000026915348039269138
"MM476297";"MM476297";"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3CCCN2CCCCC2)cc2ccccc21";"FWPLUVHDRWZXEC-BKFWDETESA-N";464.65;4.18;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.62;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.0000239883291901949
"MM476299";"MM476299";"CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1";"LDIUIXFIAWISPB-UHFFFAOYSA-N";456.49;5.67;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1035569/target=_blank>CHEMBL1035569</a>";;-4.28;"Lahue BR, Ma Y, Shipps GW, Seghezzi W, Herbst R.: Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors. Bioorg Med Chem Lett, Volume 19 (13), 2009";"CACO-2";0.00005248074602497723
"MM476300";"MM476300";"CO/N=C1/C(=O)N(Cc2nc3ccccc3n2CCCC#N)c2ncccc21";"ZEJXRDWOQCJRJI-HKOYGPOVSA-N";374.4;2.63;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.8;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.00001584893192461114
"MM476302";"MM476302";"O=C1/C(=N/OCCF)c2cccnc2N1Cc1nc2ccccc2n1CCCCO";"MLJMXQOBSLWQPB-NCELDCMTSA-N";411.44;2.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.94;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000011481536214968817
"MM476304";"MM476304";"N#CCCCn1c(CN2C(=O)/C(=N/O)c3cccnc32)nc2ccccc21";"DAZZHWVOCHMWCL-HAVVHWLPSA-N";360.38;2.46;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-5.38;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000004168693834703355
"MM476307";"MM476307";"N#CCCCn1c(CN2C(=O)/C(=N/OCCF)c3cccnc32)nc2ccccc21";"GLMHDFLHDDUQKX-LGUFXXKBSA-N";406.42;2.97;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.81;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000015488166189124828
"MM476316";"MM476316";"CO/N=C1/C(=O)N(Cc2nc3ccccc3n2CCCCO)c2ncccc21";"LOMNIUZUACUQTQ-PTGBLXJZSA-N";379.42;2.1;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1054839/target=_blank>CHEMBL1054839</a>";;-4.85;"Sin N, Venables BL, Combrink KD, Gulgeze HB, Yu KL, Civiello RL, Thuring J, Wang XA, Yang Z, Zadjura L, Marino A, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett, Volume 19 (16), 2009";"CACO-2";0.000014125375446227555
"MM476322";"MM476322";"CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1";"PKOKKGWFSDPGGQ-UHFFFAOYSA-N";488.49;4.35;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1035569/target=_blank>CHEMBL1035569</a>";;-5.74;"Lahue BR, Ma Y, Shipps GW, Seghezzi W, Herbst R.: Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors. Bioorg Med Chem Lett, Volume 19 (13), 2009";"CACO-2";0.0000018197008586099826
"MM476325";"MM476325";"Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12";"BFBTVZNKWXWKNZ-HWKANZROSA-N";592.33;7.33;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045325/target=_blank>CHEMBL1045325</a>";;-4.95;"Singh J, Zeller W, Zhou N, Hategan G, Mishra RK, Polozov A, Yu P, Onua E, Zhang J, RamĂ­rez JL, Sigthorsson G, Thorsteinnsdottir M, Kiselyov AS, Zembower DE, AndrĂ©sson T, Gurney ME.: Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem, Volume 53 (1), 2010";"CACO-2";0.00001122018454301963
"MM476333";"MM476333";"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4";"BLUAFEHZUWYNDE-DKGJTOOQSA-N";282.34;2.39;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-4.52;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000030199517204020192
"MM476335";"MM476335";"CC(C)C1CN(C(=O)C(=O)c2c[nH]c3cccc(F)c23)CCN1C(=O)c1ccccc1";"JQDOTZVNBIPURF-UHFFFAOYSA-N";421.47;3.5;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.79;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.0000162181009735893
"MM476339";"MM476339";"CC(C)(C)C1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"OBEHZHAPFOBKFJ-UHFFFAOYSA-N";435.5;3.89;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.77;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.00001698243652461746
"MM476340";"MM476340";"CCCCCC1CN(C(=O)C(=O)c2c[nH]c3cccc(F)c23)CCN1C(=O)c1ccccc1";"FWERABPXCIEUKX-UHFFFAOYSA-N";449.53;4.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-5.16;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.0000069183097091893625
"MM476341";"MM476341";"CCCC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"ATGNIAKOMZKQIA-UHFFFAOYSA-N";421.47;3.64;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.76;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000017378008287493764
"MM476342";"MM476342";"CCCCCC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"VOVABKAMAGNWNV-UHFFFAOYSA-N";449.53;4.42;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.81;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000015488166189124828
"MM476345";"MM476345";"C[C@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"GJIOAZQCBADHSB-AWEZNQCLSA-N";393.42;2.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-5.06;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000008709635899560814
"MM476347";"MM476347";"CCC1CN(C(=O)C(=O)c2c[nH]c3cccc(F)c23)CCN1C(=O)c1ccccc1";"JIYDSLCGNMDXBR-UHFFFAOYSA-N";407.45;3.25;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.77;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.00001698243652461746
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL859786/target=_blank>CHEMBL859786</a>";;-4.59;"Voets M, Antes I, Scherer C, MĂĽller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.: Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem, Volume 49 (7), 2006";"CACO-2";0.000025703957827688645
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1032443/target=_blank>CHEMBL1032443</a>";;-4.59;"Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW.: Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem, Volume 51 (21), 2008";"CACO-2";0.000025703957827688645
"MM476348";"MM476348";"CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"GJIOAZQCBADHSB-UHFFFAOYSA-N";393.42;2.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-5.14;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000007244359600749906
"MM476349";"MM476349";"CCCC1CN(C(=O)C(=O)c2c[nH]c3cccc(F)c23)CCN1C(=O)c1ccccc1";"OHMAVAINSFOTRQ-UHFFFAOYSA-N";421.47;3.64;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.81;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000015488166189124828
"MM476350";"MM476350";"COc1cccc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12";"YWHUPMDHHBIXPR-OAHLLOKOSA-N";405.45;2.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-5.34;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000004570881896148752
"MM476353";"MM476353";"CCC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"UOQQQRFMXIOQQJ-UHFFFAOYSA-N";407.45;3.25;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.82;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000015135612484362071
"MM476354";"MM476354";"CC(C)CC1CN(C(=O)C(=O)c2c[nH]c3cccc(F)c23)CCN1C(=O)c1ccccc1";"WSCMWUHPGDJGCX-UHFFFAOYSA-N";435.5;3.89;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.72;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000019054607179632484
"MM476355";"MM476355";"C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"GJIOAZQCBADHSB-CQSZACIVSA-N";393.42;2.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-5.27;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000005370317963702533
"MM476356";"MM476356";"CC(C)C1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"UMIRVWYLVYLOHJ-UHFFFAOYSA-N";421.47;3.5;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.78;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.000016595869074375598
"MM476357";"MM476357";"CC(C)[C@H](NC(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)C(=O)NCC(F)(F)F";"GCKBHEHXTWPFBD-CDNLURBZSA-N";701.74;2.47;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1036995/target=_blank>CHEMBL1036995</a>";;-5.54;"Adrian Meredith J, Wallberg H, Vrang L, Oscarson S, Parkes K, Hallberg A, Samuelsson B.: Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors. Eur J Med Chem, Volume 45 (1), 2010";"CACO-2";0.000002884031503126606
"MM476359";"MM476359";"CC(C)[C@H](NC(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)C(=O)NCCF";"YAKLVQLNBNXLLB-MLPSMZPESA-N";665.76;1.88;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1036995/target=_blank>CHEMBL1036995</a>";;-5.8;"Adrian Meredith J, Wallberg H, Vrang L, Oscarson S, Parkes K, Hallberg A, Samuelsson B.: Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors. Eur J Med Chem, Volume 45 (1), 2010";"CACO-2";0.000001584893192461114
"MM476360";"MM476360";"CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)C(C)C";"VZNNJZGVQVNHCM-CDNLURBZSA-N";633.74;1.54;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1036995/target=_blank>CHEMBL1036995</a>";;-5.85;"Adrian Meredith J, Wallberg H, Vrang L, Oscarson S, Parkes K, Hallberg A, Samuelsson B.: Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors. Eur J Med Chem, Volume 45 (1), 2010";"CACO-2";0.0000014125375446227554
"MM476361";"MM476361";"COC(=O)N[C@H](C(=O)NN(CC[C@@](O)(Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)Cc1ccc(Br)cc1)C(C)(C)C";"YIGWEZGHVPDQGX-IRYJCKHSSA-N";695.66;4.19;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048544/target=_blank>CHEMBL1048544</a>";;-4.38;"Mahalingam AK, Axelsson L, Ekegren JK, Wannberg J, KihlstrĂ¶m J, Unge T, Wallberg H, Samuelsson B, Larhed M, Hallberg A.: HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.00004168693834703355
"MM476366";"MM476366";"COC(=O)N[C@H](C(=O)NN(CC[C@@](O)(Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)Cc1ccc(-c2ccccn2)cc1)C(C)(C)C";"AWOPQBWUWCOWJO-UKVDXBKXSA-N";693.85;4.49;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048544/target=_blank>CHEMBL1048544</a>";;-5.46;"Mahalingam AK, Axelsson L, Ekegren JK, Wannberg J, KihlstrĂ¶m J, Unge T, Wallberg H, Samuelsson B, Larhed M, Hallberg A.: HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.000003467368504525317
"MM476367";"MM476367";"COC(=O)N[C@H](C(=O)NN(CC[C@@](O)(Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)Cc1ccc(-c2cccnc2)cc1)C(C)(C)C";"DEWMMLXUMBSCSB-UKVDXBKXSA-N";693.85;4.49;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048544/target=_blank>CHEMBL1048544</a>";;-4.59;"Mahalingam AK, Axelsson L, Ekegren JK, Wannberg J, KihlstrĂ¶m J, Unge T, Wallberg H, Samuelsson B, Larhed M, Hallberg A.: HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells. J Med Chem, Volume 53 (2), 2010";"CACO-2";0.000025703957827688645
"MM476368";"MM476368";"CC1CN(C(=O)C(=O)c2c[nH]c3cccc(F)c23)CCN1C(=O)c1ccccc1";"PNJPCIYMKXINDN-UHFFFAOYSA-N";393.42;2.86;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-5.44;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.0000036307805477010103
"MM476371";"MM476371";"CN1C[C@@H](OC(=O)N2CCCCC2)C[C@H](C(=O)NO)[C@H]1C(=O)N1CCN(c2ccccc2)CC1";"PDNKMRBXZXHUFT-ACRUOGEOSA-N";473.57;1.15;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1043551/target=_blank>CHEMBL1043551</a>";;-6.05;"Li YL, Shi E, Burns D, Li Y, Covington MB, Pan M, Scherle P, Friedman S, Metcalf B, Yao W.: Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.0000008912509381337459
"MM476372";"MM476372";"CC(C)CC1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccc(F)c12";"KMKYQGQHWZOOBS-UHFFFAOYSA-N";435.5;3.89;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045523/target=_blank>CHEMBL1045523</a>";;-4.77;"Wang T, Kadow JF, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadjura L, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA.: Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett, Volume 19 (17), 2009";"CACO-2";0.00001698243652461746
"MM476375";"MM476375";"Nc1nonc1/C(=N/O)Nc1ccc(F)c(Cl)c1";"HGXSLPIXNPASGZ-UHFFFAOYSA-N";271.64;1.69;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1042999/target=_blank>CHEMBL1042999</a>";;-4.44;"Yue EW, Douty B, Wayland B, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Liu C, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Metcalf B, Scherle PA, Combs AP.: Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem, Volume 52 (23), 2009";"CACO-2";0.0000363078054770101
"MM476377";"MM476377";"Nc1nonc1/C(=N/O)NCc1ccccc1";"RDNDSCCANZUONG-UHFFFAOYSA-N";233.23;0.58;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1042999/target=_blank>CHEMBL1042999</a>";;-4.41;"Yue EW, Douty B, Wayland B, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Liu C, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Metcalf B, Scherle PA, Combs AP.: Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem, Volume 52 (23), 2009";"CACO-2";0.000038904514499428046
"MM476382";"MM476382";"O=C(O)c1ccc(Cn2nnc(-c3ccnc(C(=O)NCc4cccc(F)c4)c3)n2)cc1";"VMAHZFWSXKJIIT-UHFFFAOYSA-N";432.42;2.55;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069311/target=_blank>CHEMBL1069311</a>";;-4.99;"Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.: Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett, Volume 20 (2), 2010";"CACO-2";0.000010232929922807536
"MM476386";"MM476386";"Cc1cc(-c2nnn(Cc3ccc(C(=O)O)cc3)n2)cc(C(=O)NCc2ccccc2)n1";"NGSHRTUKGSZFAB-UHFFFAOYSA-N";428.45;2.72;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069311/target=_blank>CHEMBL1069311</a>";;-5.24;"Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.: Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett, Volume 20 (2), 2010";"CACO-2";0.000005754399373371567
"MM476387";"MM476387";"COC(=O)N(C)c1cc2c(NCc3ccc(OC)c(Cl)c3)ncnc2c(CCO)c1OC";"HHYZCHIATOFILW-UHFFFAOYSA-N";460.92;3.65;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1068549/target=_blank>CHEMBL1068549</a>";;-4.46;"Choi H, Lee J, Kim YH, Im DS, Hwang IC, Kim SJ, Moon SK, Lee HW, Lee SS, Ahn SK, Kim SW, Choi NS, Lee KJ.: Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533). Bioorg Med Chem Lett, Volume 20 (1), 2010";"CACO-2";0.00003467368504525317
"MM476388";"MM476388";"CN(C)CC(O)COc1ccc(CCOC2CC2)cc1";"QXKZYKFVUJEGTM-UHFFFAOYSA-N";279.38;1.71;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-4.81;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000015488166189124828
"trans-4-((5-(2-(4-fluorobenzylcarbamoyl)-6-methylpyridin-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylic acid";"MM18015";"Cc1cc(-c2nnn(C[C@H]3CC[C@H](C(=O)O)CC3)n2)cc(C(=O)NCc2ccc(F)cc2)n1";"KOTGODCEORJYIF-UHFFFAOYSA-N";452.49;3;"25183768";"CHEMBL603656";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069311/target=_blank>CHEMBL1069311</a>";;-5;"Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.: Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett, Volume 20 (2), 2010";"CACO-2";0.00001
"MM476393";"MM476393";"Cc1cc(-c2nnn(Cc3ccc(C(=O)O)cc3)n2)cc(C(=O)NCc2ccc(F)c(F)c2)n1";"DDIZQGYTODZYGV-UHFFFAOYSA-N";464.43;3;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069311/target=_blank>CHEMBL1069311</a>";;-5.57;"Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.: Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett, Volume 20 (2), 2010";"CACO-2";0.0000026915348039269138
"MM476394";"MM476394";"COc1ccc(CNC(=O)c2cc(-c3nnn(Cc4ccc(C(=O)O)cc4)n3)cc(C)n2)cc1";"MVLDDHUTICQDIF-UHFFFAOYSA-N";458.48;2.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069311/target=_blank>CHEMBL1069311</a>";;-5.55;"Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.: Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett, Volume 20 (2), 2010";"CACO-2";0.000002818382931264455
"Indomethacin";"MM00656";"COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1";"CGIGDMFJXJATDK-UHFFFAOYSA-N";357.79;3.93;"3715";"CHEMBL6";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619358/target=_blank>CHEMBL619358</a>";;-4.69;"Mandagere AK, Thompson TN, Hwang KK.: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem, Volume 45 (2), 2002";"CACO-2";0.000020417379446695274
"MM476399";"MM476399";"CCC(=O)N(C)c1cc2c(NCc3ccc(OC)c(Cl)c3)ncnc2c(CCO)c1OC";"JVYRZEUKHPHYCW-UHFFFAOYSA-N";458.95;3.82;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1068549/target=_blank>CHEMBL1068549</a>";;-4.77;"Choi H, Lee J, Kim YH, Im DS, Hwang IC, Kim SJ, Moon SK, Lee HW, Lee SS, Ahn SK, Kim SW, Choi NS, Lee KJ.: Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533). Bioorg Med Chem Lett, Volume 20 (1), 2010";"CACO-2";0.00001698243652461746
"MM476400";"MM476400";"COc1cccc(CNC(=O)c2cc(-c3nnn(Cc4ccc(C(=O)O)cc4)n3)cc(C)n2)c1";"NAQYQAFYLLAUJD-UHFFFAOYSA-N";458.48;2.73;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069311/target=_blank>CHEMBL1069311</a>";;-5.01;"Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.: Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett, Volume 20 (2), 2010";"CACO-2";0.000009772372209558111
"MM476403";"MM476403";"O=C(/N=C(/NCc1ccccc1)NC(=O)OCc1ccccc1)OCc1ccccc1";"BZLGCNUKBJMRCG-UHFFFAOYSA-N";417.47;4.4;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656467/target=_blank>CHEMBL656467</a>";;-6.29;"10.1016/S0960-894X(01)80549-7";"CACO-2";0.0000005128613839913648
"MM476404";"MM476404";"O=C(Cc1ccccc1)OCOC(=O)/N=C(/NCc1ccccc1)NC(=O)OCOC(=O)Cc1ccccc1";"DDPYJJVDRKGJHG-UHFFFAOYSA-N";533.54;3.48;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656467/target=_blank>CHEMBL656467</a>";;-5.07;"10.1016/S0960-894X(01)80549-7";"CACO-2";0.00000851138038202376
"MM476405";"MM476405";"O=C(/N=C(/NCc1ccccc1)NC(=O)Oc1ccccc1)Oc1ccccc1";"DRGOQQJFEZMLSM-UHFFFAOYSA-N";389.41;4.12;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656467/target=_blank>CHEMBL656467</a>";;-5.19;"10.1016/S0960-894X(01)80549-7";"CACO-2";0.000006456542290346549
"Alfentanil";"MM00439";"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1";"IDBPHNDTYPBSNI-UHFFFAOYSA-N";416.53;1.38;"51263";"CHEMBL634";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-4.08;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00008317637711026709
"Alfentanil";"MM00439";"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1";"IDBPHNDTYPBSNI-UHFFFAOYSA-N";416.53;1.38;"51263";"CHEMBL634";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-3.51;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0003090295432513592
"Acebutolol";"MM00437";"CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1";"GOEMGAFJFRBGGG-OAHLLOKOSA-N";336.43;2.37;"1978";"CHEMBL642";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-5.83;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000001479108388168207
"MM476406";"MM476406";"CC1CCN(C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)c2ccc3ccccc3c2)CC1";"PXJYHBGLVOUKAU-FQEVSTJZSA-N";445.59;1.8;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656468/target=_blank>CHEMBL656468</a>";;-6.4;"10.1016/S0960-894X(00)80064-5";"CACO-2";0.0000003981071705534969
"Foscarnet Sodium";"MM17213";"C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]";"ZJAOAACCNHFJAH-UHFFFAOYSA-N";126;-0.16;"44561";;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-7.35;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.000000044668359215096346
"Foscarnet Sodium";"MM17213";"C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]";"ZJAOAACCNHFJAH-UHFFFAOYSA-N";126;-0.16;"44561";;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-7.3;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.00000005011872336272725
"MM476407";"MM476407";"CC1CCN(C(=O)[C@H](CCCNc2cccnn2)NS(=O)(=O)c2ccc3ccccc3c2)CC1";"RBZAVTOBLCUJMN-QHCPKHFHSA-N";481.62;3.43;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656468/target=_blank>CHEMBL656468</a>";;-4.91;"10.1016/S0960-894X(00)80064-5";"CACO-2";0.00001230268770812381
"MM476408";"MM476408";"CC1CCN(C(=O)[C@H](CCCNc2ncccn2)NS(=O)(=O)c2ccc3ccccc3c2)CC1";"ZYJKUCRTVPIMSK-QHCPKHFHSA-N";481.62;3.43;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656468/target=_blank>CHEMBL656468</a>";;-4.86;"10.1016/S0960-894X(00)80064-5";"CACO-2";0.000013803842646028839
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905629/target=_blank>CHEMBL905629</a>";;-6.26;"Chan E, Amon M, Marano RJ, Wimmer N, Kearns PS, Manolios N, Rakoczy PE, Toth I.: Novel cationic lipophilic peptides for oligodeoxynucleotide delivery. Bioorg Med Chem, Volume 15 (12), 2007";"CACO-2";0.0000005495408738576248
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898108/target=_blank>CHEMBL898108</a>";;-7.08;"Wessling ST, Ross BP, Koda Y, Blanchfield JT, Toth I.: Caco-2 cell permeability and stability of two d-glucopyranuronamide conjugates of thyrotropin-releasing hormone. Bioorg Med Chem, Volume 15 (14), 2007";"CACO-2";0.00000008317637711026709
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619358/target=_blank>CHEMBL619358</a>";;-5.7;"Mandagere AK, Thompson TN, Hwang KK.: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem, Volume 45 (2), 2002";"CACO-2";0.0000019952623149688787
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL657442/target=_blank>CHEMBL657442</a>";;-5.23;"Blanchfield JT, Dutton JL, Hogg RC, Gallagher OP, Craik DJ, Jones A, Adams DJ, Lewis RJ, Alewood PF, Toth I.: Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of alpha-conotoxin MII. J Med Chem, Volume 46 (7), 2003";"CACO-2";0.000005888436553555884
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL854467/target=_blank>CHEMBL854467</a>";;-5.66;"Tian X, Field TB, Switzer AG, Mazur AW, Ebetino FH, Wos JA, Berberich SM, Jayasinghe LR, Obringer CM, Dowty ME, Pinney BB, Farmer JA, Crossdoersen D, Sheldon RJ.: Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach. J Med Chem, Volume 49 (15), 2006";"CACO-2";0.0000021877616239495517
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL854468/target=_blank>CHEMBL854468</a>";;-5.74;"Tian X, Field TB, Switzer AG, Mazur AW, Ebetino FH, Wos JA, Berberich SM, Jayasinghe LR, Obringer CM, Dowty ME, Pinney BB, Farmer JA, Crossdoersen D, Sheldon RJ.: Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach. J Med Chem, Volume 49 (15), 2006";"CACO-2";0.0000018197008586099826
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901110/target=_blank>CHEMBL901110</a>";;-5.66;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000021877616239495517
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902034/target=_blank>CHEMBL902034</a>";;-6.05;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"CACO-2";0.0000008912509381337459
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932308/target=_blank>CHEMBL932308</a>";;-5.69;"Hess S, Linde Y, Ovadia O, Safrai E, Shalev DE, Swed A, Halbfinger E, Lapidot T, Winkler I, Gabinet Y, Faier A, Yarden D, Xiang Z, Portillo FP, Haskell-Luevano C, Gilon C, Hoffman A.: Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem, Volume 51 (4), 2008";"CACO-2";0.0000020417379446695273
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619358/target=_blank>CHEMBL619358</a>";;-4.16;"Mandagere AK, Thompson TN, Hwang KK.: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem, Volume 45 (2), 2002";"CACO-2";0.00006918309709189363
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL840608/target=_blank>CHEMBL840608</a>";;-5.14;"Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.: In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem, Volume 48 (3), 2005";"CACO-2";0.000007244359600749906
"Practolol";"MM00544";"CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1";"DURULFYMVIFBIR-UHFFFAOYSA-N";266.34;1.38;"4883";"CHEMBL6995";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-5.74;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000018197008586099826
"Practolol";"MM00544";"CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1";"DURULFYMVIFBIR-UHFFFAOYSA-N";266.34;1.38;"4883";"CHEMBL6995";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-5.46;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.000003467368504525317
"Practolol";"MM00544";"CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1";"DURULFYMVIFBIR-UHFFFAOYSA-N";266.34;1.38;"4883";"CHEMBL6995";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL634342/target=_blank>CHEMBL634342</a>";;-5.46;"Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.: Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem, Volume 41 (27), 1998";"CACO-2";0.000003467368504525317
"MM476409";"MM476409";"COc1ccc2ccc(S(=O)(=O)N[C@@H](CCCNc3cccnn3)C(=O)N3CCC(C)CC3)cc2c1";"AAQOQDDVXLLHAW-DEOSSOPVSA-N";511.65;3.44;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL656468/target=_blank>CHEMBL656468</a>";;-4.92;"10.1016/S0960-894X(00)80064-5";"CACO-2";0.000012022644346174132
"MM476410";"MM476410";"CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H]2SC(C)(C)[C@@H]3C(=O)O)c2ccccc2)C(=O)C1=O";"IVBHGBMCVLDMKU-GXNBUGAJSA-N";517.56;-0.24;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL898879/target=_blank>CHEMBL898879</a>";;-7.49;"Falconer RA, Toth I.: Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. Bioorg Med Chem, Volume 15 (22), 2007";"CACO-2";0.00000003235936569296281
"Chlorpromazine";"MM00461";"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21";"ZPEIMTDSQAKGNT-UHFFFAOYSA-N";318.87;4.89;"2726";"CHEMBL71";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-4.7;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.000019952623149688786
"Chlorpromazine";"MM00461";"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21";"ZPEIMTDSQAKGNT-UHFFFAOYSA-N";318.87;4.89;"2726";"CHEMBL71";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638187/target=_blank>CHEMBL638187</a>";;-4.7;"Wohnsland F, Faller B.: High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem, Volume 44 (6), 2001";"CACO-2";0.000019952623149688786
"Desipramine";"MM00474";"CNCCCN1c2ccccc2CCc2ccccc21";"HCYAFALTSJYZDH-UHFFFAOYSA-N";266.39;3.53;"2995";"CHEMBL72";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638187/target=_blank>CHEMBL638187</a>";;-4.6;"Wohnsland F, Faller B.: High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem, Volume 44 (6), 2001";"CACO-2";0.000025118864315095822
"MM476411";"MM476411";"NC(=O)N(O)CCC#Cc1ccc(CN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)o1";"GLXQEUGDWMYWCC-AREMUKBSSA-N";493.01;4.35;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619360/target=_blank>CHEMBL619360</a>";;-5;"Lewis TA, Bayless L, Eckman JB, Ellis JL, Grewal G, Libertine L, Marie Nicolas J, Scannell RT, Wels BF, Wenberg K, Wypij DM.: 5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"CACO-2";0.00001
"MM476412";"MM476412";"CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12";"IKBKZGMPCYNSLU-RGVLZGJSSA-N";301.39;2.81;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1052562/target=_blank>CHEMBL1052562</a>";;-4.96;"McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, Shaw JP, Smith JA, Turner SD, Vickery RG.: A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem, Volume 52 (17), 2009";"CACO-2";0.000010964781961431852
"MM476413";"MM476413";"CN(C(=O)[C@H](Cc1ccc(C(=N)N)cc1)NS(=O)(=O)c1ccc2ccccc2c1)C1CCCC1";"TVTAJKGLDXBFHL-DEOSSOPVSA-N";478.62;3.41;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619357/target=_blank>CHEMBL619357</a>";;-6.7;"Lee K, Jung WH, Park CW, Hong CY, Kim IC, Kim S, Oh YS, Kwon OH, Lee SH, Park HD, Kim SW, Lee YH, Yoo YJ.: Benzylamine-based selective and orally bioavailable inhibitors of thrombin. Bioorg Med Chem Lett, Volume 8 (18), 1998";"CACO-2";0.00000019952623149688787
"MM476417";"MM476417";"CN(C(=O)[C@H](Cc1ccc(C(=N)NN)cc1)NS(=O)(=O)c1ccc2ccccc2c1)C1CCCC1";"ZPDICRPCOSQEDS-DEOSSOPVSA-N";493.63;2.92;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL619357/target=_blank>CHEMBL619357</a>";;-5.77;"Lee K, Jung WH, Park CW, Hong CY, Kim IC, Kim S, Oh YS, Kwon OH, Lee SH, Park HD, Kim SW, Lee YH, Yoo YJ.: Benzylamine-based selective and orally bioavailable inhibitors of thrombin. Bioorg Med Chem Lett, Volume 8 (18), 1998";"CACO-2";0.000001698243652461746
"Ciprofloxacin";"MM00726";"O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O";"MYSWGUAQZAJSOK-UHFFFAOYSA-N";331.35;1.58;"2764";"CHEMBL8";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-5.77;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.000001698243652461746
"Ciprofloxacin";"MM00726";"O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O";"MYSWGUAQZAJSOK-UHFFFAOYSA-N";331.35;1.58;"2764";"CHEMBL8";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-5.72;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000019054607179632483
"Chlorothiazide";"MM00641";"NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O";"JBMKAUGHUNFTOL-UHFFFAOYSA-N";295.73;0.13;"2720";"CHEMBL842";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-6.72;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.00000019054607179632483
"Metolazone";"MM00390";"Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C";"AQCHWTWZEMGIFD-UHFFFAOYSA-N";365.84;2.71;"4170";"CHEMBL878";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-5.21;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.000006165950018614822
"Metolazone";"MM00390";"Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C";"AQCHWTWZEMGIFD-UHFFFAOYSA-N";365.84;2.71;"4170";"CHEMBL878";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-5.21;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.000006165950018614822
"MM476421";"MM476421";"NC(=O)c1cc(OCCc2ccc(Cl)cc2Cl)cc(C(=O)NCC2CCN(c3ccncc3)CC2)c1";"ZKSQIMPBUMVRHT-UHFFFAOYSA-N";527.45;4.76;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL657446/target=_blank>CHEMBL657446</a>";;-5.91;"NazarĂ© M, Matter H, Klingler O, Al-Obeidi F, Schreuder H, Zoller G, Czech J, Lorenz M, Dudda A, Peyman A, Nestler HP, Urmann M, Bauer A, Laux V, Wehner V, Will DW.: Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand. Bioorg Med Chem Lett, Volume 14 (11), 2004";"CACO-2";0.0000012302687708123811
"MM476422";"MM476422";"COc1ccc2ccc(S(=O)(=O)NC(Cc3cc4c(N)nccc4s3)C(=O)N3CCN(S(C)(=O)=O)CC3)cc2c1";"JSHTULLJXFHMCL-UHFFFAOYSA-N";603.75;2.03;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-6;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.000001
"Amiloride";"MM00267";"N=C(N)NC(=O)c1nc(Cl)c(N)nc1N";"XSDQTOBWRPYKKA-UHFFFAOYSA-N";229.63;-1.08;"16231";"CHEMBL945";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-6.15;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.0000007079457843841374
"Amiloride";"MM00267";"N=C(N)NC(=O)c1nc(Cl)c(N)nc1N";"XSDQTOBWRPYKKA-UHFFFAOYSA-N";229.63;-1.08;"16231";"CHEMBL945";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL635760/target=_blank>CHEMBL635760</a>";;-6.25;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.000000562341325190349
"Amiloride";"MM00267";"N=C(N)NC(=O)c1nc(Cl)c(N)nc1N";"XSDQTOBWRPYKKA-UHFFFAOYSA-N";229.63;-1.08;"16231";"CHEMBL945";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL638024/target=_blank>CHEMBL638024</a>";;-6.11;"Stenberg P, Norinder U, Luthman K, Artursson P.: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem, Volume 44 (12), 2001";"CACO-2";0.0000007762471166286911
"MM476423";"MM476423";"COc1ccc2ccc(S(=O)(=O)NC(Cc3cc4c(N)nccc4s3)C(=O)N3CCC(C)CC3)cc2c1";"YHZXQULQLNKEPU-UHFFFAOYSA-N";538.7;4.19;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-4.92;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.000012022644346174132
"Bosentan";"MM01433";"CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC";"GJPICJJJRGTNOD-UHFFFAOYSA-N";551.63;4.2;"104865";"957";"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074672/target=_blank>CHEMBL1074672</a>";;-5.98;"Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.: Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem, Volume 17 (19), 2009";"CACO-2";0.0000010471285480508985
"MM476424";"MM476424";"COc1ccc(C(=O)NCC2CCN(c3ccncc3)CC2)cc1OCCc1ccc(Cl)cc1Cl";"UVSAHJWEJXWVGO-UHFFFAOYSA-N";514.45;5.66;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL657446/target=_blank>CHEMBL657446</a>";;-5.32;"NazarĂ© M, Matter H, Klingler O, Al-Obeidi F, Schreuder H, Zoller G, Czech J, Lorenz M, Dudda A, Peyman A, Nestler HP, Urmann M, Bauer A, Laux V, Wehner V, Will DW.: Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand. Bioorg Med Chem Lett, Volume 14 (11), 2004";"CACO-2";0.00000478630092322638
"MM476425";"MM476425";"CC1CCN(C(=O)C(Cc2cccc(C(=N)N)c2)NS(=O)(=O)c2ccc3ccccc3c2)CC1";"NXVHWZWNOYBQDB-UHFFFAOYSA-N";478.62;3.27;;;"CACO";"ECACO";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL877667/target=_blank>CHEMBL877667</a>";;-4.85;"Rewinkel JB, Lucas H, Smit MJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.: Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors. Bioorg Med Chem Lett, Volume 9 (19), 1999";"CACO-2";0.000014125375446227555
"MM476458";"MM476458";"CS(=O)(=O)CCCn1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2ccccc21";"JCKCWXHGOVMLGZ-UHFFFAOYSA-N";425.51;2.37;;;"CACO";"ECACO";"25";"0";"meanlogPermvalue,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-5.49;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000003235936569296281
"MM474142";"MM474142";"O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CC1";"KSHJXDWYTZJUEI-UHFFFAOYSA-N";377.45;2.7;;;"CACO";"ECACO";"25";"0";"meanlogPermvalue,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.9;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000012589254117941661
"MM476459";"MM476459";"N#CCCCn1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2ccccc21";"NZRPQYGGRRBSKG-UHFFFAOYSA-N";372.43;3.23;;;"CACO";"ECACO";"25";"0";"meanlogPermvalue,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891578/target=_blank>CHEMBL891578</a>";;-4.76;"Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.: Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett, Volume 17 (4), 2007";"CACO-2";0.000017378008287493764
"Boc-Trp";"MM01089";"CC(C)(C)OC(=O)NC(Cc1cc2ccccc2[nH]1)C(=O)O";"WXYGVKADAIJGHB-UHFFFAOYSA-N";304.35;2.69;"44424848";;"PL-A";"EPAM";"25";;;;-5.74;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000018197008586099826
"Cbz-Trp";"MM01090";"O=C(NC(Cc1cc2ccccc2[nH]1)C(=O)O)OCc1ccccc1";"DZJWNXSZBKGYKP-UHFFFAOYSA-N";338.36;3.09;"44424857";;"PL-A";"EPAM";"25";;;;-5.55;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000002818382931264455
"Fmoc-Trp";"MM01091";"O=C(NC(Cc1cc2ccccc2[nH]1)C(=O)O)OCC1c2ccccc2-c2ccccc21";"KUROROGTRLAIQQ-UHFFFAOYSA-N";426.47;4.7;"44424858";;"PL-A";"EPAM";"25";;;;-4.9;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000012589254117941661
"L-Tryptophanamide";"MM01079";"NC(=O)C(N)Cc1c[nH]c2ccccc12";"JLSKPBDKNIXMBS-UHFFFAOYSA-N";203.25;0.52;"439356";;"PL-A";"EPAM";"25";;;;-5.56;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000002754228703338169
"(2S)-2-acetamido-3-(1H-indol-3-yl)propanamide";"MM01076";"CC(=O)NC(Cc1c[nH]c2ccccc12)C(N)=O";"HNGIZKAMDMBRKJ-UHFFFAOYSA-N";245.28;0.7;"94230";;"PL-A";"EPAM";"25";;;;-5.72;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000019054607179632483
"Gly-Trp-NH2";"MM01081";"NCC(=O)NC(Cc1c[nH]c2ccccc12)C(N)=O";"YZMFLZVJQTUTKK-UHFFFAOYSA-N";260.3;-0.36;"3081965";;"PL-A";"EPAM";"25";;;;-6.38;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000004168693834703355
"Phe-Trp-NH2";"MM01083";"NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(N)Cc1ccccc1";"GVIJYQOEFGLWKI-UHFFFAOYSA-N";350.42;1.25;"7020143";;"PL-A";"EPAM";"25";;;;-5.22;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000006025595860743581
"Trp-Ala-Val-NH2";"MM01092";"CC(NC(=O)C(N)Cc1c[nH]c2ccccc12)C(=O)NC(C(N)=O)C(C)C";"FSIVAWBKYORDEB-UHFFFAOYSA-N";373.46;0.17;"44424859";;"PL-A";"EPAM";"25";;;;-6.62;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000000239883291901949
"Ac-Trp-Val-NH2";"MM01093";"CC(C)[C@@H](C(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C";"ZFFQYIRICYOHAN-UHFFFAOYSA-N";344.42;0.84;"44424860";;"PL-A";"EPAM";"25";;;;-6.18;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000006606934480075964
"Ac-D-Trp-Val-NH2";"MM01094";"CC(C)[C@@H](C(=O)N)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)C";"ZFFQYIRICYOHAN-UHFFFAOYSA-N";344.42;0.84;"44424861";;"PL-A";"EPAM";"25";;;;-6.14;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000007244359600749906
"Ac-Tyr-Leu-NH2";"MM01088";"CC(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(N)=O";"WGDDMZFVKNOORS-UHFFFAOYSA-N";335.4;0.46;"14562813";;"PL-A";"EPAM";"25";;;;-6.54;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00000028840315031266057
"Ac-Tyr-Phe-NH2";"MM01086";"CC(=O)NC(Cc1ccc(O)cc1)C(=O)NC(Cc1ccccc1)C(N)=O";"QJOFRQKWYZAXIZ-UHFFFAOYSA-N";369.42;0.65;"11068626";;"PL-A";"EPAM";"25";;;;-6.92;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00000012022644346174132
"Cyclo(-Gly-Trp)";"MM01082";"O=C1CNC(=O)C(Cc2c[nH]c3ccccc23)N1";"IFQZEERDQXQTLJ-UHFFFAOYSA-N";243.27;0.33;"6997508";;"PL-A";"EPAM";"25";;;;-6.01;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000000977237220955811
"Cyclo(-Trp-Tyr)";"MM01087";"O=C1N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H]1Cc1ccc(O)cc1";"ZJDMXAAEAVGGSK-ROUUACIJSA-N";349.39;1.64;;;"PL-A";"EPAM";"25";;;;-6.17;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000006760829753919819
"Cyclo(-Trp-Trp)";"MM01084";"O=C1NC(Cc2c[nH]c3ccccc23)C(=O)NC1Cc1c[nH]c2ccccc12";"DNHODRZUCGXYKU-UHFFFAOYSA-N";372.43;2.42;"7091706";;"PL-A";"EPAM";"25";;;;-5.04;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000009120108393559096
"1H-indole";"MM01048";"c1ccc2[nH]ccc2c1";"SIKJAQJRHWYJAI-UHFFFAOYSA-N";117.15;2.17;"798";;"PL-A";"EPAM";"25";;;;-4.5;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000031622776601683795
"2-(1H-indol-3-yl)ethanol";"MM01064";"OCCc1c[nH]c2ccccc12";"MBBOMCVGYCRMEA-UHFFFAOYSA-N";161.2;1.7;"10685";;"PL-A";"EPAM";"25";;;;-4.72;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000019054607179632484
"Tryptamine";"MM00582";"NCCc1c[nH]c2ccccc12";"APJYDQYYACXCRM-UHFFFAOYSA-N";160.22;1.67;"1150";"CHEMBL6640";"PL-A";"EPAM";"25";;;;-5.27;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000005370317963702533
"Indole-3-carboxylic Acid";"MM01072";"O=C(O)c1c[nH]c2ccccc12";"KMAKOBLIOCQGJP-UHFFFAOYSA-N";161.16;1.87;"69867";;"PL-A";"EPAM";"25";;;;-6.1;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000007943282347242822
"Indole-3-acetic Acid";"MM01049";"O=C(O)Cc1c[nH]c2ccccc12";"SEOVTRFCIGRIMH-UHFFFAOYSA-N";175.19;1.8;"802";;"PL-A";"EPAM";"25";;;;-6.4;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000003981071705534969
"3-Indolepropionic Acid";"MM01051";"O=C(O)CCc1c[nH]c2ccccc12";"GOLXRNDWAUTYKT-UHFFFAOYSA-N";189.21;2.19;"3744";;"PL-A";"EPAM";"25";;;;-5.68;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000020892961308540407
"Acebutolol";"MM00437";"CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1";"GOEMGAFJFRBGGG-OAHLLOKOSA-N";336.43;2.37;"1978";"CHEMBL642";"PL-A";"EPAM";"25";;;;-6.44;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000000363078054770101
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"PL-A";"EPAM";"25";;;;-6.04;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000009120108393559096
"Alprenolol";"MM00440";"C=CCc1ccccc1OC[C@H](O)CNC(C)C";"PAZJSJFMUHDSTF-CQSZACIVSA-N";249.35;2.15;"2119";"CHEMBL266195";"PL-A";"EPAM";"25";;;;-4.94;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000011481536214968817
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"PL-A";"EPAM";"25";;;;-5.54;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000002884031503126606
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"PL-A";"EPAM";"25";;;;-5.41;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000003890451449942805
"Chloramphenicol";"MM00342";"O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl";"WIIZWVCIJKGZOK-UHFFFAOYSA-N";323.13;0.91;"5959";"CHEMBL130";"PL-A";"EPAM";"25";;;;-5.41;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000003890451449942805
"Clonidine";"MM00344";"Clc1cccc(Cl)c1N=C1NCCN1";"GJSURZIOUXUGAL-UHFFFAOYSA-N";230.1;2.17;"2803";"CHEMBL134";"PL-A";"EPAM";"25";;;;-4.98;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000010471285480508985
"Corticosterone";"MM00346";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12";"OMFXVFTZEKFJBZ-UHFFFAOYSA-N";346.47;2.67;"5753";"CHEMBL110739";"PL-A";"EPAM";"25";;;;-4.77;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00001698243652461746
"Coumarin";"MM00042";"O=c1ccc2ccccc2o1";"ZYGHJZDHTFUPRJ-UHFFFAOYSA-N";146.15;1.79;"323";"CHEMBL6466";"PL-A";"EPAM";"25";;;;-4.55;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00002818382931264455
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"PL-A";"EPAM";"25";;;;-5.37;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000004265795188015926
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"PL-A";"EPAM";"25";;;;-6.47;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00000033884415613920274
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"PL-A";"EPAM";"25";;;;-6.7;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00000019952623149688787
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"PL-A";"EPAM";"25";;;;-5.45;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000003548133892335753
"Ibuprofen";"MM00045";"CC(C)Cc1ccc(C(C)C(=O)O)cc1";"HEFNNWSXXWATRW-UHFFFAOYSA-N";206.29;3.07;"3672";"CHEMBL521";"PL-A";"EPAM";"25";;;;-4.67;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000021379620895022323
"Imipramine";"MM00504";"CN(C)CCCN1c2ccccc2CCc2ccccc21";"BCGWQEUPMDMJNV-UHFFFAOYSA-N";280.42;3.88;"3696";"CHEMBL11";"PL-A";"EPAM";"25";;;;-4.71;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000019498445997580456
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"PL-A";"EPAM";"25";;;;-5.55;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000002818382931264455
"Labetalol";"MM00507";"CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1";"SGUAFYQXFOLMHL-UHFFFAOYSA-N";328.41;2.14;"3869";"CHEMBL429";"PL-A";"EPAM";"25";;;;-5.18;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000006606934480075964
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"PL-A";"EPAM";"25";;;;-5.1;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000007943282347242822
"Nadolol";"MM00525";"CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2";"VWPOSFSPZNDTMJ-UHFFFAOYSA-N";309.41;0.63;"39147";"CHEMBL649";"PL-A";"EPAM";"25";;;;-6.15;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000007079457843841374
"Naproxen";"MM00672";"COc1ccc2cc(C(C)C(=O)O)ccc2c1";"CMWTZPSULFXXJA-UHFFFAOYSA-N";230.26;3.04;"156391";"CHEMBL154";"PL-A";"EPAM";"25";;;;-5.3;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000005011872336272725
"Norfloxacin";"MM00768";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21";"OGJPXUAPXNRGGI-UHFFFAOYSA-N";319.34;1.27;"4539";"CHEMBL9";"PL-A";"EPAM";"25";;;;-6.72;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00000019054607179632483
"Oxprenolol";"MM00289";"C=CCOc1ccccc1OCC(O)CNC(C)C";"CEMAWMOMDPGJMB-UHFFFAOYSA-N";265.35;1.99;"4631";"CHEMBL546";"PL-A";"EPAM";"25";;;;-4.83;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000014791083881682072
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"PL-A";"EPAM";"25";;;;-5.31;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000004897788193684467
"Practolol";"MM00544";"CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1";"DURULFYMVIFBIR-UHFFFAOYSA-N";266.34;1.38;"4883";"CHEMBL6995";"PL-A";"EPAM";"25";;;;-5.97;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000001071519305237607
"Prednisolone";"MM00297";"CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"OIGNJSKKLXVSLS-UHFFFAOYSA-N";360.45;1.56;"5755";"CHEMBL131";"PL-A";"EPAM";"25";;;;-5.47;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000033884415613920275
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"PL-A";"EPAM";"25";;;;-4.58;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000026302679918953814
"Ranitidine";"MM01053";"CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1";"VMXUWOKSQNHOCA-UHFFFAOYSA-N";314.41;1.46;"5039";;"PL-A";"EPAM";"25";;;;-6.06;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000008709635899560814
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"PL-A";"EPAM";"25";;;;-5.92;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000012022644346174132
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"PL-A";"EPAM";"25";;;;-4.95;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00001122018454301963
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"PL-A";"EPAM";"25";;;;-5.32;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00000478630092322638
"Trimethoprim";"MM00581";"COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC";"IEDVJHCEMCRBQM-UHFFFAOYSA-N";290.32;1.26;"5578";"CHEMBL22";"PL-A";"EPAM";"25";;;;-5.5;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000003162277660168379
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"PL-A";"EPAM";"25";;;;-4.64;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00002290867652767775
"4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one";"MM00331";"Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C";"RMMXTBMQSGEXHJ-UHFFFAOYSA-N";231.3;1.55;"6009";"CHEMBL288470";"PL-A";"EPAM";"25";;;;-4.76;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000017378008287493764
"Desipramine";"MM00474";"CNCCCN1c2ccccc2CCc2ccccc21";"HCYAFALTSJYZDH-UHFFFAOYSA-N";266.39;3.53;"2995";"CHEMBL72";"PL-A";"EPAM";"25";;;;-4.77;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.00001698243652461746
"Phenytoin";"MM00406";"O=C1N=C(O)NC1(c1ccccc1)c1ccccc1";"CXOFVDLJLONNDW-UHFFFAOYSA-N";252.27;1.97;"1775";"CHEMBL16";"PL-A";"EPAM";"25";;;;-4.41;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000038904514499428046
"Piroxicam";"MM00682";"CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O";"QYSPLQLAKJAUJT-UHFFFAOYSA-N";331.35;1.58;"54676228";"CHEMBL527";"PL-A";"EPAM";"25";;;;-4.96;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.000010964781961431852
"11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one";"MM00543";"CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1";"RMHMFHUVIITRHF-UHFFFAOYSA-N";351.41;1.56;"4848";"CHEMBL9967";"PL-A";"EPAM";"25";;;;-6.05;"Fujikawa M., Ano R., Nakao K., Shimizu R., Akamatsu M., Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: Application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 13 (2005) 4721-4732";"PAMPA";0.0000008912509381337459
"Acebutolol";"MM00437";"CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1";"GOEMGAFJFRBGGG-OAHLLOKOSA-N";336.43;2.37;"1978";"CHEMBL642";"MDCK";"EMDCK";"25";;;;-5.77;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000001698243652461746
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"MDCK";"EMDCK";"25";;;;-4.46;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00003467368504525317
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"MDCK";"EMDCK";"25";;;;-5.13;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000007413102413009177
"Acrivastine";"MM00715";"Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1";"PWACSDKDOHSSQD-IUTFFREVSA-N";348.45;4.02;"5284514";"CHEMBL1224";"MDCK";"EMDCK";"25";;;;-5.66;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000021877616239495517
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"MDCK";"EMDCK";"25";;;;-6.68;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00000020892961308540409
"Alprenolol";"MM00440";"C=CCc1ccccc1OC[C@H](O)CNC(C)C";"PAZJSJFMUHDSTF-CQSZACIVSA-N";249.35;2.15;"2119";"CHEMBL266195";"MDCK";"EMDCK";"25";;;;-3.8;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00015848931924611142
"Amoxicillin";"MM00716";"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O";"LSQZJLSUYDQPKJ-NJBDSQKTSA-N";365.41;0.02;"33613";"CHEMBL1082";"MDCK";"EMDCK";"25";;;;-6.62;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000000239883291901949
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"MDCK";"EMDCK";"25";;;;-3.82;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00015135612484362088
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"MDCK";"EMDCK";"25";;;;-5.74;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000018197008586099826
"Zidovudine";"MM00077";"Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O";"HBOMLICNUCNMMY-UHFFFAOYSA-N";267.25;-0.2;"35370";"CHEMBL129";"MDCK";"EMDCK";"25";;;;-5.22;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000006025595860743581
"Bupropion";"MM00455";"C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1";"SNPPWIUOZRMYNY-VIFPVBQESA-N";239.75;3.3;"444";"CHEMBL894";"MDCK";"EMDCK";"25";;;;-3.89;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00012882495516931337
"Cefuroxime";"MM01507";"CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(N)=O)CSC12)c1ccco1";"JFPVXVDWJQMJEE-UHFFFAOYSA-N";424.39;-0.54;;;"MDCK";"EMDCK";"25";;;;-6.8;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000001584893192461114
"Cephalexin";"MM00721";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1";"ZAIPMKNFIOOWCQ-UHFFFAOYSA-N";347.4;0.44;"27447";"CHEMBL1727";"MDCK";"EMDCK";"25";;;;-6.32;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000000478630092322638
"Chlorothiazide";"MM00641";"NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O";"JBMKAUGHUNFTOL-UHFFFAOYSA-N";295.73;0.13;"2720";"CHEMBL842";"MDCK";"EMDCK";"25";;;;-6.52;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000003019951720402019
"Corticosterone";"MM00346";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12";"OMFXVFTZEKFJBZ-UHFFFAOYSA-N";346.47;2.67;"5753";"CHEMBL110739";"MDCK";"EMDCK";"25";;;;-3.85;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0001412537544622754
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"MDCK";"EMDCK";"25";;;;-4.7;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000019952623149688786
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"MDCK";"EMDCK";"25";;;;-6.21;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000006165950018614822
"Gabapentin";"MM00737";"NCC1(CC(=O)O)CCCCC1";"UGJMXCAKCUNAIE-UHFFFAOYSA-N";171.24;1.37;"3446";"CHEMBL940";"MDCK";"EMDCK";"25";;;;-6.44;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000000363078054770101
"Guanabenz";"MM00497";"N=C(N)NN=Cc1c(Cl)cccc1Cl";"WDZVGELJXXEGPV-UHFFFAOYSA-N";231.09;1.81;"5702063";"CHEMBL420";"MDCK";"EMDCK";"25";;;;-3.72;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00019054607179632462
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"MDCK";"EMDCK";"25";;;;-6;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000001
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"MDCK";"EMDCK";"25";;;;-4.51;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00003090295432513592
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"MDCK";"EMDCK";"25";;;;-4.7;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000019952623149688786
"Labetalol";"MM00507";"CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1";"SGUAFYQXFOLMHL-UHFFFAOYSA-N";328.41;2.14;"3869";"CHEMBL429";"MDCK";"EMDCK";"25";;;;-4.6;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000025118864315095822
"Lamotrigine";"MM00383";"Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1";"PYZRQGJRPPTADH-UHFFFAOYSA-N";256.1;2.01;"3878";"CHEMBL741";"MDCK";"EMDCK";"25";;;;-4.06;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00008709635899560814
"Lisinopril";"MM00763";"NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O";"RLAWWYSOJDYHDC-UHFFFAOYSA-N";405.5;1.24;"5362119";"CHEMBL1237";"MDCK";"EMDCK";"25";;;;-6.74;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00000018197008586099824
"Loracarbef";"MM01552";"NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CCC12)c1ccccc1";"JAPHQRWPEGVNBT-UHFFFAOYSA-N";349.77;0.71;"5284585";;"MDCK";"EMDCK";"25";;;;-6.04;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000009120108393559096
"Methylprednisolone";"MM00388";"CC1CC2C(C(O)CC3(C)C2CCC3(O)C(=O)CO)C2(C)C=CC(=O)C=C12";"VHRSUDSXCMQTMA-UHFFFAOYSA-N";374.48;1.8;"6741";"CHEMBL650";"MDCK";"EMDCK";"25";;;;-4.8;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00001584893192461114
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"MDCK";"EMDCK";"25";;;;-3.82;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00015135612484362088
"Nadolol";"MM00525";"CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2";"VWPOSFSPZNDTMJ-UHFFFAOYSA-N";309.41;0.63;"39147";"CHEMBL649";"MDCK";"EMDCK";"25";;;;-5.85;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000014125375446227554
"Netivudine";"MM00395";"CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O";"QLOCVMVCRJOTTM-SDNRWEOFSA-N";282.25;-2.48;"55281";"CHEMBL1097615";"MDCK";"EMDCK";"25";;;;-5.85;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000014125375446227554
"Olsalazine";"MM01437";"O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O";"QQBDLJCYGRGAKP-FOCLMDBBSA-N";302.24;2.91;"22419";"CHEMBL1201013";"MDCK";"EMDCK";"25";;;;-7.32;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000000478630092322638
"Ondansetron";"MM00531";"Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O";"FELGMEQIXOGIFQ-UHFFFAOYSA-N";293.37;3.13;"4595";"CHEMBL46";"MDCK";"EMDCK";"25";;;;-3.96;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00010964781961431851
"Phenytoin";"MM00406";"O=C1N=C(O)NC1(c1ccccc1)c1ccccc1";"CXOFVDLJLONNDW-UHFFFAOYSA-N";252.27;1.97;"1775";"CHEMBL16";"MDCK";"EMDCK";"25";;;;-3.92;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00012022644346174131
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"MDCK";"EMDCK";"25";;;;-4.23;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00005888436553555884
"Practolol";"MM00544";"CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1";"DURULFYMVIFBIR-UHFFFAOYSA-N";266.34;1.38;"4883";"CHEMBL6995";"MDCK";"EMDCK";"25";;;;-5.89;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000001288249551693135
"Progesterone";"MM00198";"CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C";"RJKFOVLPORLFTN-UHFFFAOYSA-N";314.47;4.72;"5994";"CHEMBL103";"MDCK";"EMDCK";"25";;;;-3.8;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00015848931924611142
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"MDCK";"EMDCK";"25";;;;-3.77;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00016982436524617443
"6-propyl-2-sulfanylidene-1H-pyrimidin-4-one";"MM00415";"CCCc1cc(=O)[nH]c(=S)[nH]1";"KNAHARQHSZJURB-UHFFFAOYSA-N";170.24;1.38;"657298";"CHEMBL1518";"MDCK";"EMDCK";"25";;;;-4.39;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000407380277804113
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"MDCK";"EMDCK";"25";;;;-5;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00001
"Sotalol";"MM00567";"CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1";"ZBMZVLHSJCTVON-UHFFFAOYSA-N";272.37;1.09;"5253";"CHEMBL471";"MDCK";"EMDCK";"25";;;;-5.32;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00000478630092322638
"Sulfasalazine";"MM00690";"O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O";"NCEXYHBECQHGNR-UHFFFAOYSA-N";398.4;3.7;"5359476";"CHEMBL421";"MDCK";"EMDCK";"25";;;;-6.32;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000000478630092322638
"1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide";"MM00569";"CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1";"KQKPFRSPSRPDEB-UHFFFAOYSA-N";295.41;1.32;"5358";"CHEMBL128";"MDCK";"EMDCK";"25";;;;-5.72;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0000019054607179632483
"5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol";"MM00306";"CC(C)(C)NCC(O)c1cc(O)cc(O)c1";"XWTYSIMOBUGWOL-UHFFFAOYSA-N";225.29;1.52;"5403";"CHEMBL1760";"MDCK";"EMDCK";"25";;;;-6;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000001
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"MDCK";"EMDCK";"25";;;;-3.85;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.0001412537544622754
"(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol";"MM00573";"CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1";"BLJRIMJGRPQVNF-UHFFFAOYSA-N";316.43;0.5;"33624";"CHEMBL499";"MDCK";"EMDCK";"25";;;;-4.26;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00005495408738576248
"Trimethoprim";"MM00581";"COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC";"IEDVJHCEMCRBQM-UHFFFAOYSA-N";290.32;1.26;"5578";"CHEMBL22";"MDCK";"EMDCK";"25";;;;-4.28;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.00005248074602497723
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"MDCK";"EMDCK";"25";;;;-4.36;"Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR.: MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci, Volume 88 (1), 28-33, 1999";"MDCK";0.000043651583224016566
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"MDCK";"EMDCK";"25";;;;-6.74;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020";"MDCK";0.00000018197008586099824
"Quinidine";"MM00558";"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-LHHVKLHASA-N";324.42;3.17;"441074";"CHEMBL1294";"MDCK";"EMDCK";"25";;;;-4.94;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020";"MDCK";0.000011481536214968817
"Methotrexate";"MM00270";"CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1";"FBOZXECLQNJBKD-UHFFFAOYSA-N";454.45;0.27;"126941";"CHEMBL34259";"MDCK";"EMDCK";"25";;;;-7.05;"Furubayashi T, Inoue D, Nishiyama N, Tanaka A, Yutani R, Kimura S, Katsumi H, Yamamoto A, Sakane T.: Comparison of Various Cell Lines and Three-Dimensional Mucociliary Tissue Model Systems to Estimate Drug Permeability Using an In Vitro Transport Study to Predict Nasal Drug Absorption in Rats. Pharmaceutics, Volume 12 (1), 2020";"MDCK";0.00000008912509381337459
"1,1,2-Trichloroethane";"MM00984";"ClCC(Cl)Cl";"UBOXGVDOUJQMTN-UHFFFAOYSA-N";133.41;2.03;"6574";;"DOPC";"CCM18";"25";"0";;;-0.59;"in-house calculations";"COSMOperm";0.2570395782768864
"1,1,2,2-Tetrachloroethane";"MM00985";"ClC(Cl)C(Cl)Cl";"QPFMBZIOSGYJDE-UHFFFAOYSA-N";167.85;2.59;"6591";;"DOPC";"CCM18";"25";"0";;;0.21;"in-house calculations";"COSMOperm";1.62181009735893
"1,2-Dichloroethane";"MM00986";"ClCCCl";"WSLDOOZREJYCGB-UHFFFAOYSA-N";98.96;1.46;"11";"CHEMBL16370";"DOPC";"CCM18";"25";"0";;;-0.9;"in-house calculations";"COSMOperm";0.12589254117941673
"1,2-Dichloropropane";"MM00987";"CC(Cl)CCl";"KNKRKFALVUDBJE-UHFFFAOYSA-N";112.99;1.85;"6564";;"DOPC";"CCM18";"25";"0";;;-0.87;"in-house calculations";"COSMOperm";0.13489628825916536
"Propylene Glycol";"MM00414";"CC(O)CO";"DNIAPMSPPWPWGF-UHFFFAOYSA-N";76.1;-0.64;"1030";"CHEMBL286398";"DOPC";"CCM18";"25";"0";;-5.23849;-4;"in-house calculations";"COSMOperm";0.0001
"1,2-Decanediol";"MM00002";"CCCCCCCCC(O)CO";"YSRSBDQINUMTIF-UHFFFAOYSA-N";174.28;2.09;"10888425";;"DOPC";"CCM18";"25";"0";;;0.74;"in-house calculations";"COSMOperm";5.495408738576246
"1,2-Hexanediol";"MM00003";"CCCCC(O)CO";"FHKSXSQHXQEMOK-UHFFFAOYSA-N";118.18;0.53;"94335";;"DOPC";"CCM18";"25";"0";;;-1.69;"in-house calculations";"COSMOperm";0.020417379446695295
"1,2-Octanediol";"MM00004";"CCCCCCC(O)CO";"AEIJTFQOBWATKX-UHFFFAOYSA-N";146.23;1.31;"14231";;"DOPC";"CCM18";"25";"0";;;-0.19;"in-house calculations";"COSMOperm";0.6456542290346555
"1,2,4-Benzenetriol";"MM00992";"Oc1ccc(O)c(O)c1";"GGNQRNBDZQJCCN-UHFFFAOYSA-N";126.11;0.8;"10787";;"DOPC";"CCM18";"25";"0";;;-4.51;"in-house calculations";"COSMOperm";0.00003090295432513592
"1,3-Dichloropropene";"MM00993";"Cl/C=C/CCl";"UOORRWUZONOOLO-OWOJBTEDSA-N";110.97;1.98;"24726";;"DOPC";"CCM18";"25";"0";;1.8303;-0.79;"in-house calculations";"COSMOperm";0.16218100973589297
"1,3-Propanediol";"MM00313";"OCCCO";"YPFDHNVEDLHUCE-UHFFFAOYSA-N";76.1;-0.64;"10442";"CHEMBL379652";"DOPC";"CCM18";"25";"0";;-5.37329;-4.41;"in-house calculations";"COSMOperm";0.000038904514499428046
"1,3-Decanediol";"MM00005";"CCCCCCCC(O)CCO";"ANWMPOLHSRXCNH-UHFFFAOYSA-N";174.28;2.09;"201483";;"DOPC";"CCM18";"25";"0";;;0.22;"in-house calculations";"COSMOperm";1.6595869074375607
"1,3-Dimethyluric Acid";"MM00996";"Cn1c(=O)c2[nH]c(=O)[nH]c2n(C)c1=O";"OTSBKHHWSQYEHK-UHFFFAOYSA-N";196.17;-1.75;"70346";;"DOPC";"CCM18";"25";"0";;-0.82549;-8.41;"in-house calculations";"COSMOperm";0.000000003890451449942805
"1,3-Indanedione";"MM00997";"O=C1CC(=O)c2ccccc21";"UHKAJLSKXBADFT-UHFFFAOYSA-N";146.15;1.46;"11815";;"DOPC";"CCM18";"25";"0";;;-1.46;"in-house calculations";"COSMOperm";0.034673685045253165
"1,3,7-Trimethyluric Acid";"MM00998";"Cn1c(=O)c2c([nH]c(=O)n2C)n(C)c1=O";"BYXCFUMGEBZDDI-UHFFFAOYSA-N";210.19;-1.74;"79437";;"DOPC";"CCM18";"25";"0";;-0.808819;-5.61;"in-house calculations";"COSMOperm";0.0000024547089156850284
"1,4-Butanediol";"MM00314";"OCCCCO";"WERYXYBDKMZEQL-UHFFFAOYSA-N";90.12;-0.25;"8064";"CHEMBL171623";"DOPC";"CCM18";"25";"0";;-1.32641;-3.79;"in-house calculations";"COSMOperm";0.00016218100973589298
"1,4-Decanediol";"MM00006";"CCCCCCC(O)CCCO";"GFICPCFLWFXIJC-UHFFFAOYSA-N";174.28;2.09;"12485271";;"DOPC";"CCM18";"25";"0";;;0.23;"in-house calculations";"COSMOperm";1.6982436524617444
"1,5-Decanediol";"MM00007";"CCCCCC(O)CCCCO";"BMHXYCAVLBMDOD-UHFFFAOYSA-N";174.28;2.09;"11499301";;"DOPC";"CCM18";"25";"0";;;0.06;"in-house calculations";"COSMOperm";1.1481536214968828
"1,6-Hexanediol";"MM00009";"C[C@@H](O)CC[C@@H](C)O";"OHMBHFSEKCCCBW-PHDIDXHHSA-N";118.18;0.53;"43078";"CHEMBL458616";"DOPC";"CCM18";"25";"0";;-0.0690951;-2.46;"in-house calculations";"COSMOperm";0.0034673685045253167
"1,6-Decanediol";"MM00008";"CCCCC(O)CCCCCO";"WMTNCXUJZRJFHB-UHFFFAOYSA-N";174.28;2.09;"11073917";;"DOPC";"CCM18";"25";"0";;;-0.14;"in-house calculations";"COSMOperm";0.72443596007499
"1,7-Dimethyluric Acid";"MM00973";"Cn1c(=O)[nH]c2[nH]c(=O)n(C)c2c1=O";"NOFNCLGCUJJPKU-UHFFFAOYSA-N";196.17;-1.75;"91611";;"DOPC";"CCM18";"25";"0";;-0.743882;-8;"in-house calculations";"COSMOperm";0.00000001
"1,7-Decanediol";"MM00010";"CCCC(O)CCCCCCO";"QGNYXNXFYTZJHR-UHFFFAOYSA-N";174.28;2.09;"22617082";;"DOPC";"CCM18";"25";"0";;;-0.37;"in-house calculations";"COSMOperm";0.42657951880159267
"1,8-Decanediol";"MM00011";"CCC(O)CCCCCCCO";"GXNQEVBKQUQPGE-UHFFFAOYSA-N";174.28;2.09;"17914602";;"DOPC";"CCM18";"25";"0";;;-0.6;"in-house calculations";"COSMOperm";0.251188643150958
"1,8-Octanediol";"MM00012";"OCCCCCCCCO";"OEIJHBUUFURJLI-UHFFFAOYSA-N";146.23;1.31;"69420";;"DOPC";"CCM18";"25";"0";;;-1.5;"in-house calculations";"COSMOperm";0.03162277660168379
"1,9-Decadiene";"MM01008";"C=CCCCCCCC=C";"NLDGJRWPPOSWLC-UHFFFAOYSA-N";138.25;3.7;"15439";;"DOPC";"CCM18";"25";"0";;;-0.44;"in-house calculations";"COSMOperm";0.36307805477010135
"1,9-Decanediol";"MM00013";"CC(O)CCCCCCCCO";"BRBMYNGGGPTKKL-UHFFFAOYSA-N";174.28;2.09;"10910076";;"DOPC";"CCM18";"25";"0";;;-1.05;"in-house calculations";"COSMOperm";0.08912509381337455
"2-Amino-4-Nitrophenol";"MM00790";"Nc1cc([N+](=O)[O-])ccc1O";"VLZVIIYRNMWPSN-UHFFFAOYSA-N";154.13;0.88;"3613389";;"DOPC";"CCM18";"25";"0";;;-2.5;"in-house calculations";"COSMOperm";0.0031622776601683794
"2-Butanone";"MM00791";"CCC(C)=O";"ZWEHNKRNPOVVGH-UHFFFAOYSA-N";72.11;0.99;"6569";;"DOPC";"CCM18";"25";"0";;;-1.59;"in-house calculations";"COSMOperm";0.025703957827688632
"2-Chlorophenol";"MM00219";"Oc1ccccc1Cl";"ISPYQTSUDJAMAB-UHFFFAOYSA-N";128.56;2.05;"7245";"CHEMBL108877";"DOPC";"CCM18";"25";"0";;;-0.55;"in-house calculations";"COSMOperm";0.28183829312644537
"2-Deoxyadenosine";"MM00320";"Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1";"OLXZPDWKRNYJJZ-RRKCRQDMSA-N";251.25;-0.95;"13730";;"DOPC";"CCM18";"25";"0";;-5.47331;-6.26;"in-house calculations";"COSMOperm";0.0000005495408738576248
"2-Ethoxyethanol";"MM00792";"CCOCCO";"ZNQVEEAIQZEUHB-UHFFFAOYSA-N";90.12;0.02;"8076";"CHEMBL119596";"DOPC";"CCM18";"25";"0";;-0.315349;-2.02;"in-house calculations";"COSMOperm";0.009549925860214359
"2-Isopropoxyethanol";"MM00023";"CC(C)OCCO";"HCGFUIQPSOCUHI-UHFFFAOYSA-N";104.15;0.4;"7996";;"DOPC";"CCM18";"25";"0";;;-1.65;"in-house calculations";"COSMOperm";0.0223872113856834
"2-Naphthol";"MM00793";"Oc1ccc2ccccc2c1";"JWAZRIHNYRIHIV-UHFFFAOYSA-N";144.17;2.55;"8663";;"DOPC";"CCM18";"25";"0";;;-0.19;"in-house calculations";"COSMOperm";0.6456542290346555
"2-Phenyl-1,3-Propanediol Monocarbamate";"MM01010";"NC(=O)OCC(CO)c1ccccc1";"JQVQIZWJBLGVRW-UHFFFAOYSA-N";195.22;0.86;"213060";;"DOPC";"CCM18";"25";"0";;;-2.73;"in-house calculations";"COSMOperm";0.0018620871366628676
"2-Phenylethanol";"MM00794";"OCCc1ccccc1";"WRMNZCZEMHIOCP-UHFFFAOYSA-N";122.17;1.22;"6054";"CHEMBL448500";"DOPC";"CCM18";"25";"0";;;-1.04;"in-house calculations";"COSMOperm";0.09120108393559097
"2-Butoxyethanol";"MM00024";"CCCCOCCO";"POAOYUHQDCAZBD-UHFFFAOYSA-N";118.18;0.8;"8133";;"DOPC";"CCM18";"25";"0";;;-1.01;"in-house calculations";"COSMOperm";0.09772372209558107
"2-chloro-1,4-naphthoquinone";"MM01011";"O=C1C=C(Cl)C(=O)c2ccccc21";"CCTJHVLTAJTPBV-UHFFFAOYSA-N";192.6;2.19;;;"DOPC";"CCM18";"25";"0";;;-1.09;"in-house calculations";"COSMOperm";0.0812830516164099
"4-Trifluoromethylsalicylic Acid";"MM01013";"O=C(O)c1ccc(C(F)(F)F)cc1O";"XMLFPUBZFSJWCN-UHFFFAOYSA-N";206.12;2.11;"164578";;"DOPC";"CCM18";"25";"0";;;0.17;"in-house calculations";"COSMOperm";1.4791083881682074
"2-Hydroxyclomipramine";"MM01014";"CN(C)CCCN1c2ccccc2CCc2cc(O)c(Cl)cc21";"QXZNSJJZRXNDJQ-UHFFFAOYSA-N";330.86;4.23;"10246110";;"DOPC";"CCM18";"25";"0";;;-0.86;"in-house calculations";"COSMOperm";0.1380384264602885
"2-Hydroxydesipramine";"MM00019";"CNCCCN1c2ccccc2CCc2cc(O)ccc21";"NVJBOLMRGMDGLD-UHFFFAOYSA-N";282.39;3.24;"121249";;"DOPC";"CCM18";"25";"0";;;-0.41;"in-house calculations";"COSMOperm";0.3890451449942806
"2-Hydroxyflutamide";"MM01017";"CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1";"YPQLFJODEKMJEF-UHFFFAOYSA-N";292.21;2.32;"91649";;"DOPC";"CCM18";"25";"0";;2.3014;-0.99;"in-house calculations";"COSMOperm";0.10232929922807542
"2-Hydroxyimipramine";"MM01019";"CN(C)CCCN1c2ccccc2CCc2cc(O)ccc21";"ROTCPJFWLNDKHU-UHFFFAOYSA-N";296.41;3.58;"108051";;"DOPC";"CCM18";"25";"0";;;-0.47;"in-house calculations";"COSMOperm";0.33884415613920255
"2-Hydroxymethylolanzapine";"MM01021";"CN1CCN(C2=c3cc(CO)sc3=Nc3ccccc3N2)CC1";"RVFCERGZNZDVTA-UHFFFAOYSA-N";328.44;0.93;"9840400";;"DOPC";"CCM18";"25";"0";;;-1.5;"in-house calculations";"COSMOperm";0.03162277660168379
"2-Hydroxymexiletine";"MM00020";"Cc1cc(O)cc(C)c1OCC(C)N";"YWOSWRCXWBDSRQ-UHFFFAOYSA-N";195.26;1.74;"93285";;"DOPC";"CCM18";"25";"0";;;-1.66;"in-house calculations";"COSMOperm";0.02187761623949553
"2-Mercaptopropionic Acid";"MM01024";"CC(S)C(=O)O";"PMNLUUOXGOOLSP-UHFFFAOYSA-N";106.15;0.39;"62326";;"DOPC";"CCM18";"25";"0";;0.40558;-1.69;"in-house calculations";"COSMOperm";0.020417379446695295
"2-Naphthylamine";"MM00025";"Nc1ccc2ccccc2c1";"JBIJLHTVPXGSAM-UHFFFAOYSA-N";143.19;2.42;"7057";;"DOPC";"CCM18";"25";"0";;;-0.41;"in-house calculations";"COSMOperm";0.3890451449942806
"2-Nitro-P-phenylenediamine";"MM00797";"Nc1cccc([N+](=O)[O-])c1N";"IOCXBXZBNOYTLQ-UHFFFAOYSA-N";153.14;0.76;"4359525";;"DOPC";"CCM18";"25";"0";;;-1.78;"in-house calculations";"COSMOperm";0.016595869074375606
"2-Nitrotoluene";"MM00140";"Cc1ccccc1[N+](=O)[O-]";"PLAZTCDQAHEYBI-UHFFFAOYSA-N";137.14;1.9;"6944";;"DOPC";"CCM18";"25";"0";;;-0.56;"in-house calculations";"COSMOperm";0.2754228703338166
"2-Phenoxyethanol";"MM00026";"OCCOc1ccccc1";"QCDWFXQBSFUVSP-UHFFFAOYSA-N";138.17;1.06;"31236";"CHEMBL1229846";"DOPC";"CCM18";"25";"0";;;-0.94;"in-house calculations";"COSMOperm";0.1148153621496883
"2-Pyridylacetic Acid";"MM01027";"O=C(O)Cc1ccccn1";"BPSNETAIJADFTO-UHFFFAOYSA-N";137.14;0.71;"85318";;"DOPC";"CCM18";"25";"0";;;-1.36;"in-house calculations";"COSMOperm";0.043651583224016584
"3-Nitrophenol";"MM00225";"O=[N+]([O-])c1cccc(O)c1";"RTZZCYNQPHTPPL-UHFFFAOYSA-N";139.11;1.3;"11137";;"DOPC";"CCM18";"25";"0";;;-1;"in-house calculations";"COSMOperm";0.1
"3-Hydroxycarbamazepine";"MM00021";"NC(=O)N1c2ccccc2C=Cc2ccc(O)cc21";"QQCFBZCATDIWTH-UHFFFAOYSA-N";252.27;3.09;"135290";;"DOPC";"CCM18";"25";"0";;;-2.93;"in-house calculations";"COSMOperm";0.001174897554939529
"Pregnenolone Sulfate";"MM01028";"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C";"DIJBBUIOWGGQOP-QGVNFLHTSA-N";396.55;4.34;"105074";"CHEMBL1179605";"DOPC";"CCM18";"25";"0";;;-0.77;"in-house calculations";"COSMOperm";0.16982436524617442
"5-Fluorouracil";"MM00829";"O=c1[nH]cc(F)c(=O)[nH]1";"GHASVSINZRGABV-UHFFFAOYSA-N";130.08;-0.8;"3385";"CHEMBL185";"DOPC";"CCM18";"25";"0";;-0.0908871;-6.04;"in-house calculations";"COSMOperm";0.0000009120108393559096
"5-Carboxyfluorescein";"MM00053";"O=C(O)c1ccc2c(c1)C(=O)OC21c2ccc(O)cc2Oc2cc(O)ccc21";"NJYVEMPWNAYQQN-UHFFFAOYSA-N";376.32;3.36;"123755";;"DOPC";"CCM18";"25";"0";;;-2.56;"in-house calculations";"COSMOperm";0.002754228703338166
"6-Methylcoumarin";"MM00830";"Cc1ccc2oc(=O)ccc2c1";"FXFYOPQLGGEACP-UHFFFAOYSA-N";160.17;2.1;"7092";;"DOPC";"CCM18";"25";"0";;;-0.25;"in-house calculations";"COSMOperm";0.5623413251903491
"7-ethoxycoumarin";"MM00831";"CCOc1ccc2ccc(=O)oc2c1";"LIFAQMGORKPVDH-UHFFFAOYSA-N";190.2;2.19;"35703";;"DOPC";"CCM18";"25";"0";;;-0.26;"in-house calculations";"COSMOperm";0.5495408738576245
"2-bromo-2-chloroacetonitrile";"MM00924";"N#CC(Cl)Br";"BMWPPNAUMLRKML-UHFFFAOYSA-N";154.39;1.47;"55004";;"DOPC";"CCM18";"25";"0";;;-0.88;"in-house calculations";"COSMOperm";0.1318256738556407
"Bromocriptine";"MM00338";"CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12";"OZVBMTJYIDMWIL-AYFBDAFISA-N";654.61;3.19;"31101";"CHEMBL493";"DOPC";"CCM18";"25";"0";;;-1.71;"in-house calculations";"COSMOperm";0.019498445997580455
"Bromo(dichloro)methane";"MM00925";"ClC(Cl)Br";"FMWLUWPQPKEARP-UHFFFAOYSA-N";163.83;2.14;"6359";;"DOPC";"CCM18";"25";"0";;;-0.46;"in-house calculations";"COSMOperm";0.3467368504525316
"Bromoform";"MM00027";"BrC(Br)Br";"DIKBFYAXUHHXCS-UHFFFAOYSA-N";252.73;2.45;"5558";"CHEMBL345248";"DOPC";"CCM18";"25";"0";;;0.2;"in-house calculations";"COSMOperm";1.5848931924611136
"3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine";"MM00453";"CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1";"ZDIGNSYAACHWNL-HNNXBMFYSA-N";319.25;3.93;"6834";"CHEMBL811";"DOPC";"CCM18";"25";"0";;;-1.06;"in-house calculations";"COSMOperm";0.08709635899560805
"Budesonide";"MM00339";"CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1";"VOVIALXJUBGFJZ-VXKMTNQYSA-N";430.54;2.72;"5281004";"CHEMBL1370";"DOPC";"CCM18";"25";"0";;;-2.68;"in-house calculations";"COSMOperm";0.0020892961308540386
"1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide";"MM00454";"CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C";"LEBVLXFERQHONN-INIZCTEOSA-N";288.44;3.9;"2474";"CHEMBL1098";"DOPC";"CCM18";"25";"0";;;-0.81;"in-house calculations";"COSMOperm";0.1548816618912481
"Bupropion";"MM00455";"C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1";"SNPPWIUOZRMYNY-VIFPVBQESA-N";239.75;3.3;"444";"CHEMBL894";"DOPC";"CCM18";"25";"0";;;-0.88;"in-house calculations";"COSMOperm";0.1318256738556407
"8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione";"MM00456";"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1";"QWCRAEMEVRGPNT-UHFFFAOYSA-N";385.51;2.09;"2477";"CHEMBL49";"DOPC";"CCM18";"25";"0";;;-1.61;"in-house calculations";"COSMOperm";0.024547089156850298
"3-(dibutylamino)propyl 4-aminobenzoate";"MM00457";"CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1";"HQFWVSGBVLEQGA-UHFFFAOYSA-N";306.45;3.72;"2480";;"DOPC";"CCM18";"25";"0";;;0.45;"in-house calculations";"COSMOperm";2.8183829312644537
"1-butanol";"MM00340";"CCCCO";"LRHPLDYGYMQRHN-UHFFFAOYSA-N";74.12;0.78;"263";"CHEMBL14245";"DOPC";"CCM18";"25";"0";;;-1.18;"in-house calculations";"COSMOperm";0.06606934480075961
"5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione";"MM00844";"CCCCC1(CC)C(=O)NC(=O)NC1=O";"STDBAQMTJLUMFW-UHFFFAOYSA-N";212.25;0.94;"6473";"CHEMBL404422";"DOPC";"CCM18";"25";"0";;;-2.97;"in-house calculations";"COSMOperm";0.001071519305237606
"Butyl P-aminobenzoate";"MM00028";"CCCCOC(=O)c1ccc(N)cc1";"IUWVALYLNVXWKX-UHFFFAOYSA-N";193.25;2.23;"2482";"CHEMBL127516";"DOPC";"CCM18";"25";"0";;;-0.32;"in-house calculations";"COSMOperm";0.4786300923226383
"Butyl 4-hydroxybenzoate";"MM00029";"CCCCOC(=O)c1ccc(O)cc1";"QFOHBWFCKVYLES-UHFFFAOYSA-N";194.23;2.35;"7184";;"DOPC";"CCM18";"25";"0";;2.8085;-0.17;"in-house calculations";"COSMOperm";0.6760829753919817
"Cyclothiazide";"MM00350";"NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O";"BOCUKUHCLICSIY-UHFFFAOYSA-N";389.89;1.23;"2910";"CHEMBL61593";"DOPC";"CCM18";"25";"0";;;-4.81;"in-house calculations";"COSMOperm";0.000015488166189124828
"4-(dibenzo[1,2-a:2',1'-d][7]annulen-11-ylidene)-1-methyl-piperidine";"MM00472";"CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1";"JJCFRYNCJDLXIK-UHFFFAOYSA-N";287.41;4.7;"2913";"CHEMBL516";"DOPC";"CCM18";"25";"0";;;-0.98;"in-house calculations";"COSMOperm";0.10471285480508996
"Cytarabine";"MM00929";"Nc1ccn(C2OC(CO)C(O)C2O)c(=O)n1";"UHDGCWIWMRVCDJ-UHFFFAOYSA-N";243.22;-2.56;"6253";"CHEMBL803";"DOPC";"CCM18";"25";"0";;-5.47713;-11.61;"in-house calculations";"COSMOperm";0.0000000000024547089156850334
"D-Fructose";"MM00351";"OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O";"LKDRXBCSQODPBY-VRPWFDPXSA-N";180.16;-3.22;"2723872";;"DOPC";"CCM18";"25";"0";;-5.47635;-6.74;"in-house calculations";"COSMOperm";0.00000018197008586099824
"D-Glucose";"MM00352";"OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O";"WQZGKKKJIJFFOK-GASJEMHNSA-N";180.16;-3.22;"5793";;"DOPC";"CCM18";"25";"0";;-4.09189;-9.43;"in-house calculations";"COSMOperm";0.0000000003715352290971728
"Morphine";"MM00524";"CN1CCC23c4c5ccc(O)c4OC2C(O)C=CC3C1C5";"BQJCRHHNABKAKU-UHFFFAOYSA-N";285.34;1.2;"5288826";"CHEMBL70";"DOPC";"CCM18";"25";"0";;1.4625;-1.25;"in-house calculations";"COSMOperm";0.05623413251903491
"D8-tetrahydrocannabinol";"MM00852";"CCCCCc1cc(O)c2c(c1)OC(C)(C)C1CC=C(C)CC21";"HCAWPGARWVBULJ-UHFFFAOYSA-N";314.47;5.74;"2977";;"DOPC";"CCM18";"25";"0";;;0.07;"in-house calculations";"COSMOperm";1.1748975549395295
"DPDPE";"MM00731";"CC1(C)SSC(C)(C)C(NC(=O)C(N)Cc2ccc(O)cc2)C(=O)NCC(=O)NC(Cc2ccccc2)C(=O)NC1C(=O)O";"MCMMCRYPQBNCPH-UHFFFAOYSA-N";645.8;1.11;"104787";"CHEMBL31421";"DOPC";"CCM18";"25";"0";;;-6.62;"in-house calculations";"COSMOperm";0.000000239883291901949
"7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one";"MM00930";"O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12";"ZQSIJRDFPHDXIC-UHFFFAOYSA-N";254.24;2.87;"5281708";;"DOPC";"CCM18";"25";"0";;1.5864;-2;"in-house calculations";"COSMOperm";0.01
"Danazol";"MM00353";"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C";"POZRVZJJTULAOH-LHZXLZLDSA-N";337.46;4.22;"28417";"CHEMBL1479";"DOPC";"CCM18";"25";"0";;;-1.2;"in-house calculations";"COSMOperm";0.06309573444801933
"Decan-1-ol";"MM00853";"CCCCCCCCCCO";"MWKFXSUHUHTGQN-UHFFFAOYSA-N";158.29;3.12;"8174";;"DOPC";"CCM18";"25";"0";;;1.18;"in-house calculations";"COSMOperm";15.13561248436208
"Desipramine";"MM00474";"CNCCCN1c2ccccc2CCc2ccccc21";"HCYAFALTSJYZDH-UHFFFAOYSA-N";266.39;3.53;"2995";"CHEMBL72";"DOPC";"CCM18";"25";"0";;;-0.81;"in-house calculations";"COSMOperm";0.1548816618912481
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"DOPC";"CCM18";"25";"0";;;-2.26;"in-house calculations";"COSMOperm";0.005495408738576248
"Dextromethorphan";"MM00475";"COc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3";"MKXZASYAUGDDCJ-UHFFFAOYSA-N";271.4;3.38;"5360696";"CHEMBL52440";"DOPC";"CCM18";"25";"0";;;-1.32;"in-house calculations";"COSMOperm";0.047863009232263824
"(1S,9S,10S)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol";"MM00476";"CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(O)cc13";"JAQUASYNZVUNQP-PVAVHDDUSA-N";257.38;3.08;"5360697";;"DOPC";"CCM18";"25";"0";;;-0.63;"in-house calculations";"COSMOperm";0.2344228815319922
"1,2-bis(oxiran-2-yl)ethane-1,2-diol";"MM00356";"OC(C1CO1)C(O)C1CO1";"AAFJXZWCNVJTMK-UHFFFAOYSA-N";146.14;-1.49;"31789";"CHEMBL3137322";"DOPC";"CCM18";"25";"0";;-2.55415;-3.8;"in-house calculations";"COSMOperm";0.00015848931924611142
"Diazepam";"MM00094";"CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21";"AAOVKJBEBIDNHE-UHFFFAOYSA-N";284.75;3.15;"3016";"CHEMBL12";"DOPC";"CCM18";"25";"0";;2.88;-0.75;"in-house calculations";"COSMOperm";0.1778279410038923
"Diethoxy-(6-methyl-2-propan-2-ylpyrimidin-4-yl)oxy-sulfanylidene-lambda5-phosphane";"MM00931";"CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1";"FHIVAFMUCKRCQO-UHFFFAOYSA-N";304.35;3.58;"3017";;"DOPC";"CCM18";"25";"0";;;-1.14;"in-house calculations";"COSMOperm";0.07244359600749903
"2,2-dibromoacetonitrile";"MM00933";"N#CC(Br)Br";"NDSBDLSWTGLNQA-UHFFFAOYSA-N";198.85;1.63;"18617";;"DOPC";"CCM18";"25";"0";;;-0.62;"in-house calculations";"COSMOperm";0.23988329190194904
"2,2-dichloroacetonitrile";"MM00935";"N#CC(Cl)Cl";"STZZWJCGRKXEFF-UHFFFAOYSA-N";109.94;1.31;"18177";;"DOPC";"CCM18";"25";"0";;;-0.81;"in-house calculations";"COSMOperm";0.1548816618912481
"Diclofenac";"MM00090";"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl";"DCOPUUMXTXDBNB-UHFFFAOYSA-N";296.15;4.36;"3033";"CHEMBL139";"DOPC";"CCM18";"25";"0";;;0.02;"in-house calculations";"COSMOperm";1.0471285480508996
"N,N-diethyl-4-methylpiperazine-1-carboxamide";"MM00854";"CCN(CC)C(=O)N1CCN(C)CC1";"RCKMWOKWVGPNJF-UHFFFAOYSA-N";199.3;0.7;"3052";"CHEMBL684";"DOPC";"CCM18";"25";"0";;;-1.16;"in-house calculations";"COSMOperm";0.06918309709189366
"2-(2-hydroxyethoxy)ethanol";"MM00014";"OCCOCCO";"MTHSVFCYNBDYFN-UHFFFAOYSA-N";106.12;-1.01;"8117";;"DOPC";"CCM18";"25";"0";;-2.29946;-3.07;"in-house calculations";"COSMOperm";0.0008511380382023768
"Diethylene Glycol Butyl Ether";"MM00855";"CCCCOCCOCCOCCCC";"KZVBBTZJMSWGTK-UHFFFAOYSA-N";218.34;2.64;"8177";;"DOPC";"CCM18";"25";"0";;;-1.27;"in-house calculations";"COSMOperm";0.05370317963702527
"Ethoxyethane";"MM00936";"CCOCC";"RTZKZFJDLAIYFH-UHFFFAOYSA-N";74.12;1.04;"3283";;"DOPC";"CCM18";"25";"0";;;-1.36;"in-house calculations";"COSMOperm";0.043651583224016584
"Digitoxin";"MM00857";"CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CCC5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O";"WDJUZGPOPHTGOT-UHFFFAOYSA-N";764.95;3.25;"441207";"CHEMBL254219";"DOPC";"CCM18";"25";"0";;;-2.34;"in-house calculations";"COSMOperm";0.004570881896148752
"Digoxin";"MM00357";"CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O";"LTMHDMANZUZIPE-UHFFFAOYSA-N";780.95;2.22;"2724385";"CHEMBL1751";"DOPC";"CCM18";"25";"0";;;-4.52;"in-house calculations";"COSMOperm";0.000030199517204020192
"Dihydromorphine";"MM00858";"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)CC[C@H]3[C@H]1C5";"IJVCSMSMFSCRME-KBQPJGBKSA-N";287.36;1.42;"5359421";"CHEMBL1500";"DOPC";"CCM18";"25";"0";;;-1.3;"in-house calculations";"COSMOperm";0.05011872336272722
"Diltiazem";"MM00477";"COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1";"HSUGRBWQSSZJOP-UHFFFAOYSA-N";414.53;3.37;"39186";"CHEMBL23";"DOPC";"CCM18";"25";"0";;;-2.07;"in-house calculations";"COSMOperm";0.008511380382023767
"2-dimethoxyphosphinothioylsulfanyl-N-methylacetamide";"MM00937";"CNC(=O)CSP(=S)(OC)OC";"MCWXGJITAZMZEV-UHFFFAOYSA-N";229.26;0.98;"3082";;"DOPC";"CCM18";"25";"0";;;-1.54;"in-house calculations";"COSMOperm";0.028840315031266057
"N,N-dimethylethanamine";"MM00859";"CCN(C)C";"DAZXVJBJRMWXJP-UHFFFAOYSA-N";73.14;0.57;"11723";;"DOPC";"CCM18";"25";"0";;;-1.2;"in-house calculations";"COSMOperm";0.06309573444801933
"Diphenhydramine";"MM00478";"CN(C)CCOC(c1ccccc1)c1ccccc1";"ZZVUWRFHKOJYTH-UHFFFAOYSA-N";255.36;3.35;"3100";"CHEMBL657";"DOPC";"CCM18";"25";"0";;;-0.91;"in-house calculations";"COSMOperm";0.12302687708123815
"Dipyridamole";"MM00479";"OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1";"IZEKFCXSFNUWAM-UHFFFAOYSA-N";504.64;-0.02;"3108";"CHEMBL932";"DOPC";"CCM18";"25";"0";;;-3.18;"in-house calculations";"COSMOperm";0.0006606934480075957
"4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide";"MM00480";"CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C";"UVTNFZQICZKOEM-UHFFFAOYSA-N";339.48;3.36;"3114";"CHEMBL517";"DOPC";"CCM18";"25";"0";;;-0.57;"in-house calculations";"COSMOperm";0.2691534803926916
"Domperidone";"MM00481";"O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1";"FGXWKSZFVQUSTL-UHFFFAOYSA-N";425.92;3.35;"3151";"CHEMBL219916";"DOPC";"CCM18";"25";"0";;;-1.43;"in-house calculations";"COSMOperm";0.03715352290971726
"Donepezil";"MM00482";"COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2";"ADEBPBSSDYVVLD-UHFFFAOYSA-N";379.5;4.36;"3152";"CHEMBL502";"DOPC";"CCM18";"25";"0";;6.1607;-0.87;"in-house calculations";"COSMOperm";0.13489628825916536
"L-dopamine";"MM00483";"NCCc1ccc(O)c(O)c1";"VYFYYTLLBUKUHU-UHFFFAOYSA-N";153.18;0.6;"681";"CHEMBL59";"DOPC";"CCM18";"25";"0";;;-2.74;"in-house calculations";"COSMOperm";0.0018197008586099826
"(3Z)-3-(dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine";"MM00484";"CN(C)CCC=C1c2ccccc2COc2ccccc21";"ODQWQRRAPPTVAG-UHFFFAOYSA-N";279.38;3.96;"667477";"CHEMBL101740";"DOPC";"CCM18";"25";"0";;;-0.98;"in-house calculations";"COSMOperm";0.10471285480508996
"2-Propylideneoctanoic Acid";"MM00860";"CCC=C(CCCCCC)C(=O)O";"WAYFJTUZNWOHQH-UHFFFAOYSA-N";184.28;3.38;"54421236";;"DOPC";"CCM18";"25";"0";;;0.25;"in-house calculations";"COSMOperm";1.7782794100389228
"Enalaprilat";"MM00732";"CC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O";"LZFZMUMEGBBDTC-UHFFFAOYSA-N";348.4;1.13;"5462501";"CHEMBL577";"DOPC";"CCM18";"25";"0";;;-1.51;"in-house calculations";"COSMOperm";0.030902954325135904
"Enoxacin";"MM00733";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21";"IDYZIJYBMGIQMJ-UHFFFAOYSA-N";320.32;0.66;"3229";"CHEMBL826";"DOPC";"CCM18";"25";"0";;;-2.58;"in-house calculations";"COSMOperm";0.0026302679918953813
"Enrofloxacin";"MM00734";"CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1";"SPFYMRJSYKOXGV-UHFFFAOYSA-N";359.4;2.32;"71188";;"DOPC";"CCM18";"25";"0";;3.2747;-1.06;"in-house calculations";"COSMOperm";0.08709635899560805
"(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol";"MM00486";"CN[C@@H](C)[C@H](O)c1ccccc1";"KWGRBVOPPLSCSI-WPRPVWTQSA-N";165.24;1.33;"9294";"CHEMBL211456";"DOPC";"CCM18";"25";"0";;;-1.1;"in-house calculations";"COSMOperm";0.07943282347242814
"L-epinephrine";"MM00644";"CNCC(O)c1ccc(O)c(O)c1";"UCTWMZQNUQWSLP-UHFFFAOYSA-N";183.21;0.35;"5816";"CHEMBL679";"DOPC";"CCM18";"25";"0";;;-3.58;"in-house calculations";"COSMOperm";0.00026302679918953814
"Ergonovine";"MM00487";"CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1";"WVVSZNPYNCNODU-UHFFFAOYSA-N";325.41;1.53;"443884";"CHEMBL119443";"DOPC";"CCM18";"25";"0";;;-1.69;"in-house calculations";"COSMOperm";0.020417379446695295
"Ergotamine";"MM00488";"CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21";"XCGSFFUVFURLIX-VFGNJEKYSA-N";581.67;1.99;"8223";"CHEMBL442";"DOPC";"CCM18";"25";"0";;;-1.78;"in-house calculations";"COSMOperm";0.016595869074375606
"Meso-erythritol";"MM00068";"OC[C@H](O)[C@H](O)CO";"UNXHWFMMPAWVPI-ZXZARUISSA-N";122.12;-2.31;"222285";"CHEMBL349605";"DOPC";"CCM18";"25";"0";;-5.44031;-5;"in-house calculations";"COSMOperm";0.00001
"Erythromycin";"MM00489";"CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O";"ULGZDMOVFRHVEP-UHFFFAOYSA-N";733.94;1.79;"12560";"CHEMBL532";"DOPC";"CCM18";"25";"0";;;-2.93;"in-house calculations";"COSMOperm";0.001174897554939529
"Estradiol";"MM00197";"CC12CCC3c4ccc(O)cc4CCC3C1CCC2O";"VOXZDWNPVJITMN-UHFFFAOYSA-N";272.39;3.61;"5757";"CHEMBL135";"DOPC";"CCM18";"25";"0";;;-0.94;"in-house calculations";"COSMOperm";0.1148153621496883
"Estriol";"MM00201";"C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O";"PROQIPRRNZUXQM-ZXXIGWHRSA-N";288.39;2.58;"5756";"CHEMBL193482";"DOPC";"CCM18";"25";"0";;;-1.85;"in-house calculations";"COSMOperm";0.01412537544622754
"Estrone";"MM00114";"CC12CCC3c4ccc(O)cc4CCC3C1CCC2=O";"DNXHEGUUPJUMQT-UHFFFAOYSA-N";270.37;3.82;"5870";"CHEMBL1405";"DOPC";"CCM18";"25";"0";;;-1.07;"in-house calculations";"COSMOperm";0.08511380382023763
"Ethanolamine";"MM00490";"NCCO";"HZAXFHJVJLSVMW-UHFFFAOYSA-N";61.08;-1.06;"700";"CHEMBL104943";"DOPC";"CCM18";"25";"0";;-5.37549;-4.42;"in-house calculations";"COSMOperm";0.000038018939632056124
"3-ethyl-3-methylpyrrolidine-2,5-dione";"MM00359";"CCC1(C)CC(=O)NC1=O";"HAPOVYFOVVWLRS-UHFFFAOYSA-N";141.17;0.45;"3291";"CHEMBL696";"DOPC";"CCM18";"25";"0";;;-2.87;"in-house calculations";"COSMOperm";0.0013489628825916532
"Ethanamine";"MM00491";"CCN";"QUSNBJAOOMFDIB-UHFFFAOYSA-N";45.09;-0.04;"6341";;"DOPC";"CCM18";"25";"0";;-0.0988084;-1.85;"in-house calculations";"COSMOperm";0.01412537544622754
"Ethylbenzene";"MM00861";"CCc1ccccc1";"YNQLUTRBYVCPMQ-UHFFFAOYSA-N";106.17;2.25;"7500";;"DOPC";"CCM18";"25";"0";;;-0.53;"in-house calculations";"COSMOperm";0.29512092266663853
"2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid";"MM00946";"CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3";"NNYBQONXHNTVIJ-UHFFFAOYSA-N";287.36;3.38;"3308";"CHEMBL622";"DOPC";"CCM18";"25";"0";;;-0.4;"in-house calculations";"COSMOperm";0.3981071705534972
"Etoposide";"MM00361";"COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O";"VJJPUSNTGOMMGY-UHFFFAOYSA-N";588.56;1.34;"36462";"CHEMBL44657";"DOPC";"CCM18";"25";"0";;;-2.88;"in-house calculations";"COSMOperm";0.0013182567385564075
"MM01031";"MM01031";"Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1";"MNJVRJDLRVPLFE-UHFFFAOYSA-N";358.85;4.18;;;"DOPC";"CCM18";"25";"0";;;-1.54;"in-house calculations";"COSMOperm";0.028840315031266057
"Etorphine";"MM00863";"CCC[C@@](C)(O)[C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(C)[C@@H]3C5";"CAHCBJPUTCKATP-FAWZKKEFSA-N";411.54;3.16;"644209";;"DOPC";"CCM18";"25";"0";;;-1.19;"in-house calculations";"COSMOperm";0.06456542290346556
"3-methylimidazo[4,5-f]quinolin-2-amine";"MM00880";"Cn1c(N)nc2c3cccnc3ccc21";"ARZWATDYIYAUTA-UHFFFAOYSA-N";198.23;1.7;"53462";;"DOPC";"CCM18";"25";"0";;;-2.74;"in-house calculations";"COSMOperm";0.0018197008586099826
"Ibuprofen";"MM00045";"CC(C)Cc1ccc(C(C)C(=O)O)cc1";"HEFNNWSXXWATRW-UHFFFAOYSA-N";206.29;3.07;"3672";"CHEMBL521";"DOPC";"CCM18";"25";"0";;;0.32;"in-house calculations";"COSMOperm";2.0892961308540396
"Imatinib";"MM00503";"Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1";"KTUFNOKKBVMGRW-UHFFFAOYSA-N";493.62;4.59;"5291";"CHEMBL941";"DOPC";"CCM18";"25";"0";;;-1.35;"in-house calculations";"COSMOperm";0.0446683592150963
"Imipramine";"MM00504";"CN(C)CCCN1c2ccccc2CCc2ccccc21";"BCGWQEUPMDMJNV-UHFFFAOYSA-N";280.42;3.88;"3696";"CHEMBL11";"DOPC";"CCM18";"25";"0";;;-0.94;"in-house calculations";"COSMOperm";0.1148153621496883
"Indomethacin";"MM00656";"COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1";"CGIGDMFJXJATDK-UHFFFAOYSA-N";357.79;3.93;"3715";"CHEMBL6";"DOPC";"CCM18";"25";"0";;;-0.36;"in-house calculations";"COSMOperm";0.436515832240166
"Iso-thymol";"MM00954";"Cc1ccc(C(C)C)cc1O";"RECUKUPTGUEGMW-UHFFFAOYSA-N";150.22;2.82;"10364";;"DOPC";"CCM18";"25";"0";;;-0.3;"in-house calculations";"COSMOperm";0.5011872336272722
"Isobutyramide";"MM00378";"CC(C)C(N)=O";"WFKAJVHLWXSISD-UHFFFAOYSA-N";87.12;0.13;"68424";;"DOPC";"CCM18";"25";"0";;-0.0242024;-2.77;"in-house calculations";"COSMOperm";0.0016982436524617442
"N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide";"MM00379";"Cc1cc(C(=O)NNCc2ccccc2)no1";"XKFPYPQQHFEXRZ-UHFFFAOYSA-N";231.26;1.42;"3759";;"DOPC";"CCM18";"25";"0";;1.3611;-1.4;"in-house calculations";"COSMOperm";0.039810717055349734
"2-methoxy-4-[(E)-prop-1-enyl]phenol";"MM00881";"C/C=C/c1ccc(O)c(OC)c1";"BJIOGJUNALELMI-ONEGZZNKSA-N";164.2;2.43;"853433";;"DOPC";"CCM18";"25";"0";;;-0.16;"in-house calculations";"COSMOperm";0.6918309709189365
"Propan-2-ol";"MM00380";"CC(C)O";"KFZMGEQAYNKOFK-UHFFFAOYSA-N";60.1;0.39;"3776";"CHEMBL582";"DOPC";"CCM18";"25";"0";;-0.0437329;-1.8;"in-house calculations";"COSMOperm";0.015848931924611134
"Isoquinoline";"MM00882";"c1ccc2cnccc2c1";"AWJUIBRHMBBTKR-UHFFFAOYSA-N";129.16;2.23;"8405";"CHEMBL12315";"DOPC";"CCM18";"25";"0";;;-0.67;"in-house calculations";"COSMOperm";0.2137962089502232
"Isoxicam";"MM00660";"Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1";"YYUAYBYLJSNDCX-UHFFFAOYSA-N";335.34;1.48;"54677972";"CHEMBL53292";"DOPC";"CCM18";"25";"0";;;-0.87;"in-house calculations";"COSMOperm";0.13489628825916536
"3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one";"MM00661";"O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12";"IYRMWMYZSQPJKC-UHFFFAOYSA-N";286.24;2.28;"5280863";"CHEMBL150";"DOPC";"CCM18";"25";"0";;;-0.58;"in-house calculations";"COSMOperm";0.2630267991895382
"1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one";"MM00956";"CCC(=O)C1(c2cccc(O)c2)CCN(C)CC1";"ALFGKMXHOUSVAD-UHFFFAOYSA-N";247.34;2.33;"10101";"CHEMBL47072";"DOPC";"CCM18";"25";"0";;;-1.05;"in-house calculations";"COSMOperm";0.08912509381337455
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"DOPC";"CCM18";"25";"0";;;-0.57;"in-house calculations";"COSMOperm";0.2691534803926916
"5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid";"MM00957";"O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O";"OZWKMVRBQXNZKK-UHFFFAOYSA-N";255.27;2.29;"3826";"CHEMBL469";"DOPC";"CCM18";"25";"0";;;-0.72;"in-house calculations";"COSMOperm";0.19054607179632474
"L-Dopa";"MM00746";"NC(Cc1ccc(O)c(O)c1)C(=O)O";"WTDRDQBEARUVNC-UHFFFAOYSA-N";197.19;0.05;"6047";"CHEMBL1009";"DOPC";"CCM18";"25";"0";;;-4.53;"in-house calculations";"COSMOperm";0.00002951209226666384
"L-Kynurenine";"MM00751";"Nc1ccccc1C(=O)C[C@H](N)C(=O)O";"YGPSJZOEDVAXAB-QMMMGPOBSA-N";208.22;0.25;"161166";"CHEMBL498416";"DOPC";"CCM18";"25";"0";;;-2.19;"in-house calculations";"COSMOperm";0.006456542290346556
"L-alanyl-L-tryptophan";"MM00883";"CC(N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)O";"WUGMRIBZSVSJNP-UHFFFAOYSA-N";275.31;0.63;"85362";;"DOPC";"CCM18";"25";"0";;;-4.65;"in-house calculations";"COSMOperm";0.00002238721138568338
"Labetalol";"MM00507";"CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1";"SGUAFYQXFOLMHL-UHFFFAOYSA-N";328.41;2.14;"3869";"CHEMBL429";"DOPC";"CCM18";"25";"0";;;0.21;"in-house calculations";"COSMOperm";1.62181009735893
"4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one";"MM00382";"Nc1ccn(C2CSC(CO)O2)c(=O)n1";"JTEGQNOMFQHVDC-UHFFFAOYSA-N";229.26;-0.59;"60825";"CHEMBL141";"DOPC";"CCM18";"25";"0";;-1.14851;-7.95;"in-house calculations";"COSMOperm";0.00000001122018454301963
"Lamotrigine";"MM00383";"Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1";"PYZRQGJRPPTADH-UHFFFAOYSA-N";256.1;2.01;"3878";"CHEMBL741";"DOPC";"CCM18";"25";"0";;0.9884;-2.63;"in-house calculations";"COSMOperm";0.0023442288153199225
"Lansoprazole";"MM00384";"Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1";"MJIHNNLFOKEZEW-UHFFFAOYSA-N";369.37;3.52;"3883";"CHEMBL480";"DOPC";"CCM18";"25";"0";;;-0.85;"in-house calculations";"COSMOperm";0.14125375446227545
"Levofloxacin";"MM00762";"C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23";"GSDSWSVVBLHKDQ-JTQLQIEISA-N";361.37;1.54;"149096";"CHEMBL33";"DOPC";"CCM18";"25";"0";;;-3.02;"in-house calculations";"COSMOperm";0.0009549925860214359
"Lidocaine";"MM00092";"CCN(CC)CC(=O)Nc1c(C)cccc1C";"NNJVILVZKWQKPM-UHFFFAOYSA-N";234.34;2.58;"3676";"CHEMBL79";"DOPC";"CCM18";"25";"0";;;-0.75;"in-house calculations";"COSMOperm";0.1778279410038923
"Lomefloxacin";"MM00764";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21";"ZEKZLJVOYLTDKK-UHFFFAOYSA-N";351.35;1.8;"3948";"CHEMBL561";"DOPC";"CCM18";"25";"0";;;-3;"in-house calculations";"COSMOperm";0.001
"Loratadine";"MM00385";"CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1";"JCCNYMKQOSZNPW-UHFFFAOYSA-N";382.89;4.89;"3957";"CHEMBL998";"DOPC";"CCM18";"25";"0";;;-1.24;"in-house calculations";"COSMOperm";0.057543993733715694
"6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide";"MM00960";"CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O";"WLHQHAUOOXYABV-UHFFFAOYSA-N";371.83;2.3;"54690031";"CHEMBL1569487";"DOPC";"CCM18";"25";"0";;;-0.6;"in-house calculations";"COSMOperm";0.251188643150958
"8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine";"MM00510";"CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1";"XJGVXQDUIWGIRW-UHFFFAOYSA-N";327.82;3.77;"3964";"CHEMBL831";"DOPC";"CCM18";"25";"0";;;-1.29;"in-house calculations";"COSMOperm";0.05128613839913648
"Methylurea";"MM00389";"CNC(N)=O";"XGEGHDBEHXKFPX-UHFFFAOYSA-N";74.08;-0.72;"11719";;"DOPC";"CCM18";"25";"0";;-0.786375;-5.62;"in-house calculations";"COSMOperm";0.0000023988329190194897
"Metipranolol";"MM00516";"CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C";"BQIPXWYNLPYNHW-UHFFFAOYSA-N";309.41;2.27;"31477";"CHEMBL1291";"DOPC";"CCM18";"25";"0";;3.1538;-1.41;"in-house calculations";"COSMOperm";0.03890451449942807
"4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide";"MM00517";"CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC";"TTWJBBZEZQICBI-UHFFFAOYSA-N";299.8;2;"4168";"CHEMBL86";"DOPC";"CCM18";"25";"0";;;-0.84;"in-house calculations";"COSMOperm";0.14454397707459277
"Metolazone";"MM00390";"Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C";"AQCHWTWZEMGIFD-UHFFFAOYSA-N";365.84;2.71;"4170";"CHEMBL878";"DOPC";"CCM18";"25";"0";;2.4125;-3.84;"in-house calculations";"COSMOperm";0.0001445439770745928
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"DOPC";"CCM18";"25";"0";;;-1.14;"in-house calculations";"COSMOperm";0.07244359600749903
"Metronidazole";"MM00391";"Cc1ncc([N+](=O)[O-])n1CCO";"VAOCPAMSLUNLGC-UHFFFAOYSA-N";171.16;0.09;"4173";"CHEMBL137";"DOPC";"CCM18";"25";"0";;;-2.41;"in-house calculations";"COSMOperm";0.003890451449942805
"1-(2,6-dimethylphenoxy)propan-2-amine";"MM00518";"Cc1cccc(C)c1OCC(C)N";"VLPIATFUUWWMKC-UHFFFAOYSA-N";179.26;2.03;"4178";"CHEMBL558";"DOPC";"CCM18";"25";"0";;;-0.7;"in-house calculations";"COSMOperm";0.19952623149688797
"1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole";"MM00088";"Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1";"BYBLEWFAAKGYCD-UHFFFAOYSA-N";416.14;6.45;"4189";"CHEMBL91";"DOPC";"CCM18";"25";"0";;;-0.69;"in-house calculations";"COSMOperm";0.20417379446695297
"Midazolam";"MM00519";"Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2";"DDLIGBOFAVUZHB-UHFFFAOYSA-N";325.77;4.32;"4192";"CHEMBL655";"DOPC";"CCM18";"25";"0";;;-0.84;"in-house calculations";"COSMOperm";0.14454397707459277
"5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene";"MM00520";"CN1CCN2c3ncccc3Cc3ccccc3C2C1";"RONZAEMNMFQXRA-UHFFFAOYSA-N";265.36;2.48;"4205";"CHEMBL654";"DOPC";"CCM18";"25";"0";;;-1;"in-house calculations";"COSMOperm";0.1
"1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol";"MM00521";"COCC(O)Cn1ccnc1[N+](=O)[O-]";"OBBCSXFCDPPXOL-UHFFFAOYSA-N";201.18;-0.2;"26105";"CHEMBL42161";"DOPC";"CCM18";"25";"0";;;-2.69;"in-house calculations";"COSMOperm";0.0020417379446695297
"Montelukast";"MM00669";"CC(C)(O)c1ccccc1CCC(SCC1(CC(=O)O)CC1)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1";"UCHDWCPVSPXUMX-UHFFFAOYSA-N";586.2;8.95;"5281040";"CHEMBL787";"DOPC";"CCM18";"25";"0";;;-0.68;"in-house calculations";"COSMOperm";0.20892961308540392
"1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine";"MM00523";"Cc1ccsc1/C=C/C1=NCCCN1C";"NVEPPWDVLBMNMB-SNAWJCMRSA-N";220.34;2.8;"5353792";;"DOPC";"CCM18";"25";"0";;4.1203;-0.6;"in-house calculations";"COSMOperm";0.251188643150958
"Morphine";"MM00524";"CN1CCC23c4c5ccc(O)c4OC2C(O)C=CC3C1C5";"BQJCRHHNABKAKU-UHFFFAOYSA-N";285.34;1.2;"5288826";"CHEMBL70";"DOPC";"CCM18";"25";"0";;;-1.37;"in-house calculations";"COSMOperm";0.04265795188015926
"Moxifloxacin";"MM00767";"COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12";"FABPRXSRWADJSP-MEDUHNTESA-N";401.44;2.37;"152946";"CHEMBL32";"DOPC";"CCM18";"25";"0";;3.1616;-1.87;"in-house calculations";"COSMOperm";0.013489628825916533
"Nadolol";"MM00525";"CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2";"VWPOSFSPZNDTMJ-UHFFFAOYSA-N";309.41;0.63;"39147";"CHEMBL649";"DOPC";"CCM18";"25";"0";;;-1.2;"in-house calculations";"COSMOperm";0.06309573444801933
"Nalbuphine";"MM00526";"Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314";"NETZHAKZCGBWSS-CEDHKZHLSA-N";357.45;1.71;"5311304";"CHEMBL895";"DOPC";"CCM18";"25";"0";;;-0.33;"in-house calculations";"COSMOperm";0.4677351412871982
"Naloxone";"MM00277";"C=CCN1CCC23c4c5ccc(O)c4OC2C(=O)CCC3(O)C1C5";"UZHSEJADLWPNLE-UHFFFAOYSA-N";327.38;1.3;"5284596";"CHEMBL80";"DOPC";"CCM18";"25";"0";;1.7917;-0.99;"in-house calculations";"COSMOperm";0.10232929922807542
"Naltrindole";"MM00527";"Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314";"WIYUZYBFCWCCQJ-IFKAHUTRSA-N";414.51;3.57;"5497186";;"DOPC";"CCM18";"25";"0";;;-0.37;"in-house calculations";"COSMOperm";0.42657951880159267
"Naphthalene";"MM00890";"c1ccc2ccccc2c1";"UFWIBTONFRDIAS-UHFFFAOYSA-N";128.17;2.84;"931";;"DOPC";"CCM18";"25";"0";;3.8262;-0.18;"in-house calculations";"COSMOperm";0.660693448007596
"Naproxen";"MM00672";"COc1ccc2cc(C(C)C(=O)O)ccc2c1";"CMWTZPSULFXXJA-UHFFFAOYSA-N";230.26;3.04;"156391";"CHEMBL154";"DOPC";"CCM18";"25";"0";;;-0.15;"in-house calculations";"COSMOperm";0.7079457843841379
"Naringenin";"MM00673";"O=C1CC(c2ccc(O)cc2)Oc2cc(O)cc(O)c21";"FTVWIRXFELQLPI-UHFFFAOYSA-N";272.26;2.51;"932";"CHEMBL9352";"DOPC";"CCM18";"25";"0";;;-1.09;"in-house calculations";"COSMOperm";0.0812830516164099
"Neotrofin";"MM00674";"O=C(CCn1cnc2c(=O)nc[nH]c21)Nc1ccc(C(=O)[O-])cc1.[K+]";"MICLTPPSCUXHJT-UHFFFAOYSA-M";365.39;-3.48;"23663995";;"DOPC";"CCM18";"25";"0";;;-7.07;"in-house calculations";"COSMOperm";0.00000008511380382023759
"Netivudine";"MM00395";"CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O";"QLOCVMVCRJOTTM-SDNRWEOFSA-N";282.25;-2.48;"55281";"CHEMBL1097615";"DOPC";"CCM18";"25";"0";;-1.47863;-8.4;"in-house calculations";"COSMOperm";0.000000003981071705534969
"Nicardipine";"MM00278";"COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1";"ZBBHBTPTTSWHBA-UHFFFAOYSA-N";479.53;3.68;"4474";"CHEMBL1484";"DOPC";"CCM18";"25";"0";;;-1.47;"in-house calculations";"COSMOperm";0.033884415613920256
"2-(pyridine-3-carbonylamino)ethyl nitrate";"MM00891";"O=C(NCCO[N+](=O)[O-])c1cccnc1";"LBHIOVVIQHSOQN-UHFFFAOYSA-N";211.18;0.02;"47528";"CHEMBL284906";"DOPC";"CCM18";"25";"0";;1.3924;-1.16;"in-house calculations";"COSMOperm";0.06918309709189366
"(s)-3-(1-methylpyrrolidin-2-yl)pyridine";"MM00529";"CN1CCCC1c1cccnc1";"SNICXCGAKADSCV-UHFFFAOYSA-N";162.24;1.85;"89594";"CHEMBL3";"DOPC";"CCM18";"25";"0";;;-0.78;"in-house calculations";"COSMOperm";0.16595869074375605
"4-nitro-2-phenoxymethanesulfonanilide";"MM00279";"CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1";"HYWYRSMBCFDLJT-UHFFFAOYSA-N";308.32;2.76;"4495";"CHEMBL56367";"DOPC";"CCM18";"25";"0";;;-0.41;"in-house calculations";"COSMOperm";0.3890451449942806
"Nitrobenzene";"MM00136";"O=[N+]([O-])c1ccccc1";"LQNUZADURLCDLV-UHFFFAOYSA-N";123.11;1.59;"7416";;"DOPC";"CCM18";"25";"0";;1.5118;-0.7;"in-house calculations";"COSMOperm";0.19952623149688797
"Propane-1,2,3-triyl trinitrate";"MM00893";"O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]";"SNIOPGDIGTZGOP-UHFFFAOYSA-N";227.09;-1.02;"4510";"CHEMBL730";"DOPC";"CCM18";"25";"0";;;-0.08;"in-house calculations";"COSMOperm";0.831763771102671
"Nizatidine";"MM00084";"CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1";"SGXXNSQHWDMGGP-UHFFFAOYSA-N";331.47;1.32;"3033637";"CHEMBL3183075";"DOPC";"CCM18";"25";"0";;1.5536;-1.69;"in-house calculations";"COSMOperm";0.020417379446695295
"Nonan-1-ol";"MM00894";"CCCCCCCCCO";"ZWRUINPWMLAQRD-UHFFFAOYSA-N";144.26;2.73;"8914";"CHEMBL24563";"DOPC";"CCM18";"25";"0";;;1.07;"in-house calculations";"COSMOperm";11.748975549395297
"Norfloxacin";"MM00768";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21";"OGJPXUAPXNRGGI-UHFFFAOYSA-N";319.34;1.27;"4539";"CHEMBL9";"DOPC";"CCM18";"25";"0";;;-4.92;"in-house calculations";"COSMOperm";0.000012022644346174132
"Nortriptyline";"MM00280";"CNCCC=C1c2ccccc2CCc2ccccc21";"PHVGLTMQBUFIQQ-UHFFFAOYSA-N";263.38;3.83;"4543";"CHEMBL445";"DOPC";"CCM18";"25";"0";;;-0.59;"in-house calculations";"COSMOperm";0.2570395782768864
"2-methylphenol";"MM01283";"Cc1ccccc1O";"QWVGKYWNOKOFNN-UHFFFAOYSA-N";108.14;1.7;"335";;"DOPC";"CCM18";"25";"0";;;-0.85;"in-house calculations";"COSMOperm";0.14125375446227545
"O-Phenylenediamine";"MM00282";"Nc1ccccc1N";"GEYOCULIXLDCMW-UHFFFAOYSA-N";108.14;0.85;"7243";;"DOPC";"CCM18";"25";"0";;-0.144029;-2.05;"in-house calculations";"COSMOperm";0.008912509381337459
"O-toluidine";"MM00284";"Cc1ccccc1N";"RNVCVTLRINQCPJ-UHFFFAOYSA-N";107.16;1.58;"7242";;"DOPC";"CCM18";"25";"0";;;-1.01;"in-house calculations";"COSMOperm";0.09772372209558107
"O-Tolunitrile";"MM00285";"Cc1ccccc1C#N";"NWPNXBQSRGKSJB-UHFFFAOYSA-N";117.15;1.87;"10721";;"DOPC";"CCM18";"25";"0";;;-0.52;"in-house calculations";"COSMOperm";0.3019951720402016
"Octan-1-ol";"MM00895";"CCCCCCCCO";"KBPLFHHGFOOTCA-UHFFFAOYSA-N";130.23;2.34;"957";"CHEMBL26215";"DOPC";"CCM18";"25";"0";;;0.82;"in-house calculations";"COSMOperm";6.606934480075959
"Octyl 4-hydroxybenzoate";"MM00287";"CCCCCCCCOC(=O)c1ccc(O)cc1";"RIKCMEDSBFQFAL-UHFFFAOYSA-N";250.34;3.91;"14642";;"DOPC";"CCM18";"25";"0";;;0.86;"in-house calculations";"COSMOperm";7.244359600749901
"Ouabain";"MM00896";"CC1OC(OC2CC(O)C3(CO)C4C(O)CC5(C)C(C6=CC(=O)OC6)CCC5(O)C4CCC3(O)C2)C(O)C(O)C1O";"LPMXVESGRSUGHW-UHFFFAOYSA-N";584.66;-1.52;"439501";"CHEMBL222863";"DOPC";"CCM18";"25";"0";;-3.22862;-11.43;"in-house calculations";"COSMOperm";0.0000000000037153522909717275
"Oxazolone";"MM00897";"CCOC=C1N=C(c2ccccc2)OC1=O";"SJHPCNCNNSSLPL-UHFFFAOYSA-N";217.22;1.87;"1712094";;"DOPC";"CCM18";"25";"0";;;-0.81;"in-house calculations";"COSMOperm";0.1548816618912481
"Oxprenolol";"MM00289";"C=CCOc1ccccc1OCC(O)CNC(C)C";"CEMAWMOMDPGJMB-UHFFFAOYSA-N";265.35;1.99;"4631";"CHEMBL546";"DOPC";"CCM18";"25";"0";;;-1.31;"in-house calculations";"COSMOperm";0.04897788193684462
"Oxycodone";"MM00533";"COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314";"BRUQQQPBMZOVGD-XFKAJCMBSA-N";315.37;1.05;"5284603";"CHEMBL656";"DOPC";"CCM18";"25";"0";;1.7342;-1.38;"in-house calculations";"COSMOperm";0.04168693834703355
"Propanamide";"MM00413";"CCC(N)=O";"QLNJFJADRCOGBJ-UHFFFAOYSA-N";73.1;-0.12;"6578";"CHEMBL1235716";"DOPC";"CCM18";"25";"0";;-0.484378;-3.53;"in-house calculations";"COSMOperm";0.0002951209226666387
"Propoxyphene";"MM00552";"CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C";"XLMALTXPSGQGBX-GCJKJVERSA-N";339.48;4.28;"10100";"CHEMBL1213351";"DOPC";"CCM18";"25";"0";;;-1.5;"in-house calculations";"COSMOperm";0.03162277660168379
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"DOPC";"CCM18";"25";"0";;;-0.78;"in-house calculations";"COSMOperm";0.16595869074375605
"Propyl 4-hydroxybenzoate";"MM00299";"CCCOC(=O)c1ccc(O)cc1";"QELSKZZBTMNZEB-UHFFFAOYSA-N";180.2;1.96;"7175";;"DOPC";"CCM18";"25";"0";;2.2912;-0.47;"in-house calculations";"COSMOperm";0.33884415613920255
"6-propyl-2-sulfanylidene-1H-pyrimidin-4-one";"MM00415";"CCCc1cc(=O)[nH]c(=S)[nH]1";"KNAHARQHSZJURB-UHFFFAOYSA-N";170.24;1.38;"657298";"CHEMBL1518";"DOPC";"CCM18";"25";"0";;;-3.3;"in-house calculations";"COSMOperm";0.0005011872336272725
"Pumafentrine";"MM00554";"CCOc1cc2c(cc1OC)C(c1ccc(C(=O)N(C(C)C)C(C)C)cc1)=N[C@@H]1CCN(C)C[C@H]21";"CVDXFPBVOIERBH-JWQCQUIFSA-N";477.65;4.99;"3052763";;"DOPC";"CCM18";"25";"0";;6.67985;-1.78;"in-house calculations";"COSMOperm";0.016595869074375606
"Pyridoxine";"MM00555";"Cc1ncc(CO)c(CO)c1O";"LXNHXLLTXMVWPM-UHFFFAOYSA-N";169.18;0.08;"1054";"CHEMBL1364";"DOPC";"CCM18";"25";"0";;-0.227191;-6.42;"in-house calculations";"COSMOperm";0.00000038018939632056126
"5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine";"MM00556";"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1";"WKSAUQYGYAYLPV-UHFFFAOYSA-N";248.72;2.52;"4993";"CHEMBL36";"DOPC";"CCM18";"25";"0";;;-0.54;"in-house calculations";"COSMOperm";0.28840315031266056
"Benzene-1,2,3-triol";"MM00300";"Oc1cccc(O)c1O";"WQGWDDDVZFFDIG-UHFFFAOYSA-N";126.11;0.8;"1057";;"DOPC";"CCM18";"25";"0";;;-2.46;"in-house calculations";"COSMOperm";0.0034673685045253167
"Quercetin";"MM00047";"O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12";"REFJWTPEDVJJIY-UHFFFAOYSA-N";302.24;1.99;"5280343";"CHEMBL50";"DOPC";"CCM18";"25";"0";;;-1.84;"in-house calculations";"COSMOperm";0.014454397707459272
"2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol";"MM00557";"OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1";"URKOMYMAXPYINW-UHFFFAOYSA-N";383.52;2.86;"5002";"CHEMBL716";"DOPC";"CCM18";"25";"0";;;-0.94;"in-house calculations";"COSMOperm";0.1148153621496883
"Quinidine";"MM00558";"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-LHHVKLHASA-N";324.42;3.17;"441074";"CHEMBL1294";"DOPC";"CCM18";"25";"0";;3.5466;-1.15;"in-house calculations";"COSMOperm";0.0707945784384138
"Quinine";"MM00559";"C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-WZBLMQSHSA-N";324.42;3.17;"3034034";"CHEMBL170";"DOPC";"CCM18";"25";"0";;;-0.99;"in-house calculations";"COSMOperm";0.10232929922807542
"1,2,3,4,5-pentachloro-6-nitrobenzene";"MM00416";"O=[N+]([O-])c1c(Cl)c(Cl)c(Cl)c(Cl)c1Cl";"LKPLKUMXSAEKID-UHFFFAOYSA-N";295.34;4.86;"6720";;"DOPC";"CCM18";"25";"0";;;0.09;"in-house calculations";"COSMOperm";1.2302687708123816
"Raffinose";"MM00301";"OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO[C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O";"MUPFEKGTMRGPLJ-ZQSKZDJDSA-N";504.44;-7.57;"439242";;"DOPC";"CCM18";"25";"0";;-5.47713;-14.96;"in-house calculations";"COSMOperm";0.0000000000000010964781961431829
"Ranitidine";"MM01053";"CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1";"VMXUWOKSQNHOCA-UHFFFAOYSA-N";314.41;1.46;"5039";;"DOPC";"CCM18";"25";"0";;;-1.14;"in-house calculations";"COSMOperm";0.07244359600749903
"Resorcinol";"MM00903";"Oc1cccc(O)c1";"GHMLBKRAJCXXBS-UHFFFAOYSA-N";110.11;1.1;"5054";"CHEMBL24147";"DOPC";"CCM18";"25";"0";;;-2.92;"in-house calculations";"COSMOperm";0.001202264434617413
"Resveratrol";"MM00418";"Oc1ccc(C=Cc2cc(O)cc(O)c2)cc1";"LUKBXSAWLPMMSZ-UHFFFAOYSA-N";228.25;2.97;"445154";"CHEMBL1237022";"DOPC";"CCM18";"25";"0";;;-2.23;"in-house calculations";"COSMOperm";0.00588843655355589
"1-(1-adamantyl)ethanamine";"MM00560";"CC(N)C12CC3CC(CC(C3)C1)C2";"UBCHPRBFMUDMNC-UHFFFAOYSA-N";179.31;2.55;"5071";"CHEMBL959";"DOPC";"CCM18";"25";"0";;;0.25;"in-house calculations";"COSMOperm";1.7782794100389228
"Risperidone";"MM00561";"Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2";"RAPZEAPATHNIPO-UHFFFAOYSA-N";410.49;3.59;"5073";"CHEMBL85";"DOPC";"CCM18";"25";"0";;;-1.14;"in-house calculations";"COSMOperm";0.07244359600749903
"N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine";"MM00562";"CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12";"ULFRLSNUDGIQQP-UHFFFAOYSA-N";269.35;1.91;"5078";"CHEMBL905";"DOPC";"CCM18";"25";"0";;;-1.13;"in-house calculations";"COSMOperm";0.07413102413009177
"2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one";"MM00576";"O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12";"PHLBKPHSAVXXEF-UHFFFAOYSA-N";371.87;2.36;"5533";"CHEMBL621";"DOPC";"CCM18";"25";"0";;;-1.12;"in-house calculations";"COSMOperm";0.07585775750291836
"Triamcinolone";"MM00307";"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO";"GFNANZIMVAIWHM-OBYCQNJPSA-N";394.44;0.62;"31307";"CHEMBL1451";"DOPC";"CCM18";"25";"0";;-0.0838858;-4.04;"in-house calculations";"COSMOperm";0.00009120108393559096
"6-phenylpteridine-2,4,7-triamine";"MM00577";"Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1";"FNYLWPVRPXGIIP-UHFFFAOYSA-N";253.27;0.83;"5546";"CHEMBL585";"DOPC";"CCM18";"25";"0";;;-4.36;"in-house calculations";"COSMOperm";0.000043651583224016566
"Chloroform";"MM00912";"ClC(Cl)Cl";"HEDRZPFGACZZDS-UHFFFAOYSA-N";119.38;1.99;"6212";;"DOPC";"CCM18";"25";"0";;;-0.14;"in-house calculations";"COSMOperm";0.72443596007499
"Triclosan";"MM00310";"Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl";"XEFQLINVKFYRCS-UHFFFAOYSA-N";289.55;5.14;"5564";"CHEMBL849";"DOPC";"CCM18";"25";"0";;;0.03;"in-house calculations";"COSMOperm";1.0715193052376064
"10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine";"MM00578";"CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1";"ZEWQUBUPAILYHI-UHFFFAOYSA-N";407.51;4.95;"5566";"CHEMBL422";"DOPC";"CCM18";"25";"0";;;-1.35;"in-house calculations";"COSMOperm";0.0446683592150963
"1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol";"MM00580";"OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1";"HWHLPVGTWGOCJO-UHFFFAOYSA-N";301.47;4.33;"5572";"CHEMBL1490";"DOPC";"CCM18";"25";"0";;;-0.81;"in-house calculations";"COSMOperm";0.1548816618912481
"Trimethoprim";"MM00581";"COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC";"IEDVJHCEMCRBQM-UHFFFAOYSA-N";290.32;1.26;"5578";"CHEMBL22";"DOPC";"CCM18";"25";"0";;;-2.46;"in-house calculations";"COSMOperm";0.0034673685045253167
"Trimipramine";"MM00254";"CC(CN(C)C)CN1c2ccccc2CCc2ccccc21";"ZSCDBOWYZJWBIY-UHFFFAOYSA-N";294.44;4.12;"5584";"CHEMBL644";"DOPC";"CCM18";"25";"0";;;-1.04;"in-house calculations";"COSMOperm";0.09120108393559097
"2,5,9-trimethylfuro[3,2-g]chromen-7-one";"MM00429";"Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1";"FMHHVULEAZTJMA-UHFFFAOYSA-N";228.25;3.46;"5585";"CHEMBL1475";"DOPC";"CCM18";"25";"0";;;-0.18;"in-house calculations";"COSMOperm";0.660693448007596
"Trovafloxacin";"MM00774";"NC1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12";"WVPSKSLAZQPAKQ-SOSAQKQKSA-N";416.36;1.89;"62959";"CHEMBL428";"DOPC";"CCM18";"25";"0";;;-1.3;"in-house calculations";"COSMOperm";0.05011872336272722
"Tryptamine";"MM00582";"NCCc1c[nH]c2ccccc12";"APJYDQYYACXCRM-UHFFFAOYSA-N";160.22;1.67;"1150";"CHEMBL6640";"DOPC";"CCM18";"25";"0";;;-0.97;"in-house calculations";"COSMOperm";0.10715193052376065
"N-methyl-2-phenyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide";"MM00583";"CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1";"PGZRDDYTKFZSFR-ONTIZHBOSA-N";356.51;3.25;"105104";;"DOPC";"CCM18";"25";"0";;;-1.93;"in-house calculations";"COSMOperm";0.011748975549395297
"Urea";"MM00065";"NC(N)=O";"XSQUKJJJFZCRTK-UHFFFAOYSA-N";60.06;-0.98;"1176";"CHEMBL985";"DOPC";"CCM18";"25";"0";;-0.403734;-5.39;"in-house calculations";"COSMOperm";0.000004073802778041131
"4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide";"MM00430";"Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1";"LNPDTQAFDNKSHK-UHFFFAOYSA-N";314.37;2.96;"119607";"CHEMBL865";"DOPC";"CCM18";"25";"0";;;-0.97;"in-house calculations";"COSMOperm";0.10715193052376065
"Valsartan";"MM00311";"CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)C(C(=O)O)C(C)C";"ACWBQPMHZXGDFX-UHFFFAOYSA-N";435.53;4.16;"60846";"CHEMBL1069";"DOPC";"CCM18";"25";"0";;;-1.21;"in-house calculations";"COSMOperm";0.06165950018614822
"4-hydroxy-3-methoxybenzaldehyde";"MM00913";"COc1cc(C=O)ccc1O";"MWOOGOJBHIARFG-UHFFFAOYSA-N";152.15;1.21;"1183";;"DOPC";"CCM18";"25";"0";;;-1.22;"in-house calculations";"COSMOperm";0.06025595860743578
"1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol";"MM00584";"COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1";"PNVNVHUZROJLTJ-UHFFFAOYSA-N";277.41;3.04;"5656";"CHEMBL637";"DOPC";"CCM18";"25";"0";;;-1.19;"in-house calculations";"COSMOperm";0.06456542290346556
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"DOPC";"CCM18";"25";"0";;;-1.65;"in-house calculations";"COSMOperm";0.0223872113856834
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"DOPC";"CCM18";"25";"0";;;-0.69;"in-house calculations";"COSMOperm";0.20417379446695297
"Water";"MM00431";"O";"XLYOFNOQVPJJNP-UHFFFAOYSA-N";18.02;-0.82;"962";"CHEMBL1098659";"DOPC";"CCM18";"25";"0";;-1.84384;-4.61;"in-house calculations";"COSMOperm";0.000024547089156850286
"Zaleplon";"MM00434";"CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1";"HUNXMJYCHXQEGX-UHFFFAOYSA-N";305.34;2.64;"5719";"CHEMBL1521";"DOPC";"CCM18";"25";"0";;;-1.58;"in-house calculations";"COSMOperm";0.026302679918953815
"Zearalenone";"MM00312";"C[C@H]1CCCC(=O)CCC/C=C/c2cc(O)cc(O)c2C(=O)O1";"MBMQEIFVQACCCH-QBODLPLBSA-N";318.37;3.58;"5281576";;"DOPC";"CCM18";"25";"0";;;-1.05;"in-house calculations";"COSMOperm";0.08912509381337455
"Zidovudine";"MM00077";"Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O";"HBOMLICNUCNMMY-UHFFFAOYSA-N";267.25;-0.2;"35370";"CHEMBL129";"DOPC";"CCM18";"25";"0";;-0.0703064;-4.63;"in-house calculations";"COSMOperm";0.00002344228815319923
"(Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine";"MM00588";"CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1";"OYPPVKRFBIWMSX-SXGWCWSVSA-N";317.23;3.84;"5365247";"CHEMBL37744";"DOPC";"CCM18";"25";"0";;;-1.11;"in-house calculations";"COSMOperm";0.07762471166286916
"5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one";"MM00589";"O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1";"MVWVFYHBGMAFLY-UHFFFAOYSA-N";412.95;3.81;"60854";"CHEMBL708";"DOPC";"CCM18";"25";"0";;;-0.62;"in-house calculations";"COSMOperm";0.23988329190194904
"(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one";"MM00590";"CN(C)CCc1c[nH]c2ccc(CC3COC(=O)N3)cc12";"ULSDMUVEXKOYBU-UHFFFAOYSA-N";287.36;1.92;"60857";"CHEMBL1185";"DOPC";"CCM18";"25";"0";;;-0.98;"in-house calculations";"COSMOperm";0.10471285480508996
"N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide";"MM00591";"Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1";"ZAFYATHCZYHLPB-UHFFFAOYSA-N";307.4;3.25;"5732";"CHEMBL911";"DOPC";"CCM18";"25";"0";;;-1.03;"in-house calculations";"COSMOperm";0.0933254300796991
"2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetic acid";"MM00713";"Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1";"ZXVNMYWKKDOREA-UHFFFAOYSA-N";291.73;2.85;"5733";"CHEMBL19490";"DOPC";"CCM18";"25";"0";;3.1335;-0.39;"in-house calculations";"COSMOperm";0.40738027780411273
"1,4-Butanediol";"MM00314";"OCCCCO";"WERYXYBDKMZEQL-UHFFFAOYSA-N";90.12;-0.25;"8064";"CHEMBL171623";"DOPC";"CCM18";"25";"0";;-1.08;-3.79;"in-house calculations";"COSMOperm";0.00016218100973589298
"1,6-Hexanediol";"MM00009";"C[C@@H](O)CC[C@@H](C)O";"OHMBHFSEKCCCBW-PHDIDXHHSA-N";118.18;0.53;"43078";"CHEMBL458616";"DOPC";"CCM18";"25";"0";;0.08;-2.46;"in-house calculations";"COSMOperm";0.0034673685045253167
"1-Naphthoic Acid";"MM00592";"O=C(O)c1cccc2ccccc12";"LNETULKMXZVUST-UHFFFAOYSA-N";172.18;2.54;"6847";;"DOPC";"CCM18";"25";"0";;2.22;-0.19;"in-house calculations";"COSMOperm";0.6456542290346555
"2,4-Dihydroxybenzoic Acid";"MM00595";"O=C(O)c1ccc(O)cc1O";"UIAFKZKHHVMJGS-UHFFFAOYSA-N";154.12;0.8;"1491";"CHEMBL328910";"DOPC";"CCM18";"25";"0";;0.82;-2.57;"in-house calculations";"COSMOperm";0.0026915348039269166
"2-Deoxyadenosine";"MM00320";"Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1";"OLXZPDWKRNYJJZ-RRKCRQDMSA-N";251.25;-0.95;"13730";;"DOPC";"CCM18";"25";"0";;-5.47;-6.26;"in-house calculations";"COSMOperm";0.0000005495408738576248
"2-Hydroxybutyric Acid";"MM00597";"CC[C@H](O)C(=O)O";"AFENDNXGAFYKQO-VKHMYHEASA-N";104.11;-0.16;"11266";;"DOPC";"CCM18";"25";"0";;-0.07;-3.29;"in-house calculations";"COSMOperm";0.0005128613839913648
"2-Hydroxycaproic Acid";"MM00598";"CCCC[C@H](O)C(=O)O";"NYHNVHGFPZAZGA-YFKPBYRVSA-N";132.16;0.62;"99824";;"DOPC";"CCM18";"25";"0";;0.72;-2.15;"in-house calculations";"COSMOperm";0.00707945784384138
"2-Hydroxyvaleric Acid";"MM00600";"CCC[C@H](O)C(=O)O";"JRHWHSJDIILJAT-BYPYZUCNSA-N";118.13;0.23;"98009";;"DOPC";"CCM18";"25";"0";;0.47;-2.39;"in-house calculations";"COSMOperm";0.004073802778041126
"2-Naphthoic Acid";"MM00601";"O=C(O)c1ccc2ccccc2c1";"UOBYKYZJUGYBDK-UHFFFAOYSA-N";172.18;2.54;"7123";"114648";"DOPC";"CCM18";"25";"0";;2.62;0.16;"in-house calculations";"COSMOperm";1.4454397707459274
"4-carboxymethylphenyl Acetyl_NHMe";"MM01305";"CNC(=O)Cc1ccc(C(=O)O)cc1";"YPRZYKHZGFQSPK-UHFFFAOYSA-N";193.2;0.67;;;"DOPC";"CCM18";"25";"0";;0.44;-2.96;"in-house calculations";"COSMOperm";0.0010964781961431851
"4-carboxymethylphenyl Acetyl-Gly-NMe2";"MM01304";"CN(C)C(=O)CNC(=O)Cc1ccc(C(=O)O)cc1";"GDAMBRWKLGWCQC-UHFFFAOYSA-N";264.28;0.13;;;"DOPC";"CCM18";"25";"0";;0.45;-3.09;"in-house calculations";"COSMOperm";0.0008128305161640995
"4-carboxymethylphenyl Acetyl-NMe2";"MM01306";"CN(C)C(=O)Cc1ccc(C(=O)O)cc1";"LJTQUFHONBMKSS-UHFFFAOYSA-N";207.23;1.02;;;"DOPC";"CCM18";"25";"0";;0.96;-2.78;"in-house calculations";"COSMOperm";0.0016595869074375613
"4-Hydroxybenzoic Acid";"MM00609";"O=C(O)c1ccc(O)cc1";"FJKROLUGYXJWQN-UHFFFAOYSA-N";138.12;1.09;"135";"CHEMBL441343";"DOPC";"CCM18";"25";"0";;0.72;-2.91;"in-house calculations";"COSMOperm";0.0012302687708123812
"4-Methylbenzoic Acid";"MM00610";"Cc1ccc(C(=O)O)cc1";"LPNBBFKOUUSUDB-UHFFFAOYSA-N";136.15;1.69;"7470";;"DOPC";"CCM18";"25";"0";;1.71;-0.45;"in-house calculations";"COSMOperm";0.35481338923357547
"4-Methylphenylacetic Acid";"MM00611";"Cc1ccc(CC(=O)O)cc1";"GXXXUZIRGXYDFP-UHFFFAOYSA-N";150.18;1.62;"248474";;"DOPC";"CCM18";"25";"0";;1.61;-0.6;"in-house calculations";"COSMOperm";0.251188643150958
"9-Anthroic Acid";"MM00612";"O=C(O)c1c2ccccc2cc2ccccc12";"XGWFJBFNAQHLEF-UHFFFAOYSA-N";222.24;3.69;"2201";;"DOPC";"CCM18";"25";"0";;3.49;0.34;"in-house calculations";"COSMOperm";2.1877616239495525
"Acetamide";"MM00321";"CC(N)=O";"DLFVBJFMPXGRIB-UHFFFAOYSA-N";59.07;-0.51;"178";"CHEMBL16081";"DOPC";"CCM18";"25";"0";;-0.84;-4.35;"in-house calculations";"COSMOperm";0.00004466835921509635
"Acetic Acid";"MM00613";"CC(=O)O";"QTBSBXVTEAMEQO-UHFFFAOYSA-N";60.05;0.09;"176";"CHEMBL539";"DOPC";"CCM18";"25";"0";;-0.19;-2.35;"in-house calculations";"COSMOperm";0.0044668359215096305
"Adenine";"MM00324";"Nc1ncnc2nc[nH]c12";"GFFGJBXGBJISGV-UHFFFAOYSA-N";135.13;-0.06;"190";"CHEMBL226345";"DOPC";"CCM18";"25";"0";;-0.5;-6.01;"in-house calculations";"COSMOperm";0.000000977237220955811
"Alpha-Carbamoyl-methylhippuric Acid";"MM00615";"Cc1ccc(C(=O)NC(C(N)=O)C(=O)O)cc1";"XJHVEOWGYHOARJ-UHFFFAOYSA-N";236.23;-0.34;"54472514";;"DOPC";"CCM18";"25";"0";;-0.02;-7.51;"in-house calculations";"COSMOperm";0.00000003090295432513592
"Alpha-Carbamoyl-p-Toluic Acid";"MM01303";"NC(=O)Cc1ccc(C(=O)O)cc1";"YMKXCDDRWMQOBA-UHFFFAOYSA-N";179.18;0.41;"23273690";;"DOPC";"CCM18";"25";"0";;0.16;-4.34;"in-house calculations";"COSMOperm";0.000045708818961487516
"Alpha-Carboxy-p-methylhippuric Acid";"MM00617";"Cc1ccc(C(=O)NC(C(=O)O)C(=O)O)cc1";"UMFHYXBPSFCHSI-UHFFFAOYSA-N";237.21;0.26;"17851005";;"DOPC";"CCM18";"25";"0";;0.34;-6.57;"in-house calculations";"COSMOperm";0.0000002691534803926914
"Alpha-Carboxy-p-Toluic Acid";"MM00618";"O=C(O)Cc1ccc(C(=O)O)cc1";"DMEDOWYXHVUPMO-UHFFFAOYSA-N";180.16;1.01;"220005";;"DOPC";"CCM18";"25";"0";;0.61;-4.42;"in-house calculations";"COSMOperm";0.000038018939632056124
"Alpha-Cyano-p-methylhippuric Acid";"MM00621";"Cc1ccc(C(=O)NC(C#N)C(=O)O)cc1";"ALQYGLQIKVIMRP-UHFFFAOYSA-N";218.21;0.7;"129821670";;"DOPC";"CCM18";"25";"0";;0.29;-5.13;"in-house calculations";"COSMOperm";0.000007413102413009177
"Alpha-Cyano-p-Toluic Acid";"MM00622";"N#CCc1ccc(C(=O)O)cc1";"RSGBXCFAYHOKQZ-UHFFFAOYSA-N";161.16;1.45;"270871";;"DOPC";"CCM18";"25";"0";;0.84;-1.65;"in-house calculations";"COSMOperm";0.0223872113856834
"Alpha-Hydroxy-p-Toluic Acid";"MM00624";"O=C(O)c1ccc(CO)cc1";"WWYFPDXEIFBNKE-UHFFFAOYSA-N";152.15;0.88;"76360";;"DOPC";"CCM18";"25";"0";;0.2;-3.22;"in-house calculations";"COSMOperm";0.0006025595860743575
"Alpha-Chloro-p-methylhippuric Acid";"MM00619";"Cc1ccc(C(=O)NC(Cl)C(=O)O)cc1";"JYSJDCPCSAHBNY-UHFFFAOYSA-N";227.65;1.37;"129821671";;"DOPC";"CCM18";"25";"0";;1.26;-3.15;"in-house calculations";"COSMOperm";0.000707945784384138
"Alpha-Chloro-p-Toluic Acid";"MM00620";"O=C(O)c1ccc(CCl)cc1";"OITNBJHJJGMFBN-UHFFFAOYSA-N";170.6;2.12;"74234";;"DOPC";"CCM18";"25";"0";;1.69;-0.55;"in-house calculations";"COSMOperm";0.28183829312644537
"Ammonia";"MM00445";"N";"QGZKDVFQNNGYKY-UHFFFAOYSA-N";17.03;0.16;"222";;"DOPC";"CCM18";"25";"0";;-2.15;-2.78;"in-house calculations";"COSMOperm";0.0016595869074375613
"Benzoic Acid";"MM00630";"O=C(O)c1ccccc1";"WPYMKLBDIGXBTP-UHFFFAOYSA-N";122.12;1.38;"243";"CHEMBL541";"DOPC";"CCM18";"25";"0";;1.3;-0.77;"in-house calculations";"COSMOperm";0.16982436524617442
"Bromoacetic Acid";"MM00633";"O=C(O)CBr";"KDPAWGWELVVRCH-UHFFFAOYSA-N";138.95;0.47;"6227";"CHEMBL60851";"DOPC";"CCM18";"25";"0";;0.27;-2.38;"in-house calculations";"COSMOperm";0.004168693834703355
"Butyric Acid";"MM00634";"CCCC(=O)O";"FERIUCNNQQJTOY-UHFFFAOYSA-N";88.11;0.87;"264";"CHEMBL14227";"DOPC";"CCM18";"25";"0";;0.59;-1.41;"in-house calculations";"COSMOperm";0.03890451449942807
"Citric Acid";"MM00642";"O=C(O)CC(O)(CC(=O)O)C(=O)O";"KRKNYBCHXYNGOX-UHFFFAOYSA-N";192.12;-1.25;"311";"CHEMBL1261";"DOPC";"CCM18";"25";"0";;0.35;-4.38;"in-house calculations";"COSMOperm";0.00004168693834703355
"Codeine";"MM00470";"COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314";"OROGSEYTTFOCAN-DNJOTXNNSA-N";299.37;1.5;"5284371";"CHEMBL485";"DOPC";"CCM18";"25";"0";;2.08;-1.24;"in-house calculations";"COSMOperm";0.057543993733715694
"Capric Acid";"MM00635";"CCCCCCCCCC(=O)O";"GHVNFZFCNZKVNT-UHFFFAOYSA-N";172.27;3.21;"2969";"CHEMBL107498";"DOPC";"CCM18";"25";"0";;4.9;1.05;"in-house calculations";"COSMOperm";11.220184543019636
"D-Fructose";"MM00351";"OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O";"LKDRXBCSQODPBY-VRPWFDPXSA-N";180.16;-3.22;"2723872";;"DOPC";"CCM18";"25";"0";;-5.48;-6.74;"in-house calculations";"COSMOperm";0.00000018197008586099824
"D-Glucose";"MM00352";"OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O";"WQZGKKKJIJFFOK-GASJEMHNSA-N";180.16;-3.22;"5793";;"DOPC";"CCM18";"25";"0";;-4.58;-9.43;"in-house calculations";"COSMOperm";0.0000000003715352290971728
"Dipicolinic Acid";"MM00643";"O=C(O)c1cccc(C(=O)O)n1";"WJJMNDUMQPNECX-UHFFFAOYSA-N";167.12;0.48;"10367";;"DOPC";"CCM18";"25";"0";;0.47;-2.03;"in-house calculations";"COSMOperm";0.009332543007969915
"Meso-erythritol";"MM00068";"OC[C@H](O)[C@H](O)CO";"UNXHWFMMPAWVPI-ZXZARUISSA-N";122.12;-2.31;"222285";"CHEMBL349605";"DOPC";"CCM18";"25";"0";;-5.4;-5;"in-house calculations";"COSMOperm";0.00001
"Ethanolamine";"MM00490";"NCCO";"HZAXFHJVJLSVMW-UHFFFAOYSA-N";61.08;-1.06;"700";"CHEMBL104943";"DOPC";"CCM18";"25";"0";;-5.28;-4.42;"in-house calculations";"COSMOperm";0.000038018939632056124
"Ethanamine";"MM00491";"CCN";"QUSNBJAOOMFDIB-UHFFFAOYSA-N";45.09;-0.04;"6341";;"DOPC";"CCM18";"25";"0";;-0.01;-1.85;"in-house calculations";"COSMOperm";0.01412537544622754
"Ethylene glycol";"MM00360";"OCCO";"LYCAIKOWRPUZTN-UHFFFAOYSA-N";62.07;-1.03;"174";;"DOPC";"CCM18";"25";"0";;-5.27;-4.36;"in-house calculations";"COSMOperm";0.000043651583224016566
"Formamide";"MM00365";"NC=O";"ZHNUHDYFZUAESO-UHFFFAOYSA-N";45.04;-0.9;"713";;"DOPC";"CCM18";"25";"0";;-1;-4.39;"in-house calculations";"COSMOperm";0.0000407380277804113
"Formic Acid";"MM00649";"O=CO";"BDAGIHXWWSANSR-UHFFFAOYSA-N";46.03;-0.3;"284";"CHEMBL116736";"DOPC";"CCM18";"25";"0";;-0.25;-2.56;"in-house calculations";"COSMOperm";0.002754228703338166
"Glycerol";"MM00067";"OCC(O)CO";"PEDCQBHIVMGVHV-UHFFFAOYSA-N";92.09;-1.67;"753";"CHEMBL692";"DOPC";"CCM18";"25";"0";;-3.7;-5.15;"in-house calculations";"COSMOperm";0.000007079457843841373
"Caproic Acid";"MM00636";"CCCCCC(=O)O";"FUZZWVXGSFPDMH-UHFFFAOYSA-N";116.16;1.65;"8892";;"DOPC";"CCM18";"25";"0";;1.65;-0.51;"in-house calculations";"COSMOperm";0.30902954325135906
"Histamine";"MM00500";"NCCc1cnc[nH]1";"NTYJJOPFIAHURM-UHFFFAOYSA-N";111.15;-0.09;"774";"CHEMBL90";"DOPC";"CCM18";"25";"0";;-0.34;-4.59;"in-house calculations";"COSMOperm";0.000025703957827688645
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"DOPC";"CCM18";"25";"0";;0.78;-2.51;"in-house calculations";"COSMOperm";0.003090295432513592
"Hydrofluoric Acid";"MM00655";"F";"KRHYYFGTRYWZRS-UHFFFAOYSA-N";20.01;0.15;"14917";"CHEMBL1232767";"DOPC";"CCM18";"25";"0";;0.34;-2.96;"in-house calculations";"COSMOperm";0.0010964781961431851
"Hydrochloric Acid";"MM00654";"Cl";"VEXZGXHMUGYJMC-UHFFFAOYSA-N";36.46;0.42;"313";;"DOPC";"CCM18";"25";"0";;0.53;-1.22;"in-house calculations";"COSMOperm";0.06025595860743578
"Chloroacetic Acid";"MM00032";"O=C(O)CCl";"FOCAUTSVDIKZOP-UHFFFAOYSA-N";94.5;0.31;"300";;"DOPC";"CCM18";"25";"0";;0.2;-2.47;"in-house calculations";"COSMOperm";0.003388441561392024
"Chlorpromazine";"MM00461";"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21";"ZPEIMTDSQAKGNT-UHFFFAOYSA-N";318.87;4.89;"2726";"CHEMBL71";"DOPC";"CCM18";"25";"0";;6.22;-0.99;"in-house calculations";"COSMOperm";0.10232929922807542
"Isobutyramide";"MM00378";"CC(C)C(N)=O";"WFKAJVHLWXSISD-UHFFFAOYSA-N";87.12;0.13;"68424";;"DOPC";"CCM18";"25";"0";;0.06;-2.77;"in-house calculations";"COSMOperm";0.0016982436524617442
"Isobutyric Acid";"MM00658";"CC(C)C(=O)O";"KQNPFQTWMSNSAP-UHFFFAOYSA-N";88.11;0.73;"6590";"CHEMBL108778";"DOPC";"CCM18";"25";"0";;0.62;-1.4;"in-house calculations";"COSMOperm";0.039810717055349734
"Isovaleric Acid";"MM00659";"CC(C)CC(=O)O";"GWYFCOCPABKNJV-UHFFFAOYSA-N";102.13;1.12;"10430";"CHEMBL568737";"DOPC";"CCM18";"25";"0";;1.1;-0.95;"in-house calculations";"COSMOperm";0.11220184543019636
"L-Lactic Acid";"MM00664";"CC(O)C(=O)O";"JVTAAEKCZFNVCJ-UHFFFAOYSA-N";90.08;-0.55;"107689";;"DOPC";"CCM18";"25";"0";;-0.28;-3.05;"in-house calculations";"COSMOperm";0.0008912509381337459
"Loperamide";"MM00509";"CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1";"RDOIQAHITMMDAJ-UHFFFAOYSA-N";477.05;5.09;"3955";"CHEMBL841";"DOPC";"CCM18";"25";"0";;6.29;-1.16;"in-house calculations";"COSMOperm";0.06918309709189366
"Malic Acid";"MM00666";"O=C(O)CC(O)C(=O)O";"BJEPYKJPYRNKOW-UHFFFAOYSA-N";134.09;-1.09;"525";"CHEMBL1455497";"DOPC";"CCM18";"25";"0";;-0.18;-4.62;"in-house calculations";"COSMOperm";0.0000239883291901949
"Methylamine";"MM00515";"CN";"BAVYZALUXZFZLV-UHFFFAOYSA-N";31.06;-0.43;"6329";"CHEMBL43280";"DOPC";"CCM18";"25";"0";;-0.58;-2.24;"in-house calculations";"COSMOperm";0.005754399373371567
"Nitric Acid";"MM00675";"O=[N+]([O-])O";"GRYLNZFGIOXLOG-UHFFFAOYSA-N";63.01;-0.35;"944";;"DOPC";"CCM18";"25";"0";;0.62;-1.46;"in-house calculations";"COSMOperm";0.034673685045253165
"Octanoic Acid";"MM00676";"CCCCCCCC(=O)O";"WWZKQHOCKIZLMA-UHFFFAOYSA-N";144.21;2.43;"379";"CHEMBL324846";"DOPC";"CCM18";"25";"0";;3.1;0.44;"in-house calculations";"COSMOperm";2.7542287033381663
"Pentanamide";"MM00403";"CCCCC(N)=O";"IPWFJLQDVFKJDU-UHFFFAOYSA-N";101.15;0.66;"12298";;"DOPC";"CCM18";"25";"0";;0.51;-2.29;"in-house calculations";"COSMOperm";0.005128613839913648
"Phenylacetic Acid";"MM00679";"O=C(O)Cc1ccccc1";"WLJVXDMOQOGPHL-UHFFFAOYSA-N";136.15;1.31;"999";"CHEMBL1044";"DOPC";"CCM18";"25";"0";;0.99;-1.69;"in-house calculations";"COSMOperm";0.020417379446695295
"Phloretin";"MM00681";"O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O";"VGEREEWJJVICBM-UHFFFAOYSA-N";274.27;2.32;"4788";"CHEMBL45068";"DOPC";"CCM18";"25";"0";;1.68;-2.82;"in-house calculations";"COSMOperm";0.0015135612484362087
"Pivalic Acid";"MM00683";"CC(C)(C)C(=O)O";"IUGYQRQAERSCNH-UHFFFAOYSA-N";102.13;1.12;"6417";;"DOPC";"CCM18";"25";"0";;1.13;-0.95;"in-house calculations";"COSMOperm";0.11220184543019636
"Prednisolone";"MM00297";"CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"OIGNJSKKLXVSLS-UHFFFAOYSA-N";360.45;1.56;"5755";"CHEMBL131";"DOPC";"CCM18";"25";"0";;1;-2.65;"in-house calculations";"COSMOperm";0.00223872113856834
"1-Propanol";"MM00061";"CCCO";"BDERNNFJNOPAEC-UHFFFAOYSA-N";60.1;0.39;"1031";"CHEMBL14687";"DOPC";"CCM18";"25";"0";;0.23;-1.64;"in-house calculations";"COSMOperm";0.022908676527677734
"Propanamide";"MM00413";"CCC(N)=O";"QLNJFJADRCOGBJ-UHFFFAOYSA-N";73.1;-0.12;"6578";"CHEMBL1235716";"DOPC";"CCM18";"25";"0";;-0.4;-3.53;"in-house calculations";"COSMOperm";0.0002951209226666387
"Propionic Acid";"MM00685";"CCC(=O)O";"XBDQKXXYIPTUBI-UHFFFAOYSA-N";74.08;0.48;"1032";"CHEMBL14021";"DOPC";"CCM18";"25";"0";;0.09;-1.95;"in-house calculations";"COSMOperm";0.011220184543019636
"Propylene Glycol";"MM00414";"CC(O)CO";"DNIAPMSPPWPWGF-UHFFFAOYSA-N";76.1;-0.64;"1030";"CHEMBL286398";"DOPC";"CCM18";"25";"0";;-2.08;-4;"in-house calculations";"COSMOperm";0.0001
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"DOPC";"CCM18";"25";"0";;1.31;-0.72;"in-house calculations";"COSMOperm";0.19054607179632474
"Sebacic Acid";"MM00689";"O=C(O)CCCCCCCCC(=O)O";"CXMXRPHRNRROMY-UHFFFAOYSA-N";202.25;2.28;"5192";"CHEMBL1232164";"DOPC";"CCM18";"25";"0";;1.78;-0.93;"in-house calculations";"COSMOperm";0.11748975549395294
"Sucrose";"MM00421";"OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O";"CZMRCDWAGMRECN-UGDNZRGBSA-N";342.3;-5.4;"5988";"CHEMBL253582";"DOPC";"CCM18";"25";"0";;-5.48;-13.16;"in-house calculations";"COSMOperm";0.00000000000006918309709189363
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"DOPC";"CCM18";"25";"0";;-0.71;-3.96;"in-house calculations";"COSMOperm";0.00010964781961431851
"Thiocyanic Acid";"MM00692";"N#CS";"ZMZDMBWJUHKJPS-UHFFFAOYSA-N";59.09;0.4;"781";;"DOPC";"CCM18";"25";"0";;0.17;-1.61;"in-house calculations";"COSMOperm";0.024547089156850298
"Tiglic Acid";"MM00694";"C/C=C(\C)C(=O)O";"UIERETOOQGIECD-ONEGZZNKSA-N";100.12;1.04;"125468";;"DOPC";"CCM18";"25";"0";;0.88;-1.21;"in-house calculations";"COSMOperm";0.06165950018614822
"Tol-Ala";"MM00695";"Cc1ccc(C(=O)N[C@@H](C)C(=O)O)cc1";"LUQFCOKRPYVJGV-QMMMGPOBSA-N";207.23;1.2;"702949";;"DOPC";"CCM18";"25";"0";;1.64;-0.91;"in-house calculations";"COSMOperm";0.12302687708123815
"Tol-Ala-Ala";"MM00696";"Cc1ccc(C(=O)N[C@@H](C)C(=O)NC(C)C(=O)O)cc1";"FBAZKLTYPHRTPD-RGURZIINSA-N";278.31;0.7;;;"DOPC";"CCM18";"25";"0";;1.71;-2.83;"in-house calculations";"COSMOperm";0.0014791083881682072
"Tol-Ala-Ala-Ala";"MM00697";"Cc1ccc(C(=O)N[C@@H](C)C(=O)NC(C)C(=O)NC(C)C(=O)O)cc1";"AWXUDMFMJWEFLI-CXQJBGSLSA-N";349.39;0.21;;;"DOPC";"CCM18";"25";"0";;1.3;-5.85;"in-house calculations";"COSMOperm";0.0000014125375446227554
"Tol-Gly";"MM00698";"Cc1ccc(C(=O)NCC(=O)O)cc1";"NRSCPTLHWVWLLH-UHFFFAOYSA-N";193.2;0.81;"97479";;"DOPC";"CCM18";"25";"0";;1.1;-3.79;"in-house calculations";"COSMOperm";0.00016218100973589298
"Tol-Gly-Gly";"MM00699";"Cc1ccc(C(=O)NCC(=O)NCC(=O)O)cc1";"GFMIXHRADKOCKD-UHFFFAOYSA-N";250.25;-0.07;"1612474";;"DOPC";"CCM18";"25";"0";;0.82;-6.28;"in-house calculations";"COSMOperm";0.0000005248074602497723
"Tol-Gly-Gly-Gly";"MM00700";"Cc1ccc(C(=O)NCC(=O)NCC(=O)NCC(=O)O)cc1";"OQIOHQJDADAQRO-UHFFFAOYSA-N";307.31;-0.96;;;"DOPC";"CCM18";"25";"0";;1.04;-8.69;"in-house calculations";"COSMOperm";0.0000000020417379446695317
"Tol-Gly-Gly-Sar";"MM00701";"Cc1ccc(C(=O)NCC(=O)NCC(=O)N(C)CC(=O)O)cc1";"GPOXNQMQXBXEJG-UHFFFAOYSA-N";321.33;-0.62;;;"DOPC";"CCM18";"25";"0";;0.36;-8.84;"in-house calculations";"COSMOperm";0.000000001445439770745928
"Tol-Gly-Sar";"MM00702";"Cc1ccc(C(=O)NCC(=O)N(C)CC(=O)O)cc1";"LKGQGAPFEYAOCE-UHFFFAOYSA-N";264.28;0.27;"43356167";;"DOPC";"CCM18";"25";"0";;1.3;-3.2;"in-house calculations";"COSMOperm";0.000630957344480193
"Tol-Gly-Sar-Gly";"MM00703";"Cc1ccc(C(=O)NCC(=O)N(C)CC(=O)NCC(=O)O)cc1";"VDLFQRLCHVTMPD-UHFFFAOYSA-N";321.33;-0.62;;;"DOPC";"CCM18";"25";"0";;0.37;-8.07;"in-house calculations";"COSMOperm";0.000000008511380382023759
"Tol-Sar";"MM00704";"Cc1ccc(C(=O)N(C)CC(=O)O)cc1";"WKEPQHRTXMIHLM-UHFFFAOYSA-N";207.23;1.15;"16777360";;"DOPC";"CCM18";"25";"0";;1.28;-3.25;"in-house calculations";"COSMOperm";0.0005623413251903491
"Tol-Sar-Gly";"MM00705";"Cc1ccc(C(=O)N(C)CC(=O)NCC(=O)O)cc1";"JDZZMSKJRWYDMH-UHFFFAOYSA-N";264.28;0.27;;;"DOPC";"CCM18";"25";"0";;1.31;-3.95;"in-house calculations";"COSMOperm";0.0001122018454301963
"Tol-Sar-Gly-Gly";"MM00706";"Cc1ccc(C(=O)N(C)CC(=O)NCC(=O)NCC(=O)O)cc1";"GQINUZIFINBVAM-UHFFFAOYSA-N";321.33;-0.62;;;"DOPC";"CCM18";"25";"0";;0.75;-6.92;"in-house calculations";"COSMOperm";0.00000012022644346174132
"Tol-Sar-Sar-Gly";"MM00707";"Cc1ccc(C(=O)N(C)CC(=O)N(C)CC(=O)NCC(=O)O)cc1";"GQJNIDFZAHXWIX-UHFFFAOYSA-N";335.36;-0.27;;;"DOPC";"CCM18";"25";"0";;0.59;-7.28;"in-house calculations";"COSMOperm";0.00000005248074602497723
"L-Tryptophan";"MM00759";"N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O";"QIVBCDIJIAJPQS-VIFPVBQESA-N";204.23;1.12;"6305";"CHEMBL54976";"DOPC";"CCM18";"25";"0";;1.28;-1.15;"in-house calculations";"COSMOperm";0.0707945784384138
"Urea";"MM00065";"NC(N)=O";"XSQUKJJJFZCRTK-UHFFFAOYSA-N";60.06;-0.98;"1176";"CHEMBL985";"DOPC";"CCM18";"25";"0";;-0.47;-5.39;"in-house calculations";"COSMOperm";0.000004073802778041131
"Valeric Acid";"MM00710";"CCCCC(=O)O";"NQPDZGIKBAWPEJ-UHFFFAOYSA-N";102.13;1.26;"7991";"CHEMBL268736";"DOPC";"CCM18";"25";"0";;1.13;-0.92;"in-house calculations";"COSMOperm";0.12022644346174129
"Vanillic Acid";"MM00712";"COc1cc(C(=O)O)ccc1O";"WKOLLVMJNQIZCI-UHFFFAOYSA-N";168.15;1.1;"8468";"CHEMBL120568";"DOPC";"CCM18";"25";"0";;0.87;-1.55;"in-house calculations";"COSMOperm";0.028183829312644536
"Water";"MM00431";"O";"XLYOFNOQVPJJNP-UHFFFAOYSA-N";18.02;-0.82;"962";"CHEMBL1098659";"DOPC";"CCM18";"25";"0";;-1.95;-4.61;"in-house calculations";"COSMOperm";0.000024547089156850286
"12-Hydroxydodecanoic Acid";"MM00593";"O=C(O)CCCCCCCCCCCO";"ZDHCZVWCTKTBRY-UHFFFAOYSA-N";216.32;2.96;"79034";"CHEMBL55068";"DOPC";"CCM18";"25";"0";;;-0.58;"in-house calculations";"COSMOperm";0.2630267991895382
"2-Hydroxynicotinic Acid";"MM00599";"O=C(O)c1ccc[nH]c1=O";"UEYQJQVBUVAELZ-UHFFFAOYSA-N";139.11;0.07;"69114";;"DOPC";"CCM18";"25";"0";;;-7.27;"in-house calculations";"COSMOperm";0.000000053703179637025324
"3,4-Dihydroxyphenylacetic Acid";"MM00602";"O=C(O)Cc1ccc(O)c(O)c1";"CFFZDZCDUFSOFZ-UHFFFAOYSA-N";168.15;0.72;"547";"CHEMBL1284";"DOPC";"CCM18";"25";"0";;;-3.82;"in-house calculations";"COSMOperm";0.00015135612484362088
"3,5-Dichlorobenzoic Acid";"MM00603";"O=C(O)c1cc(Cl)cc(Cl)c1";"CXKCZFDUOYMOOP-UHFFFAOYSA-N";191.01;2.69;"5811";;"DOPC";"CCM18";"25";"0";;;0.2;"in-house calculations";"COSMOperm";1.5848931924611136
"3-Hydroxyphenylacetic Acid";"MM00604";"O=C(O)Cc1cccc(O)c1";"FVMDYYGIDFPZAX-UHFFFAOYSA-N";152.15;1.02;"12122";"190035";"DOPC";"CCM18";"25";"0";;;-4.03;"in-house calculations";"COSMOperm";0.00009332543007969905
"3-Phenylpropionic Acid";"MM00605";"O=C(O)CCc1ccccc1";"XMIIGOLPHOKFCH-UHFFFAOYSA-N";150.18;1.7;"107";"CHEMBL851";"DOPC";"CCM18";"25";"0";;;-0.47;"in-house calculations";"COSMOperm";0.33884415613920255
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"DOPC";"CCM18";"25";"0";;;-1.21;"in-house calculations";"COSMOperm";0.06165950018614822
"2-Aminobenzoic Acid";"MM00596";"Nc1ccccc1C(=O)O";"RWZYAGGXGHYGMB-UHFFFAOYSA-N";137.14;0.97;"227";"CHEMBL14173";"DOPC";"CCM18";"25";"0";;;-1.33;"in-house calculations";"COSMOperm";0.046773514128719815
"Ascorbic Acid";"MM00628";"O=C1O[C@H]([C@@H](O)CO)C(O)=C1O";"CIWBSHSKHKDKBQ-JLAZNSOCSA-N";176.12;-1.41;"54670067";"CHEMBL196";"DOPC";"CCM18";"25";"0";;;-7.44;"in-house calculations";"COSMOperm";0.0000000363078054770101
"L-Aspartic Acid";"MM00745";"N[C@@H](CC(=O)O)C(=O)O";"CKLJMWTZIZZHCS-REOHCLBHSA-N";133.1;-1.13;"5960";"CHEMBL274323";"DOPC";"CCM18";"25";"0";;;-5.47;"in-house calculations";"COSMOperm";0.0000033884415613920275
"Flufenamic Acid";"MM00645";"O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1";"LPEPZBJOKDYZAD-UHFFFAOYSA-N";281.23;4.15;"3371";"CHEMBL23588";"DOPC";"CCM18";"25";"0";;;0.37;"in-house calculations";"COSMOperm";2.344228815319922
"L-Glutamic Acid";"MM00747";"NC(CCC(=O)O)C(=O)O";"WHUUTDBJXJRKMK-UHFFFAOYSA-N";147.13;-0.74;"33032";"CHEMBL575060";"DOPC";"CCM18";"25";"0";;;-4.57;"in-house calculations";"COSMOperm";0.00002691534803926914
"Iodoacetic Acid";"MM00657";"O=C(O)CI";"JDNTWHVOXJZDSN-UHFFFAOYSA-N";185.95;0.51;"5240";;"DOPC";"CCM18";"25";"0";;;-2.42;"in-house calculations";"COSMOperm";0.0038018939632056127
"Lactic Acid";"MM01543";"CC(O)C(=O)O";"JVTAAEKCZFNVCJ-UHFFFAOYSA-N";90.08;-0.55;"612";;"DOPC";"CCM18";"25";"0";;;-3.05;"in-house calculations";"COSMOperm";0.0008912509381337459
"Rosmarinic Acid";"MM00687";"O=C(/C=C/c1ccc(O)c(O)c1)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O";"DOUMFZQKYFQNTF-WUTVXBCWSA-N";360.32;1.76;"5281792";;"DOPC";"CCM18";"25";"0";;;-3.42;"in-house calculations";"COSMOperm";0.00038018939632056124
"11-Dehydrocorticosterone";"MM00315";"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO";"FUFLCEKSBBHCMO-KJQYFISQSA-N";344.45;2.87;"5311364";;"DOPC";"CCM18";"25";"0";;;-2.33;"in-house calculations";"COSMOperm";0.004677351412871981
"Cortexolone";"MM00036";"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO";"WHBHBVVOGNECLV-OBQKJFGGSA-N";346.47;2.81;"440707";;"DOPC";"CCM18";"25";"0";;;-2.12;"in-house calculations";"COSMOperm";0.007585775750291836
"4-Phenylbutylamine";"MM00096";"NCCCCc1ccccc1";"AGNFWIZBEATIAK-UHFFFAOYSA-N";149.24;1.97;"83242";"CHEMBL79512";"DOPC";"CCM18";"25";"0";;;-0.59;"in-house calculations";"COSMOperm";0.2570395782768864
"Acebutolol";"MM00437";"CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1";"GOEMGAFJFRBGGG-OAHLLOKOSA-N";336.43;2.37;"1978";"CHEMBL642";"DOPC";"CCM18";"25";"0";;;-1.24;"in-house calculations";"COSMOperm";0.057543993733715694
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"DOPC";"CCM18";"25";"0";;;-3.6;"in-house calculations";"COSMOperm";0.00025118864315095795
"Acrivastine";"MM00715";"Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1";"PWACSDKDOHSSQD-IUTFFREVSA-N";348.45;4.02;"5284514";"CHEMBL1224";"DOPC";"CCM18";"25";"0";;;-0.01;"in-house calculations";"COSMOperm";0.9772372209558107
"2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one";"MM476464";"Nc1nc2c(ncn2COCCO)c(=O)[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"135398513";;"DOPC";"CCM18";"25";"0";;;-10.75;"in-house calculations";"COSMOperm";0.000000000017782794100389227
"Adenosine";"MM00325";"Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"OIRDTQYFTABQOQ-KQYNXXCUSA-N";267.25;-1.98;"60961";"CHEMBL477";"DOPC";"CCM18";"25";"0";;;-7.46;"in-house calculations";"COSMOperm";0.000000034673685045253164
"L-Alanine";"MM00743";"C[C@H](N)C(=O)O";"QNAYBMKLOCPYGJ-REOHCLBHSA-N";89.09;-0.58;"5950";"CHEMBL279597";"DOPC";"CCM18";"25";"0";;;-2.57;"in-house calculations";"COSMOperm";0.0026915348039269166
"Methyl 5-(propylsulfinyl)-1h-benzimidazol-2-ylcarbamate";"MM00326";"CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1";"HXHWSAZORRCQMX-UHFFFAOYSA-N";265.34;3.24;"2082";"CHEMBL1483";"DOPC";"CCM18";"25";"0";;;-0.43;"in-house calculations";"COSMOperm";0.37153522909717257
"4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol";"MM00438";"CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1";"NDAUXUAQIAJITI-GFCCVEGCSA-N";239.32;1.31;"2083";"CHEMBL714";"DOPC";"CCM18";"25";"0";;;-1.18;"in-house calculations";"COSMOperm";0.06606934480075961
"Aldosterone";"MM00327";"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12";"PQSUYGKTWSAVDQ-ZVIOFETBSA-N";360.45;1.85;"5839";"CHEMBL273453";"DOPC";"CCM18";"25";"0";;;-2.56;"in-house calculations";"COSMOperm";0.002754228703338166
"Alfentanil";"MM00439";"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1";"IDBPHNDTYPBSNI-UHFFFAOYSA-N";416.53;1.38;"51263";"CHEMBL634";"DOPC";"CCM18";"25";"0";;;-2.26;"in-house calculations";"COSMOperm";0.005495408738576248
"Alfuzosin";"MM00328";"COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC";"WNMJYKCGWZFFKR-UHFFFAOYSA-N";389.46;1.35;"2092";"CHEMBL709";"DOPC";"CCM18";"25";"0";;;-1.76;"in-house calculations";"COSMOperm";0.017378008287493755
"Alprazolam";"MM00329";"C[C@@H]1NN[C@H]2CN[C@@H](c3ccccc3)c3cc(Cl)ccc3N12";"IYQBGWNRKQNSIE-LQAWEQHXSA-N";314.82;2.62;"2118";"CHEMBL661";"DOPC";"CCM18";"25";"0";;;-0.85;"in-house calculations";"COSMOperm";0.14125375446227545
"Alprenolol";"MM00440";"C=CCc1ccccc1OC[C@H](O)CNC(C)C";"PAZJSJFMUHDSTF-CQSZACIVSA-N";249.35;2.15;"2119";"CHEMBL266195";"DOPC";"CCM18";"25";"0";;;-0.89;"in-house calculations";"COSMOperm";0.1288249551693134
"Adamantan-1-amine";"MM00441";"N[C@]12C[C@H]3C[C@H](C[C@H](C3)C1)C2";"DKNWSYNQZKUICI-CHIWXEEVSA-N";151.25;1.91;"2130";"CHEMBL660";"DOPC";"CCM18";"25";"0";;;-0.14;"in-house calculations";"COSMOperm";0.72443596007499
"Amiloride";"MM00267";"N=C(N)NC(=O)c1nc(Cl)c(N)nc1N";"XSDQTOBWRPYKKA-UHFFFAOYSA-N";229.63;-1.08;"16231";"CHEMBL945";"DOPC";"CCM18";"25";"0";;;-7.01;"in-house calculations";"COSMOperm";0.00000009772372209558111
"3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione";"MM00330";"CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O";"ROBVIMPUHSLWNV-ZDUSSCGKSA-N";232.28;1.35;"2145";"CHEMBL488";"DOPC";"CCM18";"25";"0";;;-2.08;"in-house calculations";"COSMOperm";0.008317637711026709
"Aminoguanidine";"MM00442";"NN=C(N)N";"HAMNKKUPIHEESI-UHFFFAOYSA-N";74.09;-1.87;"2146";"CHEMBL225304";"DOPC";"CCM18";"25";"0";;;-7.12;"in-house calculations";"COSMOperm";0.00000007585775750291836
"4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one";"MM00331";"Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C";"RMMXTBMQSGEXHJ-UHFFFAOYSA-N";231.3;1.55;"6009";"CHEMBL288470";"DOPC";"CCM18";"25";"0";;;-0.82;"in-house calculations";"COSMOperm";0.15135612484362082
"Amitriptyline";"MM00444";"CN(C)CCC=C1c2ccccc2CCc2ccccc21";"KRMDCWKBEZIMAB-UHFFFAOYSA-N";277.41;4.17;"2160";"CHEMBL629";"DOPC";"CCM18";"25";"0";;;-0.88;"in-house calculations";"COSMOperm";0.1318256738556407
"Amlodipine";"MM00098";"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@H]1c1ccccc1Cl";"HTIQEAQVCYTUBX-QGZVFWFLSA-N";408.88;2.27;"2162";"CHEMBL1491";"DOPC";"CCM18";"25";"0";;;-1.98;"in-house calculations";"COSMOperm";0.010471285480508996
"4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol";"MM00446";"CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O";"OVCDSSHSILBFBN-UHFFFAOYSA-N";355.87;5.18;"2165";"CHEMBL682";"DOPC";"CCM18";"25";"0";;;-0.35;"in-house calculations";"COSMOperm";0.44668359215096315
"8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine";"MM00447";"Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2";"QWGDMFLQWFTERH-UHFFFAOYSA-N";313.79;3.43;"2170";"CHEMBL1113";"DOPC";"CCM18";"25";"0";;;-0.94;"in-house calculations";"COSMOperm";0.1148153621496883
"Amoxicillin";"MM00716";"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O";"LSQZJLSUYDQPKJ-NJBDSQKTSA-N";365.41;0.02;"33613";"CHEMBL1082";"DOPC";"CCM18";"25";"0";;;-6.1;"in-house calculations";"COSMOperm";0.0000007943282347242822
"Ampicillin";"MM00627";"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O";"AVKUERGKIZMTKX-NJBDSQKTSA-N";349.41;0.32;"6249";"CHEMBL174";"DOPC";"CCM18";"25";"0";;;-2.7;"in-house calculations";"COSMOperm";0.001995262314968879
"Amprenavir";"MM00332";"CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1";"YMARZQAQMVYCKC-OEMFJLHTSA-N";505.64;2.4;"65016";"CHEMBL116";"DOPC";"CCM18";"25";"0";;;-1.3;"in-house calculations";"COSMOperm";0.05011872336272722
"Aniline";"MM00039";"Nc1ccccc1";"PAYRUJLWNCNPSJ-UHFFFAOYSA-N";93.13;1.27;"6115";"CHEMBL538";"DOPC";"CCM18";"25";"0";;;-1.13;"in-house calculations";"COSMOperm";0.07413102413009177
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"DOPC";"CCM18";"25";"0";;;-1.16;"in-house calculations";"COSMOperm";0.06918309709189366
"(3R,4S,5S)-oxane-2,3,4,5-tetrol";"MM00334";"OC1OC[C@H](O)[C@H](O)[C@H]1O";"SRBFZHDQGSBBOR-HWQSCIPKSA-N";150.13;-2.58;"439195";;"DOPC";"CCM18";"25";"0";;;-7.17;"in-house calculations";"COSMOperm";0.00000006760829753919818
"L-Arginine";"MM00744";"NC(N)=NCCC[C@H](N)C(=O)O";"ODKSFYDXXFIFQN-BYPYZUCNSA-N";174.2;-1.55;"6322";"CHEMBL1485";"DOPC";"CCM18";"25";"0";;;-7.26;"in-house calculations";"COSMOperm";0.00000005495408738576248
"Astemizole";"MM00448";"COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1";"GXDALQBWZGODGZ-UHFFFAOYSA-N";458.58;5.35;"2247";"CHEMBL296419";"DOPC";"CCM18";"25";"0";;;-1.05;"in-house calculations";"COSMOperm";0.08912509381337455
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"DOPC";"CCM18";"25";"0";;;-2.78;"in-house calculations";"COSMOperm";0.0016595869074375613
"Atomoxetine";"MM00449";"CNCC[C@@H](Oc1ccccc1C)c1ccccc1";"VHGCDTVCOLNTBX-QGZVFWFLSA-N";255.36;3.72;"54841";"CHEMBL641";"DOPC";"CCM18";"25";"0";;;-0.82;"in-house calculations";"COSMOperm";0.15135612484362082
"MM476465";"MM476465";"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O";"MQTOSJVFKKJCRP-BICOPXKESA-N";749;1.9;"447043";;"DOPC";"CCM18";"25";"0";;;-3.5;"in-house calculations";"COSMOperm";0.00031622776601683794
"Beclomethasone";"MM00335";"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"NBMKJKDGKREAPL-DVTGEIKXSA-N";408.92;2.17;"20469";;"DOPC";"CCM18";"25";"0";;;-2.36;"in-house calculations";"COSMOperm";0.004365158322401661
"Benazepril";"MM00629";"CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O";"XPCFTKFZXHTYIP-PMACEKPBSA-N";424.5;2.57;"5362124";"CHEMBL838";"DOPC";"CCM18";"25";"0";;;-0.96;"in-house calculations";"COSMOperm";0.1096478196143185
"Bendroflumethiazide";"MM00336";"NS(=O)(=O)c1cc2c(cc1C(F)(F)F)N[C@@H](Cc1ccccc1)NS2(=O)=O";"HDWIHXWEUNVBIY-CQSZACIVSA-N";421.42;1.63;"2315";"CHEMBL1684";"DOPC";"CCM18";"25";"0";;;-2.92;"in-house calculations";"COSMOperm";0.001202264434617413
"2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide";"MM00337";"NC(CO)C(=O)NNCc1ccc(O)c(O)c1O";"BNQDCRGUHNALGH-UHFFFAOYSA-N";257.25;-1.76;"2327";"CHEMBL1096979";"DOPC";"CCM18";"25";"0";;;-9.19;"in-house calculations";"COSMOperm";0.0000000006456542290346563
"3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide";"MM00631";"NS(=O)(=O)c1cc2c(cc1Cl)N[C@H](CSCc1ccccc1)NS2(=O)=O";"ZUNJWRJEKCRIMZ-HNNXBMFYSA-N";433.96;1.95;"2343";"CHEMBL1201039";"DOPC";"CCM18";"25";"0";;;-5.65;"in-house calculations";"COSMOperm";0.0000022387211385683376
"1-isobutoxy-2-pyrrolidino-3[n-benzylanilino] propane";"MM00451";"CC(C)COC[C@@H](CN(Cc1ccccc1)c1ccccc1)N1CCCC1";"UIEATEWHFDRYRU-XMMPIXPASA-N";366.55;4.83;"2351";"CHEMBL1008";"DOPC";"CCM18";"25";"0";;;-1.59;"in-house calculations";"COSMOperm";0.025703957827688632
"Bremazocine";"MM00452";"CC[C@]12CCN(CC3(O)CC3)[C@H](Cc3ccc(O)cc31)C2(C)C";"ZDXGFIXMPOUDFF-XLIONFOSSA-N";315.46;3.22;"443406";;"DOPC";"CCM18";"25";"0";;;-1.31;"in-house calculations";"COSMOperm";0.04897788193684462
"Bromocriptine";"MM00338";"CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12";"OZVBMTJYIDMWIL-AYFBDAFISA-N";654.61;3.19;"31101";"CHEMBL493";"DOPC";"CCM18";"25";"0";;;-1.49;"in-house calculations";"COSMOperm";0.03235936569296283
"3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine";"MM00453";"CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1";"ZDIGNSYAACHWNL-HNNXBMFYSA-N";319.25;3.93;"6834";"CHEMBL811";"DOPC";"CCM18";"25";"0";;;-1.1;"in-house calculations";"COSMOperm";0.07943282347242814
"Budesonide";"MM00339";"CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1";"VOVIALXJUBGFJZ-VXKMTNQYSA-N";430.54;2.72;"5281004";"CHEMBL1370";"DOPC";"CCM18";"25";"0";;;-2.74;"in-house calculations";"COSMOperm";0.0018197008586099826
"1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide";"MM00454";"CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C";"LEBVLXFERQHONN-INIZCTEOSA-N";288.44;3.9;"2474";"CHEMBL1098";"DOPC";"CCM18";"25";"0";;;-0.79;"in-house calculations";"COSMOperm";0.16218100973589297
"Bupropion";"MM00455";"C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1";"SNPPWIUOZRMYNY-VIFPVBQESA-N";239.75;3.3;"444";"CHEMBL894";"DOPC";"CCM18";"25";"0";;;-0.96;"in-house calculations";"COSMOperm";0.1096478196143185
"8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione";"MM00456";"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1";"QWCRAEMEVRGPNT-UHFFFAOYSA-N";385.51;2.09;"2477";"CHEMBL49";"DOPC";"CCM18";"25";"0";;;-1.55;"in-house calculations";"COSMOperm";0.028183829312644536
"1-Butylamine";"MM00435";"CCCCN";"HQABUPZFAYXKJW-UHFFFAOYSA-N";73.14;0.75;"8007";"CHEMBL13968";"DOPC";"CCM18";"25";"0";;;-1.12;"in-house calculations";"COSMOperm";0.07585775750291836
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"DOPC";"CCM18";"25";"0";;;-2.54;"in-house calculations";"COSMOperm";0.0028840315031266055
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"DOPC";"CCM18";"25";"0";;;-0.41;"in-house calculations";"COSMOperm";0.3890451449942806
"1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol";"MM00458";"COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12";"OGHNVEJMJSYVRP-UHFFFAOYSA-N";406.48;3.74;"2585";"CHEMBL723";"DOPC";"CCM18";"25";"0";;;-0.52;"in-house calculations";"COSMOperm";0.3019951720402016
"Cefaclor";"MM00717";"NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CSC12)c1ccccc1";"QYIYFLOTGYLRGG-UHFFFAOYSA-N";367.81;0.62;"51039";"CHEMBL680";"DOPC";"CCM18";"25";"0";;;-2.55;"in-house calculations";"COSMOperm";0.002818382931264455
"Cefadroxil";"MM00718";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccc(O)cc3)C2SC1";"BOEGTKLJZSQCCD-UHFFFAOYSA-N";363.4;0.15;"47965";"CHEMBL1644";"DOPC";"CCM18";"25";"0";;;-8.49;"in-house calculations";"COSMOperm";0.000000003235936569296281
"Cefatrizine";"MM00719";"N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cn[nH]n3)CS[C@H]12)c1ccc(O)cc1";"UOCJDOLVGGIYIQ-PBFPGSCMSA-N";462.51;0.04;"6410758";;"DOPC";"CCM18";"25";"0";;;-9.93;"in-house calculations";"COSMOperm";0.00000000011748975549395304
"Ceftibuten";"MM00637";"Nc1nc(C(=CCC(=O)O)C(=O)NC2C(=O)N3C(C(=O)O)=CCSC23)cs1";"UNJFKXSSGBWRBZ-UHFFFAOYSA-N";410.43;-0.05;"5282242";"CHEMBL1605";"DOPC";"CCM18";"25";"0";;;-8.42;"in-house calculations";"COSMOperm";0.0000000038018939632056126
"Cephalexin";"MM00721";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1";"ZAIPMKNFIOOWCQ-UHFFFAOYSA-N";347.4;0.44;"27447";"CHEMBL1727";"DOPC";"CCM18";"25";"0";;;-6.38;"in-house calculations";"COSMOperm";0.0000004168693834703355
"Cephaloglycin";"MM00722";"CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1";"FUBBGQLTSCSAON-PBFPGSCMSA-N";405.43;-0.01;"19150";"CHEMBL1200971";"DOPC";"CCM18";"25";"0";;;-4.75;"in-house calculations";"COSMOperm";0.00001778279410038923
"Cephradine";"MM00723";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)C3=CCC=CC3)C2SC1";"RDLPVSKMFDYCOR-UHFFFAOYSA-N";349.41;0.35;"38103";"CHEMBL1604";"DOPC";"CCM18";"25";"0";;;-5.16;"in-house calculations";"COSMOperm";0.0000069183097091893625
"Cerivastatin";"MM00639";"COCc1c(C(C)C)nc(C(C)C)c(C=CC(O)CC(O)CC(=O)O)c1-c1ccc(F)cc1";"SEERZIQQUAZTOL-UHFFFAOYSA-N";459.56;4.88;"446156";"CHEMBL1477";"DOPC";"CCM18";"25";"0";;;-0.62;"in-house calculations";"COSMOperm";0.23988329190194904
"Cetirizine";"MM00724";"O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1";"ZKLPARSLTMPFCP-UHFFFAOYSA-N";388.9;3.15;"2678";;"DOPC";"CCM18";"25";"0";;;-0.71;"in-house calculations";"COSMOperm";0.19498445997580455
"Chlorambucil";"MM00640";"O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1";"JCKYGMPEJWAADB-UHFFFAOYSA-N";304.22;3.38;"2708";"CHEMBL515";"DOPC";"CCM18";"25";"0";;;-0.27;"in-house calculations";"COSMOperm";0.5370317963702527
"Chloramphenicol";"MM00342";"O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl";"WIIZWVCIJKGZOK-UHFFFAOYSA-N";323.13;0.91;"5959";"CHEMBL130";"DOPC";"CCM18";"25";"0";;;-1.84;"in-house calculations";"COSMOperm";0.014454397707459272
"N4-(7-chloro-quinolin-4-yl)-n1,n1-diethyl-pentane-1,4-diamine";"MM00459";"CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12";"WHTVZRBIWZFKQO-UHFFFAOYSA-N";319.88;4.81;"2719";"CHEMBL76";"DOPC";"CCM18";"25";"0";;;-0.68;"in-house calculations";"COSMOperm";0.20892961308540392
"Chlorothiazide";"MM00641";"NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O";"JBMKAUGHUNFTOL-UHFFFAOYSA-N";295.73;0.13;"2720";"CHEMBL842";"DOPC";"CCM18";"25";"0";;;-7.94;"in-house calculations";"COSMOperm";0.000000011481536214968817
"Chlorpheniramine";"MM00460";"CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1";"SOYKEARSMXGVTM-UHFFFAOYSA-N";274.8;3.82;"2725";"CHEMBL505";"DOPC";"CCM18";"25";"0";;;-1.07;"in-house calculations";"COSMOperm";0.08511380382023763
"(3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine";"MM00462";"CN(C)CCC=C1c2ccccc2Sc2ccc(Cl)cc21";"WSPOMRSOLSGNFJ-UHFFFAOYSA-N";315.87;5.19;"667467";"CHEMBL90125";"DOPC";"CCM18";"25";"0";;;-0.86;"in-house calculations";"COSMOperm";0.1380384264602885
"Chlortetracycline";"MM00725";"CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12";"DHPRQBPJLMKORJ-XRNKAMNCSA-N";478.89;0.28;"54675777";"CHEMBL404520";"DOPC";"CCM18";"25";"0";;;-3.22;"in-house calculations";"COSMOperm";0.0006025595860743575
"Chlorthalidone";"MM00343";"NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl";"JIVPVXMEBJLZRO-UHFFFAOYSA-N";338.77;0.92;"2732";"CHEMBL1055";"DOPC";"CCM18";"25";"0";;;-9.22;"in-house calculations";"COSMOperm";0.0000000006025595860743569
"Cimetidine";"MM00463";"CNC(=NCCSCc1nc[nH]c1C)NC#N";"AQIXAKUUQRKLND-UHFFFAOYSA-N";252.35;0.6;"2756";"CHEMBL30";"DOPC";"CCM18";"25";"0";;;-4.14;"in-house calculations";"COSMOperm";0.00007244359600749906
"1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine";"MM00464";"C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1";"DERZBLKQOCDDDZ-UHFFFAOYSA-N";368.52;5.11;"1547484";"CHEMBL43064";"DOPC";"CCM18";"25";"0";;;-0.78;"in-house calculations";"COSMOperm";0.16595869074375605
"Ciprofloxacin";"MM00726";"O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O";"MYSWGUAQZAJSOK-UHFFFAOYSA-N";331.35;1.58;"2764";"CHEMBL8";"DOPC";"CCM18";"25";"0";;;-1.97;"in-house calculations";"COSMOperm";0.010715193052376065
"1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile";"MM00465";"CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21";"WSEQXVZVJXJVFP-UHFFFAOYSA-N";324.4;3.81;"2771";"CHEMBL549";"DOPC";"CCM18";"25";"0";;;-1.57;"in-house calculations";"COSMOperm";0.026915348039269153
"(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine";"MM00466";"CN1CCCC1CCOC(C)(c1ccccc1)c1ccc(Cl)cc1";"YNNUSGIPVFPVBX-UHFFFAOYSA-N";343.9;5.1;"26987";"CHEMBL1626";"DOPC";"CCM18";"25";"0";;;-1.39;"in-house calculations";"COSMOperm";0.04073802778041128
"Clonidine";"MM00344";"Clc1cccc(Cl)c1N=C1NCCN1";"GJSURZIOUXUGAL-UHFFFAOYSA-N";230.1;2.17;"2803";"CHEMBL134";"DOPC";"CCM18";"25";"0";;;-0.58;"in-house calculations";"COSMOperm";0.2630267991895382
"1-[(2-chlorophenyl)-diphenylmethyl]imidazole";"MM00468";"Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1";"VNFPBHJOKIVQEB-UHFFFAOYSA-N";344.85;5.38;"2812";"CHEMBL104";"DOPC";"CCM18";"25";"0";;;-0.49;"in-house calculations";"COSMOperm";0.32359365692962827
"3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine";"MM476466";"CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1";"QZUDBNBUXVUHMW-UHFFFAOYSA-N";326.83;3.72;"135398737";;"DOPC";"CCM18";"25";"0";;;-1.13;"in-house calculations";"COSMOperm";0.07413102413009177
"Colchicine";"MM00345";"COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2";"IAKHMKGGTNLKSZ-UHFFFAOYSA-N";399.44;2.87;"6167";"CHEMBL87";"DOPC";"CCM18";"25";"0";;;-2.18;"in-house calculations";"COSMOperm";0.006606934480075957
"Corticosterone";"MM00346";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12";"OMFXVFTZEKFJBZ-UHFFFAOYSA-N";346.47;2.67;"5753";"CHEMBL110739";"DOPC";"CCM18";"25";"0";;;-2.42;"in-house calculations";"COSMOperm";0.0038018939632056127
"Cortisone";"MM00347";"CC12CCC(O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO";"LPYXTAPPNYMYOP-UHFFFAOYSA-N";362.47;1.78;"222786";;"DOPC";"CCM18";"25";"0";;;-2.35;"in-house calculations";"COSMOperm";0.0044668359215096305
"CP-141938";"MM00471";"COc1ccc(N(C)S(C)(=O)=O)cc1CNC1CCCNC1c1ccccc1";"GZLOIBNBDUHEFY-UHFFFAOYSA-N";403.55;2.67;"10363809";;"DOPC";"CCM18";"25";"0";;;-1.47;"in-house calculations";"COSMOperm";0.033884415613920256
"Danazol";"MM00353";"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C";"POZRVZJJTULAOH-LHZXLZLDSA-N";337.46;4.22;"28417";"CHEMBL1479";"DOPC";"CCM18";"25";"0";;;-1.18;"in-house calculations";"COSMOperm";0.06606934480075961
"Daunorubicin";"MM00473";"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(C)=O)CC3OC1CC(N)C(O)C(C)O1";"STQGQHZAVUOBTE-UHFFFAOYSA-N";527.53;1.03;"30323";"CHEMBL178";"DOPC";"CCM18";"25";"0";;;-2.02;"in-house calculations";"COSMOperm";0.009549925860214359
"Cortexone";"MM00037";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(C(=O)CO)CCC12";"ZESRJSPZRDMNHY-UHFFFAOYSA-N";330.47;3.7;"6166";;"DOPC";"CCM18";"25";"0";;;-2.29;"in-house calculations";"COSMOperm";0.005128613839913648
"Desipramine";"MM00474";"CNCCCN1c2ccccc2CCc2ccccc21";"HCYAFALTSJYZDH-UHFFFAOYSA-N";266.39;3.53;"2995";"CHEMBL72";"DOPC";"CCM18";"25";"0";;;-0.79;"in-house calculations";"COSMOperm";0.16218100973589297
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"DOPC";"CCM18";"25";"0";;;-2.25;"in-house calculations";"COSMOperm";0.005623413251903491
"(1S,9S,10S)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol";"MM00476";"CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(O)cc13";"JAQUASYNZVUNQP-PVAVHDDUSA-N";257.38;3.08;"5360697";;"DOPC";"CCM18";"25";"0";;;-0.66;"in-house calculations";"COSMOperm";0.21877616239495523
"(1S,2R)-1-[(2S)-oxiran-2-yl]-2-[(2R)-oxiran-2-yl]ethane-1,2-diol";"MM476467";"O[C@H]([C@H](O)[C@@H]1CO1)[C@H]1CO1";"AAFJXZWCNVJTMK-GUCUJZIJSA-N";146.14;-1.49;"15942827";;"DOPC";"CCM18";"25";"0";;;-4.81;"in-house calculations";"COSMOperm";0.000015488166189124828
"Diazepam";"MM00094";"CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21";"AAOVKJBEBIDNHE-UHFFFAOYSA-N";284.75;3.15;"3016";"CHEMBL12";"DOPC";"CCM18";"25";"0";;;-0.73;"in-house calculations";"COSMOperm";0.18620871366628675
"Digoxin";"MM00357";"CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O";"LTMHDMANZUZIPE-UHFFFAOYSA-N";780.95;2.22;"2724385";"CHEMBL1751";"DOPC";"CCM18";"25";"0";;;-4.19;"in-house calculations";"COSMOperm";0.00006456542290346549
"Diltiazem";"MM00477";"COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1";"HSUGRBWQSSZJOP-UHFFFAOYSA-N";414.53;3.37;"39186";"CHEMBL23";"DOPC";"CCM18";"25";"0";;;-1.49;"in-house calculations";"COSMOperm";0.03235936569296283
"Diphenhydramine";"MM00478";"CN(C)CCOC(c1ccccc1)c1ccccc1";"ZZVUWRFHKOJYTH-UHFFFAOYSA-N";255.36;3.35;"3100";"CHEMBL657";"DOPC";"CCM18";"25";"0";;;-1.02;"in-house calculations";"COSMOperm";0.09549925860214359
"Dipyridamole";"MM00479";"OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1";"IZEKFCXSFNUWAM-UHFFFAOYSA-N";504.64;-0.02;"3108";"CHEMBL932";"DOPC";"CCM18";"25";"0";;;-2.75;"in-house calculations";"COSMOperm";0.0017782794100389228
"4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide";"MM00480";"CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C";"UVTNFZQICZKOEM-UHFFFAOYSA-N";339.48;3.36;"3114";"CHEMBL517";"DOPC";"CCM18";"25";"0";;;-0.63;"in-house calculations";"COSMOperm";0.2344228815319922
"Donepezil";"MM00482";"COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2";"ADEBPBSSDYVVLD-UHFFFAOYSA-N";379.5;4.36;"3152";"CHEMBL502";"DOPC";"CCM18";"25";"0";;;-1.03;"in-house calculations";"COSMOperm";0.0933254300796991
"L-dopamine";"MM00483";"NCCc1ccc(O)c(O)c1";"VYFYYTLLBUKUHU-UHFFFAOYSA-N";153.18;0.6;"681";"CHEMBL59";"DOPC";"CCM18";"25";"0";;;-2.52;"in-house calculations";"COSMOperm";0.003019951720402016
"DPDPE";"MM00731";"CC1(C)SSC(C)(C)C(NC(=O)C(N)Cc2ccc(O)cc2)C(=O)NCC(=O)NC(Cc2ccccc2)C(=O)NC1C(=O)O";"MCMMCRYPQBNCPH-UHFFFAOYSA-N";645.8;1.11;"104787";"CHEMBL31421";"DOPC";"CCM18";"25";"0";;;-10.65;"in-house calculations";"COSMOperm";0.000000000022387211385683377
"Enalaprilat";"MM00732";"CC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O";"LZFZMUMEGBBDTC-UHFFFAOYSA-N";348.4;1.13;"5462501";"CHEMBL577";"DOPC";"CCM18";"25";"0";;;-1.49;"in-house calculations";"COSMOperm";0.03235936569296283
"Enoxacin";"MM00733";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21";"IDYZIJYBMGIQMJ-UHFFFAOYSA-N";320.32;0.66;"3229";"CHEMBL826";"DOPC";"CCM18";"25";"0";;;-3.3;"in-house calculations";"COSMOperm";0.0005011872336272725
"Enrofloxacin";"MM00734";"CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1";"SPFYMRJSYKOXGV-UHFFFAOYSA-N";359.4;2.32;"71188";;"DOPC";"CCM18";"25";"0";;;-1.07;"in-house calculations";"COSMOperm";0.08511380382023763
"(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol";"MM00486";"CN[C@@H](C)[C@H](O)c1ccccc1";"KWGRBVOPPLSCSI-WPRPVWTQSA-N";165.24;1.33;"9294";"CHEMBL211456";"DOPC";"CCM18";"25";"0";;;-1.07;"in-house calculations";"COSMOperm";0.08511380382023763
"Ergonovine";"MM00487";"CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1";"WVVSZNPYNCNODU-UHFFFAOYSA-N";325.41;1.53;"443884";"CHEMBL119443";"DOPC";"CCM18";"25";"0";;;-1.05;"in-house calculations";"COSMOperm";0.08912509381337455
"Ergotamine";"MM00488";"CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21";"XCGSFFUVFURLIX-VFGNJEKYSA-N";581.67;1.99;"8223";"CHEMBL442";"DOPC";"CCM18";"25";"0";;;-2.23;"in-house calculations";"COSMOperm";0.00588843655355589
"Estradiol";"MM00197";"CC12CCC3c4ccc(O)cc4CCC3C1CCC2O";"VOXZDWNPVJITMN-UHFFFAOYSA-N";272.39;3.61;"5757";"CHEMBL135";"DOPC";"CCM18";"25";"0";;;-0.95;"in-house calculations";"COSMOperm";0.11220184543019636
"3-ethyl-3-methylpyrrolidine-2,5-dione";"MM00359";"CCC1(C)CC(=O)NC1=O";"HAPOVYFOVVWLRS-UHFFFAOYSA-N";141.17;0.45;"3291";"CHEMBL696";"DOPC";"CCM18";"25";"0";;;-2.74;"in-house calculations";"COSMOperm";0.0018197008586099826
"Flumequine";"MM00646";"CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23";"DPSPPJIUMHPXMA-UHFFFAOYSA-N";261.25;2.35;"3374";"CHEMBL370252";"DOPC";"CCM18";"25";"0";;;-3.5;"in-house calculations";"COSMOperm";0.00031622776601683794
"2-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-benzoic acid";"MM00054";"O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21";"GNBHRKFJIUUOQI-UHFFFAOYSA-N";332.31;3.67;"16850";"CHEMBL1057";"DOPC";"CCM18";"25";"0";;;-0.41;"in-house calculations";"COSMOperm";0.3890451449942806
"Fluoxetine";"MM00082";"CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1";"RTHCYVBBDHJXIQ-UHFFFAOYSA-N";309.33;4.44;"3386";"CHEMBL41";"DOPC";"CCM18";"25";"0";;;-0.65;"in-house calculations";"COSMOperm";0.22387211385683395
"2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol";"MM00494";"OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1";"PLDUPXSUYLZYBN-UHFFFAOYSA-N";437.53;4.31;"3372";"CHEMBL726";"DOPC";"CCM18";"25";"0";;;-0.9;"in-house calculations";"COSMOperm";0.12589254117941673
"Flurbiprofen";"MM00647";"CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1";"SYTBZMRGLBWNTM-UHFFFAOYSA-N";244.27;3.68;"3394";"CHEMBL563";"DOPC";"CCM18";"25";"0";;;0.19;"in-house calculations";"COSMOperm";1.5488166189124815
"(E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid";"MM00648";"CC(C)n1c(C=CC(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21";"FJLGEFLZQAZZCD-UHFFFAOYSA-N";411.47;4.63;"446155";"CHEMBL350239";"DOPC";"CCM18";"25";"0";;;-0.75;"in-house calculations";"COSMOperm";0.1778279410038923
"Fluvoxamine";"MM00495";"COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1";"CJOFXWAVKWHTFT-UHFFFAOYSA-N";318.34;3.2;"5324346";"CHEMBL814";"DOPC";"CCM18";"25";"0";;;-0.97;"in-house calculations";"COSMOperm";0.10715193052376065
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"DOPC";"CCM18";"25";"0";;;-4.26;"in-house calculations";"COSMOperm";0.00005495408738576248
"Gabapentin";"MM00737";"NCC1(CC(=O)O)CCCCC1";"UGJMXCAKCUNAIE-UHFFFAOYSA-N";171.24;1.37;"3446";"CHEMBL940";"DOPC";"CCM18";"25";"0";;;-1.09;"in-house calculations";"COSMOperm";0.0812830516164099
"(2R,3S,4R,5S)-hexane-1,2,3,4,5,6-hexol";"MM00366";"OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-GUCUJZIJSA-N";182.17;-3.59;"11850";;"DOPC";"CCM18";"25";"0";;;-6.18;"in-house calculations";"COSMOperm";0.0000006606934480075964
"Galantamine";"MM00496";"COc1ccc2c3c1OC1CC(O)C=CC31CCN(C)C2";"ASUTZQLVASHGKV-UHFFFAOYSA-N";287.36;1.85;"9651";"CHEMBL659";"DOPC";"CCM18";"25";"0";;;-1.37;"in-house calculations";"COSMOperm";0.04265795188015926
"2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one";"MM476468";"Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1";"IRSCQMHQWWYFCW-UHFFFAOYSA-N";255.23;-1.97;"135398740";;"DOPC";"CCM18";"25";"0";;;-11.14;"in-house calculations";"COSMOperm";0.000000000007244359600749891
"Gatifloxacin";"MM00738";"COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12";"XUBOMFCQGDBHNK-UHFFFAOYSA-N";375.4;1.98;"5379";"CHEMBL31";"DOPC";"CCM18";"25";"0";;;-2.59;"in-house calculations";"COSMOperm";0.0025703957827688645
"5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid";"MM00650";"Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1";"HEMJJKBWTPKOJG-UHFFFAOYSA-N";250.34;3.57;"3463";"CHEMBL457";"DOPC";"CCM18";"25";"0";;;0.11;"in-house calculations";"COSMOperm";1.288249551693134
"Genistein";"MM00368";"O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12";"TZBJGXHYKVUXJN-UHFFFAOYSA-N";270.24;2.58;"5280961";"CHEMBL44";"DOPC";"CCM18";"25";"0";;;-1.1;"in-house calculations";"COSMOperm";0.07943282347242814
"Glipizide";"MM00651";"Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1";"ZJJXGWJIGJFDTL-UHFFFAOYSA-N";445.55;2.08;"3478";"CHEMBL1073";"DOPC";"CCM18";"25";"0";;;-1.41;"in-house calculations";"COSMOperm";0.03890451449942807
"L-Glutamine";"MM00748";"NC(=O)CC[C@H](N)C(=O)O";"ZDXPYRJPNDTMRX-VKHMYHEASA-N";146.15;-1.34;"5961";"CHEMBL930";"DOPC";"CCM18";"25";"0";;;-7.02;"in-house calculations";"COSMOperm";0.00000009549925860214369
"Glycine";"MM00741";"NCC(=O)O";"DHMQDGOQFOQNFH-UHFFFAOYSA-N";75.07;-0.97;"750";"CHEMBL773";"DOPC";"CCM18";"25";"0";;;-3.34;"in-house calculations";"COSMOperm";0.0004570881896148752
"Grepafloxacin";"MM00742";"Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1";"AIJTTZAVMXIJGM-UHFFFAOYSA-N";359.4;2.28;"72474";"CHEMBL583";"DOPC";"CCM18";"25";"0";;;-1.88;"in-house calculations";"COSMOperm";0.013182567385564075
"Griseofulvin";"MM00369";"COC1=CC(=O)CC(C)C12Oc1c(Cl)c(OC)cc(OC)c1C2=O";"DDUHZTYCFQRHIY-UHFFFAOYSA-N";352.77;2.81;"441140";"CHEMBL562";"DOPC";"CCM18";"25";"0";;;-1.02;"in-house calculations";"COSMOperm";0.09549925860214359
"Guanabenz";"MM00497";"N=C(N)NN=Cc1c(Cl)cccc1Cl";"WDZVGELJXXEGPV-UHFFFAOYSA-N";231.09;1.81;"5702063";"CHEMBL420";"DOPC";"CCM18";"25";"0";;;-1.49;"in-house calculations";"COSMOperm";0.03235936569296283
"Guanfacine";"MM00370";"N=C(N)NC(=O)Cc1c(Cl)cccc1Cl";"INJOMKTZOLKMBF-UHFFFAOYSA-N";246.1;1.55;"3519";"CHEMBL862";"DOPC";"CCM18";"25";"0";;;-1.66;"in-house calculations";"COSMOperm";0.02187761623949553
"Haloperidol";"MM00499";"O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1";"LNEPOXFFQSENCJ-UHFFFAOYSA-N";375.87;4.43;"3559";"CHEMBL54";"DOPC";"CCM18";"25";"0";;;-0.88;"in-house calculations";"COSMOperm";0.1318256738556407
"Hesperetin";"MM00371";"COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O";"AIONOLUJZLIMTK-AWEZNQCLSA-N";302.28;2.52;"72281";"CHEMBL399121";"DOPC";"CCM18";"25";"0";;;-0.52;"in-house calculations";"COSMOperm";0.3019951720402016
"5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxychromen-4-one";"MM00372";"COc1c(O)cc2oc(-c3ccc(O)cc3)cc(=O)c2c1O";"IHFBPDAQLQOCBX-UHFFFAOYSA-N";300.27;2.59;"5281628";;"DOPC";"CCM18";"25";"0";;;-0.4;"in-house calculations";"COSMOperm";0.3981071705534972
"L-Histidine";"MM00749";"N[C@@H](Cc1cnc[nH]1)C(=O)O";"HNDVDQJCIGZPNO-YFKPBYRVSA-N";155.16;-0.64;"6274";"CHEMBL17962";"DOPC";"CCM18";"25";"0";;;-7.05;"in-house calculations";"COSMOperm";0.00000008912509381337459
"1-hydrazinophthalazine";"MM00501";"NNc1nncc2ccccc12";"RPTUSVTUFVMDQK-UHFFFAOYSA-N";160.18;0.92;"3637";"CHEMBL276832";"DOPC";"CCM18";"25";"0";;;-4.52;"in-house calculations";"COSMOperm";0.000030199517204020192
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"DOPC";"CCM18";"25";"0";;;-7.33;"in-house calculations";"COSMOperm";0.000000046773514128719815
"L-Lysine";"MM00753";"NCCCC[C@H](N)C(=O)O";"KDXKERNSBIXSRK-YFKPBYRVSA-N";146.19;-0.47;"5962";"CHEMBL8085";"DOPC";"CCM18";"25";"0";;;-3.76;"in-house calculations";"COSMOperm";0.00017378008287493763
"Norfloxacin";"MM00768";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21";"OGJPXUAPXNRGGI-UHFFFAOYSA-N";319.34;1.27;"4539";"CHEMBL9";"DOPC";"CCM18";"25";"0";;;-4.76;"in-house calculations";"COSMOperm";0.000017378008287493764
"Pefloxacin";"MM00770";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21";"FHFYDNQZQSQIAI-UHFFFAOYSA-N";333.36;1.61;"51081";"CHEMBL267648";"DOPC";"CCM18";"25";"0";;;-1.14;"in-house calculations";"COSMOperm";0.07244359600749903
"Amylamine";"MM00537";"CCCCCN";"DPBLXKKOBLCELK-UHFFFAOYSA-N";87.17;1.14;"8060";;"DOPC";"CCM18";"25";"0";;;-0.63;"in-house calculations";"COSMOperm";0.2344228815319922
"L-Phenylalanine";"MM00756";"N[C@@H](Cc1ccccc1)C(=O)O";"COLNVLDHVKWLRT-QMMMGPOBSA-N";165.19;0.64;"6140";"CHEMBL301523";"DOPC";"CCM18";"25";"0";;;-1.6;"in-house calculations";"COSMOperm";0.025118864315095794
"Prednisone";"MM00408";"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO";"XOFYZVNMUHMLCC-ZPOLXVRWSA-N";358.43;1.77;"5865";"CHEMBL635";"DOPC";"CCM18";"25";"0";;;-2.41;"in-house calculations";"COSMOperm";0.003890451449942805
"MM476470";"MM476470";"CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1";"VMXUWOKSQNHOCA-UKTHLTGXSA-N";314.41;1.46;"3001055";;"DOPC";"CCM18";"25";"0";;;-1.68;"in-house calculations";"COSMOperm";0.020892961308540396
"Resveratrol";"MM00418";"Oc1ccc(C=Cc2cc(O)cc(O)c2)cc1";"LUKBXSAWLPMMSZ-UHFFFAOYSA-N";228.25;2.97;"445154";"CHEMBL1237022";"DOPC";"CCM18";"25";"0";;;-2.29;"in-house calculations";"COSMOperm";0.005128613839913648
"1-(1-adamantyl)ethanamine";"MM00560";"CC(N)C12CC3CC(CC(C3)C1)C2";"UBCHPRBFMUDMNC-UHFFFAOYSA-N";179.31;2.55;"5071";"CHEMBL959";"DOPC";"CCM18";"25";"0";;;0.21;"in-house calculations";"COSMOperm";1.62181009735893
"Risperidone";"MM00561";"Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2";"RAPZEAPATHNIPO-UHFFFAOYSA-N";410.49;3.59;"5073";"CHEMBL85";"DOPC";"CCM18";"25";"0";;;-1.08;"in-house calculations";"COSMOperm";0.08317637711026708
"N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine";"MM00562";"CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12";"ULFRLSNUDGIQQP-UHFFFAOYSA-N";269.35;1.91;"5078";"CHEMBL905";"DOPC";"CCM18";"25";"0";;;-0.84;"in-house calculations";"COSMOperm";0.14454397707459277
"6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";"MM00771";"O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O";"XBHBWNFJWIASRO-UHFFFAOYSA-N";385.37;2.38;"56208";"CHEMBL37858";"DOPC";"CCM18";"25";"0";;;-1.9;"in-house calculations";"COSMOperm";0.012589254117941675
"Scopolamine";"MM00564";"CN1[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@H]1O[C@@H]21";"STECJAGHUSJQJN-USLFZFAMSA-N";303.36;0.92;"3000322";"CHEMBL569713";"DOPC";"CCM18";"25";"0";;;-1.85;"in-house calculations";"COSMOperm";0.01412537544622754
"(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine";"MM00565";"C#CCN(C)[C@H](C)Cc1ccccc1";"MEZLKOACVSPNER-GFCCVEGCSA-N";187.29;2.18;"26757";"CHEMBL972";"DOPC";"CCM18";"25";"0";;;-0.65;"in-house calculations";"COSMOperm";0.22387211385683395
"Sertraline";"MM00566";"CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21";"VGKDLMBJGBXTGI-SJCJKPOMSA-N";306.24;5.18;"68617";"CHEMBL809";"DOPC";"CCM18";"25";"0";;;-0.93;"in-house calculations";"COSMOperm";0.11748975549395294
"Silibinin";"MM00420";"COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O";"SEBFKMXJBCUCAI-HKTJVKLFSA-N";482.44;2.36;"31553";"CHEMBL431701";"DOPC";"CCM18";"25";"0";;;-1.23;"in-house calculations";"COSMOperm";0.0588843655355589
"Sotalol";"MM00567";"CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1";"ZBMZVLHSJCTVON-UHFFFAOYSA-N";272.37;1.09;"5253";"CHEMBL471";"DOPC";"CCM18";"25";"0";;;-1.44;"in-house calculations";"COSMOperm";0.03630780547701014
"Sparfloxacin";"MM00772";"CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)CC(C)N1";"DZZWHBIBMUVIIW-UHFFFAOYSA-N";392.41;2.08;"60464";"CHEMBL850";"DOPC";"CCM18";"25";"0";;;-1.57;"in-house calculations";"COSMOperm";0.026915348039269153
"Sufentanil";"MM00304";"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1";"GGCSSNBKKAUURC-UHFFFAOYSA-N";386.56;4.21;"41693";"CHEMBL658";"DOPC";"CCM18";"25";"0";;;-1.79;"in-house calculations";"COSMOperm";0.0162181009735893
"Sulpiride";"MM00568";"CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC";"BGRJTUBHPOOWDU-UHFFFAOYSA-N";341.43;0.56;"5355";"CHEMBL26";"DOPC";"CCM18";"25";"0";;;-3.62;"in-house calculations";"COSMOperm";0.000239883291901949
"1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide";"MM00569";"CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1";"KQKPFRSPSRPDEB-UHFFFAOYSA-N";295.41;1.32;"5358";"CHEMBL128";"DOPC";"CCM18";"25";"0";;;-1.15;"in-house calculations";"COSMOperm";0.0707945784384138
"2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine";"MM00570";"CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1";"NKANXQFJJICGDU-UHFFFAOYSA-N";371.52;6;"2733526";"CHEMBL83";"DOPC";"CCM18";"25";"0";;;-0.97;"in-house calculations";"COSMOperm";0.10715193052376065
"7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one";"MM00422";"CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21";"SEQDDYPDSLOBDC-UHFFFAOYSA-N";300.75;2.47;"5391";"CHEMBL967";"DOPC";"CCM18";"25";"0";;;-0.73;"in-house calculations";"COSMOperm";0.18620871366628675
"1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol";"MM00571";"CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1";"GUGOEEXESWIERI-UHFFFAOYSA-N";471.69;6.45;"5405";"CHEMBL17157";"DOPC";"CCM18";"25";"0";;;-0.92;"in-house calculations";"COSMOperm";0.12022644346174129
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"DOPC";"CCM18";"25";"0";;;-1.82;"in-house calculations";"COSMOperm";0.01513561248436208
"Theobromine";"MM00424";"Cn1cnc2c1c(=O)[nH]c(=O)n2C";"YAPQBXQYLJRXSA-UHFFFAOYSA-N";180.17;-1.04;"5429";"CHEMBL1114";"DOPC";"CCM18";"25";"0";;;-4.17;"in-house calculations";"COSMOperm";0.00006760829753919819
"2-(1,3-thiazol-4-yl)-1h-benzimidazole";"MM00425";"c1ccc2[nH]c(-c3cscn3)nc2c1";"WJCNZQLZVWNLKY-UHFFFAOYSA-N";201.25;2.69;"5430";"CHEMBL625";"DOPC";"CCM18";"25";"0";;;-1.03;"in-house calculations";"COSMOperm";0.0933254300796991
"10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine";"MM00572";"CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2";"KLBQZWRITKRQQV-UHFFFAOYSA-N";370.59;5.89;"5452";"CHEMBL479";"DOPC";"CCM18";"25";"0";;;-1.04;"in-house calculations";"COSMOperm";0.09120108393559097
"(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide";"MM00693";"CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1";"GFBKORZTTCHDGY-UWVJOHFNSA-N";443.64;3.47;"941651";"CHEMBL1201";"DOPC";"CCM18";"25";"0";;;-1.78;"in-house calculations";"COSMOperm";0.016595869074375606
"L-Threonine";"MM00758";"C[C@@H](O)[C@H](N)C(=O)O";"AYFVYJQAPQTCCC-GBXIJSLDSA-N";119.12;-1.22;"6288";"CHEMBL291747";"DOPC";"CCM18";"25";"0";;;-3.34;"in-house calculations";"COSMOperm";0.0004570881896148752
"L-deoxythymidine";"MM00427";"Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O";"IQFYYKKMVGJFEH-XLPZGREQSA-N";242.23;-1.51;"5789";"CHEMBL374731";"DOPC";"CCM18";"25";"0";;;-7.76;"in-house calculations";"COSMOperm";0.000000017378008287493763
"Thymine";"MM00428";"Cc1c[nH]c(=O)[nH]c1=O";"RWQNBRDOKXIBIV-UHFFFAOYSA-N";126.12;-0.63;"1135";"CHEMBL993";"DOPC";"CCM18";"25";"0";;;-5.57;"in-house calculations";"COSMOperm";0.0000026915348039269138
"(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid";"MM00773";"Cc1ccsc1C(=CCCN1CCCC(C(=O)O)C1)c1sccc1C";"PBJUNZJWGZTSKL-UHFFFAOYSA-N";375.56;5.04;"60648";"CHEMBL1027";"DOPC";"CCM18";"25";"0";;;-0.81;"in-house calculations";"COSMOperm";0.1548816618912481
"(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol";"MM00573";"CC(C)(C)NCC(O)COc1nsnc1N1CCOCC1";"BLJRIMJGRPQVNF-UHFFFAOYSA-N";316.43;0.5;"33624";"CHEMBL499";"DOPC";"CCM18";"25";"0";;;-2.08;"in-house calculations";"COSMOperm";0.008317637711026709
"Tolbutamide";"MM00708";"CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1";"JLRGJRBPOGGCBT-UHFFFAOYSA-N";270.35;1.78;"5505";"CHEMBL782";"DOPC";"CCM18";"25";"0";;;-0.26;"in-house calculations";"COSMOperm";0.5495408738576245
"Topotecan";"MM00575";"CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1";"UCFGDBYHRUNTLO-UHFFFAOYSA-N";421.45;1.85;"60700";"CHEMBL84";"DOPC";"CCM18";"25";"0";;;-1.15;"in-house calculations";"COSMOperm";0.0707945784384138
"6-phenylpteridine-2,4,7-triamine";"MM00577";"Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1";"FNYLWPVRPXGIIP-UHFFFAOYSA-N";253.27;0.83;"5546";"CHEMBL585";"DOPC";"CCM18";"25";"0";;;-4.37;"in-house calculations";"COSMOperm";0.00004265795188015926
"10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine";"MM00578";"CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1";"ZEWQUBUPAILYHI-UHFFFAOYSA-N";407.51;4.95;"5566";"CHEMBL422";"DOPC";"CCM18";"25";"0";;;-1.3;"in-house calculations";"COSMOperm";0.05011872336272722
"N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine";"MM00579";"CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21";"XSCGXQMFQXDFCW-UHFFFAOYSA-N";352.43;5.26;"5568";"CHEMBL570";"DOPC";"CCM18";"25";"0";;;-0.97;"in-house calculations";"COSMOperm";0.10715193052376065
"Zaleplon";"MM00434";"CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1";"HUNXMJYCHXQEGX-UHFFFAOYSA-N";305.34;2.64;"5719";"CHEMBL1521";"DOPC";"CCM18";"25";"0";;;-1.45;"in-house calculations";"COSMOperm";0.03548133892335755
"(Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine";"MM00588";"CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1";"OYPPVKRFBIWMSX-SXGWCWSVSA-N";317.23;3.84;"5365247";"CHEMBL37744";"DOPC";"CCM18";"25";"0";;;-1.31;"in-house calculations";"COSMOperm";0.04897788193684462
"5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one";"MM00589";"O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1";"MVWVFYHBGMAFLY-UHFFFAOYSA-N";412.95;3.81;"60854";"CHEMBL708";"DOPC";"CCM18";"25";"0";;;-0.59;"in-house calculations";"COSMOperm";0.2570395782768864
"(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one";"MM00590";"CN(C)CCc1c[nH]c2ccc(CC3COC(=O)N3)cc12";"ULSDMUVEXKOYBU-UHFFFAOYSA-N";287.36;1.92;"60857";"CHEMBL1185";"DOPC";"CCM18";"25";"0";;;-0.85;"in-house calculations";"COSMOperm";0.14125375446227545
"2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetic acid";"MM00713";"Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1";"ZXVNMYWKKDOREA-UHFFFAOYSA-N";291.73;2.85;"5733";"CHEMBL19490";"DOPC";"CCM18";"25";"0";;;-0.33;"in-house calculations";"COSMOperm";0.4677351412871982
"Butyramide";"MM00059";"CCCC(N)=O";"DNSISZSEWVHGLH-UHFFFAOYSA-N";87.12;0.27;"10927";"CHEMBL1231396";"DOPC";"CCM18";"25";"0";;;-2.83;"in-house calculations";"COSMOperm";0.0014791083881682072
"Hexane-1,6-diol";"MM476473";"OCCCCCCO";"XXMIOPMDWAUFGU-UHFFFAOYSA-N";118.18;0.53;"12374";;"DOPC";"CCM18";"25";"0";;;-1.88;"in-house calculations";"COSMOperm";0.013182567385564075
"11beta-Hydroxyprogesterone";"MM00317";"CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C";"BFZHCUBIASXHPK-ATWVFEABSA-N";330.47;3.69;"101788";;"DOPC";"CCM18";"25";"0";;;-2.08;"in-house calculations";"COSMOperm";0.008317637711026709
"2,3-Dideoxyadenosine";"MM00318";"Nc1ncnc2c1ncn2[C@H]1CC[C@@H](CO)O1";"WVXRAFOPTSTNLL-NKWVEPMBSA-N";235.25;0.08;"20039";;"DOPC";"CCM18";"25";"0";;;-5.11;"in-house calculations";"COSMOperm";0.00000776247116628691
"2,4-Dibromoestradiol";"MM00319";"CC12CCC3c4cc(Br)c(O)c(Br)c4CCC3C1CCC2O";"UTXNYGUZJLLOSP-UHFFFAOYSA-N";430.18;5.13;"266051";;"DOPC";"CCM18";"25";"0";;;-0.9;"in-house calculations";"COSMOperm";0.12589254117941673
"N-Octylmalonic Acid";"MM00670";"CCCCCCCCC(C(=O)O)C(=O)O";"QJGNSTCICFBACB-UHFFFAOYSA-N";216.28;2.52;"12972";;"DOPC";"CCM18";"25";"0";;;0.01;"in-house calculations";"COSMOperm";1.023292992280754
"Alpha-Methoxy-p-Toluic Acid";"MM00626";"COCc1ccc(C(=O)O)cc1";"OORFINRYBCDBEN-UHFFFAOYSA-N";166.18;1.53;"308473";;"DOPC";"CCM18";"25";"0";;;-0.67;"in-house calculations";"COSMOperm";0.2137962089502232
"5-Aminolevulinic Acid";"MM00714";"NCC(=O)CCC(=O)O";"ZGXJTSGNIOSYLO-UHFFFAOYSA-N";131.13;-0.62;"137";"CHEMBL601";"DOPC";"CCM18";"25";"0";;;-4.8;"in-house calculations";"COSMOperm";0.00001584893192461114
"Biochanin A";"MM00632";"COc1ccc(-c2coc3cc(O)cc(O)c3c2=O)cc1";"WUADCCWRTIWANL-UHFFFAOYSA-N";284.27;2.88;"5280373";;"DOPC";"CCM18";"25";"0";;;-0.38;"in-house calculations";"COSMOperm";0.4168693834703354
"CNV97100";"MM00727";"CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CCN1.O=C(O)C(F)(F)F";"URJUNYOPXJPQGS-UHFFFAOYSA-N";459.4;2.61;"46781144";;"DOPC";"CCM18";"25";"0";;;-3.77;"in-house calculations";"COSMOperm";0.00016982436524617443
"MM476474";"MM476474";"CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)C[C@H]1C";"POMKZSJIYNWBRP-GFCCVEGCSA-N";373.43;2.7;;;"DOPC";"CCM18";"25";"0";;;-2.11;"in-house calculations";"COSMOperm";0.00776247116628692
"MM476475";"MM476475";"CCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)C[C@H]1C";"WPGHZQMHNTXSAF-CYBMUJFWSA-N";387.46;3.09;;;"DOPC";"CCM18";"25";"0";;;-1.8;"in-house calculations";"COSMOperm";0.015848931924611134
"MM476476";"MM476476";"CCCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)C[C@H]1C";"QPVCGSGGZMAACV-CQSZACIVSA-N";401.48;3.48;;;"DOPC";"CCM18";"25";"0";;;-0.78;"in-house calculations";"COSMOperm";0.16595869074375605
"DMP-450";"MM00358";"Nc1cccc(CN2C(=O)N(Cc3cccc(N)c3)[C@H](Cc3ccccc3)[C@H](O)[C@@H](O)[C@H]2Cc2ccccc2)c1";"KYRSNWPSSXSNEP-ZRTHHSRSSA-N";536.68;4.23;"154044";"CHEMBL223824";"DOPC";"CCM18";"25";"0";;;-1.74;"in-house calculations";"COSMOperm";0.018197008586099836
"MM476477";"MM476477";"NCC(=O)N1CCC[C@H]1C(=O)O";"KZNQNBZMBZJQJO-YFKPBYRVSA-N";172.18;-0.98;;;"DOPC";"CCM18";"25";"0";;;-3.19;"in-house calculations";"COSMOperm";0.0006456542290346556
"2-[(2-aminoacetyl)-methylamino]acetic acid";"MM00740";"CN(CC(=O)O)C(=O)CN";"VYAMLSCELQQRAE-UHFFFAOYSA-N";146.15;-1.51;"93131";;"DOPC";"CCM18";"25";"0";;;-6.61;"in-house calculations";"COSMOperm";0.00000024547089156850283
"MM476479";"MM476479";"COCc1ccc(C(=O)NCC(=O)O)cc1";"QYJPIRDOGBXKAT-UHFFFAOYSA-N";223.23;0.65;;;"DOPC";"CCM18";"25";"0";;;-3.58;"in-house calculations";"COSMOperm";0.00026302679918953814
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.8;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.000001584893192461114
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620239/target=_blank>CHEMBL3620239</a>";;-3.89;"Ling T, Tran M, GonzĂˇlez MA, Gautam LN, Connelly M, Wood RK, Fatima I, Miranda-Carboni G, Rivas F.: (+)-Dehydroabietylamine derivatives target triple-negative breast cancer. Eur J Med Chem, Volume 102, 2015";"PAMPA";0.00012882495516931337
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3270245/target=_blank>CHEMBL3270245</a>";;-3.89;"Van Horn KS, Burda WN, Fleeman R, Shaw LN, Manetsch R.: Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines. J Med Chem, Volume 57 (7), 2014";"PAMPA";0.00012882495516931337
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3370143/target=_blank>CHEMBL3370143</a>";;-3.95;"Cross RM, Flanigan DL, Monastyrskyi A, LaCrue AN, SĂˇenz FE, Maignan JR, Mutka TS, White KL, Shackleford DM, Bathurst I, Fronczek FR, Wojtas L, Guida WC, Charman SA, Burrows JN, Kyle DE, Manetsch R.: Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium. J Med Chem, Volume 57 (21), 2014";"PAMPA";0.0001122018454301963
"MM471854";"MM471854";"CCOC(=O)c1c(-c2cccc(OC)c2)[nH]c2cc(OC)ccc2c1=O";"KWRPQBUOZRTWTK-UHFFFAOYSA-N";353.37;3.39;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.77;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.00016982436524617443
"MM471851";"MM471851";"CCOC(=O)c1c(-c2cccc(Cl)c2)[nH]c2cc(OC)ccc2c1=O";"LWEMFPJHVREVBZ-UHFFFAOYSA-N";357.79;4.03;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.02;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0009549925860214359
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-6.52;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000003019951720402019
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.75;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.000001778279410038923
"MM471395";"MM471395";"N#Cc1ccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)cc2)cc1";"DCZNYNMIRSBGHQ-GFEQUFNTSA-N";357.36;0.4;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419536/target=_blank>CHEMBL3419536</a>";;-5.7;"Kleeb S, Pang L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, LĂĽdin N, BezenĂ§on J, Schwardt O, Maier T, Ernst B.: FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.0000019952623149688787
"MM471388";"MM471388";"OC[C@H]1O[C@H](Oc2ccc(-c3ccccc3)cc2)[C@@H](O)[C@@H](O)[C@@H]1O";"SZBKRKVDBPBJHL-ZBRFXRBCSA-N";332.35;0.53;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419536/target=_blank>CHEMBL3419536</a>";;-4.7;"Kleeb S, Pang L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, LĂĽdin N, BezenĂ§on J, Schwardt O, Maier T, Ernst B.: FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.000019952623149688786
"MM471575";"MM471575";"O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3ccc(Cl)cc3c(O)c21";"SLRIULRRADAUHV-UHFFFAOYSA-N";392.67;5.81;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.7;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000019952623149688786
"MM471518";"MM471518";"CCN1CCC[C@H]1CNC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"IUTRAWUFJOFGJK-FQEVSTJZSA-N";418.55;3.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228256/target=_blank>CHEMBL1228256</a>";;-4.64;"Shimizu H, Tanaka S, Toki T, Yasumatsu I, Akimoto T, Morishita K, Yamasaki T, Yasukochi T, Iimura S.: Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.00002290867652767775
"MM471595";"MM471595";"O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"VDTACYBUGLTWCI-SFHVURJKSA-N";390.49;2.7;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1809899/target=_blank>CHEMBL1809899</a>";;-6.08;"Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 3: exploration of effective compounds in arthritis models. Bioorg Med Chem Lett, Volume 21 (15), 2011";"PAMPA";0.0000008317637711026709
"MM471517";"MM471517";"CN(C)CCNC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"DVIFVYZZPLRXHC-UHFFFAOYSA-N";378.48;2.51;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228256/target=_blank>CHEMBL1228256</a>";;-4.3;"Shimizu H, Tanaka S, Toki T, Yasumatsu I, Akimoto T, Morishita K, Yamasaki T, Yasukochi T, Iimura S.: Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.00005011872336272725
"MM471519";"MM471519";"O=C(NC[C@@H]1CCCCN1)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"VCULOSHGZWNQPI-IBGZPJMESA-N";404.52;3.09;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228256/target=_blank>CHEMBL1228256</a>";;-5.64;"Shimizu H, Tanaka S, Toki T, Yasumatsu I, Akimoto T, Morishita K, Yamasaki T, Yasukochi T, Iimura S.: Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.0000022908676527677747
"MM471557";"MM471557";"Cc1cc(NC(=O)Nc2ccc(Cl)cc2)c2ccccc2n1";"JQMQNDGGSXZDNL-UHFFFAOYSA-N";311.77;4.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.27;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0005370317963702527
"MM471523";"MM471523";"CCc1c(C)[nH]c2cc(OC)c(F)cc2c1=O";"ZCUUVDIRRJZGFY-UHFFFAOYSA-N";235.26;2.55;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1261030/target=_blank>CHEMBL1261030</a>";;-4.72;"Cross RM, Monastyrskyi A, Mutka TS, Burrows JN, Kyle DE, Manetsch R.: Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity. J Med Chem, Volume 53 (19), 2010";"PAMPA";0.000019054607179632484
"MM471531";"MM471531";"COc1ccc2c(=O)cc(C)[nH]c2c1";"VXLZVELXYBOECH-UHFFFAOYSA-N";189.21;1.85;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1261030/target=_blank>CHEMBL1261030</a>";;-5.05;"Cross RM, Monastyrskyi A, Mutka TS, Burrows JN, Kyle DE, Manetsch R.: Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity. J Med Chem, Volume 53 (19), 2010";"PAMPA";0.00000891250938133746
"MM471915";"MM471915";"Cc1cccc(-n2cnc3cc(C(=O)N4CCCCC4)ccc32)c1";"YQNOQZALLOQMPY-UHFFFAOYSA-N";319.41;3.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-2.92;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.001202264434617413
"MM471314";"MM471314";"O=c1c2cc(F)ccc2sn1-c1ccccc1";"ZTQXZKHEMCRFEP-UHFFFAOYSA-N";245.28;3.19;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777057/target=_blank>CHEMBL1777057</a>";;-3.2;"Dahl R, Bravo Y, Sharma V, Ichikawa M, Dhanya RP, Hedrick M, Brown B, Rascon J, Vicchiarelli M, Mangravita-Novo A, Yang L, Stonich D, Su Y, Smith LH, Sergienko E, Freeze HH, Cosford ND.: Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem, Volume 54 (10), 2011";"PAMPA";0.000630957344480193
"MM471921";"MM471921";"Cc1cc(-c2nnc3n2CCCCC3)c(C)n1-c1ccccc1";"SGHSEHOWYLRAPR-UHFFFAOYSA-N";306.41;4.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-3.22;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.0006025595860743575
"MM471421";"MM471421";"Cc1ccccc1C(=O)N1CCc2cc(-c3nc(NC(=O)Cc4ccc5c(c4)OCO5)sc3C)ccc21";"LINHYWKZVCNAMQ-UHFFFAOYSA-N";511.6;5.54;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3877060/target=_blank>CHEMBL3877060</a>";;1.04;"Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X.: Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem, Volume 25 (3), 2017";"PAMPA";10.964781961431852
"MM471749";"MM471749";"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO";"MFYSYFVPBJMHGN-ZPOLXVRWSA-N";360.45;1.99;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146840/target=_blank>CHEMBL4146840</a>";;-4.77;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.00001698243652461746
"MM471734";"MM471734";"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O";"QZPQTZZNNJUOLS-UHFFFAOYSA-N";242.27;2.75;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4131170/target=_blank>CHEMBL4131170</a>";;-4.33;"Zhang X, Bian J, Li X, Wu X, Dong Y, You Q.: 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.00004677351412871981
"MM471998";"MM471998";"O=C(CCc1ccccc1)NO";"HYBGBWAPFWWJRE-UHFFFAOYSA-N";165.19;1.12;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801192/target=_blank>CHEMBL3801192</a>";;-5.3;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.000005011872336272725
"MM471315";"MM471315";"Cc1ccc(C)c(-n2sc3ccc(F)cc3c2=O)c1";"KVSHNLSLZGDCNM-UHFFFAOYSA-N";273.33;3.81;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777057/target=_blank>CHEMBL1777057</a>";;-2.9;"Dahl R, Bravo Y, Sharma V, Ichikawa M, Dhanya RP, Hedrick M, Brown B, Rascon J, Vicchiarelli M, Mangravita-Novo A, Yang L, Stonich D, Su Y, Smith LH, Sergienko E, Freeze HH, Cosford ND.: Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem, Volume 54 (10), 2011";"PAMPA";0.0012589254117941675
"MM471540";"MM471540";"Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1F)nc2[C@H]1CC[C@H](C(=O)Nc2nncs2)CC1";"IYHDQGNBIDQYLJ-MXVIHJGJSA-N";564.65;6.1;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1670386/target=_blank>CHEMBL1670386</a>";;-4.07;"Jin M, Kleinberg A, Cooke A, Gokhale PC, Foreman K, Dong H, Siu KW, Bittner MA, Mulvihill KM, Yao Y, Landfair D, O'Connor M, Mak G, Pachter JA, Wild R, Rosenfeld-Franklin M, Ji Q, Mulvihill MJ.: Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy. Bioorg Med Chem Lett, Volume 21 (4), 2011";"PAMPA";0.0000851138038202376
"MM471542";"MM471542";"CO[C@H]1CCN[C@@H]1CNC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"JXUBMUQJWOBLQL-QUCCMNQESA-N";420.52;2.32;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1671203/target=_blank>CHEMBL1671203</a>";;-5.19;"Shimizu H, Yasumatsu I, Hamada T, Yoneda Y, Yamasaki T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 2: improvement of potency in vitro and in vivo. Bioorg Med Chem Lett, Volume 21 (3), 2011";"PAMPA";0.000006456542290346549
"MM471543";"MM471543";"O=C(NC[C@@H]1C[C@@H](F)CN1)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"FCDBCRNHJZQDCG-MSOLQXFVSA-N";408.48;2.65;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1671203/target=_blank>CHEMBL1671203</a>";;-4.44;"Shimizu H, Yasumatsu I, Hamada T, Yoneda Y, Yamasaki T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 2: improvement of potency in vitro and in vivo. Bioorg Med Chem Lett, Volume 21 (3), 2011";"PAMPA";0.0000363078054770101
"MM471544";"MM471544";"CN(C[C@@H]1CCCN1)C(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"AKWSIDWVFMPINB-IBGZPJMESA-N";404.52;3.04;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1671203/target=_blank>CHEMBL1671203</a>";;-5.21;"Shimizu H, Yasumatsu I, Hamada T, Yoneda Y, Yamasaki T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 2: improvement of potency in vitro and in vivo. Bioorg Med Chem Lett, Volume 21 (3), 2011";"PAMPA";0.000006165950018614822
"MM471545";"MM471545";"CCN(C[C@@H]1C[C@@H](F)CN1)C(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"TWEYJMZZQBJMDD-UXHICEINSA-N";436.54;3.38;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1671203/target=_blank>CHEMBL1671203</a>";;-4.38;"Shimizu H, Yasumatsu I, Hamada T, Yoneda Y, Yamasaki T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 2: improvement of potency in vitro and in vivo. Bioorg Med Chem Lett, Volume 21 (3), 2011";"PAMPA";0.00004168693834703355
"MM471546";"MM471546";"O=C(c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1)N(Cc1ccc(Cl)cc1)C[C@@H]1C[C@@H](F)CN1";"JHAQDACUOASJFN-RPBOFIJWSA-N";533.05;5.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1671203/target=_blank>CHEMBL1671203</a>";;-4.41;"Shimizu H, Yasumatsu I, Hamada T, Yoneda Y, Yamasaki T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 2: improvement of potency in vitro and in vivo. Bioorg Med Chem Lett, Volume 21 (3), 2011";"PAMPA";0.000038904514499428046
"MM471547";"MM471547";"O=C(O)CN(C[C@@H]1C[C@@H](F)CN1)C(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1";"FERXNRXQECFJAW-MOPGFXCFSA-N";466.52;2.45;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1671203/target=_blank>CHEMBL1671203</a>";;-4.85;"Shimizu H, Yasumatsu I, Hamada T, Yoneda Y, Yamasaki T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 2: improvement of potency in vitro and in vivo. Bioorg Med Chem Lett, Volume 21 (3), 2011";"PAMPA";0.000014125375446227555
"MM471548";"MM471548";"O=C(c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1)N(CCO)C[C@@H]1C[C@@H](F)CN1";"FCIZALUMQYUBST-UXHICEINSA-N";452.53;2.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1671203/target=_blank>CHEMBL1671203</a>";;-4.82;"Shimizu H, Yasumatsu I, Hamada T, Yoneda Y, Yamasaki T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 2: improvement of potency in vitro and in vivo. Bioorg Med Chem Lett, Volume 21 (3), 2011";"PAMPA";0.000015135612484362071
"MM471550";"MM471550";"Cc1cc(NC(=O)Nc2ccc(C)c(Cl)c2)c2ccccc2n1";"XGJCNQIEHUPXTE-UHFFFAOYSA-N";325.8;5.15;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.58;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.00026302679918953814
"MM471552";"MM471552";"CCc1ccc(NC(=O)Nc2cc(C)nc3ccccc23)cc1";"HNGJNHNCKIZJCK-UHFFFAOYSA-N";305.38;4.75;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.27;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0005370317963702527
"MM471553";"MM471553";"Cc1ccc(NC(=O)Nc2cc(C)nc3ccccc23)cc1";"HPZZLUMHLOCFLV-UHFFFAOYSA-N";291.35;4.5;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.17;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0006760829753919819
"MM471554";"MM471554";"Cc1cc(NC(=O)Nc2cccc(Cl)c2)c2ccccc2n1";"BWCYDFBYHRCCKX-UHFFFAOYSA-N";311.77;4.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.25;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0005623413251903491
"MM471555";"MM471555";"Cc1cc(NC(=O)Nc2ccc(Cl)c(Cl)c2)c2ccccc2n1";"ADMPDKDPAUHBGP-UHFFFAOYSA-N";346.22;5.49;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.71;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.00019498445997580456
"MM471556";"MM471556";"Cc1cc(NC(=O)Nc2ccc(Cl)cc2Cl)c2ccccc2n1";"SZPJCVSCONGCGU-UHFFFAOYSA-N";346.22;5.49;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-5.22;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.000006025595860743581
"MM471558";"MM471558";"Cc1cc(NC(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)c2ccccc2n1";"CVSOPPYMGJDQET-UHFFFAOYSA-N";379.77;5.86;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-4.2;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.00006309573444801929
"MM471559";"MM471559";"Cc1cc(NC(=O)Nc2ccccc2F)c2ccccc2n1";"NCDCHPMCNVQSPX-UHFFFAOYSA-N";295.32;4.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.09;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0008128305161640995
"MM471560";"MM471560";"Cc1cc(NC(=O)Nc2ccc(F)cc2)c2ccccc2n1";"LNIHAMGNOIKRMR-UHFFFAOYSA-N";295.32;4.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.1;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0007943282347242813
"MM471561";"MM471561";"Cc1cc(NC(=O)Nc2ccc(F)cc2F)c2ccccc2n1";"CPGURSRCDYMDNZ-UHFFFAOYSA-N";313.31;4.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.19;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0006456542290346556
"MM471562";"MM471562";"Cc1cc(NC(=O)Nc2cc(F)ccc2F)c2ccccc2n1";"ZFPLGIGDAMVSQN-UHFFFAOYSA-N";313.31;4.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.27;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0005370317963702527
"MM471563";"MM471563";"Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)c2ccccc2n1";"PQDQXZBTLSPWDP-UHFFFAOYSA-N";313.31;4.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.32;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.00047863009232263854
"MM471564";"MM471564";"COc1ccc(NC(=O)Nc2cc(C)nc3ccccc23)cc1F";"IYNBUUHJWNFIIW-UHFFFAOYSA-N";325.34;4.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-4.3;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.00005011872336272725
"MM471565";"MM471565";"Cc1cccc(NC(=O)Nc2cc(C)nc3ccccc23)c1";"DOWRGPZCQNQNQM-UHFFFAOYSA-N";291.35;4.5;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-5.4;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.000003981071705534969
"MM471312";"MM471312";"CC(C)(C)c1ccc(-n2sc3ccccc3c2=O)cc1";"LSWCOOVGYNLMFY-UHFFFAOYSA-N";283.4;4.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777057/target=_blank>CHEMBL1777057</a>";;-2.8;"Dahl R, Bravo Y, Sharma V, Ichikawa M, Dhanya RP, Hedrick M, Brown B, Rascon J, Vicchiarelli M, Mangravita-Novo A, Yang L, Stonich D, Su Y, Smith LH, Sergienko E, Freeze HH, Cosford ND.: Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem, Volume 54 (10), 2011";"PAMPA";0.001584893192461114
"MM471313";"MM471313";"Cc1ccc(C)c(-n2sc3cc(F)ccc3c2=O)c1";"GRGDWLDSVPJEJU-UHFFFAOYSA-N";273.33;3.81;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777057/target=_blank>CHEMBL1777057</a>";;-2.9;"Dahl R, Bravo Y, Sharma V, Ichikawa M, Dhanya RP, Hedrick M, Brown B, Rascon J, Vicchiarelli M, Mangravita-Novo A, Yang L, Stonich D, Su Y, Smith LH, Sergienko E, Freeze HH, Cosford ND.: Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem, Volume 54 (10), 2011";"PAMPA";0.0012589254117941675
"Cephalexin";"MM00721";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1";"ZAIPMKNFIOOWCQ-UHFFFAOYSA-N";347.4;0.44;"27447";"CHEMBL1727";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-7.82;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.000000015135612484362072
"MM471568";"MM471568";"CC(Cn1ncc2c(Nc3cccc(Cl)c3)ncnc21)c1ccccc1";"XFCBZNMZGGDLOU-UHFFFAOYSA-N";363.85;5.03;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1775364/target=_blank>CHEMBL1775364</a>";;-4.87;"Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M.: Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J Med Chem, Volume 54 (8), 2011";"PAMPA";0.000013489628825916533
"MM471570";"MM471570";"ClC(Cn1ncc2c(NCc3ccccc3)nc(SCCN3CCOCC3)nc21)c1ccccc1";"NBRVSSMSYRPVCE-UHFFFAOYSA-N";509.08;4.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1775364/target=_blank>CHEMBL1775364</a>";;-5.04;"Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M.: Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J Med Chem, Volume 54 (8), 2011";"PAMPA";0.000009120108393559096
"MM471567";"MM471567";"Clc1cccc(Nc2nc(N3CCOCC3)nc3c2cnn3CC(Cl)c2ccccc2)c1";"OTWMXTGUDMPDEI-UHFFFAOYSA-N";469.38;5.04;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1775364/target=_blank>CHEMBL1775364</a>";;-4.83;"Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M.: Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J Med Chem, Volume 54 (8), 2011";"PAMPA";0.000014791083881682072
"MM471574";"MM471574";"OCCNc1nc(NCCc2ccccc2)c2cnn(/C=C\c3ccccc3)c2n1";"LAOYAWHHLUVMFT-QINSGFPZSA-N";400.49;3.51;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1775364/target=_blank>CHEMBL1775364</a>";;-5.59;"Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M.: Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J Med Chem, Volume 54 (8), 2011";"PAMPA";0.0000025703957827688647
"MM471573";"MM471573";"Clc1ccc(C(Cl)Cn2ncc3c(NCc4ccncc4)ncnc32)cc1";"LHXWTIIFWARQLP-UHFFFAOYSA-N";399.29;4.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1775364/target=_blank>CHEMBL1775364</a>";;-5.27;"Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M.: Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J Med Chem, Volume 54 (8), 2011";"PAMPA";0.000005370317963702533
"MM471802";"MM471802";"O=P(O)(O)CCc1ccccc1";"BFDYSJCMAFSRDH-UHFFFAOYSA-N";186.15;1.41;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801192/target=_blank>CHEMBL3801192</a>";;-7.03;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.00000009332543007969905
"MM471594";"MM471594";"O=c1c2c([nH]c3ccc(Cl)cc13)CCCC2";"STQOKXJKHUNULH-UHFFFAOYSA-N";233.7;3.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.24;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000057543993733715664
"MM471576";"MM471576";"COc1ccc2c(=O)c3c([nH]c2c1)CCC3";"XRHIRCKOKLQWFR-UHFFFAOYSA-N";215.25;2.03;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.96;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000010964781961431852
"MM471577";"MM471577";"COc1ccc2c(=O)c3c([nH]c2c1)CCCC3";"LSVXWLDSOHBOOX-UHFFFAOYSA-N";229.28;2.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.6;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000025118864315095822
"MM471578";"MM471578";"COc1ccc2c(=O)c3c([nH]c2c1)CCCCC3";"QXUXBOSZPNMVDU-UHFFFAOYSA-N";243.31;2.81;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.41;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000038904514499428046
"MM471579";"MM471579";"COc1ccc2c(=O)c3c([nH]c2c1)CCCCCC3";"YXOCXGPUHWAIKT-UHFFFAOYSA-N";257.33;3.2;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.14;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00007244359600749906
"MM471580";"MM471580";"O=c1c2c([nH]c3cc(C(F)(F)F)ccc13)CCC2";"WFMYOWVLTUNEOK-UHFFFAOYSA-N";253.22;3.04;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.22;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000060255958607435806
"MM471581";"MM471581";"O=c1c2c([nH]c3cc(C(F)(F)F)ccc13)CCCC2";"HMGHQUBMNPHEHV-UHFFFAOYSA-N";267.25;3.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.14;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00007244359600749906
"MM471582";"MM471582";"O=c1c2c([nH]c3cc(C(F)(F)F)ccc13)CCCCC2";"WTAYGPWOLMJSHX-UHFFFAOYSA-N";281.28;3.82;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-3.88;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00013182567385564074
"MM471583";"MM471583";"O=c1c2c([nH]c3cc(C(F)(F)F)ccc13)CCCCCC2";"LOHSFVWYARXTIS-UHFFFAOYSA-N";295.3;4.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-3.6;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00025118864315095795
"MM471585";"MM471585";"COc1cccc2c(=O)c3c([nH]c12)CCCC3";"DRTNPMJEVFCBHD-UHFFFAOYSA-N";229.28;2.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.8;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00001584893192461114
"MM471586";"MM471586";"COc1ccc2[nH]c3c(c(=O)c2c1)CCCC3";"NAKOPQZYTOAWQJ-UHFFFAOYSA-N";229.28;2.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.8;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00001584893192461114
"MM471587";"MM471587";"COc1cccc2[nH]c3c(c(=O)c12)CCCC3";"YCJXMWQCDPTWNB-UHFFFAOYSA-N";229.28;2.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.77;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00001698243652461746
"MM471588";"MM471588";"Cc1cccc2c(=O)c3c([nH]c12)CCCC3";"BVXFTEWGRDIUJD-UHFFFAOYSA-N";213.28;2.72;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.59;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000025703957827688645
"MM471589";"MM471589";"Cc1ccc2c(=O)c3c([nH]c2c1)CCCC3";"FWDFPYDVWVFYKM-UHFFFAOYSA-N";213.28;2.72;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.57;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00002691534803926914
"MM471590";"MM471590";"Cc1ccc2[nH]c3c(c(=O)c2c1)CCCC3";"FFRHGRTZMLXUMO-UHFFFAOYSA-N";213.28;2.72;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.72;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000019054607179632484
"MM471591";"MM471591";"Cc1cccc2[nH]c3c(c(=O)c12)CCCC3";"IPPASRLNICEBAG-UHFFFAOYSA-N";213.28;2.72;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.06;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00008709635899560814
"MM471592";"MM471592";"O=c1c2c([nH]c3c(Cl)cccc13)CCCC2";"ZRAIXTUKQRXQBM-UHFFFAOYSA-N";233.7;3.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-3.97;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00010715193052376059
"MM471596";"MM471596";"O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1F";"XYEYHGKCPQJHPX-INIZCTEOSA-N";408.48;2.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1809899/target=_blank>CHEMBL1809899</a>";;-4.72;"Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 3: exploration of effective compounds in arthritis models. Bioorg Med Chem Lett, Volume 21 (15), 2011";"PAMPA";0.000019054607179632484
"MM471597";"MM471597";"O=C(NC[C@@H]1CCCN1)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)cc1Cl";"PLRJTOPQRBZHFY-INIZCTEOSA-N";424.94;3.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1809899/target=_blank>CHEMBL1809899</a>";;-4.85;"Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 3: exploration of effective compounds in arthritis models. Bioorg Med Chem Lett, Volume 21 (15), 2011";"PAMPA";0.000014125375446227555
"MM471598";"MM471598";"CN(C)CCNC(=O)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)nc1";"LTSGHDUZMWKTJB-UHFFFAOYSA-N";379.47;1.9;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1809899/target=_blank>CHEMBL1809899</a>";;-4.85;"Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 3: exploration of effective compounds in arthritis models. Bioorg Med Chem Lett, Volume 21 (15), 2011";"PAMPA";0.000014125375446227555
"MM471599";"MM471599";"O=C(NCCN1CCCC1)c1ccc(-c2cnc3ccc(NCC4CC4)nn23)nc1";"RTPQNRJJDVLYPV-UHFFFAOYSA-N";405.51;2.44;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1809899/target=_blank>CHEMBL1809899</a>";;-4.96;"Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 3: exploration of effective compounds in arthritis models. Bioorg Med Chem Lett, Volume 21 (15), 2011";"PAMPA";0.000010964781961431852
"MM471600";"MM471600";"CSCCCNc1ccc2ncc(-c3ccc(C(=O)NC[C@@H]4C[C@@H](F)CN4)c(F)c3)n2n1";"IAHJEADTZSOQLR-CVEARBPZSA-N";460.55;3.13;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1809899/target=_blank>CHEMBL1809899</a>";;-4.4;"Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 3: exploration of effective compounds in arthritis models. Bioorg Med Chem Lett, Volume 21 (15), 2011";"PAMPA";0.000039810717055349695
"MM471601";"MM471601";"O=C(NC[C@@H]1C[C@@H](F)CN1)c1ccc(-c2cnc3ccc(NCCCF)nn23)cc1F";"WCGKVUGNISNLJH-CABCVRRESA-N";432.45;2.74;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1809899/target=_blank>CHEMBL1809899</a>";;-4.48;"Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 3: exploration of effective compounds in arthritis models. Bioorg Med Chem Lett, Volume 21 (15), 2011";"PAMPA";0.000033113112148259076
"MM471602";"MM471602";"O=C(NC[C@@H]1C[C@@H](F)CN1)c1ccc(-c2cnc3ccc(NCCCCCF)nn23)cc1F";"HAADVGFSSKITLQ-SJORKVTESA-N";460.5;3.52;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1809899/target=_blank>CHEMBL1809899</a>";;-4.43;"Shimizu H, Yamasaki T, Yoneda Y, Muro F, Hamada T, Yasukochi T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.: Discovery of imidazo[1,2-b]pyridazines as IKKÎ˛ inhibitors. Part 3: exploration of effective compounds in arthritis models. Bioorg Med Chem Lett, Volume 21 (15), 2011";"PAMPA";0.00003715352290971728
"MM471603";"MM471603";"Cc1cc(-c2cccc(Cl)c2)ncc1[C@H]1CCCN1C(=O)c1nccs1";"GCSDBTCZHROCLZ-GOSISDBHSA-N";383.9;5.14;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1810108/target=_blank>CHEMBL1810108</a>";;-4.82;"Weiss JM, Jimenez HN, Li G, April M, Uberti MA, Bacolod MD, Brodbeck RM, Doller D.: 6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett, Volume 21 (16), 2011";"PAMPA";0.000015135612484362071
"MM471605";"MM471605";"COc1ccc(Oc2ccc3c(NCCCNCc4ccco4)ccnc3c2)cc1";"BGDNFVNBVKOWAX-UHFFFAOYSA-N";403.48;5.22;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471606";"MM471606";"COc1ccc(F)cc1CNCCCNc1ccnc2cc(Oc3cccc(N(C)C)c3)ccc12";"BPOAUWBFJOUOKG-UHFFFAOYSA-N";474.58;5.83;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471607";"MM471607";"c1ccc(Oc2ccc3c(NCCCNCc4ccc5c(c4)OCO5)ccnc3c2)cc1";"IEMBQFCUMBJOEI-UHFFFAOYSA-N";427.5;5.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471608";"MM471608";"COc1ccccc1Oc1ccc2c(NCCCNCc3ccco3)ccnc2c1";"XGEIVJJDAKGRLA-UHFFFAOYSA-N";403.48;5.22;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471609";"MM471609";"Fc1ccc(Oc2ccc3c(NCCCNCc4ccco4)ccnc3c2)cc1";"RFWBCMIHMRCBCF-UHFFFAOYSA-N";391.45;5.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471610";"MM471610";"COc1ccc(F)cc1CNCCCNc1ccnc2cc(Oc3ccc(Cl)cc3)ccc12";"SHCCOLVWBRCRBD-UHFFFAOYSA-N";465.96;6.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471611";"MM471611";"COc1ccc(F)cc1CNCCCNc1ccnc2cc(Oc3ccc(F)cc3)ccc12";"IGPDNXFHIVFNAJ-UHFFFAOYSA-N";449.5;5.91;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471612";"MM471612";"COc1ccc(F)cc1CNCCCNc1ccnc2cc(Oc3ccccc3)ccc12";"AVJAAXINKHZLGT-UHFFFAOYSA-N";431.51;5.77;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471613";"MM471613";"COc1cccc(Oc2ccc3c(NCCCNCc4ccco4)ccnc3c2)c1";"ZMRYSWOSFHVMQZ-UHFFFAOYSA-N";403.48;5.22;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471614";"MM471614";"CN(C)c1cccc(Oc2ccc3c(NCCCNCc4ccco4)ccnc3c2)c1";"RCKMFSJLMAJGGG-UHFFFAOYSA-N";416.53;5.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471615";"MM471615";"COc1cccc(CNCCCNc2ccnc3cc(Oc4ccc(C(C)(C)C)cc4)ccc23)c1O";"BXYAHDTWWYCEEF-UHFFFAOYSA-N";485.63;6.63;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471616";"MM471616";"COc1cccc(Oc2ccc3c(NCCCNCc4cc(F)ccc4OC)ccnc3c2)c1";"VZAORDHRWQXOKK-UHFFFAOYSA-N";461.54;5.78;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471617";"MM471617";"Clc1ccc(Oc2ccc3c(NCCCNCc4ccc5c(c4)OCO5)ccnc3c2)cc1";"KDIBZFAVIJOCTM-UHFFFAOYSA-N";461.95;6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471618";"MM471618";"COc1ccc(Oc2ccc3c(NCCCNCc4cccc(OC)c4O)ccnc3c2)cc1";"ZNPXRAIQHVQTFF-UHFFFAOYSA-N";459.55;5.34;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471619";"MM471619";"COc1ccccc1Oc1ccc2c(NCCCNCc3ccc4c(c3)OCO4)ccnc2c1";"HNIIHQVJOZGRCP-UHFFFAOYSA-N";457.53;5.36;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471620";"MM471620";"COc1cccc(Oc2ccc3c(NCCCNCc4ccc5c(c4)OCO5)ccnc3c2)c1";"PMLUMEIQOLGEAB-UHFFFAOYSA-N";457.53;5.36;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471621";"MM471621";"COc1ccc(Oc2ccc3c(NCCCNCc4cc(F)ccc4OC)ccnc3c2)cc1";"ZXMXSYGRUYATLC-UHFFFAOYSA-N";461.54;5.78;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471622";"MM471622";"Fc1ccc(Oc2ccc3c(NCCCNCc4ccc5c(c4)OCO5)ccnc3c2)cc1";"UEWQAJBUMUNJRZ-UHFFFAOYSA-N";445.49;5.49;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471623";"MM471623";"COc1cccc(CNCCCNc2ccnc3cc(Oc4ccc(Cl)cc4)ccc23)c1O";"HEUQEMNEAFXENH-UHFFFAOYSA-N";463.97;5.99;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"MM471624";"MM471624";"Clc1ccc(Oc2ccc3c(NCCCNCc4ccco4)ccnc3c2)cc1";"IVHAGHYALPYDPQ-UHFFFAOYSA-N";407.9;5.87;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837545/target=_blank>CHEMBL1837545</a>";;-3.5;"Hwang JY, Kawasuji T, Lowes DJ, Clark JA, Connelly MC, Zhu F, Guiguemde WA, Sigal MS, Wilson EB, Derisi JL, Guy RK.: Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J Med Chem, Volume 54 (20), 2011";"PAMPA";0.00031622776601683794
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146843/target=_blank>CHEMBL4146843</a>";;-6.4;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000003981071705534969
"MM471841";"MM471841";"O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCN(C(c2ccccc2)c2ccccc2)CC1";"YRDBYJNFZJBXNY-UHFFFAOYSA-N";534.7;5.65;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2160416/target=_blank>CHEMBL2160416</a>";;-5.64;"Lowes D, Pradhan A, Iyer LV, Parman T, Gow J, Zhu F, Furimsky A, Lemoff A, Guiguemde WA, Sigal M, Clark JA, Wilson E, Tang L, Connelly MC, Derisi JL, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of antimalarial propafenone analogues. J Med Chem, Volume 55 (13), 2012";"PAMPA";0.0000022908676527677747
"MM471843";"MM471843";"O=C(CCc1ccccc1)c1ccccc1OCC(O)CN1CCC(c2ccccc2)CC1";"ZHUPKALTWVLYNU-UHFFFAOYSA-N";443.59;5.12;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2160416/target=_blank>CHEMBL2160416</a>";;-3.31;"Lowes D, Pradhan A, Iyer LV, Parman T, Gow J, Zhu F, Furimsky A, Lemoff A, Guiguemde WA, Sigal M, Clark JA, Wilson E, Tang L, Connelly MC, Derisi JL, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of antimalarial propafenone analogues. J Med Chem, Volume 55 (13), 2012";"PAMPA";0.0004897788193684461
"MM471842";"MM471842";"O=C(CCc1ccccc1)c1cc(F)ccc1OCC(O)CN1CCN(C(c2ccccc2)c2ccccc2)CC1";"KTGYQSLCEGJTLM-UHFFFAOYSA-N";552.69;5.79;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2160416/target=_blank>CHEMBL2160416</a>";;-6.1;"Lowes D, Pradhan A, Iyer LV, Parman T, Gow J, Zhu F, Furimsky A, Lemoff A, Guiguemde WA, Sigal M, Clark JA, Wilson E, Tang L, Connelly MC, Derisi JL, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of antimalarial propafenone analogues. J Med Chem, Volume 55 (13), 2012";"PAMPA";0.0000007943282347242822
"MM472034";"MM472034";"COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C";"FKRSSPOQAMALKA-CUPIEXAXSA-N";738.89;6.22;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.3;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00005011872336272725
"MM471460";"MM471460";"CC(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)Cc6sc(N)nc6C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12";"RASMIZWADITSSW-NXEQSAOGSA-N";512.8;7.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4315699/target=_blank>CHEMBL4315699</a>";;-5.34;"BorkovĂˇ L, Frydrych I, JakubcovĂˇ N, AdĂˇmek R, LiĹˇkovĂˇ B, GurskĂˇ S, MedvedĂ­kovĂˇ M, HajdĂşch M, Urban M.: Synthesis and biological evaluation of triterpenoid thiazoles derived from betulonic acid, dihydrobetulonic acid, and ursonic acid. Eur J Med Chem, Volume 185, 2020";"PAMPA";0.000004570881896148752
"MM471333";"MM471333";"Cc1[nH]c2ccccc2c1C(Nc1ccccc1)c1ccccc1";"GYRJMFJIIQWJSF-UHFFFAOYSA-N";312.42;5.68;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000001
"MM471334";"MM471334";"Cc1[nH]c2ccccc2c1C(Nc1ccccc1)c1ccc(Cl)cc1";"XECLBYVJWQYBLT-UHFFFAOYSA-N";346.86;6.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.03;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000009332543007969905
"MM471332";"MM471332";"COc1ccc(C(Nc2ccccc2)c2c(C)[nH]c3ccccc23)cc1";"XUEXVGQESDMUCX-UHFFFAOYSA-N";342.44;5.69;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.1;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000007943282347242822
"MM471331";"MM471331";"Cc1ccc(C(Nc2ccccc2)c2c(C)[nH]c3ccccc23)cc1";"ZSRRDAVCCVHDTL-UHFFFAOYSA-N";326.44;5.99;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.34;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.00000045708818961487516
"MM471329";"MM471329";"Cc1[nH]c2ccccc2c1C(Nc1ccccc1)c1ccc(N(C)C)cc1";"ODVYIAMUSCZGRO-UHFFFAOYSA-N";355.49;5.74;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.88;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.00000013182567385564074
"MM471328";"MM471328";"Cc1[nH]c2ccccc2c1C(C)Nc1ccccc1";"DDGANMJHQGZTFA-UHFFFAOYSA-N";250.35;4.65;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.4;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000003981071705534969
"MM471327";"MM471327";"Cc1[nH]c2ccccc2c1C(Nc1ccccc1)c1ccc2ccccc2c1";"QOAYZHCBPQVSGD-UHFFFAOYSA-N";362.48;6.83;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.3;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000005011872336272725
"MM471325";"MM471325";"Cc1[nH]c2ccccc2c1C(Nc1ccccc1)c1ccc(CCCO)cc1";"KAOODWWVZHYMNZ-UHFFFAOYSA-N";370.5;5.6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.83;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000001479108388168207
"MM471326";"MM471326";"Cc1[nH]c2ccccc2c1C(Nc1ccccc1)c1ccccc1Cl";"KKYPVDWXGFTXDX-UHFFFAOYSA-N";346.86;6.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.41;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000003890451449942805
"MM471324";"MM471324";"Cc1[nH]c2ccccc2c1C(Nc1ccc(Cl)cc1)c1ccccc1Cl";"FYALZEQZMVNQCR-UHFFFAOYSA-N";381.31;6.98;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.24;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000005754399373371567
"MM471323";"MM471323";"COc1ccc(NC(c2ccccc2Cl)c2c(C)[nH]c3ccccc23)cc1";"NMSSLXZRBIVVTN-UHFFFAOYSA-N";376.89;6.34;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.3;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000005011872336272725
"MM471322";"MM471322";"Cc1ccc(NC(c2ccccc2Cl)c2c(C)[nH]c3ccccc23)cc1";"WGMLMTFVAKEION-UHFFFAOYSA-N";360.89;6.64;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.45;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000003548133892335753
"MM471320";"MM471320";"Cc1[nH]c2ccccc2c1C(Nc1ccc(N(C)C)cc1)c1ccccc1Cl";"HIZIBVCJGAJFLN-UHFFFAOYSA-N";389.93;6.4;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-7.28;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.00000005248074602497723
"MM471318";"MM471318";"COc1ccccc1NC(c1ccccc1Cl)c1c(C)[nH]c2ccccc12";"WYOHPJDZAQURHE-UHFFFAOYSA-N";376.89;6.34;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.22;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000006025595860743581
"MM471319";"MM471319";"Cn1cc(C(Nc2ccccc2)c2ccccc2Cl)c2ccccc21";"YRXMYKUYMUGZIR-UHFFFAOYSA-N";346.86;6.03;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.58;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.00000026302679918953816
"MM471316";"MM471316";"Clc1ccccc1C(Nc1ccccc1)c1c[nH]c2ccccc12";"QACDMNBMSITDOR-UHFFFAOYSA-N";332.83;6.02;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.51;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000003090295432513592
"MM471317";"MM471317";"Cc1[nH]c2ccccc2c1C(Sc1ccccc1)c1ccccc1Cl";"YUPCEFFCHQWZDR-UHFFFAOYSA-N";363.91;7.01;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2073150/target=_blank>CHEMBL2073150</a>";;-6.89;"Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.: Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.00000012882495516931348
"MM471804";"MM471804";"O=C(O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)c(Cl)c(Cl)c1O";"SMIZKRHOEQTUGE-LURJTMIESA-N";374.63;2.59;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868184/target=_blank>CHEMBL868184</a>";;-7.7;"Gopalsamy A, Chopra R, Lim K, Ciszewski G, Shi M, Curran KJ, Sukits SF, Svenson K, Bard J, Ellingboe JW, Agarwal A, Krishnamurthy G, Howe AY, Orlowski M, Feld B, O'Connell J, Mansour TS.: Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. J Med Chem, Volume 49 (11), 2006";"PAMPA";0.000000019952623149688786
"MM471420";"MM471420";"Cc1ccc(C)n1-c1ccc(C(=O)O)cc1";"WNZAIUIEXCYTCY-UHFFFAOYSA-N";215.25;2.79;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3877060/target=_blank>CHEMBL3877060</a>";;0.06;"Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X.: Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem, Volume 25 (3), 2017";"PAMPA";1.1481536214968828
"MM472019";"MM472019";"c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2";"OCKIPDMKGPYYJS-ZDUSSCGKSA-N";216.28;1.48;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2340857/target=_blank>CHEMBL2340857</a>";;-4.29;"McDonald IM, Mate RA, Zusi FC, Huang H, Post-Munson DJ, Ferrante MA, Gallagher L, Bertekap RL, Knox RJ, Robertson BJ, Harden DG, Morgan DG, Lodge NJ, Dworetzky SI, Olson RE, Macor JE.: Discovery of a novel series of quinolone Î±7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem Lett, Volume 23 (6), 2013";"PAMPA";0.00005128613839913648
"MM471845";"MM471845";"COc1cc2[nH]c(-c3cccc(Oc4ccccc4)c3)c(C(=O)OCCO)c(=O)c2cc1F";"ZNUGFQFCUNUYJO-UHFFFAOYSA-N";449.43;4.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.21;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0006165950018614823
"MM471850";"MM471850";"CCOC(=O)c1c(-c2cccc(Oc3ccccc3)c2)[nH]c2cc(OC)c(F)cc2c1=O";"ZFKZCGYBLXYLJA-UHFFFAOYSA-N";433.44;5.31;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.25;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0005623413251903491
"MM471849";"MM471849";"CCOC(=O)c1c(-c2cccc(Cl)c2)[nH]c2cc(OC)c(F)cc2c1=O";"ZIRLMVDCUSOULK-UHFFFAOYSA-N";375.78;4.17;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.39;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0004073802778041126
"MM471848";"MM471848";"CCOC(=O)c1c(-c2cccc(Br)c2)[nH]c2cc(OC)c(F)cc2c1=O";"SUXJWGAAWOVYLH-UHFFFAOYSA-N";420.23;4.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.17;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0006760829753919819
"MM471847";"MM471847";"CCOC(=O)c1c(-c2cc(F)cc(OC)c2)[nH]c2cc(OC)c(F)cc2c1=O";"WDRQAWOIGOJIIL-UHFFFAOYSA-N";389.35;3.67;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.64;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.00022908676527677723
"MM471856";"MM471856";"CCOC(=O)c1c(-c2cccc(-c3ccccc3)c2)[nH]c2cc(OC)ccc2c1=O";"OEVZQVIGGVNLLJ-UHFFFAOYSA-N";399.45;5.05;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-2.54;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0028840315031266055
"MM471855";"MM471855";"CCOC(=O)c1c(-c2cccc(OCC)c2)[nH]c2cc(OC)ccc2c1=O";"OKRMQSDORUSWSS-UHFFFAOYSA-N";367.4;3.78;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.59;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0002570395782768865
"MM471853";"MM471853";"CCCOc1cccc(-c2[nH]c3cc(OC)ccc3c(=O)c2C(=O)OCC)c1";"HLZLABVDBYMCKV-UHFFFAOYSA-N";381.43;4.17;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.47;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0003388441561392024
"MM471852";"MM471852";"CCOC(=O)c1c(-c2cccc(Oc3ccccc3)c2)[nH]c2cc(OC)ccc2c1=O";"PZODNGYXJBSPAW-UHFFFAOYSA-N";415.45;5.17;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-3.12;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0007585775750291836
"MM471352";"MM471352";"O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCC5)sc4c3)c2)ccc1Cl";"SKQGZCVEAKVCCM-UHFFFAOYSA-N";465.96;6.39;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.4;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.000003981071705534969
"MM471351";"MM471351";"CC(C)Cn1sc2cc(OCc3cccc(-c4ccc(Cl)c(C(=O)O)c4)c3)ccc2c1=O";"FTYLVJNMIZIOOL-UHFFFAOYSA-N";467.97;6.32;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.00001
"MM471350";"MM471350";"O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CC5)sc4c3)c2)ccc1Cl";"RBQZSTHTHNKFHW-UHFFFAOYSA-N";451.93;6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.5;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.000003162277660168379
"MM471349";"MM471349";"CC(C)CCn1sc2cc(OCc3cccc(-c4ccc(Cl)c(C(=O)O)c4)c3)ccc2c1=O";"JUSYYLGFTXAHLX-UHFFFAOYSA-N";482;6.71;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-7.5;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.00000003162277660168379
"MM471348";"MM471348";"COc1ccc(C(=O)O)cc1-c1cccc(COc2ccc3c(c2)CN(C2CCCC2)C3=O)c1";"BUZSAAKSFZMGDU-UHFFFAOYSA-N";457.53;5.54;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.6;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.0000025118864315095823
"MM471347";"MM471347";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1O";"HLQQHKJXQSBRLN-UHFFFAOYSA-N";443.5;5.23;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-6.5;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.0000003162277660168379
"MM471346";"MM471346";"COc1cc(C(=O)O)cc(OC)c1-c1cccc(COc2ccc3c(c2)CN(C2CCCC2)C3=O)c1";"OIEJBPSIAOJISX-UHFFFAOYSA-N";487.55;5.55;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.5;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.000003162277660168379
"MM471345";"MM471345";"O=C(O)c1ccc(Cl)c(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)c1";"WLNNHBHTIDYGLP-UHFFFAOYSA-N";461.95;6.18;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.9;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.0000012589254117941661
"MM471344";"MM471344";"O=C(O)c1ccc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)c(Cl)c1";"PVRNAOFIVADFMO-UHFFFAOYSA-N";461.95;6.18;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-6.5;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.0000003162277660168379
"MM471343";"MM471343";"Cc1ccc(C(=O)O)cc1-c1cccc(COc2ccc3c(c2)CN(C2CCCC2)C3=O)c1";"WXJPZVBSFWJYDQ-UHFFFAOYSA-N";441.53;5.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.8;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.000001584893192461114
"MM471342";"MM471342";"O=C(O)c1cc(F)cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)c1";"JHBVDFXAWLGDRG-UHFFFAOYSA-N";445.49;5.67;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-6;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.000001
"MM471341";"MM471341";"COc1ccc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)cc1C(=O)O";"REJFICNMUKYPKE-UHFFFAOYSA-N";457.53;5.54;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.6;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.0000025118864315095823
"MM471340";"MM471340";"O=C1c2ccc(OCc3cccc(-c4ccccc4)c3)cc2CN1C1CCCC1";"POPKTGVNWBKZTD-UHFFFAOYSA-N";383.49;5.83;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-6.9;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.00000012589254117941662
"MM471339";"MM471339";"Cc1ccc(C(=O)O)cc1-c1cccc(COc2ccc3c(=O)n(C4CCCC4)sc3c2)c1";"VUMIBIDABVTRIS-UHFFFAOYSA-N";459.57;6.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.4;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.000003981071705534969
"MM471337";"MM471337";"O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1F";"GVYAOWRIIRTALC-UHFFFAOYSA-N";463.53;6.26;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.4;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.000003981071705534969
"MM471336";"MM471336";"CN(C)C(=O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl";"UXFVICYNSDZOSR-UHFFFAOYSA-N";507.06;6.78;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.7;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.0000019952623149688787
"MM471335";"MM471335";"O=C(O)c1cc(-c2cccc(-c3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1Cl";"PPCUNFCLHSRGJB-UHFFFAOYSA-N";431.92;6.27;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2184420/target=_blank>CHEMBL2184420</a>";;-5.7;"Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND.: Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem, Volume 55 (22), 2012";"PAMPA";0.0000019952623149688787
"MM472021";"MM472021";"O=c1cc(-c2ccccc2)c2ccccc2n1CC1CN2CCC1(F)CC2";"WAKWRGXSRGAPEP-UHFFFAOYSA-N";362.45;4.1;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2340857/target=_blank>CHEMBL2340857</a>";;-4.42;"McDonald IM, Mate RA, Zusi FC, Huang H, Post-Munson DJ, Ferrante MA, Gallagher L, Bertekap RL, Knox RJ, Robertson BJ, Harden DG, Morgan DG, Lodge NJ, Dworetzky SI, Olson RE, Macor JE.: Discovery of a novel series of quinolone Î±7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem Lett, Volume 23 (6), 2013";"PAMPA";0.000038018939632056124
"MM472022";"MM472022";"CC(=O)NCc1cccc(-c2cc(=O)n(CC3CN4CCC3CC4)c3ccccc23)c1";"UJGOADHVWOJKPW-UHFFFAOYSA-N";415.54;3.65;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2340857/target=_blank>CHEMBL2340857</a>";;-7;"McDonald IM, Mate RA, Zusi FC, Huang H, Post-Munson DJ, Ferrante MA, Gallagher L, Bertekap RL, Knox RJ, Robertson BJ, Harden DG, Morgan DG, Lodge NJ, Dworetzky SI, Olson RE, Macor JE.: Discovery of a novel series of quinolone Î±7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem Lett, Volume 23 (6), 2013";"PAMPA";0.0000001
"MM472020";"MM472020";"O=c1cc(-c2cccc3[nH]ccc23)c2ccccc2n1CC1CN2CCC1CC2";"IOTQYEJCFAERLM-UHFFFAOYSA-N";383.5;4.49;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2340857/target=_blank>CHEMBL2340857</a>";;-4.4;"McDonald IM, Mate RA, Zusi FC, Huang H, Post-Munson DJ, Ferrante MA, Gallagher L, Bertekap RL, Knox RJ, Robertson BJ, Harden DG, Morgan DG, Lodge NJ, Dworetzky SI, Olson RE, Macor JE.: Discovery of a novel series of quinolone Î±7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem Lett, Volume 23 (6), 2013";"PAMPA";0.000039810717055349695
"MM472017";"MM472017";"O=c1cc(-c2ccccc2)c2ccccc2n1CC1CN2CCC1CC2";"GIVLVDCIMORORF-UHFFFAOYSA-N";344.46;4.01;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2340857/target=_blank>CHEMBL2340857</a>";;-4.05;"McDonald IM, Mate RA, Zusi FC, Huang H, Post-Munson DJ, Ferrante MA, Gallagher L, Bertekap RL, Knox RJ, Robertson BJ, Harden DG, Morgan DG, Lodge NJ, Dworetzky SI, Olson RE, Macor JE.: Discovery of a novel series of quinolone Î±7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem Lett, Volume 23 (6), 2013";"PAMPA";0.00008912509381337459
"MM472018";"MM472018";"O=c1cc(-c2ccccc2)c2ccccc2n1CC1CNCCO1";"NCANIKGDAMBPHY-UHFFFAOYSA-N";320.39;2.66;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2340857/target=_blank>CHEMBL2340857</a>";;-4.26;"McDonald IM, Mate RA, Zusi FC, Huang H, Post-Munson DJ, Ferrante MA, Gallagher L, Bertekap RL, Knox RJ, Robertson BJ, Harden DG, Morgan DG, Lodge NJ, Dworetzky SI, Olson RE, Macor JE.: Discovery of a novel series of quinolone Î±7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem Lett, Volume 23 (6), 2013";"PAMPA";0.00005495408738576248
"MM471727";"MM471727";"Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12";"YOZBGTLTNGAVFU-UHFFFAOYSA-N";352.35;2.86;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4124467/target=_blank>CHEMBL4124467</a>";;-4.9;"Wu Y, Jiang Z, Li Z, Gu J, You Q, Zhang X.: Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. J Med Chem, Volume 61 (12), 2018";"PAMPA";0.000012589254117941661
"MM471462";"MM471462";"CCCCCCc1ccc(C(=O)CCN(C)CCc2ccccc2)cc1";"FGWKZYSXJPDHSP-UHFFFAOYSA-N";351.53;5.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-4.24;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.000057543993733715664
"MM471477";"MM471477";"C=C(CC(=O)Nc1ccc(CCCCCC)cc1)C(=O)O";"KDVFCGVJCOQNTK-UHFFFAOYSA-N";289.38;3.78;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-4.24;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.000057543993733715664
"MM471801";"MM471801";"CSc1nc(NCCc2cccc(F)c2)c2cnn(CC(Cl)c3ccccc3)c2n1";"MFMNTKJASBOAKJ-UHFFFAOYSA-N";441.96;5.32;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-6.06;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000008709635899560814
"MM471471";"MM471471";"CCCCCCc1ccc(C(=O)CCN(C)CCO)cc1";"GWWLXQSKLVUJGE-UHFFFAOYSA-N";291.44;3.31;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-3.02;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.0009549925860214359
"MM471466";"MM471466";"CCCCCCc1ccc(C(=O)CCN(C)C)cc1";"KDBREDBLOZXWHK-UHFFFAOYSA-N";261.41;3.94;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-2.63;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.0023442288153199225
"MM471470";"MM471470";"CCCCCCc1ccc(C(=O)CCN(C(C)C)C(C)C)cc1";"ZKWDUQIOLWFBHX-UHFFFAOYSA-N";317.52;5.5;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-3.13;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.0007413102413009177
"MM471469";"MM471469";"CCCCCCc1ccc(C(=O)CCN2CCOCC2)cc1";"DRNLQHKMQJOYPM-UHFFFAOYSA-N";303.45;3.71;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-2.92;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.001202264434617413
"MM471468";"MM471468";"CCCCCCc1ccc(C(=O)CCN2CCC(C(=O)OC)CC2)cc1";"QESMLDAGHLHSQF-UHFFFAOYSA-N";359.51;4.27;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-3.84;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.0001445439770745928
"MM471465";"MM471465";"CCCCCCc1ccc(C(=O)CCN(C)Cc2ccco2)cc1";"LSYGPUMMLSCEHD-UHFFFAOYSA-N";327.47;5.11;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-3.17;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.0006760829753919819
"MM471797";"MM471797";"CSc1nc(NCc2ccccc2Cl)c2cnn(CC(Cl)c3ccccc3)c2n1";"XNWHPCMDUYIUSL-UHFFFAOYSA-N";444.39;5.79;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.84;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.000001445439770745928
"MM471475";"MM471475";"C=CC(=O)c1ccc(CCCCCC)cc1";"IINHTEWASPUCMH-UHFFFAOYSA-N";216.32;4.18;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-4.42;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.000038018939632056124
"MM471474";"MM471474";"CCCCCCc1ccc(C(=O)/C=C\C(=O)O)cc1";"HKEVTQICMJNUNY-QXMHVHEDSA-N";260.33;3.63;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-4.18;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.00006606934480075965
"MM471472";"MM471472";"C=C(C)C(=O)c1ccc(CCCCCCC)cc1";"LFTHMBBMKKTEDY-UHFFFAOYSA-N";244.38;4.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-4.37;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.00004265795188015926
"MM471891";"MM471891";"O=C(O)Cc1ccc(Nc2nc(-c3ccccc3)nc3c2S(=O)(=O)CCC3)cc1";"LKPAOLJJSTXDIZ-UHFFFAOYSA-N";409.47;3.23;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2389977/target=_blank>CHEMBL2389977</a>";;-5.24;"Goto T, Shiina A, Yoshino T, Mizukami K, Hirahara K, Suzuki O, Sogawa Y, Takahashi T, Mikkaichi T, Nakao N, Takahashi M, Hasegawa M, Sasaki S.: Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. Bioorg Med Chem Lett, Volume 23 (11), 2013";"PAMPA";0.000005754399373371567
"MM471895";"MM471895";"CC(=O)N1CCC(n2cc(-c3coc4c(O[C@H](C)c5c(Cl)ccc(F)c5Cl)c(N)ncc34)cn2)CC1";"MBGJDTXAMHYTKV-CYBMUJFWSA-N";532.4;6.04;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2406488/target=_blank>CHEMBL2406488</a>";;-3.5;"Steinig AG, Li AH, Wang J, Chen X, Dong H, Ferraro C, Jin M, Kadalbajoo M, Kleinberg A, Stolz KM, Tavares-Greco PA, Wang T, Albertella MR, Peng Y, Crew L, Kahler J, Kan J, Schulz R, Cooke A, Bittner M, Turton RW, Franklin M, Gokhale P, Landfair D, Mantis C, Workman J, Wild R, Pachter J, Epstein D, Mulvihill MJ.: Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases. Bioorg Med Chem Lett, Volume 23 (15), 2013";"PAMPA";0.00031622776601683794
"MM471896";"MM471896";"CC(=O)N1CC=C(c2coc3c(O[C@H](C)c4c(Cl)ccc(F)c4Cl)c(N)ncc23)CC1";"JHXOYBYPYLVIMP-LLVKDONJSA-N";464.32;5.63;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2406488/target=_blank>CHEMBL2406488</a>";;-3.7;"Steinig AG, Li AH, Wang J, Chen X, Dong H, Ferraro C, Jin M, Kadalbajoo M, Kleinberg A, Stolz KM, Tavares-Greco PA, Wang T, Albertella MR, Peng Y, Crew L, Kahler J, Kan J, Schulz R, Cooke A, Bittner M, Turton RW, Franklin M, Gokhale P, Landfair D, Mantis C, Workman J, Wild R, Pachter J, Epstein D, Mulvihill MJ.: Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases. Bioorg Med Chem Lett, Volume 23 (15), 2013";"PAMPA";0.00019952623149688788
"MM471894";"MM471894";"C[C@@H](Oc1c(N)ncc2c(C3=CCN(C(N)=O)CC3)coc12)c1c(Cl)ccc(F)c1Cl";"LVYXERPKYAQGKM-SNVBAGLBSA-N";465.31;5.16;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2406488/target=_blank>CHEMBL2406488</a>";;-3.44;"Steinig AG, Li AH, Wang J, Chen X, Dong H, Ferraro C, Jin M, Kadalbajoo M, Kleinberg A, Stolz KM, Tavares-Greco PA, Wang T, Albertella MR, Peng Y, Crew L, Kahler J, Kan J, Schulz R, Cooke A, Bittner M, Turton RW, Franklin M, Gokhale P, Landfair D, Mantis C, Workman J, Wild R, Pachter J, Epstein D, Mulvihill MJ.: Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases. Bioorg Med Chem Lett, Volume 23 (15), 2013";"PAMPA";0.0003630780547701014
"MM471904";"MM471904";"O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccc(C(=O)O)cc3)n[nH]c2c1";"FOMWYZMFUGYYLZ-ADFPNGHDSA-N";407.43;4.92;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410116/target=_blank>CHEMBL2410116</a>";;-5.68;"Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Beletskaya I, Mason JM, Luo X, Wei X, Yao Y, Feher M, Ban F, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.: The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem, Volume 56 (15), 2013";"PAMPA";0.0000020892961308540407
"MM471909";"MM471909";"O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1";"CZFUYZPXZGGWKC-SRQUHQSVSA-N";364.41;4.62;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410116/target=_blank>CHEMBL2410116</a>";;-3.71;"Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Beletskaya I, Mason JM, Luo X, Wei X, Yao Y, Feher M, Ban F, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.: The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem, Volume 56 (15), 2013";"PAMPA";0.00019498445997580456
"MM471908";"MM471908";"O=C1Nc2ccc(O)cc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1";"YKIVNICLNFURQO-NHSDSWEZSA-N";380.41;4.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410116/target=_blank>CHEMBL2410116</a>";;-5.4;"Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Beletskaya I, Mason JM, Luo X, Wei X, Yao Y, Feher M, Ban F, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.: The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem, Volume 56 (15), 2013";"PAMPA";0.000003981071705534969
"MM471907";"MM471907";"CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1";"HCLJFCCORISDCX-NLUXTTPZSA-N";420.52;5.29;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410116/target=_blank>CHEMBL2410116</a>";;-3.56;"Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Beletskaya I, Mason JM, Luo X, Wei X, Yao Y, Feher M, Ban F, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.: The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem, Volume 56 (15), 2013";"PAMPA";0.0002754228703338166
"MM471906";"MM471906";"CN1CCN(c2ccc(/C=C/c3n[nH]c4cc(/C=C5/C(=O)Nc6ccccc65)ccc34)cn2)CC1";"FQWPBCFJZAKNEQ-CBVNATGFSA-N";462.56;4.37;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410116/target=_blank>CHEMBL2410116</a>";;-3.47;"Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Beletskaya I, Mason JM, Luo X, Wei X, Yao Y, Feher M, Ban F, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.: The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem, Volume 56 (15), 2013";"PAMPA";0.0003388441561392024
"MM471905";"MM471905";"COc1ccc2c(c1)/C(=C\c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2";"GBUDRABUNBYJKG-WWAWLHJKSA-N";492.58;4.38;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410116/target=_blank>CHEMBL2410116</a>";;-3.79;"Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, Plotnikova O, Leung G, Hodgson R, Beletskaya I, Mason JM, Luo X, Wei X, Yao Y, Feher M, Ban F, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.: The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem, Volume 56 (15), 2013";"PAMPA";0.00016218100973589298
"MM472024";"MM472024";"CN(C)CCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1cc2scc(Br)c2n1-c1ccc(F)cc1";"LLZQBQNEWUCTIB-UHFFFAOYSA-N";569.33;7.1;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2416481/target=_blank>CHEMBL2416481</a>";;-5.39;"Hirayama T, Okaniwa M, Imada T, Ohashi A, Ohori M, Iwai K, Mori K, Kawamoto T, Yokota A, Tanaka T, Ishikawa T.: Synthetic studies of centromere-associated protein-E (CENP-E) inhibitors: 1.Exploration of fused bicyclic core scaffolds using electrostatic potential map. Bioorg Med Chem, Volume 21 (17), 2013";"PAMPA";0.000004073802778041131
"MM472023";"MM472023";"CN(C)CCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nc2cccc(Br)n2c1-c1ccc(F)cc1";"ZATPRXWLTXOXAQ-UHFFFAOYSA-N";564.29;6.41;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2416481/target=_blank>CHEMBL2416481</a>";;-4.45;"Hirayama T, Okaniwa M, Imada T, Ohashi A, Ohori M, Iwai K, Mori K, Kawamoto T, Yokota A, Tanaka T, Ishikawa T.: Synthetic studies of centromere-associated protein-E (CENP-E) inhibitors: 1.Exploration of fused bicyclic core scaffolds using electrostatic potential map. Bioorg Med Chem, Volume 21 (17), 2013";"PAMPA";0.000035481338923357534
"MM471792";"MM471792";"CSc1nc(NCc2cccc(F)c2)c2cnn(CC(Cl)c3ccccc3)c2n1";"JDCIDTFQSPPSQG-UHFFFAOYSA-N";427.94;5.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.51;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.000003090295432513592
"MM471795";"MM471795";"CSc1nc(NCc2ccc(F)cc2)c2cnn(CC(Cl)c3ccccc3)c2n1";"ZDVMCRNBPCIWEL-UHFFFAOYSA-N";427.94;5.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.7;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000019952623149688787
"MM471799";"MM471799";"CSc1nc(NCc2ccccc2)c2cnn(CC(Cl)c3ccc(Cl)cc3)c2n1";"JUBQMCOOSJGKFM-UHFFFAOYSA-N";444.39;5.79;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.87;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000013489628825916533
"MM471796";"MM471796";"CSc1nc(NCc2ccccc2)c2cnn(CC(Cl)c3ccc(F)cc3)c2n1";"GGEDDOAPJMUBJS-UHFFFAOYSA-N";427.94;5.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.62;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000023988329190194897
"MM472025";"MM472025";"Cc1cc(Cn2ccnc2C(Cc2cc(C)c3[nH]ncc3c2)NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)cc(Cl)n1";"VPVMAWOPPJSTCZ-UHFFFAOYSA-N";638.18;5.98;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2433978/target=_blank>CHEMBL2433978</a>";;-5.42;"Tora G, Degnan AP, Conway CM, Kostich WA, Davis CD, Pin SS, Schartman R, Xu C, Widmann KA, Macor JE, Dubowchik GM.: Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists. Bioorg Med Chem Lett, Volume 23 (20), 2013";"PAMPA";0.000003801893963205613
"MM472028";"MM472028";"CNC(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O";"CXZGZTKUARYIDS-UHFFFAOYSA-N";393.27;2.52;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2444172/target=_blank>CHEMBL2444172</a>";;-5.06;"Devasthale P, Wang Y, Wang W, Fevig J, Feng J, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Moulin F, Li YX, Zahler R, Kirby MS, Hamann LG.: Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem, Volume 56 (18), 2013";"PAMPA";0.000008709635899560814
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3873507/target=_blank>CHEMBL3873507</a>";;-5.33;"Shchegol'kov EV, Shchur IV, Burgart YV, Saloutin VI, Trefilova AN, Ljushina GA, Solodnikov SY, Markova LN, Maslova VV, Krasnykh OP, Borisevich SS, Khursan SL.: Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation. Bioorg Med Chem, Volume 25 (1), 2017";"PAMPA";0.000004677351412871981
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-5;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.00001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428918/target=_blank>CHEMBL3428918</a>";;-3.89;"Wu Y, Hu M, Yang L, Li X, Bian J, Jiang F, Sun H, You Q, Zhang X.: Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency. Bioorg Med Chem Lett, Volume 25 (12), 2015";"PAMPA";0.00012882495516931337
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018083/target=_blank>CHEMBL4018083</a>";;-5.01;"Botta L, Maccari G, Calandro P, Tiberi M, Brai A, Zamperini C, Canducci F, Chiariello M, MartĂ­-Centelles R, Falomir E, Carda M.: One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000009772372209558111
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-6.68;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.00000020892961308540409
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-3.93;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.0001174897554939529
"MM471569";"MM471569";"Fc1ccc(CNc2ncnc3c2cnn3CC(Cl)c2ccc(F)cc2)cc1";"VAORLJQUVFIABJ-UHFFFAOYSA-N";399.83;4.7;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1775364/target=_blank>CHEMBL1775364</a>";;-4.96;"Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M.: Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J Med Chem, Volume 54 (8), 2011";"PAMPA";0.000010964781961431852
"MM471999";"MM471999";"CC(=O)N(O)CCc1ccccc1";"HMPMPDUKHGMZEE-UHFFFAOYSA-N";179.22;1.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801192/target=_blank>CHEMBL3801192</a>";;-5.34;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.000004570881896148752
"MM471790";"MM471790";"CSc1nc(NCc2ccccc2)c2cnn(CC(Cl)c3ccccc3)c2n1";"VRYGLOHNGHJHFM-UHFFFAOYSA-N";409.95;5.14;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.4;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.000003981071705534969
"MM471686";"MM471686";"CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)O)CC[C@]3(C)CC[C@]12C";"KQJSQWZMSAGSHN-JJWQIEBTSA-N";450.62;6.7;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-4.88;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.000013182567385564074
"MM471910";"MM471910";"COc1cc(C(=O)N[C@H]2CCCN(Cc3ccc(Br)cc3)C2)ccc1-n1cnc(C)c1";"WNAODUGGPXHAQZ-NRFANRHFSA-N";483.41;4.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3101590/target=_blank>CHEMBL3101590</a>";;-4.3;"Kobayashi T, Iwama S, Fusano A, Kato Y, Ikeda A, Teranishi Y, Nishihara A, Tobe M.: Design and synthesis of an aminopiperidine series of Îł-secretase modulators. Bioorg Med Chem Lett, Volume 24 (1), 2014";"PAMPA";0.00005011872336272725
"MM471920";"MM471920";"Cc1cc(-c2nnc3n2CCCCC3)c(C)n1-c1ccc(Cl)c(Cl)c1";"XPTYTHZOTIZQJV-UHFFFAOYSA-N";375.3;5.39;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-2.78;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.0016595869074375613
"MM471919";"MM471919";"Cc1cc(-c2nnc3n2CCCCC3)c(C)n1-c1cccc(Cl)c1";"UDWPNWGFSDYVPQ-UHFFFAOYSA-N";340.86;4.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-2.96;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.0010964781961431851
"MM471918";"MM471918";"Cc1cc(-c2nnc3n2CCCCC3)c(C)n1-c1cccc(C(F)(F)F)c1";"PPPSKWGJGYDJPC-UHFFFAOYSA-N";374.41;5.1;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-2.82;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.0015135612484362087
"MM471917";"MM471917";"Cc1ccc(-n2c(C)cc(-c3nnc4n3CCCCC4)c2C)cc1";"QKPPIMNVHFZLLI-UHFFFAOYSA-N";320.44;4.39;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-2.88;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.0013182567385564075
"MM471916";"MM471916";"Cc1cc(-c2nnc3n2CCCCC3)c(C)n1-c1cccc(C#N)c1";"UTEZZOAYXICASM-UHFFFAOYSA-N";331.42;3.95;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-3.64;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.00022908676527677723
"MM471914";"MM471914";"Cc1cccc(-n2cnc3cc(C(=O)N4CCCC(C)(C)C4)ccc32)c1";"LZKKTPSYBZSUGJ-UHFFFAOYSA-N";347.46;4.6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-2.64;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.0022908676527677724
"MM471913";"MM471913";"O=C(c1ccc2c(c1)ncn2-c1cccc(Cl)c1)N1CCCCC1";"XODGBXPZOXYLFN-UHFFFAOYSA-N";339.83;4.31;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-3.05;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.0008912509381337459
"MM471912";"MM471912";"O=C(c1ccc2c(c1)ncn2-c1cccc(C(F)(F)F)c1)N1CCCCC1";"JKFSLVDEDNJILV-UHFFFAOYSA-N";373.38;4.67;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-2.87;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.0013489628825916532
"MM471911";"MM471911";"COc1ccc(-n2cnc3cc(C(=O)N4CCCCC4)ccc32)cc1";"FUCWZIFGSAFUAO-UHFFFAOYSA-N";335.41;3.66;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3107149/target=_blank>CHEMBL3107149</a>";;-3.2;"Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.: Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorg Med Chem Lett, Volume 24 (2), 2014";"PAMPA";0.000630957344480193
"MM471387";"MM471387";"COc1ccc(C(Nc2ccc(C(F)(F)F)cc2)c2c(C)[nH]c3ccccc23)cc1";"NNTQFFZNUZBJND-UHFFFAOYSA-N";410.44;6.71;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.36;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000043651583224016567
"MM471386";"MM471386";"Cc1[nH]c2ccccc2c1C(NCc1ccccc1)c1ccccc1Cl";"FCLRKOQXOJBTEP-UHFFFAOYSA-N";360.89;6.01;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.21;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000006165950018614822
"MM471385";"MM471385";"Cc1ccc2c(C(NCc3ccccc3)c3ccccc3Cl)c(C)[nH]c2c1";"AQLSREXSXCXYPP-UHFFFAOYSA-N";374.92;6.32;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-5.6;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000025118864315095823
"MM471384";"MM471384";"Cc1ccc2c(C(NCc3ccc(C(F)(F)F)cc3)c3ccccc3Cl)c(C)[nH]c2c1";"DOCFQDHUGXVTQU-UHFFFAOYSA-N";442.91;7.34;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.67;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000021379620895022324
"MM471383";"MM471383";"Cc1ccc(CNC(c2ccccc2Cl)c2c(C)[nH]c3cc(C)ccc23)cc1";"HKAUCVLSMSXIQN-UHFFFAOYSA-N";388.94;6.63;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.41;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000003890451449942805
"MM471382";"MM471382";"Cc1[nH]c2ccccc2c1C(Nc1ccc(Cl)cc1)c1cccnc1";"VUJJZSHDRCEVLA-UHFFFAOYSA-N";347.85;5.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.47;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000033884415613920274
"MM471381";"MM471381";"Cc1[nH]c2ccccc2c1C(Nc1ccc(Cl)cc1)c1ccncc1";"MRHUTOXNFGNPFA-UHFFFAOYSA-N";347.85;5.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.5;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000003162277660168379
"MM471380";"MM471380";"COc1ncccc1C(Nc1ccc(Cl)cc1)c1c(C)[nH]c2ccccc12";"HMKDBXFQTIAIEW-UHFFFAOYSA-N";377.88;5.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-7.57;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000002691534803926914
"MM471379";"MM471379";"Cc1[nH]c2ccccc2c1C(Nc1ccc(Cl)cc1)c1ncc[nH]1";"ZQJUNMKUHZNGTJ-UHFFFAOYSA-N";336.83;5.05;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.71;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000019498445997580455
"MM471378";"MM471378";"Cc1[nH]c2ccccc2c1C(Nc1ccc(Cl)cc1)c1nccs1";"CKYVDHZHFCZJBC-UHFFFAOYSA-N";353.88;5.79;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.14;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000007244359600749906
"MM471377";"MM471377";"Cc1[nH]c2ccccc2c1C(O)c1ccccc1Cl";"WJKAQKGFTKOYBL-UHFFFAOYSA-N";271.75;4.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.92;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000012022644346174132
"MM471376";"MM471376";"Cc1nc2cc(NC(c3ccccc3Cl)c3c(C)[nH]c4ccccc34)ccc2s1";"GCSKLLBVPVSKGW-UHFFFAOYSA-N";417.97;7.25;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.68;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000020892961308540409
"MM471375";"MM471375";"COc1ncccc1NC(c1ccccc1Cl)c1c(C)[nH]c2cc(C)ccc12";"ZNNPOFQTZBGADB-UHFFFAOYSA-N";391.9;6.04;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-5.87;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000013489628825916533
"MM471374";"MM471374";"Cc1ccc2c(C(Nc3cccnc3)c3ccccc3Cl)c(C)[nH]c2c1";"FPDIMVPBSSBDFS-UHFFFAOYSA-N";361.88;6.03;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.09;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000008128305161640995
"MM471373";"MM471373";"COc1ccc(NC(c2nccs2)c2c(C)[nH]c3ccccc23)cc1OC";"LLMRMIHLJLRSNK-UHFFFAOYSA-N";379.49;5.15;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-6.14;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000007244359600749906
"MM471372";"MM471372";"COc1ncccc1NC(c1cccnc1)c1c(C)[nH]c2cc(C)ccc12";"MWRFNJNGUSICNX-UHFFFAOYSA-N";358.45;4.78;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-5.78;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000016595869074375596
"MM471371";"MM471371";"COc1ncccc1NC(c1cccnc1)c1c(C)[nH]c2ccccc12";"PLDRFPAQBXALIC-UHFFFAOYSA-N";344.42;4.48;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111316/target=_blank>CHEMBL3111316</a>";;-5.88;"Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.: Development of novel Vitamin D Receptor-Coactivator Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000013182567385564074
"MM471922";"MM471922";"Cn1cc(-c2cc3cnc(Nc4ccc(-c5cncn5C)cc4Cl)cc3n2C(=O)OC(C)(C)C)cn1";"BXKNUXDLZJPPBO-UHFFFAOYSA-N";503.99;6.02;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3111612/target=_blank>CHEMBL3111612</a>";;-4.74;"Naud S, Westwood IM, Faisal A, Sheldrake P, Bavetsias V, Atrash B, Cheung KM, Liu M, Hayes A, Schmitt J, Wood A, Choi V, Boxall K, Mak G, Gurden M, Valenti M, de Haven Brandon A, Henley A, Baker R, McAndrew C, Matijssen B, Burke R, Hoelder S, Eccles SA, Raynaud FI, Linardopoulos S, van Montfort RL, Blagg J.: Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1). J Med Chem, Volume 56 (24), 2013";"PAMPA";0.000018197008586099827
"MM471927";"MM471927";"COc1cccc(CNc2ccc(S(=O)(=O)Nc3nc4ccccc4s3)cc2)c1O";"OWHBVKBNNRYMIN-UHFFFAOYSA-N";441.53;4.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3119083/target=_blank>CHEMBL3119083</a>";;-3.4;"Luci DK, Jameson JB, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J, Kerns EH, Schultz L, Holinstat M, Nadler JL, Taylor-Fishwick DA, Jadhav A, Simeonov A, Holman TR, Maloney DJ.: Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase. J Med Chem, Volume 57 (2), 2014";"PAMPA";0.00039810717055349735
"MM471926";"MM471926";"COc1cccc(CNc2ccc(S(=O)(=O)Nc3nc4ccccc4o3)cc2)c1O";"PLLGXMASDDMGST-UHFFFAOYSA-N";425.47;3.95;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3119083/target=_blank>CHEMBL3119083</a>";;-3.77;"Luci DK, Jameson JB, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J, Kerns EH, Schultz L, Holinstat M, Nadler JL, Taylor-Fishwick DA, Jadhav A, Simeonov A, Holman TR, Maloney DJ.: Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase. J Med Chem, Volume 57 (2), 2014";"PAMPA";0.00016982436524617443
"MM471925";"MM471925";"COc1cccc(CNc2ccc(S(=O)(=O)Nc3cccc(C(C)C)c3)cc2)c1O";"SMFFPQDLUGWSOM-UHFFFAOYSA-N";426.54;4.94;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3119083/target=_blank>CHEMBL3119083</a>";;-4.41;"Luci DK, Jameson JB, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J, Kerns EH, Schultz L, Holinstat M, Nadler JL, Taylor-Fishwick DA, Jadhav A, Simeonov A, Holman TR, Maloney DJ.: Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase. J Med Chem, Volume 57 (2), 2014";"PAMPA";0.000038904514499428046
"MM471924";"MM471924";"COc1cccc(CNc2ccc(S(=O)(=O)Nc3nc4ccc(F)cc4s3)cc2)c1O";"DCPQZFQYOJQYFZ-UHFFFAOYSA-N";459.52;4.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3119083/target=_blank>CHEMBL3119083</a>";;-4.19;"Luci DK, Jameson JB, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J, Kerns EH, Schultz L, Holinstat M, Nadler JL, Taylor-Fishwick DA, Jadhav A, Simeonov A, Holman TR, Maloney DJ.: Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase. J Med Chem, Volume 57 (2), 2014";"PAMPA";0.00006456542290346549
"MM471923";"MM471923";"COc1ccc(-c2nc3c(c(Nc4ccc(CC(=O)O)c(F)c4)n2)S(=O)(=O)CCC3)cc1F";"ONTYRRHLBFPVPK-UHFFFAOYSA-N";475.47;3.52;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3117332/target=_blank>CHEMBL3117332</a>";;-4.84;"Goto T, Shiina A, Murata T, Tomii M, Yamazaki T, Yoshida K, Yoshino T, Suzuki O, Sogawa Y, Mizukami K, Takagi N, Yoshitomi T, Etori M, Tsuchida H, Mikkaichi T, Nakao N, Takahashi M, Takahashi H, Sasaki S.: Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors. Bioorg Med Chem Lett, Volume 24 (3), 2014";"PAMPA";0.00001445439770745928
"MM472035";"MM472035";"CC[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@H](CC)NC(=O)OC)[nH]4)cc3)cc2)[nH]1";"YBVNONPLRJIVKN-KOUWNTBJSA-N";710.84;5.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.42;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000038018939632056124
"MM472033";"MM472033";"COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)[nH]4)cc3)cc2)[nH]1)[C@@H](C)OC";"PDXDRMNNOXHMKS-PVDPSSSFSA-N";770.89;4.98;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.56;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00002754228703338169
"MM472032";"MM472032";"COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C5CC5)[nH]4)cc3)cc2)[nH]1)C1CC1";"HLIPLFQSNFGEBV-CUPIEXAXSA-N";734.86;5.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.3;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00005011872336272725
"MM472031";"MM472031";"CCN(CC)[C@@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@H](C)NC(=O)OC)[nH]4)cc3)cc2)[nH]1)c1ccccc1";"XGOPQHNOBPMOHT-QQFMLMFISA-N";742.93;7.29;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.6;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000025118864315095822
"MM472030";"MM472030";"CC[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](c5ccccc5)N(CC)CC)[nH]4)cc3)cc2)[nH]1";"XEOBFNKXGTZKAX-AECIOGPLSA-N";756.95;7.68;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.44;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.0000363078054770101
"MM472029";"MM472029";"CCN(CC)[C@@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)c1ccccc1";"XMAZSFZDDZFBNC-IJERZTCISA-N";770.98;7.92;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.15;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00007079457843841373
"MM472044";"MM472044";"COC(=O)N[C@@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)CNC(C)=O)[nH]4)cc3)cc2)[nH]1)c1ccccc1";"GFTWVAQPXPBIOS-IXQHYERASA-N";714.83;5.69;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-5.92;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.0000012022644346174132
"MM472043";"MM472043";"COC(=O)N[C@@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](C)NC(C)=O)[nH]4)cc3)cc2)[nH]1)c1ccccc1";"UUYKXFQVUGBWHR-RXDRZPENSA-N";728.85;6.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-5.55;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000002818382931264455
"MM472042";"MM472042";"COC(=O)N[C@@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@H](C)NC(C)=O)[nH]4)cc3)cc2)[nH]1)c1ccccc1";"UUYKXFQVUGBWHR-NIRYMDOFSA-N";728.85;6.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-5;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00001
"MM472041";"MM472041";"COC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@H](NC(=O)OC)c5ccccc5)[nH]4)cc3)cc2)[nH]1";"FKXRJGFBBIQBKT-RTZKUTJSSA-N";744.85;6.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.44;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.0000363078054770101
"MM472040";"MM472040";"COC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@H](C)NC(=O)OC)[nH]4)cc3)cc2)[nH]1";"QKVLNVCKLMSHBX-OBMDHMNCSA-N";682.78;4.95;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.68;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00002089296130854041
"MM472039";"MM472039";"COC(=O)N[C@H](C)C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](C)NC(=O)OC)[nH]4)cc3)cc2)[nH]1";"QKVLNVCKLMSHBX-UFDDTGEXSA-N";682.78;4.95;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-5.33;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000004677351412871981
"MM472038";"MM472038";"CCOC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@H](C)NC(=O)OCC)[nH]4)cc3)cc2)[nH]1";"CGRSHTWPPAJABY-UDRQUUIHSA-N";710.84;5.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-4.35;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00004466835921509635
"MM472037";"MM472037";"COC(=O)NC(C)(C)C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)C(C)(C)NC(=O)OC)[nH]4)cc3)cc2)[nH]1";"RMQAYIMLUPWQHX-KYJUHHDHSA-N";710.84;5.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-5.59;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.0000025703957827688647
"MM472036";"MM472036";"COC(=O)NC1(C(=O)N2CCC[C@H]2c2ncc(-c3ccc(-c4ccc(-c5cnc([C@@H]6CCCN6C(=O)C6(NC(=O)OC)CC6)[nH]5)cc4)cc3)[nH]2)CC1";"AGKUGPSLMQAOEN-KYJUHHDHSA-N";706.8;5.24;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3123748/target=_blank>CHEMBL3123748</a>";;-6.7;"Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG.: Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00000019952623149688787
"MM472058";"MM472058";"COc1ccc2c(c1)C1CC1(C(=O)N1CCN(C(C)=O)CC1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"BBLJZPXJPLUHQR-UHFFFAOYSA-N";661.83;4.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.47;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000033884415613920276
"MM472057";"MM472057";"COc1ccc2c(c1)C1CC1(C(=O)N1CCN(C(=O)N(C)C)CC1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"AQLUFAYJVJVBOX-UHFFFAOYSA-N";690.87;4.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.37;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00004265795188015926
"MM472056";"MM472056";"COc1ccc2c(c1)C1CC1(C(=O)N1C3CNCC1C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"QQJQXOIBORDNRE-UHFFFAOYSA-N";631.8;3.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-5.22;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000006025595860743581
"MM472055";"MM472055";"COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"SSVBJRBZPBDWRB-FTOUIILSSA-N";645.83;4.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.37;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00004265795188015926
"MM472054";"MM472054";"CCN1CC2CC(C1)N2C(=O)[C@]12C[C@H]1c1cc(OC)ccc1-c1c(C3CCCCC3)c3ccc(C(=O)NS(=O)(=O)N(C)C)cc3n1C2";"IUJMDPKKCAMEQP-VSBZUFFNSA-N";659.85;4.69;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.57;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00002691534803926914
"MM472053";"MM472053";"COc1ccc2c(c1)C1CC1(C(=O)N1C3CC1CN(Cc1ccccc1)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"OWKZVJNUMQYDCJ-UHFFFAOYSA-N";721.92;5.87;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.25;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00005623413251903491
"MM472052";"MM472052";"COc1ccc2c(c1)C1CC1(C(=O)N1C3CCC1CNC3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"UCNRDEOTNRRDSE-UHFFFAOYSA-N";645.83;4.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-5.4;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000003981071705534969
"MM472051";"MM472051";"COc1ccc2c(c1)C1CC1(C(=O)N1CC3CCC(C1)N3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"WVRQVQYNLHTOMY-UHFFFAOYSA-N";645.83;4.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-6.7;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00000019952623149688787
"MM472049";"MM472049";"COc1ccc2c(c1)C1CC1(C(=O)N1CC3CCC(C1)N3C)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"NGOKHMMSOIFOKA-UHFFFAOYSA-N";659.85;4.69;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.68;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00002089296130854041
"MM472048";"MM472048";"CCN1CC2CCC(C1)N2C(=O)C12CC1c1cc(OC)ccc1-c1c(C3CCCCC3)c3ccc(C(=O)NS(=O)(=O)N(C)C)cc3n1C2";"MTTZZZXOFXUQFU-UHFFFAOYSA-N";673.88;5.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.39;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.0000407380277804113
"MM472047";"MM472047";"COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"ZTTKEBYSXUCBSE-VSBZUFFNSA-N";659.85;4.69;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.19;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00006456542290346549
"MM472064";"MM472064";"COc1ccc2c(c1)C1CC1(C(=O)N1CC(O)(C(C)C)C1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"BEKAPBGCIVTEMM-UHFFFAOYSA-N";648.83;4.62;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.13;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.00007413102413009176
"MM472063";"MM472063";"COc1ccc2c(c1)C1CC1(C(=O)N1CC(O)(C3CC3)C1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"KBOWNPDZDFUNKA-UHFFFAOYSA-N";646.81;4.37;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.72;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000019054607179632484
"MM472062";"MM472062";"COc1ccc2c(c1)C1CC1(C(=O)N1CC(O)(c3ccccc3)C1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"KOESFBTYPLWGFO-UHFFFAOYSA-N";682.84;5.12;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.41;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000038904514499428046
"MM472061";"MM472061";"COc1ccc2c(c1)C1CC1(C(=O)N1C[C@@H](C)N[C@@H](C)C1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"WNCJWMBZJAIJFT-IKUAJPQESA-N";647.84;4.6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.85;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000014125375446227555
"MM472060";"MM472060";"COc1ccc2c(c1)C1CC1(C(=O)N1C[C@@H](C)N(C)[C@@H](C)C1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"BDIRYRDVYCQVOY-AVKWDMCDSA-N";661.87;4.94;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.32;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000047863009232263804
"MM472059";"MM472059";"COc1ccc2c(c1)C1CC1(C(=O)N1C[C@@H](C)N(C(C)=O)[C@@H](C)C1)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21";"HTOYEVBOEUHJBV-GZERJIQXSA-N";689.88;4.86;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128697/target=_blank>CHEMBL3128697</a>";;-4.32;"Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.: Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.000047863009232263804
"MM472065";"MM472065";"CN(C)[C@@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](c5ccccc5)N(C)C)[nH]4)cc3)cc2)[nH]1)c1ccccc1";"IUKDDNWJLHYBGC-ATUXXYJQSA-N";746.96;8.07;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3128780/target=_blank>CHEMBL3128780</a>";;-6.15;"Belema M, Nguyen VN, Romine JL, St Laurent DR, Lopez OD, Goodrich JT, Nower PT, O'Boyle DR, Lemm JA, Fridell RA, Gao M, Fang H, Krause RG, Wang YK, Oliver AJ, Good AC, Knipe JO, Meanwell NA, Snyder LB.: Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons. J Med Chem, Volume 57 (5), 2014";"PAMPA";0.0000007079457843841374
"MM472261";"MM472261";"CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](NC(=O)c3cccc(C(F)(F)F)c3)C2=O)[C@H](CS(C)(=O)=O)C1";"KZYUPKXEHNEFIY-NRDMVMEKSA-N";517.61;2.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4339727/target=_blank>CHEMBL4339727</a>";;-5.03;"Yang MG, Xiao Z, Cherney RJ, Tebben AJ, Batt DG, Brown GD, Chen J, Cvijic ME, Dabros M, Duncia JV, Galella M, Gardner DS, Khandelwal P, Ko SS, Malley MF, Mo R, Pang J, Rose AV, Santella JB, Shi H, Srivastava A, Traeger SC, Wang B, Xu S, Zhao R, Barrish JC, Mandlekar S, Zhao Q, Carter PH.: Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Med Chem Lett, Volume 10 (3), 2019";"PAMPA";0.000009332543007969906
"MM472066";"MM472066";"CNC(=O)N1CC23COCC2(C1)CN(C(=O)[C@]12C[C@H]1c1cc(OC)ccc1-c1c(C4CCCCC4)c4ccc(C(=O)NS(=O)(=O)C(C)C)cc4n1C2)C3";"YEJJWLBSPTUOIO-MIWMFXFDSA-N";743.93;4.82;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3240496/target=_blank>CHEMBL3240496</a>";;-5.74;"Eastman KJ, Yang Z, Bender JA, Mosure K, Lemm JA, Meanwell NA, Roberts SB, Knipe J, Kadow JF.: Identification of a novel series of potent HCV NS5B Site I inhibitors. Bioorg Med Chem Lett, Volume 24 (8), 2014";"PAMPA";0.0000018197008586099826
"MM472067";"MM472067";"CNC(=O)N1CC23COCC2(C1)CN(C(=O)[C@]12C[C@H]1c1cc(OC)ccc1-c1c(C4CCCCC4)c4ccc(C(=O)NS(=O)(=O)N(C)C)cc4n1C2)C3";"RTNZIQNUUDZXNK-LPPCMUASSA-N";744.92;3.89;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3240496/target=_blank>CHEMBL3240496</a>";;-5.43;"Eastman KJ, Yang Z, Bender JA, Mosure K, Lemm JA, Meanwell NA, Roberts SB, Knipe J, Kadow JF.: Identification of a novel series of potent HCV NS5B Site I inhibitors. Bioorg Med Chem Lett, Volume 24 (8), 2014";"PAMPA";0.0000037153522909717276
"MM471632";"MM471632";"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCCCNC2CCOC2=O)c1";"XZTGPNPNISFWHR-UHFFFAOYSA-N";490.29;3.92;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-5.14;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.000007244359600749906
"MM471633";"MM471633";"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCCCNC(CCO)C(=O)O)c1";"DTTYAFWXCJLSCM-UHFFFAOYSA-N";508.31;3.44;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-7.7;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.000000019952623149688786
"MM471634";"MM471634";"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCCCSC2CCOC2=O)c1";"DHNXZPUYXNQSME-UHFFFAOYSA-N";507.34;5.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-5.18;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.000006606934480075964
"MM471635";"MM471635";"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCCCSC(CCO)C(=O)O)c1";"HDZSCMIJCHVDIQ-UHFFFAOYSA-N";525.36;4.58;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-6.85;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.00000014125375446227555
"MM471636";"MM471636";"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCCCCNC2CCOC2=O)c1";"DXCZVUGSWTZEKE-UHFFFAOYSA-N";504.32;4.31;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-5.33;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.000004677351412871981
"MM471637";"MM471637";"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCCCCNC(CCO)C(=O)O)c1";"MRLBVOBMAVAAQH-UHFFFAOYSA-N";522.33;3.83;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-7.52;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.000000030199517204020194
"MM471638";"MM471638";"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCCCCSC2CCOC2=O)c1";"FBVIQYXJLZDUSS-UHFFFAOYSA-N";521.37;5.45;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-5.6;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.0000025118864315095823
"MM471639";"MM471639";"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCCCCSC(CCO)C(=O)O)c1";"HRFYVOPZMBRDKK-UHFFFAOYSA-N";539.38;4.97;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-7.3;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.00000005011872336272725
"MM471640";"MM471640";"COC(=O)CNCCCOc1cc(C(=O)Nc2c(Cl)cncc2Cl)ccc1OC(F)F";"WNYHKXSTAUQMNM-UHFFFAOYSA-N";478.28;3.77;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3374903/target=_blank>CHEMBL3374903</a>";;-5.05;"Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.: Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorg Med Chem Lett, Volume 24 (18), 2014";"PAMPA";0.00000891250938133746
"MM471643";"MM471643";"CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C";"JAHXQCZCZURPTI-UHFFFAOYSA-N";477.59;3.68;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3367716/target=_blank>CHEMBL3367716</a>";;-4.72;"Laufer R, Ng G, Liu Y, Patel NK, Edwards LG, Lang Y, Li SW, Feher M, Awrey DE, Leung G, Beletskaya I, Plotnikova O, Mason JM, Hodgson R, Wei X, Mao G, Luo X, Huang P, Green E, Kiarash R, Lin DC, Harris-Brandts M, Ban F, Nadeem V, Mak TW, Pan GJ, Qiu W, Chirgadze NY, Pauls HW.: Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides. Bioorg Med Chem, Volume 22 (17), 2014";"PAMPA";0.000019054607179632484
"MM471642";"MM471642";"NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1";"JBZRAEUHDPMQSF-UHFFFAOYSA-N";481.6;3.71;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3367716/target=_blank>CHEMBL3367716</a>";;-5.38;"Laufer R, Ng G, Liu Y, Patel NK, Edwards LG, Lang Y, Li SW, Feher M, Awrey DE, Leung G, Beletskaya I, Plotnikova O, Mason JM, Hodgson R, Wei X, Mao G, Luo X, Huang P, Green E, Kiarash R, Lin DC, Harris-Brandts M, Ban F, Nadeem V, Mak TW, Pan GJ, Qiu W, Chirgadze NY, Pauls HW.: Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides. Bioorg Med Chem, Volume 22 (17), 2014";"PAMPA";0.000004168693834703355
"MM471780";"MM471780";"C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C";"DUYJMQONPNNFPI-UHFFFAOYSA-N";499.62;4.51;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4324133/target=_blank>CHEMBL4324133</a>";;-5.57;"Engelhardt H, BĂ¶se D, Petronczki M, Scharn D, Bader G, Baum A, Bergner A, Chong E, DĂ¶bel S, Egger G, Engelhardt C, Ettmayer P, Fuchs JE, Gerstberger T, Gonnella N, Grimm A, Grondal E, Haddad N, Hopfgartner B, Kousek R, Krawiec M, Kriz M, Lamarre L, Leung J, Mayer M, Patel ND, Simov BP, Reeves JT, Schnitzer R, Schrenk A, Sharps B, Solca F, StadtmĂĽller H, Tan Z, Wunberg T, Zoephel A, McConnell DB.: Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.0000026915348039269138
"MM471644";"MM471644";"COc1cc2[nH]c(C)c(-c3ccc(Cl)cc3C)c(=O)c2cc1Cl";"RVFXNHKTJITXMU-UHFFFAOYSA-N";348.23;5.13;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3370143/target=_blank>CHEMBL3370143</a>";;-3.43;"Cross RM, Flanigan DL, Monastyrskyi A, LaCrue AN, SĂˇenz FE, Maignan JR, Mutka TS, White KL, Shackleford DM, Bathurst I, Fronczek FR, Wojtas L, Guida WC, Charman SA, Burrows JN, Kyle DE, Manetsch R.: Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium. J Med Chem, Volume 57 (21), 2014";"PAMPA";0.0003715352290971724
"MM471645";"MM471645";"COc1cc2[nH]c(C)c(-c3ccc(-c4ccc(C(F)(F)F)cc4F)nc3)c(=O)c2cc1Cl";"UVTSZEAYMDMKSO-UHFFFAOYSA-N";462.83;6.39;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3370143/target=_blank>CHEMBL3370143</a>";;-2.97;"Cross RM, Flanigan DL, Monastyrskyi A, LaCrue AN, SĂˇenz FE, Maignan JR, Mutka TS, White KL, Shackleford DM, Bathurst I, Fronczek FR, Wojtas L, Guida WC, Charman SA, Burrows JN, Kyle DE, Manetsch R.: Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium. J Med Chem, Volume 57 (21), 2014";"PAMPA";0.001071519305237606
"MM472070";"MM472070";"NC[C@H]1CC[C@H](C(=O)N[C@@H](Cc2ccccc2)c2nc(-c3ccc4c(N)n[nH]c4c3)c(Cl)[nH]2)CC1";"IOLSRAXZCKDSPO-FIKGOQFSSA-N";492.03;4.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3399898/target=_blank>CHEMBL3399898</a>";;-7.52;"Pinto DJ, Smallheer JM, Corte JR, Austin EJ, Wang C, Fang T, Smith LM, Rossi KA, Rendina AR, Bozarth JM, Zhang G, Wei A, Ramamurthy V, Sheriff S, Myers JE, Morin PE, Luettgen JM, Seiffert DA, Quan ML, Wexler RR.: Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. Bioorg Med Chem Lett, Volume 25 (7), 2015";"PAMPA";0.000000030199517204020194
"MM472071";"MM472071";"Nc1nccc2c1CCC(C(=O)N[C@@H](Cc1ccccc1)c1nc(-c3ccc4c(N)n[nH]c4c3)c(Cl)[nH]1)C2";"ICSJXVUUSDNFIJ-YSYXNDDBSA-N";527.03;4.37;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3399898/target=_blank>CHEMBL3399898</a>";;-6.82;"Pinto DJ, Smallheer JM, Corte JR, Austin EJ, Wang C, Fang T, Smith LM, Rossi KA, Rendina AR, Bozarth JM, Zhang G, Wei A, Ramamurthy V, Sheriff S, Myers JE, Morin PE, Luettgen JM, Seiffert DA, Quan ML, Wexler RR.: Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. Bioorg Med Chem Lett, Volume 25 (7), 2015";"PAMPA";0.00000015135612484362072
"MM472072";"MM472072";"Nc1nccc2cc(C(=O)N[C@@H](Cc3ccccc3)c3nc(-c4ccc5c(N)n[nH]c5c4)c(Cl)[nH]3)ccc12";"KWHJKKRXFUNBAJ-QFIPXVFZSA-N";523;5.03;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3399898/target=_blank>CHEMBL3399898</a>";;-5.42;"Pinto DJ, Smallheer JM, Corte JR, Austin EJ, Wang C, Fang T, Smith LM, Rossi KA, Rendina AR, Bozarth JM, Zhang G, Wei A, Ramamurthy V, Sheriff S, Myers JE, Morin PE, Luettgen JM, Seiffert DA, Quan ML, Wexler RR.: Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. Bioorg Med Chem Lett, Volume 25 (7), 2015";"PAMPA";0.000003801893963205613
"MM472073";"MM472073";"C[C@H]1CC[C@H](C(=O)N[C@@H](Cc2ccccc2)c2nc(-c3ccc4c(N)n[nH]c4c3)c(Cl)[nH]2)CC1";"ZTZYRDIKEKUGBU-WJPUGNRLSA-N";477.01;5.41;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3399898/target=_blank>CHEMBL3399898</a>";;-6.34;"Pinto DJ, Smallheer JM, Corte JR, Austin EJ, Wang C, Fang T, Smith LM, Rossi KA, Rendina AR, Bozarth JM, Zhang G, Wei A, Ramamurthy V, Sheriff S, Myers JE, Morin PE, Luettgen JM, Seiffert DA, Quan ML, Wexler RR.: Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. Bioorg Med Chem Lett, Volume 25 (7), 2015";"PAMPA";0.00000045708818961487516
"MM472074";"MM472074";"Cc1ccc(C(=O)N[C@@H](Cc2ccccc2)c2nc(-c3ccc4c(N)n[nH]c4c3)c(Cl)[nH]2)c(F)c1";"NVCGCCVEGKNTRF-NRFANRHFSA-N";488.95;5.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3399898/target=_blank>CHEMBL3399898</a>";;-4.26;"Pinto DJ, Smallheer JM, Corte JR, Austin EJ, Wang C, Fang T, Smith LM, Rossi KA, Rendina AR, Bozarth JM, Zhang G, Wei A, Ramamurthy V, Sheriff S, Myers JE, Morin PE, Luettgen JM, Seiffert DA, Quan ML, Wexler RR.: Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. Bioorg Med Chem Lett, Volume 25 (7), 2015";"PAMPA";0.00005495408738576248
"MM472075";"MM472075";"COc1cc(F)c(C(=O)N[C@@H](Cc2ccccc2)c2nc(-c3ccc4c(N)n[nH]c4c3)c(Cl)[nH]2)c(F)c1";"HNWLIQJSOKYYOW-FQEVSTJZSA-N";522.94;5.19;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3399898/target=_blank>CHEMBL3399898</a>";;-4.63;"Pinto DJ, Smallheer JM, Corte JR, Austin EJ, Wang C, Fang T, Smith LM, Rossi KA, Rendina AR, Bozarth JM, Zhang G, Wei A, Ramamurthy V, Sheriff S, Myers JE, Morin PE, Luettgen JM, Seiffert DA, Quan ML, Wexler RR.: Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. Bioorg Med Chem Lett, Volume 25 (7), 2015";"PAMPA";0.00002344228815319923
"MM471389";"MM471389";"NC(=O)c1ccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)cc2)cc1";"IDLZIWXYDQEECE-GJGATLCTSA-N";375.38;-0.37;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419536/target=_blank>CHEMBL3419536</a>";;-6.8;"Kleeb S, Pang L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, LĂĽdin N, BezenĂ§on J, Schwardt O, Maier T, Ernst B.: FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.0000001584893192461114
"MM471390";"MM471390";"CNC(=O)c1ccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)cc2)cc1";"ZJRAHAOGKBGQKG-JGLNRKDHSA-N";389.4;-0.11;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419536/target=_blank>CHEMBL3419536</a>";;-9.2;"Kleeb S, Pang L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, LĂĽdin N, BezenĂ§on J, Schwardt O, Maier T, Ernst B.: FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.0000000006309573444801942
"MM471392";"MM471392";"CS(=O)(=O)c1ccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)cc2)cc1";"LBNMSMJAVMIAAT-GFEQUFNTSA-N";410.44;-0.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419536/target=_blank>CHEMBL3419536</a>";;-7.2;"Kleeb S, Pang L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, LĂĽdin N, BezenĂ§on J, Schwardt O, Maier T, Ernst B.: FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.0000000630957344480193
"MM471393";"MM471393";"CNS(=O)(=O)c1ccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)cc2)cc1";"CVQPQNFDTNLHAE-GFEQUFNTSA-N";425.46;-0.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419536/target=_blank>CHEMBL3419536</a>";;-8.6;"Kleeb S, Pang L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, LĂĽdin N, BezenĂ§on J, Schwardt O, Maier T, Ernst B.: FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.000000002511886431509582
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-8.7;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000000019952623149688828
"MM472264";"MM472264";"CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(C(F)(F)F)cc23)C1=O";"NUJWKQSEJDYCDB-GNRVTEMESA-N";491.6;5.34;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4339727/target=_blank>CHEMBL4339727</a>";;-4.28;"Yang MG, Xiao Z, Cherney RJ, Tebben AJ, Batt DG, Brown GD, Chen J, Cvijic ME, Dabros M, Duncia JV, Galella M, Gardner DS, Khandelwal P, Ko SS, Malley MF, Mo R, Pang J, Rose AV, Santella JB, Shi H, Srivastava A, Traeger SC, Wang B, Xu S, Zhao R, Barrish JC, Mandlekar S, Zhao Q, Carter PH.: Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Med Chem Lett, Volume 10 (3), 2019";"PAMPA";0.00005248074602497723
"MM472077";"MM472077";"O=C1CCCN1c1cc(S(=O)(=O)Nc2ccc(F)cc2F)cc2c1N(C(=O)Nc1ccc(C(F)(F)F)cc1)CC2";"RGDHGNPUKLLPLT-UHFFFAOYSA-N";580.54;5.51;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3583918/target=_blank>CHEMBL3583918</a>";;-4.4;"Sato K, Takahagi H, Yoshikawa T, Morimoto S, Takai T, Hidaka K, Kamaura M, Kubo O, Adachi R, Ishii T, Maki T, Mochida T, Takekawa S, Nakakariya M, Amano N, Kitazaki T.: Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors. J Med Chem, Volume 58 (9), 2015";"PAMPA";0.000039810717055349695
"MM472076";"MM472076";"O=C1NCCN1c1cc(S(=O)(=O)Nc2ccc(F)cc2F)cc2c1N(C(=O)Nc1ccc(C(F)(F)F)cc1)CC2";"YVXDLDVRCSNFPF-UHFFFAOYSA-N";581.52;4.91;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3583918/target=_blank>CHEMBL3583918</a>";;-5.03;"Sato K, Takahagi H, Yoshikawa T, Morimoto S, Takai T, Hidaka K, Kamaura M, Kubo O, Adachi R, Ishii T, Maki T, Mochida T, Takekawa S, Nakakariya M, Amano N, Kitazaki T.: Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors. J Med Chem, Volume 58 (9), 2015";"PAMPA";0.000009332543007969906
"MM471966";"MM471966";"c1ccc(-c2nc(-c3ccc4nc[nH]c4c3)no2)cc1";"XQYPDQDCEUEGEZ-UHFFFAOYSA-N";262.27;3.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-5.28;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.000005248074602497723
"MM471967";"MM471967";"FC(F)(F)c1ccccc1-c1nc(-c2ccc3nc[nH]c3c2)no1";"WUCCIHPTYOFNDJ-UHFFFAOYSA-N";330.27;4.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-5.32;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.00000478630092322638
"MM471968";"MM471968";"Brc1ccc(-c2nc(-c3ccc4nc[nH]c4c3)no2)cc1";"WDSQNMSWLYROHT-UHFFFAOYSA-N";341.17;4.04;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-4.95;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.00001122018454301963
"MM471969";"MM471969";"Clc1ccc(-c2nc(-c3ccc4nc[nH]c4c3)no2)cc1";"KYGBWCBTIJLPCN-UHFFFAOYSA-N";296.72;3.93;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-4.99;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.000010232929922807536
"MM471970";"MM471970";"Fc1ccc(-c2nc(-c3ccc4nc[nH]c4c3)no2)cc1";"LBOBFSYTLJJUGA-UHFFFAOYSA-N";280.26;3.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-4.71;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.000019498445997580456
"MM471971";"MM471971";"OCCCCCc1ccc(-c2nc(-c3ccc4nc[nH]c4c3)no2)cc1";"RFJSAPHKUYDIBR-UHFFFAOYSA-N";348.41;3.99;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-5.11;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.00000776247116628691
"MM471972";"MM471972";"c1ccc2cc(-c3nc(-c4ccc5nc[nH]c5c4)no3)ccc2c1";"VTPHOSVCGFGYKL-UHFFFAOYSA-N";312.33;4.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-5.06;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.000008709635899560814
"MM471973";"MM471973";"CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@H](OCCC3CCOCC3)C2)cc1";"QMDKVNSQXPVCRD-RQNOJGIXSA-N";442.6;3.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3591662/target=_blank>CHEMBL3591662</a>";;-7;"Mitchell LH, Drew AE, Ribich SA, Rioux N, Swinger KK, Jacques SL, Lingaraj T, Boriack-Sjodin PA, Waters NJ, Wigle TJ, Moradei O, Jin L, Riera T, Porter-Scott M, Moyer MP, Smith JJ, Chesworth R, Copeland RA.: Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Med Chem Lett, Volume 6 (6), 2015";"PAMPA";0.0000001
"MM471976";"MM471976";"N#Cc1ccc(N2CCC(Nc3c(C(N)=O)cnc4[nH]ccc34)CC2)nc1";"XFSMWLHLZSVJAB-UHFFFAOYSA-N";361.41;2.01;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3594795/target=_blank>CHEMBL3594795</a>";;-4.59;"Nakajima Y, Inoue T, Nakai K, Mukoyoshi K, Hamaguchi H, Hatanaka K, Sasaki H, Tanaka A, Takahashi F, Kunikawa S, Usuda H, Moritomo A, Higashi Y, Inami M, Shirakami S.: Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. Bioorg Med Chem, Volume 23 (15), 2015";"PAMPA";0.000025703957827688645
"MM471975";"MM471975";"N#Cc1ccc(N2CC[C@@H](Nc3c(C(N)=O)cnc4[nH]ccc34)[C@@H](F)C2)nc1";"OHNNRNYUHNGDNO-LSDHHAIUSA-N";379.4;1.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3594795/target=_blank>CHEMBL3594795</a>";;-5.05;"Nakajima Y, Inoue T, Nakai K, Mukoyoshi K, Hamaguchi H, Hatanaka K, Sasaki H, Tanaka A, Takahashi F, Kunikawa S, Usuda H, Moritomo A, Higashi Y, Inami M, Shirakami S.: Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. Bioorg Med Chem, Volume 23 (15), 2015";"PAMPA";0.00000891250938133746
"MM471974";"MM471974";"N#Cc1ccc(N2CC[C@H](Nc3c(C(N)=O)cnc4[nH]ccc34)[C@H](F)C2)nc1";"OHNNRNYUHNGDNO-CABCVRRESA-N";379.4;1.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3594795/target=_blank>CHEMBL3594795</a>";;-5.3;"Nakajima Y, Inoue T, Nakai K, Mukoyoshi K, Hamaguchi H, Hatanaka K, Sasaki H, Tanaka A, Takahashi F, Kunikawa S, Usuda H, Moritomo A, Higashi Y, Inami M, Shirakami S.: Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. Bioorg Med Chem, Volume 23 (15), 2015";"PAMPA";0.000005011872336272725
"MM471984";"MM471984";"Cc1c(Cl)cccc1CCCCOc1ccc(C#Cc2cccc3c(CCC(=O)O)c(C)n(CC(=O)O)c23)cc1";"XNFPKWJBSFIUNB-UHFFFAOYSA-N";558.07;6.81;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3599264/target=_blank>CHEMBL3599264</a>";;-6.15;"Itadani S, Yashiro K, Aratani Y, Sekiguchi T, Kinoshita A, Moriguchi H, Ohta N, Takahashi S, Ishida A, Tajima Y, Hisaichi K, Ima M, Ueda J, Egashira H, Sekioka T, Kadode M, Yonetomi Y, Nakao T, Inoue A, Nomura H, Kitamine T, Fujita M, Nabe T, Yamaura Y, Matsumura N, Imagawa A, Nakayama Y, Takeuchi J, Ohmoto K.: Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. J Med Chem, Volume 58 (15), 2015";"PAMPA";0.0000007079457843841374
"MM471985";"MM471985";"Cc1c(Cl)cccc1CCCCOc1ccc(C#Cc2cccc3c(CCCC(=O)O)c(C)n(CC(=O)O)c23)cc1";"HMRYVKBVRIXMOC-UHFFFAOYSA-N";572.1;7.2;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3599264/target=_blank>CHEMBL3599264</a>";;-5.49;"Itadani S, Yashiro K, Aratani Y, Sekiguchi T, Kinoshita A, Moriguchi H, Ohta N, Takahashi S, Ishida A, Tajima Y, Hisaichi K, Ima M, Ueda J, Egashira H, Sekioka T, Kadode M, Yonetomi Y, Nakao T, Inoue A, Nomura H, Kitamine T, Fujita M, Nabe T, Yamaura Y, Matsumura N, Imagawa A, Nakayama Y, Takeuchi J, Ohmoto K.: Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. J Med Chem, Volume 58 (15), 2015";"PAMPA";0.000003235936569296281
"MM471986";"MM471986";"Cc1c(Cl)cccc1CCCCOc1ccc(C#Cc2cccc3c(CC(=O)O)c(C)n(CCC(=O)O)c23)cc1";"VWQZNSNDHXIKHH-UHFFFAOYSA-N";558.07;6.81;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3599264/target=_blank>CHEMBL3599264</a>";;-5.14;"Itadani S, Yashiro K, Aratani Y, Sekiguchi T, Kinoshita A, Moriguchi H, Ohta N, Takahashi S, Ishida A, Tajima Y, Hisaichi K, Ima M, Ueda J, Egashira H, Sekioka T, Kadode M, Yonetomi Y, Nakao T, Inoue A, Nomura H, Kitamine T, Fujita M, Nabe T, Yamaura Y, Matsumura N, Imagawa A, Nakayama Y, Takeuchi J, Ohmoto K.: Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. J Med Chem, Volume 58 (15), 2015";"PAMPA";0.000007244359600749906
"MM471987";"MM471987";"Cc1c(Cl)cccc1CCCCOc1ccc(C#Cc2cccc3c(CCC(=O)O)c(C)n(CCC(=O)O)c23)cc1";"YNAKCKVBIRBVSO-UHFFFAOYSA-N";572.1;7.2;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3599264/target=_blank>CHEMBL3599264</a>";;-5.44;"Itadani S, Yashiro K, Aratani Y, Sekiguchi T, Kinoshita A, Moriguchi H, Ohta N, Takahashi S, Ishida A, Tajima Y, Hisaichi K, Ima M, Ueda J, Egashira H, Sekioka T, Kadode M, Yonetomi Y, Nakao T, Inoue A, Nomura H, Kitamine T, Fujita M, Nabe T, Yamaura Y, Matsumura N, Imagawa A, Nakayama Y, Takeuchi J, Ohmoto K.: Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. J Med Chem, Volume 58 (15), 2015";"PAMPA";0.0000036307805477010103
"MM471988";"MM471988";"Cc1c(Cl)cccc1CCCCOc1ccc(C#Cc2cccc3c(CCCC(=O)O)c(C)n(CCC(=O)O)c23)cc1";"FXHVWKSLLGLWNF-UHFFFAOYSA-N";586.13;7.6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3599264/target=_blank>CHEMBL3599264</a>";;-5.52;"Itadani S, Yashiro K, Aratani Y, Sekiguchi T, Kinoshita A, Moriguchi H, Ohta N, Takahashi S, Ishida A, Tajima Y, Hisaichi K, Ima M, Ueda J, Egashira H, Sekioka T, Kadode M, Yonetomi Y, Nakao T, Inoue A, Nomura H, Kitamine T, Fujita M, Nabe T, Yamaura Y, Matsumura N, Imagawa A, Nakayama Y, Takeuchi J, Ohmoto K.: Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. J Med Chem, Volume 58 (15), 2015";"PAMPA";0.0000030199517204020193
"MM471665";"MM471665";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C)NC(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C1=O";"WRYMAGLGOZIEQC-BBYXVEBWSA-N";721.93;2.72;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.28;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000005248074602497723
"MM471664";"MM471664";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C)NC(=O)c2csc(n2)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O";"VYYBCILESAYSSU-ABJITVNWSA-N";721.93;2.72;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.25;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000005623413251903491
"MM471663";"MM471663";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C)NC(=O)c2csc1n2";"XRBJRRUDGYDQMD-ABJITVNWSA-N";721.93;2.72;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.28;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000005248074602497723
"MM471662";"MM471662";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C)NC(=O)c2csc(n2)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C1=O";"TVYRJMOFWNDDGD-HIFWOLGQSA-N";707.9;2.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.32;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.00000478630092322638
"MM471661";"MM471661";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C)NC(=O)c2csc1n2";"HEXGUSGVAUKXFA-HIFWOLGQSA-N";707.9;2.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.31;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000004897788193684467
"MM471660";"MM471660";"CC(C)[C@@H]1NC(=O)c2csc(n2)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC1=O";"ZJZYPFMFNGDOEQ-POPCVQDUSA-N";721.93;2.57;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.33;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000004677351412871981
"MM471659";"MM471659";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C)NC(=O)c2csc1n2";"BTAGUDKMHRNOJG-ANSWJGDTSA-N";709.87;1.05;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-6.7;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.00000019952623149688787
"MM471658";"MM471658";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C)N(C)C(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C1=O";"QPNBXLHLCGFWJX-KUXUZMBDSA-N";735.95;3.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-6.3;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.0000005011872336272725
"MM471657";"MM471657";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C)NC(=O)c2csc1n2";"LBPNFHXZFSPLPM-KUXUZMBDSA-N";735.95;3.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.89;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000001288249551693135
"MM471656";"MM471656";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](C)NC(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C1=O";"SBMUNCPYFGCZIQ-YQZNXJQNSA-N";735.95;3.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-4.96;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000010964781961431852
"MM471655";"MM471655";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](C)NC(=O)c2csc1n2";"BQTAMBWEFHWTBU-FOIAGIETSA-N";721.93;2.67;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.04;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000009120108393559096
"MM471654";"MM471654";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C(C)(C)C)NC(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C1=O";"QNILUMLOKSTVOM-XSOUIOSLSA-N";764.01;3.75;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.66;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.0000021877616239495517
"MM471653";"MM471653";"CC[C@H](C)[C@@H]1NC(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC1=O";"MAVYAHYLEKLCNP-FQOMANLJSA-N";764.01;3.75;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.21;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000006165950018614822
"MM471652";"MM471652";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C1=O";"NMJOBNXJXFKPSI-ICCDRXOOSA-N";764.01;3.75;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.33;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000004677351412871981
"MM471651";"MM471651";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C1=O";"HIVTXBSWOJIFPY-MZMJYJJTSA-N";778.03;4.09;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.68;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.0000020892961308540407
"MM471650";"MM471650";"CC[C@H](C)[C@@H]1NC(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)N(C)C1=O";"SVQGJGIIXWJVFW-VNVWLANGSA-N";778.03;4.09;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-5.82;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.0000015135612484362072
"MM471649";"MM471649";"CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](CC(C)C)NC(=O)c2csc(n2)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C1=O";"GZWPGOBWQGMSJI-RIRKSLKXSA-N";778.03;4.09;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620851/target=_blank>CHEMBL3620851</a>";;-4.76;"Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, Lokey RS.: Going Out on a Limb: Delineating The Effects of Î˛-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. J Med Chem, Volume 58 (18), 2015";"PAMPA";0.000017378008287493764
"MM471989";"MM471989";"CC(C)c1ccc2c(c1)CC[C@H]1[C@](C)(CNS(=O)(=O)c3c(F)c(F)c(F)c(F)c3F)CCC[C@]21C";"JYSJXBUZXYKFST-LGIRGXTLSA-N";515.59;6.49;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620239/target=_blank>CHEMBL3620239</a>";;-4.2;"Ling T, Tran M, GonzĂˇlez MA, Gautam LN, Connelly M, Wood RK, Fatima I, Miranda-Carboni G, Rivas F.: (+)-Dehydroabietylamine derivatives target triple-negative breast cancer. Eur J Med Chem, Volume 102, 2015";"PAMPA";0.00006309573444801929
"MM472078";"MM472078";"CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)c(C)s3)nc21";"IHSTUTBJVPZZHZ-UHFFFAOYSA-N";449.58;4.53;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3625500/target=_blank>CHEMBL3625500</a>";;-4.27;"Hart AC, Schroeder GM, Wan H, Grebinski J, Inghrim J, Kempson J, Guo J, Pitts WJ, Tokarski JS, Sack JS, Khan JA, Lippy J, Lorenzi MV, You D, McDevitt T, Vuppugalla R, Zhang Y, Lombardo LJ, Trainor GL, Purandare AV.: Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors. ACS Med Chem Lett, Volume 6 (8), 2015";"PAMPA";0.000053703179637025325
"MM471673";"MM471673";"CCOC(=O)N1[C@@H]2CC[C@H]1C[C@H](CN1CC[C@@H](N3Cc4ccccc4NC3=O)C1)C2";"BUYVTPGEWYQFCF-RSPOEFSDSA-N";412.53;3.51;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3635139/target=_blank>CHEMBL3635139</a>";;-4.27;"Uruno Y, Konishi Y, Suwa A, Takai K, Tojo K, Nakako T, Sakai M, Enomoto T, Matsuda H, Kitamura A, Sumiyoshi T.: Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M(1) and M(4) muscarinic acetylcholine receptors agonists. Bioorg Med Chem Lett, Volume 25 (22), 2015";"PAMPA";0.000053703179637025325
"MM472080";"MM472080";"CCN(C)S(=O)(=O)NC(=O)c1ccc2c(C3CCCCC3)c3n(c2c1)CC1(C(=O)N2C4CCC2CN(C)C4)CC1c1cc(OC)ccc1-3";"SCOZLIDMZQPYPL-UHFFFAOYSA-N";673.88;5.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3762773/target=_blank>CHEMBL3762773</a>";;-4.25;"Hewawasam P, Tu Y, Gao M, Hanumegowda U, Knipe J, Lemm JA, Parker DD, Rigat KL, Roberts SB, Meanwell NA, Kadow JF.: Discovery and preclinical evaluation of potent, orally bioavailable, metabolically stable cyclopropylindolobenzazepine acylsulfonamides as thumb site 1 inhibitors of the hepatitis c virus NS5B RNA-dependent, RNA polymerase. Bioorg Med Chem Lett, Volume 26 (3), 2016";"PAMPA";0.00005623413251903491
"MM472081";"MM472081";"COc1ccc2c(c1)C1CC1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N3CCC3)cc21";"MGIQLBCZSZRNNJ-UHFFFAOYSA-N";671.86;4.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3762773/target=_blank>CHEMBL3762773</a>";;-4.18;"Hewawasam P, Tu Y, Gao M, Hanumegowda U, Knipe J, Lemm JA, Parker DD, Rigat KL, Roberts SB, Meanwell NA, Kadow JF.: Discovery and preclinical evaluation of potent, orally bioavailable, metabolically stable cyclopropylindolobenzazepine acylsulfonamides as thumb site 1 inhibitors of the hepatitis c virus NS5B RNA-dependent, RNA polymerase. Bioorg Med Chem Lett, Volume 26 (3), 2016";"PAMPA";0.00006606934480075965
"MM471993";"MM471993";"Cc1c(Cc2c(Cl)cccc2Cl)nc(N(C)Cc2ccc(N3CCOCC3)cc2)[nH]c1=O";"UBCUBPKNCZZRLM-UHFFFAOYSA-N";473.4;4.45;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3791521/target=_blank>CHEMBL3791521</a>";;-4.66;"Tintori C, Brai A, Dasso Lang MC, Deodato D, Greco AM, Bizzarri BM, Cascone L, Casian A, Zamperini C, Dreassi E, Crespan E, Maga G, Vanham G, Ceresola E, Canducci F, AriĂ«n KK, Botta M.: Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family. J Med Chem, Volume 59 (6), 2016";"PAMPA";0.00002187761623949552
"MM471995";"MM471995";"Cc1c(C(C)c2c(Cl)cccc2Cl)nc(N(C)Cc2ccc(N3CCN(C)CC3)cc2)[nH]c1=O";"HPEPSXQDXQIPLK-UHFFFAOYSA-N";500.47;4.93;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3791521/target=_blank>CHEMBL3791521</a>";;-6.04;"Tintori C, Brai A, Dasso Lang MC, Deodato D, Greco AM, Bizzarri BM, Cascone L, Casian A, Zamperini C, Dreassi E, Crespan E, Maga G, Vanham G, Ceresola E, Canducci F, AriĂ«n KK, Botta M.: Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family. J Med Chem, Volume 59 (6), 2016";"PAMPA";0.0000009120108393559096
"MM472082";"MM472082";"O=C(O)C1CN(Cc2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1";"RRPYZEWVBYBTJC-UHFFFAOYSA-N";470.41;4.59;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3803548/target=_blank>CHEMBL3803548</a>";;-3.99;"Watterson SH, Guo J, Spergel SH, Langevine CM, Moquin RV, Shen DR, Yarde M, Cvijic ME, Banas D, Liu R, Suchard SJ, Gillooly K, Taylor T, Rex-Rabe S, Shuster DJ, McIntyre KW, Cornelius G, D'Arienzo C, Marino A, Balimane P, Warrack B, Salter-Cid L, McKinnon M, Barrish JC, Carter PH, Pitts WJ, Xie J, Dyckman AJ.: Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series. J Med Chem, Volume 59 (6), 2016";"PAMPA";0.00010232929922807536
"MM472001";"MM472001";"CC(=O)NOCCc1ccccc1";"RAQUZYWMEJZUFJ-UHFFFAOYSA-N";179.22;1.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801192/target=_blank>CHEMBL3801192</a>";;-5.34;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.000004570881896148752
"MM471413";"MM471413";"Oc1cc(Cc2ccccc2)on1";"SCVUKJARUFFBII-UHFFFAOYSA-N";175.19;1.97;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801194/target=_blank>CHEMBL3801194</a>";;-5.33;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.000004677351412871981
"MM472000";"MM472000";"CONC(=O)CCc1ccccc1";"HMXIQGDRQJPMQI-UHFFFAOYSA-N";179.22;1.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801192/target=_blank>CHEMBL3801192</a>";;-5.14;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.000007244359600749906
"MM471416";"MM471416";"CC1=C(O)CC(Cc2ccccc2)C1=O";"GWGQROXXNKCSLW-UHFFFAOYSA-N";202.25;2.65;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801194/target=_blank>CHEMBL3801194</a>";;-6.58;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.00000026302679918953816
"MM471415";"MM471415";"O=C1C=C(O)CC1Cc1ccccc1";"MUZSAHAQLBVTPM-UHFFFAOYSA-N";188.23;2.26;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801194/target=_blank>CHEMBL3801194</a>";;-6.67;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.00000021379620895022324
"MM471411";"MM471411";"O=S1NC(CCc2ccccc2)=NO1";"YBZGIOKQLBGMBC-UHFFFAOYSA-N";210.26;1.13;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801194/target=_blank>CHEMBL3801194</a>";;-6.96;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.00000010964781961431852
"MM471412";"MM471412";"S=c1[nH]c(CCc2ccccc2)no1";"ASNKYVLXSCWECJ-UHFFFAOYSA-N";206.27;2.52;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801194/target=_blank>CHEMBL3801194</a>";;-6.49;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.0000003235936569296281
"MM471414";"MM471414";"O=C1CC(=O)C(Cc2ccccc2)N1";"KXJCIAXLTIETRA-UHFFFAOYSA-N";189.21;0.69;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801194/target=_blank>CHEMBL3801194</a>";;-5.6;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.0000025118864315095823
"MM471422";"MM471422";"Cc1cc(OCCCc2c(C(=O)Nc3cccc(C(=O)O)c3)n(C)c3c(-c4c(C)nn(C)c4C)c(Cl)ccc23)cc(C)c1Cl";"RSGIEHXOEKBXKV-UHFFFAOYSA-N";633.58;8.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3877060/target=_blank>CHEMBL3877060</a>";;2.35;"Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X.: Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem, Volume 25 (3), 2017";"PAMPA";223.872113856834
"MM471417";"MM471417";"CC(C)N1CCC(N2CCN(Cc3cnc(-c4ccccc4Cl)o3)CC2CCO)CC1";"PYGYSSWMMPISBT-UHFFFAOYSA-N";447.02;3.74;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3877060/target=_blank>CHEMBL3877060</a>";;1.2;"Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X.: Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem, Volume 25 (3), 2017";"PAMPA";15.848931924611133
"MM471419";"MM471419";"Cc1ccc([C@H]2[C@H]3C=CC[C@@H](C)[C@@H]3C(=O)N2Cc2ccc(Cl)cc2)cc1C";"WKLJAOILHSYETC-FGSBKAERSA-N";379.93;5.87;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3877060/target=_blank>CHEMBL3877060</a>";;1.24;"Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X.: Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem, Volume 25 (3), 2017";"PAMPA";17.378008287493753
"MM471423";"MM471423";"CCc1cccc(-c2cc(-c3nn(-c4nc(C(=O)O)cs4)cc3Cc3ccc(S(N)(=O)=O)cc3)ccc2F)c1";"SIUPBMLRYIEUFI-UHFFFAOYSA-N";562.65;5.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3877060/target=_blank>CHEMBL3877060</a>";;2.08;"Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X.: Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem, Volume 25 (3), 2017";"PAMPA";120.22644346174131
"MM471425";"MM471425";"CN1CCN(Cc2ccc3c(c2)nc(NC(=O)c2ccc(-c4cn[nH]c4)s2)n3CC(C)(C)O)CC1";"ZTJWHGJPUYPGOA-UHFFFAOYSA-N";493.64;3.26;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3877060/target=_blank>CHEMBL3877060</a>";;0.08;"Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X.: Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem, Volume 25 (3), 2017";"PAMPA";1.202264434617413
"MM471424";"MM471424";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)cccc24)CCCN(Cc2ccc(C(=O)O)cc2)C3=O)cc(C)c1Cl";"FFBWADDWUILNRC-UHFFFAOYSA-N";639.2;7.68;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3877060/target=_blank>CHEMBL3877060</a>";;0.74;"Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X.: Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem, Volume 25 (3), 2017";"PAMPA";5.495408738576246
"MM471685";"MM471685";"CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)NCCCn4ccnc4)CC[C@]3(C)CC[C@]12C";"JUJKMJAXAIXDRM-GTKRWHGSSA-N";557.78;7.02;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-6.22;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.0000006025595860743581
"MM472090";"MM472090";"CN1CCC(C)(C2CC(=O)N(CCOc3ccc(F)c(C#N)c3)C2)CC1";"BWWTUVDRVAUSCR-UHFFFAOYSA-N";359.45;2.66;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861799/target=_blank>CHEMBL3861799</a>";;-4.68;"Woolford AJ, Day PJ, BĂ©nĂ©ton V, Berdini V, Coyle JE, Dudit Y, Grondin P, Huet P, Lee LY, Manas ES, McMenamin RL, Murray CW, Page LW, Patel VK, Potvain F, Rich SJ, Sang Y, Somers DO, Trottet L, Wan Z, Zhang X.: Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>). J Med Chem, Volume 59 (23), 2016";"PAMPA";0.00002089296130854041
"MM472104";"MM472104";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(C)c[nH]c(=O)c3c2)c2ccc(OC)c(OC)c2)c1";"JSTISVSMTAUNFT-AKGWNBJDSA-N";676.79;5.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.77;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00001698243652461746
"MM471683";"MM471683";"CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)NCCN4CCOCC4)CC[C@]3(C)CC[C@]12C";"AQUSDUJSHMMSQY-GTKRWHGSSA-N";562.8;6.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-4.94;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.000011481536214968817
"MM472113";"MM472113";"CC(=O)N(O)C(CS(=O)(=O)c1ccc(-c2cccc(CNC(=O)c3nc4ccccc4c(=O)[nH]3)c2)cc1)C(C)C";"YXPTXTBBPCLWPQ-UHFFFAOYSA-N";562.65;3.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3868409/target=_blank>CHEMBL3868409</a>";;-4.34;"Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.: Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. Bioorg Med Chem, Volume 24 (23), 2016";"PAMPA";0.000045708818961487516
"MM471681";"MM471681";"CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)NCCN4CCCC4)CC[C@]3(C)CC[C@]12C";"FYSKEGGIPNCCDV-GTKRWHGSSA-N";546.8;6.83;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-4.64;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.00002290867652767775
"MM471794";"MM471794";"CSc1nc(NCc2ccccc2F)c2cnn(CC(Cl)c3ccccc3)c2n1";"VFCMZLUYFAKLPR-UHFFFAOYSA-N";427.94;5.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.6;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000025118864315095823
"MM471476";"MM471476";"CCCCCCc1ccc(NC(=O)CCC(=O)O)cc1";"SRDCUULDAZDTJU-UHFFFAOYSA-N";277.36;3.61;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-4.32;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.000047863009232263804
"MM472094";"MM472094";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@@H]2CCCN2C(=O)[C@H](Nc2ccc3c(N)nccc3c2)c2ccc(OC)c(OC)c2)c1";"JAXUEOKMIODUOS-JTSJOTPCSA-N";661.78;5.71;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-6.7;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00000019952623149688787
"MM472096";"MM472096";"CNC(=O)c1cccc(N[C@@H](C(=O)N2CCC[C@@H]2c2cc(NC(=O)OC)ccc2S(=O)(=O)C(C)C)c2ccc(OC)c(OC)c2)c1";"FVBPDJDCDXVVLW-PDDLMNHVSA-N";652.77;4.94;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-5;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00001
"MM472091";"MM472091";"CC1([C@@H]2CC(=O)N(CCOc3ccc(F)c(C#N)c3)C2)CCS(=O)(=O)CC1";"SYEMWCXBADSSGE-OAHLLOKOSA-N";394.47;2.14;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861799/target=_blank>CHEMBL3861799</a>";;-5.44;"Woolford AJ, Day PJ, BĂ©nĂ©ton V, Berdini V, Coyle JE, Dudit Y, Grondin P, Huet P, Lee LY, Manas ES, McMenamin RL, Murray CW, Page LW, Patel VK, Potvain F, Rich SJ, Sang Y, Somers DO, Trottet L, Wan Z, Zhang X.: Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>). J Med Chem, Volume 59 (23), 2016";"PAMPA";0.0000036307805477010103
"MM471800";"MM471800";"CCSc1nc(NCCc2ccccc2)c2cnn(CC(Cl)c3ccccc3)c2n1";"GWPZAFFIOBYFPC-UHFFFAOYSA-N";438;5.57;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.9;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000012589254117941661
"MM471679";"MM471679";"CCN(CC)CCNC(=O)[C@]1(C)CC[C@]2(C)CC[C@]3(C)C4=CC=C5C(=CC(=O)C(O)=C5C)[C@]4(C)CC[C@@]3(C)[C@@H]2C1";"ZIHPFKVTWNZDPH-GTKRWHGSSA-N";548.81;7.07;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-4.27;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.000053703179637025325
"MM472112";"MM472112";"CCOCCC1(Oc2ccc(-c3cccc(CNC(=O)c4nc5ccccc5c(=O)[nH]4)c3)cc2)C(=O)NC(=O)NC1=O";"UGWWPGUNBPZMDD-UHFFFAOYSA-N";569.57;2.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3868409/target=_blank>CHEMBL3868409</a>";;-5.02;"Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.: Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. Bioorg Med Chem, Volume 24 (23), 2016";"PAMPA";0.000009549925860214369
"MM472110";"MM472110";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(c2F)C(=O)NC3)c2ccc(OC)c(OC)c2)c1";"LDFNHHRVRPDDMT-AYWVHJORSA-N";668.74;4.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.8;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00001584893192461114
"MM472098";"MM472098";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3nc[nH]c(=O)c3c2)c2ccc(OC)c(OC)c2)c1";"MKSPPMKQQXZJQN-PDDLMNHVSA-N";663.75;4.82;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-6.22;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.0000006025595860743581
"MM472103";"MM472103";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(Br)c[nH]c(=O)c3c2)c2ccc(OC)c(OC)c2)c1";"FUCLSMCPJUEZKS-DLFZDVPBSA-N";741.66;6.19;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.16;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00006918309709189363
"MM472108";"MM472108";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(c2)C(=O)NC[C@@H]3C)c2ccc(OC)c(OC)c2)c1";"QSGFPANUKSDPNC-ORPCDBMOSA-N";678.81;5.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.48;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.000033113112148259076
"MM472095";"MM472095";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(c2)C(=O)NCC3)c2ccc(OC)c(OC)c2)c1";"XGQHTIIEXCNFSG-DLFZDVPBSA-N";664.78;4.87;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.8;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00001584893192461114
"MM471680";"MM471680";"CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)NCCN(C(C)C)C(C)C)CC[C@]3(C)CC[C@]12C";"DFOXDAIWMLZPLA-SUNMMQDUSA-N";576.87;7.85;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-4.45;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.000035481338923357534
"MM472105";"MM472105";"CCc1c[nH]c(=O)c2cc(N[C@@H](C(=O)N3CCC[C@@H]3c3cc(NC(=O)OC)ccc3S(=O)(=O)C(C)C)c3ccc(OC)c(OC)c3)ccc12";"DOGQKPSHNITKEI-CYTLCNBWSA-N";690.82;5.99;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.36;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.000043651583224016566
"MM472102";"MM472102";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(Cl)c[nH]c(=O)c3c2)c2ccc(OC)c(OC)c2)c1";"FBEAGFCSACTTHE-DLFZDVPBSA-N";697.21;6.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.36;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.000043651583224016566
"MM472093";"MM472093";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@@H]2CCCN2C(=O)[C@H](Nc2cccc(C(N)=O)c2)c2ccc(OC)c(OC)c2)c1";"ZGFXBLAVLPKAMU-ABYGYWHVSA-N";638.74;4.68;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-5.62;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.0000023988329190194897
"MM472097";"MM472097";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3cc[nH]c(=O)c3c2)c2ccc(OC)c(OC)c2)c1";"QMDGBKOOYLXRQW-DLFZDVPBSA-N";662.77;5.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-5.06;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.000008709635899560814
"MM472115";"MM472115";"CN1CCc2cccc(c2)[C@@H](Nc2ccc3c(N)ncc(F)c3c2)C(=O)N(C)Cc2cc(ccc2S(=O)(=O)C2CC2)NC1=O";"BCCZSVOMVPSNRH-GDLZYMKVSA-N";616.72;4.72;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3871152/target=_blank>CHEMBL3871152</a>";;-4.66;"Richter JM, Cheney DL, Bates JA, Wei A, Luettgen JM, Rendina AR, Harper TM, Narayanan R, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors. ACS Med Chem Lett, Volume 8 (1), 2017";"PAMPA";0.00002187761623949552
"MM471678";"MM471678";"CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)NCCN(C)C)CC[C@]3(C)CC[C@]12C";"DMDYLUPOMROPNN-CDKFMWKUSA-N";520.76;6.29;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-4.35;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.00004466835921509635
"MM472107";"MM472107";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(c2)C(=O)NC[C@H]3C)c2ccc(OC)c(OC)c2)c1";"QSGFPANUKSDPNC-NTYRGRDKSA-N";678.81;5.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.42;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.000038018939632056124
"MM472092";"MM472092";"CC1([C@@H]2CC(=O)N(CCOc3ccc(F)c(F)c3)C2)CCS(=O)(=O)CC1";"BTLIVXFEOFQGEG-CYBMUJFWSA-N";387.45;2.41;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861799/target=_blank>CHEMBL3861799</a>";;-4.77;"Woolford AJ, Day PJ, BĂ©nĂ©ton V, Berdini V, Coyle JE, Dudit Y, Grondin P, Huet P, Lee LY, Manas ES, McMenamin RL, Murray CW, Page LW, Patel VK, Potvain F, Rich SJ, Sang Y, Somers DO, Trottet L, Wan Z, Zhang X.: Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>). J Med Chem, Volume 59 (23), 2016";"PAMPA";0.00001698243652461746
"MM472099";"MM472099";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3cn[nH]c(=O)c3c2)c2ccc(OC)c(OC)c2)c1";"MQUVSOWBUJPWKF-PDDLMNHVSA-N";663.75;4.82;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-5.12;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.000007585775750291836
"MM471467";"MM471467";"CCCCCCc1ccc(C(=O)CCN(CCCC)CCCC)cc1";"UMFRWWULZNWTFF-UHFFFAOYSA-N";345.57;6.28;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-2.71;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.0019498445997580456
"MM471473";"MM471473";"C/C=C/C(=O)c1ccc(CCCCCCC)cc1";"LCSOCUYXJADQCV-RUDMXATFSA-N";244.38;4.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-5.15;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.000007079457843841373
"MM472109";"MM472109";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2cc3c(cc2F)CNC3=O)c2ccc(OC)c(OC)c2)c1";"BPIJQVAKJCDFPD-PDDLMNHVSA-N";668.74;4.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.8;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00001584893192461114
"MM471684";"MM471684";"CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)NCCN4CCN(C)CC4)CC[C@]3(C)CC[C@]12C";"AUHBBPFFPHASLO-WFVGHVPHSA-N";575.84;5.98;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-4.54;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.000028840315031266056
"MM472114";"MM472114";"CCN(CC)CCN(CC12CC(c3ccc(C(F)(F)F)cc3)(C1)C2)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2";"DPBVEZITSOYBHD-UHFFFAOYSA-N";656.79;6.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3871134/target=_blank>CHEMBL3871134</a>";;-4.15;"Measom ND, Down KD, Hirst DJ, Jamieson C, Manas ES, Patel VK, Somers DO.: Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA<sub>2</sub> Inhibitor. ACS Med Chem Lett, Volume 8 (1), 2017";"PAMPA";0.00007079457843841373
"MM471463";"MM471463";"CCCCCCc1ccc(C(=O)CCNCCC)cc1";"IHAKHGFZWJHPER-UHFFFAOYSA-N";275.44;4.38;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-3.6;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.00025118864315095795
"MM472100";"MM472100";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(c2)C(=O)NC3)c2ccc(OC)c(OC)c2)c1";"BLILEDRECUJVDZ-PDDLMNHVSA-N";650.75;4.82;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-5.74;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.0000018197008586099826
"MM471682";"MM471682";"CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@](C)(C(=O)NCCN4CCCCC4)CC[C@]3(C)CC[C@]12C";"AMLLISBRXNRLSF-WFVGHVPHSA-N";560.82;7.22;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861292/target=_blank>CHEMBL3861292</a>";;-4.74;"Jiang F, Wang HJ, Bao QC, Wang L, Jin YH, Zhang Q, Jiang D, You QD, Xu XL.: Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Bioorg Med Chem, Volume 24 (21), 2016";"PAMPA";0.000018197008586099827
"MM472101";"MM472101";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(F)c[nH]c(=O)c3c2)c2ccc(OC)c(OC)c2)c1";"OWZJHFYKSGTIJZ-DLFZDVPBSA-N";680.76;5.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-5;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00001
"MM472111";"MM472111";"O=C(NCc1cccc(-c2ccc(CS(=O)(=O)Cc3n[nH]c(=O)[nH]3)cc2)c1)c1nc2ccccc2c(=O)[nH]1";"GTZKIGXVCZWIAR-UHFFFAOYSA-N";530.57;2.05;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3868409/target=_blank>CHEMBL3868409</a>";;-6.15;"Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.: Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. Bioorg Med Chem, Volume 24 (23), 2016";"PAMPA";0.0000007079457843841374
"MM472106";"MM472106";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(C4CC4)c[nH]c(=O)c3c2)c2ccc(OC)c(OC)c2)c1";"CRBTZBQJUBHGJG-KAODMTDESA-N";702.83;6.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3865418/target=_blank>CHEMBL3865418</a>";;-4.05;"Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.: Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. ACS Med Chem Lett, Volume 7 (12), 2016";"PAMPA";0.00008912509381337459
"MM471791";"MM471791";"CSc1nc(Nc2ccccc2)c2cnn(CC(Cl)c3ccccc3)c2n1";"JYRWBVRMNWJXEK-UHFFFAOYSA-N";395.92;5.27;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.48;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000033113112148259077
"MM472186";"MM472186";"CNC(=O)c1cnc(Nc2ccc(C#N)cc2)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"ATEXGOLHETZNBF-IRLDBZIGSA-N";417.47;2.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-5.29;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.000005128613839913648
"MM471704";"MM471704";"O=S1(=Nc2ccc(C(F)(F)F)cc2)CCOCC1";"DKKLBNHVTGZEQO-UHFFFAOYSA-N";279.28;2.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.1;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000007943282347242822
"MM471428";"MM471428";"OC[C@H]1O[C@H](Oc2ccc(-c3ccccc3Cl)cc2Cl)[C@@H](O)[C@@H](O)[C@@H]1O";"DHBPREVJLKDYBG-ZBRFXRBCSA-N";401.24;1.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4015741/target=_blank>CHEMBL4015741</a>";;-4.4;"Mayer K, Eris D, Schwardt O, Sager CP, Rabbani S, Kleeb S, Ernst B.: Urinary Tract Infection: Which Conformation of the Bacterial Lectin FimH Is Therapeutically Relevant? J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000039810717055349695
"MM472435";"MM472435";"COc1ccc(C2NC(=O)NC(C)=C2c2nc(-c3ccc(C#N)cc3)cs2)cn1";"WBEBINCDHKIBOJ-UHFFFAOYSA-N";403.47;3.87;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-7.25;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.000000056234132519034905
"MM471722";"MM471722";"O=C(c1ccccc1)N1CCc2oc(-c3ccc(F)cn3)nc2C1";"FOPJMYBQTFPHTL-UHFFFAOYSA-N";323.33;3.07;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4046794/target=_blank>CHEMBL4046794</a>";;-4.46;"Hirose W, Kato Y, Natsutani I, Takata M, Kitaichi M, Imai S, Hayashi S, Arai Y, Hoshino K, Yoshida K.: Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators. Bioorg Med Chem Lett, Volume 27 (18), 2017";"PAMPA";0.00003467368504525317
"MM471690";"MM471690";"O=S1(=Nc2ccc(F)cc2)CCCCC1";"TVHRDRBTXXQTFZ-UHFFFAOYSA-N";227.3;3.11;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.02;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000009549925860214369
"MM472143";"MM472143";"CNC(=O)NCCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"APPXSAORNVHTLE-UHFFFAOYSA-N";643.05;3.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.4;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000003981071705534969
"MM471745";"MM471745";"COc1cc2c(cc1OC)C(=O)C(CC1C=CN(Cc3ccccc3C)C=C1C(C)=O)C2";"UXXRHYNFNMKJKO-UHFFFAOYSA-N";431.53;4.88;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146840/target=_blank>CHEMBL4146840</a>";;-4.72;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000019054607179632484
"MM472432";"MM472432";"CC1=C(c2nc(-c3ccc(C#N)cc3)cs2)C(c2cc3ccccc3n2C)NC(=O)N1";"RHHZFQYMTNDKMQ-UHFFFAOYSA-N";425.52;4.96;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-7.05;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.00000008912509381337459
"MM472144";"MM472144";"CC(C)NC(=O)NCCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"CIYZRNRZDDZVOE-UHFFFAOYSA-N";671.1;4.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.35;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000004466835921509635
"Chembl4064193";"MM469101";"CN1C(C)(C)CC(Nc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1(C)C";"KOZQVDNHYNYMCA-UHFFFAOYSA-N";461.03;4.8;;"Chembl4064193";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4009762/target=_blank>CHEMBL4009762</a>";;-4.62;"Wu YJ, Guernon J, Shi J, Ditta J, Robbins KJ, Rajamani R, Easton A, Newton A, Bourin C, Mosure K, Soars MG, Knox RJ, Matchett M, Pieschl RL, Post-Munson DJ, Wang S, Herrington J, Graef J, Newberry K, Bristow LJ, Meanwell NA, Olson R, Thompson LA, Dzierba C.: Development of New Benzenesulfonamides As Potent and Selective Na<sub>v</sub>1.7 Inhibitors for the Treatment of Pain. J Med Chem, Volume 60 (6), 2017";"PAMPA";0.0000239883291901949
"MM472154";"MM472154";"CC(=O)N1CCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C(=O)C1(C)C";"ZDXIDBRGTYDHBQ-UHFFFAOYSA-N";471.44;2.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4016649/target=_blank>CHEMBL4016649</a>";;-4.23;"Liu Q, Shi Q, Marcoux D, Batt DG, Cornelius L, Qin LY, Ruan Z, Neels J, Beaudoin-Bertrand M, Srivastava AS, Li L, Cherney RJ, Gong H, Watterson SH, Weigelt C, Gillooly KM, McIntyre KW, Xie JH, Obermeier MT, Fura A, Sleczka B, Stefanski K, Fancher RM, Padmanabhan S, Rp T, Kundu I, Rajareddy K, Smith R, Hennan JK, Xing D, Fan J, Levesque PC, Ruan Q, Pitt S, Zhang R, Pedicord D, Pan J, Yarde M, Lu H, Lippy J, Goldstine C, Skala S, Rampulla RA, Mathur A, Gupta A, Arunachalam PN, Sack JS, Muckelbauer JK, Cvijic ME, Salter-Cid LM, Bhide RS, Poss MA, Hynes J, Carter PH, Macor JE, Ruepp S, Schieven GL, Tino JA.: Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase Î´ (PI3KÎ´) Inhibitor for the Treatment of Immunological Disorders. J Med Chem, Volume 60 (12), 2017";"PAMPA";0.00005888436553555884
"MM472130";"MM472130";"Cc1ccccc1S(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"BVPUQVHCWSINBC-UHFFFAOYSA-N";633.05;5.74;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-4.58;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000026302679918953814
"MM471698";"MM471698";"CS(C)(=O)=Nc1ccc(C(F)(F)F)cc1";"ACQYNKOCIXEMKJ-UHFFFAOYSA-N";237.25;3.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.09;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000008128305161640995
"MM472155";"MM472155";"O=C1Nc2cc(=O)n(Cc3ccccc3)cc2CN1c1cccc(OCc2ccccc2)c1";"BHMKGMWMMMZMJN-UHFFFAOYSA-N";437.5;5.03;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4017295/target=_blank>CHEMBL4017295</a>";;-4.51;"Iwatani-Yoshihara M, Ito M, Klein MG, Yamamoto T, Yonemori K, Tanaka T, Miwa M, Morishita D, Endo S, Tjhen R, Qin L, Nakanishi A, Maezaki H, Kawamoto T.: Discovery of Allosteric Inhibitors Targeting the Spliceosomal RNA Helicase Brr2. J Med Chem, Volume 60 (13), 2017";"PAMPA";0.00003090295432513592
"MM472182";"MM472182";"CNC(=O)c1cnc(Nc2ccc3c(c2)CC(=O)N3)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"BDBIZNXKVNHNGQ-OFNKIYASSA-N";447.5;2.19;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-6.22;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.0000006025595860743581
"MM472137";"MM472137";"CC(C)NCCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"JPINTVTXHZKUCM-UHFFFAOYSA-N";628.08;4.37;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.35;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000004466835921509635
"MM471566";"MM471566";"Fc1ccc(CNc2ncnc3c2cnn3CC(Cl)c2ccc(Cl)cc2)cc1";"QNYNFUREPOMYSY-UHFFFAOYSA-N";416.29;5.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1775364/target=_blank>CHEMBL1775364</a>";;-4.78;"Radi M, Dreassi E, Brullo C, Crespan E, Tintori C, Bernardo V, Valoti M, Zamperini C, Daigl H, Musumeci F, Carraro F, Naldini A, Filippi I, Maga G, Schenone S, Botta M.: Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. J Med Chem, Volume 54 (8), 2011";"PAMPA";0.000016595869074375598
"MM472128";"MM472128";"CC(C)S(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"ULPBFZOWIQBKGB-UHFFFAOYSA-N";585.01;4.78;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.51;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000003090295432513592
"MM471691";"MM471691";"N#Cc1ccc(N=S2(=O)CCCCC2)cc1";"FSRPJVGBTFHEMC-UHFFFAOYSA-N";234.32;2.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.1;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000007943282347242822
"MM472188";"MM472188";"CNC(=O)c1cnc(Nc2ccc(OC)cc2)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"TWSNMEUSGKKUHC-IRLDBZIGSA-N";422.49;2.7;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-5.15;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.000007079457843841373
"MM471430";"MM471430";"COc1ccccc1-c1ccc(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c(Cl)c1";"ADBZGKPOLZHLKI-GFEQUFNTSA-N";396.82;1.19;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4015741/target=_blank>CHEMBL4015741</a>";;-4.6;"Mayer K, Eris D, Schwardt O, Sager CP, Rabbani S, Kleeb S, Ernst B.: Urinary Tract Infection: Which Conformation of the Bacterial Lectin FimH Is Therapeutically Relevant? J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000025118864315095822
"MM471437";"MM471437";"CCOC(=O)C1=C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)Cn2cc(-c3ccc(-c4ccccc4)cc3)nn2)O1";"UTLBOMGJMHHNJJ-OQMPRARUSA-N";522.56;1.05;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4059390/target=_blank>CHEMBL4059390</a>";;-8.3;"Guo T, DĂ¤twyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW.: Selective Inhibitors of Human Neuraminidase 3. J Med Chem, Volume 61 (5), 2018";"PAMPA";0.000000005011872336272715
"MM472122";"MM472122";"CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccccc2)C1";"VZAFGXCWAWRULT-UONOGXRCSA-N";377.29;2.44;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003558/target=_blank>CHEMBL4003558</a>";;-4.3;"Humphreys PG, Bamborough P, Chung CW, Craggs PD, Gordon L, Grandi P, Hayhow TG, Hussain J, Jones KL, Lindon M, Michon AM, Renaux JF, Suckling CJ, Tough DF, Prinjha RK.: Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. J Med Chem, Volume 60 (2), 2017";"PAMPA";0.00005011872336272725
"MM471688";"MM471688";"O=S1(=Nc2ccccc2)CCCCC1";"IDGITZGQHADGQO-UHFFFAOYSA-N";209.31;2.97;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.02;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000009549925860214369
"MM471431";"MM471431";"N#Cc1cccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(Cl)c2)c1";"ANHVGVWJTDOPPN-GFEQUFNTSA-N";391.81;1.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4015741/target=_blank>CHEMBL4015741</a>";;-5.1;"Mayer K, Eris D, Schwardt O, Sager CP, Rabbani S, Kleeb S, Ernst B.: Urinary Tract Infection: Which Conformation of the Bacterial Lectin FimH Is Therapeutically Relevant? J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000007943282347242822
"MM472156";"MM472156";"O=C1Nc2cc(=O)n(Cc3ccccc3)cc2CN1c1cccc(OCc2ccccn2)c1";"NZYWZQVSAMCCCA-UHFFFAOYSA-N";438.49;4.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4017295/target=_blank>CHEMBL4017295</a>";;-4.56;"Iwatani-Yoshihara M, Ito M, Klein MG, Yamamoto T, Yonemori K, Tanaka T, Miwa M, Morishita D, Endo S, Tjhen R, Qin L, Nakanishi A, Maezaki H, Kawamoto T.: Discovery of Allosteric Inhibitors Targeting the Spliceosomal RNA Helicase Brr2. J Med Chem, Volume 60 (13), 2017";"PAMPA";0.00002754228703338169
"MM472430";"MM472430";"COc1ccc(C2NC(=O)NC(C)=C2c2nc(-c3ccc(C#N)cc3)cs2)cc1";"FULOVOPQENLVDA-UHFFFAOYSA-N";402.48;4.48;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-7.11;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.00000007762471166286912
"MM472162";"MM472162";"CC(C)C[C@H]1C[C@@H](C)[C@]2(C(=O)Nc3ccc(F)cc32)N1C(=O)c1cn(C)cn1";"WAFNVKVWBPXGHK-CGSMKXTHSA-N";384.46;3.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4044710/target=_blank>CHEMBL4044710</a>";;-4.74;"Ito M, Iwatani M, Yamamoto T, Tanaka T, Kawamoto T, Morishita D, Nakanishi A, Maezaki H.: Discovery of spiro[indole-3,2'-pyrrolidin]-2(1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP. Bioorg Med Chem, Volume 25 (17), 2017";"PAMPA";0.000018197008586099827
"MM472433";"MM472433";"CC1=C(c2nc(-c3ccc(C#N)cc3)cs2)C(c2ccc(Cl)nc2)NC(=O)N1";"URZXRDLIESBEPT-UHFFFAOYSA-N";407.89;4.52;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-7.4;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.00000003981071705534969
"MM472165";"MM472165";"CC(C)C[C@@H]1C[C@H](C)[C@@]2(C(=O)Nc3ccc(F)cc32)N1C(=O)c1cn(Cc2ccccc2)cn1";"CFOBSDBTRZXUQZ-CLQOQPCJSA-N";460.55;4.81;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4044710/target=_blank>CHEMBL4044710</a>";;-4.71;"Ito M, Iwatani M, Yamamoto T, Tanaka T, Kawamoto T, Morishita D, Nakanishi A, Maezaki H.: Discovery of spiro[indole-3,2'-pyrrolidin]-2(1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP. Bioorg Med Chem, Volume 25 (17), 2017";"PAMPA";0.000019498445997580456
"MM472135";"MM472135";"O=C(NS(=O)(=O)CCN1CCCC1)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"WRPGXWJQJFHLJV-UHFFFAOYSA-N";640.09;4.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-4.91;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.00001230268770812381
"MM472183";"MM472183";"CNC(=O)c1cnc(Nc2ccc3c(c2)CC(=O)N3C)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"GSQGOUWOHGQEKS-QPPBQGQZSA-N";461.52;2.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-6.22;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.0000006025595860743581
"MM472181";"MM472181";"CNC(=O)c1cnc(Nc2ccc3ncsc3c2)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"SQGHWOMLSGMJQF-KNQAVFIVSA-N";449.54;3.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-5.72;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.0000019054607179632483
"MM471694";"MM471694";"O=S1(=Nc2ccccc2Cl)CCCCC1";"OVLAOVWXZWWYPO-UHFFFAOYSA-N";243.76;3.62;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-4.92;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000012022644346174132
"MM471433";"MM471433";"CCCCC(=O)NC[C@@H](O)[C@@H](O)[C@@H]1OC(C(=O)O)=C[C@H](O)[C@H]1NC(C)=O";"XVGFMAMZJCDOSQ-HFTJKPBSSA-N";374.39;-1.75;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4059390/target=_blank>CHEMBL4059390</a>";;-8.3;"Guo T, DĂ¤twyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW.: Selective Inhibitors of Human Neuraminidase 3. J Med Chem, Volume 61 (5), 2018";"PAMPA";0.000000005011872336272715
"MM471706";"MM471706";"C[S@](=O)(=Nc1ccc(C(F)(F)F)cc1)c1ccccc1";"GKHOMOKIJWOGMS-HXUWFJFHSA-N";299.32;4.49;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.6;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.0000025118864315095823
"MM471703";"MM471703";"O=S1(=Nc2ccc(C(F)(F)F)cc2)CCCC1";"UREBGVVUNJWDAC-UHFFFAOYSA-N";263.28;3.6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.06;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000008709635899560814
"MM472185";"MM472185";"CNC(=O)c1cnc(Nc2ccc3c(cnn3C)c2)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"XMLVFEZOONZFRD-GGAORHGYSA-N";446.51;2.58;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-5.96;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.000001096478196143185
"MM472153";"MM472153";"CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccccn5)CC4)ccc3C)cc12";"KCWQOCLBLVNNLJ-UHFFFAOYSA-N";519.58;6.39;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4015588/target=_blank>CHEMBL4015588</a>";;-4;"Yeung KS, Beno BR, Parcella K, Bender JA, Grant-Young KA, Nickel A, Gunaga P, Anjanappa P, Bora RO, Selvakumar K, Rigat K, Wang YK, Liu M, Lemm J, Mosure K, Sheriff S, Wan C, Witmer M, Kish K, Hanumegowda U, Zhuo X, Shu YZ, Parker D, Haskell R, Ng A, Gao Q, Colston E, Raybon J, Grasela DM, Santone K, Gao M, Meanwell NA, Sinz M, Soars MG, Knipe JO, Roberts SB, Kadow JF.: Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. J Med Chem, Volume 60 (10), 2017";"PAMPA";0.0001
"MM471695";"MM471695";"O=S1(=Nc2cccnc2)CCCCC1";"AMUFLKJMKKCEFN-UHFFFAOYSA-N";210.3;2.37;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.24;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000005754399373371567
"MM472126";"MM472126";"CS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"FTIQFVGYJQEBJD-UHFFFAOYSA-N";556.95;4;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.96;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000001096478196143185
"MM472004";"MM472004";"C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2ccccc2)cn1";"XZJWCJMLDPTODI-INIZCTEOSA-N";398.47;3.98;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4000300/target=_blank>CHEMBL4000300</a>";;-3.95;"Duraiswamy AJ, Lee MA, Madan B, Ang SH, Tan ES, Cheong WW, Ke Z, Pendharkar V, Ding LJ, Chew YS, Manoharan V, Sangthongpitag K, Alam J, Poulsen A, Ho SY, Virshup DM, Keller TH.: Discovery and Optimization of a Porcupine Inhibitor. J Med Chem, Volume 58 (15), 2015";"PAMPA";0.0001122018454301963
"MM471701";"MM471701";"CS(=O)(=Nc1ccc(C(F)(F)F)cc1)C1CCOCC1";"PDAAXDQLFGHKQJ-UHFFFAOYSA-N";307.34;3.61;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.02;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000009549925860214369
"MM472139";"MM472139";"O=C(NS(=O)(=O)CCNCc1ccccc1)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"BBXJNQUTWAPTJR-UHFFFAOYSA-N";676.12;5.16;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.31;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000004897788193684467
"MM471705";"MM471705";"O=S1(=Nc2ccc(C(F)(F)F)cc2)CCNCC1";"VDENYWYNQZVVRI-UHFFFAOYSA-N";278.3;2.41;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.08;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.00000831763771102671
"MM472140";"MM472140";"CC(=O)NCCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"IVWCRTMADRUUFH-UHFFFAOYSA-N";628.03;3.51;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-6.15;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.0000007079457843841374
"MM472007";"MM472007";"NS(=O)(=O)c1ccc(Cc2c(-c3cccc(-c4ccccc4)c3)nn(-c3nc(C(=O)O)cs3)c2CC2CC2)cc1";"ALJORCZKMBZYCR-UHFFFAOYSA-N";570.7;5.55;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4032350/target=_blank>CHEMBL4032350</a>";;-5.1;"Rai G, Brimacombe KR, Mott BT, Urban DJ, Hu X, Yang SM, Lee TD, Cheff DM, Kouznetsova J, Benavides GA, Pohida K, Kuenstner EJ, Luci DK, Lukacs CM, Davies DR, Dranow DM, Zhu H, Sulikowski G, Moore WJ, Stott GM, Flint AJ, Hall MD, Darley-Usmar VM, Neckers LM, Dang CV, Waterson AG, Simeonov A, Jadhav A, Maloney DJ.: Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). J Med Chem, Volume 60 (22), 2017";"PAMPA";0.000007943282347242822
"MM471693";"MM471693";"O=S1(=Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CCCCC1";"OXMFSTCFDKSEMA-UHFFFAOYSA-N";345.31;5.01;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.48;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.0000033113112148259077
"MM472133";"MM472133";"CN(C)CCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"XAJIRGSNSNONDO-UHFFFAOYSA-N";614.05;3.93;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.35;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000004466835921509635
"MM472158";"MM472158";"O=C1Nc2cc(=O)n(Cc3ccccc3)cc2CN1c1cccc(OCc2cncs2)c1";"GAWVULNDIBAUHU-UHFFFAOYSA-N";444.52;4.48;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4017295/target=_blank>CHEMBL4017295</a>";;-4.88;"Iwatani-Yoshihara M, Ito M, Klein MG, Yamamoto T, Yonemori K, Tanaka T, Miwa M, Morishita D, Endo S, Tjhen R, Qin L, Nakanishi A, Maezaki H, Kawamoto T.: Discovery of Allosteric Inhibitors Targeting the Spliceosomal RNA Helicase Brr2. J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000013182567385564074
"MM471715";"MM471715";"O=C1N=C(N2CCOCC2)S/C1=C\c1ccc(-c2ccc(C(=O)O)c(O)c2)o1";"GFVODCJPYDHGDZ-YBEGLDIGSA-N";400.41;2.65;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018083/target=_blank>CHEMBL4018083</a>";;-5.89;"Botta L, Maccari G, Calandro P, Tiberi M, Brai A, Zamperini C, Canducci F, Chiariello M, MartĂ­-Centelles R, Falomir E, Carda M.: One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000001288249551693135
"MM472136";"MM472136";"O=C(NS(=O)(=O)CCN1CCOCC1)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"HAPYRRCWQVAEGZ-UHFFFAOYSA-N";656.09;3.7;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.46;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000003467368504525317
"MM471724";"MM471724";"O=C(c1cc(F)cc(Cl)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1";"CHAFCAFCZBTARK-UHFFFAOYSA-N";375.76;3.87;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4046794/target=_blank>CHEMBL4046794</a>";;-4.43;"Hirose W, Kato Y, Natsutani I, Takata M, Kitaichi M, Imai S, Hayashi S, Arai Y, Hoshino K, Yoshida K.: Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators. Bioorg Med Chem Lett, Volume 27 (18), 2017";"PAMPA";0.00003715352290971728
"MM472187";"MM472187";"CNC(=O)c1cnc(Nc2ccc(F)cc2)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"GVBOPEDUJHEBNN-CTNGQTDRSA-N";410.45;2.83;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-4.95;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.00001122018454301963
"MM471692";"MM471692";"O=S1(=Nc2ccc(C(F)(F)F)cc2)CCCCC1";"WKVVOLKLPQHMSV-UHFFFAOYSA-N";277.31;3.99;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.11;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.00000776247116628691
"MM471436";"MM471436";"COC(=O)C1=C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)Cn2cc(-c3ccc(-c4ccccc4)cc3)nn2)O1";"JRAYIHBGTTZJGI-YMXDKZJPSA-N";508.53;0.66;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4059390/target=_blank>CHEMBL4059390</a>";;-7.8;"Guo T, DĂ¤twyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW.: Selective Inhibitors of Human Neuraminidase 3. J Med Chem, Volume 61 (5), 2018";"PAMPA";0.000000015848931924611143
"MM472005";"MM472005";"C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2cccnc2)cn1";"YBVCMIZESQAPMG-HNNXBMFYSA-N";399.46;3.38;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4000300/target=_blank>CHEMBL4000300</a>";;-4.3;"Duraiswamy AJ, Lee MA, Madan B, Ang SH, Tan ES, Cheong WW, Ke Z, Pendharkar V, Ding LJ, Chew YS, Manoharan V, Sangthongpitag K, Alam J, Poulsen A, Ho SY, Virshup DM, Keller TH.: Discovery and Optimization of a Porcupine Inhibitor. J Med Chem, Volume 58 (15), 2015";"PAMPA";0.00005011872336272725
"MM471689";"MM471689";"COc1ccc(N=S2(=O)CCCCC2)cc1";"QFJDWAWVUWTKFX-UHFFFAOYSA-N";239.34;2.98;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.04;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000009120108393559096
"MM472142";"MM472142";"O=C(NS(=O)(=O)CCNC(=O)C1CC1)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"RUNNQPIAHYEXMY-UHFFFAOYSA-N";654.07;3.9;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-7;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.0000001
"MM472434";"MM472434";"CC1=C(c2nc(-c3ccc(C#N)cc3)cs2)C(c2ccc(F)nc2)NC(=O)N1";"CLPACMYWDODQTI-UHFFFAOYSA-N";391.43;4;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-6.24;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.0000005754399373371567
"MM472429";"MM472429";"CC1=C(c2nc(-c3ccc(C#N)cc3)cs2)C(c2ccc(O)cc2)NC(=O)N1";"BENQYSGJOKEREW-UHFFFAOYSA-N";388.45;4.17;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-7.82;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.000000015135612484362072
"MM472164";"MM472164";"CC(C)C[C@H]1C[C@@H](C)[C@]2(C(=O)Nc3ccc(F)cc32)N1C(=O)c1cn(Cc2ccccc2)cn1";"CFOBSDBTRZXUQZ-AIFCEMJISA-N";460.55;4.81;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4044710/target=_blank>CHEMBL4044710</a>";;-4.74;"Ito M, Iwatani M, Yamamoto T, Tanaka T, Kawamoto T, Morishita D, Nakanishi A, Maezaki H.: Discovery of spiro[indole-3,2'-pyrrolidin]-2(1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP. Bioorg Med Chem, Volume 25 (17), 2017";"PAMPA";0.000018197008586099827
"MM471707";"MM471707";"C[S@@](=O)(=Nc1ccc(C(F)(F)F)cc1)c1ccccc1";"GKHOMOKIJWOGMS-FQEVSTJZSA-N";299.32;4.49;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.46;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000003467368504525317
"MM472131";"MM472131";"O=C(NS(=O)(=O)c1ccc(F)cc1)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"NNDKAXWMLYQJIG-UHFFFAOYSA-N";637.02;5.57;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-4.71;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000019498445997580456
"MM472151";"MM472151";"CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)c(F)c12";"LZAUGCMVNLZVJV-UHFFFAOYSA-N";538.55;5.92;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4015588/target=_blank>CHEMBL4015588</a>";;-4.01;"Yeung KS, Beno BR, Parcella K, Bender JA, Grant-Young KA, Nickel A, Gunaga P, Anjanappa P, Bora RO, Selvakumar K, Rigat K, Wang YK, Liu M, Lemm J, Mosure K, Sheriff S, Wan C, Witmer M, Kish K, Hanumegowda U, Zhuo X, Shu YZ, Parker D, Haskell R, Ng A, Gao Q, Colston E, Raybon J, Grasela DM, Santone K, Gao M, Meanwell NA, Sinz M, Soars MG, Knipe JO, Roberts SB, Kadow JF.: Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. J Med Chem, Volume 60 (10), 2017";"PAMPA";0.00009772372209558111
"MM472431";"MM472431";"CC1=C(c2nc(-c3ccc(C#N)cc3)cs2)C(c2cccnc2)NC(=O)N1C";"NHZFWUYOYJCAKK-UHFFFAOYSA-N";387.47;4.2;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-7.5;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.00000003162277660168379
"MM471716";"MM471716";"O=C1N=C(Nc2ccc(F)c(Cl)c2)S/C1=C\c1ccc(-c2ccc(C(=O)O)c(O)c2)o1";"YDFRXDRMHDKLMX-NVMNQCDNSA-N";458.85;5.23;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018083/target=_blank>CHEMBL4018083</a>";;-5.8;"Botta L, Maccari G, Calandro P, Tiberi M, Brai A, Zamperini C, Canducci F, Chiariello M, MartĂ­-Centelles R, Falomir E, Carda M.: One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000001584893192461114
"MM471435";"MM471435";"CCCCOC(=O)C1=C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)Cn2cc(-c3ccc(-c4ccccc4)cc3)nn2)O1";"UKLTUTWUHSKLAY-GMQNGPPWSA-N";550.61;1.83;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4059390/target=_blank>CHEMBL4059390</a>";;-6.5;"Guo T, DĂ¤twyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW.: Selective Inhibitors of Human Neuraminidase 3. J Med Chem, Volume 61 (5), 2018";"PAMPA";0.0000003162277660168379
"MM472134";"MM472134";"CCN(CC)CCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"MSTXAZGGZDLYJV-UHFFFAOYSA-N";642.1;4.71;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.14;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000007244359600749906
"MM472189";"MM472189";"CNC(=O)c1cnc(Nc2ccc(OC)c(F)c2)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"JCKCNGWRVGOVOL-KNQAVFIVSA-N";440.48;2.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-5.2;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.00000630957344480193
"MM471699";"MM471699";"CCS(C)(=O)=Nc1ccc(C(F)(F)F)cc1";"PURSEKFOEZFVTI-UHFFFAOYSA-N";251.27;3.45;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.11;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.00000776247116628691
"MM471429";"MM471429";"Cc1ccccc1-c1ccc(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c(Cl)c1";"WBAVSMMWQAGAGW-GFEQUFNTSA-N";380.82;1.49;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4015741/target=_blank>CHEMBL4015741</a>";;-4.6;"Mayer K, Eris D, Schwardt O, Sager CP, Rabbani S, Kleeb S, Ernst B.: Urinary Tract Infection: Which Conformation of the Bacterial Lectin FimH Is Therapeutically Relevant? J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000025118864315095822
"MM471438";"MM471438";"CCCOC(=O)C1=C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)Cn2cc(-c3ccc(-c4ccccc4)cc3)nn2)O1";"SXZXOENDBNGESL-LIOLAYKBSA-N";536.59;1.44;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4059390/target=_blank>CHEMBL4059390</a>";;-8.2;"Guo T, DĂ¤twyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW.: Selective Inhibitors of Human Neuraminidase 3. J Med Chem, Volume 61 (5), 2018";"PAMPA";0.000000006309573444801943
"MM472123";"MM472123";"CN1C[C@@H](Nc2cnn(C)c(=O)c2Br)C[C@@H](c2ccccc2)C1";"VZAFGXCWAWRULT-KGLIPLIRSA-N";377.29;2.44;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003558/target=_blank>CHEMBL4003558</a>";;-4.33;"Humphreys PG, Bamborough P, Chung CW, Craggs PD, Gordon L, Grandi P, Hayhow TG, Hussain J, Jones KL, Lindon M, Michon AM, Renaux JF, Suckling CJ, Tough DF, Prinjha RK.: Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. J Med Chem, Volume 60 (2), 2017";"PAMPA";0.00004677351412871981
"MM472125";"MM472125";"O=C(O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"FKYJDMDPNVUPKB-UHFFFAOYSA-N";479.85;5.01;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.23;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000005888436553555884
"MM471696";"MM471696";"O=S1(=Nc2ccncc2)CCCCC1";"FZBJUNSDDHHTBV-UHFFFAOYSA-N";210.3;2.37;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.24;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000005754399373371567
"MM472157";"MM472157";"O=C1Nc2cc(=O)n(Cc3ccccc3)cc2CN1c1cccc(OCc2cccnc2)c1";"PSWMJOPGLAUUCC-UHFFFAOYSA-N";438.49;4.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4017295/target=_blank>CHEMBL4017295</a>";;-4.85;"Iwatani-Yoshihara M, Ito M, Klein MG, Yamamoto T, Yonemori K, Tanaka T, Miwa M, Morishita D, Endo S, Tjhen R, Qin L, Nakanishi A, Maezaki H, Kawamoto T.: Discovery of Allosteric Inhibitors Targeting the Spliceosomal RNA Helicase Brr2. J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000014125375446227555
"MM471702";"MM471702";"O=S1(=Nc2ccc(C(F)(F)F)cc2)CCC1";"JIBPWRMMGHQEQJ-UHFFFAOYSA-N";249.26;3.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.02;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000009549925860214369
"MM471725";"MM471725";"O=C(c1cc(F)cc(Cl)c1)N1CCn2nc(-c3ccc(F)cn3)cc2C1";"PAVOURBCAONWKJ-UHFFFAOYSA-N";374.78;3.53;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4046794/target=_blank>CHEMBL4046794</a>";;-4.43;"Hirose W, Kato Y, Natsutani I, Takata M, Kitaichi M, Imai S, Hayashi S, Arai Y, Hoshino K, Yoshida K.: Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators. Bioorg Med Chem Lett, Volume 27 (18), 2017";"PAMPA";0.00003715352290971728
"MM472003";"MM472003";"C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2cccnc2)nc1";"UTBGFYWFGKMYNX-HNNXBMFYSA-N";399.46;3.38;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4000300/target=_blank>CHEMBL4000300</a>";;-4.57;"Duraiswamy AJ, Lee MA, Madan B, Ang SH, Tan ES, Cheong WW, Ke Z, Pendharkar V, Ding LJ, Chew YS, Manoharan V, Sangthongpitag K, Alam J, Poulsen A, Ho SY, Virshup DM, Keller TH.: Discovery and Optimization of a Porcupine Inhibitor. J Med Chem, Volume 58 (15), 2015";"PAMPA";0.00002691534803926914
"MM471700";"MM471700";"CS(=O)(=Nc1ccc(C(F)(F)F)cc1)C1CC1";"MTQSILGEXGPHBV-UHFFFAOYSA-N";263.28;3.6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.11;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.00000776247116628691
"MM472138";"MM472138";"CC(C)(C)CNCCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"WXGOVQCXASWGBF-UHFFFAOYSA-N";656.13;5.01;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-4.19;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.00006456542290346549
"MM472163";"MM472163";"CC(C)C[C@@H]1C[C@H](C)[C@@]2(C(=O)Nc3ccc(F)cc32)N1C(=O)c1cn(C)cn1";"WAFNVKVWBPXGHK-QDUSTFBWSA-N";384.46;3.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4044710/target=_blank>CHEMBL4044710</a>";;-4.77;"Ito M, Iwatani M, Yamamoto T, Tanaka T, Kawamoto T, Morishita D, Nakanishi A, Maezaki H.: Discovery of spiro[indole-3,2'-pyrrolidin]-2(1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP. Bioorg Med Chem, Volume 25 (17), 2017";"PAMPA";0.00001698243652461746
"MM472141";"MM472141";"CC(C)C(=O)NCCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"COCQMSWPGXJBIP-UHFFFAOYSA-N";656.09;4.14;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.89;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000001288249551693135
"MM471434";"MM471434";"CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)Cn2cc(-c3ccc(-c4ccccc4)cc3)nn2)OC(C(=O)O)=C[C@@H]1NC(=N)N";"GGROOSBUFJNXJU-LBQOOEJDSA-N";535.56;0.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4059390/target=_blank>CHEMBL4059390</a>";;-7.4;"Guo T, DĂ¤twyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW.: Selective Inhibitors of Human Neuraminidase 3. J Med Chem, Volume 61 (5), 2018";"PAMPA";0.00000003981071705534969
"MM472129";"MM472129";"O=C(NS(=O)(=O)c1ccccc1)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"QDAHXJOCDHKYCA-UHFFFAOYSA-N";619.03;5.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-4.74;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000018197008586099827
"MM472006";"MM472006";"NS(=O)(=O)c1ccc(Cc2c(-c3cccc(-c4ccccc4)c3)nn(-c3nc(C(=O)O)cs3)c2C2CC2)cc1";"JXSFBKRZYZNXNV-UHFFFAOYSA-N";556.67;5.48;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4032350/target=_blank>CHEMBL4032350</a>";;-6;"Rai G, Brimacombe KR, Mott BT, Urban DJ, Hu X, Yang SM, Lee TD, Cheff DM, Kouznetsova J, Benavides GA, Pohida K, Kuenstner EJ, Luci DK, Lukacs CM, Davies DR, Dranow DM, Zhu H, Sulikowski G, Moore WJ, Stott GM, Flint AJ, Hall MD, Darley-Usmar VM, Neckers LM, Dang CV, Waterson AG, Simeonov A, Jadhav A, Maloney DJ.: Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). J Med Chem, Volume 60 (22), 2017";"PAMPA";0.000001
"MM472436";"MM472436";"CC1=C(c2nc(-c3ccc(C#N)cc3)cs2)C(c2ccc(Br)nc2)NC(=O)N1";"ZUBNLRDUMJNJHH-UHFFFAOYSA-N";452.34;4.62;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-7.82;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.000000015135612484362072
"MM472428";"MM472428";"CC1=C(c2nc(-c3ccc(C#N)cc3)cs2)C(c2cccc(O)c2)NC(=O)N1";"AUPBYLRPPIUNRA-UHFFFAOYSA-N";388.45;4.17;;;"GENER";"EPAM";"25";"0";"ph=7.2,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4043725/target=_blank>CHEMBL4043725</a>";;-7.84;"Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.: An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Bioorg Med Chem, Volume 25 (23), 2017";"PAMPA";0.000000014454397707459279
"MM472184";"MM472184";"CNC(=O)c1cnc(Nc2ccc3[nH]ncc3c2)cc1N[C@@H](c1ccccc1)[C@H](O)CO";"HYRYSASVBDNXAO-IRLDBZIGSA-N";432.48;2.57;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4047626/target=_blank>CHEMBL4047626</a>";;-6.19;"Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.: Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.000000645654229034655
"MM472124";"MM472124";"CN1CCc2c(cccc2Nc2cnn(C)c(=O)c2Cl)C1";"YJJYUKCKKSVTAG-UHFFFAOYSA-N";304.78;2.17;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003558/target=_blank>CHEMBL4003558</a>";;-4.42;"Humphreys PG, Bamborough P, Chung CW, Craggs PD, Gordon L, Grandi P, Hayhow TG, Hussain J, Jones KL, Lindon M, Michon AM, Renaux JF, Suckling CJ, Tough DF, Prinjha RK.: Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. J Med Chem, Volume 60 (2), 2017";"PAMPA";0.000038018939632056124
"MM471723";"MM471723";"O=C(c1cccc(F)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1";"GNTAXZMHSFRNIX-UHFFFAOYSA-N";341.32;3.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4046794/target=_blank>CHEMBL4046794</a>";;-4.5;"Hirose W, Kato Y, Natsutani I, Takata M, Kitaichi M, Imai S, Hayashi S, Arai Y, Hoshino K, Yoshida K.: Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators. Bioorg Med Chem Lett, Volume 27 (18), 2017";"PAMPA";0.000031622776601683795
"MM471733";"MM471733";"Cc1cc2c(cc1C)-c1occ(C)c1C(=O)C2=O";"VCBCAXHKNPCVCB-UHFFFAOYSA-N";240.26;3.25;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4131170/target=_blank>CHEMBL4131170</a>";;-4.37;"Zhang X, Bian J, Li X, Wu X, Dong Y, You Q.: 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.00004265795188015926
"MM472132";"MM472132";"NCCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"ZEDIZPBRVQFMQS-UHFFFAOYSA-N";586;3.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-4.82;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000015135612484362071
"MM471697";"MM471697";"Cn1cc(N=S2(=O)CCCCC2)cn1";"KZDYIEXGNVLONA-UHFFFAOYSA-N";213.31;1.7;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3992821/target=_blank>CHEMBL3992821</a>";;-5.49;"Frings M, Bolm C, Blum A, Gnamm C.: Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and inÂ vitro Parameters Relevant for Drug Discovery. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000003235936569296281
"MM472152";"MM472152";"CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)cc12";"LUIDEMBRIXHMJX-UHFFFAOYSA-N";520.56;5.78;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4015588/target=_blank>CHEMBL4015588</a>";;-4.11;"Yeung KS, Beno BR, Parcella K, Bender JA, Grant-Young KA, Nickel A, Gunaga P, Anjanappa P, Bora RO, Selvakumar K, Rigat K, Wang YK, Liu M, Lemm J, Mosure K, Sheriff S, Wan C, Witmer M, Kish K, Hanumegowda U, Zhuo X, Shu YZ, Parker D, Haskell R, Ng A, Gao Q, Colston E, Raybon J, Grasela DM, Santone K, Gao M, Meanwell NA, Sinz M, Soars MG, Knipe JO, Roberts SB, Kadow JF.: Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. J Med Chem, Volume 60 (10), 2017";"PAMPA";0.00007762471166286911
"MM472127";"MM472127";"CCS(=O)(=O)NC(=O)c1ccc(Nc2nc(NC3(c4ccc(Cl)cc4)CC3)nc(OCC(F)(F)F)n2)cc1";"VXXMBJGZZLTGHZ-UHFFFAOYSA-N";570.98;4.39;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4004073/target=_blank>CHEMBL4004073</a>";;-5.55;"Mull ES, Sun LQ, Zhao Q, Eggers B, Pokornowski K, Zhai G, Rajamani R, Jenkins S, Kramer M, Wang YK, Fang H, Tenney D, Baldick CJ, Cockett MI, Meanwell NA, Scola PM.: Functionalized triazines as potent HCV entry inhibitors. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000002818382931264455
"MM471726";"MM471726";"O=C(O)CNC(=O)c1ncc(-c2cn(CCCc3ccc(Cl)cc3)nn2)cc1O";"RODNKCMKPZCZKG-UHFFFAOYSA-N";415.84;2.15;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4124467/target=_blank>CHEMBL4124467</a>";;-4.94;"Wu Y, Jiang Z, Li Z, Gu J, You Q, Zhang X.: Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. J Med Chem, Volume 61 (12), 2018";"PAMPA";0.000011481536214968817
"MM472199";"MM472199";"COCCCOc1nc(C(C)(C)C)ncc1C(=O)N(CC(C)C)[C@@H]1CNC[C@H](C(=O)N2CCOCC2)C1";"YIIUYJDPMKOTIL-RTWAWAEBSA-N";519.69;2.12;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4122886/target=_blank>CHEMBL4122886</a>";;-4.57;"Tokuhara H, Imaeda Y, Fukase Y, Iwanaga K, Taya N, Watanabe K, Kanagawa R, Matsuda K, Kajimoto Y, Kusumoto K, Kondo M, Snell G, Behnke CA, Kuroita T.: Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile. Bioorg Med Chem, Volume 26 (12), 2018";"PAMPA";0.00002691534803926914
"MM471736";"MM471736";"Cc1cc(NCCN(C)C)nc2ccc(NC(=O)c3ccc(Cl)c(Cl)c3)cc12";"IJOZBPDREPMYIP-UHFFFAOYSA-N";417.34;5.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4134985/target=_blank>CHEMBL4134985</a>";;-5.5;"Jiang F, Guo AP, Xu JC, Wang HJ, Mo XF, You QD, Xu XL.: Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90Â C-terminal inhibitors. Eur J Med Chem, Volume 141, 2017";"PAMPA";0.000003162277660168379
"MM471742";"MM471742";"COc1ccc(C(=O)CCC2C=CN(Cc3cccc(Cl)c3)C=C2C#N)cc1OC";"BOPFNLKYSPIFLY-UHFFFAOYSA-N";422.91;5.37;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146840/target=_blank>CHEMBL4146840</a>";;-4.82;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000015135612484362071
"MM472244";"MM472244";"C[C@@H]1CN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)C[C@H](C)N1";"JHHVTZUPBAYGDQ-ZHJWVTAZSA-N";419.62;3.29;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-5.41;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.000003890451449942805
"MM471746";"MM471746";"COc1cc2c(cc1OC)C(=O)C(CC1C=CN(Cc3ccccc3)C=C1C(C)=O)CC2";"HMFPNGCVUHYYTQ-UHFFFAOYSA-N";431.53;4.96;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146840/target=_blank>CHEMBL4146840</a>";;-4.69;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000020417379446695274
"MM471730";"MM471730";"Cc1cc2c(cc1C)-c1oc(CN3CCN(c4ccc(F)cc4)CC3)c(C)c1C(=O)C2=O";"PXYCJEPIYXOULK-UHFFFAOYSA-N";432.5;4.71;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4131170/target=_blank>CHEMBL4131170</a>";;-4.55;"Zhang X, Bian J, Li X, Wu X, Dong Y, You Q.: 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.00002818382931264455
"MM472232";"MM472232";"CN(C[C@@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21";"HVYXYPWZDRWKCC-REWPJTCUSA-N";391.56;2.51;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-6.4;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.0000003981071705534969
"MM471738";"MM471738";"Cc1cc(NCCN2CCCC2)nc2ccc(NC(=O)c3ccc(Cl)c(Cl)c3)cc12";"BNOKIEQEVADACR-UHFFFAOYSA-N";443.38;5.61;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4134985/target=_blank>CHEMBL4134985</a>";;-4.68;"Jiang F, Guo AP, Xu JC, Wang HJ, Mo XF, You QD, Xu XL.: Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90Â C-terminal inhibitors. Eur J Med Chem, Volume 141, 2017";"PAMPA";0.00002089296130854041
"MM471747";"MM471747";"COc1ccc2c(c1)CCC(CC1C=CN(Cc3ccccc3Cl)C=C1C(C)=O)C2=O";"QZMOKFTXANCHGF-UHFFFAOYSA-N";435.95;5.6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146840/target=_blank>CHEMBL4146840</a>";;-4.67;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000021379620895022323
"MM471732";"MM471732";"Cc1cc2c(cc1C)-c1oc(C(=O)N3CCN(Cc4ccccc4)CC3)c(C)c1C(=O)C2=O";"LUCVOLYBWQUGEI-UHFFFAOYSA-N";442.52;4.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4131170/target=_blank>CHEMBL4131170</a>";;-4.92;"Zhang X, Bian J, Li X, Wu X, Dong Y, You Q.: 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.000012022644346174132
"MM472218";"MM472218";"c1ccc2c(c1)CN[C@@H](CN(CCC1CCNCC1)[C@H]1CCCc3cccnc31)C2";"HRURMUJQOQRMOO-RPBOFIJWSA-N";404.6;3.87;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4149805/target=_blank>CHEMBL4149805</a>";;-5.72;"Tahirovic YA, Truax VM, Wilson RJ, Jecs E, Nguyen HH, Miller EJ, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Discovery of N-Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties. ACS Med Chem Lett, Volume 9 (5), 2018";"PAMPA";0.0000019054607179632483
"MM471729";"MM471729";"Cc1cc2c(cc1C)-c1oc(CNc3cccc(F)c3)c(C)c1C(=O)C2=O";"MAUDQUPICUORQZ-UHFFFAOYSA-N";363.39;5;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4131170/target=_blank>CHEMBL4131170</a>";;-4.18;"Zhang X, Bian J, Li X, Wu X, Dong Y, You Q.: 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.00006606934480075965
"MM471740";"MM471740";"Cc1cc(NCCN2CCOCC2)nc2ccc(NC(=O)c3ccc(Cl)c(Cl)c3)cc12";"JDCFMUZIDMPOGY-UHFFFAOYSA-N";459.38;4.85;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4134985/target=_blank>CHEMBL4134985</a>";;-4.3;"Jiang F, Guo AP, Xu JC, Wang HJ, Mo XF, You QD, Xu XL.: Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90Â C-terminal inhibitors. Eur J Med Chem, Volume 141, 2017";"PAMPA";0.00005011872336272725
"MM471743";"MM471743";"COc1ccc(C(=O)CCC2C=CN(Cc3cccc(Cl)c3)C=C2C(C)=O)cc1OC";"OYPCNXLINUJIIK-UHFFFAOYSA-N";439.94;5.44;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146840/target=_blank>CHEMBL4146840</a>";;-4.74;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000018197008586099827
"MM472235";"MM472235";"c1cnc2c(c1)CCC[C@@H]2N(CC1CC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1";"LVRJXLFKEYVIDK-BVAGGSTKSA-N";431.63;3.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-5.06;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.000008709635899560814
"MM472241";"MM472241";"Cc1ccc(CN(C)C[C@H]2Cc3c(cccc3N3CCNCC3)CN2)nc1";"RULCBINUQVNOQP-HXUWFJFHSA-N";365.53;1.95;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-4.65;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.00002238721138568338
"MM471737";"MM471737";"CCN(CC)CCNc1cc(C)c2cc(NC(=O)c3ccc(Cl)c(Cl)c3)ccc2n1";"YQVDHEBZAZJTPX-UHFFFAOYSA-N";445.39;5.86;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4134985/target=_blank>CHEMBL4134985</a>";;-4.55;"Jiang F, Guo AP, Xu JC, Wang HJ, Mo XF, You QD, Xu XL.: Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90Â C-terminal inhibitors. Eur J Med Chem, Volume 141, 2017";"PAMPA";0.00002818382931264455
"MM471748";"MM471748";"COc1ccc2c(c1)CCC(CC1C=CN(Cc3ccccc3C)C=C1C(N)=O)C2=O";"TUALDOHFKJXKNG-UHFFFAOYSA-N";416.52;4.15;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146840/target=_blank>CHEMBL4146840</a>";;-4.73;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000018620871366628657
"MM472233";"MM472233";"CCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21";"SIXBBSBNDNEWTQ-QPPBQGQZSA-N";405.59;2.91;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-5.12;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.000007585775750291836
"MM471741";"MM471741";"Cc1cc(NCCN2CCN(C)CC2)nc2ccc(NC(=O)c3ccc(Cl)c(Cl)c3)cc12";"AGCIIRILODTNNC-UHFFFAOYSA-N";472.42;4.76;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4134985/target=_blank>CHEMBL4134985</a>";;-5.11;"Jiang F, Guo AP, Xu JC, Wang HJ, Mo XF, You QD, Xu XL.: Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90Â C-terminal inhibitors. Eur J Med Chem, Volume 141, 2017";"PAMPA";0.00000776247116628691
"MM472240";"MM472240";"Cc1cccnc1CN(C)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1";"PVNIDCOYVLXXDG-LJQANCHMSA-N";365.53;1.95;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-4.71;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.000019498445997580456
"MM472243";"MM472243";"CN1CCN(c2cccc3c2C[C@H](CN2CCC[C@H]4CCc5cccnc5[C@H]42)NC3)CC1";"XIFOVNBYXGVAQJ-AIUHUKMKSA-N";431.63;3.25;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-4.49;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.00003235936569296281
"MM471731";"MM471731";"Cc1cc2c(cc1C)-c1oc(CNc3ccc(CN4CCOCC4)cc3)c(C)c1C(=O)C2=O";"RUEULZNGJZLPLJ-UHFFFAOYSA-N";444.53;4.7;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4131170/target=_blank>CHEMBL4131170</a>";;-4.33;"Zhang X, Bian J, Li X, Wu X, Dong Y, You Q.: 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.00004677351412871981
"MM471728";"MM471728";"Cc1cc2c(cc1C)-c1oc(CNc3ccc(F)cc3)c(C)c1C(=O)C2=O";"PAAJBITWSCFYNS-UHFFFAOYSA-N";363.39;5;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4131170/target=_blank>CHEMBL4131170</a>";;-4.38;"Zhang X, Bian J, Li X, Wu X, Dong Y, You Q.: 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.00004168693834703355
"MM471739";"MM471739";"Cc1cc(NCCN2CCCCC2)nc2ccc(NC(=O)c3ccc(Cl)c(Cl)c3)cc12";"SIOPPTKDMIHEDM-UHFFFAOYSA-N";457.41;6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4134985/target=_blank>CHEMBL4134985</a>";;-4.33;"Jiang F, Guo AP, Xu JC, Wang HJ, Mo XF, You QD, Xu XL.: Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90Â C-terminal inhibitors. Eur J Med Chem, Volume 141, 2017";"PAMPA";0.00004677351412871981
"MM472238";"MM472238";"OCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21";"SIHICXDUEJZQEF-QPPBQGQZSA-N";421.59;1.88;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-5.96;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.000001096478196143185
"MM471744";"MM471744";"COc1ccc(C(=O)CCC2C=CN(Cc3cccc(Cl)c3)C=C2C(N)=O)cc1OC";"JVHQPCGYNVTJER-UHFFFAOYSA-N";440.93;4.34;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4146840/target=_blank>CHEMBL4146840</a>";;-4.72;"Azzouz R, Peauger L, Gembus V, Ĺ˘Ă®nĹŁaĹź ML, SopkovĂˇ-de Oliveira Santos J, PapamicaĂ«l C, Levacher V.: Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000019054607179632484
"MM472236";"MM472236";"CC(C)N(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21";"MOEVWTMNJQTKGX-RDGATRHJSA-N";419.62;3.29;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-5.8;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.000001584893192461114
"MM471735";"MM471735";"CCN1CCN(c2cc(C)c3cc(NC(=O)c4ccc(Cl)c(Cl)c4)ccc3n2)CC1";"RUVCLSMODYLUHW-UHFFFAOYSA-N";443.38;5.24;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4134985/target=_blank>CHEMBL4134985</a>";;-4.59;"Jiang F, Guo AP, Xu JC, Wang HJ, Mo XF, You QD, Xu XL.: Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90Â C-terminal inhibitors. Eur J Med Chem, Volume 141, 2017";"PAMPA";0.000025703957827688645
"MM472237";"MM472237";"c1cnc2c(c1)CCC[C@@H]2N(CC1CCCCC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1";"RNLVYINGLBPILI-UHSQPCAPSA-N";473.71;4.47;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-6.05;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.0000008912509381337459
"MM472239";"MM472239";"COCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21";"BCNCPSDKLRPTET-RDGATRHJSA-N";435.62;2.53;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-7;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.0000001
"MM472242";"MM472242";"Cc1cnc2c(c1)CCC[C@@H]2N(C)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1";"RSENRXMUUIGFKE-QPPBQGQZSA-N";405.59;2.82;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-6.05;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.0000008912509381337459
"MM472234";"MM472234";"CCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21";"JUIWDKRJPDGUPN-RDGATRHJSA-N";419.62;3.3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4156818/target=_blank>CHEMBL4156818</a>";;-5.58;"Nguyen HH, Kim MB, Wilson RJ, Butch CJ, Kuo KM, Miller EJ, Tahirovic YA, Jecs E, Truax VM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. J Med Chem, Volume 61 (16), 2018";"PAMPA";0.0000026302679918953817
"MM471752";"MM471752";"Cc1cc(SC(Cc2ccccc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)ccc1OCC(=O)O";"NDMVMGJRCVLXQH-UHFFFAOYSA-N";522.59;8.22;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4234953/target=_blank>CHEMBL4234953</a>";;-5.02;"Kim DS, Lee J, Londhe AM, Kadayat TM, Joo J, Hwang H, Kim KH, Pae AN, Chin J, Cho SJ, Kang H.: Synthesis and evaluation of an orally available ""Y""-shaped biaryl peroxisome proliferator-activated receptor Î´ agonist. Bioorg Med Chem, Volume 26 (15), 2018";"PAMPA";0.000009549925860214369
"MM471759";"MM471759";"Nc1cccc(C(OCCN2CCCCC2)c2cc3nccc(C(=O)O)c3s2)c1";"FTKYSFLMVOPKTH-UHFFFAOYSA-N";411.53;4.17;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4270063/target=_blank>CHEMBL4270063</a>";;-4.28;"Horton JR, Woodcock CB, Chen Q, Liu X, Zhang X, Shanks J, Rai G, Mott BT, Jansen DJ, Kales SC, Henderson MJ, Cyr M, Pohida K, Hu X, Shah P, Xu X, Jadhav A, Maloney DJ, Hall MD, Simeonov A, Fu H, Vertino PM, Cheng X.: Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. J Med Chem, Volume 61 (23), 2018";"PAMPA";0.00005248074602497723
"MM471753";"MM471753";"O=C(O)[C@H](Cc1c[nH]c2ccccc12)N(Cc1ccccc1)Cc1ccccc1";"KWVIYTNTSHGWBK-DEOSSOPVSA-N";384.48;4.87;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4256799/target=_blank>CHEMBL4256799</a>";;-5.5;"Bertamino A, Iraci N, Ostacolo C, Ambrosino P, Musella S, Di Sarno V, Ciaglia T, Pepe G, Sala M, Soldovieri MV, Mosca I, Gonzalez-Rodriguez S, Fernandez-Carvajal A, Ferrer-Montiel A, Novellino E, Taglialatela M, Campiglia P, Gomez-Monterrey I.: Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity. J Med Chem, Volume 61 (14), 2018";"PAMPA";0.000003162277660168379
"MM471757";"MM471757";"COc1cc2c(N3CCNCC3)nc(N(C)C)nc2cc1OCCCN1CCCC1";"UNBYGYCNSFZBGG-UHFFFAOYSA-N";414.55;1.98;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4269092/target=_blank>CHEMBL4269092</a>";;-5.37;"Paul B, Rahaman O, Roy S, Pal S, Satish S, Mukherjee A, Ghosh AR, Raychaudhuri D, Bhattacharya R, Goon S, Ganguly D, Talukdar A.: Activity-guided development of potent and selective toll-like receptor 9 antagonists. Eur J Med Chem, Volume 159, 2018";"PAMPA";0.000004265795188015926
"MM471464";"MM471464";"CCCCCCc1ccc(C(=O)CCN(C2CCCCC2)C2CCCCC2)cc1";"FHPXVWCDHBUVJE-UHFFFAOYSA-N";397.65;7.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL900775/target=_blank>CHEMBL900775</a>";;-3.98;"Arnold LA, Kosinski A, EstĂ©banez-PerpiĂ±Ăˇ E, Fletterick RJ, Guy RK.: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem, Volume 50 (22), 2007";"PAMPA";0.00010471285480508996
"MM471758";"MM471758";"COc1cc2c(N3CCN(C)CC3)nc(N(C)C)nc2cc1OCCCN1CCCC1";"FJZXZNPHKBHVRG-UHFFFAOYSA-N";428.58;2.32;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4269092/target=_blank>CHEMBL4269092</a>";;-4.82;"Paul B, Rahaman O, Roy S, Pal S, Satish S, Mukherjee A, Ghosh AR, Raychaudhuri D, Bhattacharya R, Goon S, Ganguly D, Talukdar A.: Activity-guided development of potent and selective toll-like receptor 9 antagonists. Eur J Med Chem, Volume 159, 2018";"PAMPA";0.000015135612484362071
"MM472010";"MM472010";"Cc1cc(O)c([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(CCNC(=O)NC(CO)(CO)CO)cc1";"CSTNPWDBBVIJSR-RXFVIIJJSA-N";550.61;-1.64;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4269257/target=_blank>CHEMBL4269257</a>";;-6.52;"Kuroda S, Kobashi Y, Oi T, Amada H, Okumura-Kitajima L, Io F, Yamamto K, Kakinuma H.: Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes. Bioorg Med Chem Lett, Volume 28 (22), 2018";"PAMPA";0.0000003019951720402019
"MM471760";"MM471760";"CC(C)OC(=O)c1ccnc2cc(C(OCCN3CCCCC3)c3cccc(NC(=O)/C=C/CN(C)C)c3)sc12";"PVYGAXMMEOUGEL-FMIVXFBMSA-N";564.75;5.51;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4270063/target=_blank>CHEMBL4270063</a>";;-4.15;"Horton JR, Woodcock CB, Chen Q, Liu X, Zhang X, Shanks J, Rai G, Mott BT, Jansen DJ, Kales SC, Henderson MJ, Cyr M, Pohida K, Hu X, Shah P, Xu X, Jadhav A, Maloney DJ, Hall MD, Simeonov A, Fu H, Vertino PM, Cheng X.: Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. J Med Chem, Volume 61 (23), 2018";"PAMPA";0.00007079457843841373
"MM471761";"MM471761";"CC(C)OC(=O)c1ccnc2cc(C(OCCN3CCCCC3)c3cccc(N)c3)sc12";"CTRINUKXZJSOSR-UHFFFAOYSA-N";453.61;5.04;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4270063/target=_blank>CHEMBL4270063</a>";;-2.99;"Horton JR, Woodcock CB, Chen Q, Liu X, Zhang X, Shanks J, Rai G, Mott BT, Jansen DJ, Kales SC, Henderson MJ, Cyr M, Pohida K, Hu X, Shah P, Xu X, Jadhav A, Maloney DJ, Hall MD, Simeonov A, Fu H, Vertino PM, Cheng X.: Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. J Med Chem, Volume 61 (23), 2018";"PAMPA";0.0010232929922807535
"MM471754";"MM471754";"COC(=O)[C@H](Cc1c[nH]c2ccccc12)N(Cc1ccccc1)Cc1ccccc1";"HHVOOJDLCVOLKI-VWLOTQADSA-N";398.51;4.95;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4256799/target=_blank>CHEMBL4256799</a>";;-6.01;"Bertamino A, Iraci N, Ostacolo C, Ambrosino P, Musella S, Di Sarno V, Ciaglia T, Pepe G, Sala M, Soldovieri MV, Mosca I, Gonzalez-Rodriguez S, Fernandez-Carvajal A, Ferrer-Montiel A, Novellino E, Taglialatela M, Campiglia P, Gomez-Monterrey I.: Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity. J Med Chem, Volume 61 (14), 2018";"PAMPA";0.000000977237220955811
"MM471549";"MM471549";"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12";"YBLWOZUPHDKFOT-UHFFFAOYSA-N";341.8;4.85;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.47;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0003388441561392024
"MM471765";"MM471765";"Cc1cc(/C=C/C(C)(C)C(=O)NC(C)(C)CO)ccc1Cc1cc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(O)cc1C(C)C";"MWKPZSAYDCWXQK-MNTZPKNGSA-N";585.74;2.86;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4311711/target=_blank>CHEMBL4311711</a>";;-6.3;"Kuroda S, Kobashi Y, Oi T, Kawabe K, Shiozawa F, Okumura-Kitajima L, Sugisaki-Kitano M, Io F, Yamamoto K, Kakinuma H.: Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment. Bioorg Med Chem, Volume 27 (2), 2019";"PAMPA";0.0000005011872336272725
"MM471785";"MM471785";"COc1cc(C(=O)N2CCc3c(c(=O)oc4c(C)c(N5CCN(C)CC5)ccc34)C2)ccc1NS(C)(=O)=O";"JYXFPWJRSZGEBC-UHFFFAOYSA-N";540.64;2.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4338138/target=_blank>CHEMBL4338138</a>";;-4.35;"Kawai J, Toki T, Ota M, Inoue H, Takata Y, Asahi T, Suzuki M, Shimada T, Ono K, Suzuki K, Takaishi S, Ohki H, Matsui S, Tsutsumi S, Hirota Y, Nakayama K.: Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.00004466835921509635
"MM472252";"MM472252";"CCN(C(=O)OC)c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1ccc(OC)c(C(=O)NC2(c3ncccn3)CC2)c1";"GTXYAGIZFYSRDP-UHFFFAOYSA-N";637.67;6.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.18;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00006606934480075965
"MM472267";"MM472267";"CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(C(F)(F)F)cc23)C1=O";"GVOISEJVFFIGQE-YCZSINBZSA-N";506.57;3.43;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4339727/target=_blank>CHEMBL4339727</a>";;-4.35;"Yang MG, Xiao Z, Cherney RJ, Tebben AJ, Batt DG, Brown GD, Chen J, Cvijic ME, Dabros M, Duncia JV, Galella M, Gardner DS, Khandelwal P, Ko SS, Malley MF, Mo R, Pang J, Rose AV, Santella JB, Shi H, Srivastava A, Traeger SC, Wang B, Xu S, Zhao R, Barrish JC, Mandlekar S, Zhao Q, Carter PH.: Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Med Chem Lett, Volume 10 (3), 2019";"PAMPA";0.00004466835921509635
"MM472272";"MM472272";"Cn1c(C(=O)NC2(c3ccc(CO)cc3)COC2)cc2c(Cl)c(Cl)ccc21";"SOTJPDGLCOSZOR-UHFFFAOYSA-N";405.28;3.63;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-4.81;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.000015488166189124828
"MM471461";"MM471461";"C[C@H]1[C@H](C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC(Br)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@H]12";"QPQPGYRSRSALDI-ZFHJGTQRSA-N";533.59;7.67;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4315699/target=_blank>CHEMBL4315699</a>";;-4.93;"BorkovĂˇ L, Frydrych I, JakubcovĂˇ N, AdĂˇmek R, LiĹˇkovĂˇ B, GurskĂˇ S, MedvedĂ­kovĂˇ M, HajdĂşch M, Urban M.: Synthesis and biological evaluation of triterpenoid thiazoles derived from betulonic acid, dihydrobetulonic acid, and ursonic acid. Eur J Med Chem, Volume 185, 2020";"PAMPA";0.000011748975549395302
"MM472270";"MM472270";"CONC(=O)Cc1ccc(C2(NC(=O)c3cc4c(Cl)c(Cl)ccc4n3C)COC2)cc1";"PLXFEKXUZHVCCT-UHFFFAOYSA-N";462.33;3.36;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-4.56;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.00002754228703338169
"MM472251";"MM472251";"CCN(c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1ccc(OC)c(C(=O)NC2(c3ncccn3)CC2)c1)S(C)(=O)=O";"OHUDQFHGSHRNJY-UHFFFAOYSA-N";657.72;5.27;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.31;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00004897788193684466
"MM471783";"MM471783";"Cc1c(N2CCN(C)CC2)ccc2c3c(c(=O)oc12)CN(C(=O)c1ccc(NS(C)(=O)=O)cc1)CC3";"GMSDHGSEWWVTBL-UHFFFAOYSA-N";510.62;2.42;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4338138/target=_blank>CHEMBL4338138</a>";;-5.27;"Kawai J, Toki T, Ota M, Inoue H, Takata Y, Asahi T, Suzuki M, Shimada T, Ono K, Suzuki K, Takaishi S, Ohki H, Matsui S, Tsutsumi S, Hirota Y, Nakayama K.: Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.000005370317963702533
"MM472271";"MM472271";"Cn1c(C(=O)NC2(c3ccc(CC(=O)O)c(F)c3)COC2)cc2c(Cl)c(Cl)ccc21";"QGOMLLSXYOTEPC-UHFFFAOYSA-N";451.28;3.91;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-5.35;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.000004466835921509635
"MM471803";"MM471803";"CCCC1(C(=O)O)CCc2c1[nH]c1c(Cl)ccc(Cl)c21";"ZEBPOFKSMDBBIP-UHFFFAOYSA-N";312.2;4.54;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL869586/target=_blank>CHEMBL869586</a>";;-5.19;"Gopalsamy A, Shi M, Ciszewski G, Park K, Ellingboe JW, Orlowski M, Feld B, Howe AY.: Design and synthesis of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase. Bioorg Med Chem Lett, Volume 16 (9), 2006";"PAMPA";0.000006456542290346549
"MM471762";"MM471762";"Cc1cccc(Nc2nc(N[C@@H]3CCCC[C@@H]3N)c(C#N)cc2C(N)=O)c1";"XAMCCSYNPOEISO-DLBZAZTESA-N";364.45;2.79;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4305540/target=_blank>CHEMBL4305540</a>";;-4.8;"Taniguchi T, Inagaki H, Baba D, Yasumatsu I, Toyota A, Kaneta Y, Kiga M, Iimura S, Odagiri T, Shibata Y, Ueda K, Seo M, Shimizu H, Imaoka T, Nakayama K.: Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity. ACS Med Chem Lett, Volume 10 (5), 2019";"PAMPA";0.00001584893192461114
"MM472266";"MM472266";"CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1";"PJTGSIKANITYOO-RCOXNQKVSA-N";542.63;2.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4339727/target=_blank>CHEMBL4339727</a>";;-4.4;"Yang MG, Xiao Z, Cherney RJ, Tebben AJ, Batt DG, Brown GD, Chen J, Cvijic ME, Dabros M, Duncia JV, Galella M, Gardner DS, Khandelwal P, Ko SS, Malley MF, Mo R, Pang J, Rose AV, Santella JB, Shi H, Srivastava A, Traeger SC, Wang B, Xu S, Zhao R, Barrish JC, Mandlekar S, Zhao Q, Carter PH.: Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Med Chem Lett, Volume 10 (3), 2019";"PAMPA";0.000039810717055349695
"MM472262";"MM472262";"CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](NC(=O)c3cccc(C(F)(F)F)c3)C2=O)[C@H](NS(C)(=O)=O)C1";"KCGHNEUWTNNXMF-WCIQWLHISA-N";518.6;2.22;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4339727/target=_blank>CHEMBL4339727</a>";;-4.23;"Yang MG, Xiao Z, Cherney RJ, Tebben AJ, Batt DG, Brown GD, Chen J, Cvijic ME, Dabros M, Duncia JV, Galella M, Gardner DS, Khandelwal P, Ko SS, Malley MF, Mo R, Pang J, Rose AV, Santella JB, Shi H, Srivastava A, Traeger SC, Wang B, Xu S, Zhao R, Barrish JC, Mandlekar S, Zhao Q, Carter PH.: Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Med Chem Lett, Volume 10 (3), 2019";"PAMPA";0.00005888436553555884
"MM472263";"MM472263";"CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](NC(=O)c3cccc(C(F)(F)F)c3)C2=O)[C@H](N(C)S(C)(=O)=O)C1";"QOMDNJVIZCGTRR-IVAOSVALSA-N";532.63;2.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4339727/target=_blank>CHEMBL4339727</a>";;-5.19;"Yang MG, Xiao Z, Cherney RJ, Tebben AJ, Batt DG, Brown GD, Chen J, Cvijic ME, Dabros M, Duncia JV, Galella M, Gardner DS, Khandelwal P, Ko SS, Malley MF, Mo R, Pang J, Rose AV, Santella JB, Shi H, Srivastava A, Traeger SC, Wang B, Xu S, Zhao R, Barrish JC, Mandlekar S, Zhao Q, Carter PH.: Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Med Chem Lett, Volume 10 (3), 2019";"PAMPA";0.000006456542290346549
"MM472259";"MM472259";"CCN(c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1cc(C)c(OC)c(C(=O)NC2(c3ncccn3)CC2)c1)S(C)(=O)=O";"ZAPGMDYFSUZKCG-UHFFFAOYSA-N";671.75;5.58;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.39;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.0000407380277804113
"MM472265";"MM472265";"CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](CS(C)(=O)=O)C1";"CJGHKRWUTQLMOP-REIYTJMXSA-N";541.64;3.58;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4339727/target=_blank>CHEMBL4339727</a>";;-5.85;"Yang MG, Xiao Z, Cherney RJ, Tebben AJ, Batt DG, Brown GD, Chen J, Cvijic ME, Dabros M, Duncia JV, Galella M, Gardner DS, Khandelwal P, Ko SS, Malley MF, Mo R, Pang J, Rose AV, Santella JB, Shi H, Srivastava A, Traeger SC, Wang B, Xu S, Zhao R, Barrish JC, Mandlekar S, Zhao Q, Carter PH.: Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Med Chem Lett, Volume 10 (3), 2019";"PAMPA";0.0000014125375446227554
"MM471763";"MM471763";"Cc1cc(/C=C/C(C)(C)C(=O)NC(C)(C)CO)ccc1Cc1cc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(C)cc1C";"IQQXSBWTAXVZMJ-NQANJDNISA-N";555.71;2.64;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4311711/target=_blank>CHEMBL4311711</a>";;-5.12;"Kuroda S, Kobashi Y, Oi T, Kawabe K, Shiozawa F, Okumura-Kitajima L, Sugisaki-Kitano M, Io F, Yamamoto K, Kakinuma H.: Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment. Bioorg Med Chem, Volume 27 (2), 2019";"PAMPA";0.000007585775750291836
"MM472268";"MM472268";"Cn1c(C(=O)NC2(c3ccc(C(=O)O)cc3)COC2)cc2c(Cl)c(Cl)ccc21";"VTCQBZIYGBVVGY-UHFFFAOYSA-N";419.26;3.84;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-5.28;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.000005248074602497723
"MM472260";"MM472260";"CCN(c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1cc(F)c(F)c(C(=O)NC2(c3ncccn3)CC2)c1)S(C)(=O)=O";"HWHRKUXLDXFZKY-UHFFFAOYSA-N";663.68;5.54;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.14;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00007244359600749906
"MM472275";"MM472275";"Cn1c(C(=O)NC2(c3ccc(C(CC(=O)O)c4cccnc4)cc3)COC2)cc2c(Cl)c(Cl)ccc21";"GAVIPRBFFNZNSO-UHFFFAOYSA-N";524.4;5.14;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-5.8;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.000001584893192461114
"MM471788";"MM471788";"Cc1c(N2CCN(C)CC2)ccc2c3c(c(=O)oc12)CN(C(=O)c1ccc(NS(C)(=O)=O)c(OC(F)(F)F)c1)CC3";"KLPAPRYWQRQOED-UHFFFAOYSA-N";594.61;3.32;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4338138/target=_blank>CHEMBL4338138</a>";;-4.36;"Kawai J, Toki T, Ota M, Inoue H, Takata Y, Asahi T, Suzuki M, Shimada T, Ono K, Suzuki K, Takaishi S, Ohki H, Matsui S, Tsutsumi S, Hirota Y, Nakayama K.: Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.000043651583224016566
"MM472248";"MM472248";"Nc1c(C(=O)N[C@@H]2CCc3cc(OCc4ccccc4)ccc32)[nH]c(=O)[nH]c1=O";"LZSVSZJDLSTBAJ-MRXNPFEDSA-N";392.42;1.64;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4327022/target=_blank>CHEMBL4327022</a>";;-4.11;"Hu CH, Wang TC, Qiao JX, Haque L, Chen AYA, Taylor DS, Ying X, Onorato JM, Galella M, Shen H, Huang CS, Toussaint N, Li YX, Abell L, Adam LP, Gordon D, Wexler RR, Finlay HJ.: Discovery and synthesis of tetrahydropyrimidinedione-4-carboxamides as endothelial lipase inhibitors. Bioorg Med Chem Lett, Volume 28 (23-24), 2018";"PAMPA";0.00007762471166286911
"MM472278";"MM472278";"CN(C(=O)CCSc1nc2cc(Cl)ccc2o1)C1CCS(=O)(=O)CC1";"MGTOZWPIBUSAKO-UHFFFAOYSA-N";402.93;3;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4359384/target=_blank>CHEMBL4359384</a>";;-4.36;"Moure AL, Narula G, Sorrentino F, Bojang A, Tsui CKM, Sao Emani C, Porras-De Francisco E, DĂ­az B, Rebollo-LĂłpez MJ, Torres-GĂłmez PA, LĂłpez-RomĂˇn EM, Camino I, Casado Castro P, Guijarro LĂłpez L, Ortega F, Ballell L, Barros-Aguirre D, RemuiĂ±Ăˇn Blanco M, Av-Gay Y.: MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis. J Med Chem, Volume 63 (9), 2020";"PAMPA";0.000043651583224016566
"MM472256";"MM472256";"CCNc1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1ccc(OC)c(C(=O)NC2(c3ncccn3)CC2)c1";"RDPCCBKYRUVARX-UHFFFAOYSA-N";579.63;5.92;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.14;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00007244359600749906
"MM471781";"MM471781";"Cc1cc2cc(n1)-c1cnn(C)c1OCCC[C@@H](C)CN1/C(=N/C2=O)Nc2ccc(CN3CCN(C)CC3)cc21";"AIQBYZOTCIQTGW-HXUWFJFHSA-N";542.69;3.77;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4324133/target=_blank>CHEMBL4324133</a>";;-5.28;"Engelhardt H, BĂ¶se D, Petronczki M, Scharn D, Bader G, Baum A, Bergner A, Chong E, DĂ¶bel S, Egger G, Engelhardt C, Ettmayer P, Fuchs JE, Gerstberger T, Gonnella N, Grimm A, Grondal E, Haddad N, Hopfgartner B, Kousek R, Krawiec M, Kriz M, Lamarre L, Leung J, Mayer M, Patel ND, Simov BP, Reeves JT, Schnitzer R, Schrenk A, Sharps B, Solca F, StadtmĂĽller H, Tan Z, Wunberg T, Zoephel A, McConnell DB.: Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.000005248074602497723
"MM471786";"MM471786";"Cc1c(N2CCN(C)CC2)ccc2c3c(c(=O)oc12)CN(C(=O)c1ccc(NS(C)(=O)=O)c(F)c1)CC3";"YIENLOQGUANJTL-UHFFFAOYSA-N";528.61;2.56;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4338138/target=_blank>CHEMBL4338138</a>";;-4.77;"Kawai J, Toki T, Ota M, Inoue H, Takata Y, Asahi T, Suzuki M, Shimada T, Ono K, Suzuki K, Takaishi S, Ohki H, Matsui S, Tsutsumi S, Hirota Y, Nakayama K.: Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.00001698243652461746
"MM472254";"MM472254";"CCN(C(C)=O)c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1ccc(OC)c(C(=O)NC2(c3ncccn3)CC2)c1";"JLTMTIKOPCSSMO-UHFFFAOYSA-N";621.67;5.86;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.33;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00004677351412871981
"MM472269";"MM472269";"Cn1c(C(=O)NC2(c3ccc(C(=O)O)nc3)COC2)cc2c(Cl)c(Cl)ccc21";"FISMMKWCBDFTBO-UHFFFAOYSA-N";420.25;3.23;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-5.89;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.000001288249551693135
"MM472258";"MM472258";"CCN(c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1cc(Cl)c(OC)c(C(=O)NC2(c3ncccn3)CC2)c1)S(C)(=O)=O";"KATMITIMPSRCKL-UHFFFAOYSA-N";692.17;5.92;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.09;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00008128305161640995
"MM471789";"MM471789";"Cc1c(N2CCN(C)CC2)ccc2c3c(c(=O)oc12)CN(C(=O)c1cc(Cl)cc(NS(C)(=O)=O)c1)CC3";"GGHDEWXYOLNPNC-UHFFFAOYSA-N";545.06;3.08;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4338138/target=_blank>CHEMBL4338138</a>";;-5.18;"Kawai J, Toki T, Ota M, Inoue H, Takata Y, Asahi T, Suzuki M, Shimada T, Ono K, Suzuki K, Takaishi S, Ohki H, Matsui S, Tsutsumi S, Hirota Y, Nakayama K.: Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.000006606934480075964
"MM471764";"MM471764";"COc1cc(C(C)C)c(Cc2ccc(/C=C/C(C)(C)C(=O)NC(C)(C)CO)cc2)cc1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O";"AJBAXXZLRODFMW-YIIQLIBHSA-N";585.74;2.85;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4311711/target=_blank>CHEMBL4311711</a>";;-5.74;"Kuroda S, Kobashi Y, Oi T, Kawabe K, Shiozawa F, Okumura-Kitajima L, Sugisaki-Kitano M, Io F, Yamamoto K, Kakinuma H.: Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment. Bioorg Med Chem, Volume 27 (2), 2019";"PAMPA";0.0000018197008586099826
"MM472274";"MM472274";"Cn1c(C(=O)NC2(c3ccc([C@H](O)c4cccnc4)cc3)COC2)cc2c(Cl)c(Cl)ccc21";"YBVGWRRPMBSVHG-QHCPKHFHSA-N";482.37;4.62;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-4.6;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.000025118864315095822
"MM471782";"MM471782";"Cc1cc2cc(n1)-c1cnn(C)c1OCCC[C@@H](C)CN1/C(=N/C2=O)Nc2ccccc21";"KHVDGZRHSTVJLQ-OAHLLOKOSA-N";430.51;4.03;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4324133/target=_blank>CHEMBL4324133</a>";;-6.7;"Engelhardt H, BĂ¶se D, Petronczki M, Scharn D, Bader G, Baum A, Bergner A, Chong E, DĂ¶bel S, Egger G, Engelhardt C, Ettmayer P, Fuchs JE, Gerstberger T, Gonnella N, Grimm A, Grondal E, Haddad N, Hopfgartner B, Kousek R, Krawiec M, Kriz M, Lamarre L, Leung J, Mayer M, Patel ND, Simov BP, Reeves JT, Schnitzer R, Schrenk A, Sharps B, Solca F, StadtmĂĽller H, Tan Z, Wunberg T, Zoephel A, McConnell DB.: Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.00000019952623149688787
"MM472255";"MM472255";"CCN(C(=O)C(F)(F)F)c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1ccc(OC)c(C(=O)NC2(c3ncccn3)CC2)c1";"KTLDBFJVHFKOIM-UHFFFAOYSA-N";675.64;6.4;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.08;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00008317637711026709
"MM472277";"MM472277";"O=C(CCSc1nc2cc(Cl)ccc2o1)N1CCCC1";"ZEVBOEDJZZOGNS-UHFFFAOYSA-N";310.81;3.59;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4359384/target=_blank>CHEMBL4359384</a>";;-4.11;"Moure AL, Narula G, Sorrentino F, Bojang A, Tsui CKM, Sao Emani C, Porras-De Francisco E, DĂ­az B, Rebollo-LĂłpez MJ, Torres-GĂłmez PA, LĂłpez-RomĂˇn EM, Camino I, Casado Castro P, Guijarro LĂłpez L, Ortega F, Ballell L, Barros-Aguirre D, RemuiĂ±Ăˇn Blanco M, Av-Gay Y.: MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis. J Med Chem, Volume 63 (9), 2020";"PAMPA";0.00007762471166286911
"MM472253";"MM472253";"CCN(C(=O)N(C)C)c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1ccc(OC)c(C(=O)NC2(c3ncccn3)CC2)c1";"OYGULRZSBOLZIQ-UHFFFAOYSA-N";650.71;5.99;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.24;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.000057543993733715664
"MM472257";"MM472257";"CCN(c1cc2oc(-c3ccc(F)cc3)c(C(=O)NC)c2cc1-c1cc(F)c(OC)c(C(=O)NC2(c3ncccn3)CC2)c1)S(C)(=O)=O";"GNVCMYILVHMRRT-UHFFFAOYSA-N";675.71;5.41;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329907/target=_blank>CHEMBL4329907</a>";;-4.18;"Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF.: Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00006606934480075965
"MM472273";"MM472273";"Cn1c(C(=O)NC2(c3ccc([C@@H](O)c4cccnc4)cc3)COC2)cc2c(Cl)c(Cl)ccc21";"YBVGWRRPMBSVHG-HSZRJFAPSA-N";482.37;4.62;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-4.68;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.00002089296130854041
"MM472276";"MM472276";"CC(=O)OC(C)OC(=O)C(c1ccc(C2(NC(=O)c3cc4c(Cl)c(Cl)ccc4n3C)COC2)cc1)c1cccnc1";"DMTXRTLDBZBPQQ-UHFFFAOYSA-N";596.47;5.12;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4350236/target=_blank>CHEMBL4350236</a>";;-4.93;"Mullarky E, Xu J, Robin AD, Huggins DJ, Jennings A, Noguchi N, Olland A, Lakshminarasimhan D, Miller M, Tomita D, Michino M, Su T, Zhang G, Stamford AW, Meinke PT, Kargman S, Cantley LC.: Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells. Bioorg Med Chem Lett, Volume 29 (17), 2019";"PAMPA";0.000011748975549395302
"MM471459";"MM471459";"C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)Cc6sc(N)nc6C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12";"ODIHQYMUHPRVPR-NXEQSAOGSA-N";510.79;7.48;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4315699/target=_blank>CHEMBL4315699</a>";;-5.34;"BorkovĂˇ L, Frydrych I, JakubcovĂˇ N, AdĂˇmek R, LiĹˇkovĂˇ B, GurskĂˇ S, MedvedĂ­kovĂˇ M, HajdĂşch M, Urban M.: Synthesis and biological evaluation of triterpenoid thiazoles derived from betulonic acid, dihydrobetulonic acid, and ursonic acid. Eur J Med Chem, Volume 185, 2020";"PAMPA";0.000004570881896148752
"MM471784";"MM471784";"Cc1cc(C(=O)N2CCc3c(c(=O)oc4c(C)c(N5CCN(C)CC5)ccc34)C2)ccc1NS(C)(=O)=O";"KKBRRNNDFZASCJ-UHFFFAOYSA-N";524.64;2.73;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4338138/target=_blank>CHEMBL4338138</a>";;-4.64;"Kawai J, Toki T, Ota M, Inoue H, Takata Y, Asahi T, Suzuki M, Shimada T, Ono K, Suzuki K, Takaishi S, Ohki H, Matsui S, Tsutsumi S, Hirota Y, Nakayama K.: Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity. J Med Chem, Volume 62 (22), 2019";"PAMPA";0.00002290867652767775
"MM471493";"MM471493";"CCOCCOc1ccc(C(=O)CCN(C)C)cc1";"YVMIKURCTBEMCU-UHFFFAOYSA-N";265.35;2.24;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.8;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00015848931924611142
"Haloperidol";"MM00499";"O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1";"LNEPOXFFQSENCJ-UHFFFAOYSA-N";375.87;4.43;"3559";"CHEMBL54";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3532288/target=_blank>CHEMBL3532288</a>";;-4.47;"Nishimuta H, Nakagawa T, Nomura N, Yabuki M.: Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes. Drug Metab Dispos, Volume 41 (5), 2013";"PAMPA";0.000033884415613920276
"MM471479";"MM471479";"CCCCCCOc1ccc(C(=O)CCNc2cccc(Cl)c2)cc1";"KNPWKYPFGSHIOM-UHFFFAOYSA-N";359.9;5.98;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-5.7;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.0000019952623149688787
"MM471551";"MM471551";"COc1ccc(NC(=O)Nc2cc(C)nc3ccccc23)cc1Cl";"XHNLBHIDLMMRFX-UHFFFAOYSA-N";341.8;4.85;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696258/target=_blank>CHEMBL1696258</a>";;-3.47;"Zhang Y, Anderson M, Weisman JL, Lu M, Choy CJ, Boyd VA, Price J, Sigal M, Clark J, Connelly M, Zhu F, Guiguemde WA, Jeffries C, Yang L, Lemoff A, Liou AP, Webb TR, Derisi JL, Guy RK.: Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Med Chem Lett, Volume 1 (9), 2010";"PAMPA";0.0003388441561392024
"MM471494";"MM471494";"CCCCCCSc1cc(C)c(C(=O)CCN2CCN(S(=O)(=O)CC)CC2)c(C)c1";"JCPLAMNBZJOBSS-UHFFFAOYSA-N";454.7;4.52;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.8;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00015848931924611142
"MM471478";"MM471478";"CCCCCCOc1ccc(C(=O)CCNc2ccccc2)cc1";"FDHFMTGLJWTADB-UHFFFAOYSA-N";325.45;5.33;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-6.7;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00000019952623149688787
"MM471489";"MM471489";"CCN1CCC(Cc2ccc(C(=O)CCN(C)C)cc2)CC1";"MJKBOVKEXYJGBQ-UHFFFAOYSA-N";302.46;3.1;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.85;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.0001412537544622754
"MM471483";"MM471483";"CCCCCCSc1ccc(C(=O)CCN2CCN(S(=O)(=O)CC)CC2)c(Cl)c1Cl";"MMZLNKJLYDEBGH-UHFFFAOYSA-N";495.54;5.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-4.52;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.000030199517204020192
"MM471798";"MM471798";"COc1ccc(CNc2nc(SC)nc3c2cnn3CC(Cl)c2ccccc2)cc1";"MDRRJZBAXQKICB-UHFFFAOYSA-N";439.97;5.15;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-5.82;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.0000015135612484362072
"MM471487";"MM471487";"CCCCCCOc1ccc(C(=O)CCN(C)C)c(Br)c1";"LZOVXMFTOXYNNG-UHFFFAOYSA-N";356.3;4.54;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-4.1;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00007943282347242822
"MM471491";"MM471491";"CCCCCCSc1cc(Cl)c(C(=O)CCN2CC2C)cc1Cl";"BOTHSWILLQNCAB-UHFFFAOYSA-N";374.38;5.94;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.85;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.0001412537544622754
"MM471496";"MM471496";"CCCCCCOc1ccc(C(=O)CCN(C)C)c(N(C)C)c1";"YJUFQRISAJWTSK-UHFFFAOYSA-N";320.48;3.85;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.77;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00016982436524617443
"MM471484";"MM471484";"CCCCCS(=O)(=O)Nc1ccc(C(=O)CCN(C)C)cc1";"JMSFRMCZMZKUOB-UHFFFAOYSA-N";326.46;2.75;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-4.3;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00005011872336272725
"MM471481";"MM471481";"CCCCCCSc1cc(Cl)c(C(=O)CCN2CCOCC2)c(Cl)c1";"QEIBGAYGXNALFP-UHFFFAOYSA-N";404.4;5.57;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-5;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00001
"MM471485";"MM471485";"CCCCCCSc1cc(Cl)c(C(=O)CCN2CCN(S(=O)(=O)CC)CC2)c(Cl)c1";"HCWMJBYRQCDHLK-UHFFFAOYSA-N";495.54;5.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-4.3;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00005011872336272725
"MM471486";"MM471486";"CCCCCCSc1ccc(C(=O)CCN2CC2C)c(Cl)c1Cl";"APGLOJXHKLCBCF-UHFFFAOYSA-N";374.38;5.94;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-4.15;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00007079457843841373
"MM471497";"MM471497";"CCCCCCSc1ccc(C(=O)CCN2CCOCC2)c(Cl)c1Cl";"ITQVSIWATSZQNW-UHFFFAOYSA-N";404.4;5.57;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.77;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00016982436524617443
"MM471490";"MM471490";"CCCCCCSc1ccc(C(=O)CCN(C)C)c(Cl)c1Cl";"DGPOADAMPHAWGG-UHFFFAOYSA-N";362.37;5.8;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.85;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.0001412537544622754
"MM471480";"MM471480";"CCCCNC(=O)Nc1ccc(C(=O)CCN(C)C)cc1";"QNUZULQSJOIIBQ-UHFFFAOYSA-N";291.4;2.74;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-5;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00001
"MM471482";"MM471482";"CCCCCCSc1cc(Cl)c(C(=O)CCN2CCN(S(=O)(=O)CC)CC2)cc1Cl";"OJASFOKEQJZOBK-UHFFFAOYSA-N";495.54;5.21;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-4.7;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.000019952623149688786
"MM471488";"MM471488";"CCCCCCS(=O)(=O)c1cc(Cl)c(C(=O)CCN(C)C)cc1Cl";"HHHRTHAUTLVXEZ-UHFFFAOYSA-N";394.36;4.48;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-4.05;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00008912509381337459
"MM471495";"MM471495";"CCCCCCS(=O)(=O)c1ccc(C(=O)CCN2CC2C)c(Cl)c1";"HXLHSQSKXGQBDL-UHFFFAOYSA-N";371.93;3.97;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.8;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00015848931924611142
"MM471492";"MM471492";"CCCCCCOc1ccc(-c2ccc(C(=O)CCN(C)C)cc2)cc1";"MNCVIWUMQIDQDU-UHFFFAOYSA-N";353.51;5.45;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1034536/target=_blank>CHEMBL1034536</a>";;-3.82;"Hwang JY, Arnold LA, Zhu F, Kosinski A, Mangano TJ, Setola V, Roth BL, Guy RK.: Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem, Volume 52 (13), 2009";"PAMPA";0.00015135612484362088
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3873507/target=_blank>CHEMBL3873507</a>";;-5.52;"Shchegol'kov EV, Shchur IV, Burgart YV, Saloutin VI, Trefilova AN, Ljushina GA, Solodnikov SY, Markova LN, Maslova VV, Krasnykh OP, Borisevich SS, Khursan SL.: Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation. Bioorg Med Chem, Volume 25 (1), 2017";"PAMPA";0.0000030199517204020193
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428918/target=_blank>CHEMBL3428918</a>";;-5.74;"Wu Y, Hu M, Yang L, Li X, Bian J, Jiang F, Sun H, You Q, Zhang X.: Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency. Bioorg Med Chem Lett, Volume 25 (12), 2015";"PAMPA";0.0000018197008586099826
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1056608/target=_blank>CHEMBL1056608</a>";;-6.39;"Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.: Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem, Volume 44 (9), 2009";"PAMPA";0.00000040738027780411303
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4131170/target=_blank>CHEMBL4131170</a>";;-5.71;"Zhang X, Bian J, Li X, Wu X, Dong Y, You Q.: 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000019498445997580454
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3587134/target=_blank>CHEMBL3587134</a>";;-5.71;"Xu LL, Zhu JF, Xu XL, Zhu J, Li L, Xi MY, Jiang ZY, Zhang MY, Liu F, Lu MC, Bao QC, Li Q, Zhang C, Wei JL, Zhang XJ, Zhang LS, You QD, Sun HP.: Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. J Med Chem, Volume 58 (14), 2015";"PAMPA";0.0000019498445997580454
"MM471458";"MM471458";"CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)Cc6sc(N)nc6C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1";"KRVCHLIPXSYGHJ-KNVGJEHWSA-N";510.79;7.63;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4315699/target=_blank>CHEMBL4315699</a>";;-7.16;"BorkovĂˇ L, Frydrych I, JakubcovĂˇ N, AdĂˇmek R, LiĹˇkovĂˇ B, GurskĂˇ S, MedvedĂ­kovĂˇ M, HajdĂşch M, Urban M.: Synthesis and biological evaluation of triterpenoid thiazoles derived from betulonic acid, dihydrobetulonic acid, and ursonic acid. Eur J Med Chem, Volume 185, 2020";"PAMPA";0.00000006918309709189362
"MM471857";"MM471857";"CCOC(=O)c1c(-c2ccc3c(c2)OCO3)[nH]c2cc(OC)ccc2c1=O";"WPUKTSSXIZKTLM-UHFFFAOYSA-N";367.36;3.11;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2175311/target=_blank>CHEMBL2175311</a>";;-4;"Zhang Y, Clark JA, Connelly MC, Zhu F, Min J, Guiguemde WA, Pradhan A, Iyer L, Furimsky A, Gow J, Parman T, El Mazouni F, Phillips MA, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem, Volume 55 (9), 2012";"PAMPA";0.0001
"MM471536";"MM471536";"Cc1[nH]c2ccccc2c(=O)c1Br";"RPUCDXLAFUWPHF-UHFFFAOYSA-N";238.08;2.6;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1261030/target=_blank>CHEMBL1261030</a>";;-4.87;"Cross RM, Monastyrskyi A, Mutka TS, Burrows JN, Kyle DE, Manetsch R.: Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity. J Med Chem, Volume 53 (19), 2010";"PAMPA";0.000013489628825916533
"MM471593";"MM471593";"O=c1c2c([nH]c3cc(Cl)ccc13)CCCC2";"HIIMAULBOMFTFN-UHFFFAOYSA-N";233.7;3.06;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-4.12;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00007585775750291836
"MM471509";"MM471509";"CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1";"DWZAEMINVBZMHQ-UHFFFAOYSA-N";615.74;3.02;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-7;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.0000001
"MM471508";"MM471508";"CN(C)CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1";"QDYDLDKGDBEEOL-UHFFFAOYSA-N";575.67;2.15;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-7;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.0000001
"MM471506";"MM471506";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"FVOXAVYMKTXHTN-UHFFFAOYSA-N";462.51;2.25;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-5.85;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.0000014125375446227554
"MM471500";"MM471500";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"AGNQWSRFQIXLBD-UHFFFAOYSA-N";413.48;1.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-6.15;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.0000007079457843841374
"MM471503";"MM471503";"O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"MIPSHXJPVYIDDC-UHFFFAOYSA-N";491.55;2.35;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-6.7;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.00000019952623149688787
"MM471502";"MM471502";"Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1";"RAOFVTJVOVNPMR-UHFFFAOYSA-N";475.55;3.16;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-5.25;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.000005623413251903491
"MM471501";"MM471501";"O=C(Nc1ccc(F)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"WTWXJMUDRHOZFG-UHFFFAOYSA-N";479.52;2.99;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-6;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.000001
"MM471507";"MM471507";"COC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1";"HRRNDHFMTPCCMO-UHFFFAOYSA-N";519.56;2.64;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-6.22;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.0000006025595860743581
"MM471504";"MM471504";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1cccs1";"IJAVTPLMQUWYCR-UHFFFAOYSA-N";467.56;2.92;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-5.62;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.0000023988329190194897
"MM471505";"MM471505";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1cccnc1";"LWSJQJQMKYBWTR-UHFFFAOYSA-N";462.51;2.25;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-6.3;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.0000005011872336272725
"MM471584";"MM471584";"O=c1c2c([nH]c3ccccc13)CCCC2";"CVEXTAUZJWYDJX-UHFFFAOYSA-N";199.25;2.41;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1804799/target=_blank>CHEMBL1804799</a>";;-5;"Cross RM, Maignan JR, Mutka TS, Luong L, Sargent J, Kyle DE, Manetsch R.: Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00001
"MM471498";"MM471498";"N[C@@H]1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)C1";"OPTAOWZLDMSBKX-OAHLLOKOSA-N";392.48;3.09;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073467/target=_blank>CHEMBL1073467</a>";;-6.72;"Haydar SN, Yun H, Andrae PM, Mattes J, Zhang J, Kramer A, Smith DL, Huselton C, Graf R, Aschmies S, Schechter LE, Comery TA, Robichaud AJ.: 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.00000019054607179632483
"MM471499";"MM471499";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"HRNGMKXGIBFNBE-UHFFFAOYSA-N";461.53;2.86;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1065054/target=_blank>CHEMBL1065054</a>";;-6.7;"Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham RT, Chaudhary I, Mansour TS.: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem, Volume 53 (6), 2010";"PAMPA";0.00000019952623149688787
"1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one";"MM00551";"CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1";"JWHAUXFOSRPERK-UHFFFAOYSA-N";341.45;3.24;"4932";"CHEMBL631";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2160416/target=_blank>CHEMBL2160416</a>";;-2.82;"Lowes D, Pradhan A, Iyer LV, Parman T, Gow J, Zhu F, Furimsky A, Lemoff A, Guiguemde WA, Sigal M, Clark JA, Wilson E, Tang L, Connelly MC, Derisi JL, Kyle DE, Mirsalis J, Guy RK.: Lead optimization of antimalarial propafenone analogues. J Med Chem, Volume 55 (13), 2012";"PAMPA";0.0015135612484362087
"MM471965";"MM471965";"COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1";"OPXLLQIJSORQAM-UHFFFAOYSA-N";295.3;2.97;;;"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3532288/target=_blank>CHEMBL3532288</a>";;-4.31;"Nishimuta H, Nakagawa T, Nomura N, Yabuki M.: Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes. Drug Metab Dispos, Volume 41 (5), 2013";"PAMPA";0.00004897788193684466
"5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one";"MM00589";"O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1";"MVWVFYHBGMAFLY-UHFFFAOYSA-N";412.95;3.81;"60854";"CHEMBL708";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3532288/target=_blank>CHEMBL3532288</a>";;-4.17;"Nishimuta H, Nakagawa T, Nomura N, Yabuki M.: Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes. Drug Metab Dispos, Volume 41 (5), 2013";"PAMPA";0.00006760829753919819
"N4-(7-chloro-quinolin-4-yl)-n1,n1-diethyl-pentane-1,4-diamine";"MM00459";"CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12";"WHTVZRBIWZFKQO-UHFFFAOYSA-N";319.88;4.81;"2719";"CHEMBL76";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1103809/target=_blank>CHEMBL1103809</a>";;-3.11;"Ray S, Madrid PB, Catz P, LeValley SE, Furniss MJ, Rausch LL, Guy RK, DeRisi JL, Iyer LV, Green CE, Mirsalis JC.: Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. J Med Chem, Volume 53 (9), 2010";"PAMPA";0.0007762471166286919
"3-Phenylpropionic Acid";"MM00605";"O=C(O)CCc1ccccc1";"XMIIGOLPHOKFCH-UHFFFAOYSA-N";150.18;1.7;"107";"CHEMBL851";"GENER";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3801192/target=_blank>CHEMBL3801192</a>";;-5.78;"Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, Ballatore C.: Structure Property Relationships of Carboxylic Acid Isosteres. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.0000016595869074375596
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"PL-A";"EPAM";"25";"0";"ph=7.4";;-8.15;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.0000000070794578438413736
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"PL-A";"EPAM";"25";"0";"ph=7.4";;-6.09;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.0000008128305161640995
"Digoxin";"MM00357";"CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O";"LTMHDMANZUZIPE-UHFFFAOYSA-N";780.95;2.22;"2724385";"CHEMBL1751";"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.52;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.000030199517204020192
"MM471873";"MM471873";"CC(C)=CCC12OC[C@@H]3[C@@H](CN(C)C)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"DGSALVZLMXELPV-LPIQBNQASA-N";409.48;2.76;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-3.72;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00019054607179632462
"MM471883";"MM471883";"CCCCN(CCCC)C[C@@H]1[C@H]2COC3(CC=C(C)C)C(=O)[C@@H]1C=C1C(=O)c4c(O)cccc4O[C@]123";"AKMLVNWGCVAXDQ-HQCJEUBQSA-N";493.64;5.1;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.3;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00005011872336272725
"MM471872";"MM471872";"CC(C)=CCC12OC[C@@H]3[C@@H](CN(CCO)CCO)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"SQCQXQYVRPHUJV-RRADVTQGSA-N";469.53;1.49;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-3.71;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00019498445997580456
"MM471877";"MM471877";"CC(C)=CCC12OC[C@@H]3[C@@H](COC(C)C)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"YGVBIDJABJLVOL-DGTITLQCSA-N";424.49;3.63;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-3.91;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.0001230268770812381
"MM471879";"MM471879";"CC(C)=CCC12OC[C@@H]3[C@@H](COCc4ccccc4)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"XTBWCIYKONYIDG-AQOIPSNVSA-N";472.54;4.42;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.08;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00008317637711026709
"MM471876";"MM471876";"CC(=O)OC[C@@H]1[C@H]2COC3(CC=C(C)C)C(=O)[C@@H]1C=C1C(=O)c4c(O)cccc4O[C@]123";"PJRSCTLUXRMVLG-LPIQBNQASA-N";424.45;2.77;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-3.84;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.0001445439770745928
"MM471882";"MM471882";"CC(C)=CCC12OC[C@@H]3[C@@H](COC(=O)Cc4ccccc4)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"VZIUOBFNNRUPAK-QBELJZEMSA-N";500.55;3.99;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.17;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00006760829753919819
"MM471881";"MM471881";"CC(C)=CCC12OC[C@@H]3[C@@H](CN4CCN(c5ccccc5)CC4)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"FDQCMNZJDZSNSO-AKVKRZPISA-N";526.63;4.02;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.11;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00007762471166286911
"MM471884";"MM471884";"CC(C)=CCc1c(O)cc(O)c2c1O[C@@]13C(=C[C@H]4C(=O)C1(CC=C(C)C)OC[C@@H]3[C@H]4CN(C)C)C2=O";"BFWOATMLPBMAGZ-RGAUDQMMSA-N";493.6;3.98;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.38;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00004168693834703355
"MM471887";"MM471887";"CC(=O)OC[C@@H]1[C@H]2COC3(CC=C(C)C)C(=O)[C@@H]1C=C1C(=O)c4c(O)cc(O)c(CC=C(C)C)c4O[C@]123";"XAUUFNQHVHEWRB-RGAUDQMMSA-N";508.57;3.98;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.47;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.000033884415613920276
"MM471878";"MM471878";"CC(C)=CCC12OC[C@@H]3[C@@H](CN4CCCC4)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"WHJWIMGVRAXDAG-RRADVTQGSA-N";435.52;3.3;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-3.97;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00010715193052376059
"MM471875";"MM471875";"CC(C)=CCC12OC[C@@H]3[C@@H](CN4CCOCC4)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"OKZLQEMFGUVIIO-RRADVTQGSA-N";451.52;2.53;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-3.81;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.0001548816618912481
"MM471885";"MM471885";"CC(C)=CCC12OC[C@@H]3[C@@H](CN4CCNCC4)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"ZWUIYHCRZFZHSZ-RRADVTQGSA-N";450.54;2.11;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.43;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00003715352290971728
"MM471874";"MM471874";"CC(C)=CCC12OC[C@@H]3[C@@H](CN4CCN(C)CC4)[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"ZHNYTCAVYDPJHL-FAJRVWBFSA-N";464.56;2.45;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-3.81;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.0001548816618912481
"MM471886";"MM471886";"CC(C)=CCC12OC[C@@H]3[C@@H](CN4CCOCC4)[C@@H](C=C4C(=O)c5c(O)cc6c(c5O[C@]431)C=CC(C)(C)O6)C2=O";"CNZPDAQEGUHBIG-GPLVRGGGSA-N";533.62;3.72;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.44;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.0000363078054770101
"MM471889";"MM471889";"CC(C)=CCc1c(O)cc2c(c1O)C(=O)C1=C[C@H]3C(=O)C4(CC=C(C)C)OC[C@H]([C@H]3CN3CCOCC3)[C@]14O2";"XWMXKRFKQNHZRZ-BSIBGSSKSA-N";535.64;3.75;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.55;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00002818382931264455
"MM471880";"MM471880";"CC(C)=CCC12OC(C)(C)[C@@H]3C[C@@H](C=C4C(=O)c5c(O)cccc5O[C@]431)C2=O";"XZPYBDPGHSLINX-OHTINKFRSA-N";380.44;3.76;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.11;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00007762471166286911
"MM471888";"MM471888";"CC(C)=CCC12OC(C)(C)[C@@H]3C[C@@H](C=C4C(=O)c5ccccc5O[C@]431)C2=O";"ZWXWLIRGVCGFJK-PUVDAUEISA-N";364.44;4.05;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-4.53;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.00002951209226666384
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4130770/target=_blank>CHEMBL4130770</a>";;-3.95;"Xu XL, Yang YR, Mo XF, Wei JL, Zhang XJ, You QD.: Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1Î± pathway. Eur J Med Chem, Volume 137, 2017";"PAMPA";0.0001122018454301963
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342435/target=_blank>CHEMBL2342435</a>";;-3.27;"Zhang X, Li X, Sun H, Wang X, Zhao L, Gao Y, Liu X, Zhang S, Wang Y, Yang Y, Zeng S, Guo Q, You Q.: Garcinia  xanthones as orally active antitumor agents. J Med Chem, Volume 56 (1), 2013";"PAMPA";0.0005370317963702527
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-5.8;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.000001584893192461114
"MM471047";"MM471047";"Cn1ncc2cc(C(=O)Nc3ccc(Cl)c(Cl)c3)ccc21";"OIDIFCINLNNUKU-UHFFFAOYSA-N";320.18;4.13;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3996837/target=_blank>CHEMBL3996837</a>";;-4.73;"Tzvetkov NT, Stammler HG, Neumann B, Hristova S, Antonov L, Gastreich M.: Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem, Volume 127, 2017";"PAMPA";0.000018620871366628657
"MM471048";"MM471048";"Cn1cc2cc(C(=O)Nc3ccc(Cl)c(Cl)c3)ccc2n1";"IJGQJSMRACUEMU-UHFFFAOYSA-N";320.18;4.13;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3996837/target=_blank>CHEMBL3996837</a>";;-4.75;"Tzvetkov NT, Stammler HG, Neumann B, Hristova S, Antonov L, Gastreich M.: Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem, Volume 127, 2017";"PAMPA";0.00001778279410038923
"MM474762";"MM474762";"COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2ccc[nH]2)cc1";"LBAGNMNWIAWTLK-WQRHYEAKSA-N";402.41;3.48;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3380445/target=_blank>CHEMBL3380445</a>";;-6.17;"Jagtap AD, Chang PT, Liu JR, Wang HC, Kondekar NB, Shen LJ, Tseng HW, Chen GS, Chern JW.: Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. Eur J Med Chem, Volume 85, 2014";"PAMPA";0.0000006760829753919819
"MM474763";"MM474763";"COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)O)c2C)cc1";"MUEJCYLSAWKRDN-WQRHYEAKSA-N";474.47;3.79;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3380445/target=_blank>CHEMBL3380445</a>";;-6.64;"Jagtap AD, Chang PT, Liu JR, Wang HC, Kondekar NB, Shen LJ, Tseng HW, Chen GS, Chern JW.: Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. Eur J Med Chem, Volume 85, 2014";"PAMPA";0.00000022908676527677748
"MM474764";"MM474764";"COc1ccc(C(=O)NC(=O)Nc2cc3c(cc2F)/C(=C/c2[nH]c(C)c(C(=O)O)c2C)C(=O)N3)cc1";"BGVHRAAMOSNTDT-SXGWCWSVSA-N";492.46;3.93;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3380445/target=_blank>CHEMBL3380445</a>";;-5.61;"Jagtap AD, Chang PT, Liu JR, Wang HC, Kondekar NB, Shen LJ, Tseng HW, Chen GS, Chern JW.: Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. Eur J Med Chem, Volume 85, 2014";"PAMPA";0.0000024547089156850284
"MM474765";"MM474765";"COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)O)c2C)c(F)c1";"RVVGEXZEXCMBCG-YVLHZVERSA-N";492.46;3.93;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3380445/target=_blank>CHEMBL3380445</a>";;-5.6;"Jagtap AD, Chang PT, Liu JR, Wang HC, Kondekar NB, Shen LJ, Tseng HW, Chen GS, Chern JW.: Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. Eur J Med Chem, Volume 85, 2014";"PAMPA";0.0000025118864315095823
"MM474766";"MM474766";"COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1";"NKKNQMFHKZEGQU-KQWNVCNZSA-N";588.64;4.06;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3380445/target=_blank>CHEMBL3380445</a>";;-5.75;"Jagtap AD, Chang PT, Liu JR, Wang HC, Kondekar NB, Shen LJ, Tseng HW, Chen GS, Chern JW.: Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. Eur J Med Chem, Volume 85, 2014";"PAMPA";0.000001778279410038923
"MM470981";"MM470981";"COc1cc(C2/C(=C\c3ccc(O)c(O)c3)C(=O)c3cccn32)ccc1O";"BNQCNHAVQQYUDU-NTEUORMPSA-N";363.37;3.48;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-4.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.000012589254117941661
"MM470980";"MM470980";"COc1ccc(C2/C(=C\c3ccc(O)c(OC)c3)C(=O)c3cccn32)cc1O";"NQNCYUCZJVGCAV-XNTDXEJSSA-N";377.4;3.79;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-3.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.00012589254117941674
"MM470985";"MM470985";"COc1cc(C2/C(=C\c3cc(OC)c(OC)c(OC)c3)C(=O)c3cccn32)ccc1O";"NOOLFHUGTFEHAD-MHWRWJLKSA-N";421.45;4.1;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-3.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.00012589254117941674
"MM470977";"MM470977";"COc1cc(/C=C2/C(=O)c3cccn3C2c2ccccc2)ccc1O";"DWJJQMLNNOGQQT-FOWTUZBSSA-N";331.37;4.07;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-3.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.00012589254117941674
"MM470974";"MM470974";"O=C1/C(=C/c2ccccc2)C(c2ccccc2)n2cccc21";"DSBKTCLJBPZYKV-SAPNQHFASA-N";285.35;4.36;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-4;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.0001
"MM470979";"MM470979";"COc1ccc(/C=C2/C(=O)c3cccn3C2c2ccc(OC)c(O)c2)cc1O";"COQUAHWYJYLREY-XNTDXEJSSA-N";377.4;3.79;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-3.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.00012589254117941674
"MM470986";"MM470986";"COc1cc(C2/C(=C\c3cc(OC)c(O)c(OC)c3)C(=O)c3cccn32)ccc1O";"VXLIXBPEBAEVIJ-OQLLNIDSSA-N";407.42;3.79;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-3.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.00012589254117941674
"MM470987";"MM470987";"O=C1/C(=C/c2ccc(O)c(O)c2)C(c2ccc(O)c(O)c2)n2cccc21";"QRRWGDQOWXRNRP-MDWZMJQESA-N";349.34;3.18;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-5.7;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.0000019952623149688787
"MM470975";"MM470975";"COc1cc(C2/C(=C\c3ccc(OCc4ccccc4)c(OCc4ccccc4)c3)C(=O)c3cccn32)ccc1OCc1ccccc1";"UGHISKUKVIUYBA-JWHWKPFMSA-N";633.74;9.1;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-10;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.0000000001
"MM470982";"MM470982";"COc1ccc(/C=C2/C(=O)c3cccn3C2c2ccc(O)c(OC)c2)cc1O";"DMVCNOVKHNEBEL-XNTDXEJSSA-N";377.4;3.79;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-4.4;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.000039810717055349695
"MM470978";"MM470978";"COc1ccc(C2/C(=C\c3ccc(O)c(O)c3)C(=O)c3cccn32)cc1O";"YSSULCVGNRKDCX-NTEUORMPSA-N";363.37;3.48;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-4.4;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.000039810717055349695
"MM470983";"MM470983";"COc1cc(/C=C2/C(=O)c3cccn3C2c2ccc(O)c(OC)c2)ccc1O";"WTMOQRUSGZWIBR-XNTDXEJSSA-N";377.4;3.79;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-3.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.00012589254117941674
"MM470984";"MM470984";"COc1ccc(/C=C2/C(=O)c3cccn3C2c2ccc(O)c(OC)c2)c(OC)c1";"XICZBHZGTCROHM-GZTJUZNOSA-N";391.42;4.09;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-3.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.00012589254117941674
"MM470976";"MM470976";"O=C1/C(=C/c2ccc(O)c(O)c2)C(c2ccccc2)n2cccc21";"FNDVAELMPYVSGS-RVDMUPIBSA-N";317.34;3.77;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-3.9;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.00012589254117941674
"MM471049";"MM471049";"Cn1ncc2cc(C(=O)Nc3ccc(F)c(Cl)c3)ccc21";"ISZVIYGCASWHFG-UHFFFAOYSA-N";303.72;3.62;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3996837/target=_blank>CHEMBL3996837</a>";;-4.5;"Tzvetkov NT, Stammler HG, Neumann B, Hristova S, Antonov L, Gastreich M.: Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem, Volume 127, 2017";"PAMPA";0.000031622776601683795
"MM471050";"MM471050";"Cn1cc2cc(C(=O)Nc3ccc(F)c(Cl)c3)ccc2n1";"BAPSXXUHQQELCY-UHFFFAOYSA-N";303.72;3.62;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3996837/target=_blank>CHEMBL3996837</a>";;-5.03;"Tzvetkov NT, Stammler HG, Neumann B, Hristova S, Antonov L, Gastreich M.: Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem, Volume 127, 2017";"PAMPA";0.000009332543007969906
"MM472009";"MM472009";"Cc1c(C(=O)NC2CCN(C)CC2)oc2ccc(N(Cc3ccc(Br)cc3)S(=O)(=O)c3ccc(Br)cc3)cc12";"SHUUTVAUPGSLJQ-UHFFFAOYSA-N";675.44;6.49;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4130770/target=_blank>CHEMBL4130770</a>";;-5.18;"Xu XL, Yang YR, Mo XF, Wei JL, Zhang XJ, You QD.: Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1Î± pathway. Eur J Med Chem, Volume 137, 2017";"PAMPA";0.000006606934480075964
"MM472008";"MM472008";"CCN(CC)CCNC(=O)c1oc2ccc(N(Cc3ccc(Br)cc3)S(=O)(=O)c3ccc(Br)cc3)cc2c1C";"MKSIQLOFEKFGAN-UHFFFAOYSA-N";677.46;6.73;;;"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4130770/target=_blank>CHEMBL4130770</a>";;-5.6;"Xu XL, Yang YR, Mo XF, Wei JL, Zhang XJ, You QD.: Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1Î± pathway. Eur J Med Chem, Volume 137, 2017";"PAMPA";0.0000025118864315095823
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3795358/target=_blank>CHEMBL3795358</a>";;-5.8;"Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-FrĂ©on A, Rochais C, Dallemagne P.: Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem, Volume 114, 2016";"PAMPA";0.000001584893192461114
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4130770/target=_blank>CHEMBL4130770</a>";;-5.35;"Xu XL, Yang YR, Mo XF, Wei JL, Zhang XJ, You QD.: Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1Î± pathway. Eur J Med Chem, Volume 137, 2017";"PAMPA";0.000004466835921509635
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"GIT-0";"EPAM";"25";"0";"ph=7.4,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3996837/target=_blank>CHEMBL3996837</a>";;-4.61;"Tzvetkov NT, Stammler HG, Neumann B, Hristova S, Antonov L, Gastreich M.: Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem, Volume 127, 2017";"PAMPA";0.000024547089156850286
"2-Deoxyadenosine";"MM00320";"Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1";"OLXZPDWKRNYJJZ-RRKCRQDMSA-N";251.25;-0.95;"13730";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.78;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000016595869074375631
"Acetamide";"MM00321";"CC(N)=O";"DLFVBJFMPXGRIB-UHFFFAOYSA-N";59.07;-0.51;"178";"CHEMBL16081";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.1;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0007943282347242813
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.32;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.004786300923226385
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.92;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000001202264434617413
"Adenine";"MM00324";"Nc1ncnc2nc[nH]c12";"GFFGJBXGBJISGV-UHFFFAOYSA-N";135.13;-0.06;"190";"CHEMBL226345";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000020417379446695274
"Alfuzosin";"MM00328";"COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC";"WNMJYKCGWZFFKR-UHFFFAOYSA-N";389.46;1.35;"2092";"CHEMBL709";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000005128613839913648
"Amprenavir";"MM00332";"CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1";"YMARZQAQMVYCKC-OEMFJLHTSA-N";505.64;2.4;"65016";"CHEMBL116";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.27;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000005370317963702533
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.76;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.7543993733715695
"Bromocriptine";"MM00338";"CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12";"OZVBMTJYIDMWIL-AYFBDAFISA-N";654.61;3.19;"31101";"CHEMBL493";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005128613839913648
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";3.630780547701014
"Chloramphenicol";"MM00342";"O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl";"WIIZWVCIJKGZOK-UHFFFAOYSA-N";323.13;0.91;"5959";"CHEMBL130";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000008709635899560814
"Chlorothiazide";"MM00641";"NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O";"JBMKAUGHUNFTOL-UHFFFAOYSA-N";295.73;0.13;"2720";"CHEMBL842";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.16;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000006918309709189363
"Clonidine";"MM00344";"Clc1cccc(Cl)c1N=C1NCCN1";"GJSURZIOUXUGAL-UHFFFAOYSA-N";230.1;2.17;"2803";"CHEMBL134";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.09;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008128305161640995
"2-amino-3-methyl-4H-imidazol-5-one";"MM00348";"CN1CC(=O)N=C1N";"DDRJAANPRJIHGJ-UHFFFAOYSA-N";113.12;-1.23;"588";"CHEMBL65567";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000021379620895022324
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.68;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000020892961308540407
"D-Glucose";"MM00352";"OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O";"WQZGKKKJIJFFOK-GASJEMHNSA-N";180.16;-3.22;"5793";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-12.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000000007244359600749892
"Diazepam";"MM00094";"CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21";"AAOVKJBEBIDNHE-UHFFFAOYSA-N";284.75;3.15;"3016";"CHEMBL12";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.45;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.35481338923357547
"Digoxin";"MM00357";"CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O";"LTMHDMANZUZIPE-UHFFFAOYSA-N";780.95;2.22;"2724385";"CHEMBL1751";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000028840315031266057
"Meso-erythritol";"MM00068";"OC[C@H](O)[C@H](O)CO";"UNXHWFMMPAWVPI-ZXZARUISSA-N";122.12;-2.31;"222285";"CHEMBL349605";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000008317637711026709
"Estradiol";"MM00197";"CC12CCC3c4ccc(O)cc4CCC3C1CCC2O";"VOXZDWNPVJITMN-UHFFFAOYSA-N";272.39;3.61;"5757";"CHEMBL135";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.76;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.7543993733715695
"3-ethyl-3-methylpyrrolidine-2,5-dione";"MM00359";"CCC1(C)CC(=O)NC1=O";"HAPOVYFOVVWLRS-UHFFFAOYSA-N";141.17;0.45;"3291";"CHEMBL696";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0007413102413009177
"Etoposide";"MM00361";"COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O";"VJJPUSNTGOMMGY-UHFFFAOYSA-N";588.56;1.34;"36462";"CHEMBL44657";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000001621810097358933
"Famciclovir";"MM00362";"CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O";"GGXKWVWZWMLJEH-UHFFFAOYSA-N";321.34;0.54;"3324";"CHEMBL880";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.98;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000010471285480508985
"2-phenylchromen-4-one";"MM00364";"O=c1cc(-c2ccccc2)oc2ccccc12";"VHBFFQKBGNRLFZ-UHFFFAOYSA-N";222.24;3.46;"10680";"CHEMBL275638";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.41;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";257.03957827688646
"2-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-benzoic acid";"MM00054";"O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21";"GNBHRKFJIUUOQI-UHFFFAOYSA-N";332.31;3.67;"16850";"CHEMBL1057";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.84;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.001445439770745928
"Formamide";"MM00365";"NC=O";"ZHNUHDYFZUAESO-UHFFFAOYSA-N";45.04;-0.9;"713";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.16;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00006918309709189363
"9-(1,3-dihydroxy-propoxymethane)guanine";"MM00367";"Nc1nc(O)c2ncn(COC(CO)CO)c2n1";"IRSCQMHQWWYFCW-UHFFFAOYSA-N";255.23;-1.56;"3454";"CHEMBL182";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-13.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000000008709635899560796
"Genistein";"MM00368";"O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12";"TZBJGXHYKVUXJN-UHFFFAOYSA-N";270.24;2.58;"5280961";"CHEMBL44";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00003235936569296281
"Glycerol";"MM00067";"OCC(O)CO";"PEDCQBHIVMGVHV-UHFFFAOYSA-N";92.09;-1.67;"753";"CHEMBL692";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.02;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000009549925860214369
"Guanfacine";"MM00370";"N=C(N)NC(=O)Cc1c(Cl)cccc1Cl";"INJOMKTZOLKMBF-UHFFFAOYSA-N";246.1;1.55;"3519";"CHEMBL862";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.09;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000008128305161640995
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000043651583224016655
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.09;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000008128305161640995
"Hydroxyurea";"MM00374";"NC(=O)NO";"VSNHCAURESNICA-UHFFFAOYSA-N";76.06;-0.96;"3657";"CHEMBL467";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000039810717055349695
"Hypoxanthine";"MM00375";"O=c1nc[nH]c2nc[nH]c12";"FDGQSTZJBFJUBT-UHFFFAOYSA-N";136.11;-0.35;"790";"CHEMBL1427";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.18;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000006606934480075964
"N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide";"MM00379";"Cc1cc(C(=O)NNCc2ccccc2)no1";"XKFPYPQQHFEXRZ-UHFFFAOYSA-N";231.26;1.42;"3759";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.42;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.6302679918953817
"Lamotrigine";"MM00383";"Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1";"PYZRQGJRPPTADH-UHFFFAOYSA-N";256.1;2.01;"3878";"CHEMBL741";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.9;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000012589254117941661
"Lansoprazole";"MM00384";"Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1";"MJIHNNLFOKEZEW-UHFFFAOYSA-N";369.37;3.52;"3883";"CHEMBL480";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.75;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000001778279410038923
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-12.88;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000000013182567385564046
"Meprobamate";"MM00387";"CCCC(C)(COC(N)=O)COC(N)=O";"NPPQSCRMBWNHMW-UHFFFAOYSA-N";218.25;0.98;"4064";"CHEMBL979";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.07;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000008511380382023759
"Methanol";"MM00063";"CO";"OKKJLVBELUTLKV-UHFFFAOYSA-N";32.04;-0.39;"887";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.57;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0026915348039269166
"Methylprednisolone";"MM00388";"CC1CC2C(C(O)CC3(C)C2CCC3(O)C(=O)CO)C2(C)C=CC(=O)C=C12";"VHRSUDSXCMQTMA-UHFFFAOYSA-N";374.48;1.8;"6741";"CHEMBL650";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.95;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00001122018454301963
"Minoxidil";"MM00393";"Nc1cc(N2CCCCC2)nc(N)[n+]1[O-]";"ZFMITUMMTDLWHR-UHFFFAOYSA-N";209.25;-0.13;"4201";"CHEMBL802";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.04;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00009120108393559096
"Nicotinamide";"MM00396";"NC(=O)c1cccnc1";"DFPAKSUCGFBDDF-UHFFFAOYSA-N";122.13;0.18;"936";"CHEMBL1140";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00007244359600749906
"6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole";"MM00399";"COc1ccc2[nH]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1";"SUBDBMMJDZJVOS-UHFFFAOYSA-N";345.42;2.9;"4594";"CHEMBL1503";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000002511886431509582
"6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole";"MM00401";"COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC";"IQPSEEYGBUAQFF-UHFFFAOYSA-N";383.38;2.88;"4679";"CHEMBL1502";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.44;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000036307805477010174
"Phenytoin";"MM00406";"O=C1N=C(O)NC1(c1ccccc1)c1ccccc1";"CXOFVDLJLONNDW-UHFFFAOYSA-N";252.27;1.97;"1775";"CHEMBL16";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.38;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.004168693834703355
"2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one";"MM00407";"O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1";"FSVJFNAIGNNGKK-UHFFFAOYSA-N";312.41;2.53;"4891";"CHEMBL976";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.2754228703338166
"Prednisolone";"MM00297";"CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"OIGNJSKKLXVSLS-UHFFFAOYSA-N";360.45;1.56;"5755";"CHEMBL131";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.23;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000005888436553555884
"5-ethyl-5-phenyl-1,3-diazinane-4,6-dione";"MM00409";"CCC1(c2ccccc2)C(=O)NCNC1=O";"DQMZLTXERSFNPB-UHFFFAOYSA-N";218.26;0.54;"4909";"CHEMBL856";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0004365158322401661
"Propylene Glycol";"MM00414";"CC(O)CO";"DNIAPMSPPWPWGF-UHFFFAOYSA-N";76.1;-0.64;"1030";"CHEMBL286398";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.52;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0003019951720402016
"6-propyl-2-sulfanylidene-1H-pyrimidin-4-one";"MM00415";"CCCc1cc(=O)[nH]c(=S)[nH]1";"KNAHARQHSZJURB-UHFFFAOYSA-N";170.24;1.38;"657298";"CHEMBL1518";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.02187761623949553
"Ritonavir";"MM00419";"CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1";"NCDNCNXCDXHOMX-UHFFFAOYSA-N";720.96;5.91;"392622";"CHEMBL163";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.87;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0013489628825916532
"Sucrose";"MM00421";"OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O";"CZMRCDWAGMRECN-UGDNZRGBSA-N";342.3;-5.4;"5988";"CHEMBL253582";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-15.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000000000012302687708123811
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.78;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";6.025595860743578
"Theobromine";"MM00424";"Cn1cnc2c1c(=O)[nH]c(=O)n2C";"YAPQBXQYLJRXSA-UHFFFAOYSA-N";180.17;-1.04;"5429";"CHEMBL1114";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.99;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000010232929922807537
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.89;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000001288249551693135
"2-(1,3-thiazol-4-yl)-1h-benzimidazole";"MM00425";"c1ccc2[nH]c(-c3cscn3)nc2c1";"WJCNZQLZVWNLKY-UHFFFAOYSA-N";201.25;2.69;"5430";"CHEMBL625";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.5128613839913648
"Thiourea";"MM00426";"NC(N)=S";"UMGDCJDMYOKAJW-UHFFFAOYSA-N";76.12;-0.81;"2723790";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00008317637711026709
"Thymine";"MM00428";"Cc1c[nH]c(=O)[nH]c1=O";"RWQNBRDOKXIBIV-UHFFFAOYSA-N";126.12;-0.63;"1135";"CHEMBL993";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000831763771102671
"Urea";"MM00065";"NC(N)=O";"XSQUKJJJFZCRTK-UHFFFAOYSA-N";60.06;-0.98;"1176";"CHEMBL985";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000002754228703338169
"Xanthine";"MM00432";"O=c1[nH]c(=O)c2[nH]cnc2[nH]1";"LRFVTYWOQMYALW-UHFFFAOYSA-N";152.11;-1.06;"1188";"CHEMBL1424";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.85;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000014125375446227555
"Zidovudine";"MM00077";"Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O";"HBOMLICNUCNMMY-UHFFFAOYSA-N";267.25;-0.2;"35370";"CHEMBL129";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000001380384264602884
"Adenosine";"MM00325";"Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"OIRDTQYFTABQOQ-KQYNXXCUSA-N";267.25;-1.98;"60961";"CHEMBL477";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-13.1;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000000007943282347242822
"Methyl 5-(propylsulfinyl)-1h-benzimidazol-2-ylcarbamate";"MM00326";"CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1";"HXHWSAZORRCQMX-UHFFFAOYSA-N";265.34;3.24;"2082";"CHEMBL1483";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.74;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00018197008586099826
"Alprazolam";"MM00329";"C[C@@H]1NN[C@H]2CN[C@@H](c3ccccc3)c3cc(Cl)ccc3N12";"IYQBGWNRKQNSIE-LQAWEQHXSA-N";314.82;2.62;"2118";"CHEMBL661";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.2;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";158.48931924611142
"3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione";"MM00330";"CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O";"ROBVIMPUHSLWNV-ZDUSSCGKSA-N";232.28;1.35;"2145";"CHEMBL488";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.93;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0001174897554939529
"4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one";"MM00331";"Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C";"RMMXTBMQSGEXHJ-UHFFFAOYSA-N";231.3;1.55;"6009";"CHEMBL288470";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.71;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.19498445997580455
"Bendroflumethiazide";"MM00336";"NS(=O)(=O)c1cc2c(cc1C(F)(F)F)N[C@@H](Cc1ccccc1)NS2(=O)=O";"HDWIHXWEUNVBIY-CQSZACIVSA-N";421.42;1.63;"2315";"CHEMBL1684";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.24;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000005754399373371567
"Budesonide";"MM00339";"CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1";"VOVIALXJUBGFJZ-VXKMTNQYSA-N";430.54;2.72;"5281004";"CHEMBL1370";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0004365158322401661
"1-butanol";"MM00340";"CCCCO";"LRHPLDYGYMQRHN-UHFFFAOYSA-N";74.12;0.78;"263";"CHEMBL14245";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.32359365692962827
"Chlorthalidone";"MM00343";"NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl";"JIVPVXMEBJLZRO-UHFFFAOYSA-N";338.77;0.92;"2732";"CHEMBL1055";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000012302687708123812
"1-[(2-chlorophenyl)-diphenylmethyl]imidazole";"MM00468";"Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1";"VNFPBHJOKIVQEB-UHFFFAOYSA-N";344.85;5.38;"2812";"CHEMBL104";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;4.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";13489.628825916532
"Corticosterone";"MM00346";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12";"OMFXVFTZEKFJBZ-UHFFFAOYSA-N";346.47;2.67;"5753";"CHEMBL110739";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0007244359600749898
"Cortisone";"MM00347";"CC12CCC(O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO";"LPYXTAPPNYMYOP-UHFFFAOYSA-N";362.47;1.78;"222786";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000002818382931264455
"Cyclothiazide";"MM00350";"NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O";"BOCUKUHCLICSIY-UHFFFAOYSA-N";389.89;1.23;"2910";"CHEMBL61593";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000001
"Danazol";"MM00353";"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C";"POZRVZJJTULAOH-LHZXLZLDSA-N";337.46;4.22;"28417";"CHEMBL1479";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.48;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";301.9951720402016
"Cortexone";"MM00037";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(C(=O)CO)CCC12";"ZESRJSPZRDMNHY-UHFFFAOYSA-N";330.47;3.7;"6166";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.21;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.06165950018614822
"4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one";"MM00433";"Nc1ccn(C2CCC(CO)O2)c(=O)n1";"WREGKURFCTUGRC-UHFFFAOYSA-N";211.22;-0.5;"24066";"CHEMBL853";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000021379620895022325
"Felodipine";"MM00363";"CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl";"RZTAMFZIAATZDJ-UHFFFAOYSA-N";384.26;3.96;"3333";"CHEMBL1480";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.07244359600749903
"(2R,3S,4R,5S)-hexane-1,2,3,4,5,6-hexol";"MM00366";"OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-GUCUJZIJSA-N";182.17;-3.59;"11850";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-12.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000000001621810097358933
"Griseofulvin";"MM00369";"COC1=CC(=O)CC(C)C12Oc1c(Cl)c(OC)cc(OC)c1C2=O";"DDUHZTYCFQRHIY-UHFFFAOYSA-N";352.77;2.81;"441140";"CHEMBL562";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000013803842646028838
"Hesperetin";"MM00371";"COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O";"AIONOLUJZLIMTK-AWEZNQCLSA-N";302.28;2.52;"72281";"CHEMBL399121";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.35;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000004466835921509635
"Propan-2-ol";"MM00380";"CC(C)O";"KFZMGEQAYNKOFK-UHFFFAOYSA-N";60.1;0.39;"3776";"CHEMBL582";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.21;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.6165950018614822
"Itraconazole";"MM00381";"CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O";"VHVPQPYKVGDNFY-UHFFFAOYSA-N";705.65;5.58;"55283";"CHEMBL22587";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.6025595860743578
"4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one";"MM00382";"Nc1ccn(C2CSC(CO)O2)c(=O)n1";"JTEGQNOMFQHVDC-UHFFFAOYSA-N";229.26;-0.59;"60825";"CHEMBL141";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.27;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000005370317963702533
"Metolazone";"MM00390";"Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C";"AQCHWTWZEMGIFD-UHFFFAOYSA-N";365.84;2.71;"4170";"CHEMBL878";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00025118864315095795
"Metronidazole";"MM00391";"Cc1ncc([N+](=O)[O-])n1CCO";"VAOCPAMSLUNLGC-UHFFFAOYSA-N";171.16;0.09;"4173";"CHEMBL137";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.74;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00018197008586099826
"Mifepristone";"MM00392";"CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(c3ccc(N(C)C)cc3)CC21C";"VKHAHZOOUSRJNA-UHFFFAOYSA-N";429.6;5.41;"55245";"CHEMBL1276308";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.5;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";31.622776601683793
"Butyramide";"MM00059";"CCCC(N)=O";"DNSISZSEWVHGLH-UHFFFAOYSA-N";87.12;0.27;"10927";"CHEMBL1231396";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.17;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.006760829753919818
"Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate";"MM00397";"COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]";"HYIMSNHJOBLJNT-UHFFFAOYSA-N";346.34;2.18;"4485";"CHEMBL193";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.2;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00630957344480193
"Nitrendipine";"MM00398";"CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1";"PVHUJELLJLJGLN-UHFFFAOYSA-N";360.37;2.57;"4507";"CHEMBL475534";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.18;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.06606934480075961
"2-phenylethylhydrazine";"MM00404";"NNCCc1ccccc1";"RMUCZJUITONUFY-UHFFFAOYSA-N";136.2;0.69;"3675";"CHEMBL1089";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";724.4359600749899
"Prednisone";"MM00408";"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO";"XOFYZVNMUHMLCC-ZPOLXVRWSA-N";358.43;1.77;"5865";"CHEMBL635";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000020417379446695273
"2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol";"MM00410";"CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1";"FYPMFJGVHOHGLL-UHFFFAOYSA-N";516.86;9.91;"4912";"CHEMBL608";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;5.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";363078.05477010104
"4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide";"MM00411";"CNNCc1ccc(C(=O)NC(C)C)cc1";"CPTBDICYNRMXFX-UHFFFAOYSA-N";221.3;1.05;"4915";"CHEMBL1321";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.77;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.16982436524617442
"Progesterone";"MM00198";"CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C";"RJKFOVLPORLFTN-UHFFFAOYSA-N";314.47;4.72;"5994";"CHEMBL103";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.83;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";67.60829753919819
"1-Propanol";"MM00061";"CCCO";"BDERNNFJNOPAEC-UHFFFAOYSA-N";60.1;0.39;"1031";"CHEMBL14687";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.84;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.14454397707459277
"Resveratrol";"MM00418";"Oc1ccc(C=Cc2cc(O)cc(O)c2)cc1";"LUKBXSAWLPMMSZ-UHFFFAOYSA-N";228.25;2.97;"445154";"CHEMBL1237022";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0013803842646028853
"7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one";"MM00422";"CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21";"SEQDDYPDSLOBDC-UHFFFAOYSA-N";300.75;2.47;"5391";"CHEMBL967";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.004073802778041126
"L-deoxythymidine";"MM00427";"Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O";"IQFYYKKMVGJFEH-XLPZGREQSA-N";242.23;-1.51;"5789";"CHEMBL374731";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.73;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000018620871366628656
"2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one";"MM00576";"O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12";"PHLBKPHSAVXXEF-UHFFFAOYSA-N";371.87;2.36;"5533";"CHEMBL621";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.97;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.10715193052376065
"Triamcinolone";"MM00307";"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO";"GFNANZIMVAIWHM-OBYCQNJPSA-N";394.44;0.62;"31307";"CHEMBL1451";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.94;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000011481536214968817
"2,5,9-trimethylfuro[3,2-g]chromen-7-one";"MM00429";"Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1";"FMHHVULEAZTJMA-UHFFFAOYSA-N";228.25;3.46;"5585";"CHEMBL1475";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";114.81536214968828
"4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide";"MM00430";"Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1";"LNPDTQAFDNKSHK-UHFFFAOYSA-N";314.37;2.96;"119607";"CHEMBL865";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.73;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.18620871366628675
"Zaleplon";"MM00434";"CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1";"HUNXMJYCHXQEGX-UHFFFAOYSA-N";305.34;2.64;"5719";"CHEMBL1521";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.007413102413009177
"1,4-Butanediol";"MM00314";"OCCCCO";"WERYXYBDKMZEQL-UHFFFAOYSA-N";90.12;-0.25;"8064";"CHEMBL171623";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.03;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00009332543007969905
"2,3-Dideoxyadenosine";"MM00318";"Nc1ncnc2c1ncn2[C@H]1CC[C@@H](CO)O1";"WVXRAFOPTSTNLL-NKWVEPMBSA-N";235.25;0.08;"20039";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.26;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000005495408738576248
"2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide";"MM00337";"NC(CO)C(=O)NNCc1ccc(O)c(O)c1O";"BNQDCRGUHNALGH-UHFFFAOYSA-N";257.25;-1.76;"2327";"CHEMBL1096979";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000004073802778041122
"Ethylene glycol";"MM00360";"OCCO";"LYCAIKOWRPUZTN-UHFFFAOYSA-N";62.07;-1.03;"174";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.77;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00001698243652461746
"Netivudine";"MM00395";"CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O";"QLOCVMVCRJOTTM-SDNRWEOFSA-N";282.25;-2.48;"55281";"CHEMBL1097615";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-11.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000000020417379446695316
"Nitric Acid";"MM00675";"O=[N+]([O-])O";"GRYLNZFGIOXLOG-UHFFFAOYSA-N";63.01;-0.35;"944";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.47;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";29.512092266663856
"2-amino-5-phenyl-1,3-oxazol-4-one";"MM00402";"NC1=NC(=O)C(c2ccccc2)O1";"NRNCYVBFPDDJNE-UHFFFAOYSA-N";176.18;0.6;"4723";"CHEMBL1177";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.45;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000035481338923357534
"Phenol Red";"MM00405";"O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21";"BELBBZDIHDAJOR-UHFFFAOYSA-N";354.38;3.11;"4766";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.38;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00004168693834703355
"Beclomethasone";"MM00335";"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"NBMKJKDGKREAPL-DVTGEIKXSA-N";408.92;2.17;"20469";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.42;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000003801893963205613
"CP-141938";"MM00471";"COc1ccc(N(C)S(C)(=O)=O)cc1CNC1CCCNC1c1ccccc1";"GZLOIBNBDUHEFY-UHFFFAOYSA-N";403.55;2.67;"10363809";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.012302687708123818
"1,2-bis(oxiran-2-yl)ethane-1,2-diol";"MM00356";"OC(C1CO1)C(O)C1CO1";"AAFJXZWCNVJTMK-UHFFFAOYSA-N";146.14;-1.49;"31789";"CHEMBL3137322";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000001
"5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxychromen-4-one";"MM00372";"COc1c(O)cc2oc(-c3ccc(O)cc3)cc(=O)c2c1O";"IHFBPDAQLQOCBX-UHFFFAOYSA-N";300.27;2.59;"5281628";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.48;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000033113112148259076
"2-iodoacetamide";"MM00376";"NC(=O)CI";"PGLTVOMIXTUURA-UHFFFAOYSA-N";184.96;-0.09;"3727";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.26;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005495408738576248
"Isobutyramide";"MM00378";"CC(C)C(N)=O";"WFKAJVHLWXSISD-UHFFFAOYSA-N";87.12;0.13;"68424";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.07;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008511380382023767
"Methylurea";"MM00389";"CNC(N)=O";"XGEGHDBEHXKFPX-UHFFFAOYSA-N";74.08;-0.72;"11719";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000002884031503126606
"Propanamide";"MM00413";"CCC(N)=O";"QLNJFJADRCOGBJ-UHFFFAOYSA-N";73.1;-0.12;"6578";"CHEMBL1235716";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.51;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.003090295432513592
"1,2,3,4,5-pentachloro-6-nitrobenzene";"MM00416";"O=[N+]([O-])c1c(Cl)c(Cl)c(Cl)c(Cl)c1Cl";"LKPLKUMXSAEKID-UHFFFAOYSA-N";295.34;4.86;"6720";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.043651583224016584
"1,3-Propanediol";"MM00313";"OCCCO";"YPFDHNVEDLHUCE-UHFFFAOYSA-N";76.1;-0.64;"10442";"CHEMBL379652";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.43;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00003715352290971728
"Water";"MM00431";"O";"XLYOFNOQVPJJNP-UHFFFAOYSA-N";18.02;-0.82;"962";"CHEMBL1098659";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.32;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000047863009232263804
"Ammonia";"MM00445";"N";"QGZKDVFQNNGYKY-UHFFFAOYSA-N";17.03;0.16;"222";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.51;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0003090295432513592
"Pentanamide";"MM00403";"CCCCC(N)=O";"IPWFJLQDVFKJDU-UHFFFAOYSA-N";101.15;0.66;"12298";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.97;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.010715193052376065
"Hydrofluoric Acid";"MM00655";"F";"KRHYYFGTRYWZRS-UHFFFAOYSA-N";20.01;0.15;"14917";"CHEMBL1232767";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.6595869074375607
"11-Dehydrocorticosterone";"MM00315";"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO";"FUFLCEKSBBHCMO-KJQYFISQSA-N";344.45;2.87;"5311364";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.53;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0002951209226666387
"Aldosterone";"MM00327";"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12";"PQSUYGKTWSAVDQ-ZVIOFETBSA-N";360.45;1.85;"5839";"CHEMBL273453";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.7;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000019952623149688787
"D-Fructose";"MM00351";"OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O";"LKDRXBCSQODPBY-VRPWFDPXSA-N";180.16;-3.22;"2723872";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.46;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000034673685045253096
"Silibinin";"MM00420";"COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O";"SEBFKMXJBCUCAI-HKTJVKLFSA-N";482.44;2.36;"31553";"CHEMBL431701";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-11.12;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000007585775750291852
"DMP-450";"MM00358";"Nc1cccc(CN2C(=O)N(Cc3cccc(N)c3)[C@H](Cc3ccccc3)[C@H](O)[C@@H](O)[C@H]2Cc2ccccc2)c1";"KYRSNWPSSXSNEP-ZRTHHSRSSA-N";536.68;4.23;"154044";"CHEMBL223824";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.84;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.001445439770745928
"1,6-Hexanediol";"MM00009";"C[C@@H](O)CC[C@@H](C)O";"OHMBHFSEKCCCBW-PHDIDXHHSA-N";118.18;0.53;"43078";"CHEMBL458616";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.88;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.013182567385564075
"Loratadine";"MM00385";"CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1";"JCCNYMKQOSZNPW-UHFFFAOYSA-N";382.89;4.89;"3957";"CHEMBL998";"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.51188643150958
"4-iodo-1,5-dimethyl-2-phenylpyrazol-3-one";"MM00377";"Cc1c(I)c(=O)n(-c2ccccc2)n1C";"ZZOBLCHCPLOXCE-UHFFFAOYSA-N";314.13;2.09;"8522";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.72;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.248074602497725
"Ralimetinib Dimesylate";"MM00417";"CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21.CS(=O)(=O)O.CS(=O)(=O)O";"NARMJPIBAXVUIE-UHFFFAOYSA-N";612.75;4.56;"11570805";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";3.0902954325135905
"11beta-Hydroxyprogesterone";"MM00317";"CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C";"BFZHCUBIASXHPK-ATWVFEABSA-N";330.47;3.69;"101788";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.8709635899560807
"2,4-Dibromoestradiol";"MM00319";"CC12CCC3c4cc(Br)c(O)c(Br)c4CCC3C1CCC2O";"UTXNYGUZJLLOSP-UHFFFAOYSA-N";430.18;5.13;"266051";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.63;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";4.265795188015927
"Hydrochloric Acid";"MM00654";"Cl";"VEXZGXHMUGYJMC-UHFFFAOYSA-N";36.46;0.42;"313";;"LEC";"CPMM";"25";"0";"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.94;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";8.709635899560805
"Chlorpromazine";"MM00461";"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21";"ZPEIMTDSQAKGNT-UHFFFAOYSA-N";318.87;4.89;"2726";"CHEMBL71";"LEC";"CPMM";"25";;"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.65;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.22387211385683395
"Loratadine";"MM00385";"CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1";"JCCNYMKQOSZNPW-UHFFFAOYSA-N";382.89;4.89;"3957";"CHEMBL998";"LEC";"CPMM";"25";;"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.51188643150958
"4-iodo-1,5-dimethyl-2-phenylpyrazol-3-one";"MM00377";"Cc1c(I)c(=O)n(-c2ccccc2)n1C";"ZZOBLCHCPLOXCE-UHFFFAOYSA-N";314.13;2.09;"8522";;"LEC";"CPMM";"25";;"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.72;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.248074602497725
"Ralimetinib Dimesylate";"MM00417";"CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21.CS(=O)(=O)O.CS(=O)(=O)O";"NARMJPIBAXVUIE-UHFFFAOYSA-N";612.75;4.56;"11570805";;"LEC";"CPMM";"25";;"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";3.0902954325135905
"11beta-Hydroxyprogesterone";"MM00317";"CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C";"BFZHCUBIASXHPK-ATWVFEABSA-N";330.47;3.69;"101788";;"LEC";"CPMM";"25";;"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.8709635899560807
"2,4-Dibromoestradiol";"MM00319";"CC12CCC3c4cc(Br)c(O)c(Br)c4CCC3C1CCC2O";"UTXNYGUZJLLOSP-UHFFFAOYSA-N";430.18;5.13;"266051";;"LEC";"CPMM";"25";;"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.63;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";4.265795188015927
"Hydrochloric Acid";"MM00654";"Cl";"VEXZGXHMUGYJMC-UHFFFAOYSA-N";36.46;0.42;"313";;"LEC";"CPMM";"25";;"ph=7.4,<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.94;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";8.709635899560805
"D-Fructose";"MM00351";"OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O";"LKDRXBCSQODPBY-VRPWFDPXSA-N";180.16;-3.22;"2723872";;"EggPC";"ELIP";"25";;"ph=7.5,LUV";;-9.4;"Brunner J, Graham DE, Hauser H, Semenza G.: Ion and sugar permeabilities of lecithin bilayers: comparison of curved and planar bilayers. J Membr Biol, Volume 57 (2), 1980";"BLM";0.00000000039810717055349694
"D-Glucose";"MM00352";"OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O";"WQZGKKKJIJFFOK-GASJEMHNSA-N";180.16;-3.22;"5793";;"EggPC";"ELIP";"25";;"ph=7.5,LUV";;-10.52;"Brunner J, Graham DE, Hauser H, Semenza G.: Ion and sugar permeabilities of lecithin bilayers: comparison of curved and planar bilayers. J Membr Biol, Volume 57 (2), 1980";"BLM";0.00000000003019951720402019
"Sucrose";"MM00421";"OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O";"CZMRCDWAGMRECN-UGDNZRGBSA-N";342.3;-5.4;"5988";"CHEMBL253582";"EggPC";"ELIP";"25";;"ph=7.5,LUV";;-13.1;"Brunner J, Graham DE, Hauser H, Semenza G.: Ion and sugar permeabilities of lecithin bilayers: comparison of curved and planar bilayers. J Membr Biol, Volume 57 (2), 1980";"BLM";0.00000000000007943282347242822
"Methylamine";"MM00515";"CN";"BAVYZALUXZFZLV-UHFFFAOYSA-N";31.06;-0.43;"6329";"CHEMBL43280";"EggPC";"ELIP";"25";;"ph=7.1,MLV";;-6;"Bar-On Z, Degani H.: Permeability of alkylamines across phosphatidylcholine vesicles as studied by 1H-NMR. Biochim Biophys Acta, Volume 813 (2), 1985";"BLM";0.000001
"Amylamine";"MM00537";"CCCCCN";"DPBLXKKOBLCELK-UHFFFAOYSA-N";87.17;1.14;"8060";;"EggPC";"ELIP";"25";;"ph=7.1,MLV";;-3.4;"Bar-On Z, Degani H.: Permeability of alkylamines across phosphatidylcholine vesicles as studied by 1H-NMR. Biochim Biophys Acta, Volume 813 (2), 1985";"BLM";0.00039810717055349735
"1-Propylamine";"MM00436";"CCCN";"WGYKZJWCGVVSQN-UHFFFAOYSA-N";59.11;0.36;"7852";;"EggPC";"ELIP";"25";;"ph=7.1,MLV";;-5.37;"Bar-On Z, Degani H.: Permeability of alkylamines across phosphatidylcholine vesicles as studied by 1H-NMR. Biochim Biophys Acta, Volume 813 (2), 1985";"BLM";0.000004265795188015926
"Tol-Gly-Gly";"MM00699";"Cc1ccc(C(=O)NCC(=O)NCC(=O)O)cc1";"GFMIXHRADKOCKD-UHFFFAOYSA-N";250.25;-0.07;"1612474";;"CACO";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000021379620895022323
"Benzoic Acid";"MM00630";"O=C(O)c1ccccc1";"WPYMKLBDIGXBTP-UHFFFAOYSA-N";122.12;1.38;"243";"CHEMBL541";"CACO";"CPMM";"25";;"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.59;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0002570395782768865
"Ethylene glycol";"MM00360";"OCCO";"LYCAIKOWRPUZTN-UHFFFAOYSA-N";62.07;-1.03;"174";;"CACO";"CPMM";"25";;"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.7;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000019952623149688786
"Cefadroxil";"MM00718";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccc(O)cc3)C2SC1";"BOEGTKLJZSQCCD-UHFFFAOYSA-N";363.4;0.15;"47965";"CHEMBL1644";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.89;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000012882495516931322
"2,4-Dihydroxybenzoic Acid";"MM00595";"O=C(O)c1ccc(O)cc1O";"UIAFKZKHHVMJGS-UHFFFAOYSA-N";154.12;0.8;"1491";"CHEMBL328910";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.58;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000026302679918953814
"2-Deoxyadenosine";"MM00320";"Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1";"OLXZPDWKRNYJJZ-RRKCRQDMSA-N";251.25;-0.95;"13730";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.78;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000016595869074375631
"Acebutolol";"MM00437";"CCCC(=O)Nc1ccc(OC[C@H](O)CNC(C)C)c(C(C)=O)c1";"GOEMGAFJFRBGGG-OAHLLOKOSA-N";336.43;2.37;"1978";"CHEMBL642";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.006025595860743574
"Acetamide";"MM00321";"CC(N)=O";"DLFVBJFMPXGRIB-UHFFFAOYSA-N";59.07;-0.51;"178";"CHEMBL16081";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.1;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0007943282347242813
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.32;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.004786300923226385
"Acetic Acid";"MM00613";"CC(=O)O";"QTBSBXVTEAMEQO-UHFFFAOYSA-N";60.05;0.09;"176";"CHEMBL539";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.04;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.009120108393559097
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.3803842646028848
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.92;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000001202264434617413
"Adenine";"MM00324";"Nc1ncnc2nc[nH]c12";"GFFGJBXGBJISGV-UHFFFAOYSA-N";135.13;-0.06;"190";"CHEMBL226345";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000020417379446695274
"L-Alanine";"MM00743";"C[C@H](N)C(=O)O";"QNAYBMKLOCPYGJ-REOHCLBHSA-N";89.09;-0.58;"5950";"CHEMBL279597";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.07;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000851138038202376
"Alfuzosin";"MM00328";"COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC";"WNMJYKCGWZFFKR-UHFFFAOYSA-N";389.46;1.35;"2092";"CHEMBL709";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000005128613839913648
"Alprenolol";"MM00440";"C=CCc1ccccc1OC[C@H](O)CNC(C)C";"PAZJSJFMUHDSTF-CQSZACIVSA-N";249.35;2.15;"2119";"CHEMBL266195";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.18;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";151.35612484362088
"Adamantan-1-amine";"MM00441";"N[C@]12C[C@H]3C[C@H](C[C@H](C3)C1)C2";"DKNWSYNQZKUICI-CHIWXEEVSA-N";151.25;1.91;"2130";"CHEMBL660";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";35.48133892335755
"Amiloride";"MM00267";"N=C(N)NC(=O)c1nc(Cl)c(N)nc1N";"XSDQTOBWRPYKKA-UHFFFAOYSA-N";229.63;-1.08;"16231";"CHEMBL945";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000005128613839913658
"4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol";"MM00446";"CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O";"OVCDSSHSILBFBN-UHFFFAOYSA-N";355.87;5.18;"2165";"CHEMBL682";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.1
"8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine";"MM00447";"Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2";"QWGDMFLQWFTERH-UHFFFAOYSA-N";313.79;3.43;"2170";"CHEMBL1113";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.15;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.7079457843841379
"Amoxicillin";"MM00716";"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O";"LSQZJLSUYDQPKJ-NJBDSQKTSA-N";365.41;0.02;"33613";"CHEMBL1082";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000008709635899560796
"Ampicillin";"MM00627";"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O";"AVKUERGKIZMTKX-NJBDSQKTSA-N";349.41;0.32;"6249";"CHEMBL174";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000005128613839913648
"2-Aminobenzoic Acid";"MM00596";"Nc1ccccc1C(=O)O";"RWZYAGGXGHYGMB-UHFFFAOYSA-N";137.14;0.97;"227";"CHEMBL14173";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.62;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.023988329190194897
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.76;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.7543993733715695
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0016218100973589297
"Benzoic Acid";"MM00630";"O=C(O)c1ccccc1";"WPYMKLBDIGXBTP-UHFFFAOYSA-N";122.12;1.38;"243";"CHEMBL541";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.43;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.37153522909717257
"Bromocriptine";"MM00338";"CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12";"OZVBMTJYIDMWIL-AYFBDAFISA-N";654.61;3.19;"31101";"CHEMBL493";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005128613839913648
"3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine";"MM00453";"CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1";"ZDIGNSYAACHWNL-HNNXBMFYSA-N";319.25;3.93;"6834";"CHEMBL811";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.74;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";54.954087385762456
"Butyric Acid";"MM00634";"CCCC(=O)O";"FERIUCNNQQJTOY-UHFFFAOYSA-N";88.11;0.87;"264";"CHEMBL14227";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.17;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.06760829753919818
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";3.630780547701014
"Cefaclor";"MM00717";"NC(C(=O)NC1C(=O)N2C(C(=O)O)=C(Cl)CSC12)c1ccccc1";"QYIYFLOTGYLRGG-UHFFFAOYSA-N";367.81;0.62;"51039";"CHEMBL680";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.85;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000014125375446227554
"Ceftibuten";"MM00637";"Nc1nc(C(=CCC(=O)O)C(=O)NC2C(=O)N3C(C(=O)O)=CCSC23)cs1";"UNJFKXSSGBWRBZ-UHFFFAOYSA-N";410.43;-0.05;"5282242";"CHEMBL1605";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-11.2;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000006309573444801943
"Cephalexin";"MM00721";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccccc3)C2SC1";"ZAIPMKNFIOOWCQ-UHFFFAOYSA-N";347.4;0.44;"27447";"CHEMBL1727";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000008317637711026709
"Cephradine";"MM00723";"CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)C3=CCC=CC3)C2SC1";"RDLPVSKMFDYCOR-UHFFFAOYSA-N";349.41;0.35;"38103";"CHEMBL1604";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.95;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000001122018454301963
"Chlorambucil";"MM00640";"O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1";"JCKYGMPEJWAADB-UHFFFAOYSA-N";304.22;3.38;"2708";"CHEMBL515";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.40738027780411273
"Chloramphenicol";"MM00342";"O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl";"WIIZWVCIJKGZOK-UHFFFAOYSA-N";323.13;0.91;"5959";"CHEMBL130";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000008709635899560814
"Chloroacetic Acid";"MM00032";"O=C(O)CCl";"FOCAUTSVDIKZOP-UHFFFAOYSA-N";94.5;0.31;"300";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.62;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00239883291901949
"N4-(7-chloro-quinolin-4-yl)-n1,n1-diethyl-pentane-1,4-diamine";"MM00459";"CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12";"WHTVZRBIWZFKQO-UHFFFAOYSA-N";319.88;4.81;"2719";"CHEMBL76";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.78;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";60.25595860743578
"Chlorpheniramine";"MM00460";"CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1";"SOYKEARSMXGVTM-UHFFFAOYSA-N";274.8;3.82;"2725";"CHEMBL505";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";30.902954325135905
"Cimetidine";"MM00463";"CNC(=NCCSCc1nc[nH]c1C)NC#N";"AQIXAKUUQRKLND-UHFFFAOYSA-N";252.35;0.6;"2756";"CHEMBL30";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00021877616239495518
"Ciprofloxacin";"MM00726";"O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O";"MYSWGUAQZAJSOK-UHFFFAOYSA-N";331.35;1.58;"2764";"CHEMBL8";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000025118864315095822
"1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile";"MM00465";"CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21";"WSEQXVZVJXJVFP-UHFFFAOYSA-N";324.4;3.81;"2771";"CHEMBL549";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.19;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.06456542290346556
"(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine";"MM00466";"CN1CCCC1CCOC(C)(c1ccccc1)c1ccc(Cl)cc1";"YNNUSGIPVFPVBX-UHFFFAOYSA-N";343.9;5.1;"26987";"CHEMBL1626";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.83;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";6760.829753919819
"Clonidine";"MM00344";"Clc1cccc(Cl)c1N=C1NCCN1";"GJSURZIOUXUGAL-UHFFFAOYSA-N";230.1;2.17;"2803";"CHEMBL134";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.09;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008128305161640995
"2-amino-3-methyl-4H-imidazol-5-one";"MM00348";"CN1CC(=O)N=C1N";"DDRJAANPRJIHGJ-UHFFFAOYSA-N";113.12;-1.23;"588";"CHEMBL65567";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000021379620895022324
"Desipramine";"MM00474";"CNCCCN1c2ccccc2CCc2ccccc21";"HCYAFALTSJYZDH-UHFFFAOYSA-N";266.39;3.53;"2995";"CHEMBL72";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.63;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";426.57951880159254
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.68;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000020892961308540407
"D-Glucose";"MM00352";"OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O";"WQZGKKKJIJFFOK-GASJEMHNSA-N";180.16;-3.22;"5793";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-12.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000000007244359600749892
"Diazepam";"MM00094";"CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21";"AAOVKJBEBIDNHE-UHFFFAOYSA-N";284.75;3.15;"3016";"CHEMBL12";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.45;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.35481338923357547
"Diclofenac";"MM00090";"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl";"DCOPUUMXTXDBNB-UHFFFAOYSA-N";296.15;4.36;"3033";"CHEMBL139";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.87;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.13489628825916536
"Digoxin";"MM00357";"CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CC(O)C5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O";"LTMHDMANZUZIPE-UHFFFAOYSA-N";780.95;2.22;"2724385";"CHEMBL1751";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000028840315031266057
"Diltiazem";"MM00477";"COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1";"HSUGRBWQSSZJOP-UHFFFAOYSA-N";414.53;3.37;"39186";"CHEMBL23";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.07;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.08511380382023763
"Diphenhydramine";"MM00478";"CN(C)CCOC(c1ccccc1)c1ccccc1";"ZZVUWRFHKOJYTH-UHFFFAOYSA-N";255.36;3.35;"3100";"CHEMBL657";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.98;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";954.992586021436
"Dipyridamole";"MM00479";"OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1";"IZEKFCXSFNUWAM-UHFFFAOYSA-N";504.64;-0.02;"3108";"CHEMBL932";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.93;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000011748975549395302
"Domperidone";"MM00481";"O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1";"FGXWKSZFVQUSTL-UHFFFAOYSA-N";425.92;3.35;"3151";"CHEMBL219916";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.23;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005888436553555889
"L-dopamine";"MM00483";"NCCc1ccc(O)c(O)c1";"VYFYYTLLBUKUHU-UHFFFAOYSA-N";153.18;0.6;"681";"CHEMBL59";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.68;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00020892961308540387
"Enalaprilat";"MM00732";"CC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O";"LZFZMUMEGBBDTC-UHFFFAOYSA-N";348.4;1.13;"5462501";"CHEMBL577";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008709635899560805
"(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol";"MM00486";"CN[C@@H](C)[C@H](O)c1ccccc1";"KWGRBVOPPLSCSI-WPRPVWTQSA-N";165.24;1.33;"9294";"CHEMBL211456";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.04;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.9120108393559098
"Meso-erythritol";"MM00068";"OC[C@H](O)[C@H](O)CO";"UNXHWFMMPAWVPI-ZXZARUISSA-N";122.12;-2.31;"222285";"CHEMBL349605";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000008317637711026709
"Erythromycin";"MM00489";"CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O";"ULGZDMOVFRHVEP-UHFFFAOYSA-N";733.94;1.79;"12560";"CHEMBL532";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.77;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00001698243652461746
"Estradiol";"MM00197";"CC12CCC3c4ccc(O)cc4CCC3C1CCC2O";"VOXZDWNPVJITMN-UHFFFAOYSA-N";272.39;3.61;"5757";"CHEMBL135";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.76;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.7543993733715695
"3-ethyl-3-methylpyrrolidine-2,5-dione";"MM00359";"CCC1(C)CC(=O)NC1=O";"HAPOVYFOVVWLRS-UHFFFAOYSA-N";141.17;0.45;"3291";"CHEMBL696";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0007413102413009177
"Ethanamine";"MM00491";"CCN";"QUSNBJAOOMFDIB-UHFFFAOYSA-N";45.09;-0.04;"6341";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.04;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.09120108393559097
"Etoposide";"MM00361";"COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O";"VJJPUSNTGOMMGY-UHFFFAOYSA-N";588.56;1.34;"36462";"CHEMBL44657";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000001621810097358933
"Famciclovir";"MM00362";"CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O";"GGXKWVWZWMLJEH-UHFFFAOYSA-N";321.34;0.54;"3324";"CHEMBL880";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.98;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000010471285480508985
"Famotidine";"MM00079";"NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1";"XUFQPHANEAPEMJ-UHFFFAOYSA-N";337.46;-0.77;"3325";"CHEMBL902";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000027542287033381634
"Fentanyl";"MM00493";"CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1";"PJMPHNIQZUBGLI-UHFFFAOYSA-N";336.48;4.14;"3345";"CHEMBL596";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.98;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";9549.92586021436
"Fexofenadine";"MM00735";"CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1";"RWTNPBWLLIMQHL-UHFFFAOYSA-N";501.67;5.51;"3348";"CHEMBL914";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.87;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";7.413102413009175
"2-phenylchromen-4-one";"MM00364";"O=c1cc(-c2ccccc2)oc2ccccc12";"VHBFFQKBGNRLFZ-UHFFFAOYSA-N";222.24;3.46;"10680";"CHEMBL275638";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.41;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";257.03957827688646
"Flumequine";"MM00646";"CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23";"DPSPPJIUMHPXMA-UHFFFAOYSA-N";261.25;2.35;"3374";"CHEMBL370252";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.021379620895022326
"2-(6-hydroxy-3-oxo-3h-xanthen-9-yl)-benzoic acid";"MM00054";"O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21";"GNBHRKFJIUUOQI-UHFFFAOYSA-N";332.31;3.67;"16850";"CHEMBL1057";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.84;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.001445439770745928
"Fluoxetine";"MM00082";"CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1";"RTHCYVBBDHJXIQ-UHFFFAOYSA-N";309.33;4.44;"3386";"CHEMBL41";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.1;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";125.89254117941675
"Formamide";"MM00365";"NC=O";"ZHNUHDYFZUAESO-UHFFFAOYSA-N";45.04;-0.9;"713";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.16;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00006918309709189363
"Formic Acid";"MM00649";"O=CO";"BDAGIHXWWSANSR-UHFFFAOYSA-N";46.03;-0.3;"284";"CHEMBL116736";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0016218100973589297
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000004365158322401657
"Gabapentin";"MM00737";"NCC1(CC(=O)O)CCCCC1";"UGJMXCAKCUNAIE-UHFFFAOYSA-N";171.24;1.37;"3446";"CHEMBL940";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008317637711026709
"9-(1,3-dihydroxy-propoxymethane)guanine";"MM00367";"Nc1nc(O)c2ncn(COC(CO)CO)c2n1";"IRSCQMHQWWYFCW-UHFFFAOYSA-N";255.23;-1.56;"3454";"CHEMBL182";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-13.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000000008709635899560796
"Genistein";"MM00368";"O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12";"TZBJGXHYKVUXJN-UHFFFAOYSA-N";270.24;2.58;"5280961";"CHEMBL44";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00003235936569296281
"Glipizide";"MM00651";"Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1";"ZJJXGWJIGJFDTL-UHFFFAOYSA-N";445.55;2.08;"3478";"CHEMBL1073";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.73;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000018620871366628657
"Glycerol";"MM00067";"OCC(O)CO";"PEDCQBHIVMGVHV-UHFFFAOYSA-N";92.09;-1.67;"753";"CHEMBL692";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.02;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000009549925860214369
"Glycine";"MM00741";"NCC(=O)O";"DHMQDGOQFOQNFH-UHFFFAOYSA-N";75.07;-0.97;"750";"CHEMBL773";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.34;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000004570881896148752
"Grepafloxacin";"MM00742";"Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1";"AIJTTZAVMXIJGM-UHFFFAOYSA-N";359.4;2.28;"72474";"CHEMBL583";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0012302687708123812
"Guanabenz";"MM00497";"N=C(N)NN=Cc1c(Cl)cccc1Cl";"WDZVGELJXXEGPV-UHFFFAOYSA-N";231.09;1.81;"5702063";"CHEMBL420";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.7;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00019952623149688788
"Caproic Acid";"MM00636";"CCCCCC(=O)O";"FUZZWVXGSFPDMH-UHFFFAOYSA-N";116.16;1.65;"8892";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.3981071705534972
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000043651583224016655
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.09;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000008128305161640995
"Hydroxyurea";"MM00374";"NC(=O)NO";"VSNHCAURESNICA-UHFFFAOYSA-N";76.06;-0.96;"3657";"CHEMBL467";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000039810717055349695
"2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol";"MM00502";"OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1";"ZQDWXGKKHFNSQK-UHFFFAOYSA-N";374.91;3.06;"3658";"CHEMBL896";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.1
"Hypoxanthine";"MM00375";"O=c1nc[nH]c2nc[nH]c12";"FDGQSTZJBFJUBT-UHFFFAOYSA-N";136.11;-0.35;"790";"CHEMBL1427";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.18;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000006606934480075964
"Imipramine";"MM00504";"CN(C)CCCN1c2ccccc2CCc2ccccc21";"BCGWQEUPMDMJNV-UHFFFAOYSA-N";280.42;3.88;"3696";"CHEMBL11";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.7;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";501.18723362727246
"Indinavir";"MM00505";"CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc1ccccc1)C(=O)NC1c2ccccc2CC1O";"CBVCZFGXHXORBI-UHFFFAOYSA-N";613.8;2.87;"5362440";"CHEMBL115";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.28;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.005248074602497728
"Indomethacin";"MM00656";"COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1";"CGIGDMFJXJATDK-UHFFFAOYSA-N";357.79;3.93;"3715";"CHEMBL6";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.38;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.004168693834703355
"Isobutyric Acid";"MM00658";"CC(C)C(=O)O";"KQNPFQTWMSNSAP-UHFFFAOYSA-N";88.11;0.73;"6590";"CHEMBL108778";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.92;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.12022644346174129
"N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide";"MM00379";"Cc1cc(C(=O)NNCc2ccccc2)no1";"XKFPYPQQHFEXRZ-UHFFFAOYSA-N";231.26;1.42;"3759";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.42;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.6302679918953817
"Isovaleric Acid";"MM00659";"CC(C)CC(=O)O";"GWYFCOCPABKNJV-UHFFFAOYSA-N";102.13;1.12;"10430";"CHEMBL568737";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.20417379446695297
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.03;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.933254300796991
"Labetalol";"MM00507";"CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1";"SGUAFYQXFOLMHL-UHFFFAOYSA-N";328.41;2.14;"3869";"CHEMBL429";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.028183829312644536
"Lamotrigine";"MM00383";"Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1";"PYZRQGJRPPTADH-UHFFFAOYSA-N";256.1;2.01;"3878";"CHEMBL741";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.9;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000012589254117941661
"Lansoprazole";"MM00384";"Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1";"MJIHNNLFOKEZEW-UHFFFAOYSA-N";369.37;3.52;"3883";"CHEMBL480";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.75;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000001778279410038923
"L-Dopa";"MM00746";"NC(Cc1ccc(O)c(O)c1)C(=O)O";"WTDRDQBEARUVNC-UHFFFAOYSA-N";197.19;0.05;"6047";"CHEMBL1009";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000028840315031266057
"L-Leucine";"MM00752";"CC(C)C[C@H](N)C(=O)O";"ROHFNLRQFUQHCH-YFKPBYRVSA-N";131.18;0.44;"6106";"CHEMBL291962";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0020417379446695297
"Lisinopril";"MM00763";"NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N1CCCC1C(=O)O";"RLAWWYSOJDYHDC-UHFFFAOYSA-N";405.5;1.24;"5362119";"CHEMBL1237";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.92;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00012022644346174131
"8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine";"MM00510";"CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1";"XJGVXQDUIWGIRW-UHFFFAOYSA-N";327.82;3.77;"3964";"CHEMBL831";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.09;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.2302687708123816
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-12.88;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000000013182567385564046
"Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate";"MM00511";"CCOC(=O)C1(c2ccccc2)CCN(C)CC1";"XADCESSVHJOZHK-UHFFFAOYSA-N";247.34;2.21;"4058";"CHEMBL607";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.51;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";32.359365692962825
"Meprobamate";"MM00387";"CCCC(C)(COC(N)=O)COC(N)=O";"NPPQSCRMBWNHMW-UHFFFAOYSA-N";218.25;0.98;"4064";"CHEMBL979";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.07;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000008511380382023759
"Methanol";"MM00063";"CO";"OKKJLVBELUTLKV-UHFFFAOYSA-N";32.04;-0.39;"887";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.57;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0026915348039269166
"Methotrexate";"MM00270";"CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1";"FBOZXECLQNJBKD-UHFFFAOYSA-N";454.45;0.27;"126941";"CHEMBL34259";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-15.3;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000000000005011872336272715
"Methylamine";"MM00515";"CN";"BAVYZALUXZFZLV-UHFFFAOYSA-N";31.06;-0.43;"6329";"CHEMBL43280";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.31;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.004897788193684461
"Methylprednisolone";"MM00388";"CC1CC2C(C(O)CC3(C)C2CCC3(O)C(=O)CO)C2(C)C=CC(=O)C=C12";"VHRSUDSXCMQTMA-UHFFFAOYSA-N";374.48;1.8;"6741";"CHEMBL650";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.95;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00001122018454301963
"4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide";"MM00517";"CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC";"TTWJBBZEZQICBI-UHFFFAOYSA-N";299.8;2;"4168";"CHEMBL86";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.46;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0003467368504525317
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";19.498445997580454
"Midazolam";"MM00519";"Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2";"DDLIGBOFAVUZHB-UHFFFAOYSA-N";325.77;4.32;"4192";"CHEMBL655";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.82;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";6.606934480075959
"Minoxidil";"MM00393";"Nc1cc(N2CCCCC2)nc(N)[n+]1[O-]";"ZFMITUMMTDLWHR-UHFFFAOYSA-N";209.25;-0.13;"4201";"CHEMBL802";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.04;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00009120108393559096
"1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione";"MM00522";"O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21";"KKZJGLLVHKMTCM-UHFFFAOYSA-N";444.49;-0.14;"4212";"CHEMBL58";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000028840315031266117
"Nadolol";"MM00525";"CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2";"VWPOSFSPZNDTMJ-UHFFFAOYSA-N";309.41;0.63;"39147";"CHEMBL649";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.93;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.011748975549395297
"Nalbuphine";"MM00526";"Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314";"NETZHAKZCGBWSS-CEDHKZHLSA-N";357.45;1.71;"5311304";"CHEMBL895";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.21877616239495523
"Naproxen";"MM00672";"COc1ccc2cc(C(C)C(=O)O)ccc2c1";"CMWTZPSULFXXJA-UHFFFAOYSA-N";230.26;3.04;"156391";"CHEMBL154";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.35;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.44668359215096315
"Nelfinavir";"MM00528";"Cc1c(O)cccc1C(=O)NC(CSc1ccccc1)C(O)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C";"QAGYKUNXZHXKMR-UHFFFAOYSA-N";567.8;4.75;"64143";"CHEMBL584";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";13.489628825916533
"Nicotinamide";"MM00396";"NC(=O)c1cccnc1";"DFPAKSUCGFBDDF-UHFFFAOYSA-N";122.13;0.18;"936";"CHEMBL1140";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00007244359600749906
"Norfloxacin";"MM00768";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21";"OGJPXUAPXNRGGI-UHFFFAOYSA-N";319.34;1.27;"4539";"CHEMBL9";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.9;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000012589254117941661
"Ofloxacin";"MM00769";"CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23";"GSDSWSVVBLHKDQ-UHFFFAOYSA-N";361.37;1.54;"4583";"CHEMBL4";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.43;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000037153522909717276
"6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole";"MM00399";"COc1ccc2[nH]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1";"SUBDBMMJDZJVOS-UHFFFAOYSA-N";345.42;2.9;"4594";"CHEMBL1503";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000002511886431509582
"6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole";"MM00401";"COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC";"IQPSEEYGBUAQFF-UHFFFAOYSA-N";383.38;2.88;"4679";"CHEMBL1502";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.44;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000036307805477010174
"Phenylacetic Acid";"MM00679";"O=C(O)Cc1ccccc1";"WLJVXDMOQOGPHL-UHFFFAOYSA-N";136.15;1.31;"999";"CHEMBL1044";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.17;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.6760829753919817
"L-Phenylalanine";"MM00756";"N[C@@H](Cc1ccccc1)C(=O)O";"COLNVLDHVKWLRT-QMMMGPOBSA-N";165.19;0.64;"6140";"CHEMBL301523";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008317637711026709
"Phenytoin";"MM00406";"O=C1N=C(O)NC1(c1ccccc1)c1ccccc1";"CXOFVDLJLONNDW-UHFFFAOYSA-N";252.27;1.97;"1775";"CHEMBL16";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.38;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.004168693834703355
"4-Hydroxybenzoic Acid";"MM00609";"O=C(O)c1ccc(O)cc1";"FJKROLUGYXJWQN-UHFFFAOYSA-N";138.12;1.09;"135";"CHEMBL441343";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.27;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005370317963702527
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.1380384264602885
"11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one";"MM00543";"CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1";"RMHMFHUVIITRHF-UHFFFAOYSA-N";351.41;1.56;"4848";"CHEMBL9967";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.52;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000030199517204020192
"Piroxicam";"MM00682";"CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O";"QYSPLQLAKJAUJT-UHFFFAOYSA-N";331.35;1.58;"54676228";"CHEMBL527";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.12;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000007585775750291836
"Pivalic Acid";"MM00683";"CC(C)(C)C(=O)O";"IUGYQRQAERSCNH-UHFFFAOYSA-N";102.13;1.12;"6417";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.40738027780411273
"Practolol";"MM00544";"CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1";"DURULFYMVIFBIR-UHFFFAOYSA-N";266.34;1.38;"4883";"CHEMBL6995";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.32359365692962827
"2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one";"MM00407";"O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1";"FSVJFNAIGNNGKK-UHFFFAOYSA-N";312.41;2.53;"4891";"CHEMBL976";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.2754228703338166
"Prednisolone";"MM00297";"CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"OIGNJSKKLXVSLS-UHFFFAOYSA-N";360.45;1.56;"5755";"CHEMBL131";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.23;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000005888436553555884
"5-ethyl-5-phenyl-1,3-diazinane-4,6-dione";"MM00409";"CCC1(c2ccccc2)C(=O)NCNC1=O";"DQMZLTXERSFNPB-UHFFFAOYSA-N";218.26;0.54;"4909";"CHEMBL856";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0004365158322401661
"Propionic Acid";"MM00685";"CCC(=O)O";"XBDQKXXYIPTUBI-UHFFFAOYSA-N";74.08;0.48;"1032";"CHEMBL14021";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.5;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.03162277660168379
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.42;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2630.2679918953813
"Propylene Glycol";"MM00414";"CC(O)CO";"DNIAPMSPPWPWGF-UHFFFAOYSA-N";76.1;-0.64;"1030";"CHEMBL286398";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.52;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0003019951720402016
"6-propyl-2-sulfanylidene-1H-pyrimidin-4-one";"MM00415";"CCCc1cc(=O)[nH]c(=S)[nH]1";"KNAHARQHSZJURB-UHFFFAOYSA-N";170.24;1.38;"657298";"CHEMBL1518";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.02187761623949553
"4-Methylbenzoic Acid";"MM00610";"Cc1ccc(C(=O)O)cc1";"LPNBBFKOUUSUDB-UHFFFAOYSA-N";136.15;1.69;"7470";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.831763771102671
"N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine";"MM00512";"COc1ccc(CN(CCN(C)C)c2ccccn2)cc1";"YECBIJXISLIIDS-UHFFFAOYSA-N";285.39;2.66;"4992";"CHEMBL511";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.9498445997580451
"Quercetin";"MM00047";"O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12";"REFJWTPEDVJJIY-UHFFFAOYSA-N";302.24;1.99;"5280343";"CHEMBL50";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.24;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000057543993733715665
"Quinidine";"MM00558";"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-LHHVKLHASA-N";324.42;3.17;"441074";"CHEMBL1294";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.19;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.06456542290346556
"Quinine";"MM00559";"C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-WZBLMQSHSA-N";324.42;3.17;"3034034";"CHEMBL170";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.24;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.057543993733715694
"Ritonavir";"MM00419";"CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1";"NCDNCNXCDXHOMX-UHFFFAOYSA-N";720.96;5.91;"392622";"CHEMBL163";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.87;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0013489628825916532
"N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine";"MM00562";"CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12";"ULFRLSNUDGIQQP-UHFFFAOYSA-N";269.35;1.91;"5078";"CHEMBL905";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.2;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00630957344480193
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.64;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.022908676527677734
"6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";"MM00771";"O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O";"XBHBWNFJWIASRO-UHFFFAOYSA-N";385.37;2.38;"56208";"CHEMBL37858";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0002818382931264455
"Sotalol";"MM00567";"CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1";"ZBMZVLHSJCTVON-UHFFFAOYSA-N";272.37;1.09;"5253";"CHEMBL471";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.58;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0026302679918953813
"Sparfloxacin";"MM00772";"CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)CC(C)N1";"DZZWHBIBMUVIIW-UHFFFAOYSA-N";392.41;2.08;"60464";"CHEMBL850";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.16;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00006918309709189363
"Sucrose";"MM00421";"OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O";"CZMRCDWAGMRECN-UGDNZRGBSA-N";342.3;-5.4;"5988";"CHEMBL253582";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-15.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000000000012302687708123811
"Sulfasalazine";"MM00690";"O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O";"NCEXYHBECQHGNR-UHFFFAOYSA-N";398.4;3.7;"5359476";"CHEMBL421";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.27;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000005370317963702533
"Sulpiride";"MM00568";"CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC";"BGRJTUBHPOOWDU-UHFFFAOYSA-N";341.43;0.56;"5355";"CHEMBL26";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000016218100973589298
"1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide";"MM00569";"CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1";"KQKPFRSPSRPDEB-UHFFFAOYSA-N";295.41;1.32;"5358";"CHEMBL128";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00008317637711026709
"5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol";"MM00306";"CC(C)(C)NCC(O)c1cc(O)cc(O)c1";"XWTYSIMOBUGWOL-UHFFFAOYSA-N";225.29;1.52;"5403";"CHEMBL1760";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.59;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0002570395782768865
"1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol";"MM00571";"CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1";"GUGOEEXESWIERI-UHFFFAOYSA-N";471.69;6.45;"5405";"CHEMBL17157";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;4.23;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";16982.43652461746
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.78;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";6.025595860743578
"Theobromine";"MM00424";"Cn1cnc2c1c(=O)[nH]c(=O)n2C";"YAPQBXQYLJRXSA-UHFFFAOYSA-N";180.17;-1.04;"5429";"CHEMBL1114";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.99;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000010232929922807537
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.89;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000001288249551693135
"2-(1,3-thiazol-4-yl)-1h-benzimidazole";"MM00425";"c1ccc2[nH]c(-c3cscn3)nc2c1";"WJCNZQLZVWNLKY-UHFFFAOYSA-N";201.25;2.69;"5430";"CHEMBL625";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.5128613839913648
"Thiocyanic Acid";"MM00692";"N#CS";"ZMZDMBWJUHKJPS-UHFFFAOYSA-N";59.09;0.4;"781";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.96;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.1096478196143185
"Thiourea";"MM00426";"NC(N)=S";"UMGDCJDMYOKAJW-UHFFFAOYSA-N";76.12;-0.81;"2723790";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00008317637711026709
"Thymine";"MM00428";"Cc1c[nH]c(=O)[nH]c1=O";"RWQNBRDOKXIBIV-UHFFFAOYSA-N";126.12;-0.63;"1135";"CHEMBL993";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000831763771102671
"Tiglic Acid";"MM00694";"C/C=C(\C)C(=O)O";"UIERETOOQGIECD-ONEGZZNKSA-N";100.12;1.04;"125468";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.48;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.3311311214825911
"Tolbutamide";"MM00708";"CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1";"JLRGJRBPOGGCBT-UHFFFAOYSA-N";270.35;1.78;"5505";"CHEMBL782";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.81;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0015488166189124811
"Topotecan";"MM00575";"CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1";"UCFGDBYHRUNTLO-UHFFFAOYSA-N";421.45;1.85;"60700";"CHEMBL84";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000043651583224016566
"Trimethoprim";"MM00581";"COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC";"IEDVJHCEMCRBQM-UHFFFAOYSA-N";290.32;1.26;"5578";"CHEMBL22";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.85;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000014125375446227554
"Urea";"MM00065";"NC(N)=O";"XSQUKJJJFZCRTK-UHFFFAOYSA-N";60.06;-0.98;"1176";"CHEMBL985";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000002754228703338169
"Valeric Acid";"MM00710";"CCCCC(=O)O";"NQPDZGIKBAWPEJ-UHFFFAOYSA-N";102.13;1.26;"7991";"CHEMBL268736";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.78;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.16595869074375605
"Valproic Acid";"MM00711";"CCCC(CCC)C(=O)O";"NIJJYAXOARWZEE-UHFFFAOYSA-N";144.21;2.29;"3121";"CHEMBL109";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.88;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";7.5857757502918375
"Vanillic Acid";"MM00712";"COc1cc(C(=O)O)ccc1O";"WKOLLVMJNQIZCI-UHFFFAOYSA-N";168.15;1.1;"8468";"CHEMBL120568";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.57;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00002691534803926914
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.58;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0026302679918953813
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.15;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.4125375446227544
"Xanthine";"MM00432";"O=c1[nH]c(=O)c2[nH]cnc2[nH]1";"LRFVTYWOQMYALW-UHFFFAOYSA-N";152.11;-1.06;"1188";"CHEMBL1424";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.85;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000014125375446227555
"Zidovudine";"MM00077";"Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O";"HBOMLICNUCNMMY-UHFFFAOYSA-N";267.25;-0.2;"35370";"CHEMBL129";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000001380384264602884
"5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one";"MM00589";"O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1";"MVWVFYHBGMAFLY-UHFFFAOYSA-N";412.95;3.81;"60854";"CHEMBL708";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.64;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.022908676527677734
"(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one";"MM00590";"CN(C)CCc1c[nH]c2ccc(CC3COC(=O)N3)cc12";"ULSDMUVEXKOYBU-UHFFFAOYSA-N";287.36;1.92;"60857";"CHEMBL1185";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.93;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000011748975549395302
"12-Hydroxydodecanoic Acid";"MM00593";"O=C(O)CCCCCCCCCCCO";"ZDHCZVWCTKTBRY-UHFFFAOYSA-N";216.32;2.96;"79034";"CHEMBL55068";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.28183829312644537
"2-Hydroxybutyric Acid";"MM00597";"CC[C@H](O)C(=O)O";"AFENDNXGAFYKQO-VKHMYHEASA-N";104.11;-0.16;"11266";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.74;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00018197008586099826
"2-Hydroxycaproic Acid";"MM00598";"CCCC[C@H](O)C(=O)O";"NYHNVHGFPZAZGA-YFKPBYRVSA-N";132.16;0.62;"99824";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.96;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0010964781961431851
"2-Hydroxynicotinic Acid";"MM00599";"O=C(O)c1ccc[nH]c1=O";"UEYQJQVBUVAELZ-UHFFFAOYSA-N";139.11;0.07;"69114";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0006025595860743575
"2-Hydroxyvaleric Acid";"MM00600";"CCC[C@H](O)C(=O)O";"JRHWHSJDIILJAT-BYPYZUCNSA-N";118.13;0.23;"98009";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.34;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0004570881896148752
"3,4-Dihydroxyphenylacetic Acid";"MM00602";"O=C(O)Cc1ccc(O)c(O)c1";"CFFZDZCDUFSOFZ-UHFFFAOYSA-N";168.15;0.72;"547";"CHEMBL1284";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00002818382931264455
"3-Hydroxyphenylacetic Acid";"MM00604";"O=C(O)Cc1cccc(O)c1";"FVMDYYGIDFPZAX-UHFFFAOYSA-N";152.15;1.02;"12122";"190035";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.99;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0010232929922807535
"Adenosine";"MM00325";"Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"OIRDTQYFTABQOQ-KQYNXXCUSA-N";267.25;-1.98;"60961";"CHEMBL477";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-13.1;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000000007943282347242822
"Methyl 5-(propylsulfinyl)-1h-benzimidazol-2-ylcarbamate";"MM00326";"CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1";"HXHWSAZORRCQMX-UHFFFAOYSA-N";265.34;3.24;"2082";"CHEMBL1483";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.74;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00018197008586099826
"Alfentanil";"MM00439";"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1";"IDBPHNDTYPBSNI-UHFFFAOYSA-N";416.53;1.38;"51263";"CHEMBL634";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.043651583224016584
"Alprazolam";"MM00329";"C[C@@H]1NN[C@H]2CN[C@@H](c3ccccc3)c3cc(Cl)ccc3N12";"IYQBGWNRKQNSIE-LQAWEQHXSA-N";314.82;2.62;"2118";"CHEMBL661";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.2;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";158.48931924611142
"3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione";"MM00330";"CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O";"ROBVIMPUHSLWNV-ZDUSSCGKSA-N";232.28;1.35;"2145";"CHEMBL488";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.93;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0001174897554939529
"(2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone";"MM00443";"CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1";"IYIKLHRQXLHMJQ-UHFFFAOYSA-N";645.32;6.94;"2157";"CHEMBL633";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1949.8445997580454
"Amitriptyline";"MM00444";"CN(C)CCC=C1c2ccccc2CCc2ccccc21";"KRMDCWKBEZIMAB-UHFFFAOYSA-N";277.41;4.17;"2160";"CHEMBL629";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";6165.9500186148225
"Amlodipine";"MM00098";"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@H]1c1ccccc1Cl";"HTIQEAQVCYTUBX-QGZVFWFLSA-N";408.88;2.27;"2162";"CHEMBL1491";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.04;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00009120108393559096
"Ascorbic Acid";"MM00628";"O=C1O[C@H]([C@@H](O)CO)C(O)=C1O";"CIWBSHSKHKDKBQ-JLAZNSOCSA-N";176.12;-1.41;"54670067";"CHEMBL196";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-11;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000001
"Astemizole";"MM00448";"COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1";"GXDALQBWZGODGZ-UHFFFAOYSA-N";458.58;5.35;"2247";"CHEMBL296419";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.68;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";47.86300923226383
"Atomoxetine";"MM00449";"CNCC[C@@H](Oc1ccccc1C)c1ccccc1";"VHGCDTVCOLNTBX-QGZVFWFLSA-N";255.36;3.72;"54841";"CHEMBL641";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.94;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";870.9635899560806
"Benazepril";"MM00629";"CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O";"XPCFTKFZXHTYIP-PMACEKPBSA-N";424.5;2.57;"5362124";"CHEMBL838";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.21;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";16.218100973589298
"Bendroflumethiazide";"MM00336";"NS(=O)(=O)c1cc2c(cc1C(F)(F)F)N[C@@H](Cc1ccccc1)NS2(=O)=O";"HDWIHXWEUNVBIY-CQSZACIVSA-N";421.42;1.63;"2315";"CHEMBL1684";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.24;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000005754399373371567
"3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide";"MM00631";"NS(=O)(=O)c1cc2c(cc1Cl)N[C@H](CSCc1ccccc1)NS2(=O)=O";"ZUNJWRJEKCRIMZ-HNNXBMFYSA-N";433.96;1.95;"2343";"CHEMBL1201039";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000016218100973589298
"1-isobutoxy-2-pyrrolidino-3[n-benzylanilino] propane";"MM00451";"CC(C)COC[C@@H](CN(Cc1ccccc1)c1ccccc1)N1CCCC1";"UIEATEWHFDRYRU-XMMPIXPASA-N";366.55;4.83;"2351";"CHEMBL1008";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;4.43;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";26915.348039269138
"Budesonide";"MM00339";"CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1";"VOVIALXJUBGFJZ-VXKMTNQYSA-N";430.54;2.72;"5281004";"CHEMBL1370";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0004365158322401661
"1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide";"MM00454";"CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C";"LEBVLXFERQHONN-INIZCTEOSA-N";288.44;3.9;"2474";"CHEMBL1098";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";457.0881896148752
"Bupropion";"MM00455";"C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1";"SNPPWIUOZRMYNY-VIFPVBQESA-N";239.75;3.3;"444";"CHEMBL894";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.83;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";67.60829753919819
"8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione";"MM00456";"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1";"QWCRAEMEVRGPNT-UHFFFAOYSA-N";385.51;2.09;"2477";"CHEMBL49";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.38;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.04168693834703355
"1-butanol";"MM00340";"CCCCO";"LRHPLDYGYMQRHN-UHFFFAOYSA-N";74.12;0.78;"263";"CHEMBL14245";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.32359365692962827
"1-Butylamine";"MM00435";"CCCCN";"HQABUPZFAYXKJW-UHFFFAOYSA-N";73.14;0.75;"8007";"CHEMBL13968";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.6025595860743578
"1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol";"MM00458";"COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12";"OGHNVEJMJSYVRP-UHFFFAOYSA-N";406.48;3.74;"2585";"CHEMBL723";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.9;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.12589254117941673
"Chlorthalidone";"MM00343";"NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl";"JIVPVXMEBJLZRO-UHFFFAOYSA-N";338.77;0.92;"2732";"CHEMBL1055";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000012302687708123812
"1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine";"MM00464";"C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1";"DERZBLKQOCDDDZ-UHFFFAOYSA-N";368.52;5.11;"1547484";"CHEMBL43064";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;4.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";81283.05161640995
"Citric Acid";"MM00642";"O=C(O)CC(O)(CC(=O)O)C(=O)O";"KRKNYBCHXYNGOX-UHFFFAOYSA-N";192.12;-1.25;"311";"CHEMBL1261";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.12;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000007585775750291851
"1-[(2-chlorophenyl)-diphenylmethyl]imidazole";"MM00468";"Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1";"VNFPBHJOKIVQEB-UHFFFAOYSA-N";344.85;5.38;"2812";"CHEMBL104";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;4.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";13489.628825916532
"Corticosterone";"MM00346";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12";"OMFXVFTZEKFJBZ-UHFFFAOYSA-N";346.47;2.67;"5753";"CHEMBL110739";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0007244359600749898
"Cortisone";"MM00347";"CC12CCC(O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO";"LPYXTAPPNYMYOP-UHFFFAOYSA-N";362.47;1.78;"222786";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000002818382931264455
"Cyclothiazide";"MM00350";"NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O";"BOCUKUHCLICSIY-UHFFFAOYSA-N";389.89;1.23;"2910";"CHEMBL61593";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000001
"4-(dibenzo[1,2-a:2',1'-d][7]annulen-11-ylidene)-1-methyl-piperidine";"MM00472";"CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1";"JJCFRYNCJDLXIK-UHFFFAOYSA-N";287.41;4.7;"2913";"CHEMBL516";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.88;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";7585.775750291836
"Danazol";"MM00353";"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C";"POZRVZJJTULAOH-LHZXLZLDSA-N";337.46;4.22;"28417";"CHEMBL1479";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.48;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";301.9951720402016
"Capric Acid";"MM00635";"CCCCCCCCCC(=O)O";"GHVNFZFCNZKVNT-UHFFFAOYSA-N";172.27;3.21;"2969";"CHEMBL107498";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.18;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";15.13561248436208
"Cortexone";"MM00037";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(C(=O)CO)CCC12";"ZESRJSPZRDMNHY-UHFFFAOYSA-N";330.47;3.7;"6166";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.21;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.06165950018614822
"4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one";"MM00433";"Nc1ccn(C2CCC(CO)O2)c(=O)n1";"WREGKURFCTUGRC-UHFFFAOYSA-N";211.22;-0.5;"24066";"CHEMBL853";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000021379620895022325
"Dipicolinic Acid";"MM00643";"O=C(O)c1cccc(C(=O)O)n1";"WJJMNDUMQPNECX-UHFFFAOYSA-N";167.12;0.48;"10367";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000021877616239495517
"Donepezil";"MM00482";"COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2";"ADEBPBSSDYVVLD-UHFFFAOYSA-N";379.5;4.36;"3152";"CHEMBL502";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.02;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.0471285480508996
"Enoxacin";"MM00733";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21";"IDYZIJYBMGIQMJ-UHFFFAOYSA-N";320.32;0.66;"3229";"CHEMBL826";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.8;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00001584893192461114
"Enrofloxacin";"MM00734";"CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1";"SPFYMRJSYKOXGV-UHFFFAOYSA-N";359.4;2.32;"71188";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.23;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005888436553555889
"L-epinephrine";"MM00644";"CNCC(O)c1ccc(O)c(O)c1";"UCTWMZQNUQWSLP-UHFFFAOYSA-N";183.21;0.35;"5816";"CHEMBL679";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.48;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000033113112148259077
"Ergonovine";"MM00487";"CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1";"WVVSZNPYNCNODU-UHFFFAOYSA-N";325.41;1.53;"443884";"CHEMBL119443";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.63;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00023442288153199226
"Ergotamine";"MM00488";"CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21";"XCGSFFUVFURLIX-VFGNJEKYSA-N";581.67;1.99;"8223";"CHEMBL442";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.99;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00010232929922807536
"Ethanolamine";"MM00490";"NCCO";"HZAXFHJVJLSVMW-UHFFFAOYSA-N";61.08;-1.06;"700";"CHEMBL104943";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.65;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00002238721138568338
"Felodipine";"MM00363";"CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl";"RZTAMFZIAATZDJ-UHFFFAOYSA-N";384.26;3.96;"3333";"CHEMBL1480";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.07244359600749903
"2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol";"MM00494";"OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1";"PLDUPXSUYLZYBN-UHFFFAOYSA-N";437.53;4.31;"3372";"CHEMBL726";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.028183829312644536
"Flurbiprofen";"MM00647";"CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1";"SYTBZMRGLBWNTM-UHFFFAOYSA-N";244.27;3.68;"3394";"CHEMBL563";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.03;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";10.715193052376065
"Fluvoxamine";"MM00495";"COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1";"CJOFXWAVKWHTFT-UHFFFAOYSA-N";318.34;3.2;"5324346";"CHEMBL814";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.59;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.025703957827688632
"(2R,3S,4R,5S)-hexane-1,2,3,4,5,6-hexol";"MM00366";"OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-GUCUJZIJSA-N";182.17;-3.59;"11850";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-12.79;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000000001621810097358933
"Galantamine";"MM00496";"COc1ccc2c3c1OC1CC(O)C=CC31CCN(C)C2";"ASUTZQLVASHGKV-UHFFFAOYSA-N";287.36;1.85;"9651";"CHEMBL659";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.62;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.023988329190194897
"Gatifloxacin";"MM00738";"COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12";"XUBOMFCQGDBHNK-UHFFFAOYSA-N";375.4;1.98;"5379";"CHEMBL31";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.43;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00003715352290971728
"5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid";"MM00650";"Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1";"HEMJJKBWTPKOJG-UHFFFAOYSA-N";250.34;3.57;"3463";"CHEMBL457";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.85;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";70.79457843841381
"Griseofulvin";"MM00369";"COC1=CC(=O)CC(C)C12Oc1c(Cl)c(OC)cc(OC)c1C2=O";"DDUHZTYCFQRHIY-UHFFFAOYSA-N";352.77;2.81;"441140";"CHEMBL562";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000013803842646028838
"Guanidine";"MM00498";"N=C(N)N";"ZRALSGWEFCBTJO-UHFFFAOYSA-N";59.07;-1.16;"3520";"CHEMBL821";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.21;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000006165950018614822
"Haloperidol";"MM00499";"O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1";"LNEPOXFFQSENCJ-UHFFFAOYSA-N";375.87;4.43;"3559";"CHEMBL54";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.62;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";4.168693834703354
"Hesperetin";"MM00371";"COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O";"AIONOLUJZLIMTK-AWEZNQCLSA-N";302.28;2.52;"72281";"CHEMBL399121";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.35;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000004466835921509635
"Histamine";"MM00500";"NCCc1cnc[nH]1";"NTYJJOPFIAHURM-UHFFFAOYSA-N";111.15;-0.09;"774";"CHEMBL90";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.32;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00047863009232263854
"1-hydrazinophthalazine";"MM00501";"NNc1nncc2ccccc12";"RPTUSVTUFVMDQK-UHFFFAOYSA-N";160.18;0.92;"3637";"CHEMBL276832";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.15;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";141.2537544622754
"Imatinib";"MM00503";"Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1";"KTUFNOKKBVMGRW-UHFFFAOYSA-N";493.62;4.59;"5291";"CHEMBL941";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.11;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00776247116628692
"Propan-2-ol";"MM00380";"CC(C)O";"KFZMGEQAYNKOFK-UHFFFAOYSA-N";60.1;0.39;"3776";"CHEMBL582";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.21;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.6165950018614822
"Isotretinoin";"MM00594";"CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O";"SHGAZHPCJJPHSC-UHFFFAOYSA-N";300.44;5.6;"5282379";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;4.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";16595.869074375598
"Itraconazole";"MM00381";"CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O";"VHVPQPYKVGDNFY-UHFFFAOYSA-N";705.65;5.58;"55283";"CHEMBL22587";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.6025595860743578
"3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one";"MM00661";"O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12";"IYRMWMYZSQPJKC-UHFFFAOYSA-N";286.24;2.28;"5280863";"CHEMBL150";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.11;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000007762471166286912
"Kynurenic Acid";"MM00663";"O=C(O)c1cc(=O)c2ccccc2[nH]1";"HCZHHEIFKROPDY-UHFFFAOYSA-N";189.17;1.23;"3845";"CHEMBL299155";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.15;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00007079457843841373
"4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one";"MM00382";"Nc1ccn(C2CSC(CO)O2)c(=O)n1";"JTEGQNOMFQHVDC-UHFFFAOYSA-N";229.26;-0.59;"60825";"CHEMBL141";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.27;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000005370317963702533
"L-Arginine";"MM00744";"NC(N)=NCCC[C@H](N)C(=O)O";"ODKSFYDXXFIFQN-BYPYZUCNSA-N";174.2;-1.55;"6322";"CHEMBL1485";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.11;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000007762471166286927
"L-Aspartic Acid";"MM00745";"N[C@@H](CC(=O)O)C(=O)O";"CKLJMWTZIZZHCS-REOHCLBHSA-N";133.1;-1.13;"5960";"CHEMBL274323";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000003981071705534969
"Levofloxacin";"MM00762";"C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23";"GSDSWSVVBLHKDQ-JTQLQIEISA-N";361.37;1.54;"149096";"CHEMBL33";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00002187761623949552
"L-Glutamic Acid";"MM00747";"NC(CCC(=O)O)C(=O)O";"WHUUTDBJXJRKMK-UHFFFAOYSA-N";147.13;-0.74;"33032";"CHEMBL575060";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.34;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000004570881896148752
"L-Glutamine";"MM00748";"NC(=O)CC[C@H](N)C(=O)O";"ZDXPYRJPNDTMRX-VKHMYHEASA-N";146.15;-1.34;"5961";"CHEMBL930";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.51;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000003090295432513592
"L-Histidine";"MM00749";"N[C@@H](Cc1cnc[nH]1)C(=O)O";"HNDVDQJCIGZPNO-YFKPBYRVSA-N";155.16;-0.64;"6274";"CHEMBL17962";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.5;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000003162277660168379
"Lidocaine";"MM00092";"CCN(CC)CC(=O)Nc1c(C)cccc1C";"NNJVILVZKWQKPM-UHFFFAOYSA-N";234.34;2.58;"3676";"CHEMBL79";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";34.673685045253166
"L-Isoleucine";"MM00750";"CC[C@H](C)[C@H](N)C(=O)O";"AGPKZVBTJJNPAG-WHFBIAKZSA-N";131.18;0.44;"6306";"CHEMBL1233584";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.62;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00239883291901949
"L-Kynurenine";"MM00751";"Nc1ccccc1C(=O)C[C@H](N)C(=O)O";"YGPSJZOEDVAXAB-QMMMGPOBSA-N";208.22;0.25;"161166";"CHEMBL498416";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.33;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000004677351412871981
"L-Lysine";"MM00753";"NCCCC[C@H](N)C(=O)O";"KDXKERNSBIXSRK-YFKPBYRVSA-N";146.19;-0.47;"5962";"CHEMBL8085";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000002754228703338169
"L-Methionine";"MM00754";"CSCC[C@H](N)C(=O)O";"FFEARJCKVFRZRR-BYPYZUCNSA-N";149.22;0.15;"6137";"CHEMBL42336";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00021379620895022324
"Lomefloxacin";"MM00764";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21";"ZEKZLJVOYLTDKK-UHFFFAOYSA-N";351.35;1.8;"3948";"CHEMBL561";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.48;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000033113112148259076
"L-Ornithine";"MM00755";"NCCC[C@H](N)C(=O)O";"AHLPHDHHMVZTML-BYPYZUCNSA-N";132.16;-0.86;"6262";"CHEMBL446143";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.46;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000034673685045253164
"Losartan";"MM00665";"CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1";"PSIFNNKUMBGKDQ-UHFFFAOYSA-N";422.92;4.27;"3961";"CHEMBL191";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.74;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";54.954087385762456
"L-Threonine";"MM00758";"C[C@@H](O)[C@H](N)C(=O)O";"AYFVYJQAPQTCCC-GBXIJSLDSA-N";119.12;-1.22;"6288";"CHEMBL291747";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.08;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000008317637711026709
"L-Tryptophan";"MM00759";"N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O";"QIVBCDIJIAJPQS-VIFPVBQESA-N";204.23;1.12;"6305";"CHEMBL54976";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.72;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00019054607179632462
"L-Tyrosine";"MM00760";"N[C@@H](Cc1ccc(O)cc1)C(=O)O";"OUYCCCASQSFEME-QMMMGPOBSA-N";181.19;0.35;"6057";"CHEMBL925";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.87;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000013489628825916533
"L-Valine";"MM00761";"CC(C)[C@H](N)C(=O)O";"KZSNJWFQEVHDMF-BYPYZUCNSA-N";117.15;0.05;"6287";"CHEMBL43068";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0012302687708123812
"Mefenamic Acid";"MM00667";"Cc1cccc(Nc2ccccc2C(=O)O)c1C";"HYYBABOKPJLUIN-UHFFFAOYSA-N";241.29;3.75;"4044";"CHEMBL686";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";165.95869074375614
"(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid";"MM00766";"NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O";"SGDBTWWWUNNDEQ-UHFFFAOYSA-N";305.21;1.93;"460612";"CHEMBL852";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.24;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005754399373371566
"10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine";"MM00513";"CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21";"SLVMESMUVMCQIY-UHFFFAOYSA-N";386.59;4.9;"4078";"CHEMBL1088";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.19;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.6456542290346555
"Metipranolol";"MM00516";"CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C";"BQIPXWYNLPYNHW-UHFFFAOYSA-N";309.41;2.27;"31477";"CHEMBL1291";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.3;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.5011872336272722
"Metolazone";"MM00390";"Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C";"AQCHWTWZEMGIFD-UHFFFAOYSA-N";365.84;2.71;"4170";"CHEMBL878";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00025118864315095795
"Metronidazole";"MM00391";"Cc1ncc([N+](=O)[O-])n1CCO";"VAOCPAMSLUNLGC-UHFFFAOYSA-N";171.16;0.09;"4173";"CHEMBL137";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.74;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00018197008586099826
"1-(2,6-dimethylphenoxy)propan-2-amine";"MM00518";"Cc1cccc(C)c1OCC(C)N";"VLPIATFUUWWMKC-UHFFFAOYSA-N";179.26;2.03;"4178";"CHEMBL558";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.15;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";14.12537544622754
"1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole";"MM00088";"Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1";"BYBLEWFAAKGYCD-UHFFFAOYSA-N";416.14;6.45;"4189";"CHEMBL91";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.45;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.8183829312644537
"Mifepristone";"MM00392";"CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(c3ccc(N(C)C)cc3)CC21C";"VKHAHZOOUSRJNA-UHFFFAOYSA-N";429.6;5.41;"55245";"CHEMBL1276308";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.5;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";31.622776601683793
"5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene";"MM00520";"CN1CCN2c3ncccc3Cc3ccccc3C2C1";"RONZAEMNMFQXRA-UHFFFAOYSA-N";265.36;2.48;"4205";"CHEMBL654";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.62;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";41.68693834703355
"Montelukast";"MM00669";"CC(C)(O)c1ccccc1CCC(SCC1(CC(=O)O)CC1)c1cccc(C=Cc2ccc3ccc(Cl)cc3n2)c1";"UCHDWCPVSPXUMX-UHFFFAOYSA-N";586.2;8.95;"5281040";"CHEMBL787";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.63;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";4265.795188015925
"Moxifloxacin";"MM00767";"COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12";"FABPRXSRWADJSP-MEDUHNTESA-N";401.44;2.37;"152946";"CHEMBL32";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.52;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000030199517204020192
"Nalidixic Acid";"MM00671";"CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21";"MHWLWQUZZRMNGJ-UHFFFAOYSA-N";232.24;1.42;"4421";"CHEMBL5";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.75;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0017782794100389228
"Butyramide";"MM00059";"CCCC(N)=O";"DNSISZSEWVHGLH-UHFFFAOYSA-N";87.12;0.27;"10927";"CHEMBL1231396";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.17;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.006760829753919818
"Nicardipine";"MM00278";"COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1";"ZBBHBTPTTSWHBA-UHFFFAOYSA-N";479.53;3.68;"4474";"CHEMBL1484";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.42;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.038018939632056124
"Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate";"MM00397";"COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]";"HYIMSNHJOBLJNT-UHFFFAOYSA-N";346.34;2.18;"4485";"CHEMBL193";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.2;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00630957344480193
"Nitrendipine";"MM00398";"CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1";"PVHUJELLJLJGLN-UHFFFAOYSA-N";360.37;2.57;"4507";"CHEMBL475534";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.18;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.06606934480075961
"Nortriptyline";"MM00280";"CNCCC=C1c2ccccc2CCc2ccccc21";"PHVGLTMQBUFIQQ-UHFFFAOYSA-N";263.38;3.83;"4543";"CHEMBL445";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";4897.7881936844615
"Noscapine";"MM00530";"COc1ccc2c(c1OC)C(=O)OC2C1c2c(cc3c(c2OC)OCO3)CCN1C";"AKNNEGZIBPJZJG-UHFFFAOYSA-N";413.43;2.88;"275196";"CHEMBL364713";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.32;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000478630092322638
"Olanzapine";"MM00089";"Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1";"KVWDHTXUZHCGIO-UHFFFAOYSA-N";312.44;3.44;"4585";"CHEMBL715";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.35;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.2387211385683394
"Ondansetron";"MM00531";"Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O";"FELGMEQIXOGIFQ-UHFFFAOYSA-N";293.37;3.13;"4595";"CHEMBL46";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.03;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.933254300796991
"N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine";"MM00532";"Cc1ccccc1C(OCCN(C)C)c1ccccc1";"QVYRGXJJSLMXQH-UHFFFAOYSA-N";269.39;3.66;"4601";"CHEMBL900";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.84;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";691.8309709189363
"Oxprenolol";"MM00289";"C=CCOc1ccccc1OCC(O)CNC(C)C";"CEMAWMOMDPGJMB-UHFFFAOYSA-N";265.35;1.99;"4631";"CHEMBL546";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.44;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.36307805477010135
"Palmitic Acid";"MM00678";"CCCCCCCCCCCCCCCC(=O)O";"IPCSVZSSVZVIGE-UHFFFAOYSA-N";256.43;5.55;"985";"CHEMBL82293";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.57;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";3715.352290971724
"1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline";"MM00534";"COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC";"XQYZDYMELSJDRZ-UHFFFAOYSA-N";339.39;3.86;"4680";"CHEMBL19224";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.013803842646028845
"Pefloxacin";"MM00770";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21";"FHFYDNQZQSQIAI-UHFFFAOYSA-N";333.36;1.61;"51081";"CHEMBL267648";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.5;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000031622776601683795
"(2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol";"MM00535";"CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1";"KQXKVJAGOJTNJS-HNNXBMFYSA-N";291.44;3.47;"37464";"CHEMBL1290";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";138.03842646028852
"Pentazocine";"MM00536";"CC(C)=CCN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C";"VOKSWYLNZZRQPF-GDIGMMSISA-N";285.43;3.88;"441278";"CHEMBL560";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";229.08676527677724
"Pergolide";"MM00538";"CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21";"YEHCICAEULNIGD-MZMPZRCHSA-N";314.5;4.27;"47811";"CHEMBL531";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.5;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";316.22776601683796
"2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol";"MM00539";"OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1";"RGCVKNLCSQQDEP-UHFFFAOYSA-N";403.98;3.94;"4748";"CHEMBL567";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.59;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.025703957827688632
"2-phenylethylhydrazine";"MM00404";"NNCCc1ccccc1";"RMUCZJUITONUFY-UHFFFAOYSA-N";136.2;0.69;"3675";"CHEMBL1089";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";724.4359600749899
"4-butyl-1,2-diphenylpyrazolidine-3,5-dione";"MM00680";"CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O";"VYMDGNCVAMGZFE-UHFFFAOYSA-N";308.38;3.79;"4781";"CHEMBL101";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.53;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";338.84415613920237
"Phloretin";"MM00681";"O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O";"VGEREEWJJVICBM-UHFFFAOYSA-N";274.27;2.32;"4788";"CHEMBL45068";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.9;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000012589254117941661
"(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one";"MM00541";"CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C";"QCHFTSOMWOSFHM-WPRPVWTQSA-N";208.26;1.16;"5910";"CHEMBL550";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.53;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.029512092266663854
"(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine";"MM00545";"CCCNC1CCc2nc(N)sc2C1";"FASDKYOPVNHBLU-UHFFFAOYSA-N";211.33;1.58;"119570";"CHEMBL301265";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.028840315031266057
"Prednisone";"MM00408";"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO";"XOFYZVNMUHMLCC-ZPOLXVRWSA-N";358.43;1.77;"5865";"CHEMBL635";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000020417379446695273
"4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine";"MM00548";"COc1cc(NC(C)CCCN)c2ncccc2c1";"INDBQLZJXZLFIT-UHFFFAOYSA-N";259.35;2.78;"4908";"CHEMBL506";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.9;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.012589254117941675
"4-(dipropylsulfamoyl)benzoic acid";"MM00684";"CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1";"DBABZHXKTCFAPX-UHFFFAOYSA-N";285.37;2.2;"4911";"CHEMBL897";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.09;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008128305161640995
"2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol";"MM00410";"CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1";"FYPMFJGVHOHGLL-UHFFFAOYSA-N";516.86;9.91;"4912";"CHEMBL608";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;5.56;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";363078.05477010104
"2-(diethylamino)ethyl 4-aminobenzoate";"MM00204";"CCN(CC)CCOC(=O)c1ccc(N)cc1";"MFDFERRIHVXMIY-UHFFFAOYSA-N";236.32;1.77;"4914";"CHEMBL569";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.75;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.1778279410038923
"4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide";"MM00411";"CNNCc1ccc(C(=O)NC(C)C)cc1";"CPTBDICYNRMXFX-UHFFFAOYSA-N";221.3;1.05;"4915";"CHEMBL1321";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.77;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.16982436524617442
"1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol";"MM00549";"OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1";"WYDUSKDSKCASEF-UHFFFAOYSA-N";287.45;3.94;"4919";"CHEMBL86715";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.88;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";758.5775750291835
"Progesterone";"MM00198";"CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C";"RJKFOVLPORLFTN-UHFFFAOYSA-N";314.47;4.72;"5994";"CHEMBL103";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.83;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";67.60829753919819
"Promethazine";"MM00550";"CC(CN1c2ccccc2Sc2ccccc21)N(C)C";"PWWVAXIEGOYWEE-UHFFFAOYSA-N";284.43;4.24;"4927";"CHEMBL643";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";134.89628825916532
"1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one";"MM00551";"CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1";"JWHAUXFOSRPERK-UHFFFAOYSA-N";341.45;3.24;"4932";"CHEMBL631";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.02;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.954992586021436
"1-Propanol";"MM00061";"CCCO";"BDERNNFJNOPAEC-UHFFFAOYSA-N";60.1;0.39;"1031";"CHEMBL14687";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.84;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.14454397707459277
"1-Propylamine";"MM00436";"CCCN";"WGYKZJWCGVVSQN-UHFFFAOYSA-N";59.11;0.36;"7852";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.58;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.2630267991895382
"Protriptyline";"MM00553";"CNCCCC1c2ccccc2C=Cc2ccccc21";"BWPIARFWQZKAIA-UHFFFAOYSA-N";263.38;4.3;"4976";"CHEMBL668";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.68;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";4786.300923226385
"Pyridoxine";"MM00555";"Cc1ncc(CO)c(CO)c1O";"LXNHXLLTXMVWPM-UHFFFAOYSA-N";169.18;0.08;"1054";"CHEMBL1364";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000001380384264602884
"5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine";"MM00556";"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1";"WKSAUQYGYAYLPV-UHFFFAOYSA-N";248.72;2.52;"4993";"CHEMBL36";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.38;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0004168693834703355
"2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol";"MM00557";"OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1";"URKOMYMAXPYINW-UHFFFAOYSA-N";383.52;2.86;"5002";"CHEMBL716";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.92;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.012022644346174132
"Quinolinic Acid";"MM00686";"O=C(O)c1cccnc1C(=O)O";"GJAWHXHKYYXBSV-UHFFFAOYSA-N";167.12;0.48;"1066";"CHEMBL286204";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.71;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000019498445997580454
"Resveratrol";"MM00418";"Oc1ccc(C=Cc2cc(O)cc(O)c2)cc1";"LUKBXSAWLPMMSZ-UHFFFAOYSA-N";228.25;2.97;"445154";"CHEMBL1237022";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.86;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0013803842646028853
"1-(1-adamantyl)ethanamine";"MM00560";"CC(N)C12CC3CC(CC(C3)C1)C2";"UBCHPRBFMUDMNC-UHFFFAOYSA-N";179.31;2.55;"5071";"CHEMBL959";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.17;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";147.91083881682073
"Risperidone";"MM00561";"Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2";"RAPZEAPATHNIPO-UHFFFAOYSA-N";410.49;3.59;"5073";"CHEMBL85";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.84;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";6.918309709189364
"Rosmarinic Acid";"MM00687";"O=C(/C=C/c1ccc(O)c(O)c1)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O";"DOUMFZQKYFQNTF-WUTVXBCWSA-N";360.32;1.76;"5281792";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.81;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000015488166189124828
"Sebacic Acid";"MM00689";"O=C(O)CCCCCCCCC(=O)O";"CXMXRPHRNRROMY-UHFFFAOYSA-N";202.25;2.28;"5192";"CHEMBL1232164";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.46;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0034673685045253167
"L-Serine";"MM00757";"N[C@@H](CO)C(=O)O";"MTCFGRXMJLQNBG-REOHCLBHSA-N";105.09;-1.61;"5951";"CHEMBL11298";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.29;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000005128613839913648
"Sertraline";"MM00566";"CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21";"VGKDLMBJGBXTGI-SJCJKPOMSA-N";306.24;5.18;"68617";"CHEMBL809";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.76;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";575.4399373371566
"Sufentanil";"MM00304";"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1";"GGCSSNBKKAUURC-UHFFFAOYSA-N";386.56;4.21;"41693";"CHEMBL658";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.07;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";117.48975549395291
"Tacrine";"MM00305";"Nc1c2c(nc3ccccc13)CCCC2";"YLJREFDVOIBQDA-UHFFFAOYSA-N";198.27;2.7;"1935";"CHEMBL95";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.72;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.248074602497725
"2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine";"MM00570";"CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1";"NKANXQFJJICGDU-UHFFFAOYSA-N";371.52;6;"2733526";"CHEMBL83";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;4.47;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";29512.09226666384
"7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one";"MM00422";"CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21";"SEQDDYPDSLOBDC-UHFFFAOYSA-N";300.75;2.47;"5391";"CHEMBL967";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.004073802778041126
"10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine";"MM00572";"CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2";"KLBQZWRITKRQQV-UHFFFAOYSA-N";370.59;5.89;"5452";"CHEMBL479";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";251.18864315095797
"(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide";"MM00693";"CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1";"GFBKORZTTCHDGY-UWVJOHFNSA-N";443.64;3.47;"941651";"CHEMBL1201";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.75;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0017782794100389228
"L-deoxythymidine";"MM00427";"Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O";"IQFYYKKMVGJFEH-XLPZGREQSA-N";242.23;-1.51;"5789";"CHEMBL374731";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.73;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000018620871366628656
"(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid";"MM00773";"Cc1ccsc1C(=CCCN1CCCC(C(=O)O)C1)c1sccc1C";"PBJUNZJWGZTSKL-UHFFFAOYSA-N";375.56;5.04;"60648";"CHEMBL1027";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.71;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.1286138399136485
"1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea";"MM00709";"Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1";"NGBFQHCMQULJNZ-UHFFFAOYSA-N";348.43;2.53;"41781";"CHEMBL1148";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.26;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000054954087385762485
"2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one";"MM00576";"O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12";"PHLBKPHSAVXXEF-UHFFFAOYSA-N";371.87;2.36;"5533";"CHEMBL621";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.97;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.10715193052376065
"Triamcinolone";"MM00307";"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO";"GFNANZIMVAIWHM-OBYCQNJPSA-N";394.44;0.62;"31307";"CHEMBL1451";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.94;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000011481536214968817
"6-phenylpteridine-2,4,7-triamine";"MM00577";"Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1";"FNYLWPVRPXGIIP-UHFFFAOYSA-N";253.27;0.83;"5546";"CHEMBL585";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.51;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000003090295432513592
"10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine";"MM00578";"CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1";"ZEWQUBUPAILYHI-UHFFFAOYSA-N";407.51;4.95;"5566";"CHEMBL422";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.6595869074375607
"N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine";"MM00579";"CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21";"XSCGXQMFQXDFCW-UHFFFAOYSA-N";352.43;5.26;"5568";"CHEMBL570";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.01;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";10.232929922807541
"1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol";"MM00580";"OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1";"HWHLPVGTWGOCJO-UHFFFAOYSA-N";301.47;4.33;"5572";"CHEMBL1490";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1659.5869074375614
"Trimipramine";"MM00254";"CC(CN(C)C)CN1c2ccccc2CCc2ccccc21";"ZSCDBOWYZJWBIY-UHFFFAOYSA-N";294.44;4.12;"5584";"CHEMBL644";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;3.18;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1513.5612484362086
"2,5,9-trimethylfuro[3,2-g]chromen-7-one";"MM00429";"Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1";"FMHHVULEAZTJMA-UHFFFAOYSA-N";228.25;3.46;"5585";"CHEMBL1475";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";114.81536214968828
"Trovafloxacin";"MM00774";"NC1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12";"WVPSKSLAZQPAKQ-SOSAQKQKSA-N";416.36;1.89;"62959";"CHEMBL428";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.53;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00002951209226666384
"Tryptamine";"MM00582";"NCCc1c[nH]c2ccccc12";"APJYDQYYACXCRM-UHFFFAOYSA-N";160.22;1.67;"1150";"CHEMBL6640";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.95;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.11220184543019636
"4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide";"MM00430";"Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1";"LNPDTQAFDNKSHK-UHFFFAOYSA-N";314.37;2.96;"119607";"CHEMBL865";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.73;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.18620871366628675
"Zaleplon";"MM00434";"CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1";"HUNXMJYCHXQEGX-UHFFFAOYSA-N";305.34;2.64;"5719";"CHEMBL1521";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.007413102413009177
"N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide";"MM00591";"Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1";"ZAFYATHCZYHLPB-UHFFFAOYSA-N";307.4;3.25;"5732";"CHEMBL911";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";4.570881896148751
"1,4-Butanediol";"MM00314";"OCCCCO";"WERYXYBDKMZEQL-UHFFFAOYSA-N";90.12;-0.25;"8064";"CHEMBL171623";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.03;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00009332543007969905
"2,3-Dideoxyadenosine";"MM00318";"Nc1ncnc2c1ncn2[C@H]1CC[C@@H](CO)O1";"WVXRAFOPTSTNLL-NKWVEPMBSA-N";235.25;0.08;"20039";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.26;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000005495408738576248
"9-Anthroic Acid";"MM00612";"O=C(O)c1c2ccccc2cc2ccccc12";"XGWFJBFNAQHLEF-UHFFFAOYSA-N";222.24;3.69;"2201";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.52;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";33.11311214825911
"Acrivastine";"MM00715";"Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1";"PWACSDKDOHSSQD-IUTFFREVSA-N";348.45;4.02;"5284514";"CHEMBL1224";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";3.9810717055349722
"5-Aminolevulinic Acid";"MM00714";"NCC(=O)CCC(=O)O";"ZGXJTSGNIOSYLO-UHFFFAOYSA-N";131.13;-0.62;"137";"CHEMBL601";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.83;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000014791083881682072
"1-Naphthoic Acid";"MM00592";"O=C(O)c1cccc2ccccc12";"LNETULKMXZVUST-UHFFFAOYSA-N";172.18;2.54;"6847";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.37;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.344228815319922
"2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide";"MM00337";"NC(CO)C(=O)NNCc1ccc(O)c(O)c1O";"BNQDCRGUHNALGH-UHFFFAOYSA-N";257.25;-1.76;"2327";"CHEMBL1096979";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000004073802778041122
"2-Naphthoic Acid";"MM00601";"O=C(O)c1ccc2ccccc2c1";"UOBYKYZJUGYBDK-UHFFFAOYSA-N";172.18;2.54;"7123";"114648";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.51188643150958
"Bromoacetic Acid";"MM00633";"O=C(O)CBr";"KDPAWGWELVVRCH-UHFFFAOYSA-N";138.95;0.47;"6227";"CHEMBL60851";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.3;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.05011872336272722
"Cefatrizine";"MM00719";"N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cn[nH]n3)CS[C@H]12)c1ccc(O)cc1";"UOCJDOLVGGIYIQ-PBFPGSCMSA-N";462.51;0.04;"6410758";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.52;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000030199517204020193
"Cephaloglycin";"MM00722";"CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1";"FUBBGQLTSCSAON-PBFPGSCMSA-N";405.43;-0.01;"19150";"CHEMBL1200971";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.23;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000005888436553555884
"Cephaloridine";"MM00638";"O=C(Cc1cccs1)NC1C(=O)N2C(C(=O)O)=C(C[n+]3ccccc3)CSC12";"CZTQZXZIADLWOZ-UHFFFAOYSA-O";416.5;1.02;"5773";"CHEMBL316157";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.41;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000003890451449942805
"Daunorubicin";"MM00473";"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(C)=O)CC3OC1CC(N)C(O)C(C)O1";"STQGQHZAVUOBTE-UHFFFAOYSA-N";527.53;1.03;"30323";"CHEMBL178";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-11.03;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000009332543007969923
"Ethylene glycol";"MM00360";"OCCO";"LYCAIKOWRPUZTN-UHFFFAOYSA-N";62.07;-1.03;"174";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.77;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00001698243652461746
"Iodoacetic Acid";"MM00657";"O=C(O)CI";"JDNTWHVOXJZDSN-UHFFFAOYSA-N";185.95;0.51;"5240";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.2;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00630957344480193
"Isoxicam";"MM00660";"Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1";"YYUAYBYLJSNDCX-UHFFFAOYSA-N";335.34;1.48;"54677972";"CHEMBL53292";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.33;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00004677351412871981
"4-Methylphenylacetic Acid";"MM00611";"Cc1ccc(CC(=O)O)cc1";"GXXXUZIRGXYDFP-UHFFFAOYSA-N";150.18;1.62;"248474";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.28;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.9054607179632472
"Netivudine";"MM00395";"CC#Cc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)[nH]c1=O";"QLOCVMVCRJOTTM-SDNRWEOFSA-N";282.25;-2.48;"55281";"CHEMBL1097615";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-11.69;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000000020417379446695316
"Nitric Acid";"MM00675";"O=[N+]([O-])O";"GRYLNZFGIOXLOG-UHFFFAOYSA-N";63.01;-0.35;"944";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.47;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";29.512092266663856
"2-amino-5-phenyl-1,3-oxazol-4-one";"MM00402";"NC1=NC(=O)C(c2ccccc2)O1";"NRNCYVBFPDDJNE-UHFFFAOYSA-N";176.18;0.6;"4723";"CHEMBL1177";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.45;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000035481338923357534
"Phenol Red";"MM00405";"O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21";"BELBBZDIHDAJOR-UHFFFAOYSA-N";354.38;3.11;"4766";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.38;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00004168693834703355
"Pumafentrine";"MM00554";"CCOc1cc2c(cc1OC)C(c1ccc(C(=O)N(C(C)C)C(C)C)cc1)=N[C@@H]1CCN(C)C[C@H]21";"CVDXFPBVOIERBH-JWQCQUIFSA-N";477.65;4.99;"3052763";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.12;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";13.182567385564074
"Tolafentrine";"MM00574";"COc1cc2c(cc1OC)[C@@H]1CN(C)CC[C@@H]1N=C2c1ccc(NS(=O)(=O)c2ccc(C)cc2)cc1";"FVZJIAUYFDQQKJ-DQEYMECFSA-N";505.64;4.45;"65990";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0028840315031266055
"N-methyl-2-phenyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide";"MM00583";"CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1";"PGZRDDYTKFZSFR-ONTIZHBOSA-N";356.51;3.25;"105104";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;2.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";245.4708915685031
"2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetic acid";"MM00713";"Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1";"ZXVNMYWKKDOREA-UHFFFAOYSA-N";291.73;2.85;"5733";"CHEMBL19490";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.46;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0034673685045253167
"N-Octylmalonic Acid";"MM00670";"CCCCCCCCC(C(=O)O)C(=O)O";"QJGNSTCICFBACB-UHFFFAOYSA-N";216.28;2.52;"12972";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.05;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008912509381337459
"3,5-Dichlorobenzoic Acid";"MM00603";"O=C(O)c1cc(Cl)cc(Cl)c1";"CXKCZFDUOYMOOP-UHFFFAOYSA-N";191.01;2.69;"5811";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.028840315031266057
"3-Phenylpropionic Acid";"MM00605";"O=C(O)CCc1ccccc1";"XMIIGOLPHOKFCH-UHFFFAOYSA-N";150.18;1.7;"107";"CHEMBL851";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.3489628825916535
"4-Phenylbutylamine";"MM00096";"NCCCCc1ccccc1";"AGNFWIZBEATIAK-UHFFFAOYSA-N";149.24;1.97;"83242";"CHEMBL79512";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";24.547089156850298
"Aminoguanidine";"MM00442";"NN=C(N)N";"HAMNKKUPIHEESI-UHFFFAOYSA-N";74.09;-1.87;"2146";"CHEMBL225304";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0006025595860743575
"Beclomethasone";"MM00335";"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"NBMKJKDGKREAPL-DVTGEIKXSA-N";408.92;2.17;"20469";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.42;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000003801893963205613
"Cerivastatin";"MM00639";"COCc1c(C(C)C)nc(C(C)C)c(C=CC(O)CC(O)CC(=O)O)c1-c1ccc(F)cc1";"SEERZIQQUAZTOL-UHFFFAOYSA-N";459.56;4.88;"446156";"CHEMBL1477";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.97;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.010715193052376065
"Chlortetracycline";"MM00725";"CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12";"DHPRQBPJLMKORJ-XRNKAMNCSA-N";478.89;0.28;"54675777";"CHEMBL404520";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.93;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000000011748975549395304
"CP-141938";"MM00471";"COc1ccc(N(C)S(C)(=O)=O)cc1CNC1CCCNC1c1ccccc1";"GZLOIBNBDUHEFY-UHFFFAOYSA-N";403.55;2.67;"10363809";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.91;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.012302687708123818
"1,2-bis(oxiran-2-yl)ethane-1,2-diol";"MM00356";"OC(C1CO1)C(O)C1CO1";"AAFJXZWCNVJTMK-UHFFFAOYSA-N";146.14;-1.49;"31789";"CHEMBL3137322";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000001
"DPDPE";"MM00731";"CC1(C)SSC(C)(C)C(NC(=O)C(N)Cc2ccc(O)cc2)C(=O)NCC(=O)NC(Cc2ccccc2)C(=O)NC1C(=O)O";"MCMMCRYPQBNCPH-UHFFFAOYSA-N";645.8;1.11;"104787";"CHEMBL31421";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-11.89;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000000012882495516931323
"3,3-diphenyl-N-(1-phenylethyl)propan-1-amine";"MM00492";"CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1";"NMKSAYKQLCHXDK-UHFFFAOYSA-N";315.46;5.56;"3336";"CHEMBL254832";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;6;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1000000
"Fleroxacin";"MM00736";"CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1";"XBJBPGROQZJDOJ-UHFFFAOYSA-N";369.34;1.7;"3357";"CHEMBL6273";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.17;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000006760829753919819
"Flufenamic Acid";"MM00645";"O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1";"LPEPZBJOKDYZAD-UHFFFAOYSA-N";281.23;4.15;"3371";"CHEMBL23588";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.64;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.2290867652767773
"5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxychromen-4-one";"MM00372";"COc1c(O)cc2oc(-c3ccc(O)cc3)cc(=O)c2c1O";"IHFBPDAQLQOCBX-UHFFFAOYSA-N";300.27;2.59;"5281628";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.48;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000033113112148259076
"2-iodoacetamide";"MM00376";"NC(=O)CI";"PGLTVOMIXTUURA-UHFFFAOYSA-N";184.96;-0.09;"3727";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.26;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005495408738576248
"Isobutyramide";"MM00378";"CC(C)C(N)=O";"WFKAJVHLWXSISD-UHFFFAOYSA-N";87.12;0.13;"68424";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.07;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.008511380382023767
"Methylurea";"MM00389";"CNC(N)=O";"XGEGHDBEHXKFPX-UHFFFAOYSA-N";74.08;-0.72;"11719";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000002884031503126606
"1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol";"MM00521";"COCC(O)Cn1ccnc1[N+](=O)[O-]";"OBBCSXFCDPPXOL-UHFFFAOYSA-N";201.18;-0.2;"26105";"CHEMBL42161";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.76;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000017378008287493764
"Naltrindole";"MM00527";"Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314";"WIYUZYBFCWCCQJ-IFKAHUTRSA-N";414.51;3.57;"5497186";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.39;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.40738027780411273
"Neotrofin";"MM00674";"O=C(CCn1cnc2c(=O)nc[nH]c21)Nc1ccc(C(=O)[O-])cc1.[K+]";"MICLTPPSCUXHJT-UHFFFAOYSA-M";365.39;-3.48;"23663995";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.21;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000006165950018614809
"Oxolinic Acid";"MM00677";"CCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3";"KYGZCKSPAKDVKC-UHFFFAOYSA-N";261.23;1.45;"4628";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.65;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000022387211385683376
"Amylamine";"MM00537";"CCCCCN";"DPBLXKKOBLCELK-UHFFFAOYSA-N";87.17;1.14;"8060";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.14;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.3803842646028848
"Pramocaine";"MM00546";"CCCCOc1ccc(OCCCN2CCOCC2)cc1";"DQKXQSGTHWVTAD-UHFFFAOYSA-N";293.41;2.97;"4886";"CHEMBL1198";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.48;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";3.019951720402016
"Propanamide";"MM00413";"CCC(N)=O";"QLNJFJADRCOGBJ-UHFFFAOYSA-N";73.1;-0.12;"6578";"CHEMBL1235716";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.51;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.003090295432513592
"Tol-Gly";"MM00698";"Cc1ccc(C(=O)NCC(=O)O)cc1";"NRSCPTLHWVWLLH-UHFFFAOYSA-N";193.2;0.81;"97479";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.13;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0007413102413009177
"1,2,3,4,5-pentachloro-6-nitrobenzene";"MM00416";"O=[N+]([O-])c1c(Cl)c(Cl)c(Cl)c(Cl)c1Cl";"LKPLKUMXSAEKID-UHFFFAOYSA-N";295.34;4.86;"6720";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.36;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.043651583224016584
"1,3-Propanediol";"MM00313";"OCCCO";"YPFDHNVEDLHUCE-UHFFFAOYSA-N";76.1;-0.64;"10442";"CHEMBL379652";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.43;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00003715352290971728
"Water";"MM00431";"O";"XLYOFNOQVPJJNP-UHFFFAOYSA-N";18.02;-0.82;"962";"CHEMBL1098659";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.32;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000047863009232263804
"Ammonia";"MM00445";"N";"QGZKDVFQNNGYKY-UHFFFAOYSA-N";17.03;0.16;"222";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.51;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0003090295432513592
"Pentanamide";"MM00403";"CCCCC(N)=O";"IPWFJLQDVFKJDU-UHFFFAOYSA-N";101.15;0.66;"12298";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.97;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.010715193052376065
"Heptanoic Acid";"MM00653";"CCCCCCC(=O)O";"MNWFXJYAOYHMED-UHFFFAOYSA-N";130.19;2.04;"8094";"CHEMBL320358";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.18;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.660693448007596
"Hydrofluoric Acid";"MM00655";"F";"KRHYYFGTRYWZRS-UHFFFAOYSA-N";20.01;0.15;"14917";"CHEMBL1232767";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";1.6595869074375607
"Malic Acid";"MM00666";"O=C(O)CC(O)C(=O)O";"BJEPYKJPYRNKOW-UHFFFAOYSA-N";134.09;-1.09;"525";"CHEMBL1455497";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-8.24;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000005754399373371567
"Dextromethorphan";"MM00475";"COc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3";"MKXZASYAUGDDCJ-UHFFFAOYSA-N";271.4;3.38;"5360696";"CHEMBL52440";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";34.673685045253166
"Lincomycin";"MM00508";"CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1";"OJMMVQQUTAEWLP-KIDUDLJLSA-N";406.55;-0.86;"3000540";"CHEMBL1447";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-9.23;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000000005888436553555884
"Ranitidine";"MM01053";"CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1";"VMXUWOKSQNHOCA-UHFFFAOYSA-N";314.41;1.46;"5039";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.82;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.01513561248436208
"Saquinavir";"MM00563";"CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(O)C(Cc1ccccc1)NC(=O)C(CC(N)=O)NC(=O)c1ccc2ccccc2n1";"QWAXKHKRTORLEM-UHFFFAOYSA-N";670.86;3.09;"441243";"CHEMBL114";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.68;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00002089296130854041
"Scopolamine";"MM00564";"CN1[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@H]1O[C@@H]21";"STECJAGHUSJQJN-USLFZFAMSA-N";303.36;0.92;"3000322";"CHEMBL569713";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.37;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.04265795188015926
"11-Dehydrocorticosterone";"MM00315";"C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO";"FUFLCEKSBBHCMO-KJQYFISQSA-N";344.45;2.87;"5311364";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.53;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0002951209226666387
"Aldosterone";"MM00327";"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12";"PQSUYGKTWSAVDQ-ZVIOFETBSA-N";360.45;1.85;"5839";"CHEMBL273453";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.7;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000019952623149688787
"D-Fructose";"MM00351";"OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O";"LKDRXBCSQODPBY-VRPWFDPXSA-N";180.16;-3.22;"2723872";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-10.46;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000034673685045253096
"Ketoconazole";"MM00506";"CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1";"XMAYWYJOQHXEEK-UHFFFAOYSA-N";531.44;4.21;"456201";"CHEMBL157101";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.46;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0034673685045253167
"Naringenin";"MM00673";"O=C1CC(c2ccc(O)cc2)Oc2cc(O)cc(O)c21";"FTVWIRXFELQLPI-UHFFFAOYSA-N";272.26;2.51;"932";"CHEMBL9352";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.92;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000012022644346174132
"Silibinin";"MM00420";"COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O";"SEBFKMXJBCUCAI-HKTJVKLFSA-N";482.44;2.36;"31553";"CHEMBL431701";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-11.12;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000007585775750291852
"Cefsulodin";"MM00720";"NC(=O)c1cc[n+](CC2=C(C(=O)O)N3C(=O)C(NC(=O)C(c4ccccc4)S(=O)(=O)O)C3SC2)cc1";"SYLKGLMBLAAGSC-UHFFFAOYSA-O";533.56;-0.56;"656575";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-13.43;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000000000037153522909717275
"CNV97100";"MM00727";"CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CCN1.O=C(O)C(F)(F)F";"URJUNYOPXJPQGS-UHFFFAOYSA-N";459.4;2.61;"46781144";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000028840315031266056
"Gly-Pro";"MM00739";"NCC(=O)N1CCCC1C(=O)O";"KZNQNBZMBZJQJO-UHFFFAOYSA-N";172.18;-0.98;"79101";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000021379620895022324
"Me-ciprofloxacin";"MM01307";"CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1";"TXJIOKSSHCOKKH-UHFFFAOYSA-N";345.37;1.93;"465907";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.22;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000060255958607435806
"Tol-Gly-Gly-Sar";"MM00701";"Cc1ccc(C(=O)NCC(=O)NCC(=O)N(C)CC(=O)O)cc1";"GPOXNQMQXBXEJG-UHFFFAOYSA-N";321.33;-0.62;;;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.54;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000028840315031266057
"Tol-Ala-Ala-Ala";"MM00697";"Cc1ccc(C(=O)N[C@@H](C)C(=O)NC(C)C(=O)NC(C)C(=O)O)cc1";"AWXUDMFMJWEFLI-CXQJBGSLSA-N";349.39;0.21;;;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-5.53;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000002951209226666384
"Tol-Ala-Ala";"MM00696";"Cc1ccc(C(=O)N[C@@H](C)C(=O)NC(C)C(=O)O)cc1";"FBAZKLTYPHRTPD-RGURZIINSA-N";278.31;0.7;;;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.72;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00019054607179632462
"Tol-Ala";"MM00695";"Cc1ccc(C(=O)N[C@@H](C)C(=O)O)cc1";"LUQFCOKRPYVJGV-QMMMGPOBSA-N";207.23;1.2;"702949";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.01;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.009772372209558112
"Tol-Gly-Gly-Gly";"MM00700";"Cc1ccc(C(=O)NCC(=O)NCC(=O)NCC(=O)O)cc1";"OQIOHQJDADAQRO-UHFFFAOYSA-N";307.31;-0.96;;;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-7.94;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000011481536214968817
"Tol-Gly-Gly";"MM00699";"Cc1ccc(C(=O)NCC(=O)NCC(=O)O)cc1";"GFMIXHRADKOCKD-UHFFFAOYSA-N";250.25;-0.07;"1612474";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.67;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000021379620895022323
"Tol-Gly-Sar-Gly";"MM00703";"Cc1ccc(C(=O)NCC(=O)N(C)CC(=O)NCC(=O)O)cc1";"VDLFQRLCHVTMPD-UHFFFAOYSA-N";321.33;-0.62;;;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.32;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000000478630092322638
"Tol-Gly-Sar";"MM00702";"Cc1ccc(C(=O)NCC(=O)N(C)CC(=O)O)cc1";"LKGQGAPFEYAOCE-UHFFFAOYSA-N";264.28;0.27;"43356167";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.89;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000012882495516931348
"Tol-Sar-Gly-Gly";"MM00706";"Cc1ccc(C(=O)N(C)CC(=O)NCC(=O)NCC(=O)O)cc1";"GQINUZIFINBVAM-UHFFFAOYSA-N";321.33;-0.62;;;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.72;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.00000019054607179632483
"Tol-Sar-Gly";"MM00705";"Cc1ccc(C(=O)N(C)CC(=O)NCC(=O)O)cc1";"JDZZMSKJRWYDMH-UHFFFAOYSA-N";264.28;0.27;;;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-4.7;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.000019952623149688786
"Tol-Sar-Sar-Gly";"MM00707";"Cc1ccc(C(=O)N(C)CC(=O)N(C)CC(=O)NCC(=O)O)cc1";"GQJNIDFZAHXWIX-UHFFFAOYSA-N";335.36;-0.27;;;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-6.66;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0000002187761623949552
"Tol-Sar";"MM00704";"Cc1ccc(C(=O)N(C)CC(=O)O)cc1";"WKEPQHRTXMIHLM-UHFFFAOYSA-N";207.23;1.15;"16777360";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.09;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0008128305161640995
"1,6-Hexanediol";"MM00009";"C[C@@H](O)CC[C@@H](C)O";"OHMBHFSEKCCCBW-PHDIDXHHSA-N";118.18;0.53;"43078";"CHEMBL458616";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-1.88;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.013182567385564075
"CNV97103";"MM00729";"CCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C";"WPGHZQMHNTXSAF-UHFFFAOYSA-N";387.46;3.09;"13326823";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-3.23;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.0005888436553555889
"Loratadine";"MM00385";"CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1";"JCCNYMKQOSZNPW-UHFFFAOYSA-N";382.89;4.89;"3957";"CHEMBL998";"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.4;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";2.51188643150958
"4-iodo-1,5-dimethyl-2-phenylpyrazol-3-one";"MM00377";"Cc1c(I)c(=O)n(-c2ccccc2)n1C";"ZZOBLCHCPLOXCE-UHFFFAOYSA-N";314.13;2.09;"8522";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.72;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";5.248074602497725
"Ralimetinib Dimesylate";"MM00417";"CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21.CS(=O)(=O)O.CS(=O)(=O)O";"NARMJPIBAXVUIE-UHFFFAOYSA-N";612.75;4.56;"11570805";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";3.0902954325135905
"11beta-Hydroxyprogesterone";"MM00317";"CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C";"BFZHCUBIASXHPK-ATWVFEABSA-N";330.47;3.69;"101788";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-0.06;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.8709635899560807
"2,4-Dibromoestradiol";"MM00319";"CC12CCC3c4cc(Br)c(O)c(Br)c4CCC3C1CCC2O";"UTXNYGUZJLLOSP-UHFFFAOYSA-N";430.18;5.13;"266051";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.63;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";4.265795188015927
"Hydrochloric Acid";"MM00654";"Cl";"VEXZGXHMUGYJMC-UHFFFAOYSA-N";36.46;0.42;"313";;"LEC";"CPMM";"25";"0";"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;0.94;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";8.709635899560805
"1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol";"MM00571";"CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1";"GUGOEEXESWIERI-UHFFFAOYSA-N";471.69;6.45;"5405";"CHEMBL17157";"LEC";"CPMM";"25";;"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;1.55;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";35.48133892335755
"2-(diethylamino)ethyl 4-aminobenzoate";"MM00204";"CCN(CC)CCOC(=O)c1ccc(N)cc1";"MFDFERRIHVXMIY-UHFFFAOYSA-N";236.32;1.77;"4914";"CHEMBL569";"LEC";"CPMM";"25";;"<ahref=https://permm.phar.umich.edu/target=_blank>PerMMwebserver</a>";;-2.49;"Lomize AL, Pogozheva ID.: Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. J Chem Inf Model, Volume 59 (7), 2019";"PerMM";0.003235936569296281
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"CACO";"EPAM";"25";"0";;;-6.1;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"PAMPA";0.0000007943282347242822
"9-(1,3-dihydroxy-propoxymethane)guanine";"MM00367";"Nc1nc(O)c2ncn(COC(CO)CO)c2n1";"IRSCQMHQWWYFCW-UHFFFAOYSA-N";255.23;-1.56;"3454";"CHEMBL182";"CACO";"EPAM";"25";"0";;;-6.15;"Tam KY, Avdeef A, Tsinman O, Sun N.: The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem, Volume 53 (1), 392-401, 2010";"PAMPA";0.0000007079457843841374
"2,4-Dichlorophenoxyacetic Acid";"MM01383";"O=C(O)COc1ccc(Cl)cc1Cl";"OVSKIKFHRZPJSS-UHFFFAOYSA-N";221.04;2.46;"1486";;"DOPC";"EPAMOL";"25";"0";;;-4.38;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00004168693834703355
"2-Naphthoic Acid";"MM00601";"O=C(O)c1ccc2ccccc2c1";"UOBYKYZJUGYBDK-UHFFFAOYSA-N";172.18;2.54;"7123";"114648";"DOPC";"EPAMOL";"25";"0";;;-3.4;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00039810717055349735
"3,5-Dimethoxyphenol";"MM01385";"COc1cc(O)cc(OC)c1";"XQDNFAMOIPNVES-UHFFFAOYSA-N";154.17;1.41;"10383";;"DOPC";"EPAMOL";"25";"0";;;-4.12;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00007585775750291836
"4-Hydroxybenzoic Acid";"MM00609";"O=C(O)c1ccc(O)cc1";"FJKROLUGYXJWQN-UHFFFAOYSA-N";138.12;1.09;"135";"CHEMBL441343";"DOPC";"EPAMOL";"25";"0";;;-5.73;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0000018620871366628656
"4-Nitrophenol";"MM00819";"O=[N+]([O-])c1ccc(O)cc1";"BTJIUGUIPKRLHP-UHFFFAOYSA-N";139.11;1.3;"980";"CHEMBL14130";"DOPC";"EPAMOL";"25";"0";;;-5.25;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.000005623413251903491
"4-Phenylbutylamine";"MM00096";"NCCCCc1ccccc1";"AGNFWIZBEATIAK-UHFFFAOYSA-N";149.24;1.97;"83242";"CHEMBL79512";"DOPC";"EPAMOL";"25";"0";;;-2.13;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.007413102413009177
"4-Propoxybenzoic Acid";"MM01386";"CCCOc1ccc(C(=O)O)cc1";"GDFUWFOCYZZGQU-UHFFFAOYSA-N";180.2;2.17;"138500";;"DOPC";"EPAMOL";"25";"0";;;-3.55;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0002818382931264455
"Aniline";"MM00039";"Nc1ccccc1";"PAYRUJLWNCNPSJ-UHFFFAOYSA-N";93.13;1.27;"6115";"CHEMBL538";"DOPC";"EPAMOL";"25";"0";;;-3.36;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0004365158322401661
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"DOPC";"EPAMOL";"25";"0";;;-5.56;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.000002754228703338169
"1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol";"MM01387";"CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12";"BQXQGZPYHWWCEB-UHFFFAOYSA-N";298.39;3.06;"71739";;"DOPC";"EPAMOL";"25";"0";;;-3.98;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00010471285480508996
"Methyl N-(1H-benzimidazol-2-yl)carbamate";"MM01388";"COC(=O)Nc1nc2ccccc2[nH]1";"TWFZGCMQGLPBSX-UHFFFAOYSA-N";191.19;1.74;"25429";;"DOPC";"EPAMOL";"25";"0";;;-4.84;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00001445439770745928
"Chlorpromazine";"MM00461";"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21";"ZPEIMTDSQAKGNT-UHFFFAOYSA-N";318.87;4.89;"2726";"CHEMBL71";"DOPC";"EPAMOL";"25";"0";;;0.94;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";8.709635899560805
"Chlorthalidone";"MM00343";"NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl";"JIVPVXMEBJLZRO-UHFFFAOYSA-N";338.77;0.92;"2732";"CHEMBL1055";"DOPC";"EPAMOL";"25";"0";;;-5.97;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.000001071519305237607
"Desipramine";"MM00474";"CNCCCN1c2ccccc2CCc2ccccc21";"HCYAFALTSJYZDH-UHFFFAOYSA-N";266.39;3.53;"2995";"CHEMBL72";"DOPC";"EPAMOL";"25";"0";;;-0.83;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.14791083881682077
"Diclofenac";"MM00090";"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl";"DCOPUUMXTXDBNB-UHFFFAOYSA-N";296.15;4.36;"3033";"CHEMBL139";"DOPC";"EPAMOL";"25";"0";;;-2.58;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0026302679918953813
"Diltiazem";"MM00477";"COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1";"HSUGRBWQSSZJOP-UHFFFAOYSA-N";414.53;3.37;"39186";"CHEMBL23";"DOPC";"EPAMOL";"25";"0";;;-2.67;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0021379620895022326
"Diphenhydramine";"MM00478";"CN(C)CCOC(c1ccccc1)c1ccccc1";"ZZVUWRFHKOJYTH-UHFFFAOYSA-N";255.36;3.35;"3100";"CHEMBL657";"DOPC";"EPAMOL";"25";"0";;;-0.95;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.11220184543019636
"Physostigmine";"MM00295";"CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C";"PIJVFDBKTWXHHD-HIFRSBDPSA-N";275.35;1.77;"5983";"CHEMBL94";"DOPC";"EPAMOL";"25";"0";;;-4.62;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0000239883291901949
"5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol";"MM01389";"CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1";"LSLYOANBFKQKPT-UHFFFAOYSA-N";303.36;2.06;"3343";;"DOPC";"EPAMOL";"25";"0";;;-6.24;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0000005754399373371567
"Flumequine";"MM00646";"CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23";"DPSPPJIUMHPXMA-UHFFFAOYSA-N";261.25;2.35;"3374";"CHEMBL370252";"DOPC";"EPAMOL";"25";"0";;;-5.18;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.000006606934480075964
"Fluoxetine";"MM00082";"CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1";"RTHCYVBBDHJXIQ-UHFFFAOYSA-N";309.33;4.44;"3386";"CHEMBL41";"DOPC";"EPAMOL";"25";"0";;;0.07;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";1.1748975549395295
"Flurbiprofen";"MM00647";"CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1";"SYTBZMRGLBWNTM-UHFFFAOYSA-N";244.27;3.68;"3394";"CHEMBL563";"DOPC";"EPAMOL";"25";"0";;;-2.55;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.002818382931264455
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"DOPC";"EPAMOL";"25";"0";;;-4.96;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.000010964781961431852
"Haloperidol";"MM00499";"O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1";"LNEPOXFFQSENCJ-UHFFFAOYSA-N";375.87;4.43;"3559";"CHEMBL54";"DOPC";"EPAMOL";"25";"0";;;-2.15;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00707945784384138
"Ibuprofen";"MM00045";"CC(C)Cc1ccc(C(C)C(=O)O)cc1";"HEFNNWSXXWATRW-UHFFFAOYSA-N";206.29;3.07;"3672";"CHEMBL521";"DOPC";"EPAMOL";"25";"0";;;-2.46;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0034673685045253167
"Indomethacin";"MM00656";"COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1";"CGIGDMFJXJATDK-UHFFFAOYSA-N";357.79;3.93;"3715";"CHEMBL6";"DOPC";"EPAMOL";"25";"0";;;-3.38;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0004168693834703355
"Lidocaine";"MM00092";"CCN(CC)CC(=O)Nc1c(C)cccc1C";"NNJVILVZKWQKPM-UHFFFAOYSA-N";234.34;2.58;"3676";"CHEMBL79";"DOPC";"EPAMOL";"25";"0";;;-2.51;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.003090295432513592
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"DOPC";"EPAMOL";"25";"0";;;-4.16;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00006918309709189363
"(NE)-N-[(5-nitrofuran-2-yl)methylidene]hydroxylamine";"MM01390";"O=[N+]([O-])c1ccc(/C=N/O)o1";"PTBKFATYSVLSSD-ZZXKWVIFSA-N";156.1;1;"6478035";;"DOPC";"EPAMOL";"25";"0";;;-5.08;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00000831763771102671
"1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline";"MM00534";"COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC";"XQYZDYMELSJDRZ-UHFFFAOYSA-N";339.39;3.86;"4680";"CHEMBL19224";"DOPC";"EPAMOL";"25";"0";;;-3.06;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0008709635899560805
"(2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol";"MM00535";"CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1";"KQXKVJAGOJTNJS-HNNXBMFYSA-N";291.44;3.47;"37464";"CHEMBL1290";"DOPC";"EPAMOL";"25";"0";;;0.3;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";1.9952623149688795
"P-F-Deprenyl";"MM01391";"C#CCN(C)C(C)Cc1ccc(F)cc1";"MUDUXRHPVDVWHU-UHFFFAOYSA-N";205.28;2.32;"128418";;"DOPC";"EPAMOL";"25";"0";;;-0.73;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.18620871366628675
"Phenazopyridine";"MM00540";"Nc1ccc(N=Nc2ccccc2)c(N)n1";"QPFYXYFORQJZEC-UHFFFAOYSA-N";213.24;2.66;"4756";"CHEMBL1242";"DOPC";"EPAMOL";"25";"0";;;-2.8;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.001584893192461114
"Phenylacetic Acid";"MM00679";"O=C(O)Cc1ccccc1";"WLJVXDMOQOGPHL-UHFFFAOYSA-N";136.15;1.31;"999";"CHEMBL1044";"DOPC";"EPAMOL";"25";"0";;;-4.99;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.000010232929922807536
"2-(diethylamino)ethyl 4-aminobenzoate";"MM00204";"CCN(CC)CCOC(=O)c1ccc(N)cc1";"MFDFERRIHVXMIY-UHFFFAOYSA-N";236.32;1.77;"4914";"CHEMBL569";"DOPC";"EPAMOL";"25";"0";;;-3.99;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00010232929922807536
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"DOPC";"EPAMOL";"25";"0";;;-2.13;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.007413102413009177
"Quinine";"MM00559";"C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-WZBLMQSHSA-N";324.42;3.17;"3034034";"CHEMBL170";"DOPC";"EPAMOL";"25";"0";;;-4.14;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00007244359600749906
"Sulfacetamide";"MM01392";"CC(=O)NS(=O)(=O)c1ccc(N)cc1";"SKIVFJLNDNKQPD-UHFFFAOYSA-N";214.25;0.09;"5320";;"DOPC";"EPAMOL";"25";"0";;;-6.68;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00000020892961308540409
"Tetracaine";"MM00205";"CCCCNc1ccc(C(=O)OCCN(C)C)cc1";"GKCBAIGFKIBETG-UHFFFAOYSA-N";264.37;2.62;"5411";"CHEMBL698";"DOPC";"EPAMOL";"25";"0";;;-1.98;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.010471285480508996
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"DOPC";"EPAMOL";"25";"0";;;-6.77;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.00000016982436524617461
"Tramadol";"MM01393";"COc1cccc(C2(O)CCCCC2CN(C)C)c1";"TVYLLZQTGLZFBW-UHFFFAOYSA-N";263.38;2.63;"33741";;"DOPC";"EPAMOL";"25";"0";;;-1.49;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.03235936569296283
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"DOPC";"EPAMOL";"25";"0";;;-1.54;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.028840315031266057
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"DOPC";"EPAMOL";"25";"0";;;-2.9;"Huque F.T.T., Box K., Platts J.A., Comer J.: Permeability through DOPC/dodecane membranes: measurement and LFER modelling. J.Pharm.Sci, 23(3), 223-232, 2004.";"PAMPA";0.0012589254117941675
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"DOPC";"EPAM";"25";"0";;;-5.91;"Bennion BJ, Be NA, McNerney MW, Lao V, Carlson EM, Valdez CA, Malfatti MA, Enright HA, Nguyen TH, Lightstone FC, Carpenter TS.: Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data. J Phys Chem B, Volume 121 (20), 5228-5237, 2017";"PAMPA";0.0000012302687708123811
"Diazepam";"MM00094";"CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21";"AAOVKJBEBIDNHE-UHFFFAOYSA-N";284.75;3.15;"3016";"CHEMBL12";"DOPC";"EPAM";"25";"0";;;-5.4;"Bennion BJ, Be NA, McNerney MW, Lao V, Carlson EM, Valdez CA, Malfatti MA, Enright HA, Nguyen TH, Lightstone FC, Carpenter TS.: Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data. J Phys Chem B, Volume 121 (20), 5228-5237, 2017";"PAMPA";0.000003981071705534969
"Chlorpromazine";"MM00461";"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21";"ZPEIMTDSQAKGNT-UHFFFAOYSA-N";318.87;4.89;"2726";"CHEMBL71";"DOPC";"EPAM";"25";"0";;;-5.26;"Bennion BJ, Be NA, McNerney MW, Lao V, Carlson EM, Valdez CA, Malfatti MA, Enright HA, Nguyen TH, Lightstone FC, Carpenter TS.: Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data. J Phys Chem B, Volume 121 (20), 5228-5237, 2017";"PAMPA";0.0000054954087385762485
"Progesterone";"MM00198";"CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C";"RJKFOVLPORLFTN-UHFFFAOYSA-N";314.47;4.72;"5994";"CHEMBL103";"DOPC";"EPAM";"25";"0";;;-4.94;"Bennion BJ, Be NA, McNerney MW, Lao V, Carlson EM, Valdez CA, Malfatti MA, Enright HA, Nguyen TH, Lightstone FC, Carpenter TS.: Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data. J Phys Chem B, Volume 121 (20), 5228-5237, 2017";"PAMPA";0.000011481536214968817
"Promazine";"MM00780";"CN(C)CCCN1c2ccccc2Sc2ccccc21";"ZGUGWUXLJSTTMA-UHFFFAOYSA-N";284.43;4.24;"4926";"CHEMBL564";"DOPC";"EPAM";"25";"0";;;-4.88;"Bennion BJ, Be NA, McNerney MW, Lao V, Carlson EM, Valdez CA, Malfatti MA, Enright HA, Nguyen TH, Lightstone FC, Carpenter TS.: Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data. J Phys Chem B, Volume 121 (20), 5228-5237, 2017";"PAMPA";0.000013182567385564074
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"DOPC";"EPAM";"25";"0";;;-9;"Avdeef A.: Absorption and Drug Development: Solubility, Permeability, and Charge State; Chapter 7. Table 7.5. (2003) Wiley & Sons";"PAMPA";0.000000001
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"DOPC";"EPAM";"25";"0";;;-7.4;"Avdeef A.: Absorption and Drug Development: Solubility, Permeability, and Charge State; Chapter 7. Table 7.5. (2003) Wiley & Sons";"PAMPA";0.00000003981071705534969
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"DOPC";"EPAM";"25";"0";;;-8;"Avdeef A.: Absorption and Drug Development: Solubility, Permeability, and Charge State; Chapter 7. Table 7.5. (2003) Wiley & Sons";"PAMPA";0.00000001
"Progesterone";"MM00198";"CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C";"RJKFOVLPORLFTN-UHFFFAOYSA-N";314.47;4.72;"5994";"CHEMBL103";"DOPC";"EPAM";"25";"0";;;-5.2;"Avdeef A.: Absorption and Drug Development: Solubility, Permeability, and Charge State; Chapter 7. Table 7.5. (2003) Wiley & Sons";"PAMPA";0.00000630957344480193
"Griseofulvin";"MM00369";"COC1=CC(=O)CC(C)C12Oc1c(Cl)c(OC)cc(OC)c1C2=O";"DDUHZTYCFQRHIY-UHFFFAOYSA-N";352.77;2.81;"441140";"CHEMBL562";"DOPC";"EPAM";"25";"0";;;-4.89;"Avdeef A.: Absorption and Drug Development: Solubility, Permeability, and Charge State; Chapter 7. Table 7.5. (2003) Wiley & Sons";"PAMPA";0.000012882495516931348
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"DOPC";"EPAM";"25";"0";;;-5.15;"Avdeef A.: Absorption and Drug Development: Solubility, Permeability, and Charge State; Chapter 7. Table 7.5. (2003) Wiley & Sons";"PAMPA";0.000007079457843841373
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"DOPC";"EPAM";"25";"0";;;-6.15;"Avdeef A.: Absorption and Drug Development: Solubility, Permeability, and Charge State; Chapter 7. Table 7.5. (2003) Wiley & Sons";"PAMPA";0.0000007079457843841374
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"DOPC";"EPAM";"25";"0";;;-5.8;"Avdeef A.: Absorption and Drug Development: Solubility, Permeability, and Charge State; Chapter 7. Table 7.5. (2003) Wiley & Sons";"PAMPA";0.000001584893192461114
"MM471306";"MM471306";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2cccc(Cl)c2Cl)c1C#N";"ZLBFKMYPKZOKAL-UHFFFAOYSA-N";420.37;4.81;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.2;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.000000630957344480193
"MM471305";"MM471305";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2ccc(Cl)c(Cl)c2)c1C#N";"LBCXZVKDWDBCBU-UHFFFAOYSA-N";420.37;4.81;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.4;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.0000003981071705534969
"MM471298";"MM471298";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2ccc(Cl)cc2)c1C#N";"JOADUUODAQGQEA-UHFFFAOYSA-N";385.92;4.16;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.2;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.000000630957344480193
"MM471311";"MM471311";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2cccc(Cl)c2)c1C#N";"YJBWGUJSTOUTQX-UHFFFAOYSA-N";385.92;4.16;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.2;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.000000630957344480193
"MM471301";"MM471301";"N#Cc1c(N)nc(SCCN2CCCCC2)c(C#N)c1-c1ccco1";"JHYJLMCNMHZXNS-UHFFFAOYSA-N";353.45;3.25;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.000001
"MM471300";"MM471300";"N#Cc1c(N)nc(SCCCN2CCCCC2)c(C#N)c1-c1ccco1";"YTRFMJHJFDFTQU-UHFFFAOYSA-N";367.48;3.64;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.000001
"MM471307";"MM471307";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2cc(Cl)cc(Cl)c2)c1C#N";"FNSQIGYWZQPUST-UHFFFAOYSA-N";420.37;4.81;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.4;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.0000003981071705534969
"MM471304";"MM471304";"CN(C)CCCSc1nc(N)c(C#N)c(-c2ccco2)c1C#N";"DZWNRCZGFLXEJO-UHFFFAOYSA-N";327.41;2.71;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.5;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.0000003162277660168379
"Methotrexate";"MM00270";"CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc1";"FBOZXECLQNJBKD-UHFFFAOYSA-N";454.45;0.27;"126941";"CHEMBL34259";"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-8;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.00000001
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-7.5;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.00000003162277660168379
"MM471303";"MM471303";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2ccco2)c1C#N";"STZSFDKLTNFVGX-UHFFFAOYSA-N";341.44;3.1;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.000001
"MM471302";"MM471302";"N#Cc1c(N)nc(SCCN2CCCC2)c(C#N)c1-c1ccco1";"PDDVHVDPIATRNV-UHFFFAOYSA-N";339.42;2.86;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.2;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.000000630957344480193
"MM471310";"MM471310";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2ccccc2Cl)c1C#N";"PEYCJJOAHXJXNU-UHFFFAOYSA-N";385.92;4.16;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.000001
"MM471309";"MM471309";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2ccc(Br)cc2)c1C#N";"CHJOKERJEXTLNJ-UHFFFAOYSA-N";430.38;4.27;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.3;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.0000005011872336272725
"MM471308";"MM471308";"CCN(CC)CCSc1nc(N)c(C#N)c(-c2cccc(Br)c2)c1C#N";"BACVYUGZPXWVNF-UHFFFAOYSA-N";430.38;4.27;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.3;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.0000005011872336272725
"Chlorpromazine";"MM00461";"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21";"ZPEIMTDSQAKGNT-UHFFFAOYSA-N";318.87;4.89;"2726";"CHEMBL71";"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.3;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.0000005011872336272725
"MM471299";"MM471299";"CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12";"GPKJTRJOBQGKQK-UHFFFAOYSA-N";399.97;5.97;;;"DOPC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL912867/target=_blank>CHEMBL912867</a>";;-6.6;"May BC, Zorn JA, Witkop J, Sherrill J, Wallace AC, Legname G, Prusiner SB, Cohen FE.: Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem, Volume 50 (1), 2007";"PAMPA";0.00000025118864315095823
"MM472958";"MM472958";"COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2";"IAKHMKGGTNLKSZ-INIZCTEOSA-N";399.44;2.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963000/target=_blank>CHEMBL963000</a>";;-3.38;"Arnold LA, Ranaivo P, Guy RK.: Synthesis and characterization of BODIPY-labeled colchicine. Bioorg Med Chem Lett, Volume 18 (22), 2008";"PAMPA";0.0004168693834703355
"MM473032";"MM473032";"Cc1ncn2c1Cn1ncnc1-c1cc(Cl)ccc1-2";"FVIWEOUHYRAQKY-UHFFFAOYSA-N";271.71;2.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111373/target=_blank>CHEMBL1111373</a>";;-5.05;"Knust H, Achermann G, Ballard T, Buettelmann B, Gasser R, Fischer H, Hernandez MC, Knoflach F, Koblet A, Stadler H, Thomas AW, Trube G, Waldmeier P.: The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.00000891250938133746
"MM473033";"MM473033";"Clc1ccc2c(c1)-c1ncnn1Cc1c(Cl)ncn1-2";"VVBYXJYBLBPAEN-UHFFFAOYSA-N";292.13;2.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111373/target=_blank>CHEMBL1111373</a>";;-5.19;"Knust H, Achermann G, Ballard T, Buettelmann B, Gasser R, Fischer H, Hernandez MC, Knoflach F, Koblet A, Stadler H, Thomas AW, Trube G, Waldmeier P.: The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.000006456542290346549
"MM473051";"MM473051";"CCOc1cc(CN2CCC(Nc3nc4cc(NS(=O)(=O)c5ccccc5)ccc4o3)CC2)ccc1OC";"FPAJMJGGDZGJPZ-UHFFFAOYSA-N";536.65;5.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.66;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000021877616239495517
"MM473045";"MM473045";"CCOc1cc(CN2CCC(Nc3nc4cc(Cl)c(S(N)(=O)=O)cc4o3)CC2)ccc1OC";"GWSJPOPJXLJSLF-UHFFFAOYSA-N";495;3.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.96;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.000001096478196143185
"MM473034";"MM473034";"Cc1ncn2c1Cn1ncnc1-c1cc(Br)ccc1-2";"PVBWXOPKUUTANH-UHFFFAOYSA-N";316.16;2.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111373/target=_blank>CHEMBL1111373</a>";;-5.12;"Knust H, Achermann G, Ballard T, Buettelmann B, Gasser R, Fischer H, Hernandez MC, Knoflach F, Koblet A, Stadler H, Thomas AW, Trube G, Waldmeier P.: The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.000007585775750291836
"MM473048";"MM473048";"CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)cc(OC2CCOCC2)c1";"FDVIZOQPGHRQNB-UHFFFAOYSA-N";451.57;4.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.69;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000020417379446695273
"MM473049";"MM473049";"CCOc1cc(CN2CCC(Nc3nc4cc(NC(=O)C5CCC5)ccc4o3)CC2)ccc1OC";"YTIWDXUZCLTCIF-UHFFFAOYSA-N";478.59;5.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.96;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.000001096478196143185
"MM473035";"MM473035";"Clc1ncn2c1Cn1ncnc1-c1cc(Br)ccc1-2";"LLJUUCOIBTZXIJ-UHFFFAOYSA-N";336.58;2.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111373/target=_blank>CHEMBL1111373</a>";;-5.15;"Knust H, Achermann G, Ballard T, Buettelmann B, Gasser R, Fischer H, Hernandez MC, Knoflach F, Koblet A, Stadler H, Thomas AW, Trube G, Waldmeier P.: The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.000007079457843841373
"MM473050";"MM473050";"CCOc1cc(CN2CCC(Nc3nc4cc(Cl)c(S(N)(=O)=O)cc4o3)CC2)ccc1F";"WCUAFHYQNZBNRN-UHFFFAOYSA-N";482.97;3.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.61;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000024547089156850284
"MM473043";"MM473043";"CCOc1cc(CN2CCC(Nc3nc4cc(S(=O)(=O)CC)ccc4o3)CC2)ccc1OC";"KLQBJPKPQBLAOR-UHFFFAOYSA-N";473.6;4.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.79;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000016218100973589298
"MM473052";"MM473052";"CCOc1cc(CN2CCC(Nc3nc4cc(S(=O)(=O)N(C)C)ccc4o3)CC2)cc(OCC)c1-n1cccc1";"NYMPDEKHLLUZPU-UHFFFAOYSA-N";567.71;4.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.88;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000013182567385564074
"MM473060";"MM473060";"CCOc1cc(CN2CCC(Nc3nc4ccc(C(=O)O)cc4o3)CC2)cc(OCC)c1F";"GPUPSEARQVSUKB-UHFFFAOYSA-N";457.5;4.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.54;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.000002884031503126606
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1176651/target=_blank>CHEMBL1176651</a>";;-4.7;"Mahindroo N, Connelly MC, Punchihewa C, Yang L, Yan B, Fujii N.: Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway. Bioorg Med Chem, Volume 18 (13), 2010";"PAMPA";0.000019952623149688786
"MM473036";"MM473036";"FC(F)c1ncn2c1Cn1ncnc1-c1cc(Cl)ccc1-2";"KBFYDAGNYWSKLZ-UHFFFAOYSA-N";307.69;3.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111373/target=_blank>CHEMBL1111373</a>";;-5.2;"Knust H, Achermann G, Ballard T, Buettelmann B, Gasser R, Fischer H, Hernandez MC, Knoflach F, Koblet A, Stadler H, Thomas AW, Trube G, Waldmeier P.: The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.00000630957344480193
"MM473063";"MM473063";"Cc1ncn2c1Cn1nc(CN3CCCC3=O)nc1-c1cc(Br)ccc1-2";"VYEPAZHUFFXYDH-UHFFFAOYSA-N";413.28;2.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111461/target=_blank>CHEMBL1111461</a>";;-5.82;"Buettelmann B, Ballard TM, Gasser R, Fischer H, Hernandez MC, Knoflach F, Knust H, Stadler H, Thomas AW, Trube G.: Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.0000015135612484362072
"MM473061";"MM473061";"Cc1cc(Cc2nc3n(n2)Cc2c(C)ncn2-c2ccc(Br)cc2-3)on1";"GRHSJPRDKRVXDK-UHFFFAOYSA-N";411.26;3.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111461/target=_blank>CHEMBL1111461</a>";;-5.48;"Buettelmann B, Ballard TM, Gasser R, Fischer H, Hernandez MC, Knoflach F, Knust H, Stadler H, Thomas AW, Trube G.: Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.0000033113112148259077
"MM473057";"MM473057";"CCOc1cc(CN2CCC(Nc3nc4cc(C(N)=O)ccc4o3)CC2)cc(OCC)c1F";"FABHJNZNOHUOSL-UHFFFAOYSA-N";456.52;3.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.79;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000016218100973589298
"MM473058";"MM473058";"CCOc1cc(CN2CCC(Nc3nc4cc(C(=O)O)ccc4o3)CC2)cc(OCC)c1Cl";"DDDLCIAZEXUUFD-UHFFFAOYSA-N";473.96;5.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.68;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000020892961308540407
"MM473059";"MM473059";"CCOc1cc(CN2CCC(Nc3nc4ccc(C(=O)O)cc4o3)CC2)ccc1Cl";"MUGBUVZHEILUBD-UHFFFAOYSA-N";429.9;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.44;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000036307805477010103
"MM473037";"MM473037";"FC(F)c1ncn2c1Cn1ncnc1-c1cc(Br)ccc1-2";"AFJRYPJIKHMNGL-UHFFFAOYSA-N";352.14;3.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111373/target=_blank>CHEMBL1111373</a>";;-5.15;"Knust H, Achermann G, Ballard T, Buettelmann B, Gasser R, Fischer H, Hernandez MC, Knoflach F, Koblet A, Stadler H, Thomas AW, Trube G, Waldmeier P.: The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.000007079457843841373
"MM473054";"MM473054";"CCOc1cc(CN2CCC(Nc3nc4cc(Cl)c(S(N)(=O)=O)cc4o3)CC2)cc(OCC)c1F";"IEMOENSJCRZHOW-UHFFFAOYSA-N";527.02;4.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.61;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000024547089156850284
"MM473055";"MM473055";"CCOc1cc(CN2CCC(Nc3nc4ccc(Cl)cc4o3)CC2)ccc1Cl";"HXNRUSVXJFFABV-UHFFFAOYSA-N";420.34;5.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.32;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.00000478630092322638
"MM473056";"MM473056";"CCOc1cc(CN2CCC(Nc3nc4cc(NS(=O)(=O)c5cn(C)cn5)ccc4o3)CC2)ccc1OC";"STGHOEAVSSPORB-UHFFFAOYSA-N";540.65;3.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-6.31;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000004897788193684466
"MM473062";"MM473062";"Cc1cc(Cc2nc3n(n2)Cc2c(C)ncn2-c2ccc(Cl)cc2-3)on1";"OABMKUYJAYGQHV-UHFFFAOYSA-N";366.81;3.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1111461/target=_blank>CHEMBL1111461</a>";;-5.51;"Buettelmann B, Ballard TM, Gasser R, Fischer H, Hernandez MC, Knoflach F, Knust H, Stadler H, Thomas AW, Trube G.: Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunction. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.000003090295432513592
"MM473053";"MM473053";"CCOc1cc(CN2CCC(Nc3nc4cc(S(=O)(=O)CC)ccc4o3)CC2)cc(OC2CCOCC2)c1";"FRDOPYUUNJUZKI-UHFFFAOYSA-N";543.69;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.76;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000017378008287493763
"MM473072";"MM473072";"COc1ccc2c(c1)CCc1cnc(Nc3ccc(S(N)(=O)=O)cc3)nc1-2";"LZHPQDAZPOPFGO-UHFFFAOYSA-N";382.45;2.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-5.74;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000018197008586099826
"MM473073";"MM473073";"CC(C)(C)CC(=O)Nc1ccc(-c2ccnc(Nc3ccc(S(N)(=O)=O)cc3)n2)cc1";"OTPAEAQVAUSARI-UHFFFAOYSA-N";439.54;3.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-6.22;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000006025595860743581
"MM473069";"MM473069";"COc1ccc(-c2nc3c(N4CCN(Cc5cc(C)on5)CC4)c(Br)cnc3[nH]2)cc1";"SEYBFHKBOFYLIF-UHFFFAOYSA-N";483.37;4.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1118608/target=_blank>CHEMBL1118608</a>";;-5.22;"Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E.: Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem, Volume 53 (14), 2010";"PAMPA";0.000006025595860743581
"MM473071";"MM473071";"NS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccccc2CC3)cc1";"HVDBCHMIMRDBOY-UHFFFAOYSA-N";352.42;2.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-5.53;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.000002951209226666384
"MM473077";"MM473077";"NS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccc(NC(=O)Cc4cccs4)cc2CC3)cc1";"DQNWHAFSYYXPIU-UHFFFAOYSA-N";491.6;3.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-6.29;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000005128613839913648
"MM473031";"MM473031";"Cc1c(Nc2c(C#N)cncc2/C=C/c2cccc(CN3CCN(C)CC3)n2)ccc2[nH]ccc12";"RDFXBYJUHGEYHA-VOTSOKGWSA-N";463.59;4.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1105151/target=_blank>CHEMBL1105151</a>";;-6.41;"Boschelli DH, Subrath J, Niu C, Wu B, Wang Y, Lee J, Brennan A, Ho M, Deng B, Yang X, Xu X, Leung L, Wang J, Atherton J, Chaudhary D.: Optimization of 5-vinylaryl-3-pyridinecarbonitriles as PKCtheta inhibitors. Bioorg Med Chem Lett, Volume 20 (6), 2010";"PAMPA";0.0000003890451449942805
"MM473070";"MM473070";"NS(=O)(=O)c1ccc(Nc2nccc(-c3ccccc3)n2)cc1";"UTWPAZWEWWLNMF-UHFFFAOYSA-N";326.38;2.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-5.65;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000022387211385683376
"MM473078";"MM473078";"NS(=O)(=O)c1ccc(Nc2nccc(-c3ccsc3)n2)cc1";"JUIXZPWSSOKEIF-UHFFFAOYSA-N";332.41;2.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-6.3;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000005011872336272725
"MM473075";"MM473075";"NS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccc(NC(=O)Cc4ccccc4)cc2CC3)cc1";"GWKNVUMQTXBYAR-UHFFFAOYSA-N";485.57;3.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-5.47;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000033884415613920275
"MM473076";"MM473076";"NS(=O)(=O)c1ccc(Nc2nccc(-c3ccc(NC(=O)Cc4cccs4)cc3)n2)cc1";"MZUCCTLUJWKQJY-UHFFFAOYSA-N";465.56;3.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-6.52;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000003019951720402019
"MM473079";"MM473079";"NS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccsc2CC3)cc1";"MTDWGYRUUAGIEQ-UHFFFAOYSA-N";358.45;2.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-6.42;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.00000038018939632056126
"MM473080";"MM473080";"CN(C)CCNS(=O)(=O)c1ccc(Nc2nccc(-c3ccsc3)n2)cc1";"AUZFWDQAVYWVTD-UHFFFAOYSA-N";403.53;2.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-5.62;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000023988329190194897
"MM473081";"MM473081";"CN(C)CCNS(=O)(=O)c1ccc(Nc2ncc3c(n2)-c2ccsc2CC3)cc1";"VOKVJALZAMIMIX-UHFFFAOYSA-N";429.57;2.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-5.81;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000015488166189124828
"MM473819";"MM473819";"CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccccc1";"RIJFURMPKGXAOI-UHFFFAOYSA-N";389.4;4.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-6.16;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.0000006918309709189363
"MM473074";"MM473074";"CC(C)(C)CC(=O)Nc1ccc2c(c1)CCc1cnc(Nc3ccc(S(N)(=O)=O)cc3)nc1-2";"AGMOCPFJNJCUEI-UHFFFAOYSA-N";465.58;4.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1120482/target=_blank>CHEMBL1120482</a>";;-5.64;"Crombie AL, Sum FW, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K.: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg Med Chem Lett, Volume 20 (12), 2010";"PAMPA";0.0000022908676527677747
"MM473065";"MM473065";"CCn1cnc(CN2CCN(c3cccn4cc(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c1C";"XOVVOPXYEWLASI-UHFFFAOYSA-N";456.64;5.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1115141/target=_blank>CHEMBL1115141</a>";;-5.96;"Vera MD, Lundquist JT, Chengalvala MV, Cottom JE, Feingold IB, Garrick LM, Green DM, Hauze DB, Mann CW, Mehlmann JF, Rogers JF, Shanno L, Wrobel JE, Pelletier JC.: Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett, Volume 20 (8), 2010";"PAMPA";0.000001096478196143185
"MM474399";"MM474399";"CCn1cc(-c2ccnc3[nH]ccc23)c(-c2ccc(NC(=O)Nc3ccccc3)cc2)n1";"CZVVMRNEBRFYTL-UHFFFAOYSA-N";422.49;5.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1104789/target=_blank>CHEMBL1104789</a>";;-4.77;"Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA, Huffman WF, Koretke-Brown KK, Lai ZV, McDonald OB, Nakamura H, Newlander KA, Oleykowski CA, Parrish CA, Patrick DR, Plant R, Sarpong MA, Sasaki K, Schmidt SJ, Silva DJ, Sutton D, Tang J, Thompson CS, Tummino PJ, Wang JC, Xiang H, Yang J, Dhanak D.: Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem, Volume 53 (10), 2010";"PAMPA";0.00001698243652461746
"MM473066";"MM473066";"CCn1cc(CN2CCN(c3cccn4cc(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c(=O)[nH]c1=O";"AFAITHRNRONGKR-UHFFFAOYSA-N";486.62;3.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1115141/target=_blank>CHEMBL1115141</a>";;-5.92;"Vera MD, Lundquist JT, Chengalvala MV, Cottom JE, Feingold IB, Garrick LM, Green DM, Hauze DB, Mann CW, Mehlmann JF, Rogers JF, Shanno L, Wrobel JE, Pelletier JC.: Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett, Volume 20 (8), 2010";"PAMPA";0.0000012022644346174132
"MM473064";"MM473064";"CCc1nc(CN2CCN(c3cccn4cc(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c(C)[nH]1";"QMCIWSPCULJWEO-UHFFFAOYSA-N";456.64;5.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1115141/target=_blank>CHEMBL1115141</a>";;-6.7;"Vera MD, Lundquist JT, Chengalvala MV, Cottom JE, Feingold IB, Garrick LM, Green DM, Hauze DB, Mann CW, Mehlmann JF, Rogers JF, Shanno L, Wrobel JE, Pelletier JC.: Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett, Volume 20 (8), 2010";"PAMPA";0.00000019952623149688787
"MM474398";"MM474398";"CCCS(=O)(=O)N1CCN(c2ccc(OCC3CCN(C(=O)OC(C)C)CC3)cn2)CC1";"OTEDYPFTWYZQEE-UHFFFAOYSA-N";468.62;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1107078/target=_blank>CHEMBL1107078</a>";;-4.33;"Wu Y, Kuntz JD, Carpenter AJ, Fang J, Sauls HR, Gomez DJ, Ammala C, Xu Y, Hart S, Tadepalli S.: 2,5-Disubstituted pyridines as potent GPR119 agonists. Bioorg Med Chem Lett, Volume 20 (8), 2010";"PAMPA";0.00004677351412871981
"MM473068";"MM473068";"COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2";"SWTRIZHCIUWGAU-UHFFFAOYSA-N";448.53;1.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1103832/target=_blank>CHEMBL1103832</a>";;-4.3;"Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, Cappella P, Cappella P, Caruso M, Ceccarelli W, Ciavolella A, Cristiani C, Croci V, De Ponti A, Fachin G, Ferguson RD, Lansen J, Moll JK, Pesenti E, Posteri H, Perego R, Rocchetti M, Storici P, Volpi D, Valsasina B.: Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. J Med Chem, Volume 53 (9), 2010";"PAMPA";0.00005011872336272725
"MM473825";"MM473825";"CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1CCCS(N)(=O)=O";"DSIHXMZSDDJEHM-UHFFFAOYSA-N";400.91;1.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-4.6;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000025118864315095822
"MM472520";"MM472520";"Oc1ccc(Cl)cc1Cl";"HFZWRUODUSTPEG-UHFFFAOYSA-N";163;2.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905612/target=_blank>CHEMBL905612</a>";;-4.93;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000011748975549395302
"MM473082";"MM473082";"CC(=O)N1CCC(C(=O)N2CCC(N3CCN(C(=O)c4cc(-c5cccc(F)c5)nc(-c5ccc6[nH]ccc6c5)c4)CC3)CC2)CC1";"FFMGDOVUBJQRQK-UHFFFAOYSA-N";636.77;5.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1175372/target=_blank>CHEMBL1175372</a>";;-4.7;"Chonan T, Tanaka H, Yamamoto D, Yashiro M, Oi T, Wakasugi D, Ohoka-Sugita A, Io F, Koretsune H, Hiratate A.: Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett, Volume 20 (13), 2010";"PAMPA";0.000019952623149688786
"MM473083";"MM473083";"CC(=O)N1CCC(C(=O)N2CCC(N3CCN(C(=O)c4cc(-c5ccc(F)cc5)nc(-c5ccc6[nH]ccc6c5)c4)CC3)CC2)CC1";"GZKXHIOREJCCDY-UHFFFAOYSA-N";636.77;5.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1175372/target=_blank>CHEMBL1175372</a>";;-4.35;"Chonan T, Tanaka H, Yamamoto D, Yashiro M, Oi T, Wakasugi D, Ohoka-Sugita A, Io F, Koretsune H, Hiratate A.: Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett, Volume 20 (13), 2010";"PAMPA";0.00004466835921509635
"MM473084";"MM473084";"CC(=O)N1CCC(C(=O)N2CCC(N3CCN(C(=O)c4cc(-c5cccc(C)c5)nc(-c5ccc6[nH]ccc6c5)c4)CC3)CC2)CC1";"JKGNQCZWTAIJRT-UHFFFAOYSA-N";632.81;5.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1175372/target=_blank>CHEMBL1175372</a>";;-4.55;"Chonan T, Tanaka H, Yamamoto D, Yashiro M, Oi T, Wakasugi D, Ohoka-Sugita A, Io F, Koretsune H, Hiratate A.: Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett, Volume 20 (13), 2010";"PAMPA";0.00002818382931264455
"MM473085";"MM473085";"CC(=O)N1CCC(C(=O)N2CCC(N3CCN(C(=O)c4cc(-c5ccc(C)cc5)nc(-c5ccc6[nH]ccc6c5)c4)CC3)CC2)CC1";"ZCTNXUOUMYXZIF-UHFFFAOYSA-N";632.81;5.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1175372/target=_blank>CHEMBL1175372</a>";;-4.4;"Chonan T, Tanaka H, Yamamoto D, Yashiro M, Oi T, Wakasugi D, Ohoka-Sugita A, Io F, Koretsune H, Hiratate A.: Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett, Volume 20 (13), 2010";"PAMPA";0.000039810717055349695
"MM473086";"MM473086";"COc1ccc(-c2cc(C(=O)N3CCN(C4CCN(C(=O)C5CCN(C(C)=O)CC5)CC4)CC3)cc(-c3ccc4[nH]ccc4c3)n2)cc1";"NEOXRZPYDKSMGX-UHFFFAOYSA-N";648.81;4.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1175372/target=_blank>CHEMBL1175372</a>";;-4.67;"Chonan T, Tanaka H, Yamamoto D, Yashiro M, Oi T, Wakasugi D, Ohoka-Sugita A, Io F, Koretsune H, Hiratate A.: Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett, Volume 20 (13), 2010";"PAMPA";0.000021379620895022323
"MM473087";"MM473087";"CC(=O)N1CCC(C(=O)N2CCC(N3CCN(C(=O)c4cc(-c5ccccc5)nc(-c5ccc6[nH]ccc6c5)c4)CC3)CC2)CC1";"CGMYNKWLJMEIMQ-UHFFFAOYSA-N";618.78;4.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1175372/target=_blank>CHEMBL1175372</a>";;-4.33;"Chonan T, Tanaka H, Yamamoto D, Yashiro M, Oi T, Wakasugi D, Ohoka-Sugita A, Io F, Koretsune H, Hiratate A.: Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett, Volume 20 (13), 2010";"PAMPA";0.00004677351412871981
"MM472597";"MM472597";"COC(=O)c1ccc(-c2cccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c2)cc1";"KJXHYBWPKVGFJG-JGLNRKDHSA-N";390.39;0.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1805241/target=_blank>CHEMBL1805241</a>";;-5.01;"Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, LĂĽthi C, Scharenberg M, BezenĂ§on J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.: FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem, Volume 53 (24), 2010";"PAMPA";0.000009772372209558111
"MM473796";"MM473796";"C=CCN(C(=O)Cc1ccc(S(=O)(=O)NC)cc1)C1CCN(C[C@H]2CN(C(=O)C3CCCC3)C[C@]2(O)c2ccccc2)CC1";"XPFKJEFRGMJTEE-DODOAAEWSA-N";622.83;3.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1174114/target=_blank>CHEMBL1174114</a>";;-7.15;"Ben L, Jones ED, Zhou E, Li C, Baylis DC, Yu S, Wang M, He X, Coates JA, Rhodes DI, Pei G, Deadman JJ, Xie X, Ma D.: Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents. Bioorg Med Chem Lett, Volume 20 (14), 2010";"PAMPA";0.00000007079457843841373
"MM474402";"MM474402";"CC(CNC(=O)c1ccc2[nH]ccc2c1)c1cccc(C(=O)c2ccccc2)c1";"ZPJZVJTYHYOABS-UHFFFAOYSA-N";382.46;4.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1176651/target=_blank>CHEMBL1176651</a>";;-4.28;"Mahindroo N, Connelly MC, Punchihewa C, Yang L, Yan B, Fujii N.: Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway. Bioorg Med Chem, Volume 18 (13), 2010";"PAMPA";0.00005248074602497723
"MM474401";"MM474401";"CC(C(=O)Nc1ccc2cc[nH]c2c1)c1cccc(C(=O)c2ccccc2)c1";"JIQPYCPHUZZMDT-UHFFFAOYSA-N";368.44;5.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1176651/target=_blank>CHEMBL1176651</a>";;-4.11;"Mahindroo N, Connelly MC, Punchihewa C, Yang L, Yan B, Fujii N.: Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway. Bioorg Med Chem, Volume 18 (13), 2010";"PAMPA";0.00007762471166286911
"MM474403";"MM474403";"CCCN(C(=O)C(C)c1cccc(C(=O)c2ccccc2)c1)c1ccc2cc[nH]c2c1";"VTUGOOXWWOIQNC-UHFFFAOYSA-N";410.52;5.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1176651/target=_blank>CHEMBL1176651</a>";;-4.15;"Mahindroo N, Connelly MC, Punchihewa C, Yang L, Yan B, Fujii N.: Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway. Bioorg Med Chem, Volume 18 (13), 2010";"PAMPA";0.00007079457843841373
"MM474390";"MM474390";"CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C";"KWTWDQCKEHXFFR-SMDDNHRTSA-N";221.34;3.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.87;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000013489628825916533
"MM473102";"MM473102";"CC(=O)NCC(=O)NCc1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccccc2)c1";"CRQBPOBTROOFCT-UHFFFAOYSA-N";462.55;3.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211974/target=_blank>CHEMBL1211974</a>";;-5.13;"Liu H, Kuhn C, Feru F, Jacques SL, Deshmukh GD, Ye P, Rennie GR, Johnson T, Kazmirski S, Low S, Coli R, Ding YH, Cheng AC, Tecle H, English JM, Stanton R, Wu JC.: Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors. Bioorg Med Chem Lett, Volume 20 (16), 2010";"PAMPA";0.000007413102413009177
"MM473834";"MM473834";"CCCCCCCc1nc(-c2ccc(CNC(=O)[C@H]3NCC[C@@H]3O)cc2)no1";"CMLALAZUOVTKKV-HKUYNNGSSA-N";386.5;2.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211764/target=_blank>CHEMBL1211764</a>";;-4.34;"Xiang Y, Hirth B, Kane JL, Liao J, Noson KD, Yee C, Asmussen G, Fitzgerald M, Klaus C, Booker M.: Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.000045708818961487516
"MM473103";"MM473103";"CC(C)(C)c1cc(NC(=O)Nc2ccccc2)n(-c2cccc(CNC(=O)Cn3ccccc3=O)c2)n1";"WGGHULRIQOEEDJ-UHFFFAOYSA-N";498.59;4.29;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211974/target=_blank>CHEMBL1211974</a>";;-4.89;"Liu H, Kuhn C, Feru F, Jacques SL, Deshmukh GD, Ye P, Rennie GR, Johnson T, Kazmirski S, Low S, Coli R, Ding YH, Cheng AC, Tecle H, English JM, Stanton R, Wu JC.: Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors. Bioorg Med Chem Lett, Volume 20 (16), 2010";"PAMPA";0.000012882495516931348
"MM473104";"MM473104";"Cc1ccn(CC(=O)NCc2cccc(-n3nc(C(C)(C)C)cc3NC(=O)Nc3ccccc3)c2)n1";"RSYZKXWSKXKYNU-UHFFFAOYSA-N";485.59;4.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211974/target=_blank>CHEMBL1211974</a>";;-5.32;"Liu H, Kuhn C, Feru F, Jacques SL, Deshmukh GD, Ye P, Rennie GR, Johnson T, Kazmirski S, Low S, Coli R, Ding YH, Cheng AC, Tecle H, English JM, Stanton R, Wu JC.: Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors. Bioorg Med Chem Lett, Volume 20 (16), 2010";"PAMPA";0.00000478630092322638
"MM473835";"MM473835";"C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1";"GDJANRNMFHNVOW-DCPHZVHLSA-N";398.51;2.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211764/target=_blank>CHEMBL1211764</a>";;-4.31;"Xiang Y, Hirth B, Kane JL, Liao J, Noson KD, Yee C, Asmussen G, Fitzgerald M, Klaus C, Booker M.: Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.00004897788193684466
"MM473836";"MM473836";"C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1";"GWRUOXQHIKZCTE-ZRCAFCQKSA-N";412.53;3.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211764/target=_blank>CHEMBL1211764</a>";;-4.24;"Xiang Y, Hirth B, Kane JL, Liao J, Noson KD, Yee C, Asmussen G, Fitzgerald M, Klaus C, Booker M.: Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.000057543993733715664
"MM473837";"MM473837";"CC[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1";"OLDDAHJZTORONS-ONTIZHBOSA-N";426.56;3.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211764/target=_blank>CHEMBL1211764</a>";;-4.36;"Xiang Y, Hirth B, Kane JL, Liao J, Noson KD, Yee C, Asmussen G, Fitzgerald M, Klaus C, Booker M.: Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.000043651583224016566
"MM474509";"MM474509";"CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1";"YASAKCUCGLMORW-UHFFFAOYSA-N";357.44;2.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.12;"10.6019/CHEMBL3431459";"PAMPA";0.000007585775750291836
"MM473101";"MM473101";"CCOc1cc(CN2CCC(NC(=O)c3cncc(C)c3)CC2)cc(OCC)c1C";"CMZXJSAVTRAMNW-UHFFFAOYSA-N";411.55;3.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.63;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.0000023442288153199226
"MM473100";"MM473100";"CCOc1cc(CN2CCC(NC(=O)c3cncc(C)c3)CC2)cc(OCC)c1Cl";"DOPXZUHPZHYPBJ-UHFFFAOYSA-N";431.96;4.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.42;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.000003801893963205613
"MM473099";"MM473099";"CCOc1cc(CN2CCC(NC(=O)c3ccc(N)nc3)CC2)cc(OCC)c1-c1ccc(F)cc1";"QGLWUTISHLFURW-UHFFFAOYSA-N";492.6;4.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.86;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.0000013803842646028838
"MM473098";"MM473098";"CCOc1cc(CN2CCC(NC(=O)c3ccc(NC(C)C)nc3)CC2)cc(OCC)c1F";"YTAVDPJGDIZDSB-UHFFFAOYSA-N";458.58;4.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.62;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.0000023988329190194897
"MM473097";"MM473097";"CCOc1cc(CN2CCC(NC(=O)c3ccc(NC)nc3)CC2)cc(OCC)c1-c1ccccc1";"WXIPBSOPCYLJTO-UHFFFAOYSA-N";488.63;4.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.68;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.0000020892961308540407
"MM473096";"MM473096";"CCOc1cc(CN2CCC(NC(=O)c3cncc(C)c3)CC2)cc(OCC)c1-c1ccc(F)cc1";"XQGOSGUJZCQEOJ-UHFFFAOYSA-N";491.61;5.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-6.34;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.00000045708818961487516
"MM473095";"MM473095";"CCOc1cc(CN2CCC(NC(=O)c3cncc(C)c3)CC2)cc(OCC)c1-c1ccccc1";"NCVQBIQQTNMSSG-UHFFFAOYSA-N";473.62;5.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-6.19;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.000000645654229034655
"MM473094";"MM473094";"CCOc1cc(CN2CCC(NC(=O)c3ccc(NC)nc3)CC2)cc(OCC)c1-c1ccc(F)cc1";"AKCGOXREZJOGPS-UHFFFAOYSA-N";506.62;5.12;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.91;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.0000012302687708123811
"MM473093";"MM473093";"CCOc1cc(CN2CCC(NC(=O)c3ccc(N)nc3)CC2)cc(OCc2ccccc2)c1-c1ccc(F)cc1";"VGTBCHGQRVWGCK-UHFFFAOYSA-N";554.67;5.84;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-6.85;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.00000014125375446227555
"MM473092";"MM473092";"CCOc1cc(CN2CCC(NC(=O)c3ccc(NC)nc3)CC2)cc(OCC)c1F";"NYHCZXKEQVHUAS-UHFFFAOYSA-N";430.52;3.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.53;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.000002951209226666384
"MM473090";"MM473090";"CCOc1cc(CN2CCC(NC(=O)c3cncc(C)c3)CC2)cc(OCC)c1F";"QCJRQVJPUYADQP-UHFFFAOYSA-N";415.51;3.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.46;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.000003467368504525317
"MM473089";"MM473089";"CCOc1cc(CN2CCCC(NC(=O)c3cncc(C)c3)CC2)cc(OCC)c1-c1ccc(F)cc1";"XOKQXPCDCRWFMF-UHFFFAOYSA-N";505.63;5.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.81;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.0000015488166189124828
"MM473088";"MM473088";"CCOc1cc(CN2CC(NC(=O)c3cncc(C)c3)C2)cc(OCC)c1F";"WISBOMVTORMKRV-UHFFFAOYSA-N";387.46;2.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.71;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.0000019498445997580454
"MM473147";"MM473147";"N=C(N)NCCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)NCc1ccccc1";"HNFKXYNROBMUAI-ZXRKZBAXSA-N";653.79;1.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.33;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000004677351412871981
"MM473149";"MM473149";"N=C(N)NCCC[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1ccccc1";"FVKULCSGIXKHIC-HVCNVCAESA-N";605.75;-0.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.02;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000009549925860214369
"MM473148";"MM473148";"N=C(N)NCCC[C@H](N)C(=O)N[C@@H](Cc1ccc(NC(=N)N)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1ccccc1";"WINIFJNDPLPGFU-ZXRKZBAXSA-N";653.79;1.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.42;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.00000038018939632056126
"MM473146";"MM473146";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCc1ccccc1";"HMRLQEZRHQRGFB-HVCNVCAESA-N";605.75;-0.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.11;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000007762471166286911
"MM473142";"MM473142";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCc1ccccc1";"HRWXERFIJUKLGF-VABKMULXSA-N";566.71;-0.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-5.64;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000022908676527677747
"MM473144";"MM473144";"N=C(N)NCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccccc1";"RIYVSJKWUAHLBF-YCVJPRETSA-N";642.81;0.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.38;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000004168693834703355
"MM474404";"MM474404";"Cc1nc2nc(C(=O)N3CCCC3)cn2c(-c2ccc(Cl)cc2Cl)c1CN";"BULFOJDUFCMBCV-UHFFFAOYSA-N";404.3;3.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1218974/target=_blank>CHEMBL1218974</a>";;-4.29;"Meng W, Brigance RP, Chao HJ, Fura A, Harrity T, Marcinkeviciene J, O'Connor SP, Tamura JK, Xie D, Zhang Y, Klei HE, Kish K, Weigelt CA, Turdi H, Wang A, Zahler R, Kirby MS, Hamann LG.: Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem, Volume 53 (15), 2010";"PAMPA";0.00005128613839913648
"MM473105";"MM473105";"CS(=O)(=O)N1C[C@H](C(=O)Nc2ccc(Cl)cc2)[C@@H](C(=O)Nc2ccc(N3CCOCC3=O)cc2)C1";"SGRMXGOTTNMVGI-PMACEKPBSA-N";521;1.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1227183/target=_blank>CHEMBL1227183</a>";;-6.34;"Anselm L, Banner DW, Benz J, Zbinden KG, Himber J, Hilpert H, Huber W, Kuhn B, Mary JL, Otteneder MB, Panday N, Ricklin F, Stahl M, Thomi S, Haap W.: Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.00000045708818961487516
"MM474407";"MM474407";"O=C(Nc1ccc(F)nc1)[C@@H]1CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1";"KXJSNGUMWGPTMJ-KRWDZBQOSA-N";447.48;3.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228262/target=_blank>CHEMBL1228262</a>";;-4.11;"Sampognaro AJ, Wittman MD, Carboni JM, Chang C, Greer AF, Hurlburt WW, Sack JS, Vyas DM.: Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.00007762471166286911
"MM474408";"MM474408";"O=C(c1ccc(F)nc1)N1CCC[C@H]1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1";"XXGADWBTSMHVDF-INIZCTEOSA-N";432.46;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228262/target=_blank>CHEMBL1228262</a>";;-4.14;"Sampognaro AJ, Wittman MD, Carboni JM, Chang C, Greer AF, Hurlburt WW, Sack JS, Vyas DM.: Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.00007244359600749906
"MM474409";"MM474409";"O=C(c1ccc(F)nc1)N1CCC[C@@H]1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1";"XXGADWBTSMHVDF-MRXNPFEDSA-N";432.46;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228262/target=_blank>CHEMBL1228262</a>";;-4.03;"Sampognaro AJ, Wittman MD, Carboni JM, Chang C, Greer AF, Hurlburt WW, Sack JS, Vyas DM.: Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.00009332543007969905
"MM474410";"MM474410";"O=C1CC[C@@H](c2nc(Nc3cc(C4CC4)[nH]n3)c3cccn3n2)N1C(=O)c1ccc(F)nc1";"NDHRVVQUROWSOW-INIZCTEOSA-N";446.45;3.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228262/target=_blank>CHEMBL1228262</a>";;-4.22;"Sampognaro AJ, Wittman MD, Carboni JM, Chang C, Greer AF, Hurlburt WW, Sack JS, Vyas DM.: Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.000060255958607435806
"MM474412";"MM474412";"O=C(Nc1ccc(F)nc1)C1=C(c2nc(Nc3cc(C4CC4)[nH]n3)c3cccn3n2)CCC1";"QNHVQEHQTFEODG-UHFFFAOYSA-N";444.47;4.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228262/target=_blank>CHEMBL1228262</a>";;-4.09;"Sampognaro AJ, Wittman MD, Carboni JM, Chang C, Greer AF, Hurlburt WW, Sack JS, Vyas DM.: Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.00008128305161640995
"MM474413";"MM474413";"O=C(NCc1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1)c1ccc(F)nc1";"FQECDJFBKXFTIW-UHFFFAOYSA-N";392.4;2.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1228262/target=_blank>CHEMBL1228262</a>";;-4.28;"Sampognaro AJ, Wittman MD, Carboni JM, Chang C, Greer AF, Hurlburt WW, Sack JS, Vyas DM.: Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase. Bioorg Med Chem Lett, Volume 20 (17), 2010";"PAMPA";0.00005248074602497723
"MM474387";"MM474387";"CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(O)cc13";"JAQUASYNZVUNQP-PVAVHDDUSA-N";257.38;3.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-5.27;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000005370317963702533
"MM474414";"MM474414";"C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccc(F)cc1)C(=O)OC1CCCCC1";"RJMVGAZAYOUNNR-WQZFGADUSA-N";587.51;2.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1261497/target=_blank>CHEMBL1261497</a>";;-6.31;"Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA.: Discovery of a Î˛-d-2'-deoxy-2'-Î±-fluoro-2'-Î˛-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem, Volume 53 (19), 2010";"PAMPA";0.0000004897788193684466
"MM474415";"MM474415";"CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1";"TTZHDVOVKQGIBA-IAAJYNJHSA-N";529.46;1.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1261497/target=_blank>CHEMBL1261497</a>";;-7.34;"Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA.: Discovery of a Î˛-d-2'-deoxy-2'-Î±-fluoro-2'-Î˛-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem, Volume 53 (19), 2010";"PAMPA";0.00000004570881896148752
"MM472567";"MM472567";"CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)NCC(C)c3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)NCC(C)c3ccccc3)c2C1=O";"BBLHWQAOYOUAEN-UHFFFAOYSA-N";728.75;5.67;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273523/target=_blank>CHEMBL1273523</a>";;-7.88;"Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M.: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, Volume 53 (22), 2010";"PAMPA";0.000000013182567385564074
"MM472569";"MM472569";"CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCC3CCCCC3)C2=O)C(=O)c2cc(O)c(O)c(CCC3CCCCC3)c2C1=O";"CNRDVELNWXCONS-UHFFFAOYSA-N";626.75;7.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273523/target=_blank>CHEMBL1273523</a>";;-5.82;"Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M.: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, Volume 53 (22), 2010";"PAMPA";0.0000015135612484362072
"MM472570";"MM472570";"CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccccc3)c2C1=O";"IVBKZDLBSIWCDU-UHFFFAOYSA-N";614.65;6.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273523/target=_blank>CHEMBL1273523</a>";;-6.58;"Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M.: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, Volume 53 (22), 2010";"PAMPA";0.00000026302679918953816
"MM472571";"MM472571";"CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccc(C)cc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccc(C)cc3)c2C1=O";"KPHBSOQOTONLSS-UHFFFAOYSA-N";642.7;6.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273523/target=_blank>CHEMBL1273523</a>";;-5.59;"Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M.: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, Volume 53 (22), 2010";"PAMPA";0.0000025703957827688647
"MM472572";"MM472572";"CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCCc3ccccc3)c2C1=O";"UHLVJEYCYRBSHE-UHFFFAOYSA-N";642.7;6.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273523/target=_blank>CHEMBL1273523</a>";;-6.65;"Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M.: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, Volume 53 (22), 2010";"PAMPA";0.00000022387211385683377
"MM472573";"MM472573";"CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O";"IEJPMWKHSOLTHK-UHFFFAOYSA-N";586.6;5.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273523/target=_blank>CHEMBL1273523</a>";;-7.11;"Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M.: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, Volume 53 (22), 2010";"PAMPA";0.00000007762471166286912
"MM473108";"MM473108";"NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1cccs1";"CEKJXDVQNFUQAV-UHFFFAOYSA-N";285.33;1.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274158/target=_blank>CHEMBL1274158</a>";;-5.2;"Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, TatĂ˛ M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.: Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem, Volume 53 (20), 2010";"PAMPA";0.00000630957344480193
"MM473107";"MM473107";"NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccsc1";"GIEWZQNAONSKKX-UHFFFAOYSA-N";285.33;1.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274158/target=_blank>CHEMBL1274158</a>";;-4.73;"Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, TatĂ˛ M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.: Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem, Volume 53 (20), 2010";"PAMPA";0.000018620871366628657
"MM473113";"MM473113";"O=C(NO)c1cnc(N2C[C@H]3CN(Cc4ccc5ccccc5c4)C[C@H]3C2)nc1";"KPGKJQJLWZJYMJ-BGYRXZFFSA-N";389.46;2.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273126/target=_blank>CHEMBL1273126</a>";;-6.3;"Donald AD, Clark VL, Patel S, Day FA, Rowlands MG, Wibata J, Stimson L, Hardcastle A, Eccles SA, McNamara D, Needham LA, Raynaud FI, Aherne W, Moffat DF.: Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases. Bioorg Med Chem Lett, Volume 20 (22), 2010";"PAMPA";0.0000005011872336272725
"MM473112";"MM473112";"NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccccc1";"VOQXQYXTZZHYBF-UHFFFAOYSA-N";279.3;1.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274158/target=_blank>CHEMBL1274158</a>";;-5.22;"Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, TatĂ˛ M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.: Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem, Volume 53 (20), 2010";"PAMPA";0.000006025595860743581
"MM473110";"MM473110";"NC(=O)c1c(-c2ccccc2)[nH]c(-c2ccnc(N)n2)c1I";"ZFUUZACDRUZMSC-UHFFFAOYSA-N";405.2;2.42;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274158/target=_blank>CHEMBL1274158</a>";;-5.12;"Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, TatĂ˛ M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.: Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem, Volume 53 (20), 2010";"PAMPA";0.000007585775750291836
"MM473109";"MM473109";"CCn1c(-c2ccnc(N)n2)cc(C(N)=O)c1-c1ccccc1";"KMOZGTUUYJFWQK-UHFFFAOYSA-N";307.36;2.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274158/target=_blank>CHEMBL1274158</a>";;-4.67;"Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, TatĂ˛ M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.: Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem, Volume 53 (20), 2010";"PAMPA";0.000021379620895022323
"MM473106";"MM473106";"NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc2sccc2c1";"WPDINEQTRUOZHZ-UHFFFAOYSA-N";335.39;3.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274158/target=_blank>CHEMBL1274158</a>";;-5.07;"Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, TatĂ˛ M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.: Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem, Volume 53 (20), 2010";"PAMPA";0.00000851138038202376
"MM473111";"MM473111";"NC(=O)c1cc(-c2nc(N)ncc2F)[nH]c1-c1ccccc1";"PEQPUGZELMBNKY-UHFFFAOYSA-N";297.29;1.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274158/target=_blank>CHEMBL1274158</a>";;-5.33;"Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, TatĂ˛ M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.: Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem, Volume 53 (20), 2010";"PAMPA";0.000004677351412871981
"MM473115";"MM473115";"Cn1nc(C(N)=O)c2c1-c1nc(Nc3cc(N4CCNCC4)ccc3OC(F)(F)F)ncc1CC2";"TUWAYASUNDRSML-UHFFFAOYSA-N";488.47;2.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1272706/target=_blank>CHEMBL1272706</a>";;-5.14;"Beria I, Valsasina B, Brasca MG, Ceccarelli W, Colombo M, Cribioli S, Fachin G, Ferguson RD, Fiorentini F, Gianellini LM, Giorgini ML, Moll JK, Posteri H, Pezzetta D, Roletto F, Sola F, Tesei D, Caruso M.: 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors. Bioorg Med Chem Lett, Volume 20 (22), 2010";"PAMPA";0.000007244359600749906
"MM472566";"MM472566";"CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(C)C)C2=O)C(=O)c2cc(O)c(O)c(C(C)C)c2C1=O";"GYYXKPBLWDDQQK-UHFFFAOYSA-N";490.51;4.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273523/target=_blank>CHEMBL1273523</a>";;-5.94;"Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M.: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, Volume 53 (22), 2010";"PAMPA";0.0000011481536214968817
"MM472568";"MM472568";"CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC(C)C)C2=O)C(=O)c2cc(O)c(O)c(CC(C)C)c2C1=O";"QMQSAWHWCPIWPF-UHFFFAOYSA-N";518.56;5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1273523/target=_blank>CHEMBL1273523</a>";;-6.17;"Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M.: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem, Volume 53 (22), 2010";"PAMPA";0.0000006760829753919819
"MM473118";"MM473118";"CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cccc(S(N)(=O)=O)c1";"TYWODBAOGMISNZ-UHFFFAOYSA-N";434.93;2.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-5.8;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000001584893192461114
"MM473119";"MM473119";"CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cccc(S(N)(=O)=O)c1";"SEQMPXNPBNAKCA-UHFFFAOYSA-N";468.48;3.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-5.09;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000008128305161640995
"MM473120";"MM473120";"CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cccc(S(N)(=O)=O)n1";"BPEAQTOVXXWKSB-UHFFFAOYSA-N";435.92;2.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-5.89;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000001288249551693135
"MM473826";"MM473826";"CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cccc(S(N)(=O)=O)n1";"JIIHFLNYGVNTFP-UHFFFAOYSA-N";469.47;2.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-4.85;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000014125375446227555
"MM473827";"MM473827";"CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccnc(S(N)(=O)=O)c1";"FJTVLRBKLVJPNG-UHFFFAOYSA-N";469.47;2.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-4.92;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000012022644346174132
"MM473828";"MM473828";"CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cncc(S(N)(=O)=O)c1";"PYMNZVPHYKGZHD-UHFFFAOYSA-N";435.92;2.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-4.89;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000012882495516931348
"MM473829";"MM473829";"CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cncc(S(N)(=O)=O)c1";"PUWNHUKCXUUPPH-UHFFFAOYSA-N";469.47;2.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-4.85;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000014125375446227555
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-5.49;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.000003235936569296281
"MM473217";"MM473217";"CN(C)S(=O)(=O)c1cccc(-n2sc3ccccc3c2=O)c1";"SHVMSYDTOYCGDZ-UHFFFAOYSA-N";334.42;2.3;;"CHEMBL1339149";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3375691/target=_blank>CHEMBL3375691</a>";;-3.11;"Bravo Y, Teriete P, Dhanya RP, Dahl R, Lee PS, Kiffer-Moreira T, Ganji SR, Sergienko E, Smith LH, Farquharson C, MillĂˇn JL, Cosford ND.: Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. Bioorg Med Chem Lett, Volume 24 (17), 2014";"PAMPA";0.0007762471166286919
"MM473217";"MM473217";"CN(C)S(=O)(=O)c1cccc(-n2sc3ccccc3c2=O)c1";"SHVMSYDTOYCGDZ-UHFFFAOYSA-N";334.42;2.3;;"CHEMBL1339149";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3375692/target=_blank>CHEMBL3375692</a>";;-3.09;"Bravo Y, Teriete P, Dhanya RP, Dahl R, Lee PS, Kiffer-Moreira T, Ganji SR, Sergienko E, Smith LH, Farquharson C, MillĂˇn JL, Cosford ND.: Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. Bioorg Med Chem Lett, Volume 24 (17), 2014";"PAMPA";0.0008128305161640995
"MM473217";"MM473217";"CN(C)S(=O)(=O)c1cccc(-n2sc3ccccc3c2=O)c1";"SHVMSYDTOYCGDZ-UHFFFAOYSA-N";334.42;2.3;;"CHEMBL1339149";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3375693/target=_blank>CHEMBL3375693</a>";;-3.11;"Bravo Y, Teriete P, Dhanya RP, Dahl R, Lee PS, Kiffer-Moreira T, Ganji SR, Sergienko E, Smith LH, Farquharson C, MillĂˇn JL, Cosford ND.: Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. Bioorg Med Chem Lett, Volume 24 (17), 2014";"PAMPA";0.0007762471166286919
"MM473405";"MM473405";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCN3CCOCC3)CC2)c(C)o1";"BXYBGEAXGCDRSR-UHFFFAOYSA-N";440.59;3.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.36;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.0004365158322401661
"MM472533";"MM472533";"c1ccc(-c2ccccc2)cc1";"ZUOUZKKEUPVFJK-UHFFFAOYSA-N";154.21;3.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905612/target=_blank>CHEMBL905612</a>";;-5.95;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000001122018454301963
"MM474434";"MM474434";"COc1ccccc1OC[C@H](O)CO";"HSRJKNPTNIJEKV-MRVPVSSYSA-N";198.22;0.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2396357/target=_blank>CHEMBL2396357</a>";;-5.2;"Hadimani MB, Purohit MK, Vanampally C, Van der Ploeg R, Arballo V, Morrow D, Frizzi KE, Calcutt NA, Fernyhough P, Kotra LP.: Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy. J Med Chem, Volume 56 (12), 2013";"PAMPA";0.00000630957344480193
"MM473629";"MM473629";"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1";"ZBNZXTGUTAYRHI-UHFFFAOYSA-N";488.02;3.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-5.83;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.000001479108388168207
"MM474389";"MM474389";"COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314";"LLPOLZWFYMWNKH-CMKMFDCUSA-N";299.37;1.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-5.04;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000009120108393559096
"MM473301";"MM473301";"CN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1";"WFNAKBGANONZEQ-SFHVURJKSA-N";300.83;3.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3774145/target=_blank>CHEMBL3774145</a>";;-2.74;"He S, Xiao J, Dulcey AE, Lin B, Rolt A, Hu Z, Hu X, Wang AQ, Xu X, Southall N, Ferrer M, Zheng W, Liang TJ, Marugan JJ.: Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Med Chem, Volume 59 (3), 2016";"PAMPA";0.0018197008586099826
"MM472622";"MM472622";"CCOC(=O)C(SP(=S)(OC)OC)c1ccccc1";"XAMUDJHXFNRLCY-UHFFFAOYSA-N";320.37;3.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3066824/target=_blank>CHEMBL3066824</a>";;-6.24;"Akamatsu M.: Importance of physicochemical properties for the design of new pesticides. J Agric Food Chem, Volume 59 (7), 2011";"PAMPA";0.0000005754399373371567
"Naproxen";"MM00672";"COc1ccc2cc(C(C)C(=O)O)ccc2c1";"CMWTZPSULFXXJA-UHFFFAOYSA-N";230.26;3.04;"156391";"CHEMBL154";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3066824/target=_blank>CHEMBL3066824</a>";;-5.3;"Akamatsu M.: Importance of physicochemical properties for the design of new pesticides. J Agric Food Chem, Volume 59 (7), 2011";"PAMPA";0.000005011872336272725
"Naproxen";"MM00672";"COc1ccc2cc(C(C)C(=O)O)ccc2c1";"CMWTZPSULFXXJA-UHFFFAOYSA-N";230.26;3.04;"156391";"CHEMBL154";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3366337/target=_blank>CHEMBL3366337</a>";;-6.2;"Skoda EM, Sacher JR, Kazancioglu MZ, Saha J, Wipf P.: An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000000630957344480193
"MM474102";"MM474102";"CNc1oc(-c2cccc3ccccc23)nc1C#N";"DYXYXTDIFMDJIR-UHFFFAOYSA-N";249.27;3.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3269736/target=_blank>CHEMBL3269736</a>";;-3.14;"Rai G, Joshi N, Jung JE, Liu Y, Schultz L, Yasgar A, Perry S, Diaz G, Zhang Q, Kenyon V, Jadhav A, Simeonov A, Lo EH, van Leyen K, Maloney DJ, Holman TR.: Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.0007244359600749898
"MM472621";"MM472621";"COP(=S)(OC)Oc1ccc(SC)c(C)c1";"PNVJTZOFSHSLTO-UHFFFAOYSA-N";278.34;3.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3066824/target=_blank>CHEMBL3066824</a>";;-6.14;"Akamatsu M.: Importance of physicochemical properties for the design of new pesticides. J Agric Food Chem, Volume 59 (7), 2011";"PAMPA";0.0000007244359600749906
"MM473157";"MM473157";"CCCc1cc(-c2nc(-c3ccc(C)cc3)cs2)ccn1";"ZROSUBKIGBSZCG-UHFFFAOYSA-N";294.42;5.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1827449/target=_blank>CHEMBL1827449</a>";;-6.12;"Kamisuki S, Shirakawa T, Kugimiya A, Abu-Elheiga L, Choo HY, Yamada K, Shimogawa H, Wakil SJ, Uesugi M.: Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.0000007585775750291836
"MM474385";"MM474385";"COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)NCC3";"ILNSWVUXAPSPEH-USXIJHARSA-N";257.38;3.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.76;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000017378008287493764
"MM473816";"MM473816";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(N3CCN(C)CC3)cc2C1)C(F)(F)F";"PGCHCAHHIBWCPB-INIZCTEOSA-N";511.57;3.33;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.82;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000015135612484362072
"MM473815";"MM473815";"Cc1cccc2c1CN(C(=O)c1cc(S(C)(=O)=O)ccc1O[C@@H](C)C(F)(F)F)C2";"RZTNZANVFQAZHA-ZDUSSCGKSA-N";427.44;3.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.38;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000004168693834703355
"MM473814";"MM473814";"COc1cccc2c1CN(C(=O)c1cc(S(C)(=O)=O)ccc1O[C@@H](C)C(F)(F)F)C2";"GHFAIKMTCXYODU-LBPRGKRZSA-N";443.44;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.32;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.00000478630092322638
"MM473813";"MM473813";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cccc(C#N)c2C1)C(F)(F)F";"KZTUEUOKPCKYBS-LBPRGKRZSA-N";438.43;3.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-6.1;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000007943282347242822
"MM473812";"MM473812";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cc(C(F)(F)F)cnc2C1)C(F)(F)F";"DSFRGIKAQFSVOE-JTQLQIEISA-N";482.4;3.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.3;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000005011872336272725
"MM473811";"MM473811";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cnc(C(F)(F)F)cc2C1)C(F)(F)F";"CNUSCWXBRLDDER-JTQLQIEISA-N";482.4;3.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.41;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000003890451449942805
"MM473810";"MM473810";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(C(F)(F)F)nc2C1)C(F)(F)F";"AKNCSOCWJLAUDN-JTQLQIEISA-N";482.4;3.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.26;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000054954087385762485
"MM473809";"MM473809";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(-c3ccccn3)cc2C1)C(F)(F)F";"GXJKYQIAVVFXIE-HNNXBMFYSA-N";490.5;4.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-6.1;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000007943282347242822
"MM473808";"MM473808";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(-c3ccncc3)cc2C1)C(F)(F)F";"XICAQVBMJIEJFN-HNNXBMFYSA-N";490.5;4.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.38;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000004168693834703355
"MM473807";"MM473807";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(C3CCCCO3)cc2C1)C(F)(F)F";"NDZBXHIFLMZLMT-ZDGMYTEDSA-N";497.54;4.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-6.05;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000008912509381337459
"MM473806";"MM473806";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(C3CCOCC3)cc2C1)C(F)(F)F";"IHLMQHFPWQMCHB-HNNXBMFYSA-N";497.54;4.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.48;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000033113112148259077
"MM473805";"MM473805";"CC(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cc(C(F)(F)F)cnc2C1";"FMDCETZXKXBSAU-UHFFFAOYSA-N";428.43;3.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.39;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000004073802778041131
"MM473804";"MM473804";"CC(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(C3CCOCC3)cc2C1";"SPASPLFBANPFIF-UHFFFAOYSA-N";443.57;3.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.38;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000004168693834703355
"MM473803";"MM473803";"CC(C)COc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cc(C(F)(F)F)cnc2C1";"KKVWTQYWUKZMBL-UHFFFAOYSA-N";442.46;3.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.26;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000054954087385762485
"MM473801";"MM473801";"CS(=O)(=O)c1ccc(OCCC(F)(F)F)c(C(=O)N2Cc3ccc(C4CCOCC4)cc3C2)c1";"OKLLQEQVBOXGNV-UHFFFAOYSA-N";497.54;4.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.39;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000004073802778041131
"MM473800";"MM473800";"CS(=O)(=O)c1ccc(OCc2ccccc2)c(C(=O)N2Cc3cc(C(F)(F)F)cnc3C2)c1";"PKYPYFWOAAMLCH-UHFFFAOYSA-N";476.48;4.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-6.1;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000007943282347242822
"MM473802";"MM473802";"CS(=O)(=O)c1ccc(OCCC(F)(F)F)c(C(=O)N2Cc3cc(C(F)(F)F)cnc3C2)c1";"CBFIHQCACGMSHE-UHFFFAOYSA-N";482.4;3.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.37;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000004265795188015926
"MM473799";"MM473799";"CS(=O)(=O)c1ccc(-c2ccc(F)cc2)c(C(=O)N2Cc3ccc(C4CCOCC4)cc3C2)c1";"QMVMTEKLTFRTEL-UHFFFAOYSA-N";479.57;4.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.85;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000014125375446227554
"MM473798";"MM473798";"CS(=O)(=O)c1ccc(-c2ccc(F)c(F)c2)c(C(=O)N2Cc3cc(C(F)(F)F)cnc3C2)c1";"HXKDSNZJKHAINQ-UHFFFAOYSA-N";482.43;4.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-5.19;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.000006456542290346549
"MM473797";"MM473797";"CS(=O)(=O)c1ccc(N2CCOCC2)c(C(=O)N2Cc3cc(C(F)(F)F)cnc3C2)c1";"NVYIUOYOCQKBAB-UHFFFAOYSA-N";455.46;2.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1639761/target=_blank>CHEMBL1639761</a>";;-6.05;"Pinard E, Alberati D, Bender M, Borroni E, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Norcross RD, Schmid P, Wermuth R, Zimmerli D.: Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 20 (23), 2010";"PAMPA";0.0000008912509381337459
"MM473843";"MM473843";"CN(C)CCNC(=O)c1cc(C(C)(C)C)sc1NC(=O)Nc1ccc2[nH]ncc2c1";"QUNYYWCMQDEBCS-UHFFFAOYSA-N";428.56;3.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1646057/target=_blank>CHEMBL1646057</a>";;-5.7;"Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.: Potent and selective thiophene urea-templated inhibitors of S6K. Bioorg Med Chem Lett, Volume 21 (2), 2011";"PAMPA";0.0000019952623149688787
"MM473842";"MM473842";"CC(C)(C)c1ccc(NC(=O)Nc2ccc3[nH]ncc3c2)s1";"VCMFTYZQQOPGHM-UHFFFAOYSA-N";314.41;4.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1646057/target=_blank>CHEMBL1646057</a>";;-5.52;"Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.: Potent and selective thiophene urea-templated inhibitors of S6K. Bioorg Med Chem Lett, Volume 21 (2), 2011";"PAMPA";0.0000030199517204020193
"MM473841";"MM473841";"CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1";"BSRFCMMJUFQEOX-UHFFFAOYSA-N";358.42;4.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1646057/target=_blank>CHEMBL1646057</a>";;-4.77;"Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.: Potent and selective thiophene urea-templated inhibitors of S6K. Bioorg Med Chem Lett, Volume 21 (2), 2011";"PAMPA";0.00001698243652461746
"MM473840";"MM473840";"CC(C)(C)c1cc(C(=O)NC2CC2)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1";"CKEFKLKYCNGDMN-UHFFFAOYSA-N";397.5;4.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1646057/target=_blank>CHEMBL1646057</a>";;-5.4;"Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.: Potent and selective thiophene urea-templated inhibitors of S6K. Bioorg Med Chem Lett, Volume 21 (2), 2011";"PAMPA";0.000003981071705534969
"MM473839";"MM473839";"COCCNC(=O)c1cc(C(C)(C)C)sc1NC(=O)Nc1ccc2[nH]ncc2c1";"MYXPVTHRAONUPM-UHFFFAOYSA-N";415.52;3.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1646057/target=_blank>CHEMBL1646057</a>";;-5.4;"Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.: Potent and selective thiophene urea-templated inhibitors of S6K. Bioorg Med Chem Lett, Volume 21 (2), 2011";"PAMPA";0.000003981071705534969
"MM473838";"MM473838";"CC(C)(C)c1cc(C(=O)NCCO)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1";"HABLDKGVGUOHTL-UHFFFAOYSA-N";401.49;3.29;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1646057/target=_blank>CHEMBL1646057</a>";;-5.3;"Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.: Potent and selective thiophene urea-templated inhibitors of S6K. Bioorg Med Chem Lett, Volume 21 (2), 2011";"PAMPA";0.000005011872336272725
"MM474141";"MM474141";"O=C(CCCc1ccccc1)OC(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1";"BYFXZIUNDKEGTH-UHFFFAOYSA-N";524.08;6.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3396031/target=_blank>CHEMBL3396031</a>";;-5.28;"Sozio P, Fiorito J, Di Giacomo V, Di Stefano A, Marinelli L, Cacciatore I, Cataldi A, Pacella S, Turkez H, Parenti C, Rescifina A, Marrazzo A.: Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells. Eur J Med Chem, Volume 90, 2015";"PAMPA";0.000005248074602497723
"MM472575";"MM472575";"CC(C)(O)C(=O)N1CCN(c2ccc(C(F)(F)F)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1";"CLGRAWDGLMENOD-UHFFFAOYSA-N";526.52;3.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1657319/target=_blank>CHEMBL1657319</a>";;-5.5;"Thoma G, Nuninger F, Falchetto R, Hermes E, Tavares GA, Vangrevelinghe E, Zerwes HG.: Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.000003162277660168379
"MM472589";"MM472589";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1Cl";"DWTYHCYVKJONSP-UHFFFAOYSA-N";461.95;6.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-5.5;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.000003162277660168379
"MM472588";"MM472588";"CC(C)N1Cc2cc(OCc3cccc(-c4ccc(Cl)c(C(=O)O)c4)c3)ccc2C1=O";"IPHOWNGWSDCVGP-UHFFFAOYSA-N";435.91;5.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-6.1;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.0000007943282347242822
"MM472587";"MM472587";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(CC3CC3)C4=O)c2)ccc1Cl";"KVJSUTHOTPIBKD-UHFFFAOYSA-N";447.92;5.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-6.5;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.0000003162277660168379
"MM472586";"MM472586";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCC3)C4=O)c2)ccc1Cl";"JLNCSHRPBPSZBX-UHFFFAOYSA-N";447.92;5.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-5.6;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.0000025118864315095823
"MM472585";"MM472585";"CC(C)CN1Cc2cc(OCc3cccc(-c4ccc(Cl)c(C(=O)O)c4)c3)ccc2C1=O";"YZJZFZOHJRZNPA-UHFFFAOYSA-N";449.93;5.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-6.3;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.0000005011872336272725
"MM472584";"MM472584";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CC3)C4=O)c2)ccc1Cl";"GOWMLURUVOXADH-UHFFFAOYSA-N";433.89;5.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-5.6;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.0000025118864315095823
"MM472583";"MM472583";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(c3ccccc3)C4=O)c2)ccc1Cl";"WSJJJSYOUXIKQC-UHFFFAOYSA-N";469.92;6.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-6.6;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.00000025118864315095823
"MM472582";"MM472582";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCCC3)C4=O)c2)ccc1Cl";"IBQPSJPBASPNCR-UHFFFAOYSA-N";475.97;6.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-6.5;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.0000003162277660168379
"MM472581";"MM472581";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(Cc3ccc(C(F)(F)F)cc3)C4=O)c2)ccc1Cl";"UWTLBJDYPAUTTF-UHFFFAOYSA-N";551.95;7.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-7.8;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.000000015848931924611143
"MM472580";"MM472580";"CC(C)CCN1Cc2cc(OCc3cccc(-c4ccc(Cl)c(C(=O)O)c4)c3)ccc2C1=O";"IMHMIERAXZPLJV-UHFFFAOYSA-N";463.96;6.29;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-5.8;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.000001584893192461114
"MM472579";"MM472579";"CCCN1Cc2cc(OCc3cccc(-c4ccc(Cl)c(C(=O)O)c4)c3)ccc2C1=O";"PPCPRTGTJBOFEI-UHFFFAOYSA-N";435.91;5.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-4.9;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.000012589254117941661
"MM472578";"MM472578";"O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl";"ZQBPXBADOJMCRU-UHFFFAOYSA-N";479.99;6.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-5.4;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.000003981071705534969
"MM472577";"MM472577";"O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)oc4c3)c2)ccc1Cl";"RGJRUFROGILIAI-UHFFFAOYSA-N";463.92;6.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-6.3;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.0000005011872336272725
"MM472576";"MM472576";"O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CCN(C3CCCC3)C4=O)c2)ccc1Cl";"OAQBFIUKZFPSMN-UHFFFAOYSA-N";475.97;6.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-6.1;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.0000007943282347242822
"MM473124";"MM473124";"O=C(NC1(C(=O)N[C@@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1)c1ccc(-n2cccc2)cc1Cl";"ZUOUNFWNIKLCLI-UMSFTDKQSA-N";674.29;5.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1687458/target=_blank>CHEMBL1687458</a>";;-6.8;"Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.: hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.0000001584893192461114
"MM473125";"MM473125";"O=C(NC1(C(=O)N[C@@H](Cc2ccccc2)C(=O)NCC2CCN(CC3CCOCC3)CC2)CCCC1)c1ccc(-n2cccc2)cc1F";"ZDMDLPSBBZSJEE-UMSFTDKQSA-N";657.83;4.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1687458/target=_blank>CHEMBL1687458</a>";;-6.18;"Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.: hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.0000006606934480075964
"MM473126";"MM473126";"CCCCc1ccc(C(=O)NC2(C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)cc1";"FNWMFLJWSOZBPX-UMSFTDKQSA-N";630.87;5.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1687458/target=_blank>CHEMBL1687458</a>";;-5.8;"Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.: hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.000001584893192461114
"MM473127";"MM473127";"CCCCc1ccc(C(=O)NC2(C(=O)N[C@@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)nc1";"NUEAGESSSAENGD-XIFFEERXSA-N";631.86;4.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1687458/target=_blank>CHEMBL1687458</a>";;-5.14;"Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.: hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.000007244359600749906
"MM473128";"MM473128";"O=C(NC1(C(=O)N[C@H](CCCN2CCN(CC3CCOCC3)CC2)Cc2ccccc2)CCCC1)c1ccc2ccccc2c1";"ZXRIWIVIXXWDGK-PGUFJCEWSA-N";610.84;5.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1687458/target=_blank>CHEMBL1687458</a>";;-5.22;"Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.: hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.000006025595860743581
"MM473129";"MM473129";"O=C(NC1(C(=O)N[C@H](CCCN2CCN(CC3CCOCC3)CC2)Cc2ccccc2)CCCC1)c1cc2ccccc2cn1";"ONUCNPNYIMMSHV-MGBGTMOVSA-N";611.83;4.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1687458/target=_blank>CHEMBL1687458</a>";;-4.81;"Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.: hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.000015488166189124828
"MM473130";"MM473130";"COc1cc2ccccc2cc1C(=O)NC1(C(=O)N[C@H](CCCN2CCN(CC3CCOCC3)CC2)Cc2ccccc2)CCCC1";"MOPFRPUDCVVVPA-UUWRZZSWSA-N";640.87;5.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1687458/target=_blank>CHEMBL1687458</a>";;-4.92;"Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.: hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.000012022644346174132
"MM473131";"MM473131";"COc1c(C(=O)NC2(C(=O)N[C@H](CCCN3CCN(CC4CCOCC4)CC3)Cc3ccccc3)CCCC2)ccc2ccccc12";"OTLFJNPFYBOAPG-MGBGTMOVSA-N";640.87;5.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1687458/target=_blank>CHEMBL1687458</a>";;-5.17;"Ettorre A, D'Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D.: hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.000006760829753919819
"MM473132";"MM473132";"Cc1c(C(=O)N=C(N)N)ncn1Cc1ccc(Cl)cc1";"MBFRJCJPZMFFMU-UHFFFAOYSA-N";291.74;1.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1685366/target=_blank>CHEMBL1685366</a>";;-5.59;"Atkinson KA, Beretta EE, Brown JA, Castrodad M, Chen Y, Cosgrove JM, Du P, Litchfield J, Makowski M, Martin K, McLellan TJ, Neagu C, Perry DA, Piotrowski DW, Steppan CM, Trilles R.: N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors. Bioorg Med Chem Lett, Volume 21 (6), 2011";"PAMPA";0.0000025703957827688647
"MM473289";"MM473289";"Nc1ncc(-c2nc(N3CCOCC3)nc3c2CCN3c2cccnc2)cn1";"WZVLQVVHYKFKAZ-UHFFFAOYSA-N";376.42;1.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-5.72;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.0000019054607179632483
"MM473133";"MM473133";"N#Cc1ccccc1N1CCN(C(=O)COCc2ccccc2)CC1";"LTPGKAICNBCBPT-UHFFFAOYSA-N";335.41;2.42;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1696012/target=_blank>CHEMBL1696012</a>";;-5.66;"Zhou Y, Manka JT, Rodriguez AL, Weaver CD, Days EL, Vinson PN, Jadhav S, Hermann EJ, Jones CK, Conn PJ, Lindsley CW, Stauffer SR.: Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic Activity. ACS Med Chem Lett, Volume 1 (8), 2010";"PAMPA";0.0000021877616239495517
"MM473155";"MM473155";"CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1";"QHLVBNKYJGBCQJ-UHFFFAOYSA-N";532.53;1.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777615/target=_blank>CHEMBL1777615</a>";;-4.3;"Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.: NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett, Volume 21 (10), 2011";"PAMPA";0.00005011872336272725
"MM473333";"MM473333";"Cc1nc2ccc(Cl)cc2c(-c2ccccc2)c1C(=O)O";"DTGFDMHLQGULMA-UHFFFAOYSA-N";297.74;4.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-6.64;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.00000022908676527677748
"5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol";"MM00306";"CC(C)(C)NCC(O)c1cc(O)cc(O)c1";"XWTYSIMOBUGWOL-UHFFFAOYSA-N";225.29;1.52;"5403";"CHEMBL1760";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.4;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000003981071705534969
"MM474724";"MM474724";"CCS(=O)(=O)N1CCC(c2c[nH]c3c(C(N)=O)cc(-c4ccccc4)cc23)CC1";"UCPWBEUDVDWSCD-UHFFFAOYSA-N";411.53;3.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.6;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.000025118864315095822
"MM473844";"MM473844";"C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](Nc1ccc2c(c1)B(O)OC2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1";"AZZXZDGTQMMJCP-LUDDSFFPSA-N";780.11;2.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1762885/target=_blank>CHEMBL1762885</a>";;1.86;"Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L, Kazmierski WM, Duan M, Grimes RM, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J.: Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties. Bioorg Med Chem Lett, Volume 21 (7), 2011";"PAMPA";72.44359600749902
"MM473136";"MM473136";"CC(C)(C)c1cc(C(C)(C)C)c2[nH]c(C(C)(C)C)c(C[C@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCCc3ccccc3)c2c1";"VGDFCPGJKLCUFL-VMPREFPWSA-N";631.91;5.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-5.28;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.000005248074602497723
"MM473139";"MM473139";"NCCCC[C@H](NC(=O)[C@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)[C@@H](N)CCCCN)C(N)=O";"DAQIVHRRKUXAAO-HJOGWXRNSA-N";496.66;0.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-7.22;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.00000006025595860743581
"MM473140";"MM473140";"N=C(N)NCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(c1ccccc1)c1ccccc1)C(N)=O";"BSQXTFKJAMCRFM-ONTIZHBOSA-N";552.68;-0.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.08;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000008317637711026709
"MM473141";"MM473141";"NCCCC[C@H](NC(=O)[C@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)[C@@H](N)CCCCN)C(=O)NCc1ccccc1";"FSHXZOMORWHEPF-CHQNGUEUSA-N";586.78;2.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.59;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000002570395782768865
"MM473145";"MM473145";"N=C(N)Nc1ccc(C[C@H](NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@@H](N)Cc2ccc(NC(=N)N)cc2)C(=O)NCc2ccccc2)cc1";"SGBUNANFYAIBCR-FSEITFBQSA-N";738.9;3.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.05;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000008912509381337459
"MM473150";"MM473150";"c1ccc(Cc2ncc3c(n2)CCNCC3)cc1";"CZWQBSKNHUVZLI-UHFFFAOYSA-N";239.32;1.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1772824/target=_blank>CHEMBL1772824</a>";;-4.55;"Andrews MD, Fish PV, Blagg J, Brabham TK, Brennan PE, Bridgeland A, Brown AD, Bungay PJ, Conlon KM, Edmunds NJ, af Forselles K, Gibbons CP, Green MP, Hanton G, Holbrook M, Jessiman AS, McIntosh K, McMurray G, Nichols CL, Root JA, Storer RI, Sutton MR, Ward RV, Westbrook D, Whitlock GA.: Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence. Bioorg Med Chem Lett, Volume 21 (9), 2011";"PAMPA";0.00002818382931264455
"MM473153";"MM473153";"CN1CC=C(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3C)CC4)c2)CC1";"DFKJNGVBNCASDM-UHFFFAOYSA-N";499.5;3.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777615/target=_blank>CHEMBL1777615</a>";;-4.33;"Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.: NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett, Volume 21 (10), 2011";"PAMPA";0.00004677351412871981
"MM473154";"MM473154";"CN1CCC(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)cn3C)CC4)c2)CC1";"UPGSUYGNMGTTGT-UHFFFAOYSA-N";500.53;4.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777615/target=_blank>CHEMBL1777615</a>";;-4.43;"Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.: NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett, Volume 21 (10), 2011";"PAMPA";0.00003715352290971728
"MM473151";"MM473151";"CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCN)CC4)c2)CC1";"FNVWTCCOPVJPNB-UHFFFAOYSA-N";531.54;1.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777615/target=_blank>CHEMBL1777615</a>";;-5.3;"Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.: NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett, Volume 21 (10), 2011";"PAMPA";0.000005011872336272725
"MM473152";"MM473152";"CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCCN)CC4)c2)CC1";"YALDCBLTYPJUTR-UHFFFAOYSA-N";545.57;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1777615/target=_blank>CHEMBL1777615</a>";;-5.4;"Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.: NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett, Volume 21 (10), 2011";"PAMPA";0.000003981071705534969
"MM473117";"MM473117";"CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCF)CC4)c2)CC1";"VPWDLLHGBJTELF-UHFFFAOYSA-N";534.52;2.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1272706/target=_blank>CHEMBL1272706</a>";;-4.3;"Beria I, Valsasina B, Brasca MG, Ceccarelli W, Colombo M, Cribioli S, Fachin G, Ferguson RD, Fiorentini F, Gianellini LM, Giorgini ML, Moll JK, Posteri H, Pezzetta D, Roletto F, Sola F, Tesei D, Caruso M.: 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors. Bioorg Med Chem Lett, Volume 20 (22), 2010";"PAMPA";0.00005011872336272725
"MM473114";"MM473114";"C=Cn1nc(C(N)=O)c2c1-c1nc(Nc3cc(N4CCN(C)CC4)ccc3OC(F)(F)F)ncc1CC2";"IWNBRVJHAXKTLL-UHFFFAOYSA-N";514.51;3.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1272706/target=_blank>CHEMBL1272706</a>";;-4.71;"Beria I, Valsasina B, Brasca MG, Ceccarelli W, Colombo M, Cribioli S, Fachin G, Ferguson RD, Fiorentini F, Gianellini LM, Giorgini ML, Moll JK, Posteri H, Pezzetta D, Roletto F, Sola F, Tesei D, Caruso M.: 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors. Bioorg Med Chem Lett, Volume 20 (22), 2010";"PAMPA";0.000019498445997580456
"MM472593";"MM472593";"COC(=O)c1ccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(Cl)c2)cc1";"UYZZOIIIXKXPFB-JGLNRKDHSA-N";424.83;0.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1805241/target=_blank>CHEMBL1805241</a>";;-4.6;"Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, LĂĽthi C, Scharenberg M, BezenĂ§on J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.: FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem, Volume 53 (24), 2010";"PAMPA";0.000025118864315095822
"MM472594";"MM472594";"COC(=O)c1ccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)cc2Cl)cc1";"ZMJKGQUTBTUUJI-JGLNRKDHSA-N";424.83;0.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1805241/target=_blank>CHEMBL1805241</a>";;-4.72;"Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, LĂĽthi C, Scharenberg M, BezenĂ§on J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.: FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem, Volume 53 (24), 2010";"PAMPA";0.000019054607179632484
"MM472595";"MM472595";"COC(=O)c1ccc(-c2cc(Cl)c(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(Cl)c2)cc1";"LGMPJLJIHTWSMR-GFAJBQDWSA-N";459.28;1.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1805241/target=_blank>CHEMBL1805241</a>";;-4.29;"Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, LĂĽthi C, Scharenberg M, BezenĂ§on J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.: FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem, Volume 53 (24), 2010";"PAMPA";0.00005128613839913648
"MM472596";"MM472596";"COC(=O)c1ccc(-c2c(Cl)cc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)cc2Cl)cc1";"PRHJCSVIPWVXNC-XMUPAAEVSA-N";459.28;1.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1805241/target=_blank>CHEMBL1805241</a>";;-4.4;"Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, LĂĽthi C, Scharenberg M, BezenĂ§on J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.: FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem, Volume 53 (24), 2010";"PAMPA";0.000039810717055349695
"MM472598";"MM472598";"COC(=O)c1ccc(-c2ccc(Cl)c(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c2)cc1";"WDDBPKRIAIETTE-JGLNRKDHSA-N";424.83;0.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1805241/target=_blank>CHEMBL1805241</a>";;-4.69;"Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, LĂĽthi C, Scharenberg M, BezenĂ§on J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.: FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem, Volume 53 (24), 2010";"PAMPA";0.000020417379446695274
"MM473156";"MM473156";"CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1";"OWVIKBRKPCTDEP-UHFFFAOYSA-N";372.53;3.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1820287/target=_blank>CHEMBL1820287</a>";;-4.72;"Verhoest PR, Basak AS, Parikh V, Hayward M, Kauffman GW, Paradis V, McHardy SF, McLean S, Grimwood S, Schmidt AW, Vanase-Frawley M, Freeman J, Van Deusen J, Cox L, Wong D, Liras S.: Design and discovery of a selective small molecule Îş opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem, Volume 54 (16), 2011";"PAMPA";0.000019054607179632484
"MM473158";"MM473158";"CCCc1cc(-c2nc(-c3ccc(NC(C)C)cc3)cs2)ccn1";"GOKVUOGCZQKXQS-UHFFFAOYSA-N";337.49;5.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1827449/target=_blank>CHEMBL1827449</a>";;-5.98;"Kamisuki S, Shirakawa T, Kugimiya A, Abu-Elheiga L, Choo HY, Yamada K, Shimogawa H, Wakil SJ, Uesugi M.: Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.0000010471285480508985
"MM473159";"MM473159";"CCCc1cc(-c2nc(-c3ccc(NS(C)(=O)=O)cc3)cs2)ccn1";"OWAXXHRQPWGNTG-UHFFFAOYSA-N";373.5;4.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1827449/target=_blank>CHEMBL1827449</a>";;-4.82;"Kamisuki S, Shirakawa T, Kugimiya A, Abu-Elheiga L, Choo HY, Yamada K, Shimogawa H, Wakil SJ, Uesugi M.: Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000015135612484362071
"MM473170";"MM473170";"c1ccc(Nc2nc3c(s2)CCc2n[nH]cc2-3)nc1";"MIOXQGMSPSEKCA-UHFFFAOYSA-N";269.33;2.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.52;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.0000030199517204020193
"MM473169";"MM473169";"c1cncc(Nc2nc3c(s2)CCc2n[nH]cc2-3)c1";"YLMCUXMPYWJRLT-UHFFFAOYSA-N";269.33;2.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-4.73;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000018620871366628657
"MM473168";"MM473168";"c1cc(Nc2nc3c(s2)CCc2n[nH]cc2-3)ccn1";"FWQQWRMZPAVZRS-UHFFFAOYSA-N";269.33;2.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.6;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.0000025118864315095823
"MM473165";"MM473165";"c1cnc(Nc2nc3c(s2)CCc2n[nH]cc2-3)nc1";"DYTOOFWBTYQIBR-UHFFFAOYSA-N";270.32;2.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.47;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.0000033884415613920275
"MM473167";"MM473167";"Cc1ccnc(Nc2nc3c(s2)CCc2n[nH]cc2-3)c1";"QVXRVZDGANBLSG-UHFFFAOYSA-N";283.36;3.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-4.91;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.00001230268770812381
"MM473166";"MM473166";"Cc1ccc(Nc2nc3c(s2)CCc2n[nH]cc2-3)nc1";"JZQMRRNRLNOLIP-UHFFFAOYSA-N";283.36;3.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.72;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.0000019054607179632483
"MM473164";"MM473164";"Cc1cccc(Nc2nc3c(s2)CCc2n[nH]cc2-3)n1";"XVAGDGYSYFRXHH-UHFFFAOYSA-N";283.36;3.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.7;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.0000019952623149688787
"MM473163";"MM473163";"Cc1cc(C)nc(Nc2nc3c(s2)CCc2n[nH]cc2-3)c1";"MOSHYIZCRFOVQT-UHFFFAOYSA-N";297.39;3.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-6;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000001
"MM473162";"MM473162";"c1ccc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)nc1";"DBISXWCOHGUFSF-UHFFFAOYSA-N";283.36;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.03;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000009332543007969906
"MM473161";"MM473161";"c1cncc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)c1";"RZBNNZQLMKBBNX-UHFFFAOYSA-N";283.36;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-4.46;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.00003467368504525317
"MM473160";"MM473160";"c1cc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)ncn1";"NGZOBRYWWQNTCK-UHFFFAOYSA-N";284.35;2.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-4.39;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.0000407380277804113
"MM473171";"MM473171";"c1cnc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)cn1";"UAZAFDBTOFCZMD-UHFFFAOYSA-N";284.35;2.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.42;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000003801893963205613
"MM473172";"MM473172";"c1cnc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)nc1";"HYJWPTWQMAYKAM-UHFFFAOYSA-N";284.35;2.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.82;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.0000015135612484362072
"MM473173";"MM473173";"c1cc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)n[nH]1";"MEAAZOQWXGTOJX-UHFFFAOYSA-N";272.34;2.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-4.6;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000025118864315095822
"MM473174";"MM473174";"Cc1cc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)n[nH]1";"GJMAJJZUVKDXAJ-UHFFFAOYSA-N";286.36;2.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-4.82;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000015135612484362071
"MM473175";"MM473175";"Cn1ccc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)n1";"DHEKTOPEFWQDPU-UHFFFAOYSA-N";286.36;2.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-4.72;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000019054607179632484
"MM473176";"MM473176";"Cc1ccc(Nc2nc3c(s2)CCCc2n[nH]cc2-3)nn1";"UUBXQAQLUVZNFP-UHFFFAOYSA-N";298.38;2.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-4.51;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.00003090295432513592
"MM473177";"MM473177";"c1[nH]nc2c1-c1nc(NC3CCCCC3)sc1CCC2";"VKUVUAOMIMXLNY-UHFFFAOYSA-N";288.42;3.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.55;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000002818382931264455
"MM473178";"MM473178";"Cc1cccnc1Nc1nc2c(s1)CCCc1n[nH]cc1-2";"VYMFSHRJSVAJCD-UHFFFAOYSA-N";297.39;3.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1831602/target=_blank>CHEMBL1831602</a>";;-5.1;"Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, Peterson J, Zou ZZ, Robichaud AJ, Doller D.: Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem, Volume 54 (14), 2011";"PAMPA";0.000007943282347242822
"MM473191";"MM473191";"Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1";"HCOIQQJHIUTQMB-UHFFFAOYSA-N";337.38;2.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1839693/target=_blank>CHEMBL1839693</a>";;-4.33;"Morley A, Tomkinson N, Cook A, MacDonald C, Weaver R, King S, Jenkinson L, Unitt J, McCrae C, Phillips T.: Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. Bioorg Med Chem Lett, Volume 21 (20), 2011";"PAMPA";0.00004677351412871981
"MM471002";"MM471002";"CSc1nc(Nc2cccc(Cl)c2)c2cnn(CCc3ccccc3)c2n1";"YQKKZNSKOPPFHY-UHFFFAOYSA-N";395.92;5.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4013498/target=_blank>CHEMBL4013498</a>";;-6.6;"Vignaroli G, Iovenitti G, Zamperini C, Coniglio F, Calandro P, Molinari A, Fallacara AL, Sartucci A, Calgani A, Colecchia D, Mancini A, Festuccia C, Dreassi E, Valoti M, Musumeci F, Chiariello M, Angelucci A, Botta M, Schenone S.: Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.00000025118864315095823
"MM471003";"MM471003";"CSc1nc(Nc2cccc(Br)c2)c2cnn(CC(C)c3ccccc3)c2n1";"JSXXDWHFXXQDDJ-UHFFFAOYSA-N";454.4;5.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4013498/target=_blank>CHEMBL4013498</a>";;-8;"Vignaroli G, Iovenitti G, Zamperini C, Coniglio F, Calandro P, Molinari A, Fallacara AL, Sartucci A, Calgani A, Colecchia D, Mancini A, Festuccia C, Dreassi E, Valoti M, Musumeci F, Chiariello M, Angelucci A, Botta M, Schenone S.: Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.00000001
"MM471003";"MM471003";"CSc1nc(Nc2cccc(Br)c2)c2cnn(CC(C)c3ccccc3)c2n1";"JSXXDWHFXXQDDJ-UHFFFAOYSA-N";454.4;5.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2411066/target=_blank>CHEMBL2411066</a>";;-8;"Vignaroli G, Zamperini C, Dreassi E, Radi M, Angelucci A, SanitĂ  P, Crespan E, Kissova M, Maga G, Schenone S, Musumeci F, Botta M.: Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors. ACS Med Chem Lett, Volume 4 (7), 2013";"PAMPA";0.00000001
"MM473198";"MM473198";"CN(C)CCOc1ccc(Cn2c(=O)[nH]c3c(N)nc(C(F)(F)F)cc32)cn1";"FCIITKQVFRCXQN-UHFFFAOYSA-N";396.37;1.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-5.89;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.000001288249551693135
"MM473192";"MM473192";"CN(C)CCNc1ccc(Cn2c(=O)[nH]c3c(N)nc(C(F)(F)F)cc32)cn1";"VJQJILGCYUBXMO-UHFFFAOYSA-N";395.39;1.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-7;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.0000001
"MM473200";"MM473200";"Nc1nc(C(F)(F)F)cc2c1[nH]c(=O)n2Cc1ccc(OCCN2CCCC2)nc1";"UBAJSVZYTYHQSD-UHFFFAOYSA-N";422.41;2.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-5.33;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.000004677351412871981
"MM473193";"MM473193";"Nc1nc(C(F)(F)F)cc2c1[nH]c(=O)n2Cc1ccc(NCCN2CCCC2)nc1";"PLQSVDRLCXPXQD-UHFFFAOYSA-N";421.43;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-7;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.0000001
"MM473197";"MM473197";"CN(C)CCN(C)c1ccc(Cn2c(=O)[nH]c3c(N)nc(C(F)(F)F)cc32)cn1";"AAOTVWDBODRGRV-UHFFFAOYSA-N";409.42;1.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-6.05;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.0000008912509381337459
"MM473203";"MM473203";"CN1CCN(c2ccc(Cn3c(=O)[nH]c4c(N)nc(C(F)(F)F)cc43)cn2)CC1";"VUJWPECYEWDMSR-UHFFFAOYSA-N";407.4;1.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-4.92;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.000012022644346174132
"MM473202";"MM473202";"COCCN1CCN(c2ccc(Cn3c(=O)[nH]c4c(N)nc(C(F)(F)F)cc43)cn2)CC1";"WHYNFCSKHARUNG-UHFFFAOYSA-N";451.45;1.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-5;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.00001
"MM473194";"MM473194";"CN(C)CCN1CCN(c2ccc(Cn3c(=O)[nH]c4c(N)nc(C(F)(F)F)cc43)cn2)CC1";"DCNQTKAVOYMOSG-UHFFFAOYSA-N";464.5;1.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-7;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.0000001
"MM473201";"MM473201";"CN(CCN1CCCCC1)c1ccc(Cn2c(=O)[nH]c3c(N)nc(C(F)(F)F)cc32)cn1";"FBIKDAGCINCIRM-UHFFFAOYSA-N";449.48;2.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-5.28;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.000005248074602497723
"MM473199";"MM473199";"CCN(CC)CCN(C)c1ccc(Cn2c(=O)[nH]c3c(N)nc(C(F)(F)F)cc32)cn1";"RMZPNWGHJKRMCJ-UHFFFAOYSA-N";437.47;2.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-5.6;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.0000025118864315095823
"MM473196";"MM473196";"CN1CCN(CCN(C)c2ccc(Cn3c(=O)[nH]c4c(N)nc(C(F)(F)F)cc43)cn2)CC1";"MSKYZOPCECANKD-UHFFFAOYSA-N";464.5;1.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-6.15;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.0000007079457843841374
"MM473195";"MM473195";"Nc1nc(C(F)(F)F)cc2c1[nH]c(=O)n2Cc1ccc(NCCN2CCCCC2)nc1";"QKUWZNZVQLRNKN-UHFFFAOYSA-N";435.45;2.67;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1837704/target=_blank>CHEMBL1837704</a>";;-6.52;"Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A.: Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett, Volume 21 (19), 2011";"PAMPA";0.0000003019951720402019
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902035/target=_blank>CHEMBL902035</a>";;-8;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"PAMPA";0.00000001
"MM474392";"MM474392";"O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5";"DQCKKXVULJGBQN-XFWGSAIBSA-N";341.41;1.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.82;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000015135612484362071
"MM473205";"MM473205";"CC(=O)Nc1cn2cc(/C=C3\SC(=O)NC3=O)ccc2n1";"CCECKHDWHUIQQG-WTKPLQERSA-N";302.32;1.62;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1918901/target=_blank>CHEMBL1918901</a>";;-4.87;"Hughes SJ, Millan DS, Kilty IC, Lewthwaite RA, Mathias JP, O'Reilly MA, Pannifer A, Phelan A, StĂĽhmeier F, Baldock DA, Brown DG.: Fragment based discovery of a novel and selective PI3 kinase inhibitor. Bioorg Med Chem Lett, Volume 21 (21), 2011";"PAMPA";0.000013489628825916533
"MM473204";"MM473204";"Cc1ncc(Cn2nc(-c3nc(C(F)(F)F)n[nH]3)c3cccnc32)cn1";"QAXGZFQDGNOCEI-UHFFFAOYSA-N";360.3;2.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1918706/target=_blank>CHEMBL1918706</a>";;-4.57;"Roberts LR, Bradley PA, Bunnage ME, England KS, Fairman D, Fobian YM, Fox DN, Gymer GE, Heasley SE, Molette J, Smith GL, Schmidt MA, Tones MA, Dack KN.: Acidic triazoles as soluble guanylate cyclase stimulators. Bioorg Med Chem Lett, Volume 21 (21), 2011";"PAMPA";0.00002691534803926914
"MM474418";"MM474418";"O=C(Nc1cc(-c2cc3c([nH]2)C2(CCNCC2)CNC3=O)ccn1)c1cccc(F)c1";"KNKFHJYKSHDVBU-UHFFFAOYSA-N";419.46;2.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1937265/target=_blank>CHEMBL1937265</a>";;-6.22;"Oubrie A, Kaptein A, de Zwart E, Hoogenboom N, Goorden R, van de Kar B, van Hoek M, de Kimpe V, van der Heijden R, Borsboom J, Kazemier B, de Roos J, Scheffers M, Lommerse J, Schultz-Fademrecht C, Barf T.: Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Bioorg Med Chem Lett, Volume 22 (1), 2012";"PAMPA";0.0000006025595860743581
"MM474419";"MM474419";"Cc1ccc(C(=O)Nc2cc(-c3cc4c([nH]3)C3(CCCNC3)CNC4=O)ccn2)cc1C";"BAYAFUAQZUNFQN-UHFFFAOYSA-N";429.52;3.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1937265/target=_blank>CHEMBL1937265</a>";;-6;"Oubrie A, Kaptein A, de Zwart E, Hoogenboom N, Goorden R, van de Kar B, van Hoek M, de Kimpe V, van der Heijden R, Borsboom J, Kazemier B, de Roos J, Scheffers M, Lommerse J, Schultz-Fademrecht C, Barf T.: Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Bioorg Med Chem Lett, Volume 22 (1), 2012";"PAMPA";0.000001
"MM473208";"MM473208";"O=C(c1cc2cc(Cl)ccc2[nH]1)N1C[C@]2(CCN(C3CCNC3)C2)c2ccccc21";"SGBSKNKMLNQHSJ-VCUSLETLSA-N";420.94;3.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1935926/target=_blank>CHEMBL1935926</a>";;-7.52;"Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA.: Novel and selective spiroindoline-based inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 22 (1), 2012";"PAMPA";0.000000030199517204020194
"MM473207";"MM473207";"CN1CCN(c2ccc(OC(F)(F)F)c(Nc3nccc(-c4cc(C(N)=O)cn4C)n3)c2)CC1";"HGBZKLOZYQAERY-UHFFFAOYSA-N";475.48;2.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1936745/target=_blank>CHEMBL1936745</a>";;-4.3;"Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I.: 5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors. Bioorg Med Chem Lett, Volume 22 (1), 2012";"PAMPA";0.00005011872336272725
"MM473206";"MM473206";"CN1CCN(c2ccc(OC(F)(F)F)c(Nc3nccc(-c4cc5c(n4C)CCNC5=O)n3)c2)CC1";"CYXABCVHENZAID-UHFFFAOYSA-N";501.51;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1936745/target=_blank>CHEMBL1936745</a>";;-5.24;"Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I.: 5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors. Bioorg Med Chem Lett, Volume 22 (1), 2012";"PAMPA";0.000005754399373371567
"MM473653";"MM473653";"COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1";"JBLPUDJLELBRHC-UHFFFAOYSA-N";318.38;3.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.69;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000020417379446695274
"MM472599";"MM472599";"O=C(c1ccncc1)N1CCc2nc(-c3cc4cc(F)ccc4[nH]c3=O)[nH]c2C1";"ZPOKSLXILOTPCR-UHFFFAOYSA-N";389.39;2.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2020690/target=_blank>CHEMBL2020690</a>";;-6.2;"Han SY, Choi JW, Yang J, Chae CH, Lee J, Jung H, Lee K, Ha JD, Kim HR, Cho SY.: Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.000000630957344480193
"MM472600";"MM472600";"O=C(c1ccc(CN2CCCCC2)cc1)N1CCc2nc(-c3cc4cc(F)ccc4[nH]c3=O)[nH]c2C1";"VDTAJUONJQNBDK-UHFFFAOYSA-N";485.56;4.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2020690/target=_blank>CHEMBL2020690</a>";;-6.8;"Han SY, Choi JW, Yang J, Chae CH, Lee J, Jung H, Lee K, Ha JD, Kim HR, Cho SY.: Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.0000001584893192461114
"MM473887";"MM473887";"O=C(O)c1cc(-c2ccc(CC(C(=O)c3ccccc3)c3ccccc3)cc2)no1";"HBYWCGDPKWGHBS-UHFFFAOYSA-N";397.43;5.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-3.99;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.00010232929922807536
"MM473888";"MM473888";"O=C(O)c1csc(-c2ccc(CC(C(=O)c3ccccc3)c3ccccc3)cc2)n1";"XERPIZMHGPHYJL-UHFFFAOYSA-N";413.5;5.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-4.07;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.0000851138038202376
"MM473889";"MM473889";"O=C(O)c1cc(-c2ccc(CC(C(=O)c3ccc(F)cc3)c3ccc(F)cc3)cc2)no1";"ULDAZGFTUBQQKY-UHFFFAOYSA-N";433.41;5.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-5.1;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.000007943282347242822
"MM473890";"MM473890";"O=C(O)c1cc(-c2ccc(CC(C(=O)c3ccc(F)c(F)c3)c3ccc(F)cc3)cc2)no1";"JCAKEZHXEJRHOP-UHFFFAOYSA-N";451.4;5.67;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-4.8;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.00001584893192461114
"MM473891";"MM473891";"O=C(O)c1cc(-c2ccc(CC(C(=O)c3ccc(Cl)cc3)c3ccc(F)c(F)c3)cc2)no1";"ZVRIUVSYCXUPJZ-UHFFFAOYSA-N";467.86;6.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-3.77;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.00016982436524617443
"MM473892";"MM473892";"O=C(O)c1cc(-c2ccc(CC(c3ccccc3)c3nc(-c4ccccc4)no3)cc2)no1";"HBPZAUGQOBPKTH-UHFFFAOYSA-N";437.46;5.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-4.35;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.00004466835921509635
"MM473893";"MM473893";"COc1ccc(-c2noc(C(Cc3ccc(-c4cc(C(=O)O)on4)cc3)c3ccc(F)cc3)n2)cc1";"BXLPZCGGTVRQBF-UHFFFAOYSA-N";485.47;5.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-5.4;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.000003981071705534969
"MM473894";"MM473894";"COc1ccc(C(Cc2ccc(-c3cc(C(=O)O)on3)cc2)c2nc(-c3ccc(Cl)cc3)no2)cc1";"MZRTXTPBAYMJCA-UHFFFAOYSA-N";501.93;6.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-4.32;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.000047863009232263804
"MM473895";"MM473895";"O=C(O)c1csc(-c2ccc(CC(c3ccc(F)cc3)c3nc(-c4cccc(F)c4)no3)cc2)n1";"JTAHWKOBPUKTHD-UHFFFAOYSA-N";489.5;6.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-5;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.00001
"MM473896";"MM473896";"COc1ccc(C(Cc2ccc(-c3nc(C(=O)O)cs3)cc2)c2nc(-c3cccc(F)c3)no2)cc1";"BQGLHEJGIKPTFZ-UHFFFAOYSA-N";501.54;6.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2019338/target=_blank>CHEMBL2019338</a>";;-5.22;"Basu S, Prasad UV, Barawkar DA, De S, Palle VP, Menon S, Patel M, Thorat S, Singh UP, Das Sarma K, Waman Y, Niranjan S, Pathade V, Gaur A, Reddy S, Ansari S.: Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett, Volume 22 (8), 2012";"PAMPA";0.000006025595860743581
"MM473885";"MM473885";"NS(=O)(=O)c1ccc(CNc2nc(NCC(F)(F)F)c3nc(-c4ccc(NC(=O)C5CC5)cc4)ccc3n2)cc1";"DOCVYUGZJCOCGS-UHFFFAOYSA-N";571.59;4.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2020375/target=_blank>CHEMBL2020375</a>";;-8.4;"Lazerwith SE, Bahador G, Canales E, Cheng G, Chong L, Clarke MO, Doerffler E, Eisenberg EJ, Hayes J, Lu B, Liu Q, Matles M, Mertzman M, Mitchell ML, Morganelli P, Murray BP, Robinson M, Strickley RG, Tessler M, Tirunagari N, Wang J, Wang Y, Zhang JR, Zheng X, Zhong W, Watkins WJ.: Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors. ACS Med Chem Lett, Volume 2 (10), 2011";"PAMPA";0.000000003981071705534969
"MM473886";"MM473886";"NS(=O)(=O)c1cc(CNc2nc(NCC(F)(F)F)c3nc(-c4ccc(NC(=O)C5(C(F)(F)F)CC5)cc4)ccc3n2)cc(C(F)(F)F)c1";"TZCPEYHVSDZCOR-UHFFFAOYSA-N";707.58;6.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2020375/target=_blank>CHEMBL2020375</a>";;-7.05;"Lazerwith SE, Bahador G, Canales E, Cheng G, Chong L, Clarke MO, Doerffler E, Eisenberg EJ, Hayes J, Lu B, Liu Q, Matles M, Mertzman M, Mitchell ML, Morganelli P, Murray BP, Robinson M, Strickley RG, Tessler M, Tirunagari N, Wang J, Wang Y, Zhang JR, Zheng X, Zhong W, Watkins WJ.: Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors. ACS Med Chem Lett, Volume 2 (10), 2011";"PAMPA";0.00000008912509381337459
"Chembl2021600";"MM467820";"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(C)(C)C";"QENXTKAMWKICNF-HNNXBMFYSA-N";531.57;4.42;;"Chembl2021600";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1177045/target=_blank>CHEMBL1177045</a>";;-5.49;"Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Bourdeaux P, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marty HP, Meyer T, Moreau JL, Mory R, Narquizian R, Nettekoven M, Norcross RD, Puellmann B, Schmid P, Schmitt S, Stalder H, Wermuth R, Wettstein JG, Zimmerli D.: Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem, Volume 53 (12), 2010";"PAMPA";0.000003235936569296281
"MM473897";"MM473897";"NCCSC(c1ccccc1)(c1ccccc1)c1cccc(O)c1";"ADYMGXUUCQNFFP-UHFFFAOYSA-N";335.47;4.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2024746/target=_blank>CHEMBL2024746</a>";;-4.78;"Wang F, Good JA, Rath O, Kaan HY, Sutcliffe OB, Mackay SP, Kozielski F.: Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity. J Med Chem, Volume 55 (4), 2012";"PAMPA";0.000016595869074375598
"MM473898";"MM473898";"NCCSC(c1ccccc1)(c1ccccc1)c1cccc(C(N)=O)c1";"ZEAMYFNKGIBVEF-UHFFFAOYSA-N";362.5;3.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2024746/target=_blank>CHEMBL2024746</a>";;-4.37;"Wang F, Good JA, Rath O, Kaan HY, Sutcliffe OB, Mackay SP, Kozielski F.: Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity. J Med Chem, Volume 55 (4), 2012";"PAMPA";0.00004265795188015926
"MM473932";"MM473932";"C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2";"HWXVIOGONBBTBY-ONEGZZNKSA-N";472.59;4.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2183760/target=_blank>CHEMBL2183760</a>";;-5.03;"William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW.: Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000009332543007969906
"MM473899";"MM473899";"CC(Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O)c1ccccc1C(F)(F)F";"DNZGEPPZYMAFLN-UHFFFAOYSA-N";540.61;6.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2044863/target=_blank>CHEMBL2044863</a>";;-4.82;"Innocenti P, Cheung KM, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, Baxter JE, Aherne GW, Bayliss R, Fry AM, Hoelder S.: Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity. J Med Chem, Volume 55 (7), 2012";"PAMPA";0.000015135612484362071
"MM473900";"MM473900";"CC(/C=C\C(F)(F)F)Oc1cc(-c2cc(-c3cc(CN(C)C)cs3)cnc2N)ccc1C(N)=O";"LLEOOSLUHRQCHZ-SREVYHEPSA-N";490.55;5.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2044863/target=_blank>CHEMBL2044863</a>";;-4.56;"Innocenti P, Cheung KM, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, Baxter JE, Aherne GW, Bayliss R, Fry AM, Hoelder S.: Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity. J Med Chem, Volume 55 (7), 2012";"PAMPA";0.00002754228703338169
"MM473901";"MM473901";"Cc1cc(N2CCOCC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"OVJBNYKNHXJGSA-UHFFFAOYSA-N";407.52;3.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.4;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.00039810717055349735
"MM473902";"MM473902";"COc1cc(N2CCN(S(C)(=O)=O)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"UTMJODBGZJGLMG-UHFFFAOYSA-N";500.63;2.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.07;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.0008511380382023768
"MM473903";"MM473903";"COc1cc(N2CCN(S(=O)(=O)CCCN3CCOCC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"QAURCZMNSYPBDT-UHFFFAOYSA-N";613.79;3.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.14;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.0007244359600749898
"MM473904";"MM473904";"COc1cc(N2CCN(C(=O)C3CCC(O)CC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"SPODPLINVVTZLH-UHFFFAOYSA-N";548.69;4.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-4.09;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.00008128305161640995
"MM473905";"MM473905";"CNC(=O)C(=O)N1CCN(c2ccc(Nc3nc(NC4CCCCC4)c4nc[nH]c4n3)c(OC)c2)CC1";"GGDQYCPLGJVXCA-UHFFFAOYSA-N";507.6;2.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.01;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.000977237220955811
"MM473906";"MM473906";"COc1cc(N2CCN(Cc3ccccn3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"MMBOXQXVTMVCCQ-UHFFFAOYSA-N";513.65;4.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.01;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.000977237220955811
"MM473907";"MM473907";"COc1cc(N2CCN(CC3CCOC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"OOKFETVTUPUMHG-UHFFFAOYSA-N";506.66;4.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-2.73;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.0018620871366628676
"MM473908";"MM473908";"COc1cc(N2CCC(N3CCOCC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"CYWJZNCONMFGQE-UHFFFAOYSA-N";506.66;4.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.15;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.000707945784384138
"MM473909";"MM473909";"COc1cc(N2CCC(C(=O)N3CCOCC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"ZUPXMFKTLSYZDB-UHFFFAOYSA-N";534.67;3.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.13;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.0007413102413009177
"MM473910";"MM473910";"COc1cc(N2CCC(CN3CCOCC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"OLOBPNVGBFMVHS-UHFFFAOYSA-N";520.68;4.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-2.68;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.0020892961308540386
"MM473911";"MM473911";"COc1cc(N2CCC(CC(=O)N3CCOCC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"YLVRGBXUNULPFD-UHFFFAOYSA-N";548.69;4.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.39;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.0004073802778041126
"MM473912";"MM473912";"COc1cc(N2CCC(CC(=O)N3CCN(C)CC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"ZBPLIYROBQPFCH-UHFFFAOYSA-N";561.74;4.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.28;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.0005248074602497728
"MM473913";"MM473913";"CCN(CC)CC1CCN(c2ccc(Nc3nc(NC4CCCCC4)c4nc[nH]c4n3)c(OC)c2)CC1";"NBRIVFGOERIQOU-UHFFFAOYSA-N";506.7;5.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-3.32;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.00047863009232263854
"MM473914";"MM473914";"COc1cc(N2CCC(CC(=O)N3CCCC3)CC2)ccc1Nc1nc(NC2CCCCC2)c2nc[nH]c2n1";"VLNLMCUDDYHMLI-UHFFFAOYSA-N";532.69;5.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2049898/target=_blank>CHEMBL2049898</a>";;-2.77;"Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, Papac DI, Williams BL, Carlson RO.: Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett, Volume 22 (13), 2012";"PAMPA";0.0016982436524617442
"MM472601";"MM472601";"OC[C@H]1O[C@H](Oc2ccc(-n3ccc4ccccc43)cc2Cl)[C@@H](O)[C@@H](O)[C@@H]1O";"SKSGPURFSNZUCC-SLHNCBLASA-N";405.83;1.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-4.7;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000019952623149688786
"MM472603";"MM472603";"COc1ccc2c(ccn2-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(Cl)c2)c1";"QNLHXKRFGWUNLX-MJCUULBUSA-N";435.86;1.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-4.6;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000025118864315095822
"MM472604";"MM472604";"OC[C@H]1O[C@H](Oc2ccc(-n3ccc4cc(C(F)(F)F)ccc43)cc2Cl)[C@@H](O)[C@@H](O)[C@@H]1O";"KKQPGSKTYRQUAW-SLHNCBLASA-N";473.83;2.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-4.6;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000025118864315095822
"MM472605";"MM472605";"OC[C@H]1O[C@H](Oc2ccc(-n3ccc4ccccc43)cc2F)[C@@H](O)[C@@H](O)[C@@H]1O";"WHJGBKFQVQSSIE-SLHNCBLASA-N";389.38;0.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-4.7;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000019952623149688786
"MM472607";"MM472607";"COC(=O)c1ccc2c(ccn2-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(Cl)c2)c1";"ZNKLGBURSBJNQW-KOVVAJLHSA-N";463.87;1.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-4.4;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000039810717055349695
"MM472608";"MM472608";"O=C(Nc1ccc2c(ccn2-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(Cl)c2)c1)c1ccc(Cl)cc1";"HWJOBOGLYPEBPF-RYIFMDQWSA-N";559.4;3.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-6;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000001
"MM472609";"MM472609";"OC[C@H]1O[C@H](Oc2ccc(-n3ccc4cc(Cl)cnc43)cc2Cl)[C@@H](O)[C@@H](O)[C@@H]1O";"BWQNLPNXSSURIV-GJGATLCTSA-N";441.27;1.51;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-5;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.00001
"MM472610";"MM472610";"N#Cc1cnc2c(ccn2-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(Cl)c2)c1";"AKHFFJWFGLOXKJ-JGLNRKDHSA-N";431.83;0.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-6.3;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.0000005011872336272725
"MM472612";"MM472612";"OC[C@H]1O[C@H](Oc2ccc(N3CCc4ccccc43)cc2)[C@@H](O)[C@@H](O)[C@@H]1O";"IOBXHNSCPVURKM-SLHNCBLASA-N";373.41;0.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-4.7;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000019952623149688786
"MM472614";"MM472614";"OC[C@H]1O[C@H](Oc2ccc(N3CCc4ccccc43)cc2Cl)[C@@H](O)[C@@H](O)[C@@H]1O";"ANUJCWSZZGCCLL-SLHNCBLASA-N";407.85;1.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-4.6;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.000025118864315095822
"MM472615";"MM472615";"Cn1cnc2cc(-c3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(Cl)c3)cnc21";"NXBVNPBWHAXFHJ-GJGATLCTSA-N";421.84;0.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2067382/target=_blank>CHEMBL2067382</a>";;-8;"Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.: Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem, Volume 55 (10), 2012";"PAMPA";0.00000001
"MM473495";"MM473495";"CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1";"OHKDVDMWRKFZRB-UHFFFAOYSA-N";473.56;-0.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4179671/target=_blank>CHEMBL4179671</a>";;-6.59;"MartĂ­nez GonzĂˇlez S, HernĂˇndez AI, Ă�lvarez RM, RodrĂ­guez A, Ramos-Lima F, Bischoff JR, AlbarrĂˇn MI, CebriĂˇ A, HernĂˇndez-Encinas E, GarcĂ­a-Arocha J, CebriĂˇn D, Blanco-Aparicio C, Pastor J.: Identification of novel PI3K inhibitors through a scaffold hopping strategy. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.0000002570395782768865
"MM474586";"MM474586";"COc1ccc2nc(C)cc(OCC(=O)Nc3cc(C)cc(C)c3)c2c1";"PMKVVDYFRVLSFD-UHFFFAOYSA-N";350.42;4.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.74;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.000018197008586099827
"MM473578";"MM473578";"CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@@H](NC)C(C)C)C(C)C";"DASWEROEPLKSEI-UIJRFTGLSA-N";717.99;3.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4220926/target=_blank>CHEMBL4220926</a>";;-7.1;"Yokosaka S, Izawa A, Sakai C, Sakurada E, Morita Y, Nishio Y.: Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations. Bioorg Med Chem, Volume 26 (8), 2018";"PAMPA";0.00000007943282347242822
"MM474061";"MM474061";"COc1ccnc(NC(=S)N2CCN(c3ncc(C(F)(F)F)cc3Cl)CC2)c1";"AIKZMHUYNNXENU-UHFFFAOYSA-N";431.87;3.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3132394/target=_blank>CHEMBL3132394</a>";;-2.95;"Foley TL, Rai G, Yasgar A, Daniel T, Baker HL, Attene-Ramos M, Kosa NM, Leister W, Burkart MD, Jadhav A, Simeonov A, Maloney DJ.: 4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth. J Med Chem, Volume 57 (3), 2014";"PAMPA";0.001122018454301963
"MM474223";"MM474223";"COc1cc2ncnc(-n3nc(-c4ccccn4)nc3N)c2cc1OC";"ILBRKJBKDGCSCB-UHFFFAOYSA-N";349.35;1.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3768362/target=_blank>CHEMBL3768362</a>";;-4.02;"Min J, Guo K, Suryadevara PK, Zhu F, Holbrook G, Chen Y, Feau C, Young BM, Lemoff A, Connelly MC, Kastan MB, Guy RK.: Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. J Med Chem, Volume 59 (2), 2016";"PAMPA";0.00009549925860214369
"MM472617";"MM472617";"Cn1cc(C2=C(c3nc(N4CCNCC4)nc4ccccc34)C(=O)NC2=O)c2ccccc21";"URLJNGHIJZMXTK-UHFFFAOYSA-N";438.49;2.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2156137/target=_blank>CHEMBL2156137</a>";;-5.2;"Wagner J, von Matt P, Faller B, Cooke NG, Albert R, Sedrani R, Wiegand H, Jean C, Beerli C, Weckbecker G, Evenou JP, Zenke G, Cottens S.: Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis. J Med Chem, Volume 54 (17), 2011";"PAMPA";0.00000630957344480193
"MM473771";"MM473771";"CN1CCCCC1c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C";"HGPPRMHXEAZMCS-UHFFFAOYSA-N";374.42;1.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-4.82;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000015135612484362071
"MM474481";"MM474481";"CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C";"FAWSUKOIROHXAP-NPMXOYFQSA-N";434.92;6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3383439/target=_blank>CHEMBL3383439</a>";;-5.02;"Gosmini R, Nguyen VL, Toum J, Simon C, Brusq JM, Krysa G, Mirguet O, Riou-Eymard AM, Boursier EV, Trottet L, Bamborough P, Clark H, Chung CW, Cutler L, Demont EH, Kaur R, Lewis AJ, Schilling MB, Soden PE, Taylor S, Walker AL, Walker MD, Prinjha RK, NicodĂ¨me E.: The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem, Volume 57 (19), 2014";"PAMPA";0.000009549925860214369
"MM474423";"MM474423";"CC(C)(C)c1ccc(CCN2CC=C(CCC(=O)NO)C2=O)cc1";"WNAQYFYKELGZGO-UHFFFAOYSA-N";330.43;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2188660/target=_blank>CHEMBL2188660</a>";;-5.19;"Choi E, Lee C, Cho M, Seo JJ, Yang JS, Oh SJ, Lee K, Park SK, Kim HM, Kwon HJ, Han G.: Property-based optimization of hydroxamate-based Îł-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles. J Med Chem, Volume 55 (23), 2012";"PAMPA";0.000006456542290346549
"MM474422";"MM474422";"CC(C)(C)c1ccc(CCCN2CC=C(CCC(=O)NO)C2=O)cc1";"PZFGNWGVLQZJDE-UHFFFAOYSA-N";344.46;2.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2188660/target=_blank>CHEMBL2188660</a>";;-5.82;"Choi E, Lee C, Cho M, Seo JJ, Yang JS, Oh SJ, Lee K, Park SK, Kim HM, Kwon HJ, Han G.: Property-based optimization of hydroxamate-based Îł-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles. J Med Chem, Volume 55 (23), 2012";"PAMPA";0.0000015135612484362072
"MM474421";"MM474421";"O=C(CCC1=CCN(CCCCc2ccc(Cl)cc2)C1=O)NO";"QDZALEPHZRZMHU-UHFFFAOYSA-N";336.82;2.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2188660/target=_blank>CHEMBL2188660</a>";;-6.31;"Choi E, Lee C, Cho M, Seo JJ, Yang JS, Oh SJ, Lee K, Park SK, Kim HM, Kwon HJ, Han G.: Property-based optimization of hydroxamate-based Îł-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles. J Med Chem, Volume 55 (23), 2012";"PAMPA";0.0000004897788193684466
"MM474427";"MM474427";"O=C(CCC1=CCN(Cc2ccc(F)cc2)C1=O)NO";"OZIMHLQNMLFRMT-UHFFFAOYSA-N";278.28;1.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2188660/target=_blank>CHEMBL2188660</a>";;-5.71;"Choi E, Lee C, Cho M, Seo JJ, Yang JS, Oh SJ, Lee K, Park SK, Kim HM, Kwon HJ, Han G.: Property-based optimization of hydroxamate-based Îł-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles. J Med Chem, Volume 55 (23), 2012";"PAMPA";0.0000019498445997580454
"MM474426";"MM474426";"O=C(CCC1=CCN(Cc2ccc(Br)cc2)C1=O)NO";"RBDTUYJXXZIFKA-UHFFFAOYSA-N";339.19;2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2188660/target=_blank>CHEMBL2188660</a>";;-5.99;"Choi E, Lee C, Cho M, Seo JJ, Yang JS, Oh SJ, Lee K, Park SK, Kim HM, Kwon HJ, Han G.: Property-based optimization of hydroxamate-based Îł-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles. J Med Chem, Volume 55 (23), 2012";"PAMPA";0.0000010232929922807537
"MM474425";"MM474425";"CC(C)(C)c1ccc(CN2CC=C(CCC(=O)NO)C2=O)cc1";"SUDCYFIXSQTCJQ-UHFFFAOYSA-N";316.4;2.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2188660/target=_blank>CHEMBL2188660</a>";;-5.66;"Choi E, Lee C, Cho M, Seo JJ, Yang JS, Oh SJ, Lee K, Park SK, Kim HM, Kwon HJ, Han G.: Property-based optimization of hydroxamate-based Îł-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles. J Med Chem, Volume 55 (23), 2012";"PAMPA";0.0000021877616239495517
"MM474424";"MM474424";"O=C(CCC1=CCN(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C1=O)NO";"DVYWCDJOAHDFDQ-UHFFFAOYSA-N";396.29;3.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2188660/target=_blank>CHEMBL2188660</a>";;-5.55;"Choi E, Lee C, Cho M, Seo JJ, Yang JS, Oh SJ, Lee K, Park SK, Kim HM, Kwon HJ, Han G.: Property-based optimization of hydroxamate-based Îł-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles. J Med Chem, Volume 55 (23), 2012";"PAMPA";0.000002818382931264455
"MM473930";"MM473930";"Cc1cnc2nc1-c1cccc(c1)COCC=CCOCc1cc(ccc1OCCN1CCCC1)N2";"ZLRQBYKTDVAMPK-UHFFFAOYSA-N";486.62;5.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2183760/target=_blank>CHEMBL2183760</a>";;-4.77;"William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW.: Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00001698243652461746
"MM473929";"MM473929";"COc1ccc2cc1COCC=CCOCc1cc(ccc1OCCN1CCCC1)Nc1nccc-2n1";"HLNMMXYNDBSAPI-UHFFFAOYSA-N";502.62;4.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2183760/target=_blank>CHEMBL2183760</a>";;-5;"William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW.: Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00001
"MM473933";"MM473933";"CCN(CC)CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2";"MLIJDZYVRSRDJT-UHFFFAOYSA-N";474.61;5.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2183760/target=_blank>CHEMBL2183760</a>";;-4.8;"William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW.: Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.00001584893192461114
"MM473931";"MM473931";"C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1";"VLNBTEQPYIXIMB-UHFFFAOYSA-N";486.62;5.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2183760/target=_blank>CHEMBL2183760</a>";;-5.41;"William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW.: Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem, Volume 54 (13), 2011";"PAMPA";0.000003890451449942805
"MM474130";"MM474130";"CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)C1CC1";"MPEHLMJOBXIHAL-UHFFFAOYSA-N";435.44;4.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3377767/target=_blank>CHEMBL3377767</a>";;-5.82;"Alonso JA, AndrĂ©s M, Bravo M, Buil MA, Calbet M, Castro J, Eastwood PR, Eichhorn P, Esteve C, GĂłmez E, GonzĂˇlez J, Mir M, Petit S, Roberts RS, Vidal B, Vidal L, Vilaseca P, Zanuy M.: Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists I. Bioorg Med Chem Lett, Volume 24 (21), 2014";"PAMPA";0.0000015135612484362072
"MM473851";"MM473851";"COc1cc(Nc2c(C#N)cnc3cc(-c4coc(CN5CCN(C)CC5)c4)c(OC)cc23)c(Cl)cc1Cl";"ANUHLKPVOXDYSK-UHFFFAOYSA-N";552.46;6.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL910457/target=_blank>CHEMBL910457</a>";;-5.7;"Boschelli DH, Wu B, Ye F, Wang Y, Golas JM, Lucas J, Boschelli F.: Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem, Volume 49 (26), 2006";"PAMPA";0.0000019952623149688787
"MM474696";"MM474696";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(c2cccc(C)n2)CC1";"CLPJEHNKARSBTP-QHCPKHFHSA-N";477.61;2.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-5.06;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000008709635899560814
"MM472993";"MM472993";"CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1";"KJADKKWYZYXHBB-XBWDGYHZSA-N";339.37;-0.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1036963/target=_blank>CHEMBL1036963</a>";;-6.27;"Lopez M, Paul B, Hofmann A, Morizzi J, Wu QK, Charman SA, Innocenti A, Vullo D, Supuran CT, Poulsen SA.: S-glycosyl primary sulfonamides--a new structural class for selective inhibition of cancer-associated carbonic anhydrases. J Med Chem, Volume 52 (20), 2009";"PAMPA";0.0000005370317963702533
"MM473934";"MM473934";"CC(C)N(Cc1cnc[nH]1)c1ccc(Cl)cc1";"AOHLEOYTKMSKPD-UHFFFAOYSA-N";249.75;3.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2213511/target=_blank>CHEMBL2213511</a>";;-5.57;"Galley G, Stalder H, Goergler A, Hoener MC, Norcross RD.: Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012. Bioorg Med Chem Lett, Volume 22 (16), 2012";"PAMPA";0.0000026915348039269138
"MM473938";"MM473938";"COc1ccc(C2c3ccc4ccccc4c3Oc3nc4c(c(N)c32)CCCC4)c(OC)c1";"WVOGNNUVYUMTIT-UHFFFAOYSA-N";438.53;6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2216413/target=_blank>CHEMBL2216413</a>";;-4.84;"Maalej E, Chabchoub F, Oset-Gasque MJ, Esquivias-PĂ©rez M, GonzĂˇlez MP, Monjas L, PĂ©rez C, de los RĂ­os C, RodrĂ­guez-Franco MI, Iriepa I, Moraleda I, Chioua M, Romero A, Marco-Contelles J, Samadi A.: Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 54, 2012";"PAMPA";0.00001445439770745928
"MM473937";"MM473937";"COc1cc(C2c3ccc4ccccc4c3Oc3nc4c(c(N)c32)CCCC4)cc(OC)c1OC";"PTNYBRUJEDAMDK-UHFFFAOYSA-N";468.55;6.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2216413/target=_blank>CHEMBL2216413</a>";;-4.63;"Maalej E, Chabchoub F, Oset-Gasque MJ, Esquivias-PĂ©rez M, GonzĂˇlez MP, Monjas L, PĂ©rez C, de los RĂ­os C, RodrĂ­guez-Franco MI, Iriepa I, Moraleda I, Chioua M, Romero A, Marco-Contelles J, Samadi A.: Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 54, 2012";"PAMPA";0.00002344228815319923
"MM473935";"MM473935";"Nc1c2c(nc3c1C(c1ccc(Cl)c(Cl)c1)c1ccc4ccccc4c1O3)CCCC2";"IFYBUPQCUTZITP-UHFFFAOYSA-N";447.37;7.29;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2216413/target=_blank>CHEMBL2216413</a>";;-4.91;"Maalej E, Chabchoub F, Oset-Gasque MJ, Esquivias-PĂ©rez M, GonzĂˇlez MP, Monjas L, PĂ©rez C, de los RĂ­os C, RodrĂ­guez-Franco MI, Iriepa I, Moraleda I, Chioua M, Romero A, Marco-Contelles J, Samadi A.: Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 54, 2012";"PAMPA";0.00001230268770812381
"MM474523";"MM474523";"COc1ccc(Cl)cc1S(=O)(=O)N1CCc2ccc(C(=O)Nc3ccc(C(=O)O)cc3)cc21";"SPZKHICEEDMLAD-UHFFFAOYSA-N";486.93;4.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.56;"10.6019/CHEMBL3431459";"PAMPA";0.000002754228703338169
"MM472574";"MM472574";"C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12";"UJLAWZDWDVHWOW-YPMHNXCESA-N";312.38;1.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1657319/target=_blank>CHEMBL1657319</a>";;-5.2;"Thoma G, Nuninger F, Falchetto R, Hermes E, Tavares GA, Vangrevelinghe E, Zerwes HG.: Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.00000630957344480193
"MM474531";"MM474531";"NC(=O)c1nc(-c2cccs2)nc(O)c1O";"SCXAUENZKSNKQP-UHFFFAOYSA-N";237.24;0.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3619497/target=_blank>CHEMBL3619497</a>";;-6.15;"Chapman TM, Wallace C, Gillen KJ, Bakrania P, Khurana P, Coombs PJ, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B.: N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF. Bioorg Med Chem Lett, Volume 25 (19), 2015";"PAMPA";0.0000007079457843841374
"MM472960";"MM472960";"O=C1NCCc2[nH]c(-c3ccncc3)cc21";"DKXHSOUZPMHNIZ-UHFFFAOYSA-N";213.24;1.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1019785/target=_blank>CHEMBL1019785</a>";;-5.74;"Menichincheri M, Bargiotti A, Berthelsen J, Bertrand JA, Bossi R, Ciavolella A, Cirla A, Cristiani C, Croci V, D'Alessio R, Fasolini M, Fiorentini F, Forte B, Isacchi A, Martina K, Molinari A, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pezzetta D, Pillan A, Poggesi I, Roletto F, Scolaro A, TatĂ˛ M, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C, Vanotti E.: First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem, Volume 52 (2), 2009";"PAMPA";0.0000018197008586099826
"MM474417";"MM474417";"O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21";"OWFLADWRSCINST-UHFFFAOYSA-N";340.39;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1780730/target=_blank>CHEMBL1780730</a>";;-6.22;"Barf T, Kaptein A, de Wilde S, van der Heijden R, van Someren R, Demont D, Schultz-Fademrecht C, Versteegh J, van Zeeland M, Seegers N, Kazemier B, van de Kar B, van Hoek M, de Roos J, Klop H, Smeets R, Hofstra C, Hornberg J, Oubrie A.: Structure-based lead identification of ATP-competitive MK2 inhibitors. Bioorg Med Chem Lett, Volume 21 (12), 2011";"PAMPA";0.0000006025595860743581
"MM472527";"MM472527";"CCc1ccc(C)nc1";"NTSLROIKFLNUIJ-UHFFFAOYSA-N";121.18;1.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905612/target=_blank>CHEMBL905612</a>";;-5.55;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000002818382931264455
"MM473767";"MM473767";"O=C(NCc1ccc(F)cc1)c1nc(C2CCCCN2)nc(O)c1O";"LQEBEYDXCBIMKY-UHFFFAOYSA-N";346.36;1.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-7.15;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.00000007079457843841373
"MM473945";"MM473945";"CC[C@@H](CO)Nc1nc(Nc2cc(Cl)cc(Cl)c2)ncc1C(=O)NC1CCN(C)CC1";"DSXGDZUOCYHJFB-HNNXBMFYSA-N";467.4;3.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-5.7;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000019952623149688787
"MM473954";"MM473954";"O=C(NCCCN1CCCC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1";"VDKBGBCLPKTOGS-UHFFFAOYSA-N";505.45;4.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-7;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000001
"MM473952";"MM473952";"COc1ccccc1CNc1ncc(C(=O)NCCNC(C)=O)c(NC2CCCC2)n1";"ORYKMIWQJHCMKB-UHFFFAOYSA-N";426.52;2.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-5.72;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000019054607179632483
"MM473951";"MM473951";"COc1ccccc1CNc1ncc(C(=O)NCCc2nnn[nH]2)c(NC2CCCC2)n1";"PRVYCULSPLQIDK-UHFFFAOYSA-N";437.51;1.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-4.68;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.00002089296130854041
"MM473950";"MM473950";"COc1ccccc1CNc1ncc(C(=O)NC2CCN(C)CC2)c(NC2CCCC2)n1";"IHJZXCJKSRQJCM-UHFFFAOYSA-N";438.58;3.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-5.92;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000012022644346174132
"MM473949";"MM473949";"CN1CCC(NC(=O)c2cnc(NCc3cc(Cl)ccc3Cl)nc2NC2CCCC2)CC1";"PRAFFLMXUBGHGX-UHFFFAOYSA-N";477.44;4.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-7.7;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.000000019952623149688786
"MM473948";"MM473948";"CN1CCC(NC(=O)c2cnc(NCc3cc(Cl)ccc3Cl)nc2NC2CCC(N(C)C)CC2)CC1";"LQMDBOVNAUGROB-UHFFFAOYSA-N";534.54;4.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-5.7;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000019952623149688787
"MM473947";"MM473947";"CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)CC1";"SQKBBDOFPPNVCL-UHFFFAOYSA-N";520.51;4.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-6.52;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000003019951720402019
"MM473946";"MM473946";"CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2N[C@H]2CCCCNC2=O)CC1";"XGMASFFIBAMSSU-IBGZPJMESA-N";506.44;3.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-6.7;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.00000019952623149688787
"MM473944";"MM473944";"CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2N[C@@H]2COC[C@H]2O)CC1";"PIKLKDCPFVVYDK-QZTJIDSGSA-N";481.38;2.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-5.85;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000014125375446227554
"MM473943";"MM473943";"Cc1cc(-c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCNCC2)on1";"SFMKVXGJJGANQK-UHFFFAOYSA-N";419.32;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-6.7;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.00000019952623149688787
"MM473942";"MM473942";"Cc1cc(-c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)on1";"ZTSOUDMNSOYCTG-UHFFFAOYSA-N";461.4;5.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-7.52;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.000000030199517204020194
"MM473941";"MM473941";"O[C@@H]1COC[C@H]1Nc1nc(Nc2cc(Cl)cc(Cl)c2)ncc1-c1cccnc1";"ALEHKALCLNFZHW-IAGOWNOFSA-N";418.28;3.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-6;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.000001
"MM473940";"MM473940";"O[C@@H]1COC[C@H]1Nc1nc(Nc2cc(Cl)cc(Cl)c2)ncc1Br";"CYYFQJUQUMBOSB-VXGBXAGGSA-N";420.09;3.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-6.52;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000003019951720402019
"MM473953";"MM473953";"COc1ccccc1CNc1ncc(C(=O)NCCCO)c(NC2CCCC2)n1";"LXSBESSANKCKCG-UHFFFAOYSA-N";399.5;2.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2317797/target=_blank>CHEMBL2317797</a>";;-6.05;"Powell NA, Hoffman JK, Ciske FL, Kohrt JT, Baxi SM, Peng YW, Zhong M, Catana C, Ohren J, Perrin LA, Edmunds JJ.: Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett, Volume 23 (4), 2013";"PAMPA";0.0000008912509381337459
"MM473939";"MM473939";"O=C(N[C@H]1CCC[C@@H]1OCc1ccccc1)C1CCN(c2nc3cc(Cl)ccc3o2)CC1";"ADUCABZHOQVMAT-UNMCSNQZSA-N";453.97;4.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2321394/target=_blank>CHEMBL2321394</a>";;-5.89;"Kablaoui N, Patel S, Shao J, Demian D, Hoffmaster K, Berlioz F, Vazquez ML, Moore WM, Nugent RA.: Novel benzoxazole inhibitors of mPGES-1. Bioorg Med Chem Lett, Volume 23 (3), 2013";"PAMPA";0.000001288249551693135
"MM474428";"MM474428";"CCO[C@@H]1C[C@@H]2CN(C(=O)[C@@H](NC(=O)[C@H](C)NC)C3CCC(F)(F)CC3)[C@H](C(=O)N[C@@H]3CCOc4ccccc43)CN2C1";"WQLHYSFOEZZZDD-QAPMSZJWSA-N";605.73;2.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2318317/target=_blank>CHEMBL2318317</a>";;-5.36;"Hashimoto K, Saito B, Miyamoto N, Oguro Y, Tomita D, Shiokawa Z, Asano M, Kakei H, Taya N, Kawasaki M, Sumi H, Yabuki M, Iwai K, Yoshida S, Yoshimatsu M, Aoyama K, Kosugi Y, Kojima T, Morishita N, Dougan DR, Snell GP, Imamura S, Ishikawa T.: Design and synthesis of potent inhibitor of apoptosis (IAP) proteins antagonists bearing an octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline mimetic. J Med Chem, Volume 56 (3), 2013";"PAMPA";0.000004365158322401657
"MM473956";"MM473956";"CCc1nc2c(C)cn(Cc3ccccc3C)c(=O)c2n1[C@H]1CCc2cc(-c3ccccc3-c3nnn[nH]3)ccc21";"HMHFJSKWETWSSD-NDEPHWFRSA-N";541.66;5.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2327547/target=_blank>CHEMBL2327547</a>";;-5.15;"Casimiro-Garcia A, Heemstra RJ, Bigge CF, Chen J, Ciske FA, Davis JA, Ellis T, Esmaeil N, Flynn D, Han S, Jalaie M, Ohren JF, Powell NA.: Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Îł. Bioorg Med Chem Lett, Volume 23 (3), 2013";"PAMPA";0.000007079457843841373
"MM473955";"MM473955";"CCc1nc2c(C)cn(Cc3ccccc3C#N)c(=O)c2n1[C@H]1CCc2cc(-c3ccccc3-c3nnn[nH]3)ccc21";"RAUNYZMCEZPALE-NDEPHWFRSA-N";552.64;5.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2327547/target=_blank>CHEMBL2327547</a>";;-4.72;"Casimiro-Garcia A, Heemstra RJ, Bigge CF, Chen J, Ciske FA, Davis JA, Ellis T, Esmaeil N, Flynn D, Han S, Jalaie M, Ohren JF, Powell NA.: Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Îł. Bioorg Med Chem Lett, Volume 23 (3), 2013";"PAMPA";0.000019054607179632484
"MM473958";"MM473958";"CCc1nc2ccn(Cc3ccccc3C)c(=O)c2n1[C@H]1CCc2cc(-c3ccccc3-c3nnn[nH]3)ccc21";"RTDOCGJRLLGHRA-NDEPHWFRSA-N";527.63;5.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2327547/target=_blank>CHEMBL2327547</a>";;-5.44;"Casimiro-Garcia A, Heemstra RJ, Bigge CF, Chen J, Ciske FA, Davis JA, Ellis T, Esmaeil N, Flynn D, Han S, Jalaie M, Ohren JF, Powell NA.: Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Îł. Bioorg Med Chem Lett, Volume 23 (3), 2013";"PAMPA";0.0000036307805477010103
"MM473957";"MM473957";"CCc1nc2ccn(Cc3ccccc3C#N)c(=O)c2n1[C@H]1CCc2cc(-c3ccccc3-c3nnn[nH]3)ccc21";"NBDDZFPMRAAKFW-NDEPHWFRSA-N";538.62;5.06;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2327547/target=_blank>CHEMBL2327547</a>";;-4.97;"Casimiro-Garcia A, Heemstra RJ, Bigge CF, Chen J, Ciske FA, Davis JA, Ellis T, Esmaeil N, Flynn D, Han S, Jalaie M, Ohren JF, Powell NA.: Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Îł. Bioorg Med Chem Lett, Volume 23 (3), 2013";"PAMPA";0.00001071519305237607
"MM473705";"MM473705";"CS(=O)(=O)c1ccc(-c2nnc(/C=C/c3nnc(-c4ccc(C#N)cc4)o3)n2-c2ccccc2Cl)nc1";"HIWVLHPKZNBSBE-OUKQBFOZSA-N";529.97;4.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4345400/target=_blank>CHEMBL4345400</a>";;-4.94;"Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H.: Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. J Med Chem, Volume 63 (8), 2020";"PAMPA";0.000011481536214968817
"MM473959";"MM473959";"COc1cc(N2Cc3ccc(Sc4ccc(F)cc4)nc3C2=O)ccc1OCCN1CCCC1";"IOVNPTLMMFSPCO-UHFFFAOYSA-N";479.58;5.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2342862/target=_blank>CHEMBL2342862</a>";;-5.72;"Lim CJ, Kim JY, Lee BH, Oh KS, Yi KY.: Synthesis and SAR study of pyrrolo[3,4-b]pyridin-7(6H)-one derivatives as melanin concentrating hormone receptor 1 (MCH-R1) antagonists. Bioorg Med Chem Lett, Volume 23 (6), 2013";"PAMPA";0.0000019054607179632483
"MM472885";"MM472885";"CCCC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1N";"IYTDSNSLAQHLJL-XIRDDKMYSA-N";318.46;3.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL893073/target=_blank>CHEMBL893073</a>";;-5.6;"LĂĽbbers T, BĂ¶hringer M, Gobbi L, Hennig M, Hunziker D, Kuhn B, LĂ¶ffler B, Mattei P, Narquizian R, Peters JU, Ruff Y, Wessel HP, Wyss P.: 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett, Volume 17 (11), 2007";"PAMPA";0.0000025118864315095823
"MM472628";"MM472628";"CCNC(=O)Nc1nc2ccc(-c3ccccc3OC)cc2s1";"LGPZTQXZPZVKSU-UHFFFAOYSA-N";327.41;4.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2351844/target=_blank>CHEMBL2351844</a>";;-4.11;"Hong S, Kim J, Yun SM, Lee H, Park Y, Hong SS, Hong S.: Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant. J Med Chem, Volume 56 (9), 2013";"PAMPA";0.00007762471166286911
"MM472627";"MM472627";"COc1ccccc1-c1ccc2nc(NC(=O)NCCO)sc2c1";"LAAHHHDILCOULN-UHFFFAOYSA-N";343.41;3.09;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2351844/target=_blank>CHEMBL2351844</a>";;-4.29;"Hong S, Kim J, Yun SM, Lee H, Park Y, Hong SS, Hong S.: Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant. J Med Chem, Volume 56 (9), 2013";"PAMPA";0.00005128613839913648
"MM472626";"MM472626";"COc1ccccc1-c1ccc2nc(NC(=O)NCCN3CCN(C)CC3)sc2c1";"AIZRLMRCMYABCS-UHFFFAOYSA-N";425.56;3.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2351844/target=_blank>CHEMBL2351844</a>";;-4.93;"Hong S, Kim J, Yun SM, Lee H, Park Y, Hong SS, Hong S.: Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant. J Med Chem, Volume 56 (9), 2013";"PAMPA";0.000011748975549395302
"MM473818";"MM473818";"O=C(O)CCc1sc(/C=C2\NC(=O)CS2)nc1-c1ccccn1";"FXCKSJPZDBQRLO-KPKJPENVSA-N";347.42;2.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3106895/target=_blank>CHEMBL3106895</a>";;-6.29;"Sogame S, Suenaga Y, Atobe M, Kawanishi M, Tanaka E, Miyoshi S.: Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping. Eur J Med Chem, Volume 71, 2014";"PAMPA";0.0000005128613839913648
"MM472878";"MM472878";"O=C(O)C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1";"GXALXAKNHIROPE-QAQDUYKDSA-N";455.48;6.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4307359/target=_blank>CHEMBL4307359</a>";;-5;"Harrison TJ, Bauer D, Berdichevsky A, Chen X, Duvadie R, Hoogheem B, Hatsis P, Liu Q, Mao J, Miduturu V, Rocheford E, Zecri F, Zessis R, Zheng R, Zhu Q, Streeper R, Patel SJ.: Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor. ACS Med Chem Lett, Volume 10 (8), 2019";"PAMPA";0.00001
"MM473046";"MM473046";"CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)ccc1Cl";"JVCJWEYSNNCGKX-UHFFFAOYSA-N";385.9;4.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-6.31;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000004897788193684466
"MM474432";"MM474432";"CC(C)CCNc1ccc(-c2cnc3ccc(NC4CCN(C)CC4)nn23)cn1";"KIVBSGFPJMMGJQ-UHFFFAOYSA-N";393.54;3.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2384453/target=_blank>CHEMBL2384453</a>";;-5.09;"Chapman TM, Osborne SA, Bouloc N, Large JM, Wallace C, Birchall K, Ansell KH, Jones HM, Taylor D, Clough B, Green JL, Holder AA.: Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). Bioorg Med Chem Lett, Volume 23 (10), 2013";"PAMPA";0.000008128305161640995
"MM474431";"MM474431";"CC(C)CCNc1ccc(-c2cnc3ccc(NC4CCN(C)C4)nn23)cn1";"RUDLWCBRULBWIA-UHFFFAOYSA-N";379.51;3.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2384453/target=_blank>CHEMBL2384453</a>";;-4.94;"Chapman TM, Osborne SA, Bouloc N, Large JM, Wallace C, Birchall K, Ansell KH, Jones HM, Taylor D, Clough B, Green JL, Holder AA.: Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). Bioorg Med Chem Lett, Volume 23 (10), 2013";"PAMPA";0.000011481536214968817
"MM474430";"MM474430";"CC(C)CCNc1ccc(-c2cnc3ccc(N4CCC(N(C)C)CC4)nn23)cn1";"CEUYRPFXZOTKQS-UHFFFAOYSA-N";407.57;3.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2384453/target=_blank>CHEMBL2384453</a>";;-4.86;"Chapman TM, Osborne SA, Bouloc N, Large JM, Wallace C, Birchall K, Ansell KH, Jones HM, Taylor D, Clough B, Green JL, Holder AA.: Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). Bioorg Med Chem Lett, Volume 23 (10), 2013";"PAMPA";0.000013803842646028839
"MM474429";"MM474429";"CC(C)CCNc1ccc(-c2cnc3ccc(N4CCC(N)CC4)nn23)cn1";"WRLSFIWLUITXLE-UHFFFAOYSA-N";379.51;3.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2384453/target=_blank>CHEMBL2384453</a>";;-5.26;"Chapman TM, Osborne SA, Bouloc N, Large JM, Wallace C, Birchall K, Ansell KH, Jones HM, Taylor D, Clough B, Green JL, Holder AA.: Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). Bioorg Med Chem Lett, Volume 23 (10), 2013";"PAMPA";0.0000054954087385762485
"MM472535";"MM472535";"O=C(O)c1ccccc1Nc1ccccc1";"ZWJINEZUASEZBH-UHFFFAOYSA-N";213.24;3.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905612/target=_blank>CHEMBL905612</a>";;-4.86;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000013803842646028839
"MM472891";"MM472891";"Cc1c(N2CC(=O)NS2(=O)=O)csc1-c1cccc(NC2CCN(S(=O)(=O)Cc3ccccc3)CC2)c1";"MRPOOXOVLHKTGX-UHFFFAOYSA-N";560.72;3.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886820/target=_blank>CHEMBL886820</a>";;-6.72;"Wan ZK, Follows B, Kirincich S, Wilson D, Binnun E, Xu W, Joseph-McCarthy D, Wu J, Smith M, Zhang YL, Tam M, Erbe D, Tam S, Saiah E, Lee J.: Probing acid replacements of thiophene PTP1B inhibitors. Bioorg Med Chem Lett, Volume 17 (10), 2007";"PAMPA";0.00000019054607179632483
"MM474433";"MM474433";"COc1ccccc1OC[C@@H](O)CO";"HSRJKNPTNIJEKV-QMMMGPOBSA-N";198.22;0.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2396357/target=_blank>CHEMBL2396357</a>";;-5.09;"Hadimani MB, Purohit MK, Vanampally C, Van der Ploeg R, Arballo V, Morrow D, Frizzi KE, Calcutt NA, Fernyhough P, Kotra LP.: Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy. J Med Chem, Volume 56 (12), 2013";"PAMPA";0.000008128305161640995
"MM473975";"MM473975";"COc1c(-c2ccc3c(c2)CC=C3CNS(C)(=O)=O)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C";"NRKKCVNJJVPVTF-UHFFFAOYSA-N";495.6;2.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2393996/target=_blank>CHEMBL2393996</a>";;-5.27;"Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.: Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. Bioorg Med Chem Lett, Volume 23 (12), 2013";"PAMPA";0.000005370317963702533
"MM473974";"MM473974";"COc1c(-c2ccc3c(c2)CC=C3C(C)(C)NS(C)(=O)=O)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C";"SZESPTRIDHGUMG-UHFFFAOYSA-N";523.66;3.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2393996/target=_blank>CHEMBL2393996</a>";;-5.39;"Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.: Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. Bioorg Med Chem Lett, Volume 23 (12), 2013";"PAMPA";0.000004073802778041131
"MM473973";"MM473973";"COc1c(-c2ccc3c(c2)CC/C3=N\NS(C)(=O)=O)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C";"BSGREXYSTRLYNX-SZXQPVLSSA-N";496.59;2.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2393996/target=_blank>CHEMBL2393996</a>";;-6.33;"Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.: Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. Bioorg Med Chem Lett, Volume 23 (12), 2013";"PAMPA";0.0000004677351412871981
"MM473972";"MM473972";"COc1c(-c2ccc3c(c2)CCC3NNS(C)(=O)=O)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C";"LWUPFIBYTKEWJQ-UHFFFAOYSA-N";498.61;2.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2393996/target=_blank>CHEMBL2393996</a>";;-6.62;"Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.: Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. Bioorg Med Chem Lett, Volume 23 (12), 2013";"PAMPA";0.000000239883291901949
"MM473979";"MM473979";"COc1c(-c2ccc3c(CNS(C)(=O)=O)csc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C";"CNFBZBKPLGSFTC-UHFFFAOYSA-N";513.64;3.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2393996/target=_blank>CHEMBL2393996</a>";;-6.09;"Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.: Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. Bioorg Med Chem Lett, Volume 23 (12), 2013";"PAMPA";0.0000008128305161640995
"MM473978";"MM473978";"COc1c(-c2ccc3nc(NS(C)(=O)=O)sc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C";"VQTJHVDHKTWBNP-UHFFFAOYSA-N";500.6;3.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2393996/target=_blank>CHEMBL2393996</a>";;-5.85;"Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.: Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. Bioorg Med Chem Lett, Volume 23 (12), 2013";"PAMPA";0.0000014125375446227554
"MM473977";"MM473977";"COc1c(-c2ccc3cc(CNS(C)(=O)=O)sc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C";"NWDQPWDUNFAXND-UHFFFAOYSA-N";513.64;3.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2393996/target=_blank>CHEMBL2393996</a>";;-6.09;"Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.: Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. Bioorg Med Chem Lett, Volume 23 (12), 2013";"PAMPA";0.0000008128305161640995
"MM473976";"MM473976";"COc1c(-c2ccc3c(c2)CCC3CNS(C)(=O)=O)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C";"IYTYOXLXXMKIMX-UHFFFAOYSA-N";497.62;3.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2393996/target=_blank>CHEMBL2393996</a>";;-5.05;"Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.: Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif. Bioorg Med Chem Lett, Volume 23 (12), 2013";"PAMPA";0.00000891250938133746
"MM473970";"MM473970";"CCCn1nc(NC(=O)NC2C3CC4CC(C3)CC2C4)cc1C";"MZSJMBUEKNPGKA-UHFFFAOYSA-N";316.45;3.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.4;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.00039810717055349735
"MM473969";"MM473969";"O=C(Nc1nccs1)NC12CC3CC(CC(C3)C1)C2";"CEPVJDPYPKTWKB-UHFFFAOYSA-N";277.39;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.27;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.0005370317963702527
"MM473968";"MM473968";"Cc1csc(NC(=O)NC23CC4CC(CC(C4)C2)C3)n1";"GZINVYLOJRBPTG-UHFFFAOYSA-N";291.42;3.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.12;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.0007585775750291836
"MM473967";"MM473967";"Cc1cnc(NC(=O)NC23CC4CC(CC(C4)C2)C3)s1";"QDNCTWGSGILVRL-UHFFFAOYSA-N";291.42;3.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-4.52;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.000030199517204020192
"MM473966";"MM473966";"CC(C)c1nnc(NC(=O)NC23CC4CC(CC(C4)C2)C3)o1";"OSDZNESIEIWHIO-UHFFFAOYSA-N";304.39;3.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.48;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.0003311311214825911
"MM473965";"MM473965";"CCCn1nc(NC(=O)NC23CC4CC(CC(C4)C2)C3)cc1C";"BUYVCAFQTNKBIY-UHFFFAOYSA-N";316.45;3.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.09;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.0008128305161640995
"MM473964";"MM473964";"CC(C)(C)c1cc(NC(=O)NC2C3CC4CC(C3)CC2C4)no1";"TWENLQAITOETCW-UHFFFAOYSA-N";317.43;3.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-2.94;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.0011481536214968829
"MM473963";"MM473963";"Cc1csc(NC(=O)NC2C3CC4CC(C3)CC2C4)n1";"BZWAQJJUJUGDCR-UHFFFAOYSA-N";291.42;3.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.16;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.0006918309709189362
"MM473962";"MM473962";"CC(C)c1nnc(NC(=O)NC2C3CC4CC(C3)CC2C4)o1";"GYRPEMAUAOASTR-UHFFFAOYSA-N";304.39;3.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.32;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.00047863009232263854
"MM473961";"MM473961";"O=C(Nc1nnc(C2CC2)o1)NC1C2CC3CC(C2)CC1C3";"PABDFSBOTCYGMU-UHFFFAOYSA-N";302.38;2.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.07;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.0008511380382023768
"MM473960";"MM473960";"O=C(Nc1nnc(C2CCC2)o1)NC1C2CC3CC(C2)CC1C3";"JWRUCAWPBUBNQH-UHFFFAOYSA-N";316.41;3.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3.07;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.0008511380382023768
"MM473971";"MM473971";"CCn1nc(NC(=O)NC2C3CC4CC(C3)CC2C4)cc1C";"DJRXZTPBXKMXJQ-UHFFFAOYSA-N";302.42;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2394219/target=_blank>CHEMBL2394219</a>";;-3;"North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.: Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem, Volume 21 (9), 2013";"PAMPA";0.001
"MM473989";"MM473989";"ClC(Cn1ncc2c(Nc3cccc(Br)c3)ncnc21)c1ccccc1";"DGUCATVGNKWMHQ-UHFFFAOYSA-N";428.72;5.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2399896/target=_blank>CHEMBL2399896</a>";;-5.49;"Radi M, Tintori C, Musumeci F, Brullo C, Zamperini C, Dreassi E, Fallacara AL, Vignaroli G, Crespan E, Zanoli S, Laurenzana I, Filippi I, Maga G, Schenone S, Angelucci A, Botta M.: Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. J Med Chem, Volume 56 (13), 2013";"PAMPA";0.000003235936569296281
"MM473988";"MM473988";"Fc1cccc(Nc2ncnc3c2cnn3CC(Cl)c2ccccc2)c1";"GXIBVDBBEJEVPC-UHFFFAOYSA-N";367.82;4.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2399896/target=_blank>CHEMBL2399896</a>";;-5.12;"Radi M, Tintori C, Musumeci F, Brullo C, Zamperini C, Dreassi E, Fallacara AL, Vignaroli G, Crespan E, Zanoli S, Laurenzana I, Filippi I, Maga G, Schenone S, Angelucci A, Botta M.: Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. J Med Chem, Volume 56 (13), 2013";"PAMPA";0.000007585775750291836
"MM473986";"MM473986";"Clc1cccc(CNc2ncnc3c2cnn3CC(Cl)c2ccc(Br)cc2)c1";"QNKRFRCYRMDLLE-UHFFFAOYSA-N";477.19;5.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2399896/target=_blank>CHEMBL2399896</a>";;-5.04;"Radi M, Tintori C, Musumeci F, Brullo C, Zamperini C, Dreassi E, Fallacara AL, Vignaroli G, Crespan E, Zanoli S, Laurenzana I, Filippi I, Maga G, Schenone S, Angelucci A, Botta M.: Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. J Med Chem, Volume 56 (13), 2013";"PAMPA";0.000009120108393559096
"MM473984";"MM473984";"Clc1ccc(CNc2ncnc3c2cnn3CC(Cl)c2ccc(Br)cc2)cc1";"BDVXUKAIEGCZSB-UHFFFAOYSA-N";477.19;5.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2399896/target=_blank>CHEMBL2399896</a>";;-5.37;"Radi M, Tintori C, Musumeci F, Brullo C, Zamperini C, Dreassi E, Fallacara AL, Vignaroli G, Crespan E, Zanoli S, Laurenzana I, Filippi I, Maga G, Schenone S, Angelucci A, Botta M.: Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. J Med Chem, Volume 56 (13), 2013";"PAMPA";0.000004265795188015926
"MM473983";"MM473983";"Fc1ccc(CNc2ncnc3c2cnn3CC(Cl)c2ccc(Br)cc2)cc1";"MEFXUBVFUNBNFN-UHFFFAOYSA-N";460.74;5.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2399896/target=_blank>CHEMBL2399896</a>";;-4.97;"Radi M, Tintori C, Musumeci F, Brullo C, Zamperini C, Dreassi E, Fallacara AL, Vignaroli G, Crespan E, Zanoli S, Laurenzana I, Filippi I, Maga G, Schenone S, Angelucci A, Botta M.: Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. J Med Chem, Volume 56 (13), 2013";"PAMPA";0.00001071519305237607
"MM473982";"MM473982";"ClC(Cn1ncc2c(NCc3ccc(Br)cc3)ncnc21)c1ccc(Br)cc1";"FRNGTWDSALHYQF-UHFFFAOYSA-N";521.64;5.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2399896/target=_blank>CHEMBL2399896</a>";;-5.47;"Radi M, Tintori C, Musumeci F, Brullo C, Zamperini C, Dreassi E, Fallacara AL, Vignaroli G, Crespan E, Zanoli S, Laurenzana I, Filippi I, Maga G, Schenone S, Angelucci A, Botta M.: Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. J Med Chem, Volume 56 (13), 2013";"PAMPA";0.0000033884415613920275
"MM472630";"MM472630";"O=C(Nc1ccc(Cl)cc1)C1CCCN(C(=O)c2cccc(-c3cccs3)c2)C1";"WXBQPCKIPAMLGX-UHFFFAOYSA-N";424.95;5.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2398830/target=_blank>CHEMBL2398830</a>";;-10;"Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD.: Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett, Volume 23 (13), 2013";"PAMPA";0.0000000001
"MM472633";"MM472633";"O=C(Nc1ccc(Cl)cc1)C1CCCN(C(=O)c2cccc(-c3ccco3)c2)C1";"HERLZBNILRVHQN-UHFFFAOYSA-N";408.89;5.09;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2398830/target=_blank>CHEMBL2398830</a>";;-8.3;"Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD.: Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett, Volume 23 (13), 2013";"PAMPA";0.000000005011872336272715
"MM472632";"MM472632";"O=C(Nc1cccc(Oc2ccccc2)c1)C1CCCN(C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)C1";"QETYFFHAWUQFJS-UHFFFAOYSA-N";536.47;7.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2398830/target=_blank>CHEMBL2398830</a>";;-5.1;"Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD.: Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett, Volume 23 (13), 2013";"PAMPA";0.000007943282347242822
"MM472631";"MM472631";"O=C(Nc1cccc(Cc2ccccc2)c1)C1CCCN(C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)C1";"PIADYIGFSLLCTB-UHFFFAOYSA-N";534.5;6.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2398830/target=_blank>CHEMBL2398830</a>";;-4.7;"Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD.: Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett, Volume 23 (13), 2013";"PAMPA";0.000019952623149688786
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902035/target=_blank>CHEMBL902035</a>";;-8.7;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"PAMPA";0.0000000019952623149688828
"MM473995";"MM473995";"Cc1ccc(-c2nc3ccccc3s2)cc1NC(=O)c1cnccc1Cl";"URKTVJHBWZWGTM-UHFFFAOYSA-N";379.87;5.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.1;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0007943282347242813
"MM474009";"MM474009";"COc1ccc(-c2nc3ccccc3s2)cc1NC(=O)c1cnccc1Cl";"ASFFGFJRWLXSKV-UHFFFAOYSA-N";395.87;5.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.92;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.00012022644346174131
"MM474005";"MM474005";"O=C(Nc1cc(-c2nc3ccccc3s2)ccc1F)c1cnccc1Cl";"UNRWXUXAORADNP-UHFFFAOYSA-N";383.84;5.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.51;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0003090295432513592
"MM474000";"MM474000";"Cc1ccc(-c2nc3ccccc3o2)cc1NC(=O)c1cnccc1Cl";"GJGRLDKXWFIFJV-UHFFFAOYSA-N";363.8;5.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.19;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0006456542290346556
"MM474004";"MM474004";"COc1ccc(-c2nc3ccccc3o2)cc1NC(=O)c1cnccc1Cl";"IVUJJROKDJKGFB-UHFFFAOYSA-N";379.8;4.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.41;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0003890451449942805
"MM474007";"MM474007";"O=C(Nc1cc(-c2nc3ccccc3o2)ccc1F)c1cnccc1Cl";"QBZMYHABXDMPGR-UHFFFAOYSA-N";367.77;4.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.59;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0002570395782768865
"MM474006";"MM474006";"O=C(Nc1ccc(F)c(-c2nc3ccccc3o2)c1)c1cnccc1Cl";"CWDJUFUNGLSJJE-UHFFFAOYSA-N";367.77;4.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.52;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0003019951720402016
"MM473994";"MM473994";"C=CC(=O)Nc1cccc(-c2nc3ccccc3s2)c1";"FOCYZIXAZWHKST-UHFFFAOYSA-N";280.35;4.09;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.1;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0007943282347242813
"MM473991";"MM473991";"C/C=C/C(=O)Nc1cccc(-c2nc3ccccc3s2)c1";"RLYNKGLWVUQIAM-QHHAFSJGSA-N";294.38;4.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-2.78;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0016595869074375613
"MM473992";"MM473992";"C=C(C)C(=O)Nc1cccc(-c2nc3ccccc3s2)c1";"LIFQWIGQWZGUEX-UHFFFAOYSA-N";294.38;4.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.01;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.000977237220955811
"MM473990";"MM473990";"CN(C)CCC(=O)Nc1cccc(-c2nc3ccccc3s2)c1";"QTGJSUSNSIJBAT-UHFFFAOYSA-N";325.44;3.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-2.68;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0020892961308540386
"MM473999";"MM473999";"O=C(CCl)Nc1cccc(-c2nc3ccccc3s2)c1";"IKKWOYOCXJIEKT-UHFFFAOYSA-N";302.79;4.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.18;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0006606934480075957
"MM473996";"MM473996";"CC(Cl)C(=O)Nc1cccc(-c2nc3ccccc3s2)c1";"HIHYFMPTWYSBAC-UHFFFAOYSA-N";316.81;4.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.11;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0007762471166286919
"MM473993";"MM473993";"CC(C)(CCl)C(=O)Nc1cccc(-c2nc3ccccc3s2)c1";"YBNVQKZJZOGCRE-UHFFFAOYSA-N";344.87;5.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.05;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0008912509381337459
"MM473997";"MM473997";"O=C(Nc1cccc(-c2nc3ccccc3s2)c1)c1cnccc1Cl";"NCXWAHCXIPNKIU-UHFFFAOYSA-N";365.85;5.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.14;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0007244359600749898
"MM473998";"MM473998";"O=C(Nc1cccc(-c2nc3ccccc3s2)c1)c1cccnc1Cl";"RVBRBPXTTKBUAD-UHFFFAOYSA-N";365.85;5.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.17;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0006760829753919819
"MM474003";"MM474003";"O=C(Nc1cccc(-c2nc3ccccc3s2)c1)c1ccnc(Cl)c1";"MIPMQEAPFPCULK-UHFFFAOYSA-N";365.85;5.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.32;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.00047863009232263854
"MM474001";"MM474001";"O=C(Nc1cccc(-c2nc3ccccc3s2)c1)c1ccncc1Cl";"PJJHVUDEEHFXKO-UHFFFAOYSA-N";365.85;5.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.25;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.0005623413251903491
"MM474008";"MM474008";"O=C(Nc1cccc(-c2nc3ccccc3s2)c1)c1cnc(Cl)s1";"BMEKANQMCVMOHD-UHFFFAOYSA-N";371.87;5.33;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2405174/target=_blank>CHEMBL2405174</a>";;-3.88;"Hwang JY, Smithson DC, Holbrook G, Zhu F, Connelly MC, Kaiser M, Brun R, Kiplin Guy R.: Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorg Med Chem Lett, Volume 23 (14), 2013";"PAMPA";0.00013182567385564074
"MM473833";"MM473833";"CC1=C2CC(C)(C)/C=C/C(=O)/C(C)=C\C3=C[C@H](C)C[C@]3(O2)C1=O";"MJNNONLDVCCGCA-ZQHAHMAHSA-N";312.41;4.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2404840/target=_blank>CHEMBL2404840</a>";;-3.28;"Hadi V, Hotard M, Ling T, Salinas YG, Palacios G, Connelly M, Rivas F.: Evaluation of Jatropha isabelli natural products and their synthetic analogs as potential antimalarial therapeutic agents. Eur J Med Chem, Volume 65, 2013";"PAMPA";0.0005248074602497728
"MM473832";"MM473832";"CC1=C2CC(C)(C)/C(c3ccc(C(F)(F)F)cc3)=C/C(=O)/C(C)=C\C3=C[C@H](C)C[C@]3(O2)C1=O";"HOTXTAPRMCVGAU-NWBFCAHESA-N";456.5;6.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2404840/target=_blank>CHEMBL2404840</a>";;-3.97;"Hadi V, Hotard M, Ling T, Salinas YG, Palacios G, Connelly M, Rivas F.: Evaluation of Jatropha isabelli natural products and their synthetic analogs as potential antimalarial therapeutic agents. Eur J Med Chem, Volume 65, 2013";"PAMPA";0.00010715193052376059
"MM474438";"MM474438";"Nc1ccccc1NC(=O)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1";"SMTXKVURUPJKNQ-OAQYLSRUSA-N";402.52;4.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410090/target=_blank>CHEMBL2410090</a>";;-4.29;"Marson CM, Matthews CJ, Yiannaki E, Atkinson SJ, Soden PE, Shukla L, Lamadema N, Thomas NS.: Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit. J Med Chem, Volume 56 (15), 2013";"PAMPA";0.00005128613839913648
"MM474437";"MM474437";"Cc1ccc(-c2ccc(-n3c(Cl)cc4[nH]c(=O)c(C#N)c(O)c43)cc2)cc1";"CZDSKZBGMJONHZ-UHFFFAOYSA-N";375.82;4.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410001/target=_blank>CHEMBL2410001</a>";;-6.32;"Mirguet O, Sautet S, ClĂ©ment CA, Toum J, Donche F, Marques C, Rondet E, Pizzonero M, Beaufils B, Dudit Y, Huet P, Trottet L, Grondin P, Brusq JM, Boursier E, Saintillan Y, Nicodeme E.: Discovery of Pyridones As Oral AMPK Direct Activators. ACS Med Chem Lett, Volume 4 (7), 2013";"PAMPA";0.000000478630092322638
"MM474436";"MM474436";"CCc1ccc(-n2c(Cl)cc3[nH]c(=O)c(-c4ccccc4)c(O)c32)cc1";"CNKANSZIAKIZPN-UHFFFAOYSA-N";364.83;4.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410001/target=_blank>CHEMBL2410001</a>";;-4.82;"Mirguet O, Sautet S, ClĂ©ment CA, Toum J, Donche F, Marques C, Rondet E, Pizzonero M, Beaufils B, Dudit Y, Huet P, Trottet L, Grondin P, Brusq JM, Boursier E, Saintillan Y, Nicodeme E.: Discovery of Pyridones As Oral AMPK Direct Activators. ACS Med Chem Lett, Volume 4 (7), 2013";"PAMPA";0.000015135612484362071
"MM474435";"MM474435";"COc1cccc(-c2ccc(-n3c(Cl)cc4[nH]c(=O)c(-c5ccccc5)c(O)c43)cc2)c1O";"ZYDQKSGHSBJFMP-UHFFFAOYSA-N";458.9;5.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2410001/target=_blank>CHEMBL2410001</a>";;-4.96;"Mirguet O, Sautet S, ClĂ©ment CA, Toum J, Donche F, Marques C, Rondet E, Pizzonero M, Beaufils B, Dudit Y, Huet P, Trottet L, Grondin P, Brusq JM, Boursier E, Saintillan Y, Nicodeme E.: Discovery of Pyridones As Oral AMPK Direct Activators. ACS Med Chem Lett, Volume 4 (7), 2013";"PAMPA";0.000010964781961431852
"MM473091";"MM473091";"CCOc1cc(CN2CCC(NC(=O)c3cncc(C)c3)CC2)ccc1Cl";"DARWEDNPGILOPQ-UHFFFAOYSA-N";387.91;3.84;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1212339/target=_blank>CHEMBL1212339</a>";;-5.71;"Alker A, Binggeli A, Christ AD, Green L, Maerki HP, Martin RE, Mohr P.: Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 20 (15), 2010";"PAMPA";0.0000019498445997580454
"MM474029";"MM474029";"N#Cc1c(Cl)nc(NCCCC2CCN(Cc3ccccc3)CC2)c(C#N)c1-c1ccccc1";"PWFVTINZOVIFQP-UHFFFAOYSA-N";470.02;6.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2421447/target=_blank>CHEMBL2421447</a>";;-4.99;"Samadi A, de la Fuente Revenga M, PĂ©rez C, Iriepa I, Moraleda I, RodrĂ­guez-Franco MI, Marco-Contelles J.: Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 67, 2013";"PAMPA";0.000010232929922807536
"MM474028";"MM474028";"N#Cc1c(Cl)nc(NCCCCC2CCN(Cc3ccccc3)CC2)c(C#N)c1-c1ccccc1";"NXFUAVRJMVGTEU-UHFFFAOYSA-N";484.05;6.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2421447/target=_blank>CHEMBL2421447</a>";;-4.99;"Samadi A, de la Fuente Revenga M, PĂ©rez C, Iriepa I, Moraleda I, RodrĂ­guez-Franco MI, Marco-Contelles J.: Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 67, 2013";"PAMPA";0.000010232929922807536
"MM474027";"MM474027";"N#Cc1cc(C#N)c(NC2CCN(Cc3ccccc3)CC2)nc1Cl";"APUNUGFNNAECLO-UHFFFAOYSA-N";351.84;3.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2421447/target=_blank>CHEMBL2421447</a>";;-5.13;"Samadi A, de la Fuente Revenga M, PĂ©rez C, Iriepa I, Moraleda I, RodrĂ­guez-Franco MI, Marco-Contelles J.: Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 67, 2013";"PAMPA";0.000007413102413009177
"MM474026";"MM474026";"N#Cc1cc(C#N)c(NCCC2CCN(Cc3ccccc3)CC2)nc1Cl";"KPKNMUAGNOEDIE-UHFFFAOYSA-N";379.9;4.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2421447/target=_blank>CHEMBL2421447</a>";;-5.07;"Samadi A, de la Fuente Revenga M, PĂ©rez C, Iriepa I, Moraleda I, RodrĂ­guez-Franco MI, Marco-Contelles J.: Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 67, 2013";"PAMPA";0.00000851138038202376
"MM474025";"MM474025";"N#Cc1cc(C#N)c(NCCCC2CCN(Cc3ccccc3)CC2)nc1Cl";"CXJHSZNBWBHAQG-UHFFFAOYSA-N";393.92;4.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2421447/target=_blank>CHEMBL2421447</a>";;-5.22;"Samadi A, de la Fuente Revenga M, PĂ©rez C, Iriepa I, Moraleda I, RodrĂ­guez-Franco MI, Marco-Contelles J.: Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 67, 2013";"PAMPA";0.000006025595860743581
"MM474024";"MM474024";"N#Cc1cc(C#N)c(NCCCCC2CCN(Cc3ccccc3)CC2)nc1Cl";"VPVULNNWJJSXOM-UHFFFAOYSA-N";407.95;4.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2421447/target=_blank>CHEMBL2421447</a>";;-5.16;"Samadi A, de la Fuente Revenga M, PĂ©rez C, Iriepa I, Moraleda I, RodrĂ­guez-Franco MI, Marco-Contelles J.: Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 67, 2013";"PAMPA";0.0000069183097091893625
"MM474023";"MM474023";"N#Cc1cc(C#N)c(NC2CCN(Cc3ccccc3)CC2)nc1NC1CCN(Cc2ccccc2)CC1";"OXQRMHHRDWXOPE-UHFFFAOYSA-N";505.67;4.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2421447/target=_blank>CHEMBL2421447</a>";;-5.3;"Samadi A, de la Fuente Revenga M, PĂ©rez C, Iriepa I, Moraleda I, RodrĂ­guez-Franco MI, Marco-Contelles J.: Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem, Volume 67, 2013";"PAMPA";0.000005011872336272725
"MM471257";"MM471257";"COc1cc2nc(C3CC3)nc(N3CCN(c4ccccc4OC)CC3)c2cc1OC";"SWEOAXMICIJCQC-UHFFFAOYSA-N";420.51;3.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2433249/target=_blank>CHEMBL2433249</a>";;-2.68;"Peddibhotla S, Hedrick MP, Hershberger P, Maloney PR, Li Y, Milewski M, Gosalia P, Gray W, Mehta A, Sugarman E, Hood B, Suyama E, Nguyen K, Heynen-Genel S, Vasile S, Salaniwal S, Stonich D, Su Y, Mangravita-Novo A, Vicchiarelli M, Roth GP, Smith LH, Chung TD, Hanson GR, Thomas JB, Caron MG, Barak LS, Pinkerton AB.: Discovery of ML314, a Brain Penetrant Non-Peptidic Î˛-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor. ACS Med Chem Lett, Volume 4 (9), 2013";"PAMPA";0.0020892961308540386
"MM471257";"MM471257";"COc1cc2nc(C3CC3)nc(N3CCN(c4ccccc4OC)CC3)c2cc1OC";"SWEOAXMICIJCQC-UHFFFAOYSA-N";420.51;3.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2433250/target=_blank>CHEMBL2433250</a>";;-2.67;"Peddibhotla S, Hedrick MP, Hershberger P, Maloney PR, Li Y, Milewski M, Gosalia P, Gray W, Mehta A, Sugarman E, Hood B, Suyama E, Nguyen K, Heynen-Genel S, Vasile S, Salaniwal S, Stonich D, Su Y, Mangravita-Novo A, Vicchiarelli M, Roth GP, Smith LH, Chung TD, Hanson GR, Thomas JB, Caron MG, Barak LS, Pinkerton AB.: Discovery of ML314, a Brain Penetrant Non-Peptidic Î˛-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor. ACS Med Chem Lett, Volume 4 (9), 2013";"PAMPA";0.0021379620895022326
"MM471257";"MM471257";"COc1cc2nc(C3CC3)nc(N3CCN(c4ccccc4OC)CC3)c2cc1OC";"SWEOAXMICIJCQC-UHFFFAOYSA-N";420.51;3.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2433251/target=_blank>CHEMBL2433251</a>";;-2.93;"Peddibhotla S, Hedrick MP, Hershberger P, Maloney PR, Li Y, Milewski M, Gosalia P, Gray W, Mehta A, Sugarman E, Hood B, Suyama E, Nguyen K, Heynen-Genel S, Vasile S, Salaniwal S, Stonich D, Su Y, Mangravita-Novo A, Vicchiarelli M, Roth GP, Smith LH, Chung TD, Hanson GR, Thomas JB, Caron MG, Barak LS, Pinkerton AB.: Discovery of ML314, a Brain Penetrant Non-Peptidic Î˛-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor. ACS Med Chem Lett, Volume 4 (9), 2013";"PAMPA";0.001174897554939529
"MM474032";"MM474032";"O=C(O)c1ccc(Sc2ccc(CN3CCC(N4C(=O)N(C5CCOCC5)C[C@H]4c4ccccc4)CC3)cn2)cc1";"BZKHTWAGPLWPPO-LJAQVGFWSA-N";572.73;5.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439730/target=_blank>CHEMBL2439730</a>";;-4.93;"Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.: Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication. J Med Chem, Volume 56 (20), 2013";"PAMPA";0.000011748975549395302
"MM474033";"MM474033";"Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1";"NAYZSSQGIKJDGG-PMERELPUSA-N";570.69;5.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439730/target=_blank>CHEMBL2439730</a>";;-5.11;"Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.: Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication. J Med Chem, Volume 56 (20), 2013";"PAMPA";0.00000776247116628691
"MM474030";"MM474030";"CCc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1";"FJAGYOZYOQUDEQ-HKBQPEDESA-N";584.72;5.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439730/target=_blank>CHEMBL2439730</a>";;-4.91;"Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.: Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication. J Med Chem, Volume 56 (20), 2013";"PAMPA";0.00001230268770812381
"MM474031";"MM474031";"Cc1nc(Oc2ccc(C(N)=O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1";"OKRZBWWJVVVKHT-PMERELPUSA-N";569.71;4.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439730/target=_blank>CHEMBL2439730</a>";;-4.92;"Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.: Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication. J Med Chem, Volume 56 (20), 2013";"PAMPA";0.000012022644346174132
"MM474443";"MM474443";"CN1CCC(Nc2ccc3ncc(-c4cnn(-c5cnccn5)c4)n3n2)CC1";"TVZFZVLMJJPNJS-UHFFFAOYSA-N";375.44;1.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439446/target=_blank>CHEMBL2439446</a>";;-7.3;"Large JM, Osborne SA, Smiljanic-Hurley E, Ansell KH, Jones HM, Taylor DL, Clough B, Green JL, Holder AA.: Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. Bioorg Med Chem Lett, Volume 23 (21), 2013";"PAMPA";0.00000005011872336272725
"MM474442";"MM474442";"N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnn(-c5ccc(F)cc5)c4)n3n2)CC1";"QEVNEODRZSMEST-QAQDUYKDSA-N";391.45;3.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439446/target=_blank>CHEMBL2439446</a>";;-5.37;"Large JM, Osborne SA, Smiljanic-Hurley E, Ansell KH, Jones HM, Taylor DL, Clough B, Green JL, Holder AA.: Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. Bioorg Med Chem Lett, Volume 23 (21), 2013";"PAMPA";0.000004265795188015926
"MM474441";"MM474441";"Fc1ccc(-n2cc(-c3cnc4ccc(N[C@H]5CC[C@H](N6CCCC6)CC5)nn34)cn2)cc1";"ZTJQMIAJXJTMNB-MEMLXQNLSA-N";445.55;4.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439446/target=_blank>CHEMBL2439446</a>";;-4.98;"Large JM, Osborne SA, Smiljanic-Hurley E, Ansell KH, Jones HM, Taylor DL, Clough B, Green JL, Holder AA.: Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. Bioorg Med Chem Lett, Volume 23 (21), 2013";"PAMPA";0.000010471285480508985
"MM474440";"MM474440";"CN1CCC(Oc2ccc3ncc(-c4cnn(-c5ccc(F)cc5)c4)n3n2)CC1";"JRSLWKGUIMBYLK-UHFFFAOYSA-N";392.44;3.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439446/target=_blank>CHEMBL2439446</a>";;-4.67;"Large JM, Osborne SA, Smiljanic-Hurley E, Ansell KH, Jones HM, Taylor DL, Clough B, Green JL, Holder AA.: Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. Bioorg Med Chem Lett, Volume 23 (21), 2013";"PAMPA";0.000021379620895022323
"MM474439";"MM474439";"Fc1ccc(-n2cc(-c3cnn4ccc(C5CCCNC5)nc34)cn2)cc1";"FQRJKOPMEKMPIB-UHFFFAOYSA-N";362.41;3.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439446/target=_blank>CHEMBL2439446</a>";;-4.66;"Large JM, Osborne SA, Smiljanic-Hurley E, Ansell KH, Jones HM, Taylor DL, Clough B, Green JL, Holder AA.: Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. Bioorg Med Chem Lett, Volume 23 (21), 2013";"PAMPA";0.00002187761623949552
"MM474445";"MM474445";"c1ccc(-n2cc(-c3cnc4ccc(NC5CCNCC5)nn34)cn2)cc1";"RUELNBPHROFCEJ-UHFFFAOYSA-N";359.44;2.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439446/target=_blank>CHEMBL2439446</a>";;-5.64;"Large JM, Osborne SA, Smiljanic-Hurley E, Ansell KH, Jones HM, Taylor DL, Clough B, Green JL, Holder AA.: Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. Bioorg Med Chem Lett, Volume 23 (21), 2013";"PAMPA";0.0000022908676527677747
"MM474444";"MM474444";"CN1CCC(Nc2ccc3ncc(-c4cnn(-c5cccc(F)c5)c4)n3n2)CC1";"KAHXWCMLLCYZQC-UHFFFAOYSA-N";391.45;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2439446/target=_blank>CHEMBL2439446</a>";;-4.96;"Large JM, Osborne SA, Smiljanic-Hurley E, Ansell KH, Jones HM, Taylor DL, Clough B, Green JL, Holder AA.: Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. Bioorg Med Chem Lett, Volume 23 (21), 2013";"PAMPA";0.000010964781961431852
"MM474142";"MM474142";"O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CC1";"KSHJXDWYTZJUEI-UHFFFAOYSA-N";377.45;2.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428423/target=_blank>CHEMBL3428423</a>";;-5.66;"Feng S, Hong D, Wang B, Zheng X, Miao K, Wang L, Yun H, Gao L, Zhao S, Shen HC.: Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. ACS Med Chem Lett, Volume 6 (3), 2015";"PAMPA";0.0000021877616239495517
"MM472637";"MM472637";"CCCC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)c1ccc(/C=C2\SC(=S)N(CCCC)C2=O)cc1)C(N)=O";"IYNRFFXZCIBVIZ-OPIGBIQLSA-N";717.96;1.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2447436/target=_blank>CHEMBL2447436</a>";;-5.79;"Nitsche C, Schreier VN, Behnam MA, Kumar A, Bartenschlager R, Klein CD.: Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture. J Med Chem, Volume 56 (21), 2013";"PAMPA";0.0000016218100973589298
"MM474530";"MM474530";"O=c1[nH]cc(-c2ccc(F)cc2)cc1O";"QERVZZFDZPKURK-UHFFFAOYSA-N";205.19;1.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620434/target=_blank>CHEMBL3620434</a>";;-5.36;"Chapman TM, Gillen KJ, Wallace C, Lee MT, Bakrania P, Khurana P, Coombs PJ, Stennett L, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B.: Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF. Bioorg Med Chem Lett, Volume 25 (19), 2015";"PAMPA";0.000004365158322401657
"MM472888";"MM472888";"C[C@H]1CC[C@H](NC(=O)c2cnc(N3CCC(CO)CC3)cn2)CC1";"DHLVUBGOMDKOGF-CTYIDZIISA-N";332.45;1.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902343/target=_blank>CHEMBL902343</a>";;-4.59;"Owen DR, Dodd PG, Gayton S, Greener BS, Harbottle GW, Mantell SJ, Maw GN, Osborne SA, Rees H, Ringer TJ, Rodriguez-Lens M, Smith GF.: Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett, Volume 17 (2), 2007";"PAMPA";0.000025703957827688645
"MM472896";"MM472896";"O=C(NCCN1CCCCC1)c1nc(NCC(c2ccccc2)c2ccccc2)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1";"ZNUJAZSDJXSBIG-YVIFWTNJSA-N";601.71;1.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932006/target=_blank>CHEMBL932006</a>";;-6.7;"Mantell SJ, Stephenson PT, Monaghan SM, Maw GN, Trevethick MA, Yeadon M, Keir RF, Walker DK, Jones RM, Selby MD, Batchelor DV, Rozze S, Chavaroche H, Hobson TJ, Dodd PG, Lemaitre A, Wright KN, Stuart EF.: Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorg Med Chem Lett, Volume 18 (4), 2008";"PAMPA";0.00000019952623149688787
"Chembl257481";"MM469689";"CNCc1cc(C(=O)NC)ccc1Oc1ccc(Cl)cc1OC";"FUFMKPBBSWMURG-UHFFFAOYSA-N";334.8;3.22;;"Chembl257481";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948901/target=_blank>CHEMBL948901</a>";;-4.85;"Whitlock GA, Blagg J, Fish PV.: 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.000014125375446227555
"Chembl258060";"MM469709";"CNCc1cc(NS(C)(=O)=O)ccc1Oc1ccc(Cl)cc1C";"NTOHKBIOUPYUFZ-UHFFFAOYSA-N";354.86;3.53;;"Chembl258060";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948901/target=_blank>CHEMBL948901</a>";;-5.66;"Whitlock GA, Blagg J, Fish PV.: 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.0000021877616239495517
"Chembl258062";"MM469686";"CNCc1cc(C(=O)N(C)C)ccc1Oc1ccc(Cl)cc1Cl";"RFJRYJRDVNGNCX-UHFFFAOYSA-N";353.25;4.21;;"Chembl258062";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948901/target=_blank>CHEMBL948901</a>";;-4.85;"Whitlock GA, Blagg J, Fish PV.: 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.000014125375446227555
"Chembl258271";"MM469695";"CNCc1cc(C(N)=O)ccc1Oc1ccc(Cl)cc1Cl";"HEBFKAQNVHADTH-UHFFFAOYSA-N";325.2;3.6;;"Chembl258271";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948901/target=_blank>CHEMBL948901</a>";;-5;"Whitlock GA, Blagg J, Fish PV.: 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.00001
"MM473641";"MM473641";"COc1ccc(Cl)cc1Nc1nc(-c2sc(NC(=O)c3ccccc3)nc2C)cs1";"RDOBOPJBMQURAT-UHFFFAOYSA-N";456.98;6.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4324521/target=_blank>CHEMBL4324521</a>";;-5.09;"Tassini S, Langron E, Delang L, Mirabelli C, Lanko K, Crespan E, Kissova M, Tagliavini G, FontĂ˛ G, Bertoni S, Palese S, Giorgio C, Ravanetti F, Ragionieri L, Zamperini C, Mancini A, Dreassi E, Maga G, Vergani P, Neyts J, Radi M.: Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach â€ . J Med Chem, Volume 62 (23), 2019";"PAMPA";0.000008128305161640995
"MM472898";"MM472898";"COc1cc(Nc2c(C#N)cnc3cc(NCCCN(C)C)c(OC)cc23)c(Cl)cc1Cl";"YVRWBKAQVNQTGO-UHFFFAOYSA-N";474.39;5.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL922057/target=_blank>CHEMBL922057</a>";;-5.14;"Boschelli DH, Wu B, Ye F, Durutlic H, Golas JM, Lucas J, Boschelli F.: Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs. Bioorg Med Chem, Volume 16 (1), 2008";"PAMPA";0.000007244359600749906
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-4.01;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.00009772372209558111
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-5.2;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.00000630957344480193
"MM472894";"MM472894";"CCS(=O)(=O)CCN(C(=O)Cc1ccc(F)c(C(F)(F)F)c1)[C@H](C)c1nc(C2CC2)cn1-c1ccc(C#N)cc1";"DIIYNJJEHJXNPJ-GOSISDBHSA-N";576.62;5.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932100/target=_blank>CHEMBL932100</a>";;-5.29;"Du X, Chen X, Mihalic JT, Deignan J, Duquette J, Li AR, Lemon B, Ma J, Miao S, Ebsworth K, Sullivan TJ, Tonn G, Collins TL, Medina JC.: Design and optimization of imidazole derivatives as potent CXCR3 antagonists. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.000005128613839913648
"Chembl272493";"MM469685";"CNCc1cc(C(=O)N(C)C)ccc1Oc1ccc(Cl)cc1C";"PCZHCTVLCPQAAL-UHFFFAOYSA-N";332.83;3.86;;"Chembl272493";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948901/target=_blank>CHEMBL948901</a>";;-4.72;"Whitlock GA, Blagg J, Fish PV.: 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.000019054607179632484
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902035/target=_blank>CHEMBL902035</a>";;-5.93;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"PAMPA";0.0000011748975549395304
"MM471072";"MM471072";"CN1C(=O)C(c2ccccc2)(c2ccccc2)N=C1N";"RNWLAFWLSSMCLN-UHFFFAOYSA-N";265.32;1.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1042919/target=_blank>CHEMBL1042919</a>";;-5.52;"Nowak P, Cole DC, Aulabaugh A, Bard J, Chopra R, Cowling R, Fan KY, Hu B, Jacobsen S, Jani M, Jin G, Lo MC, Malamas MS, Manas ES, Narasimhan R, Reinhart P, Robichaud AJ, Stock JR, Subrath J, Svenson K, Turner J, Wagner E, Zhou P, Ellingboe JW.: Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett, Volume 20 (2), 2010";"PAMPA";0.0000030199517204020193
"MM474034";"MM474034";"Cc1c(Cc2cccc(NS(=O)(=O)N3CCN(C)CC3)c2)c(=O)oc2cc(OC(=O)N(C)C)c(Cl)cc12";"XRTVFJCRUVMBFK-UHFFFAOYSA-N";549.05;3.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3090632/target=_blank>CHEMBL3090632</a>";;-5.7;"Aoki T, Hyohdoh I, Furuichi N, Ozawa S, Watanabe F, Matsushita M, Sakaitani M, Ori K, Takanashi K, Harada N, Tomii Y, Tabo M, Yoshinari K, Aoki Y, Shimma N, Iikura H.: The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors. Bioorg Med Chem Lett, Volume 23 (23), 2013";"PAMPA";0.0000019952623149688787
"MM474446";"MM474446";"CN1Cc2cccc(Oc3ncccc3NC(=O)Nc3ccc(OC(F)(F)F)cc3)c2C1C(C)(C)C";"GHKPMDDCMGRGGC-UHFFFAOYSA-N";500.52;6.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3096011/target=_blank>CHEMBL3096011</a>";;-4.11;"Ruel R, L'Heureux A, Thibeault C, Lapointe P, Martel A, Qiao JX, Hua J, Price LA, Wu Q, Chang M, Zheng J, Huang CS, Wexler RR, Rehfuss R, Lam PY.: Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds. Bioorg Med Chem Lett, Volume 23 (24), 2013";"PAMPA";0.00007762471166286911
"MM474447";"MM474447";"CC(C)(C)CN1CCC(c2ccccc2Oc2ncccc2NC(=O)Nc2ccc(OC(F)(F)F)cc2)CC1";"KNECEHLDOUTFJU-UHFFFAOYSA-N";542.6;7.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3096011/target=_blank>CHEMBL3096011</a>";;-4.54;"Ruel R, L'Heureux A, Thibeault C, Lapointe P, Martel A, Qiao JX, Hua J, Price LA, Wu Q, Chang M, Zheng J, Huang CS, Wexler RR, Rehfuss R, Lam PY.: Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds. Bioorg Med Chem Lett, Volume 23 (24), 2013";"PAMPA";0.000028840315031266056
"MM474049";"MM474049";"CC1CCN(C(=O)[C@@H]2C[C@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)NC2(C#N)CC2)CC1";"YJZKURYVZRISEA-VAMGGRTRSA-N";443.57;2.29;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3096510/target=_blank>CHEMBL3096510</a>";;-5.34;"Hilpert H, Mauser H, Humm R, Anselm L, Kuehne H, Hartmann G, Gruener S, Banner DW, Benz J, Gsell B, Kuglstatter A, Stihle M, Thoma R, Sanchez RA, Iding H, Wirz B, Haap W.: Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds. J Med Chem, Volume 56 (23), 2013";"PAMPA";0.000004570881896148752
"MM474051";"MM474051";"N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCC(O)CC2)CC1";"URUISEODUFQHLN-GUDVDZBRSA-N";445.54;1.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3096510/target=_blank>CHEMBL3096510</a>";;-6.7;"Hilpert H, Mauser H, Humm R, Anselm L, Kuehne H, Hartmann G, Gruener S, Banner DW, Benz J, Gsell B, Kuglstatter A, Stihle M, Thoma R, Sanchez RA, Iding H, Wirz B, Haap W.: Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds. J Med Chem, Volume 56 (23), 2013";"PAMPA";0.00000019952623149688787
"MM474050";"MM474050";"N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCS(=O)(=O)CC2)CC1";"SCMQTMLIWAARLW-KZNAEPCWSA-N";479.58;0.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3096510/target=_blank>CHEMBL3096510</a>";;-6.7;"Hilpert H, Mauser H, Humm R, Anselm L, Kuehne H, Hartmann G, Gruener S, Banner DW, Benz J, Gsell B, Kuglstatter A, Stihle M, Thoma R, Sanchez RA, Iding H, Wirz B, Haap W.: Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds. J Med Chem, Volume 56 (23), 2013";"PAMPA";0.00000019952623149688787
"MM473817";"MM473817";"CCCC1S/C(=C/c2nc3ccccc3[nH]2)NC1=O";"VVXZPLQFCWCGBS-MDWZMJQESA-N";273.36;2.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3106895/target=_blank>CHEMBL3106895</a>";;-5.21;"Sogame S, Suenaga Y, Atobe M, Kawanishi M, Tanaka E, Miyoshi S.: Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping. Eur J Med Chem, Volume 71, 2014";"PAMPA";0.000006165950018614822
"MM474448";"MM474448";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(N)nccc3c2)c2ccc(Cl)c(OC)c2)c1";"MKOCYGRBOOMZRC-POURPWNDSA-N";666.2;6.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-5.6;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000025118864315095823
"MM474461";"MM474461";"CCOc1ccc(F)c([C@@H](Nc2ccc3c(N)nccc3c2)C(=O)N2CC[C@H](C(=O)O)[C@@H]2c2cc(NC(=O)OC)ccc2S(=O)(=O)C(C)C)c1";"ZROIOCGFCIZWFP-WXKJZWBCSA-N";707.78;5.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-7.1;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000007943282347242822
"MM474460";"MM474460";"CCS(=O)(=O)c1ccccc1[C@H]1[C@@H](C(=O)O)CCN1C(=O)[C@H](Nc1ccc2c(N)nccc2c1)c1ccc(F)c(OC)c1";"IZSJEKWHRIABKB-LBNPDIFZSA-N";606.68;4.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-7.25;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.000000056234132519034905
"MM474457";"MM474457";"CCOc1cc(C(Nc2ccc3c(N)nccc3c2)C(=O)NCc2ccccc2S(=O)(=O)C2CC2)ccc1OC(C)C";"BHTMZVVHJAAYBC-UHFFFAOYSA-N";588.73;5.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-5.59;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000025703957827688647
"MM474456";"MM474456";"CCOc1cc(C(Nc2ccc3c(N)nccc3c2)C(=O)NCc2ccccc2S(=O)(=O)C(C)C)ccc1OC(C)C";"QHJUWQXHNUKLAP-UHFFFAOYSA-N";590.75;5.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-5.92;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000012022644346174132
"MM474455";"MM474455";"CCOc1cc(C(Nc2ccc3c(N)nccc3c2)C(=O)NCc2ccccc2S(=O)(=O)CC)ccc1OC(C)C";"ZTNZCYHAMGCHNM-UHFFFAOYSA-N";576.72;5.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-6.05;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000008912509381337459
"MM474454";"MM474454";"CCOc1cc(C(Nc2ccc3c(N)nccc3c2)C(=O)N(C)Cc2ccccc2)ccc1OC(C)C";"LQQXFGZYYQHUNT-UHFFFAOYSA-N";498.63;5.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-4.64;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00002290867652767775
"MM474453";"MM474453";"CCOc1cc(C(Nc2ccc3c(N)nccc3c2)C(=O)N2CCCC2c2ccccc2)ccc1OC(C)C";"ICHSQGVMXMADMI-UHFFFAOYSA-N";524.67;6.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-5.09;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.000008128305161640995
"MM474452";"MM474452";"CCOc1cc([C@@H](Nc2ccc3c(N)nccc3c2)C(=O)N2CCC[C@@H]2c2cc(NC(=O)OC)ccc2S(=O)(=O)C(C)C)ccc1OC(C)C";"GSIPROWHYYPSSO-KAODMTDESA-N";703.86;6.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-6.15;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000007079457843841374
"MM474451";"MM474451";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(N)nccc3c2)c2ccccc2)c1";"AANRJYFZAKVMPG-XRKRLSELSA-N";601.73;5.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-5.24;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.000005754399373371567
"MM474450";"MM474450";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(N)nccc3c2)c2cccc(OC(F)F)c2)c1";"LVKNSMJYNKDZKL-XRKRLSELSA-N";667.74;6.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-6.15;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000007079457843841374
"MM474449";"MM474449";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(N)nccc3c2)c2ccc(OC)c(OC)c2)c1";"JAXUEOKMIODUOS-DLFZDVPBSA-N";661.78;5.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-6.7;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000019952623149688787
"MM474459";"MM474459";"CCOc1cc(C(Nc2ccc3c(N)nccc3c2)C(=O)NCc2ccccc2)ccc1OC(C)C";"KOLZRJYVOYSZGO-UHFFFAOYSA-N";484.6;5.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-5.32;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.00000478630092322638
"MM474458";"MM474458";"CCOc1cc(C(Nc2ccc3c(N)nccc3c2)C(=O)NCc2cccc(NC(C)=O)c2)ccc1OC(C)C";"UKRTUGXKHNJCBG-UHFFFAOYSA-N";541.65;5.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3116757/target=_blank>CHEMBL3116757</a>";;-7;"Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.: Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors. ACS Med Chem Lett, Volume 5 (2), 2014";"PAMPA";0.0000001
"MM474384";"MM474384";"CCC1(c2cccc(O)c2)CCCCN(C)C1";"JLICHNCFTLFZJN-UHFFFAOYSA-N";233.36;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.84;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.00001445439770745928
"MM474136";"MM474136";"CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(C(N)=O)C3)ccc21";"XMJJERMECHLDOH-UHFFFAOYSA-N";421.57;1.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3373671/target=_blank>CHEMBL3373671</a>";;-6.22;"Iwata Y, Ando K, Taniguchi K, Koba N, Sugiura A, Sudo M.: Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg Med Chem Lett, Volume 25 (2), 2015";"PAMPA";0.0000006025595860743581
"MM474076";"MM474076";"COCCOCn1ccc(NC(=O)c2cc(Oc3ccc(S(C)(=O)=O)cc3)cc(-c3ncccc3C)c2)n1";"YREXUDMRKQYWKW-UHFFFAOYSA-N";536.61;4.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3243427/target=_blank>CHEMBL3243427</a>";;-5.58;"Park K, Lee BM, Hyun KH, Lee DH, Choi HH, Kim H, Chong W, Kim KB, Nam SY.: Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. Bioorg Med Chem, Volume 22 (7), 2014";"PAMPA";0.0000026302679918953817
"Chembl3259928";"MM467837";"COc1cc(C(F)(F)F)cc(SC)c1C(=O)N[C@@]1(c2ccccc2)CCCN(C)C1";"SCEGQLOWLADTKA-NRFANRHFSA-N";438.52;4.79;;"Chembl3259928";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3266590/target=_blank>CHEMBL3266590</a>";;-5.13;"Pinard E, Alberati D, Alvarez-Sanchez R, Brom V, Burner S, Fischer H, Hauser N, Kolczewski S, Lengyel J, Mory R, Saladin C, Schulz-Gasch T, Stalder H.: 3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors. ACS Med Chem Lett, Volume 5 (4), 2014";"PAMPA";0.000007413102413009177
"MM474462";"MM474462";"Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1";"IGXJXMLDIIGDNE-UHFFFAOYSA-N";589.7;6.09;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3270546/target=_blank>CHEMBL3270546</a>";;-4.39;"Shi Q, Tebben A, Dyckman AJ, Li H, Liu C, Lin J, Spergel S, Burke JR, McIntyre KW, Olini GC, Strnad J, Surti N, Muckelbauer JK, Chang C, An Y, Cheng L, Ruan Q, Leftheris K, Carter PH, Tino J, De Lucca GV.: Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases. Bioorg Med Chem Lett, Volume 24 (9), 2014";"PAMPA";0.0000407380277804113
"MM474463";"MM474463";"N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ccccc5)nc4)n3n2)CC1";"KUNDZIQYLIUGDW-SAABIXHNSA-N";400.49;3.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-6.7;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.00000019952623149688787
"MM474464";"MM474464";"N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1";"BBQRBXPCOFYEMM-SHTZXODSSA-N";419.47;3.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-6.4;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000003981071705534969
"MM474465";"MM474465";"CN1CCC(Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1";"NUSGNSWNFVVVGS-UHFFFAOYSA-N";419.47;2.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-7;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000001
"MM474466";"MM474466";"CN1CCC(Nc2ccc3ncc(-c4ccc(Nc5ncccc5F)nc4)n3n2)CC1";"GJJVSRXRDRWYEN-UHFFFAOYSA-N";418.48;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-5.19;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.000006456542290346549
"MM474467";"MM474467";"Cc1ccc2ncc(-c3cnc(Nc4ncccc4F)nc3)n2n1";"GIHCWBCPXWYSOY-UHFFFAOYSA-N";321.32;2.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-4.86;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.000013803842646028839
"MM474468";"MM474468";"Fc1cccnc1Nc1ncc(-c2cnc3ccc(N4CCNCC4)nn23)cn1";"ZMGPVFCVEANUCP-UHFFFAOYSA-N";391.41;1.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-6.4;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000003981071705534969
"MM474469";"MM474469";"CN1CCN(c2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1";"RWLQLQUIWSECFE-UHFFFAOYSA-N";405.44;2.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-5.21;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.000006165950018614822
"MM474470";"MM474470";"CN1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)C1";"SHANUAHHWNWIQJ-AWEZNQCLSA-N";405.44;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-6.7;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.00000019952623149688787
"MM474471";"MM474471";"Fc1cccnc1Nc1ncc(-c2cnc3ccc(NCCN4CCOCC4)nn23)cn1";"AWBZWMFDDAZDBC-UHFFFAOYSA-N";435.47;2.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-5.57;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000026915348039269138
"MM474472";"MM474472";"CN1CCN(CCNc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1";"FOKYQBPPTCMXFQ-UHFFFAOYSA-N";448.51;2.12;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-6.4;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000003981071705534969
"MM474473";"MM474473";"Fc1cccnc1Nc1ncc(-c2cnc3ccc(NCCN4CCCC4)nn23)cn1";"RGKNLFDRKCNISS-UHFFFAOYSA-N";419.47;2.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-6.22;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000006025595860743581
"MM474474";"MM474474";"Fc1cccnc1Nc1ncc(-c2cnc3ccc(N[C@H]4CC[C@H](N5CCOCC5)CC4)nn23)cn1";"DUFJLIPMQNABSH-WGSAOQKQSA-N";489.56;3.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-5.77;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.000001698243652461746
"MM474475";"MM474475";"Fc1cccnc1Nc1ncc(-c2cnc3ccc(N[C@H]4CC[C@H](N5CCCC5)CC4)nn23)cn1";"FWEXBPHIHWIZFZ-WGSAOQKQSA-N";473.56;4.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-6.52;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000003019951720402019
"MM474476";"MM474476";"CN1CCC(Oc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1";"JQHYJLKEPNQOSJ-UHFFFAOYSA-N";420.45;2.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-5.57;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000026915348039269138
"MM474477";"MM474477";"CN1CC[C@H](Oc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)C1";"QJHLVRVUCGSGKG-AWEZNQCLSA-N";406.43;2.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-5.55;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.000002818382931264455
"MM474478";"MM474478";"CN1CCC(Cc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1";"VQPBKJQXLCYOIZ-UHFFFAOYSA-N";418.48;3.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-6.4;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.0000003981071705534969
"MM474479";"MM474479";"CN1CCC(Nc2ccc3ncc(-c4ccc(Nc5ncccc5F)cc4)n3n2)CC1";"CMNZLOPMBPOKHY-UHFFFAOYSA-N";417.49;4.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3265830/target=_blank>CHEMBL3265830</a>";;-4.77;"Chapman TM, Osborne SA, Wallace C, Birchall K, Bouloc N, Jones HM, Ansell KH, Taylor DL, Clough B, Green JL, Holder AA.: Optimization of an imidazopyridazine series of inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1). J Med Chem, Volume 57 (8), 2014";"PAMPA";0.00001698243652461746
"MM474120";"MM474120";"CNc1nc(Cc2ccccc2)nc2c1CCNC[C@@H]2C";"IHHALLDEDARSAL-LBPRGKRZSA-N";282.39;2.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3292422/target=_blank>CHEMBL3292422</a>";;-4.96;"Storer RI, Brennan PE, Brown AD, Bungay PJ, Conlon KM, Corbett MS, DePianta RP, Fish PV, Heifetz A, Ho DK, Jessiman AS, McMurray G, de Oliveira CA, Roberts LR, Root JA, Shanmugasundaram V, Shapiro MJ, Skerten M, Westbrook D, Wheeler S, Whitlock GA, Wright J.: Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HTâ‚‚C) receptor agonists with exquisite functional selectivity over 5-HTâ‚‚A and 5-HTâ‚‚B receptors. J Med Chem, Volume 57 (12), 2014";"PAMPA";0.000010964781961431852
"MM474121";"MM474121";"CNc1nc(C(F)(F)c2ccccc2)nc2c1CCNCC2";"XYHWHDGNYCZFTQ-UHFFFAOYSA-N";304.34;2.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3292422/target=_blank>CHEMBL3292422</a>";;-4.96;"Storer RI, Brennan PE, Brown AD, Bungay PJ, Conlon KM, Corbett MS, DePianta RP, Fish PV, Heifetz A, Ho DK, Jessiman AS, McMurray G, de Oliveira CA, Roberts LR, Root JA, Shanmugasundaram V, Shapiro MJ, Skerten M, Westbrook D, Wheeler S, Whitlock GA, Wright J.: Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HTâ‚‚C) receptor agonists with exquisite functional selectivity over 5-HTâ‚‚A and 5-HTâ‚‚B receptors. J Med Chem, Volume 57 (12), 2014";"PAMPA";0.000010964781961431852
"MM474119";"MM474119";"CNc1nc(Cc2ccccc2)nc2c1CCNCC2";"VIARDDXFSMLNLG-UHFFFAOYSA-N";268.36;1.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3292422/target=_blank>CHEMBL3292422</a>";;-5;"Storer RI, Brennan PE, Brown AD, Bungay PJ, Conlon KM, Corbett MS, DePianta RP, Fish PV, Heifetz A, Ho DK, Jessiman AS, McMurray G, de Oliveira CA, Roberts LR, Root JA, Shanmugasundaram V, Shapiro MJ, Skerten M, Westbrook D, Wheeler S, Whitlock GA, Wright J.: Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HTâ‚‚C) receptor agonists with exquisite functional selectivity over 5-HTâ‚‚A and 5-HTâ‚‚B receptors. J Med Chem, Volume 57 (12), 2014";"PAMPA";0.00001
"MM472656";"MM472656";"Cc1c(OCCCCOc2ccc(C(=O)O)cc2)ccc(C(=O)CC(C)C)c1O";"ULWCVJYRXWBACL-UHFFFAOYSA-N";400.47;4.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-5.17;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000006760829753919819
"MM472657";"MM472657";"Cc1c(OCCCCOc2cccc(C(=O)O)c2)ccc(C(=O)CC(C)C)c1C";"NVFAFQYWWWEFLB-UHFFFAOYSA-N";398.5;5.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-5.47;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.0000033884415613920275
"MM472658";"MM472658";"Cc1c(OCCCCOc2cccc(C(=O)O)c2)ccc(C(=O)CC(C)C)c1O";"BTAUFYWICSLREV-UHFFFAOYSA-N";400.47;4.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-5.19;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000006456542290346549
"MM472659";"MM472659";"Cc1c(OCCCCOc2cccc(C(=O)O)c2)ccc(C(=O)CC2CCCC2)c1O";"UUGVIOPJBPICMU-UHFFFAOYSA-N";426.51;5.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-4.99;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000010232929922807536
"MM472660";"MM472660";"Cc1c(OCCCCOc2ccccc2C(=O)O)ccc(C(=O)CC(C)C)c1C";"OPZYRVOATYJQKL-UHFFFAOYSA-N";398.5;5.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-4.69;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000020417379446695274
"MM472661";"MM472661";"Cc1c(OCCCCOc2ccc(C(=O)O)c(Cl)c2)ccc(C(=O)CC2CCCC2)c1O";"ZNRWBONOBRNVRG-UHFFFAOYSA-N";460.95;6.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-5.33;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000004677351412871981
"MM472662";"MM472662";"Cc1c(OCCCCOc2ccc(F)c(C(=O)O)c2)ccc(C(=O)CC(C)C)c1O";"VOAWHZVCPXGDSD-UHFFFAOYSA-N";418.46;5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-5.43;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.0000037153522909717276
"MM472663";"MM472663";"Cc1ccc(C(=O)O)cc1OCCCCOc1ccc(C(=O)CC(C)C)c(O)c1C";"IXQOSACEYQVKSU-UHFFFAOYSA-N";414.5;5.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-7.94;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000000011481536214968817
"MM472664";"MM472664";"Cc1ccc(C(=O)O)cc1OCCCCOc1ccc(C(=O)CC2CCCC2)c(O)c1C";"XCACYPAKNKDVCI-UHFFFAOYSA-N";440.54;5.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-6.73;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.00000018620871366628656
"MM472665";"MM472665";"Cc1cc(C(=O)O)ccc1OCCCCOc1ccc(C(=O)CC(C)C)c(O)c1C";"OEWHGJIKBWWFSY-UHFFFAOYSA-N";414.5;5.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-4.92;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000012022644346174132
"MM472666";"MM472666";"Cc1cc(C(=O)O)ccc1OCCCCOc1ccc(C(=O)CC2CCCC2)c(O)c1C";"CAJHCTPZQASQJH-UHFFFAOYSA-N";440.54;5.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-6.54;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.00000028840315031266057
"MM472667";"MM472667";"Cc1c(OCCCCOc2ccc(C(=O)O)cc2F)ccc(C(=O)CC(C)C)c1O";"XGADSIWWVNFIKN-UHFFFAOYSA-N";418.46;5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-7.18;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.00000006606934480075964
"MM472668";"MM472668";"Cc1c(OCCCCOc2ccc(C(=O)O)cc2F)ccc(C(=O)CC2CCCC2)c1O";"AHUPDZVGRGKGHK-UHFFFAOYSA-N";444.5;5.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-5.93;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.0000011748975549395304
"MM472669";"MM472669";"COc1cc(C(=O)O)ccc1OCCCCOc1ccc(C(=O)CC(C)C)c(O)c1C";"XJICBRVIAXTUNH-UHFFFAOYSA-N";430.5;4.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-6.36;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.00000043651583224016567
"MM472670";"MM472670";"Cc1c(OCCCCOCOc2ccc(C(=O)O)cc2)ccc(C(=O)CC2CCCC2)c1O";"WIKSLWGWAGNVMC-UHFFFAOYSA-N";456.54;5.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-6.54;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.00000028840315031266057
"MM472671";"MM472671";"Cc1c(OCCCCOc2ccc(C(=O)O)cc2Cl)ccc(C(=O)CC(C)C)c1O";"DOUCTXYLBQZORZ-UHFFFAOYSA-N";434.92;5.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-7.94;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000000011481536214968817
"MM472672";"MM472672";"Cc1c(OCCCCOc2ccc(C(=O)O)cc2Cl)ccc(C(=O)CC2CCCC2)c1O";"XIWVJTYJVVEJHE-UHFFFAOYSA-N";460.95;6.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-8.54;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.0000000028840315031266117
"MM472673";"MM472673";"Cc1cc(OCCCCOc2ccc(C(=O)CC(C)C)c(O)c2C)ccc1C(=O)O";"SZENSIMCFJFUGR-UHFFFAOYSA-N";414.5;5.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-8.24;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.000000005754399373371567
"MM472674";"MM472674";"Cc1cc(OCCCCOc2ccc(C(=O)CC3CCCC3)c(O)c2C)ccc1C(=O)O";"MFELYFVXYIXMNP-UHFFFAOYSA-N";440.54;5.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-6.82;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.00000015135612484362072
"MM472675";"MM472675";"COc1ccc(C(=O)O)cc1OCCCCOc1ccc(C(=O)CC(C)C)c(O)c1C";"TYYKQQMKUKSDJB-UHFFFAOYSA-N";430.5;4.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3293520/target=_blank>CHEMBL3293520</a>";;-6.12;"Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND.: Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem, Volume 57 (10), 2014";"PAMPA";0.0000007585775750291836
"Chembl3288755";"MM468041";"CCN1C(=O)CN(c2ccc(Cc3cc(C4OC(CO)C(O)C(O)C4O)ccc3Cl)cc2)C1=O";"OKQVIDODFGYTAX-UHFFFAOYSA-N";490.94;1.23;;"Chembl3288755";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3292478/target=_blank>CHEMBL3292478</a>";;-6.2;"Guo C, Hu M, DeOrazio RJ, Usyatinsky A, Fitzpatrick K, Zhang Z, Maeng JH, Kitchen DB, Tom S, Luche M, Khmelnitsky Y, Mhyre AJ, Guzzo PR, Liu S.: The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties. Bioorg Med Chem, Volume 22 (13), 2014";"PAMPA";0.000000630957344480193
"MM474488";"MM474488";"COc1cccc2nc(O)nc(NCC(C)(C)c3ccccc3)c12";"WAYXJKGOWYBZSE-UHFFFAOYSA-N";323.4;3.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3364873/target=_blank>CHEMBL3364873</a>";;-4.09;"Johnson JA, Xu N, Jeon Y, Finlay HJ, Kover A, Conder ML, Sun H, Li D, Levesque P, Hsueh MM, Harper TW, Wexler RR, Lloyd J.: Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.00008128305161640995
"MM474486";"MM474486";"COc1cccc2oc(=O)nc(NCC(C)(C)c3ccccc3)c12";"XYJOKKCUWQUUGY-UHFFFAOYSA-N";324.38;3.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3364873/target=_blank>CHEMBL3364873</a>";;-4.16;"Johnson JA, Xu N, Jeon Y, Finlay HJ, Kover A, Conder ML, Sun H, Li D, Levesque P, Hsueh MM, Harper TW, Wexler RR, Lloyd J.: Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.00006918309709189363
"MM474485";"MM474485";"CCNC(=O)O[C@H]1CC[C@](CNc2n[nH]c3cccc(OC)c23)(c2ccccc2)CC1";"WZZPYWCRKLLOTM-XZMJRDFISA-N";422.53;4.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3364873/target=_blank>CHEMBL3364873</a>";;-4.17;"Johnson JA, Xu N, Jeon Y, Finlay HJ, Kover A, Conder ML, Sun H, Li D, Levesque P, Hsueh MM, Harper TW, Wexler RR, Lloyd J.: Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.00006760829753919819
"MM474122";"MM474122";"CC(C)(C)CNC(=O)CC1CNC(=O)c2cc(-c3ccsc3)cn21";"PNMQDIXULZYDDT-UHFFFAOYSA-N";345.47;3.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3300847/target=_blank>CHEMBL3300847</a>";;-4.32;"Casuscelli F, Ardini E, Avanzi N, Casale E, Cervi G, D'Anello M, Donati D, Faiardi D, Ferguson RD, Fogliatto G, Galvani A, Marsiglio A, Mirizzi DG, Montemartini M, Orrenius C, Papeo G, Piutti C, Salom B, Felder ER.: Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases. Bioorg Med Chem, Volume 21 (23), 2013";"PAMPA";0.000047863009232263804
"MM472695";"MM472695";"Cc1sc(-c2ncc(C#N)cc2O)nc1CC(=O)NCCc1ccccn1";"WDYFUIZAAIQAPA-UHFFFAOYSA-N";379.45;2.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-5.8;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.000001584893192461114
"MM472704";"MM472704";"N#Cc1cnc(-c2nc(CC(=O)NCc3ccccc3)cs2)c(O)c1";"FDUAZMVEJVFVCS-UHFFFAOYSA-N";350.4;2.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-5.6;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000025118864315095823
"MM472703";"MM472703";"N#Cc1cnc(-c2nc(CC(=O)NCC(=O)O)cs2)c(O)c1";"DLXXPMPEDWANKC-UHFFFAOYSA-N";318.31;0.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-10;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000000001
"MM472702";"MM472702";"CC(C)(NC(=O)Cc1csc(-c2ncc(C#N)cc2O)n1)C(=O)O";"BUUJRGRVHGEKRK-UHFFFAOYSA-N";346.37;1.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-5.7;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000019952623149688787
"MM472701";"MM472701";"N#Cc1cnc(-c2nc(CC(=O)N[C@H](C(=O)O)c3ccccc3)cs2)c(O)c1";"KPGRSPXHOOAVBE-INIZCTEOSA-N";394.41;2.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-10;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000000001
"MM472700";"MM472700";"N#Cc1cnc(-c2nc(CC(=O)N[C@@H](C(=O)O)c3ccccc3)cs2)c(O)c1";"KPGRSPXHOOAVBE-MRXNPFEDSA-N";394.41;2.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-10;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000000001
"MM472699";"MM472699";"N#Cc1cnc(-c2nc(CC(=O)N[C@@H](CO)c3ccccc3)cs2)c(O)c1";"OPVZOSZOXQWVSN-HNNXBMFYSA-N";380.43;2.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-5.1;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.000007943282347242822
"MM472698";"MM472698";"N#Cc1cnc(-c2nc(CC(=O)N[C@H](CO)c3ccccc3)cs2)c(O)c1";"OPVZOSZOXQWVSN-OAHLLOKOSA-N";380.43;2.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-5;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.00001
"MM472697";"MM472697";"N#Cc1cnc(-c2nc(CC(=O)NCCc3ccccc3)cs2)c(O)c1";"JFDMCXCLTIPJIW-UHFFFAOYSA-N";364.43;2.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-5.4;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.000003981071705534969
"MM472696";"MM472696";"N#Cc1cnc(-c2nc(CC(=O)NCCc3ccccn3)cs2)c(O)c1";"NPGMDIQJGIQEFW-UHFFFAOYSA-N";365.42;2.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-5.8;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.000001584893192461114
"MM472694";"MM472694";"N#Cc1cnc(-c2nc(CC(=O)NCCc3ccccn3)c(-c3ccccc3)s2)c(O)c1";"AZNDVNFEFCMGHP-UHFFFAOYSA-N";441.52;3.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-4.3;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.00005011872336272725
"MM472693";"MM472693";"Cc1c(C#N)cnc(-c2nc(CC(=O)NCCc3ccccn3)cs2)c1O";"MNKLNTMHRWFUOY-UHFFFAOYSA-N";379.45;2.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-10;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000000001
"MM472692";"MM472692";"Cc1sc(-c2ncc(C#N)c(C)c2O)nc1CC(=O)NCCc1ccccn1";"CXHVPJXEVMGIEH-UHFFFAOYSA-N";393.47;2.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-3;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.001
"MM472691";"MM472691";"Cc1c(C#N)cnc(-c2nc(CC(=O)NCCc3ccccn3)c(-c3ccccc3)s2)c1O";"ICUKKSACAFOILF-UHFFFAOYSA-N";455.54;4.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-3;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.001
"MM472690";"MM472690";"CCNC(=O)Cc1nc(-c2ncc(C#N)c(C)c2O)sc1C";"FLQPXJWSHIMMJF-UHFFFAOYSA-N";316.39;2.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-4.5;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.000031622776601683795
"MM472689";"MM472689";"N#Cc1cnc(-c2nc(CC(=O)N3CCCC3)cs2)c(O)c1";"BYDZAAIFYAJBBM-UHFFFAOYSA-N";314.37;1.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-5.7;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000019952623149688787
"MM472688";"MM472688";"CCN(CC)CCNC(=O)Cc1csc(-c2ncc(C#N)c(C)c2O)n1";"JCZWZYBECXGVDR-UHFFFAOYSA-N";373.48;2.09;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-10;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000000001
"MM472687";"MM472687";"CCN(CC)CCNC(=O)Cc1nc(-c2ncc(C#N)c(C)c2O)sc1C";"WKXQBXVKTSSLJU-UHFFFAOYSA-N";387.51;2.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3362039/target=_blank>CHEMBL3362039</a>";;-10;"Hong YR, Kim HT, Ro S, Cho JM, Lee SH, Kim IS, Jung YH.: Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.0000000001
"MM473218";"MM473218";"Cn1cc(-c2ccc(Oc3nccnc3-c3ccncc3)cc2)c2ncccc21";"SWHQBIRUZBZCMN-UHFFFAOYSA-N";379.42;4.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368997/target=_blank>CHEMBL3368997</a>";;-5.53;"Das S, Shelke DE, Harde RL, Avhad VB, Khairatkar-Joshi N, Gullapalli S, Gupta PK, Gandhi MN, Bhateja DK, Bajpai M, Joshi AA, Marathe MY, Gudi GS, Jadhav SB, Mahat MY, Thomas A.: Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: part II. Bioorg Med Chem Lett, Volume 24 (15), 2014";"PAMPA";0.000002951209226666384
"MM472715";"MM472715";"CC[C@H](C)[C@H](NC(=O)C(c1cc(Cl)cc(Cl)c1)N(C)C)C(=O)NCc1ccnc(C#N)n1";"RSGATHUEAGHBQV-NXAXYOPQSA-N";477.4;3.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-3.8;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.00015848931924611142
"MM472714";"MM472714";"CC[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC#N)C(C)(C)C)c1cc(Cl)cc(Cl)c1";"KMOFPYAFCUDHAI-DOTOQJQBSA-N";441.36;2.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.3;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000005011872336272725
"MM472716";"MM472716";"CC[C@H](C)[C@H](NC(=O)[C@@H](O)c1cc(Cl)cc(Cl)c1)C(=O)NCc1ccnc(C#N)n1";"QNXJRXZVVAKZOO-NBHSMZAVSA-N";450.33;2.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.3;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000005011872336272725
"MM472717";"MM472717";"COC[C@H](NC(=O)Cc1cc(Cl)cc(Cl)c1)C(=O)NCc1ccnc(C#N)n1";"SEOPFNFBRKAXBL-HNNXBMFYSA-N";422.27;1.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-4.9;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000012589254117941661
"MM472718";"MM472718";"C[C@@H](O)[C@H](NC(=O)Cc1cc(Cl)cc(Cl)c1)C(=O)NCc1ccnc(C#N)n1";"HJVHLHRZTIEKNT-QGHHPUGFSA-N";422.27;1.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.4;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000003981071705534969
"MM472706";"MM472706";"N#CCNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)Cc1cccc(Cl)c1";"VEJLVHSRJODKDC-SFHVURJKSA-N";412.88;1.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.4;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000003981071705534969
"MM472707";"MM472707";"N#CCNC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)Cc1cc(Cl)cc(Cl)c1";"VGODPXCPYVWVSI-SFHVURJKSA-N";447.32;2.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.5;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000003162277660168379
"MM472708";"MM472708";"CC(C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)NCC#N)c1cc(Cl)cc(Cl)c1";"IJJBEOIATZKDDH-PKDNWHCCSA-N";461.35;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.3;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000005011872336272725
"MM472709";"MM472709";"N#CCNC(=O)CNC(=O)C(Cc1ccccn1)NC(=O)Cc1cc(Cl)cc(Cl)c1";"BZTAVLPRISYGFX-UHFFFAOYSA-N";448.31;1.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.5;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000003162277660168379
"MM472710";"MM472710";"N#CCNC(=O)CNC(=O)[C@H](CN)NC(=O)Cc1cc(Cl)cc(Cl)c1";"IDXJDHIREGWTEK-LBPRGKRZSA-N";386.24;-0.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.1;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000007943282347242822
"MM472711";"MM472711";"C[C@@H](O)[C@H](NC(=O)Cc1cc(Cl)cc(Cl)c1)C(=O)NCC(=O)NCC#N";"YPFUNVVIUAWVOX-PSLIRLAXSA-N";401.25;0.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.3;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000005011872336272725
"MM472712";"MM472712";"CC(C)(C)[C@H](NC(=O)Cc1cc(Cl)cc(Cl)c1)C(=O)NCC(=O)NCC#N";"QRGGIHKDVXJVNS-MRXNPFEDSA-N";413.31;1.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5.4;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.000003981071705534969
"MM472713";"MM472713";"CC[C@H](C(=O)N[C@H](C(=O)NCC(=O)NCC#N)[C@@H](C)O)c1cc(Cl)cc(Cl)c1";"UZVFCWAZNMHIFH-OOVXXXAESA-N";429.3;1.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3368150/target=_blank>CHEMBL3368150</a>";;-5;"Mac Sweeney A, Grosche P, Ellis D, Combrink K, Erbel P, Hughes N, Sirockin F, Melkko S, Bernardi A, Ramage P, Jarousse N, Altmann E.: Discovery and structure-based optimization of adenain inhibitors. ACS Med Chem Lett, Volume 5 (8), 2014";"PAMPA";0.00001
"MM474131";"MM474131";"CCN(Cc1cc(C(F)(F)F)ccc1-c1nn(CC(=O)O)c2ccccc12)C(=O)C1CC1";"QSCQYNXQLOPYJJ-UHFFFAOYSA-N";445.44;4.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3377767/target=_blank>CHEMBL3377767</a>";;-6.74;"Alonso JA, AndrĂ©s M, Bravo M, Buil MA, Calbet M, Castro J, Eastwood PR, Eichhorn P, Esteve C, GĂłmez E, GonzĂˇlez J, Mir M, Petit S, Roberts RS, Vidal B, Vidal L, Vilaseca P, Zanuy M.: Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists I. Bioorg Med Chem Lett, Volume 24 (21), 2014";"PAMPA";0.00000018197008586099824
"MM474132";"MM474132";"CCN(Cc1cc(C(F)(F)F)ccc1-c1cn(CC(=O)O)c2ccccc12)C(=O)C1CC1";"XURSVQTVTFZLQW-UHFFFAOYSA-N";444.45;5.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3377767/target=_blank>CHEMBL3377767</a>";;-6.22;"Alonso JA, AndrĂ©s M, Bravo M, Buil MA, Calbet M, Castro J, Eastwood PR, Eichhorn P, Esteve C, GĂłmez E, GonzĂˇlez J, Mir M, Petit S, Roberts RS, Vidal B, Vidal L, Vilaseca P, Zanuy M.: Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists I. Bioorg Med Chem Lett, Volume 24 (21), 2014";"PAMPA";0.0000006025595860743581
"MM474133";"MM474133";"CCN(Cc1cc(C(F)(F)F)ccc1-n1cc(CC(=O)O)c2cccnc21)C(=O)C1CC1";"BUAAXOZBOZWLJY-UHFFFAOYSA-N";445.44;4.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3377767/target=_blank>CHEMBL3377767</a>";;-5.96;"Alonso JA, AndrĂ©s M, Bravo M, Buil MA, Calbet M, Castro J, Eastwood PR, Eichhorn P, Esteve C, GĂłmez E, GonzĂˇlez J, Mir M, Petit S, Roberts RS, Vidal B, Vidal L, Vilaseca P, Zanuy M.: Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists I. Bioorg Med Chem Lett, Volume 24 (21), 2014";"PAMPA";0.000001096478196143185
"MM474482";"MM474482";"CCCc1cnc(N2CCC(Oc3ccn(-c4ccc(S(C)(=O)=O)cc4F)c(=O)c3)CC2)nc1";"HIJKGVNKHCXAKW-UHFFFAOYSA-N";486.57;3.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3382467/target=_blank>CHEMBL3382467</a>";;-4.49;"Wacker DA, Wang Y, Broekema M, Rossi K, O'Connor S, Hong Z, Wu G, Malmstrom SE, Hung CP, LaMarre L, Chimalakonda A, Zhang L, Xin L, Cai H, Chu C, Boehm S, Zalaznick J, Ponticiello R, Sereda L, Han SP, Zebo R, Zinker B, Luk CE, Wong R, Everlof G, Li YX, Wu CK, Lee M, Griffen S, Miller KJ, Krupinski J, Robl JA.: Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J Med Chem, Volume 57 (18), 2014";"PAMPA";0.00003235936569296281
"MM472676";"MM472676";"c1cc2c(N3CCNCC3)nc(-c3ccc4[nH]ncc4c3)nc2cn1";"GMLKJSOWCKBKLX-UHFFFAOYSA-N";331.38;1.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3387561/target=_blank>CHEMBL3387561</a>";;-7.1;"Shaw D, Hollingworth G, Soldermann N, Sprague E, Schuler W, Vangrevelinghe E, Duggan N, Thomas M, Kosaka T, Waters N, van Eis MJ.: Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension. Bioorg Med Chem Lett, Volume 24 (20), 2014";"PAMPA";0.00000007943282347242822
"MM472677";"MM472677";"c1ccc2c(N3CCNCC3)nc(-c3ccc4[nH]ncc4c3)nc2c1";"RDSJJFGKRCBYRH-UHFFFAOYSA-N";330.4;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3387561/target=_blank>CHEMBL3387561</a>";;-5.6;"Shaw D, Hollingworth G, Soldermann N, Sprague E, Schuler W, Vangrevelinghe E, Duggan N, Thomas M, Kosaka T, Waters N, van Eis MJ.: Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension. Bioorg Med Chem Lett, Volume 24 (20), 2014";"PAMPA";0.0000025118864315095823
"MM474686";"MM474686";"CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(-c2scnc2C)cc1)C(C)(C)C";"GFVIEZBZIUKYOG-SVFBPWRDSA-N";472.61;2.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-6.92;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.00000012022644346174132
"MM472686";"MM472686";"COc1ccc(C(=O)NCC(=O)NCC#N)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1";"MXZCYVQMFRKLKM-UHFFFAOYSA-N";462.33;3.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3376636/target=_blank>CHEMBL3376636</a>";;-5;"Grosche P, Sirockin F, Mac Sweeney A, Ramage P, Erbel P, Melkko S, Bernardi A, Hughes N, Ellis D, Combrink KD, Jarousse N, Altmann E.: Structure-based design and optimization of potent inhibitors of the adenoviral protease. Bioorg Med Chem Lett, Volume 25 (3), 2015";"PAMPA";0.00001
"MM472685";"MM472685";"CN(C)CCOc1ccc(C(=O)NCC(=O)NCC#N)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1";"LUHJTZQBKQQNIT-UHFFFAOYSA-N";519.43;3.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3376636/target=_blank>CHEMBL3376636</a>";;-5.5;"Grosche P, Sirockin F, Mac Sweeney A, Ramage P, Erbel P, Melkko S, Bernardi A, Hughes N, Ellis D, Combrink KD, Jarousse N, Altmann E.: Structure-based design and optimization of potent inhibitors of the adenoviral protease. Bioorg Med Chem Lett, Volume 25 (3), 2015";"PAMPA";0.000003162277660168379
"MM472684";"MM472684";"CN(C)CCOc1ccc(C(=O)NCc2ccnc(C#N)n2)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1";"HNFUPLJEUVTDOT-UHFFFAOYSA-N";540.45;4.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3376636/target=_blank>CHEMBL3376636</a>";;-4.2;"Grosche P, Sirockin F, Mac Sweeney A, Ramage P, Erbel P, Melkko S, Bernardi A, Hughes N, Ellis D, Combrink KD, Jarousse N, Altmann E.: Structure-based design and optimization of potent inhibitors of the adenoviral protease. Bioorg Med Chem Lett, Volume 25 (3), 2015";"PAMPA";0.00006309573444801929
"MM472683";"MM472683";"COc1ccc(C(=O)NCC(=O)NC/C=C/S(C)(=O)=O)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1";"SSLOWHLLWHTKDK-WEVVVXLNSA-N";541.45;3.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3376636/target=_blank>CHEMBL3376636</a>";;-4.1;"Grosche P, Sirockin F, Mac Sweeney A, Ramage P, Erbel P, Melkko S, Bernardi A, Hughes N, Ellis D, Combrink KD, Jarousse N, Altmann E.: Structure-based design and optimization of potent inhibitors of the adenoviral protease. Bioorg Med Chem Lett, Volume 25 (3), 2015";"PAMPA";0.00007943282347242822
"MM472682";"MM472682";"CC(C)(C)[C@H](NC(=O)Cc1cc(Cl)cc(Cl)c1)C(=O)NCC(=O)NC/C=C/S(C)(=O)=O";"CJPQKDCNIAERJN-SUQGKYDKSA-N";492.43;1.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3376636/target=_blank>CHEMBL3376636</a>";;-5.6;"Grosche P, Sirockin F, Mac Sweeney A, Ramage P, Erbel P, Melkko S, Bernardi A, Hughes N, Ellis D, Combrink KD, Jarousse N, Altmann E.: Structure-based design and optimization of potent inhibitors of the adenoviral protease. Bioorg Med Chem Lett, Volume 25 (3), 2015";"PAMPA";0.0000025118864315095823
"MM472681";"MM472681";"CC[C@H](C(=O)N[C@H]1CCN(CC(=O)NC/C=C/S(C)(=O)=O)C1=O)c1cc(Cl)cc(Cl)c1";"SRZWDJLAFGSPHH-ALOLOFKDSA-N";490.41;1.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3376636/target=_blank>CHEMBL3376636</a>";;-5.5;"Grosche P, Sirockin F, Mac Sweeney A, Ramage P, Erbel P, Melkko S, Bernardi A, Hughes N, Ellis D, Combrink KD, Jarousse N, Altmann E.: Structure-based design and optimization of potent inhibitors of the adenoviral protease. Bioorg Med Chem Lett, Volume 25 (3), 2015";"PAMPA";0.000003162277660168379
"MM472678";"MM472678";"CCOC(=O)[C@](C)(Cc1ccccc1)c1c(C)cnc2c(-c3ccc(C(F)(F)F)cc3)cnn12";"KWIOPQKUZLWYEN-RUZDIDTESA-N";467.49;5.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3387658/target=_blank>CHEMBL3387658</a>";;-5.4;"Azimioara M, Alper P, Cow C, Mutnick D, Nikulin V, Lelais G, Mecom J, McNeill M, Michellys PY, Wang Z, Reding E, Paliotti M, Li J, Bao D, Zoll J, Kim Y, Zimmerman M, Groessl T, Tuntland T, Joseph SB, McNamara P, Seidel HM, Epple R.: Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists. Bioorg Med Chem Lett, Volume 24 (23), 2014";"PAMPA";0.000003981071705534969
"MM472679";"MM472679";"CCOC(=O)[C@@]1(Cc2ccccc2)CCc2cnc3c(-c4ccc(C(F)(F)F)cc4)cnn3c21";"QGPDNTVBBFWXKO-RUZDIDTESA-N";465.48;5.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3387658/target=_blank>CHEMBL3387658</a>";;-5.5;"Azimioara M, Alper P, Cow C, Mutnick D, Nikulin V, Lelais G, Mecom J, McNeill M, Michellys PY, Wang Z, Reding E, Paliotti M, Li J, Bao D, Zoll J, Kim Y, Zimmerman M, Groessl T, Tuntland T, Joseph SB, McNamara P, Seidel HM, Epple R.: Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists. Bioorg Med Chem Lett, Volume 24 (23), 2014";"PAMPA";0.000003162277660168379
"MM474480";"MM474480";"CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C)[nH]2)c1O";"RWAZVTQXGWHWFP-UHFFFAOYSA-N";399.9;3.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3388270/target=_blank>CHEMBL3388270</a>";;-4.43;"Lu H, Yang T, Xu Z, Wren PB, Zhang Y, Cai X, Patel M, Dong K, Zhang Q, Zhang W, Guan X, Xiang J, Elliott JD, Lin X, Ren F.: 2-Aminopyrimidin-4(1H)-one as the novel bioisostere of urea: discovery of novel and potent CXCR2 antagonists. Bioorg Med Chem Lett, Volume 24 (23), 2014";"PAMPA";0.00003715352290971728
"MM474487";"MM474487";"COc1cccc2c1C(NCC(C)(C)c1ccccc1)=NC2=O";"WVNWIKASGFTXTN-UHFFFAOYSA-N";308.38;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3364873/target=_blank>CHEMBL3364873</a>";;-4.1;"Johnson JA, Xu N, Jeon Y, Finlay HJ, Kover A, Conder ML, Sun H, Li D, Levesque P, Hsueh MM, Harper TW, Wexler RR, Lloyd J.: Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors. Bioorg Med Chem Lett, Volume 24 (14), 2014";"PAMPA";0.00007943282347242822
"MM474135";"MM474135";"CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(C)C3)ccc21";"KAYXDULUFFZBHW-UHFFFAOYSA-N";392.57;2.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3373671/target=_blank>CHEMBL3373671</a>";;-5.11;"Iwata Y, Ando K, Taniguchi K, Koba N, Sugiura A, Sudo M.: Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg Med Chem Lett, Volume 25 (2), 2015";"PAMPA";0.00000776247116628691
"MM474137";"MM474137";"CCN1CC(S(=O)(=O)c2ccc3c(c2)nc(CC(C)(C)C)n3CCN(C)C)C1";"GPTAFFHSWDOBMS-UHFFFAOYSA-N";406.6;2.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3373671/target=_blank>CHEMBL3373671</a>";;-5;"Iwata Y, Ando K, Taniguchi K, Koba N, Sugiura A, Sudo M.: Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg Med Chem Lett, Volume 25 (2), 2015";"PAMPA";0.00001
"MM474138";"MM474138";"CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(CC(F)(F)F)C3)ccc21";"MSGJPCGXFLUMET-UHFFFAOYSA-N";460.57;3.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3373671/target=_blank>CHEMBL3373671</a>";;-4.74;"Iwata Y, Ando K, Taniguchi K, Koba N, Sugiura A, Sudo M.: Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg Med Chem Lett, Volume 25 (2), 2015";"PAMPA";0.000018197008586099827
"MM474139";"MM474139";"CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(CCO)C3)ccc21";"OAYGNQGEUIFBFA-UHFFFAOYSA-N";422.6;1.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3373671/target=_blank>CHEMBL3373671</a>";;-5.82;"Iwata Y, Ando K, Taniguchi K, Koba N, Sugiura A, Sudo M.: Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg Med Chem Lett, Volume 25 (2), 2015";"PAMPA";0.0000015135612484362072
"MM474140";"MM474140";"CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(S(C)(=O)=O)C3)ccc21";"JHHIKRYOCNHROC-UHFFFAOYSA-N";456.63;1.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3373671/target=_blank>CHEMBL3373671</a>";;-5.23;"Iwata Y, Ando K, Taniguchi K, Koba N, Sugiura A, Sudo M.: Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg Med Chem Lett, Volume 25 (2), 2015";"PAMPA";0.000005888436553555884
"MM474129";"MM474129";"Cc1cc(C)cc(S(=O)(=O)c2c(C(=O)N[C@H](C)c3ccncc3)[nH]c3ccc(Cl)cc23)c1";"WOULWISOHTZRJX-MRXNPFEDSA-N";467.98;5.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3390761/target=_blank>CHEMBL3390761</a>";;-4.91;"Famiglini V, La Regina G, Coluccia A, Pelliccia S, Brancale A, Maga G, Crespan E, Badia R, Riveira-MuĂ±oz E, EstĂ© JA, Ferretti R, Cirilli R, Zamperini C, Botta M, Schols D, Limongelli V, Agostino B, Novellino E, Silvestri R.: Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem, Volume 57 (23), 2014";"PAMPA";0.00001230268770812381
"MM473831";"MM473831";"O=C(NCCN1CCC(O)(Cc2ccc(F)cc2)CC1)Nc1ccnc2ccsc12";"KYWALWWZQPDFMG-UHFFFAOYSA-N";428.53;3.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3382940/target=_blank>CHEMBL3382940</a>";;-7.57;"Lim CJ, Oh SA, Lee BH, Oh KS, Yi KY.: Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists. Bioorg Med Chem Lett, Volume 24 (24), 2014";"PAMPA";0.00000002691534803926914
"MM474483";"MM474483";"C[C@@H](Nc1c(C(N)=O)cnn2cccc12)C(C)(C)C";"PNFSAIKBTUBIOW-SECBINFHSA-N";260.34;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3377604/target=_blank>CHEMBL3377604</a>";;-4.06;"Duan JJ, Lu Z, Jiang B, Yang BV, Doweyko LM, Nirschl DS, Haque LE, Lin S, Brown G, Hynes J, Tokarski JS, Sack JS, Khan J, Lippy JS, Zhang RF, Pitt S, Shen G, Pitts WJ, Carter PH, Barrish JC, Nadler SG, Salter-Cid LM, McKinnon M, Fura A, Schieven GL, Wrobleski ST.: Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors. Bioorg Med Chem Lett, Volume 24 (24), 2014";"PAMPA";0.00008709635899560814
"MM474484";"MM474484";"C[C@]1(F)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12";"UPBRYBJZTWHUQK-RISCZKNCSA-N";276.32;2.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3377604/target=_blank>CHEMBL3377604</a>";;-4.12;"Duan JJ, Lu Z, Jiang B, Yang BV, Doweyko LM, Nirschl DS, Haque LE, Lin S, Brown G, Hynes J, Tokarski JS, Sack JS, Khan J, Lippy JS, Zhang RF, Pitt S, Shen G, Pitts WJ, Carter PH, Barrish JC, Nadler SG, Salter-Cid LM, McKinnon M, Fura A, Schieven GL, Wrobleski ST.: Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors. Bioorg Med Chem Lett, Volume 24 (24), 2014";"PAMPA";0.00007585775750291836
"MM474365";"MM474365";"CC(C)Sc1nc(Nc2cccc(O)c2)c2cnn(CC(Cl)c3ccccc3)c2n1";"UUXGWAWTZHFHHC-UHFFFAOYSA-N";439.97;5.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.34;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.000004570881896148752
"MM473219";"MM473219";"CSc1nc(Nc2ccccc2)c2cnn(CCc3ccccc3)c2n1";"TWYBMYYYUNHDLF-UHFFFAOYSA-N";361.47;4.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.12;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000007585775750291836
"MM473220";"MM473220";"CSc1nc(Nc2cccc(F)c2)c2cnn(CCc3ccccc3)c2n1";"RSZTXRLXERZWOZ-UHFFFAOYSA-N";379.46;4.67;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.03;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000009332543007969906
"MM473221";"MM473221";"CSc1nc(Nc2cccc(Br)c2)c2cnn(CCc3ccccc3)c2n1";"QQPMWDIPJYJOBC-UHFFFAOYSA-N";440.37;5.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.49;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000003235936569296281
"MM473222";"MM473222";"CSc1nc(Nc2cccc(O)c2)c2cnn(CCc3ccccc3)c2n1";"UVACNPSFJYZFME-UHFFFAOYSA-N";377.47;4.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.28;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000005248074602497723
"MM473223";"MM473223";"Clc1cccc(Nc2nc(SCCN3CCOCC3)nc3c2cnn3CCc2ccccc2)c1";"QPZDOYCDYKNTMC-UHFFFAOYSA-N";495.05;4.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.46;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000003467368504525317
"MM473224";"MM473224";"CCSc1nc(Nc2cccc(F)c2)c2cnn(CC(C)c3ccccc3)c2n1";"NIAVOXWSIGNJIM-UHFFFAOYSA-N";407.52;5.62;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.76;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.0000017378008287493763
"MM473225";"MM473225";"CCSc1nc(Nc2cccc(Cl)c2)c2cnn(CC(C)c3ccccc3)c2n1";"NARPAPOKJAZNIR-UHFFFAOYSA-N";423.97;6.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.42;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000003801893963205613
"MM473226";"MM473226";"CCSc1nc(Nc2cccc(Br)c2)c2cnn(CC(C)c3ccccc3)c2n1";"DEQGVIVXEPZJRW-UHFFFAOYSA-N";468.42;6.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.69;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.0000020417379446695273
"MM473227";"MM473227";"CCSc1nc(Nc2cccc(O)c2)c2cnn(CC(C)c3ccccc3)c2n1";"CCXWTKZSYDAQLZ-UHFFFAOYSA-N";405.53;5.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.31;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000004897788193684467
"MM473228";"MM473228";"CC(Cn1ncc2c(Nc3ccccc3)nc(SCCN3CCOCC3)nc21)c1ccccc1";"XJFSIKHNSJQSFU-UHFFFAOYSA-N";474.63;4.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.44;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.0000036307805477010103
"MM473229";"MM473229";"CC(Cn1ncc2c(Nc3cccc(F)c3)nc(SCCN3CCOCC3)nc21)c1ccccc1";"MNVBUUPWWVLFBQ-UHFFFAOYSA-N";492.62;4.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.19;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000006456542290346549
"MM473230";"MM473230";"CC(Cn1ncc2c(Nc3cccc(Cl)c3)nc(SCCN3CCOCC3)nc21)c1ccccc1";"ZVBOQDFXWNGDLX-UHFFFAOYSA-N";509.08;5.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.26;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.0000054954087385762485
"MM473231";"MM473231";"CSc1nc(Nc2cccc(O)c2)c2cnn(CC(Cl)c3ccccc3)c2n1";"VADPBYPWJLBNMX-UHFFFAOYSA-N";411.92;4.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.23;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000005888436553555884
"MM473232";"MM473232";"CCCCSc1nc(Nc2cccc(O)c2)c2cnn(CC(Cl)c3ccccc3)c2n1";"IHSVKLJWXGPPOW-UHFFFAOYSA-N";454;6.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3395763/target=_blank>CHEMBL3395763</a>";;-5.46;"Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.: Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma. J Med Chem, Volume 58 (1), 2015";"PAMPA";0.000003467368504525317
"MM474489";"MM474489";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O";"PHOFITCOMWKZPM-PAQPNXMXSA-N";712.93;2.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-4.95;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.00001122018454301963
"MM474490";"MM474490";"CC(C)C[C@@H]1NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H]2CCCN2C(=O)[C@@H](CC(C)C)NC1=O";"PHOFITCOMWKZPM-NIEMXSESSA-N";712.93;2.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-4.38;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.00004168693834703355
"MM474491";"MM474491";"CC(C)C[C@@H]1NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC1=O";"OIEGVPNKEVPVSM-YTTLQHOZSA-N";726.96;2.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-4.84;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.00001445439770745928
"MM474492";"MM474492";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C1=O";"CVDUKFSEKHYCQK-SKYWUHBASA-N";740.99;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-4.46;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.00003467368504525317
"MM474493";"MM474493";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C1=O";"JULHAFBSUUZGPO-ULWXFTFZSA-N";755.01;3.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-4.44;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.0000363078054770101
"MM474494";"MM474494";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O";"HIRDAILKAXNCRR-PMWFVCDYSA-N";726.96;2.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-4.46;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.00003467368504525317
"MM474495";"MM474495";"CC(C)C[C@@H]1NC(=O)[C@@H](CC(C)C)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC1=O";"MFCOFPVASGPGAP-PMWFVCDYSA-N";726.96;2.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-4.77;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.00001698243652461746
"MM474500";"MM474500";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccccc2)NC1=O";"FWXXOKDDMUNAKF-LBBUGJAGSA-N";746.95;2.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-4.7;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.000019952623149688786
"MM474501";"MM474501";"CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccccn2)NC1=O";"OBVLEQWNERSLTA-CVUOCSEZSA-N";747.94;2.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-5.87;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.0000013489628825916533
"MM474502";"MM474502";"CC(C)C[C@@H]1NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H]([C@H](C)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC1=O";"SRJFDDZKPOKANN-DWJGBPRYSA-N";700.88;0.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3404986/target=_blank>CHEMBL3404986</a>";;-5.98;"Thansandote P, Harris RM, Dexter HL, Simpson GL, Pal S, Upton RJ, Valko K.: Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg Med Chem, Volume 23 (2), 2015";"PAMPA";0.0000010471285480508985
"MM473238";"MM473238";"COc1cc(C)c(-c2cnc3[nH]c(-c4c(F)cccc4Cl)cc3c2)cn1";"LKTNVFPJFKZIFM-UHFFFAOYSA-N";367.81;5.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3405054/target=_blank>CHEMBL3405054</a>";;-7;"Esteve C, GonzĂˇlez J, Gual S, Vidal L, Alzina S, Sentellas S, Jover I, Horrillo R, De Alba J, Miralpeix M, TarrasĂłn G, Vidal B.: Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma. Bioorg Med Chem Lett, Volume 25 (6), 2015";"PAMPA";0.0000001
"MM473239";"MM473239";"COc1cc(OC)c(-c2cnc3[nH]c(-c4c(F)cccc4Cl)cc3c2)cn1";"LGHQYQBHWZQKIB-UHFFFAOYSA-N";383.81;5.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3405054/target=_blank>CHEMBL3405054</a>";;-6.18;"Esteve C, GonzĂˇlez J, Gual S, Vidal L, Alzina S, Sentellas S, Jover I, Horrillo R, De Alba J, Miralpeix M, TarrasĂłn G, Vidal B.: Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma. Bioorg Med Chem Lett, Volume 25 (6), 2015";"PAMPA";0.0000006606934480075964
"MM474503";"MM474503";"COC(=O)Nc1ccc(S(=O)(=O)C(C)C)c([C@H]2CCCN2C(=O)[C@H](Nc2ccc3c(c2)C(=O)NCC3)c2cc(OC)c(OC)cc2F)c1";"FWNNISODMWKWHU-DLFZDVPBSA-N";682.77;5.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3420604/target=_blank>CHEMBL3420604</a>";;-5.74;"Cheney DL, Bozarth JM, Metzler WJ, Morin PE, Mueller L, Newitt JA, Nirschl AH, Rendina AR, Tamura JK, Wei A, Wen X, Wurtz NR, Seiffert DA, Wexler RR, Priestley ES.: Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening. J Med Chem, Volume 58 (6), 2015";"PAMPA";0.0000018197008586099826
"MM474504";"MM474504";"COc1ccc(Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1";"GHWPTWVNZOSEBR-UHFFFAOYSA-N";460.55;3.06;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419063/target=_blank>CHEMBL3419063</a>";;-9.05;"Orbe J, SĂˇnchez-Arias JA, Rabal O, RodrĂ­guez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, PĂˇramo JA, Oyarzabal J.: Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.0000000008912509381337441
"MM474505";"MM474505";"O=C(NO)C1(S(=O)(=O)c2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)CCC2(CCNCC2)C1";"PJTIDEQBVYCKIC-UHFFFAOYSA-N";514.52;3.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419063/target=_blank>CHEMBL3419063</a>";;-9.15;"Orbe J, SĂˇnchez-Arias JA, Rabal O, RodrĂ­guez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, PĂˇramo JA, Oyarzabal J.: Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.0000000007079457843841373
"MM474506";"MM474506";"CNC(=O)c1ccc(Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1";"ZUZGJCNWNOCKEB-UHFFFAOYSA-N";487.58;2.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419063/target=_blank>CHEMBL3419063</a>";;-9;"Orbe J, SĂˇnchez-Arias JA, Rabal O, RodrĂ­guez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, PĂˇramo JA, Oyarzabal J.: Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.000000001
"MM474507";"MM474507";"COc1ccc(C(=O)Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1";"AYPBWVMVAOAQCE-UHFFFAOYSA-N";488.56;2.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3419063/target=_blank>CHEMBL3419063</a>";;-9.7;"Orbe J, SĂˇnchez-Arias JA, Rabal O, RodrĂ­guez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, PĂˇramo JA, Oyarzabal J.: Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. J Med Chem, Volume 58 (5), 2015";"PAMPA";0.00000000019952623149688828
"MM474143";"MM474143";"O=c1n(Cc2nc3cc(Cl)ccn3c2CCCCO)c2cnccc2n1C1CC1";"HYWDRCNGDIQGND-UHFFFAOYSA-N";411.89;3.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428423/target=_blank>CHEMBL3428423</a>";;-5.51;"Feng S, Hong D, Wang B, Zheng X, Miao K, Wang L, Yun H, Gao L, Zhao S, Shen HC.: Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. ACS Med Chem Lett, Volume 6 (3), 2015";"PAMPA";0.000003090295432513592
"MM474144";"MM474144";"O=C(O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12";"MDXDEVDOOLNVAH-UHFFFAOYSA-N";411.85;2.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428423/target=_blank>CHEMBL3428423</a>";;-6.52;"Feng S, Hong D, Wang B, Zheng X, Miao K, Wang L, Yun H, Gao L, Zhao S, Shen HC.: Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. ACS Med Chem Lett, Volume 6 (3), 2015";"PAMPA";0.0000003019951720402019
"MM474145";"MM474145";"NC(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12";"DTYYUVKDXPAJTQ-UHFFFAOYSA-N";410.87;2.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428423/target=_blank>CHEMBL3428423</a>";;-5.6;"Feng S, Hong D, Wang B, Zheng X, Miao K, Wang L, Yun H, Gao L, Zhao S, Shen HC.: Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. ACS Med Chem Lett, Volume 6 (3), 2015";"PAMPA";0.0000025118864315095823
"MM474146";"MM474146";"O=C(CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12)NCCO";"MRWRTTJLJMGCAE-UHFFFAOYSA-N";454.92;1.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428423/target=_blank>CHEMBL3428423</a>";;-6.02;"Feng S, Hong D, Wang B, Zheng X, Miao K, Wang L, Yun H, Gao L, Zhao S, Shen HC.: Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. ACS Med Chem Lett, Volume 6 (3), 2015";"PAMPA";0.0000009549925860214369
"MM474147";"MM474147";"CS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12";"VBHUDCXGFXRLFM-UHFFFAOYSA-N";445.93;2.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428423/target=_blank>CHEMBL3428423</a>";;-5.44;"Feng S, Hong D, Wang B, Zheng X, Miao K, Wang L, Yun H, Gao L, Zhao S, Shen HC.: Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. ACS Med Chem Lett, Volume 6 (3), 2015";"PAMPA";0.0000036307805477010103
"MM474148";"MM474148";"CCS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12";"SWWRPROUTDGFFV-UHFFFAOYSA-N";459.96;2.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3428423/target=_blank>CHEMBL3428423</a>";;-5.59;"Feng S, Hong D, Wang B, Zheng X, Miao K, Wang L, Yun H, Gao L, Zhao S, Shen HC.: Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors. ACS Med Chem Lett, Volume 6 (3), 2015";"PAMPA";0.0000025703957827688647
"MM474508";"MM474508";"COc1ccc2[nH]cc(C(=O)COc3ccncc3)c2c1";"HQZXFUGUFAFHSU-UHFFFAOYSA-N";282.3;2.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-7.7;"10.6019/CHEMBL3431459";"PAMPA";0.000000019952623149688786
"MM474511";"MM474511";"O=C(Nc1ccc(-c2nnn[nH]2)cc1)c1cccc(NS(=O)(=O)c2cccc(Cl)c2)c1";"LYKJGYGOCYEOOB-UHFFFAOYSA-N";454.9;3.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-7.56;"10.6019/CHEMBL3431459";"PAMPA";0.00000002754228703338169
"MM474512";"MM474512";"NC(=O)c1ccc(-c2noc([C@H]3CCCCN3C(=O)COc3ccccc3)n2)cc1";"UOXKYURYXQHCSW-GOSISDBHSA-N";406.44;2.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.29;"10.6019/CHEMBL3431459";"PAMPA";0.000005128613839913648
"MM474513";"MM474513";"NS(=O)(=O)c1cccc(-c2noc([C@H]3CCCCN3C(=O)COc3ccccc3)n2)c1";"GRLJBXCOLCXJPE-GOSISDBHSA-N";442.5;2.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.79;"10.6019/CHEMBL3431459";"PAMPA";0.0000016218100973589298
"MM474514";"MM474514";"O=C(O)c1cccc(-c2noc([C@H]3CCCCN3C(=O)COc3ccccc3)n2)c1";"VYTGYKUFOSTDIK-GOSISDBHSA-N";407.43;3.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.72;"10.6019/CHEMBL3431459";"PAMPA";0.0000019054607179632483
"MM474515";"MM474515";"CCN(CC)C(=O)c1ccc(-c2noc([C@H]3CCCCN3C(=O)COc3ccccc3)n2)cc1";"JGMILTWDZMXZOP-JOCHJYFZSA-N";462.55;4.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.83;"10.6019/CHEMBL3431459";"PAMPA";0.000001479108388168207
"MM474516";"MM474516";"Cc1cc(C(=O)Nc2ccc(C(=O)O)cc2)cc(S(=O)(=O)Nc2cccc(C(F)(F)F)c2)c1C";"YFWYSNNYPCLHSJ-UHFFFAOYSA-N";492.48;5.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-6.08;"10.6019/CHEMBL3431459";"PAMPA";0.0000008317637711026709
"MM474517";"MM474517";"O=C(O)c1ccc(NC(=O)c2ccc(Cl)c(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)c2)cc1";"ZXVNWQMGSFGEBN-UHFFFAOYSA-N";499.76;5.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.65;"10.6019/CHEMBL3431459";"PAMPA";0.0000022387211385683376
"MM474518";"MM474518";"COc1ccc(Cl)cc1S(=O)(=O)Nc1cc(C(=O)Nc2ccc(C(=O)O)cc2)cc(OC)c1OC";"BJACXOCJPLSUML-UHFFFAOYSA-N";520.95;4.12;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.8;"10.6019/CHEMBL3431459";"PAMPA";0.000001584893192461114
"MM474519";"MM474519";"O=C(COc1ccccc1)N1CCCC[C@@H]1c1nc(-c2ccc(Cl)cc2)no1";"HZVQRAMACLKZKO-GOSISDBHSA-N";397.86;4.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-6.02;"10.6019/CHEMBL3431459";"PAMPA";0.0000009549925860214369
"MM474520";"MM474520";"NC(=O)c1cccc(-c2noc([C@H]3CCCCN3C(=O)COc3ccccc3)n2)c1";"RSKRURYFYUMARZ-GOSISDBHSA-N";406.44;2.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.59;"10.6019/CHEMBL3431459";"PAMPA";0.0000025703957827688647
"MM474521";"MM474521";"O=C(COc1ccccc1)N1CCCC[C@@H]1c1nc(-c2ccc(S(=O)(=O)NCCO)cc2)no1";"QGHNHABITPZLLZ-HXUWFJFHSA-N";486.55;2.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.64;"10.6019/CHEMBL3431459";"PAMPA";0.0000022908676527677747
"MM474522";"MM474522";"O=C(c1cc(-c2noc([C@H]3CCCCN3C(=O)COc3ccccc3)n2)ccn1)N1CCOCC1";"KNINIBIMMPVUQN-OAQYLSRUSA-N";477.52;2.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.23;"10.6019/CHEMBL3431459";"PAMPA";0.000005888436553555884
"MM474524";"MM474524";"O=C(COc1ccccc1)N1CCCC[C@@H]1c1nc(-c2ccc(-c3cnc[nH]3)cc2)no1";"XNUIVPRDANKSRO-OAQYLSRUSA-N";429.48;4.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-6.58;"10.6019/CHEMBL3431459";"PAMPA";0.00000026302679918953816
"MM474525";"MM474525";"Nc1cccc(-c2n[nH]c([C@H]3CCCCN3C(=O)COc3ccccc3)n2)c1";"VRJABBUTSONQCQ-GOSISDBHSA-N";377.45;3.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.27;"10.6019/CHEMBL3431459";"PAMPA";0.000005370317963702533
"MM474526";"MM474526";"CC(=O)Nc1cccc(-c2n[nH]c([C@H]3CCCCN3C(=O)COc3ccccc3)n2)c1";"KLCURDNWGRHKIP-HXUWFJFHSA-N";419.49;3.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.54;"10.6019/CHEMBL3431459";"PAMPA";0.000002884031503126606
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3066824/target=_blank>CHEMBL3066824</a>";;-6.47;"Akamatsu M.: Importance of physicochemical properties for the design of new pesticides. J Agric Food Chem, Volume 59 (7), 2011";"PAMPA";0.00000033884415613920274
"MM474383";"MM474383";"COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)NCC[C@]314";"RIKMCJUNPCRFMW-ISWURRPUSA-N";301.34;0.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-6.05;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.0000008912509381337459
"MM474534";"MM474534";"CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21";"JCINBYQJBYJGDM-UHFFFAOYSA-N";432.53;3.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3624201/target=_blank>CHEMBL3624201</a>";;-4.16;"Wan H, Schroeder GM, Hart AC, Inghrim J, Grebinski J, Tokarski JS, Lorenzi MV, You D, Mcdevitt T, Penhallow B, Vuppugalla R, Zhang Y, Gu X, Iyer R, Lombardo LJ, Trainor GL, Ruepp S, Lippy J, Blat Y, Sack JS, Khan JA, Stefanski K, Sleczka B, Mathur A, Sun JH, Wong MK, Wu DR, Li P, Gupta A, Arunachalam PN, Pragalathan B, Narayanan S, K C N, Kuppusamy P, Purandare AV.: Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. ACS Med Chem Lett, Volume 6 (8), 2015";"PAMPA";0.00006918309709189363
"MM474364";"MM474364";"CC(Cn1ncc2c(Nc3cccc(O)c3)nc(SCCN3CCOCC3)nc21)c1ccccc1";"ZUDSOOJFKCYWSR-UHFFFAOYSA-N";490.63;4.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.17;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.000006760829753919819
"MM474382";"MM474382";"CCC(=O)N(c1ccccc1)C1CCNCC1";"PMCBDBWCQQBSRJ-UHFFFAOYSA-N";232.33;2.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-5.59;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.0000025703957827688647
"MM474154";"MM474154";"COC[C@H](C)Oc1cc(C#Cc2cccc(N)c2)cc(C(=O)Nc2ccn(C)n2)c1";"JJZHLHHSBFBDFN-INIZCTEOSA-N";404.47;3.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3578787/target=_blank>CHEMBL3578787</a>";;-5.46;"Park K, Lee BM, Hyun KH, Han T, Lee DH, Choi HH.: Design and Synthesis of Acetylenyl Benzamide Derivatives as Novel Glucokinase Activators for the Treatment of T2DM. ACS Med Chem Lett, Volume 6 (3), 2015";"PAMPA";0.000003467368504525317
"MM473264";"MM473264";"COc1ccc(C(=O)Nc2nc3n(n2)C(c2ccccc2)C=C(C)N3)cc1";"DEEROTSPEVGSRY-UHFFFAOYSA-N";361.41;3.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3578367/target=_blank>CHEMBL3578367</a>";;-5.45;"Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, PalĂą G, Cruciani G, Loregian A, Goracci L, Tabarrini O.: A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. J Med Chem, Volume 58 (9), 2015";"PAMPA";0.000003548133892335753
"MM473265";"MM473265";"CCCOc1ccc(C(=O)Nc2nc3n(n2)C(c2ccccc2)C=C(C)N3)cc1";"JTZVIVSTNLFICQ-UHFFFAOYSA-N";389.46;4.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3578367/target=_blank>CHEMBL3578367</a>";;-5.53;"Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, PalĂą G, Cruciani G, Loregian A, Goracci L, Tabarrini O.: A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. J Med Chem, Volume 58 (9), 2015";"PAMPA";0.000002951209226666384
"MM473266";"MM473266";"Cc1cc(-c2ccccc2)nc2nc(NC(=O)c3ccccc3)nn12";"TYAKSJXUMOOQQU-UHFFFAOYSA-N";329.36;3.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3578367/target=_blank>CHEMBL3578367</a>";;-5.26;"Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, PalĂą G, Cruciani G, Loregian A, Goracci L, Tabarrini O.: A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. J Med Chem, Volume 58 (9), 2015";"PAMPA";0.0000054954087385762485
"MM473267";"MM473267";"Cc1cc(-c2ccccc2)n2nc(C(=O)Nc3sc4c(c3C(N)=O)CCCCC4)nc2n1";"RZQVZONKHSOLHN-UHFFFAOYSA-N";446.54;3.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3578367/target=_blank>CHEMBL3578367</a>";;-6.21;"Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, PalĂą G, Cruciani G, Loregian A, Goracci L, Tabarrini O.: A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. J Med Chem, Volume 58 (9), 2015";"PAMPA";0.0000006165950018614822
"MM474155";"MM474155";"COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IHWMYZQUTPMTII-UHFFFAOYSA-N";511.54;4.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3579767/target=_blank>CHEMBL3579767</a>";;-5.1;"Han F, Lin S, Liu P, Liu X, Tao J, Deng X, Yi C, Xu H.: Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors. ACS Med Chem Lett, Volume 6 (4), 2015";"PAMPA";0.000007943282347242822
"MM474156";"MM474156";"O=S(=O)(Nc1cc(-c2cc3c(-c4ccncc4)ncnc3s2)cnc1Cl)c1ccc(F)cc1F";"OGUIPHCQISNMKY-UHFFFAOYSA-N";515.95;5.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3579767/target=_blank>CHEMBL3579767</a>";;-5.15;"Han F, Lin S, Liu P, Liu X, Tao J, Deng X, Yi C, Xu H.: Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors. ACS Med Chem Lett, Volume 6 (4), 2015";"PAMPA";0.000007079457843841373
"MM474527";"MM474527";"COc1cccc(-c2cc(C(N)=O)c3[nH]c4cc(C(=O)N5CC[C@H](N(C)C)C5)ccc4c3c2)c1";"OMYRREZWXIXXHW-IBGZPJMESA-N";456.55;3.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3592860/target=_blank>CHEMBL3592860</a>";;-4.53;"Zimmermann K, Sang X, Mastalerz HA, Johnson WL, Zhang G, Liu Q, Batt D, Lombardo LJ, Vyas D, Trainor GL, Tokarski JS, Lorenzi MV, You D, Gottardis MM, Lippy J, Khan J, Sack JS, Purandare AV.: 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors. Bioorg Med Chem Lett, Volume 25 (14), 2015";"PAMPA";0.00002951209226666384
"MM474528";"MM474528";"CN1CCN(c2ccc3c(c2)[nH]c2c(C(N)=O)cc(-c4ccc5c(cnn5C)c4)cc23)CC1";"CVXWIJMWDFWQAT-UHFFFAOYSA-N";438.54;3.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3592860/target=_blank>CHEMBL3592860</a>";;-5.43;"Zimmermann K, Sang X, Mastalerz HA, Johnson WL, Zhang G, Liu Q, Batt D, Lombardo LJ, Vyas D, Trainor GL, Tokarski JS, Lorenzi MV, You D, Gottardis MM, Lippy J, Khan J, Sack JS, Purandare AV.: 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors. Bioorg Med Chem Lett, Volume 25 (14), 2015";"PAMPA";0.0000037153522909717276
"MM472748";"MM472748";"CC[C@@H](C)Oc1cc2c(cc1OC)CC(=O)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)cc1)[C@H]2c1ccc(Cl)cc1";"IXFIHZIZFSCBSU-UVAXCULCSA-N";604.24;7.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-4.4;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.000039810717055349695
"MM472747";"MM472747";"COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)cc1)C(=O)C2";"USOMPACWXVKBTM-NYRHXDHDSA-N";590.21;7.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-4.4;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.000039810717055349695
"MM472746";"MM472746";"COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CNC(=O)C4)CC3)cc1)C(=O)C2";"WRRNCSBXYMOEJA-JZVKYIDCSA-N";631.22;6.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-5.5;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.000003162277660168379
"MM472745";"MM472745";"COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCNC(=O)C4)CC3)cc1)C(=O)C2";"BZZYIHQWCXHSMZ-FMSKOOSDSA-N";645.24;6.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-5.2;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.00000630957344480193
"MM472740";"MM472740";"COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2";"CLRSLRWKONPSRQ-IIPSPAQQSA-N";659.27;6.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-4.6;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.000025118864315095822
"MM472744";"MM472744";"COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CC(=O)N(C)C4)CC3)nc1)C(=O)C2";"QHQFWUOURSTSOD-BXKNEMSHSA-N";646.23;5.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-4.6;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.000025118864315095822
"MM472743";"MM472743";"COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)nc1)C(=O)C2";"VZDNISKFMYZWGF-YFMCWZQFSA-N";660.26;5.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-4.7;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.000019952623149688786
"MM472742";"MM472742";"COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cn1)C(=O)C2";"QCZBNRNLGNLUDF-YFMCWZQFSA-N";660.26;5.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-4.5;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.000031622776601683795
"MM472741";"MM472741";"COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1cnc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cn1)C(=O)C2";"PNRKMBJQIFDKIH-BXKNEMSHSA-N";661.25;5.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3602286/target=_blank>CHEMBL3602286</a>";;-4.3;"Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, ChĂ¨ne P, Jeay S, Gessier F.: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem, Volume 58 (16), 2015";"PAMPA";0.00005011872336272725
"MM474173";"MM474173";"Cc1ccc(CN2CCC(N3Cc4cccc(C(N)=O)c4C3=O)CC2)cc1";"AHFNDPZJODGJTG-UHFFFAOYSA-N";363.46;2.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3607351/target=_blank>CHEMBL3607351</a>";;-4.3;"Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M, Fasolini M, Forte B, Galvani A, Isacchi A, Khvat A, Krasavin MY, Lupi R, Orsini P, Perego R, Pesenti E, Pezzetta D, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Sola F, Zuccotto F, Felder ER, Donati D, Montagnoli A.: Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. J Med Chem, Volume 58 (17), 2015";"PAMPA";0.00005011872336272725
"MM474171";"MM474171";"NC(=O)c1cccc2c1C(=O)N(C1CCN(Cc3ccc4[nH]ccc4c3)CC1)C2";"WFMWDGUOCLWPNZ-UHFFFAOYSA-N";388.47;2.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3607351/target=_blank>CHEMBL3607351</a>";;-4.38;"Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M, Fasolini M, Forte B, Galvani A, Isacchi A, Khvat A, Krasavin MY, Lupi R, Orsini P, Perego R, Pesenti E, Pezzetta D, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Sola F, Zuccotto F, Felder ER, Donati D, Montagnoli A.: Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. J Med Chem, Volume 58 (17), 2015";"PAMPA";0.00004168693834703355
"MM474172";"MM474172";"NC(=O)c1cccc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2";"UYRWBJIRLVJAMX-UHFFFAOYSA-N";377.44;2.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3607351/target=_blank>CHEMBL3607351</a>";;-4.54;"Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M, Fasolini M, Forte B, Galvani A, Isacchi A, Khvat A, Krasavin MY, Lupi R, Orsini P, Perego R, Pesenti E, Pezzetta D, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Sola F, Zuccotto F, Felder ER, Donati D, Montagnoli A.: Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. J Med Chem, Volume 58 (17), 2015";"PAMPA";0.000028840315031266056
"MM474174";"MM474174";"NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2";"ARYVAQSYRLZVQD-UHFFFAOYSA-N";395.43;2.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3607351/target=_blank>CHEMBL3607351</a>";;-4.54;"Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M, Fasolini M, Forte B, Galvani A, Isacchi A, Khvat A, Krasavin MY, Lupi R, Orsini P, Perego R, Pesenti E, Pezzetta D, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Sola F, Zuccotto F, Felder ER, Donati D, Montagnoli A.: Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. J Med Chem, Volume 58 (17), 2015";"PAMPA";0.000028840315031266056
"MM473268";"MM473268";"CC(=O)N1CCC(c2nc(N3CCN(C)CC3)ncc2-c2cc(C)no2)CC1";"HHFJUFNRCWNQJY-UHFFFAOYSA-N";384.48;1.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3610564/target=_blank>CHEMBL3610564</a>";;-5.7;"Del Bello F, Farande A, Giannella M, Piergentili A, Quaglia W, Benicchi T, Cappelli F, Nencini A, Salerno M, Thomas RJ, Travagli M, Varrone M.: Identification of 2-aminopyrimidine derivatives as inhibitors of the canonical Wnt signaling pathway. Bioorg Med Chem, Volume 23 (17), 2015";"PAMPA";0.0000019952623149688787
"MM473269";"MM473269";"CC(=O)N1CCC(c2nc(NCc3cccnc3)ncc2-c2cc(C)no2)CC1";"MCZNYNVUZUXTSN-UHFFFAOYSA-N";392.46;3.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3610564/target=_blank>CHEMBL3610564</a>";;-5.7;"Del Bello F, Farande A, Giannella M, Piergentili A, Quaglia W, Benicchi T, Cappelli F, Nencini A, Salerno M, Thomas RJ, Travagli M, Varrone M.: Identification of 2-aminopyrimidine derivatives as inhibitors of the canonical Wnt signaling pathway. Bioorg Med Chem, Volume 23 (17), 2015";"PAMPA";0.0000019952623149688787
"MM473270";"MM473270";"CC(=O)N1CCC(c2nc(NCc3ccccn3)ncc2-c2cc(C)no2)CC1";"LYFPYYHYWZMJNN-UHFFFAOYSA-N";392.46;3.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3610564/target=_blank>CHEMBL3610564</a>";;-5.7;"Del Bello F, Farande A, Giannella M, Piergentili A, Quaglia W, Benicchi T, Cappelli F, Nencini A, Salerno M, Thomas RJ, Travagli M, Varrone M.: Identification of 2-aminopyrimidine derivatives as inhibitors of the canonical Wnt signaling pathway. Bioorg Med Chem, Volume 23 (17), 2015";"PAMPA";0.0000019952623149688787
"MM473271";"MM473271";"COCCNc1ncc(-c2cc(C)no2)c(C2CCN(C(C)=O)CC2)n1";"BWNIJXMBJMRIIG-UHFFFAOYSA-N";359.43;2.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3610564/target=_blank>CHEMBL3610564</a>";;-5.7;"Del Bello F, Farande A, Giannella M, Piergentili A, Quaglia W, Benicchi T, Cappelli F, Nencini A, Salerno M, Thomas RJ, Travagli M, Varrone M.: Identification of 2-aminopyrimidine derivatives as inhibitors of the canonical Wnt signaling pathway. Bioorg Med Chem, Volume 23 (17), 2015";"PAMPA";0.0000019952623149688787
"MM474529";"MM474529";"O=C(Cc1ccc(Cl)cc1Cl)NCc1ccc(O)c(O)c1";"BKPCQXGBKRAJDW-UHFFFAOYSA-N";326.18;3.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3620434/target=_blank>CHEMBL3620434</a>";;-5.41;"Chapman TM, Gillen KJ, Wallace C, Lee MT, Bakrania P, Khurana P, Coombs PJ, Stennett L, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B.: Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF. Bioorg Med Chem Lett, Volume 25 (19), 2015";"PAMPA";0.000003890451449942805
"MM474532";"MM474532";"CNC(=O)c1nc(-c2cccs2)[nH]c(=O)c1O";"MAOSMWFVKCTXKC-UHFFFAOYSA-N";251.27;0.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3619497/target=_blank>CHEMBL3619497</a>";;-5.51;"Chapman TM, Wallace C, Gillen KJ, Bakrania P, Khurana P, Coombs PJ, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B.: N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF. Bioorg Med Chem Lett, Volume 25 (19), 2015";"PAMPA";0.000003090295432513592
"MM474533";"MM474533";"CCC(C)NC(=O)c1nc(-c2cccs2)[nH]c(=O)c1O";"VHPLAPYKPDNJDR-UHFFFAOYSA-N";293.35;1.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3619497/target=_blank>CHEMBL3619497</a>";;-5.01;"Chapman TM, Wallace C, Gillen KJ, Bakrania P, Khurana P, Coombs PJ, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B.: N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF. Bioorg Med Chem Lett, Volume 25 (19), 2015";"PAMPA";0.000009772372209558111
"MM472749";"MM472749";"C[C@@H](Oc1cc(-c2cnn(C)c2)cc2ncsc12)[C@H]1CNC(=O)C1";"MQEBEQHUWNEFHX-ZYHUDNBSSA-N";342.42;2.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3627502/target=_blank>CHEMBL3627502</a>";;-4.9;"Thoma G, Veenstra S, Strang R, Blanz J, Vangrevelinghe E, Berghausen J, Lee CC, Zerwes HG.: Orally bioavailable Syk inhibitors with activity in a rat PK/PD model. Bioorg Med Chem Lett, Volume 25 (20), 2015";"PAMPA";0.000012589254117941661
"MM472750";"MM472750";"C[C@@H](Oc1nc(-c2cnn(C)c2)cc2ncsc12)[C@H]1CNC(=O)C1";"ARQUPPGWWWYWOI-NXEZZACHSA-N";343.41;2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3627502/target=_blank>CHEMBL3627502</a>";;-4.9;"Thoma G, Veenstra S, Strang R, Blanz J, Vangrevelinghe E, Berghausen J, Lee CC, Zerwes HG.: Orally bioavailable Syk inhibitors with activity in a rat PK/PD model. Bioorg Med Chem Lett, Volume 25 (20), 2015";"PAMPA";0.000012589254117941661
"MM472751";"MM472751";"C[C@@H](Oc1cc(-c2cnn(C)c2)cc2nscc12)[C@H]1CNC(=O)C1";"KTRYUWPHTHSFQT-ZYHUDNBSSA-N";342.42;2.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3627502/target=_blank>CHEMBL3627502</a>";;-4.9;"Thoma G, Veenstra S, Strang R, Blanz J, Vangrevelinghe E, Berghausen J, Lee CC, Zerwes HG.: Orally bioavailable Syk inhibitors with activity in a rat PK/PD model. Bioorg Med Chem Lett, Volume 25 (20), 2015";"PAMPA";0.000012589254117941661
"MM472752";"MM472752";"C[C@@H](Oc1nc(-c2cnn(C)c2)cc2nscc12)[C@H]1CNC(=O)C1";"UVAKITWUHZQGNR-NXEZZACHSA-N";343.41;2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3627502/target=_blank>CHEMBL3627502</a>";;-4.9;"Thoma G, Veenstra S, Strang R, Blanz J, Vangrevelinghe E, Berghausen J, Lee CC, Zerwes HG.: Orally bioavailable Syk inhibitors with activity in a rat PK/PD model. Bioorg Med Chem Lett, Volume 25 (20), 2015";"PAMPA";0.000012589254117941661
"MM474179";"MM474179";"CCC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21";"ITXORCJLPUUDIY-UHFFFAOYSA-N";305.38;3.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3624658/target=_blank>CHEMBL3624658</a>";;-5.28;"Martin RE, Aebi JD, Hornsperger B, Krebs HJ, Kuhn B, Kuglstatter A, Alker AM, MĂ¤rki HP, MĂĽller S, Burger D, Ottaviani G, Riboulet W, Verry P, Tan X, Amrein K, Mayweg AV.: Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys. J Med Chem, Volume 58 (20), 2015";"PAMPA";0.000005248074602497723
"MM474180";"MM474180";"CCC(=O)N[C@@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21";"ITXORCJLPUUDIY-GOSISDBHSA-N";305.38;3.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3624658/target=_blank>CHEMBL3624658</a>";;-5.32;"Martin RE, Aebi JD, Hornsperger B, Krebs HJ, Kuhn B, Kuglstatter A, Alker AM, MĂ¤rki HP, MĂĽller S, Burger D, Ottaviani G, Riboulet W, Verry P, Tan X, Amrein K, Mayweg AV.: Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys. J Med Chem, Volume 58 (20), 2015";"PAMPA";0.00000478630092322638
"MM474192";"MM474192";"Cc1c(N2CC(N)C2)c(F)cc2c(=O)c(C(=O)O)cn(-c3nc(N)c(F)cc3F)c12";"YJRFYAWJFKONJD-UHFFFAOYSA-N";419.36;1.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3635760/target=_blank>CHEMBL3635760</a>";;-6.92;"Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A.: Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. Eur J Med Chem, Volume 103, 2015";"PAMPA";0.00000012022644346174132
"MM474193";"MM474193";"CNC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(-c4nc(N)c(F)cc4F)c3c2C)C1";"UMIUJKXRGOKQSJ-UHFFFAOYSA-N";433.39;1.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3635760/target=_blank>CHEMBL3635760</a>";;-6.72;"Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A.: Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. Eur J Med Chem, Volume 103, 2015";"PAMPA";0.00000019054607179632483
"MM474194";"MM474194";"CCNC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(-c4nc(N)c(F)cc4F)c3c2C)C1";"XIQHTMHVFRRPKO-UHFFFAOYSA-N";447.42;2.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3635760/target=_blank>CHEMBL3635760</a>";;-6.54;"Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A.: Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. Eur J Med Chem, Volume 103, 2015";"PAMPA";0.00000028840315031266057
"MM474195";"MM474195";"CCCNC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(-c4nc(N)c(F)cc4F)c3c2C)C1";"QYWWAPQGCKJESQ-UHFFFAOYSA-N";461.44;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3635760/target=_blank>CHEMBL3635760</a>";;-5.96;"Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A.: Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. Eur J Med Chem, Volume 103, 2015";"PAMPA";0.000001096478196143185
"MM474196";"MM474196";"Cc1c(N2CC(NC(C)C)C2)c(F)cc2c(=O)c(C(=O)O)cn(-c3nc(N)c(F)cc3F)c12";"MJMVUQNNSOBCGF-UHFFFAOYSA-N";461.44;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3635760/target=_blank>CHEMBL3635760</a>";;-5.92;"Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A.: Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. Eur J Med Chem, Volume 103, 2015";"PAMPA";0.0000012022644346174132
"MM472753";"MM472753";"COc1ccc([C@H](C)NC(=O)COc2cc(C(F)(F)F)c3c(-c4ccccc4)nn(C)c3n2)cc1";"GUDQJFKBBOAOIC-HNNXBMFYSA-N";484.48;4.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3635617/target=_blank>CHEMBL3635617</a>";;-4;"Behnke D, Cotesta S, Hintermann S, Fendt M, Gee CE, Jacobson LH, Laue G, Meyer A, Wagner T, Badiger S, Chaudhari V, Chebrolu M, Pandit C, Hoyer D, Betschart C.: Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs). Bioorg Med Chem Lett, Volume 25 (23), 2015";"PAMPA";0.0001
"MM472754";"MM472754";"Cc1n[nH]c(C)c1[C@H](C)NC(=O)COc1cc(C(F)(F)F)c2c(-c3ccccc3)nn(C)c2n1";"KNSSBXCHRPNPDS-LBPRGKRZSA-N";472.47;4.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3635617/target=_blank>CHEMBL3635617</a>";;-4.1;"Behnke D, Cotesta S, Hintermann S, Fendt M, Gee CE, Jacobson LH, Laue G, Meyer A, Wagner T, Badiger S, Chaudhari V, Chebrolu M, Pandit C, Hoyer D, Betschart C.: Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs). Bioorg Med Chem Lett, Volume 25 (23), 2015";"PAMPA";0.00007943282347242822
"MM474181";"MM474181";"O=c1ccc(-c2ccc(OCc3ccc4ccccc4n3)cc2)c(-c2ccccc2)[nH]1";"ZXSGFWVBKHFTBY-UHFFFAOYSA-N";404.47;5.84;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3636191/target=_blank>CHEMBL3636191</a>";;-5.54;"Lingam VS, Dahale DH, Rathi VE, Shingote YB, Thakur RR, Mindhe AS, Kummari S, Khairatkar-Joshi N, Bajpai M, Shah DM, Sapalya RS, Gullapalli S, Gupta PK, Gudi GS, Jadhav SB, Pattem R, Thomas A.: Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists. J Med Chem, Volume 58 (20), 2015";"PAMPA";0.000002884031503126606
"MM474182";"MM474182";"O=c1ccc(-c2ccc(OCc3ccc4ccccc4n3)cc2)c(-c2ccc(F)cc2)[nH]1";"OOOKPENMJKOYJM-UHFFFAOYSA-N";422.46;5.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3636191/target=_blank>CHEMBL3636191</a>";;-5.54;"Lingam VS, Dahale DH, Rathi VE, Shingote YB, Thakur RR, Mindhe AS, Kummari S, Khairatkar-Joshi N, Bajpai M, Shah DM, Sapalya RS, Gullapalli S, Gupta PK, Gudi GS, Jadhav SB, Pattem R, Thomas A.: Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists. J Med Chem, Volume 58 (20), 2015";"PAMPA";0.000002884031503126606
"MM474183";"MM474183";"O=c1ccc(-c2ccc(OCc3ccc4ccccc4n3)cc2)c(-c2ccc(F)cc2F)[nH]1";"NMRFPRMCGFXOEN-UHFFFAOYSA-N";440.45;6.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3636191/target=_blank>CHEMBL3636191</a>";;-5.54;"Lingam VS, Dahale DH, Rathi VE, Shingote YB, Thakur RR, Mindhe AS, Kummari S, Khairatkar-Joshi N, Bajpai M, Shah DM, Sapalya RS, Gullapalli S, Gupta PK, Gudi GS, Jadhav SB, Pattem R, Thomas A.: Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists. J Med Chem, Volume 58 (20), 2015";"PAMPA";0.000002884031503126606
"MM473135";"MM473135";"COC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)Cc1ccc(-c2ccccc2)cc1";"YUQJDKXEZYUTNJ-OALUTQOASA-N";411.51;0.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-5.97;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.000001071519305237607
"MM473134";"MM473134";"CC(C)(C)c1cc(C(C)(C)C)c2[nH]c(C(C)(C)C)c(C[C@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)c2c1";"UVDFAMGJNCXXNC-SFTDATJTSA-N";527.76;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-6.37;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.00000042657951880159254
"MM473306";"MM473306";"CC[C@@H](C[C@H]1COC(N)=N1)c1ccccc1";"IXDKFUBXESWHSL-JQWIXIFHSA-N";218.3;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3783769/target=_blank>CHEMBL3783769</a>";;-4.97;"Galley G, Beurier A, DĂ©coret G, Goergler A, Hutter R, Mohr S, PĂ¤hler A, Schmid P, TĂĽrck D, Unger R, Zbinden KG, Hoener MC, Norcross RD.: Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists. ACS Med Chem Lett, Volume 7 (2), 2016";"PAMPA";0.00001071519305237607
"MM474241";"MM474241";"CCCCCc1cc(O)cc2c1Oc1cc(O)cc(C(=O)CCCC)c1C(=O)O2";"ZSMRNRJMUKTCNH-UHFFFAOYSA-N";398.46;5.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3860212/target=_blank>CHEMBL3860212</a>";;-4.49;"Talapatra SK, Rath O, Clayton E, Tomasi S, Kozielski F.: Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis. J Nat Prod, Volume 79 (6), 2016";"PAMPA";0.00003235936569296281
"MM473652";"MM473652";"O=C(O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1";"YHGSTSNEOJUIRN-UHFFFAOYSA-N";478.53;2.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4326157/target=_blank>CHEMBL4326157</a>";;-6.05;"Iwamura R, Tanaka M, Okanari E, Kirihara T, Odani-Kawabata N, Shams N, Yoneda K.: Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000008912509381337459
"MM473293";"MM473293";"CN1CCN(C(=O)c2ccc(N3CCc4c(-c5cnc(N)nc5)nc(N5CCOCC5)nc43)cn2)CC1";"QLHBERFTXVZIID-UHFFFAOYSA-N";502.58;0.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-5.79;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.0000016218100973589298
"MM473290";"MM473290";"CN1CCN(Cc2ccc(N3CCc4c(-c5cnc(N)nc5)nc(N5CCOCC5)nc43)cc2)CC1";"BDNMMZKQDZZLBX-UHFFFAOYSA-N";487.61;1.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-6.04;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.0000009120108393559096
"MM473295";"MM473295";"CN1CCN(C(=O)c2cccc(N3CCc4c(-c5cnc(N)nc5)nc(N5CCOCC5)nc43)c2)CC1";"WLFNJMGPVOWFPV-UHFFFAOYSA-N";501.6;1.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-5.75;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.000001778279410038923
"MM473296";"MM473296";"CN1CCN(C(=O)c2ccc(N3CCc4c(-c5cnc(N)nc5)nc(N5CCOCC5)nc43)cc2)CC1";"AXRPBWXWDKFKQI-UHFFFAOYSA-N";501.6;1.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-5.91;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.0000012302687708123811
"MM473298";"MM473298";"Nc1ncc(-c2nc(N3CCOCC3)nc3c2CCN3c2ccc(CN3CCOCC3)cc2F)cn1";"SOQGJELWEBZPQE-UHFFFAOYSA-N";492.56;2.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-5.38;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.000004168693834703355
"MM473297";"MM473297";"Nc1ncc(-c2nc(N3CCOCC3)nc3c2CCN3c2ccc(CN3CCOCC3)cc2)cn1";"ONGPNQNAQCYDCY-UHFFFAOYSA-N";474.57;1.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-5.34;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.000004570881896148752
"MM473294";"MM473294";"CN1CCN(C(=O)c2cncc(N3CCc4c(-c5cnc(N)nc5)nc(N5CCOCC5)nc43)c2)CC1";"FSUCEMOGNYKIMJ-UHFFFAOYSA-N";502.58;0.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-6.14;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.0000007244359600749906
"MM473291";"MM473291";"Nc1ncc(-c2nc(N3CCOCC3)nc3c2CCN3c2ccc(C(=O)N3CCOCC3)cc2F)cn1";"KQFMAOYLUCFTTP-UHFFFAOYSA-N";506.54;1.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-5.5;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.000003162277660168379
"MM473292";"MM473292";"CN1CCN(C(=O)c2cc(N3CCc4c(-c5cnc(N)nc5)nc(N5CCOCC5)nc43)ccn2)CC1";"QYTYBJUOTNVWBP-UHFFFAOYSA-N";502.58;0.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3736948/target=_blank>CHEMBL3736948</a>";;-5.95;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shinma N, Tsukuda T, Ohwada J.: Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. Bioorg Med Chem, Volume 23 (24), 2015";"PAMPA";0.000001122018454301963
"MM474217";"MM474217";"CC(C)(C)c1ccc(COc2ccc([C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)c3ccc(Cl)s3)C(N)=O)cc2)cc1";"GOVQQDUPSMZDLM-FEVNIDIWSA-N";741.36;3.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3745074/target=_blank>CHEMBL3745074</a>";;-6.48;"Behnam MA, Graf D, Bartenschlager R, Zlotos DP, Klein CD.: Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzyloxyphenylglycine Residue. J Med Chem, Volume 58 (23), 2015";"PAMPA";0.0000003311311214825908
"MM474218";"MM474218";"COc1cccc(COc2ccc([C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)c3ccc(-c4cccs4)s3)C(N)=O)cc2)c1";"CRRMQORWVFJFIV-ALKXEMMNSA-N";762.96;3.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3745074/target=_blank>CHEMBL3745074</a>";;-6.19;"Behnam MA, Graf D, Bartenschlager R, Zlotos DP, Klein CD.: Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzyloxyphenylglycine Residue. J Med Chem, Volume 58 (23), 2015";"PAMPA";0.000000645654229034655
"MM472755";"MM472755";"Cc1ccc(S(=O)(=O)N(C)C2(C(=O)N[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)CC2)cc1F";"DBDHNPSFILBIEX-IDNYSXLCSA-N";463.58;2.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3744154/target=_blank>CHEMBL3744154</a>";;-4.19;"10.1039/C5MD00096C";"PAMPA";0.00006456542290346549
"MM474221";"MM474221";"COCCOc1cc2c(-n3nc(-c4ccccn4)nc3N)ncnc2cc1OC";"ZXNSGRMQSJUSGX-UHFFFAOYSA-N";393.41;1.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3768362/target=_blank>CHEMBL3768362</a>";;-3.71;"Min J, Guo K, Suryadevara PK, Zhu F, Holbrook G, Chen Y, Feau C, Young BM, Lemoff A, Connelly MC, Kastan MB, Guy RK.: Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. J Med Chem, Volume 59 (2), 2016";"PAMPA";0.00019498445997580456
"MM474222";"MM474222";"COCCOc1cc2ncnc(-n3nc(-c4ccccn4)nc3N)c2cc1OCCOC";"PBIMPTFJHKSFEY-UHFFFAOYSA-N";437.46;1.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3768362/target=_blank>CHEMBL3768362</a>";;-4.78;"Min J, Guo K, Suryadevara PK, Zhu F, Holbrook G, Chen Y, Feau C, Young BM, Lemoff A, Connelly MC, Kastan MB, Guy RK.: Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. J Med Chem, Volume 59 (2), 2016";"PAMPA";0.000016595869074375598
"MM474220";"MM474220";"COc1cc2ncnc(-n3nc(-c4ccccn4)nc3N)c2cc1OCCCNC(=O)OC(C)C";"IJHWUYUPCVHLDZ-UHFFFAOYSA-N";478.51;2.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3768362/target=_blank>CHEMBL3768362</a>";;-3.36;"Min J, Guo K, Suryadevara PK, Zhu F, Holbrook G, Chen Y, Feau C, Young BM, Lemoff A, Connelly MC, Kastan MB, Guy RK.: Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. J Med Chem, Volume 59 (2), 2016";"PAMPA";0.0004365158322401661
"MM474536";"MM474536";"Cc1cc(C[C@@H](NC(=O)N2CCN(c3cccc(Cl)c3)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12";"LZMJKALQYLMCAR-GDLZYMKVSA-N";592.19;4.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-5.28;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.000005248074602497723
"MM474540";"MM474540";"Cc1cc(C[C@@H](NC(=O)N2CCC(c3ccc(Cl)cc3Cl)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12";"VBQBLAJKPJTHLI-SSEXGKCCSA-N";625.65;6.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-5.62;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.0000023988329190194897
"MM474535";"MM474535";"CCn1cc(-c2cccc(C(F)(F)F)c2)c2sc(C(=N)NC3CCS(=O)(=O)CC3)cc2c1=O";"WRUWGLUCNBMGPS-UHFFFAOYSA-N";497.56;4.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773672/target=_blank>CHEMBL3773672</a>";;-4.68;"Theodoulou NH, Bamborough P, Bannister AJ, Becher I, Bit RA, Che KH, Chung CW, Dittmann A, Drewes G, Drewry DH, Gordon L, Grandi P, Leveridge M, Lindon M, Michon AM, Molnar J, Robson SC, Tomkinson NC, Kouzarides T, Prinjha RK, Humphreys PG.: Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. J Med Chem, Volume 59 (4), 2016";"PAMPA";0.00002089296130854041
"MM473302";"MM473302";"CCN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1";"DNCBAXHUOSCWMJ-IBGZPJMESA-N";314.86;4.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3774145/target=_blank>CHEMBL3774145</a>";;-3.29;"He S, Xiao J, Dulcey AE, Lin B, Rolt A, Hu Z, Hu X, Wang AQ, Xu X, Southall N, Ferrer M, Zheng W, Liang TJ, Marugan JJ.: Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Med Chem, Volume 59 (3), 2016";"PAMPA";0.0005128613839913648
"MM474538";"MM474538";"Cc1cc(C[C@@H](NC(=O)N2CCN(c3ccc(Br)cc3)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12";"ZTULCETYIBZDAH-GDLZYMKVSA-N";636.64;4.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-5.28;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.000005248074602497723
"MM474263";"MM474263";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)c(Cl)ccc24)CCCN(c2cccc(C(=O)O)c2)C3=O)cc(C)c1Cl";"YYPNZNHOMXJSFW-UHFFFAOYSA-N";659.61;8.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-3.51;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.0003090295432513592
"MM474542";"MM474542";"Cc1cc(C[C@@H](NC(=O)N2CCC(c3ccc(C(F)(F)F)cc3C(F)(F)F)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12";"HJRDKTXYUSZIPU-SSEXGKCCSA-N";692.75;6.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-5.15;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.000007079457843841373
"MM474543";"MM474543";"Cc1cc(C[C@@H](NC(=O)N2CCC(c3ccc4ccccc4c3)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12";"PGUPJMQJNPDQPV-UUWRZZSWSA-N";606.82;6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-5.21;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.000006165950018614822
"MM474541";"MM474541";"Cc1ccc(C2CCN(C(=O)N[C@H](Cc3cc(C)c4[nH]ncc4c3)C(=O)N3CCC(N4CCCCC4)CC3)CC2)c(Cl)c1";"UQLOLQPXCFNBCX-WJOKGBTCSA-N";605.23;5.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-4.92;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.000012022644346174132
"MM473303";"MM473303";"NCCOCCOCCOCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1";"UDJCGMDVNWTYJW-UHFFFAOYSA-N";506.09;3.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3774145/target=_blank>CHEMBL3774145</a>";;-3.17;"He S, Xiao J, Dulcey AE, Lin B, Rolt A, Hu Z, Hu X, Wang AQ, Xu X, Southall N, Ferrer M, Zheng W, Liang TJ, Marugan JJ.: Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Med Chem, Volume 59 (3), 2016";"PAMPA";0.0006760829753919819
"MM473305";"MM473305";"CCN1CCN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)CC1";"DVVTUWFUPPBVLS-UHFFFAOYSA-N";349.31;4.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3774145/target=_blank>CHEMBL3774145</a>";;-3.05;"He S, Xiao J, Dulcey AE, Lin B, Rolt A, Hu Z, Hu X, Wang AQ, Xu X, Southall N, Ferrer M, Zheng W, Liang TJ, Marugan JJ.: Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Med Chem, Volume 59 (3), 2016";"PAMPA";0.0008912509381337459
"MM474539";"MM474539";"Cc1cc(C[C@@H](NC(=O)N2CCN(c3ccc(Cl)cc3Cl)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12";"CTFYMOIQAUCHSA-MUUNZHRXSA-N";626.63;5.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-4.77;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.00001698243652461746
"MM474537";"MM474537";"Cc1cc(C[C@@H](NC(=O)N2CCN(c3ccccc3Br)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12";"RCJOARWJFBIRKK-MUUNZHRXSA-N";636.64;4.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-5.46;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.000003467368504525317
"MM474544";"MM474544";"Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4cc3Cl)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12";"XIIDPSKSRFKLGE-UUWRZZSWSA-N";641.26;6.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3773901/target=_blank>CHEMBL3773901</a>";;-5.24;"Civiello RL, Han X, Beno BR, Chaturvedula PV, Herbst JJ, Xu C, Conway CM, Macor JE, Dubowchik GM.: Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines. Bioorg Med Chem Lett, Volume 26 (4), 2016";"PAMPA";0.000005754399373371567
"MM473304";"MM473304";"CN1CCN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)CC1";"UVQVBDRHJUMBET-UHFFFAOYSA-N";335.28;4.33;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3774145/target=_blank>CHEMBL3774145</a>";;-2.99;"He S, Xiao J, Dulcey AE, Lin B, Rolt A, Hu Z, Hu X, Wang AQ, Xu X, Southall N, Ferrer M, Zheng W, Liang TJ, Marugan JJ.: Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Med Chem, Volume 59 (3), 2016";"PAMPA";0.0010232929922807535
"MM472756";"MM472756";"CC1CN(CC2CCN(Cc3ccccc3)CC2)C(=O)N(c2cccc(C(=N)N)c2)C1";"HGBLIBDRBSWLRN-UHFFFAOYSA-N";419.57;3.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3783744/target=_blank>CHEMBL3783744</a>";;-7.6;"Venukadasula PK, Owusu BY, Bansal N, Ross LJ, Hobrath JV, Bao D, Truss JW, Stackhouse M, Messick TE, Klampfer L, Galemmo RA.: Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation. ACS Med Chem Lett, Volume 7 (2), 2016";"PAMPA";0.00000002511886431509582
"MM473307";"MM473307";"Cc1c(F)cccc1[C@H]1COC(N)=N1";"IOHOUWIYOVWGHV-SECBINFHSA-N";194.21;1.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3783769/target=_blank>CHEMBL3783769</a>";;-4.84;"Galley G, Beurier A, DĂ©coret G, Goergler A, Hutter R, Mohr S, PĂ¤hler A, Schmid P, TĂĽrck D, Unger R, Zbinden KG, Hoener MC, Norcross RD.: Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists. ACS Med Chem Lett, Volume 7 (2), 2016";"PAMPA";0.00001445439770745928
"MM474545";"MM474545";"CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCN(C)CC3)nc21";"RYBRXOLQVVUVSC-UHFFFAOYSA-N";480.56;4.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3800745/target=_blank>CHEMBL3800745</a>";;-4.27;"Fabritius CH, Pesonen U, Messinger J, Horvath R, Salo H, GaĹ‚Ä™zowski M, Galek M, StefaĹ„ska K, Szeremeta-Spisak J, Olszak-PĹ‚achta M, Buda A, Adamczyk J, KrĂłl M, Prusis P, Sieprawska-Lupa M, Mikulski M, Kuokkanen K, Chapman H, Obuchowicz R, Korjamo T, Jalava N, Nowak M.: 1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett, Volume 26 (11), 2016";"PAMPA";0.000053703179637025325
"MM474546";"MM474546";"CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCNCC3)nc21";"CRZWHAXESOORIJ-UHFFFAOYSA-N";466.53;3.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3800745/target=_blank>CHEMBL3800745</a>";;-4.04;"Fabritius CH, Pesonen U, Messinger J, Horvath R, Salo H, GaĹ‚Ä™zowski M, Galek M, StefaĹ„ska K, Szeremeta-Spisak J, Olszak-PĹ‚achta M, Buda A, Adamczyk J, KrĂłl M, Prusis P, Sieprawska-Lupa M, Mikulski M, Kuokkanen K, Chapman H, Obuchowicz R, Korjamo T, Jalava N, Nowak M.: 1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett, Volume 26 (11), 2016";"PAMPA";0.00009120108393559096
"MM474225";"MM474225";"CC(=O)Nc1ccc(-c2ccc(NCC(=O)Nc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2)cn1";"ZJWPYYIRORJZPQ-UHFFFAOYSA-N";526.56;4.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3806830/target=_blank>CHEMBL3806830</a>";;-5.95;"Cherian J, Nacro K, Poh ZY, Guo S, Jeyaraj DA, Wong YX, Ho M, Yang HY, Joy JK, Kwek ZP, Liu B, Wee JL, Ong EH, Choong ML, Poulsen A, Lee MA, Pendharkar V, Ding LJ, Manoharan V, Chew YS, Sangthongpitag K, Lim S, Ong ST, Hill J, Keller TH.: Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.000001122018454301963
"MM474226";"MM474226";"O=C(CNc1ccc(-c2ccc(NC(=O)C3CC3)nc2)cc1)Nc1ccc(CN2CCNCC2)c(C(F)(F)F)c1";"FCCJIRJUDAWXRO-UHFFFAOYSA-N";552.6;4.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3806830/target=_blank>CHEMBL3806830</a>";;-5.26;"Cherian J, Nacro K, Poh ZY, Guo S, Jeyaraj DA, Wong YX, Ho M, Yang HY, Joy JK, Kwek ZP, Liu B, Wee JL, Ong EH, Choong ML, Poulsen A, Lee MA, Pendharkar V, Ding LJ, Manoharan V, Chew YS, Sangthongpitag K, Lim S, Ong ST, Hill J, Keller TH.: Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.0000054954087385762485
"MM474227";"MM474227";"CCN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(=O)C5CC5)nc4)cc3)cc2C(F)(F)F)CC1";"JONUUBFCZUAOFY-UHFFFAOYSA-N";580.66;5.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3806830/target=_blank>CHEMBL3806830</a>";;-4.46;"Cherian J, Nacro K, Poh ZY, Guo S, Jeyaraj DA, Wong YX, Ho M, Yang HY, Joy JK, Kwek ZP, Liu B, Wee JL, Ong EH, Choong ML, Poulsen A, Lee MA, Pendharkar V, Ding LJ, Manoharan V, Chew YS, Sangthongpitag K, Lim S, Ong ST, Hill J, Keller TH.: Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.00003467368504525317
"MM474224";"MM474224";"CCN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(C)=O)nc4)cc3)cc2C(F)(F)F)CC1";"RVMLNNCKNCFOFH-UHFFFAOYSA-N";554.62;4.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3806830/target=_blank>CHEMBL3806830</a>";;-4.58;"Cherian J, Nacro K, Poh ZY, Guo S, Jeyaraj DA, Wong YX, Ho M, Yang HY, Joy JK, Kwek ZP, Liu B, Wee JL, Ong EH, Choong ML, Poulsen A, Lee MA, Pendharkar V, Ding LJ, Manoharan V, Chew YS, Sangthongpitag K, Lim S, Ong ST, Hill J, Keller TH.: Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.000026302679918953814
"MM474228";"MM474228";"CN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(=O)C5CC5)nc4)cc3F)cc2C(F)(F)F)CC1";"CGMQSJXTBXHOTH-UHFFFAOYSA-N";584.62;5.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3806830/target=_blank>CHEMBL3806830</a>";;-4.51;"Cherian J, Nacro K, Poh ZY, Guo S, Jeyaraj DA, Wong YX, Ho M, Yang HY, Joy JK, Kwek ZP, Liu B, Wee JL, Ong EH, Choong ML, Poulsen A, Lee MA, Pendharkar V, Ding LJ, Manoharan V, Chew YS, Sangthongpitag K, Lim S, Ong ST, Hill J, Keller TH.: Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. J Med Chem, Volume 59 (7), 2016";"PAMPA";0.00003090295432513592
"MM473308";"MM473308";"CCN1CCN(c2cc(F)c(NC(=O)N3CCc4c(-c5cnc(N)nc5)nc(N5CCOCC5)nc43)c(F)c2)CC1";"BPFCAIMDJPJDIW-UHFFFAOYSA-N";566.62;2.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3811734/target=_blank>CHEMBL3811734</a>";;-5.96;"Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shimma N, Tsukuda T, Ohwada J.: Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents. Bioorg Med Chem, Volume 24 (13), 2016";"PAMPA";0.000001096478196143185
"MM472760";"MM472760";"NC(=O)c1ccc2c(c1)nc([C@H]1CC[C@H](O)CC1)n2CCO";"SDTXZRMORPGVBY-UMSPYCQHSA-N";303.36;1.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3817419/target=_blank>CHEMBL3817419</a>";;-4.12;"Kim H, Kim MK, Choo H, Chong Y.: Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability. Bioorg Med Chem Lett, Volume 26 (14), 2016";"PAMPA";0.00007585775750291836
"MM472758";"MM472758";"CNCCn1c(C2CCNCC2)nc2cc(C(N)=O)ccc21";"QLSPDZMEKDDYAE-UHFFFAOYSA-N";301.39;0.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3817419/target=_blank>CHEMBL3817419</a>";;-4.32;"Kim H, Kim MK, Choo H, Chong Y.: Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability. Bioorg Med Chem Lett, Volume 26 (14), 2016";"PAMPA";0.000047863009232263804
"MM472759";"MM472759";"CNCCn1c2ccc(C(N)=O)cc2nc1[C@H]1CC[C@H](O)CC1";"JJSWBDODYQEHNP-AULYBMBSSA-N";316.41;1.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3817419/target=_blank>CHEMBL3817419</a>";;-4.04;"Kim H, Kim MK, Choo H, Chong Y.: Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability. Bioorg Med Chem Lett, Volume 26 (14), 2016";"PAMPA";0.00009120108393559096
"MM473121";"MM473121";"CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O";"YWJCZGDVJQLZET-GGHFOJMISA-N";349.4;-1.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1653937/target=_blank>CHEMBL1653937</a>";;-6.89;"Barker RH, Liu H, Hirth B, Celatka CA, Fitzpatrick R, Xiang Y, Willert EK, Phillips MA, Kaiser M, Bacchi CJ, Rodriguez A, Yarlett N, Klinger JD, Sybertz E.: Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. Antimicrob Agents Chemother, Volume 53 (5), 2009";"PAMPA";0.00000012882495516931348
"MM473310";"MM473310";"CNCCNc1cc(N2CCN(C(=O)C(C)(C)c3ccccc3)CC2)nc2ccccc12";"DQWMECMNABFOQZ-UHFFFAOYSA-N";431.58;3.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3828993/target=_blank>CHEMBL3828993</a>";;-5.86;"Zheng X, Wang L, Wang B, Miao K, Xiang K, Feng S, Gao L, Shen HC, Yun H.: Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors. ACS Med Chem Lett, Volume 7 (6), 2016";"PAMPA";0.0000013803842646028838
"MM473309";"MM473309";"CC(C)(C(=O)N1CCN(c2cc(NCCN)c3ccccc3n2)CC1)c1ccccc1";"TXTHMFXJZRLBKD-UHFFFAOYSA-N";417.56;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3828993/target=_blank>CHEMBL3828993</a>";;-6.13;"Zheng X, Wang L, Wang B, Miao K, Xiang K, Feng S, Gao L, Shen HC, Yun H.: Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors. ACS Med Chem Lett, Volume 7 (6), 2016";"PAMPA";0.0000007413102413009177
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL902035/target=_blank>CHEMBL902035</a>";;-5.06;"Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.: Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem, Volume 50 (24), 2007";"PAMPA";0.000008709635899560814
"MM472519";"MM472519";"c1ccc(Nc2ccccc2)cc1";"DMBHHRLKUKUOEG-UHFFFAOYSA-N";169.23;3.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905612/target=_blank>CHEMBL905612</a>";;-5.51;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000003090295432513592
"MM473143";"MM473143";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCc1ccccc1";"IIUQVWAODMBQQA-AWCRTANDSA-N";642.81;1.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-8;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.00000001
"MM472529";"MM472529";"CC(C)OP(=O)(OC(C)C)SCc1ccccc1";"FCOAHACKGGIURQ-UHFFFAOYSA-N";288.35;4.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905612/target=_blank>CHEMBL905612</a>";;-4.93;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000011748975549395302
"MM473340";"MM473340";"O=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1";"KKPOBHHCNGNCLR-UHFFFAOYSA-N";406.87;4.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-7.22;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.00000006025595860743581
"MM474550";"MM474550";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1ccc(S(=O)(=O)C3CC3)c(c1)CN(C)C(=O)[C@@H]2Nc1ccc2c(N)nccc2c1";"DKEJQQLJGULWDZ-WENCNXQZSA-N";613.74;5.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-5.3;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.000005011872336272725
"MM474548";"MM474548";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1ccc(S(=O)(=O)C3CC3)c(c1)CN(C)C(=O)[C@@H]2Nc1cc2ccnc(N)c2cc1F";"RYNFLMWBCAHKMX-WWOZWPLTSA-N";631.73;5.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-4.74;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.000018197008586099827
"MM474547";"MM474547";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1ccc(S(=O)(=O)C3CC3)c(c1)CN(C)C(=O)[C@@H]2Nc1ccc2c(N)ncc(F)c2c1";"ZVYUEFHDJYEETD-WWOZWPLTSA-N";631.73;5.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-4.05;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.00008912509381337459
"MM474234";"MM474234";"Cc1c(F)ccc(C(=O)Nc2cc(C(=O)OC(C)C)ccc2N2CCN(C)CC2)c1Cl";"JUFBKCRECNYVRA-UHFFFAOYSA-N";447.94;4.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-4.3;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.00005011872336272725
"MM474237";"MM474237";"COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cc(N)c(F)c(C)c2Cl)c1";"PLRPRYDOPJNKDZ-UHFFFAOYSA-N";434.9;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-4.28;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.00005248074602497723
"MM474558";"MM474558";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1cccc(c1)CN(C)C(=O)[C@@H]2Nc1ccc2c(N)nccc2c1";"WGWNPJIMCIPPBO-UZTOHYMASA-N";509.61;5.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-5.89;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.000001288249551693135
"MM474549";"MM474549";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1ccc(S(=O)(=O)C3CC3)c(c1)CN(C)C(=O)[C@@H]2Nc1cc(F)c2c(N)nccc2c1";"DVTJAXWYFLZLAI-WWOZWPLTSA-N";631.73;5.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-4.7;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.000019952623149688786
"MM472886";"MM472886";"COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](c3cccc(C)c3)CN1CC2";"RQVOZSFAHBOBFK-AABGKKOBSA-N";352.48;3.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL893073/target=_blank>CHEMBL893073</a>";;-5.47;"LĂĽbbers T, BĂ¶hringer M, Gobbi L, Hennig M, Hunziker D, Kuhn B, LĂ¶ffler B, Mattei P, Narquizian R, Peters JU, Ruff Y, Wessel HP, Wyss P.: 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett, Volume 17 (11), 2007";"PAMPA";0.0000033884415613920275
"MM473353";"MM473353";"C[C@H](Nc1ncnc(N)c1C#N)c1nn2ccc(C#N)c2c(=O)n1-c1ccccc1";"QUMWKKVIZAIAHU-LBPRGKRZSA-N";397.4;1.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3875094/target=_blank>CHEMBL3875094</a>";;-5.55;"Erra M, Taltavull J, GrĂ©co A, Bernal FJ, Caturla JF, GrĂ cia J, DomĂ­nguez M, SabatĂ© M, Paris S, Soria S, HernĂˇndez B, Armengol C, Cabedo J, Bravo M, Calama E, Miralpeix M, Lehner MD.: Discovery of a Potent, Selective, and Orally Available PI3KÎ´ Inhibitor for the Treatment of Inflammatory Diseases. ACS Med Chem Lett, Volume 8 (1), 2017";"PAMPA";0.000002818382931264455
"MM474232";"MM474232";"Cc1c(F)ccc(C(=O)Nc2cc(C(=O)Oc3ccccc3)ccc2N2CCN(C)CC2)c1Cl";"FNEAREWNQVQFAL-UHFFFAOYSA-N";481.96;5.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-4.32;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.000047863009232263804
"MM473708";"MM473708";"CCNC(=O)c1cc2c(-c3cc(S(C)(=O)=O)ccc3Oc3ccc(F)cc3F)cn(C)c(=O)c2[nH]1";"GLPRVXBSUHOVMP-UHFFFAOYSA-N";501.51;3.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.97;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.00001071519305237607
"MM472889";"MM472889";"COc1cc(Nc2c(C#N)cnc3cc(C#CCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl";"ZJDFSJYCAFMEGH-UHFFFAOYSA-N";524.45;5.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL885867/target=_blank>CHEMBL885867</a>";;-5.17;"Boschelli DH, Barrios Sosa AC, Golas JM, Boschelli F.: Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of SKS-927. Bioorg Med Chem Lett, Volume 17 (5), 2007";"PAMPA";0.000006760829753919819
"MM474596";"MM474596";"N#CC1(NC(=O)[C@@H]2Cc3ccc(c(Cl)c3)OCCCCOc3cc(C(F)(F)F)ccc3C(=O)N2)CC1";"XAPRSGPLBWSEHV-IBGZPJMESA-N";521.92;4.42;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4049060/target=_blank>CHEMBL4049060</a>";;-6.4;"Giroud M, Dietzel U, Anselm L, Banner D, Kuglstatter A, Benz J, Blanc JB, Gaufreteau D, Liu H, Lin X, Stich A, Kuhn B, Schuler F, Kaiser M, Brun R, Schirmeister T, Kisker C, Diederich F, Haap W.: Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors. J Med Chem, Volume 61 (8), 2018";"PAMPA";0.0000003981071705534969
"MM474554";"MM474554";"CCN(CC)C(=O)c1ccc2cc1CN(C)C(=O)[C@H](Nc1ccc3c(N)nccc3c1)c1ccc(c(C)c1)[C@@H](C)COC(=O)N2";"KHVYVAAEFVFJSL-WKRVVKTRSA-N";608.74;6.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-5.48;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.0000033113112148259077
"MM474236";"MM474236";"CCOC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2ccc(F)c(C)c2Cl)c1";"SVLKQOVNUKFHLT-UHFFFAOYSA-N";433.91;3.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-4.35;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.00004466835921509635
"MM472890";"MM472890";"O=C1CN(c2c(Cl)sc(-c3ccccc3)c2Cl)S(=O)(=O)N1";"WAMDTAMGZONJDY-UHFFFAOYSA-N";363.25;2.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886820/target=_blank>CHEMBL886820</a>";;-5.45;"Wan ZK, Follows B, Kirincich S, Wilson D, Binnun E, Xu W, Joseph-McCarthy D, Wu J, Smith M, Zhang YL, Tam M, Erbe D, Tam S, Saiah E, Lee J.: Probing acid replacements of thiophene PTP1B inhibitors. Bioorg Med Chem Lett, Volume 17 (10), 2007";"PAMPA";0.000003548133892335753
"MM474556";"MM474556";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1ccc(C(N)=O)c(c1)CN(C)C(=O)[C@@H]2Nc1ccc2c(N)nccc2c1";"LCAJLWIUDOBMSE-XRHLQHRESA-N";552.64;4.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-5.24;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.000005754399373371567
"MM474555";"MM474555";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1ccc(C(=O)N(C)C)c(c1)CN(C)C(=O)[C@@H]2Nc1ccc2c(N)nccc2c1";"RAHPBFRSLVDBER-AFJIDDCJSA-N";580.69;5.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-5.72;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.0000019054607179632483
"MM473501";"MM473501";"CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)(F)F)cc3)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1";"SMUHRFNGPGEYHA-UHFFFAOYSA-N";518.9;7.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4181317/target=_blank>CHEMBL4181317</a>";;-6.89;"Muthukaman N, Tambe M, Deshmukh S, Pisal D, Tondlekar S, Shaikh M, Sarode N, Kattige VG, Pisat M, Sawant P, Honnegowda S, Karande V, Kulkarni A, Behera D, Jadhav SB, Sangana RR, Gudi GS, Khairatkar-Joshi N, Gharat LA.: Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1. Bioorg Med Chem Lett, Volume 27 (23), 2017";"PAMPA";0.00000012882495516931348
"MM473047";"MM473047";"CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)ccc1F";"NYAIYQKWZFWRCU-UHFFFAOYSA-N";369.44;4.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.36;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.000004365158322401657
"MM474557";"MM474557";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1ccc(OC(F)(F)F)c(c1)CN(C)C(=O)[C@@H]2Nc1ccc2c(N)nccc2c1";"YLICDVIPJRKVDF-XRHLQHRESA-N";593.61;6.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-4.64;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.00002290867652767775
"MM473044";"MM473044";"CCOc1cc(CN2CCC(Nc3nc4cc(S(N)(=O)=O)ccc4o3)CC2)ccc1OC";"SYNXMLXHBZIEOT-UHFFFAOYSA-N";460.56;2.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1113042/target=_blank>CHEMBL1113042</a>";;-5.79;"Martin RE, Mohr P, Maerki HP, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-SĂˇnchez R, Alker A, Polonchuk L, Christ AD.: Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0000016218100973589298
"MM473335";"MM473335";"O=C(O)c1c(N2CCCCC2)nc2ccc(Cl)cc2c1-c1ccccc1";"URBVMCHIBNRDKB-UHFFFAOYSA-N";366.85;5.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-5.16;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.0000069183097091893625
"MM474239";"MM474239";"COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2ccc(F)c(C)c2Cl)c1";"JFXRDCZYPFPWDU-UHFFFAOYSA-N";419.88;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-4.22;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.000060255958607435806
"MM473138";"MM473138";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(N)=O";"LBWZFNAGWGIVLH-FKBYEOEOSA-N";552.68;-0.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-8;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.00000001
"MM473334";"MM473334";"CC(C)c1nc2ccc(Cl)cc2c(-c2ccccc2)c1C(=O)O";"CDYJYWKBTLRTHP-UHFFFAOYSA-N";325.8;5.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-5.71;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.0000019498445997580454
"MM473337";"MM473337";"Cc1cc(Cl)cc2c(-c3ccccc3)c(C(=O)O)c(N3CCCCC3)nc12";"GNZUTXQJDKZNGL-UHFFFAOYSA-N";380.88;5.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-5.75;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.000001778279410038923
"MM474553";"MM474553";"Cc1cc2ccc1[C@@H](C)COC(=O)Nc1ccc(-c3ccnn3C)c(c1)CN(C)C(=O)[C@@H]2Nc1ccc2c(N)nccc2c1";"RRNRMCAVLZYWDN-JCOAXYOVSA-N";589.7;6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-5.23;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.000005888436553555884
"MM474230";"MM474230";"Cc1c(F)c(N)cc(C(=O)Nc2cc(C(=O)Oc3ccccc3)ccc2N2CCN(C)CC2)c1Cl";"VKUIARDCYFJGLG-UHFFFAOYSA-N";496.97;4.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-4.42;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.000038018939632056124
"MM473339";"MM473339";"Clc1ccc2nc(N3CCCCC3)c(-c3nnn[nH]3)c(-c3ccccc3)c2c1";"FXEKONNOBJEKPB-UHFFFAOYSA-N";390.88;4.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-5.47;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.0000033884415613920275
"MM474229";"MM474229";"Cc1c(F)c(N)cc(C(=O)Nc2cc(C(=O)OC3CCCCC3)ccc2N2CCN(C)CC2)c1Cl";"SNWJZGNROVHLJC-UHFFFAOYSA-N";503.02;4.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-5.25;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.000005623413251903491
"MM473707";"MM473707";"Cn1cc(-c2cc(S(C)(=O)=O)ccc2Oc2ccc(F)cc2F)c2cc(C(N)=O)[nH]c2c1=O";"PMFAAQHHEWEOPY-UHFFFAOYSA-N";473.46;3.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.62;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.0000023988329190194897
"MM473341";"MM473341";"S=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1";"QNSIEZUINFOQFH-UHFFFAOYSA-N";422.94;6.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-5.84;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.000001445439770745928
"MM473336";"MM473336";"O=C(O)c1c(N2CCCCC2)nc2c(Cl)cc(Cl)cc2c1-c1ccccc1";"CXDOFNPXCPTGNV-UHFFFAOYSA-N";401.29;5.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-5.53;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.000002951209226666384
"MM474551";"MM474551";"CCOP(=O)(O)c1ccc2cc1CN(C)C(=O)[C@H](Nc1ccc3c(N)nccc3c1)c1ccc(c(C)c1)[C@@H](C)COC(=O)N2";"RCTSRSYRSFZKIR-AFJIDDCJSA-N";617.64;5.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-6.52;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.0000003019951720402019
"MM473338";"MM473338";"CC(C)c1cccc(-c2c(C(=O)O)c(N(C)C)nc3ccc(Cl)cc23)c1";"CKMUEMURCFDTSJ-UHFFFAOYSA-N";368.86;5.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3861360/target=_blank>CHEMBL3861360</a>";;-5.19;"KĂĽhne H, Obst-Sander U, Kuhn B, Conte A, Ceccarelli SM, Neidhart W, Rudolph MG, Ottaviani G, Gasser R, So SS, Li S, Zhang X, Gao L, Myers M.: Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors. Bioorg Med Chem Lett, Volume 26 (20), 2016";"PAMPA";0.000006456542290346549
"MM474552";"MM474552";"CCOP(=O)(OCC)c1ccc2cc1CN(C)C(=O)[C@H](Nc1ccc3c(N)nccc3c1)c1ccc(c(C)c1)[C@@H](C)COC(=O)N2";"YIXUXJDCYJOAHT-WKRVVKTRSA-N";645.7;6.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3854661/target=_blank>CHEMBL3854661</a>";;-5.35;"Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.: Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex. J Med Chem, Volume 59 (15), 2016";"PAMPA";0.000004466835921509635
"Hydromorphone";"MM00879";"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5";"WVLOADHCBXTIJK-YNHQPCIGSA-N";285.34;1.63;"5284570";"CHEMBL398707";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-5.77;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000001698243652461746
"MM474381";"MM474381";"Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)NCC3";"IYNWSQDZXMGGGI-NUEKZKHPSA-N";243.35;2.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-6.15;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.0000007079457843841374
"Hesperetin";"MM00371";"COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O";"AIONOLUJZLIMTK-AWEZNQCLSA-N";302.28;2.52;"72281";"CHEMBL399121";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988140/target=_blank>CHEMBL988140</a>";;-4.45;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"PAMPA";0.000035481338923357534
"MM471001";"MM471001";"CSc1nc(Nc2cccc(Cl)c2)c2cnn(CC(Cl)c3ccccc3)c2n1";"ZSKSRKTYCCBGOO-UHFFFAOYSA-N";430.36;5.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4013498/target=_blank>CHEMBL4013498</a>";;-6.59;"Vignaroli G, Iovenitti G, Zamperini C, Coniglio F, Calandro P, Molinari A, Fallacara AL, Sartucci A, Calgani A, Colecchia D, Mancini A, Festuccia C, Dreassi E, Valoti M, Musumeci F, Chiariello M, Angelucci A, Botta M, Schenone S.: Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.0000002570395782768865
"MM472892";"MM472892";"Cc1c(-c2cccc(OC3CCN(S(=O)(=O)Cc4ccccc4)CC3)c2)sc(-c2nn[nH]n2)c1OCC(=O)O";"NWDNWXYXMBQAPB-UHFFFAOYSA-N";569.67;3.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL886820/target=_blank>CHEMBL886820</a>";;-6.66;"Wan ZK, Follows B, Kirincich S, Wilson D, Binnun E, Xu W, Joseph-McCarthy D, Wu J, Smith M, Zhang YL, Tam M, Erbe D, Tam S, Saiah E, Lee J.: Probing acid replacements of thiophene PTP1B inhibitors. Bioorg Med Chem Lett, Volume 17 (10), 2007";"PAMPA";0.0000002187761623949552
"Chembl401877";"MM469696";"CNCc1cc(C(N)=O)ccc1Oc1ccc(Cl)cc1OC";"VXYNDBOWMKXSIO-UHFFFAOYSA-N";320.78;2.96;;"Chembl401877";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948901/target=_blank>CHEMBL948901</a>";;-4.96;"Whitlock GA, Blagg J, Fish PV.: 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.000010964781961431852
"MM472895";"MM472895";"CNCc1cc(C(=O)N(C)C)ccc1Oc1ccc(Cl)cc1OC";"YJNSSHGTSILZGM-UHFFFAOYSA-N";348.83;3.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948901/target=_blank>CHEMBL948901</a>";;-4.82;"Whitlock GA, Blagg J, Fish PV.: 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.000015135612484362071
"MM473729";"MM473729";"Cc1c(Nc2c(C#N)cnc3sc(-c4cccc(CN(C)C)c4)cc23)ccc2[nH]ccc12";"CSCOHEYTBLBQMG-UHFFFAOYSA-N";437.57;6.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL927991/target=_blank>CHEMBL927991</a>";;-5.34;"Boschelli DH, Wu B, Barrios Sosa AC, Chen J, Asselin M, Cole DC, Lee J, Yang X, Chaudhary D.: Synthesis and PKCtheta inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles. Bioorg Med Chem Lett, Volume 18 (9), 2008";"PAMPA";0.000004570881896148752
"MM472893";"MM472893";"CCS(=O)(=O)CCN(C(=O)Cc1ccc(F)c(C(F)(F)F)c1)[C@H](C)c1nc(-c2ccccc2)cn1-c1ccc(C#N)cc1";"YCEWYVGKSIYEOE-OAQYLSRUSA-N";612.65;6.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932100/target=_blank>CHEMBL932100</a>";;-6.05;"Du X, Chen X, Mihalic JT, Deignan J, Duquette J, Li AR, Lemon B, Ma J, Miao S, Ebsworth K, Sullivan TJ, Tonn G, Collins TL, Medina JC.: Design and optimization of imidazole derivatives as potent CXCR3 antagonists. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.0000008912509381337459
"Chembl403090";"MM469707";"CNCc1cc(N2CCCS2(=O)=O)ccc1Oc1ccc(Cl)cc1C";"IDPUQOWVIAMLNB-UHFFFAOYSA-N";380.9;3.7;;"Chembl403090";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL948901/target=_blank>CHEMBL948901</a>";;-5.57;"Whitlock GA, Blagg J, Fish PV.: 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett, Volume 18 (2), 2008";"PAMPA";0.0000026915348039269138
"MM473399";"MM473399";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCN3CCC(C)CC3)CC2)c(C)o1";"VWRQNPQHOUWYTL-UHFFFAOYSA-N";452.64;4.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.37;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.00042657951880159257
"MM473406";"MM473406";"Cc1ccccc1-c1nc(CN2CCC(C(=O)N3CCN(CCN(C)C)CC3)CC2)c(C)o1";"XAENSFXNYCCTGS-UHFFFAOYSA-N";453.63;2.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-4.85;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.000014125375446227555
"MM474588";"MM474588";"COc1ccc2nccc(OCC(=O)Nc3cc(C)cc(C)c3)c2c1";"NJUREIWZHFTTGS-UHFFFAOYSA-N";336.39;3.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.55;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.00002818382931264455
"MM474597";"MM474597";"N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)nc3)n2)CC1";"BOVUCBVHLWEVEP-HNNXBMFYSA-N";537.86;2.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4049106/target=_blank>CHEMBL4049106</a>";;-6.54;"Giroud M, Kuhn B, Saint-Auret S, Kuratli C, Martin RE, Schuler F, Diederich F, Kaiser M, Brun R, Schirmeister T, Haap W.: 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design. J Med Chem, Volume 61 (8), 2018";"PAMPA";0.00000028840315031266057
"MM474591";"MM474591";"Cc1cc(C)cc(NC(=O)Cn2ccc(=O)c3ccccc32)c1";"INQNUABJHYLRFJ-UHFFFAOYSA-N";306.37;3.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.35;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.00004466835921509635
"MM472773";"MM472773";"CC1(c2ccc(/C=C/C(=O)O)cc2)c2ccc(O)cc2CCN1c1ccc(F)cc1";"NZVCGXAIFBXHCL-YIXHJXPBSA-N";403.45;4.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.1;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00007943282347242822
"MM472783";"MM472783";"CC1(c2ccc(/C=C/C(=O)O)cc2)c2ccc(O)cc2CCN1c1ccccc1";"DWSIEQFRDKUDIW-NTEUORMPSA-N";385.46;4.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.1;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00007943282347242822
"MM474266";"MM474266";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)c(Cl)ccc24)CCCN(c2cc(C(=O)O)cc4c2OCO4)C3=O)cc(C)c1Cl";"IPYGEWCBSZWZNU-UHFFFAOYSA-N";703.62;8.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-4.2;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.00006309573444801929
"MM473391";"MM473391";"COc1cccc(Nc2cc(-c3ccccc3)nc3c2C(=O)NCC3)c1";"PBJZBHKLXZKPND-UHFFFAOYSA-N";345.4;3.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4038065/target=_blank>CHEMBL4038065</a>";;-5.7;"Roberts RS, Sevilla S, Ferrer M, Taltavull J, HernĂˇndez B, Segarra V, GrĂ cia J, Lehner MD, GavaldĂ  A, AndrĂ©s M, Cabedo J, Vilella D, Eichhorn P, Calama E, Carcasona C, Miralpeix M.: 4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.0000019952623149688787
"MM474595";"MM474595";"COc1ccc2nc(C)n(CC(=O)Nc3cc(C)cc(C)c3)c(=O)c2c1";"GFJIKFMUSKDBHH-UHFFFAOYSA-N";351.41;2.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.24;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.000057543993733715664
"MM473370";"MM473370";"COC(=O)C1=C(CN2CCOC[C@H]2C(=O)O)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Cl";"QJLRUAVQNXTCMO-RDJZCZTQSA-N";494.93;2.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011436/target=_blank>CHEMBL4011436</a>";;-5.85;"Qiu Z, Lin X, Zhang W, Zhou M, Guo L, Kocer B, Wu G, Zhang Z, Liu H, Shi H, Kou B, Hu T, Hu Y, Huang M, Yan SF, Xu Z, Zhou Z, Qin N, Wang YF, Ren S, Qiu H, Zhang Y, Zhang Y, Wu X, Sun K, Zhong S, Xie J, Ottaviani G, Zhou Y, Zhu L, Tian X, Shi L, Shen F, Mao Y, Zhou X, Gao L, Young JAT, Wu JZ, Yang G, Mayweg AV, Shen HC, Tang G, Zhu W.: Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors. J Med Chem, Volume 60 (8), 2017";"PAMPA";0.0000014125375446227554
"MM472780";"MM472780";"Cc1nnc(/C=C/c2ccc(C3(C)c4ccc(O)cc4CCN3c3ccc(F)cc3)cc2)o1";"BIYDFHJZBMADSS-LHHJGKSTSA-N";441.51;5.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.0001
"MM474273";"MM474273";"COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(N2CCC(=O)NC2=O)cc1C(C)(C)C";"FNCXOQVFRIJGCX-UHFFFAOYSA-N";473.6;3.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4028508/target=_blank>CHEMBL4028508</a>";;-5.39;"Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.: Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem, Volume 61 (3), 2018";"PAMPA";0.000004073802778041131
"MM473383";"MM473383";"Cc1ncn(-c2ccc(C(=O)N[C@@H]3CCN(c4ncc(Cl)c5c(N)noc45)C3)c(Cl)c2)n1";"UHUFYIGHVDRSKL-LLVKDONJSA-N";473.32;3.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-4.94;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000011481536214968817
"MM474601";"MM474601";"CC(C)(C)n1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1";"BTDDMUHPSLOMLQ-AWEZNQCLSA-N";498.89;3.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4049106/target=_blank>CHEMBL4049106</a>";;-5.54;"Giroud M, Kuhn B, Saint-Auret S, Kuratli C, Martin RE, Schuler F, Diederich F, Kaiser M, Brun R, Schirmeister T, Haap W.: 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design. J Med Chem, Volume 61 (8), 2018";"PAMPA";0.000002884031503126606
"MM474279";"MM474279";"CC(=O)c1cc(-c2cc(C(=O)NC3CC3)ccc2C)c2ncccn12";"RPBMXJHQYJLPDN-UHFFFAOYSA-N";333.39;3.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4052887/target=_blank>CHEMBL4052887</a>";;-4.84;"Teuscher KB, Zhang M, Ji H.: A Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors. J Med Chem, Volume 60 (1), 2017";"PAMPA";0.00001445439770745928
"MM472776";"MM472776";"CC1(c2ccc(/C=C/C(=O)NCC(F)F)cc2)c2ccc(O)cc2CCN1c1ccc(F)cc1";"VGURYIFDOXQWCN-YIXHJXPBSA-N";466.5;5.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.2;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00006309573444801929
"MM474600";"MM474600";"CC(C)n1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1";"NFWSPCREWNOVLH-AWEZNQCLSA-N";484.87;2.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4049106/target=_blank>CHEMBL4049106</a>";;-6.86;"Giroud M, Kuhn B, Saint-Auret S, Kuratli C, Martin RE, Schuler F, Diederich F, Kaiser M, Brun R, Schirmeister T, Haap W.: 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design. J Med Chem, Volume 61 (8), 2018";"PAMPA";0.0000001380384264602884
"MM473387";"MM473387";"COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1";"KDOQEEMQPHIANX-REWPJTCUSA-N";539.53;5.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4022900/target=_blank>CHEMBL4022900</a>";;-6.52;"Wang X, Liu B, Searle X, Yeung C, Bogdan A, Greszler S, Singh A, Fan Y, Swensen AM, Vortherms T, Balut C, Jia Y, Desino K, Gao W, Yong H, Tse C, Kym P.: Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis. J Med Chem, Volume 61 (4), 2018";"PAMPA";0.0000003019951720402019
"MM474260";"MM474260";"Cc1cc(OCCCc2c(C(=O)Nc3ccc(C(=O)O)o3)[nH]c3c(-c4c(C)nn(C)c4C)c(Cl)ccc23)cc(C)c1Cl";"HKIVCPFWGABZSS-UHFFFAOYSA-N";609.51;7.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-5.64;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.0000022908676527677747
"MM473377";"MM473377";"Nc1noc2c(N3CC[C@@H](NC(=O)c4ccc(-n5cnc6ncccc65)cc4Cl)C3)ncc(Cl)c12";"RPLIFPNYAMSMJY-GFCCVEGCSA-N";509.36;3.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-5.51;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000003090295432513592
"MM473401";"MM473401";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCN3CC4CCCC(C4)C3)CC2)c(C)o1";"FWSMURFWIPUJLE-UHFFFAOYSA-N";478.68;4.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.48;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.0003311311214825911
"MM473400";"MM473400";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCN3[C@H](C)CCC[C@@H]3C)CC2)c(C)o1";"UFPFVIAHDVNPIL-SZPZYZBQSA-N";466.67;4.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-4.26;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.00005495408738576248
"MM473415";"MM473415";"CCS(=O)(=O)Nc1cnc2c(c1)-c1cn(C)c(=O)cc1OCCCCc1cc(F)cc(F)c1O2";"ZZSDIMNEAFZMHM-UHFFFAOYSA-N";491.52;3.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-5.05;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.00000891250938133746
"MM473382";"MM473382";"Cn1ncn(-c2ccc(C(=O)N[C@@H]3CCN(c4ncc(Cl)c5c(N)noc45)C3)c(Cl)c2)c1=O";"XRSYEDBIHQMIFZ-SNVBAGLBSA-N";489.32;2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-4.99;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000010232929922807536
"MM474271";"MM474271";"COc1c(C#Cc2ccc(NS(C)(=O)=O)cc2)cc(N2CCC(=O)NC2=O)cc1C(C)(C)C";"SNFDKUMADRJBAK-UHFFFAOYSA-N";469.56;3.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4028508/target=_blank>CHEMBL4028508</a>";;-6.08;"Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.: Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem, Volume 61 (3), 2018";"PAMPA";0.0000008317637711026709
"MM474578";"MM474578";"CS(=O)(=O)N1CCC[C@H](c2csc(-c3ccccc3NC(=O)c3ncc[nH]3)n2)C1";"WSTBNDDBNXWHQU-ZDUSSCGKSA-N";431.54;2.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4001913/target=_blank>CHEMBL4001913</a>";;-4.8;"Keung W, Boloor A, Brown J, Kiryanov A, Gangloff A, Lawson JD, Skene R, Hoffman I, Atienza J, Kahana J, De Jong R, Farrell P, Balakrishna D, Halkowycz P.: Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.00001584893192461114
"MM473395";"MM473395";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCN3C[C@H](C)C[C@@H](C)C3)CC2)c(C)o1";"MRHJNIMUABLZHR-NHCUHLMSSA-N";466.67;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.26;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.0005495408738576248
"MM473372";"MM473372";"COC(=O)C1=C(CN2CCOC[C@H]2C(=O)O)NC(c2nccs2)=N[C@H]1c1ccc(F)c(F)c1C";"VXUGWYDIMOVOBL-YJBOKZPZSA-N";492.5;2.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011436/target=_blank>CHEMBL4011436</a>";;-5.57;"Qiu Z, Lin X, Zhang W, Zhou M, Guo L, Kocer B, Wu G, Zhang Z, Liu H, Shi H, Kou B, Hu T, Hu Y, Huang M, Yan SF, Xu Z, Zhou Z, Qin N, Wang YF, Ren S, Qiu H, Zhang Y, Zhang Y, Wu X, Sun K, Zhong S, Xie J, Ottaviani G, Zhou Y, Zhu L, Tian X, Shi L, Shen F, Mao Y, Zhou X, Gao L, Young JAT, Wu JZ, Yang G, Mayweg AV, Shen HC, Tang G, Zhu W.: Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors. J Med Chem, Volume 60 (8), 2017";"PAMPA";0.0000026915348039269138
"MM472779";"MM472779";"Cn1cncc1/C=C/c1ccc(C2(C)c3ccc(O)cc3CCN2c2ccc(F)cc2)cc1";"GHMAAMUCRPDVSB-BJMVGYQFSA-N";439.53;5.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.8;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00001584893192461114
"MM474276";"MM474276";"COc1c(C(=O)N(C)c2ccc(NS(C)(=O)=O)cc2)cc(N2CCC(=O)NC2=O)cc1C(C)(C)C";"FMCZNSNFBLYZOX-UHFFFAOYSA-N";502.59;3.09;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4028508/target=_blank>CHEMBL4028508</a>";;-6.6;"Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.: Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem, Volume 61 (3), 2018";"PAMPA";0.00000025118864315095823
"MM474589";"MM474589";"COc1ccc2nc(C)cc(OCC(=O)Nc3cc(C)cc(C)c3)c2n1";"HBJVPIPPULFYOI-UHFFFAOYSA-N";351.41;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.29;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.00005128613839913648
"MM474602";"MM474602";"N#CC1(NC(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)cc3)n2)CC1";"MRUBACKMRWNERJ-SFHVURJKSA-N";487.32;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4049106/target=_blank>CHEMBL4049106</a>";;-5.97;"Giroud M, Kuhn B, Saint-Auret S, Kuratli C, Martin RE, Schuler F, Diederich F, Kaiser M, Brun R, Schirmeister T, Haap W.: 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design. J Med Chem, Volume 61 (8), 2018";"PAMPA";0.000001071519305237607
"MM473409";"MM473409";"CCS(=O)(=O)Nc1ccc2c(c1)-c1cn(C)c(=O)cc1OCCCCc1cc(Cl)ccc1O2";"ZZIGYCDFBKLWSO-UHFFFAOYSA-N";488.99;4.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-5.66;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.0000021877616239495517
"MM474582";"MM474582";"Cc1cc(C#N)ccc1-c1cc(N)cc2ncnn12";"DAEJAOGCSBFGTO-UHFFFAOYSA-N";249.28;2.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4017311/target=_blank>CHEMBL4017311</a>";;-5.23;"Ahmed S, Ayscough A, Barker GR, Canning HE, Davenport R, Downham R, Harrison D, Jenkins K, Kinsella N, Livermore DG, Wright S, Ivetac AD, Skene R, Wilkens SJ, Webster NA, Hendrick AG.: 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000005888436553555884
"MM474264";"MM474264";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)c(Cl)ccc24)CCCN(c2cc(C(=O)O)c4ccn(C)c4c2)C3=O)cc(C)c1Cl";"OTFAIFQJDQCNJT-UHFFFAOYSA-N";712.68;8.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-4.68;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.00002089296130854041
"MM472774";"MM472774";"CC1(c2ccc(CCC(=O)O)cc2)c2ccc(O)cc2CCN1c1ccc(F)cc1";"OUDAHHPZBOGICF-UHFFFAOYSA-N";405.47;4.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.4;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.000039810717055349695
"MM473768";"MM473768";"CN1CCCCC1c1nc(O)c(O)c(C(=O)NCc2ccc(F)cc2)n1";"KPXYCCGYCRCUCJ-UHFFFAOYSA-N";360.39;2.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-6.15;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.0000007079457843841374
"MM473393";"MM473393";"O=C(NC1CC1)c1cccc(-c2cccc(-c3cc(Nc4cccc5ncccc45)c4c(n3)CCNC4=O)c2)c1";"XSVZLSNCQIYEGH-UHFFFAOYSA-N";525.61;5.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4038065/target=_blank>CHEMBL4038065</a>";;-6.82;"Roberts RS, Sevilla S, Ferrer M, Taltavull J, HernĂˇndez B, Segarra V, GrĂ cia J, Lehner MD, GavaldĂ  A, AndrĂ©s M, Cabedo J, Vilella D, Eichhorn P, Calama E, Carcasona C, Miralpeix M.: 4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.00000015135612484362072
"MM473374";"MM473374";"Cn1cc(-c2ccc(C(=O)N[C@@H]3CCN(c4ncc(Cl)c5c(N)noc45)C3)c(Cl)c2)cnc1=O";"CCIDOUGFKDXCLD-CYBMUJFWSA-N";500.35;2.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-6.15;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.0000007079457843841374
"MM473366";"MM473366";"CN(C)[C@H]1CN(Cc2c(F)cccc2Br)C[C@@H]1c1cn(C)c2ccccc12";"ZNFRUVZPVKADAA-VGSWGCGISA-N";430.37;4.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4007113/target=_blank>CHEMBL4007113</a>";;-6;"Curtin ML, Pliushchev MA, Li HQ, Torrent M, Dietrich JD, Jakob CG, Zhu H, Zhao H, Wang Y, Ji Z, Clark RF, Sarris KA, Selvaraju S, Shaw B, Algire MA, He Y, Richardson PL, Sweis RF, Sun C, Chiang GG, Michaelides MR.: SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding. Bioorg Med Chem Lett, Volume 27 (7), 2017";"PAMPA";0.000001
"MM473411";"MM473411";"CCS(=O)(=O)c1ccc2c(c1)-c1cn(C)c(=O)cc1OCCCCc1cc(Cl)ccc1O2";"RTAFIPPKROYDAD-UHFFFAOYSA-N";473.98;5.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-5.12;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.000007585775750291836
"MM473413";"MM473413";"CCS(=O)(=O)c1cnc2c(c1)-c1cn(C)c(=O)cc1OCCCCc1cc(Cl)ccc1O2";"DWSPVJWMVBWDOF-UHFFFAOYSA-N";474.97;4.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-4.82;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.000015135612484362071
"MM473414";"MM473414";"CCS(=O)(=O)Nc1cnc2c(c1)-c1cn(C)c(=O)cc1OCCCCc1cc(Cl)ccc1O2";"KDSKWYPIXDDXEG-UHFFFAOYSA-N";489.98;4.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-5.14;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.000007244359600749906
"MM474278";"MM474278";"COc1c(COc2ccc(NS(C)(=O)=O)cc2)cc(N2CCC(=O)NC2=O)cc1C(C)(C)C";"RBCHYRIESDBGCR-UHFFFAOYSA-N";475.57;3.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4028508/target=_blank>CHEMBL4028508</a>";;-5.13;"Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.: Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem, Volume 61 (3), 2018";"PAMPA";0.000007413102413009177
"MM474261";"MM474261";"Cc1cc(OCCCc2c(C(=O)Nc3ccc(C(=O)O)cc3)[nH]c3c(-c4c(C)nn(C)c4C)c(Cl)ccc23)cc(C)c1Cl";"SWKNMXYCUSMXEK-UHFFFAOYSA-N";619.55;8.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-5.92;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.0000012022644346174132
"MM474583";"MM474583";"Cc1cc(C#N)ccc1-c1cccc2ncnn12";"URBXKEHMAICHMQ-UHFFFAOYSA-N";234.26;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4017311/target=_blank>CHEMBL4017311</a>";;-4.39;"Ahmed S, Ayscough A, Barker GR, Canning HE, Davenport R, Downham R, Harrison D, Jenkins K, Kinsella N, Livermore DG, Wright S, Ivetac AD, Skene R, Wilkens SJ, Webster NA, Hendrick AG.: 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. J Med Chem, Volume 60 (13), 2017";"PAMPA";0.0000407380277804113
"MM473371";"MM473371";"CCOC(=O)C1=C(CN2CCOC[C@H]2C(=O)O)NC(c2nccs2)=N[C@H]1c1cccc(F)c1Cl";"KSGFNWUBFOZLKL-YJBOKZPZSA-N";508.96;2.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011436/target=_blank>CHEMBL4011436</a>";;-5.48;"Qiu Z, Lin X, Zhang W, Zhou M, Guo L, Kocer B, Wu G, Zhang Z, Liu H, Shi H, Kou B, Hu T, Hu Y, Huang M, Yan SF, Xu Z, Zhou Z, Qin N, Wang YF, Ren S, Qiu H, Zhang Y, Zhang Y, Wu X, Sun K, Zhong S, Xie J, Ottaviani G, Zhou Y, Zhu L, Tian X, Shi L, Shen F, Mao Y, Zhou X, Gao L, Young JAT, Wu JZ, Yang G, Mayweg AV, Shen HC, Tang G, Zhu W.: Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors. J Med Chem, Volume 60 (8), 2017";"PAMPA";0.0000033113112148259077
"MM472786";"MM472786";"Cc1ccc(N2CCc3cc(O)ccc3C2(C)c2ccc(/C=C/C(=O)O)cc2)cc1";"VNCUOVJKXRLLAU-VGOFMYFVSA-N";399.49;5.12;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.0001
"MM473416";"MM473416";"Cn1cc2c(cc1=O)OCCCCc1cc(Cl)ccc1Oc1ncc(CS(C)(=O)=O)cc1-2";"UOKIJOMSTWVTHP-UHFFFAOYSA-N";474.97;4.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-4.92;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.000012022644346174132
"MM474580";"MM474580";"S=P(S)(NCc1ccccc1)c1ccc(Oc2ccccc2)cc1";"YZVIVAKGKDJJOP-UHFFFAOYSA-N";371.47;5.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003984/target=_blank>CHEMBL4003984</a>";;-5.72;"Feng W, Novera W, Peh K, Neo D, Ramanujulu PM, Moore PK, Deng LW, Dymock BW.: Discovery of medium ring thiophosphorus based heterocycles as antiproliferative agents. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.0000019054607179632483
"MM473361";"MM473361";"COc1ccc2nc(C)cc(OCC(=O)Nc3ccc(C)cc3)c2c1";"YBPDZWHPUWTGQL-UHFFFAOYSA-N";336.39;3.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003192/target=_blank>CHEMBL4003192</a>";;-4.94;"Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL, Subtil FT, Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P, Santos DS.: New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000011481536214968817
"MM473403";"MM473403";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCCN3C[C@H](C)C[C@H](C)C3)CC2)c(C)o1";"HRRLWWREWRTQPR-SZPZYZBQSA-N";480.7;5.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.54;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.00028840315031266055
"MM473369";"MM473369";"CN(C)[C@H]1CN([C@H]2CCc3cccc(F)c32)C[C@@H]1c1cn(C)c2ccccc12";"XAWMNFFOVCNWGF-OIBXWCBGSA-N";377.51;4.33;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4007113/target=_blank>CHEMBL4007113</a>";;-6;"Curtin ML, Pliushchev MA, Li HQ, Torrent M, Dietrich JD, Jakob CG, Zhu H, Zhao H, Wang Y, Ji Z, Clark RF, Sarris KA, Selvaraju S, Shaw B, Algire MA, He Y, Richardson PL, Sweis RF, Sun C, Chiang GG, Michaelides MR.: SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding. Bioorg Med Chem Lett, Volume 27 (7), 2017";"PAMPA";0.000001
"MM473407";"MM473407";"Cc1cccc(-c2nc(CN3CCC(C(=O)NCCCN4C[C@H](C)C[C@H](C)C4)CC3)c(C)o2)c1";"ITXSUUKLEMBCQO-SZPZYZBQSA-N";466.67;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.55;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.0002818382931264455
"MM474318";"MM474318";"CNC(=O)[C@@H](NC(=O)c1ccc(-c2ccc(CSc3nc4c(c(=O)[nH]3)CCC4)c(F)c2)o1)C(C)C";"NWCGLZSPRJCLHZ-NRFANRHFSA-N";498.58;3.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4158210/target=_blank>CHEMBL4158210</a>";;-5.62;"Fuerst R, Yong Choi J, Knapinska AM, Smith L, Cameron MD, Ruiz C, Fields GB, Roush WR.: Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.0000023988329190194897
"MM474274";"MM474274";"COc1c(C2CC2c2ccc(NS(C)(=O)=O)cc2)cc(N2CCC(=O)NC2=O)cc1C(C)(C)C";"HEKAVWSAFBOGOD-UHFFFAOYSA-N";485.61;4.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4028508/target=_blank>CHEMBL4028508</a>";;-5.55;"Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.: Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem, Volume 61 (3), 2018";"PAMPA";0.000002818382931264455
"MM474598";"MM474598";"N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3cccnc3)n2)CC1";"LWKXXMIGWXDPTM-INIZCTEOSA-N";519.87;2.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4049106/target=_blank>CHEMBL4049106</a>";;-6.35;"Giroud M, Kuhn B, Saint-Auret S, Kuratli C, Martin RE, Schuler F, Diederich F, Kaiser M, Brun R, Schirmeister T, Haap W.: 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design. J Med Chem, Volume 61 (8), 2018";"PAMPA";0.0000004466835921509635
"MM473398";"MM473398";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCN3CCC(C)(C)CC3)CC2)c(C)o1";"KKACEYZSTCDBIG-UHFFFAOYSA-N";466.67;4.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.62;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.000239883291901949
"MM473418";"MM473418";"Cc1cn2cc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)nc2c(C)n1";"TVJPLGCKQZRBMI-UHFFFAOYSA-N";364.45;2.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4052074/target=_blank>CHEMBL4052074</a>";;-5.62;"Pinard E, Green L, Reutlinger M, Weetall M, Naryshkin NA, Baird J, Chen KS, Paushkin SV, Metzger F, Ratni H.: Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy. J Med Chem, Volume 60 (10), 2017";"PAMPA";0.0000023988329190194897
"MM474587";"MM474587";"Cc1cc(C)cc(NC(=O)COc2ccnc3ccccc23)c1";"BKECZPGIXQEFOG-UHFFFAOYSA-N";306.37;3.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.34;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.000045708818961487516
"MM474581";"MM474581";"CC(=O)Nc1cc(-c2ccc(C#N)cc2C)n2ncnc2c1";"SOADHZFGKVPPAW-UHFFFAOYSA-N";291.31;2.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4017311/target=_blank>CHEMBL4017311</a>";;-5.54;"Ahmed S, Ayscough A, Barker GR, Canning HE, Davenport R, Downham R, Harrison D, Jenkins K, Kinsella N, Livermore DG, Wright S, Ivetac AD, Skene R, Wilkens SJ, Webster NA, Hendrick AG.: 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000002884031503126606
"MM473373";"MM473373";"Nc1noc2c(N3CC[C@@H](NC(=O)c4ccc(-n5cnnc5)cc4Cl)C3)ncc(Cl)c12";"ICXQHMRMBVPXKN-SNVBAGLBSA-N";459.3;2.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-6.15;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.0000007079457843841374
"MM474269";"MM474269";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)c(Cl)ccc24)CCCN(c2cccc4c(C(=O)O)cccc24)C3=O)cc(C)c1Cl";"HHCOJLNHWQAODR-UHFFFAOYSA-N";709.67;9.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-5.36;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.000004365158322401657
"MM474584";"MM474584";"N#Cc1ccc(-c2cccc3ncnn23)cc1";"DEYMFBHALUHGST-UHFFFAOYSA-N";220.24;2.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4017311/target=_blank>CHEMBL4017311</a>";;-4.61;"Ahmed S, Ayscough A, Barker GR, Canning HE, Davenport R, Downham R, Harrison D, Jenkins K, Kinsella N, Livermore DG, Wright S, Ivetac AD, Skene R, Wilkens SJ, Webster NA, Hendrick AG.: 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. J Med Chem, Volume 60 (13), 2017";"PAMPA";0.000024547089156850286
"MM474593";"MM474593";"Cc1cc(C)cc(NC(=O)Cn2ccc(=O)c3ccc(Cl)cc32)c1";"QTFOFDPOIUPESS-UHFFFAOYSA-N";340.81;3.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.59;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.000025703957827688645
"MM473376";"MM473376";"Nc1noc2c(N3CC[C@@H](NC(=O)c4ccc(-n5cnnc5C(F)F)cc4Cl)C3)ncc(Cl)c12";"NIYMWAUKEZOKLD-SECBINFHSA-N";509.3;3.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-5.57;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.0000026915348039269138
"MM473368";"MM473368";"Cc1cccc(F)c1CN1C[C@H](c2cn(C)c3ccccc23)[C@@H](N(C)C)C1";"MJNFUMWCOKCILM-OFNKIYASSA-N";365.5;4.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4007113/target=_blank>CHEMBL4007113</a>";;-6;"Curtin ML, Pliushchev MA, Li HQ, Torrent M, Dietrich JD, Jakob CG, Zhu H, Zhao H, Wang Y, Ji Z, Clark RF, Sarris KA, Selvaraju S, Shaw B, Algire MA, He Y, Richardson PL, Sweis RF, Sun C, Chiang GG, Michaelides MR.: SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding. Bioorg Med Chem Lett, Volume 27 (7), 2017";"PAMPA";0.000001
"MM473390";"MM473390";"COc1ccc2c(c1)O[C@@H](c1cccc(C(=O)O)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1";"LSBRKYXIZOVMPC-IFMALSPDSA-N";523.49;5.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4022900/target=_blank>CHEMBL4022900</a>";;-4.84;"Wang X, Liu B, Searle X, Yeung C, Bogdan A, Greszler S, Singh A, Fan Y, Swensen AM, Vortherms T, Balut C, Jia Y, Desino K, Gao W, Yong H, Tse C, Kym P.: Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis. J Med Chem, Volume 61 (4), 2018";"PAMPA";0.00001445439770745928
"MM472781";"MM472781";"CCCc1nnc(/C=C/c2ccc(C3(C)c4ccc(O)cc4CCN3c3ccc(F)cc3)cc2)o1";"DEVIXBKKIXIWRM-FRKPEAEDSA-N";469.56;6.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.6;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.000025118864315095822
"MM474280";"MM474280";"Cc1cc2c(cc1N1C(=O)c3cccc4c(CCCO)ccc(c34)C1=O)n(C)c(=O)n2C";"OFWWWKWUCDUISA-UHFFFAOYSA-N";429.48;3.06;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4052887/target=_blank>CHEMBL4052887</a>";;-7.1;"Teuscher KB, Zhang M, Ji H.: A Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors. J Med Chem, Volume 60 (1), 2017";"PAMPA";0.00000007943282347242822
"MM474265";"MM474265";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)c(Cl)ccc24)CCCN(c2cc(C(=O)O)cc4c2ccn4C)C3=O)cc(C)c1Cl";"BDINUPBROUJUMH-UHFFFAOYSA-N";712.68;8.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-4.89;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.000012882495516931348
"MM473599";"MM473599";"O=C(Nc1cccc(C(F)(F)F)c1)NC1CCN(Cc2ccccc2)CC1";"MXZRHPHRSQJCML-UHFFFAOYSA-N";377.41;4.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-3.17;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.0006760829753919819
"MM473362";"MM473362";"CCCc1ccc(NC(=O)COc2cc(C)nc3ccc(OC)cc23)cc1";"LGSYHXLETJBVDD-UHFFFAOYSA-N";364.45;4.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003192/target=_blank>CHEMBL4003192</a>";;-5.89;"Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL, Subtil FT, Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P, Santos DS.: New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000001288249551693135
"MM473378";"MM473378";"Nc1noc2c(N3CC[C@@H](NC(=O)c4ccc(-n5cnc6ccccc65)cc4Cl)C3)ncc(Cl)c12";"ABEOONNPOGQYDK-CYBMUJFWSA-N";508.37;4.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-5.48;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.0000033113112148259077
"MM473417";"MM473417";"Cn1cc2c(cc1=O)OCCCCc1cc(Cl)ccc1Oc1ccc(CS(C)(=O)=O)cc1-2";"VQUNBKUXJFPQGY-UHFFFAOYSA-N";473.98;4.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-5.04;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.000009120108393559096
"MM473824";"MM473824";"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1";"LKJPYSCBVHEWIU-UHFFFAOYSA-N";430.38;2.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291553/target=_blank>CHEMBL1291553</a>";;-4.6;"Yoshino H, Sato H, Shiraishi T, Tachibana K, Emura T, Honma A, Ishikura N, Tsunenari T, Watanabe M, Nishimoto A, Nakamura R, Nakagawa T, Ohta M, Takata N, Furumoto K, Kimura K, Kawata H.: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg Med Chem, Volume 18 (23), 2010";"PAMPA";0.000025118864315095822
"MM474592";"MM474592";"COc1ccc2c(c1)c(=O)ccn2CC(=O)Nc1cc(C)cc(C)c1";"YTRZPZCTRHJQQJ-UHFFFAOYSA-N";336.39;3.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.72;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.000019054607179632484
"MM473396";"MM473396";"CC[C@@H]1C[C@H](CC)CN(CCCNC(=O)C2CCN(Cc3nc(-c4ccccc4C)oc3C)CC2)C1";"PLQAAWLLFZWOAD-PLQXJYEYSA-N";494.72;5.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-2.9;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.0012589254117941675
"MM474267";"MM474267";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)c(Cl)ccc24)CCCN(c2ccc(C(=O)O)c4ccn(C)c24)C3=O)cc(C)c1Cl";"BEMIPHFYAIZMHC-UHFFFAOYSA-N";712.68;8.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-5.32;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.00000478630092322638
"MM474585";"MM474585";"C[C@H]1OC(C)(C)C(=O)N(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)[C@H]1C";"HNKLUXSZXIDIAN-NWDGAFQWSA-N";458.44;3.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4024927/target=_blank>CHEMBL4024927</a>";;-4.18;"Marcoux D, Qin LY, Ruan Z, Shi Q, Ruan Q, Weigelt C, Qiu H, Schieven G, Hynes J, Bhide R, Poss M, Tino J.: Identification of highly potent and selective PI3KÎ´ inhibitors. Bioorg Med Chem Lett, Volume 27 (13), 2017";"PAMPA";0.00006606934480075965
"MM473392";"MM473392";"COc1cccc(Nc2cc(-c3cccc(-c4ccc(C(=O)O)cc4)c3)nc3c2C(=O)NCC3)c1";"CCHBMYVOWFLKLD-UHFFFAOYSA-N";465.51;5.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4038065/target=_blank>CHEMBL4038065</a>";;-5.46;"Roberts RS, Sevilla S, Ferrer M, Taltavull J, HernĂˇndez B, Segarra V, GrĂ cia J, Lehner MD, GavaldĂ  A, AndrĂ©s M, Cabedo J, Vilella D, Eichhorn P, Calama E, Carcasona C, Miralpeix M.: 4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.000003467368504525317
"MM474270";"MM474270";"COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(N2CCC(=O)NC2=O)cc1C(C)(C)C";"OQFYZQSEUGUAKQ-RMKNXTFCSA-N";471.58;3.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4028508/target=_blank>CHEMBL4028508</a>";;-6.04;"Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.: Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem, Volume 61 (3), 2018";"PAMPA";0.0000009120108393559096
"MM474277";"MM474277";"COc1c(CNc2ccc(NS(C)(=O)=O)cc2)cc(N2CCC(=O)NC2=O)cc1C(C)(C)C";"WATVRHVGYOGMIX-UHFFFAOYSA-N";474.58;3.42;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4028508/target=_blank>CHEMBL4028508</a>";;-6.39;"Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.: Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem, Volume 61 (3), 2018";"PAMPA";0.00000040738027780411303
"MM473375";"MM473375";"Nc1noc2c(N3CC[C@@H](NC(=O)c4ccc(-n5cnc(CCO)c5)cc4Cl)C3)ncc(Cl)c12";"BGGBGEFMFFHNBU-CYBMUJFWSA-N";502.36;2.84;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-5.8;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000001584893192461114
"MM472777";"MM472777";"CC1(c2ccc(/C=C/C(=O)NCCC(F)(F)F)cc2)c2ccc(O)cc2CCN1c1ccc(F)cc1";"IIMNFQHZEPVMPJ-YIXHJXPBSA-N";498.52;5.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.1;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00007943282347242822
"MM474599";"MM474599";"Cn1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1";"MRUMLWFTDYVUFL-LBPRGKRZSA-N";456.81;1.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4049106/target=_blank>CHEMBL4049106</a>";;-6.92;"Giroud M, Kuhn B, Saint-Auret S, Kuratli C, Martin RE, Schuler F, Diederich F, Kaiser M, Brun R, Schirmeister T, Haap W.: 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design. J Med Chem, Volume 61 (8), 2018";"PAMPA";0.00000012022644346174132
"MM473388";"MM473388";"COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1";"KDOQEEMQPHIANX-NFBKMPQASA-N";539.53;5.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4022900/target=_blank>CHEMBL4022900</a>";;-6.25;"Wang X, Liu B, Searle X, Yeung C, Bogdan A, Greszler S, Singh A, Fan Y, Swensen AM, Vortherms T, Balut C, Jia Y, Desino K, Gao W, Yong H, Tse C, Kym P.: Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis. J Med Chem, Volume 61 (4), 2018";"PAMPA";0.000000562341325190349
"MM474579";"MM474579";"CS(=O)(=O)N1CCO[C@H](c2csc(-c3cc(N4CCOCC4)ccc3NC(=O)c3ncc[nH]3)n2)C1";"WWTNLDQWEKRXNB-IBGZPJMESA-N";518.62;1.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4001913/target=_blank>CHEMBL4001913</a>";;-4.74;"Keung W, Boloor A, Brown J, Kiryanov A, Gangloff A, Lawson JD, Skene R, Hoffman I, Atienza J, Kahana J, De Jong R, Farrell P, Balakrishna D, Halkowycz P.: Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate. Bioorg Med Chem Lett, Volume 27 (4), 2017";"PAMPA";0.000018197008586099827
"MM473389";"MM473389";"O=C(NC1C[C@H](c2cccc(CO)c2)Oc2ccccc21)C1(c2ccc3c(c2)OC(F)(F)O3)CC1";"DGNDJPPKJOAWAC-GWQXNCQPSA-N";479.48;4.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4022900/target=_blank>CHEMBL4022900</a>";;-5.94;"Wang X, Liu B, Searle X, Yeung C, Bogdan A, Greszler S, Singh A, Fan Y, Swensen AM, Vortherms T, Balut C, Jia Y, Desino K, Gao W, Yong H, Tse C, Kym P.: Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis. J Med Chem, Volume 61 (4), 2018";"PAMPA";0.0000011481536214968817
"MM473363";"MM473363";"CCCCCc1ccc(NC(=O)COc2cc(C)nc3ccc(OC)cc23)cc1";"CIKXYXJJBOWGQD-UHFFFAOYSA-N";392.5;5.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003192/target=_blank>CHEMBL4003192</a>";;-5.77;"Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL, Subtil FT, Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P, Santos DS.: New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000001698243652461746
"MM473410";"MM473410";"CCS(=O)(=O)Nc1ccc2c(c1)-c1cn(C)c(=O)cc1OCCCCCc1cc(Cl)ccc1O2";"OXEPSQPFKZWCSV-UHFFFAOYSA-N";503.02;5.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-6.05;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.0000008912509381337459
"MM474262";"MM474262";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)c(Cl)ccc24)CCCN(Cc2cccc(C(=O)O)c2)C3=O)cc(C)c1Cl";"OUZJAEBUIMKQNH-UHFFFAOYSA-N";673.64;8.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-3.84;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.0001445439770745928
"MM473360";"MM473360";"COc1ccc2nc(C)cc(OCC(=O)Nc3ccc(C)c(C)c3)c2c1";"JOCYDTIBUFTHTA-UHFFFAOYSA-N";350.42;4.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003192/target=_blank>CHEMBL4003192</a>";;-5.23;"Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL, Subtil FT, Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P, Santos DS.: New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000005888436553555884
"MM473379";"MM473379";"Cn1cc(-c2ccc(C(=O)N[C@@H]3CCN(c4ncc(Cl)c5c(N)noc45)C3)c(Cl)c2)ccc1=O";"JQBSDZXMCJAJKM-CQSZACIVSA-N";499.36;3.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-5.19;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000006456542290346549
"MM473367";"MM473367";"CN(C)[C@H]1CN(Cc2c(F)cccc2Cl)C[C@@H]1c1cn(C)c2ccccc12";"SGJDIPHHTWORQM-VGSWGCGISA-N";385.91;4.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4007113/target=_blank>CHEMBL4007113</a>";;-6;"Curtin ML, Pliushchev MA, Li HQ, Torrent M, Dietrich JD, Jakob CG, Zhu H, Zhao H, Wang Y, Ji Z, Clark RF, Sarris KA, Selvaraju S, Shaw B, Algire MA, He Y, Richardson PL, Sweis RF, Sun C, Chiang GG, Michaelides MR.: SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding. Bioorg Med Chem Lett, Volume 27 (7), 2017";"PAMPA";0.000001
"MM473404";"MM473404";"CCCN(CCC)CCNC(=O)C1CCN(Cc2nc(-c3ccccc3C)oc2C)CC1";"DKIVYPAUNSOQKJ-UHFFFAOYSA-N";440.63;4.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.04;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.0009120108393559096
"MM473380";"MM473380";"Cc1ncn(-c2ccc(C(=O)N[C@H]3[C@H]4CC[C@H]3N(c3ncc(Cl)c5cnoc35)C4)c(Cl)c2)n1";"PQCRELQHENQSGP-RQUSPXKASA-N";484.35;3.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-5.19;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000006456542290346549
"MM472787";"MM472787";"CCN(Cc1cccs1)C(=O)COc1ccc(C)cc1";"AUKQNHDSDFEBNH-UHFFFAOYSA-N";289.4;3.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4056651/target=_blank>CHEMBL4056651</a>";;-5.12;"Noncovich A, Priest C, Ung J, Patron AP, Servant G, Brust P, Servant N, Faber N, Liu H, Gonsalves NS, Ditschun TL.: Discovery and development of a novel class of phenoxyacetyl amides as highly potent TRPM8 agonists for use as cooling agents. Bioorg Med Chem Lett, Volume 27 (16), 2017";"PAMPA";0.000007585775750291836
"MM473397";"MM473397";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCN3CCC(C(C)C)CC3)CC2)c(C)o1";"HWFAQTCAZQTURK-UHFFFAOYSA-N";480.7;5.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.4;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.00039810717055349735
"MM474590";"MM474590";"COc1ccc2nc(C)nc(OCC(=O)Nc3cc(C)cc(C)c3)c2c1";"WMNNLXLWKSYDQY-UHFFFAOYSA-N";351.41;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.43;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.00003715352290971728
"MM474275";"MM474275";"COc1c(NC(=O)c2ccc(NS(C)(=O)=O)cc2)cc(N2CCC(=O)NC2=O)cc1C(C)(C)C";"TWBYUOROLUMUTB-UHFFFAOYSA-N";488.57;3.06;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4028508/target=_blank>CHEMBL4028508</a>";;-6.66;"Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.: Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. J Med Chem, Volume 61 (3), 2018";"PAMPA";0.0000002187761623949552
"MM473412";"MM473412";"CCS(=O)(=O)Nc1ccc2c(c1)-c1cn(C)c(=O)cc1OCCCCc1cc(F)cc(F)c1O2";"BYFSQAHWOPJWRA-UHFFFAOYSA-N";490.53;4.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4051120/target=_blank>CHEMBL4051120</a>";;-5.17;"Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.: Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. J Med Chem, Volume 60 (9), 2017";"PAMPA";0.000006760829753919819
"MM472784";"MM472784";"CC1(c2ccc(/C=C/C(=O)O)cc2)c2ccc(O)cc2CCN1c1cccc(F)c1";"UMFRQAXNRHZJGG-KPKJPENVSA-N";403.45;4.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.3;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00005011872336272725
"MM472775";"MM472775";"CNC(=O)/C=C/c1ccc(C2(C)c3ccc(O)cc3CCN2c2ccc(F)cc2)cc1";"OKYJZTJSOYPGON-LHHJGKSTSA-N";416.5;4.62;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.3;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00005011872336272725
"MM472785";"MM472785";"CC(C)c1ccc(N2CCc3cc(O)ccc3C2(C)c2ccc(/C=C/C(=O)O)cc2)cc1";"HKXVKUOGCLJVEZ-GIDUJCDVSA-N";427.54;5.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.1;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00007943282347242822
"MM473381";"MM473381";"Nc1noc2c(N3CC[C@@H](NC(=O)c4ccc(-c5cncnc5)cc4Cl)C3)ncc(Cl)c12";"TUNLMVOWHTWZFQ-CYBMUJFWSA-N";470.32;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4018087/target=_blank>CHEMBL4018087</a>";;-5.03;"Sakurada I, Endo T, Hikita K, Hirabayashi T, Hosaka Y, Kato Y, Maeda Y, Matsumoto S, Mizuno T, Nagasue H, Nishimura T, Shimada S, Shinozaki M, Taguchi K, Takeuchi K, Yokoyama T, Hruza A, Reichert P, Zhang T, Wood HB, Nakao K, Furusako S.: Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorg Med Chem Lett, Volume 27 (11), 2017";"PAMPA";0.000009332543007969906
"MM474268";"MM474268";"Cc1cc(OCCCc2c3n(c4c(-c5c(C)nn(C)c5C)c(Cl)ccc24)CCCN(c2ccc(C(=O)O)c4cccnc24)C3=O)cc(C)c1Cl";"QEACFIZDFCDWRW-UHFFFAOYSA-N";710.66;8.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4023197/target=_blank>CHEMBL4023197</a>";;-3.91;"Shaw S, Bian Z, Zhao B, Tarr JC, Veerasamy N, Jeon KO, Belmar J, Arnold AL, Fogarty SA, Perry E, Sensintaffar JL, Camper DV, Rossanese OW, Lee T, Olejniczak ET, Fesik SW.: Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. J Med Chem, Volume 61 (6), 2018";"PAMPA";0.0001230268770812381
"MM474594";"MM474594";"Cc1cc(C)cc(NC(=O)Cn2cnc3ccccc3c2=O)c1";"YZMIDTZJJQYTOU-UHFFFAOYSA-N";307.35;2.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4042140/target=_blank>CHEMBL4042140</a>";;-4.22;"Pitta E, Balabon O, Rogacki MK, GĂłmez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.: Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. Eur J Med Chem, Volume 125, 2017";"PAMPA";0.000060255958607435806
"MM473394";"MM473394";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCCN3C[C@H](C)C[C@H](C)C3)CC2)c(C)o1";"MRHJNIMUABLZHR-OYRHEFFESA-N";466.67;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.31;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.0004897788193684461
"MM473402";"MM473402";"Cc1ccccc1-c1nc(CN2CCC(C(=O)NCCN3C[C@H](C)C[C@H](C)C3)CC2)c(C)o1";"ZHMMOUICWIIUEV-BGYRXZFFSA-N";452.64;4.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4039805/target=_blank>CHEMBL4039805</a>";;-3.15;"He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, AubĂ© J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.: Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. J Med Chem, Volume 60 (14), 2017";"PAMPA";0.000707945784384138
"MM472778";"MM472778";"CC1(c2ccc(/C=C/c3cnc[nH]3)cc2)c2ccc(O)cc2CCN1c1ccc(F)cc1";"UQIDNBSEVKFIRB-RUDMXATFSA-N";425.51;5.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.8;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.00001584893192461114
"MM472782";"MM472782";"CC1(c2ccc(/C=C/c3nnc(CO)o3)cc2)c2ccc(O)cc2CCN1c1ccc(F)cc1";"JAWIDLAPCJNQSQ-YIXHJXPBSA-N";457.51;4.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4011153/target=_blank>CHEMBL4011153</a>";;-4.6;"Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.: Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERÎ±+ Breast Cancer. J Med Chem, Volume 60 (7), 2017";"PAMPA";0.000025118864315095822
"MM473359";"MM473359";"COc1ccc2nc(C)cc(OCC(=O)Nc3ccc4c(c3)CCC4)c2c1";"CKUSRNPVQNVNBP-UHFFFAOYSA-N";362.43;4.06;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4003192/target=_blank>CHEMBL4003192</a>";;-4.88;"Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL, Subtil FT, Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P, Santos DS.: New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. Eur J Med Chem, Volume 126, 2017";"PAMPA";0.000013182567385564074
"MM473822";"MM473822";"C[C@]12C[C@@]34C=CC(=O)[C@@](C)(CCC(=O)Nc5c(O)ccc(C(=O)O)c5O)[C@@H]3[C@H](C[C@@H]1C4)O2";"CSOMAHTTWTVBFL-OFBLZTNGSA-N";441.48;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3997472/target=_blank>CHEMBL3997472</a>";;-6.89;"Dong LB, Rudolf JD, Lin L, Ruiz C, Cameron MD, Shen B.: In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin. Bioorg Med Chem, Volume 25 (6), 2017";"PAMPA";0.00000012882495516931348
"MM473463";"MM473463";"CC1(C)c2cccc(C(=O)NO)c2CN1c1cnc(C(F)(F)F)cn1";"XCLPBILTRRWOIL-UHFFFAOYSA-N";352.32;2.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4123083/target=_blank>CHEMBL4123083</a>";;-4.89;"Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.: Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.000012882495516931348
"MM473456";"MM473456";"CC1(C)c2cccc(C(=O)NO)c2CN1c1nc2ccc(C(F)(F)F)cc2[nH]1";"ASSXNRYAUYXUGB-UHFFFAOYSA-N";390.37;3.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4123083/target=_blank>CHEMBL4123083</a>";;-7;"Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.: Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.0000001
"MM473460";"MM473460";"CC1(C)c2cccc(C(=O)NO)c2CN1c1ccc(C(F)(F)F)nc1";"IAFXYBQUVZBTAG-UHFFFAOYSA-N";351.33;3.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4123083/target=_blank>CHEMBL4123083</a>";;-5.1;"Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.: Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.000007943282347242822
"MM473461";"MM473461";"CC1(C)c2cccc(C(=O)NO)c2CN1c1ncc(C(F)(F)F)cn1";"BDILQALLYCHDBI-UHFFFAOYSA-N";352.32;2.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4123083/target=_blank>CHEMBL4123083</a>";;-4.74;"Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.: Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.000018197008586099827
"MM473458";"MM473458";"CC1(C)c2cccc(C(=O)NO)c2CN1c1nc2ncccc2o1";"PLKUOGQAYYNHLT-UHFFFAOYSA-N";324.34;2.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4123083/target=_blank>CHEMBL4123083</a>";;-6.15;"Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.: Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.0000007079457843841374
"MM473459";"MM473459";"CC1(C)c2cccc(C(=O)NO)c2CN1c1ccc(C(F)(F)F)cn1";"LKTXDGRWJDTGPL-UHFFFAOYSA-N";351.33;3.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4123083/target=_blank>CHEMBL4123083</a>";;-4.92;"Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.: Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.000012022644346174132
"MM473462";"MM473462";"CC1(C)c2cccc(C(N)=O)c2CN1c1cnc(C(F)(F)F)cn1";"WTZJBEDUYUCGGN-UHFFFAOYSA-N";336.32;2.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4123083/target=_blank>CHEMBL4123083</a>";;-4.77;"Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.: Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.00001698243652461746
"MM472803";"MM472803";"Nc1cccnc1N1CCC(C(=O)Nc2ccc(-n3nccn3)c(Cl)c2)CC1";"DECWMEUVVFELTP-UHFFFAOYSA-N";397.87;2.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4122933/target=_blank>CHEMBL4122933</a>";;-4.4;"Schlapbach A, Revesz L, Pissot Soldermann C, Zoller T, RĂ©gnier CH, Bornancin F, Radimerski T, Blank J, Schuffenhauer A, Renatus M, Erbel P, Melkko S, Heng R, Simic O, Endres R, Wartmann M, Quancard J.: N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.000039810717055349695
"MM473457";"MM473457";"CC1(C)c2cccc(C(=O)NO)c2CN1c1nc2cc(C(F)(F)F)ccc2o1";"ONXUVVDDBCZNTM-UHFFFAOYSA-N";391.35;4.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4123083/target=_blank>CHEMBL4123083</a>";;-5.15;"Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.: Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett, Volume 28 (12), 2018";"PAMPA";0.000007079457843841373
"MM473468";"MM473468";"CS(=O)(=O)CCCn1c(Cn2nc(S(C)(=O)=O)c3ccccc32)nc2cc(Cl)ccc21";"JVMZBPJCKHAIMJ-UHFFFAOYSA-N";481;2.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.56;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.000002754228703338169
"MM474314";"MM474314";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3ccccn3)cc21";"FEKVOIYCAPBRPC-UHFFFAOYSA-N";375.38;4.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-5.66;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.0000021877616239495517
"MM474306";"MM474306";"Cc1cc(C)cc(Oc2ccc3nc(COc4cccc(C(=O)O)c4)n(C)c3n2)c1";"CUMFGWIRHJJSSZ-UHFFFAOYSA-N";403.44;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.76;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000017378008287493764
"MM474321";"MM474321";"Cc1ccc2nc(N3CCCc4ccc(F)cc4C3)cc(NCCO)c2c1";"GVLXAEVMZNYKHZ-UHFFFAOYSA-N";365.45;4.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4158586/target=_blank>CHEMBL4158586</a>";;-5.82;"Zheng X, Liang C, Wang L, Wang B, Liu Y, Feng S, Wu JZ, Gao L, Feng L, Chen L, Guo T, Shen HC, Yun H.: Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. J Med Chem, Volume 61 (22), 2018";"PAMPA";0.0000015135612484362072
"MM474637";"MM474637";"Cn1cc(-c2ccc(N(C(=O)NCc3ccccc3)[C@H]3CC[C@H](Nc4ccc(C#N)cn4)CC3)cc2)ccc1=O";"HDJBGURZVALLMD-KWQFAZJVSA-N";532.65;5.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4151503/target=_blank>CHEMBL4151503</a>";;-4.56;"Ito M, Tanaka T, Toita A, Uchiyama N, Kokubo H, Morishita N, Klein MG, Zou H, Murakami M, Kondo M, Sameshima T, Araki S, Endo S, Kawamoto T, Morin GB, Aparicio SA, Nakanishi A, Maezaki H, Imaeda Y.: Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors. J Med Chem, Volume 61 (17), 2018";"PAMPA";0.00002754228703338169
"MM473466";"MM473466";"CS(=O)(=O)CCCn1c(Cn2cc(S(C)(=O)=O)c3ccccc32)nc2cc(Cl)ccc21";"PXXRWCSUEXLSQD-UHFFFAOYSA-N";480.01;3.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.81;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000015488166189124828
"MM474301";"MM474301";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3ccc(Cl)c(F)c3)nc21";"SVZOKVCQNVFKPF-UHFFFAOYSA-N";427.82;4.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.59;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000025703957827688645
"MM473471";"MM473471";"CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CCCCO)c2cnccc12";"CCEVTLUASIOTJJ-UHFFFAOYSA-N";433.92;2.66;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.62;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000023988329190194897
"MM474636";"MM474636";"N[C@H]1CC[C@@H](N(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1";"HMEWDDRNEULPCX-LWSSLDFYSA-N";390.58;3.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4144850/target=_blank>CHEMBL4144850</a>";;-6;"Jecs E, Miller EJ, Wilson RJ, Nguyen HH, Tahirovic YA, Katzman BM, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. ACS Med Chem Lett, Volume 9 (2), 2018";"PAMPA";0.000001
"MM474305";"MM474305";"Cc1ccc(Oc2ccc3nc(COc4cccc(C(=O)O)c4)n(C)c3n2)c(C)c1";"ATVMATMJVBIANN-UHFFFAOYSA-N";403.44;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.54;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000028840315031266056
"MM474319";"MM474319";"NCCNc1cc(N2CCCc3ccccc3C2)nc2ccccc12";"JUWZQBRMSFXSPH-UHFFFAOYSA-N";332.45;3.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4158586/target=_blank>CHEMBL4158586</a>";;-6;"Zheng X, Liang C, Wang L, Wang B, Liu Y, Feng S, Wu JZ, Gao L, Feng L, Chen L, Guo T, Shen HC, Yun H.: Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. J Med Chem, Volume 61 (22), 2018";"PAMPA";0.000001
"MM474308";"MM474308";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3ccc4c(c3)CCC4)nc21";"ZNQAYBXPYCPXSY-UHFFFAOYSA-N";415.45;4.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.5;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000031622776601683795
"MM473490";"MM473490";"CNC(=O)Nc1ccc2c(c1)CC[C@]21NC(=O)N(CC(=O)N(Cc2ccccc2)[C@@H](C)C2CC2)C1=O";"LVVCZEJBVPEPGJ-SOKVYYICSA-N";489.58;2.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4144320/target=_blank>CHEMBL4144320</a>";;-6.33;"Michaelides MR, Kluge A, Patane M, Van Drie JH, Wang C, Hansen TM, Risi RM, Mantei R, Hertel C, Karukurichi K, Nesterov A, McElligott D, de Vries P, Langston JW, Cole PA, Marmorstein R, Liu H, Lasko L, Bromberg KD, Lai A, Kesicki EA.: Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases. ACS Med Chem Lett, Volume 9 (1), 2018";"PAMPA";0.0000004677351412871981
"MM472818";"MM472818";"C[C@H](Oc1ncc(NC(=O)Cc2ccncc2)cc1Cl)c1ccccc1";"IQFACHIXVNTGSA-AWEZNQCLSA-N";367.84;4.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4137938/target=_blank>CHEMBL4137938</a>";;-3.7;"Carcache DA, Vulpetti A, Kallen J, Mattes H, Orain D, Stringer R, Vangrevelinghe E, Wolf RM, Kaupmann K, Ottl J, Dawson J, Cooke NG, Hoegenauer K, Billich A, Wagner J, Guntermann C, Hintermann S.: Optimizing a Weakly Binding Fragment into a Potent RORÎłt Inverse Agonist with Efficacy in an in Vivo Inflammation Model. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.00019952623149688788
"MM473470";"MM473470";"CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CCCO)c2cnccc12";"ZHBRVCZEHASCGY-UHFFFAOYSA-N";419.89;2.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.46;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.000003467368504525317
"MM473137";"MM473137";"NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCN=C(N)N";"CJPRHIHRLZZAPV-SZMVWBNQSA-N";515.62;-2.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-5.63;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.0000023442288153199226
"MM474299";"MM474299";"Cc1cnc(Oc2ccc3nc(COc4cccc(C(=O)O)c4)n(C)c3c2)c(C)c1";"GEGLFSVXCSGSOB-UHFFFAOYSA-N";403.44;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.89;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000012882495516931348
"MM474300";"MM474300";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3ccc(Cl)c(F)c3)cc21";"QCDBYUFGXWPSLV-UHFFFAOYSA-N";426.83;5.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.41;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000038904514499428046
"MM474630";"MM474630";"FC1(F)CCC(NC/C=C\CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1";"UOJYAHYPXYXUMQ-DKGWXTDUSA-N";480.65;5.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4144849/target=_blank>CHEMBL4144849</a>";;-5.89;"Jecs E, Miller EJ, Wilson RJ, Nguyen HH, Tahirovic YA, Katzman BM, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. ACS Med Chem Lett, Volume 9 (2), 2018";"PAMPA";0.000001288249551693135
"MM474320";"MM474320";"Cc1ccc2nc(N3CCS(=O)(=O)c4ccccc4C3)cc(NCCN)c2c1";"MAEZLZJVRSSWHN-UHFFFAOYSA-N";396.52;2.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4158586/target=_blank>CHEMBL4158586</a>";;-6.92;"Zheng X, Liang C, Wang L, Wang B, Liu Y, Feng S, Wu JZ, Gao L, Feng L, Chen L, Guo T, Shen HC, Yun H.: Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. J Med Chem, Volume 61 (22), 2018";"PAMPA";0.00000012022644346174132
"MM473476";"MM473476";"CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CCC(F)(F)F)c2cnccc12";"FRIWQLZYNOSZMX-UHFFFAOYSA-N";457.87;3.84;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.55;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.000002818382931264455
"MM474303";"MM474303";"Cc1ccc(Oc2ccc3nc(COc4cccc(C(=O)O)c4)n(C)c3n2)cc1";"ADEWPQIVNWFIED-UHFFFAOYSA-N";389.41;4.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.9;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000012589254117941661
"MM473489";"MM473489";"CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccccc2)[C@@H](C)C2CC2)C1=O";"DREXABSQFKJHIP-CBZJRKILSA-N";490.56;3.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4144320/target=_blank>CHEMBL4144320</a>";;-5.63;"Michaelides MR, Kluge A, Patane M, Van Drie JH, Wang C, Hansen TM, Risi RM, Mantei R, Hertel C, Karukurichi K, Nesterov A, McElligott D, de Vries P, Langston JW, Cole PA, Marmorstein R, Liu H, Lasko L, Bromberg KD, Lai A, Kesicki EA.: Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases. ACS Med Chem Lett, Volume 9 (1), 2018";"PAMPA";0.0000023442288153199226
"MM474313";"MM474313";"Cn1c(COc2cccc(C(=O)O)c2)nc2cnc(Oc3ccc4c(c3)CCC4)cc21";"ZMUIWKSDUAMTTO-UHFFFAOYSA-N";415.45;4.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.78;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000016595869074375598
"MM474310";"MM474310";"Cn1c(COc2cccc(C(=O)O)c2)nc2cnc(Oc3ccc(Cl)c(F)c3)cc21";"BHXRPIJAPPYOTD-UHFFFAOYSA-N";427.82;4.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.95;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.00001122018454301963
"MM474635";"MM474635";"NCC1=C(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CCCC1";"HCZHUJUTBCLSTK-FTJBHMTQSA-N";416.61;4.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4144850/target=_blank>CHEMBL4144850</a>";;-4.77;"Jecs E, Miller EJ, Wilson RJ, Nguyen HH, Tahirovic YA, Katzman BM, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. ACS Med Chem Lett, Volume 9 (2), 2018";"PAMPA";0.00001698243652461746
"MM473494";"MM473494";"Cc1ccn2nc([C@H](C)Nc3ncnc4[nH]cc(-c5cc(NS(C)(=O)=O)cc6[nH]ccc56)c34)n(-c3ccccc3)c(=O)c12";"KHJNCYCXAKBENU-SFHVURJKSA-N";593.67;4.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4158785/target=_blank>CHEMBL4158785</a>";;-6.7;"Erra M, Taltavull J, Bernal FJ, Caturla JF, Carrascal M, PagĂ¨s L, Mir M, Espinosa S, GrĂ cia J, DomĂ­nguez M, SabatĂ© M, Paris S, Maldonado M, HernĂˇndez B, Bravo M, Calama E, Miralpeix M, Lehner MD, Calbet M.: Discovery of a Novel Inhaled PI3KÎ´ Inhibitor for the Treatment of Respiratory Diseases. J Med Chem, Volume 61 (21), 2018";"PAMPA";0.00000019952623149688787
"MM474307";"MM474307";"Cc1ccc(Oc2ccc3nc(COc4cccc(C(=O)O)c4)n(C)c3n2)cc1C";"IXIHCRICOXHXQT-UHFFFAOYSA-N";403.44;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.91;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.00001230268770812381
"MM473464";"MM473464";"CS(=O)(=O)CCn1c(Cn2cc(S(C)(=O)=O)c3ccccc32)nc2cc(Cl)ccc21";"RVWSPSOEJVDDPF-UHFFFAOYSA-N";465.98;3.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.64;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000022908676527677747
"MM474317";"MM474317";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3cc(Cl)ccn3)cc21";"QTICEWFECZQHII-UHFFFAOYSA-N";409.83;4.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.99;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000010232929922807536
"MM473475";"MM473475";"CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CCC(O)C(F)(F)F)c2cnccc12";"IBCACDUJLGHIGJ-UHFFFAOYSA-N";487.89;3.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.37;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.000004265795188015926
"MM474627";"MM474627";"C/C(CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)=C(/F)CN";"MLQQKXMYXPIYTH-XXGJDRSASA-N";394.54;3.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4144849/target=_blank>CHEMBL4144849</a>";;-4.15;"Jecs E, Miller EJ, Wilson RJ, Nguyen HH, Tahirovic YA, Katzman BM, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. ACS Med Chem Lett, Volume 9 (2), 2018";"PAMPA";0.00007079457843841373
"MM473477";"MM473477";"CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CCCCC(F)(F)F)c2cnccc12";"WCMRGMBGNDBJFG-UHFFFAOYSA-N";485.92;4.62;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-6.02;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000009549925860214369
"MM474315";"MM474315";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3cccc(Cl)n3)cc21";"YWSJFUQEEQUFAT-UHFFFAOYSA-N";409.83;4.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-5.12;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000007585775750291836
"MM474633";"MM474633";"N[C@H]1CC[C@H](CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1";"GSKIEMCFCQSCTJ-KXMWUTRISA-N";404.6;3.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4144849/target=_blank>CHEMBL4144849</a>";;-5.92;"Jecs E, Miller EJ, Wilson RJ, Nguyen HH, Tahirovic YA, Katzman BM, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. ACS Med Chem Lett, Volume 9 (2), 2018";"PAMPA";0.0000012022644346174132
"MM473465";"MM473465";"CS(=O)(=O)CCn1c(Cn2cc(S(C)(=O)=O)c3ccccc32)nc2ccccc21";"BTQIICSIWXXENL-UHFFFAOYSA-N";431.54;2.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.31;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.000004897788193684467
"MM473472";"MM473472";"CC(C)(O)CCn1c(Cn2nc(S(C)(=O)=O)c3ccncc32)nc2cc(Cl)ccc21";"ONOKYKSBUJAQHT-UHFFFAOYSA-N";447.95;3.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.62;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000023988329190194897
"MM474639";"MM474639";"N#Cc1ccc(N[C@H]2CC[C@H](N(C(=O)NCc3ccccc3)c3ccc(-c4cccnc4)cc3)CC2)nc1";"QQIVUNFCAOZJSD-KWQFAZJVSA-N";502.62;6.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4151503/target=_blank>CHEMBL4151503</a>";;-4.55;"Ito M, Tanaka T, Toita A, Uchiyama N, Kokubo H, Morishita N, Klein MG, Zou H, Murakami M, Kondo M, Sameshima T, Araki S, Endo S, Kawamoto T, Morin GB, Aparicio SA, Nakanishi A, Maezaki H, Imaeda Y.: Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors. J Med Chem, Volume 61 (17), 2018";"PAMPA";0.00002818382931264455
"MM474304";"MM474304";"Cc1ccc(Oc2ccc3nc(COc4cccc(C(=O)O)c4)n(C)c3n2)cc1F";"JQXZOYWNDOHYKA-UHFFFAOYSA-N";407.4;4.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.83;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000014791083881682072
"MM474638";"MM474638";"Cn1cc(-c2ccc(N(C(=O)NCc3ccccc3)[C@H]3CC[C@H](Nc4ccc(C#N)cn4)CC3)cc2)cn1";"KHMZQQYEYPDOBI-FBSWEULCSA-N";505.63;5.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4151503/target=_blank>CHEMBL4151503</a>";;-4.54;"Ito M, Tanaka T, Toita A, Uchiyama N, Kokubo H, Morishita N, Klein MG, Zou H, Murakami M, Kondo M, Sameshima T, Araki S, Endo S, Kawamoto T, Morin GB, Aparicio SA, Nakanishi A, Maezaki H, Imaeda Y.: Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors. J Med Chem, Volume 61 (17), 2018";"PAMPA";0.000028840315031266056
"MM473474";"MM473474";"CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CCOCCO)c2cnccc12";"LQPNESYHCCMBLU-UHFFFAOYSA-N";449.92;1.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.51;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.000003090295432513592
"MM474309";"MM474309";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3ccc4c(c3)OCC4)nc21";"ZECLUEQHECZEQQ-UHFFFAOYSA-N";417.42;3.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-5.04;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000009120108393559096
"MM473469";"MM473469";"CS(=O)(=O)CCCn1c(Cn2nc(S(C)(=O)=O)c3ccncc32)nc2cc(Cl)ccc21";"CKZJUYRQRNRQHH-UHFFFAOYSA-N";481.99;2.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.81;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000015488166189124828
"MM474323";"MM474323";"Cc1ccc2nc(N3CCCc4ccc(F)cc4C3)cc(NCC3(N)COC3)c2c1";"BNHKKAWGNKMZHC-UHFFFAOYSA-N";406.51;3.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4158586/target=_blank>CHEMBL4158586</a>";;-6.14;"Zheng X, Liang C, Wang L, Wang B, Liu Y, Feng S, Wu JZ, Gao L, Feng L, Chen L, Guo T, Shen HC, Yun H.: Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. J Med Chem, Volume 61 (22), 2018";"PAMPA";0.0000007244359600749906
"MM474640";"MM474640";"Cn1ccc(-c2ccc(N(C(=O)NCc3ccccc3)[C@H]3CC[C@H](Nc4ccc(C#N)cn4)CC3)cc2)cc1=O";"GXGRNWVRDQTYLG-KWQFAZJVSA-N";532.65;5.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4151503/target=_blank>CHEMBL4151503</a>";;-4.61;"Ito M, Tanaka T, Toita A, Uchiyama N, Kokubo H, Morishita N, Klein MG, Zou H, Murakami M, Kondo M, Sameshima T, Araki S, Endo S, Kawamoto T, Morin GB, Aparicio SA, Nakanishi A, Maezaki H, Imaeda Y.: Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors. J Med Chem, Volume 61 (17), 2018";"PAMPA";0.000024547089156850286
"MM474312";"MM474312";"Cn1c(COc2cccc(C(=O)O)c2)nc2cnc(Oc3ccc4c(c3)OCC4)cc21";"HGLUSLQAEOTCFZ-UHFFFAOYSA-N";417.42;3.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-5.44;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.0000036307805477010103
"MM472819";"MM472819";"CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1";"VMHNMQCWPLURSW-INIZCTEOSA-N";458.97;4.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4137938/target=_blank>CHEMBL4137938</a>";;-4.2;"Carcache DA, Vulpetti A, Kallen J, Mattes H, Orain D, Stringer R, Vangrevelinghe E, Wolf RM, Kaupmann K, Ottl J, Dawson J, Cooke NG, Hoegenauer K, Billich A, Wagner J, Guntermann C, Hintermann S.: Optimizing a Weakly Binding Fragment into a Potent RORÎłt Inverse Agonist with Efficacy in an in Vivo Inflammation Model. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.00006309573444801929
"MM473467";"MM473467";"CN(C)S(=O)(=O)c1cn(Cc2nc3cc(Cl)ccc3n2CCCS(C)(=O)=O)c2ccccc12";"KXEBAHZXFYBNHJ-UHFFFAOYSA-N";509.05;3.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.81;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000015488166189124828
"MM474629";"MM474629";"C/C(CN)=C(/F)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21";"VUKMAAVKUIIBCS-XXGJDRSASA-N";394.54;3.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4144849/target=_blank>CHEMBL4144849</a>";;-4.66;"Jecs E, Miller EJ, Wilson RJ, Nguyen HH, Tahirovic YA, Katzman BM, Truax VM, Kim MB, Kuo KM, Wang T, Sum CS, Cvijic ME, Schroeder GM, Wilson LJ, Liotta DC.: Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. ACS Med Chem Lett, Volume 9 (2), 2018";"PAMPA";0.00002187761623949552
"MM473473";"MM473473";"CC(C)(O)CCCn1c(Cn2nc(S(C)(=O)=O)c3ccncc32)nc2cc(Cl)ccc21";"XPHPTPUAKPYADB-UHFFFAOYSA-N";461.98;3.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.59;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.0000025703957827688647
"MM474302";"MM474302";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3ccc(F)cc3)nc21";"QDNCSUMDZIPGHG-UHFFFAOYSA-N";393.37;4.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-5.07;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.00000851138038202376
"MM474322";"MM474322";"Cc1ccc2nc(N3CCCc4ccc(F)cc4C3)cc(NC3(CN)COC3)c2c1";"LDHDNVRPASCZTE-UHFFFAOYSA-N";406.51;3.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4158586/target=_blank>CHEMBL4158586</a>";;-6.23;"Zheng X, Liang C, Wang L, Wang B, Liu Y, Feng S, Wu JZ, Gao L, Feng L, Chen L, Guo T, Shen HC, Yun H.: Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. J Med Chem, Volume 61 (22), 2018";"PAMPA";0.0000005888436553555884
"MM474316";"MM474316";"Cn1c(COc2cccc(C(=O)O)c2)nc2ccc(Oc3ccc(Cl)cn3)cc21";"WNNQSUDKRDMZHR-UHFFFAOYSA-N";409.83;4.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-4.79;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.0000162181009735893
"MM473493";"MM473493";"Cc1ccn2nc([C@H](C)Nc3ncnc(N)c3-c3ccc(O)c(F)c3)n(-c3ccccc3)c(=O)c12";"IZHWRLKLKIUFPI-HNNXBMFYSA-N";471.5;3.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4158785/target=_blank>CHEMBL4158785</a>";;-5.77;"Erra M, Taltavull J, Bernal FJ, Caturla JF, Carrascal M, PagĂ¨s L, Mir M, Espinosa S, GrĂ cia J, DomĂ­nguez M, SabatĂ© M, Paris S, Maldonado M, HernĂˇndez B, Bravo M, Calama E, Miralpeix M, Lehner MD, Calbet M.: Discovery of a Novel Inhaled PI3KÎ´ Inhibitor for the Treatment of Respiratory Diseases. J Med Chem, Volume 61 (21), 2018";"PAMPA";0.000001698243652461746
"MM474311";"MM474311";"Cc1ccc(Oc2cc3c(cn2)nc(COc2cccc(C(=O)O)c2)n3C)cc1";"QMSODTPQJKTFTH-UHFFFAOYSA-N";389.41;4.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4157977/target=_blank>CHEMBL4157977</a>";;-5.17;"Shinozuka T, Tsukada T, Fujii K, Tokumaru E, Shimada K, Onishi Y, Matsui Y, Wakimoto S, Kuroha M, Ogata T, Araki K, Ohsumi J, Sawamura R, Watanabe N, Yamamoto H, Fujimoto K, Tani Y, Mori M, Tanaka J.: Discovery of DS-6930, a potent selective PPARÎł modulator. Part II: Lead optimization. Bioorg Med Chem, Volume 26 (18), 2018";"PAMPA";0.000006760829753919819
"MM473478";"MM473478";"CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CC2COC2)c2cnccc12";"JCRHWUFAMLOIEZ-UHFFFAOYSA-N";431.91;2.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4132438/target=_blank>CHEMBL4132438</a>";;-5.49;"Feng S, Li C, Chen D, Zheng X, Yun H, Gao L, Shen HC.: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. Eur J Med Chem, Volume 138, 2017";"PAMPA";0.000003235936569296281
"MM472822";"MM472822";"Nc1ncnc2c1ncn2CCOC(=O)c1ccc(S(=O)(=O)F)cc1";"AIKXDIFYOJHYOB-UHFFFAOYSA-N";365.35;0.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-5.47;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.0000033884415613920275
"MM472854";"MM472854";"COC(=O)c1cccc(OCc2oc(-c3ccccc3OC)nc2C)c1";"BCWHVDGZTARFIJ-UHFFFAOYSA-N";353.37;4.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.42;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00038018939632056124
"MM473512";"MM473512";"CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C(F)F)cc5)cnc4cn3)cc2)CC1";"ZLXQWGHPSCNGQC-UHFFFAOYSA-N";447.49;4.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.12;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00007585775750291836
"MM472838";"MM472838";"COc1cccc(-c2nc(C)c(COc3ccc(C(=O)O)cc3)o2)c1";"WLLPOQTXQFZNGT-UHFFFAOYSA-N";339.35;3.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.77;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00016982436524617443
"MM473502";"MM473502";"CN1CCN(c2ccc(CNc3nc(N4CCOCC4)nc4c3ncn4-c3cccc(F)c3)cc2)CC1";"SWBOENCRQCSBMY-UHFFFAOYSA-N";502.6;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4187220/target=_blank>CHEMBL4187220</a>";;-6.52;"Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.: Development of dual casein kinase 1Î´/1Îµ (CK1Î´/Îµ) inhibitors for treatment of breast cancer. Bioorg Med Chem, Volume 26 (3), 2018";"PAMPA";0.0000003019951720402019
"MM474657";"MM474657";"COc1cc2c(NCC3CCN(C(C)C)CC3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"ZAWYCUBKBPHGBY-UHFFFAOYSA-N";520.72;6.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.72;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000019054607179632483
"MM473524";"MM473524";"N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCOCC5)cc4)nn23)cc1";"CARBAQLLNJEQRM-UHFFFAOYSA-N";409.45;3.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.52;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000030199517204020192
"MM474662";"MM474662";"CCc1ccc(-c2cc(NC3CCC34CCN(C)CC4)c3cc(OC)c(OCCCN4CCCC4)cc3n2)o1";"KJOYGBHVQOPLES-UHFFFAOYSA-N";532.73;6.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.42;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.000003801893963205613
"MM472825";"MM472825";"Cc1nc(N)c2cnn(CCCNC(=O)c3ccc(S(=O)(=O)F)cc3)c2n1";"CFIJILHCAGJIIH-UHFFFAOYSA-N";392.42;1.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-5.74;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.0000018197008586099826
"MM473521";"MM473521";"CN1CCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc(C#N)cc5)n4c3)cc2)CC1";"SRVMCTQCWVQBNL-UHFFFAOYSA-N";421.5;3.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.09;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00008128305161640995
"MM474659";"MM474659";"COc1cc2c(NC3CC4(CCN(C(C)C)CC4)C3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"PCZXRYSXMPNRDU-UHFFFAOYSA-N";546.76;6.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.71;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000019498445997580454
"MM473511";"MM473511";"CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C(N)=O)cc5)cnc4cn3)cc2)CC1";"TWYKNRDHNFNBDF-UHFFFAOYSA-N";440.51;2.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-5.75;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000001778279410038923
"MM474669";"MM474669";"CCc1ccc(-c2cc(NC3CCN(C)CC3)c3cc(OC)c(OCCCN4CCC5(CC5)C4)cc3n2)o1";"BBJDFTWFOONSLK-UHFFFAOYSA-N";518.7;5.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.44;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000036307805477010103
"MM472841";"MM472841";"COc1ccccc1-c1nc(C)c(COc2ccc(CCC(=O)O)cc2)o1";"YRLKLZDJOAVSSF-UHFFFAOYSA-N";367.4;4.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.59;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.0002570395782768865
"MM474666";"MM474666";"COc1cc2c(NC3CC4CCC(C3)N4C)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"UNRCZHRRDXQTEH-UHFFFAOYSA-N";504.68;5.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-6.44;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.000000363078054770101
"MM473500";"MM473500";"CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1";"IZSUSVHQPBIXPL-UHFFFAOYSA-N";509;-0.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4179671/target=_blank>CHEMBL4179671</a>";;-5.82;"MartĂ­nez GonzĂˇlez S, HernĂˇndez AI, Ă�lvarez RM, RodrĂ­guez A, Ramos-Lima F, Bischoff JR, AlbarrĂˇn MI, CebriĂˇ A, HernĂˇndez-Encinas E, GarcĂ­a-Arocha J, CebriĂˇn D, Blanco-Aparicio C, Pastor J.: Identification of novel PI3K inhibitors through a scaffold hopping strategy. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.0000015135612484362072
"MM472845";"MM472845";"COc1ccccc1-c1nc(C)c(COc2ccccc2C(=O)O)o1";"BQNCBDJCTMMQQF-UHFFFAOYSA-N";339.35;3.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.63;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00023442288153199226
"MM472840";"MM472840";"COc1cccc(-c2nc(C)c(COc3ccccc3C(=O)O)o2)c1";"NGLARNTYMMPJOU-UHFFFAOYSA-N";339.35;3.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.63;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00023442288153199226
"MM474658";"MM474658";"COc1cc2c(NC3CC4(CCN(C)CC4)C3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"UDDYBHJZHUMVFR-UHFFFAOYSA-N";518.7;5.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.98;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000010471285480508985
"MM474330";"MM474330";"CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2-c2ccc(C3(C#N)CC3)cc2)CC1";"WIXZFNIBMHEUJH-UHFFFAOYSA-N";478.55;3.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4190043/target=_blank>CHEMBL4190043</a>";;-3.41;"Yang SM, Martinez NJ, Yasgar A, Danchik C, Johansson C, Wang Y, Baljinnyam B, Wang AQ, Xu X, Shah P, Cheff D, Wang XS, Roth J, Lal-Nag M, Dunford JE, Oppermann U, Vasiliou V, Simeonov A, Jadhav A, Maloney DJ.: Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity. J Med Chem, Volume 61 (11), 2018";"PAMPA";0.0003890451449942805
"MM472830";"MM472830";"Cc1nc(N)c2ccn(C3CCN(C(=O)c4ccc(S(=O)(=O)F)cc4)CC3)c2n1";"BSMZMGQPZSLAMT-UHFFFAOYSA-N";417.47;2.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-4.99;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.000010232929922807536
"MM474329";"MM474329";"CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2N2CCC(C#N)(c3ccccc3)CC2)CC1";"XMNLWOQHMQRHDV-UHFFFAOYSA-N";521.62;3.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4190043/target=_blank>CHEMBL4190043</a>";;-3.14;"Yang SM, Martinez NJ, Yasgar A, Danchik C, Johansson C, Wang Y, Baljinnyam B, Wang AQ, Xu X, Shah P, Cheff D, Wang XS, Roth J, Lal-Nag M, Dunford JE, Oppermann U, Vasiliou V, Simeonov A, Jadhav A, Maloney DJ.: Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity. J Med Chem, Volume 61 (11), 2018";"PAMPA";0.0007244359600749898
"MM474652";"MM474652";"O=C(O)c1ccncc1NC[C@@H]1CCCc2cc(Oc3ccccc3)ccc21";"RUIDTLFWDJICDV-KRWDZBQOSA-N";374.44;5.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4193849/target=_blank>CHEMBL4193849</a>";;-5.49;"Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O'Connell SM, Shi L, Stafford JA, Stansfield RK, Veal JM, Weiss MS, Yuen NY, Wallace MB.: Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. ACS Med Chem Lett, Volume 8 (8), 2017";"PAMPA";0.000003235936569296281
"MM472834";"MM472834";"Nc1cc(OCCCNCc2ccc(S(=O)(=O)F)cc2)ccn1";"ACXPNANZFJLCTM-UHFFFAOYSA-N";339.39;1.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-8;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.00000001
"MM474664";"MM474664";"COc1cc2c(NC3C4CCC3CN(C)C4)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"KXENQCUVSMIIGA-UHFFFAOYSA-N";504.68;5.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.47;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000033884415613920275
"MM472853";"MM472853";"COC(=O)c1ccc(OCc2oc(-c3ccccc3OC)nc2C)cc1";"SRSMLFMLORSOQO-UHFFFAOYSA-N";353.37;4.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.35;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00044668359215096305
"MM474668";"MM474668";"CCc1ccc(-c2cc(NC3CCN(C)CC3)c3cc(OC)c(OCCCN(C)C)cc3n2)o1";"AJHIQURHJXOCCP-UHFFFAOYSA-N";466.63;4.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.83;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.000001479108388168207
"MM474655";"MM474655";"COc1cc2c(NCC3CCN(C)CC3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"VMMRDFLDWHFNOX-UHFFFAOYSA-N";492.66;5.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.96;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.000001096478196143185
"MM474671";"MM474671";"COc1cc2c(NC3CCN(C)CC3)cc(-c3ccc(C)o3)nc2cc1OCC1CCNCC1";"RUPLHSKMNNTYKA-UHFFFAOYSA-N";464.61;4.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-6.54;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.00000028840315031266057
"MM473498";"MM473498";"CS(=O)(=O)N1CCN(Cc2cn3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1";"MZDVYDDLVZYLGV-UHFFFAOYSA-N";474.55;-0.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4179671/target=_blank>CHEMBL4179671</a>";;-5.45;"MartĂ­nez GonzĂˇlez S, HernĂˇndez AI, Ă�lvarez RM, RodrĂ­guez A, Ramos-Lima F, Bischoff JR, AlbarrĂˇn MI, CebriĂˇ A, HernĂˇndez-Encinas E, GarcĂ­a-Arocha J, CebriĂˇn D, Blanco-Aparicio C, Pastor J.: Identification of novel PI3K inhibitors through a scaffold hopping strategy. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.000003548133892335753
"MM473548";"MM473548";"Cn1cc2c3c(c[nH]c3c1=O)CN(c1ccccn1)c1ccc(CS(C)(=O)=O)cc1-2";"LJLJARSDBHJRGG-UHFFFAOYSA-N";420.49;3.12;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4194889/target=_blank>CHEMBL4194889</a>";;-5.22;"Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.: Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.000006025595860743581
"MM473545";"MM473545";"Cn1cc2c3c(c[nH]c3c1=O)CN(C1CCC(F)(F)CC1)c1ccc(CS(C)(=O)=O)cc1-2";"UBDHSLJGTMISPN-UHFFFAOYSA-N";461.53;3.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4194889/target=_blank>CHEMBL4194889</a>";;-5.14;"Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.: Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.000007244359600749906
"MM473507";"MM473507";"CN(C)C1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C#N)cc5)cnc4cn3)cc2)CC1";"HIPFDFQYWKJHND-UHFFFAOYSA-N";450.55;4.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.19;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00006456542290346549
"MM473523";"MM473523";"N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCNCC5)cc4)nn23)cc1";"TVBANCDFRJJEKJ-UHFFFAOYSA-N";408.47;2.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.34;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000045708818961487516
"MM474661";"MM474661";"COc1cc2c(NC3CCC34CCN(C)CC4)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"FWEMDGGXZBEQDX-UHFFFAOYSA-N";518.7;5.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.8;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.000001584893192461114
"MM473508";"MM473508";"CC(=O)N1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(O)cc5)cnc4cn3)cc2)CC1";"KJZWOUQMPQCYIK-UHFFFAOYSA-N";441.49;3.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-5.55;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000002818382931264455
"MM472835";"MM472835";"Nc1cc(OCCCNC(=O)c2ccc(S(=O)(=O)F)cc2)ccn1";"OUEDRONOCICJBQ-UHFFFAOYSA-N";353.38;1.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-6.44;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.000000363078054770101
"MM472847";"MM472847";"COC(=O)Cc1ccc(OCc2oc(-c3cccc(OC)c3)nc2C)cc1";"GFUKCIXVOZBJQK-UHFFFAOYSA-N";367.4;3.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.32;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00047863009232263854
"MM473518";"MM473518";"CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(O)cc5)cnc4cn3)cc2)CC1";"ZROBKNPXIOQRBD-UHFFFAOYSA-N";413.48;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.46;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00003467368504525317
"MM472843";"MM472843";"COc1ccccc1-c1nc(C)c(COc2ccc(C(=O)O)cc2)o1";"MFBJHAACEMGJFK-UHFFFAOYSA-N";339.35;3.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.67;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00021379620895022324
"MM472833";"MM472833";"Nc1cc(OC2CCN(C(=O)c3ccc(S(=O)(=O)F)cc3)CC2)ccn1";"JZCRDRWTEAZDJD-UHFFFAOYSA-N";379.41;2.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-5.11;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.00000776247116628691
"MM472823";"MM472823";"Nc1ncnc2c1ncn2C1CCN(C(=O)c2ccc(S(=O)(=O)F)cc2)CC1";"NVKCMEFGMGNTPO-UHFFFAOYSA-N";404.43;1.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-8;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.00000001
"MM473510";"MM473510";"O=C(c1ccc(-c2cn3c(-c4ccc(O)cc4)cnc3cn2)cc1)N1CCOCC1";"FXUCGEVPOQUSIH-UHFFFAOYSA-N";400.44;3.24;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.3;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00005011872336272725
"MM474670";"MM474670";"CCc1ccc(-c2cc(NC3CCN(C)CC3)c3cc(OC)c(OCCCN4CCCCC4)cc3n2)o1";"HXTSAISPABOHHN-UHFFFAOYSA-N";506.69;5.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-6.08;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000008317637711026709
"MM473544";"MM473544";"Cn1cc2c3c(c[nH]c(=O)c31)CN(CC1CC1)c1ccc(CS(C)(=O)=O)cc1-2";"PIHQGPVOVWMLAH-UHFFFAOYSA-N";397.5;2.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4194889/target=_blank>CHEMBL4194889</a>";;-5.6;"Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.: Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.0000025118864315095823
"MM472842";"MM472842";"COc1ccccc1-c1nc(C)c(COc2ccc(CC(=O)O)cc2)o1";"RFDFZQHRBRPMGD-UHFFFAOYSA-N";353.37;3.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.72;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00019054607179632462
"MM472852";"MM472852";"COC(=O)Cc1ccc(OCc2oc(-c3ccccc3OC)nc2C)cc1";"GWVLKHYLZIYXAO-UHFFFAOYSA-N";367.4;3.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.56;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.0002754228703338166
"MM472824";"MM472824";"Cc1nc(N)c2ncn(C3CCN(Cc4ccc(S(=O)(=O)F)cc4)CC3)c2n1";"NCBOVQFRUVFWEM-UHFFFAOYSA-N";404.47;2.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-4.05;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.00008912509381337459
"MM472850";"MM472850";"COC(=O)c1ccccc1OCc1oc(-c2cccc(OC)c2)nc1C";"WCDXOQLDSYHFNS-UHFFFAOYSA-N";353.37;4.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.29;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.0005128613839913648
"MM473503";"MM473503";"CN1CCN(c2ccc(CNc3nc(N4CCOCC4)nc4c3ncn4-c3cccc(F)c3)nc2)CC1";"DUDGJCLIJOMHFB-UHFFFAOYSA-N";503.59;2.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4187220/target=_blank>CHEMBL4187220</a>";;-5.15;"Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.: Development of dual casein kinase 1Î´/1Îµ (CK1Î´/Îµ) inhibitors for treatment of breast cancer. Bioorg Med Chem, Volume 26 (3), 2018";"PAMPA";0.000007079457843841373
"MM473506";"MM473506";"Fc1cccc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1";"CEBMEQPREMCWOL-UHFFFAOYSA-N";480.45;3.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4187220/target=_blank>CHEMBL4187220</a>";;-6.4;"Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.: Development of dual casein kinase 1Î´/1Îµ (CK1Î´/Îµ) inhibitors for treatment of breast cancer. Bioorg Med Chem, Volume 26 (3), 2018";"PAMPA";0.0000003981071705534969
"MM473520";"MM473520";"N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCOCC5)cc4)cn23)cc1";"FWRFPHJSGLYXTD-UHFFFAOYSA-N";408.46;4.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.13;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00007413102413009176
"MM474665";"MM474665";"CCc1ccc(-c2cc(NCC3C4CCC3CN(C)C4)c3cc(OC)c(OCCCN4CCCC4)cc3n2)o1";"JWHZKAWJXRZCOW-UHFFFAOYSA-N";532.73;5.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.44;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000036307805477010103
"MM472827";"MM472827";"Cc1nc(N)c2cnn(C3CCN(Cc4ccc(S(=O)(=O)F)cc4)CC3)c2n1";"OLUFQLZXUKQCST-UHFFFAOYSA-N";404.47;2.21;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-5.15;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.000007079457843841373
"MM473514";"MM473514";"CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(Cl)cc5)cnc4cn3)cc2)CC1";"KKUMLZFCIPKXAO-UHFFFAOYSA-N";431.93;4.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.15;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00007079457843841373
"MM472836";"MM472836";"COc1cccc(-c2nc(C)c(COc3ccc(CCC(=O)O)cc3)o2)c1";"VALUMKQQQXLNRL-UHFFFAOYSA-N";367.4;4.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.92;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00012022644346174131
"MM474651";"MM474651";"COc1ccc2c(c1)CCC[C@H]2CNc1cnccc1C(=O)O";"NXQKMWGCRMQRSS-ZDUSSCGKSA-N";312.37;3.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4193849/target=_blank>CHEMBL4193849</a>";;-5.73;"Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O'Connell SM, Shi L, Stafford JA, Stansfield RK, Veal JM, Weiss MS, Yuen NY, Wallace MB.: Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. ACS Med Chem Lett, Volume 8 (8), 2017";"PAMPA";0.0000018620871366628656
"MM472848";"MM472848";"COC(=O)c1ccc(OCc2oc(-c3cccc(OC)c3)nc2C)cc1";"SYFIGKNOBXITNY-UHFFFAOYSA-N";353.37;4.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.43;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.0003715352290971724
"MM473543";"MM473543";"Cn1cc2c3c(c[nH]c3c1=O)CN(CC1CC1)c1ccc(CS(C)(=O)=O)cc1-2";"AGRVPCMMHQFJTH-UHFFFAOYSA-N";397.5;2.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4194889/target=_blank>CHEMBL4194889</a>";;-5.37;"Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.: Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.000004265795188015926
"MM473513";"MM473513";"CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C(F)(F)F)cc5)cnc4cn3)cc2)CC1";"PFHIDQUYVRCLAG-UHFFFAOYSA-N";465.48;4.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.06;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00008709635899560814
"MM474663";"MM474663";"COc1cc2c(NC3CCC34CCN(C)C4)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"MJGRJTGEKSYWOA-UHFFFAOYSA-N";504.68;5.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-6.12;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000007585775750291836
"MM473496";"MM473496";"CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1";"XEBRAMSBPJUGET-UHFFFAOYSA-N";473.56;-0.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4179671/target=_blank>CHEMBL4179671</a>";;-6.03;"MartĂ­nez GonzĂˇlez S, HernĂˇndez AI, Ă�lvarez RM, RodrĂ­guez A, Ramos-Lima F, Bischoff JR, AlbarrĂˇn MI, CebriĂˇ A, HernĂˇndez-Encinas E, GarcĂ­a-Arocha J, CebriĂˇn D, Blanco-Aparicio C, Pastor J.: Identification of novel PI3K inhibitors through a scaffold hopping strategy. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.0000009332543007969905
"MM473519";"MM473519";"NC(=O)c1ccc(-c2cn3c(-c4ccc(O)cc4)cnc3cn2)cc1";"LKFLRBIQIXBCCO-UHFFFAOYSA-N";330.35;2.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.64;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00002290867652767775
"MM473546";"MM473546";"Cn1cc2c3c(c[nH]c3c1=O)CN(c1ccc(F)cc1)c1ccc(CS(C)(=O)=O)cc1-2";"XGXZJWFQBZMXON-UHFFFAOYSA-N";437.5;3.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4194889/target=_blank>CHEMBL4194889</a>";;-5.18;"Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.: Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.000006606934480075964
"MM472849";"MM472849";"COC(=O)c1cccc(OCc2oc(-c3cccc(OC)c3)nc2C)c1";"GIRBBNOMYMMYEM-UHFFFAOYSA-N";353.37;4.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.37;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00042657951880159257
"MM474656";"MM474656";"CCc1ccc(-c2cc(NCC3CCN(C)CC3)c3cc(OC)c(OCCCN4CCCC4)cc3n2)o1";"PQJVPCANHLGIOZ-UHFFFAOYSA-N";506.69;5.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.79;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000016218100973589298
"MM473499";"MM473499";"CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1";"NOCRVEDBMWCMTR-UHFFFAOYSA-N";508.01;0.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4179671/target=_blank>CHEMBL4179671</a>";;-6.16;"MartĂ­nez GonzĂˇlez S, HernĂˇndez AI, Ă�lvarez RM, RodrĂ­guez A, Ramos-Lima F, Bischoff JR, AlbarrĂˇn MI, CebriĂˇ A, HernĂˇndez-Encinas E, GarcĂ­a-Arocha J, CebriĂˇn D, Blanco-Aparicio C, Pastor J.: Identification of novel PI3K inhibitors through a scaffold hopping strategy. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.0000006918309709189363
"MM473525";"MM473525";"CN1CCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc(C#N)cc5)n4n3)cc2)CC1";"PEHQJHHHTXOGJK-UHFFFAOYSA-N";422.49;3.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.6;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000025118864315095822
"MM473550";"MM473550";"Cn1cc2c3c(c[nH]c(=O)c31)-c1cc(CS(C)(=O)=O)ccc1N(c1ccccn1)C2";"AUJSICQRNVBQDS-UHFFFAOYSA-N";420.49;3.12;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4194889/target=_blank>CHEMBL4194889</a>";;-5.23;"Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.: Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.000005888436553555884
"MM474648";"MM474648";"CC(=O)N1c2ccc(-c3cnc(C(N)=O)nc3)cc2N(Cc2ccccc2CO)C[C@@H]1C1CC1";"JVAKWUYUZCOCKR-XMMPIXPASA-N";457.53;2.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189297/target=_blank>CHEMBL4189297</a>";;-4.87;"Law RP, Atkinson SJ, Bamborough P, Chung CW, Demont EH, Gordon LJ, Lindon M, Prinjha RK, Watson AJB, Hirst DJ.: Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000013489628825916533
"MM473509";"MM473509";"N#Cc1ccc(-c2cnc3cnc(-c4ccc(C(=O)N5CCOCC5)cc4)cn23)cc1";"DKRBCZRLAIEHLG-UHFFFAOYSA-N";409.45;3.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.37;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00004265795188015926
"MM472851";"MM472851";"COC(=O)CCc1ccc(OCc2oc(-c3ccccc3OC)nc2C)cc1";"DZHLDLVIMLRUBO-UHFFFAOYSA-N";381.43;4.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.34;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.0004570881896148752
"MM474685";"MM474685";"Cc1onc(C(=O)O)c1-c1cccc(-c2cc(Cl)c(O)c(Cl)c2)c1";"RHLHXHOGVCAPFR-UHFFFAOYSA-N";364.18;5.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4201138/target=_blank>CHEMBL4201138</a>";;-5.11;"Vickers CF, Silva APG, Chakraborty A, Fernandez P, Kurepina N, Saville C, Naranjo Y, Pons M, Schnettger LS, Gutierrez MG, Park S, Kreiswith BN, Perlin DS, Thomas EJ, Cavet JS, Tabernero L.: Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo. J Med Chem, Volume 61 (18), 2018";"PAMPA";0.00000776247116628691
"MM472832";"MM472832";"Nc1cc(OCCNC(=O)c2ccc(S(=O)(=O)F)cc2)ccn1";"NACBDQGNOSECCI-UHFFFAOYSA-N";339.35;1.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-8;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.00000001
"MM472844";"MM472844";"COc1ccccc1-c1nc(C)c(COc2cccc(C(=O)O)c2)o1";"XSCVRDILABREMU-UHFFFAOYSA-N";339.35;3.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.58;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00026302679918953814
"MM472837";"MM472837";"COc1cccc(-c2nc(C)c(COc3ccc(CC(=O)O)cc3)o2)c1";"BTEJSQVRGFHBMU-UHFFFAOYSA-N";353.37;3.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.88;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00013182567385564074
"MM474667";"MM474667";"Cc1ccc(-c2cc(NC3CCN(C)CC3)c3cc(Cl)c(OCCCN4CCCC4)cc3n2)o1";"FKRRYTPCUFOKGU-UHFFFAOYSA-N";483.06;5.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-5.61;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000024547089156850284
"MM472826";"MM472826";"Cc1nc(N)c2ncn(C3CCN(C(=O)c4ccc(S(=O)(=O)F)cc4)CC3)c2n1";"XZQDVLFMAUJPRB-UHFFFAOYSA-N";418.45;1.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-5.59;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.0000025703957827688647
"MM473504";"MM473504";"Fc1cccc(-n2cnc3c(NCc4ncc[nH]4)nc(N4CCOCC4)nc32)c1";"BAKZCLXZBMYRGA-UHFFFAOYSA-N";394.41;2.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4187220/target=_blank>CHEMBL4187220</a>";;-7;"Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.: Development of dual casein kinase 1Î´/1Îµ (CK1Î´/Îµ) inhibitors for treatment of breast cancer. Bioorg Med Chem, Volume 26 (3), 2018";"PAMPA";0.0000001
"MM473549";"MM473549";"Cn1cc2c3c(c[nH]c(=O)c31)-c1cc(CS(C)(=O)=O)ccc1N(c1ccc(F)cc1)C2";"QGTJNNMFLDHNQH-UHFFFAOYSA-N";437.5;3.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4194889/target=_blank>CHEMBL4194889</a>";;-5.29;"Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.: Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.000005128613839913648
"MM474650";"MM474650";"CN(c1ccccc1)c1ccc2c(c1)CCC[C@H]2CNc1cnccc1C(=O)O";"XSMABFRQESMONQ-SFHVURJKSA-N";387.48;5.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4193849/target=_blank>CHEMBL4193849</a>";;-5.29;"Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O'Connell SM, Shi L, Stafford JA, Stansfield RK, Veal JM, Weiss MS, Yuen NY, Wallace MB.: Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. ACS Med Chem Lett, Volume 8 (8), 2017";"PAMPA";0.000005128613839913648
"MM473517";"MM473517";"CN1CCN(C(=O)c2ccc(-c3cn4c(-c5cccc(O)c5)cnc4cn3)cc2)CC1";"NTKMBZXHYFBSOK-UHFFFAOYSA-N";413.48;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.48;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000033113112148259076
"MM473522";"MM473522";"CN(C)C1CCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc(C#N)cc5)n4n3)cc2)CC1";"KTBKRHUBYKAUFQ-UHFFFAOYSA-N";450.55;4.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-4.12;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00007585775750291836
"MM474660";"MM474660";"COc1cc2c(NC3CC4(CCN(C)C4)C3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"RDPYODVIYQQQFZ-UHFFFAOYSA-N";504.68;5.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-6.48;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.0000003311311214825908
"MM474653";"MM474653";"O=C(O)c1ccncc1NC[C@@H]1CCCc2cc(Sc3ccccc3)ccc21";"DZVIPXUKOHSZJK-KRWDZBQOSA-N";390.51;5.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4193849/target=_blank>CHEMBL4193849</a>";;-5.29;"Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O'Connell SM, Shi L, Stafford JA, Stansfield RK, Veal JM, Weiss MS, Yuen NY, Wallace MB.: Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models. ACS Med Chem Lett, Volume 8 (8), 2017";"PAMPA";0.000005128613839913648
"MM472855";"MM472855";"COC(=O)c1ccccc1OCc1oc(-c2ccccc2OC)nc1C";"PJVJIKFRSSTPHA-UHFFFAOYSA-N";353.37;4.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.33;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00046773514128719813
"MM473515";"MM473515";"CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C#N)cc5)cnc4cn3)cc2)CC1";"LXZQZRCDEXIVBU-UHFFFAOYSA-N";422.49;3.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-3.99;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00010232929922807536
"MM472821";"MM472821";"Nc1ncnc2c1ncn2CCCNC(=O)c1ccc(S(=O)(=O)F)cc1";"JZXYQYYFJXLMJZ-UHFFFAOYSA-N";378.39;0.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-5.18;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.000006606934480075964
"MM473505";"MM473505";"Fc1cccc(-n2cnc3c(NCc4ccccn4)nc(N4CCOCC4)nc32)c1";"BKTDJFYZVSLYHT-UHFFFAOYSA-N";405.44;2.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4187220/target=_blank>CHEMBL4187220</a>";;-5.17;"Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.: Development of dual casein kinase 1Î´/1Îµ (CK1Î´/Îµ) inhibitors for treatment of breast cancer. Bioorg Med Chem, Volume 26 (3), 2018";"PAMPA";0.000006760829753919819
"MM474654";"MM474654";"COc1cc2c(NC3CCN(C)C(=O)C3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1";"FDUSNRNFGPEONK-UHFFFAOYSA-N";492.62;4.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4195577/target=_blank>CHEMBL4195577</a>";;-6.47;"Rabal O, SĂˇnchez-Arias JA, San JosĂ©-EnĂ©riz E, Agirre X, de Miguel I, Garate L, Miranda E, SĂˇez E, Roa S, MartĂ­nez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J.: Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.00000033884415613920274
"MM473516";"MM473516";"CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C(=O)O)cc5)cnc4cn3)cc2)CC1";"PZNMULIOTSQSJK-UHFFFAOYSA-N";441.49;3.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189500/target=_blank>CHEMBL4189500</a>";;-7;"Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.: Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.0000001
"MM472829";"MM472829";"Nc1ncnc2c1cnn2C1CCN(C(=O)c2ccc(S(=O)(=O)F)cc2)CC1";"AKZZVXRTBVBUTI-UHFFFAOYSA-N";404.43;1.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-6.1;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.0000007943282347242822
"MM473497";"MM473497";"CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1";"LFNUJWZBIXHQJT-UHFFFAOYSA-N";474.55;-0.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4179671/target=_blank>CHEMBL4179671</a>";;-5.72;"MartĂ­nez GonzĂˇlez S, HernĂˇndez AI, Ă�lvarez RM, RodrĂ­guez A, Ramos-Lima F, Bischoff JR, AlbarrĂˇn MI, CebriĂˇ A, HernĂˇndez-Encinas E, GarcĂ­a-Arocha J, CebriĂˇn D, Blanco-Aparicio C, Pastor J.: Identification of novel PI3K inhibitors through a scaffold hopping strategy. Bioorg Med Chem Lett, Volume 27 (21), 2017";"PAMPA";0.0000019054607179632483
"MM473547";"MM473547";"Cn1cc2c3c(c[nH]c3c1=O)CN(c1ccc(F)cc1F)c1ccc(CS(C)(=O)=O)cc1-2";"UNODBAFOZVBZBF-UHFFFAOYSA-N";455.49;4.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4194889/target=_blank>CHEMBL4194889</a>";;-4.89;"Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.: Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.000012882495516931348
"MM472839";"MM472839";"COc1cccc(-c2nc(C)c(COc3cccc(C(=O)O)c3)o2)c1";"KBDJKXRBZJTLTC-UHFFFAOYSA-N";339.35;3.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.88;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.00013182567385564074
"MM472828";"MM472828";"Cc1nc(N)c2cnn(C3CCN(C(=O)c4ccc(S(=O)(=O)F)cc4)CC3)c2n1";"LOCKTYLDSLKJBO-UHFFFAOYSA-N";418.45;1.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-5.79;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.0000016218100973589298
"MM472831";"MM472831";"Nc1ncnc2c1ccn2C1CCN(C(=O)c2ccc(S(=O)(=O)F)cc2)CC1";"STSQSRRMLHZFPL-UHFFFAOYSA-N";403.44;2.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-5.26;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.0000054954087385762485
"MM472846";"MM472846";"COC(=O)CCc1ccc(OCc2oc(-c3cccc(OC)c3)nc2C)cc1";"JYYKAPLKPNEVIM-UHFFFAOYSA-N";381.43;4.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4184929/target=_blank>CHEMBL4184929</a>";;-3.34;"Teske KA, Bogart JW, Arnold LA.: Novel VDR antagonists based on the GW0742 scaffold. Bioorg Med Chem Lett, Volume 28 (3), 2018";"PAMPA";0.0004570881896148752
"MM474649";"MM474649";"CC(=O)N1c2ccc(C3=CCNCC3)cc2N(Cc2ccccc2CO)C[C@@H]1C1CC1";"ARWMKZDWGIOCEU-AREMUKBSSA-N";417.55;3.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4189297/target=_blank>CHEMBL4189297</a>";;-4.96;"Law RP, Atkinson SJ, Bamborough P, Chung CW, Demont EH, Gordon LJ, Lindon M, Prinjha RK, Watson AJB, Hirst DJ.: Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000010964781961431852
"MM473593";"MM473593";"CC1(C)Cc2c(c(C(=O)Nc3ccccc3C(F)(F)F)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1";"DYVRXKKGZCZAFB-UHFFFAOYSA-N";518.9;7.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4221873/target=_blank>CHEMBL4221873</a>";;-6.92;"Muthukaman N, Deshmukh S, Tambe M, Pisal D, Tondlekar S, Shaikh M, Sarode N, Kattige VG, Sawant P, Pisat M, Karande V, Honnegowda S, Kulkarni A, Behera D, Jadhav SB, Sangana RR, Gudi GS, Khairatkar-Joshi N, Gharat LA.: Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2. Bioorg Med Chem Lett, Volume 28 (7), 2018";"PAMPA";0.00000012022644346174132
"MM473600";"MM473600";"Cc1ccccc1CN1CCC(NC(=O)Nc2cccc(C(F)(F)F)c2)CC1";"NTVLCEYGKMDMPJ-UHFFFAOYSA-N";391.44;4.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-2.92;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.001202264434617413
"MM472860";"MM472860";"CCc1c(C)nn(CCNC(=O)C2C(c3ccc(F)cc3)C2(C)C)c1C";"GQZOLOMMBPRALU-UHFFFAOYSA-N";357.47;3.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223597/target=_blank>CHEMBL4223597</a>";;-4.4;"Nair RR, Geldenhuys WJ, Piktel D, Sadana P, Gibson LF.: Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.000039810717055349695
"MM473596";"MM473596";"CC1(C)Cc2c(c(C(=O)Nc3ccc(F)c(C(F)(F)F)c3)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1";"RNSBVQNXRDUTET-UHFFFAOYSA-N";536.89;7.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4221873/target=_blank>CHEMBL4221873</a>";;-6.48;"Muthukaman N, Deshmukh S, Tambe M, Pisal D, Tondlekar S, Shaikh M, Sarode N, Kattige VG, Sawant P, Pisat M, Karande V, Honnegowda S, Kulkarni A, Behera D, Jadhav SB, Sangana RR, Gudi GS, Khairatkar-Joshi N, Gharat LA.: Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2. Bioorg Med Chem Lett, Volume 28 (7), 2018";"PAMPA";0.0000003311311214825908
"MM473603";"MM473603";"O=C(Nc1cccc(C(F)(F)F)c1)NC1CCN(Cc2cccc(Cl)c2)CC1";"VKWPMMIKZVOWQM-UHFFFAOYSA-N";411.86;5.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-2.77;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.0016982436524617442
"MM474702";"MM474702";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(c2ccc(C(F)(F)F)nc2)CC1";"JDLXDLRUJFWBQX-QFIPXVFZSA-N";531.58;2.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-5.05;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00000891250938133746
"MM473601";"MM473601";"O=C(Nc1cccc(C(F)(F)F)c1)NC1CCN(Cc2ccccc2Cl)CC1";"WSXXWFWKCZIWBN-UHFFFAOYSA-N";411.86;5.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-3.08;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.0008317637711026709
"MM474689";"MM474689";"Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)cc1";"GFNCBUDQFXZVNN-SVFBPWRDSA-N";516.64;2.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-5.57;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.0000026915348039269138
"MM474342";"MM474342";"Cc1cc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5cc(F)ccc5nc4C(F)(F)F)CN3C2=O)no1";"MXUVYGOUNHBREQ-NIDJOPNUSA-N";791.78;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219998/target=_blank>CHEMBL4219998</a>";;-5.29;"DeGoey DA, Chen HJ, Cox PB, Wendt MD.: Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.000005128613839913648
"MM474690";"MM474690";"Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(C#N)CC2)C(C)(C)C)cc1";"NDVQUNZCNAMROD-RZUBCFFCSA-N";523.66;2.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-5.71;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.0000019498445997580454
"MM474704";"MM474704";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(C(=O)c2ccc(F)cc2)CC1";"FHPSMRJHTSYURF-DEOSSOPVSA-N";508.59;2.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-5.52;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.0000030199517204020193
"MM474694";"MM474694";"Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2COC2)C(C)(C)C)cc1";"NKBZEWGYKXYCGU-RZUBCFFCSA-N";514.65;1.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-7.52;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.000000030199517204020194
"MM473602";"MM473602";"O=C(Nc1cccc(C(F)(F)F)c1)NC1CCN(Cc2ccccc2F)CC1";"AXQWAOFRIRMEQQ-UHFFFAOYSA-N";395.4;4.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-2.82;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.0015135612484362087
"MM474687";"MM474687";"Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CO)C(C)(C)C)cc1";"OFCMFZVSIVJIET-LVCYWYKZSA-N";488.61;1.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-8;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.00000001
"MM473576";"MM473576";"COc1ncc(-c2cc3c(C)nc(N)nc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F";"VAWUMMRNRUYZAS-UHFFFAOYSA-N";463.49;3.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4220372/target=_blank>CHEMBL4220372</a>";;-5.32;"Lin S, Wang C, Ji M, Wu D, Lv Y, Sheng L, Han F, Dong Y, Zhang K, Yang Y, Li Y, Chen X, Xu H.: Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. Bioorg Med Chem, Volume 26 (3), 2018";"PAMPA";0.00000478630092322638
"MM474706";"MM474706";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(S(=O)(=O)c2cccc3c(N(C)C)cccc23)CC1";"ITOAEXJJBTZGFZ-NDEPHWFRSA-N";619.79;2.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-5.11;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00000776247116628691
"MM473597";"MM473597";"Cc1cccc(Cl)c1Nc1nc2cc(C(=O)Nc3cc(C(F)(F)F)ccc3F)c3c(c2[nH]1)CC(C)(C)O3";"NEDYVEZMEJJRFC-UHFFFAOYSA-N";532.93;7.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4221873/target=_blank>CHEMBL4221873</a>";;-5.87;"Muthukaman N, Deshmukh S, Tambe M, Pisal D, Tondlekar S, Shaikh M, Sarode N, Kattige VG, Sawant P, Pisat M, Karande V, Honnegowda S, Kulkarni A, Behera D, Jadhav SB, Sangana RR, Gudi GS, Khairatkar-Joshi N, Gharat LA.: Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2. Bioorg Med Chem Lett, Volume 28 (7), 2018";"PAMPA";0.0000013489628825916533
"MM473607";"MM473607";"O=C(Nc1cccc(-n2cccc2)c1)NC1CCN(Cc2ccccc2)CC1";"XGNKUIUINUHCLE-UHFFFAOYSA-N";374.49;4.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-3.03;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.0009332543007969915
"MM474699";"MM474699";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(c2cccc(-c3ccccc3)n2)CC1";"FRCGVDAQVWFVTG-NDEPHWFRSA-N";539.68;3.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.66;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00002187761623949552
"MM474710";"MM474710";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1F)C(=O)N1CCN(c2cccc(C)n2)CC1";"ARHYUUNSDCDOJQ-QHCPKHFHSA-N";495.6;2.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.94;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000011481536214968817
"MM474701";"MM474701";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(c2ccc(F)nc2)CC1";"VBBPTJBIXWFFTD-QFIPXVFZSA-N";481.57;2.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-5.45;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000003548133892335753
"MM474708";"MM474708";"C=CC(=O)NCCCC[C@H](NC(=O)c1ccc(F)cc1)C(=O)N1CCN(c2cccc(C)n2)CC1";"HWCPOPURFYACDJ-QFIPXVFZSA-N";481.57;2.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.9;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000012589254117941661
"MM474707";"MM474707";"C=CC(=O)NCCCC[C@H](NC(=O)Nc1ccc(F)cc1)C(=O)N1CCN(c2cccc(C)n2)CC1";"WFNSMSYRZSTVOQ-QFIPXVFZSA-N";496.59;2.84;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.9;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000012589254117941661
"MM473595";"MM473595";"Cc1cc(C(F)(F)F)ccc1NC(=O)c1cc2nc(Nc3c(F)cccc3Cl)[nH]c2c2c1OC(C)(C)C2";"IGHAUGKWUXJQHG-UHFFFAOYSA-N";532.93;7.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4221873/target=_blank>CHEMBL4221873</a>";;-6.51;"Muthukaman N, Deshmukh S, Tambe M, Pisal D, Tondlekar S, Shaikh M, Sarode N, Kattige VG, Sawant P, Pisat M, Karande V, Honnegowda S, Kulkarni A, Behera D, Jadhav SB, Sangana RR, Gudi GS, Khairatkar-Joshi N, Gharat LA.: Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2. Bioorg Med Chem Lett, Volume 28 (7), 2018";"PAMPA";0.0000003090295432513592
"MM474344";"MM474344";"Cc1cc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3(C)CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5c5ccc(F)cc45)CN3C2=O)no1";"SIFYZFMJVHIGMJ-MPWCDZDGSA-N";786.88;4.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219998/target=_blank>CHEMBL4219998</a>";;-6.72;"DeGoey DA, Chen HJ, Cox PB, Wendt MD.: Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.00000019054607179632483
"MM472861";"MM472861";"Cc1ccnn1CCCCNC(=O)C1(C)CC1(Br)Br";"OJCRHIAVGZRPPR-UHFFFAOYSA-N";393.12;2.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223597/target=_blank>CHEMBL4223597</a>";;-4.53;"Nair RR, Geldenhuys WJ, Piktel D, Sadana P, Gibson LF.: Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia. Bioorg Med Chem Lett, Volume 28 (10), 2018";"PAMPA";0.00002951209226666384
"MM473604";"MM473604";"O=C(Nc1cccc(C(F)(F)F)c1)NC1CCN(Cc2ccc(Cl)cc2)CC1";"XBFANBVJNPHYGC-UHFFFAOYSA-N";411.86;5.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-2.89;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.0012882495516931337
"MM474695";"MM474695";"C[C@@H]1c2n[nH]cc2CN1C1=NC(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2N1";"RLIXQSWDLDFNLY-ZIFPNCEFSA-N";487.46;3.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222831/target=_blank>CHEMBL4222831</a>";;-4.83;"Deaton DN, Haffner CD, Henke BR, Jeune MR, Shearer BG, Stewart EL, Stuart JD, Ulrich JC.: 2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure-activity relationships. Bioorg Med Chem, Volume 26 (8), 2018";"PAMPA";0.000014791083881682072
"MM474711";"MM474711";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1cccc(F)c1)C(=O)N1CCN(c2cccc(C)n2)CC1";"FDKHGRMWEAUKFJ-QHCPKHFHSA-N";495.6;2.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.9;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000012589254117941661
"MM474688";"MM474688";"Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2CC2)C(C)(C)C)cc1";"TXHVAXXHWXOMKR-RZUBCFFCSA-N";498.65;2.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-6.21;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.0000006165950018614822
"MM474709";"MM474709";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccc(F)cc1)C(=O)N1CCN(c2cccc(C)n2)CC1";"ILNDCUSHOUWBMI-QHCPKHFHSA-N";495.6;2.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.94;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000011481536214968817
"MM474341";"MM474341";"Cc1cc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5nc4C)CN3C2=O)no1";"ROLLVSISWGPMTH-GRIPIFRISA-N";719.82;2.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219998/target=_blank>CHEMBL4219998</a>";;-5.46;"DeGoey DA, Chen HJ, Cox PB, Wendt MD.: Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.000003467368504525317
"MM474697";"MM474697";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(c2cccc(F)n2)CC1";"JPCKSGYJCGBAGG-NRFANRHFSA-N";481.57;2.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.88;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000013182567385564074
"MM474705";"MM474705";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(Cc2ccc(F)cc2)CC1";"RRXFUAUMMDCRBT-VWLOTQADSA-N";494.61;2.67;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.99;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.000010232929922807536
"MM474698";"MM474698";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(c2cccc(C(C)(C)C)n2)CC1";"ALAZHWIZHNQBFD-DEOSSOPVSA-N";519.69;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-4.66;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00002187761623949552
"MM474692";"MM474692";"CC(=O)NC1(C(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCc2ccc(-c3scnc3C)cc2)C(C)(C)C)CC1";"SFLOLDSFURSREE-FUPPJEDESA-N";555.7;1.9;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-8;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.00000001
"MM473605";"MM473605";"O=C(Nc1cccc(C(F)(F)F)c1)NC1CCN(C(=O)c2ccccc2)CC1";"ASGWCWZMRINVOL-UHFFFAOYSA-N";391.39;4.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-3.04;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.0009120108393559096
"MM473594";"MM473594";"CC1(C)Cc2c(c(C(=O)Nc3cc(C(F)(F)F)ccc3F)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1";"DNVUWMRRGUVVRF-UHFFFAOYSA-N";536.89;7.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4221873/target=_blank>CHEMBL4221873</a>";;-6.21;"Muthukaman N, Deshmukh S, Tambe M, Pisal D, Tondlekar S, Shaikh M, Sarode N, Kattige VG, Sawant P, Pisat M, Karande V, Honnegowda S, Kulkarni A, Behera D, Jadhav SB, Sangana RR, Gudi GS, Khairatkar-Joshi N, Gharat LA.: Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2. Bioorg Med Chem Lett, Volume 28 (7), 2018";"PAMPA";0.0000006165950018614822
"MM473577";"MM473577";"COc1ncc(-c2cc3c(C)nc(NC(C)=O)nc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F";"RGNZNWVPZKJPFW-UHFFFAOYSA-N";505.53;4.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4220372/target=_blank>CHEMBL4220372</a>";;-5.02;"Lin S, Wang C, Ji M, Wu D, Lv Y, Sheng L, Han F, Dong Y, Zhang K, Yang Y, Li Y, Chen X, Xu H.: Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. Bioorg Med Chem, Volume 26 (3), 2018";"PAMPA";0.000009549925860214369
"MM474691";"MM474691";"CC(=O)C1(C(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCc2ccc(-c3scnc3C)cc2)C(C)(C)C)CC1";"JNBFSDQPUBSKFV-FUPPJEDESA-N";540.69;2.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-5.82;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.0000015135612484362072
"MM473598";"MM473598";"CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)(F)F)cn3)cc3nc(Nc4c(Cl)cccc4Cl)[nH]c23)O1";"QEIIWOFOFSQYRJ-UHFFFAOYSA-N";536.34;6.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4221873/target=_blank>CHEMBL4221873</a>";;-6.2;"Muthukaman N, Deshmukh S, Tambe M, Pisal D, Tondlekar S, Shaikh M, Sarode N, Kattige VG, Sawant P, Pisat M, Karande V, Honnegowda S, Kulkarni A, Behera D, Jadhav SB, Sangana RR, Gudi GS, Khairatkar-Joshi N, Gharat LA.: Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2. Bioorg Med Chem Lett, Volume 28 (7), 2018";"PAMPA";0.000000630957344480193
"MM474703";"MM474703";"C=CC(=O)NCCCC[C@H](NC(=O)Cc1ccccc1)C(=O)N1CCN(c2ccncc2)CC1";"NMCYQGLOFWXBDX-QHCPKHFHSA-N";463.58;1.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-6.29;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.0000005128613839913648
"MM474693";"MM474693";"Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2CCC2)C(C)(C)C)cc1";"DKNMIOWXDLCWDG-FUPPJEDESA-N";512.68;3.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4219886/target=_blank>CHEMBL4219886</a>";;-5.94;"Soares P, Gadd MS, Frost J, Galdeano C, Ellis L, Epemolu O, Rocha S, Read KD, Ciulli A.: Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J Med Chem, Volume 61 (2), 2018";"PAMPA";0.0000011481536214968817
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3066824/target=_blank>CHEMBL3066824</a>";;-5.92;"Akamatsu M.: Importance of physicochemical properties for the design of new pesticides. J Agric Food Chem, Volume 59 (7), 2011";"PAMPA";0.0000012022644346174132
"MM474348";"MM474348";"COc1ccc(-c2ccc(S[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(C)c2)cn1";"KLVGDKOONMJQQH-RBPQIDMKSA-N";393.46;0.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4233910/target=_blank>CHEMBL4233910</a>";;-4.92;"Sattigeri JA, Garg M, Bhateja P, Soni A, Rauf ARA, Gupta M, Deshmukh MS, Jain T, Alekar N, Barman TK, Jha P, Chaira T, Bambal RB, Upadhyay DJ, Nishi T.: Synthesis and evaluation of thiomannosides, potent and orally active FimH inhibitors. Bioorg Med Chem Lett, Volume 28 (17), 2018";"PAMPA";0.000012022644346174132
"MM472862";"MM472862";"CCCc1cc(C(=O)OC)c(NC(=O)C2CCN(C(C)=O)CC2)s1";"IHQFYSBFEDCARV-UHFFFAOYSA-N";352.46;2.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4234721/target=_blank>CHEMBL4234721</a>";;-4.5;"Ozen Z, Dash RC, McCarthy KR, Chow SA, Rizzo AA, Korzhnev DM, Hadden MK.: Small molecule scaffolds that disrupt the Rev1-CT/RIR protein-protein interaction. Bioorg Med Chem, Volume 26 (14), 2018";"PAMPA";0.000031622776601683795
"MM474347";"MM474347";"COc1ncc(-c2cc(OC[C@@H]3CCCN(CCC4CCOCC4)C3)c3cnn(C)c3n2)cc1NS(C)(=O)=O";"IHEZCWZVYIBFRC-HXUWFJFHSA-N";558.71;3.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4232717/target=_blank>CHEMBL4232717</a>";;-4.66;"Hamajima T, Takahashi F, Kato K, Sugano Y, Yamaki S, Moritomo A, Kubo S, Nakamura K, Yamagami K, Hamakawa N, Yokoo K, Fukahori H.: Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3KÎ´ inhibitor. Bioorg Med Chem, Volume 26 (14), 2018";"PAMPA";0.00002187761623949552
"MM474380";"MM474380";"COc1ccc(-c2ccc(Sc3cc(=O)n(O)c(=O)[nH]3)cc2)cc1OC";"VFQDFESUBBNARZ-UHFFFAOYSA-N";372.4;2.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4273396/target=_blank>CHEMBL4273396</a>";;-6.05;"Wang L, Tang J, Huber AD, Casey MC, Kirby KA, Wilson DJ, Kankanala J, Xie J, Parniak MA, Sarafianos SG, Wang Z.: 6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. Eur J Med Chem, Volume 156, 2018";"PAMPA";0.0000008912509381337459
"MM472869";"MM472869";"CN(c1ccc(-c2cc3cccnc3cc2O)nn1)C1CC(C)(C)NC(C)(C)C1";"NBDLBNPFPBBYKY-UHFFFAOYSA-N";391.52;4.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4260939/target=_blank>CHEMBL4260939</a>";;-4.5;"Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, Cody E, Sun R, Fazal A, Fridrich C, Sanchez CC, Tomlinson RC, Jain M, Deng L, Hoffmaster K, Song C, Van Hoosear M, Shin Y, Servais R, Towler C, Hild M, Curtis D, Dietrich WF, Hamann LG, Briner K, Chen KS, Kobayashi D, Sivasankaran R, Dales NA.: Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000031622776601683795
"MM473617";"MM473617";"NS(=O)(=O)c1ccc(-c2cnn3cc(-c4ccc(C5CCNCC5)cc4)cnc23)c2ccccc12";"MIPSILMPJSYIFB-UHFFFAOYSA-N";483.6;4.33;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-4.1;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.00007943282347242822
"MM472863";"MM472863";"CN1CC2(CNC(=O)c3c2[nH]c2c3CCc3cnc(-c4cccc(F)c4)c(F)c3-2)C1";"HZYGUYMZIQSDQB-UHFFFAOYSA-N";406.44;3.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4256512/target=_blank>CHEMBL4256512</a>";;-4.1;"Velcicky J, Schlapbach A, Heng R, Revesz L, Pflieger D, Blum E, Hawtin S, Huppertz C, Feifel R, Hersperger R.: Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure. ACS Med Chem Lett, Volume 9 (4), 2018";"PAMPA";0.00007943282347242822
"MM474368";"MM474368";"CSc1nc(Nc2cc(O)ccc2Cl)c2cnn(CC(Cl)c3ccccc3)c2n1";"OPDQSMNCCLSERS-UHFFFAOYSA-N";446.36;5.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.49;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.000003235936569296281
"MM473619";"MM473619";"CC(C)(CN1CCCCC1)Oc1ccc(-c2cnc3c(-c4ccc(S(N)(=O)=O)c5ccccc45)cnn3c2)cc1";"DAFARWVYCHDMTM-UHFFFAOYSA-N";555.7;5.51;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-2.72;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.0019054607179632462
"MM474367";"MM474367";"CSc1nc(Nc2cc(O)ccc2Cl)c2cnn(CC(C)c3ccccc3)c2n1";"WMAZRAKOIJGGJC-UHFFFAOYSA-N";425.95;5.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.08;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.00000831763771102671
"MM472870";"MM472870";"CN(c1ccc(-c2cc3cnccc3cc2O)nn1)C1CC(C)(C)NC(C)(C)C1";"UISGQKNCYSNSMB-UHFFFAOYSA-N";391.52;4.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4260939/target=_blank>CHEMBL4260939</a>";;-4.3;"Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, Cody E, Sun R, Fazal A, Fridrich C, Sanchez CC, Tomlinson RC, Jain M, Deng L, Hoffmaster K, Song C, Van Hoosear M, Shin Y, Servais R, Towler C, Hild M, Curtis D, Dietrich WF, Hamann LG, Briner K, Chen KS, Kobayashi D, Sivasankaran R, Dales NA.: Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem, Volume 61 (24), 2018";"PAMPA";0.00005011872336272725
"MM473615";"MM473615";"CN(C)CCOc1ccc(-c2cnc3c(-c4ccc(S(N)(=O)=O)c5ccccc45)cnn3c2)cn1";"NEWWJMLDJTYMCU-UHFFFAOYSA-N";488.57;3.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-5.06;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.000008709635899560814
"MM472874";"MM472874";"CC1(C)CC(Cc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1";"SJIRMWMHWILMPD-UHFFFAOYSA-N";391.52;4.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4260939/target=_blank>CHEMBL4260939</a>";;-5.3;"Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, Cody E, Sun R, Fazal A, Fridrich C, Sanchez CC, Tomlinson RC, Jain M, Deng L, Hoffmaster K, Song C, Van Hoosear M, Shin Y, Servais R, Towler C, Hild M, Curtis D, Dietrich WF, Hamann LG, Briner K, Chen KS, Kobayashi D, Sivasankaran R, Dales NA.: Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000005011872336272725
"MM473614";"MM473614";"NS(=O)(=O)c1ccc(-c2cnn3cc(-c4ccc(N5CCNCC5)nc4)cnc23)c2ccccc12";"XFJVPVBSVAEFDT-UHFFFAOYSA-N";485.57;2.67;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-5.08;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.00000831763771102671
"MM473623";"MM473623";"NS(=O)(=O)c1ccc(-c2cnn3cc(-c4ccc(CN5CCCC5)cc4)cnc23)c2ccccc12";"XWGDXVQVFWLJTN-UHFFFAOYSA-N";483.6;4.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-3.33;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.00046773514128719813
"MM474718";"MM474718";"COc1ccc(-c2nc(C)ccc2OCc2cc(C)ccn2)cc1";"FMOCTBWTIGZFKK-UHFFFAOYSA-N";320.39;4.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268687/target=_blank>CHEMBL4268687</a>";;-4.48;"Barker MD, Liddle J, Atkinson FL, Wilson DM, Dickson MC, Ramirez-Molina C, Lewis H, Davis RP, Somers DO, Neu M, Jones E, Watson R.: Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.000033113112148259076
"MM474374";"MM474374";"Oc1cccc(Nc2nc(SCCN3CCOCC3)nc3c2cnn3CC(Cl)c2ccccc2)c1";"IEYDYHPFPKSECG-UHFFFAOYSA-N";511.05;4.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.35;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.000004466835921509635
"MM473622";"MM473622";"CC(C)(N)c1ccc(-c2cnc3c(-c4ccc(S(N)(=O)=O)c5ccccc45)cnn3c2)cc1";"AUMUDSIJXFAGAL-UHFFFAOYSA-N";457.56;4.06;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-5.03;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.000009332543007969906
"MM472873";"MM472873";"CN(c1ccc(-c2ccc(-c3cn[nH]c3)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1";"XSBJQWNBBMWICJ-UHFFFAOYSA-N";406.53;3.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4260939/target=_blank>CHEMBL4260939</a>";;-5.4;"Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, Cody E, Sun R, Fazal A, Fridrich C, Sanchez CC, Tomlinson RC, Jain M, Deng L, Hoffmaster K, Song C, Van Hoosear M, Shin Y, Servais R, Towler C, Hild M, Curtis D, Dietrich WF, Hamann LG, Briner K, Chen KS, Kobayashi D, Sivasankaran R, Dales NA.: Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000003981071705534969
"MM474372";"MM474372";"OCCNc1nc(Nc2cc(O)ccc2Cl)c2cnn(CC(Cl)c3ccccc3)c2n1";"BSXZBINSNZUPHA-UHFFFAOYSA-N";459.34;4.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.57;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.0000026915348039269138
"MM473624";"MM473624";"CC(c1ccc(-c2cnc3c(-c4ccc(S(N)(=O)=O)c5ccccc45)cnn3c2)cc1)N1CCCC1";"IPESYYFOXATSFJ-UHFFFAOYSA-N";497.62;5.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-2.95;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.001122018454301963
"MM473618";"MM473618";"NS(=O)(=O)c1ccc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)c2ccccc12";"ZFWFUCVUVAVKEL-UHFFFAOYSA-N";527.65;4.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-3.32;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.00047863009232263854
"MM474366";"MM474366";"Oc1ccc(Cl)c(Nc2ncnc3c2cnn3CC(Cl)c2ccccc2)c1";"VVZUXGYMJIQUBC-UHFFFAOYSA-N";400.27;4.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.36;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.000004365158322401657
"MM474722";"MM474722";"Nc1cc(C(F)F)c(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cn1";"UGDKPWVVBKHRDK-UHFFFAOYSA-N";445.47;2.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4276466/target=_blank>CHEMBL4276466</a>";;-5.28;"Rageot D, Bohnacker T, Melone A, Langlois JB, Borsari C, Hillmann P, Sele AM, Beaufils F, Zvelebil M, Hebeisen P, LĂ¶scher W, Burke J, Fabbro D, Wymann MP.: Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. J Med Chem, Volume 61 (22), 2018";"PAMPA";0.000005248074602497723
"MM474716";"MM474716";"CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1";"LIGMPEYLZKWWSR-UHFFFAOYSA-N";516.67;4.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4267046/target=_blank>CHEMBL4267046</a>";;-5.24;"Tsagris DJ, Birchall K, Bouloc N, Large JM, Merritt A, Smiljanic-Hurley E, Wheldon M, Ansell KH, Kettleborough C, Whalley D, Stewart LB, Bowyer PW, Baker DA, Osborne SA.: Trisubstituted thiazoles as potent and selective inhibitors of Plasmodium falciparum protein kinase G (PfPKG). Bioorg Med Chem Lett, Volume 28 (19), 2018";"PAMPA";0.000005754399373371567
"MM474370";"MM474370";"Oc1ccc(Cl)c(Nc2nc(SCCN3CCOCC3)nc3c2cnn3CC(Cl)c2ccccc2)c1";"UIJQBIDJNBKOKC-UHFFFAOYSA-N";545.5;5.33;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.01;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.000009772372209558111
"MM472871";"MM472871";"CN(c1ccc(-c2ccc(-n3ccc(N)n3)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1";"IUQMBINWIGHFMS-UHFFFAOYSA-N";421.55;3.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4260939/target=_blank>CHEMBL4260939</a>";;-5.2;"Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, Cody E, Sun R, Fazal A, Fridrich C, Sanchez CC, Tomlinson RC, Jain M, Deng L, Hoffmaster K, Song C, Van Hoosear M, Shin Y, Servais R, Towler C, Hild M, Curtis D, Dietrich WF, Hamann LG, Briner K, Chen KS, Kobayashi D, Sivasankaran R, Dales NA.: Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem, Volume 61 (24), 2018";"PAMPA";0.00000630957344480193
"MM474717";"MM474717";"CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1";"GJHIMWIYQKRLGZ-UHFFFAOYSA-N";529.69;5.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4267046/target=_blank>CHEMBL4267046</a>";;-5.12;"Tsagris DJ, Birchall K, Bouloc N, Large JM, Merritt A, Smiljanic-Hurley E, Wheldon M, Ansell KH, Kettleborough C, Whalley D, Stewart LB, Bowyer PW, Baker DA, Osborne SA.: Trisubstituted thiazoles as potent and selective inhibitors of Plasmodium falciparum protein kinase G (PfPKG). Bioorg Med Chem Lett, Volume 28 (19), 2018";"PAMPA";0.000007585775750291836
"MM474721";"MM474721";"OC12CC3CC(C1)CC(NCc1ccc(Br)s1)(C3)C2";"RMQRQXUFKDZJEU-UHFFFAOYSA-N";342.3;3.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4270391/target=_blank>CHEMBL4270391</a>";;-4.6;"Hu Y, Hau RK, Wang Y, Tuohy P, Zhang Y, Xu S, Ma C, Wang J.: Structure-Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers. ACS Med Chem Lett, Volume 9 (11), 2018";"PAMPA";0.000025118864315095822
"MM474369";"MM474369";"CC(Cn1ncc2c(Nc3cc(O)ccc3Cl)nc(SCCN3CCOCC3)nc21)c1ccccc1";"SKWOKWBIUUHOLJ-UHFFFAOYSA-N";525.08;5.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-4.95;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.00001122018454301963
"MM473620";"MM473620";"NS(=O)(=O)c1ccc(-c2cnn3cc(-c4ccc(OCCN5CCCC5)cc4)cnc23)c2ccccc12";"QBEIGPCAOHBNPR-UHFFFAOYSA-N";513.62;4.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-3.5;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.00031622776601683794
"MM473613";"MM473613";"C[C@@H]1CNC[C@H](C)N1c1ccc(-c2cnc3c(-c4ccc(S(N)(=O)=O)c5ccccc45)cnn3c2)cc1";"WFQFEVBCBPDEQQ-KDURUIRLSA-N";512.64;4.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-5.26;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.0000054954087385762485
"MM474377";"MM474377";"O=c1cc(Sc2ccc(Cl)cc2)[nH]c(=O)n1O";"KQVCAKJYDIYLPP-UHFFFAOYSA-N";270.7;1.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4273396/target=_blank>CHEMBL4273396</a>";;-6.46;"Wang L, Tang J, Huber AD, Casey MC, Kirby KA, Wilson DJ, Kankanala J, Xie J, Parniak MA, Sarafianos SG, Wang Z.: 6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. Eur J Med Chem, Volume 156, 2018";"PAMPA";0.00000034673685045253164
"MM473625";"MM473625";"Cc1noc(C)c1-c1ccc2nc(-c3cnn(CCO)c3)nc(N3CCOCC3c3ccccc3)c2c1";"XGGMHAKFCUIDSF-UHFFFAOYSA-N";496.57;4.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4264649/target=_blank>CHEMBL4264649</a>";;-2.66;"Yang SM, Urban DJ, Yoshioka M, Strovel JW, Fletcher S, Wang AQ, Xu X, Shah P, Hu X, Hall MD, Jadhav A, Maloney DJ.: Discovery and lead identification of quinazoline-based BRD4 inhibitors. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.002187761623949552
"MM472875";"MM472875";"CC1(C)CC(Oc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1";"STWTUEAWRAIWJG-UHFFFAOYSA-N";393.49;3.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4260939/target=_blank>CHEMBL4260939</a>";;-4.9;"Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, Cody E, Sun R, Fazal A, Fridrich C, Sanchez CC, Tomlinson RC, Jain M, Deng L, Hoffmaster K, Song C, Van Hoosear M, Shin Y, Servais R, Towler C, Hild M, Curtis D, Dietrich WF, Hamann LG, Briner K, Chen KS, Kobayashi D, Sivasankaran R, Dales NA.: Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000012589254117941661
"MM474375";"MM474375";"CC(Cn1ncc2c(Nc3cccc(O)c3)nc(NCCO)nc21)c1ccccc1";"AHATUIZODRKCIG-UHFFFAOYSA-N";404.47;3.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-6.7;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.00000019952623149688787
"MM470959";"MM470959";"Clc1cc(-c2nnn[nH]2)ccc1-c1ccc(-n2ccnc2)cc1";"BQLUXQRYHTVVRM-UHFFFAOYSA-N";322.76;3.37;;"CHEMBL4290485";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4260561/target=_blank>CHEMBL4260561</a>";;-6.92;"Muthukaman N, Deshmukh S, Tondlekar S, Tambe M, Pisal D, Sarode N, Mhatre S, Chakraborti S, Shah D, Bhosale VM, Kulkarni A, Mahat MYA, Jadhav SB, Gudi GS, Khairatkar-Joshi N, Gharat LA.: Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD. Bioorg Med Chem Lett, Volume 28 (23-24), 2018";"PAMPA";0.00000012022644346174132
"MM473616";"MM473616";"NS(=O)(=O)c1ccc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)nc4)cnc23)c2ccccc12";"FXLGFEGZMVWCIO-UHFFFAOYSA-N";528.64;4.12;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-3.44;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.0003630780547701014
"MM472872";"MM472872";"CN(c1ccc(-c2ccc(-n3cc(CO)cn3)cc2O)nn1)C1CC(C)(C)NC(C)(C)C1";"HVYYWJDRZBFWQO-UHFFFAOYSA-N";436.56;3.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4260939/target=_blank>CHEMBL4260939</a>";;-5.5;"Cheung AK, Hurley B, Kerrigan R, Shu L, Chin DN, Shen Y, O'Brien G, Sung MJ, Hou Y, Axford J, Cody E, Sun R, Fazal A, Fridrich C, Sanchez CC, Tomlinson RC, Jain M, Deng L, Hoffmaster K, Song C, Van Hoosear M, Shin Y, Servais R, Towler C, Hild M, Curtis D, Dietrich WF, Hamann LG, Briner K, Chen KS, Kobayashi D, Sivasankaran R, Dales NA.: Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000003162277660168379
"MM474373";"MM474373";"CC(Cn1ncc2c(Nc3cc(O)ccc3Cl)nc(NCCN)nc21)c1ccccc1";"YPVYLNANXKPTGX-UHFFFAOYSA-N";437.94;4.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-5.66;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.0000021877616239495517
"MM474719";"MM474719";"Cc1ccnc(COc2ccc(C)nc2-c2ccc3c(c2)CCNCC3)c1";"KUVJIFPAOJEBMN-UHFFFAOYSA-N";359.47;4.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268687/target=_blank>CHEMBL4268687</a>";;-4.36;"Barker MD, Liddle J, Atkinson FL, Wilson DM, Dickson MC, Ramirez-Molina C, Lewis H, Davis RP, Somers DO, Neu M, Jones E, Watson R.: Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.000043651583224016566
"MM474376";"MM474376";"Cc1ccc(Sc2cc(=O)n(O)c(=O)[nH]2)cc1";"ADEKHVBAFHNWSI-UHFFFAOYSA-N";250.28;1.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4273396/target=_blank>CHEMBL4273396</a>";;-6.04;"Wang L, Tang J, Huber AD, Casey MC, Kirby KA, Wilson DJ, Kankanala J, Xie J, Parniak MA, Sarafianos SG, Wang Z.: 6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. Eur J Med Chem, Volume 156, 2018";"PAMPA";0.0000009120108393559096
"MM474379";"MM474379";"O=c1cc(Sc2ccc(-c3ccc(O)cc3)cc2)[nH]c(=O)n1O";"MBXVAZICFZAFMX-UHFFFAOYSA-N";328.35;2.3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4273396/target=_blank>CHEMBL4273396</a>";;-7.41;"Wang L, Tang J, Huber AD, Casey MC, Kirby KA, Wilson DJ, Kankanala J, Xie J, Parniak MA, Sarafianos SG, Wang Z.: 6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. Eur J Med Chem, Volume 156, 2018";"PAMPA";0.00000003890451449942805
"MM474720";"MM474720";"OC12CC3CC(C1)CC(NCc1ccc(I)s1)(C3)C2";"YYXVKXPXGNYCLX-UHFFFAOYSA-N";389.3;3.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4270391/target=_blank>CHEMBL4270391</a>";;-4.69;"Hu Y, Hau RK, Wang Y, Tuohy P, Zhang Y, Xu S, Ma C, Wang J.: Structure-Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers. ACS Med Chem Lett, Volume 9 (11), 2018";"PAMPA";0.000020417379446695274
"MM473621";"MM473621";"CC(N)c1ccc(-c2cnc3c(-c4ccc(S(N)(=O)=O)c5ccccc45)cnn3c2)cc1";"NEDLDPMBQCLFFX-UHFFFAOYSA-N";443.53;3.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4263980/target=_blank>CHEMBL4263980</a>";;-4.85;"Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.: Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (20), 2018";"PAMPA";0.000014125375446227555
"MM474371";"MM474371";"CC(Cn1ncc2c(Nc3cc(O)ccc3Cl)nc(NCCO)nc21)c1ccccc1";"ZAZXISVLNYMWGS-UHFFFAOYSA-N";438.92;4.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4268759/target=_blank>CHEMBL4268759</a>";;-7;"Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M.: Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorg Med Chem Lett, Volume 28 (21), 2018";"PAMPA";0.0000001
"MM472897";"MM472897";"COc1cc(Nc2c(C#N)cnc3cc(NCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl";"PUEYQRUPNCJAHW-UHFFFAOYSA-N";529.47;5.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL922057/target=_blank>CHEMBL922057</a>";;-4.97;"Boschelli DH, Wu B, Ye F, Durutlic H, Golas JM, Lucas J, Boschelli F.: Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs. Bioorg Med Chem, Volume 16 (1), 2008";"PAMPA";0.00001071519305237607
"MM473651";"MM473651";"C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O";"NEQYWYXGTJDAKR-JTQLQIEISA-N";354.8;2.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4325730/target=_blank>CHEMBL4325730</a>";;-4.7;"Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Kershaw M, Yao L, Toms AV, Barr KJ, Dinsmore CJ, Walker D, Ashwell S, Lu W.: Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. J Med Chem, Volume 63 (4), 2020";"PAMPA";0.000019952623149688786
"MM473830";"MM473830";"CC(C)OC(=O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1";"VIQCWEGEHRBLAC-UHFFFAOYSA-N";520.62;3.42;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4326157/target=_blank>CHEMBL4326157</a>";;-4.55;"Iwamura R, Tanaka M, Okanari E, Kirihara T, Odani-Kawabata N, Shams N, Yoneda K.: Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl. J Med Chem, Volume 61 (15), 2018";"PAMPA";0.00002818382931264455
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4223782/target=_blank>CHEMBL4223782</a>";;-7.22;"Wodtke R, Hauser C, Ruiz-GĂłmez G, JĂ¤ckel E, Bauer D, Lohse M, Wong A, Pufe J, Ludwig FA, Fischer S, Hauser S, Greif D, Pisabarro MT, Pietzsch J, Pietsch M, LĂ¶ser R.: N<sup>Îµ</sup>-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling. J Med Chem, Volume 61 (10), 2018";"PAMPA";0.00000006025595860743581
"MM473716";"MM473716";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3c(C)cccc3Br)cn(C)c(=O)c2[nH]1";"ZOAMPPWASMABDR-UHFFFAOYSA-N";572.48;4.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.98;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000010471285480508985
"MM472879";"MM472879";"O=C(O)C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4nnc(C5CCC5)o4)cn3)cc2)CC1";"MPSPDEXLSVLZRT-QAQDUYKDSA-N";432.52;5.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4307359/target=_blank>CHEMBL4307359</a>";;-5.8;"Harrison TJ, Bauer D, Berdichevsky A, Chen X, Duvadie R, Hoogheem B, Hatsis P, Liu Q, Mao J, Miduturu V, Rocheford E, Zecri F, Zessis R, Zheng R, Zhu Q, Streeper R, Patel SJ.: Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor. ACS Med Chem Lett, Volume 10 (8), 2019";"PAMPA";0.000001584893192461114
"MM473657";"MM473657";"CN(C)CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1";"OTJCUPAITLBALS-UHFFFAOYSA-N";389.5;4.01;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-5.61;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.0000024547089156850284
"MM473682";"MM473682";"O=C(c1ccccn1)N1CCCC(c2cc3ncccc3[nH]2)C1";"BWWDNXKYAUAMIX-UHFFFAOYSA-N";306.37;2.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.63;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.0000023442288153199226
"MM474726";"MM474726";"NC(=O)c1cc(-c2ccccc2)cc2c(C3CCN(S(=O)(=O)CCCN4CCCC4)CC3)c[nH]c12";"ROHVMXPLAXOWHS-UHFFFAOYSA-N";494.66;3.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.8;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00001584893192461114
"MM473633";"MM473633";"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCOCCOCCNC(=O)CS(=O)(=O)O)CC2)n1";"JCNVRKBMXOPADG-UHFFFAOYSA-N";697.24;2.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-7.56;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.00000002754228703338169
"MM473718";"MM473718";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3c(C)cccc3C#N)cn(C)c(=O)c2[nH]1";"GDGJQPSTAOPEFI-UHFFFAOYSA-N";518.6;4.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.82;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000015135612484362071
"MM473681";"MM473681";"N#Cc1ccc(C(=O)N2CCCC(c3cc4ncccc4[nH]3)C2)cc1";"JCACGVWVECBJKF-UHFFFAOYSA-N";330.39;3.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-6.42;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.00000038018939632056126
"MM473687";"MM473687";"Cn1nccc1C(=O)N1CCCC(c2cc3ncccc3[nH]2)C1";"DJGUBJNSDYCHOS-UHFFFAOYSA-N";309.37;2.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.99;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.0000010232929922807537
"MM473728";"MM473728";"COc1cc2[nH]c(=O)c([C@H](C)Nc3ncc(C#N)c(OC)n3)cc2cc1Cl";"DIDCUOGCZYTDKE-VIFPVBQESA-N";385.81;3.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4360263/target=_blank>CHEMBL4360263</a>";;-4.9;"Lin J, Lu W, Caravella JA, Campbell AM, Diebold RB, Ericsson A, Fritzen E, Gustafson GR, Lancia DR, Shelekhin T, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Diep H, Kershaw M, Yao L, Kauffman G, Hubbs SE, Luke GP, Toms AV, Wang L, Bair KW, Barr KJ, Dinsmore C, Walker D, Ashwell S.: Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors. J Med Chem, Volume 62 (14), 2019";"PAMPA";0.000012589254117941661
"MM473697";"MM473697";"COc1ccc2[nH]c(C3CCCN(C(=O)c4ccc(F)cc4)C3)cc2n1";"QWKVPQREGQLXFO-UHFFFAOYSA-N";353.4;3.73;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-4.84;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.00001445439770745928
"MM473690";"MM473690";"O=C(c1cc(C(F)(F)F)no1)N1CCCC(c2cc3ncccc3[nH]2)C1";"MNKDWPQWYVYQPR-UHFFFAOYSA-N";364.33;3.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.46;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000003467368504525317
"MM473702";"MM473702";"CN1CCCc2c1nc(N1CCC3(CC1)C(=O)N(CCO)c1cc(F)cc(F)c13)[nH]c2=O";"AONMVAKCMAYUDD-UHFFFAOYSA-N";445.47;1.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4345400/target=_blank>CHEMBL4345400</a>";;-5.52;"Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H.: Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. J Med Chem, Volume 63 (8), 2020";"PAMPA";0.0000030199517204020193
"MM473678";"MM473678";"O=C(c1ccccc1)N1CCCC(c2cc3ncccc3[nH]2)C1";"PFNLTZRVHPTCMC-UHFFFAOYSA-N";305.38;3.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.54;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000002884031503126606
"MM474738";"MM474738";"COc1ccccc1S(=O)(=O)Nc1ccc2c3c(cc(-n4cnc(C)c4)nc13)C(=O)N2C";"FSMTUHGXWGJNKK-UHFFFAOYSA-N";449.49;3.13;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4357144/target=_blank>CHEMBL4357144</a>";;-6.93;"Jiang F, Hu Q, Zhang Z, Li H, Li H, Zhang D, Li H, Ma Y, Xu J, Chen H, Cui Y, Zhi Y, Zhang Y, Xu J, Zhu J, Lu T, Chen Y.: Discovery of Benzo[<i>cd</i>]indol-2(1<i>H</i>)-ones and Pyrrolo[4,3,2-<i>de</i>]quinolin-2(1<i>H</i>)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis. J Med Chem, Volume 62 (24), 2019";"PAMPA";0.00000011748975549395303
"MM473683";"MM473683";"O=C(c1cccc(C(F)(F)F)n1)N1CCCC(c2cc3ncccc3[nH]2)C1";"IQZZJWFSJULHCV-UHFFFAOYSA-N";374.37;4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-6.23;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.0000005888436553555884
"MM473658";"MM473658";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1";"JRVSFZKYQCETAH-OAHLLOKOSA-N";332.4;4.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.71;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000019498445997580456
"MM473700";"MM473700";"O=c1[nH]c(N2CCC3(CC2)CN(CCO)c2cc(F)cc(F)c23)nc2c1CCCC2";"FZQYCOUBRJEYBC-UHFFFAOYSA-N";416.47;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4345400/target=_blank>CHEMBL4345400</a>";;-5.7;"Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H.: Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. J Med Chem, Volume 63 (8), 2020";"PAMPA";0.0000019952623149688787
"MM473704";"MM473704";"C[C@@H]1CN(c2cc(F)c3c(c2)N(C)C(=O)C32CCN(c3nc4c(c(=O)[nH]3)CCCN4C)CC2)C[C@H](C)O1";"KZUPFZKALLNBBV-CALCHBBNSA-N";510.61;2.42;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4345400/target=_blank>CHEMBL4345400</a>";;-4.91;"Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H.: Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. J Med Chem, Volume 63 (8), 2020";"PAMPA";0.00001230268770812381
"MM473636";"MM473636";"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCOCCOCCNC(=O)C3C(C(=O)O)C(C(=O)O)C3C(=O)O)CC2)n1";"CZCGARLOFSDTBA-UHFFFAOYSA-N";789.27;2.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-7.91;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.000000012302687708123811
"MM473727";"MM473727";"COc1nc(N[C@@H](C)c2cc3cc(Cl)ccc3[nH]c2=O)ncc1C#N";"QAFWVLDKBWIXLX-VIFPVBQESA-N";355.79;3.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4360263/target=_blank>CHEMBL4360263</a>";;-4.74;"Lin J, Lu W, Caravella JA, Campbell AM, Diebold RB, Ericsson A, Fritzen E, Gustafson GR, Lancia DR, Shelekhin T, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Diep H, Kershaw M, Yao L, Kauffman G, Hubbs SE, Luke GP, Toms AV, Wang L, Bair KW, Barr KJ, Dinsmore C, Walker D, Ashwell S.: Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors. J Med Chem, Volume 62 (14), 2019";"PAMPA";0.000018197008586099827
"MM473695";"MM473695";"O=C(c1ccccc1)N1CCCC(c2cc3ncccn3n2)C1";"GXMLCAAABYAZAI-UHFFFAOYSA-N";306.37;2.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-4.78;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000016595869074375598
"MM473724";"MM473724";"CCNC(=O)c1cc2c(-c3ccccc3Cc3c(C)cccc3C)cn(C)c(=O)c2[nH]1";"CESAFSCPFRQYED-UHFFFAOYSA-N";413.52;4.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.42;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000003801893963205613
"MM473654";"MM473654";"CCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1";"GMIZJSJFNDLUOV-UHFFFAOYSA-N";332.4;4.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.74;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000018197008586099827
"MM473710";"MM473710";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3ccc(F)cc3F)cn(C)c(=O)c2[nH]1";"PAKGLIDSBPIWCA-UHFFFAOYSA-N";515.54;4.15;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.5;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000003162277660168379
"MM473714";"MM473714";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3c(C)cccc3F)cn(C)c(=O)c2[nH]1";"CMCPHDRIQLBEGG-UHFFFAOYSA-N";511.58;4.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.81;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000015488166189124828
"MM472936";"MM472936";"CCCCc1ccc(C(=O)NC2(C(=O)N[C@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)nc1";"NUEAGESSSAENGD-MGBGTMOVSA-N";631.86;4.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967980/target=_blank>CHEMBL967980</a>";;-5.14;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"PAMPA";0.000007244359600749906
"MM473725";"MM473725";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3-c3c(C)cccc3C)cn(C)c(=O)c2[nH]1";"FSBNPJYGIOIOPL-UHFFFAOYSA-N";491.61;4.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.05;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.00000891250938133746
"MM474731";"MM474731";"NCCS(=O)(=O)N1CCC(c2c[nH]c3c(C(N)=O)cc(-c4ccccc4)cc23)CC1";"AWEOCCDQVPBWPZ-UHFFFAOYSA-N";426.54;2.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-6.52;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.0000003019951720402019
"MM473699";"MM473699";"NCc1cccc(C2CCN(C(=O)/C=C/c3ccc(O)c(O)c3)CC2)c1";"VOAAOCWLJBGRLO-FNORWQNLSA-N";352.43;2.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4344458/target=_blank>CHEMBL4344458</a>";;-8;"Giardina SF, Werner DS, Pingle M, Feinberg PB, Foreman KW, Bergstrom DE, Arnold LD, Barany F.: Novel, Self-Assembling Dimeric Inhibitors of Human Î˛ Tryptase. J Med Chem, Volume 63 (6), 2020";"PAMPA";0.00000001
"MM473659";"MM473659";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1";"JEFRBITWIOXMNQ-CQSZACIVSA-N";350.39;4.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.83;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000014791083881682072
"MM473689";"MM473689";"CC(C)(C)c1cc(C(=O)N2CCCC(c3cc4ncccc4[nH]3)C2)on1";"SEEMNNCNSOUAFK-UHFFFAOYSA-N";352.44;3.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.53;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000002951209226666384
"MM473661";"MM473661";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2)c1";"MBRVCJRFWYHVHE-CQSZACIVSA-N";333.39;3.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.71;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000019498445997580456
"MM474723";"MM474723";"c1ccc(CCc2nc3cc(-c4ccco4)cnc3[nH]2)cc1";"ZZFHGBAWBUYRGR-UHFFFAOYSA-N";289.34;4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323082/target=_blank>CHEMBL4323082</a>";;-4.48;"Takada H, Kaieda A, Tawada M, Nagino T, Sasa K, Oikawa T, Oki A, Sameshima T, Miyamoto K, Miyamoto M, Kokubu Y, Tozawa R, Sakurai H, Saito B.: Identification of 2,6-Disubstituted 3H-Imidazo[4,5-b]pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells. J Med Chem, Volume 62 (20), 2019";"PAMPA";0.000033113112148259076
"MM473720";"MM473720";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3cc(C)cc(C)c3)cn(C)c(=O)c2[nH]1";"TXUGGVDAFKSHBC-UHFFFAOYSA-N";507.61;4.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.51;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000003090295432513592
"MM474727";"MM474727";"NC(=O)c1cc(-c2ccccc2)cc2c(C3CCN(S(=O)(=O)CCCN4CCCCC4)CC3)c[nH]c12";"VPANJYSDPHFHOO-UHFFFAOYSA-N";508.69;4.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.62;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.0000239883291901949
"MM473717";"MM473717";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3c(C)cccc3C)cn(C)c(=O)c2[nH]1";"OPEBMJVHBSSVLY-UHFFFAOYSA-N";507.61;4.49;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.11;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.00000776247116628691
"MM473691";"MM473691";"CC(C)(O)c1cc(C(=O)N2CCCC(c3cc4ncccc4[nH]3)C2)on1";"ALQNTWYDXLVNEG-UHFFFAOYSA-N";354.41;2.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-6.35;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.0000004466835921509635
"MM473639";"MM473639";"Cc1nn(CCOCCOCCN)cc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1";"NJNBEEGJKOFJCB-HXUWFJFHSA-N";451.62;3.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-7.61;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.000000024547089156850285
"MM473665";"MM473665";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CCC[C@@H](CN)C2)c1";"GVEIJKANJLOMJH-MOPGFXCFSA-N";445.57;3.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-5.6;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.0000025118864315095823
"MM474728";"MM474728";"NC(=O)c1cc(-c2ccccc2)cc2c(C3CCN(S(=O)(=O)CCCN4CCOCC4)CC3)c[nH]c12";"GMIQJWKIKIPZJZ-UHFFFAOYSA-N";510.66;3.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.5;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.000031622776601683795
"MM472881";"MM472881";"Cc1ncnc2c1c1c(ccn1C)n2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"FFIKXEFPABQZHN-QGMIFYJMSA-N";318.33;-0.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4330289/target=_blank>CHEMBL4330289</a>";;-6.87;"Tokarenko A, LiĹˇkovĂˇ B, SmoleĹ„ S, TĂˇborskĂˇ N, TichĂ˝ M, GurskĂˇ S, PerlĂ­kovĂˇ P, Frydrych I, TlouĹˇt'ovĂˇ E, Znojek P, MertlĂ­kovĂˇ-KaiserovĂˇ H, PoĹˇtovĂˇ SlavÄ›tĂ­nskĂˇ L, Pohl R, KlepetĂˇĹ™ovĂˇ B, Khalid NU, Wenren Y, Laposa RR, DĹľubĂˇk P, HajdĂşch M, Hocek M.: Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides. J Med Chem, Volume 61 (20), 2018";"PAMPA";0.00000013489628825916533
"MM473668";"MM473668";"CCCOc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1";"VAMDLIMJLAPZGX-QGZVFWFLSA-N";360.46;5.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.73;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000018620871366628657
"MM473715";"MM473715";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3c(C)cccc3Cl)cn(C)c(=O)c2[nH]1";"OCYNKQMSOZDDMV-UHFFFAOYSA-N";528.03;4.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.56;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000002754228703338169
"MM473631";"MM473631";"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCOCCOCCNC(=O)OC(C)(C)C)CC2)n1";"ZKQTVBGLURSDIR-UHFFFAOYSA-N";675.26;4.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-8.19;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.000000006456542290346562
"MM473711";"MM473711";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3ccccc3C)cn(C)c(=O)c2[nH]1";"YHGHNENRTHFHIW-UHFFFAOYSA-N";493.59;4.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.43;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.0000037153522909717276
"MM473685";"MM473685";"Cc1nc(C)c(C(=O)N2CCCC(c3cc4ncccc4[nH]3)C2)o1";"HAZWCBBZPXYGHA-UHFFFAOYSA-N";324.38;3.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.81;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.0000015488166189124828
"MM473634";"MM473634";"NCc1cccc(C(=O)N2CCC(CCCCNC(=O)/C=C/c3cccnc3)CC2)c1";"WEPGGNXWWVQUNN-MDZDMXLPSA-N";420.56;3.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-7.04;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.00000009120108393559096
"MM473660";"MM473660";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1";"HSMAACWXVBSPJQ-CQSZACIVSA-N";350.39;4.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.67;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000021379620895022323
"MM473679";"MM473679";"O=C(c1ccc(F)cc1)N1CCCC(c2cc3ncccc3[nH]2)C1";"YDVZODJEUINLGA-UHFFFAOYSA-N";323.37;3.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-6.2;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000000630957344480193
"MM474739";"MM474739";"COc1ccccc1S(=O)(=O)Nc1ccc2c3c(cc(-c4ccc(C)o4)cc13)C(=O)N2C";"LXMRIQOUXRGUQR-UHFFFAOYSA-N";448.5;4.81;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4357144/target=_blank>CHEMBL4357144</a>";;-8.22;"Jiang F, Hu Q, Zhang Z, Li H, Li H, Zhang D, Li H, Ma Y, Xu J, Chen H, Cui Y, Zhi Y, Zhang Y, Xu J, Zhu J, Lu T, Chen Y.: Discovery of Benzo[<i>cd</i>]indol-2(1<i>H</i>)-ones and Pyrrolo[4,3,2-<i>de</i>]quinolin-2(1<i>H</i>)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis. J Med Chem, Volume 62 (24), 2019";"PAMPA";0.000000006025595860743569
"MM474733";"MM474733";"NC(=O)c1cc(-c2ccccc2)cc2c(C3CCN(S(=O)(=O)CCN4CCOCC4)CC3)c[nH]c12";"IBHBSLBQSHEYEW-UHFFFAOYSA-N";496.63;2.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.51;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00003090295432513592
"MM473632";"MM473632";"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCOCCOCCN)CC2)n1";"VYEYNLSRVXXGPW-UHFFFAOYSA-N";575.14;3.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-7.25;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.000000056234132519034905
"MM473655";"MM473655";"CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1";"LFGRESLGCGHUEH-UHFFFAOYSA-N";346.43;4.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.79;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.0000162181009735893
"MM473721";"MM473721";"CCNC(=O)c1cc2c(-c3cc(S(C)(=O)=O)ccc3Oc3c(C)cccc3C)cn(C)c(=O)c2[nH]1";"MYOFYUNIPWRAOL-UHFFFAOYSA-N";493.59;4.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.97;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.00001071519305237607
"MM472923";"MM472923";"Clc1ccccc1C1Cc2nccn2C1";"SPZWSHWMHHYVPO-UHFFFAOYSA-N";218.69;2.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.29;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.00005128613839913648
"MM472931";"MM472931";"CC(C)CNc1nc(C#N)nc(N2CCOCC2)c1N";"LADNPCFYVROVIW-UHFFFAOYSA-N";276.34;0.83;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021996/target=_blank>CHEMBL1021996</a>";;-4.57;"Morley AD, Kenny PW, Burton B, Heald RA, Macfaul PA, Mullett J, Page K, Porres SS, Ribeiro LR, Smith P, Ward S, Wilkinson TJ.: 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 19 (6), 2009";"PAMPA";0.00002691534803926914
"MM473701";"MM473701";"CN1CCCc2c1nc(N1CCC3(CC1)CN(CCO)c1cc(F)cc(F)c13)[nH]c2=O";"VXRWQCMYTRYKQD-UHFFFAOYSA-N";431.49;1.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4345400/target=_blank>CHEMBL4345400</a>";;-5.48;"Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H.: Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. J Med Chem, Volume 63 (8), 2020";"PAMPA";0.0000033113112148259077
"MM473656";"MM473656";"O=C(NCc1cccc2c1OCCO2)c1ccc(-c2ccncc2)cc1";"FWFHXPGGGOSSPF-UHFFFAOYSA-N";346.39;3.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.83;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000014791083881682072
"MM474730";"MM474730";"NC(=O)c1cc(-c2ccccc2)cc2c(C3CCN(S(=O)(=O)CCCNC4CCCC4)CC3)c[nH]c12";"XQIGPOYHURHPMV-UHFFFAOYSA-N";508.69;4.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.85;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.000014125375446227555
"MM474729";"MM474729";"NC(=O)c1cc(-c2ccccc2)cc2c(C3CCN(S(=O)(=O)CCCN4CCCCCC4)CC3)c[nH]c12";"RZYUQVVDRRDXNT-UHFFFAOYSA-N";522.72;4.71;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.54;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.000028840315031266056
"MM474732";"MM474732";"CN(C)CCS(=O)(=O)N1CCC(c2c[nH]c3c(C(N)=O)cc(-c4ccccc4)cc23)CC1";"MJWPHYZQZROWPH-UHFFFAOYSA-N";454.6;3;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.57;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00002691534803926914
"MM473692";"MM473692";"COc1cc(C(=O)N2CCCC(c3cc4ncccc4[nH]3)C2)on1";"SOOXOFOIQRSLHO-UHFFFAOYSA-N";326.36;2.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.2;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.00000630957344480193
"MM474725";"MM474725";"CCN(CC)CCCS(=O)(=O)N1CCC(c2c[nH]c3c(C(N)=O)cc(-c4ccccc4)cc23)CC1";"VQIIDCSRXUTGCN-UHFFFAOYSA-N";496.68;4.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.7;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.000019952623149688786
"MM473673";"MM473673";"CC[C@H](C)[C@@H]1NC(=O)[C@H](C)N(C)C(=O)[C@H](Cc2ccccc2)NC(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)N(C)C(=O)[C@H](CC(C)C)NC1=O";"XAYYGPXTFXAIPJ-DCUUSGBQSA-N";788;2.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328889/target=_blank>CHEMBL4328889</a>";;-5.23;"Naylor MR, Ly AM, Handford MJ, Ramos DP, Pye CR, Furukawa A, Klein VG, Noland RP, Edmondson Q, Turmon AC, Hewitt WM, Schwochert J, Townsend CE, Kelly CN, Blanco MJ, Lokey RS.: Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000005888436553555884
"MM473630";"MM473630";"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCNCC2)n1";"DOBZFFWLHXORTB-UHFFFAOYSA-N";443.96;3.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-7.43;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.00000003715352290971728
"MM473726";"MM473726";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3-c3ccccc3C)cn(C)c(=O)c2[nH]1";"OANIEISAWKUQBJ-UHFFFAOYSA-N";477.59;4.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.99;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000010232929922807536
"MM473696";"MM473696";"O=C(c1ccccc1)N1CCCC(c2cn3cccnc3n2)C1";"FKGXERUHEQMSPS-UHFFFAOYSA-N";306.37;2.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.56;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000002754228703338169
"MM473684";"MM473684";"O=C(c1ccc(C(F)(F)F)nc1)N1CCCC(c2cc3ncccc3[nH]2)C1";"OUPIDEAYKWCYML-UHFFFAOYSA-N";374.37;4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-6.05;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.0000008912509381337459
"MM473706";"MM473706";"C[C@@H]1C[C@H](C)CN(c2ncc(Cl)c(Nc3ccc4c(c3)n(CCC(C)(C)O)c(=O)n4C)n2)C1";"SZOQWJDRAIBTQM-IYBDPMFKSA-N";473.02;4.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4345702/target=_blank>CHEMBL4345702</a>";;-4.44;"Bellenie BR, Cheung KJ, Varela A, Pierrat OA, Collie GW, Box GM, Bright MD, Gowan S, Hayes A, Rodrigues MJ, Shetty KN, Carter M, Davis OA, Henley AT, Innocenti P, Johnson LD, Liu M, de Klerk S, Le Bihan YV, Lloyd MG, McAndrew PC, Shehu E, Talbot R, Woodward HL, Burke R, Kirkin V, van Montfort RLM, Raynaud FI, Rossanese OW, Hoelder S.: Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. J Med Chem, Volume 63 (8), 2020";"PAMPA";0.0000363078054770101
"MM473694";"MM473694";"O=C(c1ccccc1)N1CCCC(c2cn3ncccc3n2)C1";"MCFCCBZLJGOXFC-UHFFFAOYSA-N";306.37;2.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-4.86;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000013803842646028839
"MM473719";"MM473719";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3c(C)cccc3C(F)(F)F)cn(C)c(=O)c2[nH]1";"RNNIEDANKZEVPX-UHFFFAOYSA-N";561.58;5.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.82;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000015135612484362071
"MM473712";"MM473712";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3ccccc3Cl)cn(C)c(=O)c2[nH]1";"CVLVVVZJWFPMCQ-UHFFFAOYSA-N";514;4.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.86;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000013803842646028839
"MM473663";"MM473663";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CC[C@@H](CN)C2)c1";"PKLARINHGWEPSR-MSOLQXFVSA-N";431.54;3.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-5.85;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.0000014125375446227554
"MM474391";"MM474391";"CCOC(=O)[C@@]1(c2ccccc2)CCC=C[C@@H]1N(C)C";"WDEFBBTXULIOBB-DOTOQJQBSA-N";273.38;2.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.5;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000031622776601683795
"MM473709";"MM473709";"CCN(C)C(=O)c1cc2c(-c3cc(S(C)(=O)=O)ccc3Oc3ccc(F)cc3F)cn(C)c(=O)c2[nH]1";"NVEKHYPVMGLKLG-UHFFFAOYSA-N";515.54;4.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-4.8;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.00001584893192461114
"MM473680";"MM473680";"COc1ccc(C(=O)N2CCCC(c3cc4ncccc4[nH]3)C2)cc1OC";"XDKXEEXTLWFEGQ-UHFFFAOYSA-N";365.43;3.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.8;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000001584893192461114
"MM473713";"MM473713";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)CC)ccc3Oc3ccccc3C(C)(C)C)cn(C)c(=O)c2[nH]1";"JXZVUCMTCJJHJS-UHFFFAOYSA-N";535.67;5.17;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.25;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.000005623413251903491
"MM473666";"MM473666";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCC4CC4)c3)cc2)c1";"SCOXTVBTPMVBKV-QGZVFWFLSA-N";401.51;5.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-5.29;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000005128613839913648
"MM473664";"MM473664";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2N2CCC[C@H](CN)C2)c1";"GVEIJKANJLOMJH-RTBURBONSA-N";445.57;3.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-5.59;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.0000025703957827688647
"MM472880";"MM472880";"O=C(O)CC12CCC(c3ccc(-c4ccc(Nc5nnc(C6CCC6)o5)cn4)cc3)(CC1)CO2";"CQDYBKWJJPPSNB-UHFFFAOYSA-N";460.53;5.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4307359/target=_blank>CHEMBL4307359</a>";;-7.1;"Harrison TJ, Bauer D, Berdichevsky A, Chen X, Duvadie R, Hoogheem B, Hatsis P, Liu Q, Mao J, Miduturu V, Rocheford E, Zecri F, Zessis R, Zheng R, Zhu Q, Streeper R, Patel SJ.: Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor. ACS Med Chem Lett, Volume 10 (8), 2019";"PAMPA";0.00000007943282347242822
"MM474735";"MM474735";"NC(=O)c1cc(-c2ccc(F)cc2)cc2c(C3CCS(=O)(=O)CC3)c[nH]c12";"CKNZVFDNPYSVSS-UHFFFAOYSA-N";386.45;3.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.55;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00002818382931264455
"MM473722";"MM473722";"CCNC(=O)c1cc2c(-c3cc(S(=O)(=O)C4CC4)ccc3Oc3c(C)cccc3C)cn(C)c(=O)c2[nH]1";"OVBFFNLXWQHEOI-UHFFFAOYSA-N";519.62;4.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.08;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.00000831763771102671
"MM473628";"MM473628";"NCCOCCOCC(=O)N1CCN(C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)CC1";"BXZXQGJRHFJBKR-UHFFFAOYSA-N";511.55;0.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-8.92;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.0000000012022644346174132
"MM474737";"MM474737";"CC1(C)C[C@H](c2c[nH]c3c(C(N)=O)cc(-c4ccc(F)cc4)cc23)CCS1(=O)=O";"YGYGASJNJTYNOL-CQSZACIVSA-N";414.5;4.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.55;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00002818382931264455
"MM472882";"MM472882";"CSc1ncnc2c1c1c(ccn1C)n2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"UZNOKGGVHLKRMJ-PMXXHBEXSA-N";350.4;0.26;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4330289/target=_blank>CHEMBL4330289</a>";;-5.69;"Tokarenko A, LiĹˇkovĂˇ B, SmoleĹ„ S, TĂˇborskĂˇ N, TichĂ˝ M, GurskĂˇ S, PerlĂ­kovĂˇ P, Frydrych I, TlouĹˇt'ovĂˇ E, Znojek P, MertlĂ­kovĂˇ-KaiserovĂˇ H, PoĹˇtovĂˇ SlavÄ›tĂ­nskĂˇ L, Pohl R, KlepetĂˇĹ™ovĂˇ B, Khalid NU, Wenren Y, Laposa RR, DĹľubĂˇk P, HajdĂşch M, Hocek M.: Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides. J Med Chem, Volume 61 (20), 2018";"PAMPA";0.0000020417379446695273
"MM473723";"MM473723";"CCNC(=O)c1cc2c(-c3cc(S(C)(=O)=O)ccc3Nc3c(C)cccc3C)cn(C)c(=O)c2[nH]1";"SYQXWMGRKFNROA-UHFFFAOYSA-N";492.6;4.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4346341/target=_blank>CHEMBL4346341</a>";;-5.44;"Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker K, Qiu W, Torrent M, Kovar PJ, Bui M, Faivre E, Huang X, Lin X, Wilcox D, Zhang L, Shen Y, Albert DH, Magoc TJ, Rajaraman G, Kati WM, McDaniel KF.: Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain. J Med Chem, Volume 63 (10), 2020";"PAMPA";0.0000036307805477010103
"MM474298";"MM474298";"O=C(N[C@H]1CC[C@H](O)CC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F";"IZIPWCFRXVNDNX-MGCOHNPYSA-N";364.35;1.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4151788/target=_blank>CHEMBL4151788</a>";;-4.51;"Hazlitt RA, Teitz T, Bonga JD, Fang J, Diao S, Iconaru L, Yang L, Goktug AN, Currier DG, Chen T, Rankovic Z, Min J, Zuo J.: Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss. J Med Chem, Volume 61 (17), 2018";"PAMPA";0.00003090295432513592
"MM473693";"MM473693";"O=C(c1ccccc1)N1CCCC(c2nc3ncccc3[nH]2)C1";"JZHLZZNVUDHUFP-UHFFFAOYSA-N";306.37;2.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.61;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.0000024547089156850284
"MM473642";"MM473642";"CC(=O)c1cccc(N(CCO)c2nc(-c3sc(NC(=O)C(C)(C)C)nc3C)cs2)c1";"KHNUPLUQJFLSLN-UHFFFAOYSA-N";458.61;4.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4324521/target=_blank>CHEMBL4324521</a>";;-5.96;"Tassini S, Langron E, Delang L, Mirabelli C, Lanko K, Crespan E, Kissova M, Tagliavini G, FontĂ˛ G, Bertoni S, Palese S, Giorgio C, Ravanetti F, Ragionieri L, Zamperini C, Mancini A, Dreassi E, Maga G, Vergani P, Neyts J, Radi M.: Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach â€ . J Med Chem, Volume 62 (23), 2019";"PAMPA";0.000001096478196143185
"MM474736";"MM474736";"CC1(C)CC(c2c[nH]c3c(C(N)=O)cc(-c4ccccc4)cc23)CCS1(=O)=O";"PZNOTHUZGPKYEZ-UHFFFAOYSA-N";396.51;4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.48;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.000033113112148259076
"MM473640";"MM473640";"Cc1nn(CCOCCOCCNC(=O)OC(C)(C)C)cc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1";"AFOHSYLABSAJBV-HSZRJFAPSA-N";551.73;4.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-6.06;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.0000008709635899560814
"MM473686";"MM473686";"O=C(c1cc(C(F)(F)F)n[nH]1)N1CCCC(c2cc3ncccc3[nH]2)C1";"UCYDPBRUQDHQIG-UHFFFAOYSA-N";363.34;3.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-6.06;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.0000008709635899560814
"MM473703";"MM473703";"CN1CCN(c2cc(F)c3c(c2)N(C)C(=O)C32CCN(c3nc4c(c(=O)[nH]3)CCCN4C)CC2)CC1";"PAMGRUFJDHRZSY-UHFFFAOYSA-N";495.6;1.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4345400/target=_blank>CHEMBL4345400</a>";;-4.89;"Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, Nagamori A, Okue M, Watanabe T, Kitamura K, Shitara E, Honma T, Umehara T, Shirouzu M, Fukami T, Seimiya H, Yoshida M, Koyama H.: Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. J Med Chem, Volume 63 (8), 2020";"PAMPA";0.000012882495516931348
"MM473698";"MM473698";"NCc1cccc(C2CCN(C(=O)c3cccc4ccc(B(O)O)cc34)CC2)c1";"GNVCVDWHRVFTIC-UHFFFAOYSA-N";388.28;2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4344458/target=_blank>CHEMBL4344458</a>";;-5.69;"Giardina SF, Werner DS, Pingle M, Feinberg PB, Foreman KW, Bergstrom DE, Arnold LD, Barany F.: Novel, Self-Assembling Dimeric Inhibitors of Human Î˛ Tryptase. J Med Chem, Volume 63 (6), 2020";"PAMPA";0.0000020417379446695273
"MM473662";"MM473662";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnnc3)cc2)c1";"FCHCWQPKXAUAEQ-CQSZACIVSA-N";333.39;3.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-4.9;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000012589254117941661
"MM472883";"MM472883";"Cc1ncnc2c1c1occc1n2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"FFRYCGOSSQOBHH-IDTAVKCVSA-N";305.29;0.1;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4330289/target=_blank>CHEMBL4330289</a>";;-6.88;"Tokarenko A, LiĹˇkovĂˇ B, SmoleĹ„ S, TĂˇborskĂˇ N, TichĂ˝ M, GurskĂˇ S, PerlĂ­kovĂˇ P, Frydrych I, TlouĹˇt'ovĂˇ E, Znojek P, MertlĂ­kovĂˇ-KaiserovĂˇ H, PoĹˇtovĂˇ SlavÄ›tĂ­nskĂˇ L, Pohl R, KlepetĂˇĹ™ovĂˇ B, Khalid NU, Wenren Y, Laposa RR, DĹľubĂˇk P, HajdĂşch M, Hocek M.: Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides. J Med Chem, Volume 61 (20), 2018";"PAMPA";0.00000013182567385564074
"MM473667";"MM473667";"COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(NCCCO)c3)cc2)c1";"JITJVUCWRMTDAV-QGZVFWFLSA-N";405.5;4.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4328672/target=_blank>CHEMBL4328672</a>";;-5.04;"Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.: Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. J Med Chem, Volume 61 (24), 2018";"PAMPA";0.000009120108393559096
"MM473637";"MM473637";"Cc1nn(CCOCCOCCNC(=O)C2C(C(=O)O)C(C(=O)O)C2C(=O)O)cc1-c1ccc2cc(CCN3CCC[C@H]3C)ccc2n1";"UPIRPVAFRMKUTD-QNYSQSKBSA-N";665.74;2.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-7.88;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.000000013182567385564074
"MM474734";"MM474734";"NC(=O)c1cc(-c2ccccc2)cc2c(C3CCS(=O)(=O)CC3)c[nH]c12";"XNXQMKGGFGDFEC-UHFFFAOYSA-N";368.46;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4329666/target=_blank>CHEMBL4329666</a>";;-4.56;"Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.: 3,5-Disubstituted-indole-7-carboxamides as IKKÎ˛ Inhibitors: Optimization of Oral Activity via the C3 Substituent. ACS Med Chem Lett, Volume 9 (12), 2018";"PAMPA";0.00002754228703338169
"MM473688";"MM473688";"O=C(c1cc(C2CC2)no1)N1CCCC(c2cc3ncccc3[nH]2)C1";"GEMRJPCLJHHBIJ-UHFFFAOYSA-N";336.4;3.45;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4343676/target=_blank>CHEMBL4343676</a>";;-5.5;"Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC.: Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett, Volume 30 (1), 2020";"PAMPA";0.000003162277660168379
"MM472884";"MM472884";"CSc1ncnc2c1c1occc1n2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O";"SWQLIPCORWXTQV-AKAIJSEGSA-N";337.36;0.51;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4330289/target=_blank>CHEMBL4330289</a>";;-5.99;"Tokarenko A, LiĹˇkovĂˇ B, SmoleĹ„ S, TĂˇborskĂˇ N, TichĂ˝ M, GurskĂˇ S, PerlĂ­kovĂˇ P, Frydrych I, TlouĹˇt'ovĂˇ E, Znojek P, MertlĂ­kovĂˇ-KaiserovĂˇ H, PoĹˇtovĂˇ SlavÄ›tĂ­nskĂˇ L, Pohl R, KlepetĂˇĹ™ovĂˇ B, Khalid NU, Wenren Y, Laposa RR, DĹľubĂˇk P, HajdĂşch M, Hocek M.: Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides. J Med Chem, Volume 61 (20), 2018";"PAMPA";0.0000010232929922807537
"MM472965";"MM472965";"Cc1ccc(C)c(CNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)c1";"WQCDXFCLSJKPFB-GUYCJALGSA-N";555.48;1.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.38;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000004168693834703355
"MM472964";"MM472964";"Cc1ccc(CNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)cc1C";"PDYZTSBNHZTQRX-GUYCJALGSA-N";555.48;1.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.43;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.0000037153522909717276
"MM472962";"MM472962";"C[C@H](NC(=O)C(=O)NCc1ccc(Cl)cc1Cl)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"KQRRQQVJYJAUOH-VFZGTOFNSA-N";596.32;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.57;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.0000026915348039269138
"MM472974";"MM472974";"C[C@H](NC(=O)C(=O)NCc1c(Cl)cccc1Cl)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"OXXVIIFSOFDDMQ-VFZGTOFNSA-N";596.32;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.34;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000004570881896148752
"MM472975";"MM472975";"C[C@H](NC(=O)C(=O)NCc1cc(Cl)cc(Cl)c1)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"HOUYHRJRNPINGW-VFZGTOFNSA-N";596.32;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.59;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.0000025703957827688647
"MM472920";"MM472920";"Clc1ccccc1C1CCc2nc[nH]c2C1";"QJISVABLQCOWQF-UHFFFAOYSA-N";232.71;3.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.47;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.000033884415613920276
"MM472963";"MM472963";"C[C@H](NC(=O)C(=O)NCc1cccc(Cl)c1Cl)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"TZXQGLNSFUEYKD-XPTSAGLGSA-N";596.32;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.51;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000003090295432513592
"MM472918";"MM472918";"c1ccc(C2CCc3nc[nH]c3C2)cc1";"FNAMNTIDTBOHMV-UHFFFAOYSA-N";198.27;2.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.33;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.00004677351412871981
"MM472933";"MM472933";"Cc1cc(OCc2c(-c3c(Cl)cncc3Cl)noc2C(C)C)ccc1-c1ccc2c(C(=O)O)cn(C)c2c1";"JTRRVYQZHXAOGI-UHFFFAOYSA-N";550.44;7.91;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL980678/target=_blank>CHEMBL980678</a>";;-6.72;"Feng S, Yang M, Zhang Z, Wang Z, Hong D, Richter H, Benson GM, Bleicher K, Grether U, Martin RE, Plancher JM, Kuhn B, Rudolph MG, Chen L.: Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorg Med Chem Lett, Volume 19 (9), 2009";"PAMPA";0.00000019054607179632483
"MM472979";"MM472979";"Cc1ccc(C)c(CCNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)c1";"IRXSNMCFWBVFSF-KSSFIOAISA-N";569.51;1.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.37;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000004265795188015926
"MM472935";"MM472935";"COc1ccc(Cl)c(-c2noc(C(C)C)c2COc2ccc(-c3ccc4c(C(=O)O)cn(C)c4c3)c(C)c2)n1";"LOUFJUUIECUECD-UHFFFAOYSA-N";546.02;7.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL980678/target=_blank>CHEMBL980678</a>";;-6.15;"Feng S, Yang M, Zhang Z, Wang Z, Hong D, Richter H, Benson GM, Bleicher K, Grether U, Martin RE, Plancher JM, Kuhn B, Rudolph MG, Chen L.: Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorg Med Chem Lett, Volume 19 (9), 2009";"PAMPA";0.0000007079457843841374
"MM473122";"MM473122";"Cc1nc(N)c2ncn([C@@H]3O[C@H](CN(C)C/C=C\CN)[C@@H](O)[C@H]3O)c2n1";"MTDBNJKMVASAKC-LNNUBQDUSA-N";363.42;-1.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1653937/target=_blank>CHEMBL1653937</a>";;-6.66;"Barker RH, Liu H, Hirth B, Celatka CA, Fitzpatrick R, Xiang Y, Willert EK, Phillips MA, Kaiser M, Bacchi CJ, Rodriguez A, Yarlett N, Klinger JD, Sybertz E.: Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. Antimicrob Agents Chemother, Volume 53 (5), 2009";"PAMPA";0.0000002187761623949552
"MM472939";"MM472939";"Cc1c(Nc2c(C#N)cncc2-c2ccc(OCCN3CCN(C)CC3)cc2)ccc2[nH]ccc12";"LTGPAFCQBMWTBC-UHFFFAOYSA-N";466.59;4.78;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1007491/target=_blank>CHEMBL1007491</a>";;-6.55;"Boschelli DH, Wang D, Prashad AS, Subrath J, Wu B, Niu C, Lee J, Yang X, Brennan A, Chaudhary D.: Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCtheta inhibitors. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.0000002818382931264455
"MM472924";"MM472924";"Clc1ccc(C2Cc3nccn3C2)cc1";"NMYFTUWMFYFIEY-UHFFFAOYSA-N";218.69;2.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.47;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.000033884415613920276
"MM472925";"MM472925";"COc1ccccc1C1Cc2nccn2C1";"JOZLKCRZSXEYJL-UHFFFAOYSA-N";214.27;2.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.24;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.000057543993733715664
"MM472928";"MM472928";"FC(F)Oc1ccccc1C1Cc2nccn2C1";"DCZFXJLVCNQIPP-UHFFFAOYSA-N";250.25;2.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.46;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.00003467368504525317
"MM472929";"MM472929";"N#Cc1ccccc1C1Cc2nccn2C1";"KMOFNRDXTFJLAO-UHFFFAOYSA-N";209.25;2.09;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.64;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.00002290867652767775
"MM473123";"MM473123";"CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)nc(Cl)nc32)[C@H](O)[C@@H]1O";"DVPZNDPOWUEVAP-UKSTWOGXSA-N";383.84;-0.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1653937/target=_blank>CHEMBL1653937</a>";;-6.44;"Barker RH, Liu H, Hirth B, Celatka CA, Fitzpatrick R, Xiang Y, Willert EK, Phillips MA, Kaiser M, Bacchi CJ, Rodriguez A, Yarlett N, Klinger JD, Sybertz E.: Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. Antimicrob Agents Chemother, Volume 53 (5), 2009";"PAMPA";0.000000363078054770101
"MM474396";"MM474396";"C[C@H](N)C(=O)NCc1cccc(-n2nc(C(F)(F)F)cc2-c2nnc(-c3cccc4ncsc34)o2)c1";"KODBDIFHMBDFOH-LBPRGKRZSA-N";513.51;4.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL971421/target=_blank>CHEMBL971421</a>";;-4.57;"Huynh T, Chen Z, Pang S, Geng J, Bandiera T, Bindi S, Vianello P, Roletto F, Thieffine S, Galvani A, Vaccaro W, Poss MA, Trainor GL, Lorenzi MV, Gottardis M, Jayaraman L, Purandare AV.: Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.00002691534803926914
"MM472932";"MM472932";"CC(C)c1onc(-c2c(Cl)cncc2Cl)c1COc1ccc(/C=C/c2cccc(C(=O)O)c2)c(Cl)c1";"CCOJMMHFLKMSGW-VOTSOKGWSA-N";543.83;8.27;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL980678/target=_blank>CHEMBL980678</a>";;-7.05;"Feng S, Yang M, Zhang Z, Wang Z, Hong D, Richter H, Benson GM, Bleicher K, Grether U, Martin RE, Plancher JM, Kuhn B, Rudolph MG, Chen L.: Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorg Med Chem Lett, Volume 19 (9), 2009";"PAMPA";0.00000008912509381337459
"MM472976";"MM472976";"Cc1ccccc1CCNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"RNKVSYPRGAILIK-GUYCJALGSA-N";555.48;1.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.8;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000001584893192461114
"MM472977";"MM472977";"Cc1cccc(CCNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)c1";"XVZQSTFHSSMRCP-GUYCJALGSA-N";555.48;1.32;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.77;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000001698243652461746
"MM472978";"MM472978";"Cc1ccc(CCNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)c(C)c1";"FIWUHSLZKDSRRX-KSSFIOAISA-N";569.51;1.63;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.13;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000007413102413009177
"MM472966";"MM472966";"Cc1ccc(CNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)c(C)c1";"ZQBGZBYBWNWBDJ-GUYCJALGSA-N";555.48;1.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.4;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000003981071705534969
"MM472930";"MM472930";"CC(C)CNc1nc(C#N)nc(N2CCNCC2)c1N";"PCCGUZVUPBIHJH-UHFFFAOYSA-N";275.36;0.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021996/target=_blank>CHEMBL1021996</a>";;-5.7;"Morley AD, Kenny PW, Burton B, Heald RA, Macfaul PA, Mullett J, Page K, Porres SS, Ribeiro LR, Smith P, Ward S, Wilkinson TJ.: 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 19 (6), 2009";"PAMPA";0.0000019952623149688787
"MM472970";"MM472970";"C[C@H](NC(=O)C(=O)NCc1ccccc1F)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"PTMBHNACBLDOOT-BONVTDFDSA-N";545.42;1.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-6.52;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.0000003019951720402019
"MM472938";"MM472938";"COc1ccc(CN(C)C)c(-c2cc3c(Nc4ccc5[nH]ccc5c4C)c(C#N)cnc3s2)c1";"ZZARJEJPLRJJQO-UHFFFAOYSA-N";467.6;6.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL991262/target=_blank>CHEMBL991262</a>";;-5.98;"Wu B, Boschelli DH, Lee J, Yang X, Chaudhary D.: Second generation 4-(4-methyl-1H-indol-5-ylamino)-2-phenylthieno[2,3-b]pyridine-5-carbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett, Volume 19 (3), 2009";"PAMPA";0.0000010471285480508985
"MM472972";"MM472972";"Cc1cccc(CNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)c1";"QLZYBGAPTZHWPU-LRDDRELGSA-N";541.45;1.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.92;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.0000012022644346174132
"MM472971";"MM472971";"Cc1ccc(CNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)cc1";"YWIHNJYCSCLNBC-LRDDRELGSA-N";541.45;1.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.96;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000001096478196143185
"MM472973";"MM472973";"Cc1ccccc1CNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"TZZWQKUMLBKMAW-LRDDRELGSA-N";541.45;1.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.89;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000001288249551693135
"MM472969";"MM472969";"C[C@H](NC(=O)C(=O)NCc1cccc(F)c1)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"SEDSCLRDBPXFSO-BONVTDFDSA-N";545.42;1.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-6.52;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.0000003019951720402019
"MM472968";"MM472968";"C[C@H](NC(=O)C(=O)NCc1ccc(F)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"CUUQUNCVQNLLLW-BONVTDFDSA-N";545.42;1.11;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-6.4;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.0000003981071705534969
"Codeine";"MM00470";"COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314";"OROGSEYTTFOCAN-DNJOTXNNSA-N";299.37;1.5;"5284371";"CHEMBL485";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-5.1;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000007943282347242822
"MM474297";"MM474297";"Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C";"WJRRGYBTGDJBFX-UHFFFAOYSA-N";371.47;3.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4151788/target=_blank>CHEMBL4151788</a>";;-3.52;"Hazlitt RA, Teitz T, Bonga JD, Fang J, Diao S, Iconaru L, Yang L, Goktug AN, Currier DG, Chen T, Rankovic Z, Min J, Zuo J.: Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss. J Med Chem, Volume 61 (17), 2018";"PAMPA";0.0003019951720402016
"MM472954";"MM472954";"CCN1CCN(CC/C=C/c2ccc3c(Nc4ccc(Sc5nccn5C)c(Cl)c4)c(C#N)cnc3c2)CC1";"OYAMULIHRWEUAR-GQCTYLIASA-N";558.16;6.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL991687/target=_blank>CHEMBL991687</a>";;-6.35;"Berger DM, Dutia M, Powell D, Floyd MB, Torres N, Mallon R, Wojciechowicz D, Kim S, Feldberg L, Collins K, Chaudhary I.: 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors. Bioorg Med Chem, Volume 16 (20), 2008";"PAMPA";0.0000004466835921509635
"MM472820";"MM472820";"Nc1ncnc2c1ncn2[C@@H]1O[C@H](COC(=O)c2ccc(S(=O)(=O)F)cc2)[C@@H](O)[C@H]1O";"AQZGKOBMIMVGMG-XNIJJKJLSA-N";453.41;-0.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4182564/target=_blank>CHEMBL4182564</a>";;-7.2;"Jiao GS, Kim S, Moayeri M, Thai A, Cregar-Hernandez L, McKasson L, O'Malley S, Leppla SH, Johnson AT.: Small molecule inhibitors of anthrax edema factor. Bioorg Med Chem Lett, Volume 28 (2), 2018";"PAMPA";0.0000000630957344480193
"MM473627";"MM473627";"O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCNCC1";"MFFUYEOGICAKCK-UHFFFAOYSA-N";366.4;1.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-7.09;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.00000008128305161640995
"MM472951";"MM472951";"N#Cc1cnc2c(Cl)cc(NCc3cn(CC(=O)O)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"BFAVZGMITXUKBS-UHFFFAOYSA-N";486.29;4.58;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-7.4;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.00000003981071705534969
"MM472943";"MM472943";"N#Cc1cnc2c(Cl)cc(NCc3cn(CCC4CCCN4)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"MNOSVXZMVQUZQR-UHFFFAOYSA-N";525.42;5.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-6.24;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.0000005754399373371567
"MM472944";"MM472944";"CCCN1CCC(n2cc(CNc3cc(Cl)c4ncc(C#N)c(Nc5ccc(F)c(Cl)c5)c4c3)nn2)CC1";"DATRTCJGCFQUHH-UHFFFAOYSA-N";553.47;6.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-6.32;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.000000478630092322638
"MM472940";"MM472940";"N#Cc1cnc2c(Br)cc(NCc3cn(CC(=O)O)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"SHTIVTKXVWFHIV-UHFFFAOYSA-N";530.75;4.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-5.74;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.0000018197008586099826
"MM472900";"MM472900";"CC(=O)c1ccc(N2CCN(C(=O)c3cc(S(N)(=O)=O)ccc3N3CCOCC3)CC2)c(F)c1";"RBFGIFBKMSGFGJ-UHFFFAOYSA-N";490.56;1.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1007116/target=_blank>CHEMBL1007116</a>";;-5.48;"Pinard E, Alberati D, Borroni E, Fischer H, Hainzl D, Jolidon S, Moreau JL, Narquizian R, Nettekoven M, Norcross RD, Stalder H, Thomas AW.: Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 18 (18), 2008";"PAMPA";0.0000033113112148259077
"MM472950";"MM472950";"CC(C)(C)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1";"SRNSJXJGQHZBMC-UHFFFAOYSA-N";484.37;6.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-7;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.0000001
"MM472903";"MM472903";"CC(=O)c1ccc(N2CCN(C(=O)c3cc(C#N)ccc3N3CCOCC3)CC2)c(F)c1";"UIOCFWCJDKQTSI-UHFFFAOYSA-N";436.49;2.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1007116/target=_blank>CHEMBL1007116</a>";;-5.21;"Pinard E, Alberati D, Borroni E, Fischer H, Hainzl D, Jolidon S, Moreau JL, Narquizian R, Nettekoven M, Norcross RD, Stalder H, Thomas AW.: Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 18 (18), 2008";"PAMPA";0.000006165950018614822
"MM472942";"MM472942";"N#Cc1cnc2c(Br)cc(NCc3cn(CCC4CCCN4)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"FIMFYDKNWOUFLC-UHFFFAOYSA-N";569.87;5.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-6.14;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.0000007244359600749906
"MM472902";"MM472902";"CNS(=O)(=O)c1ccc(N2CCOCC2)c(C(=O)N2CCN(c3ccc(C(C)=O)cc3F)CC2)c1";"WIGSBOSBGAGALY-UHFFFAOYSA-N";504.58;1.74;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1007116/target=_blank>CHEMBL1007116</a>";;-5.28;"Pinard E, Alberati D, Borroni E, Fischer H, Hainzl D, Jolidon S, Moreau JL, Narquizian R, Nettekoven M, Norcross RD, Stalder H, Thomas AW.: Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 18 (18), 2008";"PAMPA";0.000005248074602497723
"MM472904";"MM472904";"CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2CCN(c3ccc(C#N)cc3F)CC2)c1";"IOSCQMWDOQVSFE-UHFFFAOYSA-N";457.53;2.85;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1007116/target=_blank>CHEMBL1007116</a>";;-5.49;"Pinard E, Alberati D, Borroni E, Fischer H, Hainzl D, Jolidon S, Moreau JL, Narquizian R, Nettekoven M, Norcross RD, Stalder H, Thomas AW.: Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 18 (18), 2008";"PAMPA";0.000003235936569296281
"MM472952";"MM472952";"N#Cc1cnc2c(Cl)cc(NCc3cn(C4CCNCC4)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"YIFLRNURKJVDHB-UHFFFAOYSA-N";511.39;5.42;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-7.52;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.000000030199517204020194
"MM472946";"MM472946";"CN1CCC(n2cc(CNc3cc(Cl)c4ncc(C#N)c(Nc5ccc(F)c(Cl)c5)c4c3)nn2)CC1";"ZLCJQOQCUYDZNR-UHFFFAOYSA-N";525.42;5.77;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-6.41;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.0000003890451449942805
"MM472948";"MM472948";"N#Cc1cnc2c(Cl)cc(NCc3cn(Cc4cccnc4)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"XWHXNBMNAZBIQQ-UHFFFAOYSA-N";519.37;5.94;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-6.74;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.00000018197008586099824
"Quercetin";"MM00047";"O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12";"REFJWTPEDVJJIY-UHFFFAOYSA-N";302.24;1.99;"5280343";"CHEMBL50";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2398996/target=_blank>CHEMBL2398996</a>";;-4.44;"Cho SY, Kim MK, Park KS, Choo H, Chong Y.: Quercetin-POC conjugates: Differential stability and bioactivity profiles between breast cancer (MCF-7) and colorectal carcinoma (HCT116) cell lines. Bioorg Med Chem, Volume 21 (7), 2013";"PAMPA";0.0000363078054770101
"Quercetin";"MM00047";"O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12";"REFJWTPEDVJJIY-UHFFFAOYSA-N";302.24;1.99;"5280343";"CHEMBL50";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2398998/target=_blank>CHEMBL2398998</a>";;-4.14;"Cho SY, Kim MK, Park KS, Choo H, Chong Y.: Quercetin-POC conjugates: Differential stability and bioactivity profiles between breast cancer (MCF-7) and colorectal carcinoma (HCT116) cell lines. Bioorg Med Chem, Volume 21 (7), 2013";"PAMPA";0.00007244359600749906
"MM472945";"MM472945";"N#Cc1cnc2c(Cl)cc(NCc3cn(C4CCN(C5CCC5)CC4)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"YGHNIYXOYMJYDH-UHFFFAOYSA-N";565.48;6.69;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-6.37;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.00000042657951880159254
"MM472927";"MM472927";"COc1ccc(C2Cc3nccn3C2)cc1";"CQPRHMLRHXLMEL-UHFFFAOYSA-N";214.27;2.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.24;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.000057543993733715664
"MM472921";"MM472921";"Clc1cccc(C2CCc3nc[nH]c3C2)c1";"SNFFBYPCULSUGT-UHFFFAOYSA-N";232.71;3.34;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.41;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.000038904514499428046
"MM472937";"MM472937";"CCCCc1ccc(C(=O)NC2(C(=O)N[C@H](Cc3ccccc3)C(=O)NCC3CCN(CC4CCOCC4)CC3)CCCC2)cc1";"FNWMFLJWSOZBPX-UUWRZZSWSA-N";630.87;5.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL967980/target=_blank>CHEMBL967980</a>";;-5.8;"Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, Fattori D.: Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett, Volume 18 (16), 2008";"PAMPA";0.000001584893192461114
"MM472926";"MM472926";"COc1cccc(C2Cc3nccn3C2)c1";"OZJCKBRXCUUNCT-UHFFFAOYSA-N";214.27;2.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015850/target=_blank>CHEMBL1015850</a>";;-4.33;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.00004677351412871981
"MM474395";"MM474395";"C[C@H](N)C(=O)NCc1cccc(-n2nc(C(F)(F)F)cc2-c2nnc(-c3ccccc3)o2)c1";"KRZYPYCEMGWWDP-ZDUSSCGKSA-N";456.43;3.57;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL971421/target=_blank>CHEMBL971421</a>";;-4.97;"Huynh T, Chen Z, Pang S, Geng J, Bandiera T, Bindi S, Vianello P, Roletto F, Thieffine S, Galvani A, Vaccaro W, Poss MA, Trainor GL, Lorenzi MV, Gottardis M, Jayaraman L, Purandare AV.: Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). Bioorg Med Chem Lett, Volume 19 (11), 2009";"PAMPA";0.00001071519305237607
"MM472967";"MM472967";"Cc1cccc(CNC(=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)c1C";"ULKKTMITCULOQW-GUYCJALGSA-N";555.48;1.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.52;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.0000030199517204020193
"MM472957";"MM472957";"CC(C)(C)c1ccc(-c2nc3c(N4CCN(Cc5c[nH]c(=O)[nH]c5=O)CC4)cccc3[nH]2)cc1";"GCTTXJNUVGNBBQ-UHFFFAOYSA-N";458.57;3.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL963648/target=_blank>CHEMBL963648</a>";;-6.22;"Pelletier JC, Chengalvala M, Cottom J, Feingold I, Garrick L, Green D, Hauze D, Huselton C, Jetter J, Kao W, Kopf GS, Lundquist JT, Mann C, Mehlmann J, Rogers J, Shanno L, Wrobel J.: 2-phenyl-4-piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem, Volume 16 (13), 2008";"PAMPA";0.0000006025595860743581
"MM472961";"MM472961";"C[C@H](NC(=O)C(=O)NCc1cc(Cl)ccc1Cl)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F";"ZZSAMDYIJUUGQK-VFZGTOFNSA-N";596.32;2.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1021345/target=_blank>CHEMBL1021345</a>";;-5.49;"Ueno H, Kawai M, Shimokawa H, Hirota M, Ohmi M, Sudo R, Ohta A, Arano Y, Hattori K, Ohmi T, Kato N, Kojima M, Ueno Y, Yamamoto M, Moriguchi Y, Eda H, Masubuchi K.: Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease. Bioorg Med Chem Lett, Volume 19 (1), 2009";"PAMPA";0.000003235936569296281
"MM473067";"MM473067";"CCn1cnc(CN2CCN(c3cccc4[nH]c(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c1C";"IDBJLYFVNIELJW-UHFFFAOYSA-N";456.64;5.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1115141/target=_blank>CHEMBL1115141</a>";;-5.57;"Vera MD, Lundquist JT, Chengalvala MV, Cottom JE, Feingold IB, Garrick LM, Green DM, Hauze DB, Mann CW, Mehlmann JF, Rogers JF, Shanno L, Wrobel JE, Pelletier JC.: Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett, Volume 20 (8), 2010";"PAMPA";0.0000026915348039269138
"MM472941";"MM472941";"N#Cc1cnc2c(Br)cc(NCc3cn(-c4ccccc4)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"KWNJYWRZSXRMEA-UHFFFAOYSA-N";548.81;6.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-5.92;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.0000012022644346174132
"Dextromethorphan";"MM00475";"COc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3";"MKXZASYAUGDDCJ-UHFFFAOYSA-N";271.4;3.38;"5360696";"CHEMBL52440";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.2;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.00006309573444801929
"MM472949";"MM472949";"N#Cc1cnc2c(Br)cc(NCc3cn(Cc4cccnc4)nn3)cc2c1Nc1ccc(F)c(Cl)c1";"NDZILMRCELWAKE-UHFFFAOYSA-N";563.82;6.05;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-6.89;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.00000012882495516931348
"MM472899";"MM472899";"CC(=O)c1ccc(N2CCN(C(=O)c3cc(S(C)(=O)=O)ccc3N3CCOCC3)CC2)c(F)c1";"TUPJMQWUSDJIDL-UHFFFAOYSA-N";489.57;2.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1007116/target=_blank>CHEMBL1007116</a>";;-5.51;"Pinard E, Alberati D, Borroni E, Fischer H, Hainzl D, Jolidon S, Moreau JL, Narquizian R, Nettekoven M, Norcross RD, Stalder H, Thomas AW.: Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg Med Chem Lett, Volume 18 (18), 2008";"PAMPA";0.000003090295432513592
"MM472947";"MM472947";"CCN1CCC(n2cc(CNc3cc(Cl)c4ncc(C#N)c(Nc5ccc(F)c(Cl)c5)c4c3)nn2)CC1";"PHNZIIMWDVXPGG-UHFFFAOYSA-N";539.45;6.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1000660/target=_blank>CHEMBL1000660</a>";;-6.44;"Wu J, Green N, Hotchandani R, Hu Y, Condon J, Huang A, Kaila N, Li HQ, Guler S, Li W, Tam SY, Wang Q, Pelker J, Marusic S, Hsu S, Perry Hall J, Telliez JB, Cui J, Lin LL.: Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett, Volume 19 (13), 2009";"PAMPA";0.000000363078054770101
"Benzene-1,4-diol";"MM00951";"Oc1ccc(O)cc1";"QIGBRXMKCJKVMJ-UHFFFAOYSA-N";110.11;1.1;"785";"CHEMBL537";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL905612/target=_blank>CHEMBL905612</a>";;-5.14;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000007244359600749906
"MM472991";"MM472991";"CSc1ccc2c(=O)n(C(c3ccccc3)c3ccccc3)c(=O)n(C/C=C/COc3ccc(C(=O)O)cc3)c2c1";"PEDRGXMPMZOSLJ-CMDGGOBGSA-N";564.66;5.86;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059836/target=_blank>CHEMBL1059836</a>";;-5.35;"Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC.: Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem, Volume 17 (13), 2009";"PAMPA";0.000004466835921509635
"MM472988";"MM472988";"O=C(O)c1ccc(OC/C=C/Cn2c(=O)n(C(c3ccccc3)c3ccccc3)c(=O)c3ccc(N4CCOCC4)cc32)cc1";"ZQPKBYQQGAQUAK-BQYQJAHWSA-N";603.68;4.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059836/target=_blank>CHEMBL1059836</a>";;-6;"Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC.: Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem, Volume 17 (13), 2009";"PAMPA";0.000001
"MM473752";"MM473752";"CC(C)N1CCC(Oc2ccc3cc(C(=O)N4CCOCC4)ccc3c2)CC1";"WPBLHQJDLOPHGT-UHFFFAOYSA-N";382.5;3.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1055927/target=_blank>CHEMBL1055927</a>";;-5.6;"RodrĂ­guez Sarmiento RM, Nettekoven MH, Taylor S, Plancher JM, Richter H, Roche O.: Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs. Bioorg Med Chem Lett, Volume 19 (15), 2009";"PAMPA";0.0000025118864315095823
"MM473756";"MM473756";"CN1CCCCC1(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)[nH]1";"DWCBYHSUKCYVPJ-UHFFFAOYSA-N";374.42;1.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.66;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.0000021877616239495517
"MM473762";"MM473762";"CC(=O)N1CCN(C)C(C)(c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)C1";"NFEPQYVYHPMREC-UHFFFAOYSA-N";431.47;0.56;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.24;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000005754399373371567
"MM472984";"MM472984";"Nc1ccc2c(=O)n(C(c3ccccc3)c3ccccc3)c(=O)n(C/C=C/COc3ccc(C(=O)O)cc3)c2c1";"HOZIQVZNFYBTSZ-BQYQJAHWSA-N";533.58;4.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059836/target=_blank>CHEMBL1059836</a>";;-6.4;"Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC.: Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem, Volume 17 (13), 2009";"PAMPA";0.0000003981071705534969
"MM473758";"MM473758";"Cc1nc(C)c(C(=O)N2CCCCC2(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)[nH]2)s1";"ICPPCODEZYGZTO-UHFFFAOYSA-N";499.57;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-4.39;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.0000407380277804113
"MM473754";"MM473754";"CC(=O)N1CCC[C@@]1(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)[nH]1";"VSANFJNPTKNGGX-IBGZPJMESA-N";388.4;1.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-4.91;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.00001230268770812381
"MM473761";"MM473761";"CN1CCN(C(=O)c2cnccn2)C(C)(c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)[nH]2)C1";"HJVVPRFMGAXBBU-UHFFFAOYSA-N";481.49;0.64;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.27;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000005370317963702533
"MM472986";"MM472986";"O=C(O)c1ccc(OC/C=C/Cn2c(=O)n(C(c3ccccc3)c3ccccc3)c(=O)c3ccc(-n4cncn4)cc32)cc1";"VEJRGNIFKIKVEQ-BQYQJAHWSA-N";585.62;4.72;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059836/target=_blank>CHEMBL1059836</a>";;-5.8;"Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC.: Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem, Volume 17 (13), 2009";"PAMPA";0.000001584893192461114
"MM472989";"MM472989";"COc1ccc2c(=O)n(C(c3ccccc3)c3ccccc3)c(=O)n(C/C=C/COc3ccc(C(=O)O)cc3)c2c1";"FUNJNMYYSNZGQH-CMDGGOBGSA-N";548.6;5.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059836/target=_blank>CHEMBL1059836</a>";;-5.74;"Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC.: Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem, Volume 17 (13), 2009";"PAMPA";0.0000018197008586099826
"MM472990";"MM472990";"CS(=O)(=O)c1ccc2c(=O)n(C(c3ccccc3)c3ccccc3)c(=O)n(C/C=C/COc3ccc(C(=O)O)cc3)c2c1";"HSWBYAFNAMYGMZ-CMDGGOBGSA-N";596.66;4.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059836/target=_blank>CHEMBL1059836</a>";;-6.52;"Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC.: Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem, Volume 17 (13), 2009";"PAMPA";0.0000003019951720402019
"MM473753";"MM473753";"C[C@@]1(c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)[nH]2)CCCN1";"UBSNJOHDWFHFOY-KRWDZBQOSA-N";346.36;1.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.19;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000006456542290346549
"MM472992";"MM472992";"CC1CCN(C(=O)c2ccc3cc(OCCCN4CCCCC4)ccc3c2)CC1";"PXUAIMJAHKAYPP-UHFFFAOYSA-N";394.56;4.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1055927/target=_blank>CHEMBL1055927</a>";;-5.59;"RodrĂ­guez Sarmiento RM, Nettekoven MH, Taylor S, Plancher JM, Richter H, Roche O.: Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs. Bioorg Med Chem Lett, Volume 19 (15), 2009";"PAMPA";0.0000025703957827688647
"MM474400";"MM474400";"CC(C(=O)NCCc1ccc(O)cc1)c1cccc(C(=O)c2ccccc2)c1";"COWWJJYAVDPTMJ-UHFFFAOYSA-N";373.45;4.09;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1176651/target=_blank>CHEMBL1176651</a>";;-4.22;"Mahindroo N, Connelly MC, Punchihewa C, Yang L, Yan B, Fujii N.: Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway. Bioorg Med Chem, Volume 18 (13), 2010";"PAMPA";0.000060255958607435806
"MM473747";"MM473747";"O=C(NC[C@@H](NS(=O)(=O)c1cccc(Cl)c1Cl)C(=O)O)c1ccsc1";"VKUPUJBOOYACFB-SNVBAGLBSA-N";423.3;2.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053406/target=_blank>CHEMBL1053406</a>";;-7.34;"Elliot D, Henshaw E, MacFaul PA, Morley AD, Newham P, Oldham K, Page K, Rankine N, Sharpe P, Ting A, Wood CM.: Novel inhibitors of the alphavbeta3 integrin--lead identification strategy. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.00000004570881896148752
"MM472987";"MM472987";"COC(=O)C1CCN(c2ccc3c(=O)n(C(c4ccccc4)c4ccccc4)c(=O)n(C/C=C/COc4ccc(C(=O)O)cc4)c3c2)CC1";"IQFLLOYPBGABOZ-CMDGGOBGSA-N";659.74;5.52;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059836/target=_blank>CHEMBL1059836</a>";;-6;"Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC.: Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem, Volume 17 (13), 2009";"PAMPA";0.000001
"MM473760";"MM473760";"CC(=O)N1CCN(C)CC1(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)[nH]1";"ZJNVQCQCAACIOY-UHFFFAOYSA-N";417.44;0.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-4.67;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000021379620895022323
"MM473770";"MM473770";"Cc1nc(C)c(C(=O)N2CCCCC2c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)[nH]2)s1";"PRWHXEBMSODDSY-UHFFFAOYSA-N";485.54;2.99;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.24;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000005754399373371567
"MM474416";"MM474416";"COC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1";"SASYBZIIPQSWBV-HJDNSYGMSA-N";501.4;0.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1261497/target=_blank>CHEMBL1261497</a>";;-8.15;"Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA.: Discovery of a Î˛-d-2'-deoxy-2'-Î±-fluoro-2'-Î˛-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem, Volume 53 (19), 2010";"PAMPA";0.0000000070794578438413736
"MM473772";"MM473772";"CC(=O)N1CCN(C)CC1c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)[nH]1";"NPQLJDQNIHSLCI-UHFFFAOYSA-N";403.41;0.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-6.4;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.0000003981071705534969
"MM472983";"MM472983";"Cc1ccc2c(=O)n(C(c3ccccc3)c3ccccc3)c(=O)n(C/C=C/COc3ccc(C(=O)O)cc3)c2c1";"FFTITOILIQABQD-CMDGGOBGSA-N";532.6;5.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1059836/target=_blank>CHEMBL1059836</a>";;-5.7;"Kirincich SJ, Xiang J, Green N, Tam S, Yang HY, Shim J, Shen MW, Clark JD, McKew JC.: Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem, Volume 17 (13), 2009";"PAMPA";0.0000019952623149688787
"Chembl562476";"MM469505";"CNC[C@@H](O)[C@H](c1ccccc1)n1ccc2ccccc21";"ANOKEIWYHCYLAM-MSOLQXFVSA-N";280.37;2.81;;"Chembl562476";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1038305/target=_blank>CHEMBL1038305</a>";;-5.34;"Kim CY, Mahaney PE, McConnell O, Zhang Y, Manas E, Ho DM, Deecher DC, Trybulski EJ.: Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols. Bioorg Med Chem Lett, Volume 19 (17), 2009";"PAMPA";0.000004570881896148752
"MM473759";"MM473759";"CN1CCCCC1(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C";"JIVXNDNOKBOVOD-UHFFFAOYSA-N";388.44;1.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-4.82;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000015135612484362071
"MM473763";"MM473763";"CN1CCN(S(=O)(=O)N(C)C)CC1(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C";"JDWXOQZIHBLXRS-UHFFFAOYSA-N";496.57;-0.18;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-4.24;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000057543993733715664
"MM473766";"MM473766";"CC(=O)N1CCCC1c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)[nH]1";"UTWNIOAXAGJMTO-UHFFFAOYSA-N";374.37;1.23;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.46;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.000003467368504525317
"MM473757";"MM473757";"CC(=O)N1CCCCC1(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)[nH]1";"OZQLTBGFEMVVPY-UHFFFAOYSA-N";402.43;1.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.2;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.00000630957344480193
"MM473769";"MM473769";"CC(=O)N1CCCCC1c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)[nH]1";"OSTKSXZFVKVFBY-UHFFFAOYSA-N";388.4;1.62;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.43;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.0000037153522909717276
"MM473764";"MM473764";"CN1CCN(S(C)(=O)=O)CC1(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C";"ZUEYJJHLMMKJSS-UHFFFAOYSA-N";467.52;-0.02;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-4.46;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.00003467368504525317
"MM473765";"MM473765";"O=C(NCc1ccc(F)cc1)c1nc(C2CCCN2)[nH]c(=O)c1O";"ZLOFMAVYNFGKRE-UHFFFAOYSA-N";332.34;0.97;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-6.15;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.0000007079457843841374
"MM473755";"MM473755";"CC1(c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)[nH]2)CCCCN1";"AWXUJSKCZCJLCA-UHFFFAOYSA-N";360.39;1.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1060104/target=_blank>CHEMBL1060104</a>";;-5.72;"Nizi E, Orsale MV, Crescenzi B, Pescatore G, Muraglia E, Alfieri A, Gardelli C, Spieser SA, Summa V.: Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center. Bioorg Med Chem Lett, Volume 19 (16), 2009";"PAMPA";0.0000019054607179632483
"MM472616";"MM472616";"CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1";"OAVGBZOFDPFGPJ-UHFFFAOYSA-N";438.49;2.43;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2156137/target=_blank>CHEMBL2156137</a>";;-5.3;"Wagner J, von Matt P, Faller B, Cooke NG, Albert R, Sedrani R, Wiegand H, Jean C, Beerli C, Weckbecker G, Evenou JP, Zenke G, Cottens S.: Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis. J Med Chem, Volume 54 (17), 2011";"PAMPA";0.000005011872336272725
"MM473635";"MM473635";"O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1";"KPBNHDGDUADAGP-VAWYXSNFSA-N";391.52;3.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4312050/target=_blank>CHEMBL4312050</a>";;-4.4;"Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.: Controlling cellular distribution of drugs with permeability modifying moieties. Medchemcomm, Volume 10 (6), 2019";"PAMPA";0.000039810717055349695
"MM473009";"MM473009";"Cc1c(Nc2c(C#N)cncc2/C=C/c2cccc(OCCN3CCN(C)CC3)c2)ccc2[nH]ccc12";"TUKOILYAIRACKC-VOTSOKGWSA-N";492.63;5.28;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1039951/target=_blank>CHEMBL1039951</a>";;-5.48;"Niu C, Boschelli DH, Tumey LN, Bhagirath N, Subrath J, Shim J, Wang Y, Wu B, Eid C, Lee J, Yang X, Brennan A, Chaudhary D.: First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett, Volume 19 (20), 2009";"PAMPA";0.0000033113112148259077
"MM473003";"MM473003";"CNc1nc(NCc2ccc(NC(=O)c3ccc(F)cc3)cc2)c2cc(C)ccc2n1";"UFDQFCNUXSHUFA-UHFFFAOYSA-N";415.47;4.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.89;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.000001288249551693135
"MM473001";"MM473001";"CNc1nc(NCc2ccc(NC(=O)c3ccc(C)cc3)cc2)c2ccccc2n1";"YAZBQMNCOQXTIS-UHFFFAOYSA-N";397.48;4.84;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.24;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.000005754399373371567
"MM473005";"MM473005";"CNc1nc(NCc2ccc(NC(=O)c3ccc(Cl)cc3)cc2)c2cc(C)ccc2n1";"RGPXAJSDCKQSRK-UHFFFAOYSA-N";431.93;5.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.62;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000023988329190194897
"MM473011";"MM473011";"CC(C)(C)[C@H]1C(O)=C(C2=CS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)C(=O)N1Cc1ccc(F)cc1";"RGXRFMDVMGSEIH-JOCHJYFZSA-N";535.62;3.51;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048128/target=_blank>CHEMBL1048128</a>";;-5.85;"de Vicente J, Hendricks RT, Smith DB, Fell JB, Fischer J, Spencer SR, Stengel PJ, Mohr P, Robinson JE, Blake JF, Hilgenkamp RK, Yee C, Zhao J, Elworthy TR, Tracy J, Chin E, Li J, Lui A, Wang B, Oshiro C, Harris SF, Ghate M, Leveque VJ, Najera I, Le Pogam S, Rajyaguru S, Ao-Ieong G, Alexandrova L, Fitch B, Brandl M, Masjedizadeh M, Wu SY, de Keczer S, Voronin T.: Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioorg Med Chem Lett, Volume 19 (19), 2009";"PAMPA";0.0000014125375446227554
"MM472995";"MM472995";"CNc1nc(NCc2ccc(NC(=O)c3ccc(F)cc3)cc2)c2ccccc2n1";"WWBNWNFPDKAYDJ-UHFFFAOYSA-N";401.45;4.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.38;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.000004168693834703355
"MM473016";"MM473016";"CCOC(=O)c1ncn2c1Cc1cnc(C)nc1-c1cc(Br)ccc1-2";"GOISDWFECBXUAU-UHFFFAOYSA-N";399.25;3.48;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1040221/target=_blank>CHEMBL1040221</a>";;-5.44;"Achermann G, Ballard TM, Blasco F, Broutin PE, BĂĽttelmann B, Fischer H, Graf M, Hernandez MC, Hilty P, Knoflach F, Koblet A, Knust H, Kurt A, Martin JR, Masciadri R, Porter RH, Stadler H, Thomas AW, Trube G, Wichmann J.: Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist series. Bioorg Med Chem Lett, Volume 19 (19), 2009";"PAMPA";0.0000036307805477010103
"MM473006";"MM473006";"CNc1nc(NCc2ccc(NC(=O)c3ccc(Cl)cc3)cc2)c2c(C)cccc2n1";"GSIFXTHXPURSBY-UHFFFAOYSA-N";431.93;5.5;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-6.05;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000008912509381337459
"MM473007";"MM473007";"CNc1nc(NCc2ccc(NC(=O)c3ccc(Cl)nc3)cc2)c2c(C)cccc2n1";"LLKZNBPLCIOFFO-UHFFFAOYSA-N";432.92;4.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-6.7;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.00000019952623149688787
"MM472998";"MM472998";"CNc1nc(NCc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)cc2)c2ccccc2n1";"ISTRBVPLLRSCKS-UHFFFAOYSA-N";451.45;5.55;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.28;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.000005248074602497723
"MM472999";"MM472999";"CNc1nc(NCc2ccc(NC(=O)c3cccc(Cl)c3)cc2)c2ccccc2n1";"ITHDRVHVMMIWSS-UHFFFAOYSA-N";417.9;5.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.52;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000030199517204020193
"MM473002";"MM473002";"CNc1nc(NCc2ccc(NC(=O)c3ccc(F)cc3)cc2)c2cccc(C)c2n1";"SOZJMQJCCKPSJW-UHFFFAOYSA-N";415.47;4.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.38;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.000004168693834703355
"MM472994";"MM472994";"NCC1CCN(c2nccc(-c3ccc4ccccc4c3)n2)CC1";"QHLITPHIARVDJI-UHFFFAOYSA-N";318.42;3.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1043430/target=_blank>CHEMBL1043430</a>";;-5.23;"Pelletier JC, Lundquist JT, Gilbert AM, Alon N, Bex FJ, Bhat BM, Bursavich MG, Coleburn VE, Felix LA, Green DM, Green P, Hauze DB, Kharode YP, Lam HS, Lockhead SR, Magolda RL, Matteo JJ, Mehlmann JF, Milligan C, Murrills RJ, Pirrello J, Selim S, Sharp MC, Unwalla RJ, Vera MD, Wrobel JE, Yaworsky P, Bodine PV.: (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-catenin agonist that increases bone formation rate. J Med Chem, Volume 52 (22), 2009";"PAMPA";0.000005888436553555884
"MM473012";"MM473012";"CC(C)(C)[C@H]1C(O)=C(C2=CS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)C(=O)N1Cc1ccc(F)c(Cl)c1";"LRWXMBVWGHQXJC-JOCHJYFZSA-N";570.06;4.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048128/target=_blank>CHEMBL1048128</a>";;-6.01;"de Vicente J, Hendricks RT, Smith DB, Fell JB, Fischer J, Spencer SR, Stengel PJ, Mohr P, Robinson JE, Blake JF, Hilgenkamp RK, Yee C, Zhao J, Elworthy TR, Tracy J, Chin E, Li J, Lui A, Wang B, Oshiro C, Harris SF, Ghate M, Leveque VJ, Najera I, Le Pogam S, Rajyaguru S, Ao-Ieong G, Alexandrova L, Fitch B, Brandl M, Masjedizadeh M, Wu SY, de Keczer S, Voronin T.: Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioorg Med Chem Lett, Volume 19 (19), 2009";"PAMPA";0.000000977237220955811
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3859791/target=_blank>CHEMBL3859791</a>";;-5.66;"Li DD, Wang ZH, Chen WL, Xie YY, You QD, Guo XK.: Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. Bioorg Med Chem, Volume 24 (22), 2016";"PAMPA";0.0000021877616239495517
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3066824/target=_blank>CHEMBL3066824</a>";;-5.55;"Akamatsu M.: Importance of physicochemical properties for the design of new pesticides. J Agric Food Chem, Volume 59 (7), 2011";"PAMPA";0.000002818382931264455
"MM473015";"MM473015";"Cc1c(Nc2c(C#N)cncc2-c2cc3cc(CN4CCN(C)CC4)ccc3o2)ccc2[nH]ccc12";"DZIUPOCVDSYPSY-UHFFFAOYSA-N";476.58;5.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047202/target=_blank>CHEMBL1047202</a>";;-5.4;"Prashad AS, Wang D, Subrath J, Wu B, Lin M, Zhang MY, Kagan N, Lee J, Yang X, Brennan A, Chaudhary D, Xu X, Leung L, Wang J, Boschelli DH.: C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II. Bioorg Med Chem Lett, Volume 19 (19), 2009";"PAMPA";0.000003981071705534969
"MM473013";"MM473013";"Cc1cc(CN2C(=O)C(C3=CS(=O)(=O)c4cc(NS(C)(=O)=O)ccc4N3)=C(O)[C@@H]2C(C)(C)C)ccc1F";"XXQOBDSNGHCQOE-HSZRJFAPSA-N";549.65;3.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048128/target=_blank>CHEMBL1048128</a>";;-5.79;"de Vicente J, Hendricks RT, Smith DB, Fell JB, Fischer J, Spencer SR, Stengel PJ, Mohr P, Robinson JE, Blake JF, Hilgenkamp RK, Yee C, Zhao J, Elworthy TR, Tracy J, Chin E, Li J, Lui A, Wang B, Oshiro C, Harris SF, Ghate M, Leveque VJ, Najera I, Le Pogam S, Rajyaguru S, Ao-Ieong G, Alexandrova L, Fitch B, Brandl M, Masjedizadeh M, Wu SY, de Keczer S, Voronin T.: Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioorg Med Chem Lett, Volume 19 (19), 2009";"PAMPA";0.0000016218100973589298
"MM472996";"MM472996";"CNc1nc(NCc2ccc(NC(=O)c3ccc(Cl)cc3)cc2)c2ccccc2n1";"KAMBUPZZPWFSKM-UHFFFAOYSA-N";417.9;5.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.85;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000014125375446227554
"MM473014";"MM473014";"CC(C)(C)CCN1C(=O)C(C2=CS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)=C(O)[C@@H]1C(C)(C)C";"GXOQIGPYISLRPV-HXUWFJFHSA-N";511.67;3.6;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048128/target=_blank>CHEMBL1048128</a>";;-5.74;"de Vicente J, Hendricks RT, Smith DB, Fell JB, Fischer J, Spencer SR, Stengel PJ, Mohr P, Robinson JE, Blake JF, Hilgenkamp RK, Yee C, Zhao J, Elworthy TR, Tracy J, Chin E, Li J, Lui A, Wang B, Oshiro C, Harris SF, Ghate M, Leveque VJ, Najera I, Le Pogam S, Rajyaguru S, Ao-Ieong G, Alexandrova L, Fitch B, Brandl M, Masjedizadeh M, Wu SY, de Keczer S, Voronin T.: Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioorg Med Chem Lett, Volume 19 (19), 2009";"PAMPA";0.0000018197008586099826
"MM472549";"MM472549";"CCN(CC)S(=O)(=O)c1ccc(C(CC2CCCC2)C(=O)Nc2nc3ccc(OC)nc3s2)cc1";"SLAIZTDQGUFKDC-UHFFFAOYSA-N";516.69;5.03;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-5.9;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.0000012589254117941661
"MM472557";"MM472557";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NCc4cccs4)cc3)sc2n1";"GVPVGDNTJTUVOY-UHFFFAOYSA-N";556.74;5.54;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-5.1;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000007943282347242822
"MM472564";"MM472564";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)N(C)CCO)cc3)sc2n1";"ZUWZPKWHGCQWQZ-UHFFFAOYSA-N";518.66;3.62;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.4;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000039810717055349695
"MM472545";"MM472545";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(N)(=O)=O)cc3)sc2n1";"MBGKLTPGMKMMBY-UHFFFAOYSA-N";460.58;3.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.4;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000039810717055349695
"MM472550";"MM472550";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)Nc4ccccc4)cc3)sc2n1";"JBPRBDOCDYFVCJ-UHFFFAOYSA-N";536.68;5.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-3.8;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.00015848931924611142
"MM472558";"MM472558";"COCCNS(=O)(=O)c1ccc(C(CC2CCCC2)C(=O)Nc2nc3ccc(OC)nc3s2)cc1";"PMCDFNOKUMRKOJ-UHFFFAOYSA-N";518.66;3.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-5;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.00001
"MM472555";"MM472555";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NCc4ccncc4)cc3)sc2n1";"XINJOXSXDSZPPN-UHFFFAOYSA-N";551.69;4.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.3;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.00005011872336272725
"MM472563";"MM472563";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)N(C)Cc4ccco4)cc3)sc2n1";"HYJRDIDWEFMXIE-UHFFFAOYSA-N";554.69;5.42;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-5.1;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000007943282347242822
"MM472561";"MM472561";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NCCC(=O)O)cc3)sc2n1";"ZVHJDDHGLAAUHM-UHFFFAOYSA-N";532.64;3.76;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.3;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.00005011872336272725
"MM472547";"MM472547";"CCCC(=O)NS(=O)(=O)c1ccc(C(CC2CCCC2)C(=O)Nc2nc3ccc(OC)nc3s2)cc1";"PNEQOGFCKMWIML-UHFFFAOYSA-N";530.67;4.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.4;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000039810717055349695
"MM472562";"MM472562";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)N(C)Cc4ccccc4)cc3)sc2n1";"WMAFUOVYGLDQIV-UHFFFAOYSA-N";564.73;5.82;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-5.4;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000003981071705534969
"MM472548";"MM472548";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)N(C)C)cc3)sc2n1";"PQQWGZZSLXLGEQ-UHFFFAOYSA-N";488.64;4.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-3.3;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.0005011872336272725
"MM472553";"MM472553";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NC4CC4)cc3)sc2n1";"BFVMMROZEZLKNK-UHFFFAOYSA-N";500.65;4.44;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-5.2;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.00000630957344480193
"MM472560";"MM472560";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NCC(=O)O)cc3)sc2n1";"YKLGWSWDUMWHGE-UHFFFAOYSA-N";518.62;3.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.4;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000039810717055349695
"MM472556";"MM472556";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NCc4ccco4)cc3)sc2n1";"VYCOWOUFZJFBOD-UHFFFAOYSA-N";540.67;5.07;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.9;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000012589254117941661
"MM472551";"MM472551";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NC4CCCCC4)cc3)sc2n1";"COHVEEIHPAJPAS-UHFFFAOYSA-N";542.73;5.61;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-7;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.0000001
"MM472552";"MM472552";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NC4CCOCC4)cc3)sc2n1";"LPTWSMUFAICRJY-UHFFFAOYSA-N";544.7;4.46;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.5;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000031622776601683795
"MM473000";"MM473000";"CNc1nc(NCc2ccc(NC(=O)c3ccc(C#N)cc3)cc2)c2ccccc2n1";"BUCKBHOWKWDMMK-UHFFFAOYSA-N";408.47;4.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-6.7;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.00000019952623149688787
"MM472559";"MM472559";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NCCN(C)C)cc3)sc2n1";"SNNHMOIYFKPOKT-UHFFFAOYSA-N";531.7;3.84;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.8;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.00001584893192461114
"MM472546";"MM472546";"CCC(=O)NS(=O)(=O)c1ccc(C(CC2CCCC2)C(=O)Nc2nc3ccc(OC)nc3s2)cc1";"DEWIUZLCJUAFLD-UHFFFAOYSA-N";516.65;4.22;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.1;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.00007943282347242822
"MM472554";"MM472554";"COc1ccc2nc(NC(=O)C(CC3CCCC3)c3ccc(S(=O)(=O)NCc4cccnc4)cc3)sc2n1";"VPAHKACDRIEKRM-UHFFFAOYSA-N";551.69;4.88;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1053633/target=_blank>CHEMBL1053633</a>";;-4.6;"Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.: Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem, Volume 52 (19), 2009";"PAMPA";0.000025118864315095822
"MM471071";"MM471071";"NC1=NC(c2ccccc2)(c2ccccc2)C2=NCCCN12";"UFWSJOVQEPTPNE-UHFFFAOYSA-N";290.37;2.36;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1042919/target=_blank>CHEMBL1042919</a>";;-6;"Nowak P, Cole DC, Aulabaugh A, Bard J, Chopra R, Cowling R, Fan KY, Hu B, Jacobsen S, Jani M, Jin G, Lo MC, Malamas MS, Manas ES, Narasimhan R, Reinhart P, Robichaud AJ, Stock JR, Subrath J, Svenson K, Turner J, Wagner E, Zhou P, Ellingboe JW.: Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett, Volume 20 (2), 2010";"PAMPA";0.000001
"MM472997";"MM472997";"CNc1nc(NCc2ccc(NC(=O)c3ccc(-c4ccccc4)cc3)cc2)c2ccccc2n1";"CICSICZXJDAQLA-UHFFFAOYSA-N";459.55;6.2;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.92;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000012022644346174132
"MM473008";"MM473008";"CNc1nc(NCc2ccc(NC(=O)c3ccc(Cl)nc3)cc2)c2ccc(C)cc2n1";"GXJWTRQQFNHPOC-UHFFFAOYSA-N";432.92;4.89;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-6.52;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000003019951720402019
"MM472565";"MM472565";"CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1";"QIPWTYSOANVUKJ-WZONZLPQSA-N";428.54;4.51;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1046698/target=_blank>CHEMBL1046698</a>";;-4;"Thoma G, Baenteli R, Lewis I, Wagner T, Oberer L, Blum W, Glickman F, Streiff MB, Zerwes HG.: Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead. Bioorg Med Chem Lett, Volume 19 (21), 2009";"PAMPA";0.0001
"MM473004";"MM473004";"CNc1nc(NCc2ccc(NC(=O)c3ccc(F)cc3)cc2)c2c(C)cccc2n1";"JSCRFRPIEAQXHA-UHFFFAOYSA-N";415.47;4.98;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1047017/target=_blank>CHEMBL1047017</a>";;-5.59;"Dehnhardt CM, Venkatesan AM, Chen Z, Ayral-Kaloustian S, Dos Santos O, Delos Santos E, Curran K, Follettie MT, Diesl V, Lucas J, Geng Y, Dejoy SQ, Petersen R, Chaudhary I, Brooijmans N, Mansour TS, Arndt K, Chen L.: Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000025703957827688647
"MM473010";"MM473010";"CC(C)(C)[C@H]1C(O)=C(C2=CS(=O)(=O)c3cc(NS(C)(=O)=O)ccc3N2)C(=O)N1Cc1ccccc1";"ALABQWJNSWBAKG-JOCHJYFZSA-N";517.63;3.37;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048128/target=_blank>CHEMBL1048128</a>";;-5.74;"de Vicente J, Hendricks RT, Smith DB, Fell JB, Fischer J, Spencer SR, Stengel PJ, Mohr P, Robinson JE, Blake JF, Hilgenkamp RK, Yee C, Zhao J, Elworthy TR, Tracy J, Chin E, Li J, Lui A, Wang B, Oshiro C, Harris SF, Ghate M, Leveque VJ, Najera I, Le Pogam S, Rajyaguru S, Ao-Ieong G, Alexandrova L, Fitch B, Brandl M, Masjedizadeh M, Wu SY, de Keczer S, Voronin T.: Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioorg Med Chem Lett, Volume 19 (19), 2009";"PAMPA";0.0000018197008586099826
"MM471074";"MM471074";"CN1C(=O)C(C2CCCCC2)(C2CCCCC2)N=C1N";"IAMIFCZOYVOTFD-UHFFFAOYSA-N";277.41;2.67;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1042919/target=_blank>CHEMBL1042919</a>";;-5.54;"Nowak P, Cole DC, Aulabaugh A, Bard J, Chopra R, Cowling R, Fan KY, Hu B, Jacobsen S, Jani M, Jin G, Lo MC, Malamas MS, Manas ES, Narasimhan R, Reinhart P, Robichaud AJ, Stock JR, Subrath J, Svenson K, Turner J, Wagner E, Zhou P, Ellingboe JW.: Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett, Volume 20 (2), 2010";"PAMPA";0.000002884031503126606
"MM471080";"MM471080";"O=C(c1ccc(Cn2ccc3cccc(Cl)c32)cc1)N1CC[C@H](N2CCCC2)C1";"QRZWUPXCLYWBIP-NRFANRHFSA-N";407.95;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069493/target=_blank>CHEMBL1069493</a>";;-5.19;"Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.: Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 20 (3), 2010";"PAMPA";0.000006456542290346549
"MM471081";"MM471081";"O=C(c1ccc(Cn2ccc3ccc(Cl)cc32)cc1)N1CC[C@H](N2CCCC2)C1";"HHPYIWPWLUUFOK-QFIPXVFZSA-N";407.95;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069493/target=_blank>CHEMBL1069493</a>";;-5.14;"Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.: Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 20 (3), 2010";"PAMPA";0.000007244359600749906
"MM471075";"MM471075";"Cc1ccoc1C(=O)Nc1cccc(C2(C3CCCCC3)N=C(N)N(C)C2=O)c1";"CZSNUKITORTJBZ-UHFFFAOYSA-N";394.48;3.4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1042919/target=_blank>CHEMBL1042919</a>";;-5.85;"Nowak P, Cole DC, Aulabaugh A, Bard J, Chopra R, Cowling R, Fan KY, Hu B, Jacobsen S, Jani M, Jin G, Lo MC, Malamas MS, Manas ES, Narasimhan R, Reinhart P, Robichaud AJ, Stock JR, Subrath J, Svenson K, Turner J, Wagner E, Zhou P, Ellingboe JW.: Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett, Volume 20 (2), 2010";"PAMPA";0.0000014125375446227554
"MM474388";"MM474388";"CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13";"JAQUASYNZVUNQP-USXIJHARSA-N";257.38;3.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-5.04;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000009120108393559096
"MM473023";"MM473023";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl";"VYLVEERKOLDJOU-UHFFFAOYSA-N";451.95;4.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066165/target=_blank>CHEMBL1066165</a>";;-4.62;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000239883291901949
"MM472590";"MM472590";"Cc1c(OCc2cccc(-c3ccc(C(=O)O)cc3)c2)cc2c(c1C)C(=O)C(C1CCCC1)C2";"KMKBEESNZAPKMP-UHFFFAOYSA-N";454.57;6.79;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1655207/target=_blank>CHEMBL1655207</a>";;-6.2;"Dhanya RP, Sidique S, Sheffler DJ, Nickols HH, Herath A, Yang L, Dahl R, Ardecky R, Semenova S, Markou A, Conn PJ, Cosford ND.: Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem, Volume 54 (1), 2011";"PAMPA";0.000000630957344480193
"MM473774";"MM473774";"Cc1c(Nc2c(C#N)cncc2/C=C/CCCN2CCNCC2)ccc2[nH]ccc12";"IFLKFPIAJMOXTG-HWKANZROSA-N";400.53;4.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-6.8;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.0000001584893192461114
"MM473783";"MM473783";"Cc1c(Nc2c(C#N)cncc2/C=C/CN2CCC(N)CC2)ccc2[nH]ccc12";"XUDDPIKSCLCQKJ-NSCUHMNNSA-N";386.5;3.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.52;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.000000030199517204020194
"MM473786";"MM473786";"Cc1c(Nc2c(C#N)cncc2/C=C/CN2CCNCC2)ccc2[nH]ccc12";"MODWLWDUUDGOEB-NSCUHMNNSA-N";372.48;3.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.7;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.000000019952623149688786
"MM473782";"MM473782";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC(N)CC2)ccc2[nH]ccc12";"SZJIXBKHTOPEKG-DUXPYHPUSA-N";400.53;4.31;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.4;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000003981071705534969
"MM473785";"MM473785";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC(O)CC2)ccc2[nH]ccc12";"KRSQMQFKFCQXKG-DUXPYHPUSA-N";401.51;4.35;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.7;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.000000019952623149688786
"MM474510";"MM474510";"CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1";"HYAFETHFCAUJAY-UHFFFAOYSA-N";356.45;3.16;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3431937/target=_blank>CHEMBL3431937</a>";;-5.13;"10.6019/CHEMBL3431459";"PAMPA";0.000007413102413009177
"MM473773";"MM473773";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCN(C)CC2)ccc2[nH]ccc12";"COOZRRUJSWPFHC-HWKANZROSA-N";400.53;4.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-6.07;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.0000008511380382023759
"MM473777";"MM473777";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CC[C@@H](O)C2)ccc2[nH]ccc12";"KEUYDWVTHJQHIH-NLJSWGTCSA-N";387.49;3.96;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.15;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000007079457843841373
"MM473784";"MM473784";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCN(S(C)(=O)=O)CC2)ccc2[nH]ccc12";"SUMGTNPLBQXBDN-HWKANZROSA-N";464.6;3.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.7;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.000000019952623149688786
"MM473022";"MM473022";"OC[C@H](Cc1c[nH]cn1)Nc1nccc(-c2ccc3ccccc3c2)n1";"DHVJXBQMTJFSTJ-SFHVURJKSA-N";345.41;3.04;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067308/target=_blank>CHEMBL1067308</a>";;-6.89;"Gilbert AM, Bursavich MG, Alon N, Bhat BM, Bex FJ, Cain M, Coleburn V, Gironda V, Green P, Hauze DB, Kharode Y, Krishnamurthy G, Kirisits M, Lam HS, Liu YB, Lombardi S, Matteo J, Murrills R, Robinson JA, Selim S, Sharp M, Unwalla R, Varadarajan U, Zhao W, Yaworsky PJ.: Hit to lead studies on (hetero)arylpyrimidines--agonists of the canonical Wnt-beta-catenin cellular messaging system. Bioorg Med Chem Lett, Volume 20 (1), 2010";"PAMPA";0.00000012882495516931348
"Fentanyl";"MM00493";"CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1";"PJMPHNIQZUBGLI-UHFFFAOYSA-N";336.48;4.14;"3345";"CHEMBL596";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.24;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000057543993733715664
"MM473780";"MM473780";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CC(N)C2)ccc2[nH]ccc12";"NDPCMXFATSKLHE-DUXPYHPUSA-N";372.48;3.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.22;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000006025595860743581
"MM473781";"MM473781";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC(NS(=O)(=O)C(C)C)CC2)ccc2[nH]ccc12";"NEBLJCMPKZILIG-GQCTYLIASA-N";506.68;4.68;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.3;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000005011872336272725
"MM473776";"MM473776";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCC(N(C)C)CC2)ccc2[nH]ccc12";"CLAXUCQFRATVEQ-GQCTYLIASA-N";428.58;4.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.1;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000007943282347242822
"MM473030";"MM473030";"CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2";"KOLSEKSFVMGHDV-UHFFFAOYSA-N";530.66;0.41;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1072889/target=_blank>CHEMBL1072889</a>";;-4.92;"Traquandi G, Ciomei M, Ballinari D, Casale E, Colombo N, Croci V, Fiorentini F, Isacchi A, Longo A, Mercurio C, Panzeri A, Pastori W, Pevarello P, Volpi D, Roussel P, Vulpetti A, Brasca MG.: Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors. J Med Chem, Volume 53 (5), 2010";"PAMPA";0.000012022644346174132
"MM471076";"MM471076";"CN(C)C1CCN(C(=O)c2ccc(Cn3c(-c4ccccc4)nc4ccccc43)cc2)C1";"UYKJSYAQDGARFD-UHFFFAOYSA-N";424.55;4.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069493/target=_blank>CHEMBL1069493</a>";;-5.36;"Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.: Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 20 (3), 2010";"PAMPA";0.000004365158322401657
"MM471078";"MM471078";"Cc1nc2ccccc2n1Cc1ccc(C(=O)N2CC[C@H](N3CCCC3)C2)cc1";"KUCJGGHJCKSUBY-NRFANRHFSA-N";388.52;3.7;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069493/target=_blank>CHEMBL1069493</a>";;-6.52;"Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.: Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 20 (3), 2010";"PAMPA";0.0000003019951720402019
"MM471077";"MM471077";"O=C(c1ccc(Cn2cnc3ccccc32)cc1)N1CC[C@H](N2CCCC2)C1";"NUVVLNOBNYNPKB-FQEVSTJZSA-N";374.49;3.39;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069493/target=_blank>CHEMBL1069493</a>";;-6.52;"Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.: Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 20 (3), 2010";"PAMPA";0.0000003019951720402019
"MM473025";"MM473025";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC";"RUVNTEGYLMYXCF-UHFFFAOYSA-N";459.55;3.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066165/target=_blank>CHEMBL1066165</a>";;-4.8;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.00001584893192461114
"MM473027";"MM473027";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC";"MMRPIWYTUYGTFQ-UHFFFAOYSA-N";447.54;3.95;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066165/target=_blank>CHEMBL1066165</a>";;-5;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.00001
"MM471073";"MM471073";"CN1C(=O)C(c2ccccc2)(C2CCCCC2)N=C1N";"FEZQZQTWDYTJPE-UHFFFAOYSA-N";271.36;2.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1042919/target=_blank>CHEMBL1042919</a>";;-5.14;"Nowak P, Cole DC, Aulabaugh A, Bard J, Chopra R, Cowling R, Fan KY, Hu B, Jacobsen S, Jani M, Jin G, Lo MC, Malamas MS, Manas ES, Narasimhan R, Reinhart P, Robichaud AJ, Stock JR, Subrath J, Svenson K, Turner J, Wagner E, Zhou P, Ellingboe JW.: Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett, Volume 20 (2), 2010";"PAMPA";0.000007244359600749906
"MM471082";"MM471082";"O=C(c1ccc(Cn2ccc3cc(Cl)ccc32)cc1)N1CC[C@H](N2CCCC2)C1";"CFVRXCVXEIVWEA-QFIPXVFZSA-N";407.95;4.65;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069493/target=_blank>CHEMBL1069493</a>";;-5.11;"Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.: Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 20 (3), 2010";"PAMPA";0.00000776247116628691
"MM471079";"MM471079";"O=C(c1ccc(Cn2ccc3ccccc32)cc1)N1CC[C@H](N2CCCC2)C1";"LRYZIKHXEUKDPW-QFIPXVFZSA-N";373.5;4;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1069493/target=_blank>CHEMBL1069493</a>";;-5.08;"Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.: Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists. Bioorg Med Chem Lett, Volume 20 (3), 2010";"PAMPA";0.00000831763771102671
"MM472634";"MM472634";"O=C(Nc1ccc(Cl)cc1)C1CCCN(C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)C1";"MOQCFMZWVKQBAP-UHFFFAOYSA-N";478.82;5.87;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2398830/target=_blank>CHEMBL2398830</a>";;-10;"Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD.: Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett, Volume 23 (13), 2013";"PAMPA";0.0000000001
"MM473778";"MM473778";"Cc1c(Nc2c(C#N)cncc2/C=C/CCCN2CCN(C)CC2)ccc2[nH]ccc12";"LBDMJMNVJZNONC-GQCTYLIASA-N";414.56;4.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.15;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000007079457843841373
"MM473775";"MM473775";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCNCC2)ccc2[nH]ccc12";"BUCGAQTZOOCIRW-DUXPYHPUSA-N";386.5;3.8;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-6.96;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000010964781961431852
"MM473028";"MM473028";"COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC";"ULXYUIOTBNWJFH-UHFFFAOYSA-N";425.53;2.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066165/target=_blank>CHEMBL1066165</a>";;-6.22;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000006025595860743581
"MM473029";"MM473029";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC";"AOTJVGQNGQYEAY-UHFFFAOYSA-N";445.52;3.53;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066165/target=_blank>CHEMBL1066165</a>";;-5.44;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.0000036307805477010103
"MM473024";"MM473024";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C";"ZHYPMHNQQRIWRP-UHFFFAOYSA-N";431.54;4.25;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066165/target=_blank>CHEMBL1066165</a>";;-4.68;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.00002089296130854041
"MM473026";"MM473026";"COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC";"OKHVXBABEFQOCR-UHFFFAOYSA-N";420.47;3.38;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066165/target=_blank>CHEMBL1066165</a>";;-5;"Morwick T, BĂĽttner FH, Cywin CL, Dahmann G, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Mao W, Marshall D, Paw Z, Shih CK, Wu F, Young E.: Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase. J Med Chem, Volume 53 (2), 2010";"PAMPA";0.00001
"MM473787";"MM473787";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CCCNCC2)ccc2[nH]ccc12";"HFSXGAKDODZJBV-GORDUTHDSA-N";400.53;4.19;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-8;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000001
"MM473779";"MM473779";"Cc1c(Nc2c(C#N)cncc2/C=C/CCN2CC[C@H](N)C2)ccc2[nH]ccc12";"DNZGKSANTHABGF-GVTIMSHASA-N";386.5;3.92;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1067370/target=_blank>CHEMBL1067370</a>";;-7.22;"Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH.: 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity. Bioorg Med Chem, Volume 17 (23), 2009";"PAMPA";0.00000006025595860743581
"Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate";"MM00511";"CCOC(=O)C1(c2ccccc2)CCN(C)CC1";"XADCESSVHJOZHK-UHFFFAOYSA-N";247.34;2.21;"4058";"CHEMBL607";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.4;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000039810717055349695
"MM472629";"MM472629";"O=C(CCNC(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)Nc1ccc(Cl)cc1";"OOAQCUJVRKPEEO-UHFFFAOYSA-N";438.76;5.14;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2398830/target=_blank>CHEMBL2398830</a>";;-10;"Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD.: Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett, Volume 23 (13), 2013";"PAMPA";0.0000000001
"MM473021";"MM473021";"Cc1cc(S(=O)(=O)NC(=O)Nc2ncc(Br)s2)ccc1-c1ccc(F)nc1";"MGILTQRFNXGDIM-UHFFFAOYSA-N";471.33;3.93;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1074697/target=_blank>CHEMBL1074697</a>";;-5.44;"Kitas E, Mohr P, Kuhn B, Hebeisen P, Wessel HP, Haap W, Ruf A, Benz J, Joseph C, Huber W, Sanchez RA, Paehler A, Benardeau A, Gubler M, Schott B, Tozzo E.: Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes. Bioorg Med Chem Lett, Volume 20 (2), 2010";"PAMPA";0.0000036307805477010103
"Sufentanil";"MM00304";"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1";"GGCSSNBKKAUURC-UHFFFAOYSA-N";386.56;4.21;"41693";"CHEMBL658";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-4.42;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000038018939632056124
"Morphine";"MM00524";"CN1CCC23c4c5ccc(O)c4OC2C(O)C=CC3C1C5";"BQJCRHHNABKAKU-UHFFFAOYSA-N";285.34;1.2;"5288826";"CHEMBL70";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-6.7;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.00000019952623149688787
"Desipramine";"MM00474";"CNCCCN1c2ccccc2CCc2ccccc21";"HCYAFALTSJYZDH-UHFFFAOYSA-N";266.39;3.53;"2995";"CHEMBL72";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3066824/target=_blank>CHEMBL3066824</a>";;-4.77;"Akamatsu M.: Importance of physicochemical properties for the design of new pesticides. J Agric Food Chem, Volume 59 (7), 2011";"PAMPA";0.00001698243652461746
"MM474149";"MM474149";"O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12";"GZUITABIAKMVPG-UHFFFAOYSA-N";473.59;6.08;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3536106/target=_blank>CHEMBL3536106</a>";;-5.52;"Nakamori F, Naritomi Y, Hosoya K, Moriguchi H, Tetsuka K, Furukawa T, Kadono K, Yamano K, Terashita S, Teramura T.: Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. Drug Metab Dispos, Volume 40 (9), 2012";"PAMPA";0.0000030199517204020193
"Chlorothiazide";"MM00641";"NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O";"JBMKAUGHUNFTOL-UHFFFAOYSA-N";295.73;0.13;"2720";"CHEMBL842";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1769838/target=_blank>CHEMBL1769838</a>";;-7.52;"Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.: In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem, Volume 54 (7), 2011";"PAMPA";0.000000030199517204020194
"MM472953";"MM472953";"COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O";"MBNGWHIJMBWFHU-UHFFFAOYSA-N";300.27;2.59;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988140/target=_blank>CHEMBL988140</a>";;-4.12;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"PAMPA";0.00007585775750291836
"MM473606";"MM473606";"O=C(Nc1ccccc1)NC1CCN(Cc2ccccc2)CC1";"FBRUCPZAISLOOV-UHFFFAOYSA-N";309.41;3.47;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4222546/target=_blank>CHEMBL4222546</a>";;-2.85;"Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA, Guy RK.: Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem, Volume 61 (7), 2018";"PAMPA";0.001412537544622754
"Naringenin";"MM00673";"O=C1CC(c2ccc(O)cc2)Oc2cc(O)cc(O)c21";"FTVWIRXFELQLPI-UHFFFAOYSA-N";272.26;2.51;"932";"CHEMBL9352";"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL988140/target=_blank>CHEMBL988140</a>";;-4.59;"Serra H, Mendes T, Bronze MR, SimplĂ­cio AL.: Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem, Volume 16 (7), 2008";"PAMPA";0.000025703957827688645
"MM474386";"MM474386";"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5";"UQCNKQCJZOAFTQ-ISWURRPUSA-N";301.34;0.75;;;"GENER";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4323355/target=_blank>CHEMBL4323355</a>";;-5.49;"Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, BrockmĂ¶ller J, Tzvetkov MV.: Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1. J Med Chem, Volume 62 (21), 2019";"PAMPA";0.000003235936569296281
"Ethanolamine";"MM00490";"NCCO";"HZAXFHJVJLSVMW-UHFFFAOYSA-N";61.08;-1.06;"700";"CHEMBL104943";"GENER";"ELIP";"25";;"renalliposomes";;-4.89;"Piqueras AI, Somers M, Hammond TG, Strange K, Harris HW, Gawryl M, Zeidel ML.: Permeability properties of rat renal lysosomes. Am J Physiol, Volume 266 (1 pt 1), 1994";"BLM";0.000012882495516931348
"4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one";"MM00331";"Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C";"RMMXTBMQSGEXHJ-UHFFFAOYSA-N";231.3;1.55;"6009";"CHEMBL288470";"LEC";"EPAM";"25";"0";;;-4.76;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000017378008287493764
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"LEC";"EPAM";"25";"0";;;-4.95;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00001122018454301963
"Coumarin";"MM00042";"O=c1ccc2ccccc2o1";"ZYGHJZDHTFUPRJ-UHFFFAOYSA-N";146.15;1.79;"323";"CHEMBL6466";"LEC";"EPAM";"25";"0";;;-4.55;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00002818382931264455
"2-methylphenol";"MM01283";"Cc1ccccc1O";"QWVGKYWNOKOFNN-UHFFFAOYSA-N";108.14;1.7;"335";;"LEC";"EPAM";"25";"0";;;-4.28;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00005248074602497723
"Benzene-1,4-diol";"MM00951";"Oc1ccc(O)cc1";"QIGBRXMKCJKVMJ-UHFFFAOYSA-N";110.11;1.1;"785";"CHEMBL537";"LEC";"EPAM";"25";"0";;;-5.14;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000007244359600749906
"1H-indole";"MM01048";"c1ccc2[nH]ccc2c1";"SIKJAQJRHWYJAI-UHFFFAOYSA-N";117.15;2.17;"798";;"LEC";"EPAM";"25";"0";;;-4.5;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000031622776601683795
"Phenol";"MM00206";"Oc1ccccc1";"ISWSIDIOOBJBQZ-UHFFFAOYSA-N";94.11;1.39;"996";"CHEMBL14060";"LEC";"EPAM";"25";"0";;;-4.33;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00004677351412871981
"Phenytoin";"MM00406";"O=C1N=C(O)NC1(c1ccccc1)c1ccccc1";"CXOFVDLJLONNDW-UHFFFAOYSA-N";252.27;1.97;"1775";"CHEMBL16";"LEC";"EPAM";"25";"0";;;-4.41;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000038904514499428046
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"LEC";"EPAM";"25";"0";;;-6.04;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000009120108393559096
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"LEC";"EPAM";"25";"0";;;-5.31;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000004897788193684467
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"LEC";"EPAM";"25";"0";;;-5.54;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000002884031503126606
"6-chloro-4-N-ethyl-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine";"MM01050";"CCNc1nc(Cl)nc(NC(C)C)n1";"MXWJVTOOROXGIU-UHFFFAOYSA-N";215.69;1.78;"2256";;"LEC";"EPAM";"25";"0";;;-4.53;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00002951209226666384
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"LEC";"EPAM";"25";"0";;;-5.41;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000003890451449942805
"Diethoxy-(6-methyl-2-propan-2-ylpyrimidin-4-yl)oxy-sulfanylidene-lambda5-phosphane";"MM00931";"CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1";"FHIVAFMUCKRCQO-UHFFFAOYSA-N";304.35;3.58;"3017";;"LEC";"EPAM";"25";"0";;;-5.28;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000005248074602497723
"Hydrochlorothiazide";"MM00373";"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O";"JZUFKLXOESDKRF-UHFFFAOYSA-N";297.75;-0.35;"3639";"CHEMBL435";"LEC";"EPAM";"25";"0";;;-6.59;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000002570395782768865
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"LEC";"EPAM";"25";"0";;;-5.37;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000004265795188015926
"Corticosterone";"MM00346";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C(C(=O)CO)CCC12";"OMFXVFTZEKFJBZ-UHFFFAOYSA-N";346.47;2.67;"5753";"CHEMBL110739";"LEC";"EPAM";"25";"0";;;-4.77;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00001698243652461746
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"LEC";"EPAM";"25";"0";;;-5.45;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000003548133892335753
"Prednisolone";"MM00297";"CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"OIGNJSKKLXVSLS-UHFFFAOYSA-N";360.45;1.56;"5755";"CHEMBL131";"LEC";"EPAM";"25";"0";;;-5.47;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000033884415613920275
"Chloramphenicol";"MM00342";"O=C(NC(CO)C(O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl";"WIIZWVCIJKGZOK-UHFFFAOYSA-N";323.13;0.91;"5959";"CHEMBL130";"LEC";"EPAM";"25";"0";;;-5.41;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000003890451449942805
"Aniline";"MM00039";"Nc1ccccc1";"PAYRUJLWNCNPSJ-UHFFFAOYSA-N";93.13;1.27;"6115";"CHEMBL538";"LEC";"EPAM";"25";"0";;;-4.12;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00007585775750291836
"Diethyl Phthalate";"MM00195";"CCOC(=O)c1ccccc1C(=O)OCC";"FLKPEMZONWLCSK-UHFFFAOYSA-N";222.24;2.04;"6781";;"LEC";"EPAM";"25";"0";;;-4.82;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000015135612484362071
"2-Nitroaniline";"MM01055";"Nc1ccccc1[N+](=O)[O-]";"DPJCXCZTLWNFOH-UHFFFAOYSA-N";138.13;1.18;"6946";;"LEC";"EPAM";"25";"0";;;-4.54;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000028840315031266056
"2-Nitrophenol";"MM01056";"O=[N+]([O-])c1ccccc1O";"IQUPABOKLQSFBK-UHFFFAOYSA-N";139.11;1.3;"6947";;"LEC";"EPAM";"25";"0";;;-4.24;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000057543993733715664
"2,5-Dichloronitrobenzene";"MM01057";"O=[N+]([O-])c1cc(Cl)ccc1Cl";"RZKKOBGFCAHLCZ-UHFFFAOYSA-N";192;2.9;"6977";;"LEC";"EPAM";"25";"0";;;-5.11;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00000776247116628691
"1,1'-biphenyl";"MM01058";"c1ccc(-c2ccccc2)cc1";"ZUOUZKKEUPVFJK-UHFFFAOYSA-N";154.21;3.35;"7095";;"LEC";"EPAM";"25";"0";;;-5.95;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000001122018454301963
"2-Chloroaniline";"MM01059";"Nc1ccccc1Cl";"AKCRQHGQIJBRMN-UHFFFAOYSA-N";127.57;1.92;"7240";;"LEC";"EPAM";"25";"0";;;-4.48;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000033113112148259076
"2-Chlorophenol";"MM00219";"Oc1ccccc1Cl";"ISPYQTSUDJAMAB-UHFFFAOYSA-N";128.56;2.05;"7245";"CHEMBL108877";"LEC";"EPAM";"25";"0";;;-4.3;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00005011872336272725
"3-Nitroaniline";"MM00137";"Nc1cccc([N+](=O)[O-])c1";"XJCVRTZCHMZPBD-UHFFFAOYSA-N";138.13;1.18;"7423";;"LEC";"EPAM";"25";"0";;;-4.67;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000021379620895022323
"4-Nitroaniline";"MM01060";"Nc1ccc([N+](=O)[O-])cc1";"TYMLOMAKGOJONV-UHFFFAOYSA-N";138.13;1.18;"7475";;"LEC";"EPAM";"25";"0";;;-4.68;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00002089296130854041
"5-Ethyl-2-methylpyridine";"MM01061";"CCc1ccc(C)nc1";"NTSLROIKFLNUIJ-UHFFFAOYSA-N";121.18;1.95;"7728";;"LEC";"EPAM";"25";"0";;;-5.55;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000002818382931264455
"2,4-Dimethylphenol";"MM01062";"Cc1ccc(O)c(C)c1";"KUFFULVDNCHOFZ-UHFFFAOYSA-N";122.17;2.01;"7771";;"LEC";"EPAM";"25";"0";;;-4.61;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000024547089156850286
"4-Chloroaniline";"MM00811";"Nc1ccc(Cl)cc1";"QSNSCYSYFYORTR-UHFFFAOYSA-N";127.57;1.92;"7812";;"LEC";"EPAM";"25";"0";;;-4.38;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00004168693834703355
"3-Chloroaniline";"MM01063";"Nc1cccc(Cl)c1";"PNPCRKVUWYDDST-UHFFFAOYSA-N";127.57;1.92;"7932";;"LEC";"EPAM";"25";"0";;;-4.44;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000363078054770101
"2,4-Dichlorophenol";"MM00800";"Oc1ccc(Cl)cc1Cl";"HFZWRUODUSTPEG-UHFFFAOYSA-N";163;2.7;"8449";;"LEC";"EPAM";"25";"0";;;-4.93;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000011748975549395302
"Dimethyl Phthalate";"MM00938";"COC(=O)c1ccccc1C(=O)OC";"NIQCNGHVCWTJSM-UHFFFAOYSA-N";194.19;1.26;"8554";;"LEC";"EPAM";"25";"0";;;-4.36;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000043651583224016566
"2-(1H-indol-3-yl)ethanol";"MM01064";"OCCc1c[nH]c2ccccc12";"MBBOMCVGYCRMEA-UHFFFAOYSA-N";161.2;1.7;"10685";;"LEC";"EPAM";"25";"0";;;-4.72;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000019054607179632484
"3-Nitrophenol";"MM00225";"O=[N+]([O-])c1cccc(O)c1";"RTZZCYNQPHTPPL-UHFFFAOYSA-N";139.11;1.3;"11137";;"LEC";"EPAM";"25";"0";;;-4.77;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00001698243652461746
"N-phenylaniline";"MM01065";"c1ccc(Nc2ccccc2)cc1";"DMBHHRLKUKUOEG-UHFFFAOYSA-N";169.23;3.43;"11487";;"LEC";"EPAM";"25";"0";;;-5.51;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000003090295432513592
"4-cyanophenol";"MM00231";"N#Cc1ccc(O)cc1";"CVNOWLNNPYYEOH-UHFFFAOYSA-N";119.12;1.26;"13019";;"LEC";"EPAM";"25";"0";;;-4.77;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00001698243652461746
"3-(dimethoxyphosphinothioylsulfanylmethyl)-5-methoxy-1,3,4-thiadiazol-2-one";"MM01067";"COc1nn(CSP(=S)(OC)OC)c(=O)s1";"MEBQXILRKZHVCX-UHFFFAOYSA-N";302.34;1.52;"13709";;"LEC";"EPAM";"25";"0";;;-4.97;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00001071519305237607
"(2-butan-2-ylphenyl) N-methylcarbamate";"MM01068";"CCC(C)c1ccccc1OC(=O)NC";"DIRFUJHNVNOBMY-UHFFFAOYSA-N";207.27;2.92;"19588";;"LEC";"EPAM";"25";"0";;;-4.91;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00001230268770812381
"2-methoxy-2-sulfanylidene-4H-1,3,2lambda5-benzodioxaphosphinine";"MM01069";"COP1(=S)OCc2ccccc2O1";"OUNSASXJZHBGAI-UHFFFAOYSA-N";216.2;2.47;"19657";;"LEC";"EPAM";"25";"0";;;-5.03;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000009332543007969906
"Pyrene";"MM00163";"c1cc2ccc3cccc4ccc(c1)c2c34";"BBEAQIROQSPTKN-UHFFFAOYSA-N";202.26;4.58;"31423";;"LEC";"EPAM";"25";"0";;;-5.65;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000022387211385683376
"Di(propan-2-yloxy)phosphorylsulfanylmethylbenzene";"MM01070";"CC(C)OP(=O)(OC(C)C)SCc1ccccc1";"FCOAHACKGGIURQ-UHFFFAOYSA-N";288.35;4.88;"33294";;"LEC";"EPAM";"25";"0";;;-4.93;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000011748975549395302
"S-[(4-chlorophenyl)methyl] N,N-diethylcarbamothioate";"MM01071";"CCN(CC)C(=O)SCc1ccc(Cl)cc1";"QHTQREMOGMZHJV-UHFFFAOYSA-N";257.79;4.04;"34192";;"LEC";"EPAM";"25";"0";;;-4.69;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000020417379446695274
"1,2-Dibenzoyl-1-tert-butylhydrazine";"MM01073";"CC(C)(C)N(NC(=O)c1ccccc1)C(=O)c1ccccc1";"NISLLQUWIJASOV-UHFFFAOYSA-N";296.37;3.27;"86307";;"LEC";"EPAM";"25";"0";;;-4.78;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000016595869074375598
"N-[1-[(6-chloropyridin-3-yl)methyl]-4,5-dihydroimidazol-2-yl]nitramide";"MM01074";"O=[N+]([O-])NC1=NCCN1Cc1ccc(Cl)nc1";"YWTYJOPNNQFBPC-UHFFFAOYSA-N";255.67;0.69;"86418";;"LEC";"EPAM";"25";"0";;;-5.34;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000004570881896148752
"Tebufenozide";"MM01075";"CCc1ccc(C(=O)NN(C(=O)c2cc(C)cc(C)c2)C(C)(C)C)cc1";"QYPNKSZPJQQLRK-UHFFFAOYSA-N";352.48;4.45;"91773";;"LEC";"EPAM";"25";"0";;;-4.8;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00001584893192461114
"Methoxyfenozide";"MM01077";"COc1cccc(C(=O)NN(C(=O)c2cc(C)cc(C)c2)C(C)(C)C)c1C";"QCAWEPFNJXQPAN-UHFFFAOYSA-N";368.48;4.21;"105010";;"LEC";"EPAM";"25";"0";;;-4.72;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000019054607179632484
"N'-benzoyl-N'-tert-butyl-4-chlorobenzohydrazide";"MM01078";"CC(C)(C)N(NC(=O)c1ccc(Cl)cc1)C(=O)c1ccccc1";"CNKHSLKYRMDDNQ-UHFFFAOYSA-N";330.82;3.93;"114994";;"LEC";"EPAM";"25";"0";;;-4.76;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000017378008287493764
"L-Tryptophanamide";"MM01079";"NC(=O)C(N)Cc1c[nH]c2ccccc12";"JLSKPBDKNIXMBS-UHFFFAOYSA-N";203.25;0.52;"439356";;"LEC";"EPAM";"25";"0";;;-5.56;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000002754228703338169
"Indole-3-carboxamide";"MM01080";"NC(=O)c1c[nH]c2ccccc12";"LSGKMZLPZFPAIN-UHFFFAOYSA-N";160.18;1.27;"2192542";;"LEC";"EPAM";"25";"0";;;-5.21;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000006165950018614822
"Gly-Trp-NH2";"MM01081";"NCC(=O)NC(Cc1c[nH]c2ccccc12)C(N)=O";"YZMFLZVJQTUTKK-UHFFFAOYSA-N";260.3;-0.36;"3081965";;"LEC";"EPAM";"25";"0";;;-6.38;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000004168693834703355
"Cyclo(-Gly-Trp)";"MM01082";"O=C1CNC(=O)C(Cc2c[nH]c3ccccc23)N1";"IFQZEERDQXQTLJ-UHFFFAOYSA-N";243.27;0.33;"6997508";;"LEC";"EPAM";"25";"0";;;-6.02;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000009549925860214369
"Cyclo(-Trp-Trp)";"MM01084";"O=C1NC(Cc2c[nH]c3ccccc23)C(=O)NC1Cc1c[nH]c2ccccc12";"DNHODRZUCGXYKU-UHFFFAOYSA-N";372.43;2.42;"7091706";;"LEC";"EPAM";"25";"0";;;-5.04;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000009120108393559096
"N'-tert-butyl-N'-(3,5-dimethylbenzoyl)-5-methyl-3,4-dihydro-2H-chromene-6-carbohydrazide";"MM01085";"Cc1cc(C)cc(C(=O)N(NC(=O)c2ccc3c(c2C)CCCO3)C(C)(C)C)c1";"HPNSNYBUADCFDR-UHFFFAOYSA-N";394.52;4.52;"10157484";;"LEC";"EPAM";"25";"0";;;-4.78;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.000016595869074375598
"Ac-Tyr-Phe-NH2";"MM01086";"CC(=O)NC(Cc1ccc(O)cc1)C(=O)NC(Cc1ccccc1)C(N)=O";"QJOFRQKWYZAXIZ-UHFFFAOYSA-N";369.42;0.65;"11068626";;"LEC";"EPAM";"25";"0";;;-6.92;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00000012022644346174132
"Cyclo(-Trp-Tyr)";"MM01087";"O=C1N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H]1Cc1ccc(O)cc1";"ZJDMXAAEAVGGSK-ROUUACIJSA-N";349.39;1.64;;;"LEC";"EPAM";"25";"0";;;-6.17;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000006760829753919819
"Ac-Tyr-Leu-NH2";"MM01088";"CC(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(N)=O";"WGDDMZFVKNOORS-UHFFFAOYSA-N";335.4;0.46;"14562813";;"LEC";"EPAM";"25";"0";;;-6.54;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.00000028840315031266057
"Ac-Trp-Val-NH2";"MM01093";"CC(C)[C@@H](C(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C";"ZFFQYIRICYOHAN-UHFFFAOYSA-N";344.42;0.84;"44424860";;"LEC";"EPAM";"25";"0";;;-6.18;"Fujikawa M, Nakao K, Shimizu R, Akamatsu M.: QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem, Volume 15 (11), 3756-3767, 2007";"PAMPA";0.0000006606934480075964
"[5-Amino-1-(4-methoxyphenyl)sulfonylpyrazol-3-yl] Benzoate";"MM01184";"COc1ccc(S(=O)(=O)n2nc(OC(=O)c3ccccc3)cc2N)cc1";"FQICFDBMQBCJDT-UHFFFAOYSA-N";373.39;1.93;"655490";;"GIT-0";"EPAM";"25";"0";;;-2.66;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.002187761623949552
"Emetine Hydrochloride";"MM01186";"CCC1CN2CCc3cc(OC)c(OC)cc3C2CC1CC1NCCc2cc(OC)c(OC)cc21.Cl";"HUEYSSLYFJVUIS-UHFFFAOYSA-N";517.11;5.37;"6603320";;"GIT-0";"EPAM";"25";"0";;;-3.01;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.000977237220955811
"5H-Quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide";"MM01188";"O=S1(=O)Nc2c(ccc3cccnc23)-c2ccccc21";"CYSOFAOLQAYKGU-UHFFFAOYSA-N";282.32;3.02;"659101";;"GIT-0";"EPAM";"25";"0";;;-1.88;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.013182567385564075
"Cyclohexyl Cyano[3-(4-ethylpiperazin-1-yl)quinoxalin-2-yl]acetate";"MM01189";"CCN1CCN(c2nc3ccccc3nc2C(C#N)C(=O)OC2CCCCC2)CC1";"KKTOITAISCXMHG-UHFFFAOYSA-N";407.52;3.25;"663281";;"GIT-0";"EPAM";"25";"0";;;-3.33;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.00046773514128719813
"4-(1H-Benzimidazol-2-ylmethylsulfanyl)-2-methyl-[1]benzofuro[3,2-d]pyrimidine";"MM01190";"Cc1nc(SCc2nc3ccccc3[nH]2)c2oc3ccccc3c2n1";"FSHFRKKIBVABAJ-UHFFFAOYSA-N";346.42;4.85;"664279";;"GIT-0";"EPAM";"25";"0";;;-2.86;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0013803842646028853
"2'-(1,3-benzoxazol-2-ylamino)-7',8'-dihydro-1'H-spiro[cyclopentane-1,4'-quinazolin]-5'(6'H)-one";"MM01191";"O=C1CCCC2=C1C1(CCCC1)N=C(Nc1nc3ccccc3o1)N2";"FDNVTCDQGOVLPM-UHFFFAOYSA-N";336.4;3.52;"664331";;"GIT-0";"EPAM";"25";"0";;;-2.64;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0022908676527677724
"1-(3,4-Dihydroxyphenyl)-2-[[5-(2-methoxyphenyl)-4-prop-2-enyl-1,2,4-triazol-3-yl]sulfanyl]ethanone";"MM01192";"C=CCn1c(SCC(=O)c2ccc(O)c(O)c2)nnc1-c1ccccc1OC";"HDLQKEKTQTTWGA-UHFFFAOYSA-N";397.46;3.53;"665093";;"GIT-0";"EPAM";"25";"0";;;-1.94;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.01148153621496883
"2-(4,6-Dimethylpyrimidin-2-yl)-4-(4-fluorophenyl)sulfanyl-5-methylpyrazol-3-amine";"MM01193";"Cc1cc(C)nc(-n2nc(C)c(Sc3ccc(F)cc3)c2N)n1";"UHKSHIBWGZYKCL-UHFFFAOYSA-N";329.4;3.46;"2321431";;"GIT-0";"EPAM";"25";"0";;;-3.01;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.000977237220955811
"4-(1-Methyltetrazol-5-yl)sulfanyl-5-phenylthieno[2,3-d]pyrimidine";"MM01194";"Cn1nnnc1Sc1ncnc2scc(-c3ccccc3)c12";"HIPMWEIBNDUPSH-UHFFFAOYSA-N";326.41;3.03;"2432214";;"GIT-0";"EPAM";"25";"0";;;-2.99;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0010232929922807535
"1-[2-(1-Benzyl-2,5-dimethylpyrrol-3-yl)-2-oxoethyl]pyrrolidine-2,5-dione";"MM01195";"Cc1cc(C(=O)CN2C(=O)CCC2=O)c(C)n1Cc1ccccc1";"JRESCQKIRPOOEM-UHFFFAOYSA-N";324.38;2.48;"2113511";;"GIT-0";"EPAM";"25";"0";;;-2.4;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.003981071705534973
"3-(2,5-Dimethyl-1-phenylpyrrol-3-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine";"MM01196";"Cc1cc(-c2nnc3n2CCCCC3)c(C)n1-c1ccccc1";"SGHSEHOWYLRAPR-UHFFFAOYSA-N";306.41;4.08;"2331284";;"GIT-0";"EPAM";"25";"0";;;-2.59;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0025703957827688645
"2-(2-Methoxyphenyl)-N-[4-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide";"MM01197";"COc1cccc(-c2nc(-c3ccc(NC(=O)Cc4ccccc4OC)cc3)no2)c1";"FCERKWLJIGNRPV-UHFFFAOYSA-N";415.45;4.6;"3236979";;"GIT-0";"EPAM";"25";"0";;;-2.94;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0011481536214968829
"7-Hydroxy-2,3,4,5-tetrahydro-[1]benzofuro[2,3-c]azepin-1-one";"MM01198";"O=C1NCCCc2c1oc1ccc(O)cc21";"AACFPJSJOWQNBN-UHFFFAOYSA-N";217.22;1.81;"755673";;"GIT-0";"EPAM";"25";"0";;;-1.11;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.07762471166286916
"4-(1-Methyl-2-oxoquinolin-4-yl)oxy-N-(4-methylpyridin-2-yl)butanamide";"MM01199";"Cc1ccnc(NC(=O)CCCOc2cc(=O)n(C)c3ccccc23)c1";"KRZBWKRPRKNWHY-UHFFFAOYSA-N";351.41;3.04;"3237904";;"GIT-0";"EPAM";"25";"0";;;-2.71;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0019498445997580456
"N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-(3-methylpiperidin-1-yl)-2-phenylacetamide";"MM01200";"CC1CCCN(C(C(=O)Nc2ccc3c(c2)OCCO3)c2ccccc2)C1";"ZPVUAOURUGLWNO-UHFFFAOYSA-N";366.46;3.87;"3240990";;"GIT-0";"EPAM";"25";"0";;;-3.3;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0005011872336272725
"N-[3-Oxo-3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-2,1,3-benzothiadiazole-4-sulfonamide";"MM01201";"O=C(CCNS(=O)(=O)c1cccc2nsnc12)N1CCN(c2ccccn2)CC1";"PAUICUBCWHEEDI-UHFFFAOYSA-N";432.53;1.1;"3242997";;"GIT-0";"EPAM";"25";"0";;;-2.16;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.006918309709189363
"[1-(3-Methylphenyl)benzimidazol-5-yl]-piperidin-1-ylmethanone";"MM01202";"Cc1cccc(-n2cnc3cc(C(=O)N4CCCCC4)ccc32)c1";"YQNOQZALLOQMPY-UHFFFAOYSA-N";319.41;3.96;"3243760";;"GIT-0";"EPAM";"25";"0";;;-2.87;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0013489628825916532
"2-[(6-Bromo-1H-imidazo[4,5-b]pyridin-2-yl)sulfanylmethyl]benzonitrile";"MM01203";"N#Cc1ccccc1CSc1nc2ncc(Br)cc2[nH]1";"DEYMHFHACXKPOV-UHFFFAOYSA-N";345.23;3.88;"3245059";;"GIT-0";"EPAM";"25";"0";;;-2.16;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.006918309709189363
"2-[(4-Chlorophenyl)methylsulfanyl]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one";"MM01204";"O=c1nc(SCc2ccc(Cl)cc2)[nH]c2c1CCC2";"HKDAECHYHSQLRG-UHFFFAOYSA-N";292.79;3.2;"2047223";;"GIT-0";"EPAM";"25";"0";;;-2.8;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.001584893192461114
"2-[(2-Phenylethyl)thio]nicotinic Acid";"MM01205";"O=C(O)c1cccnc1SCCc1ccccc1";"UZERZZRWECLIKE-UHFFFAOYSA-N";259.33;3.11;"888706";;"GIT-0";"EPAM";"25";"0";;;-1.23;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0588843655355589
"5-(3,4-Diethoxyphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole";"MM01206";"CCOc1ccc(-c2nc(-c3ccncc3)no2)cc1OCC";"MMKXHTDCKLZHIM-UHFFFAOYSA-N";311.34;3.6;"976135";;"GIT-0";"EPAM";"25";"0";;;-3.01;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.000977237220955811
"1-Pyrrolidin-1-yl-2-quinolin-8-ylsulfanylethanone";"MM01207";"O=C(CSc1cccc2cccnc12)N1CCCC1";"RQGNWRSISVFFMW-UHFFFAOYSA-N";272.37;2.95;"975656";;"GIT-0";"EPAM";"25";"0";;;-2;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.01
"2,5-Dimethoxy-N-quinolin-3-ylbenzenesulfonamide";"MM01208";"COc1ccc(OC)c(S(=O)(=O)Nc2cnc3ccccc3c2)c1";"JZSPHTPWUXNQGB-UHFFFAOYSA-N";344.39;3.05;"2931238";;"GIT-0";"EPAM";"25";"0";;;-2.85;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.001412537544622754
"4-Benzenesulfonamido-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamide";"MM01209";"CCc1nnc(NC(=O)c2ccc(NS(=O)(=O)c3ccccc3)cc2)s1";"YMGXUJCEBOCIIT-UHFFFAOYSA-N";388.47;3.15;"2210290";;"GIT-0";"EPAM";"25";"0";;;-2.21;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.006165950018614822
"N,N-Dicyclohexyl-5-propyl-1,2-oxazole-3-carboxamide";"MM01210";"CCCc1cc(C(=O)N(C2CCCCC2)C2CCCCC2)no1";"XTUSMJNHGPASSE-UHFFFAOYSA-N";318.46;4.73;"5309153";;"GIT-0";"EPAM";"25";"0";;;2;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";100
"7-[(E)-But-2-enyl]-3-methyl-8-(3-phenylpropylsulfanyl)purine-2,6-dione";"MM01211";"CC=CCn1c(SCCCc2ccccc2)nc2c1c(=O)[nH]c(=O)n2C";"MGHRGGHCCMMDND-UHFFFAOYSA-N";370.48;2.72;"5310346";;"GIT-0";"EPAM";"25";"0";;;-3.13;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0007413102413009177
"N-[Furan-2-yl-(8-hydroxyquinolin-7-yl)methyl]-2-methylpropanamide";"MM01212";"CC(C)C(=O)NC(c1ccco1)c1ccc2cccnc2c1O";"PBZYAPZLINAHET-UHFFFAOYSA-N";310.35;3.4;"2876959";;"GIT-0";"EPAM";"25";"0";;;-2.46;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0034673685045253167
"2-[(4-Methoxyphenyl)methylsulfanyl]-6-methyl-1H-pyrimidin-4-one";"MM01213";"COc1ccc(CSc2nc(=O)cc(C)[nH]2)cc1";"XMFWHLZTTUUQHL-UHFFFAOYSA-N";262.33;2.38;"716696";;"GIT-0";"EPAM";"25";"0";;;-2.22;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.006025595860743574
"3,5-dimethyl-1,3,5-thiadiazinane-2-thione";"MM01214";"CN1CSC(=S)N(C)C1";"QAYICIQNSGETAS-UHFFFAOYSA-N";162.28;0.8;"10788";;"GIT-0";"EPAM";"25";"0";;;-1.26;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.054954087385762455
"4-(5,6-Diphenyl-1,2,4-triazin-3-yl)morpholine";"MM01215";"c1ccc(-c2nnc(N3CCOCC3)nc2-c2ccccc2)cc1";"XAYFWWVZSYKDIS-UHFFFAOYSA-N";318.38;3.04;"2842253";;"GIT-0";"EPAM";"25";"0";;;-3.17;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0006760829753919819
"2-(5-Phenyl-2H-[1,2,4]triazol-3-yl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione";"MM01217";"O=C1C2CC=CCC2C(=O)N1c1n[nH]c(-c2ccccc2)n1";"MIQGMTKINBACMG-UHFFFAOYSA-N";294.31;1.93;"2946732";;"GIT-0";"EPAM";"25";"0";;;-1.8;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.015848931924611134
"Carbazol-9-yl-(4-methylphenyl)methanone";"MM01218";"Cc1ccc(C(=O)n2c3ccccc3c3ccccc32)cc1";"AWZNVFKAFFHLEY-UHFFFAOYSA-N";285.35;4.79;"576989";;"GIT-0";"EPAM";"25";"0";;;-2.55;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.002818382931264455
"N-(4-Chloro-2,5-dimethoxyphenyl)-5-cyclopropyl-1,2-oxazole-3-carboxamide";"MM01219";"COc1cc(NC(=O)c2cc(C3CC3)on2)c(OC)cc1Cl";"FMWABCRYNLCXOJ-UHFFFAOYSA-N";322.75;3.47;"6619100";;"GIT-0";"EPAM";"25";"0";;;-2.86;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0013803842646028853
"12-(3,4-Dimethoxy-phenyl)-10-(2-morpholin-4-yl-ethyl)-10,12-dihydro-7-oxa-8,10-diaza-benzo[a]anthra Cen-11-ylideneamine";"MM01220";"COc1ccc(C2c3c(ncn(CCN4CCOCC4)c3=N)Oc3ccc4ccccc4c32)cc1OC";"HTAQOIIMDZRODK-UHFFFAOYSA-N";498.58;4.15;"3719993";;"GIT-0";"EPAM";"25";"0";;;-3.16;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0006918309709189362
"4-Methoxy-2-(4-propoxyphenyl)quinazoline";"MM01221";"CCCOc1ccc(-c2nc(OC)c3ccccc3n2)cc1";"YWKHKRITRQRVIW-UHFFFAOYSA-N";294.35;4.09;"1612038";;"GIT-0";"EPAM";"25";"0";;;-1.41;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.03890451449942807
"2-Amino-1-(4-methylphenyl)-6-oxo-4-phenylpyridine-3,5-dicarbonitrile";"MM01222";"Cc1ccc(-n2c(N)c(C#N)c(-c3ccccc3)c(C#N)c2=O)cc1";"DWDWEGGEKMILES-UHFFFAOYSA-N";326.36;3.14;"824820";;"GIT-0";"EPAM";"25";"0";;;-1.83;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.014791083881682071
"2-(Dichloromethyl)-4-(4-methylphenyl)-6-methylsulfanyl-1,3,5-triazine";"MM01223";"CSc1nc(-c2ccc(C)cc2)nc(C(Cl)Cl)n1";"VRYFPFHGCPTRHR-UHFFFAOYSA-N";300.21;4.05;"3380841";;"GIT-0";"EPAM";"25";"0";;;-2.19;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.006456542290346556
"2-Chloro-N-[3-cyano-4-(4-methoxyphenyl)sulfanylphenyl]benzamide";"MM01224";"COc1ccc(Sc2ccc(NC(=O)c3ccccc3Cl)cc2C#N)cc1";"YZMLAJBOSVHFEW-UHFFFAOYSA-N";394.88;5.62;"2769229";;"GIT-0";"EPAM";"25";"0";;;-2.69;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0020417379446695297
"N-Naphthalen-1-yl-5-pyridin-4-yl-1,3,4-thiadiazol-2-amine";"MM01225";"c1ccc2c(Nc3nnc(-c4ccncc4)s3)cccc2c1";"FNNACNWDEVQPDH-UHFFFAOYSA-N";304.38;4.5;"1090779";;"GIT-0";"EPAM";"25";"0";;;-2.32;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.004786300923226385
"2-Bromo-N-[3-(butanoylamino)phenyl]benzamide";"MM01226";"CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1";"DFOVLSMXPWPCFH-UHFFFAOYSA-N";361.24;4.44;"1048267";;"GIT-0";"EPAM";"25";"0";;;-2.28;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.005248074602497728
"4-Chloro-3-[(2,5-dimethylphenyl)sulfamoyl]-N-(2-phenylphenyl)benzamide";"MM01227";"Cc1ccc(C)c(NS(=O)(=O)c2cc(C(=O)Nc3ccccc3-c3ccccc3)ccc2Cl)c1";"ZQJTYJZLKBRKPC-UHFFFAOYSA-N";491.01;6.68;"2228302";;"GIT-0";"EPAM";"25";"0";;;-2.4;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.003981071705534973
"4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline";"MM01228";"Brc1cc2c(cc1C1Nc3ccccc3C3C=CCC31)OCO2";"YOLTZIVRJAPVPH-UHFFFAOYSA-N";370.25;5;"3136844";;"GIT-0";"EPAM";"25";"0";;;-1.57;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.026915348039269153
"N-(4-Ethoxyphenyl)-4-[hydroxy(diphenyl)methyl]piperidine-1-carbothioamide";"MM01229";"CCOc1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1";"PMEQBGAGFZDWQX-UHFFFAOYSA-N";446.62;5.43;"2936384";;"GIT-0";"EPAM";"25";"0";;;-2.83;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0014791083881682072
"7,13-Bis[(4-nitrophenyl)methyl]-1,4,10-trioxa-7,13-diazacyclopentadecane";"MM01230";"O=[N+]([O-])c1ccc(CN2CCOCCOCCN(Cc3ccc([N+](=O)[O-])cc3)CCOCC2)cc1";"UKMHVECLTZDSBD-UHFFFAOYSA-N";488.54;2.87;"4536383";;"GIT-0";"EPAM";"25";"0";;;-3.03;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0009332543007969915
"(E)-2-(1H-Benzimidazol-2-yl)-3-(5-nitrofuran-2-yl)prop-2-enenitrile";"MM01231";"N#CC(=Cc1ccc([N+](=O)[O-])o1)c1nc2ccccc2[nH]1";"LISLUXJODLGWGJ-UHFFFAOYSA-N";280.24;3.13;"5904441";;"GIT-0";"EPAM";"25";"0";;;-2.16;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.006918309709189363
"1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]piperidine-4-carboxamide";"MM01232";"NC(=O)C1CCN(c2nc(-c3ccc(Br)cc3)cs2)CC1";"YWCKNSAYJDPHQO-UHFFFAOYSA-N";366.28;3.27;"990823";;"GIT-0";"EPAM";"25";"0";;;-2.45;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0035481338923357532
"[2-(1-Adamantylamino)-2-oxoethyl] 4-methylsulfonyl-3-nitrobenzoate";"MM01233";"CS(=O)(=O)c1ccc(C(=O)OCC(=O)NC23CC4CC(CC(C4)C2)C3)cc1[N+](=O)[O-]";"BTXTVUJWNPMQBT-UHFFFAOYSA-N";436.49;2.24;"5184800";;"GIT-0";"EPAM";"25";"0";;;-2.65;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.00223872113856834
"N-[2-(1H-Benzimidazol-2-yl)ethyl]-2-(2-bromophenoxy)acetamide";"MM01234";"O=C(COc1ccccc1Br)NCCc1nc2ccccc2[nH]1";"XWFRNTHGPRGCNS-UHFFFAOYSA-N";374.24;3.06;"1183113";;"GIT-0";"EPAM";"25";"0";;;-2.9;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0012589254117941675
"1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one";"MM01235";"CCCN1CNc2c(c(=O)[nH]c(=S)n2CCc2ccc(OC)c(OC)c2)C1";"DNWDRRNPHSEMMW-UHFFFAOYSA-N";390.51;2.76;"1512045";;"GIT-0";"EPAM";"25";"0";;;-1.88;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.013182567385564075
"1-(2,4-Dimethylphenyl)-4-piperidin-1-ylsulfonylpiperazine";"MM01236";"Cc1ccc(N2CCN(S(=O)(=O)N3CCCCC3)CC2)c(C)c1";"WPBRWZIGDANJAJ-UHFFFAOYSA-N";337.49;2.16;"701237";;"GIT-0";"EPAM";"25";"0";;;-2.42;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0038018939632056127
"N-(3,4-Dimethylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide";"MM01237";"Cc1ccc(NS(=O)(=O)c2ccc3c(c2)CCC(=O)N3)cc1C";"SNFROMRRGGKYTF-UHFFFAOYSA-N";330.41;2.99;"4547230";;"GIT-0";"EPAM";"25";"0";;;-2.79;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0016218100973589297
"9-(Pyridin-3-yl)-3,4a,5,6,7,8,8a,9-octahydro-2H-5,8-methanothiochromeno[2,3-d][1,3]thiazol-2-one";"MM01238";"O=c1[nH]c2c(s1)C(c1cccnc1)C1C3CCC(C3)C1S2";"RRGJAKVGOZYHOQ-UHFFFAOYSA-N";316.45;3.48;"4870494";;"GIT-0";"EPAM";"25";"0";;;-2.92;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.001202264434617413
"4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide";"MM01239";"COc1ccc(C2CC(c3ccccc3)=NN2c2ccc(S(N)(=O)=O)cc2)cc1";"QBNZBMVRFYREHK-UHFFFAOYSA-N";407.5;3.7;"2950007";;"GIT-0";"EPAM";"25";"0";;;-2.44;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.003630780547701014
"4-Chloro-N-(2-morpholin-4-ylcyclohexyl)benzenesulfonamide";"MM01241";"O=S(=O)(NC1CCCCC1N1CCOCC1)c1ccc(Cl)cc1";"AYQCZQKMGKDZPS-UHFFFAOYSA-N";358.89;2.26;"2911646";;"GIT-0";"EPAM";"25";"0";;;-2.91;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0012302687708123812
"3-Chloro-1-(3,4-dichlorophenyl)-4-(dimethylamino)pyrrole-2,5-dione";"MM01242";"CN(C)C1=C(Cl)C(=O)N(c2ccc(Cl)c(Cl)c2)C1=O";"UJVSRUOVYSHYAG-UHFFFAOYSA-N";319.58;2.88;"779754";;"GIT-0";"EPAM";"25";"0";;;-2.58;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0026302679918953813
"N-[1-(Cyclohexylcarbamoyl)cyclohexyl]-N-(thiophen-2-ylmethyl)pyridine-2-carboxamide";"MM01243";"O=C(c1ccccn1)N(Cc1cccs1)C1(C(=O)NC2CCCCC2)CCCCC1";"FIFDVZFCMSONTO-UHFFFAOYSA-N";425.6;4.94;"5236771";;"GIT-0";"EPAM";"25";"0";;;-3.2;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.000630957344480193
"Methyl 2-[(4-fluorobenzoyl)amino]benzoate";"MM01244";"COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1";"KIAPWMKFHIKQOZ-UHFFFAOYSA-N";273.26;2.86;"310557";;"GIT-0";"EPAM";"25";"0";;;-2.8;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.001584893192461114
"5-Methoxy-3,6-diphenyl-1,2,4-triazine";"MM01247";"COc1nc(-c2ccccc2)nnc1-c1ccccc1";"YPJMIXQBDVYQRG-UHFFFAOYSA-N";263.3;3.21;"6404603";;"GIT-0";"EPAM";"25";"0";;;-3.09;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0008128305161640995
"4-(4-Benzylpiperidin-1-yl)thieno[2,3-d]pyrimidine";"MM01248";"c1ccc(CC2CCN(c3ncnc4sccc34)CC2)cc1";"AJQCKNBBHOVJGO-UHFFFAOYSA-N";309.44;4.15;"2100018";;"GIT-0";"EPAM";"25";"0";;;-3.01;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.000977237220955811
"N-(3,4-Dimethylphenyl)-N'-[(E)-(5-nitrofuran-2-yl)methylideneamino]butanediamide";"MM01251";"Cc1ccc(NC(=O)CCC(=O)NN=Cc2ccc([N+](=O)[O-])o2)cc1C";"UKQWTRJZFLXIQL-UHFFFAOYSA-N";358.35;2.67;"6875690";;"GIT-0";"EPAM";"25";"0";;;-1.57;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.026915348039269153
"N-[(3-Ketobenzothiophen-2-ylidene)amino]-N-(2-methoxyphenyl)acetamide";"MM01252";"COc1ccccc1N(N=C1Sc2ccccc2C1=O)C(C)=O";"QYEYTJAHIFEBPH-UHFFFAOYSA-N";326.38;3.35;"5401876";;"GIT-0";"EPAM";"25";"0";;;-2.92;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.001202264434617413
"1-(4-Methylphenyl)sulfonylbenzimidazol-2-amine";"MM01255";"Cc1ccc(S(=O)(=O)n2c(N)nc3ccccc32)cc1";"SRFABRWQVPCPRG-UHFFFAOYSA-N";287.34;2.16;"1088438";;"GIT-0";"EPAM";"25";"0";;;-2.57;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0026915348039269166
"1-(4-Methoxyphenyl)-N-(naphthalen-1-ylmethyl)methanamine;oxalic Acid";"MM01256";"COc1ccc(CNCc2cccc3ccccc23)cc1";"GIFYKGIODMXYNT-UHFFFAOYSA-N";277.37;4.14;"17367817";;"GIT-0";"EPAM";"25";"0";;;-3.05;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0008912509381337459
"5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one";"MM01258";"CC(=O)c1ccc(N2CCN(S(=O)(=O)c3ccc4c(c3)CC(=O)N4)CC2)cc1";"IOWHNNUEAIMNRP-UHFFFAOYSA-N";399.47;1.89;"20969430";;"GIT-0";"EPAM";"25";"0";;;-2.29;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.005128613839913648
"1-[(4-Chlorophenyl)methyl]-4-[4-(2-methylphenyl)piperazin-1-yl]pyrazolo[3,4-d]pyrimidine";"MM01259";"Cc1ccccc1N1CCN(c2ncnc3c2cnn3Cc2ccc(Cl)cc2)CC1";"ODKPRIUYEYROGE-UHFFFAOYSA-N";418.93;4.16;"1542103";;"GIT-0";"EPAM";"25";"0";;;-3.04;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0009120108393559096
"Ethyl 2-[[2-[2-[(2,3-Dihydro-1,4-benzodioxin-6-yl)amino]-2-oxoethyl]-1,2-dihydro-1-oxo-5-isoquinolinyl]oxy]propanoate";"MM01260";"CCOC(=O)C(C)Oc1cccc2c(=O)n(CC(=O)Nc3ccc4c(c3)OCCO4)ccc12";"KWMBIIQCLUIHDI-UHFFFAOYSA-N";452.46;2.74;"4076092";;"GIT-0";"EPAM";"25";"0";;;-2.64;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0022908676527677724
"3-(2,5-dimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine";"MM01263";"COc1ccc(OC)c(-c2nnc3n2N=C(c2ccc(OC)c(OC)c2)CS3)c1";"DZAUSKKPHXFGNN-UHFFFAOYSA-N";412.47;3.34;"17757146";;"GIT-0";"EPAM";"25";"0";;;-2.77;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0016982436524617442
"2-N,2-N-Dimethyl-6-[(1-naphthalen-1-yltetrazol-5-yl)sulfanylmethyl]-1,3,5-triazine-2,4-diamine";"MM01264";"CN(C)c1nc(N)nc(CSc2nnnn2-c2cccc3ccccc23)n1";"KEGAOGGMAQQKFO-UHFFFAOYSA-N";379.45;1.94;"1517919";;"GIT-0";"EPAM";"25";"0";;;-2.43;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.003715352290971724
"[2-(Furan-2-ylmethylamino)-2-oxoethyl] Adamantane-1-carboxylate";"MM01265";"O=C(COC(=O)C12CC3CC(CC(C3)C1)C2)NCc1ccco1";"MOSOSUPDUHNNDQ-UHFFFAOYSA-N";317.39;2.66;"2998659";;"GIT-0";"EPAM";"25";"0";;;-2.29;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.005128613839913648
"2-[3-Chloro(2-chloroacetyl)-4-methoxyanilino]-N-phenethyl-2-(2-thienyl)acetamide";"MM01266";"COc1ccc(N(C(=O)CCl)C(C(=O)NCCc2ccccc2)c2cccs2)cc1Cl";"UNVKYJSNMVDZJE-UHFFFAOYSA-N";477.41;5.08;"3689413";;"GIT-0";"EPAM";"25";"0";;;-2.75;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0017782794100389228
"3-[[2-(3,5-dimethyl-1-pyrazolyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl]amino]-1-propanol";"MM01267";"Cc1cc(C)n(-c2nc(NCCCO)c3c4c(sc3n2)CCCC4)n1";"WEAXENWHNHWGBP-UHFFFAOYSA-N";357.48;3.17;"665518";;"GIT-0";"EPAM";"25";"0";;;-3.05;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.0008912509381337459
"2-{4-[(4-Chlorobenzyl)oxy]phenyl}-5-(dimethylamino)-1,3-oxazole-4-carbonitrile";"MM01268";"CN(C)c1oc(-c2ccc(OCc3ccc(Cl)cc3)cc2)nc1C#N";"CMVJGSUPZYIDHO-UHFFFAOYSA-N";353.81;4.51;"663459";;"GIT-0";"EPAM";"25";"0";;;-2.32;"Parallel artificial membrane permeability assay at pH 7.4. National Center for Biotechnology Information. PubChem BioAssay Database; AID=624339, https://pubchem.ncbi.nlm.nih.gov/bioassay/624339";"PAMPA";0.004786300923226385
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"PL-A";"EPAM";"25";"0";;;-5.74;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.0000018197008586099826
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"PL-A";"EPAM";"25";"0";;;-7.37;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.00000004265795188015925
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"PL-A";"EPAM";"25";"0";;;-5.09;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.000008128305161640995
"Colchicine";"MM00345";"COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2";"IAKHMKGGTNLKSZ-UHFFFAOYSA-N";399.44;2.87;"6167";"CHEMBL87";"PL-A";"EPAM";"25";"0";;;-7.6;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.00000002511886431509582
"Dexamethasone";"MM00355";"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO";"UREBDLICKHMUKA-CXSFZGCWSA-N";392.47;1.9;"5743";"CHEMBL384467";"PL-A";"EPAM";"25";"0";;;-6.39;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.00000040738027780411303
"Etoposide";"MM00361";"COc1cc(C2c3cc4c(cc3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)cc(OC)c1O";"VJJPUSNTGOMMGY-UHFFFAOYSA-N";588.56;1.34;"36462";"CHEMBL44657";"PL-A";"EPAM";"25";"0";;;-6.48;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.0000003311311214825908
"Loperamide";"MM00509";"CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1";"RDOIQAHITMMDAJ-UHFFFAOYSA-N";477.05;5.09;"3955";"CHEMBL841";"PL-A";"EPAM";"25";"0";;;-5.23;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.000005888436553555884
"Loratadine";"MM00385";"CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1";"JCCNYMKQOSZNPW-UHFFFAOYSA-N";382.89;4.89;"3957";"CHEMBL998";"PL-A";"EPAM";"25";"0";;;-5.52;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.0000030199517204020193
"Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate";"MM01377";"COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1";"OPXLLQIJSORQAM-UHFFFAOYSA-N";295.3;2.97;"4030";;"PL-A";"EPAM";"25";"0";;;-5.02;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.000009549925860214369
"Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate";"MM00397";"COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]";"HYIMSNHJOBLJNT-UHFFFAOYSA-N";346.34;2.18;"4485";"CHEMBL193";"PL-A";"EPAM";"25";"0";;;-4.96;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.000010964781961431852
"Reserpine";"MM01381";"COC(=O)C1C2CC3c4[nH]c5cc(OC)ccc5c4CCN3CC2CC(OC(=O)c2cc(OC)c(OC)c(OC)c2)C1OC";"QEVHRUUCFGRFIF-UHFFFAOYSA-N";608.69;4.17;"5770";;"PL-A";"EPAM";"25";"0";;;-5.21;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.000006165950018614822
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"PL-A";"EPAM";"25";"0";;;-4.74;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.000018197008586099827
"Yohimbine";"MM01382";"COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21";"BLGXFZZNTVWLAY-UHFFFAOYSA-N";354.45;2.65;"8969";;"PL-A";"EPAM";"25";"0";;;-5.31;"Kerns E. H., Di L., Petusky S., Farris M., Ley R., Jupp P.: Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J. Pharm. Sci., 93(6), 1440-1453, 2004.";"PAMPA";0.000004897788193684467
"MM474747";"MM474747";"Cc1cc(N[C@H](CCCCNCc2ccc(F)cc2)C(=O)NO)cc(C)c1F";"RCTYLDJWEDNGIO-LJQANCHMSA-N";391.46;3.83;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2013516/target=_blank>CHEMBL2013516</a>";;-5.9;"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT.: Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett, Volume 22 (6), 2012";"PAMPA";0.0000012589254117941661
"MM474746";"MM474746";"CO[C@H](C[C@H](CCCCNCc1ccc(F)cc1)C(=O)NO)c1ccc(F)cc1";"SZPWYHRMRFNOHH-GHTZIAJQSA-N";406.47;4.12;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2013516/target=_blank>CHEMBL2013516</a>";;-5.8;"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT.: Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett, Volume 22 (6), 2012";"PAMPA";0.000001584893192461114
"MM474745";"MM474745";"Cc1cc(O[C@H](CCCCNCc2ccc(F)cc2)C(=O)NO)cc(C)c1F";"DUBRLRRJAJGWMU-LJQANCHMSA-N";392.45;3.79;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2013516/target=_blank>CHEMBL2013516</a>";;-5.2;"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT.: Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett, Volume 22 (6), 2012";"PAMPA";0.00000630957344480193
"MM474742";"MM474742";"Cc1cc(C[C@H](CCCCNCc2ccc(F)cc2)C(=O)NO)cc(C)c1F";"PVPXSRWESCVIBD-IBGZPJMESA-N";390.47;4.21;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2013516/target=_blank>CHEMBL2013516</a>";;-4.8;"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT.: Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett, Volume 22 (6), 2012";"PAMPA";0.00001584893192461114
"MM474740";"MM474740";"CCC(NCCCC[C@@H](Cc1cc(C)c(F)c(C)c1)C(=O)NO)c1ccc(F)cc1";"RKZDOJQKLCPUQZ-AIBWNMTMSA-N";418.53;5.16;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2013516/target=_blank>CHEMBL2013516</a>";;-4.1;"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT.: Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett, Volume 22 (6), 2012";"PAMPA";0.00007943282347242822
"MM474744";"MM474744";"CCC(NCCCC[C@@H](Nc1cc(C)c(F)c(C)c1)C(=O)NO)c1ccc(F)cc1";"QKBHUOCFQAXIBG-BPGUCPLFSA-N";419.52;4.78;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2013516/target=_blank>CHEMBL2013516</a>";;-5.1;"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT.: Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett, Volume 22 (6), 2012";"PAMPA";0.000007943282347242822
"MM474741";"MM474741";"CCC(NCCCC[C@@H](Oc1cc(C)c(F)c(C)c1)C(=O)NO)c1ccc(F)cc1";"AWFIZJRPXRHSEA-BPGUCPLFSA-N";420.5;4.75;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2013516/target=_blank>CHEMBL2013516</a>";;-4.4;"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT.: Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett, Volume 22 (6), 2012";"PAMPA";0.000039810717055349695
"MM474743";"MM474743";"CCC(NCCCC[C@@H](C[C@@H](OC)c1ccc(F)cc1)C(=O)NO)c1ccc(F)cc1";"BPGDVHWVHMDFBK-IQWVOLIVSA-N";434.53;5.08;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2013516/target=_blank>CHEMBL2013516</a>";;-5.1;"Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT.: Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. Bioorg Med Chem Lett, Volume 22 (6), 2012";"PAMPA";0.000007943282347242822
"MM474757";"MM474757";"CC1=NN(c2ccccc2)C(=O)C1";"QELUYTUMUWHWMC-UHFFFAOYSA-N";174.2;1.8;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2172996/target=_blank>CHEMBL2172996</a>";;-3.52;"Rolando B, Filieri A, Chegaev K, Lazzarato L, Giorgis M, De Nardi C, Fruttero R, Martel S, Carrupt PA, Gasco A.: Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. Bioorg Med Chem, Volume 20 (2), 2012";"PAMPA";0.0003019951720402016
"MM474748";"MM474748";"Cc1cc(=O)oc2cc(OCc3cccc(Cl)c3)ccc12";"PADVZYVDHJUUGZ-UHFFFAOYSA-N";300.74;4.33;;;"n-HEX";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1049136/target=_blank>CHEMBL1049136</a>";;-4.13;"Pisani L, Muncipinto G, Miscioscia TF, Nicolotti O, Leonetti F, Catto M, Caccia C, Salvati P, Soto-Otero R, Mendez-Alvarez E, Passeleu C, Carotti A.: Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. J Med Chem, Volume 52 (21), 2009";"PAMPA";0.00007413102413009176
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1044750/target=_blank>CHEMBL1044750</a>";;-6;"Jeong HC, Park NJ, Chae CH, Musilek K, Kassa J, Kuca K, Jung YS.: Fluorinated pyridinium oximes as potential reactivators for acetylcholinesterases inhibited by paraoxon organophosphorus agent. Bioorg Med Chem, Volume 17 (17), 2009";"PAMPA";0.000001
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901113/target=_blank>CHEMBL901113</a>";;-8;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"PAMPA";0.00000001
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1044750/target=_blank>CHEMBL1044750</a>";;-5.1;"Jeong HC, Park NJ, Chae CH, Musilek K, Kassa J, Kuca K, Jung YS.: Fluorinated pyridinium oximes as potential reactivators for acetylcholinesterases inhibited by paraoxon organophosphorus agent. Bioorg Med Chem, Volume 17 (17), 2009";"PAMPA";0.000007943282347242822
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-4.85;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000014125375446227555
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901113/target=_blank>CHEMBL901113</a>";;-5.93;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"PAMPA";0.0000011748975549395304
"MM474157";"MM474157";"CC(C)C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-AVXDTYAOSA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-6;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000001
"MM474158";"MM474158";"CC(C)C[C@@H]1NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-VTGDPKQBSA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.1;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000007943282347242822
"MM474159";"MM474159";"CC(C)C[C@@H]1NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H](O)[C@@H](CC(C)C)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-QZTRYRPESA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-4.92;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000012022644346174132
"MM474160";"MM474160";"CC(C)C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-GWYBMRKGSA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.15;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000007079457843841373
"MM474161";"MM474161";"CC(C)C[C@@H]1NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-GTOQBJDISA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.7;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.0000019952623149688787
"MM474162";"MM474162";"CC(C)C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H](O)[C@@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-MUISJDQHSA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-4.7;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000019952623149688786
"MM474163";"MM474163";"CC(C)C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@@H](CC(C)C)N(C)C(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-FZGOKCJASA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.22;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000006025595860743581
"MM474164";"MM474164";"CC(C)C[C@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H](O)[C@@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@H]1O";"GQRZGXQUKPLNJS-NIVRRFDCSA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.4;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000003981071705534969
"MM474165";"MM474165";"CC(C)C[C@@H]1NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)C[C@@H](O)[C@@H](CC(C)C)NC(=O)[C@H]2CCCN2C(=O)[C@@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-UCIOJSPUSA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.52;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.0000030199517204020193
"MM474166";"MM474166";"CC(C)C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@@H](CC(C)C)N(C)C(=O)C[C@@H](O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)C[C@@H]1O";"GQRZGXQUKPLNJS-YWNYESAZSA-N";793.1;3.17;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.15;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000007079457843841373
"MM474167";"MM474167";"C/C1=C\[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H](O)[C@@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O";"MBKSSZAQPAQEDO-BFMADXGOSA-N";789.12;4.37;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.52;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.0000030199517204020193
"MM474168";"MM474168";"C/C1=C\[C@@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)N(C)C(=O)C[C@@H](O)[C@@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O";"MBKSSZAQPAQEDO-YODRVHRQSA-N";789.12;4.37;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-4.96;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.000010964781961431852
"MM474169";"MM474169";"C/C1=C\[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(C)C)N(C)C(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C1=O";"MBKSSZAQPAQEDO-HBHUAFJWSA-N";789.12;4.37;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5.52;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.0000030199517204020193
"MM474170";"MM474170";"C/C1=C\[C@@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(C)C)N(C)C(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C1=O";"MBKSSZAQPAQEDO-GUPKISLBSA-N";789.12;4.37;;;"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3580062/target=_blank>CHEMBL3580062</a>";;-5;"Bockus AT, Lexa KW, Pye CR, Kalgutkar AS, Gardner JW, Hund KC, Hewitt WM, Schwochert JA, Glassey E, Price DA, Mathiowetz AM, Liras S, Jacobson MP, Lokey RS.: Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. J Med Chem, Volume 58 (11), 2015";"PAMPA";0.00001
"Testosterone";"MM00423";"CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12";"MUMGGOZAMZWBJJ-UHFFFAOYSA-N";288.43;3.88;"6013";"CHEMBL386630";"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL901113/target=_blank>CHEMBL901113</a>";;-5.06;"Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.: Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem, Volume 50 (24), 2007";"PAMPA";0.000008709635899560814
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"LEC";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2379911/target=_blank>CHEMBL2379911</a>";;-4.99;"Ramanujulu PM, Yang T, Yap SQ, Wong FC, Casey PJ, Wang M, Go ML.: Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt). Eur J Med Chem, Volume 63, 2013";"PAMPA";0.000010232929922807536
"MM474184";"MM474184";"O=C(O)c1ccc(O)c2ncccc12";"JGRPKOGHYBAVMW-UHFFFAOYSA-N";189.17;1.64;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.7;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.0000019952623149688787
"MM474767";"MM474767";"CCCCCCCCn1cc(CN(CC)CC)c2cc(-c3cnc(N)nc3)ccc21";"HKAUEDVXIIXVGY-UHFFFAOYSA-N";407.61;5.88;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL2379914/target=_blank>CHEMBL2379914</a>";;-4.85;"Ramanujulu PM, Yang T, Yap SQ, Wong FC, Casey PJ, Wang M, Go ML.: Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt). Eur J Med Chem, Volume 63, 2013";"PAMPA";0.000014125375446227555
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-3.95;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.0001122018454301963
"MM474185";"MM474185";"O=C(Nc1ccccn1)c1ccc2c(C(=O)O)ccc(O)c2n1";"KWECDLRNPWIXNI-UHFFFAOYSA-N";309.28;2.29;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.54;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.000002884031503126606
"MM474186";"MM474186";"CN(C)C(=O)c1ccc2c(C(=O)O)ccc(O)c2n1";"RTCKZHLVNQLLSJ-UHFFFAOYSA-N";260.25;1.34;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.52;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.0000030199517204020193
"MM474187";"MM474187";"Cc1ccccc1NC(=O)c1ccc2c(C(=O)O)ccc(O)c2n1";"QXFOWWOUEVOISF-UHFFFAOYSA-N";322.32;3.2;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.41;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.000003890451449942805
"MM474188";"MM474188";"O=C(Nc1nc2ccccc2[nH]1)c1ccc2c(C(=O)O)ccc(O)c2n1";"RKWHBQTUWVMODN-UHFFFAOYSA-N";348.32;2.77;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.17;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.000006760829753919819
"MM474189";"MM474189";"O=C(NCCc1c[nH]c2ccccc12)c1ccc2c(C(=O)O)ccc(O)c2n1";"DDWKDMPRLULLKO-UHFFFAOYSA-N";375.38;3.09;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.44;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.0000036307805477010103
"MM474190";"MM474190";"CCN(CC)C(=O)c1ccc2c(C(=O)O)ccc(O)c2n1";"PCFYPROHAZLTDW-UHFFFAOYSA-N";288.3;2.12;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.64;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.0000022908676527677747
"MM474191";"MM474191";"CN1CCN(C(=O)c2ccc3c(C(=O)O)ccc(O)c3n2)CC1";"ZBSRPBAAJNLOAH-UHFFFAOYSA-N";315.33;1.03;;;"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.48;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.0000033113112148259077
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"GIT-0";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL3637355/target=_blank>CHEMBL3637355</a>";;-5.35;"Feng T, Li D, Wang H, Zhuang J, Liu F, Bao Q, Lei Y, Chen W, Zhang X, Xu X, Sun H, You Q, Guo X.: Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem, Volume 105, 2015";"PAMPA";0.000004466835921509635
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255025/target=_blank>CHEMBL4255025</a>";;-4.95;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.00001122018454301963
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-4.95;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.00001122018454301963
"Diclofenac";"MM00090";"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl";"DCOPUUMXTXDBNB-UHFFFAOYSA-N";296.15;4.36;"3033";"CHEMBL139";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255025/target=_blank>CHEMBL4255025</a>";;-4.9;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000012589254117941661
"Diclofenac";"MM00090";"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl";"DCOPUUMXTXDBNB-UHFFFAOYSA-N";296.15;4.36;"3033";"CHEMBL139";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-4.93;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000011748975549395302
"MM474359";"MM474359";"CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1";"VAAUVRVFOQPIGI-SPQHTLEESA-N";554.59;-1.2;;;"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-7;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000001
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-7;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000001
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-7;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000001
"MM471113";"MM471113";"O=C(CCc1c[nH]c2ccccc12)NCCC1CCN(Cc2ccccc2)CC1";"WXTKBXGKRLFVQP-UHFFFAOYSA-N";389.54;4.52;;;"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-6.15;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000007079457843841374
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255025/target=_blank>CHEMBL4255025</a>";;-5.47;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000033884415613920275
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-6.52;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000003019951720402019
"Sulfasalazine";"MM00690";"O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O";"NCEXYHBECQHGNR-UHFFFAOYSA-N";398.4;3.7;"5359476";"CHEMBL421";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255025/target=_blank>CHEMBL4255025</a>";;-7;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000001
"Sulfasalazine";"MM00690";"O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O";"NCEXYHBECQHGNR-UHFFFAOYSA-N";398.4;3.7;"5359476";"CHEMBL421";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-7;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000001
"Coumarin";"MM00042";"O=c1ccc2ccccc2o1";"ZYGHJZDHTFUPRJ-UHFFFAOYSA-N";146.15;1.79;"323";"CHEMBL6466";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255025/target=_blank>CHEMBL4255025</a>";;-4.66;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.00002187761623949552
"Coumarin";"MM00042";"O=c1ccc2ccccc2o1";"ZYGHJZDHTFUPRJ-UHFFFAOYSA-N";146.15;1.79;"323";"CHEMBL6466";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-4.71;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000019498445997580456
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255025/target=_blank>CHEMBL4255025</a>";;-5.13;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000007413102413009177
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-5.19;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.000006456542290346549
"Norfloxacin";"MM00768";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21";"OGJPXUAPXNRGGI-UHFFFAOYSA-N";319.34;1.27;"4539";"CHEMBL9";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255025/target=_blank>CHEMBL4255025</a>";;-6.05;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000008912509381337459
"Norfloxacin";"MM00768";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21";"OGJPXUAPXNRGGI-UHFFFAOYSA-N";319.34;1.27;"4539";"CHEMBL9";"PL-A";"EPAM";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL4255026/target=_blank>CHEMBL4255026</a>";;-7;"Chierrito TPC, Pedersoli-Mantoani S, Roca C, Sebastian-PĂ©rez V, MartĂ­nez-Gonzalez L, PĂ©rez DI, Perez C, Canales A, CaĂ±ada FJ, Campillo NE, Carvalho I, Martinez A, Martinez A.: Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem, Volume 145, 2018";"PAMPA";0.0000001
"MM474864";"MM474864";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(-n3ccnc3)c2)CCCCC1";"AGZWJSVSGAGFQV-IZZNHLLZSA-N";482.58;4.01;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5.72;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.0000019054607179632483
"MM474865";"MM474865";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(-n3nccn3)c2)CCCCC1";"OWCGQYLBTBEMDE-LOSJGSFVSA-N";483.56;3.4;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5.35;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.000004466835921509635
"MM474866";"MM474866";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3CCCO3)c2)CCCCC1";"ABEHCBWGIABROV-AJRFNQODSA-N";486.6;4.67;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-4.93;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.000011748975549395302
"MM474868";"MM474868";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CCCC3=O)c2)CCCCC1";"WLNJAXBWILAYMG-IZZNHLLZSA-N";499.6;3.95;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5.62;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.0000023988329190194897
"MM474869";"MM474869";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CCOC3=O)c2)CCCCC1";"YXVNISVSDYADOS-LOSJGSFVSA-N";501.57;3.78;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5.66;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.0000021877616239495517
"MM474870";"MM474870";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CCNC3=O)c2)CCCCC1";"FKHMBXUPOKQOFP-LOSJGSFVSA-N";500.59;3.35;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-6.15;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.0000007079457843841374
"MM474871";"MM474871";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3CCCC3=O)c2)CCCCC1";"BYVHUPDBTJVHPS-ZLEDJERYSA-N";498.61;4.66;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5.29;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.000005128613839913648
"MM474872";"MM474872";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3C(=O)C4CCC3C4)c2)CCCCC1";"OYEGKOBVNHEMFR-YSDFFMNWSA-N";525.64;4.34;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5.51;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.000003090295432513592
"MM474873";"MM474873";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CCCCC3=O)c2)CCCCC1";"KNSUFDSYTXUXKM-RRPNLBNLSA-N";513.63;4.34;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5.96;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.000001096478196143185
"MM474874";"MM474874";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CCOCC3=O)c2)CCCCC1";"HKSCWIPGCWNQID-IZZNHLLZSA-N";515.6;3.19;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-6.1;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.0000007943282347242822
"MM474875";"MM474875";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CCCNC3=O)c2)CCCCC1";"ZKBURWOWKRJMHV-IZZNHLLZSA-N";514.62;3.74;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-6.7;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.00000019952623149688787
"MM474876";"MM474876";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CCCOCC3=O)c2)CCCCC1";"PCWSXIPKKVFNIH-RRPNLBNLSA-N";529.63;3.58;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-6.3;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.0000005011872336272725
"MM474877";"MM474877";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3CCOCOC3)c2)CCCCC1";"SNCUIVJNMNJXKM-WHWDJVTISA-N";516.63;4.3;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-4.86;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.000013803842646028839
"MM474878";"MM474878";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CCCOCC3)c2)CCCCC1";"LKMGTFRKDSLFSR-WUFINQPMSA-N";515.65;4.05;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-4.97;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.00001071519305237607
"MM474879";"MM474879";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3CCCO3)c2)CC1";"DGXDCVZUXDMTLV-XAGPSQNTSA-N";444.52;3.5;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-4.94;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.000011481536214968817
"MM474880";"MM474880";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3(C)CCCO3)c2)CC1";"MPYBDRDFSBFESO-ZXABPTRBSA-N";458.55;3.68;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5.05;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.00000891250938133746
"MM474881";"MM474881";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3CCCCO3)c2)CC1";"OPNYLVKDDWJTDR-ZXABPTRBSA-N";458.55;3.89;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-4.95;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.00001122018454301963
"MM474882";"MM474882";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3COCCO3)c2)CC1";"NGSPCALCYZCXEJ-XAGPSQNTSA-N";460.52;2.74;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-5;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.00001
"MM474883";"MM474883";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(N3CC4CC3CO4)c2)CC1";"VVZYJILCHBDRDY-ZOOXZOTBSA-N";471.55;2.63;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1211028/target=_blank>CHEMBL1211028</a>";;-4.86;"Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM, Hom RK, Tucker JA, John V, Tung JS, Pleiss MA, Konradi AW, Sham HL, Dappen MS, TĂłth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM.: Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett, Volume 20 (16), 2010";"MDCK";0.000013803842646028839
"MM474932";"MM474932";"O=c1n(Cc2ccccn2)nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1";"OHUXKIXTONEVBL-UHFFFAOYSA-N";478.56;4.28;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1648833/target=_blank>CHEMBL1648833</a>";;-4.73;"Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, TĂłth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.: Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett, Volume 21 (1), 2011";"MDCK";0.000018620871366628657
"MM474933";"MM474933";"O=c1[nH]nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1";"IJTANTDZFOCBKK-UHFFFAOYSA-N";385.47;4.52;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1648833/target=_blank>CHEMBL1648833</a>";;-6.05;"Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, TĂłth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.: Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett, Volume 21 (1), 2011";"MDCK";0.0000008912509381337459
"MM474934";"MM474934";"O=c1[nH]nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1";"LCBNUBGZQBBNPG-UHFFFAOYSA-N";387.44;3.37;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1648833/target=_blank>CHEMBL1648833</a>";;-4.8;"Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, TĂłth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.: Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett, Volume 21 (1), 2011";"MDCK";0.00001584893192461114
"MM474935";"MM474935";"O=c1[nH]nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2cc(F)ccc2c1";"PXOJJCCSYAVCPK-UHFFFAOYSA-N";405.43;3.51;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1648833/target=_blank>CHEMBL1648833</a>";;-5.14;"Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, TĂłth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.: Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett, Volume 21 (1), 2011";"MDCK";0.000007244359600749906
"MM474936";"MM474936";"O=c1n(C2CCOC2)nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1";"JPTYCOMKVYISJL-UHFFFAOYSA-N";457.53;3.8;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1648833/target=_blank>CHEMBL1648833</a>";;-4.66;"Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, TĂłth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.: Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett, Volume 21 (1), 2011";"MDCK";0.00002187761623949552
"MM474937";"MM474937";"O=c1n(-c2ccccn2)nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1";"YPAADIPEHKVUEJ-UHFFFAOYSA-N";464.53;4.22;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1648833/target=_blank>CHEMBL1648833</a>";;-5.29;"Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, TĂłth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.: Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett, Volume 21 (1), 2011";"MDCK";0.000005128613839913648
"MM474938";"MM474938";"O=c1n(Cc2ccncc2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1";"IOZQORJWOUBHKH-UHFFFAOYSA-N";476.58;5.44;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1648833/target=_blank>CHEMBL1648833</a>";;-5.09;"Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, TĂłth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.: Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett, Volume 21 (1), 2011";"MDCK";0.000008128305161640995
"MM474948";"MM474948";"CC(CC(=O)N1C[C@@H]2C[C@H]1CN2C(=O)[C@@]1(C(C)C)CC[C@@H](NC2CCOCC2F)C1)C(F)(F)F";"DWWWMCPBDXIVTJ-FSPVYIBDSA-N";491.57;3.3;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1686108/target=_blank>CHEMBL1686108</a>";;-4.93;"Trujillo JI, Huang W, Hughes RO, Rogier DJ, Turner SR, Devraj R, Morton PA, Xue CB, Chao G, Covington MB, Newton RC, Metcalf B.: Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs. Bioorg Med Chem Lett, Volume 21 (6), 2011";"MDCK";0.000011748975549395302
"MM474949";"MM474949";"CC(C)[C@]1(C(=O)N2C[C@@H]3C[C@H]2CN3C(=O)CCC(F)(F)F)CC[C@@H](NC2CCOCC2F)C1";"VOTFTZKGSDZWFG-OBILSORKSA-N";477.54;3.05;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1686108/target=_blank>CHEMBL1686108</a>";;-5.08;"Trujillo JI, Huang W, Hughes RO, Rogier DJ, Turner SR, Devraj R, Morton PA, Xue CB, Chao G, Covington MB, Newton RC, Metcalf B.: Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs. Bioorg Med Chem Lett, Volume 21 (6), 2011";"MDCK";0.00000831763771102671
"MM475046";"MM475046";"O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1";"IPKZCLGGYKRDES-ZDUSSCGKSA-N";271.32;1.65;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932562/target=_blank>CHEMBL932562</a>";;-4.47;"Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, Tinholt PM, Walters RR, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Krause M, Li KS, Hoffmann WE, Hajos M, Hurst RS, Walker DP.: Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett, Volume 18 (12), 2008";"MDCK";0.000033884415613920276
"MM475047";"MM475047";"O=C(N[C@@H]1C[C@H]2CCN(C2)C1)c1ccc2occc2c1";"CGFMUJGGEUGESY-BXUZGUMPSA-N";270.33;2.26;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932562/target=_blank>CHEMBL932562</a>";;-5.42;"Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, Tinholt PM, Walters RR, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Krause M, Li KS, Hoffmann WE, Hajos M, Hurst RS, Walker DP.: Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett, Volume 18 (12), 2008";"MDCK";0.000003801893963205613
"MM475048";"MM475048";"O=C(N[C@@H]1C[C@H]2CCN(C2)C1)c1ccc2ncsc2c1";"BBHOTKRCKZTVKM-ZYHUDNBSSA-N";287.39;2.12;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932562/target=_blank>CHEMBL932562</a>";;-6.7;"Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, Tinholt PM, Walters RR, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Krause M, Li KS, Hoffmann WE, Hajos M, Hurst RS, Walker DP.: Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett, Volume 18 (12), 2008";"MDCK";0.00000019952623149688787
"MM475053";"MM475053";"CN1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1";"BZUIGXZUUGQBLL-UHFFFAOYSA-N";494.99;3.35;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL947910/target=_blank>CHEMBL947910</a>";;-5.02;"Ducray R, Ballard P, Barlaam BC, Hickinson MD, Kettle JG, Ogilvie DJ, Trigwell CB.: Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett, Volume 18 (3), 2008";"MDCK";0.000009549925860214369
"MM475075";"MM475075";"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCCNC3)s2)o1";"USAKOZCUIYTREA-UHFFFAOYSA-N";380.54;3.66;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-6.9;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.00000012589254117941662
"MM475049";"MM475049";"O=C(N[C@@H]1C[C@H]2CCN(C2)C1)c1cc2ccoc2cn1";"PTGWFYYEAUFEAS-ZYHUDNBSSA-N";271.32;1.65;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL932562/target=_blank>CHEMBL932562</a>";;-4.68;"Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, Tinholt PM, Walters RR, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Krause M, Li KS, Hoffmann WE, Hajos M, Hurst RS, Walker DP.: Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett, Volume 18 (12), 2008";"MDCK";0.00002089296130854041
"MM475076";"MM475076";"C[C@H]1CNC[C@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1";"SSMMYRQDZBSVCY-VXGBXAGGSA-N";394.57;3.91;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-6.36;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.00000043651583224016567
"MM475077";"MM475077";"C[C@@H]1CNC[C@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1";"SSMMYRQDZBSVCY-NWDGAFQWSA-N";394.57;3.91;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-7.1;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.00000007943282347242822
"MM475078";"MM475078";"CC1CCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CN1";"QALGDBRHRSNPSF-UHFFFAOYSA-N";394.57;4.05;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-6.4;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.0000003981071705534969
"MM475079";"MM475079";"CC1CNCC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1";"SSMMYRQDZBSVCY-UHFFFAOYSA-N";394.57;3.91;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-6.63;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.00000023442288153199228
"MM475080";"MM475080";"CC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1";"WDVFSNIVMZTNHY-UHFFFAOYSA-N";394.57;4.05;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-7.66;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.000000021877616239495518
"MM475081";"MM475081";"CCC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1";"WBUZWMNIWAQICA-UHFFFAOYSA-N";408.59;4.44;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-7.12;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.00000007585775750291836
"MM475082";"MM475082";"C[C@H]1CNC[C@@H](C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)C1";"SSMMYRQDZBSVCY-NEPJUHHUSA-N";394.57;3.91;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-6.78;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.00000016595869074375596
"MM475104";"MM475104";"O=C(Nc1ccccc1Cl)Nc1cc(F)c(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl";"BBJDKAQNUQEOHQ-ROUUACIJSA-N";578.4;6.04;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.24;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.000005754399373371567
"MM475105";"MM475105";"Cc1cc(NC(=O)Nc2ccccc2Br)c(Cl)cc1CC(=O)N1C[C@@H](F)C[C@H]1COc1ccc(C(=O)O)cc1";"RWXLEGJTWXHYFT-PMACEKPBSA-N";618.89;6.31;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.33;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.000004677351412871981
"MM475106";"MM475106";"O=C(Nc1ccccc1Cl)Nc1cc(Cl)c(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl";"HYXDOLUWKMWHER-ROUUACIJSA-N";594.85;6.55;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.05;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.00000891250938133746
"MM475107";"MM475107";"Cc1cc(NC(=O)Nc2ccccc2Cl)c(Cl)cc1CC(=O)N1C[C@@H](F)C[C@H]1COc1ccc(C(=O)O)cc1";"IIABHYNBTSJROG-PMACEKPBSA-N";574.44;6.2;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.46;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.000003467368504525317
"MM475108";"MM475108";"Cc1ccccc1NC(=O)Nc1cc(Cl)c(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl";"ICYQFAXGIFGNST-PMACEKPBSA-N";574.44;6.2;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.27;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.000005370317963702533
"MM475109";"MM475109";"Cc1ccccc1NC(=O)Nc1cc(F)c(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl";"YNJNDBAQPYNBTR-PMACEKPBSA-N";557.98;5.69;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.55;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.000002818382931264455
"MM475110";"MM475110";"Cc1ccc(F)cc1NC(=O)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl";"WRDAJCAOSGLLQW-SFTDATJTSA-N";557.98;5.69;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.59;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.0000025703957827688647
"MM475111";"MM475111";"Cc1c(F)cccc1NC(=O)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl";"TVEYZMJRXVGMPY-PMACEKPBSA-N";557.98;5.69;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.62;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.0000023988329190194897
"MM474769";"MM474769";"CC(C)(C)c1cnc(CSc2cnc(N[C@H]3CC[C@H](N)CC3)s2)o1";"JFSGUSJACVSEKX-HAQNSBGRSA-N";366.56;4.4;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1002046/target=_blank>CHEMBL1002046</a>";;-7.01;"Choong IC, Serafimova I, Fan J, Stockett D, Chan E, Cheeti S, Lu Y, Fahr B, Pham P, Arkin MR, Walker DH, Hoch U.: A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties. Bioorg Med Chem Lett, Volume 18 (21), 2008";"MDCK";0.00000009772372209558111
"MM475083";"MM475083";"CC1NCCCC1C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1";"LOUYPYUMEQLFIO-UHFFFAOYSA-N";394.57;4.05;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-6.38;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.0000004168693834703355
"MM475084";"MM475084";"CC(C)C1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1";"SYGZEVSXMXZNJX-UHFFFAOYSA-N";422.62;4.68;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL965587/target=_blank>CHEMBL965587</a>";;-7.27;"Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.: Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett, Volume 18 (23), 2008";"MDCK";0.000000053703179637025324
"MM475112";"MM475112";"Cc1cc(F)ccc1NC(=O)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl";"IXKJOSLEQCGVAX-SFTDATJTSA-N";557.98;5.69;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.92;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.0000012022644346174132
"MM475113";"MM475113";"Cc1cc(NC(=O)Nc2ccccc2C)c(Cl)cc1CC(=O)N1C[C@@H](F)C[C@H]1COc1ccc(C(=O)O)cc1";"DOJRXKAOYCDVRA-VXKWHMMOSA-N";554.02;5.86;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.74;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.0000018197008586099826
"MM475114";"MM475114";"O=C(Nc1cc(F)c(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl)Nc1ccccc1Br";"IWGNNKVAMHXIPW-ROUUACIJSA-N";622.85;6.14;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL987229/target=_blank>CHEMBL987229</a>";;-5.19;"Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, Volume 16 (23), 2008";"MDCK";0.000006456542290346549
"MM474814";"MM474814";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CN[C@]1(c2cccc(C(C)(C)C)c2)CC[C@@H](O)CC1";"GJZNABCEATUZGN-NAVOWQOKSA-N";488.62;4.09;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045215/target=_blank>CHEMBL1045215</a>";;-6.52;"Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, Jagodzinska BM, Dressen D, Wone DW, Brogley L, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Dappen MS, Toth G, Pan H, Ruslim L, Miller J, Bova MP, Sinha S, Quinn KP, Sauer JM.: Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents. Bioorg Med Chem Lett, Volume 19 (22), 2009";"MDCK";0.0000003019951720402019
"MM474817";"MM474817";"C[C@@H]1c2c[nH]nc2-c2cc(F)ccc2N1S(=O)(=O)c1ccc(Cl)cc1";"OTXHDBQTORDBPA-SNVBAGLBSA-N";377.83;4.14;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048202/target=_blank>CHEMBL1048202</a>";;-4.7;"Truong AP, Aubele DL, Probst GD, Neitzel ML, Semko CM, Bowers S, Dressen D, Hom RK, Konradi AW, Sham HL, Garofalo AW, Keim PS, Wu J, Dappen MS, Wong K, Goldbach E, Quinn KP, Sauer JM, Brigham EF, Wallace W, Nguyen L, Hemphill SS, Bova MP, Bard F, Yednock TA, Basi G.: Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.000019952623149688786
"MM474818";"MM474818";"O=S(=O)(c1ccc(C(F)(F)F)cn1)N1c2ccc(F)cc2-c2n[nH]cc2[C@H]1C1CC1";"VEHFINFYUNHULM-GOSISDBHSA-N";438.41;4.29;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1048202/target=_blank>CHEMBL1048202</a>";;-4.6;"Truong AP, Aubele DL, Probst GD, Neitzel ML, Semko CM, Bowers S, Dressen D, Hom RK, Konradi AW, Sham HL, Garofalo AW, Keim PS, Wu J, Dappen MS, Wong K, Goldbach E, Quinn KP, Sauer JM, Brigham EF, Wallace W, Nguyen L, Hemphill SS, Bova MP, Bard F, Yednock TA, Basi G.: Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.000025118864315095822
"MM474841";"MM474841";"Cc1ccc2oc(N3CCN4CCC3CC4)nc2n1";"BSNKYWSMUAGMDO-UHFFFAOYSA-N";258.33;1.82;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1070103/target=_blank>CHEMBL1070103</a>";;-4.74;"O'Donnell CJ, Rogers BN, Bronk BS, Bryce DK, Coe JW, Cook KK, Duplantier AJ, Evrard E, HajĂłs M, Hoffmann WE, Hurst RS, Maklad N, Mather RJ, McLean S, Nedza FM, O'Neill BT, Peng L, Qian W, Rottas MM, Sands SB, Schmidt AW, Shrikhande AV, Spracklin DK, Wong DF, Zhang A, Zhang L.: Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. J Med Chem, Volume 53 (3), 2010";"MDCK";0.000018197008586099827
"MM474816";"MM474816";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C)c2)CCc2n[nH]cc2C1";"BAILJXDQIBWAPX-ZDCXKQOISA-N";510.63;4.07;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1045215/target=_blank>CHEMBL1045215</a>";;-5.8;"Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, Jagodzinska BM, Dressen D, Wone DW, Brogley L, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Dappen MS, Toth G, Pan H, Ruslim L, Miller J, Bova MP, Sinha S, Quinn KP, Sauer JM.: Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents. Bioorg Med Chem Lett, Volume 19 (22), 2009";"MDCK";0.000001584893192461114
"MM474885";"MM474885";"CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccc(NS(C)(=O)=O)c3)cc2C1";"ZXEQISNRIFKVAM-UHFFFAOYSA-N";408.55;2.52;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1217492/target=_blank>CHEMBL1217492</a>";;-4.22;"Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP.: Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. J Med Chem, Volume 53 (15), 2010";"MDCK";0.000060255958607435806
"MM474886";"MM474886";"CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccc(N(C)S(C)(=O)=O)c3)cc2C1";"KJGGJMVDQRUQSH-UHFFFAOYSA-N";422.57;2.54;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1217492/target=_blank>CHEMBL1217492</a>";;-4.16;"Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP.: Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. J Med Chem, Volume 53 (15), 2010";"MDCK";0.00006918309709189363
"MM474887";"MM474887";"CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1";"QXQSUBKWSHMXDP-INIZCTEOSA-N";334.42;2.68;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1217492/target=_blank>CHEMBL1217492</a>";;-4.16;"Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP.: Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. J Med Chem, Volume 53 (15), 2010";"MDCK";0.00006918309709189363
"MM474888";"MM474888";"Cc1ccc(-c2ccc3c(c2)C[C@@H](NS(=O)(=O)C(C)C)C3)cn1";"OCJKHBCJMIOPJS-SFHVURJKSA-N";330.45;2.85;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1217492/target=_blank>CHEMBL1217492</a>";;-4.2;"Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP.: Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. J Med Chem, Volume 53 (15), 2010";"MDCK";0.00006309573444801929
"MM474889";"MM474889";"CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)cn3)cc2C1";"QJVMDGUSBHUPRY-INIZCTEOSA-N";334.42;2.68;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1217492/target=_blank>CHEMBL1217492</a>";;-4.25;"Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP.: Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. J Med Chem, Volume 53 (15), 2010";"MDCK";0.00005623413251903491
"MM474891";"MM474891";"CN(C)C(=O)N[C@H]1CC[C@@H](CCN2[C@@H]3CC[C@H]2C[C@@H](Oc2cccc(C(N)=O)c2)C3)CC1";"ZNKQZQCGGXGVRU-AGMAZQPASA-N";442.6;3.38;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1225860/target=_blank>CHEMBL1225860</a>";;-5.72;"Brugel TA, Smith RW, Balestra M, Becker C, Daniels T, Koether GM, Throner SR, Panko LM, Brown DG, Liu R, Gordon J, Peters MF.: SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett, Volume 20 (18), 2010";"MDCK";0.0000019054607179632483
"MM474892";"MM474892";"NC(=O)c1cccc(C[C@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1";"SKQZYGXREOYGMD-NUZGMZIFSA-N";334.46;3.77;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1225860/target=_blank>CHEMBL1225860</a>";;-4.85;"Brugel TA, Smith RW, Balestra M, Becker C, Daniels T, Koether GM, Throner SR, Panko LM, Brown DG, Liu R, Gordon J, Peters MF.: SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett, Volume 20 (18), 2010";"MDCK";0.000014125375446227555
"MM474895";"MM474895";"Cc1ccc([C@@H](C)N2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)cn1";"FFCXAJUMJUOFPK-KBMWQNTOSA-N";365.48;3.62;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1259366/target=_blank>CHEMBL1259366</a>";;-5.04;"Brugel TA, Smith RW, Balestra M, Becker C, Daniels T, Hoerter TN, Koether GM, Throner SR, Panko LM, Folmer JJ, Cacciola J, Hunter AM, Liu R, Edwards PD, Brown DG, Gordon J, Ledonne NC, Pietras M, Schroeder P, Sygowski LA, Hirata LT, Zacco A, Peters MF.: Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. Bioorg Med Chem Lett, Volume 20 (19), 2010";"MDCK";0.000009120108393559096
"MM474896";"MM474896";"Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](Oc2cccc(C(N)=O)c2)C3)s1";"RLHOWHVHHMGIKE-ALXJQNPVSA-N";356.49;3.73;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1259366/target=_blank>CHEMBL1259366</a>";;-4.89;"Brugel TA, Smith RW, Balestra M, Becker C, Daniels T, Hoerter TN, Koether GM, Throner SR, Panko LM, Folmer JJ, Cacciola J, Hunter AM, Liu R, Edwards PD, Brown DG, Gordon J, Ledonne NC, Pietras M, Schroeder P, Sygowski LA, Hirata LT, Zacco A, Peters MF.: Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. Bioorg Med Chem Lett, Volume 20 (19), 2010";"MDCK";0.000012882495516931348
"MM474897";"MM474897";"NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC2CCCCC2)c1";"ZKZMTIDHRGLEJP-OPVJXMOQSA-N";342.48;3.74;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1259366/target=_blank>CHEMBL1259366</a>";;-5.08;"Brugel TA, Smith RW, Balestra M, Becker C, Daniels T, Hoerter TN, Koether GM, Throner SR, Panko LM, Folmer JJ, Cacciola J, Hunter AM, Liu R, Edwards PD, Brown DG, Gordon J, Ledonne NC, Pietras M, Schroeder P, Sygowski LA, Hirata LT, Zacco A, Peters MF.: Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. Bioorg Med Chem Lett, Volume 20 (19), 2010";"MDCK";0.00000831763771102671
"MM474921";"MM474921";"COc1ccc(CC(=O)Nc2ccsc2-n2nccn2)cc1";"KHIAZVHADWMRSJ-UHFFFAOYSA-N";314.37;2.52;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291193/target=_blank>CHEMBL1291193</a>";;-4.82;"Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, TĂłth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I.: Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett, Volume 20 (24), 2010";"MDCK";0.000015135612484362071
"MM474922";"MM474922";"COc1ccc(CC(=O)Nc2ccsc2N2CCOC2=O)cc1";"JXSJAJUZRYNVGF-UHFFFAOYSA-N";332.38;2.89;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291193/target=_blank>CHEMBL1291193</a>";;-4.59;"Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, TĂłth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I.: Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett, Volume 20 (24), 2010";"MDCK";0.000025703957827688645
"MM474923";"MM474923";"COc1ccc(CC(=O)Nc2ccsc2-c2n[nH]c(N)n2)cc1";"AFCVEHHRQVGWID-UHFFFAOYSA-N";329.39;2.31;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291193/target=_blank>CHEMBL1291193</a>";;-4.61;"Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, TĂłth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I.: Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett, Volume 20 (24), 2010";"MDCK";0.000024547089156850286
"MM474924";"MM474924";"COc1ccc(CC(=O)Nc2ccsc2-c2cn(C)cn2)cc1";"RYGONSQYUUISGP-UHFFFAOYSA-N";327.41;3.34;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291193/target=_blank>CHEMBL1291193</a>";;-5.15;"Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, TĂłth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I.: Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett, Volume 20 (24), 2010";"MDCK";0.000007079457843841373
"MM474925";"MM474925";"COc1ccc(CC(=O)Nc2ccsc2-c2c[nH]c(C)n2)cc1";"LFLTYJDEZSLZGL-UHFFFAOYSA-N";327.41;3.64;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291193/target=_blank>CHEMBL1291193</a>";;-4.47;"Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, TĂłth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I.: Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett, Volume 20 (24), 2010";"MDCK";0.000033884415613920276
"MM474926";"MM474926";"COc1ccc(CC(=O)Nc2ccsc2-c2cnccn2)cc1";"RVEHZFOKUTZKBA-UHFFFAOYSA-N";325.39;3.39;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291193/target=_blank>CHEMBL1291193</a>";;-4.65;"Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, TĂłth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I.: Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett, Volume 20 (24), 2010";"MDCK";0.00002238721138568338
"MM474927";"MM474927";"O=C(Cc1cccc2ncccc12)Nc1ccsc1-c1nnc[nH]1";"MGGUVSLBKUKUGR-UHFFFAOYSA-N";335.39;3.26;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291193/target=_blank>CHEMBL1291193</a>";;-5.22;"Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, TĂłth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I.: Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett, Volume 20 (24), 2010";"MDCK";0.000006025595860743581
"MM474928";"MM474928";"O=C(Cc1cccc2cnccc12)Nc1ccsc1-c1cscn1";"FFPJBQIHDBPVHZ-UHFFFAOYSA-N";351.46;4.6;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1291193/target=_blank>CHEMBL1291193</a>";;-4.58;"Hom RK, Bowers S, Sealy JM, Truong AP, Probst GD, Neitzel ML, Neitz RJ, Fang L, Brogley L, Wu J, Konradi AW, Sham HL, TĂłth G, Pan H, Yao N, Artis DR, Quinn K, Sauer JM, Powell K, Ren Z, Bard F, Yednock TA, Griswold-Prenner I.: Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett, Volume 20 (24), 2010";"MDCK";0.000026302679918953814
"MM474842";"MM474842";"OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1";"XEEQGYMUWCZPDN-UHFFFAOYSA-N";378.32;4.45;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073110/target=_blank>CHEMBL1073110</a>";;-5.03;"Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G.: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett, Volume 20 (4), 2010";"MDCK";0.000009332543007969906
"MM472929";"MM472929";"N#Cc1ccccc1C1Cc2nccn2C1";"KMOFNRDXTFJLAO-UHFFFAOYSA-N";209.25;2.09;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015851/target=_blank>CHEMBL1015851</a>";;-4.47;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000033884415613920276
"MM475101";"MM475101";"CN(Cc1ccc(C#N)cc1)C(=O)CNC(=O)c1nc2ccccc2n1Cc1ccccc1";"FLWASHWEIGSTCQ-UHFFFAOYSA-N";437.5;3.34;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL982608/target=_blank>CHEMBL982608</a>";;-5.15;"Guo Q, Chandrasekhar J, Ihle D, Wustrow DJ, Chenard BL, Krause JE, Hutchison A, Alderman D, Cheng C, Cortright D, Broom D, Kershaw MT, Simmermacher-Mayer J, Peng Y, Hodgetts KJ.: 1-Benzylbenzimidazoles: the discovery of a novel series of bradykinin B(1) receptor antagonists. Bioorg Med Chem Lett, Volume 18 (18), 2008";"MDCK";0.000007079457843841373
"MM475103";"MM475103";"CCN(CC(=O)N1CCN(C2CCN(C)CC2)CC1)C(=O)c1nc2ccccc2n1Cc1ccccc1";"HBBWAOOGJLRAAQ-UHFFFAOYSA-N";502.66;2.79;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL982608/target=_blank>CHEMBL982608</a>";;-6.22;"Guo Q, Chandrasekhar J, Ihle D, Wustrow DJ, Chenard BL, Krause JE, Hutchison A, Alderman D, Cheng C, Cortright D, Broom D, Kershaw MT, Simmermacher-Mayer J, Peng Y, Hodgetts KJ.: 1-Benzylbenzimidazoles: the discovery of a novel series of bradykinin B(1) receptor antagonists. Bioorg Med Chem Lett, Volume 18 (18), 2008";"MDCK";0.0000006025595860743581
"MM474819";"MM474819";"OCc1cccc(-c2ccc(-c3cc(N4CCOCC4)nc(N4CCOCC4)n3)o2)c1";"BXRMHHSERKBUGT-UHFFFAOYSA-N";422.49;2.57;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1049653/target=_blank>CHEMBL1049653</a>";;-4.48;"Menear KA, Gomez S, Malagu K, Bailey C, Blackburn K, Cockcroft XL, Ewen S, Fundo A, Le Gall A, Hermann G, Sebastian L, Sunose M, Presnot T, Torode E, Hickson I, Martin NM, Smith GC, Pike KG.: Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Bioorg Med Chem Lett, Volume 19 (20), 2009";"MDCK";0.000033113112148259076
"MM474820";"MM474820";"Oc1cccc(-c2ccc(-c3cc(N4CCOCC4)nc(N4CCOCC4)n3)o2)c1";"IXIVRLBSURAIDT-UHFFFAOYSA-N";408.46;2.78;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1049653/target=_blank>CHEMBL1049653</a>";;-5.66;"Menear KA, Gomez S, Malagu K, Bailey C, Blackburn K, Cockcroft XL, Ewen S, Fundo A, Le Gall A, Hermann G, Sebastian L, Sunose M, Presnot T, Torode E, Hickson I, Martin NM, Smith GC, Pike KG.: Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Bioorg Med Chem Lett, Volume 19 (20), 2009";"MDCK";0.0000021877616239495517
"MM474821";"MM474821";"CC(C)c1cccc(CNC[C@@H](O)[C@@H]2Cc3cccc(c3)OCCCCNc3cccc(c3)C(=O)N2)c1";"QMDCLYWXGCPUJX-XZWHSSHBSA-N";501.67;4.89;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.7;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.0000019952623149688787
"MM474822";"MM474822";"Cc1cc2cc(n1)OCCCCOc1cccc(c1)C[C@@H]([C@H](O)CNCc1cccc(C(C)C)c1)NC2=O";"TVDHOONBSNHWKJ-URLMMPGGSA-N";517.67;4.56;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.89;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.000001288249551693135
"MM474823";"MM474823";"COCc1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNCc1cccc(C(C)C)c1)Cc1cccc(c1)OCCCCN2";"QIDWHGYCMKSPBT-AJQTZOPKSA-N";545.72;5.03;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-6.8;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.0000001584893192461114
"MM474824";"MM474824";"Cc1cc2cc(n1)OCCCCOc1cccc(c1)C[C@@H]([C@H](O)CNC(C)c1cccc(C(C)C)c1)NC2=O";"WRDFTFAHALVDPT-XSJQRQGXSA-N";531.7;5.12;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.89;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.000001288249551693135
"MM474825";"MM474825";"COCc1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNC(CF)c1cccc(C(C)(C)C)c1)Cc1cccc(c1)OCCCCN2";"DDKJURVNAYNPKH-LJTKZVQESA-N";591.77;5.72;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.42;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.000003801893963205613
"MM474826";"MM474826";"COCc1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNC(COC)c1cccc(C(C)(C)C)c1)Cc1cccc(c1)OCCCCN2";"KEWIBIGKBFEKRG-DWJMSNRFSA-N";603.8;5.39;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.89;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.000001288249551693135
"MM474827";"MM474827";"CCCS(=O)(=O)N(C)c1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNCc1cccc(C(C)C)c1)Cc1cccc(c1)OCCCCN2";"HWLAFZXKYIUVHI-SZAHLOSFSA-N";636.86;5.06;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-6.02;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.0000009549925860214369
"MM474828";"MM474828";"CC(C)c1cccc(CNC[C@@H](O)[C@@H]2Cc3cccc(c3)OCCCCNc3cc(cc(N4C=COC4)c3)C(=O)N2)c1";"AKKRZBQIPILXBF-JHOUSYSJSA-N";570.73;5.15;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-6.96;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.00000010964781961431852
"MM474829";"MM474829";"COCc1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNC1(c3cccc(C(C)C)c3)CC1)Cc1cccc(c1)OCCCCN2";"GCZHKZTYTMTFGU-JHOUSYSJSA-N";571.76;5.52;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.51;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.000003090295432513592
"MM474830";"MM474830";"CC(C)c1cccc(C2(NC[C@@H](O)[C@@H]3Cc4cccc(c4)OCCCCOc4cc(cc(N5CCCC5=O)c4)C(=O)N3)CC2)c1";"UPWNAHZYMBYMAH-SZAHLOSFSA-N";611.78;5.47;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-6.4;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.0000003981071705534969
"MM474831";"MM474831";"CCCS(=O)(=O)N(C)c1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNC1(c3cccc(C(C)C)c3)CC1)Cc1cccc(c1)OCCCCN2";"YTELHZGITUPWIN-OIDHKYIRSA-N";662.9;5.55;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-6.55;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.0000002818382931264455
"MM474832";"MM474832";"COCc1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNC(C)(C)c1cccc(C(C)C)c1)Cc1cccc(c1)OCCCCN2";"JQKDSQXCKPYWPA-JHOUSYSJSA-N";573.78;5.77;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.74;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.0000018197008586099826
"MM474833";"MM474833";"COCc1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNC1(c3cccc(C(C)(C)C)c3)CCC1)Cc1cccc(c1)OCCCCN2";"WTYHKZJTJZAMMO-SZAHLOSFSA-N";599.82;6.09;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.92;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.0000012022644346174132
"MM474834";"MM474834";"COCc1cc2cc(n1)OCCCCOc1cccc(c1)C[C@@H]([C@H](O)CNC1(c3cccc(C(C)C)c3)CC1)NC2=O";"ULGBSRGDBHJMRG-IOWSJCHKSA-N";573.73;4.88;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.31;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.000004897788193684467
"MM474835";"MM474835";"COCc1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNC1(c3cccc(C(C)(C)C)c3)CCCC1)Cc1cccc(c1)OCCCCN2";"PTOMBISXQDZHEZ-OIDHKYIRSA-N";613.84;6.48;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.85;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.0000014125375446227554
"MM474849";"MM474849";"Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)[C@H]2C[C@H]3CNC[C@H]3C2)c1";"VAVBDQVWHLBYKB-QDMKHBRRSA-N";410.42;3.22;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-5.68;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.0000020892961308540407
"MM474850";"MM474850";"Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@H]2C[C@H]3CNC[C@H]3C2)c1";"KBRWHYVGRXRJIC-MUJYYYPQSA-N";408.42;2.96;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-5.96;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.000001096478196143185
"MM474851";"MM474851";"Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CCC(F)(F)F)C[C@@H]3C2)c1";"ZHIFBXYCMMXVQR-BCDXTJNWSA-N";504.48;4.62;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-4.59;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.000025703957827688645
"MM474852";"MM474852";"Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CC(O)c4ccccc4)C[C@@H]3C2)c1";"KYCWFOMNQICMSP-XQLXZJNDSA-N";528.58;4.41;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-5.09;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.000008128305161640995
"Chembl598659";"MM469171";"CN1CC2CC(N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)CC2C1";"BPFSRDSVMKDEAX-UHFFFAOYSA-N";422.45;3.3;;"Chembl598659";"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-4.67;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.000021379620895022323
"MM474843";"MM474843";"COCCNCC(O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12";"NJNILOUJUMZROM-UHFFFAOYSA-N";382.3;3.54;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073110/target=_blank>CHEMBL1073110</a>";;-4.49;"Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G.: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett, Volume 20 (4), 2010";"MDCK";0.00003235936569296281
"MM474853";"MM474853";"Cn1cnc(C(=O)N(Cc2ccc(F)c(OC3CCCC3)c2)[C@H]2C[C@H]3CNC[C@H]3C2)c1";"CLMVMIDTRWHVDW-REPLKXPHSA-N";426.54;3.52;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-6.7;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.00000019952623149688787
"MM474854";"MM474854";"CC(C)Oc1cccc(CN(C(=O)c2cn(C)cn2)[C@H]2C[C@H]3CNC[C@H]3C2)c1";"UTNWHVZSHUCJTA-REPLKXPHSA-N";382.51;2.85;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-5.66;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.0000021877616239495517
"MM474844";"MM474844";"OC(NC[C@]12CC[C@@H](C1)NC2)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12";"GMHFKOCCMACCAP-HTYZCBBDSA-N";419.37;4;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073110/target=_blank>CHEMBL1073110</a>";;-5.7;"Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G.: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett, Volume 20 (4), 2010";"MDCK";0.0000019952623149688787
"Chembl599480";"MM468055";"CCN1CC2CC(N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)CC2C1";"JQEUMGMNJYJROS-UHFFFAOYSA-N";438.47;3.95;;"Chembl599480";"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-4.84;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.00001445439770745928
"Chembl599482";"MM469170";"CN1CC2CC(N(Cc3ccc(F)c(OC4CCCC4)c3)C(=O)c3cn(C)cn3)CC2C1";"BHCXDAMJQOPWKM-UHFFFAOYSA-N";440.56;3.86;;"Chembl599482";"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-4.98;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.000010471285480508985
"MM474845";"MM474845";"OC(CNCCNCc1ccccc1)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12";"PDXDKZUJFFIYQL-UHFFFAOYSA-N";457.42;4.69;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073110/target=_blank>CHEMBL1073110</a>";;-5.08;"Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G.: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett, Volume 20 (4), 2010";"MDCK";0.00000831763771102671
"MM474836";"MM474836";"Cc1cc2cc(n1)OCCCCOc1cccc(c1)C[C@@H]([C@H](O)CNC1(c3cccc(C(C)C)c3)CC1)NC2=O";"DLWWAEZPTACWPK-XZWHSSHBSA-N";543.71;5.05;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.4;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.000003981071705534969
"MM474837";"MM474837";"Cc1cc2cc(n1)NCCCCOc1cccc(c1)C[C@@H]([C@H](O)CNCc1cccc(C(C)C)c1)NC2=O";"WPGDASXVPILJSI-URLMMPGGSA-N";516.69;4.59;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-6.77;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.00000016982436524617461
"MM474846";"MM474846";"CCCCNCC(O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12";"FNAWEZUMHMJQKN-UHFFFAOYSA-N";380.33;4.7;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073110/target=_blank>CHEMBL1073110</a>";;-4.6;"Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G.: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett, Volume 20 (4), 2010";"MDCK";0.000025118864315095822
"MM474847";"MM474847";"CNCC(O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12";"SXHYASJCSPRVCT-UHFFFAOYSA-N";338.25;3.53;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073110/target=_blank>CHEMBL1073110</a>";;-4.62;"Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G.: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett, Volume 20 (4), 2010";"MDCK";0.0000239883291901949
"MM474855";"MM474855";"Cn1cnc(C(=O)N(Cc2cccc(OC3CCCC3)c2)[C@H]2C[C@H]3CNC[C@H]3C2)c1";"PAJUEHORDWKTSQ-ACDBMABISA-N";408.55;3.38;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-6.58;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.00000026302679918953816
"Chembl603695";"MM469169";"CN1CC2CC(N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)CC2C1";"QOTDZEUUPREESE-UHFFFAOYSA-N";424.44;3.56;;"Chembl603695";"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-4.89;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.000012882495516931348
"MM474856";"MM474856";"COc1ccc(CN(C(=O)c2cn(C)cn2)[C@H]2C[C@H]3CNC[C@H]3C2)cc1OC1CCCC1";"CRMAUZQHGCAUDQ-ACDBMABISA-N";438.57;3.39;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-6.54;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.00000028840315031266057
"Chembl604805";"MM468056";"CCN1CC2CC(N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)CC2C1";"MCVXWPPVTYUESA-UHFFFAOYSA-N";436.48;3.69;;"Chembl604805";"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-4.52;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.000030199517204020192
"MM474857";"MM474857";"CC(F)CN1C[C@H]2C[C@@H](N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1";"AZPCJFGZZMKYRM-BSUDQKQGSA-N";468.5;4.03;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-4.34;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.000045708818961487516
"MM474858";"MM474858";"Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CC(C)(C)O)C[C@@H]3C2)c1";"ARKYOPPYXOUDRK-REPLKXPHSA-N";480.53;3.44;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-4.75;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.00001778279410038923
"MM474859";"MM474859";"Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)[C@@H]2C[C@H]3CNC[C@H]3C2)c1";"VAVBDQVWHLBYKB-FICVDOATSA-N";410.42;3.22;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073603/target=_blank>CHEMBL1073603</a>";;-6.7;"Lowe JA, Deninno SL, Drozda SE, Schmidt CJ, Ward KM, David Tingley F, Sanner M, Tunucci D, Valentine J.: An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 20 (3), 2010";"MDCK";0.00000019952623149688787
"MM474838";"MM474838";"COCc1cc2cc(c1)C(=O)N[C@H]([C@H](O)CNC(c1cccc(C(C)(C)C)c1)C(F)(F)F)Cc1cccc(c1)OCCCCN2";"VNZSVUSLCTXQLM-JGIBFQFJSA-N";627.75;6.31;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1050386/target=_blank>CHEMBL1050386</a>";;-5.25;"Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U.: Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett, Volume 20 (2), 2010";"MDCK";0.000005623413251903491
"MM474848";"MM474848";"CSCCCNCC(O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12";"CXWFUEQMTADWKS-UHFFFAOYSA-N";412.4;4.65;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1073110/target=_blank>CHEMBL1073110</a>";;-4.42;"Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G.: Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett, Volume 20 (4), 2010";"MDCK";0.000038018939632056124
"MM474908";"MM474908";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(-n3cccn3)c2)CCOCC1";"UDAQMKVSZXLZGC-LOSJGSFVSA-N";484.55;2.85;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-5.32;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.00000478630092322638
"MM474909";"MM474909";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3CCOC3)c2)CCOCC1";"KBLUIKVYUUMQFP-PBTPRMJDSA-N";488.58;3.17;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-5.92;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.0000012022644346174132
"MM474910";"MM474910";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(C(C)(C)C)c1";"GUUXSDASFBPWFQ-FCHUYYIVSA-N";404.5;3.46;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-5.89;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.000001288249551693135
"MM474911";"MM474911";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC(C)(C)c1cccc(C(C)(C)C)c1";"LDGMEHDJYJLXOB-XZOQPEGZSA-N";432.56;4.2;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-6.15;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.0000007079457843841374
"MM474912";"MM474912";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(-n3cccn3)c2)CC1";"FJIMJPFTRLZRAJ-XZOQPEGZSA-N";440.49;2.84;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-4.84;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.00001445439770745928
"MM474913";"MM474913";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C3CCOC3)c2)CC1";"IROUFPLAOXNCIN-ZJWHSJSFSA-N";444.52;3.16;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-4.88;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.000013182567385564074
"MM474914";"MM474914";"C=C(c1cccc(C2(NC[C@@H](O)[C@H](Cc3cc(F)cc(F)c3)NC(C)=O)CC2)c1)C(F)(F)F";"PMWZKFRZXLTHEJ-FCHUYYIVSA-N";468.47;4.23;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-4.99;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.000010232929922807536
"MM474915";"MM474915";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)CF)c2)CC1";"BOKNVVDKNIATDN-XZOQPEGZSA-N";448.53;3.9;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-4.73;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.000018620871366628657
"MM474916";"MM474916";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1";"SXBWNENFIQGMLK-FCHUYYIVSA-N";466.52;4.19;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-4.91;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.00001230268770812381
"MM474917";"MM474917";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(CF)CF)c2)CC1";"SMTZXKMQADBRPC-XZOQPEGZSA-N";466.52;3.85;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-4.77;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.00001698243652461746
"MM474918";"MM474918";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C)c2)CCC1";"CQJCMAHTSPVMHW-BJKOFHAPSA-N";444.57;4.34;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-6.52;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.0000003019951720402019
"MM474919";"MM474919";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CN[C@]1(c2cccc(C(C)(C)C(F)F)c2)C[C@H]1C";"QGKXETIHOAJKQD-LUQKAGKMSA-N";480.55;4.44;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-5.6;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.0000025118864315095823
"MM474786";"MM474786";"O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1";"QWEWGXUTRTXFRF-KBPBESRZSA-N";366.42;0.2;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1022013/target=_blank>CHEMBL1022013</a>";;-4.96;"Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soglia CB, Treadway JL, VanVolkenburg MA, Wilder DC, Piotrowski DW.: (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor. Bioorg Med Chem Lett, Volume 19 (7), 2009";"MDCK";0.000010964781961431852
"MM474920";"MM474920";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(-n3cccn3)c2)CCCCC1";"QXNFPOMRKODYSK-IZZNHLLZSA-N";482.58;4.01;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1274835/target=_blank>CHEMBL1274835</a>";;-5.14;"Truong AP, TĂłth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, Soriano F, Cole T, Brigham EF, Wong K, Zmolek W, Goldbach E, Samant B, Chen L, Zhang H, Nakamura DF, Quinn KP, Yednock TA, Sauer JM.: Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett, Volume 20 (21), 2010";"MDCK";0.000007244359600749906
"MM472929";"MM472929";"N#Cc1ccccc1C1Cc2nccn2C1";"KMOFNRDXTFJLAO-UHFFFAOYSA-N";209.25;2.09;;;"MDCK";"EMDCK";"25";"0";"fromBtoA,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1015852/target=_blank>CHEMBL1015852</a>";;-4.39;"Whitlock GA, Brennan PE, Roberts LR, Stobie A.: Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.0000407380277804113
"Caffeine";"MM00040";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"RYYVLZVUVIJVGH-UHFFFAOYSA-N";194.19;-1.03;"2519";"CHEMBL113";"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066303/target=_blank>CHEMBL1066303</a>";;-4.77;"Peng J, Kudrimoti S, Prasanna S, Odde S, Doerksen RJ, Pennaka HK, Choo YM, Rao KV, Tekwani BL, Madgula V, Khan SI, Wang B, Mayer AM, Jacob MR, Tu LC, Gertsch J, Hamann MT.: Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. J Med Chem, Volume 53 (1), 2010";"MDCK";0.00001698243652461746
"MM474840";"MM474840";"O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@H]12";"FUCSLKWLLSEMDQ-MKYGIPPKSA-N";548.78;6.86;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1066303/target=_blank>CHEMBL1066303</a>";;-6.06;"Peng J, Kudrimoti S, Prasanna S, Odde S, Doerksen RJ, Pennaka HK, Choo YM, Rao KV, Tekwani BL, Madgula V, Khan SI, Wang B, Mayer AM, Jacob MR, Tu LC, Gertsch J, Hamann MT.: Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. J Med Chem, Volume 53 (1), 2010";"MDCK";0.0000008709635899560814
"MM474806";"MM474806";"O=c1cc2c(nn1Cc1ccccc1)CCNCC2";"ZRDIIBAKWCLJAI-UHFFFAOYSA-N";255.32;0.98;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1041008/target=_blank>CHEMBL1041008</a>";;-4.6;"Brennan PE, Whitlock GA, Ho DK, Conlon K, McMurray G.: Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.000025118864315095822
"MM474807";"MM474807";"c1ccc(Cn2ncc3c2CCNCC3)cc1";"ZGIWZGNMDGBKKJ-UHFFFAOYSA-N";227.31;1.62;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1041008/target=_blank>CHEMBL1041008</a>";;-4.51;"Brennan PE, Whitlock GA, Ho DK, Conlon K, McMurray G.: Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.00003090295432513592
"MM474808";"MM474808";"N#Cc1ccc(Cn2nc3c(cc2=O)CCNCC3)cc1";"AIPWHVDDZUPBMQ-UHFFFAOYSA-N";280.33;0.85;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1041008/target=_blank>CHEMBL1041008</a>";;-4.96;"Brennan PE, Whitlock GA, Ho DK, Conlon K, McMurray G.: Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.000010964781961431852
"MM474809";"MM474809";"c1ccc(Cn2cc3c(n2)CCNCC3)cc1";"TVPVLONBSRPTBW-UHFFFAOYSA-N";227.31;1.62;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1041008/target=_blank>CHEMBL1041008</a>";;-4.57;"Brennan PE, Whitlock GA, Ho DK, Conlon K, McMurray G.: Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.00002691534803926914
"MM474810";"MM474810";"Cn1c2c(c(=O)n1Cc1ccccc1)CCNCC2";"UMCHVGPMZOXWPI-UHFFFAOYSA-N";257.34;0.92;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1041008/target=_blank>CHEMBL1041008</a>";;-4.89;"Brennan PE, Whitlock GA, Ho DK, Conlon K, McMurray G.: Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.000012882495516931348
"MM474811";"MM474811";"O=c1cc2c(nn1Cc1cccc(Cl)c1)CCNCC2";"YUWCEECEVXHQPF-UHFFFAOYSA-N";289.77;1.63;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1041008/target=_blank>CHEMBL1041008</a>";;-4.49;"Brennan PE, Whitlock GA, Ho DK, Conlon K, McMurray G.: Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.00003235936569296281
"MM474812";"MM474812";"O=c1c2c([nH]n1Cc1ccccc1)CCNCC2";"HPTRPGKTBJNXBW-UHFFFAOYSA-N";243.31;0.91;;;"MDCK";"EMDCK";"25";"0";"fromAtoB,MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1041008/target=_blank>CHEMBL1041008</a>";;-5.7;"Brennan PE, Whitlock GA, Ho DK, Conlon K, McMurray G.: Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence. Bioorg Med Chem Lett, Volume 19 (17), 2009";"MDCK";0.0000019952623149688787
"MM474890";"MM474890";"NC(=O)c1cnc(-c2cnc3c(Nc4ccc(C(F)(F)F)cn4)ccnc3n2)c(C(F)(F)F)c1";"YPYYPOYQUMYMKR-UHFFFAOYSA-N";479.34;4.36;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1217661/target=_blank>CHEMBL1217661</a>";;-4.47;"Hodgetts KJ, Blum CA, Caldwell T, Bakthavatchalam R, Zheng X, Capitosti S, Krause JE, Cortright D, Crandall M, Murphy BA, Boyce S, Brian Jones A, Chenard BL.: Pyrido[2,3-b]pyrazines, discovery of TRPV1 antagonists with reduced potential for the formation of reactive metabolites. Bioorg Med Chem Lett, Volume 20 (15), 2010";"MDCK";0.000033884415613920276
"MM474900";"MM474900";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cncc(CC(C)(C)C)c2)CC1";"WETWCOGJYRYKDB-XZOQPEGZSA-N";445.55;3.64;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1260851/target=_blank>CHEMBL1260851</a>";;-4.87;"Probst GD, Bowers S, Sealy JM, Stupi B, Dressen D, Jagodzinska BM, Aquino J, Gailunas A, Truong AP, Tso L, Xu YZ, Hom RK, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Sham HL, Jagodzinski J, Toth G, Brecht E, Yao N, Pan H, Lin M, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Gauby S, Zmolek W, Quinn KP, Sauer JM.: Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Bioorg Med Chem Lett, Volume 20 (20), 2010";"MDCK";0.000013489628825916533
"MM474901";"MM474901";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2nc(CC(C)(C)C)cs2)CC1";"IVEXILNYIOKCOY-VQTJNVASSA-N";451.58;3.7;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1260851/target=_blank>CHEMBL1260851</a>";;-4.95;"Probst GD, Bowers S, Sealy JM, Stupi B, Dressen D, Jagodzinska BM, Aquino J, Gailunas A, Truong AP, Tso L, Xu YZ, Hom RK, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Sham HL, Jagodzinski J, Toth G, Brecht E, Yao N, Pan H, Lin M, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Gauby S, Zmolek W, Quinn KP, Sauer JM.: Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Bioorg Med Chem Lett, Volume 20 (20), 2010";"MDCK";0.00001122018454301963
"MM474903";"MM474903";"CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cc(CC(C)(C)C)no2)CCCCC1";"DDSJVMZLEUXJNA-XZOQPEGZSA-N";477.6;4.4;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1260851/target=_blank>CHEMBL1260851</a>";;-4.74;"Probst GD, Bowers S, Sealy JM, Stupi B, Dressen D, Jagodzinska BM, Aquino J, Gailunas A, Truong AP, Tso L, Xu YZ, Hom RK, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Sham HL, Jagodzinski J, Toth G, Brecht E, Yao N, Pan H, Lin M, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Gauby S, Zmolek W, Quinn KP, Sauer JM.: Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Bioorg Med Chem Lett, Volume 20 (20), 2010";"MDCK";0.000018197008586099827
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL840609/target=_blank>CHEMBL840609</a>";;-4.42;"Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.: In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem, Volume 48 (3), 2005";"MDCK";0.000038018939632056124
"MM474947";"MM474947";"CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3nc(C(=O)O)ccc3c2)cc1";"SZUHDKKQQZPOGX-UHFFFAOYSA-N";533.41;8.26;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1678725/target=_blank>CHEMBL1678725</a>";;-4.74;"Bass JY, Caravella JA, Chen L, Creech KL, Deaton DN, Madauss KP, Marr HB, McFadyen RB, Miller AB, Mills WY, Navas F, Parks DJ, Smalley TL, Spearing PK, Todd D, Williams SP, Wisely GB.: Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg Med Chem Lett, Volume 21 (4), 2011";"MDCK";0.000018197008586099827
"MM474981";"MM474981";"CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[C@@H]1C(=O)CN(S(=O)(=O)c2ccccn2)CC[C@@H]1C";"LMZYZVWKTJFLSL-KHOMTPLRSA-N";540.64;2.76;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL863720/target=_blank>CHEMBL863720</a>";;-4.26;"Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh HJ, Jeong JU, Erhard KF, Ward KW, Roethke TJ, Smith BR, Cheng HY, Geng X, Lin F, Offen PH, Wang B, Nevins N, Head MS, Haltiwanger RC, Narducci Sarjeant AA, Liable-Sands LM, Zhao B, Smith WW, Janson CA, Gao E, Tomaszek T, McQueney M, James IE, Gress CJ, Zembryki DL, Lark MW, Veber DF.: Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem, Volume 49 (5), 2006";"MDCK";0.00005495408738576248
"MM474964";"MM474964";"CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2cccnc2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1";"ONBHKIJPHBOPAS-RZFNWQHOSA-N";522.6;3.19;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860621/target=_blank>CHEMBL860621</a>";;-4.68;"Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 16 (6), 2006";"MDCK";0.00002089296130854041
"MM474991";"MM474991";"CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1";"QQZSKYDYMQGTTF-UKILVPOCSA-N";623.7;5.21;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891434/target=_blank>CHEMBL891434</a>";;-4.8;"Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.: Acyclic, orally bioavailable ketone-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 17 (1), 2007";"MDCK";0.00001584893192461114
"MM474985";"MM474985";"CCCC[C@@H](/C=N/NS(=O)(=O)N(C)C)NC(=O)OC(C)(C)C";"BJFRDRHGFCXAIX-IWQAVIMZSA-N";336.46;1.45;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868303/target=_blank>CHEMBL868303</a>";;-4.11;"Adkison KK, Barrett DG, Deaton DN, Gampe RT, Hassell AM, Long ST, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors? Bioorg Med Chem Lett, Volume 16 (4), 2006";"MDCK";0.00007762471166286911
"MM474982";"MM474982";"CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[C@H]1CC[C@@H](C)N(S(=O)(=O)c2ccccn2)CC1=O";"BWYBBMQLUKXECQ-GIVPXCGWSA-N";540.64;2.9;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL863720/target=_blank>CHEMBL863720</a>";;-4.33;"Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh HJ, Jeong JU, Erhard KF, Ward KW, Roethke TJ, Smith BR, Cheng HY, Geng X, Lin F, Offen PH, Wang B, Nevins N, Head MS, Haltiwanger RC, Narducci Sarjeant AA, Liable-Sands LM, Zhao B, Smith WW, Janson CA, Gao E, Tomaszek T, McQueney M, James IE, Gress CJ, Zembryki DL, Lark MW, Veber DF.: Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem, Volume 49 (5), 2006";"MDCK";0.00004677351412871981
"MM474986";"MM474986";"CCCC[C@@H](/C=N/NC(=O)N1CCCC1)NC(=O)OC(C)(C)C";"SPKPMLLMVWOADV-VLURKWGBSA-N";326.44;2.86;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868303/target=_blank>CHEMBL868303</a>";;-4.7;"Adkison KK, Barrett DG, Deaton DN, Gampe RT, Hassell AM, Long ST, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors? Bioorg Med Chem Lett, Volume 16 (4), 2006";"MDCK";0.000019952623149688786
"MM474965";"MM474965";"CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)Cc2ccccc2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1";"MGLRRRHJJHGHTM-UVWWXKGLSA-N";535.64;3.72;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860621/target=_blank>CHEMBL860621</a>";;-4.39;"Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 16 (6), 2006";"MDCK";0.0000407380277804113
"MM474987";"MM474987";"CCCC[C@@H](/C=N/NC(=O)N1CCOCC1)NC(=O)O[C@@H](C)Cc1ccccc1";"VUVLQWZOUOAKHY-UQQRSYNHSA-N";404.51;2.93;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868303/target=_blank>CHEMBL868303</a>";;-4.85;"Adkison KK, Barrett DG, Deaton DN, Gampe RT, Hassell AM, Long ST, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors? Bioorg Med Chem Lett, Volume 16 (4), 2006";"MDCK";0.000014125375446227555
"MM474983";"MM474983";"CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[C@H]1C[C@H](C)CN(S(=O)(=O)c2ccccn2)CC1=O";"MCKCVIDASJTQSU-JBACZVJFSA-N";540.64;2.76;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL863720/target=_blank>CHEMBL863720</a>";;-4.31;"Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh HJ, Jeong JU, Erhard KF, Ward KW, Roethke TJ, Smith BR, Cheng HY, Geng X, Lin F, Offen PH, Wang B, Nevins N, Head MS, Haltiwanger RC, Narducci Sarjeant AA, Liable-Sands LM, Zhao B, Smith WW, Janson CA, Gao E, Tomaszek T, McQueney M, James IE, Gress CJ, Zembryki DL, Lark MW, Veber DF.: Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem, Volume 49 (5), 2006";"MDCK";0.00004897788193684466
"MM474988";"MM474988";"CCCC[C@@H](/C=N/NC(=O)N1CCOCC1)NC(=O)OC(C)(C)C";"LOTRMFMPZMRMGH-VLURKWGBSA-N";342.44;2.1;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868303/target=_blank>CHEMBL868303</a>";;-5.21;"Adkison KK, Barrett DG, Deaton DN, Gampe RT, Hassell AM, Long ST, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors? Bioorg Med Chem Lett, Volume 16 (4), 2006";"MDCK";0.000006165950018614822
"MM474966";"MM474966";"CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)Nc2ccc(C(F)(F)F)cc2)CC1(C)C)C(=O)C(=O)Nc1cc[nH]n1";"PTNBWGAJLBFPEI-QFBILLFUSA-N";566.54;3.69;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860621/target=_blank>CHEMBL860621</a>";;-5.74;"Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 16 (6), 2006";"MDCK";0.0000018197008586099826
"MM474967";"MM474967";"CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2nc3ccccc3s2)CC1(C)C)C(=O)C(=O)Nc1cc[nH]n1";"YYMVVRDPBXFOTR-HNAYVOBHSA-N";540.6;2.89;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860621/target=_blank>CHEMBL860621</a>";;-4.6;"Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 16 (6), 2006";"MDCK";0.000025118864315095822
"MM474990";"MM474990";"O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1";"DGENZVKCTGIDRZ-UHFFFAOYSA-N";347.41;5.11;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL890950/target=_blank>CHEMBL890950</a>";;-4.22;"McKeown SC, Corbett DF, Goetz AS, Littleton TR, Bigham E, Briscoe CP, Peat AJ, Watson SP, Hickey DM.: Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. Bioorg Med Chem Lett, Volume 17 (6), 2007";"MDCK";0.000060255958607435806
"MM475023";"MM475023";"O=C(Nc1ccccc1F)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O";"MTPVBMVUENFFLL-HXUWFJFHSA-N";388.4;3.76;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL918041/target=_blank>CHEMBL918041</a>";;-4.89;"Henderson EA, Alber DG, Baxter RC, Bithell SK, Budworth J, Carter MC, Chubb A, Cockerill GS, Dowdell VC, Fraser IJ, Harris RA, Keegan SJ, Kelsey RD, Lumley JA, Stables JN, Weerasekera N, Wilson LJ, Powell KL.: 1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem, Volume 50 (7), 2007";"MDCK";0.000012882495516931348
"MM475009";"MM475009";"COc1ccccc1NC(=O)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1OC";"UIGJZBBMXXMIRM-SFTDATJTSA-N";551.57;4.61;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-6.36;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.00000043651583224016567
"MM475010";"MM475010";"Cc1cc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)ccc1NC(=O)Nc1ccccc1Br";"QQBPXAXSFYBAFJ-SFTDATJTSA-N";584.44;5.66;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.52;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.0000030199517204020193
"MM475011";"MM475011";"O=C(Nc1ccccc1Cl)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Br";"DJDNQYHILBKCSK-OALUTQOASA-N";604.86;6.01;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.35;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.000004466835921509635
"MM475012";"MM475012";"O=C(Nc1ccccc1Br)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Br";"QEPXZBPJIPFLAZ-OALUTQOASA-N";649.31;6.11;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.47;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.0000033884415613920275
"MM474992";"MM474992";"CCCC[C@H](NC(=O)O[C@H](Cn1ccc(C(F)(F)F)n1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1";"ZPQUDRGVSRMTTR-QFBILLFUSA-N";547.6;3.54;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891434/target=_blank>CHEMBL891434</a>";;-4.47;"Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.: Acyclic, orally bioavailable ketone-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 17 (1), 2007";"MDCK";0.000033884415613920276
"MM474993";"MM474993";"CCCC[C@H](NC(=O)O[C@H](Cn1cnc2cc(Cl)c(Cl)cc21)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1";"CTAIZAPBSQNUAF-WMZHIEFXSA-N";598.55;4.99;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891434/target=_blank>CHEMBL891434</a>";;-4.82;"Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.: Acyclic, orally bioavailable ketone-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 17 (1), 2007";"MDCK";0.000015135612484362071
"MM474994";"MM474994";"CCCC[C@H](NC(=O)O[C@H](Cn1cnc(-c2ccc(C(F)(F)F)cc2)c1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1";"XHGOLGYGBDIOFD-WIOPSUGQSA-N";623.7;5.21;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891434/target=_blank>CHEMBL891434</a>";;-4.72;"Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.: Acyclic, orally bioavailable ketone-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 17 (1), 2007";"MDCK";0.000019054607179632484
"MM474995";"MM474995";"CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)C(=O)Nc1ccn[nH]1";"NFPHFQIUODNJRD-LEWJYISDSA-N";562.59;5.2;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891434/target=_blank>CHEMBL891434</a>";;-5.04;"Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.: Acyclic, orally bioavailable ketone-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 17 (1), 2007";"MDCK";0.000009120108393559096
"MM475024";"MM475024";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccccc1Oc1ccccc1)C(=O)O";"NJJGKDPBXMIWPF-LJHODMEESA-N";387.5;3.94;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475025";"MM475025";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(OCc2ccc(F)c(F)c2)cc1)C(=O)O";"RBSIIEZEHKNSIW-CWVNLOTRSA-N";437.51;4;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475026";"MM475026";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(OCc2ccc(C(F)(F)F)cc2)cc1)C(=O)O";"SPKWKCKXVBTLTB-UAOJZALGSA-N";469.53;4.74;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475027";"MM475027";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1cccc(Oc2ccccc2)c1)C(=O)O";"BVTSBOHKQXLEPE-CCKFTAQKSA-N";387.5;3.94;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475028";"MM475028";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(OCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1)C(=O)O";"XQUOBCBFYSAISV-CWVNLOTRSA-N";537.52;5.76;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475029";"MM475029";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(-c2ccccc2)cc1)C(=O)O";"BKIADFDXLKFQRT-CCKFTAQKSA-N";371.5;3.81;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475030";"MM475030";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O";"KSLQUEKUGQKSAJ-ICCXJUOJSA-N";311.4;1.85;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475031";"MM475031";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc2ccccc2c1)C(=O)O";"DOLNCCYFNWYJPI-DQYPLSBCSA-N";345.46;3.3;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475032";"MM475032";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(Oc2ccccc2)cc1)C(=O)O";"HRBJATPCNVWLGP-CCKFTAQKSA-N";387.5;3.94;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475033";"MM475033";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccccc1OCc1ccccc1)C(=O)O";"KWBQBHZSTYVPSB-BPAFIMBUSA-N";401.53;3.72;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475034";"MM475034";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1cccc(OCc2ccccc2)c1)C(=O)O";"HSJQIQUIXIQNLN-XPGWFJOJSA-N";401.53;3.72;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475035";"MM475035";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)O";"RUTFYHHMLQZRQB-XPGWFJOJSA-N";401.53;3.72;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475036";"MM475036";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](C)C(=O)O";"OUSUIQLLVUDFMT-VQVTYTSYSA-N";219.31;0.92;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475037";"MM475037";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(OCc2ccc(F)cc2)cc1)C(=O)O";"KZAYYAIBZWKHEY-UAOJZALGSA-N";419.52;3.86;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475054";"MM475054";"COc1ccc(-c2ccc(-n3cc(NC(N)=O)c(C(N)=O)n3)cc2F)cc1C";"VMXKKYTUPXTLIY-UHFFFAOYSA-N";383.38;2.58;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475055";"MM475055";"NC(=O)Nc1cn(-c2ccc(-c3ccc(O)c(F)c3)c(O)c2)nc1C(N)=O";"OJDXZMSTKRWOLB-UHFFFAOYSA-N";371.33;1.68;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475056";"MM475056";"Cc1cc(-c2ccc(-n3cc(NC(N)=O)c(C(N)=O)n3)cc2)cc(C)c1O";"BPBKICHTDUGKBZ-UHFFFAOYSA-N";365.39;2.45;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475057";"MM475057";"CCOc1cc(-n2cc(NC(N)=O)c(C(N)=O)n2)ccc1-c1ccc(O)c(F)c1";"XMRUQTFGZYEAPD-UHFFFAOYSA-N";399.38;2.37;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475058";"MM475058";"NC(=O)Nc1cn(-c2ccc(-c3ccc(O)c(O)c3)cc2)nc1C(N)=O";"WBAXMDZQOGAPPQ-UHFFFAOYSA-N";353.34;1.54;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475059";"MM475059";"COc1ccc(-c2ccc(-n3cc(NC(N)=O)c(C(N)=O)n3)cc2C)cc1C";"PPZKBXPUTQVUBO-UHFFFAOYSA-N";379.42;2.75;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475060";"MM475060";"Cc1cc(-n2cc(NC(N)=O)c(C(N)=O)n2)ccc1-c1ccc(O)c(F)c1";"UHYFVRLAOSAAHV-UHFFFAOYSA-N";369.36;2.28;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475061";"MM475061";"Cc1cc(O)ccc1-c1ccc(-n2cc(NC(N)=O)c(C(N)=O)n2)cc1";"UVYTZSAHTTUFBW-UHFFFAOYSA-N";351.37;2.14;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475062";"MM475062";"COc1cc(F)c(-c2ccc(-n3cc(NC(N)=O)c(C(N)=O)n3)cc2C)c(F)c1";"KVLVWTNOGZYWTP-UHFFFAOYSA-N";401.37;2.72;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475063";"MM475063";"NC(=O)Nc1cn(-c2ccc(-c3ccc(O)cc3)c(Cl)c2)nc1C(N)=O";"PWIMNIIIHHNFLT-UHFFFAOYSA-N";371.78;2.49;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475064";"MM475064";"COc1cc(-c2ccc(-n3cc(NC(N)=O)c(C(N)=O)n3)cc2C)ccc1O";"SSKUYPHIUNEULS-UHFFFAOYSA-N";381.39;2.15;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475065";"MM475065";"Cc1cc(-n2cc(NC(N)=O)c(C(N)=O)n2)ccc1-c1cc(C)c(O)c(Br)c1";"AYJZGZZDRNHTDA-UHFFFAOYSA-N";444.29;3.21;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475066";"MM475066";"Cc1cc(O)ccc1-c1ccc(-n2cc(NC(N)=O)c(C(N)=O)n2)cc1C";"TZZSQLUXEXIBKL-UHFFFAOYSA-N";365.39;2.45;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL840609/target=_blank>CHEMBL840609</a>";;-4.46;"Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.: In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem, Volume 48 (3), 2005";"MDCK";0.00003467368504525317
"MM475013";"MM475013";"COc1cc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)ccc1NC(=O)Nc1ccccc1Br";"XFVTZTQCGZVSDX-PMACEKPBSA-N";600.44;5.36;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.58;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.0000026302679918953817
"MM475067";"MM475067";"Cc1cc(-c2ccc(-n3cc(NC(N)=O)c(C(N)=O)n3)cc2F)ccc1O";"MRNIIMUYTPPZDO-UHFFFAOYSA-N";369.36;2.28;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM474984";"MM474984";"CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[C@H]1CCCN(S(=O)(=O)c2ccccn2)CC1=O";"VBPPNJCVXGAZDD-PMACEKPBSA-N";526.62;2.51;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL863720/target=_blank>CHEMBL863720</a>";;-4.24;"Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh HJ, Jeong JU, Erhard KF, Ward KW, Roethke TJ, Smith BR, Cheng HY, Geng X, Lin F, Offen PH, Wang B, Nevins N, Head MS, Haltiwanger RC, Narducci Sarjeant AA, Liable-Sands LM, Zhao B, Smith WW, Janson CA, Gao E, Tomaszek T, McQueney M, James IE, Gress CJ, Zembryki DL, Lark MW, Veber DF.: Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem, Volume 49 (5), 2006";"MDCK";0.000057543993733715664
"MM474950";"MM474950";"Fc1ccc(/C=N/Nc2ncnc3c2cnn3-c2ccccc2)cc1";"WXZHKVLOSBCWDY-LSHDLFTRSA-N";332.34;3.4;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-6.3;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.0000005011872336272725
"MM474951";"MM474951";"CN(C)CCNC(=O)c1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc3[nH]cnc23)cc1";"QNUBZASKWDMCAQ-PNQUVVCRSA-N";468.53;2.43;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-5.82;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.0000015135612484362072
"MM474952";"MM474952";"COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1";"PVIMTNAWPMEBAK-LSHDLFTRSA-N";345.37;2.67;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-4.9;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.000012589254117941661
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL840609/target=_blank>CHEMBL840609</a>";;-6.57;"Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.: In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem, Volume 48 (3), 2005";"MDCK";0.0000002691534803926914
"MM474968";"MM474968";"CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)Nc2c(C)noc2C)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1";"JBAPSUGYURPCRH-NIJIEXERSA-N";555.63;3.79;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860621/target=_blank>CHEMBL860621</a>";;-5.92;"Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 16 (6), 2006";"MDCK";0.0000012022644346174132
"MM474989";"MM474989";"CCCC[C@@H](/C=N/NC(=O)N1CCc2ccccc21)NC(=O)OC(C)(C)C";"XFJFXJUUFGRLHF-YIRPMMGJSA-N";374.49;3.83;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL868303/target=_blank>CHEMBL868303</a>";;-4.82;"Adkison KK, Barrett DG, Deaton DN, Gampe RT, Hassell AM, Long ST, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors? Bioorg Med Chem Lett, Volume 16 (4), 2006";"MDCK";0.000015135612484362071
"MM474969";"MM474969";"CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)NCc2ccccc2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1";"DEAALBPCNSJIPH-JHMXWDHMSA-N";550.66;3.86;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860621/target=_blank>CHEMBL860621</a>";;-4.68;"Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 16 (6), 2006";"MDCK";0.00002089296130854041
"MM474970";"MM474970";"CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2nnc(C(F)(F)F)s2)CC1(C)C)C(=O)C(=O)Nc1cc[nH]n1";"LECXOAIUCLJFBA-GXFFZTMASA-N";559.53;2.15;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860621/target=_blank>CHEMBL860621</a>";;-4.92;"Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 16 (6), 2006";"MDCK";0.000012022644346174132
"MM474971";"MM474971";"CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2ccno2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1";"NGSRRUWCODUIPK-PLMTUMEDSA-N";512.56;2.78;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL860621/target=_blank>CHEMBL860621</a>";;-4.32;"Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL.: Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 16 (6), 2006";"MDCK";0.000047863009232263804
"MM475014";"MM475014";"O=C(Nc1ccccc1Cl)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl";"REDKKVINILPCFB-OALUTQOASA-N";560.41;5.9;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.26;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.0000054954087385762485
"MM475015";"MM475015";"O=C(Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Cl)Nc1ccccc1Br";"IFGXOTDKEWTBFF-OALUTQOASA-N";604.86;6.01;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.28;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.000005248074602497723
"MM475016";"MM475016";"Cc1cc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)ccc1NC(=O)Nc1ccccc1Cl";"GMINLGKKNUFSSX-SFTDATJTSA-N";539.99;5.55;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.52;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.0000030199517204020193
"MM475017";"MM475017";"COc1cc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)ccc1NC(=O)Nc1ccccc1C";"HIRZLJKWWPKJHG-VXKWHMMOSA-N";535.57;4.91;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-6.15;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.0000007079457843841374
"MM475018";"MM475018";"Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(=O)O)CC2)cc1";"ITXAAOWFOURIHK-DEOSSOPVSA-N";522.6;3.12;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-7.7;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.000000019952623149688786
"MM475019";"MM475019";"COc1cc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)ccc1NC(=O)Nc1ccccc1Cl";"AZWIIFCIAADKFM-PMACEKPBSA-N";555.99;5.25;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.77;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.000001698243652461746
"MM474788";"MM474788";"OCC1(N2CCN(C3CCc4ccc(OCc5noc(-c6ccc(Cl)cc6)n5)cc43)CC2)CCCC1";"GPSVSZZDAKVKII-UHFFFAOYSA-N";509.05;4.88;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-5.77;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000001698243652461746
"MM474996";"MM474996";"CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccncc2)n1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1";"NHFKTEZZOWFJBK-LADGPHEKSA-N";556.69;3.59;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891434/target=_blank>CHEMBL891434</a>";;-5.17;"Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.: Acyclic, orally bioavailable ketone-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 17 (1), 2007";"MDCK";0.000006760829753919819
"MM475038";"MM475038";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccccc1-c1ccccc1)C(=O)O";"JIKXDFOHRKWQIU-CCKFTAQKSA-N";371.5;3.81;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475039";"MM475039";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccc(OCc2ccc(F)cc2F)cc1)C(=O)O";"UHSLUGVLSJUOHH-CWVNLOTRSA-N";437.51;4;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475040";"MM475040";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1ccccc1)C(=O)O";"DPPTZNUVUSKYMF-WXHSDQCUSA-N";295.4;2.14;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475041";"MM475041";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1cccc2ccccc12)C(=O)O";"ASOTUXAPLNMLBP-DQYPLSBCSA-N";345.46;3.3;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475042";"MM475042";"CC[C@@H](C)[C@H](S)C(=O)NCC(=O)O";"OKMLPKRGXRLVMI-VDTYLAMSSA-N";205.28;0.53;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475043";"MM475043";"CC[C@@H](C)[C@H](S)C(=O)N[C@@H](Cc1cccc(-c2ccccc2)c1)C(=O)O";"RZCHYBYQQJXXGU-CCKFTAQKSA-N";371.5;3.81;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL928322/target=_blank>CHEMBL928322</a>";;-6.3;"Deaton DN, Graham KP, Gross JW, Miller AB.: Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite. Bioorg Med Chem Lett, Volume 18 (5), 2008";"MDCK";0.0000005011872336272725
"MM475068";"MM475068";"Cc1cc(-n2cc(NC(N)=O)c(C(N)=O)n2)ccc1-c1cc(C)c(O)c(C)c1";"BTWVXGQJZPRRBH-UHFFFAOYSA-N";379.42;2.76;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475069";"MM475069";"Cc1cc(-n2cc(NC(N)=O)c(C(N)=O)n2)ccc1-c1ccc(O)c(C)c1C";"IJMHFPIVVQMWGO-UHFFFAOYSA-N";379.42;2.76;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475070";"MM475070";"Cc1cc(-n2cc(NC(N)=O)c(C(N)=O)n2)ccc1-c1c(F)cc(O)cc1F";"GMTYZITWVVOKMY-UHFFFAOYSA-N";387.35;2.42;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475021";"MM475021";"Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1C";"FHRCPGGLVYYPQM-GOTSBHOMSA-N";519.57;5.21;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-6.6;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.00000025118864315095823
"MM475022";"MM475022";"Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2C[C@@H](F)C[C@H]2COc2ccc(C(=O)O)cc2)cc1Br";"NVSWYFNJDUCDCI-SFTDATJTSA-N";584.44;5.66;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL903787/target=_blank>CHEMBL903787</a>";;-5.72;"Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.: Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorg Med Chem, Volume 15 (4), 2007";"MDCK";0.0000019054607179632483
"MM475071";"MM475071";"NC(=O)Nc1cn(-c2ccc(-c3ccc(O)c(F)c3)cc2)nc1C(N)=O";"QTRAAJZUCZOQBU-UHFFFAOYSA-N";355.33;1.97;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475072";"MM475072";"Cc1cc(O)ccc1-c1ccc(-n2cc(NC(N)=O)c(C(N)=O)n2)cc1C(F)(F)F";"LLQGNSYWIFSDCQ-UHFFFAOYSA-N";419.36;3.16;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475073";"MM475073";"Cc1cc(-n2cc(NC(N)=O)c(C(N)=O)n2)ccc1-c1ccc(O)cc1";"VZKLDCIMFQMYKQ-UHFFFAOYSA-N";351.37;2.14;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL952863/target=_blank>CHEMBL952863</a>";;-5.52;"Lai Y, Xing L, Poda GI, Hu Y.: Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): the role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos, Volume 35 (6), 2007";"MDCK";0.0000030199517204020193
"MM475085";"MM475085";"CC(C)c1n[nH]c2c(=O)[nH]c(Cc3ccccc3OCCN3CCOCC3)nc12";"DQQIKKSUASWOMX-UHFFFAOYSA-N";397.48;2.07;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-4.82;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.000015135612484362071
"MM475086";"MM475086";"CC(C)c1nn(C)c2c(=O)[nH]c(Cc3ccccc3OCCN3CCOCC3)nc12";"MMFHEXODWCOMFW-UHFFFAOYSA-N";411.51;2.08;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-4.47;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.000033884415613920276
"MM475087";"MM475087";"CC(C)c1n[nH]c2c(=O)[nH]c(C[C@@H]3CCCC[C@H]3NC(=O)CN3CCCC3)nc12";"SEYCIBHCEGUQNB-LSDHHAIUSA-N";400.53;2.08;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-6.3;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.0000005011872336272725
"MM475088";"MM475088";"CC(C)c1n[nH]c2c(=O)[nH]c(C[C@@H]3CCCC[C@H]3NC(=O)NCCCN3CCOCC3)nc12";"WXHYNZHWBZIGJP-DLBZAZTESA-N";459.6;1.89;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-6.15;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.0000007079457843841374
"MM475089";"MM475089";"CC(C)c1n[nH]c2c(=O)[nH]c(C[C@@H]3CCCC[C@H]3Nc3ncccn3)nc12";"BJVCVIRGZHSCSW-QWHCGFSZSA-N";367.46;2.77;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-4.89;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.000012882495516931348
"MM475090";"MM475090";"CC(C)c1n[nH]c2c(=O)[nH]c(C[C@@H]3CCCC[C@H]3NC(=O)CC3CCOCC3)nc12";"YYXRNUDRJVHKAD-JKSUJKDBSA-N";415.54;2.8;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-6.12;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.0000007585775750291836
"MM475091";"MM475091";"CC(C)c1n[nH]c2c(=O)[nH]c(Cc3ccccc3OC(F)(F)F)nc12";"RCKCFOKBILAFJF-UHFFFAOYSA-N";352.32;3.26;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-4.97;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.00001071519305237607
"MM475100";"MM475100";"CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1";"TUOXXRMLFZBSTB-UHFFFAOYSA-N";532.42;8.87;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL982038/target=_blank>CHEMBL982038</a>";;-4.72;"Akwabi-Ameyaw A, Bass JY, Caldwell RD, Caravella JA, Chen L, Creech KL, Deaton DN, Jones SA, Kaldor I, Liu Y, Madauss KP, Marr HB, McFadyen RB, Miller AB, Navas F, Parks DJ, Spearing PK, Todd D, Williams SP, Wisely GB.: Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett, Volume 18 (15), 2008";"MDCK";0.000019054607179632484
"MM475092";"MM475092";"CC(C)c1n[nH]c2c(=O)[nH]c(Cc3cccc(Cl)c3)nc12";"UORHIBXCPUHXFY-UHFFFAOYSA-N";302.77;3.01;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-4.77;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.00001698243652461746
"MM475093";"MM475093";"CC(C)c1n[nH]c2c(=O)[nH]c(C[C@@H]3CCCC[C@H]3OCCN3CCOCC3)nc12";"DHNHXAUERSTPRA-JKSUJKDBSA-N";403.53;2.22;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-5.2;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.00000630957344480193
"MM475094";"MM475094";"Cc1ccc(N[C@@H]2CCCC[C@H]2Cc2nc3c(C(C)C)n[nH]c3c(=O)[nH]2)nn1";"PMRWYXIODMVINY-UONOGXRCSA-N";381.48;3.08;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL966927/target=_blank>CHEMBL966927</a>";;-5.77;"Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E.: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett, Volume 19 (9), 2009";"MDCK";0.000001698243652461746
"Chembl537965";"MM469167";"CN1CC2C(C1)C2CN(Cc1cccc(Cl)c1)C(=O)c1cn(C)cn1";"GGOFKOFOQJFNFE-UHFFFAOYSA-N";358.87;2.52;;"Chembl537965";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-4.85;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000014125375446227555
"MM474997";"MM474997";"C[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1";"KCXVQPRWXYAYNA-HTAPYJJXSA-N";581.62;4.04;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL891434/target=_blank>CHEMBL891434</a>";;-4.52;"Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.: Acyclic, orally bioavailable ketone-based cathepsin K inhibitors. Bioorg Med Chem Lett, Volume 17 (1), 2007";"MDCK";0.000030199517204020192
"MM474789";"MM474789";"Cc1ccc(C(=O)c2ccc(O[C@H](CCN(C)CC(=O)O)c3ccccc3)cc2)cc1";"HNBKNDFZJLEZLZ-XMMPIXPASA-N";417.51;4.75;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-5.77;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000001698243652461746
"Chembl551424";"MM468053";"CCN1CC2C(C1)C2CN(Cc1cccc(Cl)c1)C(=O)c1cn(C)cn1";"IVZJROIOJSZARI-UHFFFAOYSA-N";372.9;2.91;;"Chembl551424";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-4.91;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.00001230268770812381
"Chembl556247";"MM469168";"CN1CC2C(C1)C2CN(Cc1cccc(OC(F)(F)F)c1)C(=O)c1cn(C)cn1";"AZPNIOXCMXPLKP-UHFFFAOYSA-N";408.42;2.77;;"Chembl556247";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-4.86;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000013803842646028839
"MM474790";"MM474790";"Cn1cnc(C(=O)N(Cc2ccc(F)c(Cl)c2)C[C@H]2[C@@H]3CNC[C@@H]32)c1";"HTUXUNBQNWREPD-WDNDVIMCSA-N";362.84;2.32;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-6.05;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.0000008912509381337459
"MM474791";"MM474791";"Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C[C@H]2[C@@H]3CN(CC4CC4)C[C@@H]32)c1";"DKYPWVLLGYCVPS-PMOLBWCYSA-N";448.49;3.55;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-4.8;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.00001584893192461114
"MM474792";"MM474792";"Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C[C@H]2[C@@H]3CN(CC4CCCC4)C[C@@H]32)c1";"DBQBAHSSKFGSRU-ZBYYUNFXSA-N";476.54;4.33;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-5.12;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000007585775750291836
"MM474793";"MM474793";"CN1C[C@@H]2[C@H](C1)[C@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1";"KYLOBHXXQOZRKK-FICVDOATSA-N";376.86;2.66;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-4.88;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000013182567385564074
"Chembl563761";"MM470702";"Cn1cnc(C(=O)N(Cc2cccc(Cl)c2)[C@H]2CC[C@@H](N)CC2)c1";"DNRRPNHABAPADP-IYBDPMFKSA-N";346.86;2.99;;"Chembl563761";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-6.3;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.0000005011872336272725
"MM474794";"MM474794";"Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)C[C@H]2[C@@H]3CNC[C@@H]32)c1";"LAXUUXLIBVHUAY-ZSHCYNCHSA-N";394.4;2.43;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-5.77;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000001698243652461746
"Chembl564919";"MM468054";"CCN1CC2C(C1)C2CN(Cc1cccc(OC(F)(F)F)c1)C(=O)c1cn(C)cn1";"QEIUUWQTMLQILI-UHFFFAOYSA-N";422.45;3.16;;"Chembl564919";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-4.92;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000012022644346174132
"MM474795";"MM474795";"Cn1cnc(C(=O)N(Cc2cccc(Cl)c2)C[C@H]2[C@@H]3CNC[C@@H]32)c1";"QSFJWJIJRKTTAK-ZSHCYNCHSA-N";344.85;2.18;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1023475/target=_blank>CHEMBL1023475</a>";;-5.49;"Lowe JA, Hou X, Schmidt C, David Tingley F, McHardy S, Kalman M, Deninno S, Sanner M, Ward K, Lebel L, Tunucci D, Valentine J, Bronk BS, Schaeffer E.: The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg Med Chem Lett, Volume 19 (11), 2009";"MDCK";0.000003235936569296281
"MM474953";"MM474953";"C(=N/Nc1ncnc2c1cnn2-c1ccccc1)\c1ccncc1";"BYTNUXIIMYFFMP-UFFVCSGVSA-N";315.34;2.66;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-5;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.00001
"MM474954";"MM474954";"COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1";"RAOQCDVBADRLDK-AUEPDCJTSA-N";362.37;3.41;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-6.3;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.0000005011872336272725
"MM474955";"MM474955";"C(=N/Nc1ncnc2c1cnn2-c1cccc2[nH]cnc12)\c1ccncc1";"CJOZQFXWSCXETF-KTZMUZOWSA-N";355.37;2.53;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-4.67;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.000021379620895022323
"MM474956";"MM474956";"COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)O)cc4)ncnc32)c1";"FMUADIGMEFLZAN-AUEPDCJTSA-N";388.39;2.97;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-5.19;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.000006456542290346549
"MM474957";"MM474957";"O=C(O)c1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc3[nH]cnc23)cc1";"AKYXUYKRNRLTAG-ZNLRHDTNSA-N";398.39;2.84;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-5.77;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.000001698243652461746
"MM474958";"MM474958";"COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1";"WKJFLAJZSWRICW-FOKLQQMPSA-N";422.47;2.67;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-4.77;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.00001698243652461746
"MM474959";"MM474959";"Fc1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc3[nH]cnc23)cc1";"ZFIMJZNGNMRTHA-ZNLRHDTNSA-N";372.37;3.28;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-5.04;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.000009120108393559096
"MM474960";"MM474960";"CN(C)CCNC(=O)c1ccc(/C=N/Nc2ncnc3c2cnn3-c2ccccc2)cc1";"POXGYBNJJBFCDU-MZJWZYIUSA-N";428.5;2.55;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-5.01;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.000009772372209558111
"MM474961";"MM474961";"COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1";"PGJTVDLNKJZVEU-CCVNUDIWSA-N";458.53;2.56;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-5.82;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.0000015135612484362072
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL840609/target=_blank>CHEMBL840609</a>";;-4.78;"Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.: In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem, Volume 48 (3), 2005";"MDCK";0.000016595869074375598
"MM474962";"MM474962";"CS(=O)(=O)c1ccc(/C=N/Nc2ncnc3c2cnn3-c2cccc3[nH]cnc23)cc1";"BTEDJGZRXQWYSZ-YCPBAFNGSA-N";432.47;2.54;;;"MDCK";"EMDCK";"25";"0";"<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL713284/target=_blank>CHEMBL713284</a>";;-5.21;"Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.: Novel GSK-3 inhibitors with improved cellular activity. Bioorg Med Chem Lett, Volume 14 (9), 2004";"MDCK";0.000006165950018614822
"Salmeterol";"MM474773";"OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O";"GIIZNNXWQWCKIB-UHFFFAOYSA-N";415.57;4.11;;;"MDCK";"EMDCK";"25";"0";"MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1019686/target=_blank>CHEMBL1019686</a>";;-4.92;"Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Butchers PR, Coe DM, Conroy R, Edney DD, Field RN, Ford AJ, Guntrip SB, Looker BE, McLay IM, Monteith MJ, Morrison VS, Mutch PJ, Richards SA, Sasse R, Smith CE.: Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups. J Med Chem, Volume 52 (8), 2009";"MDCK";0.000012022644346174132
"MM475044";"MM475044";"C[C@@H](Oc1cccc2ncnc(Nc3ccc4c(cnn4Cc4nccs4)c3)c12)C(=O)N1CCOCC1";"RZPOCZHUFDCVQZ-QGZVFWFLSA-N";515.6;3.85;;;"MDCK";"EMDCK";"25";"0";"MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL929940/target=_blank>CHEMBL929940</a>";;-5;"Barlaam B, Acton DG, Ballard P, Bradbury RH, Cross D, Ducray R, Germain H, Hudson K, Klinowska T, Magnien F, Ogilvie DJ, Olivier A, Ross HS, Smith R, Trigwell CB, Vautier M, Wright L.: Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorg Med Chem Lett, Volume 18 (6), 2008";"MDCK";0.00001
"MM474774";"MM474774";"NS(=O)(=O)c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1";"GBTODAKMABNGIJ-VWLOTQADSA-N";494.65;2.75;;;"MDCK";"EMDCK";"25";"0";"MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL1019686/target=_blank>CHEMBL1019686</a>";;-6.35;"Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Butchers PR, Coe DM, Conroy R, Edney DD, Field RN, Ford AJ, Guntrip SB, Looker BE, McLay IM, Monteith MJ, Morrison VS, Mutch PJ, Richards SA, Sasse R, Smith CE.: Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups. J Med Chem, Volume 52 (8), 2009";"MDCK";0.0000004466835921509635
"MM475074";"MM475074";"CC(=O)Nc1cc(-c2cccc(N3CCN(C)CC3)n2)nc(-n2nc(C)cc2C)n1";"CQMWNSQCEMHNIW-UHFFFAOYSA-N";406.49;2.05;;;"MDCK";"EMDCK";"25";"0";"MDCK-MDR,<ahref=https://www.ebi.ac.uk/chembl/assay_report_card/CHEMBL953154/target=_blank>CHEMBL953154</a>";;-4.81;"Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O'Brien Z, Stotz CE, Crespo MI, DĂ­az JL, Slee DH.: Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease. J Med Chem, Volume 51 (22), 2008";"MDCK";0.000015488166189124828
"2-(Chloromethyl)benzoic Acid";"MM01496";"O=C(O)c1ccccc1CCl";"YTEUDCIEJDRJTM-UHFFFAOYSA-N";170.6;2.12;"296106";;"PL-A";"EPAMOL";"25";;;;-4.41;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.000038904514499428046
"3-Methylsalicylic Acid";"MM01497";"Cc1cccc(C(=O)O)c1O";"WHSXTWFYRGOBGO-UHFFFAOYSA-N";152.15;1.4;"6738";;"PL-A";"EPAMOL";"25";;;;-6.22;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0000006025595860743581
"2-Naphthoic Acid";"MM00601";"O=C(O)c1ccc2ccccc2c1";"UOBYKYZJUGYBDK-UHFFFAOYSA-N";172.18;2.54;"7123";"114648";"n-HEX";"EPAMOL";"25";;;;-3.67;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.00021379620895022324
"Benzoic Acid";"MM00630";"O=C(O)c1ccccc1";"WPYMKLBDIGXBTP-UHFFFAOYSA-N";122.12;1.38;"243";"CHEMBL541";"n-HEX";"EPAMOL";"25";;;;-4.52;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.000030199517204020192
"Carbamazepine";"MM00341";"NC(=O)N1c2ccccc2C=Cc2ccccc21";"FFGPTBGBLSHEPO-UHFFFAOYSA-N";236.27;3.39;"2554";"CHEMBL108";"n-HEX";"EPAMOL";"25";;;;-5.33;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.000004677351412871981
"Chlorpromazine";"MM00461";"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21";"ZPEIMTDSQAKGNT-UHFFFAOYSA-N";318.87;4.89;"2726";"CHEMBL71";"n-HEX";"EPAMOL";"25";;;;0.93;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";8.511380382023766
"Desipramine";"MM00474";"CNCCCN1c2ccccc2CCc2ccccc21";"HCYAFALTSJYZDH-UHFFFAOYSA-N";266.39;3.53;"2995";"CHEMBL72";"n-HEX";"EPAMOL";"25";;;;-1.01;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.09772372209558107
"Diclofenac";"MM00090";"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl";"DCOPUUMXTXDBNB-UHFFFAOYSA-N";296.15;4.36;"3033";"CHEMBL139";"n-HEX";"EPAMOL";"25";;;;-3;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.001
"Diltiazem";"MM00477";"COc1ccc(C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(C)=O)cc1";"HSUGRBWQSSZJOP-UHFFFAOYSA-N";414.53;3.37;"39186";"CHEMBL23";"n-HEX";"EPAMOL";"25";;;;-3.07;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0008511380382023768
"Diphenhydramine";"MM00478";"CN(C)CCOC(c1ccccc1)c1ccccc1";"ZZVUWRFHKOJYTH-UHFFFAOYSA-N";255.36;3.35;"3100";"CHEMBL657";"n-HEX";"EPAMOL";"25";;;;-0.61;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.24547089156850305
"Flumequine";"MM00646";"CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23";"DPSPPJIUMHPXMA-UHFFFAOYSA-N";261.25;2.35;"3374";"CHEMBL370252";"n-HEX";"EPAMOL";"25";;;;-5.41;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.000003890451449942805
"Flurbiprofen";"MM00647";"CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1";"SYTBZMRGLBWNTM-UHFFFAOYSA-N";244.27;3.68;"3394";"CHEMBL563";"n-HEX";"EPAMOL";"25";;;;-3.08;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0008317637711026709
"Haloperidol";"MM00499";"O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1";"LNEPOXFFQSENCJ-UHFFFAOYSA-N";375.87;4.43;"3559";"CHEMBL54";"n-HEX";"EPAMOL";"25";;;;-2.54;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0028840315031266055
"Ibuprofen";"MM00045";"CC(C)Cc1ccc(C(C)C(=O)O)cc1";"HEFNNWSXXWATRW-UHFFFAOYSA-N";206.29;3.07;"3672";"CHEMBL521";"n-HEX";"EPAMOL";"25";;;;-3.04;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0009120108393559096
"Imipramine";"MM00504";"CN(C)CCCN1c2ccccc2CCc2ccccc21";"BCGWQEUPMDMJNV-UHFFFAOYSA-N";280.42;3.88;"3696";"CHEMBL11";"n-HEX";"EPAMOL";"25";;;;0.31;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";2.041737944669529
"Indomethacin";"MM00656";"COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1";"CGIGDMFJXJATDK-UHFFFAOYSA-N";357.79;3.93;"3715";"CHEMBL6";"n-HEX";"EPAMOL";"25";;;;-3.52;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0003019951720402016
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"n-HEX";"EPAMOL";"25";;;;-4.32;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.000047863009232263804
"Lidocaine";"MM00092";"CCN(CC)CC(=O)Nc1c(C)cccc1C";"NNJVILVZKWQKPM-UHFFFAOYSA-N";234.34;2.58;"3676";"CHEMBL79";"n-HEX";"EPAMOL";"25";;;;-2.85;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.001412537544622754
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"n-HEX";"EPAMOL";"25";;;;-4.26;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.00005495408738576248
"Naproxen";"MM00672";"COc1ccc2cc(C(C)C(=O)O)ccc2c1";"CMWTZPSULFXXJA-UHFFFAOYSA-N";230.26;3.04;"156391";"CHEMBL154";"n-HEX";"EPAMOL";"25";;;;-3.41;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0003890451449942805
"Phenazopyridine";"MM00540";"Nc1ccc(N=Nc2ccccc2)c(N)n1";"QPFYXYFORQJZEC-UHFFFAOYSA-N";213.24;2.66;"4756";"CHEMBL1242";"n-HEX";"EPAMOL";"25";;;;-3.24;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0005754399373371566
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"n-HEX";"EPAMOL";"25";;;;-2.56;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.002754228703338166
"Quinine";"MM00559";"C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-WZBLMQSHSA-N";324.42;3.17;"3034034";"CHEMBL170";"n-HEX";"EPAMOL";"25";;;;-4.48;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.000033113112148259076
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"n-HEX";"EPAMOL";"25";;;;-4.52;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.000030199517204020192
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"n-HEX";"EPAMOL";"25";;;;-1.62;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.023988329190194897
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"n-HEX";"EPAMOL";"25";;;;-3.26;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0005495408738576248
"N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide";"MM00591";"Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1";"ZAFYATHCZYHLPB-UHFFFAOYSA-N";307.4;3.25;"5732";"CHEMBL911";"n-HEX";"EPAMOL";"25";;;;-4.08;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.00008317637711026709
"Amitriptyline";"MM00444";"CN(C)CCC=C1c2ccccc2CCc2ccccc21";"KRMDCWKBEZIMAB-UHFFFAOYSA-N";277.41;4.17;"2160";"CHEMBL629";"n-HEX";"EPAMOL";"25";;;;0.47;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";2.9512092266663856
"Griseofulvin";"MM00369";"COC1=CC(=O)CC(C)C12Oc1c(Cl)c(OC)cc(OC)c1C2=O";"DDUHZTYCFQRHIY-UHFFFAOYSA-N";352.77;2.81;"441140";"CHEMBL562";"n-HEX";"EPAMOL";"25";;;;-3.54;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.00028840315031266055
"Rhodamine B";"MM01359";"CCN(CC)c1ccc2c(-c3ccccc3C(=O)O)c3ccc(=[N+](CC)CC)cc-3oc2c1";"CVAVMIODJQHEEH-UHFFFAOYSA-O";443.57;5.56;;;"n-HEX";"EPAMOL";"25";;;;-4.23;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.00005888436553555884
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"LEC";"EPAMOL";"25";;;;-5.81;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0000015488166189124828
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"LEC";"EPAMOL";"25";;;;-4.45;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.000035481338923357534
"Amitriptyline";"MM00444";"CN(C)CCC=C1c2ccccc2CCc2ccccc21";"KRMDCWKBEZIMAB-UHFFFAOYSA-N";277.41;4.17;"2160";"CHEMBL629";"LEC";"EPAMOL";"25";;;;1.31;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";20.417379446695296
"Diphenhydramine";"MM00478";"CN(C)CCOC(c1ccccc1)c1ccccc1";"ZZVUWRFHKOJYTH-UHFFFAOYSA-N";255.36;3.35;"3100";"CHEMBL657";"LEC";"EPAMOL";"25";;;;-0.71;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.19498445997580455
"Griseofulvin";"MM00369";"COC1=CC(=O)CC(C)C12Oc1c(Cl)c(OC)cc(OC)c1C2=O";"DDUHZTYCFQRHIY-UHFFFAOYSA-N";352.77;2.81;"441140";"CHEMBL562";"LEC";"EPAMOL";"25";;;;-3.54;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.00028840315031266055
"Haloperidol";"MM00499";"O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1";"LNEPOXFFQSENCJ-UHFFFAOYSA-N";375.87;4.43;"3559";"CHEMBL54";"LEC";"EPAMOL";"25";;;;0.05;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";1.1220184543019633
"Lidocaine";"MM00092";"CCN(CC)CC(=O)Nc1c(C)cccc1C";"NNJVILVZKWQKPM-UHFFFAOYSA-N";234.34;2.58;"3676";"CHEMBL79";"LEC";"EPAMOL";"25";;;;-1.42;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.038018939632056124
"Rhodamine B";"MM01359";"CCN(CC)c1ccc2c(-c3ccccc3C(=O)O)c3ccc(=[N+](CC)CC)cc-3oc2c1";"CVAVMIODJQHEEH-UHFFFAOYSA-O";443.57;5.56;;;"LEC";"EPAMOL";"25";;;;-3.07;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0008511380382023768
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"LEC";"EPAMOL";"25";;;;-2.64;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0022908676527677724
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"LEC";"EPAMOL";"25";;;;-5.99;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0000010232929922807537
"N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide";"MM00591";"Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1";"ZAFYATHCZYHLPB-UHFFFAOYSA-N";307.4;3.25;"5732";"CHEMBL911";"LEC";"EPAMOL";"25";;;;-3.06;"Avdeef A.,  Tsinman O.: PAMPA - A drug absorption in vitro model: 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur. J. Pharm. Sci., 28, 43â€“50, 2006.";"PAMPA";0.0008709635899560805
"Acetaminophen";"MM00322";"CC(=O)Nc1ccc(O)cc1";"RZVAJINKPMORJF-UHFFFAOYSA-N";151.17;1.35;"1983";"CHEMBL112";"PL-A";"EPAMOL";"22";;;;-5.5;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.000003162277660168379
"Antipyrine";"MM00333";"Cc1cc(=O)n(-c2ccccc2)n1C";"VEQOALNAAJBPNY-UHFFFAOYSA-N";188.23;1.48;"2206";"CHEMBL277474";"PL-A";"EPAMOL";"22";;;;-5.09;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.000008128305161640995
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"PL-A";"EPAMOL";"22";;;;-2.43;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.003715352290971724
"Betamethasone";"MM00920";"CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO";"UREBDLICKHMUKA-UHFFFAOYSA-N";392.47;1.9;"9782";"CHEMBL632";"PL-A";"EPAMOL";"22";;;;-3.98;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.00010471285480508996
"Cefixime";"MM15167";"C=CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(=NOCC(=O)O)c3csc(N)n3)C2SC1";"OKBVVJOGVLARMR-UHFFFAOYSA-N";453.46;-0.54;;;"PL-A";"EPAMOL";"22";;;;-0.71;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.19498445997580455
"Cephalothin";"MM01541";"CC(=O)OCC1=C(C(=O)O)N2C(=O)C(NC(=O)Cc3cccs3)C2SC1";"XIURVHNZVLADCM-UHFFFAOYSA-N";396.45;0.59;;;"PL-A";"EPAMOL";"22";;;;-1.52;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.03019951720402016
"Cetirizine";"MM00724";"O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1";"ZKLPARSLTMPFCP-UHFFFAOYSA-N";388.9;3.15;"2678";;"PL-A";"EPAMOL";"22";;;;-4.12;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.00007585775750291836
"Chlorpheniramine";"MM00460";"CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1";"SOYKEARSMXGVTM-UHFFFAOYSA-N";274.8;3.82;"2725";"CHEMBL505";"PL-A";"EPAMOL";"22";;;;-0.94;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.1148153621496883
"Chlorthalidone";"MM00343";"NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl";"JIVPVXMEBJLZRO-UHFFFAOYSA-N";338.77;0.92;"2732";"CHEMBL1055";"PL-A";"EPAMOL";"22";;;;-4.7;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.000019952623149688786
"Colchicine";"MM00345";"COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2";"IAKHMKGGTNLKSZ-UHFFFAOYSA-N";399.44;2.87;"6167";"CHEMBL87";"PL-A";"EPAMOL";"22";;;;-5.48;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.0000033113112148259077
"Diclofenac";"MM00090";"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl";"DCOPUUMXTXDBNB-UHFFFAOYSA-N";296.15;4.36;"3033";"CHEMBL139";"PL-A";"EPAMOL";"22";;;;-0.9;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.12589254117941673
"Eprosartan";"MM15168";"CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1";"OROAFUQRIXKEMV-UHFFFAOYSA-N";424.52;4.74;;;"PL-A";"EPAMOL";"22";;;;-3.73;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.00018620871366628676
"Fexofenadine";"MM00735";"CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1";"RWTNPBWLLIMQHL-UHFFFAOYSA-N";501.67;5.51;"3348";"CHEMBL914";"PL-A";"EPAMOL";"22";;;;-4.6;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.000025118864315095822
"Gatifloxacin";"MM00738";"COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12";"XUBOMFCQGDBHNK-UHFFFAOYSA-N";375.4;1.98;"5379";"CHEMBL31";"PL-A";"EPAMOL";"22";;;;-5.23;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.000005888436553555884
"Midazolam";"MM00519";"Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2";"DDLIGBOFAVUZHB-UHFFFAOYSA-N";325.77;4.32;"4192";"CHEMBL655";"PL-A";"EPAMOL";"22";;;;3.03;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";1071.519305237606
"Nafcillin";"MM12938";"CCOc1ccc2ccccc2c1C(=O)NC1C(=O)N2C1SC(C)(C)C2C(=O)O";"GPXLMGHLHQJAGZ-UHFFFAOYSA-N";414.48;2.48;;;"PL-A";"EPAMOL";"22";;;;-1;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.1
"Naproxen";"MM00672";"COc1ccc2cc(C(C)C(=O)O)ccc2c1";"CMWTZPSULFXXJA-UHFFFAOYSA-N";230.26;3.04;"156391";"CHEMBL154";"PL-A";"EPAMOL";"22";;;;-1.69;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.020417379446695295
"Norfloxacin";"MM00768";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21";"OGJPXUAPXNRGGI-UHFFFAOYSA-N";319.34;1.27;"4539";"CHEMBL9";"PL-A";"EPAMOL";"22";;;;-5.24;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.000005754399373371567
"Oxybutynin";"MM15170";"CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1";"XIQVNETUBQGFHX-UHFFFAOYSA-N";357.49;3.34;;;"PL-A";"EPAMOL";"22";;;;-2.43;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.003715352290971724
"Pindolol";"MM00542";"CC(C)NCC(O)COc1cccc2[nH]ccc12";"JZQKKSLKJUAGIC-UHFFFAOYSA-N";248.33;1.91;"4828";"CHEMBL500";"PL-A";"EPAMOL";"22";;;;-1.98;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.010471285480508996
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"PL-A";"EPAMOL";"22";;;;-0.21;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.6165950018614822
"Pyridoxine";"MM00555";"Cc1ncc(CO)c(CO)c1O";"LXNHXLLTXMVWPM-UHFFFAOYSA-N";169.18;0.08;"1054";"CHEMBL1364";"PL-A";"EPAMOL";"22";;;;-5.1;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.000007943282347242822
"Quinine";"MM00559";"C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12";"LOUPRKONTZGTKE-WZBLMQSHSA-N";324.42;3.17;"3034034";"CHEMBL170";"PL-A";"EPAMOL";"22";;;;-1.55;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.028183829312644536
"Risperidone";"MM00561";"Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2";"RAPZEAPATHNIPO-UHFFFAOYSA-N";410.49;3.59;"5073";"CHEMBL85";"PL-A";"EPAMOL";"22";;;;-2.19;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.006456542290346556
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"PL-A";"EPAMOL";"22";;;;-0.66;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.21877616239495523
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"PL-A";"EPAMOL";"22";;;;-5.76;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.0000017378008287493763
"Tolbutamide";"MM00708";"CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1";"JLRGJRBPOGGCBT-UHFFFAOYSA-N";270.35;1.78;"5505";"CHEMBL782";"PL-A";"EPAMOL";"22";;;;-2.71;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.0019498445997580456
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"PL-A";"EPAMOL";"22";;;;-0.89;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.1288249551693134
"Warfarin";"MM00095";"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O";"PJVWKTKQMONHTI-UHFFFAOYSA-N";308.33;3.61;"54678486";"CHEMBL1464";"PL-A";"EPAMOL";"22";;;;-2.21;"VelickĂ˝ M, Tam KY, Dryfe RA.: In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans. Eur J Pharm Sci, Volume 44 (3), 299-309, 2011";"PAMPA";0.006165950018614822
"9-hyroxyethoxymethylguanine";"MM00074";"Nc1nc(=O)c2ncn(COCCO)c2[nH]1";"MKUXAQIIEYXACX-UHFFFAOYSA-N";225.21;-1.33;"2022";"CHEMBL184";"PL-A";"EPAM";"25";;;;-6.08;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.0000008317637711026709
"Atenolol";"MM00078";"CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1";"METKIMKYRPQLGS-GFCCVEGCSA-N";266.34;0.45;"2249";"CHEMBL24";"PL-A";"EPAM";"25";;;;-5.62;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.0000023988329190194897
"N,N-diethyl-4-methylpiperazine-1-carboxamide";"MM00854";"CCN(CC)C(=O)N1CCN(C)CC1";"RCKMWOKWVGPNJF-UHFFFAOYSA-N";199.3;0.7;"3052";"CHEMBL684";"PL-A";"EPAM";"25";;;;-4.56;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.00002754228703338169
"Chlorpheniramine";"MM00460";"CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1";"SOYKEARSMXGVTM-UHFFFAOYSA-N";274.8;3.82;"2725";"CHEMBL505";"PL-A";"EPAM";"25";;;;-5.07;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.00000851138038202376
"Coumarin";"MM00042";"O=c1ccc2ccccc2o1";"ZYGHJZDHTFUPRJ-UHFFFAOYSA-N";146.15;1.79;"323";"CHEMBL6466";"PL-A";"EPAM";"25";;;;-4.32;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.000047863009232263804
"4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide";"MM00480";"CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C";"UVTNFZQICZKOEM-UHFFFAOYSA-N";339.48;3.36;"3114";"CHEMBL517";"PL-A";"EPAM";"25";;;;-5.57;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.0000026915348039269138
"Furosemide";"MM00083";"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl";"ZZUFCTLCJUWOSV-UHFFFAOYSA-N";330.75;1.89;"3440";"CHEMBL35";"PL-A";"EPAM";"25";;;;-6.24;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.0000005754399373371567
"Indomethacin";"MM00656";"COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1";"CGIGDMFJXJATDK-UHFFFAOYSA-N";357.79;3.93;"3715";"CHEMBL6";"PL-A";"EPAM";"25";;;;-4.91;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.00001230268770812381
"Ketoprofen";"MM00662";"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1";"DKYWVDODHFEZIM-UHFFFAOYSA-N";254.29;3.11;"3825";"CHEMBL571";"PL-A";"EPAM";"25";;;;-4.9;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.000012589254117941661
"D-mannitol";"MM00386";"OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO";"FBPFZTCFMRRESA-KVTDHHQDSA-N";182.17;-3.59;"6251";"CHEMBL689";"PL-A";"EPAM";"25";;;;-7.74;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.000000018197008586099826
"Metoprolol";"MM00275";"COCCc1ccc(OCC(O)CNC(C)C)cc1";"IUBSYMUCCVWXPE-UHFFFAOYSA-N";267.37;1.61;"4171";"CHEMBL13";"PL-A";"EPAM";"25";;;;-5.82;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.0000015135612484362072
"Naproxen";"MM00672";"COc1ccc2cc(C(C)C(=O)O)ccc2c1";"CMWTZPSULFXXJA-UHFFFAOYSA-N";230.26;3.04;"156391";"CHEMBL154";"PL-A";"EPAM";"25";;;;-4.38;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.00004168693834703355
"Propranolol";"MM00085";"CC(C)NCC(O)COc1cccc2ccccc12";"AQHHHDLHHXJYJD-UHFFFAOYSA-N";259.35;2.58;"4946";"CHEMBL27";"PL-A";"EPAM";"25";;;;-5.37;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.000004265795188015926
"Ranitidine";"MM01053";"CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1";"VMXUWOKSQNHOCA-UHFFFAOYSA-N";314.41;1.46;"5039";;"PL-A";"EPAM";"25";;;;-6.17;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.0000006760829753919819
"Theophylline";"MM00048";"Cn1c(=O)c2nc[nH]c2n(C)c1=O";"ZFXYFBGIUFBOJW-UHFFFAOYSA-N";180.17;-1.04;"2153";"CHEMBL190";"PL-A";"EPAM";"25";;;;-5.07;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.00000851138038202376
"Verapamil";"MM00585";"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC";"SGTNSNPWRIOYBX-UHFFFAOYSA-N";454.61;5.09;"2520";"CHEMBL6966";"PL-A";"EPAM";"25";;;;-5.03;"Teksin ZS, Seo PR, Polli JE.: Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J, Volume 12 (2), 238-241, 2010";"PAMPA";0.000009332543007969906
"Norfloxacin";"MM00768";"CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21";"OGJPXUAPXNRGGI-UHFFFAOYSA-N";319.34;1.27;"4539";"CHEMBL9";"EggPC";"EPAM";"25";;;;-6.15;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., GonzĂˇlez I., FernĂˇndez C., SĂˇnchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429â€“441, 2004.";"PAMPA";0.0000007079457843841374
"CNV97100";"MM00727";"CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CCN1.O=C(O)C(F)(F)F";"URJUNYOPXJPQGS-UHFFFAOYSA-N";459.4;2.61;"46781144";;"EggPC";"EPAM";"25";;;;-5.42;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., GonzĂˇlez I., FernĂˇndez C., SĂˇnchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429â€“441, 2004.";"PAMPA";0.000003801893963205613
"1-cyclopropyl-7-(4-ethyl-3-methylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid";"MM00728";"CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C";"POMKZSJIYNWBRP-UHFFFAOYSA-N";373.43;2.7;"10109876";;"EggPC";"EPAM";"25";;;;-4.29;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., GonzĂˇlez I., FernĂˇndez C., SĂˇnchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429â€“441, 2004.";"PAMPA";0.00005128613839913648
"CNV97103";"MM00729";"CCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C";"WPGHZQMHNTXSAF-UHFFFAOYSA-N";387.46;3.09;"13326823";;"EggPC";"EPAM";"25";;;;-3.8;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., GonzĂˇlez I., FernĂˇndez C., SĂˇnchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429â€“441, 2004.";"PAMPA";0.00015848931924611142
"7-(4-butyl-3-methylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid";"MM00730";"CCCCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1C";"QPVCGSGGZMAACV-UHFFFAOYSA-N";401.48;3.48;"13385166";;"EggPC";"EPAM";"25";;;;-3.38;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., GonzĂˇlez I., FernĂˇndez C., SĂˇnchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429â€“441, 2004.";"PAMPA";0.0004168693834703355
"6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid";"MM00771";"O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O";"XBHBWNFJWIASRO-UHFFFAOYSA-N";385.37;2.38;"56208";"CHEMBL37858";"EggPC";"EPAM";"25";;;;-4.85;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., GonzĂˇlez I., FernĂˇndez C., SĂˇnchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429â€“441, 2004.";"PAMPA";0.000014125375446227555
"Sparfloxacin";"MM00772";"CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)CC(C)N1";"DZZWHBIBMUVIIW-UHFFFAOYSA-N";392.41;2.08;"60464";"CHEMBL850";"EggPC";"EPAM";"25";;;;-4.04;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., GonzĂˇlez I., FernĂˇndez C., SĂˇnchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429â€“441, 2004.";"PAMPA";0.00009120108393559096
"Flumequine";"MM00646";"CC1CCc2cc(F)cc3c(=O)c(C(=O)O)cn1c23";"DPSPPJIUMHPXMA-UHFFFAOYSA-N";261.25;2.35;"3374";"CHEMBL370252";"EggPC";"EPAM";"25";;;;-3.84;"Bermejo M., Avdeef A., Ruiz A., Nalda R., Ruell J.A., Tsinman O., GonzĂˇlez I., FernĂˇndez C., SĂˇnchez G., Garrigues T.M, Merino V.: PAMPA - A drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429â€“441, 2004.";"PAMPA";0.0001445439770745928
"Ammonia";"MM00445";"N";"QGZKDVFQNNGYKY-UHFFFAOYSA-N";17.03;0.16;"222";;"SoyPC";"EBLM";"25";;;;-1.86;"Antonenko YN, Pohl P, Denisov GA.: Permeation of ammonia across bilayer lipid membranes studied by ammonium ion selective microelectrodes. Biophys J, Volume 72 (5), 1997";"BLM";0.013803842646028845
"2-Naphthoic Acid";"MM00601";"O=C(O)c1ccc2ccccc2c1";"UOBYKYZJUGYBDK-UHFFFAOYSA-N";172.18;2.54;"7123";"114648";"EggPC";"EBLM";"25";;;;1.23;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";16.982436524617444
"9-Anthroic Acid";"MM00612";"O=C(O)c1c2ccccc2cc2ccccc12";"XGWFJBFNAQHLEF-UHFFFAOYSA-N";222.24;3.69;"2201";;"EggPC";"EBLM";"25";;;;0.51;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";3.2359365692962827
"Hydrochloric Acid";"MM00654";"Cl";"VEXZGXHMUGYJMC-UHFFFAOYSA-N";36.46;0.42;"313";;"EggPC";"EBLM";"25";;;;0.46;"https://doi.org/10.1007/BF01870145";"BLM";2.884031503126606
"Thiocyanic Acid";"MM00692";"N#CS";"ZMZDMBWJUHKJPS-UHFFFAOYSA-N";59.09;0.4;"781";;"EggPC";"EBLM";"25";;;;0.41;"https://doi.org/10.1007/BF01870135";"BLM";2.5703957827688635
"1-Naphthoic Acid";"MM00592";"O=C(O)c1cccc2ccccc12";"LNETULKMXZVUST-UHFFFAOYSA-N";172.18;2.54;"6847";;"EggPC";"EBLM";"25";;;;0.36;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";2.290867652767773
"Caproic Acid";"MM00636";"CCCCCC(=O)O";"FUZZWVXGSFPDMH-UHFFFAOYSA-N";116.16;1.65;"8892";;"EggPC";"EBLM";"25";;;;0.04;"https://doi.org/10.1007/BF01870137";"BLM";1.096478196143185
"4-Methylbenzoic Acid";"MM00610";"Cc1ccc(C(=O)O)cc1";"LPNBBFKOUUSUDB-UHFFFAOYSA-N";136.15;1.69;"7470";;"EggPC";"EBLM";"25";;;;0.04;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";1.096478196143185
"2-Deoxyadenosine";"MM00320";"Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1";"OLXZPDWKRNYJJZ-RRKCRQDMSA-N";251.25;-0.95;"13730";;"EggPC";"EBLM";"25";;;;-6.03;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.0000009332543007969905
"Urea";"MM00065";"NC(N)=O";"XSQUKJJJFZCRTK-UHFFFAOYSA-N";60.06;-0.98;"1176";"CHEMBL985";"EggPC";"EBLM";"25";;;;-5.4;"https://doi.org/10.1007/BF01870136";"BLM";0.000003981071705534969
"Glycerol";"MM00067";"OCC(O)CO";"PEDCQBHIVMGVHV-UHFFFAOYSA-N";92.09;-1.67;"753";"CHEMBL692";"EggPC";"EBLM";"25";;;;-5.27;"https://doi.org/10.1007/BF01870130";"BLM";0.000005370317963702533
"Adenine";"MM00324";"Nc1ncnc2nc[nH]c12";"GFFGJBXGBJISGV-UHFFFAOYSA-N";135.13;-0.06;"190";"CHEMBL226345";"EggPC";"EBLM";"25";;;;-4.86;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.000013803842646028839
"Alpha-Carbamoyl-p-Toluic Acid";"MM01303";"NC(=O)Cc1ccc(C(=O)O)cc1";"YMKXCDDRWMQOBA-UHFFFAOYSA-N";179.18;0.41;"23273690";;"EggPC";"EBLM";"25";;;;-4.39;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.0000407380277804113
"2,3-Dideoxyadenosine";"MM00318";"Nc1ncnc2c1ncn2[C@H]1CC[C@@H](CO)O1";"WVXRAFOPTSTNLL-NKWVEPMBSA-N";235.25;0.08;"20039";;"EggPC";"EBLM";"25";;;;-4.2;"https://doi.org/10.1007/BF01870128";"BLM";0.00006309573444801929
"Ethylene glycol";"MM00360";"OCCO";"LYCAIKOWRPUZTN-UHFFFAOYSA-N";62.07;-1.03;"174";;"EggPC";"EBLM";"25";;;;-4.06;"https://doi.org/10.1007/BF01870146";"BLM";0.00008709635899560814
"2-Hydroxybutyric Acid";"MM00597";"CC[C@H](O)C(=O)O";"AFENDNXGAFYKQO-VKHMYHEASA-N";104.11;-0.16;"11266";;"EggPC";"EBLM";"25";;;;-3.91;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0001230268770812381
"Prednisolone";"MM00297";"CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"OIGNJSKKLXVSLS-UHFFFAOYSA-N";360.45;1.56;"5755";"CHEMBL131";"EggPC";"EBLM";"25";;;;-3.82;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.00015135612484362088
"Alpha-Carboxy-p-Toluic Acid";"MM00618";"O=C(O)Cc1ccc(C(=O)O)cc1";"DMEDOWYXHVUPMO-UHFFFAOYSA-N";180.16;1.01;"220005";;"EggPC";"EBLM";"25";;;;-3.74;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.00018197008586099826
"2-Hydroxycaproic Acid";"MM00598";"CCCC[C@H](O)C(=O)O";"NYHNVHGFPZAZGA-YFKPBYRVSA-N";132.16;0.62;"99824";;"EggPC";"EBLM";"25";;;;-3.67;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.00021379620895022324
"Pivalic Acid";"MM00683";"CC(C)(C)C(=O)O";"IUGYQRQAERSCNH-UHFFFAOYSA-N";102.13;1.12;"6417";;"EggPC";"EBLM";"25";;;;-3.62;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.000239883291901949
"Vanillic Acid";"MM00712";"COc1cc(C(=O)O)ccc1O";"WKOLLVMJNQIZCI-UHFFFAOYSA-N";168.15;1.1;"8468";"CHEMBL120568";"EggPC";"EBLM";"25";;;;-3.58;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.00026302679918953814
"1,4-Butanediol";"MM00314";"OCCCCO";"WERYXYBDKMZEQL-UHFFFAOYSA-N";90.12;-0.25;"8064";"CHEMBL171623";"EggPC";"EBLM";"25";;;;-3.57;"https://doi.org/10.1007/BF01870127";"BLM";0.00026915348039269167
"Propylene Glycol";"MM00414";"CC(O)CO";"DNIAPMSPPWPWGF-UHFFFAOYSA-N";76.1;-0.64;"1030";"CHEMBL286398";"EggPC";"EBLM";"25";;;;-3.55;"https://doi.org/10.1007/BF01870133";"BLM";0.0002818382931264455
"Acetamide";"MM00321";"CC(N)=O";"DLFVBJFMPXGRIB-UHFFFAOYSA-N";59.07;-0.51;"178";"CHEMBL16081";"EggPC";"EBLM";"25";;;;-3.54;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.00028840315031266055
"2-Hydroxyvaleric Acid";"MM00600";"CCC[C@H](O)C(=O)O";"JRHWHSJDIILJAT-BYPYZUCNSA-N";118.13;0.23;"98009";;"EggPC";"EBLM";"25";;;;-3.53;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0002951209226666387
"Hydrofluoric Acid";"MM00655";"F";"KRHYYFGTRYWZRS-UHFFFAOYSA-N";20.01;0.15;"14917";"CHEMBL1232767";"EggPC";"EBLM";"25";;;;-3.51;"https://doi.org/10.1007/BF01870144";"BLM";0.0003090295432513592
"2,4-Dihydroxybenzoic Acid";"MM00595";"O=C(O)c1ccc(O)cc1O";"UIAFKZKHHVMJGS-UHFFFAOYSA-N";154.12;0.8;"1491";"CHEMBL328910";"EggPC";"EBLM";"25";;;;-3.33;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.00046773514128719813
"Hydrocortisone";"MM00044";"CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO";"JYGXADMDTFJGBT-UHFFFAOYSA-N";362.47;1.78;"5754";"CHEMBL389621";"EggPC";"EBLM";"25";;;;-3.25;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.0005623413251903491
"Phenylacetic Acid";"MM00679";"O=C(O)Cc1ccccc1";"WLJVXDMOQOGPHL-UHFFFAOYSA-N";136.15;1.31;"999";"CHEMBL1044";"EggPC";"EBLM";"25";;;;-3.09;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0008128305161640995
"4-Hydroxybenzoic Acid";"MM00609";"O=C(O)c1ccc(O)cc1";"FJKROLUGYXJWQN-UHFFFAOYSA-N";138.12;1.09;"135";"CHEMBL441343";"EggPC";"EBLM";"25";;;;-3.08;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0008317637711026709
"Nitric Acid";"MM00675";"O=[N+]([O-])O";"GRYLNZFGIOXLOG-UHFFFAOYSA-N";63.01;-0.35;"944";;"EggPC";"EBLM";"25";;;;-3.04;"https://doi.org/10.1007/BF01870143";"BLM";0.0009120108393559096
"Isobutyric Acid";"MM00658";"CC(C)C(=O)O";"KQNPFQTWMSNSAP-UHFFFAOYSA-N";88.11;0.73;"6590";"CHEMBL108778";"EggPC";"EBLM";"25";;;;-3.03;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0009332543007969915
"Iodoacetic Acid";"MM00657";"O=C(O)CI";"JDNTWHVOXJZDSN-UHFFFAOYSA-N";185.95;0.51;"5240";;"EggPC";"EBLM";"25";;;;-2.96;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0010964781961431851
"Chloroacetic Acid";"MM00032";"O=C(O)CCl";"FOCAUTSVDIKZOP-UHFFFAOYSA-N";94.5;0.31;"300";;"EggPC";"EBLM";"25";;;;-2.94;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0011481536214968829
"Bromoacetic Acid";"MM00633";"O=C(O)CBr";"KDPAWGWELVVRCH-UHFFFAOYSA-N";138.95;0.47;"6227";"CHEMBL60851";"EggPC";"EBLM";"25";;;;-2.91;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0012302687708123812
"Isovaleric Acid";"MM00659";"CC(C)CC(=O)O";"GWYFCOCPABKNJV-UHFFFAOYSA-N";102.13;1.12;"10430";"CHEMBL568737";"EggPC";"EBLM";"25";;;;-2.88;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0013182567385564075
"Tiglic Acid";"MM00694";"C/C=C(\C)C(=O)O";"UIERETOOQGIECD-ONEGZZNKSA-N";100.12;1.04;"125468";;"EggPC";"EBLM";"25";;;;-2.87;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.0013489628825916532
"Alpha-Hydroxy-p-Toluic Acid";"MM00624";"O=C(O)c1ccc(CO)cc1";"WWYFPDXEIFBNKE-UHFFFAOYSA-N";152.15;0.88;"76360";;"EggPC";"EBLM";"25";;;;-2.8;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.001584893192461114
"Water";"MM00431";"O";"XLYOFNOQVPJJNP-UHFFFAOYSA-N";18.02;-0.82;"962";"CHEMBL1098659";"EggPC";"EBLM";"25";;;;-2.72;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.0019054607179632462
"Formic Acid";"MM00649";"O=CO";"BDAGIHXWWSANSR-UHFFFAOYSA-N";46.03;-0.3;"284";"CHEMBL116736";"EggPC";"EBLM";"25";;;;-2.54;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.0028840315031266055
"Water";"MM00431";"O";"XLYOFNOQVPJJNP-UHFFFAOYSA-N";18.02;-0.82;"962";"CHEMBL1098659";"EggPC";"EBLM";"25";;;;-2.47;"https://doi.org/10.1007/BF01870138";"BLM";0.003388441561392024
"Acetic Acid";"MM00613";"CC(=O)O";"QTBSBXVTEAMEQO-UHFFFAOYSA-N";60.05;0.09;"176";"CHEMBL539";"EggPC";"EBLM";"25";;;;-2.3;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.005011872336272725
"Alpha-Cyano-p-Toluic Acid";"MM00622";"N#CCc1ccc(C(=O)O)cc1";"RSGBXCFAYHOKQZ-UHFFFAOYSA-N";161.16;1.45;"270871";;"EggPC";"EBLM";"25";;;;-1.57;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.026915348039269153
"Propionic Acid";"MM00685";"CCC(=O)O";"XBDQKXXYIPTUBI-UHFFFAOYSA-N";74.08;0.48;"1032";"CHEMBL14021";"EggPC";"EBLM";"25";;;;-1.46;"https://doi.org/10.1007/BF01870132";"BLM";0.034673685045253165
"Butyric Acid";"MM00634";"CCCC(=O)O";"FERIUCNNQQJTOY-UHFFFAOYSA-N";88.11;0.87;"264";"CHEMBL14227";"EggPC";"EBLM";"25";;;;-1.02;"https://doi.org/10.1007/BF01870140";"BLM";0.09549925860214359
"Ethanamine";"MM00491";"CCN";"QUSNBJAOOMFDIB-UHFFFAOYSA-N";45.09;-0.04;"6341";;"EggPC";"EBLM";"25";;;;-0.92;"https://doi.org/10.1007/BF01870142";"BLM";0.12022644346174129
"Ammonia";"MM00445";"N";"QGZKDVFQNNGYKY-UHFFFAOYSA-N";17.03;0.16;"222";;"EggPC";"EBLM";"25";;;;-0.89;"https://doi.org/10.1007/BF01870139";"BLM";0.1288249551693134
"Codeine";"MM00470";"COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314";"OROGSEYTTFOCAN-DNJOTXNNSA-N";299.37;1.5;"5284371";"CHEMBL485";"EggPC";"EBLM";"25";;;;-0.85;"https://doi.org/10.1007/BF01870141";"BLM";0.14125375446227545
"Acetylsalicylic Acid";"MM00080";"CC(=O)Oc1ccccc1C(=O)O";"BSYNRYMUTXBXSQ-UHFFFAOYSA-N";180.16;1.31;"2244";"CHEMBL25";"EggPC";"EBLM";"25";;;;-0.82;"Wolosin JM, Ginsburg H.: The permeation of organic acids through lecithin bilayers. Resemblance to diffusion in polymers. Biochim Biophys Acta, Volume 389 (1), 1975";"BLM";0.15135612484362082
"Alpha-Methoxy-p-Toluic Acid";"MM00626";"COCc1ccc(C(=O)O)cc1";"OORFINRYBCDBEN-UHFFFAOYSA-N";166.18;1.53;"308473";;"EggPC";"EBLM";"25";;;;-0.46;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.3467368504525316
"Benzoic Acid";"MM00630";"O=C(O)c1ccccc1";"WPYMKLBDIGXBTP-UHFFFAOYSA-N";122.12;1.38;"243";"CHEMBL541";"EggPC";"EBLM";"25";;;;-0.24;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.5754399373371569
"Alpha-Chloro-p-Toluic Acid";"MM00620";"O=C(O)c1ccc(CCl)cc1";"OITNBJHJJGMFBN-UHFFFAOYSA-N";170.6;2.12;"74234";;"EggPC";"EBLM";"25";;;;-0.19;"Xiang TX, Anderson BD.: The relationship between permeant size and permeability in lipid bilayer membranes. J Membr Biol, Volume 140 (2), 1994";"BLM";0.6456542290346555
"Salicylic Acid";"MM00093";"O=C(O)c1ccccc1O";"YGSDEFSMJLZEOE-UHFFFAOYSA-N";138.12;1.09;"338";"CHEMBL424";"EggPC";"EBLM";"25";;;;-0.11;"https://doi.org/10.1007/BF01870134";"BLM";0.7762471166286917
"Formamide";"MM00365";"NC=O";"ZHNUHDYFZUAESO-UHFFFAOYSA-N";45.04;-0.9;"713";;"EggPC";"EBLM";"25";;;;-4;"https://doi.org/10.1007/BF01870129";"BLM";0.0001
"4-carboxymethylphenyl Acetyl_NHMe";"MM01305";"CNC(=O)Cc1ccc(C(=O)O)cc1";"YPRZYKHZGFQSPK-UHFFFAOYSA-N";193.2;0.67;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-4.47;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000033884415613920276
"4-carboxymethylphenyl Acetyl-Gly-NMe2";"MM01304";"CN(C)C(=O)CNC(=O)Cc1ccc(C(=O)O)cc1";"GDAMBRWKLGWCQC-UHFFFAOYSA-N";264.28;0.13;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-5.8;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000001584893192461114
"4-Methylphenylacetic Acid";"MM00611";"Cc1ccc(CC(=O)O)cc1";"GXXXUZIRGXYDFP-UHFFFAOYSA-N";150.18;1.62;"248474";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-0.15;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.7079457843841379
"Alpha-Carbamoyl-methylhippuric Acid";"MM00615";"Cc1ccc(C(=O)NC(C(N)=O)C(=O)O)cc1";"XJHVEOWGYHOARJ-UHFFFAOYSA-N";236.23;-0.34;"54472514";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-8;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.00000001
"Alpha-Carboxy-p-methylhippuric Acid";"MM00617";"Cc1ccc(C(=O)NC(C(=O)O)C(=O)O)cc1";"UMFHYXBPSFCHSI-UHFFFAOYSA-N";237.21;0.26;"17851005";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-6.77;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.00000016982436524617461
"Alpha-Cyano-p-methylhippuric Acid";"MM00621";"Cc1ccc(C(=O)NC(C#N)C(=O)O)cc1";"ALQYGLQIKVIMRP-UHFFFAOYSA-N";218.21;0.7;"129821670";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-5.04;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000009120108393559096
"Alpha-Hydroxy-p-methylhippuric Acid";"MM00623";"Cc1ccc(C(=O)NC(O)C(=O)O)cc1";"AANXJMXSRIEOHT-UHFFFAOYSA-N";209.2;0.13;"129821665";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-6.26;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0000005495408738576248
"Alpha-Chloro-p-methylhippuric Acid";"MM00619";"Cc1ccc(C(=O)NC(Cl)C(=O)O)cc1";"JYSJDCPCSAHBNY-UHFFFAOYSA-N";227.65;1.37;"129821671";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-3.46;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0003467368504525317
"Alpha-Methoxy-p-methylhippuric Acid";"MM00625";"COC(NC(=O)c1ccc(C)cc1)C(=O)O";"KROOMEMGIODUJA-UHFFFAOYSA-N";223.23;0.78;"129821666";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-4;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0001
"Tol-Ala";"MM00695";"Cc1ccc(C(=O)N[C@@H](C)C(=O)O)cc1";"LUQFCOKRPYVJGV-QMMMGPOBSA-N";207.23;1.2;"702949";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-2.64;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0022908676527677724
"Tol-Ala-Ala";"MM00696";"Cc1ccc(C(=O)N[C@@H](C)C(=O)NC(C)C(=O)O)cc1";"FBAZKLTYPHRTPD-RGURZIINSA-N";278.31;0.7;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-4.96;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000010964781961431852
"Tol-Ala-Ala-Ala";"MM00697";"Cc1ccc(C(=O)N[C@@H](C)C(=O)NC(C)C(=O)NC(C)C(=O)O)cc1";"AWXUDMFMJWEFLI-CXQJBGSLSA-N";349.39;0.21;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-7.02;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.00000009549925860214369
"Tol-Gly";"MM00698";"Cc1ccc(C(=O)NCC(=O)O)cc1";"NRSCPTLHWVWLLH-UHFFFAOYSA-N";193.2;0.81;"97479";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-3.19;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0006456542290346556
"Tol-Gly-Gly";"MM00699";"Cc1ccc(C(=O)NCC(=O)NCC(=O)O)cc1";"GFMIXHRADKOCKD-UHFFFAOYSA-N";250.25;-0.07;"1612474";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-6.38;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0000004168693834703355
"Tol-Gly-Gly-Gly";"MM00700";"Cc1ccc(C(=O)NCC(=O)NCC(=O)NCC(=O)O)cc1";"OQIOHQJDADAQRO-UHFFFAOYSA-N";307.31;-0.96;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-8.77;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000000001698243652461746
"Tol-Gly-Gly-Sar";"MM00701";"Cc1ccc(C(=O)NCC(=O)NCC(=O)N(C)CC(=O)O)cc1";"GPOXNQMQXBXEJG-UHFFFAOYSA-N";321.33;-0.62;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-7.31;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000000048977881936844667
"Tol-Gly-Sar";"MM00702";"Cc1ccc(C(=O)NCC(=O)N(C)CC(=O)O)cc1";"LKGQGAPFEYAOCE-UHFFFAOYSA-N";264.28;0.27;"43356167";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-4.72;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000019054607179632484
"Tol-Gly-Sar-Gly";"MM00703";"Cc1ccc(C(=O)NCC(=O)N(C)CC(=O)NCC(=O)O)cc1";"VDLFQRLCHVTMPD-UHFFFAOYSA-N";321.33;-0.62;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-7.32;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0000000478630092322638
"Tol-Sar";"MM00704";"Cc1ccc(C(=O)N(C)CC(=O)O)cc1";"WKEPQHRTXMIHLM-UHFFFAOYSA-N";207.23;1.15;"16777360";;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-2.82;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0015135612484362087
"Tol-Sar-Gly";"MM00705";"Cc1ccc(C(=O)N(C)CC(=O)NCC(=O)O)cc1";"JDZZMSKJRWYDMH-UHFFFAOYSA-N";264.28;0.27;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-5.49;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000003235936569296281
"Tol-Sar-Gly-Gly";"MM00706";"Cc1ccc(C(=O)N(C)CC(=O)NCC(=O)NCC(=O)O)cc1";"GQINUZIFINBVAM-UHFFFAOYSA-N";321.33;-0.62;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-7.85;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.000000014125375446227554
"Tol-Sar-Sar-Gly";"MM00707";"Cc1ccc(C(=O)N(C)CC(=O)N(C)CC(=O)NCC(=O)O)cc1";"GQJNIDFZAHXWIX-UHFFFAOYSA-N";335.36;-0.27;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-7.12;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.00000007585775750291836
"4-carboxymethylphenyl Acetyl-NMe2";"MM01306";"CN(C)C(=O)Cc1ccc(C(=O)O)cc1";"LJTQUFHONBMKSS-UHFFFAOYSA-N";207.23;1.02;;;"DOPC:DOPA";"ELIP";"25";;"LUV,DOPC:DOPA=96:4";;-3.48;"Cao Y, Xiang TX, Anderson BD.: Development of structure-lipid bilayer permeability relationships for peptide-like small organic molecules. Mol Pharm, Volume 5 (3), 2008";"BLM";0.0003311311214825911
"Pentanamide";"MM00403";"CCCCC(N)=O";"IPWFJLQDVFKJDU-UHFFFAOYSA-N";101.15;0.66;"12298";;"EggPC";"ELIP";"24";;;;-3.74;"Poznansky M, Tong S, White PC, Milgram JM, Solomon AK.: Nonelectrolyte diffusion across lipid bilayer systems. J Gen Physiol, Volume 67 (1), 1976";"BLM";0.00018197008586099826
"Propanamide";"MM00413";"CCC(N)=O";"QLNJFJADRCOGBJ-UHFFFAOYSA-N";73.1;-0.12;"6578";"CHEMBL1235716";"EggPC";"ELIP";"24";;;;-4.21;"Poznansky M, Tong S, White PC, Milgram JM, Solomon AK.: Nonelectrolyte diffusion across lipid bilayer systems. J Gen Physiol, Volume 67 (1), 1976";"BLM";0.00006165950018614822
"L-epinephrine";"MM00644";"CNCC(O)c1ccc(O)c(O)c1";"UCTWMZQNUQWSLP-UHFFFAOYSA-N";183.21;0.35;"5816";"CHEMBL679";"EggPC";"ELIP";"25";;;;-5.57;"Bochain A, Estey L, Haronian G, Reale M, Rojas C, Cramer J.: Determination of catecholamine permeability coefficients for passive diffusion across phospholipid vesicle membranes. J Membr Biol, Volume 60 (1), 1981";"BLM";0.0000026915348039269138
"1-butanol";"MM00340";"CCCCO";"LRHPLDYGYMQRHN-UHFFFAOYSA-N";74.12;0.78;"263";"CHEMBL14245";"SOPC:SOPS";"ELIP";"25";;"GUV,SOPC:SOPS=99.5:0.5";;-2.92;"Ly HV, Longo ML.: The influence of short-chain alcohols on interfacial tension, mechanical properties, area/molecule, and permeability of fluid lipid bilayers. Biophys J, Volume 87 (2), 2004";"BLM";0.001202264434617413
"1-Propanol";"MM00061";"CCCO";"BDERNNFJNOPAEC-UHFFFAOYSA-N";60.1;0.39;"1031";"CHEMBL14687";"SOPC:SOPS";"ELIP";"25";;"GUV,SOPC:SOPS=99.5:0.5";;-3.55;"Ly HV, Longo ML.: The influence of short-chain alcohols on interfacial tension, mechanical properties, area/molecule, and permeability of fluid lipid bilayers. Biophys J, Volume 87 (2), 2004";"BLM";0.0002818382931264455
"Meso-erythritol";"MM00068";"OC[C@H](O)[C@H](O)CO";"UNXHWFMMPAWVPI-ZXZARUISSA-N";122.12;-2.31;"222285";"CHEMBL349605";"POPC:CHOL:DPPCA";"ELIP";"23";;"LUV,POPC:CHOL:DPPCA=20:15:2";;-6.4;"Sacerdote MG, Szostak JW.: Semipermeable lipid bilayers exhibit diastereoselectivity favoring ribose. Proc Natl Acad Sci U S A, Volume 102 (17), 2005";"BLM";0.0000003981071705534969
